<!DOCTYPE html>
<!-- saved from url=(0055)https://www.biopharmcatalyst.com/calendars/fda-calendar -->
<html xmlns="http://www.w3.org/1999/xhtml" lang="en-US"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
					<script src="./20210823_FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst_files/nr-1210.min.js.descarga"></script><script async="" src="./20210823_FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst_files/analytics.js.descarga"></script><script>
				window.csrfTokenName = "CRAFT_CSRF_TOKEN";
window.csrfTokenValue = "sHIZCmgqGKez\u007ETp54grOkzrtJFx_f7RP8j1hYYPm\u007C67b792f5123b5a1ca88248d05a6ea5c13e6e4328";
window.userDateFormat = "m/d/Y";
window.userPortfolio = [];
			</script>

			<link rel="stylesheet" href="./20210823_FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst_files/main.css">
			<script src="./20210823_FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst_files/301a32fc57.js.descarga" crossorigin="anonymous"></script><style media="all" id="fa-main">/*!
 * Font Awesome Pro 5.15.3 by @fontawesome - https://fontawesome.com
 * License - https://fontawesome.com/license (Commercial License)
 */.fa,.fab,.fad,.fal,.far,.fas{-moz-osx-font-smoothing:grayscale;-webkit-font-smoothing:antialiased;display:inline-block;font-style:normal;font-variant:normal;text-rendering:auto;line-height:1}.fa-lg{font-size:1.33333em;line-height:.75em;vertical-align:-.0667em}.fa-xs{font-size:.75em}.fa-sm{font-size:.875em}.fa-1x{font-size:1em}.fa-2x{font-size:2em}.fa-3x{font-size:3em}.fa-4x{font-size:4em}.fa-5x{font-size:5em}.fa-6x{font-size:6em}.fa-7x{font-size:7em}.fa-8x{font-size:8em}.fa-9x{font-size:9em}.fa-10x{font-size:10em}.fa-fw{text-align:center;width:1.25em}.fa-ul{list-style-type:none;margin-left:2.5em;padding-left:0}.fa-ul>li{position:relative}.fa-li{left:-2em;position:absolute;text-align:center;width:2em;line-height:inherit}.fa-border{border:.08em solid #eee;border-radius:.1em;padding:.2em .25em .15em}.fa-pull-left{float:left}.fa-pull-right{float:right}.fa.fa-pull-left,.fab.fa-pull-left,.fal.fa-pull-left,.far.fa-pull-left,.fas.fa-pull-left{margin-right:.3em}.fa.fa-pull-right,.fab.fa-pull-right,.fal.fa-pull-right,.far.fa-pull-right,.fas.fa-pull-right{margin-left:.3em}.fa-spin{-webkit-animation:fa-spin 2s linear infinite;animation:fa-spin 2s linear infinite}.fa-pulse{-webkit-animation:fa-spin 1s steps(8) infinite;animation:fa-spin 1s steps(8) infinite}@-webkit-keyframes fa-spin{0%{-webkit-transform:rotate(0deg);transform:rotate(0deg)}to{-webkit-transform:rotate(1turn);transform:rotate(1turn)}}@keyframes fa-spin{0%{-webkit-transform:rotate(0deg);transform:rotate(0deg)}to{-webkit-transform:rotate(1turn);transform:rotate(1turn)}}.fa-rotate-90{-ms-filter:"progid:DXImageTransform.Microsoft.BasicImage(rotation=1)";-webkit-transform:rotate(90deg);transform:rotate(90deg)}.fa-rotate-180{-ms-filter:"progid:DXImageTransform.Microsoft.BasicImage(rotation=2)";-webkit-transform:rotate(180deg);transform:rotate(180deg)}.fa-rotate-270{-ms-filter:"progid:DXImageTransform.Microsoft.BasicImage(rotation=3)";-webkit-transform:rotate(270deg);transform:rotate(270deg)}.fa-flip-horizontal{-ms-filter:"progid:DXImageTransform.Microsoft.BasicImage(rotation=0, mirror=1)";-webkit-transform:scaleX(-1);transform:scaleX(-1)}.fa-flip-vertical{-webkit-transform:scaleY(-1);transform:scaleY(-1)}.fa-flip-both,.fa-flip-horizontal.fa-flip-vertical,.fa-flip-vertical{-ms-filter:"progid:DXImageTransform.Microsoft.BasicImage(rotation=2, mirror=1)"}.fa-flip-both,.fa-flip-horizontal.fa-flip-vertical{-webkit-transform:scale(-1);transform:scale(-1)}:root .fa-flip-both,:root .fa-flip-horizontal,:root .fa-flip-vertical,:root .fa-rotate-90,:root .fa-rotate-180,:root .fa-rotate-270{-webkit-filter:none;filter:none}.fa-stack{display:inline-block;height:2em;line-height:2em;position:relative;vertical-align:middle;width:2.5em}.fa-stack-1x,.fa-stack-2x{left:0;position:absolute;text-align:center;width:100%}.fa-stack-1x{line-height:inherit}.fa-stack-2x{font-size:2em}.fa-inverse{color:#fff}.fa-500px:before{content:"\f26e"}.fa-abacus:before{content:"\f640"}.fa-accessible-icon:before{content:"\f368"}.fa-accusoft:before{content:"\f369"}.fa-acorn:before{content:"\f6ae"}.fa-acquisitions-incorporated:before{content:"\f6af"}.fa-ad:before{content:"\f641"}.fa-address-book:before{content:"\f2b9"}.fa-address-card:before{content:"\f2bb"}.fa-adjust:before{content:"\f042"}.fa-adn:before{content:"\f170"}.fa-adversal:before{content:"\f36a"}.fa-affiliatetheme:before{content:"\f36b"}.fa-air-conditioner:before{content:"\f8f4"}.fa-air-freshener:before{content:"\f5d0"}.fa-airbnb:before{content:"\f834"}.fa-alarm-clock:before{content:"\f34e"}.fa-alarm-exclamation:before{content:"\f843"}.fa-alarm-plus:before{content:"\f844"}.fa-alarm-snooze:before{content:"\f845"}.fa-album:before{content:"\f89f"}.fa-album-collection:before{content:"\f8a0"}.fa-algolia:before{content:"\f36c"}.fa-alicorn:before{content:"\f6b0"}.fa-alien:before{content:"\f8f5"}.fa-alien-monster:before{content:"\f8f6"}.fa-align-center:before{content:"\f037"}.fa-align-justify:before{content:"\f039"}.fa-align-left:before{content:"\f036"}.fa-align-right:before{content:"\f038"}.fa-align-slash:before{content:"\f846"}.fa-alipay:before{content:"\f642"}.fa-allergies:before{content:"\f461"}.fa-amazon:before{content:"\f270"}.fa-amazon-pay:before{content:"\f42c"}.fa-ambulance:before{content:"\f0f9"}.fa-american-sign-language-interpreting:before{content:"\f2a3"}.fa-amilia:before{content:"\f36d"}.fa-amp-guitar:before{content:"\f8a1"}.fa-analytics:before{content:"\f643"}.fa-anchor:before{content:"\f13d"}.fa-android:before{content:"\f17b"}.fa-angel:before{content:"\f779"}.fa-angellist:before{content:"\f209"}.fa-angle-double-down:before{content:"\f103"}.fa-angle-double-left:before{content:"\f100"}.fa-angle-double-right:before{content:"\f101"}.fa-angle-double-up:before{content:"\f102"}.fa-angle-down:before{content:"\f107"}.fa-angle-left:before{content:"\f104"}.fa-angle-right:before{content:"\f105"}.fa-angle-up:before{content:"\f106"}.fa-angry:before{content:"\f556"}.fa-angrycreative:before{content:"\f36e"}.fa-angular:before{content:"\f420"}.fa-ankh:before{content:"\f644"}.fa-app-store:before{content:"\f36f"}.fa-app-store-ios:before{content:"\f370"}.fa-apper:before{content:"\f371"}.fa-apple:before{content:"\f179"}.fa-apple-alt:before{content:"\f5d1"}.fa-apple-crate:before{content:"\f6b1"}.fa-apple-pay:before{content:"\f415"}.fa-archive:before{content:"\f187"}.fa-archway:before{content:"\f557"}.fa-arrow-alt-circle-down:before{content:"\f358"}.fa-arrow-alt-circle-left:before{content:"\f359"}.fa-arrow-alt-circle-right:before{content:"\f35a"}.fa-arrow-alt-circle-up:before{content:"\f35b"}.fa-arrow-alt-down:before{content:"\f354"}.fa-arrow-alt-from-bottom:before{content:"\f346"}.fa-arrow-alt-from-left:before{content:"\f347"}.fa-arrow-alt-from-right:before{content:"\f348"}.fa-arrow-alt-from-top:before{content:"\f349"}.fa-arrow-alt-left:before{content:"\f355"}.fa-arrow-alt-right:before{content:"\f356"}.fa-arrow-alt-square-down:before{content:"\f350"}.fa-arrow-alt-square-left:before{content:"\f351"}.fa-arrow-alt-square-right:before{content:"\f352"}.fa-arrow-alt-square-up:before{content:"\f353"}.fa-arrow-alt-to-bottom:before{content:"\f34a"}.fa-arrow-alt-to-left:before{content:"\f34b"}.fa-arrow-alt-to-right:before{content:"\f34c"}.fa-arrow-alt-to-top:before{content:"\f34d"}.fa-arrow-alt-up:before{content:"\f357"}.fa-arrow-circle-down:before{content:"\f0ab"}.fa-arrow-circle-left:before{content:"\f0a8"}.fa-arrow-circle-right:before{content:"\f0a9"}.fa-arrow-circle-up:before{content:"\f0aa"}.fa-arrow-down:before{content:"\f063"}.fa-arrow-from-bottom:before{content:"\f342"}.fa-arrow-from-left:before{content:"\f343"}.fa-arrow-from-right:before{content:"\f344"}.fa-arrow-from-top:before{content:"\f345"}.fa-arrow-left:before{content:"\f060"}.fa-arrow-right:before{content:"\f061"}.fa-arrow-square-down:before{content:"\f339"}.fa-arrow-square-left:before{content:"\f33a"}.fa-arrow-square-right:before{content:"\f33b"}.fa-arrow-square-up:before{content:"\f33c"}.fa-arrow-to-bottom:before{content:"\f33d"}.fa-arrow-to-left:before{content:"\f33e"}.fa-arrow-to-right:before{content:"\f340"}.fa-arrow-to-top:before{content:"\f341"}.fa-arrow-up:before{content:"\f062"}.fa-arrows:before{content:"\f047"}.fa-arrows-alt:before{content:"\f0b2"}.fa-arrows-alt-h:before{content:"\f337"}.fa-arrows-alt-v:before{content:"\f338"}.fa-arrows-h:before{content:"\f07e"}.fa-arrows-v:before{content:"\f07d"}.fa-artstation:before{content:"\f77a"}.fa-assistive-listening-systems:before{content:"\f2a2"}.fa-asterisk:before{content:"\f069"}.fa-asymmetrik:before{content:"\f372"}.fa-at:before{content:"\f1fa"}.fa-atlas:before{content:"\f558"}.fa-atlassian:before{content:"\f77b"}.fa-atom:before{content:"\f5d2"}.fa-atom-alt:before{content:"\f5d3"}.fa-audible:before{content:"\f373"}.fa-audio-description:before{content:"\f29e"}.fa-autoprefixer:before{content:"\f41c"}.fa-avianex:before{content:"\f374"}.fa-aviato:before{content:"\f421"}.fa-award:before{content:"\f559"}.fa-aws:before{content:"\f375"}.fa-axe:before{content:"\f6b2"}.fa-axe-battle:before{content:"\f6b3"}.fa-baby:before{content:"\f77c"}.fa-baby-carriage:before{content:"\f77d"}.fa-backpack:before{content:"\f5d4"}.fa-backspace:before{content:"\f55a"}.fa-backward:before{content:"\f04a"}.fa-bacon:before{content:"\f7e5"}.fa-bacteria:before{content:"\e059"}.fa-bacterium:before{content:"\e05a"}.fa-badge:before{content:"\f335"}.fa-badge-check:before{content:"\f336"}.fa-badge-dollar:before{content:"\f645"}.fa-badge-percent:before{content:"\f646"}.fa-badge-sheriff:before{content:"\f8a2"}.fa-badger-honey:before{content:"\f6b4"}.fa-bags-shopping:before{content:"\f847"}.fa-bahai:before{content:"\f666"}.fa-balance-scale:before{content:"\f24e"}.fa-balance-scale-left:before{content:"\f515"}.fa-balance-scale-right:before{content:"\f516"}.fa-ball-pile:before{content:"\f77e"}.fa-ballot:before{content:"\f732"}.fa-ballot-check:before{content:"\f733"}.fa-ban:before{content:"\f05e"}.fa-band-aid:before{content:"\f462"}.fa-bandcamp:before{content:"\f2d5"}.fa-banjo:before{content:"\f8a3"}.fa-barcode:before{content:"\f02a"}.fa-barcode-alt:before{content:"\f463"}.fa-barcode-read:before{content:"\f464"}.fa-barcode-scan:before{content:"\f465"}.fa-bars:before{content:"\f0c9"}.fa-baseball:before{content:"\f432"}.fa-baseball-ball:before{content:"\f433"}.fa-basketball-ball:before{content:"\f434"}.fa-basketball-hoop:before{content:"\f435"}.fa-bat:before{content:"\f6b5"}.fa-bath:before{content:"\f2cd"}.fa-battery-bolt:before{content:"\f376"}.fa-battery-empty:before{content:"\f244"}.fa-battery-full:before{content:"\f240"}.fa-battery-half:before{content:"\f242"}.fa-battery-quarter:before{content:"\f243"}.fa-battery-slash:before{content:"\f377"}.fa-battery-three-quarters:before{content:"\f241"}.fa-battle-net:before{content:"\f835"}.fa-bed:before{content:"\f236"}.fa-bed-alt:before{content:"\f8f7"}.fa-bed-bunk:before{content:"\f8f8"}.fa-bed-empty:before{content:"\f8f9"}.fa-beer:before{content:"\f0fc"}.fa-behance:before{content:"\f1b4"}.fa-behance-square:before{content:"\f1b5"}.fa-bell:before{content:"\f0f3"}.fa-bell-exclamation:before{content:"\f848"}.fa-bell-on:before{content:"\f8fa"}.fa-bell-plus:before{content:"\f849"}.fa-bell-school:before{content:"\f5d5"}.fa-bell-school-slash:before{content:"\f5d6"}.fa-bell-slash:before{content:"\f1f6"}.fa-bells:before{content:"\f77f"}.fa-betamax:before{content:"\f8a4"}.fa-bezier-curve:before{content:"\f55b"}.fa-bible:before{content:"\f647"}.fa-bicycle:before{content:"\f206"}.fa-biking:before{content:"\f84a"}.fa-biking-mountain:before{content:"\f84b"}.fa-bimobject:before{content:"\f378"}.fa-binoculars:before{content:"\f1e5"}.fa-biohazard:before{content:"\f780"}.fa-birthday-cake:before{content:"\f1fd"}.fa-bitbucket:before{content:"\f171"}.fa-bitcoin:before{content:"\f379"}.fa-bity:before{content:"\f37a"}.fa-black-tie:before{content:"\f27e"}.fa-blackberry:before{content:"\f37b"}.fa-blanket:before{content:"\f498"}.fa-blender:before{content:"\f517"}.fa-blender-phone:before{content:"\f6b6"}.fa-blind:before{content:"\f29d"}.fa-blinds:before{content:"\f8fb"}.fa-blinds-open:before{content:"\f8fc"}.fa-blinds-raised:before{content:"\f8fd"}.fa-blog:before{content:"\f781"}.fa-blogger:before{content:"\f37c"}.fa-blogger-b:before{content:"\f37d"}.fa-bluetooth:before{content:"\f293"}.fa-bluetooth-b:before{content:"\f294"}.fa-bold:before{content:"\f032"}.fa-bolt:before{content:"\f0e7"}.fa-bomb:before{content:"\f1e2"}.fa-bone:before{content:"\f5d7"}.fa-bone-break:before{content:"\f5d8"}.fa-bong:before{content:"\f55c"}.fa-book:before{content:"\f02d"}.fa-book-alt:before{content:"\f5d9"}.fa-book-dead:before{content:"\f6b7"}.fa-book-heart:before{content:"\f499"}.fa-book-medical:before{content:"\f7e6"}.fa-book-open:before{content:"\f518"}.fa-book-reader:before{content:"\f5da"}.fa-book-spells:before{content:"\f6b8"}.fa-book-user:before{content:"\f7e7"}.fa-bookmark:before{content:"\f02e"}.fa-books:before{content:"\f5db"}.fa-books-medical:before{content:"\f7e8"}.fa-boombox:before{content:"\f8a5"}.fa-boot:before{content:"\f782"}.fa-booth-curtain:before{content:"\f734"}.fa-bootstrap:before{content:"\f836"}.fa-border-all:before{content:"\f84c"}.fa-border-bottom:before{content:"\f84d"}.fa-border-center-h:before{content:"\f89c"}.fa-border-center-v:before{content:"\f89d"}.fa-border-inner:before{content:"\f84e"}.fa-border-left:before{content:"\f84f"}.fa-border-none:before{content:"\f850"}.fa-border-outer:before{content:"\f851"}.fa-border-right:before{content:"\f852"}.fa-border-style:before{content:"\f853"}.fa-border-style-alt:before{content:"\f854"}.fa-border-top:before{content:"\f855"}.fa-bow-arrow:before{content:"\f6b9"}.fa-bowling-ball:before{content:"\f436"}.fa-bowling-pins:before{content:"\f437"}.fa-box:before{content:"\f466"}.fa-box-alt:before{content:"\f49a"}.fa-box-ballot:before{content:"\f735"}.fa-box-check:before{content:"\f467"}.fa-box-fragile:before{content:"\f49b"}.fa-box-full:before{content:"\f49c"}.fa-box-heart:before{content:"\f49d"}.fa-box-open:before{content:"\f49e"}.fa-box-tissue:before{content:"\e05b"}.fa-box-up:before{content:"\f49f"}.fa-box-usd:before{content:"\f4a0"}.fa-boxes:before{content:"\f468"}.fa-boxes-alt:before{content:"\f4a1"}.fa-boxing-glove:before{content:"\f438"}.fa-brackets:before{content:"\f7e9"}.fa-brackets-curly:before{content:"\f7ea"}.fa-braille:before{content:"\f2a1"}.fa-brain:before{content:"\f5dc"}.fa-bread-loaf:before{content:"\f7eb"}.fa-bread-slice:before{content:"\f7ec"}.fa-briefcase:before{content:"\f0b1"}.fa-briefcase-medical:before{content:"\f469"}.fa-bring-forward:before{content:"\f856"}.fa-bring-front:before{content:"\f857"}.fa-broadcast-tower:before{content:"\f519"}.fa-broom:before{content:"\f51a"}.fa-browser:before{content:"\f37e"}.fa-brush:before{content:"\f55d"}.fa-btc:before{content:"\f15a"}.fa-buffer:before{content:"\f837"}.fa-bug:before{content:"\f188"}.fa-building:before{content:"\f1ad"}.fa-bullhorn:before{content:"\f0a1"}.fa-bullseye:before{content:"\f140"}.fa-bullseye-arrow:before{content:"\f648"}.fa-bullseye-pointer:before{content:"\f649"}.fa-burger-soda:before{content:"\f858"}.fa-burn:before{content:"\f46a"}.fa-buromobelexperte:before{content:"\f37f"}.fa-burrito:before{content:"\f7ed"}.fa-bus:before{content:"\f207"}.fa-bus-alt:before{content:"\f55e"}.fa-bus-school:before{content:"\f5dd"}.fa-business-time:before{content:"\f64a"}.fa-buy-n-large:before{content:"\f8a6"}.fa-buysellads:before{content:"\f20d"}.fa-cabinet-filing:before{content:"\f64b"}.fa-cactus:before{content:"\f8a7"}.fa-calculator:before{content:"\f1ec"}.fa-calculator-alt:before{content:"\f64c"}.fa-calendar:before{content:"\f133"}.fa-calendar-alt:before{content:"\f073"}.fa-calendar-check:before{content:"\f274"}.fa-calendar-day:before{content:"\f783"}.fa-calendar-edit:before{content:"\f333"}.fa-calendar-exclamation:before{content:"\f334"}.fa-calendar-minus:before{content:"\f272"}.fa-calendar-plus:before{content:"\f271"}.fa-calendar-star:before{content:"\f736"}.fa-calendar-times:before{content:"\f273"}.fa-calendar-week:before{content:"\f784"}.fa-camcorder:before{content:"\f8a8"}.fa-camera:before{content:"\f030"}.fa-camera-alt:before{content:"\f332"}.fa-camera-home:before{content:"\f8fe"}.fa-camera-movie:before{content:"\f8a9"}.fa-camera-polaroid:before{content:"\f8aa"}.fa-camera-retro:before{content:"\f083"}.fa-campfire:before{content:"\f6ba"}.fa-campground:before{content:"\f6bb"}.fa-canadian-maple-leaf:before{content:"\f785"}.fa-candle-holder:before{content:"\f6bc"}.fa-candy-cane:before{content:"\f786"}.fa-candy-corn:before{content:"\f6bd"}.fa-cannabis:before{content:"\f55f"}.fa-capsules:before{content:"\f46b"}.fa-car:before{content:"\f1b9"}.fa-car-alt:before{content:"\f5de"}.fa-car-battery:before{content:"\f5df"}.fa-car-building:before{content:"\f859"}.fa-car-bump:before{content:"\f5e0"}.fa-car-bus:before{content:"\f85a"}.fa-car-crash:before{content:"\f5e1"}.fa-car-garage:before{content:"\f5e2"}.fa-car-mechanic:before{content:"\f5e3"}.fa-car-side:before{content:"\f5e4"}.fa-car-tilt:before{content:"\f5e5"}.fa-car-wash:before{content:"\f5e6"}.fa-caravan:before{content:"\f8ff"}.fa-caravan-alt:before{content:"\e000"}.fa-caret-circle-down:before{content:"\f32d"}.fa-caret-circle-left:before{content:"\f32e"}.fa-caret-circle-right:before{content:"\f330"}.fa-caret-circle-up:before{content:"\f331"}.fa-caret-down:before{content:"\f0d7"}.fa-caret-left:before{content:"\f0d9"}.fa-caret-right:before{content:"\f0da"}.fa-caret-square-down:before{content:"\f150"}.fa-caret-square-left:before{content:"\f191"}.fa-caret-square-right:before{content:"\f152"}.fa-caret-square-up:before{content:"\f151"}.fa-caret-up:before{content:"\f0d8"}.fa-carrot:before{content:"\f787"}.fa-cars:before{content:"\f85b"}.fa-cart-arrow-down:before{content:"\f218"}.fa-cart-plus:before{content:"\f217"}.fa-cash-register:before{content:"\f788"}.fa-cassette-tape:before{content:"\f8ab"}.fa-cat:before{content:"\f6be"}.fa-cat-space:before{content:"\e001"}.fa-cauldron:before{content:"\f6bf"}.fa-cc-amazon-pay:before{content:"\f42d"}.fa-cc-amex:before{content:"\f1f3"}.fa-cc-apple-pay:before{content:"\f416"}.fa-cc-diners-club:before{content:"\f24c"}.fa-cc-discover:before{content:"\f1f2"}.fa-cc-jcb:before{content:"\f24b"}.fa-cc-mastercard:before{content:"\f1f1"}.fa-cc-paypal:before{content:"\f1f4"}.fa-cc-stripe:before{content:"\f1f5"}.fa-cc-visa:before{content:"\f1f0"}.fa-cctv:before{content:"\f8ac"}.fa-centercode:before{content:"\f380"}.fa-centos:before{content:"\f789"}.fa-certificate:before{content:"\f0a3"}.fa-chair:before{content:"\f6c0"}.fa-chair-office:before{content:"\f6c1"}.fa-chalkboard:before{content:"\f51b"}.fa-chalkboard-teacher:before{content:"\f51c"}.fa-charging-station:before{content:"\f5e7"}.fa-chart-area:before{content:"\f1fe"}.fa-chart-bar:before{content:"\f080"}.fa-chart-line:before{content:"\f201"}.fa-chart-line-down:before{content:"\f64d"}.fa-chart-network:before{content:"\f78a"}.fa-chart-pie:before{content:"\f200"}.fa-chart-pie-alt:before{content:"\f64e"}.fa-chart-scatter:before{content:"\f7ee"}.fa-check:before{content:"\f00c"}.fa-check-circle:before{content:"\f058"}.fa-check-double:before{content:"\f560"}.fa-check-square:before{content:"\f14a"}.fa-cheese:before{content:"\f7ef"}.fa-cheese-swiss:before{content:"\f7f0"}.fa-cheeseburger:before{content:"\f7f1"}.fa-chess:before{content:"\f439"}.fa-chess-bishop:before{content:"\f43a"}.fa-chess-bishop-alt:before{content:"\f43b"}.fa-chess-board:before{content:"\f43c"}.fa-chess-clock:before{content:"\f43d"}.fa-chess-clock-alt:before{content:"\f43e"}.fa-chess-king:before{content:"\f43f"}.fa-chess-king-alt:before{content:"\f440"}.fa-chess-knight:before{content:"\f441"}.fa-chess-knight-alt:before{content:"\f442"}.fa-chess-pawn:before{content:"\f443"}.fa-chess-pawn-alt:before{content:"\f444"}.fa-chess-queen:before{content:"\f445"}.fa-chess-queen-alt:before{content:"\f446"}.fa-chess-rook:before{content:"\f447"}.fa-chess-rook-alt:before{content:"\f448"}.fa-chevron-circle-down:before{content:"\f13a"}.fa-chevron-circle-left:before{content:"\f137"}.fa-chevron-circle-right:before{content:"\f138"}.fa-chevron-circle-up:before{content:"\f139"}.fa-chevron-double-down:before{content:"\f322"}.fa-chevron-double-left:before{content:"\f323"}.fa-chevron-double-right:before{content:"\f324"}.fa-chevron-double-up:before{content:"\f325"}.fa-chevron-down:before{content:"\f078"}.fa-chevron-left:before{content:"\f053"}.fa-chevron-right:before{content:"\f054"}.fa-chevron-square-down:before{content:"\f329"}.fa-chevron-square-left:before{content:"\f32a"}.fa-chevron-square-right:before{content:"\f32b"}.fa-chevron-square-up:before{content:"\f32c"}.fa-chevron-up:before{content:"\f077"}.fa-child:before{content:"\f1ae"}.fa-chimney:before{content:"\f78b"}.fa-chrome:before{content:"\f268"}.fa-chromecast:before{content:"\f838"}.fa-church:before{content:"\f51d"}.fa-circle:before{content:"\f111"}.fa-circle-notch:before{content:"\f1ce"}.fa-city:before{content:"\f64f"}.fa-clarinet:before{content:"\f8ad"}.fa-claw-marks:before{content:"\f6c2"}.fa-clinic-medical:before{content:"\f7f2"}.fa-clipboard:before{content:"\f328"}.fa-clipboard-check:before{content:"\f46c"}.fa-clipboard-list:before{content:"\f46d"}.fa-clipboard-list-check:before{content:"\f737"}.fa-clipboard-prescription:before{content:"\f5e8"}.fa-clipboard-user:before{content:"\f7f3"}.fa-clock:before{content:"\f017"}.fa-clone:before{content:"\f24d"}.fa-closed-captioning:before{content:"\f20a"}.fa-cloud:before{content:"\f0c2"}.fa-cloud-download:before{content:"\f0ed"}.fa-cloud-download-alt:before{content:"\f381"}.fa-cloud-drizzle:before{content:"\f738"}.fa-cloud-hail:before{content:"\f739"}.fa-cloud-hail-mixed:before{content:"\f73a"}.fa-cloud-meatball:before{content:"\f73b"}.fa-cloud-moon:before{content:"\f6c3"}.fa-cloud-moon-rain:before{content:"\f73c"}.fa-cloud-music:before{content:"\f8ae"}.fa-cloud-rain:before{content:"\f73d"}.fa-cloud-rainbow:before{content:"\f73e"}.fa-cloud-showers:before{content:"\f73f"}.fa-cloud-showers-heavy:before{content:"\f740"}.fa-cloud-sleet:before{content:"\f741"}.fa-cloud-snow:before{content:"\f742"}.fa-cloud-sun:before{content:"\f6c4"}.fa-cloud-sun-rain:before{content:"\f743"}.fa-cloud-upload:before{content:"\f0ee"}.fa-cloud-upload-alt:before{content:"\f382"}.fa-cloudflare:before{content:"\e07d"}.fa-clouds:before{content:"\f744"}.fa-clouds-moon:before{content:"\f745"}.fa-clouds-sun:before{content:"\f746"}.fa-cloudscale:before{content:"\f383"}.fa-cloudsmith:before{content:"\f384"}.fa-cloudversify:before{content:"\f385"}.fa-club:before{content:"\f327"}.fa-cocktail:before{content:"\f561"}.fa-code:before{content:"\f121"}.fa-code-branch:before{content:"\f126"}.fa-code-commit:before{content:"\f386"}.fa-code-merge:before{content:"\f387"}.fa-codepen:before{content:"\f1cb"}.fa-codiepie:before{content:"\f284"}.fa-coffee:before{content:"\f0f4"}.fa-coffee-pot:before{content:"\e002"}.fa-coffee-togo:before{content:"\f6c5"}.fa-coffin:before{content:"\f6c6"}.fa-coffin-cross:before{content:"\e051"}.fa-cog:before{content:"\f013"}.fa-cogs:before{content:"\f085"}.fa-coin:before{content:"\f85c"}.fa-coins:before{content:"\f51e"}.fa-columns:before{content:"\f0db"}.fa-comet:before{content:"\e003"}.fa-comment:before{content:"\f075"}.fa-comment-alt:before{content:"\f27a"}.fa-comment-alt-check:before{content:"\f4a2"}.fa-comment-alt-dollar:before{content:"\f650"}.fa-comment-alt-dots:before{content:"\f4a3"}.fa-comment-alt-edit:before{content:"\f4a4"}.fa-comment-alt-exclamation:before{content:"\f4a5"}.fa-comment-alt-lines:before{content:"\f4a6"}.fa-comment-alt-medical:before{content:"\f7f4"}.fa-comment-alt-minus:before{content:"\f4a7"}.fa-comment-alt-music:before{content:"\f8af"}.fa-comment-alt-plus:before{content:"\f4a8"}.fa-comment-alt-slash:before{content:"\f4a9"}.fa-comment-alt-smile:before{content:"\f4aa"}.fa-comment-alt-times:before{content:"\f4ab"}.fa-comment-check:before{content:"\f4ac"}.fa-comment-dollar:before{content:"\f651"}.fa-comment-dots:before{content:"\f4ad"}.fa-comment-edit:before{content:"\f4ae"}.fa-comment-exclamation:before{content:"\f4af"}.fa-comment-lines:before{content:"\f4b0"}.fa-comment-medical:before{content:"\f7f5"}.fa-comment-minus:before{content:"\f4b1"}.fa-comment-music:before{content:"\f8b0"}.fa-comment-plus:before{content:"\f4b2"}.fa-comment-slash:before{content:"\f4b3"}.fa-comment-smile:before{content:"\f4b4"}.fa-comment-times:before{content:"\f4b5"}.fa-comments:before{content:"\f086"}.fa-comments-alt:before{content:"\f4b6"}.fa-comments-alt-dollar:before{content:"\f652"}.fa-comments-dollar:before{content:"\f653"}.fa-compact-disc:before{content:"\f51f"}.fa-compass:before{content:"\f14e"}.fa-compass-slash:before{content:"\f5e9"}.fa-compress:before{content:"\f066"}.fa-compress-alt:before{content:"\f422"}.fa-compress-arrows-alt:before{content:"\f78c"}.fa-compress-wide:before{content:"\f326"}.fa-computer-classic:before{content:"\f8b1"}.fa-computer-speaker:before{content:"\f8b2"}.fa-concierge-bell:before{content:"\f562"}.fa-confluence:before{content:"\f78d"}.fa-connectdevelop:before{content:"\f20e"}.fa-construction:before{content:"\f85d"}.fa-container-storage:before{content:"\f4b7"}.fa-contao:before{content:"\f26d"}.fa-conveyor-belt:before{content:"\f46e"}.fa-conveyor-belt-alt:before{content:"\f46f"}.fa-cookie:before{content:"\f563"}.fa-cookie-bite:before{content:"\f564"}.fa-copy:before{content:"\f0c5"}.fa-copyright:before{content:"\f1f9"}.fa-corn:before{content:"\f6c7"}.fa-cotton-bureau:before{content:"\f89e"}.fa-couch:before{content:"\f4b8"}.fa-cow:before{content:"\f6c8"}.fa-cowbell:before{content:"\f8b3"}.fa-cowbell-more:before{content:"\f8b4"}.fa-cpanel:before{content:"\f388"}.fa-creative-commons:before{content:"\f25e"}.fa-creative-commons-by:before{content:"\f4e7"}.fa-creative-commons-nc:before{content:"\f4e8"}.fa-creative-commons-nc-eu:before{content:"\f4e9"}.fa-creative-commons-nc-jp:before{content:"\f4ea"}.fa-creative-commons-nd:before{content:"\f4eb"}.fa-creative-commons-pd:before{content:"\f4ec"}.fa-creative-commons-pd-alt:before{content:"\f4ed"}.fa-creative-commons-remix:before{content:"\f4ee"}.fa-creative-commons-sa:before{content:"\f4ef"}.fa-creative-commons-sampling:before{content:"\f4f0"}.fa-creative-commons-sampling-plus:before{content:"\f4f1"}.fa-creative-commons-share:before{content:"\f4f2"}.fa-creative-commons-zero:before{content:"\f4f3"}.fa-credit-card:before{content:"\f09d"}.fa-credit-card-blank:before{content:"\f389"}.fa-credit-card-front:before{content:"\f38a"}.fa-cricket:before{content:"\f449"}.fa-critical-role:before{content:"\f6c9"}.fa-croissant:before{content:"\f7f6"}.fa-crop:before{content:"\f125"}.fa-crop-alt:before{content:"\f565"}.fa-cross:before{content:"\f654"}.fa-crosshairs:before{content:"\f05b"}.fa-crow:before{content:"\f520"}.fa-crown:before{content:"\f521"}.fa-crutch:before{content:"\f7f7"}.fa-crutches:before{content:"\f7f8"}.fa-css3:before{content:"\f13c"}.fa-css3-alt:before{content:"\f38b"}.fa-cube:before{content:"\f1b2"}.fa-cubes:before{content:"\f1b3"}.fa-curling:before{content:"\f44a"}.fa-cut:before{content:"\f0c4"}.fa-cuttlefish:before{content:"\f38c"}.fa-d-and-d:before{content:"\f38d"}.fa-d-and-d-beyond:before{content:"\f6ca"}.fa-dagger:before{content:"\f6cb"}.fa-dailymotion:before{content:"\e052"}.fa-dashcube:before{content:"\f210"}.fa-database:before{content:"\f1c0"}.fa-deaf:before{content:"\f2a4"}.fa-debug:before{content:"\f7f9"}.fa-deer:before{content:"\f78e"}.fa-deer-rudolph:before{content:"\f78f"}.fa-deezer:before{content:"\e077"}.fa-delicious:before{content:"\f1a5"}.fa-democrat:before{content:"\f747"}.fa-deploydog:before{content:"\f38e"}.fa-deskpro:before{content:"\f38f"}.fa-desktop:before{content:"\f108"}.fa-desktop-alt:before{content:"\f390"}.fa-dev:before{content:"\f6cc"}.fa-deviantart:before{content:"\f1bd"}.fa-dewpoint:before{content:"\f748"}.fa-dharmachakra:before{content:"\f655"}.fa-dhl:before{content:"\f790"}.fa-diagnoses:before{content:"\f470"}.fa-diamond:before{content:"\f219"}.fa-diaspora:before{content:"\f791"}.fa-dice:before{content:"\f522"}.fa-dice-d10:before{content:"\f6cd"}.fa-dice-d12:before{content:"\f6ce"}.fa-dice-d20:before{content:"\f6cf"}.fa-dice-d4:before{content:"\f6d0"}.fa-dice-d6:before{content:"\f6d1"}.fa-dice-d8:before{content:"\f6d2"}.fa-dice-five:before{content:"\f523"}.fa-dice-four:before{content:"\f524"}.fa-dice-one:before{content:"\f525"}.fa-dice-six:before{content:"\f526"}.fa-dice-three:before{content:"\f527"}.fa-dice-two:before{content:"\f528"}.fa-digg:before{content:"\f1a6"}.fa-digging:before{content:"\f85e"}.fa-digital-ocean:before{content:"\f391"}.fa-digital-tachograph:before{content:"\f566"}.fa-diploma:before{content:"\f5ea"}.fa-directions:before{content:"\f5eb"}.fa-disc-drive:before{content:"\f8b5"}.fa-discord:before{content:"\f392"}.fa-discourse:before{content:"\f393"}.fa-disease:before{content:"\f7fa"}.fa-divide:before{content:"\f529"}.fa-dizzy:before{content:"\f567"}.fa-dna:before{content:"\f471"}.fa-do-not-enter:before{content:"\f5ec"}.fa-dochub:before{content:"\f394"}.fa-docker:before{content:"\f395"}.fa-dog:before{content:"\f6d3"}.fa-dog-leashed:before{content:"\f6d4"}.fa-dollar-sign:before{content:"\f155"}.fa-dolly:before{content:"\f472"}.fa-dolly-empty:before{content:"\f473"}.fa-dolly-flatbed:before{content:"\f474"}.fa-dolly-flatbed-alt:before{content:"\f475"}.fa-dolly-flatbed-empty:before{content:"\f476"}.fa-donate:before{content:"\f4b9"}.fa-door-closed:before{content:"\f52a"}.fa-door-open:before{content:"\f52b"}.fa-dot-circle:before{content:"\f192"}.fa-dove:before{content:"\f4ba"}.fa-download:before{content:"\f019"}.fa-draft2digital:before{content:"\f396"}.fa-drafting-compass:before{content:"\f568"}.fa-dragon:before{content:"\f6d5"}.fa-draw-circle:before{content:"\f5ed"}.fa-draw-polygon:before{content:"\f5ee"}.fa-draw-square:before{content:"\f5ef"}.fa-dreidel:before{content:"\f792"}.fa-dribbble:before{content:"\f17d"}.fa-dribbble-square:before{content:"\f397"}.fa-drone:before{content:"\f85f"}.fa-drone-alt:before{content:"\f860"}.fa-dropbox:before{content:"\f16b"}.fa-drum:before{content:"\f569"}.fa-drum-steelpan:before{content:"\f56a"}.fa-drumstick:before{content:"\f6d6"}.fa-drumstick-bite:before{content:"\f6d7"}.fa-drupal:before{content:"\f1a9"}.fa-dryer:before{content:"\f861"}.fa-dryer-alt:before{content:"\f862"}.fa-duck:before{content:"\f6d8"}.fa-dumbbell:before{content:"\f44b"}.fa-dumpster:before{content:"\f793"}.fa-dumpster-fire:before{content:"\f794"}.fa-dungeon:before{content:"\f6d9"}.fa-dyalog:before{content:"\f399"}.fa-ear:before{content:"\f5f0"}.fa-ear-muffs:before{content:"\f795"}.fa-earlybirds:before{content:"\f39a"}.fa-ebay:before{content:"\f4f4"}.fa-eclipse:before{content:"\f749"}.fa-eclipse-alt:before{content:"\f74a"}.fa-edge:before{content:"\f282"}.fa-edge-legacy:before{content:"\e078"}.fa-edit:before{content:"\f044"}.fa-egg:before{content:"\f7fb"}.fa-egg-fried:before{content:"\f7fc"}.fa-eject:before{content:"\f052"}.fa-elementor:before{content:"\f430"}.fa-elephant:before{content:"\f6da"}.fa-ellipsis-h:before{content:"\f141"}.fa-ellipsis-h-alt:before{content:"\f39b"}.fa-ellipsis-v:before{content:"\f142"}.fa-ellipsis-v-alt:before{content:"\f39c"}.fa-ello:before{content:"\f5f1"}.fa-ember:before{content:"\f423"}.fa-empire:before{content:"\f1d1"}.fa-empty-set:before{content:"\f656"}.fa-engine-warning:before{content:"\f5f2"}.fa-envelope:before{content:"\f0e0"}.fa-envelope-open:before{content:"\f2b6"}.fa-envelope-open-dollar:before{content:"\f657"}.fa-envelope-open-text:before{content:"\f658"}.fa-envelope-square:before{content:"\f199"}.fa-envira:before{content:"\f299"}.fa-equals:before{content:"\f52c"}.fa-eraser:before{content:"\f12d"}.fa-erlang:before{content:"\f39d"}.fa-ethereum:before{content:"\f42e"}.fa-ethernet:before{content:"\f796"}.fa-etsy:before{content:"\f2d7"}.fa-euro-sign:before{content:"\f153"}.fa-evernote:before{content:"\f839"}.fa-exchange:before{content:"\f0ec"}.fa-exchange-alt:before{content:"\f362"}.fa-exclamation:before{content:"\f12a"}.fa-exclamation-circle:before{content:"\f06a"}.fa-exclamation-square:before{content:"\f321"}.fa-exclamation-triangle:before{content:"\f071"}.fa-expand:before{content:"\f065"}.fa-expand-alt:before{content:"\f424"}.fa-expand-arrows:before{content:"\f31d"}.fa-expand-arrows-alt:before{content:"\f31e"}.fa-expand-wide:before{content:"\f320"}.fa-expeditedssl:before{content:"\f23e"}.fa-external-link:before{content:"\f08e"}.fa-external-link-alt:before{content:"\f35d"}.fa-external-link-square:before{content:"\f14c"}.fa-external-link-square-alt:before{content:"\f360"}.fa-eye:before{content:"\f06e"}.fa-eye-dropper:before{content:"\f1fb"}.fa-eye-evil:before{content:"\f6db"}.fa-eye-slash:before{content:"\f070"}.fa-facebook:before{content:"\f09a"}.fa-facebook-f:before{content:"\f39e"}.fa-facebook-messenger:before{content:"\f39f"}.fa-facebook-square:before{content:"\f082"}.fa-fan:before{content:"\f863"}.fa-fan-table:before{content:"\e004"}.fa-fantasy-flight-games:before{content:"\f6dc"}.fa-farm:before{content:"\f864"}.fa-fast-backward:before{content:"\f049"}.fa-fast-forward:before{content:"\f050"}.fa-faucet:before{content:"\e005"}.fa-faucet-drip:before{content:"\e006"}.fa-fax:before{content:"\f1ac"}.fa-feather:before{content:"\f52d"}.fa-feather-alt:before{content:"\f56b"}.fa-fedex:before{content:"\f797"}.fa-fedora:before{content:"\f798"}.fa-female:before{content:"\f182"}.fa-field-hockey:before{content:"\f44c"}.fa-fighter-jet:before{content:"\f0fb"}.fa-figma:before{content:"\f799"}.fa-file:before{content:"\f15b"}.fa-file-alt:before{content:"\f15c"}.fa-file-archive:before{content:"\f1c6"}.fa-file-audio:before{content:"\f1c7"}.fa-file-certificate:before{content:"\f5f3"}.fa-file-chart-line:before{content:"\f659"}.fa-file-chart-pie:before{content:"\f65a"}.fa-file-check:before{content:"\f316"}.fa-file-code:before{content:"\f1c9"}.fa-file-contract:before{content:"\f56c"}.fa-file-csv:before{content:"\f6dd"}.fa-file-download:before{content:"\f56d"}.fa-file-edit:before{content:"\f31c"}.fa-file-excel:before{content:"\f1c3"}.fa-file-exclamation:before{content:"\f31a"}.fa-file-export:before{content:"\f56e"}.fa-file-image:before{content:"\f1c5"}.fa-file-import:before{content:"\f56f"}.fa-file-invoice:before{content:"\f570"}.fa-file-invoice-dollar:before{content:"\f571"}.fa-file-medical:before{content:"\f477"}.fa-file-medical-alt:before{content:"\f478"}.fa-file-minus:before{content:"\f318"}.fa-file-music:before{content:"\f8b6"}.fa-file-pdf:before{content:"\f1c1"}.fa-file-plus:before{content:"\f319"}.fa-file-powerpoint:before{content:"\f1c4"}.fa-file-prescription:before{content:"\f572"}.fa-file-search:before{content:"\f865"}.fa-file-signature:before{content:"\f573"}.fa-file-spreadsheet:before{content:"\f65b"}.fa-file-times:before{content:"\f317"}.fa-file-upload:before{content:"\f574"}.fa-file-user:before{content:"\f65c"}.fa-file-video:before{content:"\f1c8"}.fa-file-word:before{content:"\f1c2"}.fa-files-medical:before{content:"\f7fd"}.fa-fill:before{content:"\f575"}.fa-fill-drip:before{content:"\f576"}.fa-film:before{content:"\f008"}.fa-film-alt:before{content:"\f3a0"}.fa-film-canister:before{content:"\f8b7"}.fa-filter:before{content:"\f0b0"}.fa-fingerprint:before{content:"\f577"}.fa-fire:before{content:"\f06d"}.fa-fire-alt:before{content:"\f7e4"}.fa-fire-extinguisher:before{content:"\f134"}.fa-fire-smoke:before{content:"\f74b"}.fa-firefox:before{content:"\f269"}.fa-firefox-browser:before{content:"\e007"}.fa-fireplace:before{content:"\f79a"}.fa-first-aid:before{content:"\f479"}.fa-first-order:before{content:"\f2b0"}.fa-first-order-alt:before{content:"\f50a"}.fa-firstdraft:before{content:"\f3a1"}.fa-fish:before{content:"\f578"}.fa-fish-cooked:before{content:"\f7fe"}.fa-fist-raised:before{content:"\f6de"}.fa-flag:before{content:"\f024"}.fa-flag-alt:before{content:"\f74c"}.fa-flag-checkered:before{content:"\f11e"}.fa-flag-usa:before{content:"\f74d"}.fa-flame:before{content:"\f6df"}.fa-flashlight:before{content:"\f8b8"}.fa-flask:before{content:"\f0c3"}.fa-flask-poison:before{content:"\f6e0"}.fa-flask-potion:before{content:"\f6e1"}.fa-flickr:before{content:"\f16e"}.fa-flipboard:before{content:"\f44d"}.fa-flower:before{content:"\f7ff"}.fa-flower-daffodil:before{content:"\f800"}.fa-flower-tulip:before{content:"\f801"}.fa-flushed:before{content:"\f579"}.fa-flute:before{content:"\f8b9"}.fa-flux-capacitor:before{content:"\f8ba"}.fa-fly:before{content:"\f417"}.fa-fog:before{content:"\f74e"}.fa-folder:before{content:"\f07b"}.fa-folder-download:before{content:"\e053"}.fa-folder-minus:before{content:"\f65d"}.fa-folder-open:before{content:"\f07c"}.fa-folder-plus:before{content:"\f65e"}.fa-folder-times:before{content:"\f65f"}.fa-folder-tree:before{content:"\f802"}.fa-folder-upload:before{content:"\e054"}.fa-folders:before{content:"\f660"}.fa-font:before{content:"\f031"}.fa-font-awesome:before{content:"\f2b4"}.fa-font-awesome-alt:before{content:"\f35c"}.fa-font-awesome-flag:before{content:"\f425"}.fa-font-awesome-logo-full:before{content:"\f4e6"}.fa-font-case:before{content:"\f866"}.fa-fonticons:before{content:"\f280"}.fa-fonticons-fi:before{content:"\f3a2"}.fa-football-ball:before{content:"\f44e"}.fa-football-helmet:before{content:"\f44f"}.fa-forklift:before{content:"\f47a"}.fa-fort-awesome:before{content:"\f286"}.fa-fort-awesome-alt:before{content:"\f3a3"}.fa-forumbee:before{content:"\f211"}.fa-forward:before{content:"\f04e"}.fa-foursquare:before{content:"\f180"}.fa-fragile:before{content:"\f4bb"}.fa-free-code-camp:before{content:"\f2c5"}.fa-freebsd:before{content:"\f3a4"}.fa-french-fries:before{content:"\f803"}.fa-frog:before{content:"\f52e"}.fa-frosty-head:before{content:"\f79b"}.fa-frown:before{content:"\f119"}.fa-frown-open:before{content:"\f57a"}.fa-fulcrum:before{content:"\f50b"}.fa-function:before{content:"\f661"}.fa-funnel-dollar:before{content:"\f662"}.fa-futbol:before{content:"\f1e3"}.fa-galactic-republic:before{content:"\f50c"}.fa-galactic-senate:before{content:"\f50d"}.fa-galaxy:before{content:"\e008"}.fa-game-board:before{content:"\f867"}.fa-game-board-alt:before{content:"\f868"}.fa-game-console-handheld:before{content:"\f8bb"}.fa-gamepad:before{content:"\f11b"}.fa-gamepad-alt:before{content:"\f8bc"}.fa-garage:before{content:"\e009"}.fa-garage-car:before{content:"\e00a"}.fa-garage-open:before{content:"\e00b"}.fa-gas-pump:before{content:"\f52f"}.fa-gas-pump-slash:before{content:"\f5f4"}.fa-gavel:before{content:"\f0e3"}.fa-gem:before{content:"\f3a5"}.fa-genderless:before{content:"\f22d"}.fa-get-pocket:before{content:"\f265"}.fa-gg:before{content:"\f260"}.fa-gg-circle:before{content:"\f261"}.fa-ghost:before{content:"\f6e2"}.fa-gift:before{content:"\f06b"}.fa-gift-card:before{content:"\f663"}.fa-gifts:before{content:"\f79c"}.fa-gingerbread-man:before{content:"\f79d"}.fa-git:before{content:"\f1d3"}.fa-git-alt:before{content:"\f841"}.fa-git-square:before{content:"\f1d2"}.fa-github:before{content:"\f09b"}.fa-github-alt:before{content:"\f113"}.fa-github-square:before{content:"\f092"}.fa-gitkraken:before{content:"\f3a6"}.fa-gitlab:before{content:"\f296"}.fa-gitter:before{content:"\f426"}.fa-glass:before{content:"\f804"}.fa-glass-champagne:before{content:"\f79e"}.fa-glass-cheers:before{content:"\f79f"}.fa-glass-citrus:before{content:"\f869"}.fa-glass-martini:before{content:"\f000"}.fa-glass-martini-alt:before{content:"\f57b"}.fa-glass-whiskey:before{content:"\f7a0"}.fa-glass-whiskey-rocks:before{content:"\f7a1"}.fa-glasses:before{content:"\f530"}.fa-glasses-alt:before{content:"\f5f5"}.fa-glide:before{content:"\f2a5"}.fa-glide-g:before{content:"\f2a6"}.fa-globe:before{content:"\f0ac"}.fa-globe-africa:before{content:"\f57c"}.fa-globe-americas:before{content:"\f57d"}.fa-globe-asia:before{content:"\f57e"}.fa-globe-europe:before{content:"\f7a2"}.fa-globe-snow:before{content:"\f7a3"}.fa-globe-stand:before{content:"\f5f6"}.fa-gofore:before{content:"\f3a7"}.fa-golf-ball:before{content:"\f450"}.fa-golf-club:before{content:"\f451"}.fa-goodreads:before{content:"\f3a8"}.fa-goodreads-g:before{content:"\f3a9"}.fa-google:before{content:"\f1a0"}.fa-google-drive:before{content:"\f3aa"}.fa-google-pay:before{content:"\e079"}.fa-google-play:before{content:"\f3ab"}.fa-google-plus:before{content:"\f2b3"}.fa-google-plus-g:before{content:"\f0d5"}.fa-google-plus-square:before{content:"\f0d4"}.fa-google-wallet:before{content:"\f1ee"}.fa-gopuram:before{content:"\f664"}.fa-graduation-cap:before{content:"\f19d"}.fa-gramophone:before{content:"\f8bd"}.fa-gratipay:before{content:"\f184"}.fa-grav:before{content:"\f2d6"}.fa-greater-than:before{content:"\f531"}.fa-greater-than-equal:before{content:"\f532"}.fa-grimace:before{content:"\f57f"}.fa-grin:before{content:"\f580"}.fa-grin-alt:before{content:"\f581"}.fa-grin-beam:before{content:"\f582"}.fa-grin-beam-sweat:before{content:"\f583"}.fa-grin-hearts:before{content:"\f584"}.fa-grin-squint:before{content:"\f585"}.fa-grin-squint-tears:before{content:"\f586"}.fa-grin-stars:before{content:"\f587"}.fa-grin-tears:before{content:"\f588"}.fa-grin-tongue:before{content:"\f589"}.fa-grin-tongue-squint:before{content:"\f58a"}.fa-grin-tongue-wink:before{content:"\f58b"}.fa-grin-wink:before{content:"\f58c"}.fa-grip-horizontal:before{content:"\f58d"}.fa-grip-lines:before{content:"\f7a4"}.fa-grip-lines-vertical:before{content:"\f7a5"}.fa-grip-vertical:before{content:"\f58e"}.fa-gripfire:before{content:"\f3ac"}.fa-grunt:before{content:"\f3ad"}.fa-guilded:before{content:"\e07e"}.fa-guitar:before{content:"\f7a6"}.fa-guitar-electric:before{content:"\f8be"}.fa-guitars:before{content:"\f8bf"}.fa-gulp:before{content:"\f3ae"}.fa-h-square:before{content:"\f0fd"}.fa-h1:before{content:"\f313"}.fa-h2:before{content:"\f314"}.fa-h3:before{content:"\f315"}.fa-h4:before{content:"\f86a"}.fa-hacker-news:before{content:"\f1d4"}.fa-hacker-news-square:before{content:"\f3af"}.fa-hackerrank:before{content:"\f5f7"}.fa-hamburger:before{content:"\f805"}.fa-hammer:before{content:"\f6e3"}.fa-hammer-war:before{content:"\f6e4"}.fa-hamsa:before{content:"\f665"}.fa-hand-heart:before{content:"\f4bc"}.fa-hand-holding:before{content:"\f4bd"}.fa-hand-holding-box:before{content:"\f47b"}.fa-hand-holding-heart:before{content:"\f4be"}.fa-hand-holding-magic:before{content:"\f6e5"}.fa-hand-holding-medical:before{content:"\e05c"}.fa-hand-holding-seedling:before{content:"\f4bf"}.fa-hand-holding-usd:before{content:"\f4c0"}.fa-hand-holding-water:before{content:"\f4c1"}.fa-hand-lizard:before{content:"\f258"}.fa-hand-middle-finger:before{content:"\f806"}.fa-hand-paper:before{content:"\f256"}.fa-hand-peace:before{content:"\f25b"}.fa-hand-point-down:before{content:"\f0a7"}.fa-hand-point-left:before{content:"\f0a5"}.fa-hand-point-right:before{content:"\f0a4"}.fa-hand-point-up:before{content:"\f0a6"}.fa-hand-pointer:before{content:"\f25a"}.fa-hand-receiving:before{content:"\f47c"}.fa-hand-rock:before{content:"\f255"}.fa-hand-scissors:before{content:"\f257"}.fa-hand-sparkles:before{content:"\e05d"}.fa-hand-spock:before{content:"\f259"}.fa-hands:before{content:"\f4c2"}.fa-hands-heart:before{content:"\f4c3"}.fa-hands-helping:before{content:"\f4c4"}.fa-hands-usd:before{content:"\f4c5"}.fa-hands-wash:before{content:"\e05e"}.fa-handshake:before{content:"\f2b5"}.fa-handshake-alt:before{content:"\f4c6"}.fa-handshake-alt-slash:before{content:"\e05f"}.fa-handshake-slash:before{content:"\e060"}.fa-hanukiah:before{content:"\f6e6"}.fa-hard-hat:before{content:"\f807"}.fa-hashtag:before{content:"\f292"}.fa-hat-chef:before{content:"\f86b"}.fa-hat-cowboy:before{content:"\f8c0"}.fa-hat-cowboy-side:before{content:"\f8c1"}.fa-hat-santa:before{content:"\f7a7"}.fa-hat-winter:before{content:"\f7a8"}.fa-hat-witch:before{content:"\f6e7"}.fa-hat-wizard:before{content:"\f6e8"}.fa-hdd:before{content:"\f0a0"}.fa-head-side:before{content:"\f6e9"}.fa-head-side-brain:before{content:"\f808"}.fa-head-side-cough:before{content:"\e061"}.fa-head-side-cough-slash:before{content:"\e062"}.fa-head-side-headphones:before{content:"\f8c2"}.fa-head-side-mask:before{content:"\e063"}.fa-head-side-medical:before{content:"\f809"}.fa-head-side-virus:before{content:"\e064"}.fa-head-vr:before{content:"\f6ea"}.fa-heading:before{content:"\f1dc"}.fa-headphones:before{content:"\f025"}.fa-headphones-alt:before{content:"\f58f"}.fa-headset:before{content:"\f590"}.fa-heart:before{content:"\f004"}.fa-heart-broken:before{content:"\f7a9"}.fa-heart-circle:before{content:"\f4c7"}.fa-heart-rate:before{content:"\f5f8"}.fa-heart-square:before{content:"\f4c8"}.fa-heartbeat:before{content:"\f21e"}.fa-heat:before{content:"\e00c"}.fa-helicopter:before{content:"\f533"}.fa-helmet-battle:before{content:"\f6eb"}.fa-hexagon:before{content:"\f312"}.fa-highlighter:before{content:"\f591"}.fa-hiking:before{content:"\f6ec"}.fa-hippo:before{content:"\f6ed"}.fa-hips:before{content:"\f452"}.fa-hire-a-helper:before{content:"\f3b0"}.fa-history:before{content:"\f1da"}.fa-hive:before{content:"\e07f"}.fa-hockey-mask:before{content:"\f6ee"}.fa-hockey-puck:before{content:"\f453"}.fa-hockey-sticks:before{content:"\f454"}.fa-holly-berry:before{content:"\f7aa"}.fa-home:before{content:"\f015"}.fa-home-alt:before{content:"\f80a"}.fa-home-heart:before{content:"\f4c9"}.fa-home-lg:before{content:"\f80b"}.fa-home-lg-alt:before{content:"\f80c"}.fa-hood-cloak:before{content:"\f6ef"}.fa-hooli:before{content:"\f427"}.fa-horizontal-rule:before{content:"\f86c"}.fa-hornbill:before{content:"\f592"}.fa-horse:before{content:"\f6f0"}.fa-horse-head:before{content:"\f7ab"}.fa-horse-saddle:before{content:"\f8c3"}.fa-hospital:before{content:"\f0f8"}.fa-hospital-alt:before{content:"\f47d"}.fa-hospital-symbol:before{content:"\f47e"}.fa-hospital-user:before{content:"\f80d"}.fa-hospitals:before{content:"\f80e"}.fa-hot-tub:before{content:"\f593"}.fa-hotdog:before{content:"\f80f"}.fa-hotel:before{content:"\f594"}.fa-hotjar:before{content:"\f3b1"}.fa-hourglass:before{content:"\f254"}.fa-hourglass-end:before{content:"\f253"}.fa-hourglass-half:before{content:"\f252"}.fa-hourglass-start:before{content:"\f251"}.fa-house:before{content:"\e00d"}.fa-house-damage:before{content:"\f6f1"}.fa-house-day:before{content:"\e00e"}.fa-house-flood:before{content:"\f74f"}.fa-house-leave:before{content:"\e00f"}.fa-house-night:before{content:"\e010"}.fa-house-return:before{content:"\e011"}.fa-house-signal:before{content:"\e012"}.fa-house-user:before{content:"\e065"}.fa-houzz:before{content:"\f27c"}.fa-hryvnia:before{content:"\f6f2"}.fa-html5:before{content:"\f13b"}.fa-hubspot:before{content:"\f3b2"}.fa-humidity:before{content:"\f750"}.fa-hurricane:before{content:"\f751"}.fa-i-cursor:before{content:"\f246"}.fa-ice-cream:before{content:"\f810"}.fa-ice-skate:before{content:"\f7ac"}.fa-icicles:before{content:"\f7ad"}.fa-icons:before{content:"\f86d"}.fa-icons-alt:before{content:"\f86e"}.fa-id-badge:before{content:"\f2c1"}.fa-id-card:before{content:"\f2c2"}.fa-id-card-alt:before{content:"\f47f"}.fa-ideal:before{content:"\e013"}.fa-igloo:before{content:"\f7ae"}.fa-image:before{content:"\f03e"}.fa-image-polaroid:before{content:"\f8c4"}.fa-images:before{content:"\f302"}.fa-imdb:before{content:"\f2d8"}.fa-inbox:before{content:"\f01c"}.fa-inbox-in:before{content:"\f310"}.fa-inbox-out:before{content:"\f311"}.fa-indent:before{content:"\f03c"}.fa-industry:before{content:"\f275"}.fa-industry-alt:before{content:"\f3b3"}.fa-infinity:before{content:"\f534"}.fa-info:before{content:"\f129"}.fa-info-circle:before{content:"\f05a"}.fa-info-square:before{content:"\f30f"}.fa-inhaler:before{content:"\f5f9"}.fa-innosoft:before{content:"\e080"}.fa-instagram:before{content:"\f16d"}.fa-instagram-square:before{content:"\e055"}.fa-instalod:before{content:"\e081"}.fa-integral:before{content:"\f667"}.fa-intercom:before{content:"\f7af"}.fa-internet-explorer:before{content:"\f26b"}.fa-intersection:before{content:"\f668"}.fa-inventory:before{content:"\f480"}.fa-invision:before{content:"\f7b0"}.fa-ioxhost:before{content:"\f208"}.fa-island-tropical:before{content:"\f811"}.fa-italic:before{content:"\f033"}.fa-itch-io:before{content:"\f83a"}.fa-itunes:before{content:"\f3b4"}.fa-itunes-note:before{content:"\f3b5"}.fa-jack-o-lantern:before{content:"\f30e"}.fa-java:before{content:"\f4e4"}.fa-jedi:before{content:"\f669"}.fa-jedi-order:before{content:"\f50e"}.fa-jenkins:before{content:"\f3b6"}.fa-jira:before{content:"\f7b1"}.fa-joget:before{content:"\f3b7"}.fa-joint:before{content:"\f595"}.fa-joomla:before{content:"\f1aa"}.fa-journal-whills:before{content:"\f66a"}.fa-joystick:before{content:"\f8c5"}.fa-js:before{content:"\f3b8"}.fa-js-square:before{content:"\f3b9"}.fa-jsfiddle:before{content:"\f1cc"}.fa-jug:before{content:"\f8c6"}.fa-kaaba:before{content:"\f66b"}.fa-kaggle:before{content:"\f5fa"}.fa-kazoo:before{content:"\f8c7"}.fa-kerning:before{content:"\f86f"}.fa-key:before{content:"\f084"}.fa-key-skeleton:before{content:"\f6f3"}.fa-keybase:before{content:"\f4f5"}.fa-keyboard:before{content:"\f11c"}.fa-keycdn:before{content:"\f3ba"}.fa-keynote:before{content:"\f66c"}.fa-khanda:before{content:"\f66d"}.fa-kickstarter:before{content:"\f3bb"}.fa-kickstarter-k:before{content:"\f3bc"}.fa-kidneys:before{content:"\f5fb"}.fa-kiss:before{content:"\f596"}.fa-kiss-beam:before{content:"\f597"}.fa-kiss-wink-heart:before{content:"\f598"}.fa-kite:before{content:"\f6f4"}.fa-kiwi-bird:before{content:"\f535"}.fa-knife-kitchen:before{content:"\f6f5"}.fa-korvue:before{content:"\f42f"}.fa-lambda:before{content:"\f66e"}.fa-lamp:before{content:"\f4ca"}.fa-lamp-desk:before{content:"\e014"}.fa-lamp-floor:before{content:"\e015"}.fa-landmark:before{content:"\f66f"}.fa-landmark-alt:before{content:"\f752"}.fa-language:before{content:"\f1ab"}.fa-laptop:before{content:"\f109"}.fa-laptop-code:before{content:"\f5fc"}.fa-laptop-house:before{content:"\e066"}.fa-laptop-medical:before{content:"\f812"}.fa-laravel:before{content:"\f3bd"}.fa-lasso:before{content:"\f8c8"}.fa-lastfm:before{content:"\f202"}.fa-lastfm-square:before{content:"\f203"}.fa-laugh:before{content:"\f599"}.fa-laugh-beam:before{content:"\f59a"}.fa-laugh-squint:before{content:"\f59b"}.fa-laugh-wink:before{content:"\f59c"}.fa-layer-group:before{content:"\f5fd"}.fa-layer-minus:before{content:"\f5fe"}.fa-layer-plus:before{content:"\f5ff"}.fa-leaf:before{content:"\f06c"}.fa-leaf-heart:before{content:"\f4cb"}.fa-leaf-maple:before{content:"\f6f6"}.fa-leaf-oak:before{content:"\f6f7"}.fa-leanpub:before{content:"\f212"}.fa-lemon:before{content:"\f094"}.fa-less:before{content:"\f41d"}.fa-less-than:before{content:"\f536"}.fa-less-than-equal:before{content:"\f537"}.fa-level-down:before{content:"\f149"}.fa-level-down-alt:before{content:"\f3be"}.fa-level-up:before{content:"\f148"}.fa-level-up-alt:before{content:"\f3bf"}.fa-life-ring:before{content:"\f1cd"}.fa-light-ceiling:before{content:"\e016"}.fa-light-switch:before{content:"\e017"}.fa-light-switch-off:before{content:"\e018"}.fa-light-switch-on:before{content:"\e019"}.fa-lightbulb:before{content:"\f0eb"}.fa-lightbulb-dollar:before{content:"\f670"}.fa-lightbulb-exclamation:before{content:"\f671"}.fa-lightbulb-on:before{content:"\f672"}.fa-lightbulb-slash:before{content:"\f673"}.fa-lights-holiday:before{content:"\f7b2"}.fa-line:before{content:"\f3c0"}.fa-line-columns:before{content:"\f870"}.fa-line-height:before{content:"\f871"}.fa-link:before{content:"\f0c1"}.fa-linkedin:before{content:"\f08c"}.fa-linkedin-in:before{content:"\f0e1"}.fa-linode:before{content:"\f2b8"}.fa-linux:before{content:"\f17c"}.fa-lips:before{content:"\f600"}.fa-lira-sign:before{content:"\f195"}.fa-list:before{content:"\f03a"}.fa-list-alt:before{content:"\f022"}.fa-list-music:before{content:"\f8c9"}.fa-list-ol:before{content:"\f0cb"}.fa-list-ul:before{content:"\f0ca"}.fa-location:before{content:"\f601"}.fa-location-arrow:before{content:"\f124"}.fa-location-circle:before{content:"\f602"}.fa-location-slash:before{content:"\f603"}.fa-lock:before{content:"\f023"}.fa-lock-alt:before{content:"\f30d"}.fa-lock-open:before{content:"\f3c1"}.fa-lock-open-alt:before{content:"\f3c2"}.fa-long-arrow-alt-down:before{content:"\f309"}.fa-long-arrow-alt-left:before{content:"\f30a"}.fa-long-arrow-alt-right:before{content:"\f30b"}.fa-long-arrow-alt-up:before{content:"\f30c"}.fa-long-arrow-down:before{content:"\f175"}.fa-long-arrow-left:before{content:"\f177"}.fa-long-arrow-right:before{content:"\f178"}.fa-long-arrow-up:before{content:"\f176"}.fa-loveseat:before{content:"\f4cc"}.fa-low-vision:before{content:"\f2a8"}.fa-luchador:before{content:"\f455"}.fa-luggage-cart:before{content:"\f59d"}.fa-lungs:before{content:"\f604"}.fa-lungs-virus:before{content:"\e067"}.fa-lyft:before{content:"\f3c3"}.fa-mace:before{content:"\f6f8"}.fa-magento:before{content:"\f3c4"}.fa-magic:before{content:"\f0d0"}.fa-magnet:before{content:"\f076"}.fa-mail-bulk:before{content:"\f674"}.fa-mailbox:before{content:"\f813"}.fa-mailchimp:before{content:"\f59e"}.fa-male:before{content:"\f183"}.fa-mandalorian:before{content:"\f50f"}.fa-mandolin:before{content:"\f6f9"}.fa-map:before{content:"\f279"}.fa-map-marked:before{content:"\f59f"}.fa-map-marked-alt:before{content:"\f5a0"}.fa-map-marker:before{content:"\f041"}.fa-map-marker-alt:before{content:"\f3c5"}.fa-map-marker-alt-slash:before{content:"\f605"}.fa-map-marker-check:before{content:"\f606"}.fa-map-marker-edit:before{content:"\f607"}.fa-map-marker-exclamation:before{content:"\f608"}.fa-map-marker-minus:before{content:"\f609"}.fa-map-marker-plus:before{content:"\f60a"}.fa-map-marker-question:before{content:"\f60b"}.fa-map-marker-slash:before{content:"\f60c"}.fa-map-marker-smile:before{content:"\f60d"}.fa-map-marker-times:before{content:"\f60e"}.fa-map-pin:before{content:"\f276"}.fa-map-signs:before{content:"\f277"}.fa-markdown:before{content:"\f60f"}.fa-marker:before{content:"\f5a1"}.fa-mars:before{content:"\f222"}.fa-mars-double:before{content:"\f227"}.fa-mars-stroke:before{content:"\f229"}.fa-mars-stroke-h:before{content:"\f22b"}.fa-mars-stroke-v:before{content:"\f22a"}.fa-mask:before{content:"\f6fa"}.fa-mastodon:before{content:"\f4f6"}.fa-maxcdn:before{content:"\f136"}.fa-mdb:before{content:"\f8ca"}.fa-meat:before{content:"\f814"}.fa-medal:before{content:"\f5a2"}.fa-medapps:before{content:"\f3c6"}.fa-medium:before{content:"\f23a"}.fa-medium-m:before{content:"\f3c7"}.fa-medkit:before{content:"\f0fa"}.fa-medrt:before{content:"\f3c8"}.fa-meetup:before{content:"\f2e0"}.fa-megaphone:before{content:"\f675"}.fa-megaport:before{content:"\f5a3"}.fa-meh:before{content:"\f11a"}.fa-meh-blank:before{content:"\f5a4"}.fa-meh-rolling-eyes:before{content:"\f5a5"}.fa-memory:before{content:"\f538"}.fa-mendeley:before{content:"\f7b3"}.fa-menorah:before{content:"\f676"}.fa-mercury:before{content:"\f223"}.fa-meteor:before{content:"\f753"}.fa-microblog:before{content:"\e01a"}.fa-microchip:before{content:"\f2db"}.fa-microphone:before{content:"\f130"}.fa-microphone-alt:before{content:"\f3c9"}.fa-microphone-alt-slash:before{content:"\f539"}.fa-microphone-slash:before{content:"\f131"}.fa-microphone-stand:before{content:"\f8cb"}.fa-microscope:before{content:"\f610"}.fa-microsoft:before{content:"\f3ca"}.fa-microwave:before{content:"\e01b"}.fa-mind-share:before{content:"\f677"}.fa-minus:before{content:"\f068"}.fa-minus-circle:before{content:"\f056"}.fa-minus-hexagon:before{content:"\f307"}.fa-minus-octagon:before{content:"\f308"}.fa-minus-square:before{content:"\f146"}.fa-mistletoe:before{content:"\f7b4"}.fa-mitten:before{content:"\f7b5"}.fa-mix:before{content:"\f3cb"}.fa-mixcloud:before{content:"\f289"}.fa-mixer:before{content:"\e056"}.fa-mizuni:before{content:"\f3cc"}.fa-mobile:before{content:"\f10b"}.fa-mobile-alt:before{content:"\f3cd"}.fa-mobile-android:before{content:"\f3ce"}.fa-mobile-android-alt:before{content:"\f3cf"}.fa-modx:before{content:"\f285"}.fa-monero:before{content:"\f3d0"}.fa-money-bill:before{content:"\f0d6"}.fa-money-bill-alt:before{content:"\f3d1"}.fa-money-bill-wave:before{content:"\f53a"}.fa-money-bill-wave-alt:before{content:"\f53b"}.fa-money-check:before{content:"\f53c"}.fa-money-check-alt:before{content:"\f53d"}.fa-money-check-edit:before{content:"\f872"}.fa-money-check-edit-alt:before{content:"\f873"}.fa-monitor-heart-rate:before{content:"\f611"}.fa-monkey:before{content:"\f6fb"}.fa-monument:before{content:"\f5a6"}.fa-moon:before{content:"\f186"}.fa-moon-cloud:before{content:"\f754"}.fa-moon-stars:before{content:"\f755"}.fa-mortar-pestle:before{content:"\f5a7"}.fa-mosque:before{content:"\f678"}.fa-motorcycle:before{content:"\f21c"}.fa-mountain:before{content:"\f6fc"}.fa-mountains:before{content:"\f6fd"}.fa-mouse:before{content:"\f8cc"}.fa-mouse-alt:before{content:"\f8cd"}.fa-mouse-pointer:before{content:"\f245"}.fa-mp3-player:before{content:"\f8ce"}.fa-mug:before{content:"\f874"}.fa-mug-hot:before{content:"\f7b6"}.fa-mug-marshmallows:before{content:"\f7b7"}.fa-mug-tea:before{content:"\f875"}.fa-music:before{content:"\f001"}.fa-music-alt:before{content:"\f8cf"}.fa-music-alt-slash:before{content:"\f8d0"}.fa-music-slash:before{content:"\f8d1"}.fa-napster:before{content:"\f3d2"}.fa-narwhal:before{content:"\f6fe"}.fa-neos:before{content:"\f612"}.fa-network-wired:before{content:"\f6ff"}.fa-neuter:before{content:"\f22c"}.fa-newspaper:before{content:"\f1ea"}.fa-nimblr:before{content:"\f5a8"}.fa-node:before{content:"\f419"}.fa-node-js:before{content:"\f3d3"}.fa-not-equal:before{content:"\f53e"}.fa-notes-medical:before{content:"\f481"}.fa-npm:before{content:"\f3d4"}.fa-ns8:before{content:"\f3d5"}.fa-nutritionix:before{content:"\f3d6"}.fa-object-group:before{content:"\f247"}.fa-object-ungroup:before{content:"\f248"}.fa-octagon:before{content:"\f306"}.fa-octopus-deploy:before{content:"\e082"}.fa-odnoklassniki:before{content:"\f263"}.fa-odnoklassniki-square:before{content:"\f264"}.fa-oil-can:before{content:"\f613"}.fa-oil-temp:before{content:"\f614"}.fa-old-republic:before{content:"\f510"}.fa-om:before{content:"\f679"}.fa-omega:before{content:"\f67a"}.fa-opencart:before{content:"\f23d"}.fa-openid:before{content:"\f19b"}.fa-opera:before{content:"\f26a"}.fa-optin-monster:before{content:"\f23c"}.fa-orcid:before{content:"\f8d2"}.fa-ornament:before{content:"\f7b8"}.fa-osi:before{content:"\f41a"}.fa-otter:before{content:"\f700"}.fa-outdent:before{content:"\f03b"}.fa-outlet:before{content:"\e01c"}.fa-oven:before{content:"\e01d"}.fa-overline:before{content:"\f876"}.fa-page-break:before{content:"\f877"}.fa-page4:before{content:"\f3d7"}.fa-pagelines:before{content:"\f18c"}.fa-pager:before{content:"\f815"}.fa-paint-brush:before{content:"\f1fc"}.fa-paint-brush-alt:before{content:"\f5a9"}.fa-paint-roller:before{content:"\f5aa"}.fa-palette:before{content:"\f53f"}.fa-palfed:before{content:"\f3d8"}.fa-pallet:before{content:"\f482"}.fa-pallet-alt:before{content:"\f483"}.fa-paper-plane:before{content:"\f1d8"}.fa-paperclip:before{content:"\f0c6"}.fa-parachute-box:before{content:"\f4cd"}.fa-paragraph:before{content:"\f1dd"}.fa-paragraph-rtl:before{content:"\f878"}.fa-parking:before{content:"\f540"}.fa-parking-circle:before{content:"\f615"}.fa-parking-circle-slash:before{content:"\f616"}.fa-parking-slash:before{content:"\f617"}.fa-passport:before{content:"\f5ab"}.fa-pastafarianism:before{content:"\f67b"}.fa-paste:before{content:"\f0ea"}.fa-patreon:before{content:"\f3d9"}.fa-pause:before{content:"\f04c"}.fa-pause-circle:before{content:"\f28b"}.fa-paw:before{content:"\f1b0"}.fa-paw-alt:before{content:"\f701"}.fa-paw-claws:before{content:"\f702"}.fa-paypal:before{content:"\f1ed"}.fa-peace:before{content:"\f67c"}.fa-pegasus:before{content:"\f703"}.fa-pen:before{content:"\f304"}.fa-pen-alt:before{content:"\f305"}.fa-pen-fancy:before{content:"\f5ac"}.fa-pen-nib:before{content:"\f5ad"}.fa-pen-square:before{content:"\f14b"}.fa-pencil:before{content:"\f040"}.fa-pencil-alt:before{content:"\f303"}.fa-pencil-paintbrush:before{content:"\f618"}.fa-pencil-ruler:before{content:"\f5ae"}.fa-pennant:before{content:"\f456"}.fa-penny-arcade:before{content:"\f704"}.fa-people-arrows:before{content:"\e068"}.fa-people-carry:before{content:"\f4ce"}.fa-pepper-hot:before{content:"\f816"}.fa-perbyte:before{content:"\e083"}.fa-percent:before{content:"\f295"}.fa-percentage:before{content:"\f541"}.fa-periscope:before{content:"\f3da"}.fa-person-booth:before{content:"\f756"}.fa-person-carry:before{content:"\f4cf"}.fa-person-dolly:before{content:"\f4d0"}.fa-person-dolly-empty:before{content:"\f4d1"}.fa-person-sign:before{content:"\f757"}.fa-phabricator:before{content:"\f3db"}.fa-phoenix-framework:before{content:"\f3dc"}.fa-phoenix-squadron:before{content:"\f511"}.fa-phone:before{content:"\f095"}.fa-phone-alt:before{content:"\f879"}.fa-phone-laptop:before{content:"\f87a"}.fa-phone-office:before{content:"\f67d"}.fa-phone-plus:before{content:"\f4d2"}.fa-phone-rotary:before{content:"\f8d3"}.fa-phone-slash:before{content:"\f3dd"}.fa-phone-square:before{content:"\f098"}.fa-phone-square-alt:before{content:"\f87b"}.fa-phone-volume:before{content:"\f2a0"}.fa-photo-video:before{content:"\f87c"}.fa-php:before{content:"\f457"}.fa-pi:before{content:"\f67e"}.fa-piano:before{content:"\f8d4"}.fa-piano-keyboard:before{content:"\f8d5"}.fa-pie:before{content:"\f705"}.fa-pied-piper:before{content:"\f2ae"}.fa-pied-piper-alt:before{content:"\f1a8"}.fa-pied-piper-hat:before{content:"\f4e5"}.fa-pied-piper-pp:before{content:"\f1a7"}.fa-pied-piper-square:before{content:"\e01e"}.fa-pig:before{content:"\f706"}.fa-piggy-bank:before{content:"\f4d3"}.fa-pills:before{content:"\f484"}.fa-pinterest:before{content:"\f0d2"}.fa-pinterest-p:before{content:"\f231"}.fa-pinterest-square:before{content:"\f0d3"}.fa-pizza:before{content:"\f817"}.fa-pizza-slice:before{content:"\f818"}.fa-place-of-worship:before{content:"\f67f"}.fa-plane:before{content:"\f072"}.fa-plane-alt:before{content:"\f3de"}.fa-plane-arrival:before{content:"\f5af"}.fa-plane-departure:before{content:"\f5b0"}.fa-plane-slash:before{content:"\e069"}.fa-planet-moon:before{content:"\e01f"}.fa-planet-ringed:before{content:"\e020"}.fa-play:before{content:"\f04b"}.fa-play-circle:before{content:"\f144"}.fa-playstation:before{content:"\f3df"}.fa-plug:before{content:"\f1e6"}.fa-plus:before{content:"\f067"}.fa-plus-circle:before{content:"\f055"}.fa-plus-hexagon:before{content:"\f300"}.fa-plus-octagon:before{content:"\f301"}.fa-plus-square:before{content:"\f0fe"}.fa-podcast:before{content:"\f2ce"}.fa-podium:before{content:"\f680"}.fa-podium-star:before{content:"\f758"}.fa-police-box:before{content:"\e021"}.fa-poll:before{content:"\f681"}.fa-poll-h:before{content:"\f682"}.fa-poll-people:before{content:"\f759"}.fa-poo:before{content:"\f2fe"}.fa-poo-storm:before{content:"\f75a"}.fa-poop:before{content:"\f619"}.fa-popcorn:before{content:"\f819"}.fa-portal-enter:before{content:"\e022"}.fa-portal-exit:before{content:"\e023"}.fa-portrait:before{content:"\f3e0"}.fa-pound-sign:before{content:"\f154"}.fa-power-off:before{content:"\f011"}.fa-pray:before{content:"\f683"}.fa-praying-hands:before{content:"\f684"}.fa-prescription:before{content:"\f5b1"}.fa-prescription-bottle:before{content:"\f485"}.fa-prescription-bottle-alt:before{content:"\f486"}.fa-presentation:before{content:"\f685"}.fa-print:before{content:"\f02f"}.fa-print-search:before{content:"\f81a"}.fa-print-slash:before{content:"\f686"}.fa-procedures:before{content:"\f487"}.fa-product-hunt:before{content:"\f288"}.fa-project-diagram:before{content:"\f542"}.fa-projector:before{content:"\f8d6"}.fa-pump-medical:before{content:"\e06a"}.fa-pump-soap:before{content:"\e06b"}.fa-pumpkin:before{content:"\f707"}.fa-pushed:before{content:"\f3e1"}.fa-puzzle-piece:before{content:"\f12e"}.fa-python:before{content:"\f3e2"}.fa-qq:before{content:"\f1d6"}.fa-qrcode:before{content:"\f029"}.fa-question:before{content:"\f128"}.fa-question-circle:before{content:"\f059"}.fa-question-square:before{content:"\f2fd"}.fa-quidditch:before{content:"\f458"}.fa-quinscape:before{content:"\f459"}.fa-quora:before{content:"\f2c4"}.fa-quote-left:before{content:"\f10d"}.fa-quote-right:before{content:"\f10e"}.fa-quran:before{content:"\f687"}.fa-r-project:before{content:"\f4f7"}.fa-rabbit:before{content:"\f708"}.fa-rabbit-fast:before{content:"\f709"}.fa-racquet:before{content:"\f45a"}.fa-radar:before{content:"\e024"}.fa-radiation:before{content:"\f7b9"}.fa-radiation-alt:before{content:"\f7ba"}.fa-radio:before{content:"\f8d7"}.fa-radio-alt:before{content:"\f8d8"}.fa-rainbow:before{content:"\f75b"}.fa-raindrops:before{content:"\f75c"}.fa-ram:before{content:"\f70a"}.fa-ramp-loading:before{content:"\f4d4"}.fa-random:before{content:"\f074"}.fa-raspberry-pi:before{content:"\f7bb"}.fa-ravelry:before{content:"\f2d9"}.fa-raygun:before{content:"\e025"}.fa-react:before{content:"\f41b"}.fa-reacteurope:before{content:"\f75d"}.fa-readme:before{content:"\f4d5"}.fa-rebel:before{content:"\f1d0"}.fa-receipt:before{content:"\f543"}.fa-record-vinyl:before{content:"\f8d9"}.fa-rectangle-landscape:before{content:"\f2fa"}.fa-rectangle-portrait:before{content:"\f2fb"}.fa-rectangle-wide:before{content:"\f2fc"}.fa-recycle:before{content:"\f1b8"}.fa-red-river:before{content:"\f3e3"}.fa-reddit:before{content:"\f1a1"}.fa-reddit-alien:before{content:"\f281"}.fa-reddit-square:before{content:"\f1a2"}.fa-redhat:before{content:"\f7bc"}.fa-redo:before{content:"\f01e"}.fa-redo-alt:before{content:"\f2f9"}.fa-refrigerator:before{content:"\e026"}.fa-registered:before{content:"\f25d"}.fa-remove-format:before{content:"\f87d"}.fa-renren:before{content:"\f18b"}.fa-repeat:before{content:"\f363"}.fa-repeat-1:before{content:"\f365"}.fa-repeat-1-alt:before{content:"\f366"}.fa-repeat-alt:before{content:"\f364"}.fa-reply:before{content:"\f3e5"}.fa-reply-all:before{content:"\f122"}.fa-replyd:before{content:"\f3e6"}.fa-republican:before{content:"\f75e"}.fa-researchgate:before{content:"\f4f8"}.fa-resolving:before{content:"\f3e7"}.fa-restroom:before{content:"\f7bd"}.fa-retweet:before{content:"\f079"}.fa-retweet-alt:before{content:"\f361"}.fa-rev:before{content:"\f5b2"}.fa-ribbon:before{content:"\f4d6"}.fa-ring:before{content:"\f70b"}.fa-rings-wedding:before{content:"\f81b"}.fa-road:before{content:"\f018"}.fa-robot:before{content:"\f544"}.fa-rocket:before{content:"\f135"}.fa-rocket-launch:before{content:"\e027"}.fa-rocketchat:before{content:"\f3e8"}.fa-rockrms:before{content:"\f3e9"}.fa-route:before{content:"\f4d7"}.fa-route-highway:before{content:"\f61a"}.fa-route-interstate:before{content:"\f61b"}.fa-router:before{content:"\f8da"}.fa-rss:before{content:"\f09e"}.fa-rss-square:before{content:"\f143"}.fa-ruble-sign:before{content:"\f158"}.fa-ruler:before{content:"\f545"}.fa-ruler-combined:before{content:"\f546"}.fa-ruler-horizontal:before{content:"\f547"}.fa-ruler-triangle:before{content:"\f61c"}.fa-ruler-vertical:before{content:"\f548"}.fa-running:before{content:"\f70c"}.fa-rupee-sign:before{content:"\f156"}.fa-rust:before{content:"\e07a"}.fa-rv:before{content:"\f7be"}.fa-sack:before{content:"\f81c"}.fa-sack-dollar:before{content:"\f81d"}.fa-sad-cry:before{content:"\f5b3"}.fa-sad-tear:before{content:"\f5b4"}.fa-safari:before{content:"\f267"}.fa-salad:before{content:"\f81e"}.fa-salesforce:before{content:"\f83b"}.fa-sandwich:before{content:"\f81f"}.fa-sass:before{content:"\f41e"}.fa-satellite:before{content:"\f7bf"}.fa-satellite-dish:before{content:"\f7c0"}.fa-sausage:before{content:"\f820"}.fa-save:before{content:"\f0c7"}.fa-sax-hot:before{content:"\f8db"}.fa-saxophone:before{content:"\f8dc"}.fa-scalpel:before{content:"\f61d"}.fa-scalpel-path:before{content:"\f61e"}.fa-scanner:before{content:"\f488"}.fa-scanner-image:before{content:"\f8f3"}.fa-scanner-keyboard:before{content:"\f489"}.fa-scanner-touchscreen:before{content:"\f48a"}.fa-scarecrow:before{content:"\f70d"}.fa-scarf:before{content:"\f7c1"}.fa-schlix:before{content:"\f3ea"}.fa-school:before{content:"\f549"}.fa-screwdriver:before{content:"\f54a"}.fa-scribd:before{content:"\f28a"}.fa-scroll:before{content:"\f70e"}.fa-scroll-old:before{content:"\f70f"}.fa-scrubber:before{content:"\f2f8"}.fa-scythe:before{content:"\f710"}.fa-sd-card:before{content:"\f7c2"}.fa-search:before{content:"\f002"}.fa-search-dollar:before{content:"\f688"}.fa-search-location:before{content:"\f689"}.fa-search-minus:before{content:"\f010"}.fa-search-plus:before{content:"\f00e"}.fa-searchengin:before{content:"\f3eb"}.fa-seedling:before{content:"\f4d8"}.fa-sellcast:before{content:"\f2da"}.fa-sellsy:before{content:"\f213"}.fa-send-back:before{content:"\f87e"}.fa-send-backward:before{content:"\f87f"}.fa-sensor:before{content:"\e028"}.fa-sensor-alert:before{content:"\e029"}.fa-sensor-fire:before{content:"\e02a"}.fa-sensor-on:before{content:"\e02b"}.fa-sensor-smoke:before{content:"\e02c"}.fa-server:before{content:"\f233"}.fa-servicestack:before{content:"\f3ec"}.fa-shapes:before{content:"\f61f"}.fa-share:before{content:"\f064"}.fa-share-all:before{content:"\f367"}.fa-share-alt:before{content:"\f1e0"}.fa-share-alt-square:before{content:"\f1e1"}.fa-share-square:before{content:"\f14d"}.fa-sheep:before{content:"\f711"}.fa-shekel-sign:before{content:"\f20b"}.fa-shield:before{content:"\f132"}.fa-shield-alt:before{content:"\f3ed"}.fa-shield-check:before{content:"\f2f7"}.fa-shield-cross:before{content:"\f712"}.fa-shield-virus:before{content:"\e06c"}.fa-ship:before{content:"\f21a"}.fa-shipping-fast:before{content:"\f48b"}.fa-shipping-timed:before{content:"\f48c"}.fa-shirtsinbulk:before{content:"\f214"}.fa-shish-kebab:before{content:"\f821"}.fa-shoe-prints:before{content:"\f54b"}.fa-shopify:before{content:"\e057"}.fa-shopping-bag:before{content:"\f290"}.fa-shopping-basket:before{content:"\f291"}.fa-shopping-cart:before{content:"\f07a"}.fa-shopware:before{content:"\f5b5"}.fa-shovel:before{content:"\f713"}.fa-shovel-snow:before{content:"\f7c3"}.fa-shower:before{content:"\f2cc"}.fa-shredder:before{content:"\f68a"}.fa-shuttle-van:before{content:"\f5b6"}.fa-shuttlecock:before{content:"\f45b"}.fa-sickle:before{content:"\f822"}.fa-sigma:before{content:"\f68b"}.fa-sign:before{content:"\f4d9"}.fa-sign-in:before{content:"\f090"}.fa-sign-in-alt:before{content:"\f2f6"}.fa-sign-language:before{content:"\f2a7"}.fa-sign-out:before{content:"\f08b"}.fa-sign-out-alt:before{content:"\f2f5"}.fa-signal:before{content:"\f012"}.fa-signal-1:before{content:"\f68c"}.fa-signal-2:before{content:"\f68d"}.fa-signal-3:before{content:"\f68e"}.fa-signal-4:before{content:"\f68f"}.fa-signal-alt:before{content:"\f690"}.fa-signal-alt-1:before{content:"\f691"}.fa-signal-alt-2:before{content:"\f692"}.fa-signal-alt-3:before{content:"\f693"}.fa-signal-alt-slash:before{content:"\f694"}.fa-signal-slash:before{content:"\f695"}.fa-signal-stream:before{content:"\f8dd"}.fa-signature:before{content:"\f5b7"}.fa-sim-card:before{content:"\f7c4"}.fa-simplybuilt:before{content:"\f215"}.fa-sink:before{content:"\e06d"}.fa-siren:before{content:"\e02d"}.fa-siren-on:before{content:"\e02e"}.fa-sistrix:before{content:"\f3ee"}.fa-sitemap:before{content:"\f0e8"}.fa-sith:before{content:"\f512"}.fa-skating:before{content:"\f7c5"}.fa-skeleton:before{content:"\f620"}.fa-sketch:before{content:"\f7c6"}.fa-ski-jump:before{content:"\f7c7"}.fa-ski-lift:before{content:"\f7c8"}.fa-skiing:before{content:"\f7c9"}.fa-skiing-nordic:before{content:"\f7ca"}.fa-skull:before{content:"\f54c"}.fa-skull-cow:before{content:"\f8de"}.fa-skull-crossbones:before{content:"\f714"}.fa-skyatlas:before{content:"\f216"}.fa-skype:before{content:"\f17e"}.fa-slack:before{content:"\f198"}.fa-slack-hash:before{content:"\f3ef"}.fa-slash:before{content:"\f715"}.fa-sledding:before{content:"\f7cb"}.fa-sleigh:before{content:"\f7cc"}.fa-sliders-h:before{content:"\f1de"}.fa-sliders-h-square:before{content:"\f3f0"}.fa-sliders-v:before{content:"\f3f1"}.fa-sliders-v-square:before{content:"\f3f2"}.fa-slideshare:before{content:"\f1e7"}.fa-smile:before{content:"\f118"}.fa-smile-beam:before{content:"\f5b8"}.fa-smile-plus:before{content:"\f5b9"}.fa-smile-wink:before{content:"\f4da"}.fa-smog:before{content:"\f75f"}.fa-smoke:before{content:"\f760"}.fa-smoking:before{content:"\f48d"}.fa-smoking-ban:before{content:"\f54d"}.fa-sms:before{content:"\f7cd"}.fa-snake:before{content:"\f716"}.fa-snapchat:before{content:"\f2ab"}.fa-snapchat-ghost:before{content:"\f2ac"}.fa-snapchat-square:before{content:"\f2ad"}.fa-snooze:before{content:"\f880"}.fa-snow-blowing:before{content:"\f761"}.fa-snowboarding:before{content:"\f7ce"}.fa-snowflake:before{content:"\f2dc"}.fa-snowflakes:before{content:"\f7cf"}.fa-snowman:before{content:"\f7d0"}.fa-snowmobile:before{content:"\f7d1"}.fa-snowplow:before{content:"\f7d2"}.fa-soap:before{content:"\e06e"}.fa-socks:before{content:"\f696"}.fa-solar-panel:before{content:"\f5ba"}.fa-solar-system:before{content:"\e02f"}.fa-sort:before{content:"\f0dc"}.fa-sort-alpha-down:before{content:"\f15d"}.fa-sort-alpha-down-alt:before{content:"\f881"}.fa-sort-alpha-up:before{content:"\f15e"}.fa-sort-alpha-up-alt:before{content:"\f882"}.fa-sort-alt:before{content:"\f883"}.fa-sort-amount-down:before{content:"\f160"}.fa-sort-amount-down-alt:before{content:"\f884"}.fa-sort-amount-up:before{content:"\f161"}.fa-sort-amount-up-alt:before{content:"\f885"}.fa-sort-circle:before{content:"\e030"}.fa-sort-circle-down:before{content:"\e031"}.fa-sort-circle-up:before{content:"\e032"}.fa-sort-down:before{content:"\f0dd"}.fa-sort-numeric-down:before{content:"\f162"}.fa-sort-numeric-down-alt:before{content:"\f886"}.fa-sort-numeric-up:before{content:"\f163"}.fa-sort-numeric-up-alt:before{content:"\f887"}.fa-sort-shapes-down:before{content:"\f888"}.fa-sort-shapes-down-alt:before{content:"\f889"}.fa-sort-shapes-up:before{content:"\f88a"}.fa-sort-shapes-up-alt:before{content:"\f88b"}.fa-sort-size-down:before{content:"\f88c"}.fa-sort-size-down-alt:before{content:"\f88d"}.fa-sort-size-up:before{content:"\f88e"}.fa-sort-size-up-alt:before{content:"\f88f"}.fa-sort-up:before{content:"\f0de"}.fa-soundcloud:before{content:"\f1be"}.fa-soup:before{content:"\f823"}.fa-sourcetree:before{content:"\f7d3"}.fa-spa:before{content:"\f5bb"}.fa-space-shuttle:before{content:"\f197"}.fa-space-station-moon:before{content:"\e033"}.fa-space-station-moon-alt:before{content:"\e034"}.fa-spade:before{content:"\f2f4"}.fa-sparkles:before{content:"\f890"}.fa-speakap:before{content:"\f3f3"}.fa-speaker:before{content:"\f8df"}.fa-speaker-deck:before{content:"\f83c"}.fa-speakers:before{content:"\f8e0"}.fa-spell-check:before{content:"\f891"}.fa-spider:before{content:"\f717"}.fa-spider-black-widow:before{content:"\f718"}.fa-spider-web:before{content:"\f719"}.fa-spinner:before{content:"\f110"}.fa-spinner-third:before{content:"\f3f4"}.fa-splotch:before{content:"\f5bc"}.fa-spotify:before{content:"\f1bc"}.fa-spray-can:before{content:"\f5bd"}.fa-sprinkler:before{content:"\e035"}.fa-square:before{content:"\f0c8"}.fa-square-full:before{content:"\f45c"}.fa-square-root:before{content:"\f697"}.fa-square-root-alt:before{content:"\f698"}.fa-squarespace:before{content:"\f5be"}.fa-squirrel:before{content:"\f71a"}.fa-stack-exchange:before{content:"\f18d"}.fa-stack-overflow:before{content:"\f16c"}.fa-stackpath:before{content:"\f842"}.fa-staff:before{content:"\f71b"}.fa-stamp:before{content:"\f5bf"}.fa-star:before{content:"\f005"}.fa-star-and-crescent:before{content:"\f699"}.fa-star-christmas:before{content:"\f7d4"}.fa-star-exclamation:before{content:"\f2f3"}.fa-star-half:before{content:"\f089"}.fa-star-half-alt:before{content:"\f5c0"}.fa-star-of-david:before{content:"\f69a"}.fa-star-of-life:before{content:"\f621"}.fa-star-shooting:before{content:"\e036"}.fa-starfighter:before{content:"\e037"}.fa-starfighter-alt:before{content:"\e038"}.fa-stars:before{content:"\f762"}.fa-starship:before{content:"\e039"}.fa-starship-freighter:before{content:"\e03a"}.fa-staylinked:before{content:"\f3f5"}.fa-steak:before{content:"\f824"}.fa-steam:before{content:"\f1b6"}.fa-steam-square:before{content:"\f1b7"}.fa-steam-symbol:before{content:"\f3f6"}.fa-steering-wheel:before{content:"\f622"}.fa-step-backward:before{content:"\f048"}.fa-step-forward:before{content:"\f051"}.fa-stethoscope:before{content:"\f0f1"}.fa-sticker-mule:before{content:"\f3f7"}.fa-sticky-note:before{content:"\f249"}.fa-stocking:before{content:"\f7d5"}.fa-stomach:before{content:"\f623"}.fa-stop:before{content:"\f04d"}.fa-stop-circle:before{content:"\f28d"}.fa-stopwatch:before{content:"\f2f2"}.fa-stopwatch-20:before{content:"\e06f"}.fa-store:before{content:"\f54e"}.fa-store-alt:before{content:"\f54f"}.fa-store-alt-slash:before{content:"\e070"}.fa-store-slash:before{content:"\e071"}.fa-strava:before{content:"\f428"}.fa-stream:before{content:"\f550"}.fa-street-view:before{content:"\f21d"}.fa-stretcher:before{content:"\f825"}.fa-strikethrough:before{content:"\f0cc"}.fa-stripe:before{content:"\f429"}.fa-stripe-s:before{content:"\f42a"}.fa-stroopwafel:before{content:"\f551"}.fa-studiovinari:before{content:"\f3f8"}.fa-stumbleupon:before{content:"\f1a4"}.fa-stumbleupon-circle:before{content:"\f1a3"}.fa-subscript:before{content:"\f12c"}.fa-subway:before{content:"\f239"}.fa-suitcase:before{content:"\f0f2"}.fa-suitcase-rolling:before{content:"\f5c1"}.fa-sun:before{content:"\f185"}.fa-sun-cloud:before{content:"\f763"}.fa-sun-dust:before{content:"\f764"}.fa-sun-haze:before{content:"\f765"}.fa-sunglasses:before{content:"\f892"}.fa-sunrise:before{content:"\f766"}.fa-sunset:before{content:"\f767"}.fa-superpowers:before{content:"\f2dd"}.fa-superscript:before{content:"\f12b"}.fa-supple:before{content:"\f3f9"}.fa-surprise:before{content:"\f5c2"}.fa-suse:before{content:"\f7d6"}.fa-swatchbook:before{content:"\f5c3"}.fa-swift:before{content:"\f8e1"}.fa-swimmer:before{content:"\f5c4"}.fa-swimming-pool:before{content:"\f5c5"}.fa-sword:before{content:"\f71c"}.fa-sword-laser:before{content:"\e03b"}.fa-sword-laser-alt:before{content:"\e03c"}.fa-swords:before{content:"\f71d"}.fa-swords-laser:before{content:"\e03d"}.fa-symfony:before{content:"\f83d"}.fa-synagogue:before{content:"\f69b"}.fa-sync:before{content:"\f021"}.fa-sync-alt:before{content:"\f2f1"}.fa-syringe:before{content:"\f48e"}.fa-table:before{content:"\f0ce"}.fa-table-tennis:before{content:"\f45d"}.fa-tablet:before{content:"\f10a"}.fa-tablet-alt:before{content:"\f3fa"}.fa-tablet-android:before{content:"\f3fb"}.fa-tablet-android-alt:before{content:"\f3fc"}.fa-tablet-rugged:before{content:"\f48f"}.fa-tablets:before{content:"\f490"}.fa-tachometer:before{content:"\f0e4"}.fa-tachometer-alt:before{content:"\f3fd"}.fa-tachometer-alt-average:before{content:"\f624"}.fa-tachometer-alt-fast:before{content:"\f625"}.fa-tachometer-alt-fastest:before{content:"\f626"}.fa-tachometer-alt-slow:before{content:"\f627"}.fa-tachometer-alt-slowest:before{content:"\f628"}.fa-tachometer-average:before{content:"\f629"}.fa-tachometer-fast:before{content:"\f62a"}.fa-tachometer-fastest:before{content:"\f62b"}.fa-tachometer-slow:before{content:"\f62c"}.fa-tachometer-slowest:before{content:"\f62d"}.fa-taco:before{content:"\f826"}.fa-tag:before{content:"\f02b"}.fa-tags:before{content:"\f02c"}.fa-tally:before{content:"\f69c"}.fa-tanakh:before{content:"\f827"}.fa-tape:before{content:"\f4db"}.fa-tasks:before{content:"\f0ae"}.fa-tasks-alt:before{content:"\f828"}.fa-taxi:before{content:"\f1ba"}.fa-teamspeak:before{content:"\f4f9"}.fa-teeth:before{content:"\f62e"}.fa-teeth-open:before{content:"\f62f"}.fa-telegram:before{content:"\f2c6"}.fa-telegram-plane:before{content:"\f3fe"}.fa-telescope:before{content:"\e03e"}.fa-temperature-down:before{content:"\e03f"}.fa-temperature-frigid:before{content:"\f768"}.fa-temperature-high:before{content:"\f769"}.fa-temperature-hot:before{content:"\f76a"}.fa-temperature-low:before{content:"\f76b"}.fa-temperature-up:before{content:"\e040"}.fa-tencent-weibo:before{content:"\f1d5"}.fa-tenge:before{content:"\f7d7"}.fa-tennis-ball:before{content:"\f45e"}.fa-terminal:before{content:"\f120"}.fa-text:before{content:"\f893"}.fa-text-height:before{content:"\f034"}.fa-text-size:before{content:"\f894"}.fa-text-width:before{content:"\f035"}.fa-th:before{content:"\f00a"}.fa-th-large:before{content:"\f009"}.fa-th-list:before{content:"\f00b"}.fa-the-red-yeti:before{content:"\f69d"}.fa-theater-masks:before{content:"\f630"}.fa-themeco:before{content:"\f5c6"}.fa-themeisle:before{content:"\f2b2"}.fa-thermometer:before{content:"\f491"}.fa-thermometer-empty:before{content:"\f2cb"}.fa-thermometer-full:before{content:"\f2c7"}.fa-thermometer-half:before{content:"\f2c9"}.fa-thermometer-quarter:before{content:"\f2ca"}.fa-thermometer-three-quarters:before{content:"\f2c8"}.fa-theta:before{content:"\f69e"}.fa-think-peaks:before{content:"\f731"}.fa-thumbs-down:before{content:"\f165"}.fa-thumbs-up:before{content:"\f164"}.fa-thumbtack:before{content:"\f08d"}.fa-thunderstorm:before{content:"\f76c"}.fa-thunderstorm-moon:before{content:"\f76d"}.fa-thunderstorm-sun:before{content:"\f76e"}.fa-ticket:before{content:"\f145"}.fa-ticket-alt:before{content:"\f3ff"}.fa-tiktok:before{content:"\e07b"}.fa-tilde:before{content:"\f69f"}.fa-times:before{content:"\f00d"}.fa-times-circle:before{content:"\f057"}.fa-times-hexagon:before{content:"\f2ee"}.fa-times-octagon:before{content:"\f2f0"}.fa-times-square:before{content:"\f2d3"}.fa-tint:before{content:"\f043"}.fa-tint-slash:before{content:"\f5c7"}.fa-tire:before{content:"\f631"}.fa-tire-flat:before{content:"\f632"}.fa-tire-pressure-warning:before{content:"\f633"}.fa-tire-rugged:before{content:"\f634"}.fa-tired:before{content:"\f5c8"}.fa-toggle-off:before{content:"\f204"}.fa-toggle-on:before{content:"\f205"}.fa-toilet:before{content:"\f7d8"}.fa-toilet-paper:before{content:"\f71e"}.fa-toilet-paper-alt:before{content:"\f71f"}.fa-toilet-paper-slash:before{content:"\e072"}.fa-tombstone:before{content:"\f720"}.fa-tombstone-alt:before{content:"\f721"}.fa-toolbox:before{content:"\f552"}.fa-tools:before{content:"\f7d9"}.fa-tooth:before{content:"\f5c9"}.fa-toothbrush:before{content:"\f635"}.fa-torah:before{content:"\f6a0"}.fa-torii-gate:before{content:"\f6a1"}.fa-tornado:before{content:"\f76f"}.fa-tractor:before{content:"\f722"}.fa-trade-federation:before{content:"\f513"}.fa-trademark:before{content:"\f25c"}.fa-traffic-cone:before{content:"\f636"}.fa-traffic-light:before{content:"\f637"}.fa-traffic-light-go:before{content:"\f638"}.fa-traffic-light-slow:before{content:"\f639"}.fa-traffic-light-stop:before{content:"\f63a"}.fa-trailer:before{content:"\e041"}.fa-train:before{content:"\f238"}.fa-tram:before{content:"\f7da"}.fa-transgender:before{content:"\f224"}.fa-transgender-alt:before{content:"\f225"}.fa-transporter:before{content:"\e042"}.fa-transporter-1:before{content:"\e043"}.fa-transporter-2:before{content:"\e044"}.fa-transporter-3:before{content:"\e045"}.fa-transporter-empty:before{content:"\e046"}.fa-trash:before{content:"\f1f8"}.fa-trash-alt:before{content:"\f2ed"}.fa-trash-restore:before{content:"\f829"}.fa-trash-restore-alt:before{content:"\f82a"}.fa-trash-undo:before{content:"\f895"}.fa-trash-undo-alt:before{content:"\f896"}.fa-treasure-chest:before{content:"\f723"}.fa-tree:before{content:"\f1bb"}.fa-tree-alt:before{content:"\f400"}.fa-tree-christmas:before{content:"\f7db"}.fa-tree-decorated:before{content:"\f7dc"}.fa-tree-large:before{content:"\f7dd"}.fa-tree-palm:before{content:"\f82b"}.fa-trees:before{content:"\f724"}.fa-trello:before{content:"\f181"}.fa-triangle:before{content:"\f2ec"}.fa-triangle-music:before{content:"\f8e2"}.fa-tripadvisor:before{content:"\f262"}.fa-trophy:before{content:"\f091"}.fa-trophy-alt:before{content:"\f2eb"}.fa-truck:before{content:"\f0d1"}.fa-truck-container:before{content:"\f4dc"}.fa-truck-couch:before{content:"\f4dd"}.fa-truck-loading:before{content:"\f4de"}.fa-truck-monster:before{content:"\f63b"}.fa-truck-moving:before{content:"\f4df"}.fa-truck-pickup:before{content:"\f63c"}.fa-truck-plow:before{content:"\f7de"}.fa-truck-ramp:before{content:"\f4e0"}.fa-trumpet:before{content:"\f8e3"}.fa-tshirt:before{content:"\f553"}.fa-tty:before{content:"\f1e4"}.fa-tumblr:before{content:"\f173"}.fa-tumblr-square:before{content:"\f174"}.fa-turkey:before{content:"\f725"}.fa-turntable:before{content:"\f8e4"}.fa-turtle:before{content:"\f726"}.fa-tv:before{content:"\f26c"}.fa-tv-alt:before{content:"\f8e5"}.fa-tv-music:before{content:"\f8e6"}.fa-tv-retro:before{content:"\f401"}.fa-twitch:before{content:"\f1e8"}.fa-twitter:before{content:"\f099"}.fa-twitter-square:before{content:"\f081"}.fa-typewriter:before{content:"\f8e7"}.fa-typo3:before{content:"\f42b"}.fa-uber:before{content:"\f402"}.fa-ubuntu:before{content:"\f7df"}.fa-ufo:before{content:"\e047"}.fa-ufo-beam:before{content:"\e048"}.fa-uikit:before{content:"\f403"}.fa-umbraco:before{content:"\f8e8"}.fa-umbrella:before{content:"\f0e9"}.fa-umbrella-beach:before{content:"\f5ca"}.fa-uncharted:before{content:"\e084"}.fa-underline:before{content:"\f0cd"}.fa-undo:before{content:"\f0e2"}.fa-undo-alt:before{content:"\f2ea"}.fa-unicorn:before{content:"\f727"}.fa-union:before{content:"\f6a2"}.fa-uniregistry:before{content:"\f404"}.fa-unity:before{content:"\e049"}.fa-universal-access:before{content:"\f29a"}.fa-university:before{content:"\f19c"}.fa-unlink:before{content:"\f127"}.fa-unlock:before{content:"\f09c"}.fa-unlock-alt:before{content:"\f13e"}.fa-unsplash:before{content:"\e07c"}.fa-untappd:before{content:"\f405"}.fa-upload:before{content:"\f093"}.fa-ups:before{content:"\f7e0"}.fa-usb:before{content:"\f287"}.fa-usb-drive:before{content:"\f8e9"}.fa-usd-circle:before{content:"\f2e8"}.fa-usd-square:before{content:"\f2e9"}.fa-user:before{content:"\f007"}.fa-user-alien:before{content:"\e04a"}.fa-user-alt:before{content:"\f406"}.fa-user-alt-slash:before{content:"\f4fa"}.fa-user-astronaut:before{content:"\f4fb"}.fa-user-chart:before{content:"\f6a3"}.fa-user-check:before{content:"\f4fc"}.fa-user-circle:before{content:"\f2bd"}.fa-user-clock:before{content:"\f4fd"}.fa-user-cog:before{content:"\f4fe"}.fa-user-cowboy:before{content:"\f8ea"}.fa-user-crown:before{content:"\f6a4"}.fa-user-edit:before{content:"\f4ff"}.fa-user-friends:before{content:"\f500"}.fa-user-graduate:before{content:"\f501"}.fa-user-hard-hat:before{content:"\f82c"}.fa-user-headset:before{content:"\f82d"}.fa-user-injured:before{content:"\f728"}.fa-user-lock:before{content:"\f502"}.fa-user-md:before{content:"\f0f0"}.fa-user-md-chat:before{content:"\f82e"}.fa-user-minus:before{content:"\f503"}.fa-user-music:before{content:"\f8eb"}.fa-user-ninja:before{content:"\f504"}.fa-user-nurse:before{content:"\f82f"}.fa-user-plus:before{content:"\f234"}.fa-user-robot:before{content:"\e04b"}.fa-user-secret:before{content:"\f21b"}.fa-user-shield:before{content:"\f505"}.fa-user-slash:before{content:"\f506"}.fa-user-tag:before{content:"\f507"}.fa-user-tie:before{content:"\f508"}.fa-user-times:before{content:"\f235"}.fa-user-unlock:before{content:"\e058"}.fa-user-visor:before{content:"\e04c"}.fa-users:before{content:"\f0c0"}.fa-users-class:before{content:"\f63d"}.fa-users-cog:before{content:"\f509"}.fa-users-crown:before{content:"\f6a5"}.fa-users-medical:before{content:"\f830"}.fa-users-slash:before{content:"\e073"}.fa-usps:before{content:"\f7e1"}.fa-ussunnah:before{content:"\f407"}.fa-utensil-fork:before{content:"\f2e3"}.fa-utensil-knife:before{content:"\f2e4"}.fa-utensil-spoon:before{content:"\f2e5"}.fa-utensils:before{content:"\f2e7"}.fa-utensils-alt:before{content:"\f2e6"}.fa-vaadin:before{content:"\f408"}.fa-vacuum:before{content:"\e04d"}.fa-vacuum-robot:before{content:"\e04e"}.fa-value-absolute:before{content:"\f6a6"}.fa-vector-square:before{content:"\f5cb"}.fa-venus:before{content:"\f221"}.fa-venus-double:before{content:"\f226"}.fa-venus-mars:before{content:"\f228"}.fa-vest:before{content:"\e085"}.fa-vest-patches:before{content:"\e086"}.fa-vhs:before{content:"\f8ec"}.fa-viacoin:before{content:"\f237"}.fa-viadeo:before{content:"\f2a9"}.fa-viadeo-square:before{content:"\f2aa"}.fa-vial:before{content:"\f492"}.fa-vials:before{content:"\f493"}.fa-viber:before{content:"\f409"}.fa-video:before{content:"\f03d"}.fa-video-plus:before{content:"\f4e1"}.fa-video-slash:before{content:"\f4e2"}.fa-vihara:before{content:"\f6a7"}.fa-vimeo:before{content:"\f40a"}.fa-vimeo-square:before{content:"\f194"}.fa-vimeo-v:before{content:"\f27d"}.fa-vine:before{content:"\f1ca"}.fa-violin:before{content:"\f8ed"}.fa-virus:before{content:"\e074"}.fa-virus-slash:before{content:"\e075"}.fa-viruses:before{content:"\e076"}.fa-vk:before{content:"\f189"}.fa-vnv:before{content:"\f40b"}.fa-voicemail:before{content:"\f897"}.fa-volcano:before{content:"\f770"}.fa-volleyball-ball:before{content:"\f45f"}.fa-volume:before{content:"\f6a8"}.fa-volume-down:before{content:"\f027"}.fa-volume-mute:before{content:"\f6a9"}.fa-volume-off:before{content:"\f026"}.fa-volume-slash:before{content:"\f2e2"}.fa-volume-up:before{content:"\f028"}.fa-vote-nay:before{content:"\f771"}.fa-vote-yea:before{content:"\f772"}.fa-vr-cardboard:before{content:"\f729"}.fa-vuejs:before{content:"\f41f"}.fa-wagon-covered:before{content:"\f8ee"}.fa-walker:before{content:"\f831"}.fa-walkie-talkie:before{content:"\f8ef"}.fa-walking:before{content:"\f554"}.fa-wallet:before{content:"\f555"}.fa-wand:before{content:"\f72a"}.fa-wand-magic:before{content:"\f72b"}.fa-warehouse:before{content:"\f494"}.fa-warehouse-alt:before{content:"\f495"}.fa-washer:before{content:"\f898"}.fa-watch:before{content:"\f2e1"}.fa-watch-calculator:before{content:"\f8f0"}.fa-watch-fitness:before{content:"\f63e"}.fa-watchman-monitoring:before{content:"\e087"}.fa-water:before{content:"\f773"}.fa-water-lower:before{content:"\f774"}.fa-water-rise:before{content:"\f775"}.fa-wave-sine:before{content:"\f899"}.fa-wave-square:before{content:"\f83e"}.fa-wave-triangle:before{content:"\f89a"}.fa-waveform:before{content:"\f8f1"}.fa-waveform-path:before{content:"\f8f2"}.fa-waze:before{content:"\f83f"}.fa-webcam:before{content:"\f832"}.fa-webcam-slash:before{content:"\f833"}.fa-weebly:before{content:"\f5cc"}.fa-weibo:before{content:"\f18a"}.fa-weight:before{content:"\f496"}.fa-weight-hanging:before{content:"\f5cd"}.fa-weixin:before{content:"\f1d7"}.fa-whale:before{content:"\f72c"}.fa-whatsapp:before{content:"\f232"}.fa-whatsapp-square:before{content:"\f40c"}.fa-wheat:before{content:"\f72d"}.fa-wheelchair:before{content:"\f193"}.fa-whistle:before{content:"\f460"}.fa-whmcs:before{content:"\f40d"}.fa-wifi:before{content:"\f1eb"}.fa-wifi-1:before{content:"\f6aa"}.fa-wifi-2:before{content:"\f6ab"}.fa-wifi-slash:before{content:"\f6ac"}.fa-wikipedia-w:before{content:"\f266"}.fa-wind:before{content:"\f72e"}.fa-wind-turbine:before{content:"\f89b"}.fa-wind-warning:before{content:"\f776"}.fa-window:before{content:"\f40e"}.fa-window-alt:before{content:"\f40f"}.fa-window-close:before{content:"\f410"}.fa-window-frame:before{content:"\e04f"}.fa-window-frame-open:before{content:"\e050"}.fa-window-maximize:before{content:"\f2d0"}.fa-window-minimize:before{content:"\f2d1"}.fa-window-restore:before{content:"\f2d2"}.fa-windows:before{content:"\f17a"}.fa-windsock:before{content:"\f777"}.fa-wine-bottle:before{content:"\f72f"}.fa-wine-glass:before{content:"\f4e3"}.fa-wine-glass-alt:before{content:"\f5ce"}.fa-wix:before{content:"\f5cf"}.fa-wizards-of-the-coast:before{content:"\f730"}.fa-wodu:before{content:"\e088"}.fa-wolf-pack-battalion:before{content:"\f514"}.fa-won-sign:before{content:"\f159"}.fa-wordpress:before{content:"\f19a"}.fa-wordpress-simple:before{content:"\f411"}.fa-wpbeginner:before{content:"\f297"}.fa-wpexplorer:before{content:"\f2de"}.fa-wpforms:before{content:"\f298"}.fa-wpressr:before{content:"\f3e4"}.fa-wreath:before{content:"\f7e2"}.fa-wrench:before{content:"\f0ad"}.fa-x-ray:before{content:"\f497"}.fa-xbox:before{content:"\f412"}.fa-xing:before{content:"\f168"}.fa-xing-square:before{content:"\f169"}.fa-y-combinator:before{content:"\f23b"}.fa-yahoo:before{content:"\f19e"}.fa-yammer:before{content:"\f840"}.fa-yandex:before{content:"\f413"}.fa-yandex-international:before{content:"\f414"}.fa-yarn:before{content:"\f7e3"}.fa-yelp:before{content:"\f1e9"}.fa-yen-sign:before{content:"\f157"}.fa-yin-yang:before{content:"\f6ad"}.fa-yoast:before{content:"\f2b1"}.fa-youtube:before{content:"\f167"}.fa-youtube-square:before{content:"\f431"}.fa-zhihu:before{content:"\f63f"}.sr-only{border:0;clip:rect(0,0,0,0);height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;width:1px}.sr-only-focusable:active,.sr-only-focusable:focus{clip:auto;height:auto;margin:0;overflow:visible;position:static;width:auto}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.0.svg#fontawesome) format("svg");unicode-range:U+f081,U+f08c,U+f092,U+f099,U+f09b,U+f0d2-f0d5,U+f113,U+f136,U+f13b-f13c,U+f15a,U+f167-f169,U+f16c-f16e,U+f170,U+f173-f174,U+f17a,U+f17c-f17e,U+f180,U+f184,U+f189-f18c,U+f194,U+f19a-f19b,U+f1a0-f1a4,U+f1a6-f1a7,U+f1a9-f1aa,U+f1b4,U+f1b6-f1b7,U+f1bc-f1be,U+f1ca-f1cc,U+f1d0-f1d1,U+f1d4-f1d6,U+f1e7,U+f1ed-f1ee,U+f1f0-f1f2,U+f1f4-f1f5,U+f202,U+f208-f209,U+f20d-f20e,U+f211-f213,U+f215,U+f231-f232,U+f237,U+f23a-f23b,U+f23d-f23e,U+f24b-f24c,U+f260-f261,U+f263-f266,U+f268,U+f26a-f26b,U+f26d-f26e,U+f270,U+f27d-f27e,U+f280-f281,U+f284-f285,U+f287-f28a,U+f293-f294,U+f297-f299,U+f2a5-f2a6,U+f2a9,U+f2ab-f2ad,U+f2b0,U+f2b2,U+f2b4,U+f2b8,U+f2c4,U+f2c6,U+f2d6-f2d8,U+f2da,U+f2dd-f2de,U+f2e0,U+f35c,U+f368-f374,U+f378-f37d,U+f37f-f380,U+f383-f385,U+f388,U+f38b-f38f,U+f392,U+f394-f397,U+f399-f39a,U+f3a1-f3a4,U+f3a6-f3b2,U+f3b4-f3b8,U+f3ba-f3bc,U+f3c0,U+f3c3-f3c4,U+f3c6-f3c8,U+f3ca,U+f3cc,U+f3d0,U+f3d2,U+f3d4,U+f3d6-f3d7,U+f3da-f3db,U+f3df,U+f3e1-f3e3,U+f3e6-f3e7,U+f3e9-f3ec,U+f3ee-f3ef,U+f3f5-f3f6,U+f3f8-f3f9,U+f3fe,U+f402-f405,U+f407-f408,U+f40a-f40d,U+f411-f417,U+f419,U+f41b-f41d,U+f41f,U+f421,U+f426}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.1.svg#fontawesome) format("svg");unicode-range:U+f16b,U+f425}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.2.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.2.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.2.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.2.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.2.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.2.svg#fontawesome) format("svg");unicode-range:U+f42d-f42f}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.3.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.3.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.3.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.3.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.3.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.3.svg#fontawesome) format("svg");unicode-range:U+f18d,U+f1b5,U+f1d7,U+f210,U+f216,U+f286,U+f2b1,U+f393,U+f3b9,U+f3cb,U+f3d3,U+f3d8-f3d9,U+f3dc,U+f409,U+f423,U+f429,U+f430-f431}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.5.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.5.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.5.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.5.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.5.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.5.svg#fontawesome) format("svg");unicode-range:U+f452,U+f457}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.9.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.9.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.9.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.9.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.9.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.9.svg#fontawesome) format("svg");unicode-range:U+f44d}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.10.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.10.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.10.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.10.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.10.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.10.svg#fontawesome) format("svg");unicode-range:U+f4d5,U+f4e5}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.11.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.11.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.11.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.11.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.11.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.11.svg#fontawesome) format("svg");unicode-range:U+f203,U+f4e6-f4f2,U+f4f8}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.12.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.12.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.12.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.12.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.12.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.0.12.svg#fontawesome) format("svg");unicode-range:U+f4f7,U+f50a,U+f50c-f50d,U+f510,U+f512-f513}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.1.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.1.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.1.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.1.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.1.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.1.0.svg#fontawesome) format("svg");unicode-range:U+f25e,U+f375,U+f5a3,U+f5be,U+f5cc,U+f5cf}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.2.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.2.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.2.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.2.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.2.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.2.0.svg#fontawesome) format("svg");unicode-range:U+f5f1,U+f63f}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.3.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.3.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.3.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.3.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.3.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.3.0.svg#fontawesome) format("svg");unicode-range:U+f642}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.4.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.4.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.4.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.4.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.4.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.4.0.svg#fontawesome) format("svg");unicode-range:U+f4f3,U+f6ca,U+f6cc,U+f6dc,U+f704,U+f730}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.4.2.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.4.2.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.4.2.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.4.2.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.4.2.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.4.2.svg#fontawesome) format("svg");unicode-range:U+f3e4}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.6.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.6.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.6.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.6.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.6.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.6.0.svg#fontawesome) format("svg");unicode-range:U+f181,U+f77b,U+f78d,U+f790,U+f797,U+f7af-f7b1,U+f7b3,U+f7bb,U+f7df,U+f7e3}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.7.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.7.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.7.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.7.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.7.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.7.0.svg#fontawesome) format("svg");unicode-range:U+f198,U+f1a5,U+f1a8,U+f1f3,U+f214,U+f23c,U+f296,U+f2aa,U+f391,U+f39d,U+f3f7,U+f427,U+f4f4,U+f50e,U+f60f}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.8.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.8.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.8.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.8.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.8.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.8.0.svg#fontawesome) format("svg");unicode-range:U+f171,U+f179,U+f1e9,U+f27c,U+f3f3,U+f41a,U+f41e,U+f420,U+f428,U+f42a-f42c,U+f459,U+f4e4,U+f4f6,U+f4f9,U+f50b,U+f50f,U+f511,U+f514,U+f592,U+f5a8,U+f5b2,U+f5b5,U+f5c6,U+f5f7,U+f5fa,U+f612,U+f69d,U+f6af,U+f6c9,U+f731,U+f75d,U+f77a,U+f785,U+f789,U+f791,U+f798-f799,U+f7c6,U+f7d3,U+f7d6,U+f7e0-f7e1,U+f834-f83d,U+f83f-f840}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.8.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.8.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.8.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.8.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.8.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.8.1.svg#fontawesome) format("svg");unicode-range:U+f0e1}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.8.2.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.8.2.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.8.2.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.8.2.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.8.2.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.8.2.svg#fontawesome) format("svg");unicode-range:U+f082,U+f09a,U+f1d2-f1d3,U+f39e,U+f59e,U+f7bc,U+f841-f842}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.9.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.9.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.9.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.9.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.9.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.9.0.svg#fontawesome) format("svg");unicode-range:U+f39f}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.10.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.10.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.10.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.10.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.10.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.10.0.svg#fontawesome) format("svg");unicode-range:U+f89e}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.11.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.11.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.11.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.11.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.11.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.11.0.svg#fontawesome) format("svg");unicode-range:U+f4f5,U+f8a6,U+f8ca,U+f8d2,U+f8e1,U+f8e8}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.11.2.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.11.2.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.11.2.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.11.2.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.11.2.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.11.2.svg#fontawesome) format("svg");unicode-range:U+f3bd}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.12.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.12.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.12.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.12.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.12.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.12.0.svg#fontawesome) format("svg");unicode-range:U+f17b,U+f1e8,U+f267,U+f269,U+f2ae,U+f2c5}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.12.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.12.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.12.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.12.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.12.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.12.1.svg#fontawesome) format("svg");unicode-range:U+f282}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.13.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.13.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.13.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.13.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.13.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.13.1.svg#fontawesome) format("svg");unicode-range:U+f19e,U+f2b3,U+f2d5}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.14.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.14.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.14.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.14.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.14.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.14.0.svg#fontawesome) format("svg");unicode-range:U+e007,U+e013,U+e01a,U+e01e,U+e049,U+e052,U+e055-e057,U+e077-e07c,U+f262}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.15.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.15.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.15.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.15.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.15.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.15.0.svg#fontawesome) format("svg");unicode-range:U+e07d-e084,U+e087-e088,U+f3d5,U+f3e8}@font-face{font-family:"Font Awesome 5 Brands";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.15.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.15.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.15.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.15.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.15.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-brands-400-5.15.1.svg#fontawesome) format("svg");unicode-range:U+f2d9}.fab{font-family:"Font Awesome 5 Brands";font-weight:400}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.0.svg#fontawesome) format("svg");unicode-range:U+f002,U+f008-f009,U+f00b-f00c,U+f00e,U+f011,U+f013,U+f019,U+f01c,U+f022-f025,U+f02a-f02b,U+f02d,U+f030,U+f040-f041,U+f044,U+f047,U+f049-f04a,U+f04e,U+f050,U+f052-f055,U+f057-f05b,U+f05e,U+f060-f066,U+f068-f06a,U+f074,U+f077-f07a,U+f07c-f07e,U+f085,U+f089,U+f08b,U+f090,U+f093-f094,U+f098,U+f09c-f09e,U+f0a4-f0ab,U+f0b2,U+f0c1,U+f0c3,U+f0c6,U+f0c9,U+f0ce,U+f0d7-f0db,U+f0e2-f0e3,U+f0e9-f0ea,U+f0ec,U+f0f4,U+f0f8,U+f0fa-f0fe,U+f100-f103,U+f106-f108,U+f10a-f10b,U+f11c,U+f120-f122,U+f124,U+f126-f128,U+f12e,U+f134,U+f137-f13a,U+f13e,U+f141-f143,U+f146,U+f14a-f14d,U+f150-f154,U+f156-f159,U+f175-f178,U+f182-f183,U+f188,U+f191-f192,U+f195,U+f199,U+f1ad-f1ae,U+f1b0,U+f1b2-f1b3,U+f1b8,U+f1bb,U+f1c0,U+f1cd,U+f1d8,U+f1da,U+f1e0-f1e2,U+f1ea,U+f1fa,U+f1fd-f1fe,U+f204-f206,U+f20b,U+f217-f218,U+f21c,U+f222,U+f224,U+f226-f229,U+f233,U+f238-f239,U+f240-f244,U+f246,U+f255-f258,U+f25a-f25c,U+f28b,U+f28d,U+f290-f292,U+f295,U+f2a1-f2a4,U+f2a8,U+f2c7-f2cb,U+f2ce,U+f2d0,U+f2d2-f2d3,U+f2db,U+f2e6-f2e7,U+f2ea,U+f2f0-f2f1,U+f2f5-f2f7,U+f2f9,U+f2fd,U+f301,U+f303,U+f308-f30f,U+f31d,U+f320-f322,U+f325-f326,U+f328-f32e,U+f330-f332,U+f336-f337,U+f339-f33c,U+f33e,U+f340-f34c,U+f350-f353,U+f355,U+f358-f35b,U+f360-f367,U+f376,U+f37e,U+f387,U+f389-f38a,U+f390,U+f39b-f39c,U+f3a0,U+f3b3,U+f3be-f3bf,U+f3c2,U+f3c5,U+f3cd-f3cf,U+f3de,U+f3e5,U+f3ed,U+f3f0,U+f3f2,U+f3fa-f3fc,U+f400-f401,U+f40e-f410,U+10f002,U+10f008-10f009,U+10f00b-10f00c,U+10f00e,U+10f011,U+10f013,U+10f019,U+10f01c,U+10f022-10f025,U+10f02a-10f02b,U+10f02d,U+10f030,U+10f040-10f041,U+10f044,U+10f047,U+10f049-10f04a,U+10f04e,U+10f050,U+10f052-10f055,U+10f057-10f05b,U+10f05e,U+10f060-10f066,U+10f068-10f06a,U+10f074,U+10f077-10f07a,U+10f07c-10f07e,U+10f085,U+10f089,U+10f08b,U+10f090,U+10f093-10f094,U+10f098,U+10f09c-10f09e,U+10f0a4-10f0ab,U+10f0b2,U+10f0c1,U+10f0c3,U+10f0c6,U+10f0c9,U+10f0ce,U+10f0d7-10f0db,U+10f0e2-10f0e3,U+10f0e9-10f0ea,U+10f0ec,U+10f0f4,U+10f0f8,U+10f0fa-10f0fe,U+10f100-10f103,U+10f106-10f108,U+10f10a-10f10b,U+10f11c,U+10f120-10f122,U+10f124,U+10f126-10f128,U+10f12e,U+10f134,U+10f137-10f13a,U+10f13e,U+10f141-10f143,U+10f146,U+10f14a-10f14d,U+10f150-10f154,U+10f156-10f159,U+10f175-10f178,U+10f182-10f183,U+10f188,U+10f191-10f192,U+10f195,U+10f199,U+10f1ad-10f1ae,U+10f1b0,U+10f1b2-10f1b3,U+10f1b8,U+10f1bb,U+10f1c0,U+10f1cd,U+10f1d8,U+10f1da,U+10f1e0-10f1e2,U+10f1ea,U+10f1fa,U+10f1fd-10f1fe,U+10f204-10f206,U+10f20b,U+10f217-10f218,U+10f21c,U+10f222,U+10f224,U+10f226-10f229,U+10f233,U+10f238-10f239,U+10f240-10f244,U+10f246,U+10f255-10f258,U+10f25a-10f25c,U+10f28b,U+10f28d,U+10f290-10f292,U+10f295,U+10f2a1-10f2a4,U+10f2a8,U+10f2c7-10f2cb,U+10f2ce,U+10f2d0,U+10f2d2-10f2d3,U+10f2db,U+10f2e6-10f2e7,U+10f2ea,U+10f2f0-10f2f1,U+10f2f5-10f2f7,U+10f2f9,U+10f2fd,U+10f301,U+10f303,U+10f308-10f30f,U+10f31d,U+10f320-10f322,U+10f325-10f326,U+10f328-10f32e,U+10f330-10f332,U+10f336-10f337,U+10f339-10f33c,U+10f33e,U+10f340-10f34c,U+10f350-10f353,U+10f355,U+10f358-10f35b,U+10f360-10f367,U+10f376,U+10f37e,U+10f387,U+10f389-10f38a,U+10f390,U+10f39b-10f39c,U+10f3a0,U+10f3b3,U+10f3be-10f3bf,U+10f3c2,U+10f3c5,U+10f3cd-10f3cf,U+10f3de,U+10f3e5,U+10f3ed,U+10f3f0,U+10f3f2,U+10f3fa-10f3fc,U+10f400-10f401,U+10f40e-10f410}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.1.svg#fontawesome) format("svg");unicode-range:U+f3c1,U+10f3c1}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.3.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.3.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.3.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.3.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.3.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.3.svg#fontawesome) format("svg");unicode-range:U+f245,U+f2b9,U+f2bb,U+f2c1,U+f3e0,U+10f245,U+10f2b9,U+10f2bb,U+10f2c1,U+10f3e0}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.5.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.5.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.5.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.5.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.5.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.5.svg#fontawesome) format("svg");unicode-range:U+f1e3,U+f432,U+f437-f438,U+f449-f44c,U+f44f-f451,U+f453,U+f455,U+f458,U+f45a-f45b,U+f45d,U+10f1e3,U+10f432,U+10f437-10f438,U+10f449-10f44c,U+10f44f-10f451,U+10f453,U+10f455,U+10f458,U+10f45a-10f45b,U+10f45d}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.7.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.7.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.7.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.7.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.7.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.7.svg#fontawesome) format("svg");unicode-range:U+f0d1,U+f0f1,U+f0f9,U+f21e,U+f461,U+f463-f46f,U+f472-f475,U+f479-f47a,U+f47d-f47e,U+f481-f487,U+f489,U+f48b-f496,U+10f0d1,U+10f0f1,U+10f0f9,U+10f21e,U+10f461,U+10f463-10f46f,U+10f472-10f475,U+10f479-10f47a,U+10f47d-10f47e,U+10f481-10f487,U+10f489,U+10f48b-10f496}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.9.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.9.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.9.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.9.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.9.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.9.svg#fontawesome) format("svg");unicode-range:U+f03d,U+f06c,U+f086,U+f0f2,U+f10d-f10e,U+f187,U+f2b5,U+f2e9,U+f2fe,U+f3dd,U+f47b-f47c,U+f498,U+f49a-f49b,U+f49d,U+f49f-f4b9,U+f4bb-f4bf,U+f4c2-f4c6,U+f4c8,U+f4cb-f4d2,U+f4d4,U+f4d6,U+f4d8-f4d9,U+f4db-f4e2,U+10f03d,U+10f06c,U+10f086,U+10f0f2,U+10f10d-10f10e,U+10f187,U+10f2b5,U+10f2e9,U+10f2fe,U+10f3dd,U+10f47b-10f47c,U+10f498,U+10f49a-10f49b,U+10f49d,U+10f49f-10f4b9,U+10f4bb-10f4bf,U+10f4c2-10f4c6,U+10f4c8,U+10f4cb-10f4d2,U+10f4d4,U+10f4d6,U+10f4d8-10f4d9,U+10f4db-10f4e2}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.10.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.10.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.10.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.10.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.10.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.10.svg#fontawesome) format("svg");unicode-range:U+f471,U+f4ca,U+10f471,U+10f4ca}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.11.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.11.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.11.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.11.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.11.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.11.svg#fontawesome) format("svg");unicode-range:U+f007,U+f0c0,U+f0c2,U+f0ed-f0ee,U+f0f0,U+f1de,U+f21b,U+f234-f235,U+f381-f382,U+f3f1,U+f406,U+f4e6,U+f4fa-f501,U+f503-f509,U+10f007,U+10f0c0,U+10f0c2,U+10f0ed-10f0ee,U+10f0f0,U+10f1de,U+10f21b,U+10f234-10f235,U+10f381-10f382,U+10f3f1,U+10f406,U+10f4e6,U+10f4fa-10f501,U+10f503-10f509}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.13.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.13.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.13.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.13.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.13.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.0.13.svg#fontawesome) format("svg");unicode-range:U+f010,U+f067,U+f072,U+f0ad,U+f0d6,U+f0e8,U+f130-f131,U+f24e,U+f3c9,U+f3d1,U+f517,U+f519-f51e,U+f520-f52c,U+f52e,U+f530-f533,U+f535-f543,U+f545-f54b,U+f54d,U+f54f-f552,U+f554-f555,U+10f010,U+10f067,U+10f072,U+10f0ad,U+10f0d6,U+10f0e8,U+10f130-10f131,U+10f24e,U+10f3c9,U+10f3d1,U+10f517,U+10f519-10f51e,U+10f520-10f52c,U+10f52e,U+10f530-10f533,U+10f535-10f543,U+10f545-10f54b,U+10f54d,U+10f54f-10f552,U+10f554-10f555}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.1.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.1.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.1.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.1.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.1.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.1.0.svg#fontawesome) format("svg");unicode-range:U+f043,U+f0c4,U+f0d0,U+f125,U+f1ba,U+f1fb-f1fc,U+f207,U+f236,U+f279,U+f304-f305,U+f52d,U+f557-f558,U+f55a-f55f,U+f562-f566,U+f568,U+f56a-f56b,U+f575-f577,U+f57b,U+f586,U+f588,U+f58d-f590,U+f593-f595,U+f59d,U+f59f-f5a2,U+f5a6-f5a7,U+f5a9-f5af,U+f5b1,U+f5b6,U+f5b9-f5bd,U+f5c4-f5c5,U+f5c7,U+f5c9-f5cb,U+f5cd,U+10f043,U+10f0c4,U+10f0d0,U+10f125,U+10f1ba,U+10f1fb-10f1fc,U+10f207,U+10f236,U+10f279,U+10f304-10f305,U+10f52d,U+10f557-10f558,U+10f55a-10f55f,U+10f562-10f566,U+10f568,U+10f56a-10f56b,U+10f575-10f577,U+10f57b,U+10f586,U+10f588,U+10f58d-10f590,U+10f593-10f595,U+10f59d,U+10f59f-10f5a2,U+10f5a6-10f5a7,U+10f5a9-10f5af,U+10f5b1,U+10f5b6,U+10f5b9-10f5bd,U+10f5c4-10f5c5,U+10f5c7,U+10f5c9-10f5cb,U+10f5cd}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.1.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.1.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.1.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.1.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.1.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.1.1.svg#fontawesome) format("svg");unicode-range:U+f386,U+10f386}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.2.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.2.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.2.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.2.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.2.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.2.0.svg#fontawesome) format("svg");unicode-range:U+f018,U+f0e4,U+f109,U+f1b9,U+f1e5,U+f1f6,U+f21d,U+f276-f277,U+f3fd,U+f4d7,U+f518,U+f5d1,U+f5d4-f5da,U+f5dd,U+f5df-f5e5,U+f5e8-f5ea,U+f5ed-f5f0,U+f5f2,U+f5f4-f5f5,U+f5f8-f5f9,U+f5fb-f600,U+f603-f60e,U+f610,U+f614,U+f617-f619,U+f61c-f61e,U+f620-f621,U+f623-f62f,U+f633,U+f635-f63d,U+10f018,U+10f0e4,U+10f109,U+10f1b9,U+10f1e5,U+10f1f6,U+10f21d,U+10f276-10f277,U+10f3fd,U+10f4d7,U+10f518,U+10f5d1,U+10f5d4-10f5da,U+10f5dd,U+10f5df-10f5e5,U+10f5e8-10f5ea,U+10f5ed-10f5f0,U+10f5f2,U+10f5f4-10f5f5,U+10f5f8-10f5f9,U+10f5fb-10f600,U+10f603-10f60e,U+10f610,U+10f614,U+10f617-10f619,U+10f61c-10f61e,U+10f620-10f621,U+10f623-10f62f,U+10f633,U+10f635-10f63d}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.3.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.3.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.3.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.3.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.3.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.3.0.svg#fontawesome) format("svg");unicode-range:U+f027-f028,U+f080,U+f0a1,U+f0b1,U+f0eb,U+f200-f201,U+f2e2,U+f61a,U+f640,U+f643-f647,U+f64a-f64b,U+f64d-f653,U+f655-f656,U+f65d,U+f65f-f663,U+f665,U+f667-f669,U+f66b-f671,U+f673-f675,U+f678-f67b,U+f67d-f680,U+f683-f689,U+f68b,U+f694-f695,U+f697-f699,U+f69b-f69c,U+f69e-f69f,U+f6a1-f6a9,U+f6ac,U+10f027-10f028,U+10f080,U+10f0a1,U+10f0b1,U+10f0eb,U+10f200-10f201,U+10f2e2,U+10f61a,U+10f640,U+10f643-10f647,U+10f64a-10f64b,U+10f64d-10f653,U+10f655-10f656,U+10f65d,U+10f65f-10f663,U+10f665,U+10f667-10f669,U+10f66b-10f671,U+10f673-10f675,U+10f678-10f67b,U+10f67d-10f680,U+10f683-10f689,U+10f68b,U+10f694-10f695,U+10f697-10f699,U+10f69b-10f69c,U+10f69e-10f69f,U+10f6a1-10f6a9,U+10f6ac}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.4.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.4.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.4.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.4.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.4.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.4.0.svg#fontawesome) format("svg");unicode-range:U+f499,U+f676,U+f6ae,U+f6b0-f6b3,U+f6b5-f6bc,U+f6bf,U+f6c2,U+f6c5,U+f6c7-f6c8,U+f6cb,U+f6cd-f6d2,U+f6d5,U+f6d8-f6d9,U+f6db,U+f6de,U+f6e2-f6e3,U+f6e5-f6e7,U+f6e9-f6ec,U+f6ee,U+f6f1-f6f3,U+f6f5-f6f8,U+f6fc-f6fd,U+f6ff-f703,U+f707,U+f70a-f70b,U+f711-f713,U+f715-f71d,U+f720-f724,U+f726-f729,U+f72b,U+f72d,U+f72f,U+10f499,U+10f676,U+10f6ae,U+10f6b0-10f6b3,U+10f6b5-10f6bc,U+10f6bf,U+10f6c2,U+10f6c5,U+10f6c7-10f6c8,U+10f6cb,U+10f6cd-10f6d2,U+10f6d5,U+10f6d8-10f6d9,U+10f6db,U+10f6de,U+10f6e2-10f6e3,U+10f6e5-10f6e7,U+10f6e9-10f6ec,U+10f6ee,U+10f6f1-10f6f3,U+10f6f5-10f6f8,U+10f6fc-10f6fd,U+10f6ff-10f703,U+10f707,U+10f70a-10f70b,U+10f711-10f713,U+10f715-10f71d,U+10f720-10f724,U+10f726-10f729,U+10f72b,U+10f72d,U+10f72f}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.4.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.4.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.4.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.4.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.4.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.4.1.svg#fontawesome) format("svg");unicode-range:U+f72a,U+10f72a}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.5.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.5.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.5.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.5.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.5.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.5.0.svg#fontawesome) format("svg");unicode-range:U+f0e7,U+f185,U+f2dc,U+f6c3-f6c4,U+f72e,U+f732-f735,U+f737-f750,U+f752,U+f754-f758,U+f75a,U+f75c,U+f75e-f761,U+f763-f76e,U+f771-f776,U+10f0e7,U+10f185,U+10f2dc,U+10f6c3-10f6c4,U+10f72e,U+10f732-10f735,U+10f737-10f750,U+10f752,U+10f754-10f758,U+10f75a,U+10f75c,U+10f75e-10f761,U+10f763-10f76e,U+10f771-10f776}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.6.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.6.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.6.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.6.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.6.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.6.0.svg#fontawesome) format("svg");unicode-range:U+f06b,U+f5b7,U+f77d,U+f77f,U+f781-f782,U+f788,U+f78a-f78c,U+f78e-f78f,U+f792-f796,U+f79a-f7a1,U+f7a3-f7a4,U+f7a7-f7a8,U+f7aa,U+f7ac-f7ae,U+f7b4-f7b6,U+f7b8,U+f7bd-f7be,U+f7c1-f7c3,U+f7c5,U+f7c7-f7d2,U+f7d4,U+f7d7-f7d8,U+f7da-f7dc,U+f7de,U+f7e2,U+10f06b,U+10f5b7,U+10f77d,U+10f77f,U+10f781-10f782,U+10f788,U+10f78a-10f78c,U+10f78e-10f78f,U+10f792-10f796,U+10f79a-10f7a1,U+10f7a3-10f7a4,U+10f7a7-10f7a8,U+10f7aa,U+10f7ac-10f7ae,U+10f7b4-10f7b6,U+10f7b8,U+10f7bd-10f7be,U+10f7c1-10f7c3,U+10f7c5,U+10f7c7-10f7d2,U+10f7d4,U+10f7d7-10f7d8,U+10f7da-10f7dc,U+10f7de,U+10f7e2}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.6.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.6.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.6.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.6.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.6.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.6.1.svg#fontawesome) format("svg");unicode-range:U+f071,U+10f071}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.6.3.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.6.3.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.6.3.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.6.3.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.6.3.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.6.3.svg#fontawesome) format("svg");unicode-range:U+f7e4,U+10f7e4}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.7.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.7.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.7.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.7.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.7.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.7.0.svg#fontawesome) format("svg");unicode-range:U+f00a,U+f015,U+f06e,U+f070,U+f1e4,U+f2a0,U+f377,U+f470,U+f49c,U+f49e,U+f4c9,U+f6d6-f6d7,U+f705,U+f725,U+f77e,U+f780,U+f7e5-f7e7,U+f7e9-f7f0,U+f7f2-f7fc,U+f7fe,U+f800-f802,U+f804-f805,U+f807-f80f,U+f811-f812,U+f814-f818,U+f81b,U+f81e-f823,U+f825-f827,U+f82c-f82e,U+f830-f833,U+10f00a,U+10f015,U+10f06e,U+10f070,U+10f1e4,U+10f2a0,U+10f377,U+10f470,U+10f49c,U+10f49e,U+10f4c9,U+10f6d6-10f6d7,U+10f705,U+10f725,U+10f77e,U+10f780,U+10f7e5-10f7e7,U+10f7e9-10f7f0,U+10f7f2-10f7fc,U+10f7fe,U+10f800-10f802,U+10f804-10f805,U+10f807-10f80f,U+10f811-10f812,U+10f814-10f818,U+10f81b,U+10f81e-10f823,U+10f825-10f827,U+10f82c-10f82e,U+10f830-10f833}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.7.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.7.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.7.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.7.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.7.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.7.1.svg#fontawesome) format("svg");unicode-range:U+f7f1,U+10f7f1}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.8.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.8.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.8.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.8.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.8.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.8.0.svg#fontawesome) format("svg");unicode-range:U+f01e,U+f021,U+f026,U+f076,U+f12d,U+f31e,U+f356,U+f45f,U+f5b0,U+f83e,U+10f01e,U+10f021,U+10f026,U+10f076,U+10f12d,U+10f31e,U+10f356,U+10f45f,U+10f5b0,U+10f83e}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.8.2.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.8.2.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.8.2.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.8.2.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.8.2.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.8.2.svg#fontawesome) format("svg");unicode-range:U+f560,U+10f560}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.9.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.9.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.9.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.9.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.9.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.9.0.svg#fontawesome) format("svg");unicode-range:U+f036-f03c,U+f0ae,U+f0ca-f0cd,U+f15d-f15e,U+f160-f163,U+f1dd,U+f313-f315,U+f34e,U+f439-f448,U+f502,U+f677,U+f843-f855,U+f858-f85e,U+f860-f862,U+f864,U+f866-f878,U+f87a,U+f87c-f87d,U+f880-f892,U+f897-f89b,U+10f036-10f03c,U+10f0ae,U+10f0ca-10f0cd,U+10f15d-10f15e,U+10f160-10f163,U+10f1dd,U+10f313-10f315,U+10f34e,U+10f439-10f448,U+10f502,U+10f677,U+10f843-10f855,U+10f858-10f85e,U+10f860-10f862,U+10f864,U+10f866-10f878,U+10f87a,U+10f87c-10f87d,U+10f880-10f892,U+10f897-10f89b}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.10.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.10.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.10.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.10.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.10.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.10.1.svg#fontawesome) format("svg");unicode-range:U+f000,U+f012,U+f029,U+f03e,U+f06d,U+f075,U+f07b,U+f083-f084,U+f0a0,U+f11e,U+f140,U+f19d,U+f20a,U+f247-f248,U+f251-f254,U+f25d,U+f275,U+f27a,U+f2c2,U+f2d1,U+f302,U+f310-f311,U+f34d,U+f3a5,U+f435,U+f454,U+f456,U+f476,U+f47f-f480,U+f52f,U+f534,U+f561,U+f578,U+f591,U+f5db,U+f5e7,U+f5f6,U+f611,U+f613,U+f654,U+f681-f682,U+f68c-f693,U+f6be,U+f6da,U+f6e4,U+f6ed,U+f6ef-f6f0,U+f6f4,U+f6fa-f6fb,U+f6fe,U+f72c,U+f751,U+f759,U+f75b,U+f779,U+f77c,U+f786-f787,U+f7ab,U+f7b2,U+f7b7,U+f7e8,U+f813,U+f85f,U+f863,U+f87b,U+f89c-f89d,U+10f000,U+10f012,U+10f029,U+10f03e,U+10f06d,U+10f075,U+10f07b,U+10f083-10f084,U+10f0a0,U+10f11e,U+10f140,U+10f19d,U+10f20a,U+10f247-10f248,U+10f251-10f254,U+10f25d,U+10f275,U+10f27a,U+10f2c2,U+10f2d1,U+10f302,U+10f310-10f311,U+10f34d,U+10f3a5,U+10f435,U+10f454,U+10f456,U+10f476,U+10f47f-10f480,U+10f52f,U+10f534,U+10f561,U+10f578,U+10f591,U+10f5db,U+10f5e7,U+10f5f6,U+10f611,U+10f613,U+10f654,U+10f681-10f682,U+10f68c-10f693,U+10f6be,U+10f6da,U+10f6e4,U+10f6ed,U+10f6ef-10f6f0,U+10f6f4,U+10f6fa-10f6fb,U+10f6fe,U+10f72c,U+10f751,U+10f759,U+10f75b,U+10f779,U+10f77c,U+10f786-10f787,U+10f7ab,U+10f7b2,U+10f7b7,U+10f7e8,U+10f813,U+10f85f,U+10f863,U+10f87b,U+10f89c-10f89d}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.10.2.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.10.2.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.10.2.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.10.2.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.10.2.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.10.2.svg#fontawesome) format("svg");unicode-range:U+f004-f005,U+f02c,U+f02e,U+f031-f035,U+f04b-f04d,U+f056,U+f073,U+f08d,U+f095,U+f0a3,U+f0c5,U+f0c7-f0c8,U+f0dc-f0de,U+f0e0,U+f110-f111,U+f129-f12c,U+f132-f133,U+f144-f145,U+f15b-f15c,U+f164-f165,U+f193,U+f197,U+f1ab,U+f1c1-f1c9,U+f1ce,U+f1dc,U+f1f8-f1f9,U+f219,U+f249,U+f271-f274,U+f29a,U+f29e,U+f2a7,U+f2b6,U+f2e1,U+f2e3-f2e5,U+f2ec-f2ed,U+f2f2,U+f2f4,U+f2fa-f2fc,U+f306,U+f312,U+f316,U+f31a,U+f31c,U+f327,U+f333-f335,U+f3f4,U+f3ff,U+f45c,U+f460,U+f462,U+f477-f478,U+f497,U+f4ba,U+f4d3,U+f54c,U+f553,U+f559,U+f56c-f574,U+f5bf,U+f5c1,U+f5f3,U+f630-f632,U+f634,U+f63e,U+f641,U+f659-f65c,U+f696,U+f6a0,U+f6b4,U+f6bd,U+f6dd,U+f706,U+f708-f709,U+f70d-f710,U+f714,U+f71e-f71f,U+f736,U+f76f-f770,U+f777,U+f783-f784,U+f7a9,U+f7c4,U+f7d5,U+f7d9,U+f7dd,U+f7fd,U+f81c-f81d,U+f824,U+f828-f82a,U+f856-f857,U+f865,U+f879,U+f87e,U+f893-f896,U+10f004-10f005,U+10f02c,U+10f02e,U+10f031-10f035,U+10f04b-10f04d,U+10f056,U+10f073,U+10f08d,U+10f095,U+10f0a3,U+10f0c5,U+10f0c7-10f0c8,U+10f0dc-10f0de,U+10f0e0,U+10f110-10f111,U+10f129-10f12c,U+10f132-10f133,U+10f144-10f145,U+10f15b-10f15c,U+10f164-10f165,U+10f193,U+10f197,U+10f1ab,U+10f1c1-10f1c9,U+10f1ce,U+10f1dc,U+10f1f8-10f1f9,U+10f219,U+10f249,U+10f271-10f274,U+10f29a,U+10f29e,U+10f2a7,U+10f2b6,U+10f2e1,U+10f2e3-10f2e5,U+10f2ec-10f2ed,U+10f2f2,U+10f2f4,U+10f2fa-10f2fc,U+10f306,U+10f312,U+10f316,U+10f31a,U+10f31c,U+10f327,U+10f333-10f335,U+10f3f4,U+10f3ff,U+10f45c,U+10f460,U+10f462,U+10f477-10f478,U+10f497,U+10f4ba,U+10f4d3,U+10f54c,U+10f553,U+10f559,U+10f56c-10f574,U+10f5bf,U+10f5c1,U+10f5f3,U+10f630-10f632,U+10f634,U+10f63e,U+10f641,U+10f659-10f65c,U+10f696,U+10f6a0,U+10f6b4,U+10f6bd,U+10f6dd,U+10f706,U+10f708-10f709,U+10f70d-10f710,U+10f714,U+10f71e-10f71f,U+10f736,U+10f76f-10f770,U+10f777,U+10f783-10f784,U+10f7a9,U+10f7c4,U+10f7d5,U+10f7d9,U+10f7dd,U+10f7fd,U+10f81c-10f81d,U+10f824,U+10f828-10f82a,U+10f856-10f857,U+10f865,U+10f879,U+10f87e,U+10f893-10f896}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.11.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.11.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.11.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.11.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.11.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.11.0.svg#fontawesome) format("svg");unicode-range:U+f001,U+f02f,U+f042,U+f08e,U+f091,U+f0f3,U+f104-f105,U+f11b,U+f13d,U+f149,U+f1ac,U+f1ec,U+f223,U+f225,U+f22a-f22c,U+f24d,U+f26c,U+f29d,U+f2eb,U+f2ee,U+f2f3,U+f300,U+f307,U+f323-f324,U+f338,U+f33d,U+f35d,U+f48a,U+f4c0,U+f569,U+f5dc,U+f5eb,U+f601,U+f61b,U+f64c,U+f664,U+f66a,U+f68a,U+f6c0-f6c1,U+f6df-f6e1,U+f6e8,U+f6f9,U+f70c,U+f7a6,U+f81a,U+f89f-f8a5,U+f8a7-f8b6,U+f8b8-f8b9,U+f8bb-f8c9,U+f8cb-f8d1,U+f8d3,U+f8d5-f8dd,U+f8df-f8e0,U+f8e2-f8e7,U+f8e9-f8ed,U+f8ef-f8f2,U+10f001,U+10f02f,U+10f042,U+10f08e,U+10f091,U+10f0f3,U+10f104-10f105,U+10f11b,U+10f13d,U+10f149,U+10f1ac,U+10f1ec,U+10f223,U+10f225,U+10f22a-10f22c,U+10f24d,U+10f26c,U+10f29d,U+10f2eb,U+10f2ee,U+10f2f3,U+10f300,U+10f307,U+10f323-10f324,U+10f338,U+10f33d,U+10f35d,U+10f48a,U+10f4c0,U+10f569,U+10f5dc,U+10f5eb,U+10f601,U+10f61b,U+10f64c,U+10f664,U+10f66a,U+10f68a,U+10f6c0-10f6c1,U+10f6df-10f6e1,U+10f6e8,U+10f6f9,U+10f70c,U+10f7a6,U+10f81a,U+10f89f-10f8a5,U+10f8a7-10f8b6,U+10f8b8-10f8b9,U+10f8bb-10f8c9,U+10f8cb-10f8d1,U+10f8d3,U+10f8d5-10f8dd,U+10f8df-10f8e0,U+10f8e2-10f8e7,U+10f8e9-10f8ed,U+10f8ef-10f8f2}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.11.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.11.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.11.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.11.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.11.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.11.1.svg#fontawesome) format("svg");unicode-range:U+f00d,U+f048,U+f051,U+f0ac,U+f0b0,U+f118-f11a,U+f148,U+f14e,U+f155,U+f186,U+f19c,U+f1eb,U+f21a,U+f221,U+f22d,U+f2bd,U+f2e8,U+f2f8,U+f354,U+f357,U+f433-f434,U+f436,U+f44e,U+f45e,U+f4c7,U+f4da,U+f4e3,U+f51f,U+f54e,U+f556,U+f567,U+f579-f57a,U+f57c-f585,U+f587,U+f589-f58a,U+f58c,U+f596-f59c,U+f5a4-f5a5,U+f5b3-f5b4,U+f5b8,U+f5c0,U+f5c2-f5c3,U+f5c8,U+f5ce,U+f5de,U+f5e6,U+f5ec,U+f602,U+f615-f616,U+f622,U+f648-f649,U+f67c,U+f69a,U+f6aa-f6ab,U+f6ad,U+f7a2,U+f7a5,U+f7b9-f7ba,U+f7ff,U+f803,U+f806,U+f810,U+f819,U+f82b,U+f87f,U+f8de,U+f8ee,U+10f00d,U+10f048,U+10f051,U+10f0ac,U+10f0b0,U+10f118-10f11a,U+10f148,U+10f14e,U+10f155,U+10f186,U+10f19c,U+10f1eb,U+10f21a,U+10f221,U+10f22d,U+10f2bd,U+10f2e8,U+10f2f8,U+10f354,U+10f357,U+10f433-10f434,U+10f436,U+10f44e,U+10f45e,U+10f4c7,U+10f4da,U+10f4e3,U+10f51f,U+10f54e,U+10f556,U+10f567,U+10f579-10f57a,U+10f57c-10f585,U+10f587,U+10f589-10f58a,U+10f58c,U+10f596-10f59c,U+10f5a4-10f5a5,U+10f5b3-10f5b4,U+10f5b8,U+10f5c0,U+10f5c2-10f5c3,U+10f5c8,U+10f5ce,U+10f5de,U+10f5e6,U+10f5ec,U+10f602,U+10f615-10f616,U+10f622,U+10f648-10f649,U+10f67c,U+10f69a,U+10f6aa-10f6ab,U+10f6ad,U+10f7a2,U+10f7a5,U+10f7b9-10f7ba,U+10f7ff,U+10f803,U+10f806,U+10f810,U+10f819,U+10f82b,U+10f87f,U+10f8de,U+10f8ee}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.11.2.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.11.2.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.11.2.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.11.2.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.11.2.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.11.2.svg#fontawesome) format("svg");unicode-range:U+f488,U+f8b7,U+f8f3,U+10f488,U+10f8b7,U+10f8f3}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.12.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.12.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.12.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.12.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.12.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.12.0.svg#fontawesome) format("svg");unicode-range:U+f135,U+f1e6,U+f259,U+f2cc-f2cd,U+f422,U+f424,U+f515-f516,U+f544,U+f58b,U+f5d2-f5d3,U+f61f,U+f657-f658,U+f666,U+f672,U+f6d3-f6d4,U+f753,U+f762,U+f7bf-f7c0,U+f82f,U+f8ba,U+f8d4,U+f8f4-f8ff,U+10f135,U+10f1e6,U+10f259,U+10f2cc-10f2cd,U+10f422,U+10f424,U+10f515-10f516,U+10f544,U+10f58b,U+10f5d2-10f5d3,U+10f61f,U+10f657-10f658,U+10f666,U+10f672,U+10f6d3-10f6d4,U+10f753,U+10f762,U+10f7bf-10f7c0,U+10f82f,U+10f8ba,U+10f8d4,U+10f8f4-10f8ff}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.12.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.12.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.12.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.12.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.12.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.12.1.svg#fontawesome) format("svg");unicode-range:U+f017,U+f317-f319,U+f65e,U+f6c6,U+10f017,U+10f317-10f319,U+10f65e,U+10f6c6}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.13.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.13.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.13.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.13.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.13.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.13.0.svg#fontawesome) format("svg");unicode-range:U+f4c1,U+10f4c1}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.14.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.14.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.14.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.14.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.14.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.14.0.svg#fontawesome) format("svg");unicode-range:U+e000-e006,U+e008-e012,U+e014-e019,U+e01b-e01d,U+e01f-e048,U+e04a-e051,U+e053-e054,U+e058-e076,U+10e000-10e006,U+10e008-10e012,U+10e014-10e019,U+10e01b-10e01d,U+10e01f-10e048,U+10e04a-10e051,U+10e053-10e054,U+10e058-10e076}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.15.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.15.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.15.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.15.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.15.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.15.1.svg#fontawesome) format("svg");unicode-range:U+e085-e086,U+10e085-10e086}@font-face{font-family:"Font Awesome 5 Duotone";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.15.3.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.15.3.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.15.3.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.15.3.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.15.3.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-duotone-900-5.15.3.svg#fontawesome) format("svg");unicode-range:U+f5d0,U+10f5d0}.fad{position:relative;font-family:"Font Awesome 5 Duotone";font-weight:900}.fad:before{position:absolute;color:var(--fa-primary-color,inherit);opacity:1;opacity:var(--fa-primary-opacity,1)}.fad:after{color:var(--fa-secondary-color,inherit)}.fa-swap-opacity .fad:before,.fad.fa-swap-opacity:before,.fad:after{opacity:.4;opacity:var(--fa-secondary-opacity,.4)}.fa-swap-opacity .fad:after,.fad.fa-swap-opacity:after{opacity:1;opacity:var(--fa-primary-opacity,1)}.fad.fa-inverse{color:#fff}.fad.fa-stack-1x,.fad.fa-stack-2x{position:absolute}.fad.fa-fw:before,.fad.fa-stack-1x:before,.fad.fa-stack-2x:before{left:50%;-webkit-transform:translateX(-50%);transform:translateX(-50%)}.fad.fa-abacus:after{content:"\10f640"}.fad.fa-acorn:after{content:"\10f6ae"}.fad.fa-ad:after{content:"\10f641"}.fad.fa-address-book:after{content:"\10f2b9"}.fad.fa-address-card:after{content:"\10f2bb"}.fad.fa-adjust:after{content:"\10f042"}.fad.fa-air-conditioner:after{content:"\10f8f4"}.fad.fa-air-freshener:after{content:"\10f5d0"}.fad.fa-alarm-clock:after{content:"\10f34e"}.fad.fa-alarm-exclamation:after{content:"\10f843"}.fad.fa-alarm-plus:after{content:"\10f844"}.fad.fa-alarm-snooze:after{content:"\10f845"}.fad.fa-album:after{content:"\10f89f"}.fad.fa-album-collection:after{content:"\10f8a0"}.fad.fa-alicorn:after{content:"\10f6b0"}.fad.fa-alien:after{content:"\10f8f5"}.fad.fa-alien-monster:after{content:"\10f8f6"}.fad.fa-align-center:after{content:"\10f037"}.fad.fa-align-justify:after{content:"\10f039"}.fad.fa-align-left:after{content:"\10f036"}.fad.fa-align-right:after{content:"\10f038"}.fad.fa-align-slash:after{content:"\10f846"}.fad.fa-allergies:after{content:"\10f461"}.fad.fa-ambulance:after{content:"\10f0f9"}.fad.fa-american-sign-language-interpreting:after{content:"\10f2a3"}.fad.fa-amp-guitar:after{content:"\10f8a1"}.fad.fa-analytics:after{content:"\10f643"}.fad.fa-anchor:after{content:"\10f13d"}.fad.fa-angel:after{content:"\10f779"}.fad.fa-angle-double-down:after{content:"\10f103"}.fad.fa-angle-double-left:after{content:"\10f100"}.fad.fa-angle-double-right:after{content:"\10f101"}.fad.fa-angle-double-up:after{content:"\10f102"}.fad.fa-angle-down:after{content:"\10f107"}.fad.fa-angle-left:after{content:"\10f104"}.fad.fa-angle-right:after{content:"\10f105"}.fad.fa-angle-up:after{content:"\10f106"}.fad.fa-angry:after{content:"\10f556"}.fad.fa-ankh:after{content:"\10f644"}.fad.fa-apple-alt:after{content:"\10f5d1"}.fad.fa-apple-crate:after{content:"\10f6b1"}.fad.fa-archive:after{content:"\10f187"}.fad.fa-archway:after{content:"\10f557"}.fad.fa-arrow-alt-circle-down:after{content:"\10f358"}.fad.fa-arrow-alt-circle-left:after{content:"\10f359"}.fad.fa-arrow-alt-circle-right:after{content:"\10f35a"}.fad.fa-arrow-alt-circle-up:after{content:"\10f35b"}.fad.fa-arrow-alt-down:after{content:"\10f354"}.fad.fa-arrow-alt-from-bottom:after{content:"\10f346"}.fad.fa-arrow-alt-from-left:after{content:"\10f347"}.fad.fa-arrow-alt-from-right:after{content:"\10f348"}.fad.fa-arrow-alt-from-top:after{content:"\10f349"}.fad.fa-arrow-alt-left:after{content:"\10f355"}.fad.fa-arrow-alt-right:after{content:"\10f356"}.fad.fa-arrow-alt-square-down:after{content:"\10f350"}.fad.fa-arrow-alt-square-left:after{content:"\10f351"}.fad.fa-arrow-alt-square-right:after{content:"\10f352"}.fad.fa-arrow-alt-square-up:after{content:"\10f353"}.fad.fa-arrow-alt-to-bottom:after{content:"\10f34a"}.fad.fa-arrow-alt-to-left:after{content:"\10f34b"}.fad.fa-arrow-alt-to-right:after{content:"\10f34c"}.fad.fa-arrow-alt-to-top:after{content:"\10f34d"}.fad.fa-arrow-alt-up:after{content:"\10f357"}.fad.fa-arrow-circle-down:after{content:"\10f0ab"}.fad.fa-arrow-circle-left:after{content:"\10f0a8"}.fad.fa-arrow-circle-right:after{content:"\10f0a9"}.fad.fa-arrow-circle-up:after{content:"\10f0aa"}.fad.fa-arrow-down:after{content:"\10f063"}.fad.fa-arrow-from-bottom:after{content:"\10f342"}.fad.fa-arrow-from-left:after{content:"\10f343"}.fad.fa-arrow-from-right:after{content:"\10f344"}.fad.fa-arrow-from-top:after{content:"\10f345"}.fad.fa-arrow-left:after{content:"\10f060"}.fad.fa-arrow-right:after{content:"\10f061"}.fad.fa-arrow-square-down:after{content:"\10f339"}.fad.fa-arrow-square-left:after{content:"\10f33a"}.fad.fa-arrow-square-right:after{content:"\10f33b"}.fad.fa-arrow-square-up:after{content:"\10f33c"}.fad.fa-arrow-to-bottom:after{content:"\10f33d"}.fad.fa-arrow-to-left:after{content:"\10f33e"}.fad.fa-arrow-to-right:after{content:"\10f340"}.fad.fa-arrow-to-top:after{content:"\10f341"}.fad.fa-arrow-up:after{content:"\10f062"}.fad.fa-arrows:after{content:"\10f047"}.fad.fa-arrows-alt:after{content:"\10f0b2"}.fad.fa-arrows-alt-h:after{content:"\10f337"}.fad.fa-arrows-alt-v:after{content:"\10f338"}.fad.fa-arrows-h:after{content:"\10f07e"}.fad.fa-arrows-v:after{content:"\10f07d"}.fad.fa-assistive-listening-systems:after{content:"\10f2a2"}.fad.fa-asterisk:after{content:"\10f069"}.fad.fa-at:after{content:"\10f1fa"}.fad.fa-atlas:after{content:"\10f558"}.fad.fa-atom:after{content:"\10f5d2"}.fad.fa-atom-alt:after{content:"\10f5d3"}.fad.fa-audio-description:after{content:"\10f29e"}.fad.fa-award:after{content:"\10f559"}.fad.fa-axe:after{content:"\10f6b2"}.fad.fa-axe-battle:after{content:"\10f6b3"}.fad.fa-baby:after{content:"\10f77c"}.fad.fa-baby-carriage:after{content:"\10f77d"}.fad.fa-backpack:after{content:"\10f5d4"}.fad.fa-backspace:after{content:"\10f55a"}.fad.fa-backward:after{content:"\10f04a"}.fad.fa-bacon:after{content:"\10f7e5"}.fad.fa-bacteria:after{content:"\10e059"}.fad.fa-bacterium:after{content:"\10e05a"}.fad.fa-badge:after{content:"\10f335"}.fad.fa-badge-check:after{content:"\10f336"}.fad.fa-badge-dollar:after{content:"\10f645"}.fad.fa-badge-percent:after{content:"\10f646"}.fad.fa-badge-sheriff:after{content:"\10f8a2"}.fad.fa-badger-honey:after{content:"\10f6b4"}.fad.fa-bags-shopping:after{content:"\10f847"}.fad.fa-bahai:after{content:"\10f666"}.fad.fa-balance-scale:after{content:"\10f24e"}.fad.fa-balance-scale-left:after{content:"\10f515"}.fad.fa-balance-scale-right:after{content:"\10f516"}.fad.fa-ball-pile:after{content:"\10f77e"}.fad.fa-ballot:after{content:"\10f732"}.fad.fa-ballot-check:after{content:"\10f733"}.fad.fa-ban:after{content:"\10f05e"}.fad.fa-band-aid:after{content:"\10f462"}.fad.fa-banjo:after{content:"\10f8a3"}.fad.fa-barcode:after{content:"\10f02a"}.fad.fa-barcode-alt:after{content:"\10f463"}.fad.fa-barcode-read:after{content:"\10f464"}.fad.fa-barcode-scan:after{content:"\10f465"}.fad.fa-bars:after{content:"\10f0c9"}.fad.fa-baseball:after{content:"\10f432"}.fad.fa-baseball-ball:after{content:"\10f433"}.fad.fa-basketball-ball:after{content:"\10f434"}.fad.fa-basketball-hoop:after{content:"\10f435"}.fad.fa-bat:after{content:"\10f6b5"}.fad.fa-bath:after{content:"\10f2cd"}.fad.fa-battery-bolt:after{content:"\10f376"}.fad.fa-battery-empty:after{content:"\10f244"}.fad.fa-battery-full:after{content:"\10f240"}.fad.fa-battery-half:after{content:"\10f242"}.fad.fa-battery-quarter:after{content:"\10f243"}.fad.fa-battery-slash:after{content:"\10f377"}.fad.fa-battery-three-quarters:after{content:"\10f241"}.fad.fa-bed:after{content:"\10f236"}.fad.fa-bed-alt:after{content:"\10f8f7"}.fad.fa-bed-bunk:after{content:"\10f8f8"}.fad.fa-bed-empty:after{content:"\10f8f9"}.fad.fa-beer:after{content:"\10f0fc"}.fad.fa-bell:after{content:"\10f0f3"}.fad.fa-bell-exclamation:after{content:"\10f848"}.fad.fa-bell-on:after{content:"\10f8fa"}.fad.fa-bell-plus:after{content:"\10f849"}.fad.fa-bell-school:after{content:"\10f5d5"}.fad.fa-bell-school-slash:after{content:"\10f5d6"}.fad.fa-bell-slash:after{content:"\10f1f6"}.fad.fa-bells:after{content:"\10f77f"}.fad.fa-betamax:after{content:"\10f8a4"}.fad.fa-bezier-curve:after{content:"\10f55b"}.fad.fa-bible:after{content:"\10f647"}.fad.fa-bicycle:after{content:"\10f206"}.fad.fa-biking:after{content:"\10f84a"}.fad.fa-biking-mountain:after{content:"\10f84b"}.fad.fa-binoculars:after{content:"\10f1e5"}.fad.fa-biohazard:after{content:"\10f780"}.fad.fa-birthday-cake:after{content:"\10f1fd"}.fad.fa-blanket:after{content:"\10f498"}.fad.fa-blender:after{content:"\10f517"}.fad.fa-blender-phone:after{content:"\10f6b6"}.fad.fa-blind:after{content:"\10f29d"}.fad.fa-blinds:after{content:"\10f8fb"}.fad.fa-blinds-open:after{content:"\10f8fc"}.fad.fa-blinds-raised:after{content:"\10f8fd"}.fad.fa-blog:after{content:"\10f781"}.fad.fa-bold:after{content:"\10f032"}.fad.fa-bolt:after{content:"\10f0e7"}.fad.fa-bomb:after{content:"\10f1e2"}.fad.fa-bone:after{content:"\10f5d7"}.fad.fa-bone-break:after{content:"\10f5d8"}.fad.fa-bong:after{content:"\10f55c"}.fad.fa-book:after{content:"\10f02d"}.fad.fa-book-alt:after{content:"\10f5d9"}.fad.fa-book-dead:after{content:"\10f6b7"}.fad.fa-book-heart:after{content:"\10f499"}.fad.fa-book-medical:after{content:"\10f7e6"}.fad.fa-book-open:after{content:"\10f518"}.fad.fa-book-reader:after{content:"\10f5da"}.fad.fa-book-spells:after{content:"\10f6b8"}.fad.fa-book-user:after{content:"\10f7e7"}.fad.fa-bookmark:after{content:"\10f02e"}.fad.fa-books:after{content:"\10f5db"}.fad.fa-books-medical:after{content:"\10f7e8"}.fad.fa-boombox:after{content:"\10f8a5"}.fad.fa-boot:after{content:"\10f782"}.fad.fa-booth-curtain:after{content:"\10f734"}.fad.fa-border-all:after{content:"\10f84c"}.fad.fa-border-bottom:after{content:"\10f84d"}.fad.fa-border-center-h:after{content:"\10f89c"}.fad.fa-border-center-v:after{content:"\10f89d"}.fad.fa-border-inner:after{content:"\10f84e"}.fad.fa-border-left:after{content:"\10f84f"}.fad.fa-border-none:after{content:"\10f850"}.fad.fa-border-outer:after{content:"\10f851"}.fad.fa-border-right:after{content:"\10f852"}.fad.fa-border-style:after{content:"\10f853"}.fad.fa-border-style-alt:after{content:"\10f854"}.fad.fa-border-top:after{content:"\10f855"}.fad.fa-bow-arrow:after{content:"\10f6b9"}.fad.fa-bowling-ball:after{content:"\10f436"}.fad.fa-bowling-pins:after{content:"\10f437"}.fad.fa-box:after{content:"\10f466"}.fad.fa-box-alt:after{content:"\10f49a"}.fad.fa-box-ballot:after{content:"\10f735"}.fad.fa-box-check:after{content:"\10f467"}.fad.fa-box-fragile:after{content:"\10f49b"}.fad.fa-box-full:after{content:"\10f49c"}.fad.fa-box-heart:after{content:"\10f49d"}.fad.fa-box-open:after{content:"\10f49e"}.fad.fa-box-tissue:after{content:"\10e05b"}.fad.fa-box-up:after{content:"\10f49f"}.fad.fa-box-usd:after{content:"\10f4a0"}.fad.fa-boxes:after{content:"\10f468"}.fad.fa-boxes-alt:after{content:"\10f4a1"}.fad.fa-boxing-glove:after{content:"\10f438"}.fad.fa-brackets:after{content:"\10f7e9"}.fad.fa-brackets-curly:after{content:"\10f7ea"}.fad.fa-braille:after{content:"\10f2a1"}.fad.fa-brain:after{content:"\10f5dc"}.fad.fa-bread-loaf:after{content:"\10f7eb"}.fad.fa-bread-slice:after{content:"\10f7ec"}.fad.fa-briefcase:after{content:"\10f0b1"}.fad.fa-briefcase-medical:after{content:"\10f469"}.fad.fa-bring-forward:after{content:"\10f856"}.fad.fa-bring-front:after{content:"\10f857"}.fad.fa-broadcast-tower:after{content:"\10f519"}.fad.fa-broom:after{content:"\10f51a"}.fad.fa-browser:after{content:"\10f37e"}.fad.fa-brush:after{content:"\10f55d"}.fad.fa-bug:after{content:"\10f188"}.fad.fa-building:after{content:"\10f1ad"}.fad.fa-bullhorn:after{content:"\10f0a1"}.fad.fa-bullseye:after{content:"\10f140"}.fad.fa-bullseye-arrow:after{content:"\10f648"}.fad.fa-bullseye-pointer:after{content:"\10f649"}.fad.fa-burger-soda:after{content:"\10f858"}.fad.fa-burn:after{content:"\10f46a"}.fad.fa-burrito:after{content:"\10f7ed"}.fad.fa-bus:after{content:"\10f207"}.fad.fa-bus-alt:after{content:"\10f55e"}.fad.fa-bus-school:after{content:"\10f5dd"}.fad.fa-business-time:after{content:"\10f64a"}.fad.fa-cabinet-filing:after{content:"\10f64b"}.fad.fa-cactus:after{content:"\10f8a7"}.fad.fa-calculator:after{content:"\10f1ec"}.fad.fa-calculator-alt:after{content:"\10f64c"}.fad.fa-calendar:after{content:"\10f133"}.fad.fa-calendar-alt:after{content:"\10f073"}.fad.fa-calendar-check:after{content:"\10f274"}.fad.fa-calendar-day:after{content:"\10f783"}.fad.fa-calendar-edit:after{content:"\10f333"}.fad.fa-calendar-exclamation:after{content:"\10f334"}.fad.fa-calendar-minus:after{content:"\10f272"}.fad.fa-calendar-plus:after{content:"\10f271"}.fad.fa-calendar-star:after{content:"\10f736"}.fad.fa-calendar-times:after{content:"\10f273"}.fad.fa-calendar-week:after{content:"\10f784"}.fad.fa-camcorder:after{content:"\10f8a8"}.fad.fa-camera:after{content:"\10f030"}.fad.fa-camera-alt:after{content:"\10f332"}.fad.fa-camera-home:after{content:"\10f8fe"}.fad.fa-camera-movie:after{content:"\10f8a9"}.fad.fa-camera-polaroid:after{content:"\10f8aa"}.fad.fa-camera-retro:after{content:"\10f083"}.fad.fa-campfire:after{content:"\10f6ba"}.fad.fa-campground:after{content:"\10f6bb"}.fad.fa-candle-holder:after{content:"\10f6bc"}.fad.fa-candy-cane:after{content:"\10f786"}.fad.fa-candy-corn:after{content:"\10f6bd"}.fad.fa-cannabis:after{content:"\10f55f"}.fad.fa-capsules:after{content:"\10f46b"}.fad.fa-car:after{content:"\10f1b9"}.fad.fa-car-alt:after{content:"\10f5de"}.fad.fa-car-battery:after{content:"\10f5df"}.fad.fa-car-building:after{content:"\10f859"}.fad.fa-car-bump:after{content:"\10f5e0"}.fad.fa-car-bus:after{content:"\10f85a"}.fad.fa-car-crash:after{content:"\10f5e1"}.fad.fa-car-garage:after{content:"\10f5e2"}.fad.fa-car-mechanic:after{content:"\10f5e3"}.fad.fa-car-side:after{content:"\10f5e4"}.fad.fa-car-tilt:after{content:"\10f5e5"}.fad.fa-car-wash:after{content:"\10f5e6"}.fad.fa-caravan:after{content:"\10f8ff"}.fad.fa-caravan-alt:after{content:"\10e000"}.fad.fa-caret-circle-down:after{content:"\10f32d"}.fad.fa-caret-circle-left:after{content:"\10f32e"}.fad.fa-caret-circle-right:after{content:"\10f330"}.fad.fa-caret-circle-up:after{content:"\10f331"}.fad.fa-caret-down:after{content:"\10f0d7"}.fad.fa-caret-left:after{content:"\10f0d9"}.fad.fa-caret-right:after{content:"\10f0da"}.fad.fa-caret-square-down:after{content:"\10f150"}.fad.fa-caret-square-left:after{content:"\10f191"}.fad.fa-caret-square-right:after{content:"\10f152"}.fad.fa-caret-square-up:after{content:"\10f151"}.fad.fa-caret-up:after{content:"\10f0d8"}.fad.fa-carrot:after{content:"\10f787"}.fad.fa-cars:after{content:"\10f85b"}.fad.fa-cart-arrow-down:after{content:"\10f218"}.fad.fa-cart-plus:after{content:"\10f217"}.fad.fa-cash-register:after{content:"\10f788"}.fad.fa-cassette-tape:after{content:"\10f8ab"}.fad.fa-cat:after{content:"\10f6be"}.fad.fa-cat-space:after{content:"\10e001"}.fad.fa-cauldron:after{content:"\10f6bf"}.fad.fa-cctv:after{content:"\10f8ac"}.fad.fa-certificate:after{content:"\10f0a3"}.fad.fa-chair:after{content:"\10f6c0"}.fad.fa-chair-office:after{content:"\10f6c1"}.fad.fa-chalkboard:after{content:"\10f51b"}.fad.fa-chalkboard-teacher:after{content:"\10f51c"}.fad.fa-charging-station:after{content:"\10f5e7"}.fad.fa-chart-area:after{content:"\10f1fe"}.fad.fa-chart-bar:after{content:"\10f080"}.fad.fa-chart-line:after{content:"\10f201"}.fad.fa-chart-line-down:after{content:"\10f64d"}.fad.fa-chart-network:after{content:"\10f78a"}.fad.fa-chart-pie:after{content:"\10f200"}.fad.fa-chart-pie-alt:after{content:"\10f64e"}.fad.fa-chart-scatter:after{content:"\10f7ee"}.fad.fa-check:after{content:"\10f00c"}.fad.fa-check-circle:after{content:"\10f058"}.fad.fa-check-double:after{content:"\10f560"}.fad.fa-check-square:after{content:"\10f14a"}.fad.fa-cheese:after{content:"\10f7ef"}.fad.fa-cheese-swiss:after{content:"\10f7f0"}.fad.fa-cheeseburger:after{content:"\10f7f1"}.fad.fa-chess:after{content:"\10f439"}.fad.fa-chess-bishop:after{content:"\10f43a"}.fad.fa-chess-bishop-alt:after{content:"\10f43b"}.fad.fa-chess-board:after{content:"\10f43c"}.fad.fa-chess-clock:after{content:"\10f43d"}.fad.fa-chess-clock-alt:after{content:"\10f43e"}.fad.fa-chess-king:after{content:"\10f43f"}.fad.fa-chess-king-alt:after{content:"\10f440"}.fad.fa-chess-knight:after{content:"\10f441"}.fad.fa-chess-knight-alt:after{content:"\10f442"}.fad.fa-chess-pawn:after{content:"\10f443"}.fad.fa-chess-pawn-alt:after{content:"\10f444"}.fad.fa-chess-queen:after{content:"\10f445"}.fad.fa-chess-queen-alt:after{content:"\10f446"}.fad.fa-chess-rook:after{content:"\10f447"}.fad.fa-chess-rook-alt:after{content:"\10f448"}.fad.fa-chevron-circle-down:after{content:"\10f13a"}.fad.fa-chevron-circle-left:after{content:"\10f137"}.fad.fa-chevron-circle-right:after{content:"\10f138"}.fad.fa-chevron-circle-up:after{content:"\10f139"}.fad.fa-chevron-double-down:after{content:"\10f322"}.fad.fa-chevron-double-left:after{content:"\10f323"}.fad.fa-chevron-double-right:after{content:"\10f324"}.fad.fa-chevron-double-up:after{content:"\10f325"}.fad.fa-chevron-down:after{content:"\10f078"}.fad.fa-chevron-left:after{content:"\10f053"}.fad.fa-chevron-right:after{content:"\10f054"}.fad.fa-chevron-square-down:after{content:"\10f329"}.fad.fa-chevron-square-left:after{content:"\10f32a"}.fad.fa-chevron-square-right:after{content:"\10f32b"}.fad.fa-chevron-square-up:after{content:"\10f32c"}.fad.fa-chevron-up:after{content:"\10f077"}.fad.fa-child:after{content:"\10f1ae"}.fad.fa-chimney:after{content:"\10f78b"}.fad.fa-church:after{content:"\10f51d"}.fad.fa-circle:after{content:"\10f111"}.fad.fa-circle-notch:after{content:"\10f1ce"}.fad.fa-city:after{content:"\10f64f"}.fad.fa-clarinet:after{content:"\10f8ad"}.fad.fa-claw-marks:after{content:"\10f6c2"}.fad.fa-clinic-medical:after{content:"\10f7f2"}.fad.fa-clipboard:after{content:"\10f328"}.fad.fa-clipboard-check:after{content:"\10f46c"}.fad.fa-clipboard-list:after{content:"\10f46d"}.fad.fa-clipboard-list-check:after{content:"\10f737"}.fad.fa-clipboard-prescription:after{content:"\10f5e8"}.fad.fa-clipboard-user:after{content:"\10f7f3"}.fad.fa-clock:after{content:"\10f017"}.fad.fa-clone:after{content:"\10f24d"}.fad.fa-closed-captioning:after{content:"\10f20a"}.fad.fa-cloud:after{content:"\10f0c2"}.fad.fa-cloud-download:after{content:"\10f0ed"}.fad.fa-cloud-download-alt:after{content:"\10f381"}.fad.fa-cloud-drizzle:after{content:"\10f738"}.fad.fa-cloud-hail:after{content:"\10f739"}.fad.fa-cloud-hail-mixed:after{content:"\10f73a"}.fad.fa-cloud-meatball:after{content:"\10f73b"}.fad.fa-cloud-moon:after{content:"\10f6c3"}.fad.fa-cloud-moon-rain:after{content:"\10f73c"}.fad.fa-cloud-music:after{content:"\10f8ae"}.fad.fa-cloud-rain:after{content:"\10f73d"}.fad.fa-cloud-rainbow:after{content:"\10f73e"}.fad.fa-cloud-showers:after{content:"\10f73f"}.fad.fa-cloud-showers-heavy:after{content:"\10f740"}.fad.fa-cloud-sleet:after{content:"\10f741"}.fad.fa-cloud-snow:after{content:"\10f742"}.fad.fa-cloud-sun:after{content:"\10f6c4"}.fad.fa-cloud-sun-rain:after{content:"\10f743"}.fad.fa-cloud-upload:after{content:"\10f0ee"}.fad.fa-cloud-upload-alt:after{content:"\10f382"}.fad.fa-clouds:after{content:"\10f744"}.fad.fa-clouds-moon:after{content:"\10f745"}.fad.fa-clouds-sun:after{content:"\10f746"}.fad.fa-club:after{content:"\10f327"}.fad.fa-cocktail:after{content:"\10f561"}.fad.fa-code:after{content:"\10f121"}.fad.fa-code-branch:after{content:"\10f126"}.fad.fa-code-commit:after{content:"\10f386"}.fad.fa-code-merge:after{content:"\10f387"}.fad.fa-coffee:after{content:"\10f0f4"}.fad.fa-coffee-pot:after{content:"\10e002"}.fad.fa-coffee-togo:after{content:"\10f6c5"}.fad.fa-coffin:after{content:"\10f6c6"}.fad.fa-coffin-cross:after{content:"\10e051"}.fad.fa-cog:after{content:"\10f013"}.fad.fa-cogs:after{content:"\10f085"}.fad.fa-coin:after{content:"\10f85c"}.fad.fa-coins:after{content:"\10f51e"}.fad.fa-columns:after{content:"\10f0db"}.fad.fa-comet:after{content:"\10e003"}.fad.fa-comment:after{content:"\10f075"}.fad.fa-comment-alt:after{content:"\10f27a"}.fad.fa-comment-alt-check:after{content:"\10f4a2"}.fad.fa-comment-alt-dollar:after{content:"\10f650"}.fad.fa-comment-alt-dots:after{content:"\10f4a3"}.fad.fa-comment-alt-edit:after{content:"\10f4a4"}.fad.fa-comment-alt-exclamation:after{content:"\10f4a5"}.fad.fa-comment-alt-lines:after{content:"\10f4a6"}.fad.fa-comment-alt-medical:after{content:"\10f7f4"}.fad.fa-comment-alt-minus:after{content:"\10f4a7"}.fad.fa-comment-alt-music:after{content:"\10f8af"}.fad.fa-comment-alt-plus:after{content:"\10f4a8"}.fad.fa-comment-alt-slash:after{content:"\10f4a9"}.fad.fa-comment-alt-smile:after{content:"\10f4aa"}.fad.fa-comment-alt-times:after{content:"\10f4ab"}.fad.fa-comment-check:after{content:"\10f4ac"}.fad.fa-comment-dollar:after{content:"\10f651"}.fad.fa-comment-dots:after{content:"\10f4ad"}.fad.fa-comment-edit:after{content:"\10f4ae"}.fad.fa-comment-exclamation:after{content:"\10f4af"}.fad.fa-comment-lines:after{content:"\10f4b0"}.fad.fa-comment-medical:after{content:"\10f7f5"}.fad.fa-comment-minus:after{content:"\10f4b1"}.fad.fa-comment-music:after{content:"\10f8b0"}.fad.fa-comment-plus:after{content:"\10f4b2"}.fad.fa-comment-slash:after{content:"\10f4b3"}.fad.fa-comment-smile:after{content:"\10f4b4"}.fad.fa-comment-times:after{content:"\10f4b5"}.fad.fa-comments:after{content:"\10f086"}.fad.fa-comments-alt:after{content:"\10f4b6"}.fad.fa-comments-alt-dollar:after{content:"\10f652"}.fad.fa-comments-dollar:after{content:"\10f653"}.fad.fa-compact-disc:after{content:"\10f51f"}.fad.fa-compass:after{content:"\10f14e"}.fad.fa-compass-slash:after{content:"\10f5e9"}.fad.fa-compress:after{content:"\10f066"}.fad.fa-compress-alt:after{content:"\10f422"}.fad.fa-compress-arrows-alt:after{content:"\10f78c"}.fad.fa-compress-wide:after{content:"\10f326"}.fad.fa-computer-classic:after{content:"\10f8b1"}.fad.fa-computer-speaker:after{content:"\10f8b2"}.fad.fa-concierge-bell:after{content:"\10f562"}.fad.fa-construction:after{content:"\10f85d"}.fad.fa-container-storage:after{content:"\10f4b7"}.fad.fa-conveyor-belt:after{content:"\10f46e"}.fad.fa-conveyor-belt-alt:after{content:"\10f46f"}.fad.fa-cookie:after{content:"\10f563"}.fad.fa-cookie-bite:after{content:"\10f564"}.fad.fa-copy:after{content:"\10f0c5"}.fad.fa-copyright:after{content:"\10f1f9"}.fad.fa-corn:after{content:"\10f6c7"}.fad.fa-couch:after{content:"\10f4b8"}.fad.fa-cow:after{content:"\10f6c8"}.fad.fa-cowbell:after{content:"\10f8b3"}.fad.fa-cowbell-more:after{content:"\10f8b4"}.fad.fa-credit-card:after{content:"\10f09d"}.fad.fa-credit-card-blank:after{content:"\10f389"}.fad.fa-credit-card-front:after{content:"\10f38a"}.fad.fa-cricket:after{content:"\10f449"}.fad.fa-croissant:after{content:"\10f7f6"}.fad.fa-crop:after{content:"\10f125"}.fad.fa-crop-alt:after{content:"\10f565"}.fad.fa-cross:after{content:"\10f654"}.fad.fa-crosshairs:after{content:"\10f05b"}.fad.fa-crow:after{content:"\10f520"}.fad.fa-crown:after{content:"\10f521"}.fad.fa-crutch:after{content:"\10f7f7"}.fad.fa-crutches:after{content:"\10f7f8"}.fad.fa-cube:after{content:"\10f1b2"}.fad.fa-cubes:after{content:"\10f1b3"}.fad.fa-curling:after{content:"\10f44a"}.fad.fa-cut:after{content:"\10f0c4"}.fad.fa-dagger:after{content:"\10f6cb"}.fad.fa-database:after{content:"\10f1c0"}.fad.fa-deaf:after{content:"\10f2a4"}.fad.fa-debug:after{content:"\10f7f9"}.fad.fa-deer:after{content:"\10f78e"}.fad.fa-deer-rudolph:after{content:"\10f78f"}.fad.fa-democrat:after{content:"\10f747"}.fad.fa-desktop:after{content:"\10f108"}.fad.fa-desktop-alt:after{content:"\10f390"}.fad.fa-dewpoint:after{content:"\10f748"}.fad.fa-dharmachakra:after{content:"\10f655"}.fad.fa-diagnoses:after{content:"\10f470"}.fad.fa-diamond:after{content:"\10f219"}.fad.fa-dice:after{content:"\10f522"}.fad.fa-dice-d10:after{content:"\10f6cd"}.fad.fa-dice-d12:after{content:"\10f6ce"}.fad.fa-dice-d20:after{content:"\10f6cf"}.fad.fa-dice-d4:after{content:"\10f6d0"}.fad.fa-dice-d6:after{content:"\10f6d1"}.fad.fa-dice-d8:after{content:"\10f6d2"}.fad.fa-dice-five:after{content:"\10f523"}.fad.fa-dice-four:after{content:"\10f524"}.fad.fa-dice-one:after{content:"\10f525"}.fad.fa-dice-six:after{content:"\10f526"}.fad.fa-dice-three:after{content:"\10f527"}.fad.fa-dice-two:after{content:"\10f528"}.fad.fa-digging:after{content:"\10f85e"}.fad.fa-digital-tachograph:after{content:"\10f566"}.fad.fa-diploma:after{content:"\10f5ea"}.fad.fa-directions:after{content:"\10f5eb"}.fad.fa-disc-drive:after{content:"\10f8b5"}.fad.fa-disease:after{content:"\10f7fa"}.fad.fa-divide:after{content:"\10f529"}.fad.fa-dizzy:after{content:"\10f567"}.fad.fa-dna:after{content:"\10f471"}.fad.fa-do-not-enter:after{content:"\10f5ec"}.fad.fa-dog:after{content:"\10f6d3"}.fad.fa-dog-leashed:after{content:"\10f6d4"}.fad.fa-dollar-sign:after{content:"\10f155"}.fad.fa-dolly:after{content:"\10f472"}.fad.fa-dolly-empty:after{content:"\10f473"}.fad.fa-dolly-flatbed:after{content:"\10f474"}.fad.fa-dolly-flatbed-alt:after{content:"\10f475"}.fad.fa-dolly-flatbed-empty:after{content:"\10f476"}.fad.fa-donate:after{content:"\10f4b9"}.fad.fa-door-closed:after{content:"\10f52a"}.fad.fa-door-open:after{content:"\10f52b"}.fad.fa-dot-circle:after{content:"\10f192"}.fad.fa-dove:after{content:"\10f4ba"}.fad.fa-download:after{content:"\10f019"}.fad.fa-drafting-compass:after{content:"\10f568"}.fad.fa-dragon:after{content:"\10f6d5"}.fad.fa-draw-circle:after{content:"\10f5ed"}.fad.fa-draw-polygon:after{content:"\10f5ee"}.fad.fa-draw-square:after{content:"\10f5ef"}.fad.fa-dreidel:after{content:"\10f792"}.fad.fa-drone:after{content:"\10f85f"}.fad.fa-drone-alt:after{content:"\10f860"}.fad.fa-drum:after{content:"\10f569"}.fad.fa-drum-steelpan:after{content:"\10f56a"}.fad.fa-drumstick:after{content:"\10f6d6"}.fad.fa-drumstick-bite:after{content:"\10f6d7"}.fad.fa-dryer:after{content:"\10f861"}.fad.fa-dryer-alt:after{content:"\10f862"}.fad.fa-duck:after{content:"\10f6d8"}.fad.fa-dumbbell:after{content:"\10f44b"}.fad.fa-dumpster:after{content:"\10f793"}.fad.fa-dumpster-fire:after{content:"\10f794"}.fad.fa-dungeon:after{content:"\10f6d9"}.fad.fa-ear:after{content:"\10f5f0"}.fad.fa-ear-muffs:after{content:"\10f795"}.fad.fa-eclipse:after{content:"\10f749"}.fad.fa-eclipse-alt:after{content:"\10f74a"}.fad.fa-edit:after{content:"\10f044"}.fad.fa-egg:after{content:"\10f7fb"}.fad.fa-egg-fried:after{content:"\10f7fc"}.fad.fa-eject:after{content:"\10f052"}.fad.fa-elephant:after{content:"\10f6da"}.fad.fa-ellipsis-h:after{content:"\10f141"}.fad.fa-ellipsis-h-alt:after{content:"\10f39b"}.fad.fa-ellipsis-v:after{content:"\10f142"}.fad.fa-ellipsis-v-alt:after{content:"\10f39c"}.fad.fa-empty-set:after{content:"\10f656"}.fad.fa-engine-warning:after{content:"\10f5f2"}.fad.fa-envelope:after{content:"\10f0e0"}.fad.fa-envelope-open:after{content:"\10f2b6"}.fad.fa-envelope-open-dollar:after{content:"\10f657"}.fad.fa-envelope-open-text:after{content:"\10f658"}.fad.fa-envelope-square:after{content:"\10f199"}.fad.fa-equals:after{content:"\10f52c"}.fad.fa-eraser:after{content:"\10f12d"}.fad.fa-ethernet:after{content:"\10f796"}.fad.fa-euro-sign:after{content:"\10f153"}.fad.fa-exchange:after{content:"\10f0ec"}.fad.fa-exchange-alt:after{content:"\10f362"}.fad.fa-exclamation:after{content:"\10f12a"}.fad.fa-exclamation-circle:after{content:"\10f06a"}.fad.fa-exclamation-square:after{content:"\10f321"}.fad.fa-exclamation-triangle:after{content:"\10f071"}.fad.fa-expand:after{content:"\10f065"}.fad.fa-expand-alt:after{content:"\10f424"}.fad.fa-expand-arrows:after{content:"\10f31d"}.fad.fa-expand-arrows-alt:after{content:"\10f31e"}.fad.fa-expand-wide:after{content:"\10f320"}.fad.fa-external-link:after{content:"\10f08e"}.fad.fa-external-link-alt:after{content:"\10f35d"}.fad.fa-external-link-square:after{content:"\10f14c"}.fad.fa-external-link-square-alt:after{content:"\10f360"}.fad.fa-eye:after{content:"\10f06e"}.fad.fa-eye-dropper:after{content:"\10f1fb"}.fad.fa-eye-evil:after{content:"\10f6db"}.fad.fa-eye-slash:after{content:"\10f070"}.fad.fa-fan:after{content:"\10f863"}.fad.fa-fan-table:after{content:"\10e004"}.fad.fa-farm:after{content:"\10f864"}.fad.fa-fast-backward:after{content:"\10f049"}.fad.fa-fast-forward:after{content:"\10f050"}.fad.fa-faucet:after{content:"\10e005"}.fad.fa-faucet-drip:after{content:"\10e006"}.fad.fa-fax:after{content:"\10f1ac"}.fad.fa-feather:after{content:"\10f52d"}.fad.fa-feather-alt:after{content:"\10f56b"}.fad.fa-female:after{content:"\10f182"}.fad.fa-field-hockey:after{content:"\10f44c"}.fad.fa-fighter-jet:after{content:"\10f0fb"}.fad.fa-file:after{content:"\10f15b"}.fad.fa-file-alt:after{content:"\10f15c"}.fad.fa-file-archive:after{content:"\10f1c6"}.fad.fa-file-audio:after{content:"\10f1c7"}.fad.fa-file-certificate:after{content:"\10f5f3"}.fad.fa-file-chart-line:after{content:"\10f659"}.fad.fa-file-chart-pie:after{content:"\10f65a"}.fad.fa-file-check:after{content:"\10f316"}.fad.fa-file-code:after{content:"\10f1c9"}.fad.fa-file-contract:after{content:"\10f56c"}.fad.fa-file-csv:after{content:"\10f6dd"}.fad.fa-file-download:after{content:"\10f56d"}.fad.fa-file-edit:after{content:"\10f31c"}.fad.fa-file-excel:after{content:"\10f1c3"}.fad.fa-file-exclamation:after{content:"\10f31a"}.fad.fa-file-export:after{content:"\10f56e"}.fad.fa-file-image:after{content:"\10f1c5"}.fad.fa-file-import:after{content:"\10f56f"}.fad.fa-file-invoice:after{content:"\10f570"}.fad.fa-file-invoice-dollar:after{content:"\10f571"}.fad.fa-file-medical:after{content:"\10f477"}.fad.fa-file-medical-alt:after{content:"\10f478"}.fad.fa-file-minus:after{content:"\10f318"}.fad.fa-file-music:after{content:"\10f8b6"}.fad.fa-file-pdf:after{content:"\10f1c1"}.fad.fa-file-plus:after{content:"\10f319"}.fad.fa-file-powerpoint:after{content:"\10f1c4"}.fad.fa-file-prescription:after{content:"\10f572"}.fad.fa-file-search:after{content:"\10f865"}.fad.fa-file-signature:after{content:"\10f573"}.fad.fa-file-spreadsheet:after{content:"\10f65b"}.fad.fa-file-times:after{content:"\10f317"}.fad.fa-file-upload:after{content:"\10f574"}.fad.fa-file-user:after{content:"\10f65c"}.fad.fa-file-video:after{content:"\10f1c8"}.fad.fa-file-word:after{content:"\10f1c2"}.fad.fa-files-medical:after{content:"\10f7fd"}.fad.fa-fill:after{content:"\10f575"}.fad.fa-fill-drip:after{content:"\10f576"}.fad.fa-film:after{content:"\10f008"}.fad.fa-film-alt:after{content:"\10f3a0"}.fad.fa-film-canister:after{content:"\10f8b7"}.fad.fa-filter:after{content:"\10f0b0"}.fad.fa-fingerprint:after{content:"\10f577"}.fad.fa-fire:after{content:"\10f06d"}.fad.fa-fire-alt:after{content:"\10f7e4"}.fad.fa-fire-extinguisher:after{content:"\10f134"}.fad.fa-fire-smoke:after{content:"\10f74b"}.fad.fa-fireplace:after{content:"\10f79a"}.fad.fa-first-aid:after{content:"\10f479"}.fad.fa-fish:after{content:"\10f578"}.fad.fa-fish-cooked:after{content:"\10f7fe"}.fad.fa-fist-raised:after{content:"\10f6de"}.fad.fa-flag:after{content:"\10f024"}.fad.fa-flag-alt:after{content:"\10f74c"}.fad.fa-flag-checkered:after{content:"\10f11e"}.fad.fa-flag-usa:after{content:"\10f74d"}.fad.fa-flame:after{content:"\10f6df"}.fad.fa-flashlight:after{content:"\10f8b8"}.fad.fa-flask:after{content:"\10f0c3"}.fad.fa-flask-poison:after{content:"\10f6e0"}.fad.fa-flask-potion:after{content:"\10f6e1"}.fad.fa-flower:after{content:"\10f7ff"}.fad.fa-flower-daffodil:after{content:"\10f800"}.fad.fa-flower-tulip:after{content:"\10f801"}.fad.fa-flushed:after{content:"\10f579"}.fad.fa-flute:after{content:"\10f8b9"}.fad.fa-flux-capacitor:after{content:"\10f8ba"}.fad.fa-fog:after{content:"\10f74e"}.fad.fa-folder:after{content:"\10f07b"}.fad.fa-folder-download:after{content:"\10e053"}.fad.fa-folder-minus:after{content:"\10f65d"}.fad.fa-folder-open:after{content:"\10f07c"}.fad.fa-folder-plus:after{content:"\10f65e"}.fad.fa-folder-times:after{content:"\10f65f"}.fad.fa-folder-tree:after{content:"\10f802"}.fad.fa-folder-upload:after{content:"\10e054"}.fad.fa-folders:after{content:"\10f660"}.fad.fa-font:after{content:"\10f031"}.fad.fa-font-awesome-logo-full:after{content:"\10f4e6"}.fad.fa-font-case:after{content:"\10f866"}.fad.fa-football-ball:after{content:"\10f44e"}.fad.fa-football-helmet:after{content:"\10f44f"}.fad.fa-forklift:after{content:"\10f47a"}.fad.fa-forward:after{content:"\10f04e"}.fad.fa-fragile:after{content:"\10f4bb"}.fad.fa-french-fries:after{content:"\10f803"}.fad.fa-frog:after{content:"\10f52e"}.fad.fa-frosty-head:after{content:"\10f79b"}.fad.fa-frown:after{content:"\10f119"}.fad.fa-frown-open:after{content:"\10f57a"}.fad.fa-function:after{content:"\10f661"}.fad.fa-funnel-dollar:after{content:"\10f662"}.fad.fa-futbol:after{content:"\10f1e3"}.fad.fa-galaxy:after{content:"\10e008"}.fad.fa-game-board:after{content:"\10f867"}.fad.fa-game-board-alt:after{content:"\10f868"}.fad.fa-game-console-handheld:after{content:"\10f8bb"}.fad.fa-gamepad:after{content:"\10f11b"}.fad.fa-gamepad-alt:after{content:"\10f8bc"}.fad.fa-garage:after{content:"\10e009"}.fad.fa-garage-car:after{content:"\10e00a"}.fad.fa-garage-open:after{content:"\10e00b"}.fad.fa-gas-pump:after{content:"\10f52f"}.fad.fa-gas-pump-slash:after{content:"\10f5f4"}.fad.fa-gavel:after{content:"\10f0e3"}.fad.fa-gem:after{content:"\10f3a5"}.fad.fa-genderless:after{content:"\10f22d"}.fad.fa-ghost:after{content:"\10f6e2"}.fad.fa-gift:after{content:"\10f06b"}.fad.fa-gift-card:after{content:"\10f663"}.fad.fa-gifts:after{content:"\10f79c"}.fad.fa-gingerbread-man:after{content:"\10f79d"}.fad.fa-glass:after{content:"\10f804"}.fad.fa-glass-champagne:after{content:"\10f79e"}.fad.fa-glass-cheers:after{content:"\10f79f"}.fad.fa-glass-citrus:after{content:"\10f869"}.fad.fa-glass-martini:after{content:"\10f000"}.fad.fa-glass-martini-alt:after{content:"\10f57b"}.fad.fa-glass-whiskey:after{content:"\10f7a0"}.fad.fa-glass-whiskey-rocks:after{content:"\10f7a1"}.fad.fa-glasses:after{content:"\10f530"}.fad.fa-glasses-alt:after{content:"\10f5f5"}.fad.fa-globe:after{content:"\10f0ac"}.fad.fa-globe-africa:after{content:"\10f57c"}.fad.fa-globe-americas:after{content:"\10f57d"}.fad.fa-globe-asia:after{content:"\10f57e"}.fad.fa-globe-europe:after{content:"\10f7a2"}.fad.fa-globe-snow:after{content:"\10f7a3"}.fad.fa-globe-stand:after{content:"\10f5f6"}.fad.fa-golf-ball:after{content:"\10f450"}.fad.fa-golf-club:after{content:"\10f451"}.fad.fa-gopuram:after{content:"\10f664"}.fad.fa-graduation-cap:after{content:"\10f19d"}.fad.fa-gramophone:after{content:"\10f8bd"}.fad.fa-greater-than:after{content:"\10f531"}.fad.fa-greater-than-equal:after{content:"\10f532"}.fad.fa-grimace:after{content:"\10f57f"}.fad.fa-grin:after{content:"\10f580"}.fad.fa-grin-alt:after{content:"\10f581"}.fad.fa-grin-beam:after{content:"\10f582"}.fad.fa-grin-beam-sweat:after{content:"\10f583"}.fad.fa-grin-hearts:after{content:"\10f584"}.fad.fa-grin-squint:after{content:"\10f585"}.fad.fa-grin-squint-tears:after{content:"\10f586"}.fad.fa-grin-stars:after{content:"\10f587"}.fad.fa-grin-tears:after{content:"\10f588"}.fad.fa-grin-tongue:after{content:"\10f589"}.fad.fa-grin-tongue-squint:after{content:"\10f58a"}.fad.fa-grin-tongue-wink:after{content:"\10f58b"}.fad.fa-grin-wink:after{content:"\10f58c"}.fad.fa-grip-horizontal:after{content:"\10f58d"}.fad.fa-grip-lines:after{content:"\10f7a4"}.fad.fa-grip-lines-vertical:after{content:"\10f7a5"}.fad.fa-grip-vertical:after{content:"\10f58e"}.fad.fa-guitar:after{content:"\10f7a6"}.fad.fa-guitar-electric:after{content:"\10f8be"}.fad.fa-guitars:after{content:"\10f8bf"}.fad.fa-h-square:after{content:"\10f0fd"}.fad.fa-h1:after{content:"\10f313"}.fad.fa-h2:after{content:"\10f314"}.fad.fa-h3:after{content:"\10f315"}.fad.fa-h4:after{content:"\10f86a"}.fad.fa-hamburger:after{content:"\10f805"}.fad.fa-hammer:after{content:"\10f6e3"}.fad.fa-hammer-war:after{content:"\10f6e4"}.fad.fa-hamsa:after{content:"\10f665"}.fad.fa-hand-heart:after{content:"\10f4bc"}.fad.fa-hand-holding:after{content:"\10f4bd"}.fad.fa-hand-holding-box:after{content:"\10f47b"}.fad.fa-hand-holding-heart:after{content:"\10f4be"}.fad.fa-hand-holding-magic:after{content:"\10f6e5"}.fad.fa-hand-holding-medical:after{content:"\10e05c"}.fad.fa-hand-holding-seedling:after{content:"\10f4bf"}.fad.fa-hand-holding-usd:after{content:"\10f4c0"}.fad.fa-hand-holding-water:after{content:"\10f4c1"}.fad.fa-hand-lizard:after{content:"\10f258"}.fad.fa-hand-middle-finger:after{content:"\10f806"}.fad.fa-hand-paper:after{content:"\10f256"}.fad.fa-hand-peace:after{content:"\10f25b"}.fad.fa-hand-point-down:after{content:"\10f0a7"}.fad.fa-hand-point-left:after{content:"\10f0a5"}.fad.fa-hand-point-right:after{content:"\10f0a4"}.fad.fa-hand-point-up:after{content:"\10f0a6"}.fad.fa-hand-pointer:after{content:"\10f25a"}.fad.fa-hand-receiving:after{content:"\10f47c"}.fad.fa-hand-rock:after{content:"\10f255"}.fad.fa-hand-scissors:after{content:"\10f257"}.fad.fa-hand-sparkles:after{content:"\10e05d"}.fad.fa-hand-spock:after{content:"\10f259"}.fad.fa-hands:after{content:"\10f4c2"}.fad.fa-hands-heart:after{content:"\10f4c3"}.fad.fa-hands-helping:after{content:"\10f4c4"}.fad.fa-hands-usd:after{content:"\10f4c5"}.fad.fa-hands-wash:after{content:"\10e05e"}.fad.fa-handshake:after{content:"\10f2b5"}.fad.fa-handshake-alt:after{content:"\10f4c6"}.fad.fa-handshake-alt-slash:after{content:"\10e05f"}.fad.fa-handshake-slash:after{content:"\10e060"}.fad.fa-hanukiah:after{content:"\10f6e6"}.fad.fa-hard-hat:after{content:"\10f807"}.fad.fa-hashtag:after{content:"\10f292"}.fad.fa-hat-chef:after{content:"\10f86b"}.fad.fa-hat-cowboy:after{content:"\10f8c0"}.fad.fa-hat-cowboy-side:after{content:"\10f8c1"}.fad.fa-hat-santa:after{content:"\10f7a7"}.fad.fa-hat-winter:after{content:"\10f7a8"}.fad.fa-hat-witch:after{content:"\10f6e7"}.fad.fa-hat-wizard:after{content:"\10f6e8"}.fad.fa-hdd:after{content:"\10f0a0"}.fad.fa-head-side:after{content:"\10f6e9"}.fad.fa-head-side-brain:after{content:"\10f808"}.fad.fa-head-side-cough:after{content:"\10e061"}.fad.fa-head-side-cough-slash:after{content:"\10e062"}.fad.fa-head-side-headphones:after{content:"\10f8c2"}.fad.fa-head-side-mask:after{content:"\10e063"}.fad.fa-head-side-medical:after{content:"\10f809"}.fad.fa-head-side-virus:after{content:"\10e064"}.fad.fa-head-vr:after{content:"\10f6ea"}.fad.fa-heading:after{content:"\10f1dc"}.fad.fa-headphones:after{content:"\10f025"}.fad.fa-headphones-alt:after{content:"\10f58f"}.fad.fa-headset:after{content:"\10f590"}.fad.fa-heart:after{content:"\10f004"}.fad.fa-heart-broken:after{content:"\10f7a9"}.fad.fa-heart-circle:after{content:"\10f4c7"}.fad.fa-heart-rate:after{content:"\10f5f8"}.fad.fa-heart-square:after{content:"\10f4c8"}.fad.fa-heartbeat:after{content:"\10f21e"}.fad.fa-heat:after{content:"\10e00c"}.fad.fa-helicopter:after{content:"\10f533"}.fad.fa-helmet-battle:after{content:"\10f6eb"}.fad.fa-hexagon:after{content:"\10f312"}.fad.fa-highlighter:after{content:"\10f591"}.fad.fa-hiking:after{content:"\10f6ec"}.fad.fa-hippo:after{content:"\10f6ed"}.fad.fa-history:after{content:"\10f1da"}.fad.fa-hockey-mask:after{content:"\10f6ee"}.fad.fa-hockey-puck:after{content:"\10f453"}.fad.fa-hockey-sticks:after{content:"\10f454"}.fad.fa-holly-berry:after{content:"\10f7aa"}.fad.fa-home:after{content:"\10f015"}.fad.fa-home-alt:after{content:"\10f80a"}.fad.fa-home-heart:after{content:"\10f4c9"}.fad.fa-home-lg:after{content:"\10f80b"}.fad.fa-home-lg-alt:after{content:"\10f80c"}.fad.fa-hood-cloak:after{content:"\10f6ef"}.fad.fa-horizontal-rule:after{content:"\10f86c"}.fad.fa-horse:after{content:"\10f6f0"}.fad.fa-horse-head:after{content:"\10f7ab"}.fad.fa-horse-saddle:after{content:"\10f8c3"}.fad.fa-hospital:after{content:"\10f0f8"}.fad.fa-hospital-alt:after{content:"\10f47d"}.fad.fa-hospital-symbol:after{content:"\10f47e"}.fad.fa-hospital-user:after{content:"\10f80d"}.fad.fa-hospitals:after{content:"\10f80e"}.fad.fa-hot-tub:after{content:"\10f593"}.fad.fa-hotdog:after{content:"\10f80f"}.fad.fa-hotel:after{content:"\10f594"}.fad.fa-hourglass:after{content:"\10f254"}.fad.fa-hourglass-end:after{content:"\10f253"}.fad.fa-hourglass-half:after{content:"\10f252"}.fad.fa-hourglass-start:after{content:"\10f251"}.fad.fa-house:after{content:"\10e00d"}.fad.fa-house-damage:after{content:"\10f6f1"}.fad.fa-house-day:after{content:"\10e00e"}.fad.fa-house-flood:after{content:"\10f74f"}.fad.fa-house-leave:after{content:"\10e00f"}.fad.fa-house-night:after{content:"\10e010"}.fad.fa-house-return:after{content:"\10e011"}.fad.fa-house-signal:after{content:"\10e012"}.fad.fa-house-user:after{content:"\10e065"}.fad.fa-hryvnia:after{content:"\10f6f2"}.fad.fa-humidity:after{content:"\10f750"}.fad.fa-hurricane:after{content:"\10f751"}.fad.fa-i-cursor:after{content:"\10f246"}.fad.fa-ice-cream:after{content:"\10f810"}.fad.fa-ice-skate:after{content:"\10f7ac"}.fad.fa-icicles:after{content:"\10f7ad"}.fad.fa-icons:after{content:"\10f86d"}.fad.fa-icons-alt:after{content:"\10f86e"}.fad.fa-id-badge:after{content:"\10f2c1"}.fad.fa-id-card:after{content:"\10f2c2"}.fad.fa-id-card-alt:after{content:"\10f47f"}.fad.fa-igloo:after{content:"\10f7ae"}.fad.fa-image:after{content:"\10f03e"}.fad.fa-image-polaroid:after{content:"\10f8c4"}.fad.fa-images:after{content:"\10f302"}.fad.fa-inbox:after{content:"\10f01c"}.fad.fa-inbox-in:after{content:"\10f310"}.fad.fa-inbox-out:after{content:"\10f311"}.fad.fa-indent:after{content:"\10f03c"}.fad.fa-industry:after{content:"\10f275"}.fad.fa-industry-alt:after{content:"\10f3b3"}.fad.fa-infinity:after{content:"\10f534"}.fad.fa-info:after{content:"\10f129"}.fad.fa-info-circle:after{content:"\10f05a"}.fad.fa-info-square:after{content:"\10f30f"}.fad.fa-inhaler:after{content:"\10f5f9"}.fad.fa-integral:after{content:"\10f667"}.fad.fa-intersection:after{content:"\10f668"}.fad.fa-inventory:after{content:"\10f480"}.fad.fa-island-tropical:after{content:"\10f811"}.fad.fa-italic:after{content:"\10f033"}.fad.fa-jack-o-lantern:after{content:"\10f30e"}.fad.fa-jedi:after{content:"\10f669"}.fad.fa-joint:after{content:"\10f595"}.fad.fa-journal-whills:after{content:"\10f66a"}.fad.fa-joystick:after{content:"\10f8c5"}.fad.fa-jug:after{content:"\10f8c6"}.fad.fa-kaaba:after{content:"\10f66b"}.fad.fa-kazoo:after{content:"\10f8c7"}.fad.fa-kerning:after{content:"\10f86f"}.fad.fa-key:after{content:"\10f084"}.fad.fa-key-skeleton:after{content:"\10f6f3"}.fad.fa-keyboard:after{content:"\10f11c"}.fad.fa-keynote:after{content:"\10f66c"}.fad.fa-khanda:after{content:"\10f66d"}.fad.fa-kidneys:after{content:"\10f5fb"}.fad.fa-kiss:after{content:"\10f596"}.fad.fa-kiss-beam:after{content:"\10f597"}.fad.fa-kiss-wink-heart:after{content:"\10f598"}.fad.fa-kite:after{content:"\10f6f4"}.fad.fa-kiwi-bird:after{content:"\10f535"}.fad.fa-knife-kitchen:after{content:"\10f6f5"}.fad.fa-lambda:after{content:"\10f66e"}.fad.fa-lamp:after{content:"\10f4ca"}.fad.fa-lamp-desk:after{content:"\10e014"}.fad.fa-lamp-floor:after{content:"\10e015"}.fad.fa-landmark:after{content:"\10f66f"}.fad.fa-landmark-alt:after{content:"\10f752"}.fad.fa-language:after{content:"\10f1ab"}.fad.fa-laptop:after{content:"\10f109"}.fad.fa-laptop-code:after{content:"\10f5fc"}.fad.fa-laptop-house:after{content:"\10e066"}.fad.fa-laptop-medical:after{content:"\10f812"}.fad.fa-lasso:after{content:"\10f8c8"}.fad.fa-laugh:after{content:"\10f599"}.fad.fa-laugh-beam:after{content:"\10f59a"}.fad.fa-laugh-squint:after{content:"\10f59b"}.fad.fa-laugh-wink:after{content:"\10f59c"}.fad.fa-layer-group:after{content:"\10f5fd"}.fad.fa-layer-minus:after{content:"\10f5fe"}.fad.fa-layer-plus:after{content:"\10f5ff"}.fad.fa-leaf:after{content:"\10f06c"}.fad.fa-leaf-heart:after{content:"\10f4cb"}.fad.fa-leaf-maple:after{content:"\10f6f6"}.fad.fa-leaf-oak:after{content:"\10f6f7"}.fad.fa-lemon:after{content:"\10f094"}.fad.fa-less-than:after{content:"\10f536"}.fad.fa-less-than-equal:after{content:"\10f537"}.fad.fa-level-down:after{content:"\10f149"}.fad.fa-level-down-alt:after{content:"\10f3be"}.fad.fa-level-up:after{content:"\10f148"}.fad.fa-level-up-alt:after{content:"\10f3bf"}.fad.fa-life-ring:after{content:"\10f1cd"}.fad.fa-light-ceiling:after{content:"\10e016"}.fad.fa-light-switch:after{content:"\10e017"}.fad.fa-light-switch-off:after{content:"\10e018"}.fad.fa-light-switch-on:after{content:"\10e019"}.fad.fa-lightbulb:after{content:"\10f0eb"}.fad.fa-lightbulb-dollar:after{content:"\10f670"}.fad.fa-lightbulb-exclamation:after{content:"\10f671"}.fad.fa-lightbulb-on:after{content:"\10f672"}.fad.fa-lightbulb-slash:after{content:"\10f673"}.fad.fa-lights-holiday:after{content:"\10f7b2"}.fad.fa-line-columns:after{content:"\10f870"}.fad.fa-line-height:after{content:"\10f871"}.fad.fa-link:after{content:"\10f0c1"}.fad.fa-lips:after{content:"\10f600"}.fad.fa-lira-sign:after{content:"\10f195"}.fad.fa-list:after{content:"\10f03a"}.fad.fa-list-alt:after{content:"\10f022"}.fad.fa-list-music:after{content:"\10f8c9"}.fad.fa-list-ol:after{content:"\10f0cb"}.fad.fa-list-ul:after{content:"\10f0ca"}.fad.fa-location:after{content:"\10f601"}.fad.fa-location-arrow:after{content:"\10f124"}.fad.fa-location-circle:after{content:"\10f602"}.fad.fa-location-slash:after{content:"\10f603"}.fad.fa-lock:after{content:"\10f023"}.fad.fa-lock-alt:after{content:"\10f30d"}.fad.fa-lock-open:after{content:"\10f3c1"}.fad.fa-lock-open-alt:after{content:"\10f3c2"}.fad.fa-long-arrow-alt-down:after{content:"\10f309"}.fad.fa-long-arrow-alt-left:after{content:"\10f30a"}.fad.fa-long-arrow-alt-right:after{content:"\10f30b"}.fad.fa-long-arrow-alt-up:after{content:"\10f30c"}.fad.fa-long-arrow-down:after{content:"\10f175"}.fad.fa-long-arrow-left:after{content:"\10f177"}.fad.fa-long-arrow-right:after{content:"\10f178"}.fad.fa-long-arrow-up:after{content:"\10f176"}.fad.fa-loveseat:after{content:"\10f4cc"}.fad.fa-low-vision:after{content:"\10f2a8"}.fad.fa-luchador:after{content:"\10f455"}.fad.fa-luggage-cart:after{content:"\10f59d"}.fad.fa-lungs:after{content:"\10f604"}.fad.fa-lungs-virus:after{content:"\10e067"}.fad.fa-mace:after{content:"\10f6f8"}.fad.fa-magic:after{content:"\10f0d0"}.fad.fa-magnet:after{content:"\10f076"}.fad.fa-mail-bulk:after{content:"\10f674"}.fad.fa-mailbox:after{content:"\10f813"}.fad.fa-male:after{content:"\10f183"}.fad.fa-mandolin:after{content:"\10f6f9"}.fad.fa-map:after{content:"\10f279"}.fad.fa-map-marked:after{content:"\10f59f"}.fad.fa-map-marked-alt:after{content:"\10f5a0"}.fad.fa-map-marker:after{content:"\10f041"}.fad.fa-map-marker-alt:after{content:"\10f3c5"}.fad.fa-map-marker-alt-slash:after{content:"\10f605"}.fad.fa-map-marker-check:after{content:"\10f606"}.fad.fa-map-marker-edit:after{content:"\10f607"}.fad.fa-map-marker-exclamation:after{content:"\10f608"}.fad.fa-map-marker-minus:after{content:"\10f609"}.fad.fa-map-marker-plus:after{content:"\10f60a"}.fad.fa-map-marker-question:after{content:"\10f60b"}.fad.fa-map-marker-slash:after{content:"\10f60c"}.fad.fa-map-marker-smile:after{content:"\10f60d"}.fad.fa-map-marker-times:after{content:"\10f60e"}.fad.fa-map-pin:after{content:"\10f276"}.fad.fa-map-signs:after{content:"\10f277"}.fad.fa-marker:after{content:"\10f5a1"}.fad.fa-mars:after{content:"\10f222"}.fad.fa-mars-double:after{content:"\10f227"}.fad.fa-mars-stroke:after{content:"\10f229"}.fad.fa-mars-stroke-h:after{content:"\10f22b"}.fad.fa-mars-stroke-v:after{content:"\10f22a"}.fad.fa-mask:after{content:"\10f6fa"}.fad.fa-meat:after{content:"\10f814"}.fad.fa-medal:after{content:"\10f5a2"}.fad.fa-medkit:after{content:"\10f0fa"}.fad.fa-megaphone:after{content:"\10f675"}.fad.fa-meh:after{content:"\10f11a"}.fad.fa-meh-blank:after{content:"\10f5a4"}.fad.fa-meh-rolling-eyes:after{content:"\10f5a5"}.fad.fa-memory:after{content:"\10f538"}.fad.fa-menorah:after{content:"\10f676"}.fad.fa-mercury:after{content:"\10f223"}.fad.fa-meteor:after{content:"\10f753"}.fad.fa-microchip:after{content:"\10f2db"}.fad.fa-microphone:after{content:"\10f130"}.fad.fa-microphone-alt:after{content:"\10f3c9"}.fad.fa-microphone-alt-slash:after{content:"\10f539"}.fad.fa-microphone-slash:after{content:"\10f131"}.fad.fa-microphone-stand:after{content:"\10f8cb"}.fad.fa-microscope:after{content:"\10f610"}.fad.fa-microwave:after{content:"\10e01b"}.fad.fa-mind-share:after{content:"\10f677"}.fad.fa-minus:after{content:"\10f068"}.fad.fa-minus-circle:after{content:"\10f056"}.fad.fa-minus-hexagon:after{content:"\10f307"}.fad.fa-minus-octagon:after{content:"\10f308"}.fad.fa-minus-square:after{content:"\10f146"}.fad.fa-mistletoe:after{content:"\10f7b4"}.fad.fa-mitten:after{content:"\10f7b5"}.fad.fa-mobile:after{content:"\10f10b"}.fad.fa-mobile-alt:after{content:"\10f3cd"}.fad.fa-mobile-android:after{content:"\10f3ce"}.fad.fa-mobile-android-alt:after{content:"\10f3cf"}.fad.fa-money-bill:after{content:"\10f0d6"}.fad.fa-money-bill-alt:after{content:"\10f3d1"}.fad.fa-money-bill-wave:after{content:"\10f53a"}.fad.fa-money-bill-wave-alt:after{content:"\10f53b"}.fad.fa-money-check:after{content:"\10f53c"}.fad.fa-money-check-alt:after{content:"\10f53d"}.fad.fa-money-check-edit:after{content:"\10f872"}.fad.fa-money-check-edit-alt:after{content:"\10f873"}.fad.fa-monitor-heart-rate:after{content:"\10f611"}.fad.fa-monkey:after{content:"\10f6fb"}.fad.fa-monument:after{content:"\10f5a6"}.fad.fa-moon:after{content:"\10f186"}.fad.fa-moon-cloud:after{content:"\10f754"}.fad.fa-moon-stars:after{content:"\10f755"}.fad.fa-mortar-pestle:after{content:"\10f5a7"}.fad.fa-mosque:after{content:"\10f678"}.fad.fa-motorcycle:after{content:"\10f21c"}.fad.fa-mountain:after{content:"\10f6fc"}.fad.fa-mountains:after{content:"\10f6fd"}.fad.fa-mouse:after{content:"\10f8cc"}.fad.fa-mouse-alt:after{content:"\10f8cd"}.fad.fa-mouse-pointer:after{content:"\10f245"}.fad.fa-mp3-player:after{content:"\10f8ce"}.fad.fa-mug:after{content:"\10f874"}.fad.fa-mug-hot:after{content:"\10f7b6"}.fad.fa-mug-marshmallows:after{content:"\10f7b7"}.fad.fa-mug-tea:after{content:"\10f875"}.fad.fa-music:after{content:"\10f001"}.fad.fa-music-alt:after{content:"\10f8cf"}.fad.fa-music-alt-slash:after{content:"\10f8d0"}.fad.fa-music-slash:after{content:"\10f8d1"}.fad.fa-narwhal:after{content:"\10f6fe"}.fad.fa-network-wired:after{content:"\10f6ff"}.fad.fa-neuter:after{content:"\10f22c"}.fad.fa-newspaper:after{content:"\10f1ea"}.fad.fa-not-equal:after{content:"\10f53e"}.fad.fa-notes-medical:after{content:"\10f481"}.fad.fa-object-group:after{content:"\10f247"}.fad.fa-object-ungroup:after{content:"\10f248"}.fad.fa-octagon:after{content:"\10f306"}.fad.fa-oil-can:after{content:"\10f613"}.fad.fa-oil-temp:after{content:"\10f614"}.fad.fa-om:after{content:"\10f679"}.fad.fa-omega:after{content:"\10f67a"}.fad.fa-ornament:after{content:"\10f7b8"}.fad.fa-otter:after{content:"\10f700"}.fad.fa-outdent:after{content:"\10f03b"}.fad.fa-outlet:after{content:"\10e01c"}.fad.fa-oven:after{content:"\10e01d"}.fad.fa-overline:after{content:"\10f876"}.fad.fa-page-break:after{content:"\10f877"}.fad.fa-pager:after{content:"\10f815"}.fad.fa-paint-brush:after{content:"\10f1fc"}.fad.fa-paint-brush-alt:after{content:"\10f5a9"}.fad.fa-paint-roller:after{content:"\10f5aa"}.fad.fa-palette:after{content:"\10f53f"}.fad.fa-pallet:after{content:"\10f482"}.fad.fa-pallet-alt:after{content:"\10f483"}.fad.fa-paper-plane:after{content:"\10f1d8"}.fad.fa-paperclip:after{content:"\10f0c6"}.fad.fa-parachute-box:after{content:"\10f4cd"}.fad.fa-paragraph:after{content:"\10f1dd"}.fad.fa-paragraph-rtl:after{content:"\10f878"}.fad.fa-parking:after{content:"\10f540"}.fad.fa-parking-circle:after{content:"\10f615"}.fad.fa-parking-circle-slash:after{content:"\10f616"}.fad.fa-parking-slash:after{content:"\10f617"}.fad.fa-passport:after{content:"\10f5ab"}.fad.fa-pastafarianism:after{content:"\10f67b"}.fad.fa-paste:after{content:"\10f0ea"}.fad.fa-pause:after{content:"\10f04c"}.fad.fa-pause-circle:after{content:"\10f28b"}.fad.fa-paw:after{content:"\10f1b0"}.fad.fa-paw-alt:after{content:"\10f701"}.fad.fa-paw-claws:after{content:"\10f702"}.fad.fa-peace:after{content:"\10f67c"}.fad.fa-pegasus:after{content:"\10f703"}.fad.fa-pen:after{content:"\10f304"}.fad.fa-pen-alt:after{content:"\10f305"}.fad.fa-pen-fancy:after{content:"\10f5ac"}.fad.fa-pen-nib:after{content:"\10f5ad"}.fad.fa-pen-square:after{content:"\10f14b"}.fad.fa-pencil:after{content:"\10f040"}.fad.fa-pencil-alt:after{content:"\10f303"}.fad.fa-pencil-paintbrush:after{content:"\10f618"}.fad.fa-pencil-ruler:after{content:"\10f5ae"}.fad.fa-pennant:after{content:"\10f456"}.fad.fa-people-arrows:after{content:"\10e068"}.fad.fa-people-carry:after{content:"\10f4ce"}.fad.fa-pepper-hot:after{content:"\10f816"}.fad.fa-percent:after{content:"\10f295"}.fad.fa-percentage:after{content:"\10f541"}.fad.fa-person-booth:after{content:"\10f756"}.fad.fa-person-carry:after{content:"\10f4cf"}.fad.fa-person-dolly:after{content:"\10f4d0"}.fad.fa-person-dolly-empty:after{content:"\10f4d1"}.fad.fa-person-sign:after{content:"\10f757"}.fad.fa-phone:after{content:"\10f095"}.fad.fa-phone-alt:after{content:"\10f879"}.fad.fa-phone-laptop:after{content:"\10f87a"}.fad.fa-phone-office:after{content:"\10f67d"}.fad.fa-phone-plus:after{content:"\10f4d2"}.fad.fa-phone-rotary:after{content:"\10f8d3"}.fad.fa-phone-slash:after{content:"\10f3dd"}.fad.fa-phone-square:after{content:"\10f098"}.fad.fa-phone-square-alt:after{content:"\10f87b"}.fad.fa-phone-volume:after{content:"\10f2a0"}.fad.fa-photo-video:after{content:"\10f87c"}.fad.fa-pi:after{content:"\10f67e"}.fad.fa-piano:after{content:"\10f8d4"}.fad.fa-piano-keyboard:after{content:"\10f8d5"}.fad.fa-pie:after{content:"\10f705"}.fad.fa-pig:after{content:"\10f706"}.fad.fa-piggy-bank:after{content:"\10f4d3"}.fad.fa-pills:after{content:"\10f484"}.fad.fa-pizza:after{content:"\10f817"}.fad.fa-pizza-slice:after{content:"\10f818"}.fad.fa-place-of-worship:after{content:"\10f67f"}.fad.fa-plane:after{content:"\10f072"}.fad.fa-plane-alt:after{content:"\10f3de"}.fad.fa-plane-arrival:after{content:"\10f5af"}.fad.fa-plane-departure:after{content:"\10f5b0"}.fad.fa-plane-slash:after{content:"\10e069"}.fad.fa-planet-moon:after{content:"\10e01f"}.fad.fa-planet-ringed:after{content:"\10e020"}.fad.fa-play:after{content:"\10f04b"}.fad.fa-play-circle:after{content:"\10f144"}.fad.fa-plug:after{content:"\10f1e6"}.fad.fa-plus:after{content:"\10f067"}.fad.fa-plus-circle:after{content:"\10f055"}.fad.fa-plus-hexagon:after{content:"\10f300"}.fad.fa-plus-octagon:after{content:"\10f301"}.fad.fa-plus-square:after{content:"\10f0fe"}.fad.fa-podcast:after{content:"\10f2ce"}.fad.fa-podium:after{content:"\10f680"}.fad.fa-podium-star:after{content:"\10f758"}.fad.fa-police-box:after{content:"\10e021"}.fad.fa-poll:after{content:"\10f681"}.fad.fa-poll-h:after{content:"\10f682"}.fad.fa-poll-people:after{content:"\10f759"}.fad.fa-poo:after{content:"\10f2fe"}.fad.fa-poo-storm:after{content:"\10f75a"}.fad.fa-poop:after{content:"\10f619"}.fad.fa-popcorn:after{content:"\10f819"}.fad.fa-portal-enter:after{content:"\10e022"}.fad.fa-portal-exit:after{content:"\10e023"}.fad.fa-portrait:after{content:"\10f3e0"}.fad.fa-pound-sign:after{content:"\10f154"}.fad.fa-power-off:after{content:"\10f011"}.fad.fa-pray:after{content:"\10f683"}.fad.fa-praying-hands:after{content:"\10f684"}.fad.fa-prescription:after{content:"\10f5b1"}.fad.fa-prescription-bottle:after{content:"\10f485"}.fad.fa-prescription-bottle-alt:after{content:"\10f486"}.fad.fa-presentation:after{content:"\10f685"}.fad.fa-print:after{content:"\10f02f"}.fad.fa-print-search:after{content:"\10f81a"}.fad.fa-print-slash:after{content:"\10f686"}.fad.fa-procedures:after{content:"\10f487"}.fad.fa-project-diagram:after{content:"\10f542"}.fad.fa-projector:after{content:"\10f8d6"}.fad.fa-pump-medical:after{content:"\10e06a"}.fad.fa-pump-soap:after{content:"\10e06b"}.fad.fa-pumpkin:after{content:"\10f707"}.fad.fa-puzzle-piece:after{content:"\10f12e"}.fad.fa-qrcode:after{content:"\10f029"}.fad.fa-question:after{content:"\10f128"}.fad.fa-question-circle:after{content:"\10f059"}.fad.fa-question-square:after{content:"\10f2fd"}.fad.fa-quidditch:after{content:"\10f458"}.fad.fa-quote-left:after{content:"\10f10d"}.fad.fa-quote-right:after{content:"\10f10e"}.fad.fa-quran:after{content:"\10f687"}.fad.fa-rabbit:after{content:"\10f708"}.fad.fa-rabbit-fast:after{content:"\10f709"}.fad.fa-racquet:after{content:"\10f45a"}.fad.fa-radar:after{content:"\10e024"}.fad.fa-radiation:after{content:"\10f7b9"}.fad.fa-radiation-alt:after{content:"\10f7ba"}.fad.fa-radio:after{content:"\10f8d7"}.fad.fa-radio-alt:after{content:"\10f8d8"}.fad.fa-rainbow:after{content:"\10f75b"}.fad.fa-raindrops:after{content:"\10f75c"}.fad.fa-ram:after{content:"\10f70a"}.fad.fa-ramp-loading:after{content:"\10f4d4"}.fad.fa-random:after{content:"\10f074"}.fad.fa-raygun:after{content:"\10e025"}.fad.fa-receipt:after{content:"\10f543"}.fad.fa-record-vinyl:after{content:"\10f8d9"}.fad.fa-rectangle-landscape:after{content:"\10f2fa"}.fad.fa-rectangle-portrait:after{content:"\10f2fb"}.fad.fa-rectangle-wide:after{content:"\10f2fc"}.fad.fa-recycle:after{content:"\10f1b8"}.fad.fa-redo:after{content:"\10f01e"}.fad.fa-redo-alt:after{content:"\10f2f9"}.fad.fa-refrigerator:after{content:"\10e026"}.fad.fa-registered:after{content:"\10f25d"}.fad.fa-remove-format:after{content:"\10f87d"}.fad.fa-repeat:after{content:"\10f363"}.fad.fa-repeat-1:after{content:"\10f365"}.fad.fa-repeat-1-alt:after{content:"\10f366"}.fad.fa-repeat-alt:after{content:"\10f364"}.fad.fa-reply:after{content:"\10f3e5"}.fad.fa-reply-all:after{content:"\10f122"}.fad.fa-republican:after{content:"\10f75e"}.fad.fa-restroom:after{content:"\10f7bd"}.fad.fa-retweet:after{content:"\10f079"}.fad.fa-retweet-alt:after{content:"\10f361"}.fad.fa-ribbon:after{content:"\10f4d6"}.fad.fa-ring:after{content:"\10f70b"}.fad.fa-rings-wedding:after{content:"\10f81b"}.fad.fa-road:after{content:"\10f018"}.fad.fa-robot:after{content:"\10f544"}.fad.fa-rocket:after{content:"\10f135"}.fad.fa-rocket-launch:after{content:"\10e027"}.fad.fa-route:after{content:"\10f4d7"}.fad.fa-route-highway:after{content:"\10f61a"}.fad.fa-route-interstate:after{content:"\10f61b"}.fad.fa-router:after{content:"\10f8da"}.fad.fa-rss:after{content:"\10f09e"}.fad.fa-rss-square:after{content:"\10f143"}.fad.fa-ruble-sign:after{content:"\10f158"}.fad.fa-ruler:after{content:"\10f545"}.fad.fa-ruler-combined:after{content:"\10f546"}.fad.fa-ruler-horizontal:after{content:"\10f547"}.fad.fa-ruler-triangle:after{content:"\10f61c"}.fad.fa-ruler-vertical:after{content:"\10f548"}.fad.fa-running:after{content:"\10f70c"}.fad.fa-rupee-sign:after{content:"\10f156"}.fad.fa-rv:after{content:"\10f7be"}.fad.fa-sack:after{content:"\10f81c"}.fad.fa-sack-dollar:after{content:"\10f81d"}.fad.fa-sad-cry:after{content:"\10f5b3"}.fad.fa-sad-tear:after{content:"\10f5b4"}.fad.fa-salad:after{content:"\10f81e"}.fad.fa-sandwich:after{content:"\10f81f"}.fad.fa-satellite:after{content:"\10f7bf"}.fad.fa-satellite-dish:after{content:"\10f7c0"}.fad.fa-sausage:after{content:"\10f820"}.fad.fa-save:after{content:"\10f0c7"}.fad.fa-sax-hot:after{content:"\10f8db"}.fad.fa-saxophone:after{content:"\10f8dc"}.fad.fa-scalpel:after{content:"\10f61d"}.fad.fa-scalpel-path:after{content:"\10f61e"}.fad.fa-scanner:after{content:"\10f488"}.fad.fa-scanner-image:after{content:"\10f8f3"}.fad.fa-scanner-keyboard:after{content:"\10f489"}.fad.fa-scanner-touchscreen:after{content:"\10f48a"}.fad.fa-scarecrow:after{content:"\10f70d"}.fad.fa-scarf:after{content:"\10f7c1"}.fad.fa-school:after{content:"\10f549"}.fad.fa-screwdriver:after{content:"\10f54a"}.fad.fa-scroll:after{content:"\10f70e"}.fad.fa-scroll-old:after{content:"\10f70f"}.fad.fa-scrubber:after{content:"\10f2f8"}.fad.fa-scythe:after{content:"\10f710"}.fad.fa-sd-card:after{content:"\10f7c2"}.fad.fa-search:after{content:"\10f002"}.fad.fa-search-dollar:after{content:"\10f688"}.fad.fa-search-location:after{content:"\10f689"}.fad.fa-search-minus:after{content:"\10f010"}.fad.fa-search-plus:after{content:"\10f00e"}.fad.fa-seedling:after{content:"\10f4d8"}.fad.fa-send-back:after{content:"\10f87e"}.fad.fa-send-backward:after{content:"\10f87f"}.fad.fa-sensor:after{content:"\10e028"}.fad.fa-sensor-alert:after{content:"\10e029"}.fad.fa-sensor-fire:after{content:"\10e02a"}.fad.fa-sensor-on:after{content:"\10e02b"}.fad.fa-sensor-smoke:after{content:"\10e02c"}.fad.fa-server:after{content:"\10f233"}.fad.fa-shapes:after{content:"\10f61f"}.fad.fa-share:after{content:"\10f064"}.fad.fa-share-all:after{content:"\10f367"}.fad.fa-share-alt:after{content:"\10f1e0"}.fad.fa-share-alt-square:after{content:"\10f1e1"}.fad.fa-share-square:after{content:"\10f14d"}.fad.fa-sheep:after{content:"\10f711"}.fad.fa-shekel-sign:after{content:"\10f20b"}.fad.fa-shield:after{content:"\10f132"}.fad.fa-shield-alt:after{content:"\10f3ed"}.fad.fa-shield-check:after{content:"\10f2f7"}.fad.fa-shield-cross:after{content:"\10f712"}.fad.fa-shield-virus:after{content:"\10e06c"}.fad.fa-ship:after{content:"\10f21a"}.fad.fa-shipping-fast:after{content:"\10f48b"}.fad.fa-shipping-timed:after{content:"\10f48c"}.fad.fa-shish-kebab:after{content:"\10f821"}.fad.fa-shoe-prints:after{content:"\10f54b"}.fad.fa-shopping-bag:after{content:"\10f290"}.fad.fa-shopping-basket:after{content:"\10f291"}.fad.fa-shopping-cart:after{content:"\10f07a"}.fad.fa-shovel:after{content:"\10f713"}.fad.fa-shovel-snow:after{content:"\10f7c3"}.fad.fa-shower:after{content:"\10f2cc"}.fad.fa-shredder:after{content:"\10f68a"}.fad.fa-shuttle-van:after{content:"\10f5b6"}.fad.fa-shuttlecock:after{content:"\10f45b"}.fad.fa-sickle:after{content:"\10f822"}.fad.fa-sigma:after{content:"\10f68b"}.fad.fa-sign:after{content:"\10f4d9"}.fad.fa-sign-in:after{content:"\10f090"}.fad.fa-sign-in-alt:after{content:"\10f2f6"}.fad.fa-sign-language:after{content:"\10f2a7"}.fad.fa-sign-out:after{content:"\10f08b"}.fad.fa-sign-out-alt:after{content:"\10f2f5"}.fad.fa-signal:after{content:"\10f012"}.fad.fa-signal-1:after{content:"\10f68c"}.fad.fa-signal-2:after{content:"\10f68d"}.fad.fa-signal-3:after{content:"\10f68e"}.fad.fa-signal-4:after{content:"\10f68f"}.fad.fa-signal-alt:after{content:"\10f690"}.fad.fa-signal-alt-1:after{content:"\10f691"}.fad.fa-signal-alt-2:after{content:"\10f692"}.fad.fa-signal-alt-3:after{content:"\10f693"}.fad.fa-signal-alt-slash:after{content:"\10f694"}.fad.fa-signal-slash:after{content:"\10f695"}.fad.fa-signal-stream:after{content:"\10f8dd"}.fad.fa-signature:after{content:"\10f5b7"}.fad.fa-sim-card:after{content:"\10f7c4"}.fad.fa-sink:after{content:"\10e06d"}.fad.fa-siren:after{content:"\10e02d"}.fad.fa-siren-on:after{content:"\10e02e"}.fad.fa-sitemap:after{content:"\10f0e8"}.fad.fa-skating:after{content:"\10f7c5"}.fad.fa-skeleton:after{content:"\10f620"}.fad.fa-ski-jump:after{content:"\10f7c7"}.fad.fa-ski-lift:after{content:"\10f7c8"}.fad.fa-skiing:after{content:"\10f7c9"}.fad.fa-skiing-nordic:after{content:"\10f7ca"}.fad.fa-skull:after{content:"\10f54c"}.fad.fa-skull-cow:after{content:"\10f8de"}.fad.fa-skull-crossbones:after{content:"\10f714"}.fad.fa-slash:after{content:"\10f715"}.fad.fa-sledding:after{content:"\10f7cb"}.fad.fa-sleigh:after{content:"\10f7cc"}.fad.fa-sliders-h:after{content:"\10f1de"}.fad.fa-sliders-h-square:after{content:"\10f3f0"}.fad.fa-sliders-v:after{content:"\10f3f1"}.fad.fa-sliders-v-square:after{content:"\10f3f2"}.fad.fa-smile:after{content:"\10f118"}.fad.fa-smile-beam:after{content:"\10f5b8"}.fad.fa-smile-plus:after{content:"\10f5b9"}.fad.fa-smile-wink:after{content:"\10f4da"}.fad.fa-smog:after{content:"\10f75f"}.fad.fa-smoke:after{content:"\10f760"}.fad.fa-smoking:after{content:"\10f48d"}.fad.fa-smoking-ban:after{content:"\10f54d"}.fad.fa-sms:after{content:"\10f7cd"}.fad.fa-snake:after{content:"\10f716"}.fad.fa-snooze:after{content:"\10f880"}.fad.fa-snow-blowing:after{content:"\10f761"}.fad.fa-snowboarding:after{content:"\10f7ce"}.fad.fa-snowflake:after{content:"\10f2dc"}.fad.fa-snowflakes:after{content:"\10f7cf"}.fad.fa-snowman:after{content:"\10f7d0"}.fad.fa-snowmobile:after{content:"\10f7d1"}.fad.fa-snowplow:after{content:"\10f7d2"}.fad.fa-soap:after{content:"\10e06e"}.fad.fa-socks:after{content:"\10f696"}.fad.fa-solar-panel:after{content:"\10f5ba"}.fad.fa-solar-system:after{content:"\10e02f"}.fad.fa-sort:after{content:"\10f0dc"}.fad.fa-sort-alpha-down:after{content:"\10f15d"}.fad.fa-sort-alpha-down-alt:after{content:"\10f881"}.fad.fa-sort-alpha-up:after{content:"\10f15e"}.fad.fa-sort-alpha-up-alt:after{content:"\10f882"}.fad.fa-sort-alt:after{content:"\10f883"}.fad.fa-sort-amount-down:after{content:"\10f160"}.fad.fa-sort-amount-down-alt:after{content:"\10f884"}.fad.fa-sort-amount-up:after{content:"\10f161"}.fad.fa-sort-amount-up-alt:after{content:"\10f885"}.fad.fa-sort-circle:after{content:"\10e030"}.fad.fa-sort-circle-down:after{content:"\10e031"}.fad.fa-sort-circle-up:after{content:"\10e032"}.fad.fa-sort-down:after{content:"\10f0dd"}.fad.fa-sort-numeric-down:after{content:"\10f162"}.fad.fa-sort-numeric-down-alt:after{content:"\10f886"}.fad.fa-sort-numeric-up:after{content:"\10f163"}.fad.fa-sort-numeric-up-alt:after{content:"\10f887"}.fad.fa-sort-shapes-down:after{content:"\10f888"}.fad.fa-sort-shapes-down-alt:after{content:"\10f889"}.fad.fa-sort-shapes-up:after{content:"\10f88a"}.fad.fa-sort-shapes-up-alt:after{content:"\10f88b"}.fad.fa-sort-size-down:after{content:"\10f88c"}.fad.fa-sort-size-down-alt:after{content:"\10f88d"}.fad.fa-sort-size-up:after{content:"\10f88e"}.fad.fa-sort-size-up-alt:after{content:"\10f88f"}.fad.fa-sort-up:after{content:"\10f0de"}.fad.fa-soup:after{content:"\10f823"}.fad.fa-spa:after{content:"\10f5bb"}.fad.fa-space-shuttle:after{content:"\10f197"}.fad.fa-space-station-moon:after{content:"\10e033"}.fad.fa-space-station-moon-alt:after{content:"\10e034"}.fad.fa-spade:after{content:"\10f2f4"}.fad.fa-sparkles:after{content:"\10f890"}.fad.fa-speaker:after{content:"\10f8df"}.fad.fa-speakers:after{content:"\10f8e0"}.fad.fa-spell-check:after{content:"\10f891"}.fad.fa-spider:after{content:"\10f717"}.fad.fa-spider-black-widow:after{content:"\10f718"}.fad.fa-spider-web:after{content:"\10f719"}.fad.fa-spinner:after{content:"\10f110"}.fad.fa-spinner-third:after{content:"\10f3f4"}.fad.fa-splotch:after{content:"\10f5bc"}.fad.fa-spray-can:after{content:"\10f5bd"}.fad.fa-sprinkler:after{content:"\10e035"}.fad.fa-square:after{content:"\10f0c8"}.fad.fa-square-full:after{content:"\10f45c"}.fad.fa-square-root:after{content:"\10f697"}.fad.fa-square-root-alt:after{content:"\10f698"}.fad.fa-squirrel:after{content:"\10f71a"}.fad.fa-staff:after{content:"\10f71b"}.fad.fa-stamp:after{content:"\10f5bf"}.fad.fa-star:after{content:"\10f005"}.fad.fa-star-and-crescent:after{content:"\10f699"}.fad.fa-star-christmas:after{content:"\10f7d4"}.fad.fa-star-exclamation:after{content:"\10f2f3"}.fad.fa-star-half:after{content:"\10f089"}.fad.fa-star-half-alt:after{content:"\10f5c0"}.fad.fa-star-of-david:after{content:"\10f69a"}.fad.fa-star-of-life:after{content:"\10f621"}.fad.fa-star-shooting:after{content:"\10e036"}.fad.fa-starfighter:after{content:"\10e037"}.fad.fa-starfighter-alt:after{content:"\10e038"}.fad.fa-stars:after{content:"\10f762"}.fad.fa-starship:after{content:"\10e039"}.fad.fa-starship-freighter:after{content:"\10e03a"}.fad.fa-steak:after{content:"\10f824"}.fad.fa-steering-wheel:after{content:"\10f622"}.fad.fa-step-backward:after{content:"\10f048"}.fad.fa-step-forward:after{content:"\10f051"}.fad.fa-stethoscope:after{content:"\10f0f1"}.fad.fa-sticky-note:after{content:"\10f249"}.fad.fa-stocking:after{content:"\10f7d5"}.fad.fa-stomach:after{content:"\10f623"}.fad.fa-stop:after{content:"\10f04d"}.fad.fa-stop-circle:after{content:"\10f28d"}.fad.fa-stopwatch:after{content:"\10f2f2"}.fad.fa-stopwatch-20:after{content:"\10e06f"}.fad.fa-store:after{content:"\10f54e"}.fad.fa-store-alt:after{content:"\10f54f"}.fad.fa-store-alt-slash:after{content:"\10e070"}.fad.fa-store-slash:after{content:"\10e071"}.fad.fa-stream:after{content:"\10f550"}.fad.fa-street-view:after{content:"\10f21d"}.fad.fa-stretcher:after{content:"\10f825"}.fad.fa-strikethrough:after{content:"\10f0cc"}.fad.fa-stroopwafel:after{content:"\10f551"}.fad.fa-subscript:after{content:"\10f12c"}.fad.fa-subway:after{content:"\10f239"}.fad.fa-suitcase:after{content:"\10f0f2"}.fad.fa-suitcase-rolling:after{content:"\10f5c1"}.fad.fa-sun:after{content:"\10f185"}.fad.fa-sun-cloud:after{content:"\10f763"}.fad.fa-sun-dust:after{content:"\10f764"}.fad.fa-sun-haze:after{content:"\10f765"}.fad.fa-sunglasses:after{content:"\10f892"}.fad.fa-sunrise:after{content:"\10f766"}.fad.fa-sunset:after{content:"\10f767"}.fad.fa-superscript:after{content:"\10f12b"}.fad.fa-surprise:after{content:"\10f5c2"}.fad.fa-swatchbook:after{content:"\10f5c3"}.fad.fa-swimmer:after{content:"\10f5c4"}.fad.fa-swimming-pool:after{content:"\10f5c5"}.fad.fa-sword:after{content:"\10f71c"}.fad.fa-sword-laser:after{content:"\10e03b"}.fad.fa-sword-laser-alt:after{content:"\10e03c"}.fad.fa-swords:after{content:"\10f71d"}.fad.fa-swords-laser:after{content:"\10e03d"}.fad.fa-synagogue:after{content:"\10f69b"}.fad.fa-sync:after{content:"\10f021"}.fad.fa-sync-alt:after{content:"\10f2f1"}.fad.fa-syringe:after{content:"\10f48e"}.fad.fa-table:after{content:"\10f0ce"}.fad.fa-table-tennis:after{content:"\10f45d"}.fad.fa-tablet:after{content:"\10f10a"}.fad.fa-tablet-alt:after{content:"\10f3fa"}.fad.fa-tablet-android:after{content:"\10f3fb"}.fad.fa-tablet-android-alt:after{content:"\10f3fc"}.fad.fa-tablet-rugged:after{content:"\10f48f"}.fad.fa-tablets:after{content:"\10f490"}.fad.fa-tachometer:after{content:"\10f0e4"}.fad.fa-tachometer-alt:after{content:"\10f3fd"}.fad.fa-tachometer-alt-average:after{content:"\10f624"}.fad.fa-tachometer-alt-fast:after{content:"\10f625"}.fad.fa-tachometer-alt-fastest:after{content:"\10f626"}.fad.fa-tachometer-alt-slow:after{content:"\10f627"}.fad.fa-tachometer-alt-slowest:after{content:"\10f628"}.fad.fa-tachometer-average:after{content:"\10f629"}.fad.fa-tachometer-fast:after{content:"\10f62a"}.fad.fa-tachometer-fastest:after{content:"\10f62b"}.fad.fa-tachometer-slow:after{content:"\10f62c"}.fad.fa-tachometer-slowest:after{content:"\10f62d"}.fad.fa-taco:after{content:"\10f826"}.fad.fa-tag:after{content:"\10f02b"}.fad.fa-tags:after{content:"\10f02c"}.fad.fa-tally:after{content:"\10f69c"}.fad.fa-tanakh:after{content:"\10f827"}.fad.fa-tape:after{content:"\10f4db"}.fad.fa-tasks:after{content:"\10f0ae"}.fad.fa-tasks-alt:after{content:"\10f828"}.fad.fa-taxi:after{content:"\10f1ba"}.fad.fa-teeth:after{content:"\10f62e"}.fad.fa-teeth-open:after{content:"\10f62f"}.fad.fa-telescope:after{content:"\10e03e"}.fad.fa-temperature-down:after{content:"\10e03f"}.fad.fa-temperature-frigid:after{content:"\10f768"}.fad.fa-temperature-high:after{content:"\10f769"}.fad.fa-temperature-hot:after{content:"\10f76a"}.fad.fa-temperature-low:after{content:"\10f76b"}.fad.fa-temperature-up:after{content:"\10e040"}.fad.fa-tenge:after{content:"\10f7d7"}.fad.fa-tennis-ball:after{content:"\10f45e"}.fad.fa-terminal:after{content:"\10f120"}.fad.fa-text:after{content:"\10f893"}.fad.fa-text-height:after{content:"\10f034"}.fad.fa-text-size:after{content:"\10f894"}.fad.fa-text-width:after{content:"\10f035"}.fad.fa-th:after{content:"\10f00a"}.fad.fa-th-large:after{content:"\10f009"}.fad.fa-th-list:after{content:"\10f00b"}.fad.fa-theater-masks:after{content:"\10f630"}.fad.fa-thermometer:after{content:"\10f491"}.fad.fa-thermometer-empty:after{content:"\10f2cb"}.fad.fa-thermometer-full:after{content:"\10f2c7"}.fad.fa-thermometer-half:after{content:"\10f2c9"}.fad.fa-thermometer-quarter:after{content:"\10f2ca"}.fad.fa-thermometer-three-quarters:after{content:"\10f2c8"}.fad.fa-theta:after{content:"\10f69e"}.fad.fa-thumbs-down:after{content:"\10f165"}.fad.fa-thumbs-up:after{content:"\10f164"}.fad.fa-thumbtack:after{content:"\10f08d"}.fad.fa-thunderstorm:after{content:"\10f76c"}.fad.fa-thunderstorm-moon:after{content:"\10f76d"}.fad.fa-thunderstorm-sun:after{content:"\10f76e"}.fad.fa-ticket:after{content:"\10f145"}.fad.fa-ticket-alt:after{content:"\10f3ff"}.fad.fa-tilde:after{content:"\10f69f"}.fad.fa-times:after{content:"\10f00d"}.fad.fa-times-circle:after{content:"\10f057"}.fad.fa-times-hexagon:after{content:"\10f2ee"}.fad.fa-times-octagon:after{content:"\10f2f0"}.fad.fa-times-square:after{content:"\10f2d3"}.fad.fa-tint:after{content:"\10f043"}.fad.fa-tint-slash:after{content:"\10f5c7"}.fad.fa-tire:after{content:"\10f631"}.fad.fa-tire-flat:after{content:"\10f632"}.fad.fa-tire-pressure-warning:after{content:"\10f633"}.fad.fa-tire-rugged:after{content:"\10f634"}.fad.fa-tired:after{content:"\10f5c8"}.fad.fa-toggle-off:after{content:"\10f204"}.fad.fa-toggle-on:after{content:"\10f205"}.fad.fa-toilet:after{content:"\10f7d8"}.fad.fa-toilet-paper:after{content:"\10f71e"}.fad.fa-toilet-paper-alt:after{content:"\10f71f"}.fad.fa-toilet-paper-slash:after{content:"\10e072"}.fad.fa-tombstone:after{content:"\10f720"}.fad.fa-tombstone-alt:after{content:"\10f721"}.fad.fa-toolbox:after{content:"\10f552"}.fad.fa-tools:after{content:"\10f7d9"}.fad.fa-tooth:after{content:"\10f5c9"}.fad.fa-toothbrush:after{content:"\10f635"}.fad.fa-torah:after{content:"\10f6a0"}.fad.fa-torii-gate:after{content:"\10f6a1"}.fad.fa-tornado:after{content:"\10f76f"}.fad.fa-tractor:after{content:"\10f722"}.fad.fa-trademark:after{content:"\10f25c"}.fad.fa-traffic-cone:after{content:"\10f636"}.fad.fa-traffic-light:after{content:"\10f637"}.fad.fa-traffic-light-go:after{content:"\10f638"}.fad.fa-traffic-light-slow:after{content:"\10f639"}.fad.fa-traffic-light-stop:after{content:"\10f63a"}.fad.fa-trailer:after{content:"\10e041"}.fad.fa-train:after{content:"\10f238"}.fad.fa-tram:after{content:"\10f7da"}.fad.fa-transgender:after{content:"\10f224"}.fad.fa-transgender-alt:after{content:"\10f225"}.fad.fa-transporter:after{content:"\10e042"}.fad.fa-transporter-1:after{content:"\10e043"}.fad.fa-transporter-2:after{content:"\10e044"}.fad.fa-transporter-3:after{content:"\10e045"}.fad.fa-transporter-empty:after{content:"\10e046"}.fad.fa-trash:after{content:"\10f1f8"}.fad.fa-trash-alt:after{content:"\10f2ed"}.fad.fa-trash-restore:after{content:"\10f829"}.fad.fa-trash-restore-alt:after{content:"\10f82a"}.fad.fa-trash-undo:after{content:"\10f895"}.fad.fa-trash-undo-alt:after{content:"\10f896"}.fad.fa-treasure-chest:after{content:"\10f723"}.fad.fa-tree:after{content:"\10f1bb"}.fad.fa-tree-alt:after{content:"\10f400"}.fad.fa-tree-christmas:after{content:"\10f7db"}.fad.fa-tree-decorated:after{content:"\10f7dc"}.fad.fa-tree-large:after{content:"\10f7dd"}.fad.fa-tree-palm:after{content:"\10f82b"}.fad.fa-trees:after{content:"\10f724"}.fad.fa-triangle:after{content:"\10f2ec"}.fad.fa-triangle-music:after{content:"\10f8e2"}.fad.fa-trophy:after{content:"\10f091"}.fad.fa-trophy-alt:after{content:"\10f2eb"}.fad.fa-truck:after{content:"\10f0d1"}.fad.fa-truck-container:after{content:"\10f4dc"}.fad.fa-truck-couch:after{content:"\10f4dd"}.fad.fa-truck-loading:after{content:"\10f4de"}.fad.fa-truck-monster:after{content:"\10f63b"}.fad.fa-truck-moving:after{content:"\10f4df"}.fad.fa-truck-pickup:after{content:"\10f63c"}.fad.fa-truck-plow:after{content:"\10f7de"}.fad.fa-truck-ramp:after{content:"\10f4e0"}.fad.fa-trumpet:after{content:"\10f8e3"}.fad.fa-tshirt:after{content:"\10f553"}.fad.fa-tty:after{content:"\10f1e4"}.fad.fa-turkey:after{content:"\10f725"}.fad.fa-turntable:after{content:"\10f8e4"}.fad.fa-turtle:after{content:"\10f726"}.fad.fa-tv:after{content:"\10f26c"}.fad.fa-tv-alt:after{content:"\10f8e5"}.fad.fa-tv-music:after{content:"\10f8e6"}.fad.fa-tv-retro:after{content:"\10f401"}.fad.fa-typewriter:after{content:"\10f8e7"}.fad.fa-ufo:after{content:"\10e047"}.fad.fa-ufo-beam:after{content:"\10e048"}.fad.fa-umbrella:after{content:"\10f0e9"}.fad.fa-umbrella-beach:after{content:"\10f5ca"}.fad.fa-underline:after{content:"\10f0cd"}.fad.fa-undo:after{content:"\10f0e2"}.fad.fa-undo-alt:after{content:"\10f2ea"}.fad.fa-unicorn:after{content:"\10f727"}.fad.fa-union:after{content:"\10f6a2"}.fad.fa-universal-access:after{content:"\10f29a"}.fad.fa-university:after{content:"\10f19c"}.fad.fa-unlink:after{content:"\10f127"}.fad.fa-unlock:after{content:"\10f09c"}.fad.fa-unlock-alt:after{content:"\10f13e"}.fad.fa-upload:after{content:"\10f093"}.fad.fa-usb-drive:after{content:"\10f8e9"}.fad.fa-usd-circle:after{content:"\10f2e8"}.fad.fa-usd-square:after{content:"\10f2e9"}.fad.fa-user:after{content:"\10f007"}.fad.fa-user-alien:after{content:"\10e04a"}.fad.fa-user-alt:after{content:"\10f406"}.fad.fa-user-alt-slash:after{content:"\10f4fa"}.fad.fa-user-astronaut:after{content:"\10f4fb"}.fad.fa-user-chart:after{content:"\10f6a3"}.fad.fa-user-check:after{content:"\10f4fc"}.fad.fa-user-circle:after{content:"\10f2bd"}.fad.fa-user-clock:after{content:"\10f4fd"}.fad.fa-user-cog:after{content:"\10f4fe"}.fad.fa-user-cowboy:after{content:"\10f8ea"}.fad.fa-user-crown:after{content:"\10f6a4"}.fad.fa-user-edit:after{content:"\10f4ff"}.fad.fa-user-friends:after{content:"\10f500"}.fad.fa-user-graduate:after{content:"\10f501"}.fad.fa-user-hard-hat:after{content:"\10f82c"}.fad.fa-user-headset:after{content:"\10f82d"}.fad.fa-user-injured:after{content:"\10f728"}.fad.fa-user-lock:after{content:"\10f502"}.fad.fa-user-md:after{content:"\10f0f0"}.fad.fa-user-md-chat:after{content:"\10f82e"}.fad.fa-user-minus:after{content:"\10f503"}.fad.fa-user-music:after{content:"\10f8eb"}.fad.fa-user-ninja:after{content:"\10f504"}.fad.fa-user-nurse:after{content:"\10f82f"}.fad.fa-user-plus:after{content:"\10f234"}.fad.fa-user-robot:after{content:"\10e04b"}.fad.fa-user-secret:after{content:"\10f21b"}.fad.fa-user-shield:after{content:"\10f505"}.fad.fa-user-slash:after{content:"\10f506"}.fad.fa-user-tag:after{content:"\10f507"}.fad.fa-user-tie:after{content:"\10f508"}.fad.fa-user-times:after{content:"\10f235"}.fad.fa-user-unlock:after{content:"\10e058"}.fad.fa-user-visor:after{content:"\10e04c"}.fad.fa-users:after{content:"\10f0c0"}.fad.fa-users-class:after{content:"\10f63d"}.fad.fa-users-cog:after{content:"\10f509"}.fad.fa-users-crown:after{content:"\10f6a5"}.fad.fa-users-medical:after{content:"\10f830"}.fad.fa-users-slash:after{content:"\10e073"}.fad.fa-utensil-fork:after{content:"\10f2e3"}.fad.fa-utensil-knife:after{content:"\10f2e4"}.fad.fa-utensil-spoon:after{content:"\10f2e5"}.fad.fa-utensils:after{content:"\10f2e7"}.fad.fa-utensils-alt:after{content:"\10f2e6"}.fad.fa-vacuum:after{content:"\10e04d"}.fad.fa-vacuum-robot:after{content:"\10e04e"}.fad.fa-value-absolute:after{content:"\10f6a6"}.fad.fa-vector-square:after{content:"\10f5cb"}.fad.fa-venus:after{content:"\10f221"}.fad.fa-venus-double:after{content:"\10f226"}.fad.fa-venus-mars:after{content:"\10f228"}.fad.fa-vest:after{content:"\10e085"}.fad.fa-vest-patches:after{content:"\10e086"}.fad.fa-vhs:after{content:"\10f8ec"}.fad.fa-vial:after{content:"\10f492"}.fad.fa-vials:after{content:"\10f493"}.fad.fa-video:after{content:"\10f03d"}.fad.fa-video-plus:after{content:"\10f4e1"}.fad.fa-video-slash:after{content:"\10f4e2"}.fad.fa-vihara:after{content:"\10f6a7"}.fad.fa-violin:after{content:"\10f8ed"}.fad.fa-virus:after{content:"\10e074"}.fad.fa-virus-slash:after{content:"\10e075"}.fad.fa-viruses:after{content:"\10e076"}.fad.fa-voicemail:after{content:"\10f897"}.fad.fa-volcano:after{content:"\10f770"}.fad.fa-volleyball-ball:after{content:"\10f45f"}.fad.fa-volume:after{content:"\10f6a8"}.fad.fa-volume-down:after{content:"\10f027"}.fad.fa-volume-mute:after{content:"\10f6a9"}.fad.fa-volume-off:after{content:"\10f026"}.fad.fa-volume-slash:after{content:"\10f2e2"}.fad.fa-volume-up:after{content:"\10f028"}.fad.fa-vote-nay:after{content:"\10f771"}.fad.fa-vote-yea:after{content:"\10f772"}.fad.fa-vr-cardboard:after{content:"\10f729"}.fad.fa-wagon-covered:after{content:"\10f8ee"}.fad.fa-walker:after{content:"\10f831"}.fad.fa-walkie-talkie:after{content:"\10f8ef"}.fad.fa-walking:after{content:"\10f554"}.fad.fa-wallet:after{content:"\10f555"}.fad.fa-wand:after{content:"\10f72a"}.fad.fa-wand-magic:after{content:"\10f72b"}.fad.fa-warehouse:after{content:"\10f494"}.fad.fa-warehouse-alt:after{content:"\10f495"}.fad.fa-washer:after{content:"\10f898"}.fad.fa-watch:after{content:"\10f2e1"}.fad.fa-watch-calculator:after{content:"\10f8f0"}.fad.fa-watch-fitness:after{content:"\10f63e"}.fad.fa-water:after{content:"\10f773"}.fad.fa-water-lower:after{content:"\10f774"}.fad.fa-water-rise:after{content:"\10f775"}.fad.fa-wave-sine:after{content:"\10f899"}.fad.fa-wave-square:after{content:"\10f83e"}.fad.fa-wave-triangle:after{content:"\10f89a"}.fad.fa-waveform:after{content:"\10f8f1"}.fad.fa-waveform-path:after{content:"\10f8f2"}.fad.fa-webcam:after{content:"\10f832"}.fad.fa-webcam-slash:after{content:"\10f833"}.fad.fa-weight:after{content:"\10f496"}.fad.fa-weight-hanging:after{content:"\10f5cd"}.fad.fa-whale:after{content:"\10f72c"}.fad.fa-wheat:after{content:"\10f72d"}.fad.fa-wheelchair:after{content:"\10f193"}.fad.fa-whistle:after{content:"\10f460"}.fad.fa-wifi:after{content:"\10f1eb"}.fad.fa-wifi-1:after{content:"\10f6aa"}.fad.fa-wifi-2:after{content:"\10f6ab"}.fad.fa-wifi-slash:after{content:"\10f6ac"}.fad.fa-wind:after{content:"\10f72e"}.fad.fa-wind-turbine:after{content:"\10f89b"}.fad.fa-wind-warning:after{content:"\10f776"}.fad.fa-window:after{content:"\10f40e"}.fad.fa-window-alt:after{content:"\10f40f"}.fad.fa-window-close:after{content:"\10f410"}.fad.fa-window-frame:after{content:"\10e04f"}.fad.fa-window-frame-open:after{content:"\10e050"}.fad.fa-window-maximize:after{content:"\10f2d0"}.fad.fa-window-minimize:after{content:"\10f2d1"}.fad.fa-window-restore:after{content:"\10f2d2"}.fad.fa-windsock:after{content:"\10f777"}.fad.fa-wine-bottle:after{content:"\10f72f"}.fad.fa-wine-glass:after{content:"\10f4e3"}.fad.fa-wine-glass-alt:after{content:"\10f5ce"}.fad.fa-won-sign:after{content:"\10f159"}.fad.fa-wreath:after{content:"\10f7e2"}.fad.fa-wrench:after{content:"\10f0ad"}.fad.fa-x-ray:after{content:"\10f497"}.fad.fa-yen-sign:after{content:"\10f157"}.fad.fa-yin-yang:after{content:"\10f6ad"}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.0.svg#fontawesome) format("svg");unicode-range:U+f002,U+f008-f009,U+f00b-f00c,U+f00e,U+f011,U+f013,U+f019,U+f01c,U+f022-f025,U+f02a-f02b,U+f02d,U+f030,U+f040-f041,U+f044,U+f047,U+f049-f04a,U+f04e,U+f050,U+f052-f055,U+f057-f05b,U+f05e,U+f060-f066,U+f068-f06a,U+f074,U+f077-f07a,U+f07c-f07e,U+f085,U+f089,U+f08b,U+f090,U+f093-f094,U+f098,U+f09c-f09e,U+f0a4-f0ab,U+f0b2,U+f0c1,U+f0c3,U+f0c6,U+f0c9,U+f0ce,U+f0d7-f0db,U+f0e2-f0e3,U+f0e9-f0ea,U+f0ec,U+f0f4,U+f0f8,U+f0fa-f0fe,U+f100-f103,U+f106-f108,U+f10a-f10b,U+f11c,U+f120-f122,U+f124,U+f126-f128,U+f12e,U+f134,U+f137-f13a,U+f13e,U+f141-f143,U+f146,U+f14a-f14d,U+f150-f154,U+f156-f159,U+f175-f178,U+f182-f183,U+f188,U+f191-f192,U+f195,U+f199,U+f1ad-f1ae,U+f1b0,U+f1b2-f1b3,U+f1b8,U+f1bb,U+f1c0,U+f1cd,U+f1d8,U+f1da,U+f1e0-f1e2,U+f1ea,U+f1fa,U+f1fd-f1fe,U+f204-f206,U+f20b,U+f217-f218,U+f21c,U+f222,U+f224,U+f226-f229,U+f233,U+f238-f239,U+f240-f244,U+f246,U+f255-f258,U+f25a-f25c,U+f28b,U+f28d,U+f290-f292,U+f295,U+f2a1-f2a4,U+f2a8,U+f2c7-f2cb,U+f2ce,U+f2d0,U+f2d2-f2d3,U+f2db,U+f2e6-f2e7,U+f2ea,U+f2f0-f2f1,U+f2f5-f2f7,U+f2f9,U+f2fd,U+f301,U+f303,U+f308-f30f,U+f31d,U+f320-f322,U+f325-f326,U+f328-f32e,U+f330-f332,U+f336-f337,U+f339-f33c,U+f33e,U+f340-f34c,U+f350-f353,U+f355,U+f358-f35b,U+f360-f367,U+f376,U+f37e,U+f387,U+f389-f38a,U+f390,U+f39b-f39c,U+f3a0,U+f3b3,U+f3be-f3bf,U+f3c2,U+f3c5,U+f3cd-f3cf,U+f3de,U+f3e5,U+f3ed,U+f3f0,U+f3f2,U+f3fa-f3fc,U+f400-f401,U+f40e-f410}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.1.svg#fontawesome) format("svg");unicode-range:U+f3c1}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.3.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.3.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.3.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.3.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.3.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.3.svg#fontawesome) format("svg");unicode-range:U+f245,U+f2b9,U+f2bb,U+f2c1,U+f3e0}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.5.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.5.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.5.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.5.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.5.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.5.svg#fontawesome) format("svg");unicode-range:U+f1e3,U+f432,U+f437-f438,U+f449-f44c,U+f44f-f451,U+f453,U+f455,U+f458,U+f45a-f45b,U+f45d}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.7.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.7.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.7.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.7.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.7.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.7.svg#fontawesome) format("svg");unicode-range:U+f0d1,U+f0f1,U+f0f9,U+f21e,U+f461,U+f463-f46f,U+f472-f475,U+f479-f47a,U+f47d-f47e,U+f481-f487,U+f489,U+f48b-f496}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.9.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.9.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.9.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.9.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.9.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.9.svg#fontawesome) format("svg");unicode-range:U+f03d,U+f06c,U+f086,U+f0f2,U+f10d-f10e,U+f187,U+f2b5,U+f2e9,U+f2fe,U+f3dd,U+f47b-f47c,U+f498,U+f49a-f49b,U+f49d,U+f49f-f4b9,U+f4bb-f4bf,U+f4c2-f4c6,U+f4c8,U+f4cb-f4d2,U+f4d4,U+f4d6,U+f4d8-f4d9,U+f4db-f4e2}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.10.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.10.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.10.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.10.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.10.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.10.svg#fontawesome) format("svg");unicode-range:U+f471,U+f4ca}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.11.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.11.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.11.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.11.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.11.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.11.svg#fontawesome) format("svg");unicode-range:U+f007,U+f0c0,U+f0c2,U+f0ed-f0ee,U+f0f0,U+f1de,U+f21b,U+f234-f235,U+f381-f382,U+f3f1,U+f406,U+f4e6,U+f4fa-f501,U+f503-f509}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.13.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.13.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.13.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.13.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.13.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.0.13.svg#fontawesome) format("svg");unicode-range:U+f010,U+f067,U+f072,U+f0ad,U+f0d6,U+f0e8,U+f130-f131,U+f24e,U+f3c9,U+f3d1,U+f517,U+f519-f51e,U+f520-f52c,U+f52e,U+f530-f533,U+f535-f543,U+f545-f54b,U+f54d,U+f54f-f552,U+f554-f555}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.1.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.1.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.1.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.1.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.1.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.1.0.svg#fontawesome) format("svg");unicode-range:U+f043,U+f0c4,U+f0d0,U+f125,U+f1ba,U+f1fb-f1fc,U+f207,U+f236,U+f279,U+f304-f305,U+f52d,U+f557-f558,U+f55a-f55f,U+f562-f566,U+f568,U+f56a-f56b,U+f575-f577,U+f57b,U+f586,U+f588,U+f58d-f590,U+f593-f595,U+f59d,U+f59f-f5a2,U+f5a6-f5a7,U+f5a9-f5af,U+f5b1,U+f5b6,U+f5b9-f5bd,U+f5c4-f5c5,U+f5c7,U+f5c9-f5cb,U+f5cd}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.1.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.1.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.1.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.1.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.1.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.1.1.svg#fontawesome) format("svg");unicode-range:U+f386}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.2.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.2.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.2.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.2.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.2.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.2.0.svg#fontawesome) format("svg");unicode-range:U+f018,U+f0e4,U+f109,U+f1b9,U+f1e5,U+f1f6,U+f21d,U+f276-f277,U+f3fd,U+f4d7,U+f518,U+f5d1,U+f5d4-f5da,U+f5dd,U+f5df-f5e5,U+f5e8-f5ea,U+f5ed-f5f0,U+f5f2,U+f5f4-f5f5,U+f5f8-f5f9,U+f5fb-f600,U+f603-f60e,U+f610,U+f614,U+f617-f619,U+f61c-f61e,U+f620-f621,U+f623-f62f,U+f633,U+f635-f63d}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.3.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.3.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.3.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.3.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.3.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.3.0.svg#fontawesome) format("svg");unicode-range:U+f027-f028,U+f080,U+f0a1,U+f0b1,U+f0eb,U+f200-f201,U+f2e2,U+f61a,U+f640,U+f643-f647,U+f64a-f64b,U+f64d-f653,U+f655-f656,U+f65d,U+f65f-f663,U+f665,U+f667-f669,U+f66b-f671,U+f673-f675,U+f678-f67b,U+f67d-f680,U+f683-f689,U+f68b,U+f694-f695,U+f697-f699,U+f69b-f69c,U+f69e-f69f,U+f6a1-f6a9,U+f6ac}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.4.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.4.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.4.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.4.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.4.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.4.0.svg#fontawesome) format("svg");unicode-range:U+f499,U+f676,U+f6ae,U+f6b0-f6b3,U+f6b5-f6bc,U+f6bf,U+f6c2,U+f6c5,U+f6c7-f6c8,U+f6cb,U+f6cd-f6d2,U+f6d5,U+f6d8-f6d9,U+f6db,U+f6de,U+f6e2-f6e3,U+f6e5-f6e7,U+f6e9-f6ec,U+f6ee,U+f6f1-f6f3,U+f6f5-f6f8,U+f6fc-f6fd,U+f6ff-f703,U+f707,U+f70a-f70b,U+f711-f713,U+f715-f71d,U+f720-f724,U+f726-f729,U+f72b,U+f72d,U+f72f}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.4.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.4.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.4.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.4.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.4.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.4.1.svg#fontawesome) format("svg");unicode-range:U+f72a}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.5.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.5.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.5.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.5.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.5.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.5.0.svg#fontawesome) format("svg");unicode-range:U+f0e7,U+f185,U+f2dc,U+f6c3-f6c4,U+f72e,U+f732-f735,U+f737-f750,U+f752,U+f754-f758,U+f75a,U+f75c,U+f75e-f761,U+f763-f76e,U+f771-f776}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.6.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.6.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.6.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.6.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.6.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.6.0.svg#fontawesome) format("svg");unicode-range:U+f06b,U+f5b7,U+f77d,U+f77f,U+f781-f782,U+f788,U+f78a-f78c,U+f78e-f78f,U+f792-f796,U+f79a-f7a1,U+f7a3-f7a4,U+f7a7-f7a8,U+f7aa,U+f7ac-f7ae,U+f7b4-f7b6,U+f7b8,U+f7bd-f7be,U+f7c1-f7c3,U+f7c5,U+f7c7-f7d2,U+f7d4,U+f7d7-f7d8,U+f7da-f7dc,U+f7de,U+f7e2}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.6.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.6.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.6.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.6.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.6.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.6.1.svg#fontawesome) format("svg");unicode-range:U+f071}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.6.3.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.6.3.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.6.3.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.6.3.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.6.3.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.6.3.svg#fontawesome) format("svg");unicode-range:U+f7e4}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.7.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.7.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.7.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.7.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.7.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.7.0.svg#fontawesome) format("svg");unicode-range:U+f00a,U+f015,U+f06e,U+f070,U+f1e4,U+f2a0,U+f377,U+f470,U+f49c,U+f49e,U+f4c9,U+f6d6-f6d7,U+f705,U+f725,U+f77e,U+f780,U+f7e5-f7e7,U+f7e9-f7f0,U+f7f2-f7fc,U+f7fe,U+f800-f802,U+f804-f805,U+f807-f80f,U+f811-f812,U+f814-f818,U+f81b,U+f81e-f823,U+f825-f827,U+f82c-f82e,U+f830-f833}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.7.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.7.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.7.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.7.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.7.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.7.1.svg#fontawesome) format("svg");unicode-range:U+f7f1}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.8.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.8.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.8.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.8.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.8.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.8.0.svg#fontawesome) format("svg");unicode-range:U+f01e,U+f021,U+f026,U+f076,U+f12d,U+f31e,U+f356,U+f45f,U+f5b0,U+f83e}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.8.2.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.8.2.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.8.2.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.8.2.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.8.2.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.8.2.svg#fontawesome) format("svg");unicode-range:U+f560}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.9.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.9.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.9.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.9.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.9.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.9.0.svg#fontawesome) format("svg");unicode-range:U+f036-f03c,U+f0ae,U+f0ca-f0cd,U+f15d-f15e,U+f160-f163,U+f1dd,U+f313-f315,U+f34e,U+f439-f448,U+f502,U+f677,U+f843-f855,U+f858-f85e,U+f860-f862,U+f864,U+f866-f878,U+f87a,U+f87c-f87d,U+f880-f892,U+f897-f89b}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.10.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.10.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.10.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.10.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.10.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.10.1.svg#fontawesome) format("svg");unicode-range:U+f000,U+f012,U+f029,U+f03e,U+f06d,U+f075,U+f07b,U+f083-f084,U+f0a0,U+f11e,U+f140,U+f19d,U+f20a,U+f247-f248,U+f251-f254,U+f25d,U+f275,U+f27a,U+f2c2,U+f2d1,U+f302,U+f310-f311,U+f34d,U+f3a5,U+f435,U+f454,U+f456,U+f476,U+f47f-f480,U+f52f,U+f534,U+f561,U+f578,U+f591,U+f5db,U+f5e7,U+f5f6,U+f611,U+f613,U+f654,U+f681-f682,U+f68c-f693,U+f6be,U+f6da,U+f6e4,U+f6ed,U+f6ef-f6f0,U+f6f4,U+f6fa-f6fb,U+f6fe,U+f72c,U+f751,U+f759,U+f75b,U+f779,U+f77c,U+f786-f787,U+f7ab,U+f7b2,U+f7b7,U+f7e8,U+f813,U+f85f,U+f863,U+f87b,U+f89c-f89d}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.10.2.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.10.2.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.10.2.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.10.2.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.10.2.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.10.2.svg#fontawesome) format("svg");unicode-range:U+f004-f005,U+f02c,U+f02e,U+f031-f035,U+f04b-f04d,U+f056,U+f073,U+f08d,U+f095,U+f0a3,U+f0c5,U+f0c7-f0c8,U+f0dc-f0de,U+f0e0,U+f110-f111,U+f129-f12c,U+f132-f133,U+f144-f145,U+f15b-f15c,U+f164-f165,U+f193,U+f197,U+f1ab,U+f1c1-f1c9,U+f1ce,U+f1dc,U+f1f8-f1f9,U+f219,U+f249,U+f271-f274,U+f29a,U+f29e,U+f2a7,U+f2b6,U+f2e1,U+f2e3-f2e5,U+f2ec-f2ed,U+f2f2,U+f2f4,U+f2fa-f2fc,U+f306,U+f312,U+f316,U+f31a,U+f31c,U+f327,U+f333-f335,U+f3f4,U+f3ff,U+f45c,U+f460,U+f462,U+f477-f478,U+f497,U+f4ba,U+f4d3,U+f54c,U+f553,U+f559,U+f56c-f574,U+f5bf,U+f5c1,U+f5f3,U+f630-f632,U+f634,U+f63e,U+f641,U+f659-f65c,U+f696,U+f6a0,U+f6b4,U+f6bd,U+f6dd,U+f706,U+f708-f709,U+f70d-f710,U+f714,U+f71e-f71f,U+f736,U+f76f-f770,U+f777,U+f783-f784,U+f7a9,U+f7c4,U+f7d5,U+f7d9,U+f7dd,U+f7fd,U+f81c-f81d,U+f824,U+f828-f82a,U+f856-f857,U+f865,U+f879,U+f87e,U+f893-f896}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.11.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.11.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.11.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.11.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.11.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.11.0.svg#fontawesome) format("svg");unicode-range:U+f001,U+f02f,U+f042,U+f08e,U+f091,U+f0f3,U+f104-f105,U+f11b,U+f13d,U+f149,U+f1ac,U+f1ec,U+f223,U+f225,U+f22a-f22c,U+f24d,U+f26c,U+f29d,U+f2eb,U+f2ee,U+f2f3,U+f300,U+f307,U+f323-f324,U+f338,U+f33d,U+f35d,U+f48a,U+f4c0,U+f569,U+f5dc,U+f5eb,U+f601,U+f61b,U+f64c,U+f664,U+f66a,U+f68a,U+f6c0-f6c1,U+f6df-f6e1,U+f6e8,U+f6f9,U+f70c,U+f7a6,U+f81a,U+f89f-f8a5,U+f8a7-f8b6,U+f8b8-f8b9,U+f8bb-f8c9,U+f8cb-f8d1,U+f8d3,U+f8d5-f8dd,U+f8df-f8e0,U+f8e2-f8e7,U+f8e9-f8ed,U+f8ef-f8f2}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.11.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.11.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.11.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.11.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.11.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.11.1.svg#fontawesome) format("svg");unicode-range:U+f00d,U+f048,U+f051,U+f0ac,U+f0b0,U+f118-f11a,U+f148,U+f14e,U+f155,U+f186,U+f19c,U+f1eb,U+f21a,U+f221,U+f22d,U+f2bd,U+f2e8,U+f2f8,U+f354,U+f357,U+f433-f434,U+f436,U+f44e,U+f45e,U+f4c7,U+f4da,U+f4e3,U+f51f,U+f54e,U+f556,U+f567,U+f579-f57a,U+f57c-f585,U+f587,U+f589-f58a,U+f58c,U+f596-f59c,U+f5a4-f5a5,U+f5b3-f5b4,U+f5b8,U+f5c0,U+f5c2-f5c3,U+f5c8,U+f5ce,U+f5de,U+f5e6,U+f5ec,U+f602,U+f615-f616,U+f622,U+f648-f649,U+f67c,U+f69a,U+f6aa-f6ab,U+f6ad,U+f7a2,U+f7a5,U+f7b9-f7ba,U+f7ff,U+f803,U+f806,U+f810,U+f819,U+f82b,U+f87f,U+f8de,U+f8ee}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.11.2.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.11.2.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.11.2.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.11.2.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.11.2.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.11.2.svg#fontawesome) format("svg");unicode-range:U+f488,U+f8b7,U+f8f3}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.12.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.12.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.12.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.12.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.12.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.12.0.svg#fontawesome) format("svg");unicode-range:U+f135,U+f1e6,U+f259,U+f2cc-f2cd,U+f422,U+f424,U+f515-f516,U+f544,U+f58b,U+f5d2-f5d3,U+f61f,U+f657-f658,U+f666,U+f672,U+f6d3-f6d4,U+f753,U+f762,U+f7bf-f7c0,U+f82f,U+f8ba,U+f8d4,U+f8f4-f8ff}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.12.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.12.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.12.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.12.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.12.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.12.1.svg#fontawesome) format("svg");unicode-range:U+f017,U+f317-f319,U+f65e,U+f6c6}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.13.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.13.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.13.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.13.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.13.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.13.0.svg#fontawesome) format("svg");unicode-range:U+f4c1}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.14.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.14.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.14.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.14.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.14.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.14.0.svg#fontawesome) format("svg");unicode-range:U+e000-e006,U+e008-e012,U+e014-e019,U+e01b-e01d,U+e01f-e048,U+e04a-e051,U+e053-e054,U+e058-e076}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.15.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.15.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.15.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.15.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.15.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.15.1.svg#fontawesome) format("svg");unicode-range:U+e085-e086}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:300;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.15.3.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.15.3.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.15.3.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.15.3.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.15.3.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-light-300-5.15.3.svg#fontawesome) format("svg");unicode-range:U+f5d0}.fal{font-weight:300}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.0.svg#fontawesome) format("svg");unicode-range:U+f022,U+f024,U+f044,U+f057-f059,U+f07c,U+f089,U+f094,U+f09d,U+f0a4-f0a7,U+f0f8,U+f0fe,U+f11c,U+f146,U+f14a,U+f14d,U+f150-f152,U+f191-f192,U+f1ad,U+f1cd,U+f1d8,U+f1ea,U+f255-f258,U+f25a-f25b,U+f28b,U+f28d,U+f2d0,U+f2d2,U+f328,U+f358-f35b,U+f410}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.0.svg#fontawesome) format("svg");unicode-range:U+f002,U+f008-f009,U+f00b-f00c,U+f00e,U+f011,U+f013,U+f019,U+f01c,U+f023,U+f025,U+f02a-f02b,U+f02d,U+f030,U+f040-f041,U+f047,U+f049-f04a,U+f04e,U+f050,U+f052-f055,U+f05a-f05b,U+f05e,U+f060-f066,U+f068-f06a,U+f074,U+f077-f07a,U+f07d-f07e,U+f085,U+f08b,U+f090,U+f093,U+f098,U+f09c,U+f09e,U+f0a8-f0ab,U+f0b2,U+f0c1,U+f0c3,U+f0c6,U+f0c9,U+f0ce,U+f0d7-f0db,U+f0e2-f0e3,U+f0e9-f0ea,U+f0ec,U+f0f4,U+f0fa-f0fd,U+f100-f103,U+f106-f108,U+f10a-f10b,U+f120-f122,U+f124,U+f126-f128,U+f12e,U+f134,U+f137-f13a,U+f13e,U+f141-f143,U+f14b-f14c,U+f153-f154,U+f156-f159,U+f175-f178,U+f182-f183,U+f188,U+f195,U+f199,U+f1ae,U+f1b0,U+f1b2-f1b3,U+f1b8,U+f1bb,U+f1c0,U+f1da,U+f1e0-f1e2,U+f1fa,U+f1fd-f1fe,U+f204-f206,U+f20b,U+f217-f218,U+f21c,U+f222,U+f224,U+f226-f229,U+f233,U+f238-f239,U+f240-f244,U+f246,U+f25c,U+f290-f292,U+f295,U+f2a1-f2a4,U+f2a8,U+f2c7-f2cb,U+f2ce,U+f2d3,U+f2db,U+f2e6-f2e7,U+f2ea,U+f2f0-f2f1,U+f2f5-f2f7,U+f2f9,U+f2fd,U+f301,U+f303,U+f308-f30f,U+f31d,U+f320-f322,U+f325-f326,U+f329-f32e,U+f330-f332,U+f336-f337,U+f339-f33c,U+f33e,U+f340-f34c,U+f350-f353,U+f355,U+f360-f367,U+f376,U+f37e,U+f387,U+f389-f38a,U+f390,U+f39b-f39c,U+f3a0,U+f3b3,U+f3be-f3bf,U+f3c2,U+f3c5,U+f3cd-f3cf,U+f3de,U+f3e5,U+f3ed,U+f3f0,U+f3f2,U+f3fa-f3fc,U+f400-f401,U+f40e-f40f}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.1.svg#fontawesome) format("svg");unicode-range:U+f3c1}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.3.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.3.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.3.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.3.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.3.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.3.svg#fontawesome) format("svg");unicode-range:U+f2b9,U+f2bb,U+f2c1}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.3.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.3.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.3.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.3.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.3.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.3.svg#fontawesome) format("svg");unicode-range:U+f245,U+f3e0}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.5.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.5.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.5.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.5.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.5.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.5.svg#fontawesome) format("svg");unicode-range:U+f1e3}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.5.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.5.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.5.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.5.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.5.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.5.svg#fontawesome) format("svg");unicode-range:U+f432,U+f437-f438,U+f449-f44c,U+f44f-f451,U+f453,U+f455,U+f458,U+f45a-f45b,U+f45d}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.7.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.7.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.7.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.7.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.7.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.7.svg#fontawesome) format("svg");unicode-range:U+f0d1,U+f0f1,U+f0f9,U+f21e,U+f461,U+f463-f46f,U+f472-f475,U+f479-f47a,U+f47d-f47e,U+f481-f487,U+f489,U+f48b-f496}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.9.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.9.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.9.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.9.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.9.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.9.svg#fontawesome) format("svg");unicode-range:U+f086,U+f2b5,U+f4ad}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.9.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.9.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.9.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.9.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.9.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.9.svg#fontawesome) format("svg");unicode-range:U+f03d,U+f06c,U+f0f2,U+f10d-f10e,U+f187,U+f2e9,U+f2fe,U+f3dd,U+f47b-f47c,U+f498,U+f49a-f49b,U+f49d,U+f49f-f4ac,U+f4ae-f4b9,U+f4bb-f4bf,U+f4c2-f4c6,U+f4c8,U+f4cb-f4d2,U+f4d4,U+f4d6,U+f4d8-f4d9,U+f4db-f4e2}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.10.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.10.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.10.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.10.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.10.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.10.svg#fontawesome) format("svg");unicode-range:U+f471,U+f4ca}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.11.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.11.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.11.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.11.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.11.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.11.svg#fontawesome) format("svg");unicode-range:U+f007,U+f4e6}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.11.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.11.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.11.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.11.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.11.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.11.svg#fontawesome) format("svg");unicode-range:U+f0c0,U+f0c2,U+f0ed-f0ee,U+f0f0,U+f1de,U+f21b,U+f234-f235,U+f381-f382,U+f3f1,U+f406,U+f4fa-f501,U+f503-f509}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.13.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.13.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.13.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.13.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.13.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.13.svg#fontawesome) format("svg");unicode-range:U+f3d1}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.13.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.13.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.13.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.13.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.13.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.0.13.svg#fontawesome) format("svg");unicode-range:U+f010,U+f067,U+f072,U+f0ad,U+f0d6,U+f0e8,U+f130-f131,U+f24e,U+f3c9,U+f517,U+f519-f51e,U+f520-f52c,U+f52e,U+f530-f533,U+f535-f543,U+f545-f54b,U+f54d,U+f54f-f552,U+f554-f555}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.1.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.1.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.1.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.1.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.1.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.1.0.svg#fontawesome) format("svg");unicode-range:U+f279,U+f586,U+f588}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.1.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.1.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.1.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.1.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.1.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.1.0.svg#fontawesome) format("svg");unicode-range:U+f043,U+f0c4,U+f0d0,U+f125,U+f1ba,U+f1fb-f1fc,U+f207,U+f236,U+f304-f305,U+f52d,U+f557-f558,U+f55a-f55f,U+f562-f566,U+f568,U+f56a-f56b,U+f575-f577,U+f57b,U+f58d-f590,U+f593-f595,U+f59d,U+f59f-f5a2,U+f5a6-f5a7,U+f5a9-f5af,U+f5b1,U+f5b6,U+f5b9-f5bd,U+f5c4-f5c5,U+f5c7,U+f5c9-f5cb,U+f5cd}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.1.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.1.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.1.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.1.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.1.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.1.1.svg#fontawesome) format("svg");unicode-range:U+f386}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.2.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.2.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.2.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.2.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.2.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.2.0.svg#fontawesome) format("svg");unicode-range:U+f1f6}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.2.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.2.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.2.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.2.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.2.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.2.0.svg#fontawesome) format("svg");unicode-range:U+f018,U+f0e4,U+f109,U+f1b9,U+f1e5,U+f21d,U+f276-f277,U+f3fd,U+f4d7,U+f518,U+f5d1,U+f5d4-f5da,U+f5dd,U+f5df-f5e5,U+f5e8-f5ea,U+f5ed-f5f0,U+f5f2,U+f5f4-f5f5,U+f5f8-f5f9,U+f5fb-f600,U+f603-f60e,U+f610,U+f614,U+f617-f619,U+f61c-f61e,U+f620-f621,U+f623-f62f,U+f633,U+f635-f63d}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.3.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.3.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.3.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.3.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.3.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.3.0.svg#fontawesome) format("svg");unicode-range:U+f080,U+f0eb}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.3.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.3.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.3.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.3.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.3.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.3.0.svg#fontawesome) format("svg");unicode-range:U+f027-f028,U+f0a1,U+f0b1,U+f200-f201,U+f2e2,U+f61a,U+f640,U+f643-f647,U+f64a-f64b,U+f64d-f653,U+f655-f656,U+f65d,U+f65f-f663,U+f665,U+f667-f669,U+f66b-f671,U+f673-f675,U+f678-f67b,U+f67d-f680,U+f683-f689,U+f68b,U+f694-f695,U+f697-f699,U+f69b-f69c,U+f69e-f69f,U+f6a1-f6a9,U+f6ac}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.4.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.4.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.4.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.4.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.4.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.4.0.svg#fontawesome) format("svg");unicode-range:U+f499,U+f676,U+f6ae,U+f6b0-f6b3,U+f6b5-f6bc,U+f6bf,U+f6c2,U+f6c5,U+f6c7-f6c8,U+f6cb,U+f6cd-f6d2,U+f6d5,U+f6d8-f6d9,U+f6db,U+f6de,U+f6e2-f6e3,U+f6e5-f6e7,U+f6e9-f6ec,U+f6ee,U+f6f1-f6f3,U+f6f5-f6f8,U+f6fc-f6fd,U+f6ff-f703,U+f707,U+f70a-f70b,U+f711-f713,U+f715-f71d,U+f720-f724,U+f726-f729,U+f72b,U+f72d,U+f72f}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.4.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.4.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.4.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.4.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.4.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.4.1.svg#fontawesome) format("svg");unicode-range:U+f72a}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.5.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.5.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.5.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.5.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.5.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.5.0.svg#fontawesome) format("svg");unicode-range:U+f185,U+f2dc}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.5.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.5.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.5.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.5.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.5.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.5.0.svg#fontawesome) format("svg");unicode-range:U+f0e7,U+f6c3-f6c4,U+f72e,U+f732-f735,U+f737-f750,U+f752,U+f754-f758,U+f75a,U+f75c,U+f75e-f761,U+f763-f76e,U+f771-f776}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.6.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.6.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.6.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.6.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.6.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.6.0.svg#fontawesome) format("svg");unicode-range:U+f06b,U+f5b7,U+f77d,U+f77f,U+f781-f782,U+f788,U+f78a-f78c,U+f78e-f78f,U+f792-f796,U+f79a-f7a1,U+f7a3-f7a4,U+f7a7-f7a8,U+f7aa,U+f7ac-f7ae,U+f7b4-f7b6,U+f7b8,U+f7bd-f7be,U+f7c1-f7c3,U+f7c5,U+f7c7-f7d2,U+f7d4,U+f7d7-f7d8,U+f7da-f7dc,U+f7de,U+f7e2}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.6.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.6.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.6.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.6.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.6.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.6.1.svg#fontawesome) format("svg");unicode-range:U+f071}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.6.3.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.6.3.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.6.3.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.6.3.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.6.3.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.6.3.svg#fontawesome) format("svg");unicode-range:U+f7e4}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.7.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.7.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.7.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.7.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.7.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.7.0.svg#fontawesome) format("svg");unicode-range:U+f06e,U+f070}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.7.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.7.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.7.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.7.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.7.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.7.0.svg#fontawesome) format("svg");unicode-range:U+f00a,U+f015,U+f1e4,U+f2a0,U+f377,U+f470,U+f49c,U+f49e,U+f4c9,U+f6d6-f6d7,U+f705,U+f725,U+f77e,U+f780,U+f7e5-f7e7,U+f7e9-f7f0,U+f7f2-f7fc,U+f7fe,U+f800-f802,U+f804-f805,U+f807-f80f,U+f811-f812,U+f814-f818,U+f81b,U+f81e-f823,U+f825-f827,U+f82c-f82e,U+f830-f833}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.7.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.7.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.7.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.7.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.7.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.7.1.svg#fontawesome) format("svg");unicode-range:U+f7f1}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.8.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.8.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.8.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.8.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.8.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.8.0.svg#fontawesome) format("svg");unicode-range:U+f01e,U+f021,U+f026,U+f076,U+f12d,U+f31e,U+f356,U+f45f,U+f5b0,U+f83e}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.8.2.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.8.2.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.8.2.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.8.2.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.8.2.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.8.2.svg#fontawesome) format("svg");unicode-range:U+f560}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.9.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.9.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.9.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.9.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.9.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.9.0.svg#fontawesome) format("svg");unicode-range:U+f036-f03c,U+f0ae,U+f0ca-f0cd,U+f15d-f15e,U+f160-f163,U+f1dd,U+f313-f315,U+f34e,U+f439-f448,U+f502,U+f677,U+f843-f855,U+f858-f85e,U+f860-f862,U+f864,U+f866-f878,U+f87a,U+f87c-f87d,U+f880-f892,U+f897-f89b}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.1.svg#fontawesome) format("svg");unicode-range:U+f03e,U+f075,U+f07b,U+f0a0,U+f20a,U+f247-f248,U+f254,U+f25d,U+f27a,U+f2c2,U+f2d1,U+f302,U+f3a5}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.1.svg#fontawesome) format("svg");unicode-range:U+f000,U+f012,U+f029,U+f06d,U+f083-f084,U+f11e,U+f140,U+f19d,U+f251-f253,U+f275,U+f310-f311,U+f34d,U+f435,U+f454,U+f456,U+f476,U+f47f-f480,U+f52f,U+f534,U+f561,U+f578,U+f591,U+f5db,U+f5e7,U+f5f6,U+f611,U+f613,U+f654,U+f681-f682,U+f68c-f693,U+f6be,U+f6da,U+f6e4,U+f6ed,U+f6ef-f6f0,U+f6f4,U+f6fa-f6fb,U+f6fe,U+f72c,U+f751,U+f759,U+f75b,U+f779,U+f77c,U+f786-f787,U+f7ab,U+f7b2,U+f7b7,U+f7e8,U+f813,U+f85f,U+f863,U+f87b,U+f89c-f89d}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.2.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.2.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.2.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.2.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.2.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.2.svg#fontawesome) format("svg");unicode-range:U+f004-f005,U+f02e,U+f073,U+f0c5,U+f0c7-f0c8,U+f0e0,U+f111,U+f133,U+f144,U+f15b-f15c,U+f164-f165,U+f1c1-f1c9,U+f1f9,U+f249,U+f271-f274,U+f2b6,U+f2ed}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.2.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.2.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.2.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.2.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.2.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.10.2.svg#fontawesome) format("svg");unicode-range:U+f02c,U+f031-f035,U+f04b-f04d,U+f056,U+f08d,U+f095,U+f0a3,U+f0dc-f0de,U+f110,U+f129-f12c,U+f132,U+f145,U+f193,U+f197,U+f1ab,U+f1ce,U+f1dc,U+f1f8,U+f219,U+f29a,U+f29e,U+f2a7,U+f2e1,U+f2e3-f2e5,U+f2ec,U+f2f2,U+f2f4,U+f2fa-f2fc,U+f306,U+f312,U+f316,U+f31a,U+f31c,U+f327,U+f333-f335,U+f3f4,U+f3ff,U+f45c,U+f460,U+f462,U+f477-f478,U+f497,U+f4ba,U+f4d3,U+f54c,U+f553,U+f559,U+f56c-f574,U+f5bf,U+f5c1,U+f5f3,U+f630-f632,U+f634,U+f63e,U+f641,U+f659-f65c,U+f696,U+f6a0,U+f6b4,U+f6bd,U+f6dd,U+f706,U+f708-f709,U+f70d-f710,U+f714,U+f71e-f71f,U+f736,U+f76f-f770,U+f777,U+f783-f784,U+f7a9,U+f7c4,U+f7d5,U+f7d9,U+f7dd,U+f7fd,U+f81c-f81d,U+f824,U+f828-f82a,U+f856-f857,U+f865,U+f879,U+f87e,U+f893-f896}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.0.svg#fontawesome) format("svg");unicode-range:U+f0f3,U+f24d}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.0.svg#fontawesome) format("svg");unicode-range:U+f001,U+f02f,U+f042,U+f08e,U+f091,U+f104-f105,U+f11b,U+f13d,U+f149,U+f1ac,U+f1ec,U+f223,U+f225,U+f22a-f22c,U+f26c,U+f29d,U+f2eb,U+f2ee,U+f2f3,U+f300,U+f307,U+f323-f324,U+f338,U+f33d,U+f35d,U+f48a,U+f4c0,U+f569,U+f5dc,U+f5eb,U+f601,U+f61b,U+f64c,U+f664,U+f66a,U+f68a,U+f6c0-f6c1,U+f6df-f6e1,U+f6e8,U+f6f9,U+f70c,U+f7a6,U+f81a,U+f89f-f8a5,U+f8a7-f8b6,U+f8b8-f8b9,U+f8bb-f8c9,U+f8cb-f8d1,U+f8d3,U+f8d5-f8dd,U+f8df-f8e0,U+f8e2-f8e7,U+f8e9-f8ed,U+f8ef-f8f2}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.1.svg#fontawesome) format("svg");unicode-range:U+f118-f11a,U+f14e,U+f186,U+f2bd,U+f4da,U+f556,U+f567,U+f579-f57a,U+f57f-f585,U+f587,U+f589-f58a,U+f58c,U+f596-f59c,U+f5a4-f5a5,U+f5b3-f5b4,U+f5b8,U+f5c2,U+f5c8}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.1.svg#fontawesome) format("svg");unicode-range:U+f00d,U+f048,U+f051,U+f0ac,U+f0b0,U+f148,U+f155,U+f19c,U+f1eb,U+f21a,U+f221,U+f22d,U+f2e8,U+f2f8,U+f354,U+f357,U+f433-f434,U+f436,U+f44e,U+f45e,U+f4c7,U+f4e3,U+f51f,U+f54e,U+f57c-f57e,U+f5c0,U+f5c3,U+f5ce,U+f5de,U+f5e6,U+f5ec,U+f602,U+f615-f616,U+f622,U+f648-f649,U+f67c,U+f69a,U+f6aa-f6ab,U+f6ad,U+f7a2,U+f7a5,U+f7b9-f7ba,U+f7ff,U+f803,U+f806,U+f810,U+f819,U+f82b,U+f87f,U+f8de,U+f8ee}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.2.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.2.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.2.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.2.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.2.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.11.2.svg#fontawesome) format("svg");unicode-range:U+f488,U+f8b7,U+f8f3}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.0.svg#fontawesome) format("svg");unicode-range:U+f259,U+f58b}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.0.svg#fontawesome) format("svg");unicode-range:U+f135,U+f1e6,U+f2cc-f2cd,U+f422,U+f424,U+f515-f516,U+f544,U+f5d2-f5d3,U+f61f,U+f657-f658,U+f666,U+f672,U+f6d3-f6d4,U+f753,U+f762,U+f7bf-f7c0,U+f82f,U+f8ba,U+f8d4,U+f8f4-f8ff}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.1.svg#fontawesome) format("svg");unicode-range:U+f017}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.12.1.svg#fontawesome) format("svg");unicode-range:U+f317-f319,U+f65e,U+f6c6}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.13.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.13.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.13.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.13.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.13.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.13.0.svg#fontawesome) format("svg");unicode-range:U+f4c1}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.14.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.14.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.14.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.14.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.14.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.14.0.svg#fontawesome) format("svg");unicode-range:U+e000-e006,U+e008-e012,U+e014-e019,U+e01b-e01d,U+e01f-e048,U+e04a-e051,U+e053-e054,U+e058-e076}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.15.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.15.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.15.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.15.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.15.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.15.1.svg#fontawesome) format("svg");unicode-range:U+e085-e086}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:400;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.15.3.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.15.3.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.15.3.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.15.3.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.15.3.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-regular-400-5.15.3.svg#fontawesome) format("svg");unicode-range:U+f5d0}.fal,.far{font-family:"Font Awesome 5 Pro"}.far{font-weight:400}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.0.svg#fontawesome) format("svg");unicode-range:U+f002,U+f008-f009,U+f00b-f00c,U+f00e,U+f011,U+f013,U+f019,U+f01c,U+f022-f025,U+f02a-f02b,U+f02d,U+f030,U+f041,U+f044,U+f049-f04a,U+f04e,U+f050,U+f052-f055,U+f057-f05b,U+f05e,U+f060-f066,U+f068-f06a,U+f074,U+f077-f07a,U+f07c,U+f085,U+f089,U+f093-f094,U+f098,U+f09c-f09e,U+f0a4-f0ab,U+f0b2,U+f0c1,U+f0c3,U+f0c6,U+f0c9,U+f0ce,U+f0d7-f0db,U+f0e2-f0e3,U+f0e9-f0ea,U+f0f4,U+f0f8,U+f0fa-f0fe,U+f100-f103,U+f106-f108,U+f10a-f10b,U+f11c,U+f120-f122,U+f124,U+f126-f128,U+f12e,U+f134,U+f137-f13a,U+f13e,U+f141-f143,U+f146,U+f14a-f14b,U+f14d,U+f150-f154,U+f156-f159,U+f182-f183,U+f188,U+f191-f192,U+f195,U+f199,U+f1ad-f1ae,U+f1b0,U+f1b2-f1b3,U+f1b8,U+f1bb,U+f1c0,U+f1cd,U+f1d8,U+f1da,U+f1e0-f1e2,U+f1ea,U+f1fa,U+f1fd-f1fe,U+f204-f206,U+f20b,U+f217-f218,U+f21c,U+f222,U+f224,U+f226-f229,U+f233,U+f238-f239,U+f240-f244,U+f246,U+f255-f258,U+f25a-f25c,U+f28b,U+f28d,U+f290-f292,U+f295,U+f2a1-f2a4,U+f2a8,U+f2c7-f2cb,U+f2ce,U+f2d0,U+f2d2,U+f2db,U+f2e7,U+f2ea,U+f2f1,U+f2f5-f2f6,U+f2f9,U+f303,U+f309-f30c,U+f328,U+f337,U+f358-f35b,U+f360,U+f362,U+f3be-f3bf,U+f3c5,U+f3cd,U+f3e5,U+f3ed,U+f3fa,U+f410}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.0.svg#fontawesome) format("svg");unicode-range:U+f040,U+f047,U+f07d-f07e,U+f08b,U+f090,U+f0ec,U+f14c,U+f175-f178,U+f2d3,U+f2e6,U+f2f0,U+f2f7,U+f2fd,U+f301,U+f308,U+f30d-f30f,U+f31d,U+f320-f322,U+f325-f326,U+f329-f32e,U+f330-f332,U+f336,U+f339-f33c,U+f33e,U+f340-f34c,U+f350-f353,U+f355,U+f361,U+f363-f367,U+f376,U+f37e,U+f387,U+f389-f38a,U+f390,U+f39b-f39c,U+f3a0,U+f3b3,U+f3c2,U+f3ce-f3cf,U+f3de,U+f3f0,U+f3f2,U+f3fb-f3fc,U+f400-f401,U+f40e-f40f}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.1.svg#fontawesome) format("svg");unicode-range:U+f3c1}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.3.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.3.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.3.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.3.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.3.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.3.svg#fontawesome) format("svg");unicode-range:U+f245,U+f2b9,U+f2bb,U+f2c1,U+f3e0}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.5.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.5.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.5.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.5.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.5.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.5.svg#fontawesome) format("svg");unicode-range:U+f1e3,U+f44b,U+f450,U+f453,U+f458,U+f45d}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.5.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.5.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.5.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.5.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.5.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.5.svg#fontawesome) format("svg");unicode-range:U+f432,U+f437-f438,U+f449-f44a,U+f44c,U+f44f,U+f451,U+f455,U+f45a-f45b}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.7.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.7.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.7.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.7.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.7.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.7.svg#fontawesome) format("svg");unicode-range:U+f0d1,U+f0f1,U+f0f9,U+f21e,U+f461,U+f466,U+f468-f46d,U+f472,U+f474,U+f479,U+f47d-f47e,U+f481-f482,U+f484-f487,U+f48b,U+f48d-f48e,U+f490-f494,U+f496}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.7.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.7.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.7.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.7.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.7.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.7.svg#fontawesome) format("svg");unicode-range:U+f463-f465,U+f467,U+f46e-f46f,U+f473,U+f475,U+f47a,U+f483,U+f489,U+f48c,U+f48f,U+f495}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.9.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.9.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.9.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.9.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.9.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.9.svg#fontawesome) format("svg");unicode-range:U+f03d,U+f06c,U+f086,U+f0f2,U+f10d-f10e,U+f187,U+f2b5,U+f2fe,U+f3dd,U+f4ad,U+f4b3,U+f4b8-f4b9,U+f4bd-f4be,U+f4c2,U+f4c4,U+f4cd-f4ce,U+f4d6,U+f4d8-f4d9,U+f4db,U+f4de-f4df,U+f4e2}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.9.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.9.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.9.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.9.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.9.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.9.svg#fontawesome) format("svg");unicode-range:U+f2e9,U+f47b-f47c,U+f498,U+f49a-f49b,U+f49d,U+f49f-f4ac,U+f4ae-f4b2,U+f4b4-f4b7,U+f4bb-f4bc,U+f4bf,U+f4c3,U+f4c5-f4c6,U+f4c8,U+f4cb-f4cc,U+f4cf-f4d2,U+f4d4,U+f4dc-f4dd,U+f4e0-f4e1}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.10.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.10.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.10.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.10.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.10.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.10.svg#fontawesome) format("svg");unicode-range:U+f471}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.10.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.10.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.10.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.10.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.10.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.10.svg#fontawesome) format("svg");unicode-range:U+f4ca}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.11.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.11.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.11.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.11.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.11.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.11.svg#fontawesome) format("svg");unicode-range:U+f007,U+f0c0,U+f0c2,U+f0f0,U+f1de,U+f21b,U+f234-f235,U+f381-f382,U+f406,U+f4e6,U+f4fa-f501,U+f503-f509}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.11.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.11.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.11.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.11.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.11.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.11.svg#fontawesome) format("svg");unicode-range:U+f0ed-f0ee,U+f3f1}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.13.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.13.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.13.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.13.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.13.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.0.13.svg#fontawesome) format("svg");unicode-range:U+f010,U+f067,U+f072,U+f0ad,U+f0d6,U+f0e8,U+f130-f131,U+f24e,U+f3c9,U+f3d1,U+f517,U+f519-f51e,U+f520-f52c,U+f52e,U+f530-f533,U+f535-f543,U+f545-f54b,U+f54d,U+f54f-f552,U+f554-f555}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.1.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.1.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.1.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.1.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.1.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.1.0.svg#fontawesome) format("svg");unicode-range:U+f043,U+f0c4,U+f0d0,U+f125,U+f1ba,U+f1fb-f1fc,U+f207,U+f236,U+f279,U+f304-f305,U+f52d,U+f557-f558,U+f55a-f55f,U+f562-f566,U+f568,U+f56a-f56b,U+f575-f577,U+f57b,U+f586,U+f588,U+f58d-f590,U+f593-f595,U+f59d,U+f59f-f5a2,U+f5a6-f5a7,U+f5aa-f5af,U+f5b1,U+f5b6,U+f5ba-f5bd,U+f5c4-f5c5,U+f5c7,U+f5c9-f5cb,U+f5cd}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.1.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.1.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.1.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.1.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.1.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.1.0.svg#fontawesome) format("svg");unicode-range:U+f5a9,U+f5b9}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.1.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.1.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.1.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.1.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.1.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.1.1.svg#fontawesome) format("svg");unicode-range:U+f386}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.2.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.2.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.2.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.2.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.2.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.2.0.svg#fontawesome) format("svg");unicode-range:U+f018,U+f109,U+f1b9,U+f1e5,U+f1f6,U+f21d,U+f276-f277,U+f3fd,U+f4d7,U+f518,U+f5d1,U+f5d7,U+f5da,U+f5df,U+f5e1,U+f5e4,U+f5ee,U+f5fc-f5fd,U+f604,U+f610,U+f619,U+f621,U+f62e-f62f,U+f637,U+f63b-f63c}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.2.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.2.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.2.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.2.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.2.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.2.0.svg#fontawesome) format("svg");unicode-range:U+f0e4,U+f5d4-f5d6,U+f5d8-f5d9,U+f5dd,U+f5e0,U+f5e2-f5e3,U+f5e5,U+f5e8-f5ea,U+f5ed,U+f5ef-f5f0,U+f5f2,U+f5f4-f5f5,U+f5f8-f5f9,U+f5fb,U+f5fe-f600,U+f603,U+f605-f60e,U+f614,U+f617-f618,U+f61c-f61e,U+f620,U+f623-f62d,U+f633,U+f635-f636,U+f638-f63a,U+f63d}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.3.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.3.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.3.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.3.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.3.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.3.0.svg#fontawesome) format("svg");unicode-range:U+f027-f028,U+f080,U+f0a1,U+f0b1,U+f0eb,U+f200-f201,U+f644,U+f647,U+f64a,U+f64f,U+f651,U+f653,U+f655,U+f65d,U+f662,U+f665,U+f669,U+f66b,U+f66d,U+f66f,U+f674,U+f678-f679,U+f67b,U+f67f,U+f683-f684,U+f687-f689,U+f698-f699,U+f69b,U+f6a1,U+f6a7,U+f6a9}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.3.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.3.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.3.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.3.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.3.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.3.0.svg#fontawesome) format("svg");unicode-range:U+f2e2,U+f61a,U+f640,U+f643,U+f645-f646,U+f64b,U+f64d-f64e,U+f650,U+f652,U+f656,U+f65f-f661,U+f663,U+f667-f668,U+f66c,U+f66e,U+f670-f671,U+f673,U+f675,U+f67a,U+f67d-f67e,U+f680,U+f685-f686,U+f68b,U+f694-f695,U+f697,U+f69c,U+f69e-f69f,U+f6a2-f6a6,U+f6a8,U+f6ac}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.4.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.4.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.4.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.4.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.4.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.4.0.svg#fontawesome) format("svg");unicode-range:U+f676,U+f6b6-f6b7,U+f6bb,U+f6cf,U+f6d1,U+f6d5,U+f6d9,U+f6de,U+f6e2-f6e3,U+f6e6,U+f6ec,U+f6f1-f6f2,U+f6fc,U+f6ff-f700,U+f70b,U+f715,U+f717,U+f722,U+f728-f729,U+f72f}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.4.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.4.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.4.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.4.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.4.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.4.0.svg#fontawesome) format("svg");unicode-range:U+f499,U+f6ae,U+f6b0-f6b3,U+f6b5,U+f6b8-f6ba,U+f6bc,U+f6bf,U+f6c2,U+f6c5,U+f6c7-f6c8,U+f6cb,U+f6cd-f6ce,U+f6d0,U+f6d2,U+f6d8,U+f6db,U+f6e5,U+f6e7,U+f6e9-f6eb,U+f6ee,U+f6f3,U+f6f5-f6f8,U+f6fd,U+f701-f703,U+f707,U+f70a,U+f711-f713,U+f716,U+f718-f71d,U+f720-f721,U+f723-f724,U+f726-f727,U+f72b,U+f72d}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.4.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.4.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.4.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.4.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.4.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.4.1.svg#fontawesome) format("svg");unicode-range:U+f72a}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.5.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.5.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.5.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.5.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.5.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.5.0.svg#fontawesome) format("svg");unicode-range:U+f0e7,U+f185,U+f2dc,U+f6c3-f6c4,U+f72e,U+f73b-f73d,U+f740,U+f743,U+f747,U+f74d,U+f756,U+f75a,U+f75e-f75f,U+f769,U+f76b,U+f772-f773}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.5.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.5.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.5.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.5.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.5.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.5.0.svg#fontawesome) format("svg");unicode-range:U+f732-f735,U+f737-f73a,U+f73e-f73f,U+f741-f742,U+f744-f746,U+f748-f74c,U+f74e-f750,U+f752,U+f754-f755,U+f757-f758,U+f75c,U+f760-f761,U+f763-f768,U+f76a,U+f76c-f76e,U+f771,U+f774-f776}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.0.svg#fontawesome) format("svg");unicode-range:U+f06b,U+f5b7,U+f77d,U+f781,U+f788,U+f78c,U+f793-f794,U+f796,U+f79c,U+f79f-f7a0,U+f7a4,U+f7aa,U+f7ad-f7ae,U+f7b5-f7b6,U+f7bd,U+f7c2,U+f7c5,U+f7c9-f7ca,U+f7cc-f7ce,U+f7d0,U+f7d2,U+f7d7-f7d8,U+f7da}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.0.svg#fontawesome) format("svg");unicode-range:U+f77f,U+f782,U+f78a-f78b,U+f78e-f78f,U+f792,U+f795,U+f79a-f79b,U+f79d-f79e,U+f7a1,U+f7a3,U+f7a7-f7a8,U+f7ac,U+f7b4,U+f7b8,U+f7be,U+f7c1,U+f7c3,U+f7c7-f7c8,U+f7cb,U+f7cf,U+f7d1,U+f7d4,U+f7db-f7dc,U+f7de,U+f7e2}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.1.svg#fontawesome) format("svg");unicode-range:U+f071}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.3.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.3.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.3.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.3.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.3.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.6.3.svg#fontawesome) format("svg");unicode-range:U+f7e4}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.7.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.7.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.7.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.7.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.7.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.7.0.svg#fontawesome) format("svg");unicode-range:U+f00a,U+f015,U+f06e,U+f070,U+f1e4,U+f2a0,U+f470,U+f49e,U+f6d7,U+f780,U+f7e5-f7e6,U+f7ec,U+f7ef,U+f7f2,U+f7f5,U+f7f7,U+f7fa-f7fb,U+f805,U+f807,U+f80d,U+f80f,U+f812,U+f815-f816,U+f818}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.7.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.7.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.7.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.7.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.7.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.7.0.svg#fontawesome) format("svg");unicode-range:U+f377,U+f49c,U+f4c9,U+f6d6,U+f705,U+f725,U+f77e,U+f7e7,U+f7e9-f7eb,U+f7ed-f7ee,U+f7f0,U+f7f3-f7f4,U+f7f6,U+f7f8-f7f9,U+f7fc,U+f7fe,U+f800-f802,U+f804,U+f808-f80c,U+f80e,U+f811,U+f814,U+f817,U+f81b,U+f81e-f823,U+f825-f827,U+f82c-f82e,U+f830-f833}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.7.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.7.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.7.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.7.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.7.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.7.1.svg#fontawesome) format("svg");unicode-range:U+f7f1}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.8.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.8.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.8.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.8.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.8.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.8.0.svg#fontawesome) format("svg");unicode-range:U+f01e,U+f021,U+f026,U+f076,U+f12d,U+f31e,U+f45f,U+f5b0,U+f83e}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.8.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.8.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.8.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.8.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.8.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.8.0.svg#fontawesome) format("svg");unicode-range:U+f356}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.8.2.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.8.2.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.8.2.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.8.2.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.8.2.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.8.2.svg#fontawesome) format("svg");unicode-range:U+f560}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.9.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.9.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.9.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.9.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.9.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.9.0.svg#fontawesome) format("svg");unicode-range:U+f036-f03c,U+f0ae,U+f0ca-f0cd,U+f15d-f15e,U+f160-f163,U+f1dd,U+f439-f43a,U+f43c,U+f43f,U+f441,U+f443,U+f445,U+f447,U+f502,U+f84a,U+f84c,U+f850,U+f853,U+f86d,U+f87c-f87d,U+f881-f882,U+f884-f887,U+f891,U+f897}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.9.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.9.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.9.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.9.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.9.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.9.0.svg#fontawesome) format("svg");unicode-range:U+f313-f315,U+f34e,U+f43b,U+f43d-f43e,U+f440,U+f442,U+f444,U+f446,U+f448,U+f677,U+f843-f849,U+f84b,U+f84d-f84f,U+f851-f852,U+f854-f855,U+f858-f85e,U+f860-f862,U+f864,U+f866-f86c,U+f86e-f878,U+f87a,U+f880,U+f883,U+f888-f890,U+f892,U+f898-f89b}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.1.svg#fontawesome) format("svg");unicode-range:U+f000,U+f012,U+f029,U+f03e,U+f06d,U+f075,U+f07b,U+f083-f084,U+f0a0,U+f11e,U+f140,U+f19d,U+f20a,U+f247-f248,U+f251-f254,U+f25d,U+f275,U+f27a,U+f2c2,U+f2d1,U+f302,U+f3a5,U+f47f,U+f52f,U+f534,U+f561,U+f578,U+f591,U+f5e7,U+f613,U+f654,U+f681-f682,U+f6be,U+f6ed,U+f6f0,U+f6fa,U+f75b,U+f77c,U+f786-f787,U+f7ab,U+f863,U+f87b}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.1.svg#fontawesome) format("svg");unicode-range:U+f310-f311,U+f34d,U+f435,U+f454,U+f456,U+f476,U+f480,U+f5db,U+f5f6,U+f611,U+f68c-f693,U+f6da,U+f6e4,U+f6ef,U+f6f4,U+f6fb,U+f6fe,U+f72c,U+f751,U+f759,U+f779,U+f7b2,U+f7b7,U+f7e8,U+f813,U+f85f,U+f89c-f89d}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.2.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.2.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.2.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.2.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.2.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.2.svg#fontawesome) format("svg");unicode-range:U+f004-f005,U+f02c,U+f02e,U+f031-f035,U+f04b-f04d,U+f056,U+f073,U+f08d,U+f095,U+f0a3,U+f0c5,U+f0c7-f0c8,U+f0dc-f0de,U+f0e0,U+f110-f111,U+f129-f12c,U+f133,U+f144,U+f15b-f15c,U+f164-f165,U+f193,U+f197,U+f1ab,U+f1c1-f1c9,U+f1ce,U+f1dc,U+f1f8-f1f9,U+f249,U+f271-f274,U+f29a,U+f29e,U+f2a7,U+f2b6,U+f2e5,U+f2ed,U+f2f2,U+f3ff,U+f45c,U+f462,U+f477-f478,U+f497,U+f4ba,U+f4d3,U+f54c,U+f553,U+f559,U+f56c-f574,U+f5bf,U+f5c1,U+f630,U+f641,U+f696,U+f6a0,U+f6dd,U+f70e,U+f714,U+f71e,U+f783-f784,U+f7a9,U+f7c4,U+f7d9,U+f829-f82a,U+f879}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.2.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.2.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.2.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.2.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.2.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.10.2.svg#fontawesome) format("svg");unicode-range:U+f132,U+f145,U+f219,U+f2e1,U+f2e3-f2e4,U+f2ec,U+f2f4,U+f2fa-f2fc,U+f306,U+f312,U+f316,U+f31a,U+f31c,U+f327,U+f333-f335,U+f3f4,U+f460,U+f5f3,U+f631-f632,U+f634,U+f63e,U+f659-f65c,U+f6b4,U+f6bd,U+f706,U+f708-f709,U+f70d,U+f70f-f710,U+f71f,U+f736,U+f76f-f770,U+f777,U+f7d5,U+f7dd,U+f7fd,U+f81c-f81d,U+f824,U+f828,U+f856-f857,U+f865,U+f87e,U+f893-f896}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.0.svg#fontawesome) format("svg");unicode-range:U+f001,U+f02f,U+f042,U+f091,U+f0f3,U+f104-f105,U+f11b,U+f13d,U+f1ac,U+f1ec,U+f223,U+f225,U+f22a-f22c,U+f24d,U+f26c,U+f29d,U+f338,U+f35d,U+f4c0,U+f569,U+f5dc,U+f5eb,U+f664,U+f66a,U+f6c0,U+f6e8,U+f70c,U+f7a6,U+f8c0-f8c1,U+f8cc,U+f8d9}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.0.svg#fontawesome) format("svg");unicode-range:U+f08e,U+f149,U+f2eb,U+f2ee,U+f2f3,U+f300,U+f307,U+f323-f324,U+f33d,U+f48a,U+f601,U+f61b,U+f64c,U+f68a,U+f6c1,U+f6df-f6e1,U+f6f9,U+f81a,U+f89f-f8a5,U+f8a7-f8b6,U+f8b8-f8b9,U+f8bb-f8bf,U+f8c2-f8c9,U+f8cb,U+f8cd-f8d1,U+f8d3,U+f8d5-f8d8,U+f8da-f8dd,U+f8df-f8e0,U+f8e2-f8e7,U+f8e9-f8ed,U+f8ef-f8f2}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.1.svg#fontawesome) format("svg");unicode-range:U+f00d,U+f048,U+f051,U+f0ac,U+f0b0,U+f118-f11a,U+f14e,U+f155,U+f186,U+f19c,U+f1eb,U+f21a,U+f221,U+f22d,U+f2bd,U+f433-f434,U+f436,U+f44e,U+f4da,U+f4e3,U+f51f,U+f54e,U+f556,U+f567,U+f579-f57a,U+f57c-f585,U+f587,U+f589-f58a,U+f58c,U+f596-f59c,U+f5a4-f5a5,U+f5b3-f5b4,U+f5b8,U+f5c0,U+f5c2-f5c3,U+f5c8,U+f5ce,U+f5de,U+f67c,U+f69a,U+f6ad,U+f7a2,U+f7a5,U+f7b9-f7ba,U+f806,U+f810}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.1.svg#fontawesome) format("svg");unicode-range:U+f148,U+f2e8,U+f2f8,U+f354,U+f357,U+f45e,U+f4c7,U+f5e6,U+f5ec,U+f602,U+f615-f616,U+f622,U+f648-f649,U+f6aa-f6ab,U+f7ff,U+f803,U+f819,U+f82b,U+f87f,U+f8de,U+f8ee}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.2.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.2.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.2.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.2.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.2.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.11.2.svg#fontawesome) format("svg");unicode-range:U+f488,U+f8b7,U+f8f3}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.0.svg#fontawesome) format("svg");unicode-range:U+f135,U+f1e6,U+f259,U+f2cc-f2cd,U+f422,U+f424,U+f515-f516,U+f544,U+f58b,U+f5d2,U+f61f,U+f658,U+f666,U+f6d3,U+f753,U+f7bf-f7c0,U+f82f,U+f8ff}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.0.svg#fontawesome) format("svg");unicode-range:U+f5d3,U+f657,U+f672,U+f6d4,U+f762,U+f8ba,U+f8d4,U+f8f4-f8fe}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.1.svg#fontawesome) format("svg");unicode-range:U+f017,U+f65e}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.12.1.svg#fontawesome) format("svg");unicode-range:U+f317-f319,U+f6c6}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.13.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.13.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.13.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.13.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.13.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.13.0.svg#fontawesome) format("svg");unicode-range:U+f4c1}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.14.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.14.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.14.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.14.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.14.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.14.0.svg#fontawesome) format("svg");unicode-range:U+e005,U+e041,U+e059-e076}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.14.0.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.14.0.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.14.0.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.14.0.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.14.0.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.14.0.svg#fontawesome) format("svg");unicode-range:U+e000-e004,U+e006,U+e008-e012,U+e014-e019,U+e01b-e01d,U+e01f-e040,U+e042-e048,U+e04a-e051,U+e053-e054,U+e058}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.15.1.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.15.1.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.15.1.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.15.1.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.15.1.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.15.1.svg#fontawesome) format("svg");unicode-range:U+e085-e086}@font-face{font-family:"Font Awesome 5 Pro";font-style:normal;font-weight:900;font-display:block;src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.15.3.eot);src:url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.15.3.eot?#iefix) format("embedded-opentype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.15.3.woff2) format("woff2"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.15.3.woff) format("woff"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.15.3.ttf) format("truetype"),url(https://ka-p.fontawesome.com/releases/v5.15.3/webfonts/pro-fa-solid-900-5.15.3.svg#fontawesome) format("svg");unicode-range:U+f5d0}.fa,.fas{font-family:"Font Awesome 5 Pro";font-weight:900}</style>
			<script src="./20210823_FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst_files/manifest.js.descarga" defer=""></script>
			<script src="./20210823_FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst_files/vendor.js.descarga" defer=""></script>
			<script src="./20210823_FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst_files/main.js.descarga" defer=""></script>
			<meta http-equiv="X-UA-Compatible" content="IE=edge">
			<script type="text/javascript">(window.NREUM||(NREUM={})).loader_config={licenseKey:"NRJS-26cb7ae1e63182183ea",applicationID:"440198580"};window.NREUM||(NREUM={}),__nr_require=function(t,e,n){function r(n){if(!e[n]){var i=e[n]={exports:{}};t[n][0].call(i.exports,function(e){var i=t[n][1][e];return r(i||e)},i,i.exports)}return e[n].exports}if("function"==typeof __nr_require)return __nr_require;for(var i=0;i<n.length;i++)r(n[i]);return r}({1:[function(t,e,n){function r(){}function i(t,e,n){return function(){return o(t,[u.now()].concat(f(arguments)),e?null:this,n),e?void 0:this}}var o=t("handle"),a=t(8),f=t(9),c=t("ee").get("tracer"),u=t("loader"),s=NREUM;"undefined"==typeof window.newrelic&&(newrelic=s);var d=["setPageViewName","setCustomAttribute","setErrorHandler","finished","addToTrace","inlineHit","addRelease"],p="api-",l=p+"ixn-";a(d,function(t,e){s[e]=i(p+e,!0,"api")}),s.addPageAction=i(p+"addPageAction",!0),s.setCurrentRouteName=i(p+"routeName",!0),e.exports=newrelic,s.interaction=function(){return(new r).get()};var m=r.prototype={createTracer:function(t,e){var n={},r=this,i="function"==typeof e;return o(l+"tracer",[u.now(),t,n],r),function(){if(c.emit((i?"":"no-")+"fn-start",[u.now(),r,i],n),i)try{return e.apply(this,arguments)}catch(t){throw c.emit("fn-err",[arguments,this,t],n),t}finally{c.emit("fn-end",[u.now()],n)}}}};a("actionText,setName,setAttribute,save,ignore,onEnd,getContext,end,get".split(","),function(t,e){m[e]=i(l+e)}),newrelic.noticeError=function(t,e){"string"==typeof t&&(t=new Error(t)),o("err",[t,u.now(),!1,e])}},{}],2:[function(t,e,n){function r(t){if(NREUM.init){for(var e=NREUM.init,n=t.split("."),r=0;r<n.length-1;r++)if(e=e[n[r]],"object"!=typeof e)return;return e=e[n[n.length-1]]}}e.exports={getConfiguration:r}},{}],3:[function(t,e,n){function r(){return f.exists&&performance.now?Math.round(performance.now()):(o=Math.max((new Date).getTime(),o))-a}function i(){return o}var o=(new Date).getTime(),a=o,f=t(10);e.exports=r,e.exports.offset=a,e.exports.getLastTimestamp=i},{}],4:[function(t,e,n){function r(t){return!(!t||!t.protocol||"file:"===t.protocol)}e.exports=r},{}],5:[function(t,e,n){function r(t,e){var n=t.getEntries();n.forEach(function(t){"first-paint"===t.name?d("timing",["fp",Math.floor(t.startTime)]):"first-contentful-paint"===t.name&&d("timing",["fcp",Math.floor(t.startTime)])})}function i(t,e){var n=t.getEntries();n.length>0&&d("lcp",[n[n.length-1]])}function o(t){t.getEntries().forEach(function(t){t.hadRecentInput||d("cls",[t])})}function a(t){if(t instanceof m&&!g){var e=Math.round(t.timeStamp),n={type:t.type};e<=p.now()?n.fid=p.now()-e:e>p.offset&&e<=Date.now()?(e-=p.offset,n.fid=p.now()-e):e=p.now(),g=!0,d("timing",["fi",e,n])}}function f(t){"hidden"===t&&d("pageHide",[p.now()])}if(!("init"in NREUM&&"page_view_timing"in NREUM.init&&"enabled"in NREUM.init.page_view_timing&&NREUM.init.page_view_timing.enabled===!1)){var c,u,s,d=t("handle"),p=t("loader"),l=t(7),m=NREUM.o.EV;if("PerformanceObserver"in window&&"function"==typeof window.PerformanceObserver){c=new PerformanceObserver(r);try{c.observe({entryTypes:["paint"]})}catch(v){}u=new PerformanceObserver(i);try{u.observe({entryTypes:["largest-contentful-paint"]})}catch(v){}s=new PerformanceObserver(o);try{s.observe({type:"layout-shift",buffered:!0})}catch(v){}}if("addEventListener"in document){var g=!1,h=["click","keydown","mousedown","pointerdown","touchstart"];h.forEach(function(t){document.addEventListener(t,a,!1)})}l(f)}},{}],6:[function(t,e,n){function r(t,e){if(!i)return!1;if(t!==i)return!1;if(!e)return!0;if(!o)return!1;for(var n=o.split("."),r=e.split("."),a=0;a<r.length;a++)if(r[a]!==n[a])return!1;return!0}var i=null,o=null,a=/Version\/(\S+)\s+Safari/;if(navigator.userAgent){var f=navigator.userAgent,c=f.match(a);c&&f.indexOf("Chrome")===-1&&f.indexOf("Chromium")===-1&&(i="Safari",o=c[1])}e.exports={agent:i,version:o,match:r}},{}],7:[function(t,e,n){function r(t){function e(){t(a&&document[a]?document[a]:document[i]?"hidden":"visible")}"addEventListener"in document&&o&&document.addEventListener(o,e,!1)}e.exports=r;var i,o,a;"undefined"!=typeof document.hidden?(i="hidden",o="visibilitychange",a="visibilityState"):"undefined"!=typeof document.msHidden?(i="msHidden",o="msvisibilitychange"):"undefined"!=typeof document.webkitHidden&&(i="webkitHidden",o="webkitvisibilitychange",a="webkitVisibilityState")},{}],8:[function(t,e,n){function r(t,e){var n=[],r="",o=0;for(r in t)i.call(t,r)&&(n[o]=e(r,t[r]),o+=1);return n}var i=Object.prototype.hasOwnProperty;e.exports=r},{}],9:[function(t,e,n){function r(t,e,n){e||(e=0),"undefined"==typeof n&&(n=t?t.length:0);for(var r=-1,i=n-e||0,o=Array(i<0?0:i);++r<i;)o[r]=t[e+r];return o}e.exports=r},{}],10:[function(t,e,n){e.exports={exists:"undefined"!=typeof window.performance&&window.performance.timing&&"undefined"!=typeof window.performance.timing.navigationStart}},{}],ee:[function(t,e,n){function r(){}function i(t){function e(t){return t&&t instanceof r?t:t?u(t,c,a):a()}function n(n,r,i,o,a){if(a!==!1&&(a=!0),!l.aborted||o){t&&a&&t(n,r,i);for(var f=e(i),c=v(n),u=c.length,s=0;s<u;s++)c[s].apply(f,r);var p=d[w[n]];return p&&p.push([b,n,r,f]),f}}function o(t,e){y[t]=v(t).concat(e)}function m(t,e){var n=y[t];if(n)for(var r=0;r<n.length;r++)n[r]===e&&n.splice(r,1)}function v(t){return y[t]||[]}function g(t){return p[t]=p[t]||i(n)}function h(t,e){l.aborted||s(t,function(t,n){e=e||"feature",w[n]=e,e in d||(d[e]=[])})}var y={},w={},b={on:o,addEventListener:o,removeEventListener:m,emit:n,get:g,listeners:v,context:e,buffer:h,abort:f,aborted:!1};return b}function o(t){return u(t,c,a)}function a(){return new r}function f(){(d.api||d.feature)&&(l.aborted=!0,d=l.backlog={})}var c="nr@context",u=t("gos"),s=t(8),d={},p={},l=e.exports=i();e.exports.getOrSetContext=o,l.backlog=d},{}],gos:[function(t,e,n){function r(t,e,n){if(i.call(t,e))return t[e];var r=n();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(t,e,{value:r,writable:!0,enumerable:!1}),r}catch(o){}return t[e]=r,r}var i=Object.prototype.hasOwnProperty;e.exports=r},{}],handle:[function(t,e,n){function r(t,e,n,r){i.buffer([t],r),i.emit(t,e,n)}var i=t("ee").get("handle");e.exports=r,r.ee=i},{}],id:[function(t,e,n){function r(t){var e=typeof t;return!t||"object"!==e&&"function"!==e?-1:t===window?0:a(t,o,function(){return i++})}var i=1,o="nr@id",a=t("gos");e.exports=r},{}],loader:[function(t,e,n){function r(){if(!R++){var t=M.info=NREUM.info,e=v.getElementsByTagName("script")[0];if(setTimeout(u.abort,3e4),!(t&&t.licenseKey&&t.applicationID&&e))return u.abort();c(E,function(e,n){t[e]||(t[e]=n)});var n=a();f("mark",["onload",n+M.offset],null,"api"),f("timing",["load",n]);var r=v.createElement("script");0===t.agent.indexOf("http://")||0===t.agent.indexOf("https://")?r.src=t.agent:r.src=l+"://"+t.agent,e.parentNode.insertBefore(r,e)}}function i(){"complete"===v.readyState&&o()}function o(){f("mark",["domContent",a()+M.offset],null,"api")}var a=t(3),f=t("handle"),c=t(8),u=t("ee"),s=t(6),d=t(4),p=t(2),l=p.getConfiguration("ssl")===!1?"http":"https",m=window,v=m.document,g="addEventListener",h="attachEvent",y=m.XMLHttpRequest,w=y&&y.prototype,b=!d(m.location);NREUM.o={ST:setTimeout,SI:m.setImmediate,CT:clearTimeout,XHR:y,REQ:m.Request,EV:m.Event,PR:m.Promise,MO:m.MutationObserver};var x=""+location,E={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-1210.min.js"},O=y&&w&&w[g]&&!/CriOS/.test(navigator.userAgent),M=e.exports={offset:a.getLastTimestamp(),now:a,origin:x,features:{},xhrWrappable:O,userAgent:s,disabled:b};if(!b){t(1),t(5),v[g]?(v[g]("DOMContentLoaded",o,!1),m[g]("load",r,!1)):(v[h]("onreadystatechange",i),m[h]("onload",r)),f("mark",["firstbyte",a.getLastTimestamp()],null,"api");var R=0}},{}],"wrap-function":[function(t,e,n){function r(t,e){function n(e,n,r,c,u){function nrWrapper(){var o,a,s,p;try{a=this,o=d(arguments),s="function"==typeof r?r(o,a):r||{}}catch(l){i([l,"",[o,a,c],s],t)}f(n+"start",[o,a,c],s,u);try{return p=e.apply(a,o)}catch(m){throw f(n+"err",[o,a,m],s,u),m}finally{f(n+"end",[o,a,p],s,u)}}return a(e)?e:(n||(n=""),nrWrapper[p]=e,o(e,nrWrapper,t),nrWrapper)}function r(t,e,r,i,o){r||(r="");var f,c,u,s="-"===r.charAt(0);for(u=0;u<e.length;u++)c=e[u],f=t[c],a(f)||(t[c]=n(f,s?c+r:r,i,c,o))}function f(n,r,o,a){if(!m||e){var f=m;m=!0;try{t.emit(n,r,o,e,a)}catch(c){i([c,n,r,o],t)}m=f}}return t||(t=s),n.inPlace=r,n.flag=p,n}function i(t,e){e||(e=s);try{e.emit("internal-error",t)}catch(n){}}function o(t,e,n){if(Object.defineProperty&&Object.keys)try{var r=Object.keys(t);return r.forEach(function(n){Object.defineProperty(e,n,{get:function(){return t[n]},set:function(e){return t[n]=e,e}})}),e}catch(o){i([o],n)}for(var a in t)l.call(t,a)&&(e[a]=t[a]);return e}function a(t){return!(t&&t instanceof Function&&t.apply&&!t[p])}function f(t,e){var n=e(t);return n[p]=t,o(t,n,s),n}function c(t,e,n){var r=t[e];t[e]=f(r,n)}function u(){for(var t=arguments.length,e=new Array(t),n=0;n<t;++n)e[n]=arguments[n];return e}var s=t("ee"),d=t(9),p="nr@original",l=Object.prototype.hasOwnProperty,m=!1;e.exports=r,e.exports.wrapFunction=f,e.exports.wrapInPlace=c,e.exports.argsToArray=u},{}]},{},["loader"]);</script>
						<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no">
			<link rel="apple-touch-icon" sizes="180x180" href="https://www.biopharmcatalyst.com/apple-touch-icon.png">
			<link rel="icon" type="image/png" sizes="32x32" href="https://www.biopharmcatalyst.com/favicon-32x32.png">
			<link rel="icon" type="image/png" sizes="16x16" href="https://www.biopharmcatalyst.com/favicon-16x16.png">
			<link rel="manifest" href="https://www.biopharmcatalyst.com/site.webmanifest">
			<link rel="mask-icon" href="https://www.biopharmcatalyst.com/safari-pinned-tab.svg" color="#5bbad5">
			<meta name="msapplication-TileColor" content="#da532c">
			<meta name="theme-color" content="#ffffff">
			<!-- BEGIN SEOmatic rendered SEO Meta -->

<title>FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst </title>

<!-- Standard SEO -->


<meta name="referrer" content="no-referrer-when-downgrade">
<meta name="robots" content="all">
<meta name="description" content="FDA Calendar contains dates for FDA Approval PDUFA decisions, Advisory Committee and clinical trial catalysts and various financial data of biotech stocks.">
<meta name="generator" content="SEOmatic">
<link rel="canonical" href="https://www.biopharmcatalyst.com/calendars/fda-calendar">
<link rel="alternate" href="https://www.biopharmcatalyst.com/calendars/fda-calendar" hreflang="x-default">
<meta name="geo.placename" content="BiopharmCatalyst ">

<!-- Dublin Core basic info -->

<meta name="dcterms.Identifier" content="https://www.biopharmcatalyst.com/calendars/fda-calendar">
<meta name="dcterms.Format" content="text/html">
<meta name="dcterms.Relation" content="BioPharmCatalyst ">
<meta name="dcterms.Language" content="en">
<meta name="dcterms.Publisher" content="BioPharmCatalyst ">
<meta name="dcterms.Type" content="text/html">
<meta name="dcterms.Coverage" content="https://www.biopharmcatalyst.com/">
<meta name="dcterms.Rights" content="Copyright ©2021 BiopharmCatalyst .">
<meta name="dcterms.Title" content="FDA Calendar of Biotech Stock Catalysts">
<meta name="dcterms.Creator" content="The Fold Ltd">
<meta name="dcterms.Subject" content="">
<meta name="dcterms.Contributor" content="BioPharmCatalyst ">
<meta name="dcterms.Date" content="2021-08-23">
<meta name="dcterms.Description" content="FDA Calendar contains dates for FDA Approval PDUFA decisions, Advisory Committee and clinical trial catalysts and various financial data of biotech stocks.">

<!-- Facebook OpenGraph -->

<meta property="og:type" content="article">
<meta property="og:locale" content="en_us">
<meta property="og:url" content="https://www.biopharmcatalyst.com/calendars/fda-calendar">
<meta property="og:title" content="FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst ">
<meta property="og:description" content="FDA Calendar contains dates for FDA Approval PDUFA decisions, Advisory Committee and clinical trial catalysts and various financial data of biotech stocks.">
<meta property="og:image" content="http://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/prod/_facebook/logo-stacked.png">
<meta property="og:image:type" content="image/png">
<meta property="og:image:width" content="1073">
<meta property="og:image:height" content="630">
<meta property="og:site_name" content="BioPharmCatalyst ">
<meta property="og:see_also" content="https://twitter.com/crusadernz">
<meta property="og:see_also" content="https://www.facebook.com/Biopharmcatalyst">
<meta property="og:see_also" content="https://www.youtube.com/user/Biopharmcatalyst">
<meta property="article:author" content="https://www.facebook.com/Biopharmcatalyst">
<meta property="article:publisher" content="https://www.facebook.com/Biopharmcatalyst">
<meta property="article:modified_time" content="2020-12-30T20:39:56+0000">
<meta property="article:published_time" content="2016-06-27T06:48:00+0000">

<!-- Twitter Card -->

<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@crusadernz">
<meta name="twitter:creator" content="@crusadernz">
<meta name="twitter:title" content="FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst ">
<meta name="twitter:description" content="FDA Calendar contains dates for FDA Approval PDUFA decisions, Advisory Committee and clinical trial catalysts and various financial data of biotech stocks.">
<meta name="twitter:image" content="http://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/prod/_twitter/logo-stacked.png">


<!-- Humans.txt authorship http://humanstxt.org -->

<link type="text/plain" rel="author" href="https://www.biopharmcatalyst.com/humans.txt">

<!-- Domain verification -->


<!-- Identity -->

<script type="application/ld+json">
{
    "@context": "http://schema.org",
    "@type": "Corporation",
    "name": "BiopharmCatalyst ",
    "url": "http://biopharmcatalyst.thefold.co.nz",
    "sameAs": ["https://twitter.com/crusadernz","https://www.facebook.com/Biopharmcatalyst","https://www.youtube.com/user/Biopharmcatalyst"],
    "image": {
        "@type": "ImageObject",
        "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
        "height": "130",
        "width": "578" 
    },
    "email": "&#105;&#110;&#102;&#111;&#64;&#98;&#105;&#111;&#112;&#104;&#97;&#114;&#109;&#99;&#97;&#116;&#97;&#108;&#121;&#115;&#116;&#46;&#99;&#111;&#109;",
    "logo": {
        "@type": "ImageObject",
        "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
        "height": "130",
        "width": "578" 
    },
    "location": {
        "@type": "Place",
        "name": "BiopharmCatalyst ",
        "image": {
            "@type": "ImageObject",
            "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
            "height": "130",
            "width": "578" 
        },
        "logo": {
            "@type": "ImageObject",
            "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
            "height": "130",
            "width": "578" 
        },
        "url": "http://biopharmcatalyst.thefold.co.nz",
        "sameAs": ["https://twitter.com/crusadernz","https://www.facebook.com/Biopharmcatalyst","https://www.youtube.com/user/Biopharmcatalyst"] 
    } 
}
</script>

<!-- WebSite -->

<script type="application/ld+json">
{
    "@context": "http://schema.org",
    "@type": "WebSite",
    "name": "BioPharmCatalyst ",
    "description": "Profit on the stock market by investing in biotech stocks",
    "url": "https://www.biopharmcatalyst.com",
    "image": "http://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/prod/logo-stacked.png",
    "potentialAction": {
        "@type": "SearchAction",
        "target": ["/companies/search?q={search_term_string}"],
        "query-input": "required name=search_term_string" 
    },
    "sameAs": ["https://twitter.com/crusadernz","https://www.facebook.com/Biopharmcatalyst","https://www.youtube.com/user/Biopharmcatalyst"],
    "copyrightHolder": {
        "@type": "Corporation",
        "name": "BiopharmCatalyst ",
        "url": "http://biopharmcatalyst.thefold.co.nz",
        "sameAs": ["https://twitter.com/crusadernz","https://www.facebook.com/Biopharmcatalyst","https://www.youtube.com/user/Biopharmcatalyst"],
        "image": {
            "@type": "ImageObject",
            "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
            "height": "130",
            "width": "578" 
        },
        "email": "&#105;&#110;&#102;&#111;&#64;&#98;&#105;&#111;&#112;&#104;&#97;&#114;&#109;&#99;&#97;&#116;&#97;&#108;&#121;&#115;&#116;&#46;&#99;&#111;&#109;",
        "logo": {
            "@type": "ImageObject",
            "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
            "height": "130",
            "width": "578" 
        },
        "location": {
            "@type": "Place",
            "name": "BiopharmCatalyst ",
            "image": {
                "@type": "ImageObject",
                "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
                "height": "130",
                "width": "578" 
            },
            "logo": {
                "@type": "ImageObject",
                "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
                "height": "130",
                "width": "578" 
            },
            "url": "http://biopharmcatalyst.thefold.co.nz",
            "sameAs": ["https://twitter.com/crusadernz","https://www.facebook.com/Biopharmcatalyst","https://www.youtube.com/user/Biopharmcatalyst"] 
        } 
    },
    "author": {
        "@type": "Corporation",
        "name": "BiopharmCatalyst ",
        "url": "http://biopharmcatalyst.thefold.co.nz",
        "sameAs": ["https://twitter.com/crusadernz","https://www.facebook.com/Biopharmcatalyst","https://www.youtube.com/user/Biopharmcatalyst"],
        "image": {
            "@type": "ImageObject",
            "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
            "height": "130",
            "width": "578" 
        },
        "email": "&#105;&#110;&#102;&#111;&#64;&#98;&#105;&#111;&#112;&#104;&#97;&#114;&#109;&#99;&#97;&#116;&#97;&#108;&#121;&#115;&#116;&#46;&#99;&#111;&#109;",
        "logo": {
            "@type": "ImageObject",
            "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
            "height": "130",
            "width": "578" 
        },
        "location": {
            "@type": "Place",
            "name": "BiopharmCatalyst ",
            "image": {
                "@type": "ImageObject",
                "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
                "height": "130",
                "width": "578" 
            },
            "logo": {
                "@type": "ImageObject",
                "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
                "height": "130",
                "width": "578" 
            },
            "url": "http://biopharmcatalyst.thefold.co.nz",
            "sameAs": ["https://twitter.com/crusadernz","https://www.facebook.com/Biopharmcatalyst","https://www.youtube.com/user/Biopharmcatalyst"] 
        } 
    },
    "creator": {
        "@type": "Organization",
        "name": "The Fold Ltd",
        "description": "A small team of pationate web designers and developers.",
        "url": "http://thefold.co.nz",
        "email": "&#104;&#101;&#108;&#108;&#111;&#64;&#116;&#104;&#101;&#102;&#111;&#108;&#100;&#46;&#99;&#111;&#46;&#110;&#122;",
        "address": {
            "@type": "PostalAddress",
            "streetAddress": "1 Beresford Square",
            "addressLocality": "Newton",
            "addressRegion": "Auckland",
            "postalCode": "1011",
            "addressCountry": "New Zealand" 
        },
        "location": {
            "@type": "Place",
            "name": "The Fold Ltd",
            "description": "A small team of pationate web designers and developers.",
            "hasMap": "http://maps.google.com/maps?q=The+Fold+Ltd%2C+1+Beresford+Square%2C+Newton%2C+Auckland+1011%2C+New+Zealand",
            "url": "http://thefold.co.nz",
            "geo": {
                "@type": "GeoCoordinates",
                "latitude": "-36.8554876",
                "longitude": "174.755296" 
            },
            "address": {
                "@type": "PostalAddress",
                "streetAddress": "1 Beresford Square",
                "addressLocality": "Newton",
                "addressRegion": "Auckland",
                "postalCode": "1011",
                "addressCountry": "New Zealand" 
            } 
        } 
    } 
}
</script>

<!-- Place -->

<script type="application/ld+json">
{
    "@context": "http://schema.org",
    "@type": "Place",
    "name": "BiopharmCatalyst ",
    "image": {
        "@type": "ImageObject",
        "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
        "height": "130",
        "width": "578" 
    },
    "logo": {
        "@type": "ImageObject",
        "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
        "height": "130",
        "width": "578" 
    },
    "url": "http://biopharmcatalyst.thefold.co.nz",
    "sameAs": ["https://twitter.com/crusadernz","https://www.facebook.com/Biopharmcatalyst","https://www.youtube.com/user/Biopharmcatalyst"] 
}
</script>

<!-- Main Entity of Page -->

<script type="application/ld+json">
{
    "@context": "http://schema.org",
    "@type": "WebPage",
    "name": "FDA Calendar of Biotech Stock Catalysts",
    "description": "FDA Calendar contains dates for FDA Approval PDUFA decisions, Advisory Committee and clinical trial catalysts and various financial data of biotech stocks.",
    "image": {
        "@type": "ImageObject",
        "url": "http://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/prod/logo-stacked.png",
        "width": "896",
        "height": "526" 
    },
    "url": "https://www.biopharmcatalyst.com/calendars/fda-calendar",
    "mainEntityOfPage": "https://www.biopharmcatalyst.com/calendars/fda-calendar",
    "inLanguage": "en_us",
    "headline": "FDA Calendar of Biotech Stock Catalysts",
    "dateCreated": "2016-06-27T07:48:48+0000",
    "dateModified": "2020-12-30T20:39:56+0000",
    "datePublished": "2016-06-27T06:48:00+0000",
    "copyrightYear": "2016",
    "author": {
        "@type": "Corporation",
        "name": "BiopharmCatalyst ",
        "url": "http://biopharmcatalyst.thefold.co.nz",
        "sameAs": ["https://twitter.com/crusadernz","https://www.facebook.com/Biopharmcatalyst","https://www.youtube.com/user/Biopharmcatalyst"],
        "image": {
            "@type": "ImageObject",
            "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
            "height": "130",
            "width": "578" 
        },
        "email": "&#105;&#110;&#102;&#111;&#64;&#98;&#105;&#111;&#112;&#104;&#97;&#114;&#109;&#99;&#97;&#116;&#97;&#108;&#121;&#115;&#116;&#46;&#99;&#111;&#109;",
        "logo": {
            "@type": "ImageObject",
            "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
            "height": "130",
            "width": "578" 
        },
        "location": {
            "@type": "Place",
            "name": "BiopharmCatalyst ",
            "image": {
                "@type": "ImageObject",
                "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
                "height": "130",
                "width": "578" 
            },
            "logo": {
                "@type": "ImageObject",
                "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
                "height": "130",
                "width": "578" 
            },
            "url": "http://biopharmcatalyst.thefold.co.nz",
            "sameAs": ["https://twitter.com/crusadernz","https://www.facebook.com/Biopharmcatalyst","https://www.youtube.com/user/Biopharmcatalyst"] 
        } 
    },
    "copyrightHolder": {
        "@type": "Corporation",
        "name": "BiopharmCatalyst ",
        "url": "http://biopharmcatalyst.thefold.co.nz",
        "sameAs": ["https://twitter.com/crusadernz","https://www.facebook.com/Biopharmcatalyst","https://www.youtube.com/user/Biopharmcatalyst"],
        "image": {
            "@type": "ImageObject",
            "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
            "height": "130",
            "width": "578" 
        },
        "email": "&#105;&#110;&#102;&#111;&#64;&#98;&#105;&#111;&#112;&#104;&#97;&#114;&#109;&#99;&#97;&#116;&#97;&#108;&#121;&#115;&#116;&#46;&#99;&#111;&#109;",
        "logo": {
            "@type": "ImageObject",
            "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
            "height": "130",
            "width": "578" 
        },
        "location": {
            "@type": "Place",
            "name": "BiopharmCatalyst ",
            "image": {
                "@type": "ImageObject",
                "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
                "height": "130",
                "width": "578" 
            },
            "logo": {
                "@type": "ImageObject",
                "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
                "height": "130",
                "width": "578" 
            },
            "url": "http://biopharmcatalyst.thefold.co.nz",
            "sameAs": ["https://twitter.com/crusadernz","https://www.facebook.com/Biopharmcatalyst","https://www.youtube.com/user/Biopharmcatalyst"] 
        } 
    },
    "publisher": {
        "@type": "Organization",
        "name": "BiopharmCatalyst ",
        "url": "http://biopharmcatalyst.thefold.co.nz",
        "sameAs": ["https://twitter.com/crusadernz","https://www.facebook.com/Biopharmcatalyst","https://www.youtube.com/user/Biopharmcatalyst"],
        "image": {
            "@type": "ImageObject",
            "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
            "height": "130",
            "width": "578" 
        },
        "email": "&#105;&#110;&#102;&#111;&#64;&#98;&#105;&#111;&#112;&#104;&#97;&#114;&#109;&#99;&#97;&#116;&#97;&#108;&#121;&#115;&#116;&#46;&#99;&#111;&#109;",
        "logo": {
            "@type": "ImageObject",
            "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
            "height": "130",
            "width": "578" 
        },
        "location": {
            "@type": "Place",
            "name": "BiopharmCatalyst ",
            "image": {
                "@type": "ImageObject",
                "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
                "height": "130",
                "width": "578" 
            },
            "logo": {
                "@type": "ImageObject",
                "url": "https://s3-ap-southeast-2.amazonaws.com/biopharmcatalyst/logo@1x.png",
                "height": "130",
                "width": "578" 
            },
            "url": "http://biopharmcatalyst.thefold.co.nz",
            "sameAs": ["https://twitter.com/crusadernz","https://www.facebook.com/Biopharmcatalyst","https://www.youtube.com/user/Biopharmcatalyst"] 
        } 
    },
    "breadcrumb": {
        "@type": "BreadcrumbList",
        "itemListElement": [
            {
                "@type": "ListItem",
                "position": "1",
                "item": {
                    "@id": "https://www.biopharmcatalyst.com",
                    "name": "Home" 
                } 
            },
            {
                "@type": "ListItem",
                "position": "2",
                "item": {
                    "@id": "https://www.biopharmcatalyst.com/calendars",
                    "name": "Calendars" 
                } 
            },
            {
                "@type": "ListItem",
                "position": "3",
                "item": {
                    "@id": "https://www.biopharmcatalyst.com/calendars/fda-calendar",
                    "name": "FDA Calendar" 
                } 
            }
        ] 
    } 
}
</script>

<!-- Breadcrumbs -->

<script type="application/ld+json">
{
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
        {
            "@type": "ListItem",
            "position": "1",
            "item": {
                "@id": "https://www.biopharmcatalyst.com",
                "name": "Home" 
            } 
        },
        {
            "@type": "ListItem",
            "position": "2",
            "item": {
                "@id": "https://www.biopharmcatalyst.com/calendars",
                "name": "Calendars" 
            } 
        },
        {
            "@type": "ListItem",
            "position": "3",
            "item": {
                "@id": "https://www.biopharmcatalyst.com/calendars/fda-calendar",
                "name": "FDA Calendar" 
            } 
        }
    ] 
}
</script>

<!-- Google Tag Manager -->


<!-- Google Analytics -->

<script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-17155946-1', 'auto', {allowLinker: true});
  ga('require', 'displayfeatures');
  ga('require', 'linkid');
  ga('require', 'linker');
  ga('send', 'pageview');
</script>
<!-- END SEOmatic rendered SEO Meta -->

			<script>

				// browser-update.org
var $buoop = {
c: 2
};
function $buo_f() {
var e = document.createElement("script");
e.src = "//browser-update.org/update.min.js";
document.body.appendChild(e);
};
try {
document.addEventListener("DOMContentLoaded", $buo_f, false)
} catch (e) {
window.attachEvent("onload", $buo_f)
}
			</script>

			
			<script src="./20210823_FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst_files/pa-5b282b59ef13ce0016000008.js.descarga" async=""></script>


			<link rel="stylesheet" type="text/css" href="./20210823_FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst_files/main(1).css">
<link rel="stylesheet" type="text/css" href="./20210823_FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst_files/cp.css">
<link rel="stylesheet" type="text/css" href="./20210823_FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst_files/cookieconsent.min.css"><meta class="foundation-mq"><style type="text/css">.vc-popover-content-wrapper[data-v-7605e1b2]{--popover-horizontal-content-offset:8px;--popover-vertical-content-offset:10px;--popover-slide-translation:15px;--popover-transition-time:0.14s ease-in-out;--popover-caret-horizontal-offset:18px;--popover-caret-vertical-offset:8px;position:absolute;display:block;outline:none;z-index:10}.vc-popover-content-wrapper[data-v-7605e1b2]:not(.is-interactive){pointer-events:none}.vc-popover-content[data-v-7605e1b2]{position:relative;outline:none;z-index:10}.vc-popover-content.direction-bottom[data-v-7605e1b2]{margin-top:var(--popover-vertical-content-offset)}.vc-popover-content.direction-top[data-v-7605e1b2]{margin-bottom:var(--popover-vertical-content-offset)}.vc-popover-content.direction-left[data-v-7605e1b2]{margin-right:var(--popover-horizontal-content-offset)}.vc-popover-content.direction-right[data-v-7605e1b2]{margin-left:var(--popover-horizontal-content-offset)}.vc-popover-caret[data-v-7605e1b2]{content:"";position:absolute;display:block;width:12px;height:12px;border-top:inherit;border-left:inherit;background:inherit;z-index:-1}.vc-popover-caret.direction-bottom[data-v-7605e1b2]{top:0}.vc-popover-caret.direction-bottom.align-left[data-v-7605e1b2]{transform:translateY(-50%) rotate(45deg)}.vc-popover-caret.direction-bottom.align-center[data-v-7605e1b2]{transform:translateX(-50%) translateY(-50%) rotate(45deg)}.vc-popover-caret.direction-bottom.align-right[data-v-7605e1b2]{transform:translateY(-50%) rotate(45deg)}.vc-popover-caret.direction-top[data-v-7605e1b2]{top:100%}.vc-popover-caret.direction-top.align-left[data-v-7605e1b2]{transform:translateY(-50%) rotate(-135deg)}.vc-popover-caret.direction-top.align-center[data-v-7605e1b2]{transform:translateX(-50%) translateY(-50%) rotate(-135deg)}.vc-popover-caret.direction-top.align-right[data-v-7605e1b2]{transform:translateY(-50%) rotate(-135deg)}.vc-popover-caret.direction-left[data-v-7605e1b2]{left:100%}.vc-popover-caret.direction-left.align-top[data-v-7605e1b2]{transform:translateX(-50%) rotate(135deg)}.vc-popover-caret.direction-left.align-middle[data-v-7605e1b2]{transform:translateY(-50%) translateX(-50%) rotate(135deg)}.vc-popover-caret.direction-left.align-bottom[data-v-7605e1b2]{transform:translateX(-50%) rotate(135deg)}.vc-popover-caret.direction-right[data-v-7605e1b2]{left:0}.vc-popover-caret.direction-right.align-top[data-v-7605e1b2]{transform:translateX(-50%) rotate(-45deg)}.vc-popover-caret.direction-right.align-middle[data-v-7605e1b2]{transform:translateY(-50%) translateX(-50%) rotate(-45deg)}.vc-popover-caret.direction-right.align-bottom[data-v-7605e1b2]{transform:translateX(-50%) rotate(-45deg)}.vc-popover-caret.align-left[data-v-7605e1b2]{left:var(--popover-caret-horizontal-offset)}.vc-popover-caret.align-center[data-v-7605e1b2]{left:50%}.vc-popover-caret.align-right[data-v-7605e1b2]{right:var(--popover-caret-horizontal-offset)}.vc-popover-caret.align-top[data-v-7605e1b2]{top:var(--popover-caret-vertical-offset)}.vc-popover-caret.align-middle[data-v-7605e1b2]{top:50%}.vc-popover-caret.align-bottom[data-v-7605e1b2]{bottom:var(--popover-caret-vertical-offset)}.fade-enter-active[data-v-7605e1b2],.fade-leave-active[data-v-7605e1b2],.slide-fade-enter-active[data-v-7605e1b2],.slide-fade-leave-active[data-v-7605e1b2]{transition:all var(--popover-transition-time);pointer-events:none}.fade-enter[data-v-7605e1b2],.fade-leave-to[data-v-7605e1b2],.slide-fade-enter[data-v-7605e1b2],.slide-fade-leave-to[data-v-7605e1b2]{opacity:0}.slide-fade-enter.direction-bottom[data-v-7605e1b2],.slide-fade-leave-to.direction-bottom[data-v-7605e1b2]{transform:translateY(calc(-1*var(--popover-slide-translation)))}.slide-fade-enter.direction-top[data-v-7605e1b2],.slide-fade-leave-to.direction-top[data-v-7605e1b2]{transform:translateY(var(--popover-slide-translation))}.slide-fade-enter.direction-left[data-v-7605e1b2],.slide-fade-leave-to.direction-left[data-v-7605e1b2]{transform:translateX(var(--popover-slide-translation))}.slide-fade-enter.direction-right[data-v-7605e1b2],.slide-fade-leave-to.direction-right[data-v-7605e1b2]{transform:translateX(calc(-1*var(--popover-slide-translation)))}</style><style type="text/css">.vc-day-popover-row[data-v-28ced894]{--day-content-transition-time:0.13s ease-in;display:flex;align-items:center;transition:all var(--day-content-transition-time)}.vc-day-popover-row[data-v-28ced894]:not(:first-child){margin-top:3px}.vc-day-popover-row-indicator[data-v-28ced894]{display:flex;justify-content:center;align-items:center;flex-grow:0;width:15px;margin-right:3px}.vc-day-popover-row-indicator span[data-v-28ced894]{transition:all var(--day-content-transition-time)}.vc-day-popover-row-content[data-v-28ced894]{display:flex;align-items:center;flex-wrap:none;flex-grow:1;width:-webkit-max-content;width:max-content}</style><style type="text/css">.vc-grid-container[data-v-3ca35a05]{position:relative;flex-shrink:1;display:grid;overflow:auto;-webkit-overflow-scrolling:touch}.vc-grid-cell[data-v-3ca35a05]{display:flex;justify-content:center;align-items:center}</style><style type="text/css">.vc-svg-icon[data-v-63f7b5ec]{display:inline-block;stroke:currentColor;stroke-width:0}.vc-svg-icon path[data-v-63f7b5ec]{fill:currentColor}</style><style type="text/css">.vc-day[data-v-2aac4f42]{position:relative;min-height:var(--day-min-height);width:100%;height:100%;z-index:1}.vc-day-layer[data-v-2aac4f42]{position:absolute;left:0;right:0;top:0;bottom:0;pointer-events:none}.vc-day-box-center-center[data-v-2aac4f42]{display:flex;justify-content:center;align-items:center;height:100%;transform-origin:50% 50%}.vc-day-box-left-center[data-v-2aac4f42]{display:flex;justify-content:flex-start;align-items:center;height:100%;transform-origin:0 50%}.vc-day-box-right-center[data-v-2aac4f42]{display:flex;justify-content:flex-end;align-items:center;height:100%;transform-origin:100% 50%}.vc-day-box-center-bottom[data-v-2aac4f42]{display:flex;justify-content:center;align-items:flex-end}.vc-day-content[data-v-2aac4f42]{display:flex;justify-content:center;align-items:center;width:var(--day-content-width);height:var(--day-content-height);margin:var(--day-content-margin);-webkit-user-select:none;-ms-user-select:none;user-select:none}.vc-day-content[data-v-2aac4f42]:hover{background-color:var(--day-content-bg-color-hover)}.vc-day-content:hover.vc-is-dark[data-v-2aac4f42]{background-color:var(--day-content-dark-bg-color-hover)}.vc-day-content[data-v-2aac4f42]:focus{background-color:var(--day-content-bg-color-focus)}.vc-day-content:focus.vc-is-dark[data-v-2aac4f42]{background-color:var(--day-content-dark-bg-color-focus)}.vc-highlights[data-v-2aac4f42]{overflow:hidden;pointer-events:none;z-index:-1}.vc-highlight[data-v-2aac4f42]{width:var(--highlight-height);height:var(--highlight-height)}.vc-highlight.vc-highlight-base-start[data-v-2aac4f42]{width:50%!important;border-radius:0!important;border-right-width:0!important}.vc-highlight.vc-highlight-base-end[data-v-2aac4f42]{width:50%!important;border-radius:0!important;border-left-width:0!important}.vc-highlight.vc-highlight-base-middle[data-v-2aac4f42]{width:100%;border-radius:0!important;border-left-width:0!important;border-right-width:0!important;margin:0 -1px}.vc-dots[data-v-2aac4f42]{display:flex;justify-content:center;align-items:center}.vc-dot[data-v-2aac4f42]{width:var(--dot-diameter);height:var(--dot-diameter);border-radius:var(--dot-border-radius);transition:all var(--day-content-transition-time)}.vc-dot[data-v-2aac4f42]:not(:last-child){margin-right:var(--dot-spacing)}.vc-bars[data-v-2aac4f42]{display:flex;justify-content:flex-start;align-items:center;width:var(--bars-width)}.vc-bar[data-v-2aac4f42]{flex-grow:1;height:var(--bar-height);transition:all var(--day-content-transition-time)}</style><style type="text/css">.vc-pane[data-v-4a5f2beb]{flex-grow:1;flex-shrink:1;display:flex;flex-direction:column;justify-content:center;align-items:stretch}.vc-horizontal-divider[data-v-4a5f2beb]{align-self:center}.vc-header[data-v-4a5f2beb]{flex-shrink:0;display:flex;align-items:stretch;-webkit-user-select:none;-ms-user-select:none;user-select:none;padding:var(--header-padding)}.vc-header.align-left[data-v-4a5f2beb]{order:-1;justify-content:flex-start}.vc-header.align-right[data-v-4a5f2beb]{order:1;justify-content:flex-end}.vc-title-layout[data-v-4a5f2beb]{display:flex;justify-content:center;align-items:center;flex-grow:1}.vc-title-layout.align-left[data-v-4a5f2beb]{justify-content:flex-start}.vc-title-layout.align-right[data-v-4a5f2beb]{justify-content:flex-end}.vc-title-wrapper[data-v-4a5f2beb]{position:relative}.vc-title[data-v-4a5f2beb]{cursor:pointer;white-space:nowrap;padding:var(--title-padding)}.vc-title[data-v-4a5f2beb],.vc-weekday[data-v-4a5f2beb]{-webkit-user-select:none;-ms-user-select:none;user-select:none}.vc-weekday[data-v-4a5f2beb]{display:flex;justify-content:center;align-items:center;flex:1;padding:var(--weekday-padding);cursor:default}.vc-weeks[data-v-4a5f2beb]{flex-shrink:1;flex-grow:1;padding:var(--weeks-padding)}</style><style type="text/css">.none-enter-active[data-v-5be4b00c],.none-leave-active[data-v-5be4b00c]{transition-duration:0s}.fade-enter-active[data-v-5be4b00c],.fade-leave-active[data-v-5be4b00c],.slide-down-enter-active[data-v-5be4b00c],.slide-down-leave-active[data-v-5be4b00c],.slide-left-enter-active[data-v-5be4b00c],.slide-left-leave-active[data-v-5be4b00c],.slide-right-enter-active[data-v-5be4b00c],.slide-right-leave-active[data-v-5be4b00c],.slide-up-enter-active[data-v-5be4b00c],.slide-up-leave-active[data-v-5be4b00c]{transition:transform var(--slide-duration) var(--slide-timing),opacity var(--slide-duration) var(--slide-timing);-webkit-backface-visibility:hidden;backface-visibility:hidden}.fade-leave-active[data-v-5be4b00c],.none-leave-active[data-v-5be4b00c],.slide-down-leave-active[data-v-5be4b00c],.slide-left-leave-active[data-v-5be4b00c],.slide-right-leave-active[data-v-5be4b00c],.slide-up-leave-active[data-v-5be4b00c]{position:absolute;width:100%}.fade-enter[data-v-5be4b00c],.fade-leave-to[data-v-5be4b00c],.none-enter[data-v-5be4b00c],.none-leave-to[data-v-5be4b00c],.slide-down-enter[data-v-5be4b00c],.slide-down-leave-to[data-v-5be4b00c],.slide-left-enter[data-v-5be4b00c],.slide-left-leave-to[data-v-5be4b00c],.slide-right-enter[data-v-5be4b00c],.slide-right-leave-to[data-v-5be4b00c],.slide-up-enter[data-v-5be4b00c],.slide-up-leave-to[data-v-5be4b00c]{opacity:0}.slide-left-enter[data-v-5be4b00c],.slide-right-leave-to[data-v-5be4b00c]{transform:translateX(var(--slide-translate))}.slide-left-leave-to[data-v-5be4b00c],.slide-right-enter[data-v-5be4b00c]{transform:translateX(calc(-1*var(--slide-translate)))}.slide-down-leave-to[data-v-5be4b00c],.slide-up-enter[data-v-5be4b00c]{transform:translateY(var(--slide-translate))}.slide-down-enter[data-v-5be4b00c],.slide-up-leave-to[data-v-5be4b00c]{transform:translateY(calc(-1*var(--slide-translate)))}</style><style type="text/css">.vc-reset,.vc-reset *{line-height:1.5;box-sizing:border-box}.vc-reset:focus,.vc-reset :focus{outline:none}.vc-reset [role=button],.vc-reset button{cursor:pointer}.vc-border,.vc-border-2,.vc-border-3{border-style:solid}.vc-appearance-none{-webkit-appearance:none;-moz-appearance:none;appearance:none}.vc-bg-fixed{background-attachment:fixed}.vc-bg-local{background-attachment:local}.vc-bg-scroll{background-attachment:scroll}.vc-bg-transparent{background-color:initial}.vc-bg-black{background-color:#000}.vc-bg-white{background-color:#fff}.vc-bg-gray-100{background-color:#f7fafc}.vc-bg-gray-200{background-color:#edf2f7}.vc-bg-gray-300{background-color:#e2e8f0}.vc-bg-gray-400{background-color:#cbd5e0}.vc-bg-gray-500{background-color:#a0aec0}.vc-bg-gray-600{background-color:#718096}.vc-bg-gray-700{background-color:#4a5568}.vc-bg-gray-800{background-color:#2d3748}.vc-bg-gray-900{background-color:#1a202c}.vc-bg-red-100{background-color:#fff5f5}.vc-bg-red-200{background-color:#fed7d7}.vc-bg-red-300{background-color:#feb2b2}.vc-bg-red-400{background-color:#fc8181}.vc-bg-red-500{background-color:#f56565}.vc-bg-red-600{background-color:#e53e3e}.vc-bg-red-700{background-color:#c53030}.vc-bg-red-800{background-color:#9b2c2c}.vc-bg-red-900{background-color:#742a2a}.vc-bg-orange-100{background-color:#fffaf0}.vc-bg-orange-200{background-color:#feebc8}.vc-bg-orange-300{background-color:#fbd38d}.vc-bg-orange-400{background-color:#f6ad55}.vc-bg-orange-500{background-color:#ed8936}.vc-bg-orange-600{background-color:#dd6b20}.vc-bg-orange-700{background-color:#c05621}.vc-bg-orange-800{background-color:#9c4221}.vc-bg-orange-900{background-color:#7b341e}.vc-bg-yellow-100{background-color:ivory}.vc-bg-yellow-200{background-color:#fefcbf}.vc-bg-yellow-300{background-color:#faf089}.vc-bg-yellow-400{background-color:#f6e05e}.vc-bg-yellow-500{background-color:#ecc94b}.vc-bg-yellow-600{background-color:#d69e2e}.vc-bg-yellow-700{background-color:#b7791f}.vc-bg-yellow-800{background-color:#975a16}.vc-bg-yellow-900{background-color:#744210}.vc-bg-green-100{background-color:#f0fff4}.vc-bg-green-200{background-color:#c6f6d5}.vc-bg-green-300{background-color:#9ae6b4}.vc-bg-green-400{background-color:#68d391}.vc-bg-green-500{background-color:#48bb78}.vc-bg-green-600{background-color:#38a169}.vc-bg-green-700{background-color:#2f855a}.vc-bg-green-800{background-color:#276749}.vc-bg-green-900{background-color:#22543d}.vc-bg-teal-100{background-color:#e6fffa}.vc-bg-teal-200{background-color:#b2f5ea}.vc-bg-teal-300{background-color:#81e6d9}.vc-bg-teal-400{background-color:#4fd1c5}.vc-bg-teal-500{background-color:#38b2ac}.vc-bg-teal-600{background-color:#319795}.vc-bg-teal-700{background-color:#2c7a7b}.vc-bg-teal-800{background-color:#285e61}.vc-bg-teal-900{background-color:#234e52}.vc-bg-blue-100{background-color:#ebf8ff}.vc-bg-blue-200{background-color:#bee3f8}.vc-bg-blue-300{background-color:#90cdf4}.vc-bg-blue-400{background-color:#63b3ed}.vc-bg-blue-500{background-color:#4299e1}.vc-bg-blue-600{background-color:#3182ce}.vc-bg-blue-700{background-color:#2b6cb0}.vc-bg-blue-800{background-color:#2c5282}.vc-bg-blue-900{background-color:#2a4365}.vc-bg-indigo-100{background-color:#ebf4ff}.vc-bg-indigo-200{background-color:#c3dafe}.vc-bg-indigo-300{background-color:#a3bffa}.vc-bg-indigo-400{background-color:#7f9cf5}.vc-bg-indigo-500{background-color:#667eea}.vc-bg-indigo-600{background-color:#5a67d8}.vc-bg-indigo-700{background-color:#4c51bf}.vc-bg-indigo-800{background-color:#434190}.vc-bg-indigo-900{background-color:#3c366b}.vc-bg-purple-100{background-color:#faf5ff}.vc-bg-purple-200{background-color:#e9d8fd}.vc-bg-purple-300{background-color:#d6bcfa}.vc-bg-purple-400{background-color:#b794f4}.vc-bg-purple-500{background-color:#9f7aea}.vc-bg-purple-600{background-color:#805ad5}.vc-bg-purple-700{background-color:#6b46c1}.vc-bg-purple-800{background-color:#553c9a}.vc-bg-purple-900{background-color:#44337a}.vc-bg-pink-100{background-color:#fff5f7}.vc-bg-pink-200{background-color:#fed7e2}.vc-bg-pink-300{background-color:#fbb6ce}.vc-bg-pink-400{background-color:#f687b3}.vc-bg-pink-500{background-color:#ed64a6}.vc-bg-pink-600{background-color:#d53f8c}.vc-bg-pink-700{background-color:#b83280}.vc-bg-pink-800{background-color:#97266d}.vc-bg-pink-900{background-color:#702459}.hover\:vc-bg-transparent:hover{background-color:initial}.hover\:vc-bg-black:hover{background-color:#000}.hover\:vc-bg-white:hover{background-color:#fff}.hover\:vc-bg-gray-100:hover{background-color:#f7fafc}.hover\:vc-bg-gray-200:hover{background-color:#edf2f7}.hover\:vc-bg-gray-300:hover{background-color:#e2e8f0}.hover\:vc-bg-gray-400:hover{background-color:#cbd5e0}.hover\:vc-bg-gray-500:hover{background-color:#a0aec0}.hover\:vc-bg-gray-600:hover{background-color:#718096}.hover\:vc-bg-gray-700:hover{background-color:#4a5568}.hover\:vc-bg-gray-800:hover{background-color:#2d3748}.hover\:vc-bg-gray-900:hover{background-color:#1a202c}.hover\:vc-bg-red-100:hover{background-color:#fff5f5}.hover\:vc-bg-red-200:hover{background-color:#fed7d7}.hover\:vc-bg-red-300:hover{background-color:#feb2b2}.hover\:vc-bg-red-400:hover{background-color:#fc8181}.hover\:vc-bg-red-500:hover{background-color:#f56565}.hover\:vc-bg-red-600:hover{background-color:#e53e3e}.hover\:vc-bg-red-700:hover{background-color:#c53030}.hover\:vc-bg-red-800:hover{background-color:#9b2c2c}.hover\:vc-bg-red-900:hover{background-color:#742a2a}.hover\:vc-bg-orange-100:hover{background-color:#fffaf0}.hover\:vc-bg-orange-200:hover{background-color:#feebc8}.hover\:vc-bg-orange-300:hover{background-color:#fbd38d}.hover\:vc-bg-orange-400:hover{background-color:#f6ad55}.hover\:vc-bg-orange-500:hover{background-color:#ed8936}.hover\:vc-bg-orange-600:hover{background-color:#dd6b20}.hover\:vc-bg-orange-700:hover{background-color:#c05621}.hover\:vc-bg-orange-800:hover{background-color:#9c4221}.hover\:vc-bg-orange-900:hover{background-color:#7b341e}.hover\:vc-bg-yellow-100:hover{background-color:ivory}.hover\:vc-bg-yellow-200:hover{background-color:#fefcbf}.hover\:vc-bg-yellow-300:hover{background-color:#faf089}.hover\:vc-bg-yellow-400:hover{background-color:#f6e05e}.hover\:vc-bg-yellow-500:hover{background-color:#ecc94b}.hover\:vc-bg-yellow-600:hover{background-color:#d69e2e}.hover\:vc-bg-yellow-700:hover{background-color:#b7791f}.hover\:vc-bg-yellow-800:hover{background-color:#975a16}.hover\:vc-bg-yellow-900:hover{background-color:#744210}.hover\:vc-bg-green-100:hover{background-color:#f0fff4}.hover\:vc-bg-green-200:hover{background-color:#c6f6d5}.hover\:vc-bg-green-300:hover{background-color:#9ae6b4}.hover\:vc-bg-green-400:hover{background-color:#68d391}.hover\:vc-bg-green-500:hover{background-color:#48bb78}.hover\:vc-bg-green-600:hover{background-color:#38a169}.hover\:vc-bg-green-700:hover{background-color:#2f855a}.hover\:vc-bg-green-800:hover{background-color:#276749}.hover\:vc-bg-green-900:hover{background-color:#22543d}.hover\:vc-bg-teal-100:hover{background-color:#e6fffa}.hover\:vc-bg-teal-200:hover{background-color:#b2f5ea}.hover\:vc-bg-teal-300:hover{background-color:#81e6d9}.hover\:vc-bg-teal-400:hover{background-color:#4fd1c5}.hover\:vc-bg-teal-500:hover{background-color:#38b2ac}.hover\:vc-bg-teal-600:hover{background-color:#319795}.hover\:vc-bg-teal-700:hover{background-color:#2c7a7b}.hover\:vc-bg-teal-800:hover{background-color:#285e61}.hover\:vc-bg-teal-900:hover{background-color:#234e52}.hover\:vc-bg-blue-100:hover{background-color:#ebf8ff}.hover\:vc-bg-blue-200:hover{background-color:#bee3f8}.hover\:vc-bg-blue-300:hover{background-color:#90cdf4}.hover\:vc-bg-blue-400:hover{background-color:#63b3ed}.hover\:vc-bg-blue-500:hover{background-color:#4299e1}.hover\:vc-bg-blue-600:hover{background-color:#3182ce}.hover\:vc-bg-blue-700:hover{background-color:#2b6cb0}.hover\:vc-bg-blue-800:hover{background-color:#2c5282}.hover\:vc-bg-blue-900:hover{background-color:#2a4365}.hover\:vc-bg-indigo-100:hover{background-color:#ebf4ff}.hover\:vc-bg-indigo-200:hover{background-color:#c3dafe}.hover\:vc-bg-indigo-300:hover{background-color:#a3bffa}.hover\:vc-bg-indigo-400:hover{background-color:#7f9cf5}.hover\:vc-bg-indigo-500:hover{background-color:#667eea}.hover\:vc-bg-indigo-600:hover{background-color:#5a67d8}.hover\:vc-bg-indigo-700:hover{background-color:#4c51bf}.hover\:vc-bg-indigo-800:hover{background-color:#434190}.hover\:vc-bg-indigo-900:hover{background-color:#3c366b}.hover\:vc-bg-purple-100:hover{background-color:#faf5ff}.hover\:vc-bg-purple-200:hover{background-color:#e9d8fd}.hover\:vc-bg-purple-300:hover{background-color:#d6bcfa}.hover\:vc-bg-purple-400:hover{background-color:#b794f4}.hover\:vc-bg-purple-500:hover{background-color:#9f7aea}.hover\:vc-bg-purple-600:hover{background-color:#805ad5}.hover\:vc-bg-purple-700:hover{background-color:#6b46c1}.hover\:vc-bg-purple-800:hover{background-color:#553c9a}.hover\:vc-bg-purple-900:hover{background-color:#44337a}.hover\:vc-bg-pink-100:hover{background-color:#fff5f7}.hover\:vc-bg-pink-200:hover{background-color:#fed7e2}.hover\:vc-bg-pink-300:hover{background-color:#fbb6ce}.hover\:vc-bg-pink-400:hover{background-color:#f687b3}.hover\:vc-bg-pink-500:hover{background-color:#ed64a6}.hover\:vc-bg-pink-600:hover{background-color:#d53f8c}.hover\:vc-bg-pink-700:hover{background-color:#b83280}.hover\:vc-bg-pink-800:hover{background-color:#97266d}.hover\:vc-bg-pink-900:hover{background-color:#702459}.vc-bg-bottom{background-position:bottom}.vc-bg-center{background-position:50%}.vc-bg-left{background-position:0}.vc-bg-left-bottom{background-position:0 100%}.vc-bg-left-top{background-position:0 0}.vc-bg-right{background-position:100%}.vc-bg-right-bottom{background-position:100% 100%}.vc-bg-right-top{background-position:100% 0}.vc-bg-top{background-position:top}.vc-bg-repeat{background-repeat:repeat}.vc-bg-no-repeat{background-repeat:no-repeat}.vc-bg-repeat-x{background-repeat:repeat-x}.vc-bg-repeat-y{background-repeat:repeat-y}.vc-bg-repeat-round{background-repeat:round}.vc-bg-repeat-space{background-repeat:space}.vc-bg-auto{background-size:auto}.vc-bg-cover{background-size:cover}.vc-bg-contain{background-size:contain}.vc-border-collapse{border-collapse:collapse}.vc-border-separate{border-collapse:initial}.vc-border-transparent{border-color:transparent}.vc-border-black{border-color:#000}.vc-border-white{border-color:#fff}.vc-border-gray-100{border-color:#f7fafc}.vc-border-gray-200{border-color:#edf2f7}.vc-border-gray-300{border-color:#e2e8f0}.vc-border-gray-400{border-color:#cbd5e0}.vc-border-gray-500{border-color:#a0aec0}.vc-border-gray-600{border-color:#718096}.vc-border-gray-700{border-color:#4a5568}.vc-border-gray-800{border-color:#2d3748}.vc-border-gray-900{border-color:#1a202c}.vc-border-red-100{border-color:#fff5f5}.vc-border-red-200{border-color:#fed7d7}.vc-border-red-300{border-color:#feb2b2}.vc-border-red-400{border-color:#fc8181}.vc-border-red-500{border-color:#f56565}.vc-border-red-600{border-color:#e53e3e}.vc-border-red-700{border-color:#c53030}.vc-border-red-800{border-color:#9b2c2c}.vc-border-red-900{border-color:#742a2a}.vc-border-orange-100{border-color:#fffaf0}.vc-border-orange-200{border-color:#feebc8}.vc-border-orange-300{border-color:#fbd38d}.vc-border-orange-400{border-color:#f6ad55}.vc-border-orange-500{border-color:#ed8936}.vc-border-orange-600{border-color:#dd6b20}.vc-border-orange-700{border-color:#c05621}.vc-border-orange-800{border-color:#9c4221}.vc-border-orange-900{border-color:#7b341e}.vc-border-yellow-100{border-color:ivory}.vc-border-yellow-200{border-color:#fefcbf}.vc-border-yellow-300{border-color:#faf089}.vc-border-yellow-400{border-color:#f6e05e}.vc-border-yellow-500{border-color:#ecc94b}.vc-border-yellow-600{border-color:#d69e2e}.vc-border-yellow-700{border-color:#b7791f}.vc-border-yellow-800{border-color:#975a16}.vc-border-yellow-900{border-color:#744210}.vc-border-green-100{border-color:#f0fff4}.vc-border-green-200{border-color:#c6f6d5}.vc-border-green-300{border-color:#9ae6b4}.vc-border-green-400{border-color:#68d391}.vc-border-green-500{border-color:#48bb78}.vc-border-green-600{border-color:#38a169}.vc-border-green-700{border-color:#2f855a}.vc-border-green-800{border-color:#276749}.vc-border-green-900{border-color:#22543d}.vc-border-teal-100{border-color:#e6fffa}.vc-border-teal-200{border-color:#b2f5ea}.vc-border-teal-300{border-color:#81e6d9}.vc-border-teal-400{border-color:#4fd1c5}.vc-border-teal-500{border-color:#38b2ac}.vc-border-teal-600{border-color:#319795}.vc-border-teal-700{border-color:#2c7a7b}.vc-border-teal-800{border-color:#285e61}.vc-border-teal-900{border-color:#234e52}.vc-border-blue-100{border-color:#ebf8ff}.vc-border-blue-200{border-color:#bee3f8}.vc-border-blue-300{border-color:#90cdf4}.vc-border-blue-400{border-color:#63b3ed}.vc-border-blue-500{border-color:#4299e1}.vc-border-blue-600{border-color:#3182ce}.vc-border-blue-700{border-color:#2b6cb0}.vc-border-blue-800{border-color:#2c5282}.vc-border-blue-900{border-color:#2a4365}.vc-border-indigo-100{border-color:#ebf4ff}.vc-border-indigo-200{border-color:#c3dafe}.vc-border-indigo-300{border-color:#a3bffa}.vc-border-indigo-400{border-color:#7f9cf5}.vc-border-indigo-500{border-color:#667eea}.vc-border-indigo-600{border-color:#5a67d8}.vc-border-indigo-700{border-color:#4c51bf}.vc-border-indigo-800{border-color:#434190}.vc-border-indigo-900{border-color:#3c366b}.vc-border-purple-100{border-color:#faf5ff}.vc-border-purple-200{border-color:#e9d8fd}.vc-border-purple-300{border-color:#d6bcfa}.vc-border-purple-400{border-color:#b794f4}.vc-border-purple-500{border-color:#9f7aea}.vc-border-purple-600{border-color:#805ad5}.vc-border-purple-700{border-color:#6b46c1}.vc-border-purple-800{border-color:#553c9a}.vc-border-purple-900{border-color:#44337a}.vc-border-pink-100{border-color:#fff5f7}.vc-border-pink-200{border-color:#fed7e2}.vc-border-pink-300{border-color:#fbb6ce}.vc-border-pink-400{border-color:#f687b3}.vc-border-pink-500{border-color:#ed64a6}.vc-border-pink-600{border-color:#d53f8c}.vc-border-pink-700{border-color:#b83280}.vc-border-pink-800{border-color:#97266d}.vc-border-pink-900{border-color:#702459}.hover\:vc-border-transparent:hover{border-color:transparent}.hover\:vc-border-black:hover{border-color:#000}.hover\:vc-border-white:hover{border-color:#fff}.hover\:vc-border-gray-100:hover{border-color:#f7fafc}.hover\:vc-border-gray-200:hover{border-color:#edf2f7}.hover\:vc-border-gray-300:hover{border-color:#e2e8f0}.hover\:vc-border-gray-400:hover{border-color:#cbd5e0}.hover\:vc-border-gray-500:hover{border-color:#a0aec0}.hover\:vc-border-gray-600:hover{border-color:#718096}.hover\:vc-border-gray-700:hover{border-color:#4a5568}.hover\:vc-border-gray-800:hover{border-color:#2d3748}.hover\:vc-border-gray-900:hover{border-color:#1a202c}.hover\:vc-border-red-100:hover{border-color:#fff5f5}.hover\:vc-border-red-200:hover{border-color:#fed7d7}.hover\:vc-border-red-300:hover{border-color:#feb2b2}.hover\:vc-border-red-400:hover{border-color:#fc8181}.hover\:vc-border-red-500:hover{border-color:#f56565}.hover\:vc-border-red-600:hover{border-color:#e53e3e}.hover\:vc-border-red-700:hover{border-color:#c53030}.hover\:vc-border-red-800:hover{border-color:#9b2c2c}.hover\:vc-border-red-900:hover{border-color:#742a2a}.hover\:vc-border-orange-100:hover{border-color:#fffaf0}.hover\:vc-border-orange-200:hover{border-color:#feebc8}.hover\:vc-border-orange-300:hover{border-color:#fbd38d}.hover\:vc-border-orange-400:hover{border-color:#f6ad55}.hover\:vc-border-orange-500:hover{border-color:#ed8936}.hover\:vc-border-orange-600:hover{border-color:#dd6b20}.hover\:vc-border-orange-700:hover{border-color:#c05621}.hover\:vc-border-orange-800:hover{border-color:#9c4221}.hover\:vc-border-orange-900:hover{border-color:#7b341e}.hover\:vc-border-yellow-100:hover{border-color:ivory}.hover\:vc-border-yellow-200:hover{border-color:#fefcbf}.hover\:vc-border-yellow-300:hover{border-color:#faf089}.hover\:vc-border-yellow-400:hover{border-color:#f6e05e}.hover\:vc-border-yellow-500:hover{border-color:#ecc94b}.hover\:vc-border-yellow-600:hover{border-color:#d69e2e}.hover\:vc-border-yellow-700:hover{border-color:#b7791f}.hover\:vc-border-yellow-800:hover{border-color:#975a16}.hover\:vc-border-yellow-900:hover{border-color:#744210}.hover\:vc-border-green-100:hover{border-color:#f0fff4}.hover\:vc-border-green-200:hover{border-color:#c6f6d5}.hover\:vc-border-green-300:hover{border-color:#9ae6b4}.hover\:vc-border-green-400:hover{border-color:#68d391}.hover\:vc-border-green-500:hover{border-color:#48bb78}.hover\:vc-border-green-600:hover{border-color:#38a169}.hover\:vc-border-green-700:hover{border-color:#2f855a}.hover\:vc-border-green-800:hover{border-color:#276749}.hover\:vc-border-green-900:hover{border-color:#22543d}.hover\:vc-border-teal-100:hover{border-color:#e6fffa}.hover\:vc-border-teal-200:hover{border-color:#b2f5ea}.hover\:vc-border-teal-300:hover{border-color:#81e6d9}.hover\:vc-border-teal-400:hover{border-color:#4fd1c5}.hover\:vc-border-teal-500:hover{border-color:#38b2ac}.hover\:vc-border-teal-600:hover{border-color:#319795}.hover\:vc-border-teal-700:hover{border-color:#2c7a7b}.hover\:vc-border-teal-800:hover{border-color:#285e61}.hover\:vc-border-teal-900:hover{border-color:#234e52}.hover\:vc-border-blue-100:hover{border-color:#ebf8ff}.hover\:vc-border-blue-200:hover{border-color:#bee3f8}.hover\:vc-border-blue-300:hover{border-color:#90cdf4}.hover\:vc-border-blue-400:hover{border-color:#63b3ed}.hover\:vc-border-blue-500:hover{border-color:#4299e1}.hover\:vc-border-blue-600:hover{border-color:#3182ce}.hover\:vc-border-blue-700:hover{border-color:#2b6cb0}.hover\:vc-border-blue-800:hover{border-color:#2c5282}.hover\:vc-border-blue-900:hover{border-color:#2a4365}.hover\:vc-border-indigo-100:hover{border-color:#ebf4ff}.hover\:vc-border-indigo-200:hover{border-color:#c3dafe}.hover\:vc-border-indigo-300:hover{border-color:#a3bffa}.hover\:vc-border-indigo-400:hover{border-color:#7f9cf5}.hover\:vc-border-indigo-500:hover{border-color:#667eea}.hover\:vc-border-indigo-600:hover{border-color:#5a67d8}.hover\:vc-border-indigo-700:hover{border-color:#4c51bf}.hover\:vc-border-indigo-800:hover{border-color:#434190}.hover\:vc-border-indigo-900:hover{border-color:#3c366b}.hover\:vc-border-purple-100:hover{border-color:#faf5ff}.hover\:vc-border-purple-200:hover{border-color:#e9d8fd}.hover\:vc-border-purple-300:hover{border-color:#d6bcfa}.hover\:vc-border-purple-400:hover{border-color:#b794f4}.hover\:vc-border-purple-500:hover{border-color:#9f7aea}.hover\:vc-border-purple-600:hover{border-color:#805ad5}.hover\:vc-border-purple-700:hover{border-color:#6b46c1}.hover\:vc-border-purple-800:hover{border-color:#553c9a}.hover\:vc-border-purple-900:hover{border-color:#44337a}.hover\:vc-border-pink-100:hover{border-color:#fff5f7}.hover\:vc-border-pink-200:hover{border-color:#fed7e2}.hover\:vc-border-pink-300:hover{border-color:#fbb6ce}.hover\:vc-border-pink-400:hover{border-color:#f687b3}.hover\:vc-border-pink-500:hover{border-color:#ed64a6}.hover\:vc-border-pink-600:hover{border-color:#d53f8c}.hover\:vc-border-pink-700:hover{border-color:#b83280}.hover\:vc-border-pink-800:hover{border-color:#97266d}.hover\:vc-border-pink-900:hover{border-color:#702459}.focus\:vc-border-transparent:focus{border-color:transparent}.focus\:vc-border-black:focus{border-color:#000}.focus\:vc-border-white:focus{border-color:#fff}.focus\:vc-border-gray-100:focus{border-color:#f7fafc}.focus\:vc-border-gray-200:focus{border-color:#edf2f7}.focus\:vc-border-gray-300:focus{border-color:#e2e8f0}.focus\:vc-border-gray-400:focus{border-color:#cbd5e0}.focus\:vc-border-gray-500:focus{border-color:#a0aec0}.focus\:vc-border-gray-600:focus{border-color:#718096}.focus\:vc-border-gray-700:focus{border-color:#4a5568}.focus\:vc-border-gray-800:focus{border-color:#2d3748}.focus\:vc-border-gray-900:focus{border-color:#1a202c}.focus\:vc-border-red-100:focus{border-color:#fff5f5}.focus\:vc-border-red-200:focus{border-color:#fed7d7}.focus\:vc-border-red-300:focus{border-color:#feb2b2}.focus\:vc-border-red-400:focus{border-color:#fc8181}.focus\:vc-border-red-500:focus{border-color:#f56565}.focus\:vc-border-red-600:focus{border-color:#e53e3e}.focus\:vc-border-red-700:focus{border-color:#c53030}.focus\:vc-border-red-800:focus{border-color:#9b2c2c}.focus\:vc-border-red-900:focus{border-color:#742a2a}.focus\:vc-border-orange-100:focus{border-color:#fffaf0}.focus\:vc-border-orange-200:focus{border-color:#feebc8}.focus\:vc-border-orange-300:focus{border-color:#fbd38d}.focus\:vc-border-orange-400:focus{border-color:#f6ad55}.focus\:vc-border-orange-500:focus{border-color:#ed8936}.focus\:vc-border-orange-600:focus{border-color:#dd6b20}.focus\:vc-border-orange-700:focus{border-color:#c05621}.focus\:vc-border-orange-800:focus{border-color:#9c4221}.focus\:vc-border-orange-900:focus{border-color:#7b341e}.focus\:vc-border-yellow-100:focus{border-color:ivory}.focus\:vc-border-yellow-200:focus{border-color:#fefcbf}.focus\:vc-border-yellow-300:focus{border-color:#faf089}.focus\:vc-border-yellow-400:focus{border-color:#f6e05e}.focus\:vc-border-yellow-500:focus{border-color:#ecc94b}.focus\:vc-border-yellow-600:focus{border-color:#d69e2e}.focus\:vc-border-yellow-700:focus{border-color:#b7791f}.focus\:vc-border-yellow-800:focus{border-color:#975a16}.focus\:vc-border-yellow-900:focus{border-color:#744210}.focus\:vc-border-green-100:focus{border-color:#f0fff4}.focus\:vc-border-green-200:focus{border-color:#c6f6d5}.focus\:vc-border-green-300:focus{border-color:#9ae6b4}.focus\:vc-border-green-400:focus{border-color:#68d391}.focus\:vc-border-green-500:focus{border-color:#48bb78}.focus\:vc-border-green-600:focus{border-color:#38a169}.focus\:vc-border-green-700:focus{border-color:#2f855a}.focus\:vc-border-green-800:focus{border-color:#276749}.focus\:vc-border-green-900:focus{border-color:#22543d}.focus\:vc-border-teal-100:focus{border-color:#e6fffa}.focus\:vc-border-teal-200:focus{border-color:#b2f5ea}.focus\:vc-border-teal-300:focus{border-color:#81e6d9}.focus\:vc-border-teal-400:focus{border-color:#4fd1c5}.focus\:vc-border-teal-500:focus{border-color:#38b2ac}.focus\:vc-border-teal-600:focus{border-color:#319795}.focus\:vc-border-teal-700:focus{border-color:#2c7a7b}.focus\:vc-border-teal-800:focus{border-color:#285e61}.focus\:vc-border-teal-900:focus{border-color:#234e52}.focus\:vc-border-blue-100:focus{border-color:#ebf8ff}.focus\:vc-border-blue-200:focus{border-color:#bee3f8}.focus\:vc-border-blue-300:focus{border-color:#90cdf4}.focus\:vc-border-blue-400:focus{border-color:#63b3ed}.focus\:vc-border-blue-500:focus{border-color:#4299e1}.focus\:vc-border-blue-600:focus{border-color:#3182ce}.focus\:vc-border-blue-700:focus{border-color:#2b6cb0}.focus\:vc-border-blue-800:focus{border-color:#2c5282}.focus\:vc-border-blue-900:focus{border-color:#2a4365}.focus\:vc-border-indigo-100:focus{border-color:#ebf4ff}.focus\:vc-border-indigo-200:focus{border-color:#c3dafe}.focus\:vc-border-indigo-300:focus{border-color:#a3bffa}.focus\:vc-border-indigo-400:focus{border-color:#7f9cf5}.focus\:vc-border-indigo-500:focus{border-color:#667eea}.focus\:vc-border-indigo-600:focus{border-color:#5a67d8}.focus\:vc-border-indigo-700:focus{border-color:#4c51bf}.focus\:vc-border-indigo-800:focus{border-color:#434190}.focus\:vc-border-indigo-900:focus{border-color:#3c366b}.focus\:vc-border-purple-100:focus{border-color:#faf5ff}.focus\:vc-border-purple-200:focus{border-color:#e9d8fd}.focus\:vc-border-purple-300:focus{border-color:#d6bcfa}.focus\:vc-border-purple-400:focus{border-color:#b794f4}.focus\:vc-border-purple-500:focus{border-color:#9f7aea}.focus\:vc-border-purple-600:focus{border-color:#805ad5}.focus\:vc-border-purple-700:focus{border-color:#6b46c1}.focus\:vc-border-purple-800:focus{border-color:#553c9a}.focus\:vc-border-purple-900:focus{border-color:#44337a}.focus\:vc-border-pink-100:focus{border-color:#fff5f7}.focus\:vc-border-pink-200:focus{border-color:#fed7e2}.focus\:vc-border-pink-300:focus{border-color:#fbb6ce}.focus\:vc-border-pink-400:focus{border-color:#f687b3}.focus\:vc-border-pink-500:focus{border-color:#ed64a6}.focus\:vc-border-pink-600:focus{border-color:#d53f8c}.focus\:vc-border-pink-700:focus{border-color:#b83280}.focus\:vc-border-pink-800:focus{border-color:#97266d}.focus\:vc-border-pink-900:focus{border-color:#702459}.vc-rounded-none{border-radius:0}.vc-rounded-sm{border-radius:18px}.vc-rounded{border-radius:4px}.vc-rounded-lg{border-radius:8px}.vc-rounded-full{border-radius:9999px}.vc-rounded-t-none{border-top-left-radius:0;border-top-right-radius:0}.vc-rounded-r-none{border-top-right-radius:0;border-bottom-right-radius:0}.vc-rounded-b-none{border-bottom-right-radius:0;border-bottom-left-radius:0}.vc-rounded-l-none{border-top-left-radius:0;border-bottom-left-radius:0}.vc-rounded-t-sm{border-top-left-radius:18px;border-top-right-radius:18px}.vc-rounded-r-sm{border-top-right-radius:18px;border-bottom-right-radius:18px}.vc-rounded-b-sm{border-bottom-right-radius:18px;border-bottom-left-radius:18px}.vc-rounded-l-sm{border-top-left-radius:18px;border-bottom-left-radius:18px}.vc-rounded-t{border-top-left-radius:4px;border-top-right-radius:4px}.vc-rounded-r{border-top-right-radius:4px}.vc-rounded-b,.vc-rounded-r{border-bottom-right-radius:4px}.vc-rounded-b,.vc-rounded-l{border-bottom-left-radius:4px}.vc-rounded-l{border-top-left-radius:4px}.vc-rounded-t-lg{border-top-left-radius:8px;border-top-right-radius:8px}.vc-rounded-r-lg{border-top-right-radius:8px;border-bottom-right-radius:8px}.vc-rounded-b-lg{border-bottom-right-radius:8px;border-bottom-left-radius:8px}.vc-rounded-l-lg{border-top-left-radius:8px;border-bottom-left-radius:8px}.vc-rounded-t-full{border-top-left-radius:9999px;border-top-right-radius:9999px}.vc-rounded-r-full{border-top-right-radius:9999px;border-bottom-right-radius:9999px}.vc-rounded-b-full{border-bottom-right-radius:9999px;border-bottom-left-radius:9999px}.vc-rounded-l-full{border-top-left-radius:9999px;border-bottom-left-radius:9999px}.vc-rounded-tl-none{border-top-left-radius:0}.vc-rounded-tr-none{border-top-right-radius:0}.vc-rounded-br-none{border-bottom-right-radius:0}.vc-rounded-bl-none{border-bottom-left-radius:0}.vc-rounded-tl-sm{border-top-left-radius:18px}.vc-rounded-tr-sm{border-top-right-radius:18px}.vc-rounded-br-sm{border-bottom-right-radius:18px}.vc-rounded-bl-sm{border-bottom-left-radius:18px}.vc-rounded-tl{border-top-left-radius:4px}.vc-rounded-tr{border-top-right-radius:4px}.vc-rounded-br{border-bottom-right-radius:4px}.vc-rounded-bl{border-bottom-left-radius:4px}.vc-rounded-tl-lg{border-top-left-radius:8px}.vc-rounded-tr-lg{border-top-right-radius:8px}.vc-rounded-br-lg{border-bottom-right-radius:8px}.vc-rounded-bl-lg{border-bottom-left-radius:8px}.vc-rounded-tl-full{border-top-left-radius:9999px}.vc-rounded-tr-full{border-top-right-radius:9999px}.vc-rounded-br-full{border-bottom-right-radius:9999px}.vc-rounded-bl-full{border-bottom-left-radius:9999px}.vc-border-solid{border-style:solid}.vc-border-dashed{border-style:dashed}.vc-border-dotted{border-style:dotted}.vc-border-double{border-style:double}.vc-border-none{border-style:none}.vc-border-0{border-width:0}.vc-border-2{border-width:2px}.vc-border-4{border-width:4px}.vc-border-8{border-width:8px}.vc-border{border-width:1px}.vc-border-t-0{border-top-width:0}.vc-border-r-0{border-right-width:0}.vc-border-b-0{border-bottom-width:0}.vc-border-l-0{border-left-width:0}.vc-border-t-2{border-top-width:2px}.vc-border-r-2{border-right-width:2px}.vc-border-b-2{border-bottom-width:2px}.vc-border-l-2{border-left-width:2px}.vc-border-t-4{border-top-width:4px}.vc-border-r-4{border-right-width:4px}.vc-border-b-4{border-bottom-width:4px}.vc-border-l-4{border-left-width:4px}.vc-border-t-8{border-top-width:8px}.vc-border-r-8{border-right-width:8px}.vc-border-b-8{border-bottom-width:8px}.vc-border-l-8{border-left-width:8px}.vc-border-t{border-top-width:1px}.vc-border-r{border-right-width:1px}.vc-border-b{border-bottom-width:1px}.vc-border-l{border-left-width:1px}.vc-cursor-pointer{cursor:pointer}.vc-cursor-not-allowed{cursor:not-allowed}.vc-flex{display:flex}.vc-items-center{align-items:center}.vc-justify-center{justify-content:center}.vc-font-medium{font-weight:500}.vc-font-semibold{font-weight:600}.focus\:vc-font-bold:focus,.vc-font-bold{font-weight:700}.vc-h-full{height:100%}.vc-leading-tight{line-height:1.25}.vc-leading-snug{line-height:1.375}.vc-mr-auto{margin-right:auto}.vc-ml-auto{margin-left:auto}.vc-min-w-full{min-width:100%}.vc-opacity-0{opacity:0}.vc-opacity-25{opacity:.25}.vc-opacity-75{opacity:.75}.hover\:vc-opacity-50:hover{opacity:.5}.hover\:vc-opacity-75:hover{opacity:.75}.focus\:vc-outline-none:focus{outline:0}.vc-overflow-hidden{overflow:hidden}.vc-p-1{padding:4px}.vc-py-1{padding-top:4px;padding-bottom:4px}.vc-py-2{padding-top:8px;padding-bottom:8px}.vc-px-2{padding-left:8px;padding-right:8px}.vc-px-3{padding-left:12px;padding-right:12px}.vc-pointer-events-none{pointer-events:none}.vc-pointer-events-auto{pointer-events:auto}.vc-relative{position:relative}.vc-shadow{box-shadow:0 1px 3px 0 rgba(0,0,0,.1),0 1px 2px 0 rgba(0,0,0,.06)}.hover\:vc-shadow-inner:hover{box-shadow:inset 0 2px 4px 0 rgba(0,0,0,.06)}.focus\:vc-shadow:focus{box-shadow:0 1px 3px 0 rgba(0,0,0,.1),0 1px 2px 0 rgba(0,0,0,.06)}.vc-text-left{text-align:left}.vc-text-center{text-align:center}.vc-text-right{text-align:right}.vc-text-justify{text-align:justify}.vc-text-transparent{color:transparent}.vc-text-black{color:#000}.vc-text-white{color:#fff}.vc-text-gray-100{color:#f7fafc}.vc-text-gray-200{color:#edf2f7}.vc-text-gray-300{color:#e2e8f0}.vc-text-gray-400{color:#cbd5e0}.vc-text-gray-500{color:#a0aec0}.vc-text-gray-600{color:#718096}.vc-text-gray-700{color:#4a5568}.vc-text-gray-800{color:#2d3748}.vc-text-gray-900{color:#1a202c}.vc-text-red-100{color:#fff5f5}.vc-text-red-200{color:#fed7d7}.vc-text-red-300{color:#feb2b2}.vc-text-red-400{color:#fc8181}.vc-text-red-500{color:#f56565}.vc-text-red-600{color:#e53e3e}.vc-text-red-700{color:#c53030}.vc-text-red-800{color:#9b2c2c}.vc-text-red-900{color:#742a2a}.vc-text-orange-100{color:#fffaf0}.vc-text-orange-200{color:#feebc8}.vc-text-orange-300{color:#fbd38d}.vc-text-orange-400{color:#f6ad55}.vc-text-orange-500{color:#ed8936}.vc-text-orange-600{color:#dd6b20}.vc-text-orange-700{color:#c05621}.vc-text-orange-800{color:#9c4221}.vc-text-orange-900{color:#7b341e}.vc-text-yellow-100{color:ivory}.vc-text-yellow-200{color:#fefcbf}.vc-text-yellow-300{color:#faf089}.vc-text-yellow-400{color:#f6e05e}.vc-text-yellow-500{color:#ecc94b}.vc-text-yellow-600{color:#d69e2e}.vc-text-yellow-700{color:#b7791f}.vc-text-yellow-800{color:#975a16}.vc-text-yellow-900{color:#744210}.vc-text-green-100{color:#f0fff4}.vc-text-green-200{color:#c6f6d5}.vc-text-green-300{color:#9ae6b4}.vc-text-green-400{color:#68d391}.vc-text-green-500{color:#48bb78}.vc-text-green-600{color:#38a169}.vc-text-green-700{color:#2f855a}.vc-text-green-800{color:#276749}.vc-text-green-900{color:#22543d}.vc-text-teal-100{color:#e6fffa}.vc-text-teal-200{color:#b2f5ea}.vc-text-teal-300{color:#81e6d9}.vc-text-teal-400{color:#4fd1c5}.vc-text-teal-500{color:#38b2ac}.vc-text-teal-600{color:#319795}.vc-text-teal-700{color:#2c7a7b}.vc-text-teal-800{color:#285e61}.vc-text-teal-900{color:#234e52}.vc-text-blue-100{color:#ebf8ff}.vc-text-blue-200{color:#bee3f8}.vc-text-blue-300{color:#90cdf4}.vc-text-blue-400{color:#63b3ed}.vc-text-blue-500{color:#4299e1}.vc-text-blue-600{color:#3182ce}.vc-text-blue-700{color:#2b6cb0}.vc-text-blue-800{color:#2c5282}.vc-text-blue-900{color:#2a4365}.vc-text-indigo-100{color:#ebf4ff}.vc-text-indigo-200{color:#c3dafe}.vc-text-indigo-300{color:#a3bffa}.vc-text-indigo-400{color:#7f9cf5}.vc-text-indigo-500{color:#667eea}.vc-text-indigo-600{color:#5a67d8}.vc-text-indigo-700{color:#4c51bf}.vc-text-indigo-800{color:#434190}.vc-text-indigo-900{color:#3c366b}.vc-text-purple-100{color:#faf5ff}.vc-text-purple-200{color:#e9d8fd}.vc-text-purple-300{color:#d6bcfa}.vc-text-purple-400{color:#b794f4}.vc-text-purple-500{color:#9f7aea}.vc-text-purple-600{color:#805ad5}.vc-text-purple-700{color:#6b46c1}.vc-text-purple-800{color:#553c9a}.vc-text-purple-900{color:#44337a}.vc-text-pink-100{color:#fff5f7}.vc-text-pink-200{color:#fed7e2}.vc-text-pink-300{color:#fbb6ce}.vc-text-pink-400{color:#f687b3}.vc-text-pink-500{color:#ed64a6}.vc-text-pink-600{color:#d53f8c}.vc-text-pink-700{color:#b83280}.vc-text-pink-800{color:#97266d}.vc-text-pink-900{color:#702459}.hover\:vc-text-transparent:hover{color:transparent}.hover\:vc-text-black:hover{color:#000}.hover\:vc-text-white:hover{color:#fff}.hover\:vc-text-gray-100:hover{color:#f7fafc}.hover\:vc-text-gray-200:hover{color:#edf2f7}.hover\:vc-text-gray-300:hover{color:#e2e8f0}.hover\:vc-text-gray-400:hover{color:#cbd5e0}.hover\:vc-text-gray-500:hover{color:#a0aec0}.hover\:vc-text-gray-600:hover{color:#718096}.hover\:vc-text-gray-700:hover{color:#4a5568}.hover\:vc-text-gray-800:hover{color:#2d3748}.hover\:vc-text-gray-900:hover{color:#1a202c}.hover\:vc-text-red-100:hover{color:#fff5f5}.hover\:vc-text-red-200:hover{color:#fed7d7}.hover\:vc-text-red-300:hover{color:#feb2b2}.hover\:vc-text-red-400:hover{color:#fc8181}.hover\:vc-text-red-500:hover{color:#f56565}.hover\:vc-text-red-600:hover{color:#e53e3e}.hover\:vc-text-red-700:hover{color:#c53030}.hover\:vc-text-red-800:hover{color:#9b2c2c}.hover\:vc-text-red-900:hover{color:#742a2a}.hover\:vc-text-orange-100:hover{color:#fffaf0}.hover\:vc-text-orange-200:hover{color:#feebc8}.hover\:vc-text-orange-300:hover{color:#fbd38d}.hover\:vc-text-orange-400:hover{color:#f6ad55}.hover\:vc-text-orange-500:hover{color:#ed8936}.hover\:vc-text-orange-600:hover{color:#dd6b20}.hover\:vc-text-orange-700:hover{color:#c05621}.hover\:vc-text-orange-800:hover{color:#9c4221}.hover\:vc-text-orange-900:hover{color:#7b341e}.hover\:vc-text-yellow-100:hover{color:ivory}.hover\:vc-text-yellow-200:hover{color:#fefcbf}.hover\:vc-text-yellow-300:hover{color:#faf089}.hover\:vc-text-yellow-400:hover{color:#f6e05e}.hover\:vc-text-yellow-500:hover{color:#ecc94b}.hover\:vc-text-yellow-600:hover{color:#d69e2e}.hover\:vc-text-yellow-700:hover{color:#b7791f}.hover\:vc-text-yellow-800:hover{color:#975a16}.hover\:vc-text-yellow-900:hover{color:#744210}.hover\:vc-text-green-100:hover{color:#f0fff4}.hover\:vc-text-green-200:hover{color:#c6f6d5}.hover\:vc-text-green-300:hover{color:#9ae6b4}.hover\:vc-text-green-400:hover{color:#68d391}.hover\:vc-text-green-500:hover{color:#48bb78}.hover\:vc-text-green-600:hover{color:#38a169}.hover\:vc-text-green-700:hover{color:#2f855a}.hover\:vc-text-green-800:hover{color:#276749}.hover\:vc-text-green-900:hover{color:#22543d}.hover\:vc-text-teal-100:hover{color:#e6fffa}.hover\:vc-text-teal-200:hover{color:#b2f5ea}.hover\:vc-text-teal-300:hover{color:#81e6d9}.hover\:vc-text-teal-400:hover{color:#4fd1c5}.hover\:vc-text-teal-500:hover{color:#38b2ac}.hover\:vc-text-teal-600:hover{color:#319795}.hover\:vc-text-teal-700:hover{color:#2c7a7b}.hover\:vc-text-teal-800:hover{color:#285e61}.hover\:vc-text-teal-900:hover{color:#234e52}.hover\:vc-text-blue-100:hover{color:#ebf8ff}.hover\:vc-text-blue-200:hover{color:#bee3f8}.hover\:vc-text-blue-300:hover{color:#90cdf4}.hover\:vc-text-blue-400:hover{color:#63b3ed}.hover\:vc-text-blue-500:hover{color:#4299e1}.hover\:vc-text-blue-600:hover{color:#3182ce}.hover\:vc-text-blue-700:hover{color:#2b6cb0}.hover\:vc-text-blue-800:hover{color:#2c5282}.hover\:vc-text-blue-900:hover{color:#2a4365}.hover\:vc-text-indigo-100:hover{color:#ebf4ff}.hover\:vc-text-indigo-200:hover{color:#c3dafe}.hover\:vc-text-indigo-300:hover{color:#a3bffa}.hover\:vc-text-indigo-400:hover{color:#7f9cf5}.hover\:vc-text-indigo-500:hover{color:#667eea}.hover\:vc-text-indigo-600:hover{color:#5a67d8}.hover\:vc-text-indigo-700:hover{color:#4c51bf}.hover\:vc-text-indigo-800:hover{color:#434190}.hover\:vc-text-indigo-900:hover{color:#3c366b}.hover\:vc-text-purple-100:hover{color:#faf5ff}.hover\:vc-text-purple-200:hover{color:#e9d8fd}.hover\:vc-text-purple-300:hover{color:#d6bcfa}.hover\:vc-text-purple-400:hover{color:#b794f4}.hover\:vc-text-purple-500:hover{color:#9f7aea}.hover\:vc-text-purple-600:hover{color:#805ad5}.hover\:vc-text-purple-700:hover{color:#6b46c1}.hover\:vc-text-purple-800:hover{color:#553c9a}.hover\:vc-text-purple-900:hover{color:#44337a}.hover\:vc-text-pink-100:hover{color:#fff5f7}.hover\:vc-text-pink-200:hover{color:#fed7e2}.hover\:vc-text-pink-300:hover{color:#fbb6ce}.hover\:vc-text-pink-400:hover{color:#f687b3}.hover\:vc-text-pink-500:hover{color:#ed64a6}.hover\:vc-text-pink-600:hover{color:#d53f8c}.hover\:vc-text-pink-700:hover{color:#b83280}.hover\:vc-text-pink-800:hover{color:#97266d}.hover\:vc-text-pink-900:hover{color:#702459}.vc-text-xs{font-size:12px}.vc-text-sm{font-size:14px}.vc-text-base{font-size:16px}.vc-text-lg{font-size:18px}.vc-text-xl{font-size:20px}.vc-text-2xl{font-size:24px}.vc-select-none{-webkit-user-select:none;-ms-user-select:none;user-select:none}.vc-w-12{width:48px}.vc-w-full{width:100%}@media (min-width:640px){.sm\:vc-bg-fixed{background-attachment:fixed}.sm\:vc-bg-local{background-attachment:local}.sm\:vc-bg-scroll{background-attachment:scroll}.sm\:vc-bg-bottom{background-position:bottom}.sm\:vc-bg-center{background-position:50%}.sm\:vc-bg-left{background-position:0}.sm\:vc-bg-left-bottom{background-position:0 100%}.sm\:vc-bg-left-top{background-position:0 0}.sm\:vc-bg-right{background-position:100%}.sm\:vc-bg-right-bottom{background-position:100% 100%}.sm\:vc-bg-right-top{background-position:100% 0}.sm\:vc-bg-top{background-position:top}.sm\:vc-bg-repeat{background-repeat:repeat}.sm\:vc-bg-no-repeat{background-repeat:no-repeat}.sm\:vc-bg-repeat-x{background-repeat:repeat-x}.sm\:vc-bg-repeat-y{background-repeat:repeat-y}.sm\:vc-bg-repeat-round{background-repeat:round}.sm\:vc-bg-repeat-space{background-repeat:space}.sm\:vc-bg-auto{background-size:auto}.sm\:vc-bg-cover{background-size:cover}.sm\:vc-bg-contain{background-size:contain}.sm\:vc-border-collapse{border-collapse:collapse}.sm\:vc-border-separate{border-collapse:initial}.sm\:vc-border-solid{border-style:solid}.sm\:vc-border-dashed{border-style:dashed}.sm\:vc-border-dotted{border-style:dotted}.sm\:vc-border-double{border-style:double}.sm\:vc-border-none{border-style:none}.sm\:vc-border-0{border-width:0}.sm\:vc-border-2{border-width:2px}.sm\:vc-border-4{border-width:4px}.sm\:vc-border-8{border-width:8px}.sm\:vc-border{border-width:1px}.sm\:vc-border-t-0{border-top-width:0}.sm\:vc-border-r-0{border-right-width:0}.sm\:vc-border-b-0{border-bottom-width:0}.sm\:vc-border-l-0{border-left-width:0}.sm\:vc-border-t-2{border-top-width:2px}.sm\:vc-border-r-2{border-right-width:2px}.sm\:vc-border-b-2{border-bottom-width:2px}.sm\:vc-border-l-2{border-left-width:2px}.sm\:vc-border-t-4{border-top-width:4px}.sm\:vc-border-r-4{border-right-width:4px}.sm\:vc-border-b-4{border-bottom-width:4px}.sm\:vc-border-l-4{border-left-width:4px}.sm\:vc-border-t-8{border-top-width:8px}.sm\:vc-border-r-8{border-right-width:8px}.sm\:vc-border-b-8{border-bottom-width:8px}.sm\:vc-border-l-8{border-left-width:8px}.sm\:vc-border-t{border-top-width:1px}.sm\:vc-border-r{border-right-width:1px}.sm\:vc-border-b{border-bottom-width:1px}.sm\:vc-border-l{border-left-width:1px}.sm\:vc-text-left{text-align:left}.sm\:vc-text-center{text-align:center}.sm\:vc-text-right{text-align:right}.sm\:vc-text-justify{text-align:justify}.sm\:vc-text-xs{font-size:12px}.sm\:vc-text-sm{font-size:14px}.sm\:vc-text-base{font-size:16px}.sm\:vc-text-lg{font-size:18px}.sm\:vc-text-xl{font-size:20px}.sm\:vc-text-2xl{font-size:24px}}@media (min-width:768px){.md\:vc-bg-fixed{background-attachment:fixed}.md\:vc-bg-local{background-attachment:local}.md\:vc-bg-scroll{background-attachment:scroll}.md\:vc-bg-bottom{background-position:bottom}.md\:vc-bg-center{background-position:50%}.md\:vc-bg-left{background-position:0}.md\:vc-bg-left-bottom{background-position:0 100%}.md\:vc-bg-left-top{background-position:0 0}.md\:vc-bg-right{background-position:100%}.md\:vc-bg-right-bottom{background-position:100% 100%}.md\:vc-bg-right-top{background-position:100% 0}.md\:vc-bg-top{background-position:top}.md\:vc-bg-repeat{background-repeat:repeat}.md\:vc-bg-no-repeat{background-repeat:no-repeat}.md\:vc-bg-repeat-x{background-repeat:repeat-x}.md\:vc-bg-repeat-y{background-repeat:repeat-y}.md\:vc-bg-repeat-round{background-repeat:round}.md\:vc-bg-repeat-space{background-repeat:space}.md\:vc-bg-auto{background-size:auto}.md\:vc-bg-cover{background-size:cover}.md\:vc-bg-contain{background-size:contain}.md\:vc-border-collapse{border-collapse:collapse}.md\:vc-border-separate{border-collapse:initial}.md\:vc-border-solid{border-style:solid}.md\:vc-border-dashed{border-style:dashed}.md\:vc-border-dotted{border-style:dotted}.md\:vc-border-double{border-style:double}.md\:vc-border-none{border-style:none}.md\:vc-border-0{border-width:0}.md\:vc-border-2{border-width:2px}.md\:vc-border-4{border-width:4px}.md\:vc-border-8{border-width:8px}.md\:vc-border{border-width:1px}.md\:vc-border-t-0{border-top-width:0}.md\:vc-border-r-0{border-right-width:0}.md\:vc-border-b-0{border-bottom-width:0}.md\:vc-border-l-0{border-left-width:0}.md\:vc-border-t-2{border-top-width:2px}.md\:vc-border-r-2{border-right-width:2px}.md\:vc-border-b-2{border-bottom-width:2px}.md\:vc-border-l-2{border-left-width:2px}.md\:vc-border-t-4{border-top-width:4px}.md\:vc-border-r-4{border-right-width:4px}.md\:vc-border-b-4{border-bottom-width:4px}.md\:vc-border-l-4{border-left-width:4px}.md\:vc-border-t-8{border-top-width:8px}.md\:vc-border-r-8{border-right-width:8px}.md\:vc-border-b-8{border-bottom-width:8px}.md\:vc-border-l-8{border-left-width:8px}.md\:vc-border-t{border-top-width:1px}.md\:vc-border-r{border-right-width:1px}.md\:vc-border-b{border-bottom-width:1px}.md\:vc-border-l{border-left-width:1px}.md\:vc-text-left{text-align:left}.md\:vc-text-center{text-align:center}.md\:vc-text-right{text-align:right}.md\:vc-text-justify{text-align:justify}.md\:vc-text-xs{font-size:12px}.md\:vc-text-sm{font-size:14px}.md\:vc-text-base{font-size:16px}.md\:vc-text-lg{font-size:18px}.md\:vc-text-xl{font-size:20px}.md\:vc-text-2xl{font-size:24px}}@media (min-width:1024px){.lg\:vc-bg-fixed{background-attachment:fixed}.lg\:vc-bg-local{background-attachment:local}.lg\:vc-bg-scroll{background-attachment:scroll}.lg\:vc-bg-bottom{background-position:bottom}.lg\:vc-bg-center{background-position:50%}.lg\:vc-bg-left{background-position:0}.lg\:vc-bg-left-bottom{background-position:0 100%}.lg\:vc-bg-left-top{background-position:0 0}.lg\:vc-bg-right{background-position:100%}.lg\:vc-bg-right-bottom{background-position:100% 100%}.lg\:vc-bg-right-top{background-position:100% 0}.lg\:vc-bg-top{background-position:top}.lg\:vc-bg-repeat{background-repeat:repeat}.lg\:vc-bg-no-repeat{background-repeat:no-repeat}.lg\:vc-bg-repeat-x{background-repeat:repeat-x}.lg\:vc-bg-repeat-y{background-repeat:repeat-y}.lg\:vc-bg-repeat-round{background-repeat:round}.lg\:vc-bg-repeat-space{background-repeat:space}.lg\:vc-bg-auto{background-size:auto}.lg\:vc-bg-cover{background-size:cover}.lg\:vc-bg-contain{background-size:contain}.lg\:vc-border-collapse{border-collapse:collapse}.lg\:vc-border-separate{border-collapse:initial}.lg\:vc-border-solid{border-style:solid}.lg\:vc-border-dashed{border-style:dashed}.lg\:vc-border-dotted{border-style:dotted}.lg\:vc-border-double{border-style:double}.lg\:vc-border-none{border-style:none}.lg\:vc-border-0{border-width:0}.lg\:vc-border-2{border-width:2px}.lg\:vc-border-4{border-width:4px}.lg\:vc-border-8{border-width:8px}.lg\:vc-border{border-width:1px}.lg\:vc-border-t-0{border-top-width:0}.lg\:vc-border-r-0{border-right-width:0}.lg\:vc-border-b-0{border-bottom-width:0}.lg\:vc-border-l-0{border-left-width:0}.lg\:vc-border-t-2{border-top-width:2px}.lg\:vc-border-r-2{border-right-width:2px}.lg\:vc-border-b-2{border-bottom-width:2px}.lg\:vc-border-l-2{border-left-width:2px}.lg\:vc-border-t-4{border-top-width:4px}.lg\:vc-border-r-4{border-right-width:4px}.lg\:vc-border-b-4{border-bottom-width:4px}.lg\:vc-border-l-4{border-left-width:4px}.lg\:vc-border-t-8{border-top-width:8px}.lg\:vc-border-r-8{border-right-width:8px}.lg\:vc-border-b-8{border-bottom-width:8px}.lg\:vc-border-l-8{border-left-width:8px}.lg\:vc-border-t{border-top-width:1px}.lg\:vc-border-r{border-right-width:1px}.lg\:vc-border-b{border-bottom-width:1px}.lg\:vc-border-l{border-left-width:1px}.lg\:vc-text-left{text-align:left}.lg\:vc-text-center{text-align:center}.lg\:vc-text-right{text-align:right}.lg\:vc-text-justify{text-align:justify}.lg\:vc-text-xs{font-size:12px}.lg\:vc-text-sm{font-size:14px}.lg\:vc-text-base{font-size:16px}.lg\:vc-text-lg{font-size:18px}.lg\:vc-text-xl{font-size:20px}.lg\:vc-text-2xl{font-size:24px}}@media (min-width:1280px){.xl\:vc-bg-fixed{background-attachment:fixed}.xl\:vc-bg-local{background-attachment:local}.xl\:vc-bg-scroll{background-attachment:scroll}.xl\:vc-bg-bottom{background-position:bottom}.xl\:vc-bg-center{background-position:50%}.xl\:vc-bg-left{background-position:0}.xl\:vc-bg-left-bottom{background-position:0 100%}.xl\:vc-bg-left-top{background-position:0 0}.xl\:vc-bg-right{background-position:100%}.xl\:vc-bg-right-bottom{background-position:100% 100%}.xl\:vc-bg-right-top{background-position:100% 0}.xl\:vc-bg-top{background-position:top}.xl\:vc-bg-repeat{background-repeat:repeat}.xl\:vc-bg-no-repeat{background-repeat:no-repeat}.xl\:vc-bg-repeat-x{background-repeat:repeat-x}.xl\:vc-bg-repeat-y{background-repeat:repeat-y}.xl\:vc-bg-repeat-round{background-repeat:round}.xl\:vc-bg-repeat-space{background-repeat:space}.xl\:vc-bg-auto{background-size:auto}.xl\:vc-bg-cover{background-size:cover}.xl\:vc-bg-contain{background-size:contain}.xl\:vc-border-collapse{border-collapse:collapse}.xl\:vc-border-separate{border-collapse:initial}.xl\:vc-border-solid{border-style:solid}.xl\:vc-border-dashed{border-style:dashed}.xl\:vc-border-dotted{border-style:dotted}.xl\:vc-border-double{border-style:double}.xl\:vc-border-none{border-style:none}.xl\:vc-border-0{border-width:0}.xl\:vc-border-2{border-width:2px}.xl\:vc-border-4{border-width:4px}.xl\:vc-border-8{border-width:8px}.xl\:vc-border{border-width:1px}.xl\:vc-border-t-0{border-top-width:0}.xl\:vc-border-r-0{border-right-width:0}.xl\:vc-border-b-0{border-bottom-width:0}.xl\:vc-border-l-0{border-left-width:0}.xl\:vc-border-t-2{border-top-width:2px}.xl\:vc-border-r-2{border-right-width:2px}.xl\:vc-border-b-2{border-bottom-width:2px}.xl\:vc-border-l-2{border-left-width:2px}.xl\:vc-border-t-4{border-top-width:4px}.xl\:vc-border-r-4{border-right-width:4px}.xl\:vc-border-b-4{border-bottom-width:4px}.xl\:vc-border-l-4{border-left-width:4px}.xl\:vc-border-t-8{border-top-width:8px}.xl\:vc-border-r-8{border-right-width:8px}.xl\:vc-border-b-8{border-bottom-width:8px}.xl\:vc-border-l-8{border-left-width:8px}.xl\:vc-border-t{border-top-width:1px}.xl\:vc-border-r{border-right-width:1px}.xl\:vc-border-b{border-bottom-width:1px}.xl\:vc-border-l{border-left-width:1px}.xl\:vc-text-left{text-align:left}.xl\:vc-text-center{text-align:center}.xl\:vc-text-right{text-align:right}.xl\:vc-text-justify{text-align:justify}.xl\:vc-text-xs{font-size:12px}.xl\:vc-text-sm{font-size:14px}.xl\:vc-text-base{font-size:16px}.xl\:vc-text-lg{font-size:18px}.xl\:vc-text-xl{font-size:20px}.xl\:vc-text-2xl{font-size:24px}}</style><style type="text/css">.vc-container{--slide-translate:22px;--slide-duration:0.15s;--slide-timing:ease;--header-padding:10px 10px 0 10px;--title-padding:0 8px;--arrows-padding:8px 10px;--arrow-font-size:26px;--weekday-padding:5px 0;--weeks-padding:5px 6px 7px 6px;--nav-container-width:170px;--day-min-height:28px;--day-content-width:28px;--day-content-height:28px;--day-content-margin:1.6px auto;--day-content-transition-time:0.13s ease-in;--day-content-bg-color-hover:rgba(204,214,224,0.3);--day-content-dark-bg-color-hover:rgba(114,129,151,0.3);--day-content-bg-color-focus:rgba(204,214,224,0.4);--day-content-dark-bg-color-focus:rgba(114,129,151,0.4);--highlight-height:28px;--dot-diameter:5px;--dot-border-radius:50%;--dot-spacing:3px;--bar-height:3px;--bars-width:75%;font-family:BlinkMacSystemFont,-apple-system,Segoe UI,Roboto,Oxygen,Ubuntu,Cantarell,Fira Sans,Droid Sans,Helvetica Neue,Helvetica,Arial,sans-serif;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale;position:relative;width:-webkit-max-content;width:max-content;-webkit-tap-highlight-color:transparent}.vc-arrows-container{width:100%;position:absolute;top:0;display:flex;justify-content:space-between;padding:var(--arrows-padding);pointer-events:none}.vc-arrows-container.title-left{justify-content:flex-end}.vc-arrows-container.title-right{justify-content:flex-start}</style><style type="text/css">[data-v-56ae83be] .vc-container{border:none}</style><style>.vue-switcher{position:relative;display:inline-block}.vue-switcher__label{display:block;font-size:10px;margin-bottom:5px}.vue-switcher input{opacity:0;width:100%;height:100%;position:absolute;z-index:1;cursor:pointer}.vue-switcher div{height:15px;width:36px;position:relative;border-radius:30px;display:-ms-flex;display:flex;align-items:center;justify-content:flex-start;cursor:pointer;transition:.2s linear,background-color .2s linear}.vue-switcher div:after{content:"";height:20px;width:20px;border-radius:100px;display:block;transition:.15s linear,background-color .15s linear;position:absolute;left:100%;margin-left:-18px;cursor:pointer;top:-3px;box-shadow:0 1px 5px 0 rgba(0,0,0,.1)}.vue-switcher--unchecked div{justify-content:flex-end}.vue-switcher--unchecked div:after{left:15px}.vue-switcher--disabled div{opacity:.3}.vue-switcher--disabled input{cursor:not-allowed}.vue-switcher--bold div{top:-8px;height:26px;width:51px}.vue-switcher--bold div:after{margin-left:-24px;top:3px}.vue-switcher--bold--unchecked div:after{left:28px}.vue-switcher--bold .vue-switcher__label span{padding-bottom:7px;display:inline-block}.vue-switcher-theme--default.vue-switcher-color--default div{background-color:#b7b7b7}.vue-switcher-theme--default.vue-switcher-color--default div:after{background-color:#9d9d9d}.vue-switcher-theme--default.vue-switcher-color--default.vue-switcher--unchecked div{background-color:#aaa}.vue-switcher-theme--default.vue-switcher-color--default.vue-switcher--unchecked div:after{background-color:#c4c4c4}.vue-switcher-theme--default.vue-switcher-color--blue div{background-color:#77b0c8}.vue-switcher-theme--default.vue-switcher-color--blue div:after{background-color:#539bb9}.vue-switcher-theme--default.vue-switcher-color--blue.vue-switcher--unchecked div{background-color:#c0dae5}.vue-switcher-theme--default.vue-switcher-color--blue.vue-switcher--unchecked div:after{background-color:#77b0c8}.vue-switcher-theme--default.vue-switcher-color--red div{background-color:#c87777}.vue-switcher-theme--default.vue-switcher-color--red div:after{background-color:#b95353}.vue-switcher-theme--default.vue-switcher-color--red.vue-switcher--unchecked div{background-color:#e5c0c0}.vue-switcher-theme--default.vue-switcher-color--red.vue-switcher--unchecked div:after{background-color:#c87777}.vue-switcher-theme--default.vue-switcher-color--yellow div{background-color:#c9c377}.vue-switcher-theme--default.vue-switcher-color--yellow div:after{background-color:#bab353}.vue-switcher-theme--default.vue-switcher-color--yellow.vue-switcher--unchecked div{background-color:#e6e3c0}.vue-switcher-theme--default.vue-switcher-color--yellow.vue-switcher--unchecked div:after{background-color:#c9c377}.vue-switcher-theme--default.vue-switcher-color--orange div{background-color:#c89577}.vue-switcher-theme--default.vue-switcher-color--orange div:after{background-color:#b97953}.vue-switcher-theme--default.vue-switcher-color--orange.vue-switcher--unchecked div{background-color:#e5cec0}.vue-switcher-theme--default.vue-switcher-color--orange.vue-switcher--unchecked div:after{background-color:#c89577}.vue-switcher-theme--default.vue-switcher-color--green div{background-color:#77c88d}.vue-switcher-theme--default.vue-switcher-color--green div:after{background-color:#53b96e}.vue-switcher-theme--default.vue-switcher-color--green.vue-switcher--unchecked div{background-color:#c0e5ca}.vue-switcher-theme--default.vue-switcher-color--green.vue-switcher--unchecked div:after{background-color:#77c88d}.vue-switcher-theme--bulma.vue-switcher-color--default div{background-color:#dcdcdc}.vue-switcher-theme--bulma.vue-switcher-color--default div:after{background-color:#f5f5f5}.vue-switcher-theme--bulma.vue-switcher-color--default.vue-switcher--unchecked div{background-color:#e8e8e8}.vue-switcher-theme--bulma.vue-switcher-color--default.vue-switcher--unchecked div:after{background-color:#f5f5f5}.vue-switcher-theme--bulma.vue-switcher-color--primary div{background-color:#05ffda}.vue-switcher-theme--bulma.vue-switcher-color--primary div:after{background-color:#00d1b2}.vue-switcher-theme--bulma.vue-switcher-color--primary.vue-switcher--unchecked div{background-color:#6bffe9}.vue-switcher-theme--bulma.vue-switcher-color--primary.vue-switcher--unchecked div:after{background-color:#05ffda}.vue-switcher-theme--bulma.vue-switcher-color--blue div{background-color:#5e91e3}.vue-switcher-theme--bulma.vue-switcher-color--blue div:after{background-color:#3273dc}.vue-switcher-theme--bulma.vue-switcher-color--blue.vue-switcher--unchecked div{background-color:#b5ccf2}.vue-switcher-theme--bulma.vue-switcher-color--blue.vue-switcher--unchecked div:after{background-color:#5e91e3}.vue-switcher-theme--bulma.vue-switcher-color--red div{background-color:#ff6b89}.vue-switcher-theme--bulma.vue-switcher-color--red div:after{background-color:#ff3860}.vue-switcher-theme--bulma.vue-switcher-color--red.vue-switcher--unchecked div{background-color:#ffd1da}.vue-switcher-theme--bulma.vue-switcher-color--red.vue-switcher--unchecked div:after{background-color:#ff6b89}.vue-switcher-theme--bulma.vue-switcher-color--yellow div{background-color:#ffe78a}.vue-switcher-theme--bulma.vue-switcher-color--yellow div:after{background-color:#ffdd57}.vue-switcher-theme--bulma.vue-switcher-color--yellow.vue-switcher--unchecked div{background-color:#fffcf0}.vue-switcher-theme--bulma.vue-switcher-color--yellow.vue-switcher--unchecked div:after{background-color:#ffe78a}.vue-switcher-theme--bulma.vue-switcher-color--green div{background-color:#3dde75}.vue-switcher-theme--bulma.vue-switcher-color--green div:after{background-color:#22c65b}.vue-switcher-theme--bulma.vue-switcher-color--green.vue-switcher--unchecked div{background-color:#94edb3}.vue-switcher-theme--bulma.vue-switcher-color--green.vue-switcher--unchecked div:after{background-color:#3dde75}.vue-switcher-theme--bootstrap.vue-switcher-color--default div{background-color:#e6e6e6}.vue-switcher-theme--bootstrap.vue-switcher-color--default div:after{background-color:#f0f0f0}.vue-switcher-theme--bootstrap.vue-switcher-color--default.vue-switcher--unchecked div{background-color:#f5f5f5}.vue-switcher-theme--bootstrap.vue-switcher-color--default.vue-switcher--unchecked div:after{background-color:#f0f0f0}.vue-switcher-theme--bootstrap.vue-switcher-color--primary div{background-color:#4f93ce}.vue-switcher-theme--bootstrap.vue-switcher-color--primary div:after{background-color:#337ab7}.vue-switcher-theme--bootstrap.vue-switcher-color--primary.vue-switcher--unchecked div{background-color:#9fc4e4}.vue-switcher-theme--bootstrap.vue-switcher-color--primary.vue-switcher--unchecked div:after{background-color:#4f93ce}.vue-switcher-theme--bootstrap.vue-switcher-color--success div{background-color:#80c780}.vue-switcher-theme--bootstrap.vue-switcher-color--success div:after{background-color:#5cb85c}.vue-switcher-theme--bootstrap.vue-switcher-color--success.vue-switcher--unchecked div{background-color:#c7e6c7}.vue-switcher-theme--bootstrap.vue-switcher-color--success.vue-switcher--unchecked div:after{background-color:#80c780}.vue-switcher-theme--bootstrap.vue-switcher-color--info div{background-color:#85d0e7}.vue-switcher-theme--bootstrap.vue-switcher-color--info div:after{background-color:#5bc0de}.vue-switcher-theme--bootstrap.vue-switcher-color--info.vue-switcher--unchecked div{background-color:#daf1f8}.vue-switcher-theme--bootstrap.vue-switcher-color--info.vue-switcher--unchecked div:after{background-color:#85d0e7}.vue-switcher-theme--bootstrap.vue-switcher-color--warning div{background-color:#f4c37d}.vue-switcher-theme--bootstrap.vue-switcher-color--warning div:after{background-color:#f0ad4e}.vue-switcher-theme--bootstrap.vue-switcher-color--warning.vue-switcher--unchecked div{background-color:#fceedb}.vue-switcher-theme--bootstrap.vue-switcher-color--warning.vue-switcher--unchecked div:after{background-color:#f4c37d}.vue-switcher-theme--bootstrap.vue-switcher-color--danger div{background-color:#d9534f}.vue-switcher-theme--bootstrap.vue-switcher-color--danger div:after{background-color:#c9302c}.vue-switcher-theme--bootstrap.vue-switcher-color--danger.vue-switcher--unchecked div{background-color:#eba5a3}.vue-switcher-theme--bootstrap.vue-switcher-color--danger.vue-switcher--unchecked div:after{background-color:#d9534f}</style><style>input{margin:0;padding:0}.vue-switcher{display:flex;top:7px}</style><style>.multiselect__input{border:0}</style><style type="text/css">.resize-observer[data-v-8859cc6c]{position:absolute;top:0;left:0;z-index:-1;width:100%;height:100%;border:none;background-color:transparent;pointer-events:none;display:block;overflow:hidden;opacity:0}.resize-observer[data-v-8859cc6c] object{display:block;position:absolute;top:0;left:0;height:100%;width:100%;overflow:hidden;pointer-events:none;z-index:-1}</style><style></style></head>
	<body class="pages"><div role="dialog" aria-live="polite" aria-label="cookieconsent" aria-describedby="cookieconsent:desc" class="cc-window cc-floating cc-type-info cc-theme-edgeless cc-bottom cc-right cc-color-override-653678594 cc-invisible" style="display: none;"><!--googleoff: all--><span id="cookieconsent:desc" class="cc-message">We use cookies to analyze traffic and to recognize users who sign in to our premium tools. By using our site, you agree to our use of cookies. For details, read our privacy policy  <a aria-label="learn more about cookies" role="button" tabindex="0" class="cc-link" href="https://www.biopharmcatalyst.com/privacy-policy" target="_blank">here</a></span><div class="cc-compliance"><a aria-label="dismiss cookie message" role="button" tabindex="0" class="cc-btn cc-dismiss">Got it!</a></div><!--googleon: all--></div>
		<script>
	window.bannerCookieName = "privacyBanner";
</script>
<div class="privacy-banner" style="display: none;background-color: #efef88;">
	<div class="padding-1 text-left content">
		<span><p><strong>The Assay Depot, Inc. (“<a href="http://scientist.com/" target="_blank" rel="noreferrer noopener">Scientist.com</a>”) Data Protection Update.</strong></p>
<p>The Assay Depot, Inc. (“<a href="http://scientist.com/" target="_blank" rel="noreferrer noopener">Scientist.com</a>”) has acquired the [bio-technology] brand BioPharmCatalyst ("BPC"). As a result, there have been updates made to the BPC privacy policy. You can access the updated BPC privacy policy information with our data privacy practices, your rights and how to contact us if you have any queries here:<a href="https://www.biopharmcatalyst.com/privacy-policy" class="sc-iwsKbI iabMoN"> Privacy Policy • BioPharmCatalyst</a>. If you would like to learn more about <a href="http://scientist.com/" target="_blank" rel="noreferrer noopener">Scientist.com</a>, please feel free to visit:<a href="https://www.scientist.com/about-us/" class="sc-iwsKbI iabMoN"><img class="smart-link-icon sc-iAyFgw iOratm" src="./20210823_FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst_files/cropped-SCIENTIST-logo_RGB-brain-05-192x192.png" alt="cropped-SCIENTIST-logo_RGB-brain-05-192x192.png" style="margin-right:4px;vertical-align:middle;height:14px;width:14px;">About Us | Scientist</a>.
</p>
<p>Yours sincerely,
</p>
<p>The <a href="http://scientist.com/" target="_blank" rel="noreferrer noopener">Scientist.com</a> Team.
</p>
		</span>

		<div class="link-wrap">
            			<a href="javascript:;" class="cta-subscribe__close js-close-banner-cta">Hide</a>

		</div>

	</div>
</div>
		
		<div id="portfolio-modal" class="manage-modal-container"><div><div class="modal-mask" style="display: none;"></div> <div class="modal-wrapper" style="display: none;"><div class="modal-container padding-vertical-1"><div class="padding-horizontal-1"><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" class="modal-default-button"><i class="fas fa-window-close size-24" aria-hidden="true"></i></a></div> <div class="padding-horizontal-1"><span class="title-label">PORTFOLIO MANAGEMENT: </span> <ul class="no-bullet"></ul></div> <form action="https://www.biopharmcatalyst.com/calendars/fda-calendar#" class="padding-horizontal-1"><span>Add New Portfolio</span> <div class="input-group margin-bottom-0"><input placeholder="portfolio name..." type="text" class="input-group-field"> <div class="input-group-button"><button class="button"><i class="far fa-save size-18" aria-hidden="true"></i> ADD</button></div></div> <!----></form></div></div></div></div>
					<header id="header">
		<nav class="site-nav">
	<a href="https://www.biopharmcatalyst.com/" class="site-nav__logo">
		<svg xmlns="http://www.w3.org/2000/svg" width="270" height="36" viewBox="0 0 270 36" class="logo"><g fill="none"><g class="logo__mark" transform="translate(1 1)"><path stroke="#fff" stroke-width="1.1" d="M26.565 19.384l.08.044v9.714l-8.828 4.857-8.828-4.857v-9.714l8.748-4.813-.08-.044v-9.714l8.828-4.857 8.828 4.857v9.714l-8.748 4.813zm-17.737-19.384l8.828 4.857v9.714l-8.828 4.857-8.828-4.857v-9.714l8.828-4.857z" stroke-linecap="round" stroke-linejoin="round"></path><path fill="#083C61" d="M10.824 19.075l8-4.5.575-.323-.647-1.151-.576.324-8 4.5-.575.323.647 1.151zM28.321 19.077l5.63-3.137.577-.321-.642-1.153-.577.321-5.63 3.136-.577.322.643 1.153zM18.176 15.575l8 4.5.576.324.647-1.151-.575-.323-8-4.5-.576-.324-.647 1.151z"></path><ellipse cx="9.06" cy="18.825" fill="#6FB7DB" stroke="#083C61" stroke-width="1.1" rx="1.998" ry="2.015"></ellipse><ellipse cx="35.498" cy="14.015" fill="#6FB7DB" stroke="#8D1E37" stroke-width="1.1" rx="1.998" ry="2.015"></ellipse><ellipse cx="26.717" cy="19.501" fill="#6FB7DB" stroke="#083C61" stroke-width="1.1" rx="1.998" ry="2.015"></ellipse><ellipse cx="17.498" cy="15.015" fill="#6FB7DB" stroke="#083C61" stroke-width="1.1" rx="1.998" ry="2.015"></ellipse></g><g class="logo__type"><path fill="#103957" d="M59.432 23v-19.195h5.669c2.057 0 3.617.424 4.68 1.272 1.063.848 1.595 2.098 1.595 3.751 0 .993-.27 1.857-.811 2.591-.541.734-1.281 1.259-2.221 1.575 1.116.246 2.015.795 2.696 1.648.681.853 1.022 1.837 1.022 2.953 0 1.696-.547 3.021-1.641 3.975-1.094.954-2.617 1.43-4.568 1.43h-6.42zm1.622-9.229v7.857h4.865c1.389 0 2.489-.354 3.302-1.061.813-.708 1.219-1.69 1.219-2.947 0-1.187-.389-2.125-1.167-2.815s-1.852-1.035-3.223-1.035h-4.997zm0-1.358h4.43c1.354-.026 2.402-.345 3.144-.956.743-.611 1.114-1.501 1.114-2.67 0-1.23-.385-2.138-1.154-2.722-.769-.584-1.931-.877-3.487-.877h-4.047v7.225zm16.321 10.586h-1.582v-14.265h1.582v14.265zm-1.859-18.391c0-.299.097-.552.29-.758.193-.207.457-.31.791-.31s.6.103.798.31c.198.207.297.459.297.758s-.099.549-.297.751c-.198.202-.464.303-.798.303s-.598-.101-.791-.303c-.193-.202-.29-.453-.29-.751zm5.273 11.048c0-1.371.266-2.606.798-3.705.532-1.099 1.283-1.953 2.254-2.564.971-.611 2.072-.916 3.302-.916 1.898 0 3.437.666 4.614 1.997 1.178 1.332 1.767 3.096 1.767 5.293v.33c0 1.38-.266 2.621-.798 3.724-.532 1.103-1.281 1.953-2.248 2.551-.967.598-2.07.896-3.309.896-1.89 0-3.426-.666-4.608-1.997-1.182-1.332-1.773-3.096-1.773-5.293v-.316zm1.582.435c0 1.705.442 3.105 1.325 4.199.883 1.094 2.041 1.641 3.474 1.641 1.424 0 2.577-.547 3.461-1.641.883-1.094 1.325-2.538 1.325-4.331v-.303c0-1.09-.202-2.087-.606-2.993-.404-.905-.971-1.606-1.701-2.103-.729-.497-1.564-.745-2.505-.745-1.406 0-2.553.552-3.441 1.655-.888 1.103-1.332 2.547-1.332 4.331v.29zm16.4-.91v7.818h-1.622v-19.195h6.539c1.995 0 3.571.51 4.726 1.529 1.156 1.02 1.734 2.421 1.734 4.206 0 1.802-.556 3.193-1.668 4.173-1.112.98-2.722 1.47-4.832 1.47h-4.878zm0-1.371h4.917c1.573 0 2.773-.374 3.599-1.121.826-.747 1.239-1.789 1.239-3.125 0-1.327-.411-2.384-1.233-3.171-.822-.787-1.989-1.189-3.5-1.206h-5.023v8.622zm16.203-2.663c.519-.853 1.182-1.512 1.991-1.978.809-.466 1.692-.699 2.65-.699 1.529 0 2.667.431 3.415 1.292.747.861 1.125 2.153 1.134 3.876v9.36h-1.569v-9.374c-.009-1.274-.279-2.224-.811-2.848-.532-.624-1.382-.936-2.551-.936-.976 0-1.839.305-2.591.916-.751.611-1.307 1.435-1.668 2.472v9.769h-1.569v-20.25h1.569v8.398zm22.254 11.852c-.158-.448-.259-1.112-.303-1.991-.554.721-1.259 1.277-2.116 1.668-.857.391-1.764.587-2.722.587-1.371 0-2.481-.382-3.329-1.147-.848-.765-1.272-1.731-1.272-2.9 0-1.389.578-2.487 1.734-3.296 1.156-.809 2.766-1.213 4.832-1.213h2.861v-1.622c0-1.02-.314-1.822-.943-2.406-.628-.584-1.545-.877-2.749-.877-1.099 0-2.008.281-2.729.844-.721.563-1.081 1.239-1.081 2.03l-1.582-.013c0-1.134.527-2.116 1.582-2.947 1.055-.831 2.351-1.246 3.889-1.246 1.591 0 2.845.398 3.764 1.193.918.795 1.391 1.905 1.417 3.329v6.75c0 1.38.145 2.413.435 3.098v.158h-1.688zm-4.957-1.134c1.055 0 1.997-.255 2.828-.765.831-.51 1.435-1.191 1.813-2.043v-3.138h-2.821c-1.573.018-2.804.305-3.691.864-.888.558-1.332 1.325-1.332 2.301 0 .8.297 1.463.89 1.991.593.527 1.364.791 2.314.791zm17.007-11.786c-.334-.062-.69-.092-1.068-.092-.984 0-1.817.275-2.498.824-.681.549-1.167 1.347-1.457 2.393v9.795h-1.569v-14.265h1.542l.026 2.268c.835-1.688 2.175-2.531 4.021-2.531.439 0 .787.057 1.042.171l-.04 1.437zm3.929-1.345l.053 2.32c.527-.861 1.187-1.507 1.978-1.938.791-.431 1.67-.646 2.637-.646 2.25 0 3.678.923 4.285 2.769.51-.888 1.191-1.571 2.043-2.05.853-.479 1.793-.719 2.821-.719 3.059 0 4.619 1.67 4.68 5.01v9.519h-1.582v-9.4c-.009-1.274-.283-2.219-.824-2.834-.541-.615-1.422-.923-2.643-.923-1.134.018-2.092.385-2.874 1.101s-1.217 1.589-1.305 2.617v9.439h-1.582v-9.519c-.009-1.222-.297-2.134-.864-2.736-.567-.602-1.439-.903-2.617-.903-.993 0-1.846.283-2.558.85-.712.567-1.239 1.408-1.582 2.525v9.782h-1.582v-14.265h1.516zm36.453 8.279c-.22 2.021-.943 3.568-2.169 4.641-1.226 1.072-2.859 1.608-4.898 1.608-1.424 0-2.683-.356-3.777-1.068-1.094-.712-1.94-1.72-2.538-3.026-.598-1.305-.901-2.797-.91-4.476v-2.492c0-1.705.299-3.217.896-4.535.598-1.318 1.457-2.336 2.577-3.052 1.121-.716 2.41-1.074 3.869-1.074 2.057 0 3.68.556 4.871 1.668 1.191 1.112 1.883 2.648 2.076 4.608h-1.635c-.404-3.261-2.175-4.891-5.313-4.891-1.74 0-3.127.65-4.159 1.951-1.033 1.301-1.549 3.098-1.549 5.392v2.347c0 2.215.503 3.981 1.51 5.3 1.006 1.318 2.366 1.978 4.08 1.978 1.696 0 2.975-.406 3.836-1.219.861-.813 1.393-2.032 1.595-3.658h1.635zm12.577 5.985c-.158-.448-.259-1.112-.303-1.991-.554.721-1.259 1.277-2.116 1.668-.857.391-1.764.587-2.722.587-1.371 0-2.481-.382-3.329-1.147-.848-.765-1.272-1.731-1.272-2.9 0-1.389.578-2.487 1.734-3.296 1.156-.809 2.766-1.213 4.832-1.213h2.861v-1.622c0-1.02-.314-1.822-.943-2.406-.628-.584-1.545-.877-2.749-.877-1.099 0-2.008.281-2.729.844-.721.563-1.081 1.239-1.081 2.03l-1.582-.013c0-1.134.527-2.116 1.582-2.947 1.055-.831 2.351-1.246 3.889-1.246 1.591 0 2.845.398 3.764 1.193.918.795 1.391 1.905 1.417 3.329v6.75c0 1.38.145 2.413.435 3.098v.158h-1.688zm-4.957-1.134c1.055 0 1.997-.255 2.828-.765.831-.51 1.435-1.191 1.813-2.043v-3.138h-2.821c-1.573.018-2.804.305-3.691.864-.888.558-1.332 1.325-1.332 2.301 0 .8.297 1.463.89 1.991.593.527 1.364.791 2.314.791zm12.867-16.783v3.652h2.953v1.292h-2.953v9.505c0 .791.143 1.38.428 1.767.286.387.762.58 1.43.58.264 0 .69-.044 1.279-.132l.066 1.292c-.413.149-.976.224-1.688.224-1.081 0-1.868-.314-2.36-.943-.492-.628-.738-1.553-.738-2.775v-9.519h-2.624v-1.292h2.624v-3.652h1.582zm15.227 17.917c-.158-.448-.259-1.112-.303-1.991-.554.721-1.259 1.277-2.116 1.668-.857.391-1.764.587-2.722.587-1.371 0-2.481-.382-3.329-1.147-.848-.765-1.272-1.731-1.272-2.9 0-1.389.578-2.487 1.734-3.296 1.156-.809 2.766-1.213 4.832-1.213h2.861v-1.622c0-1.02-.314-1.822-.943-2.406-.628-.584-1.545-.877-2.749-.877-1.099 0-2.008.281-2.729.844-.721.563-1.081 1.239-1.081 2.03l-1.582-.013c0-1.134.527-2.116 1.582-2.947 1.055-.831 2.351-1.246 3.889-1.246 1.591 0 2.845.398 3.764 1.193.918.795 1.391 1.905 1.417 3.329v6.75c0 1.38.145 2.413.435 3.098v.158h-1.688zm-4.957-1.134c1.055 0 1.997-.255 2.828-.765.831-.51 1.435-1.191 1.813-2.043v-3.138h-2.821c-1.573.018-2.804.305-3.691.864-.888.558-1.332 1.325-1.332 2.301 0 .8.297 1.463.89 1.991.593.527 1.364.791 2.314.791zm12.182 1.134h-1.582v-20.25h1.582v20.25zm8.807-2.268l4.166-11.997h1.701l-6.091 16.69-.316.738c-.782 1.731-1.991 2.597-3.625 2.597-.378 0-.782-.062-1.213-.185l-.013-1.305.817.079c.773 0 1.4-.191 1.879-.573.479-.382.885-1.039 1.219-1.971l.699-1.925-5.379-14.146h1.727l4.43 11.997zm16.849-1.358c0-.782-.314-1.411-.943-1.885-.628-.475-1.575-.846-2.841-1.114-1.266-.268-2.248-.576-2.947-.923-.699-.347-1.217-.771-1.556-1.272-.338-.501-.508-1.107-.508-1.819 0-1.125.47-2.054 1.411-2.788.94-.734 2.145-1.101 3.612-1.101 1.591 0 2.867.393 3.83 1.18.962.787 1.444 1.813 1.444 3.078h-1.582c0-.835-.349-1.529-1.048-2.083-.699-.554-1.58-.831-2.643-.831-1.037 0-1.87.231-2.498.692-.628.461-.943 1.061-.943 1.8 0 .712.261 1.263.784 1.655.523.391 1.477.749 2.861 1.074 1.384.325 2.421.672 3.111 1.042.69.369 1.202.813 1.536 1.332.334.519.501 1.147.501 1.885 0 1.204-.486 2.167-1.457 2.887-.971.721-2.239 1.081-3.803 1.081-1.661 0-3.008-.402-4.041-1.206-1.033-.804-1.549-1.822-1.549-3.052h1.582c.062.923.45 1.641 1.167 2.156.716.514 1.663.771 2.841.771 1.099 0 1.986-.242 2.663-.725.677-.483 1.015-1.094 1.015-1.833zm7.581-14.291v3.652h2.953v1.292h-2.953v9.505c0 .791.143 1.38.428 1.767.286.387.762.58 1.43.58.264 0 .69-.044 1.279-.132l.066 1.292c-.413.149-.976.224-1.688.224-1.081 0-1.868-.314-2.36-.943-.492-.628-.738-1.553-.738-2.775v-9.519h-2.624v-1.292h2.624v-3.652h1.582z"></path><path fill="#fff" d="M60.517 33.886v2.047h-.957v-5.51h2.108c.616 0 1.104.16 1.466.481.362.32.543.744.543 1.271 0 .54-.177.96-.532 1.26-.354.3-.851.45-1.489.45h-1.139zm0-.768h1.15c.341 0 .6-.08.78-.24.179-.16.269-.392.269-.694 0-.298-.091-.535-.272-.713-.182-.178-.431-.269-.749-.274h-1.177v1.922zm6.915.693h-1.067v2.123h-.957v-5.51h1.938c.636 0 1.126.143 1.472.428.346.285.518.698.518 1.237 0 .368-.089.677-.267.925-.178.248-.426.44-.744.573l1.237 2.297v.049h-1.026l-1.105-2.123zm-1.067-.768h.984c.323 0 .575-.081.757-.244.182-.163.272-.385.272-.668 0-.295-.084-.523-.252-.685-.168-.161-.418-.245-.751-.25h-1.01v1.847zm9.17.28c0 .54-.093 1.014-.28 1.421-.187.407-.453.72-.8.938-.347.218-.746.327-1.198.327-.447 0-.845-.109-1.194-.327-.349-.218-.619-.529-.81-.933-.19-.404-.287-.869-.289-1.396v-.31c0-.537.095-1.012.286-1.423.19-.411.459-.726.806-.944.347-.218.745-.327 1.194-.327.449 0 .847.108 1.194.324.347.216.615.526.804.931.189.405.285.876.288 1.413v.307zm-.957-.288c0-.611-.115-1.078-.346-1.404-.231-.325-.558-.488-.982-.488-.414 0-.737.162-.971.486-.233.324-.353.783-.358 1.376v.318c0 .605.118 1.073.354 1.404.236.33.563.496.982.496.424 0 .75-.161.978-.484.228-.323.342-.795.342-1.415v-.288zm5.98.564h-2.218v2.335h-.957v-5.51h3.5v.772h-2.543v1.639h2.218v.764zm2.987 2.335h-.954v-5.51h.954v5.51zm5.942-4.738h-1.718v4.738h-.95v-4.738h-1.703v-.772h4.371v.772zm4.247 3.455h-2.134l-.447 1.283h-.995l2.081-5.51h.859l2.085 5.51h-.999l-.45-1.283zm-1.866-.772h1.597l-.798-2.286-.798 2.286zm4.834 2.055v-5.51h1.888c.623 0 1.097.125 1.423.375.325.25.488.622.488 1.116 0 .252-.068.479-.204.681-.136.202-.336.358-.598.469.298.081.528.233.691.456.163.223.244.491.244.804 0 .517-.166.915-.498 1.192-.332.278-.807.416-1.425.416h-2.009zm.957-2.486v1.722h1.063c.3 0 .535-.074.704-.223.169-.149.254-.356.254-.621 0-.573-.293-.865-.878-.878h-1.143zm0-.704h.938c.298 0 .53-.067.698-.202.168-.135.252-.326.252-.573 0-.272-.078-.469-.233-.59-.155-.121-.397-.182-.725-.182h-.931v1.548zm5.783 2.426h2.501v.764h-3.459v-5.51h.957v4.745zm7.35-1.695h-2.263v1.695h2.645v.764h-3.603v-5.51h3.576v.772h-2.619v1.521h2.263v.757zm8.634-2.278h-1.718v4.738h-.95v-4.738h-1.703v-.772h4.371v.772zm5.908 2.127c0 .54-.093 1.014-.28 1.421-.187.407-.453.72-.8.938-.347.218-.746.327-1.198.327-.447 0-.845-.109-1.194-.327-.349-.218-.619-.529-.81-.933-.19-.404-.287-.869-.289-1.396v-.31c0-.537.095-1.012.286-1.423.19-.411.459-.726.806-.944.347-.218.745-.327 1.194-.327.449 0 .847.108 1.194.324.347.216.615.526.804.931.189.405.285.876.288 1.413v.307zm-.957-.288c0-.611-.115-1.078-.346-1.404-.231-.325-.558-.488-.982-.488-.414 0-.737.162-.971.486-.233.324-.353.783-.358 1.376v.318c0 .605.118 1.073.354 1.404.236.33.563.496.982.496.424 0 .75-.161.978-.484.228-.323.342-.795.342-1.415v-.288zm7.202.288c0 .54-.093 1.014-.28 1.421-.187.407-.453.72-.8.938-.347.218-.746.327-1.198.327-.447 0-.845-.109-1.194-.327-.349-.218-.619-.529-.81-.933-.19-.404-.287-.869-.289-1.396v-.31c0-.537.095-1.012.286-1.423.19-.411.459-.726.806-.944.347-.218.745-.327 1.194-.327.449 0 .847.108 1.194.324.347.216.615.526.804.931.189.405.285.876.288 1.413v.307zm-.957-.288c0-.611-.115-1.078-.346-1.404-.231-.325-.558-.488-.982-.488-.414 0-.737.162-.971.486-.233.324-.353.783-.358 1.376v.318c0 .605.118 1.073.354 1.404.236.33.563.496.982.496.424 0 .75-.161.978-.484.228-.323.342-.795.342-1.415v-.288zm3.763 2.134h2.501v.764h-3.459v-5.51h.957v4.745zm7.009-.655c0-.242-.085-.429-.255-.56-.17-.131-.477-.264-.921-.397-.444-.134-.797-.283-1.06-.447-.502-.315-.753-.727-.753-1.234 0-.444.181-.81.543-1.097.362-.288.832-.431 1.41-.431.383 0 .725.071 1.026.212.3.141.536.342.708.604.172.261.257.551.257.868h-.954c0-.288-.09-.513-.271-.675-.18-.163-.438-.244-.774-.244-.313 0-.556.067-.728.201-.173.134-.259.32-.259.56 0 .202.093.37.28.505.187.135.494.266.923.394.429.127.773.272 1.033.435.26.163.45.349.571.56.121.211.182.457.182.74 0 .459-.176.824-.528 1.096-.352.271-.829.407-1.432.407-.399 0-.765-.074-1.099-.221-.334-.148-.594-.351-.78-.611-.185-.26-.278-.563-.278-.908h.957c0 .313.103.555.31.727.207.172.503.257.889.257.333 0 .583-.067.751-.202.168-.135.252-.313.252-.535zm8.691-.916h-2.218v2.335h-.957v-5.51h3.5v.772h-2.543v1.639h2.218v.764zm6.374-.276c0 .54-.093 1.014-.28 1.421-.187.407-.453.72-.8.938-.347.218-.746.327-1.198.327-.447 0-.845-.109-1.194-.327-.349-.218-.619-.529-.81-.933-.19-.404-.287-.869-.289-1.396v-.31c0-.537.095-1.012.286-1.423.19-.411.459-.726.806-.944.347-.218.745-.327 1.194-.327.449 0 .847.108 1.194.324.347.216.615.526.804.931.189.405.285.876.288 1.413v.307zm-.957-.288c0-.611-.115-1.078-.346-1.404-.231-.325-.558-.488-.982-.488-.414 0-.737.162-.971.486-.233.324-.353.783-.358 1.376v.318c0 .605.118 1.073.354 1.404.236.33.563.496.982.496.424 0 .75-.161.978-.484.228-.323.342-.795.342-1.415v-.288zm4.83.776h-1.067v2.123h-.957v-5.51h1.937c.636 0 1.126.143 1.472.428.346.285.518.698.518 1.237 0 .368-.089.677-.267.925-.178.248-.426.44-.744.573l1.237 2.297v.049h-1.026l-1.105-2.123zm-1.067-.768h.984c.323 0 .575-.081.757-.244.182-.163.272-.385.272-.668 0-.295-.084-.523-.252-.685-.168-.161-.418-.245-.751-.25h-1.01v1.847zm11.351-1.847h-1.718v4.738h-.95v-4.738h-1.703v-.772h4.371v.772zm5.992 4.738h-.954v-2.448h-2.464v2.448h-.957v-5.51h.957v2.293h2.464v-2.293h.954v5.51zm5.246-2.46h-2.263v1.695h2.645v.764h-3.603v-5.51h3.576v.772h-2.619v1.521h2.263v.757zm4.88 2.46v-5.51h1.888c.623 0 1.097.125 1.423.375.325.25.488.622.488 1.116 0 .252-.068.479-.204.681-.136.202-.336.358-.598.469.298.081.528.233.691.456.163.223.244.491.244.804 0 .517-.166.915-.498 1.192-.332.278-.807.416-1.425.416h-2.009zm.957-2.486v1.722h1.063c.3 0 .535-.074.704-.223.169-.149.254-.356.254-.621 0-.573-.293-.865-.878-.878h-1.143zm0-.704h.938c.298 0 .53-.067.698-.202.168-.135.252-.326.252-.573 0-.272-.078-.469-.233-.59-.155-.121-.397-.182-.725-.182h-.931v1.548zm5.836 3.19h-.954v-5.51h.954v5.51zm6.468-2.611c0 .54-.093 1.014-.28 1.421-.187.407-.453.72-.8.938-.347.218-.746.327-1.198.327-.447 0-.845-.109-1.194-.327-.349-.218-.619-.529-.81-.933-.19-.404-.287-.869-.289-1.396v-.31c0-.537.095-1.012.286-1.423.19-.411.459-.726.806-.944.347-.218.745-.327 1.194-.327.449 0 .847.108 1.194.324.347.216.615.526.804.931.189.405.285.876.288 1.413v.307zm-.957-.288c0-.611-.115-1.078-.346-1.404-.231-.325-.558-.488-.982-.488-.414 0-.737.162-.971.486-.233.324-.353.783-.358 1.376v.318c0 .605.118 1.073.354 1.404.236.33.563.496.982.496.424 0 .75-.161.978-.484.228-.323.342-.795.342-1.415v-.288zm6.465-1.839h-1.718v4.738h-.95v-4.738h-1.703v-.772h4.371v.772zm4.837 2.278h-2.263v1.695h2.645v.764h-3.603v-5.51h3.576v.772h-2.619v1.521h2.263v.757zm6.26.666c-.056.588-.272 1.046-.651 1.376-.378.329-.882.494-1.51.494-.439 0-.826-.104-1.16-.312-.334-.208-.592-.504-.774-.887-.182-.383-.276-.829-.284-1.336v-.515c0-.52.092-.978.276-1.374.184-.396.448-.701.793-.916.344-.214.742-.322 1.194-.322.608 0 1.097.165 1.468.496.371.33.587.797.647 1.4h-.954c-.045-.396-.161-.682-.346-.857-.185-.175-.457-.263-.815-.263-.416 0-.736.152-.959.456-.223.304-.337.75-.342 1.338v.488c0 .595.107 1.049.32 1.362.213.313.525.469.937.469.376 0 .658-.085.848-.254.189-.169.309-.45.359-.844h.954zm6.124 1.794h-.954v-2.448h-2.464v2.448h-.957v-5.51h.957v2.293h2.464v-2.293h.954v5.51zm5.86 0h-.954v-5.51h.954v5.51zm6.442 0h-.957l-2.456-3.909v3.909h-.957v-5.51h.957l2.464 3.924v-3.924h.95v5.51zm3.967-1.2l1.4-4.31h1.052l-1.983 5.51h-.927l-1.975-5.51h1.048l1.385 4.31zm7.187-1.26h-2.263v1.695h2.645v.764h-3.603v-5.51h3.576v.772h-2.619v1.521h2.263v.757zm4.936 1.041c0-.242-.085-.429-.255-.56-.17-.131-.477-.264-.921-.397-.444-.134-.797-.283-1.06-.447-.502-.315-.753-.727-.753-1.234 0-.444.181-.81.543-1.097.362-.288.832-.431 1.41-.431.383 0 .725.071 1.026.212.3.141.536.342.708.604.172.261.257.551.257.868h-.954c0-.288-.09-.513-.271-.675-.18-.163-.438-.244-.774-.244-.313 0-.556.067-.728.201-.173.134-.259.32-.259.56 0 .202.093.37.28.505.187.135.494.266.923.394.429.127.773.272 1.033.435.26.163.45.349.571.56.121.211.182.457.182.74 0 .459-.176.824-.528 1.096-.352.271-.829.407-1.432.407-.399 0-.765-.074-1.099-.221-.334-.148-.594-.351-.78-.611-.185-.26-.278-.563-.278-.908h.957c0 .313.103.555.31.727.207.172.503.257.889.257.333 0 .583-.067.751-.202.168-.135.252-.313.252-.535zm6.673-3.319h-1.718v4.738h-.95v-4.738h-1.703v-.772h4.371v.772zm5.908 2.127c0 .54-.093 1.014-.28 1.421-.187.407-.453.72-.8.938-.347.218-.746.327-1.198.327-.447 0-.845-.109-1.194-.327-.349-.218-.619-.529-.81-.933-.19-.404-.287-.869-.289-1.396v-.31c0-.537.095-1.012.286-1.423.19-.411.459-.726.806-.944.347-.218.745-.327 1.194-.327.449 0 .847.108 1.194.324.347.216.615.526.804.931.189.405.285.876.288 1.413v.307zm-.957-.288c0-.611-.115-1.078-.346-1.404-.231-.325-.558-.488-.982-.488-.414 0-.737.162-.971.486-.233.324-.353.783-.358 1.376v.318c0 .605.118 1.073.354 1.404.236.33.563.496.982.496.424 0 .75-.161.978-.484.228-.323.342-.795.342-1.415v-.288zm4.83.776h-1.067v2.123h-.957v-5.51h1.938c.636 0 1.126.143 1.472.428.346.285.518.698.518 1.237 0 .368-.089.677-.267.925-.178.248-.426.44-.744.573l1.237 2.297v.049h-1.026l-1.105-2.123zm-1.067-.768h.984c.323 0 .575-.081.757-.244.182-.163.272-.385.272-.668 0-.295-.084-.523-.252-.685-.168-.161-.418-.245-.751-.25h-1.01v1.847z"></path></g></g></svg>
	</a>



	<input type="checkbox" name="menu" id="show-menu">

	
		


	<ul class="site-nav__menu no-bullet">

		<li>
			<div class="mobile-ticker-search">
		<div class="ticker-search ticker-search--mobile">
    <form class="ticker-search__form js-ticker-search" id="ticker-search-form--mobile">
        <label class="ticker-search__label" for="ticker-query">Ticker Search</label>
        <div class="ticker-search__group">
            <input class="ticker-search__input" type="search" value="" id="ticker-query--mobile" name="q" placeholder="Company search" list="tickers-list--mobile" autocomplete="off">
            <input class="ticker-search__button" type="submit" value="Go" disabled="">
            
        <ul class="datalist" id="tickers-list--mobile" style="top: 704px; left: 0px; width: 0px;"><li><span>ABBV</span><span>AbbVie Inc.</span></li><li><span>ABCL</span><span>AbCellera Biologics Inc.</span></li><li><span>ABEO</span><span>Abeona Therapeutics Inc.</span></li><li><span>ABIO</span><span>ARCA biopharma Inc.</span></li><li><span>ABOS</span><span>Acumen Pharmaceuticals Inc.</span></li><li><span>ABUS</span><span>Arbutus Biopharma Corporation</span></li><li><span>ACAD</span><span>ACADIA Pharmaceuticals Inc.</span></li><li><span>ACER</span><span>Acer Therapeutics Inc.</span></li><li><span>ACET</span><span>Adicet Bio Inc.</span></li><li><span>ACHL</span><span>Achilles Therapeutics plc</span></li><li><span>ACHV</span><span>Achieve Life Sciences Inc.</span></li><li><span>ACIU</span><span>AC Immune SA</span></li><li><span>ACOR</span><span>Acorda Therapeutics Inc.</span></li><li><span>ACRS</span><span>Aclaris Therapeutics Inc.</span></li><li><span>ACRX</span><span>AcelRx Pharmaceuticals Inc.</span></li><li><span>ACST</span><span>Acasti Pharma Inc.</span></li><li><span>ACXP</span><span>Acurx Pharmaceuticals Inc.</span></li><li><span>ADAG</span><span>Adagene Inc.</span></li><li><span>ADAP</span><span>Adaptimmune Therapeutics plc</span></li><li><span>ADCT</span><span>ADC Therapeutics SA</span></li><li><span>ADGI</span><span>Adagio Therapeutics Inc.</span></li><li><span>ADIL</span><span>Adial Pharmaceuticals Inc</span></li><li><span>ADMA</span><span>ADMA Biologics Inc</span></li><li><span>ADMP</span><span>Adamis Pharmaceuticals Corporation</span></li><li><span>ADMS</span><span>Adamas Pharmaceuticals Inc.</span></li><li><span>ADPT</span><span>Adaptive Biotechnologies Corporation</span></li><li><span>ADTX</span><span>Aditxt Inc.</span></li><li><span>ADVM</span><span>Adverum Biotechnologies Inc.</span></li><li><span>ADXS</span><span>Advaxis Inc.</span></li><li><span>AERI</span><span>Aerie Pharmaceuticals Inc.</span></li><li><span>AEZS</span><span>Aeterna Zentaris Inc.</span></li><li><span>AFMD</span><span>Affimed N.V.</span></li><li><span>AGEN</span><span>Agenus Inc.</span></li><li><span>AGIO</span><span>Agios Pharmaceuticals Inc.</span></li><li><span>AGLE</span><span>Aeglea BioTherapeutics Inc.</span></li><li><span>AGRX</span><span>Agile Therapeutics Inc.</span></li><li><span>AGTC</span><span>Applied Genetic Technologies Corporation</span></li><li><span>AIM</span><span>AIM ImmunoTech Inc.</span></li><li><span>AKBA</span><span>Akebia Therapeutics Inc.</span></li><li><span>AKRO</span><span>Akero Therapeutics Inc.</span></li><li><span>AKTX</span><span>Akari Therapeutics Plc</span></li><li><span>AKUS</span><span>Akouos Inc.</span></li><li><span>ALBO</span><span>Albireo Pharma Inc.</span></li><li><span>ALDX</span><span>Aldeyra Therapeutics Inc.</span></li><li><span>ALEC</span><span>Alector Inc.</span></li><li><span>ALGS</span><span>Aligos Therapeutics Inc.</span></li><li><span>ALIM</span><span>Alimera Sciences Inc.</span></li><li><span>ALKS</span><span>Alkermes plc</span></li><li><span>ALLK</span><span>Allakos Inc.</span></li><li><span>ALLO</span><span>Allogene Therapeutics Inc.</span></li><li><span>ALNA</span><span>Allena Pharmaceuticals Inc.</span></li><li><span>ALNY</span><span>Alnylam Pharmaceuticals Inc.</span></li><li><span>ALPN</span><span>Alpine Immune Sciences Inc.</span></li><li><span>ALRN</span><span>Aileron Therapeutics Inc.</span></li><li><span>ALT</span><span>Altimmune Inc.</span></li><li><span>ALVR</span><span>AlloVir Inc.</span></li><li><span>ALXO</span><span>ALX Oncology Holdings Inc.</span></li><li><span>ALZN</span><span>Alzamend Neuro Inc.</span></li><li><span>AMAM</span><span>Ambrx Biopharma Inc. American Depositary Shares (each representing seven)</span></li><li><span>AMGN</span><span>Amgen Inc.</span></li><li><span>AMPE</span><span>Ampio Pharmaceuticals Inc.</span></li><li><span>AMPH</span><span>Amphastar Pharmaceuticals Inc.</span></li><li><span>AMRN</span><span>Amarin Corporation plc</span></li><li><span>AMRX</span><span>Amneal Pharmaceuticals Inc. Class A</span></li><li><span>AMTI</span><span>Applied Molecular Transport Inc.</span></li><li><span>AMYT</span><span>Amryt Pharma plc</span></li><li><span>ANAB</span><span>AnaptysBio Inc.</span></li><li><span>ANEB</span><span>Anebulo Pharmaceuticals Inc.</span></li><li><span>ANGN</span><span>Angion Biomedica Corp.</span></li><li><span>ANIK</span><span>Anika Therapeutics Inc.</span></li><li><span>ANIP</span><span>ANI Pharmaceuticals Inc.</span></li><li><span>ANIX</span><span>Anixa Biosciences Inc.</span></li><li><span>ANNX</span><span>Annexon Inc.</span></li><li><span>ANVS</span><span>Annovis Bio Inc.</span></li><li><span>APLS</span><span>Apellis Pharmaceuticals Inc.</span></li><li><span>APLT</span><span>Applied Therapeutics Inc.</span></li><li><span>APRE</span><span>Aprea Therapeutics Inc.</span></li><li><span>APTO</span><span>Aptose Biosciences Inc.</span></li><li><span>APTX</span><span>Aptinyx Inc.</span></li><li><span>APVO</span><span>Aptevo Therapeutics Inc.</span></li><li><span>AQST</span><span>Aquestive Therapeutics Inc.</span></li><li><span>ARAV</span><span>Aravive Inc.</span></li><li><span>ARCT</span><span>Arcturus Therapeutics Holdings Inc.</span></li><li><span>ARDS</span><span>Aridis Pharmaceuticals Inc.</span></li><li><span>ARDX</span><span>Ardelyx Inc.</span></li><li><span>ARGX</span><span>argenx SE</span></li><li><span>ARMP</span><span>Armata Pharmaceuticals Inc.</span></li><li><span>ARNA</span><span>Arena Pharmaceuticals Inc.</span></li><li><span>ARPO</span><span>Aerpio Pharmaceuticals Inc.</span></li><li><span>ARQT</span><span>Arcutis Biotherapeutics Inc.</span></li><li><span>ARTL</span><span>Artelo Biosciences Inc.</span></li><li><span>ARVN</span><span>Arvinas Inc.</span></li><li><span>ARWR</span><span>Arrowhead Pharmaceuticals Inc.</span></li><li><span>ASLN</span><span>ASLAN Pharmaceuticals Limited</span></li><li><span>ASMB</span><span>Assembly Biosciences Inc.</span></li><li><span>ASND</span><span>Ascendis Pharma A/S</span></li><li><span>ASRT</span><span>Assertio Holdings Inc.</span></li><li><span>ATAI</span><span>ATAI Life Sciences N.V.</span></li><li><span>ATHA</span><span>Athira Pharma Inc.</span></li><li><span>ATHE</span><span>Alterity Therapeutics Limited</span></li><li><span>ATHX</span><span>Athersys Inc.</span></li><li><span>ATNF</span><span>180 Life Sciences Corp.</span></li><li><span>ATNM</span><span>Actinium Pharmaceuticals Inc. (Delaware)</span></li><li><span>ATNX</span><span>Athenex Inc.</span></li><li><span>ATOS</span><span>Atossa Therapeutics Inc.</span></li><li><span>ATRA</span><span>Atara Biotherapeutics Inc.</span></li><li><span>ATRS</span><span>Antares Pharma Inc.</span></li><li><span>ATXI</span><span>Avenue Therapeutics Inc.</span></li><li><span>AUPH</span><span>Aurinia Pharmaceuticals Inc</span></li><li><span>AUTL</span><span>Autolus Therapeutics plc</span></li><li><span>AVDL</span><span>Avadel Pharmaceuticals plc</span></li><li><span>AVEO</span><span>AVEO Pharmaceuticals Inc.</span></li><li><span>AVIR</span><span>Atea Pharmaceuticals Inc.</span></li><li><span>AVRO</span><span>AVROBIO Inc.</span></li><li><span>AVTE</span><span>Aerovate Therapeutics Inc.</span></li><li><span>AVXL</span><span>Anavex Life Sciences Corp.</span></li><li><span>AXGN</span><span>Axogen Inc.</span></li><li><span>AXLA</span><span>Axcella Health Inc.</span></li><li><span>AXSM</span><span>Axsome Therapeutics Inc.</span></li><li><span>AYLA</span><span>Ayala Pharmaceuticals Inc.</span></li><li><span>AYTU</span><span>Aytu BioPharma Inc.</span></li><li><span>AZN</span><span>AstraZeneca PLC</span></li><li><span>AZRX</span><span>AzurRx BioPharma Inc.</span></li><li><span>BBI</span><span>Brickell Biotech, Inc.</span></li><li><span>BBIO</span><span>BridgeBio Pharma Inc.</span></li><li><span>BCAB</span><span>BioAtla Inc.</span></li><li><span>BCDA</span><span>BioCardia Inc.</span></li><li><span>BCEL</span><span>Atreca Inc.</span></li><li><span>BCLI</span><span>Brainstorm Cell Therapeutics Inc.</span></li><li><span>BCRX</span><span>BioCryst Pharmaceuticals Inc.</span></li><li><span>BCTX</span><span>BriaCell Therapeutics Corp.</span></li><li><span>BCYC</span><span>Bicycle Therapeutics plc</span></li><li><span>BDSI</span><span>BioDelivery Sciences International Inc.</span></li><li><span>BDTX</span><span>Black Diamond Therapeutics Inc.</span></li><li><span>BEAM</span><span>Beam Therapeutics Inc.</span></li><li><span>BFRA</span><span>Biofrontera AG</span></li><li><span>BGNE</span><span>BeiGene Ltd.</span></li><li><span>BHC</span><span>Bausch Health Companies Inc.</span></li><li><span>BHVN</span><span>Biohaven Pharmaceutical Holding Company Ltd.</span></li><li><span>BIIB</span><span>Biogen Inc.</span></li><li><span>BLCM</span><span>Bellicum Pharmaceuticals Inc.</span></li><li><span>BLPH</span><span>Bellerophon Therapeutics Inc.</span></li><li><span>BLRX</span><span>BioLineRx Ltd.</span></li><li><span>BLU</span><span>BELLUS Health Inc.</span></li><li><span>BLUE</span><span>bluebird bio Inc.</span></li><li><span>BMEA</span><span>Biomea Fusion Inc.</span></li><li><span>BMRN</span><span>BioMarin Pharmaceutical Inc.</span></li><li><span>BMY</span><span>Bristol-Myers Squibb Company</span></li><li><span>BNTC</span><span>Benitec Biopharma Inc.</span></li><li><span>BNTX</span><span>BioNTech SE</span></li><li><span>BOLT</span><span>Bolt Biotherapeutics Inc.</span></li><li><span>BPMC</span><span>Blueprint Medicines Corporation</span></li><li><span>BPTH</span><span>Bio-Path Holdings Inc.</span></li><li><span>BPTS</span><span>Biophytis SA</span></li><li><span>BSGM</span><span>BioSig Technologies Inc.</span></li><li><span>BTAI</span><span>BioXcel Therapeutics Inc.</span></li><li><span>BTX</span><span>Brooklyn ImmunoTherapeutics Inc.</span></li><li><span>BVXV</span><span>BiondVax Pharmaceuticals Ltd.</span></li><li><span>BXRX</span><span>Baudax Bio Inc.</span></li><li><span>BYSI</span><span>BeyondSpring Inc.</span></li><li><span>CABA</span><span>Cabaletta Bio Inc.</span></li><li><span>CADL</span><span>Candel Therapeutics Inc.</span></li><li><span>CALA</span><span>Calithera Biosciences Inc.</span></li><li><span>CALT</span><span>Calliditas Therapeutics AB</span></li><li><span>CANF</span><span>Can-Fite Biopharma Ltd Sponsored ADR (Israel)</span></li><li><span>CAPR</span><span>Capricor Therapeutics Inc.</span></li><li><span>CARA</span><span>Cara Therapeutics Inc.</span></li><li><span>CASI</span><span>CASI Pharmaceuticals Inc.</span></li><li><span>CATB</span><span>Catabasis Pharmaceuticals Inc.</span></li><li><span>CBAY</span><span>CymaBay Therapeutics Inc.</span></li><li><span>CBIO</span><span>Catalyst Biosciences Inc.</span></li><li><span>CBLI</span><span>Cytocom Inc (New) Com</span></li><li><span>CCCC</span><span>C4 Therapeutics Inc.</span></li><li><span>CCXI</span><span>ChemoCentryx Inc.</span></li><li><span>CDAK</span><span>Codiak BioSciences Inc.</span></li><li><span>CDMO</span><span>Avid Bioservices Inc.</span></li><li><span>CDTX</span><span>Cidara Therapeutics Inc.</span></li><li><span>CDXS</span><span>Codexis Inc.</span></li><li><span>CELC</span><span>Celcuity Inc.</span></li><li><span>CERC</span><span>Cerecor Inc.</span></li><li><span>CERE</span><span>Cerevel Therapeutics Holdings Inc.</span></li><li><span>CERS</span><span>Cerus Corporation</span></li><li><span>CFRX</span><span>ContraFect Corporation</span></li><li><span>CGEM</span><span>Cullinan Oncology Inc.</span></li><li><span>CGEN</span><span>Compugen Ltd.</span></li><li><span>CHMA</span><span>Chiasma Inc.</span></li><li><span>CHRS</span><span>Coherus BioSciences Inc.</span></li><li><span>CKPT</span><span>Checkpoint Therapeutics Inc.</span></li><li><span>CLBS</span><span>Caladrius Biosciences Inc.</span></li><li><span>CLDX</span><span>Celldex Therapeutics Inc.</span></li><li><span>CLLS</span><span>Cellectis S.A.</span></li><li><span>CLNN</span><span>Clene Inc.</span></li><li><span>CLRB</span><span>Cellectar Biosciences Inc.</span></li><li><span>CLSD</span><span>Clearside Biomedical Inc.</span></li><li><span>CLSN</span><span>Celsion Corporation</span></li><li><span>CLVS</span><span>Clovis Oncology Inc.</span></li><li><span>CMPI</span><span>Checkmate Pharmaceuticals Inc.</span></li><li><span>CMPS</span><span>COMPASS Pathways Plc</span></li><li><span>CMPX</span><span>Compass Therapeutics Inc Com</span></li><li><span>CMRX</span><span>Chimerix Inc.</span></li><li><span>CNCE</span><span>Concert Pharmaceuticals Inc.</span></li><li><span>CNSP</span><span>CNS Pharmaceuticals Inc.</span></li><li><span>CNTA</span><span>Centessa Pharmaceuticals plc</span></li><li><span>CNTB</span><span>Connect Biopharma Holdings Limited</span></li><li><span>CNTX</span><span>Context Therapeutics Inc</span></li><li><span>COCP</span><span>Cocrystal Pharma Inc.</span></li><li><span>COGT</span><span>Cogent Biosciences Inc.</span></li><li><span>COLL</span><span>Collegium Pharmaceutical Inc.</span></li><li><span>CORT</span><span>Corcept Therapeutics Incorporated</span></li><li><span>CPIX</span><span>Cumberland Pharmaceuticals Inc.</span></li><li><span>CPRX</span><span>Catalyst Pharmaceuticals Inc.</span></li><li><span>CRBP</span><span>Corbus Pharmaceuticals Holdings Inc.</span></li><li><span>CRBU</span><span>Caribou Biosciences Inc.</span></li><li><span>CRDF</span><span>Cardiff Oncology Inc.</span></li><li><span>CRIS</span><span>Curis Inc.</span></li><li><span>CRMD</span><span>CorMedix Inc.</span></li><li><span>CRNX</span><span>Crinetics Pharmaceuticals Inc.</span></li><li><span>CRSP</span><span>CRISPR Therapeutics AG</span></li><li><span>CRTX</span><span>Cortexyme Inc.</span></li><li><span>CRVS</span><span>Corvus Pharmaceuticals Inc.</span></li><li><span>CSII</span><span>Cardiovascular Systems Inc.</span></li><li><span>CTIC</span><span>CTI BioPharma Corp.</span></li><li><span>CTMX</span><span>CytomX Therapeutics Inc.</span></li><li><span>CTXR</span><span>Citius Pharmaceuticals Inc.</span></li><li><span>CUE</span><span>Cue Biopharma Inc.</span></li><li><span>CVAC</span><span>CureVac N.V.</span></li><li><span>CVM</span><span>Cel-Sci Corporation</span></li><li><span>CWBR</span><span>CohBar Inc.</span></li><li><span>CYAD</span><span>Celyad Oncology SA</span></li><li><span>CYCC</span><span>Cyclacel Pharmaceuticals Inc.</span></li><li><span>CYCN</span><span>Cyclerion Therapeutics Inc.</span></li><li><span>CYDY</span><span>Cytodyn Inc</span></li><li><span>CYT</span><span>Cyteir Therapeutics Inc.</span></li><li><span>CYTH</span><span>Cyclo Therapeutics Inc.</span></li><li><span>CYTK</span><span>Cytokinetics Incorporated</span></li><li><span>CYTO</span><span>Altamira Therapeutics Ltd.</span></li><li><span>DARE</span><span>Dare Bioscience Inc.</span></li><li><span>DAWN</span><span>Day One Biopharmaceuticals Inc.</span></li><li><span>DBTX</span><span>Decibel Therapeutics Inc.</span></li><li><span>DBVT</span><span>DBV Technologies S.A.</span></li><li><span>DCPH</span><span>Deciphera Pharmaceuticals Inc.</span></li><li><span>DCTH</span><span>Delcath Systems Inc.</span></li><li><span>DFFN</span><span>Diffusion Pharmaceuticals Inc.</span></li><li><span>DMAC</span><span>DiaMedica Therapeutics Inc.</span></li><li><span>DNLI</span><span>Denali Therapeutics Inc.</span></li><li><span>DRMA</span><span>Dermata Therapeutics Inc.</span></li><li><span>DRNA</span><span>Dicerna Pharmaceuticals Inc.</span></li><li><span>DRRX</span><span>DURECT Corporation</span></li><li><span>DSGN</span><span>Design Therapeutics Inc.</span></li><li><span>DTIL</span><span>Precision BioSciences Inc.</span></li><li><span>DVAX</span><span>Dynavax Technologies Corporation</span></li><li><span>DYAI</span><span>Dyadic International Inc.</span></li><li><span>DYN</span><span>Dyne Therapeutics Inc.</span></li><li><span>EBS</span><span>Emergent Biosolutions Inc.</span></li><li><span>EDAP</span><span>EDAP TMS S.A.</span></li><li><span>EDIT</span><span>Editas Medicine Inc.</span></li><li><span>EDSA</span><span>Edesa Biotech Inc.</span></li><li><span>EGRX</span><span>Eagle Pharmaceuticals Inc.</span></li><li><span>EIDX</span><span>Eidos Therapeutics Inc.</span></li><li><span>EIGR</span><span>Eiger BioPharmaceuticals Inc.</span></li><li><span>ELDN</span><span>Eledon Pharmaceuticals Inc.</span></li><li><span>ELEV</span><span>Elevation Oncology Inc.</span></li><li><span>ELOX</span><span>Eloxx Pharmaceuticals Inc.</span></li><li><span>ELTX</span><span></span></li><li><span>ELYM</span><span>Eliem Therapeutics Inc</span></li><li><span>ENDP</span><span>Endo International plc</span></li><li><span>ENLV</span><span>Enlivex Therapeutics Ltd.</span></li><li><span>ENOB</span><span>Enochian Biosciences Inc.</span></li><li><span>ENTA</span><span>Enanta Pharmaceuticals Inc.</span></li><li><span>ENTX</span><span>Entera Bio Ltd.</span></li><li><span>EOLS</span><span>Evolus Inc.</span></li><li><span>EPIX</span><span>ESSA Pharma Inc.</span></li><li><span>EPZM</span><span>Epizyme Inc.</span></li><li><span>EQ</span><span>Equillium Inc.</span></li><li><span>ERAS</span><span>Erasca Inc.</span></li><li><span>ERYP</span><span>Erytech Pharma S.A.</span></li><li><span>ESPR</span><span>Esperion Therapeutics Inc.</span></li><li><span>ETNB</span><span>89bio Inc.</span></li><li><span>ETON</span><span>Eton Pharmaceuticals Inc.</span></li><li><span>ETTX</span><span>Entasis Therapeutics Holdings Inc.</span></li><li><span>EVAX</span><span>Evaxion Biotech A/S</span></li><li><span>EVFM</span><span>Evofem Biosciences Inc.</span></li><li><span>EVLO</span><span>Evelo Biosciences Inc.</span></li><li><span>EVOK</span><span>Evoke Pharma Inc.</span></li><li><span>EWTX</span><span>Edgewise Therapeutics Inc.</span></li><li><span>EXAS</span><span>Exact Sciences Corporation</span></li><li><span>EXEL</span><span>Exelixis Inc.</span></li><li><span>EYEG</span><span>Eyegate Pharmaceuticals Inc.</span></li><li><span>EYEN</span><span>Eyenovia Inc.</span></li><li><span>EYPT</span><span>EyePoint Pharmaceuticals Inc.</span></li><li><span>FATE</span><span>Fate Therapeutics Inc.</span></li><li><span>FBIO</span><span>Fortress Biotech Inc.</span></li><li><span>FBRX</span><span>Forte Biosciences Inc.</span></li><li><span>FDMT</span><span>4D Molecular Therapeutics Inc.</span></li><li><span>FENC</span><span>Fennec Pharmaceuticals Inc.</span></li><li><span>FGEN</span><span>FibroGen Inc</span></li><li><span>FHTX</span><span>Foghorn Therapeutics Inc.</span></li><li><span>FIXX</span><span>Homology Medicines Inc.</span></li><li><span>FLXN</span><span>Flexion Therapeutics Inc.</span></li><li><span>FMTX</span><span>Forma Therapeutics Holdings Inc.</span></li><li><span>FNCH</span><span>Finch Therapeutics Group Inc.</span></li><li><span>FOLD</span><span>Amicus Therapeutics Inc.</span></li><li><span>FREQ</span><span>Frequency Therapeutics Inc.</span></li><li><span>FRLN</span><span>Freeline Therapeutics Holdings plc</span></li><li><span>FSTX</span><span>F-star Therapeutics Inc.</span></li><li><span>FULC</span><span>Fulcrum Therapeutics Inc.</span></li><li><span>FUSN</span><span>Fusion Pharmaceuticals Inc.</span></li><li><span>FWP</span><span>Forward Pharma A/S</span></li><li><span>GALT</span><span>Galectin Therapeutics Inc.</span></li><li><span>GANX</span><span>Gain Therapeutics Inc.</span></li><li><span>GBIO</span><span>Generation Bio Co.</span></li><li><span>GBT</span><span>Global Blood Therapeutics Inc.</span></li><li><span>GERN</span><span>Geron Corporation</span></li><li><span>GHRS</span><span>GH Research PLC</span></li><li><span>GILD</span><span>Gilead Sciences Inc.</span></li><li><span>GKOS</span><span>Glaukos Corporation</span></li><li><span>GLMD</span><span>Galmed Pharmaceuticals Ltd.</span></li><li><span>GLPG</span><span>Galapagos NV</span></li><li><span>GLSI</span><span>Greenwich LifeSciences Inc.</span></li><li><span>GLTO</span><span>Galecto Inc.</span></li><li><span>GLYC</span><span>GlycoMimetics Inc.</span></li><li><span>GMAB</span><span>Genmab A/S</span></li><li><span>GMDA</span><span>Gamida Cell Ltd.</span></li><li><span>GMTX</span><span>Gemini Therapeutics Inc.</span></li><li><span>GNCA</span><span>Genocea Biosciences Inc.</span></li><li><span>GNFT</span><span>GENFIT S.A.</span></li><li><span>GNPX</span><span>Genprex Inc.</span></li><li><span>GOSS</span><span>Gossamer Bio Inc.</span></li><li><span>GOVX</span><span>GeoVax Labs Inc.</span></li><li><span>GRAY</span><span>Graybug Vision Inc.</span></li><li><span>GRCL</span><span>Gracell Biotechnologies Inc.</span></li><li><span>GRPH</span><span>Graphite Bio Inc.</span></li><li><span>GRTS</span><span>Gritstone bio Inc.</span></li><li><span>GRTX</span><span>Galera Therapeutics Inc.</span></li><li><span>GSK</span><span>GlaxoSmithKline PLC</span></li><li><span>GTBP</span><span>GT Biopharma Inc.</span></li><li><span>GTHX</span><span>G1 Therapeutics Inc.</span></li><li><span>HALO</span><span>Halozyme Therapeutics Inc.</span></li><li><span>HARP</span><span>Harpoon Therapeutics Inc.</span></li><li><span>HCM</span><span>HUTCHMED (China) Limited</span></li><li><span>HEPA</span><span>Hepion Pharmaceuticals Inc.</span></li><li><span>HGEN</span><span>Humanigen Inc.</span></li><li><span>HOOK</span><span>HOOKIPA Pharma Inc.</span></li><li><span>HOTH</span><span>Hoth Therapeutics Inc.</span></li><li><span>HOWL</span><span>Werewolf Therapeutics Inc.</span></li><li><span>HRMY</span><span>Harmony Biosciences Holdings Inc.</span></li><li><span>HRTX</span><span>Heron Therapeutics Inc.</span></li><li><span>HSTO</span><span>Histogen Inc.</span></li><li><span>HTBX</span><span>Heat Biologics Inc.</span></li><li><span>HZNP</span><span>Horizon Therapeutics Public Limited Company</span></li><li><span>IBIO</span><span>iBio Inc.</span></li><li><span>IBRX</span><span>ImmunityBio Inc.</span></li><li><span>ICPT</span><span>Intercept Pharmaceuticals Inc.</span></li><li><span>ICVX</span><span>Icosavax Inc.</span></li><li><span>IDRA</span><span>Idera Pharmaceuticals Inc.</span></li><li><span>IDYA</span><span>IDEAYA Biosciences Inc.</span></li><li><span>IFRX</span><span>InflaRx N.V.</span></li><li><span>IGMS</span><span>IGM Biosciences Inc.</span></li><li><span>IGXT</span><span>IntelGenx Technologies Corp</span></li><li><span>IKNA</span><span>Ikena Oncology Inc.</span></li><li><span>IKT</span><span>Inhibikase Therapeutics Inc.</span></li><li><span>IMAB</span><span>I-MAB</span></li><li><span>IMCR</span><span>Immunocore Holdings plc</span></li><li><span>IMGN</span><span>ImmunoGen Inc.</span></li><li><span>IMGO</span><span>Imago BioSciences Inc.</span></li><li><span>IMMP</span><span>Immutep Limited</span></li><li><span>IMNM</span><span>Immunome Inc.</span></li><li><span>IMPL</span><span>Impel NeuroPharma Inc.</span></li><li><span>IMRA</span><span>IMARA Inc.</span></li><li><span>IMRN</span><span>Immuron Limited</span></li><li><span>IMRX</span><span>Immuneering Corporation</span></li><li><span>IMTX</span><span>Immatics N.V.</span></li><li><span>IMUX</span><span>Immunic Inc.</span></li><li><span>IMV</span><span>IMV Inc.</span></li><li><span>IMVT</span><span>Immunovant Inc.</span></li><li><span>INAB</span><span>IN8bio Inc.</span></li><li><span>INBX</span><span>Inhibrx Inc.</span></li><li><span>INCY</span><span>Incyte Corporation</span></li><li><span>INDP</span><span>Indaptus Therapeutics Inc.</span></li><li><span>INFI</span><span>Infinity Pharmaceuticals Inc.</span></li><li><span>INMB</span><span>INmune Bio Inc.</span></li><li><span>INO</span><span>Inovio Pharmaceuticals Inc.</span></li><li><span>INSM</span><span>Insmed Inc.</span></li><li><span>INVA</span><span>Innoviva Inc.</span></li><li><span>INZY</span><span>Inozyme Pharma Inc.</span></li><li><span>IONS</span><span>Ionis Pharmaceuticals Inc.</span></li><li><span>IOVA</span><span>Iovance Biotherapeutics Inc.</span></li><li><span>IPHA</span><span>Innate Pharma S.A.</span></li><li><span>IPSC</span><span>Century Therapeutics Inc.</span></li><li><span>IRWD</span><span>Ironwood Pharmaceuticals Inc.</span></li><li><span>ISEE</span><span>IVERIC bio Inc.</span></li><li><span>ITCI</span><span>Intra-Cellular Therapies Inc.</span></li><li><span>ITOS</span><span>iTeos Therapeutics Inc.</span></li><li><span>ITRM</span><span>Iterum Therapeutics plc</span></li><li><span>IVA</span><span>Inventiva S.A.</span></li><li><span>JAGX</span><span>Jaguar Health Inc.</span></li><li><span>JANX</span><span>Janux Therapeutics Inc.</span></li><li><span>JAZZ</span><span>Jazz Pharmaceuticals plc</span></li><li><span>JNCE</span><span>Jounce Therapeutics Inc.</span></li><li><span>JNJ</span><span>Johnson &amp; Johnson</span></li><li><span>KALA</span><span>Kala Pharmaceuticals Inc.</span></li><li><span>KALV</span><span>KalVista Pharmaceuticals Inc.</span></li><li><span>KDMN</span><span>Kadmon Holdings Inc.</span></li><li><span>KDNY</span><span>Chinook Therapeutics Inc.</span></li><li><span>KLDO</span><span>Kaleido Biosciences Inc.</span></li><li><span>KMDA</span><span>Kamada Ltd.</span></li><li><span>KMPH</span><span>KemPharm Inc</span></li><li><span>KNSA</span><span>Kiniksa Pharmaceuticals Ltd.</span></li><li><span>KNTE</span><span>Kinnate Biopharma Inc.</span></li><li><span>KOD</span><span>Kodiak Sciences Inc</span></li><li><span>KPTI</span><span>Karyopharm Therapeutics Inc.</span></li><li><span>KRBP</span><span>Kiromic BioPharma Inc.</span></li><li><span>KRON</span><span>Kronos Bio Inc.</span></li><li><span>KROS</span><span>Keros Therapeutics Inc.</span></li><li><span>KRTX</span><span>Karuna Therapeutics Inc.</span></li><li><span>KRYS</span><span>Krystal Biotech Inc.</span></li><li><span>KTRA</span><span>Kintara Therapeutics Inc.</span></li><li><span>KURA</span><span>Kura Oncology Inc.</span></li><li><span>KYMR</span><span>Kymera Therapeutics Inc.</span></li><li><span>KZIA</span><span>Kazia Therapeutics Limited</span></li><li><span>KZR</span><span>Kezar Life Sciences Inc.</span></li><li><span>LABP</span><span>Landos Biopharma Inc.</span></li><li><span>LBPH</span><span>Longboard Pharmaceuticals Inc.</span></li><li><span>LCTX</span><span>Lineage Cell Therapeutics, Inc.</span></li><li><span>LEGN</span><span>Legend Biotech Corporation</span></li><li><span>LGND</span><span>Ligand Pharmaceuticals Incorporated</span></li><li><span>LGVN</span><span>Longeveron Inc.</span></li><li><span>LIFE</span><span>aTyr Pharma Inc.</span></li><li><span>LIXT</span><span>Lixte Biotechnology Holdings Inc.</span></li><li><span>LJPC</span><span>La Jolla Pharmaceutical Company</span></li><li><span>LLY</span><span>Eli Lilly and Company</span></li><li><span>LMNL</span><span>Liminal BioSciences Inc.</span></li><li><span>LNTH</span><span>Lantheus Holdings Inc.</span></li><li><span>LOGC</span><span>LogicBio Therapeutics Inc.</span></li><li><span>LPCN</span><span>Lipocine Inc.</span></li><li><span>LPTX</span><span>Leap Therapeutics Inc.</span></li><li><span>LQDA</span><span>Liquidia Corporation</span></li><li><span>LRMR</span><span>Larimar Therapeutics Inc.</span></li><li><span>LTRN</span><span>Lantern Pharma Inc.</span></li><li><span>LUMO</span><span>Lumos Pharma Inc.</span></li><li><span>LVTX</span><span>LAVA Therapeutics N.V.</span></li><li><span>LXRX</span><span>Lexicon Pharmaceuticals Inc.</span></li><li><span>LYEL</span><span>Lyell Immunopharma Inc.</span></li><li><span>LYRA</span><span>Lyra Therapeutics Inc.</span></li><li><span>MACK</span><span>Merrimack Pharmaceuticals Inc.</span></li><li><span>MBIO</span><span>Mustang Bio Inc.</span></li><li><span>MBRX</span><span>Moleculin Biotech Inc.</span></li><li><span>MCRB</span><span>Seres Therapeutics Inc.</span></li><li><span>MDGL</span><span>Madrigal Pharmaceuticals Inc.</span></li><li><span>MDNA</span><span>Medicenna Therapeutics Corp.</span></li><li><span>MDWD</span><span>MediWound Ltd.</span></li><li><span>MEIP</span><span>MEI Pharma Inc.</span></li><li><span>MESO</span><span>Mesoblast Limited</span></li><li><span>MGNX</span><span>MacroGenics Inc.</span></li><li><span>MGTA</span><span>Magenta Therapeutics Inc.</span></li><li><span>MGTX</span><span>MeiraGTx Holdings plc</span></li><li><span>MIRM</span><span>Mirum Pharmaceuticals Inc.</span></li><li><span>MIST</span><span>Milestone Pharmaceuticals Inc.</span></li><li><span>MITO</span><span>Stealth BioTherapeutics Corp.</span></li><li><span>MNKD</span><span>MannKind Corporation</span></li><li><span>MNKKQ</span><span>Mallinckrodt plc</span></li><li><span>MNOV</span><span>MediciNova Inc.</span></li><li><span>MNPR</span><span>Monopar Therapeutics Inc.</span></li><li><span>MOLN</span><span>Molecular Partners AG</span></li><li><span>MOR</span><span>MorphoSys AG</span></li><li><span>MORF</span><span>Morphic Holding Inc.</span></li><li><span>MREO</span><span>Mereo BioPharma Group plc</span></li><li><span>MRK</span><span>Merck &amp; Company Inc.</span></li><li><span>MRKR</span><span>Marker Therapeutics Inc.</span></li><li><span>MRNA</span><span>Moderna Inc.</span></li><li><span>MRNS</span><span>Marinus Pharmaceuticals Inc.</span></li><li><span>MRSN</span><span>Mersana Therapeutics Inc.</span></li><li><span>MRTX</span><span>Mirati Therapeutics Inc.</span></li><li><span>MRUS</span><span>Merus N.V.</span></li><li><span>MTCR</span><span>Metacrine Inc.</span></li><li><span>MTEM</span><span>Molecular Templates Inc.</span></li><li><span>MTNB</span><span>Matinas Biopharma Holdings Inc.</span></li><li><span>MYMD</span><span>MyMD Pharmaceuticals Inc.</span></li><li><span>MYOV</span><span>Myovant Sciences Ltd.</span></li><li><span>NAVB</span><span>Navidea Biopharmaceuticals Inc.</span></li><li><span>NBIX</span><span>Neurocrine Biosciences Inc.</span></li><li><span>NBRV</span><span>Nabriva Therapeutics plc</span></li><li><span>NBTX</span><span>Nanobiotix S.A.</span></li><li><span>NBY</span><span>NovaBay Pharmaceuticals Inc.</span></li><li><span>NCNA</span><span>NuCana plc</span></li><li><span>NERV</span><span>Minerva Neurosciences Inc</span></li><li><span>NEXI</span><span>NexImmune Inc.</span></li><li><span>NGM</span><span>NGM Biopharmaceuticals Inc.</span></li><li><span>NKTR</span><span>Nektar Therapeutics</span></li><li><span>NKTX</span><span>Nkarta Inc.</span></li><li><span>NLSP</span><span>NLS Pharmaceutics Ltd.</span></li><li><span>NLTX</span><span>Neoleukin Therapeutics Inc.</span></li><li><span>NMTR</span><span>9 Meters Biopharma Inc.</span></li><li><span>NNVC</span><span>NanoViricides Inc.</span></li><li><span>NOVN</span><span>Novan Inc.</span></li><li><span>NRBO</span><span>NeuroBo Pharmaceuticals Inc.</span></li><li><span>NRIX</span><span>Nurix Therapeutics Inc.</span></li><li><span>NRXP</span><span>NRX Pharmaceuticals Inc.</span></li><li><span>NTLA</span><span>Intellia Therapeutics Inc.</span></li><li><span>NUVB</span><span>Nuvation Bio Inc. Class A</span></li><li><span>NVAX</span><span>Novavax Inc.</span></li><li><span>NVCR</span><span>NovoCure Limited</span></li><li><span>NVIV</span><span>InVivo Therapeutics Holdings Corp.</span></li><li><span>NVO</span><span>Novo Nordisk A/S</span></li><li><span>NVS</span><span>Novartis AG</span></li><li><span>NXTC</span><span>NextCure Inc.</span></li><li><span>NYMX</span><span>Nymox Pharmaceutical Corporation</span></li><li><span>OBSV</span><span>ObsEva SA</span></li><li><span>OCEA</span><span>Ocean Biomedical Inc</span></li><li><span>OCGN</span><span>Ocugen, Inc.</span></li><li><span>OCUL</span><span>Ocular Therapeutix Inc.</span></li><li><span>OCUP</span><span>Ocuphire Pharma Inc.</span></li><li><span>ODT</span><span>Odonate Therapeutics Inc.</span></li><li><span>OGEN</span><span>Oragenics Inc.</span></li><li><span>OLMA</span><span>Olema Pharmaceuticals Inc.</span></li><li><span>OMER</span><span>Omeros Corporation</span></li><li><span>OMGA</span><span>Omega Therapeutics Inc.</span></li><li><span>ONCR</span><span>Oncorus Inc.</span></li><li><span>ONCS</span><span>OncoSec Medical Incorporated</span></li><li><span>ONCT</span><span>Oncternal Therapeutics Inc.</span></li><li><span>ONCY</span><span>Oncolytics Biotech Inc.</span></li><li><span>ONTX</span><span>Onconova Therapeutics Inc.</span></li><li><span>OPK</span><span>Opko Health Inc.</span></li><li><span>OPNT</span><span>Opiant Pharmaceuticals Inc.</span></li><li><span>OPT</span><span>Opthea Limited</span></li><li><span>OPTN</span><span>OptiNose Inc.</span></li><li><span>ORIC</span><span>Oric Pharmaceuticals Inc.</span></li><li><span>ORMP</span><span>Oramed Pharmaceuticals Inc.</span></li><li><span>ORPH</span><span>Orphazyme A/S</span></li><li><span>ORTX</span><span>Orchard Therapeutics plc</span></li><li><span>OSMT</span><span>Osmotica Pharmaceuticals plc</span></li><li><span>OTIC</span><span>Otonomy Inc.</span></li><li><span>OTLK</span><span>Outlook Therapeutics Inc.</span></li><li><span>OVID</span><span>Ovid Therapeutics Inc.</span></li><li><span>OYST</span><span>Oyster Point Pharma Inc.</span></li><li><span>PALI</span><span>Palisade Bio Inc.</span></li><li><span>PASG</span><span>Passage Bio Inc.</span></li><li><span>PBLA</span><span>Panbela Therapeutics Inc.</span></li><li><span>PBYI</span><span>Puma Biotechnology Inc</span></li><li><span>PCRX</span><span>Pacira BioSciences Inc.</span></li><li><span>PCSA</span><span>Processa Pharmaceuticals Inc.</span></li><li><span>PCVX</span><span>Vaxcyte Inc.</span></li><li><span>PDSB</span><span>PDS Biotechnology Corporation</span></li><li><span>PFE</span><span>Pfizer Inc.</span></li><li><span>PGEN</span><span>Precigen Inc.</span></li><li><span>PHAS</span><span>PhaseBio Pharmaceuticals Inc.</span></li><li><span>PHAT</span><span>Phathom Pharmaceuticals Inc.</span></li><li><span>PHIO</span><span>Phio Pharmaceuticals Corp.</span></li><li><span>PHVS</span><span>Pharvaris N.V.</span></li><li><span>PIRS</span><span>Pieris Pharmaceuticals Inc.</span></li><li><span>PLRX</span><span>Pliant Therapeutics Inc.</span></li><li><span>PLUS</span><span>ePlus inc.</span></li><li><span>PLX</span><span>Protalix BioTherapeutics Inc. (DE)</span></li><li><span>PLXP</span><span>PLx Pharma Inc.</span></li><li><span>PMCB</span><span>PharmaCyte  Biotech Inc.</span></li><li><span>PMVP</span><span>PMV Pharmaceuticals Inc.</span></li><li><span>PPBT</span><span>Purple Biotech Ltd.</span></li><li><span>PRAX</span><span>Praxis Precision Medicines Inc.</span></li><li><span>PRFX</span><span>PainReform Ltd.</span></li><li><span>PRLD</span><span>Prelude Therapeutics Incorporated</span></li><li><span>PROG</span><span>Progenity Inc.</span></li><li><span>PRQR</span><span>ProQR Therapeutics N.V.</span></li><li><span>PRTA</span><span>Prothena Corporation plc</span></li><li><span>PRTK</span><span>Paratek Pharmaceuticals Inc.</span></li><li><span>PRVB</span><span>Provention Bio Inc.</span></li><li><span>PSNL</span><span>Personalis Inc.</span></li><li><span>PSTI</span><span>Pluristem Therapeutics Inc.</span></li><li><span>PSTV</span><span>PLUS THERAPEUTICS Inc.</span></li><li><span>PSTX</span><span>Poseida Therapeutics Inc.</span></li><li><span>PTCT</span><span>PTC Therapeutics Inc.</span></li><li><span>PTGX</span><span>Protagonist Therapeutics Inc.</span></li><li><span>PTIX</span><span>Protagenic Therapeutics Inc.</span></li><li><span>PTN</span><span>Palatin Technologies Inc.</span></li><li><span>PTPI</span><span>Petros Pharmaceuticals Inc.</span></li><li><span>PULM</span><span>Pulmatrix Inc.</span></li><li><span>PYPD</span><span>PolyPid Ltd.</span></li><li><span>QLGN</span><span>Qualigen Therapeutics Inc.</span></li><li><span>QURE</span><span>uniQure N.V.</span></li><li><span>RAIN</span><span>Rain Therapeutics Inc.</span></li><li><span>RANI</span><span>Rani Therapeutics Holdings Inc.</span></li><li><span>RAPT</span><span>RAPT Therapeutics Inc.</span></li><li><span>RARE</span><span>Ultragenyx Pharmaceutical Inc.</span></li><li><span>RCKT</span><span>Rocket Pharmaceuticals Inc.</span></li><li><span>RCUS</span><span>Arcus Biosciences Inc.</span></li><li><span>RDHL</span><span>Redhill Biopharma Ltd.</span></li><li><span>RDUS</span><span>Radius Health Inc.</span></li><li><span>REGN</span><span>Regeneron Pharmaceuticals Inc.</span></li><li><span>REPH</span><span>Recro Pharma Inc.</span></li><li><span>REPL</span><span>Replimune Group Inc.</span></li><li><span>RETA</span><span>Reata Pharmaceuticals Inc.</span></li><li><span>RGEN</span><span>Repligen Corporation</span></li><li><span>RGLS</span><span>Regulus Therapeutics Inc.</span></li><li><span>RGNX</span><span>REGENXBIO Inc.</span></li><li><span>RHHBY</span><span>Roche Holding AG ADR</span></li><li><span>RIGL</span><span>Rigel Pharmaceuticals Inc.</span></li><li><span>RLAY</span><span>Relay Therapeutics Inc.</span></li><li><span>RLMD</span><span>Relmada Therapeutics Inc.</span></li><li><span>RLYB</span><span>Rallybio Corporation</span></li><li><span>RMTI</span><span>Rockwell Medical Inc.</span></li><li><span>RNA</span><span>Avidity Biosciences Inc.</span></li><li><span>RNAZ</span><span>TransCode Therapeutics Inc.</span></li><li><span>RNLX</span><span>Renalytix AI plc</span></li><li><span>RNXT</span><span>RenovoRx Inc Com</span></li><li><span>RPHM</span><span>Reneo Pharmaceuticals Inc.</span></li><li><span>RPTX</span><span>Repare Therapeutics Inc.</span></li><li><span>RUBY</span><span>Rubius Therapeutics Inc.</span></li><li><span>RVMD</span><span>Revolution Medicines Inc - Ordinary Shares</span></li><li><span>RVNC</span><span>Revance Therapeutics Inc.</span></li><li><span>RVPH</span><span>Reviva Pharmaceuticals Holdings Inc.</span></li><li><span>RXDX</span><span>Prometheus Biosciences Inc.</span></li><li><span>RXRX</span><span>Recursion Pharmaceuticals Inc.</span></li><li><span>RYTM</span><span>Rhythm Pharmaceuticals Inc.</span></li><li><span>RZLT</span><span>Rezolute Inc.</span></li><li><span>SAGE</span><span>Sage Therapeutics Inc.</span></li><li><span>SANA</span><span>Sana Biotechnology Inc.</span></li><li><span>SAVA</span><span>Cassava Sciences Inc.</span></li><li><span>SBBP</span><span>Strongbridge Biopharma plc</span></li><li><span>SBTX</span><span>Silverback Therapeutics Inc.</span></li><li><span>SCPH</span><span>scPharmaceuticals Inc.</span></li><li><span>SCPS</span><span>Scopus BioPharma Inc.</span></li><li><span>SCYX</span><span>SCYNEXIS Inc.</span></li><li><span>SDGR</span><span>Schrodinger Inc.</span></li><li><span>SEEL</span><span>Seelos Therapeutics Inc.</span></li><li><span>SELB</span><span>Selecta Biosciences Inc.</span></li><li><span>SESN</span><span>Sesen Bio Inc.</span></li><li><span>SGEN</span><span>Seagen Inc.</span></li><li><span>SGMO</span><span>Sangamo Therapeutics Inc.</span></li><li><span>SGTX</span><span>Sigilon Therapeutics Inc.</span></li><li><span>SIGA</span><span>SIGA Technologies Inc.</span></li><li><span>SIOX</span><span>Sio Gene Therapies Inc.</span></li><li><span>SLDB</span><span>Solid Biosciences Inc.</span></li><li><span>SLGL</span><span>Sol-Gel Technologies Ltd.</span></li><li><span>SLNO</span><span>Soleno Therapeutics Inc.</span></li><li><span>SLRX</span><span>Salarius Pharmaceuticals Inc.</span></li><li><span>SLS</span><span>SELLAS Life Sciences Group Inc.</span></li><li><span>SMMT</span><span>Summit Therapeutics Inc.</span></li><li><span>SNDX</span><span>Syndax Pharmaceuticals Inc.</span></li><li><span>SNGX</span><span>Soligenix Inc.</span></li><li><span>SNPX</span><span>Synaptogenix Inc.</span></li><li><span>SNSE</span><span>Sensei Biotherapeutics Inc.</span></li><li><span>SNY</span><span>Sanofi</span></li><li><span>SONN</span><span>Sonnet BioTherapeutics Holdings Inc.</span></li><li><span>SPPI</span><span>Spectrum Pharmaceuticals Inc.</span></li><li><span>SPRB</span><span>Spruce Biosciences Inc.</span></li><li><span>SPRO</span><span>Spero Therapeutics Inc.</span></li><li><span>SQZ</span><span>SQZ Biotechnologies Company</span></li><li><span>SRNE</span><span>Sorrento Therapeutics Inc.</span></li><li><span>SRPT</span><span>Sarepta Therapeutics Inc.</span></li><li><span>SRRA</span><span>Sierra Oncology Inc.</span></li><li><span>SRRK</span><span>Scholar Rock Holding Corporation</span></li><li><span>STOK</span><span>Stoke Therapeutics Inc.</span></li><li><span>STRO</span><span>Sutro Biopharma Inc.</span></li><li><span>STSA</span><span>Satsuma Pharmaceuticals Inc.</span></li><li><span>STTK</span><span>Shattuck Labs Inc.</span></li><li><span>SUPN</span><span>Supernus Pharmaceuticals Inc.</span></li><li><span>SURF</span><span>Surface Oncology Inc.</span></li><li><span>SVRA</span><span>Savara Inc.</span></li><li><span>SWTX</span><span>SpringWorks Therapeutics Inc.</span></li><li><span>SYBX</span><span>Synlogic Inc.</span></li><li><span>SYN</span><span>Synthetic Biologics Inc.</span></li><li><span>SYRS</span><span>Syros Pharmaceuticals Inc.</span></li><li><span>TAK</span><span>Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)</span></li><li><span>TALS</span><span>Talaris Therapeutics Inc.</span></li><li><span>TARA</span><span>Protara Therapeutics Inc.</span></li><li><span>TARS</span><span>Tarsus Pharmaceuticals Inc.</span></li><li><span>TBIO</span><span>Translate Bio Inc.</span></li><li><span>TBPH</span><span>Theravance Biopharma Inc.</span></li><li><span>TCDA</span><span>Tricida Inc.</span></li><li><span>TCON</span><span>TRACON Pharmaceuticals Inc.</span></li><li><span>TCRR</span><span>TCR2 Therapeutics Inc.</span></li><li><span>TCRX</span><span>TScan Therapeutics Inc.</span></li><li><span>TENX</span><span>Tenax Therapeutics Inc.</span></li><li><span>TERN</span><span>Terns Pharmaceuticals Inc.</span></li><li><span>TEVA</span><span>Teva Pharmaceutical Industries Limited American Depositary Shares</span></li><li><span>TFFP</span><span>TFF Pharmaceuticals Inc - Ordinary Shares</span></li><li><span>TGTX</span><span>TG Therapeutics Inc.</span></li><li><span>TIL</span><span>Instil Bio Inc.</span></li><li><span>TKNO</span><span>Alpha Teknova Inc.</span></li><li><span>TLC</span><span>Taiwan Liposome Company Ltd.</span></li><li><span>TLSA</span><span>Tiziana Life Sciences plc</span></li><li><span>TMBR</span><span>Timber Pharmaceuticals Inc.</span></li><li><span>TNXP</span><span>Tonix Pharmaceuticals Holding Corp.</span></li><li><span>TNYA</span><span>Tenaya Therapeutics Inc.</span></li><li><span>TPST</span><span>Tempest Therapeutics Inc.</span></li><li><span>TPTX</span><span>Turning Point Therapeutics Inc.</span></li><li><span>TRIL</span><span>Trillium Therapeutics Inc.</span></li><li><span>TRVI</span><span>Trevi Therapeutics Inc.</span></li><li><span>TRVN</span><span>Trevena Inc.</span></li><li><span>TSHA</span><span>Taysha Gene Therapies Inc.</span></li><li><span>TTNP</span><span>Titan Pharmaceuticals Inc.</span></li><li><span>TVTX</span><span>Travere Therapeutics Inc.</span></li><li><span>TXMD</span><span>TherapeuticsMD Inc.</span></li><li><span>TYME</span><span>Tyme Technologies Inc.</span></li><li><span>UBX</span><span>Unity Biotechnology Inc.</span></li><li><span>UNCY</span><span>Unicycive Therapeutics Inc.</span></li><li><span>URGN</span><span>UroGen Pharma Ltd.</span></li><li><span>UTHR</span><span>United Therapeutics Corporation</span></li><li><span>VACC</span><span>Vaccitech plc</span></li><li><span>VALN</span><span>Valneva SE</span></li><li><span>VBIV</span><span>VBI Vaccines Inc.</span></li><li><span>VBLT</span><span>Vascular Biogenics Ltd.</span></li><li><span>VCEL</span><span>Vericel Corporation</span></li><li><span>VCNX</span><span>Vaccinex Inc.</span></li><li><span>VECT</span><span>VectivBio Holding AG</span></li><li><span>VERA</span><span>Vera Therapeutics Inc.</span></li><li><span>VERU</span><span>Veru Inc.</span></li><li><span>VERV</span><span>Verve Therapeutics Inc.</span></li><li><span>VINC</span><span>Vincerx Pharma Inc.</span></li><li><span>VIR</span><span>Vir Biotechnology Inc.</span></li><li><span>VIRI</span><span>Virios Therapeutics Inc.</span></li><li><span>VIRX</span><span>Viracta Therapeutics Inc.</span></li><li><span>VKTX</span><span>Viking Therapeutics Inc.</span></li><li><span>VLON</span><span>Vallon Pharmaceuticals Inc.</span></li><li><span>VNDA</span><span>Vanda Pharmaceuticals Inc.</span></li><li><span>VOR</span><span>Vor Biopharma Inc.</span></li><li><span>VRCA</span><span>Verrica Pharmaceuticals Inc.</span></li><li><span>VRDN</span><span>Viridian Therapeutics Inc.</span></li><li><span>VRNA</span><span>Verona Pharma plc</span></li><li><span>VRPX</span><span>Virpax Pharmaceuticals Inc.</span></li><li><span>VRTX</span><span>Vertex Pharmaceuticals Incorporated</span></li><li><span>VSTM</span><span>Verastem Inc.</span></li><li><span>VTGN</span><span>VistaGen Therapeutics Inc.</span></li><li><span>VTRS</span><span>Viatris Inc.</span></li><li><span>VTVT</span><span>vTv Therapeutics Inc.</span></li><li><span>VXRT</span><span>Vaxart Inc.</span></li><li><span>VYGR</span><span>Voyager Therapeutics Inc.</span></li><li><span>VYNE</span><span>VYNE Therapeutics Inc.</span></li><li><span>WINT</span><span>Windtree Therapeutics Inc.</span></li><li><span>WVE</span><span>Wave Life Sciences Ltd.</span></li><li><span>XBIO</span><span>Xenetic Biosciences Inc.</span></li><li><span>XBIT</span><span>XBiotech Inc.</span></li><li><span>XCUR</span><span>Exicure Inc.</span></li><li><span>XENE</span><span>Xenon Pharmaceuticals Inc.</span></li><li><span>XENT</span><span>Intersect ENT Inc.</span></li><li><span>XERS</span><span>Xeris Pharmaceuticals Inc.</span></li><li><span>XFOR</span><span>X4 Pharmaceuticals Inc.</span></li><li><span>XLRN</span><span>Acceleron Pharma Inc.</span></li><li><span>XNCR</span><span>Xencor Inc.</span></li><li><span>XOMA</span><span>XOMA Corporation</span></li><li><span>XTLB</span><span>XTL Biopharmaceuticals Ltd.</span></li><li><span>YMAB</span><span>Y-mAbs Therapeutics Inc.</span></li><li><span>YMTX</span><span>Yumanity Therapeutics Inc.</span></li><li><span>ZEAL</span><span>Zealand Pharma A/S</span></li><li><span>ZGNX</span><span>Zogenix Inc.</span></li><li><span>ZIOP</span><span>ZIOPHARM Oncology Inc</span></li><li><span>ZLAB</span><span>Zai Lab Limited</span></li><li><span>ZNTL</span><span>Zentalis Pharmaceuticals Inc.</span></li><li><span>ZSAN</span><span>Zosano Pharma Corporation</span></li><li><span>ZYME</span><span>Zymeworks Inc.</span></li><li><span>ZYNE</span><span>Zynerba Pharmaceuticals Inc.</span></li></ul></div>
    </form>
</div>

	</div>
		</li>

										<li class="site-nav__menu-item no-bullet is-selected icon--calendars">
				<a href="https://www.biopharmcatalyst.com/calendars" title="Catalyst Calendars">Catalyst Calendars</a>
									<ul class="site-nav__sub-menu">
													<li>
								<a href="https://www.biopharmcatalyst.com/calendars/fda-calendar" title="FDA Calendar">FDA Calendar</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/calendars/pdufa-calendar" title="PDUFA Calendar">PDUFA Calendar</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/calendars/biotech-earnings-calendar" title="Biotech Earnings Calendar">Biotech Earnings Calendar</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/calendars/ipo-calendar" title="Biotech IPO Calendar">Biotech IPO Calendar</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/calendars/historical-catalyst-calendar" title="Historical Catalyst Calendar">Historical Catalyst Calendar</a>
							</li>
											</ul>
							</li>
		
	
										<li class="site-nav__menu-item no-bullet icon--companies">
				<a href="https://www.biopharmcatalyst.com/biotech-stocks" title="Companies">Companies</a>
									<ul class="site-nav__sub-menu">
													<li><div class="site-nav__largescreen-search js-large-screen-search">
				<div class="ticker-search ticker-search--small">
    <form class="ticker-search__form js-ticker-search" id="ticker-search-form--small">
        <label class="ticker-search__label" for="ticker-query">Ticker Search</label>
        <div class="ticker-search__group">
            <input class="ticker-search__input" type="search" value="" id="ticker-query--small" name="q" placeholder="Company search" list="tickers-list--small" autocomplete="off">
            <input class="ticker-search__button" type="submit" value="Go" disabled="">
            
        <ul class="datalist" id="tickers-list--small" style="top: 704px; left: 0px; width: 2px;"><li><span>ABBV</span><span>AbbVie Inc.</span></li><li><span>ABCL</span><span>AbCellera Biologics Inc.</span></li><li><span>ABEO</span><span>Abeona Therapeutics Inc.</span></li><li><span>ABIO</span><span>ARCA biopharma Inc.</span></li><li><span>ABOS</span><span>Acumen Pharmaceuticals Inc.</span></li><li><span>ABUS</span><span>Arbutus Biopharma Corporation</span></li><li><span>ACAD</span><span>ACADIA Pharmaceuticals Inc.</span></li><li><span>ACER</span><span>Acer Therapeutics Inc.</span></li><li><span>ACET</span><span>Adicet Bio Inc.</span></li><li><span>ACHL</span><span>Achilles Therapeutics plc</span></li><li><span>ACHV</span><span>Achieve Life Sciences Inc.</span></li><li><span>ACIU</span><span>AC Immune SA</span></li><li><span>ACOR</span><span>Acorda Therapeutics Inc.</span></li><li><span>ACRS</span><span>Aclaris Therapeutics Inc.</span></li><li><span>ACRX</span><span>AcelRx Pharmaceuticals Inc.</span></li><li><span>ACST</span><span>Acasti Pharma Inc.</span></li><li><span>ACXP</span><span>Acurx Pharmaceuticals Inc.</span></li><li><span>ADAG</span><span>Adagene Inc.</span></li><li><span>ADAP</span><span>Adaptimmune Therapeutics plc</span></li><li><span>ADCT</span><span>ADC Therapeutics SA</span></li><li><span>ADGI</span><span>Adagio Therapeutics Inc.</span></li><li><span>ADIL</span><span>Adial Pharmaceuticals Inc</span></li><li><span>ADMA</span><span>ADMA Biologics Inc</span></li><li><span>ADMP</span><span>Adamis Pharmaceuticals Corporation</span></li><li><span>ADMS</span><span>Adamas Pharmaceuticals Inc.</span></li><li><span>ADPT</span><span>Adaptive Biotechnologies Corporation</span></li><li><span>ADTX</span><span>Aditxt Inc.</span></li><li><span>ADVM</span><span>Adverum Biotechnologies Inc.</span></li><li><span>ADXS</span><span>Advaxis Inc.</span></li><li><span>AERI</span><span>Aerie Pharmaceuticals Inc.</span></li><li><span>AEZS</span><span>Aeterna Zentaris Inc.</span></li><li><span>AFMD</span><span>Affimed N.V.</span></li><li><span>AGEN</span><span>Agenus Inc.</span></li><li><span>AGIO</span><span>Agios Pharmaceuticals Inc.</span></li><li><span>AGLE</span><span>Aeglea BioTherapeutics Inc.</span></li><li><span>AGRX</span><span>Agile Therapeutics Inc.</span></li><li><span>AGTC</span><span>Applied Genetic Technologies Corporation</span></li><li><span>AIM</span><span>AIM ImmunoTech Inc.</span></li><li><span>AKBA</span><span>Akebia Therapeutics Inc.</span></li><li><span>AKRO</span><span>Akero Therapeutics Inc.</span></li><li><span>AKTX</span><span>Akari Therapeutics Plc</span></li><li><span>AKUS</span><span>Akouos Inc.</span></li><li><span>ALBO</span><span>Albireo Pharma Inc.</span></li><li><span>ALDX</span><span>Aldeyra Therapeutics Inc.</span></li><li><span>ALEC</span><span>Alector Inc.</span></li><li><span>ALGS</span><span>Aligos Therapeutics Inc.</span></li><li><span>ALIM</span><span>Alimera Sciences Inc.</span></li><li><span>ALKS</span><span>Alkermes plc</span></li><li><span>ALLK</span><span>Allakos Inc.</span></li><li><span>ALLO</span><span>Allogene Therapeutics Inc.</span></li><li><span>ALNA</span><span>Allena Pharmaceuticals Inc.</span></li><li><span>ALNY</span><span>Alnylam Pharmaceuticals Inc.</span></li><li><span>ALPN</span><span>Alpine Immune Sciences Inc.</span></li><li><span>ALRN</span><span>Aileron Therapeutics Inc.</span></li><li><span>ALT</span><span>Altimmune Inc.</span></li><li><span>ALVR</span><span>AlloVir Inc.</span></li><li><span>ALXO</span><span>ALX Oncology Holdings Inc.</span></li><li><span>ALZN</span><span>Alzamend Neuro Inc.</span></li><li><span>AMAM</span><span>Ambrx Biopharma Inc. American Depositary Shares (each representing seven)</span></li><li><span>AMGN</span><span>Amgen Inc.</span></li><li><span>AMPE</span><span>Ampio Pharmaceuticals Inc.</span></li><li><span>AMPH</span><span>Amphastar Pharmaceuticals Inc.</span></li><li><span>AMRN</span><span>Amarin Corporation plc</span></li><li><span>AMRX</span><span>Amneal Pharmaceuticals Inc. Class A</span></li><li><span>AMTI</span><span>Applied Molecular Transport Inc.</span></li><li><span>AMYT</span><span>Amryt Pharma plc</span></li><li><span>ANAB</span><span>AnaptysBio Inc.</span></li><li><span>ANEB</span><span>Anebulo Pharmaceuticals Inc.</span></li><li><span>ANGN</span><span>Angion Biomedica Corp.</span></li><li><span>ANIK</span><span>Anika Therapeutics Inc.</span></li><li><span>ANIP</span><span>ANI Pharmaceuticals Inc.</span></li><li><span>ANIX</span><span>Anixa Biosciences Inc.</span></li><li><span>ANNX</span><span>Annexon Inc.</span></li><li><span>ANVS</span><span>Annovis Bio Inc.</span></li><li><span>APLS</span><span>Apellis Pharmaceuticals Inc.</span></li><li><span>APLT</span><span>Applied Therapeutics Inc.</span></li><li><span>APRE</span><span>Aprea Therapeutics Inc.</span></li><li><span>APTO</span><span>Aptose Biosciences Inc.</span></li><li><span>APTX</span><span>Aptinyx Inc.</span></li><li><span>APVO</span><span>Aptevo Therapeutics Inc.</span></li><li><span>AQST</span><span>Aquestive Therapeutics Inc.</span></li><li><span>ARAV</span><span>Aravive Inc.</span></li><li><span>ARCT</span><span>Arcturus Therapeutics Holdings Inc.</span></li><li><span>ARDS</span><span>Aridis Pharmaceuticals Inc.</span></li><li><span>ARDX</span><span>Ardelyx Inc.</span></li><li><span>ARGX</span><span>argenx SE</span></li><li><span>ARMP</span><span>Armata Pharmaceuticals Inc.</span></li><li><span>ARNA</span><span>Arena Pharmaceuticals Inc.</span></li><li><span>ARPO</span><span>Aerpio Pharmaceuticals Inc.</span></li><li><span>ARQT</span><span>Arcutis Biotherapeutics Inc.</span></li><li><span>ARTL</span><span>Artelo Biosciences Inc.</span></li><li><span>ARVN</span><span>Arvinas Inc.</span></li><li><span>ARWR</span><span>Arrowhead Pharmaceuticals Inc.</span></li><li><span>ASLN</span><span>ASLAN Pharmaceuticals Limited</span></li><li><span>ASMB</span><span>Assembly Biosciences Inc.</span></li><li><span>ASND</span><span>Ascendis Pharma A/S</span></li><li><span>ASRT</span><span>Assertio Holdings Inc.</span></li><li><span>ATAI</span><span>ATAI Life Sciences N.V.</span></li><li><span>ATHA</span><span>Athira Pharma Inc.</span></li><li><span>ATHE</span><span>Alterity Therapeutics Limited</span></li><li><span>ATHX</span><span>Athersys Inc.</span></li><li><span>ATNF</span><span>180 Life Sciences Corp.</span></li><li><span>ATNM</span><span>Actinium Pharmaceuticals Inc. (Delaware)</span></li><li><span>ATNX</span><span>Athenex Inc.</span></li><li><span>ATOS</span><span>Atossa Therapeutics Inc.</span></li><li><span>ATRA</span><span>Atara Biotherapeutics Inc.</span></li><li><span>ATRS</span><span>Antares Pharma Inc.</span></li><li><span>ATXI</span><span>Avenue Therapeutics Inc.</span></li><li><span>AUPH</span><span>Aurinia Pharmaceuticals Inc</span></li><li><span>AUTL</span><span>Autolus Therapeutics plc</span></li><li><span>AVDL</span><span>Avadel Pharmaceuticals plc</span></li><li><span>AVEO</span><span>AVEO Pharmaceuticals Inc.</span></li><li><span>AVIR</span><span>Atea Pharmaceuticals Inc.</span></li><li><span>AVRO</span><span>AVROBIO Inc.</span></li><li><span>AVTE</span><span>Aerovate Therapeutics Inc.</span></li><li><span>AVXL</span><span>Anavex Life Sciences Corp.</span></li><li><span>AXGN</span><span>Axogen Inc.</span></li><li><span>AXLA</span><span>Axcella Health Inc.</span></li><li><span>AXSM</span><span>Axsome Therapeutics Inc.</span></li><li><span>AYLA</span><span>Ayala Pharmaceuticals Inc.</span></li><li><span>AYTU</span><span>Aytu BioPharma Inc.</span></li><li><span>AZN</span><span>AstraZeneca PLC</span></li><li><span>AZRX</span><span>AzurRx BioPharma Inc.</span></li><li><span>BBI</span><span>Brickell Biotech, Inc.</span></li><li><span>BBIO</span><span>BridgeBio Pharma Inc.</span></li><li><span>BCAB</span><span>BioAtla Inc.</span></li><li><span>BCDA</span><span>BioCardia Inc.</span></li><li><span>BCEL</span><span>Atreca Inc.</span></li><li><span>BCLI</span><span>Brainstorm Cell Therapeutics Inc.</span></li><li><span>BCRX</span><span>BioCryst Pharmaceuticals Inc.</span></li><li><span>BCTX</span><span>BriaCell Therapeutics Corp.</span></li><li><span>BCYC</span><span>Bicycle Therapeutics plc</span></li><li><span>BDSI</span><span>BioDelivery Sciences International Inc.</span></li><li><span>BDTX</span><span>Black Diamond Therapeutics Inc.</span></li><li><span>BEAM</span><span>Beam Therapeutics Inc.</span></li><li><span>BFRA</span><span>Biofrontera AG</span></li><li><span>BGNE</span><span>BeiGene Ltd.</span></li><li><span>BHC</span><span>Bausch Health Companies Inc.</span></li><li><span>BHVN</span><span>Biohaven Pharmaceutical Holding Company Ltd.</span></li><li><span>BIIB</span><span>Biogen Inc.</span></li><li><span>BLCM</span><span>Bellicum Pharmaceuticals Inc.</span></li><li><span>BLPH</span><span>Bellerophon Therapeutics Inc.</span></li><li><span>BLRX</span><span>BioLineRx Ltd.</span></li><li><span>BLU</span><span>BELLUS Health Inc.</span></li><li><span>BLUE</span><span>bluebird bio Inc.</span></li><li><span>BMEA</span><span>Biomea Fusion Inc.</span></li><li><span>BMRN</span><span>BioMarin Pharmaceutical Inc.</span></li><li><span>BMY</span><span>Bristol-Myers Squibb Company</span></li><li><span>BNTC</span><span>Benitec Biopharma Inc.</span></li><li><span>BNTX</span><span>BioNTech SE</span></li><li><span>BOLT</span><span>Bolt Biotherapeutics Inc.</span></li><li><span>BPMC</span><span>Blueprint Medicines Corporation</span></li><li><span>BPTH</span><span>Bio-Path Holdings Inc.</span></li><li><span>BPTS</span><span>Biophytis SA</span></li><li><span>BSGM</span><span>BioSig Technologies Inc.</span></li><li><span>BTAI</span><span>BioXcel Therapeutics Inc.</span></li><li><span>BTX</span><span>Brooklyn ImmunoTherapeutics Inc.</span></li><li><span>BVXV</span><span>BiondVax Pharmaceuticals Ltd.</span></li><li><span>BXRX</span><span>Baudax Bio Inc.</span></li><li><span>BYSI</span><span>BeyondSpring Inc.</span></li><li><span>CABA</span><span>Cabaletta Bio Inc.</span></li><li><span>CADL</span><span>Candel Therapeutics Inc.</span></li><li><span>CALA</span><span>Calithera Biosciences Inc.</span></li><li><span>CALT</span><span>Calliditas Therapeutics AB</span></li><li><span>CANF</span><span>Can-Fite Biopharma Ltd Sponsored ADR (Israel)</span></li><li><span>CAPR</span><span>Capricor Therapeutics Inc.</span></li><li><span>CARA</span><span>Cara Therapeutics Inc.</span></li><li><span>CASI</span><span>CASI Pharmaceuticals Inc.</span></li><li><span>CATB</span><span>Catabasis Pharmaceuticals Inc.</span></li><li><span>CBAY</span><span>CymaBay Therapeutics Inc.</span></li><li><span>CBIO</span><span>Catalyst Biosciences Inc.</span></li><li><span>CBLI</span><span>Cytocom Inc (New) Com</span></li><li><span>CCCC</span><span>C4 Therapeutics Inc.</span></li><li><span>CCXI</span><span>ChemoCentryx Inc.</span></li><li><span>CDAK</span><span>Codiak BioSciences Inc.</span></li><li><span>CDMO</span><span>Avid Bioservices Inc.</span></li><li><span>CDTX</span><span>Cidara Therapeutics Inc.</span></li><li><span>CDXS</span><span>Codexis Inc.</span></li><li><span>CELC</span><span>Celcuity Inc.</span></li><li><span>CERC</span><span>Cerecor Inc.</span></li><li><span>CERE</span><span>Cerevel Therapeutics Holdings Inc.</span></li><li><span>CERS</span><span>Cerus Corporation</span></li><li><span>CFRX</span><span>ContraFect Corporation</span></li><li><span>CGEM</span><span>Cullinan Oncology Inc.</span></li><li><span>CGEN</span><span>Compugen Ltd.</span></li><li><span>CHMA</span><span>Chiasma Inc.</span></li><li><span>CHRS</span><span>Coherus BioSciences Inc.</span></li><li><span>CKPT</span><span>Checkpoint Therapeutics Inc.</span></li><li><span>CLBS</span><span>Caladrius Biosciences Inc.</span></li><li><span>CLDX</span><span>Celldex Therapeutics Inc.</span></li><li><span>CLLS</span><span>Cellectis S.A.</span></li><li><span>CLNN</span><span>Clene Inc.</span></li><li><span>CLRB</span><span>Cellectar Biosciences Inc.</span></li><li><span>CLSD</span><span>Clearside Biomedical Inc.</span></li><li><span>CLSN</span><span>Celsion Corporation</span></li><li><span>CLVS</span><span>Clovis Oncology Inc.</span></li><li><span>CMPI</span><span>Checkmate Pharmaceuticals Inc.</span></li><li><span>CMPS</span><span>COMPASS Pathways Plc</span></li><li><span>CMPX</span><span>Compass Therapeutics Inc Com</span></li><li><span>CMRX</span><span>Chimerix Inc.</span></li><li><span>CNCE</span><span>Concert Pharmaceuticals Inc.</span></li><li><span>CNSP</span><span>CNS Pharmaceuticals Inc.</span></li><li><span>CNTA</span><span>Centessa Pharmaceuticals plc</span></li><li><span>CNTB</span><span>Connect Biopharma Holdings Limited</span></li><li><span>CNTX</span><span>Context Therapeutics Inc</span></li><li><span>COCP</span><span>Cocrystal Pharma Inc.</span></li><li><span>COGT</span><span>Cogent Biosciences Inc.</span></li><li><span>COLL</span><span>Collegium Pharmaceutical Inc.</span></li><li><span>CORT</span><span>Corcept Therapeutics Incorporated</span></li><li><span>CPIX</span><span>Cumberland Pharmaceuticals Inc.</span></li><li><span>CPRX</span><span>Catalyst Pharmaceuticals Inc.</span></li><li><span>CRBP</span><span>Corbus Pharmaceuticals Holdings Inc.</span></li><li><span>CRBU</span><span>Caribou Biosciences Inc.</span></li><li><span>CRDF</span><span>Cardiff Oncology Inc.</span></li><li><span>CRIS</span><span>Curis Inc.</span></li><li><span>CRMD</span><span>CorMedix Inc.</span></li><li><span>CRNX</span><span>Crinetics Pharmaceuticals Inc.</span></li><li><span>CRSP</span><span>CRISPR Therapeutics AG</span></li><li><span>CRTX</span><span>Cortexyme Inc.</span></li><li><span>CRVS</span><span>Corvus Pharmaceuticals Inc.</span></li><li><span>CSII</span><span>Cardiovascular Systems Inc.</span></li><li><span>CTIC</span><span>CTI BioPharma Corp.</span></li><li><span>CTMX</span><span>CytomX Therapeutics Inc.</span></li><li><span>CTXR</span><span>Citius Pharmaceuticals Inc.</span></li><li><span>CUE</span><span>Cue Biopharma Inc.</span></li><li><span>CVAC</span><span>CureVac N.V.</span></li><li><span>CVM</span><span>Cel-Sci Corporation</span></li><li><span>CWBR</span><span>CohBar Inc.</span></li><li><span>CYAD</span><span>Celyad Oncology SA</span></li><li><span>CYCC</span><span>Cyclacel Pharmaceuticals Inc.</span></li><li><span>CYCN</span><span>Cyclerion Therapeutics Inc.</span></li><li><span>CYDY</span><span>Cytodyn Inc</span></li><li><span>CYT</span><span>Cyteir Therapeutics Inc.</span></li><li><span>CYTH</span><span>Cyclo Therapeutics Inc.</span></li><li><span>CYTK</span><span>Cytokinetics Incorporated</span></li><li><span>CYTO</span><span>Altamira Therapeutics Ltd.</span></li><li><span>DARE</span><span>Dare Bioscience Inc.</span></li><li><span>DAWN</span><span>Day One Biopharmaceuticals Inc.</span></li><li><span>DBTX</span><span>Decibel Therapeutics Inc.</span></li><li><span>DBVT</span><span>DBV Technologies S.A.</span></li><li><span>DCPH</span><span>Deciphera Pharmaceuticals Inc.</span></li><li><span>DCTH</span><span>Delcath Systems Inc.</span></li><li><span>DFFN</span><span>Diffusion Pharmaceuticals Inc.</span></li><li><span>DMAC</span><span>DiaMedica Therapeutics Inc.</span></li><li><span>DNLI</span><span>Denali Therapeutics Inc.</span></li><li><span>DRMA</span><span>Dermata Therapeutics Inc.</span></li><li><span>DRNA</span><span>Dicerna Pharmaceuticals Inc.</span></li><li><span>DRRX</span><span>DURECT Corporation</span></li><li><span>DSGN</span><span>Design Therapeutics Inc.</span></li><li><span>DTIL</span><span>Precision BioSciences Inc.</span></li><li><span>DVAX</span><span>Dynavax Technologies Corporation</span></li><li><span>DYAI</span><span>Dyadic International Inc.</span></li><li><span>DYN</span><span>Dyne Therapeutics Inc.</span></li><li><span>EBS</span><span>Emergent Biosolutions Inc.</span></li><li><span>EDAP</span><span>EDAP TMS S.A.</span></li><li><span>EDIT</span><span>Editas Medicine Inc.</span></li><li><span>EDSA</span><span>Edesa Biotech Inc.</span></li><li><span>EGRX</span><span>Eagle Pharmaceuticals Inc.</span></li><li><span>EIDX</span><span>Eidos Therapeutics Inc.</span></li><li><span>EIGR</span><span>Eiger BioPharmaceuticals Inc.</span></li><li><span>ELDN</span><span>Eledon Pharmaceuticals Inc.</span></li><li><span>ELEV</span><span>Elevation Oncology Inc.</span></li><li><span>ELOX</span><span>Eloxx Pharmaceuticals Inc.</span></li><li><span>ELTX</span><span></span></li><li><span>ELYM</span><span>Eliem Therapeutics Inc</span></li><li><span>ENDP</span><span>Endo International plc</span></li><li><span>ENLV</span><span>Enlivex Therapeutics Ltd.</span></li><li><span>ENOB</span><span>Enochian Biosciences Inc.</span></li><li><span>ENTA</span><span>Enanta Pharmaceuticals Inc.</span></li><li><span>ENTX</span><span>Entera Bio Ltd.</span></li><li><span>EOLS</span><span>Evolus Inc.</span></li><li><span>EPIX</span><span>ESSA Pharma Inc.</span></li><li><span>EPZM</span><span>Epizyme Inc.</span></li><li><span>EQ</span><span>Equillium Inc.</span></li><li><span>ERAS</span><span>Erasca Inc.</span></li><li><span>ERYP</span><span>Erytech Pharma S.A.</span></li><li><span>ESPR</span><span>Esperion Therapeutics Inc.</span></li><li><span>ETNB</span><span>89bio Inc.</span></li><li><span>ETON</span><span>Eton Pharmaceuticals Inc.</span></li><li><span>ETTX</span><span>Entasis Therapeutics Holdings Inc.</span></li><li><span>EVAX</span><span>Evaxion Biotech A/S</span></li><li><span>EVFM</span><span>Evofem Biosciences Inc.</span></li><li><span>EVLO</span><span>Evelo Biosciences Inc.</span></li><li><span>EVOK</span><span>Evoke Pharma Inc.</span></li><li><span>EWTX</span><span>Edgewise Therapeutics Inc.</span></li><li><span>EXAS</span><span>Exact Sciences Corporation</span></li><li><span>EXEL</span><span>Exelixis Inc.</span></li><li><span>EYEG</span><span>Eyegate Pharmaceuticals Inc.</span></li><li><span>EYEN</span><span>Eyenovia Inc.</span></li><li><span>EYPT</span><span>EyePoint Pharmaceuticals Inc.</span></li><li><span>FATE</span><span>Fate Therapeutics Inc.</span></li><li><span>FBIO</span><span>Fortress Biotech Inc.</span></li><li><span>FBRX</span><span>Forte Biosciences Inc.</span></li><li><span>FDMT</span><span>4D Molecular Therapeutics Inc.</span></li><li><span>FENC</span><span>Fennec Pharmaceuticals Inc.</span></li><li><span>FGEN</span><span>FibroGen Inc</span></li><li><span>FHTX</span><span>Foghorn Therapeutics Inc.</span></li><li><span>FIXX</span><span>Homology Medicines Inc.</span></li><li><span>FLXN</span><span>Flexion Therapeutics Inc.</span></li><li><span>FMTX</span><span>Forma Therapeutics Holdings Inc.</span></li><li><span>FNCH</span><span>Finch Therapeutics Group Inc.</span></li><li><span>FOLD</span><span>Amicus Therapeutics Inc.</span></li><li><span>FREQ</span><span>Frequency Therapeutics Inc.</span></li><li><span>FRLN</span><span>Freeline Therapeutics Holdings plc</span></li><li><span>FSTX</span><span>F-star Therapeutics Inc.</span></li><li><span>FULC</span><span>Fulcrum Therapeutics Inc.</span></li><li><span>FUSN</span><span>Fusion Pharmaceuticals Inc.</span></li><li><span>FWP</span><span>Forward Pharma A/S</span></li><li><span>GALT</span><span>Galectin Therapeutics Inc.</span></li><li><span>GANX</span><span>Gain Therapeutics Inc.</span></li><li><span>GBIO</span><span>Generation Bio Co.</span></li><li><span>GBT</span><span>Global Blood Therapeutics Inc.</span></li><li><span>GERN</span><span>Geron Corporation</span></li><li><span>GHRS</span><span>GH Research PLC</span></li><li><span>GILD</span><span>Gilead Sciences Inc.</span></li><li><span>GKOS</span><span>Glaukos Corporation</span></li><li><span>GLMD</span><span>Galmed Pharmaceuticals Ltd.</span></li><li><span>GLPG</span><span>Galapagos NV</span></li><li><span>GLSI</span><span>Greenwich LifeSciences Inc.</span></li><li><span>GLTO</span><span>Galecto Inc.</span></li><li><span>GLYC</span><span>GlycoMimetics Inc.</span></li><li><span>GMAB</span><span>Genmab A/S</span></li><li><span>GMDA</span><span>Gamida Cell Ltd.</span></li><li><span>GMTX</span><span>Gemini Therapeutics Inc.</span></li><li><span>GNCA</span><span>Genocea Biosciences Inc.</span></li><li><span>GNFT</span><span>GENFIT S.A.</span></li><li><span>GNPX</span><span>Genprex Inc.</span></li><li><span>GOSS</span><span>Gossamer Bio Inc.</span></li><li><span>GOVX</span><span>GeoVax Labs Inc.</span></li><li><span>GRAY</span><span>Graybug Vision Inc.</span></li><li><span>GRCL</span><span>Gracell Biotechnologies Inc.</span></li><li><span>GRPH</span><span>Graphite Bio Inc.</span></li><li><span>GRTS</span><span>Gritstone bio Inc.</span></li><li><span>GRTX</span><span>Galera Therapeutics Inc.</span></li><li><span>GSK</span><span>GlaxoSmithKline PLC</span></li><li><span>GTBP</span><span>GT Biopharma Inc.</span></li><li><span>GTHX</span><span>G1 Therapeutics Inc.</span></li><li><span>HALO</span><span>Halozyme Therapeutics Inc.</span></li><li><span>HARP</span><span>Harpoon Therapeutics Inc.</span></li><li><span>HCM</span><span>HUTCHMED (China) Limited</span></li><li><span>HEPA</span><span>Hepion Pharmaceuticals Inc.</span></li><li><span>HGEN</span><span>Humanigen Inc.</span></li><li><span>HOOK</span><span>HOOKIPA Pharma Inc.</span></li><li><span>HOTH</span><span>Hoth Therapeutics Inc.</span></li><li><span>HOWL</span><span>Werewolf Therapeutics Inc.</span></li><li><span>HRMY</span><span>Harmony Biosciences Holdings Inc.</span></li><li><span>HRTX</span><span>Heron Therapeutics Inc.</span></li><li><span>HSTO</span><span>Histogen Inc.</span></li><li><span>HTBX</span><span>Heat Biologics Inc.</span></li><li><span>HZNP</span><span>Horizon Therapeutics Public Limited Company</span></li><li><span>IBIO</span><span>iBio Inc.</span></li><li><span>IBRX</span><span>ImmunityBio Inc.</span></li><li><span>ICPT</span><span>Intercept Pharmaceuticals Inc.</span></li><li><span>ICVX</span><span>Icosavax Inc.</span></li><li><span>IDRA</span><span>Idera Pharmaceuticals Inc.</span></li><li><span>IDYA</span><span>IDEAYA Biosciences Inc.</span></li><li><span>IFRX</span><span>InflaRx N.V.</span></li><li><span>IGMS</span><span>IGM Biosciences Inc.</span></li><li><span>IGXT</span><span>IntelGenx Technologies Corp</span></li><li><span>IKNA</span><span>Ikena Oncology Inc.</span></li><li><span>IKT</span><span>Inhibikase Therapeutics Inc.</span></li><li><span>IMAB</span><span>I-MAB</span></li><li><span>IMCR</span><span>Immunocore Holdings plc</span></li><li><span>IMGN</span><span>ImmunoGen Inc.</span></li><li><span>IMGO</span><span>Imago BioSciences Inc.</span></li><li><span>IMMP</span><span>Immutep Limited</span></li><li><span>IMNM</span><span>Immunome Inc.</span></li><li><span>IMPL</span><span>Impel NeuroPharma Inc.</span></li><li><span>IMRA</span><span>IMARA Inc.</span></li><li><span>IMRN</span><span>Immuron Limited</span></li><li><span>IMRX</span><span>Immuneering Corporation</span></li><li><span>IMTX</span><span>Immatics N.V.</span></li><li><span>IMUX</span><span>Immunic Inc.</span></li><li><span>IMV</span><span>IMV Inc.</span></li><li><span>IMVT</span><span>Immunovant Inc.</span></li><li><span>INAB</span><span>IN8bio Inc.</span></li><li><span>INBX</span><span>Inhibrx Inc.</span></li><li><span>INCY</span><span>Incyte Corporation</span></li><li><span>INDP</span><span>Indaptus Therapeutics Inc.</span></li><li><span>INFI</span><span>Infinity Pharmaceuticals Inc.</span></li><li><span>INMB</span><span>INmune Bio Inc.</span></li><li><span>INO</span><span>Inovio Pharmaceuticals Inc.</span></li><li><span>INSM</span><span>Insmed Inc.</span></li><li><span>INVA</span><span>Innoviva Inc.</span></li><li><span>INZY</span><span>Inozyme Pharma Inc.</span></li><li><span>IONS</span><span>Ionis Pharmaceuticals Inc.</span></li><li><span>IOVA</span><span>Iovance Biotherapeutics Inc.</span></li><li><span>IPHA</span><span>Innate Pharma S.A.</span></li><li><span>IPSC</span><span>Century Therapeutics Inc.</span></li><li><span>IRWD</span><span>Ironwood Pharmaceuticals Inc.</span></li><li><span>ISEE</span><span>IVERIC bio Inc.</span></li><li><span>ITCI</span><span>Intra-Cellular Therapies Inc.</span></li><li><span>ITOS</span><span>iTeos Therapeutics Inc.</span></li><li><span>ITRM</span><span>Iterum Therapeutics plc</span></li><li><span>IVA</span><span>Inventiva S.A.</span></li><li><span>JAGX</span><span>Jaguar Health Inc.</span></li><li><span>JANX</span><span>Janux Therapeutics Inc.</span></li><li><span>JAZZ</span><span>Jazz Pharmaceuticals plc</span></li><li><span>JNCE</span><span>Jounce Therapeutics Inc.</span></li><li><span>JNJ</span><span>Johnson &amp; Johnson</span></li><li><span>KALA</span><span>Kala Pharmaceuticals Inc.</span></li><li><span>KALV</span><span>KalVista Pharmaceuticals Inc.</span></li><li><span>KDMN</span><span>Kadmon Holdings Inc.</span></li><li><span>KDNY</span><span>Chinook Therapeutics Inc.</span></li><li><span>KLDO</span><span>Kaleido Biosciences Inc.</span></li><li><span>KMDA</span><span>Kamada Ltd.</span></li><li><span>KMPH</span><span>KemPharm Inc</span></li><li><span>KNSA</span><span>Kiniksa Pharmaceuticals Ltd.</span></li><li><span>KNTE</span><span>Kinnate Biopharma Inc.</span></li><li><span>KOD</span><span>Kodiak Sciences Inc</span></li><li><span>KPTI</span><span>Karyopharm Therapeutics Inc.</span></li><li><span>KRBP</span><span>Kiromic BioPharma Inc.</span></li><li><span>KRON</span><span>Kronos Bio Inc.</span></li><li><span>KROS</span><span>Keros Therapeutics Inc.</span></li><li><span>KRTX</span><span>Karuna Therapeutics Inc.</span></li><li><span>KRYS</span><span>Krystal Biotech Inc.</span></li><li><span>KTRA</span><span>Kintara Therapeutics Inc.</span></li><li><span>KURA</span><span>Kura Oncology Inc.</span></li><li><span>KYMR</span><span>Kymera Therapeutics Inc.</span></li><li><span>KZIA</span><span>Kazia Therapeutics Limited</span></li><li><span>KZR</span><span>Kezar Life Sciences Inc.</span></li><li><span>LABP</span><span>Landos Biopharma Inc.</span></li><li><span>LBPH</span><span>Longboard Pharmaceuticals Inc.</span></li><li><span>LCTX</span><span>Lineage Cell Therapeutics, Inc.</span></li><li><span>LEGN</span><span>Legend Biotech Corporation</span></li><li><span>LGND</span><span>Ligand Pharmaceuticals Incorporated</span></li><li><span>LGVN</span><span>Longeveron Inc.</span></li><li><span>LIFE</span><span>aTyr Pharma Inc.</span></li><li><span>LIXT</span><span>Lixte Biotechnology Holdings Inc.</span></li><li><span>LJPC</span><span>La Jolla Pharmaceutical Company</span></li><li><span>LLY</span><span>Eli Lilly and Company</span></li><li><span>LMNL</span><span>Liminal BioSciences Inc.</span></li><li><span>LNTH</span><span>Lantheus Holdings Inc.</span></li><li><span>LOGC</span><span>LogicBio Therapeutics Inc.</span></li><li><span>LPCN</span><span>Lipocine Inc.</span></li><li><span>LPTX</span><span>Leap Therapeutics Inc.</span></li><li><span>LQDA</span><span>Liquidia Corporation</span></li><li><span>LRMR</span><span>Larimar Therapeutics Inc.</span></li><li><span>LTRN</span><span>Lantern Pharma Inc.</span></li><li><span>LUMO</span><span>Lumos Pharma Inc.</span></li><li><span>LVTX</span><span>LAVA Therapeutics N.V.</span></li><li><span>LXRX</span><span>Lexicon Pharmaceuticals Inc.</span></li><li><span>LYEL</span><span>Lyell Immunopharma Inc.</span></li><li><span>LYRA</span><span>Lyra Therapeutics Inc.</span></li><li><span>MACK</span><span>Merrimack Pharmaceuticals Inc.</span></li><li><span>MBIO</span><span>Mustang Bio Inc.</span></li><li><span>MBRX</span><span>Moleculin Biotech Inc.</span></li><li><span>MCRB</span><span>Seres Therapeutics Inc.</span></li><li><span>MDGL</span><span>Madrigal Pharmaceuticals Inc.</span></li><li><span>MDNA</span><span>Medicenna Therapeutics Corp.</span></li><li><span>MDWD</span><span>MediWound Ltd.</span></li><li><span>MEIP</span><span>MEI Pharma Inc.</span></li><li><span>MESO</span><span>Mesoblast Limited</span></li><li><span>MGNX</span><span>MacroGenics Inc.</span></li><li><span>MGTA</span><span>Magenta Therapeutics Inc.</span></li><li><span>MGTX</span><span>MeiraGTx Holdings plc</span></li><li><span>MIRM</span><span>Mirum Pharmaceuticals Inc.</span></li><li><span>MIST</span><span>Milestone Pharmaceuticals Inc.</span></li><li><span>MITO</span><span>Stealth BioTherapeutics Corp.</span></li><li><span>MNKD</span><span>MannKind Corporation</span></li><li><span>MNKKQ</span><span>Mallinckrodt plc</span></li><li><span>MNOV</span><span>MediciNova Inc.</span></li><li><span>MNPR</span><span>Monopar Therapeutics Inc.</span></li><li><span>MOLN</span><span>Molecular Partners AG</span></li><li><span>MOR</span><span>MorphoSys AG</span></li><li><span>MORF</span><span>Morphic Holding Inc.</span></li><li><span>MREO</span><span>Mereo BioPharma Group plc</span></li><li><span>MRK</span><span>Merck &amp; Company Inc.</span></li><li><span>MRKR</span><span>Marker Therapeutics Inc.</span></li><li><span>MRNA</span><span>Moderna Inc.</span></li><li><span>MRNS</span><span>Marinus Pharmaceuticals Inc.</span></li><li><span>MRSN</span><span>Mersana Therapeutics Inc.</span></li><li><span>MRTX</span><span>Mirati Therapeutics Inc.</span></li><li><span>MRUS</span><span>Merus N.V.</span></li><li><span>MTCR</span><span>Metacrine Inc.</span></li><li><span>MTEM</span><span>Molecular Templates Inc.</span></li><li><span>MTNB</span><span>Matinas Biopharma Holdings Inc.</span></li><li><span>MYMD</span><span>MyMD Pharmaceuticals Inc.</span></li><li><span>MYOV</span><span>Myovant Sciences Ltd.</span></li><li><span>NAVB</span><span>Navidea Biopharmaceuticals Inc.</span></li><li><span>NBIX</span><span>Neurocrine Biosciences Inc.</span></li><li><span>NBRV</span><span>Nabriva Therapeutics plc</span></li><li><span>NBTX</span><span>Nanobiotix S.A.</span></li><li><span>NBY</span><span>NovaBay Pharmaceuticals Inc.</span></li><li><span>NCNA</span><span>NuCana plc</span></li><li><span>NERV</span><span>Minerva Neurosciences Inc</span></li><li><span>NEXI</span><span>NexImmune Inc.</span></li><li><span>NGM</span><span>NGM Biopharmaceuticals Inc.</span></li><li><span>NKTR</span><span>Nektar Therapeutics</span></li><li><span>NKTX</span><span>Nkarta Inc.</span></li><li><span>NLSP</span><span>NLS Pharmaceutics Ltd.</span></li><li><span>NLTX</span><span>Neoleukin Therapeutics Inc.</span></li><li><span>NMTR</span><span>9 Meters Biopharma Inc.</span></li><li><span>NNVC</span><span>NanoViricides Inc.</span></li><li><span>NOVN</span><span>Novan Inc.</span></li><li><span>NRBO</span><span>NeuroBo Pharmaceuticals Inc.</span></li><li><span>NRIX</span><span>Nurix Therapeutics Inc.</span></li><li><span>NRXP</span><span>NRX Pharmaceuticals Inc.</span></li><li><span>NTLA</span><span>Intellia Therapeutics Inc.</span></li><li><span>NUVB</span><span>Nuvation Bio Inc. Class A</span></li><li><span>NVAX</span><span>Novavax Inc.</span></li><li><span>NVCR</span><span>NovoCure Limited</span></li><li><span>NVIV</span><span>InVivo Therapeutics Holdings Corp.</span></li><li><span>NVO</span><span>Novo Nordisk A/S</span></li><li><span>NVS</span><span>Novartis AG</span></li><li><span>NXTC</span><span>NextCure Inc.</span></li><li><span>NYMX</span><span>Nymox Pharmaceutical Corporation</span></li><li><span>OBSV</span><span>ObsEva SA</span></li><li><span>OCEA</span><span>Ocean Biomedical Inc</span></li><li><span>OCGN</span><span>Ocugen, Inc.</span></li><li><span>OCUL</span><span>Ocular Therapeutix Inc.</span></li><li><span>OCUP</span><span>Ocuphire Pharma Inc.</span></li><li><span>ODT</span><span>Odonate Therapeutics Inc.</span></li><li><span>OGEN</span><span>Oragenics Inc.</span></li><li><span>OLMA</span><span>Olema Pharmaceuticals Inc.</span></li><li><span>OMER</span><span>Omeros Corporation</span></li><li><span>OMGA</span><span>Omega Therapeutics Inc.</span></li><li><span>ONCR</span><span>Oncorus Inc.</span></li><li><span>ONCS</span><span>OncoSec Medical Incorporated</span></li><li><span>ONCT</span><span>Oncternal Therapeutics Inc.</span></li><li><span>ONCY</span><span>Oncolytics Biotech Inc.</span></li><li><span>ONTX</span><span>Onconova Therapeutics Inc.</span></li><li><span>OPK</span><span>Opko Health Inc.</span></li><li><span>OPNT</span><span>Opiant Pharmaceuticals Inc.</span></li><li><span>OPT</span><span>Opthea Limited</span></li><li><span>OPTN</span><span>OptiNose Inc.</span></li><li><span>ORIC</span><span>Oric Pharmaceuticals Inc.</span></li><li><span>ORMP</span><span>Oramed Pharmaceuticals Inc.</span></li><li><span>ORPH</span><span>Orphazyme A/S</span></li><li><span>ORTX</span><span>Orchard Therapeutics plc</span></li><li><span>OSMT</span><span>Osmotica Pharmaceuticals plc</span></li><li><span>OTIC</span><span>Otonomy Inc.</span></li><li><span>OTLK</span><span>Outlook Therapeutics Inc.</span></li><li><span>OVID</span><span>Ovid Therapeutics Inc.</span></li><li><span>OYST</span><span>Oyster Point Pharma Inc.</span></li><li><span>PALI</span><span>Palisade Bio Inc.</span></li><li><span>PASG</span><span>Passage Bio Inc.</span></li><li><span>PBLA</span><span>Panbela Therapeutics Inc.</span></li><li><span>PBYI</span><span>Puma Biotechnology Inc</span></li><li><span>PCRX</span><span>Pacira BioSciences Inc.</span></li><li><span>PCSA</span><span>Processa Pharmaceuticals Inc.</span></li><li><span>PCVX</span><span>Vaxcyte Inc.</span></li><li><span>PDSB</span><span>PDS Biotechnology Corporation</span></li><li><span>PFE</span><span>Pfizer Inc.</span></li><li><span>PGEN</span><span>Precigen Inc.</span></li><li><span>PHAS</span><span>PhaseBio Pharmaceuticals Inc.</span></li><li><span>PHAT</span><span>Phathom Pharmaceuticals Inc.</span></li><li><span>PHIO</span><span>Phio Pharmaceuticals Corp.</span></li><li><span>PHVS</span><span>Pharvaris N.V.</span></li><li><span>PIRS</span><span>Pieris Pharmaceuticals Inc.</span></li><li><span>PLRX</span><span>Pliant Therapeutics Inc.</span></li><li><span>PLUS</span><span>ePlus inc.</span></li><li><span>PLX</span><span>Protalix BioTherapeutics Inc. (DE)</span></li><li><span>PLXP</span><span>PLx Pharma Inc.</span></li><li><span>PMCB</span><span>PharmaCyte  Biotech Inc.</span></li><li><span>PMVP</span><span>PMV Pharmaceuticals Inc.</span></li><li><span>PPBT</span><span>Purple Biotech Ltd.</span></li><li><span>PRAX</span><span>Praxis Precision Medicines Inc.</span></li><li><span>PRFX</span><span>PainReform Ltd.</span></li><li><span>PRLD</span><span>Prelude Therapeutics Incorporated</span></li><li><span>PROG</span><span>Progenity Inc.</span></li><li><span>PRQR</span><span>ProQR Therapeutics N.V.</span></li><li><span>PRTA</span><span>Prothena Corporation plc</span></li><li><span>PRTK</span><span>Paratek Pharmaceuticals Inc.</span></li><li><span>PRVB</span><span>Provention Bio Inc.</span></li><li><span>PSNL</span><span>Personalis Inc.</span></li><li><span>PSTI</span><span>Pluristem Therapeutics Inc.</span></li><li><span>PSTV</span><span>PLUS THERAPEUTICS Inc.</span></li><li><span>PSTX</span><span>Poseida Therapeutics Inc.</span></li><li><span>PTCT</span><span>PTC Therapeutics Inc.</span></li><li><span>PTGX</span><span>Protagonist Therapeutics Inc.</span></li><li><span>PTIX</span><span>Protagenic Therapeutics Inc.</span></li><li><span>PTN</span><span>Palatin Technologies Inc.</span></li><li><span>PTPI</span><span>Petros Pharmaceuticals Inc.</span></li><li><span>PULM</span><span>Pulmatrix Inc.</span></li><li><span>PYPD</span><span>PolyPid Ltd.</span></li><li><span>QLGN</span><span>Qualigen Therapeutics Inc.</span></li><li><span>QURE</span><span>uniQure N.V.</span></li><li><span>RAIN</span><span>Rain Therapeutics Inc.</span></li><li><span>RANI</span><span>Rani Therapeutics Holdings Inc.</span></li><li><span>RAPT</span><span>RAPT Therapeutics Inc.</span></li><li><span>RARE</span><span>Ultragenyx Pharmaceutical Inc.</span></li><li><span>RCKT</span><span>Rocket Pharmaceuticals Inc.</span></li><li><span>RCUS</span><span>Arcus Biosciences Inc.</span></li><li><span>RDHL</span><span>Redhill Biopharma Ltd.</span></li><li><span>RDUS</span><span>Radius Health Inc.</span></li><li><span>REGN</span><span>Regeneron Pharmaceuticals Inc.</span></li><li><span>REPH</span><span>Recro Pharma Inc.</span></li><li><span>REPL</span><span>Replimune Group Inc.</span></li><li><span>RETA</span><span>Reata Pharmaceuticals Inc.</span></li><li><span>RGEN</span><span>Repligen Corporation</span></li><li><span>RGLS</span><span>Regulus Therapeutics Inc.</span></li><li><span>RGNX</span><span>REGENXBIO Inc.</span></li><li><span>RHHBY</span><span>Roche Holding AG ADR</span></li><li><span>RIGL</span><span>Rigel Pharmaceuticals Inc.</span></li><li><span>RLAY</span><span>Relay Therapeutics Inc.</span></li><li><span>RLMD</span><span>Relmada Therapeutics Inc.</span></li><li><span>RLYB</span><span>Rallybio Corporation</span></li><li><span>RMTI</span><span>Rockwell Medical Inc.</span></li><li><span>RNA</span><span>Avidity Biosciences Inc.</span></li><li><span>RNAZ</span><span>TransCode Therapeutics Inc.</span></li><li><span>RNLX</span><span>Renalytix AI plc</span></li><li><span>RNXT</span><span>RenovoRx Inc Com</span></li><li><span>RPHM</span><span>Reneo Pharmaceuticals Inc.</span></li><li><span>RPTX</span><span>Repare Therapeutics Inc.</span></li><li><span>RUBY</span><span>Rubius Therapeutics Inc.</span></li><li><span>RVMD</span><span>Revolution Medicines Inc - Ordinary Shares</span></li><li><span>RVNC</span><span>Revance Therapeutics Inc.</span></li><li><span>RVPH</span><span>Reviva Pharmaceuticals Holdings Inc.</span></li><li><span>RXDX</span><span>Prometheus Biosciences Inc.</span></li><li><span>RXRX</span><span>Recursion Pharmaceuticals Inc.</span></li><li><span>RYTM</span><span>Rhythm Pharmaceuticals Inc.</span></li><li><span>RZLT</span><span>Rezolute Inc.</span></li><li><span>SAGE</span><span>Sage Therapeutics Inc.</span></li><li><span>SANA</span><span>Sana Biotechnology Inc.</span></li><li><span>SAVA</span><span>Cassava Sciences Inc.</span></li><li><span>SBBP</span><span>Strongbridge Biopharma plc</span></li><li><span>SBTX</span><span>Silverback Therapeutics Inc.</span></li><li><span>SCPH</span><span>scPharmaceuticals Inc.</span></li><li><span>SCPS</span><span>Scopus BioPharma Inc.</span></li><li><span>SCYX</span><span>SCYNEXIS Inc.</span></li><li><span>SDGR</span><span>Schrodinger Inc.</span></li><li><span>SEEL</span><span>Seelos Therapeutics Inc.</span></li><li><span>SELB</span><span>Selecta Biosciences Inc.</span></li><li><span>SESN</span><span>Sesen Bio Inc.</span></li><li><span>SGEN</span><span>Seagen Inc.</span></li><li><span>SGMO</span><span>Sangamo Therapeutics Inc.</span></li><li><span>SGTX</span><span>Sigilon Therapeutics Inc.</span></li><li><span>SIGA</span><span>SIGA Technologies Inc.</span></li><li><span>SIOX</span><span>Sio Gene Therapies Inc.</span></li><li><span>SLDB</span><span>Solid Biosciences Inc.</span></li><li><span>SLGL</span><span>Sol-Gel Technologies Ltd.</span></li><li><span>SLNO</span><span>Soleno Therapeutics Inc.</span></li><li><span>SLRX</span><span>Salarius Pharmaceuticals Inc.</span></li><li><span>SLS</span><span>SELLAS Life Sciences Group Inc.</span></li><li><span>SMMT</span><span>Summit Therapeutics Inc.</span></li><li><span>SNDX</span><span>Syndax Pharmaceuticals Inc.</span></li><li><span>SNGX</span><span>Soligenix Inc.</span></li><li><span>SNPX</span><span>Synaptogenix Inc.</span></li><li><span>SNSE</span><span>Sensei Biotherapeutics Inc.</span></li><li><span>SNY</span><span>Sanofi</span></li><li><span>SONN</span><span>Sonnet BioTherapeutics Holdings Inc.</span></li><li><span>SPPI</span><span>Spectrum Pharmaceuticals Inc.</span></li><li><span>SPRB</span><span>Spruce Biosciences Inc.</span></li><li><span>SPRO</span><span>Spero Therapeutics Inc.</span></li><li><span>SQZ</span><span>SQZ Biotechnologies Company</span></li><li><span>SRNE</span><span>Sorrento Therapeutics Inc.</span></li><li><span>SRPT</span><span>Sarepta Therapeutics Inc.</span></li><li><span>SRRA</span><span>Sierra Oncology Inc.</span></li><li><span>SRRK</span><span>Scholar Rock Holding Corporation</span></li><li><span>STOK</span><span>Stoke Therapeutics Inc.</span></li><li><span>STRO</span><span>Sutro Biopharma Inc.</span></li><li><span>STSA</span><span>Satsuma Pharmaceuticals Inc.</span></li><li><span>STTK</span><span>Shattuck Labs Inc.</span></li><li><span>SUPN</span><span>Supernus Pharmaceuticals Inc.</span></li><li><span>SURF</span><span>Surface Oncology Inc.</span></li><li><span>SVRA</span><span>Savara Inc.</span></li><li><span>SWTX</span><span>SpringWorks Therapeutics Inc.</span></li><li><span>SYBX</span><span>Synlogic Inc.</span></li><li><span>SYN</span><span>Synthetic Biologics Inc.</span></li><li><span>SYRS</span><span>Syros Pharmaceuticals Inc.</span></li><li><span>TAK</span><span>Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)</span></li><li><span>TALS</span><span>Talaris Therapeutics Inc.</span></li><li><span>TARA</span><span>Protara Therapeutics Inc.</span></li><li><span>TARS</span><span>Tarsus Pharmaceuticals Inc.</span></li><li><span>TBIO</span><span>Translate Bio Inc.</span></li><li><span>TBPH</span><span>Theravance Biopharma Inc.</span></li><li><span>TCDA</span><span>Tricida Inc.</span></li><li><span>TCON</span><span>TRACON Pharmaceuticals Inc.</span></li><li><span>TCRR</span><span>TCR2 Therapeutics Inc.</span></li><li><span>TCRX</span><span>TScan Therapeutics Inc.</span></li><li><span>TENX</span><span>Tenax Therapeutics Inc.</span></li><li><span>TERN</span><span>Terns Pharmaceuticals Inc.</span></li><li><span>TEVA</span><span>Teva Pharmaceutical Industries Limited American Depositary Shares</span></li><li><span>TFFP</span><span>TFF Pharmaceuticals Inc - Ordinary Shares</span></li><li><span>TGTX</span><span>TG Therapeutics Inc.</span></li><li><span>TIL</span><span>Instil Bio Inc.</span></li><li><span>TKNO</span><span>Alpha Teknova Inc.</span></li><li><span>TLC</span><span>Taiwan Liposome Company Ltd.</span></li><li><span>TLSA</span><span>Tiziana Life Sciences plc</span></li><li><span>TMBR</span><span>Timber Pharmaceuticals Inc.</span></li><li><span>TNXP</span><span>Tonix Pharmaceuticals Holding Corp.</span></li><li><span>TNYA</span><span>Tenaya Therapeutics Inc.</span></li><li><span>TPST</span><span>Tempest Therapeutics Inc.</span></li><li><span>TPTX</span><span>Turning Point Therapeutics Inc.</span></li><li><span>TRIL</span><span>Trillium Therapeutics Inc.</span></li><li><span>TRVI</span><span>Trevi Therapeutics Inc.</span></li><li><span>TRVN</span><span>Trevena Inc.</span></li><li><span>TSHA</span><span>Taysha Gene Therapies Inc.</span></li><li><span>TTNP</span><span>Titan Pharmaceuticals Inc.</span></li><li><span>TVTX</span><span>Travere Therapeutics Inc.</span></li><li><span>TXMD</span><span>TherapeuticsMD Inc.</span></li><li><span>TYME</span><span>Tyme Technologies Inc.</span></li><li><span>UBX</span><span>Unity Biotechnology Inc.</span></li><li><span>UNCY</span><span>Unicycive Therapeutics Inc.</span></li><li><span>URGN</span><span>UroGen Pharma Ltd.</span></li><li><span>UTHR</span><span>United Therapeutics Corporation</span></li><li><span>VACC</span><span>Vaccitech plc</span></li><li><span>VALN</span><span>Valneva SE</span></li><li><span>VBIV</span><span>VBI Vaccines Inc.</span></li><li><span>VBLT</span><span>Vascular Biogenics Ltd.</span></li><li><span>VCEL</span><span>Vericel Corporation</span></li><li><span>VCNX</span><span>Vaccinex Inc.</span></li><li><span>VECT</span><span>VectivBio Holding AG</span></li><li><span>VERA</span><span>Vera Therapeutics Inc.</span></li><li><span>VERU</span><span>Veru Inc.</span></li><li><span>VERV</span><span>Verve Therapeutics Inc.</span></li><li><span>VINC</span><span>Vincerx Pharma Inc.</span></li><li><span>VIR</span><span>Vir Biotechnology Inc.</span></li><li><span>VIRI</span><span>Virios Therapeutics Inc.</span></li><li><span>VIRX</span><span>Viracta Therapeutics Inc.</span></li><li><span>VKTX</span><span>Viking Therapeutics Inc.</span></li><li><span>VLON</span><span>Vallon Pharmaceuticals Inc.</span></li><li><span>VNDA</span><span>Vanda Pharmaceuticals Inc.</span></li><li><span>VOR</span><span>Vor Biopharma Inc.</span></li><li><span>VRCA</span><span>Verrica Pharmaceuticals Inc.</span></li><li><span>VRDN</span><span>Viridian Therapeutics Inc.</span></li><li><span>VRNA</span><span>Verona Pharma plc</span></li><li><span>VRPX</span><span>Virpax Pharmaceuticals Inc.</span></li><li><span>VRTX</span><span>Vertex Pharmaceuticals Incorporated</span></li><li><span>VSTM</span><span>Verastem Inc.</span></li><li><span>VTGN</span><span>VistaGen Therapeutics Inc.</span></li><li><span>VTRS</span><span>Viatris Inc.</span></li><li><span>VTVT</span><span>vTv Therapeutics Inc.</span></li><li><span>VXRT</span><span>Vaxart Inc.</span></li><li><span>VYGR</span><span>Voyager Therapeutics Inc.</span></li><li><span>VYNE</span><span>VYNE Therapeutics Inc.</span></li><li><span>WINT</span><span>Windtree Therapeutics Inc.</span></li><li><span>WVE</span><span>Wave Life Sciences Ltd.</span></li><li><span>XBIO</span><span>Xenetic Biosciences Inc.</span></li><li><span>XBIT</span><span>XBiotech Inc.</span></li><li><span>XCUR</span><span>Exicure Inc.</span></li><li><span>XENE</span><span>Xenon Pharmaceuticals Inc.</span></li><li><span>XENT</span><span>Intersect ENT Inc.</span></li><li><span>XERS</span><span>Xeris Pharmaceuticals Inc.</span></li><li><span>XFOR</span><span>X4 Pharmaceuticals Inc.</span></li><li><span>XLRN</span><span>Acceleron Pharma Inc.</span></li><li><span>XNCR</span><span>Xencor Inc.</span></li><li><span>XOMA</span><span>XOMA Corporation</span></li><li><span>XTLB</span><span>XTL Biopharmaceuticals Ltd.</span></li><li><span>YMAB</span><span>Y-mAbs Therapeutics Inc.</span></li><li><span>YMTX</span><span>Yumanity Therapeutics Inc.</span></li><li><span>ZEAL</span><span>Zealand Pharma A/S</span></li><li><span>ZGNX</span><span>Zogenix Inc.</span></li><li><span>ZIOP</span><span>ZIOPHARM Oncology Inc</span></li><li><span>ZLAB</span><span>Zai Lab Limited</span></li><li><span>ZNTL</span><span>Zentalis Pharmaceuticals Inc.</span></li><li><span>ZSAN</span><span>Zosano Pharma Corporation</span></li><li><span>ZYME</span><span>Zymeworks Inc.</span></li><li><span>ZYNE</span><span>Zynerba Pharmaceuticals Inc.</span></li></ul></div>
    </form>
</div>

	</div></li><li>
								<a href="https://www.biopharmcatalyst.com/biotech-stocks" title="Biotech Stocks">Biotech Stocks</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/biotech-stocks/company-pipeline-database" title="Drug Pipeline Database &amp; Screener">Drug Pipeline Database &amp; Screener</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/company-cash-database" title="Cash Database">Cash Database</a>
							</li>
											</ul>
							</li>
		
	
										<li class="site-nav__menu-item no-bullet icon--expert-analysis">
				<a href="https://www.biopharmcatalyst.com/expert-analysis" title="Analysis">Analysis</a>
									<ul class="site-nav__sub-menu">
													<li>
								<a href="https://www.biopharmcatalyst.com/expert-analysis/biotech-analyst-ratings" title="Biotech Analyst Ratings">Biotech Analyst Ratings</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/expert-analysis/weekly-watchlist" title="Biotech Stock Weekly Watch List">Biotech Stock Weekly Watch List</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/expert-analysis/daily-updates" title="Daily Biotech Stock Updates">Daily Biotech Stock Updates</a>
							</li>
											</ul>
							</li>
		
	
										<li class="site-nav__menu-item no-bullet icon--about">
				<a href="https://www.biopharmcatalyst.com/about" title="About">About</a>
									<ul class="site-nav__sub-menu">
													<li>
								<a href="https://www.biopharmcatalyst.com/about/website-guide" title="WEBSITE GUIDE">WEBSITE GUIDE</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/about/faq" title="Frequently Asked Questions">Frequently Asked Questions</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/about/glossary" title="Glossary">Glossary</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/about/contact" title="Contact">Contact</a>
							</li>
											</ul>
							</li>
		
	
										<li class="site-nav__menu-item no-bullet icon--premium">
				<a href="javascript:;" title="Premium Tools">Premium Tools</a>
									<ul class="site-nav__sub-menu">
													<li>
								<a href="https://www.biopharmcatalyst.com/premium-tools/premium-guide" title="PREMIUM GUIDE">PREMIUM GUIDE</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/calendars/fda-calendar" title="FDA Calendar and Screener">FDA Calendar and Screener</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/company-cash-database" title="Cash Database">Cash Database</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/premium-tools/portfolio-news" title="Portfolio News">Portfolio News</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/calendars/biotech-earnings-calendar" title="Biotech Earnings Calendar">Biotech Earnings Calendar</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/calendars/ipo-calendar" title="IPO Calendar - Lock up/Quiet Period">IPO Calendar - Lock up/Quiet Period</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/expert-analysis/biotech-analyst-ratings" title="Analyst Ratings">Analyst Ratings</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/account/notifications" title="Notification Settings">Notification Settings</a>
							</li>
													<li>
								<a href="https://www.biopharmcatalyst.com/account" title="Account">Account</a>
							</li>
											</ul>
							</li>
		
	
		
					<li class="site-nav__menu-item first icon--account">
				<a href="https://www.biopharmcatalyst.com/account" class="no-trigger" title="Your user account">Account</a>
			</li>
			<li class="site-nav__menu-item first icon--sign-out">
				<a href="https://www.biopharmcatalyst.com/account/logout" class="no-trigger" title="Premium member&#39;s sign out">Sign out</a>
			</li>
			</ul>
			<div class="site-nav__mobile-title">
			<div>
				<h1>FDA Calendar</h1>



	<a href="javascript:;" title="Help" class="js-toggle-info">
		<span class="when-inactive"><svg width="18" height="18" viewBox="0 0 18 18" fill="none" xmlns="http://www.w3.org/2000/svg">
<circle cx="9" cy="9" r="9" fill="white"></circle>
<path d="M8.12402 5.84473V4.19434H9.90771V5.84473H8.12402ZM8.12402 13.5V6.75879H9.90771V13.5H8.12402Z" fill="#4078A0"></path>
</svg>
</span>
		<span class="when-active"><svg xmlns="http://www.w3.org/2000/svg" width="23" height="23" viewBox="0 0 23 23"><g stroke="#2E9124" fill="none"><circle cx="11.5" cy="11.5" r="11"></circle><path d="M15.742 7.258l-8.485 8.485m8.485 0l-8.485-8.485"></path></g></svg></span>
	</a>
			</div>
		</div>
	
	

	<label for="show-menu" class="site-nav__icon"></label>

	
	</nav>
	</header>

	<main id="main" role="main" style="padding-bottom: 0px;">
		<div class="row">
	<div class="show-for-large small-12 large-12">
		<header>
			<div class="heading-container">

				<h1>FDA Calendar</h1>



	<a href="javascript:;" title="Help" class="js-toggle-info">
		<span class="when-inactive"><svg width="18" height="18" viewBox="0 0 18 18" fill="none" xmlns="http://www.w3.org/2000/svg">
<circle cx="9" cy="9" r="9" fill="white"></circle>
<path d="M8.12402 5.84473V4.19434H9.90771V5.84473H8.12402ZM8.12402 13.5V6.75879H9.90771V13.5H8.12402Z" fill="#4078A0"></path>
</svg>
</span>
		<span class="when-active"><svg xmlns="http://www.w3.org/2000/svg" width="23" height="23" viewBox="0 0 23 23"><g stroke="#2E9124" fill="none"><circle cx="11.5" cy="11.5" r="11"></circle><path d="M15.742 7.258l-8.485 8.485m8.485 0l-8.485-8.485"></path></g></svg></span>
	</a>
			</div>
		</header>
	</div>

			</div>


<div style="display: none;" class="body-text-container"><p>Biotech Stock Catalyst and FDA Calendar for your biotech stock investing. Use our tools on your road to profit in the stock market. Biotech stocks with key binary events/catalysts - FDA Approval/PDUFA dates, Advisory Committee and Phase 2 &amp; 3 trial data releases dates are noted. Phase 1 catalysts for small-cap companies only are listed.<br></p><p>Refer to the <a href="https://biopharmcatalyst.com/about/glossary">FDA Calendar Glossary</a> for a list of terms used in the FDA Decision Calendar and the <a href="https://biopharmcatalyst.com/calendars/historical-catalyst-calendar">Biotech Historical Catalyst Calendar</a> for completed biotech stock catalysts.</p><p><strong>NOTE: LARGE CAP CATALYSTS </strong>- generally only Phase 3 catalysts noted in company presentations and/or earnings releases are shown. Only <strong>NASDAQ</strong> and <strong>NYSE</strong> stocks are covered. Stocks listed on PINK/OTC exchanges are not covered.<br></p><p>The dates shown are provided by companies. A regulatory event, for example a PDUFA date or Advisory Committee Meeting, will be issued with an exact date by the FDA. However, most clinical release dates (i.e. Phase 1/2/3) are provided in a range format by companies (e.g, mid-2021 or 4Q 2021). Exact dates for clinical data releases are only rarely issued.<br></p><p>Click on the date for the source of the catalyst. Financial data are delayed 15-25 minutes.</p><p>Subscribe <a href="https://biopharmcatalyst.com/biotech-stock-newsletter">HERE</a> to ensure you receive your weekly FREE copy of the BioPharmCatalyst Biotech Stock Watch list and/or our daily option of an end-of-day summary of the day's Biotech Stock Price Movers and Pipeline Database updates.</p><p>Premium users - Refer to <em>FDA Calendar Abbreviations </em>in the <a href="https://biopharmcatalyst.com/about/glossary">FDA Calendar Glossary</a> for terms used in the columns and other parts of the FDA Calendar. Estimated Primary Completion dates are displayed using data sourced from <a href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</a>.</p></div>







<div id="modern-screener-container"><div><form action="https://www.biopharmcatalyst.com/calendars/fda-calendar#"><div class="screener-container"><section class="top"><div class="left"><div class="lg-flex justify-between items-center"><div class="w-full"><div class="search-wrap"><span></span> <input type="search" placeholder="Search by ticker, drug or indication" class="screener-search"></div></div></div></div> <div class="middle"><span class="dt-drug-count">Showing 1245 drugs</span></div> <div class="right"><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" class="expander"><span class="screener"><img src="./20210823_FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst_files/screener.svg"></span> <span class="text">SCREENER</span> <span class="direction active"></span></a> <div class="flex items-center relative column-options-container table-heading-label-container"><div class="column-options-list "><ul><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_ticker" type="checkbox" value="ticker"></span> <label for="col_vis_ticker" class="pl-2">Ticker</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_price" type="checkbox" value="price"></span> <label for="col_vis_price" class="pl-2">Price</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_indication" type="checkbox" value="indication"></span> <label for="col_vis_indication" class="pl-2">Drug</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_stage" type="checkbox" value="stage"></span> <label for="col_vis_stage" class="pl-2">Stage</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_catalyst" type="checkbox" value="catalyst"></span> <label for="col_vis_catalyst" class="pl-2">Catalyst</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_number_of_shares" type="checkbox" value="number_of_shares"></span> <label for="col_vis_number_of_shares" class="pl-2">No Of Shares</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_market_cap" type="checkbox" value="market_cap"></span> <label for="col_vis_market_cap" class="pl-2">Market Cap</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_volume" type="checkbox" value="volume"></span> <label for="col_vis_volume" class="pl-2">Volume</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_average_daily_volume" type="checkbox" value="average_daily_volume"></span> <label for="col_vis_average_daily_volume" class="pl-2">Average Daily Volume</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_relative_volume" type="checkbox" value="relative_volume"></span> <label for="col_vis_relative_volume" class="pl-2">Relative Volume</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_price_to_book" type="checkbox" value="price_to_book"></span> <label for="col_vis_price_to_book" class="pl-2">Price to Book</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_open" type="checkbox" value="open"></span> <label for="col_vis_open" class="pl-2">Open</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_previous_close" type="checkbox" value="previous_close"></span> <label for="col_vis_previous_close" class="pl-2">Previous close</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_estimated_primary_completion_date" type="checkbox" value="estimated_primary_completion_date"></span> <label for="col_vis_estimated_primary_completion_date" class="pl-2">est epcd</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_est_live_cash" type="checkbox" value="est_live_cash"></span> <label for="col_vis_est_live_cash" class="pl-2">est. live cash</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_monthly_cash_burn" type="checkbox" value="monthly_cash_burn"></span> <label for="col_vis_monthly_cash_burn" class="pl-2">burn(mthly)</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_est_months_cash" type="checkbox" value="est_months_cash"></span> <label for="col_vis_est_months_cash" class="pl-2">cash(mths)</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_net_cash" type="checkbox" value="net_cash"></span> <label for="col_vis_net_cash" class="pl-2">net cash</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_enterpriseValue" type="checkbox" value="enterpriseValue"></span> <label for="col_vis_enterpriseValue" class="pl-2">ent value</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_insiderholdingspct" type="checkbox" value="insiderholdingspct"></span> <label for="col_vis_insiderholdingspct" class="pl-2">Insider Holding %</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_float" type="checkbox" value="float"></span> <label for="col_vis_float" class="pl-2">Float</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_updated_at" type="checkbox" value="updated_at"></span> <label for="col_vis_updated_at" class="pl-2">last updated</label></div></li></ul></div> <div class="flex w-full"><span title="Select Columns" class="left"><svg width="15" height="15" viewBox="0 0 15 15" fill="none" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M6.22024 0H8.62809V1.78221C9.35405 1.96906 10.0232 2.29735 10.6045 2.73596L11.7352 1.60521L13.4378 3.30782L12.1765 4.56914C12.4427 5.06482 12.6367 5.60506 12.7443 6.17579H14.4026V8.58364H12.6761C12.5112 9.2468 12.2285 9.86339 11.8515 10.4099L13.1768 11.7352L11.4742 13.4378L10.0919 12.0555C9.50284 12.4059 8.84431 12.6517 8.14189 12.7671V14.5H5.73404V12.6423C5.1888 12.4927 4.67669 12.2631 4.21114 11.9668L3.02398 13.154L1.32137 11.4514L2.50235 10.2704C2.09992 9.64812 1.81717 8.94119 1.68668 8.18221H0V5.77436H1.79388C1.98538 5.05504 2.31601 4.39247 2.75521 3.81722L1.60521 2.66722L3.30782 0.964617L4.59823 2.25503C5.09882 1.98998 5.64428 1.79836 6.22024 1.69453V0Z" fill="white"></path> <circle cx="7.25004" cy="7.24992" r="2.66667" fill="#1F4966" stroke="white" stroke-width="0.5"></circle></svg></span> <span class="right">Showing  </span></div></div></div></section> <section class="bottom lg-flex  items-center active"><div class="filters-container flex flex-wrap"><div class="filter-component" active="true" field="companies.ticker" method="filterTickers" type="PortfolioSelect"><label class="filter-label">Portfolios</label> <div class="control-container"><div class="control portfolio-select-container"><div tabindex="0" class="multiselect"><div class="multiselect__select"></div>  <div class="multiselect__tags"><div class="multiselect__tags-wrap" style="display: none;"></div> <!----> <div class="multiselect__spinner" style="display: none;"></div> <!----> <span class="multiselect__single">Show All</span> <!----></div> <div tabindex="-1" class="multiselect__content-wrapper" style="max-height: 300px; display: none;"><ul class="multiselect__content" style="display: inline-block;"> <!----> <li class="multiselect__element"><span data-select="" data-selected="" data-deselect="" class="multiselect__option multiselect__option--highlight multiselect__option--selected"><span>Show All</span></span> <!----></li> <li style="display: none;"><span class="multiselect__option">No elements found. Consider changing the search query.</span></li> <li style="display: none;"><span class="multiselect__option">List is empty.</span></li> </ul></div></div> <a href="https://www.biopharmcatalyst.com/account#portfolio" class="edit-button-link"><img src="./20210823_FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst_files/pencil-2.svg"></a></div> <a href="javascript:;" class="remove-filter"><svg width="16" height="16" viewBox="0 0 16 16" fill="none" xmlns="http://www.w3.org/2000/svg"><circle cx="8" cy="8" r="8" fill="#4078a0"></circle> <path d="M11 8H5" stroke="#ffffff" stroke-linecap="round"></path></svg></a></div></div> <!----> <div class="add-filter"><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#"><svg width="16" height="16" viewBox="0 0 16 16" fill="none" xmlns="http://www.w3.org/2000/svg"><circle cx="8" cy="8" r="8" fill="white"></circle> <path d="M8 5V11" stroke="#4078A0" stroke-linecap="round"></path> <path d="M11 8H5" stroke="#4078A0" stroke-linecap="round"></path></svg> <span>Add Filter</span></a></div></div> <div class="buttons-container"><button class="apply"><!----> <span>SAVE FILTERS</span></button> <button class="reset">RESET FILTERS</button></div></section></div> <div class="relative"><div class="mob-column-toggle-container"><div class="flex items-center relative column-options-container table-heading-label-container"><div class="column-options-list "><ul><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_ticker" type="checkbox" value="ticker"></span> <label for="col_vis_ticker" class="pl-2">Ticker</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_price" type="checkbox" value="price"></span> <label for="col_vis_price" class="pl-2">Price</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_indication" type="checkbox" value="indication"></span> <label for="col_vis_indication" class="pl-2">Drug</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_stage" type="checkbox" value="stage"></span> <label for="col_vis_stage" class="pl-2">Stage</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_catalyst" type="checkbox" value="catalyst"></span> <label for="col_vis_catalyst" class="pl-2">Catalyst</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_number_of_shares" type="checkbox" value="number_of_shares"></span> <label for="col_vis_number_of_shares" class="pl-2">No Of Shares</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_market_cap" type="checkbox" value="market_cap"></span> <label for="col_vis_market_cap" class="pl-2">Market Cap</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_volume" type="checkbox" value="volume"></span> <label for="col_vis_volume" class="pl-2">Volume</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_average_daily_volume" type="checkbox" value="average_daily_volume"></span> <label for="col_vis_average_daily_volume" class="pl-2">Average Daily Volume</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_relative_volume" type="checkbox" value="relative_volume"></span> <label for="col_vis_relative_volume" class="pl-2">Relative Volume</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_price_to_book" type="checkbox" value="price_to_book"></span> <label for="col_vis_price_to_book" class="pl-2">Price to Book</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_open" type="checkbox" value="open"></span> <label for="col_vis_open" class="pl-2">Open</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_previous_close" type="checkbox" value="previous_close"></span> <label for="col_vis_previous_close" class="pl-2">Previous close</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_estimated_primary_completion_date" type="checkbox" value="estimated_primary_completion_date"></span> <label for="col_vis_estimated_primary_completion_date" class="pl-2">est epcd</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_est_live_cash" type="checkbox" value="est_live_cash"></span> <label for="col_vis_est_live_cash" class="pl-2">est. live cash</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_monthly_cash_burn" type="checkbox" value="monthly_cash_burn"></span> <label for="col_vis_monthly_cash_burn" class="pl-2">burn(mthly)</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_est_months_cash" type="checkbox" value="est_months_cash"></span> <label for="col_vis_est_months_cash" class="pl-2">cash(mths)</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_net_cash" type="checkbox" value="net_cash"></span> <label for="col_vis_net_cash" class="pl-2">net cash</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_enterpriseValue" type="checkbox" value="enterpriseValue"></span> <label for="col_vis_enterpriseValue" class="pl-2">ent value</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_insiderholdingspct" type="checkbox" value="insiderholdingspct"></span> <label for="col_vis_insiderholdingspct" class="pl-2">Insider Holding %</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_float" type="checkbox" value="float"></span> <label for="col_vis_float" class="pl-2">Float</label></div></li><li><div class="flex items-center "><span class="pl-2 pr-2"><input id="col_vis_updated_at" type="checkbox" value="updated_at"></span> <label for="col_vis_updated_at" class="pl-2">last updated</label></div></li></ul></div> <div class="flex w-full"><span title="Select Columns" class="left"><svg width="32" height="32" viewBox="0 0 32 32" fill="none" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M14.3426 0H19.5387V3.84547C21.1052 4.24868 22.5493 4.95713 23.8036 5.90363L26.2437 3.46348L29.9179 7.13764L27.1959 9.85958C27.7704 10.9292 28.1889 12.095 28.4212 13.3267H32V18.5227H28.274C27.9181 19.9538 27.3081 21.2844 26.4945 22.4638L29.3545 25.3238L25.6803 28.998L22.6972 26.0148C21.4261 26.771 20.0051 27.3013 18.4894 27.5505V31.2903H13.2934V27.281C12.1169 26.9584 11.0119 26.4629 10.0074 25.8237L7.44524 28.3858L3.77108 24.7117L6.31973 22.163C5.45119 20.8201 4.84095 19.2945 4.55932 17.6566H0.919556L0.919556 12.4605H4.79058C5.20378 10.9083 5.91724 9.47847 6.86498 8.23709L4.38348 5.75559L8.05763 2.08143L10.8421 4.86588C11.9224 4.29383 13.0996 3.88028 14.3426 3.65621V0Z" fill="white"></path> <circle cx="16.5649" cy="15.6448" r="5.46507" fill="#31628A" stroke="white" stroke-width="0.5"></circle></svg></span> <span class="right">Showing 1245 drugs</span></div></div></div> <div class="fda-table-container" style="height: 522px;"><table class="fda-table pro"><thead><tr><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">Ticker</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">Price</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">Drug</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">Stage</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th class="col-catalyst"><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up white">Catalyst</span> <span class="sort-arrow arrow-up white"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">No Of Shares</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">Market Cap</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">Volume</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">Average Daily Volume</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">Price to Book</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">Open</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">Previous close</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">est epcd</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">est. live cash</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">burn(mthly)</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">cash(mths)</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">net cash</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">ent value</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">Insider Holding %</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">Float</span> <span class="sort-arrow arrow-up inactive"></span></div></th><th><div class="flex items-center justify-between table-heading-label-container"><span class="column-label arrow-up inactive">last updated</span> <span class="sort-arrow arrow-up inactive"></span></div></th></tr></thead> <tbody><tr><td><a href="https://www.biopharmcatalyst.com/company/RVNC" class="margin-bottom-1">
                RVNC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$27.34</div> <small class="number change-up">+0.37<span>&nbsp;&nbsp;</span>+1.37%</small></td><td><strong>DAXI  (RT002)</strong> <br>Moderate to severe glabellar (frown) lines
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005976/en/">
                Decision deferred by FDA
              </a> <div class="note">PDUFA date November 25, 2020. Decision has been deferred by the the FDA as it was unable to conduct a required inspection of a manufacturing facility due to travel restrictions associated with the COVID-19 pandemic. Inspection initiated June 2021. Decision expected 2021.</div></td><td>
              72m
            </td><td>
              2.0b
            </td><td>
              79.6k
            </td><td>
              432.4k
            </td><td>
              10.56
            </td><td>
              $27.17
            </td><td>
              $26.97
            </td><td>
              N/A
            </td><td>
              306.89m
            </td><td>
              -16.33m
            </td><td>
              18.79
            </td><td>
              -147.75m
            </td><td>
              1.93b
            </td><td>
              2.5
            </td><td>
              69,053,708
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VTRS" class="margin-bottom-1">
                VTRS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.88</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+2.02%</small></td><td><strong>MYL-1402O</strong> <br>Avastin (bevacizumab) biosimilar
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.biocon.com/biocon-biologics-statement-on-the-status-of-bevacizumab-fda-action-date-in-dec-2020/">
                Decision deferred by FDA
              </a> <div class="note">BsUFA date has been deferred by the the FDA as it was unable to conduct a required inspection of a manufacturing facility due to travel restrictions associated with the COVID-19 pandemic.</div></td><td>
              1b
            </td><td>
              18.0b
            </td><td>
              4.1m
            </td><td>
              6.7m
            </td><td>
              0.85
            </td><td>
              $14.63
            </td><td>
              $14.58
            </td><td>
              N/A
            </td><td>
              1.19b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -35.59b
            </td><td>
              41.61b
            </td><td>
              0.3
            </td><td>
              1,077,478,657
            </td><td>
              12/31/2020
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SLGL" class="margin-bottom-1">
                SLGL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.20</div> <small class="number change-down">-0.17<span>&nbsp;&nbsp;</span>-1.81%</small></td><td><strong>VERED (Epsolay)</strong> <br>Papulopustular rosacea
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.sol-gel.com/news-releases/news-release-details/sol-gel-technologies-provides-update-fda-review-epsolayr">
                Decision deferred by FDA
              </a> <div class="note">PDUFA date April 26, 2021. Decision has been deferred as the FDA has not been able to conduct a pre-approval inspection of the production site due to COVID-19.</div></td><td>
              23m
            </td><td>
              211.9m
            </td><td>
              7.0k
            </td><td>
              39.4k
            </td><td>
              5.41
            </td><td>
              $9.49
            </td><td>
              $9.37
            </td><td>
              N/A
            </td><td>
              38.88m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              31.72m
            </td><td>
              178.52m
            </td><td>
              0
            </td><td>
              5,349,816
            </td><td>
              04/27/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TAK" class="margin-bottom-1">
                TAK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.97</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+1.75%</small></td><td><strong>TAK-721</strong> <br>Eosinophilic esophagitis
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20201215005640/en/">
                PDUFA date has passed
              </a> <div class="note">PDUFA date has passed. Company rep notes that discussions continue with the FDA regarding the submission and any approval is subject to the outcome of those discussions.</div></td><td>
              3b
            </td><td>
              53.4b
            </td><td>
              0.8m
            </td><td>
              1.9m
            </td><td>
              1.12
            </td><td>
              $16.84
            </td><td>
              $16.68
            </td><td>
              N/A
            </td><td>
              0.78t
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -6.63t
            </td><td>
              86.30b
            </td><td>
              0
            </td><td>
              3,145,059,016
            </td><td>
              06/22/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ABBV" class="margin-bottom-1">
                ABBV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$119.82</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+0.84%</small></td><td><strong>RINVOQ (upadacitinib)</strong> <br>Active Ankylosing Spondylitis
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/abbvie-provides-update-regarding-rinvoq-upadacitinib-in-psoriatic-arthritis-and-ankylosing-spondylitis-in-the-us-301319940.html">
                PDUFA date has passed
              </a> <div class="note">PDUFA estimate June 25, 2021 will not be met - noted June 25, 2021.</div></td><td>
              2b
            </td><td>
              211.7b
            </td><td>
              2.6m
            </td><td>
              5.7m
            </td><td>
              16.85
            </td><td>
              $119.8
            </td><td>
              $118.82
            </td><td>
              N/A
            </td><td>
              11.53b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -123.84b
            </td><td>
              283.51b
            </td><td>
              0.1
            </td><td>
              1,765,652,810
            </td><td>
              06/25/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ABBV" class="margin-bottom-1">
                ABBV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$119.82</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+0.84%</small></td><td><strong>RINVOQ (Upadacitinib)</strong> <br>Psoriatic arthritis
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/abbvie-provides-update-regarding-rinvoq-upadacitinib-in-psoriatic-arthritis-and-ankylosing-spondylitis-in-the-us-301319940.html">
                PDUFA date has passed
              </a> <div class="note">PDUFA estimate June 25, 2021 will not be met - noted June 25, 2021.</div></td><td>
              2b
            </td><td>
              211.7b
            </td><td>
              2.6m
            </td><td>
              5.7m
            </td><td>
              16.85
            </td><td>
              $119.8
            </td><td>
              $118.82
            </td><td>
              N/A
            </td><td>
              11.53b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -123.84b
            </td><td>
              283.51b
            </td><td>
              0.1
            </td><td>
              1,765,652,810
            </td><td>
              06/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ABBV" class="margin-bottom-1">
                ABBV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$119.82</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+0.84%</small></td><td><strong>RINVOQ (Upadacitinib)</strong> <br>Atopic Dermatitis
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/abbvie-provides-update-regarding-rinvoq-upadacitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-the-us-301335375.html">
                PDUFA date has passed
              </a> <div class="note">PDUFA date early 3Q 2021 not met. The FDA cited its ongoing review of Pfizer's post-marketing study, ORAL Surveillance, evaluating tofacitinib in patients with rheumatoid arthritis for the delay.</div></td><td>
              2b
            </td><td>
              211.7b
            </td><td>
              2.6m
            </td><td>
              5.7m
            </td><td>
              16.85
            </td><td>
              $119.8
            </td><td>
              $118.82
            </td><td>
              N/A
            </td><td>
              11.53b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -123.84b
            </td><td>
              283.51b
            </td><td>
              0.1
            </td><td>
              1,765,652,810
            </td><td>
              07/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INCY" class="margin-bottom-1">
                INCY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$75.55</div> <small class="number change-up">+0.65<span>&nbsp;&nbsp;</span>+0.86%</small></td><td><strong>OLUMIANT (baricitinib)</strong> <br>Atopic dermatitis
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/lilly-and-incyte-provide-update-on-supplemental-new-drug-application-for-baricitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-301335605.html">
                PDUFA date not met
              </a> <div class="note">Noted FDA will not meet assigned July 2021 PDUFA date - July 16, 2021.</div></td><td>
              221m
            </td><td>
              16.7b
            </td><td>
              283.8k
            </td><td>
              1.3m
            </td><td>
              5.68
            </td><td>
              $75.18
            </td><td>
              $74.9
            </td><td>
              N/A
            </td><td>
              2.18b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              1.22b
            </td><td>
              14.50b
            </td><td>
              1.5
            </td><td>
              155,219,007
            </td><td>
              07/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LLY" class="margin-bottom-1">
                LLY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$269.63</div> <small class="number change-down">-1.28<span>&nbsp;&nbsp;</span>-0.47%</small></td><td><strong>OLUMIANT (baricitinib)</strong> <br>Atopic dermatitis
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/lilly-and-incyte-provide-update-on-supplemental-new-drug-application-for-baricitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-301335605.html">
                PDUFA date not met
              </a> <div class="note">Noted FDA will not meet assigned July 2021 PDUFA date - July 16, 2021.</div></td><td>
              1b
            </td><td>
              257.9b
            </td><td>
              0.8m
            </td><td>
              2.8m
            </td><td>
              40.00
            </td><td>
              $272.3
            </td><td>
              $270.91
            </td><td>
              N/A
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -36.81b
            </td><td>
              272.39b
            </td><td>
              0.5
            </td><td>
              792,287,037
            </td><td>
              07/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PFE" class="margin-bottom-1">
                PFE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.98</div> <small class="number change-up">+1.25<span>&nbsp;&nbsp;</span>+2.58%</small></td><td><strong>XELJANZ (tofacitinib)</strong> <br>Ankylosing spondylitis
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210721005857/en/">
                PDUFA date not met. 
              </a> <div class="note">PDUFA of 3Q 2021 will not be met, no date has been provided. </div></td><td>
              6b
            </td><td>
              280.2b
            </td><td>
              69.5m
            </td><td>
              30.1m
            </td><td>
              4.00
            </td><td>
              $50.29
            </td><td>
              $48.72
            </td><td>
              December 19, 2019
            </td><td>
              28.48b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -71.13b
            </td><td>
              289.19b
            </td><td>
              0.3
            </td><td>
              5,605,213,314
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PFE" class="margin-bottom-1">
                PFE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.98</div> <small class="number change-up">+1.25<span>&nbsp;&nbsp;</span>+2.58%</small></td><td><strong>Abrocitinib</strong> <br>Atopic Dermatitis
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210721005857/en/">
                PDUFA date not met
              </a> <div class="note">PDUFA date of 3Q 2021 will not be met, no date provided. </div></td><td>
              6b
            </td><td>
              280.2b
            </td><td>
              69.5m
            </td><td>
              30.1m
            </td><td>
              4.00
            </td><td>
              $50.29
            </td><td>
              $48.72
            </td><td>
              August 13, 2019
            </td><td>
              28.48b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -71.13b
            </td><td>
              289.19b
            </td><td>
              0.3
            </td><td>
              5,605,213,314
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AXSM" class="margin-bottom-1">
                AXSM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$24.49</div> <small class="number change-up">+2.93<span>&nbsp;&nbsp;</span>+13.61%</small></td><td><strong>Dextromethorphan-bupropion (AXS-05)</strong> <br>Major Depressive Disorder
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-provides-update-new-drug-application-axs-05">
                PDUFA date delayed
              </a> <div class="note">PDUFA date under priority review August 22, 2021. Noted August 9, 2021 that the FDA that it has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments. Noted August 22, 2021 that the FDA informed the company that its decision has been delayed. No further details provided.</div></td><td>
              38m
            </td><td>
              0.9b
            </td><td>
              9.0m
            </td><td>
              0.9m
            </td><td>
              12.89
            </td><td>
              $25.2
            </td><td>
              $21.56
            </td><td>
              N/A
            </td><td>
              125.98m
            </td><td>
              -8.46m
            </td><td>
              14.88
            </td><td>
              54.15m
            </td><td>
              0.72b
            </td><td>
              0.5
            </td><td>
              22,349,124
            </td><td>
              08/23/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CARA" class="margin-bottom-1">
                CARA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.00</div> <small class="number change-up">+0.30<span>&nbsp;&nbsp;</span>+2.19%</small></td><td><strong>KORSUVA (CR845/difelikefalin) injection</strong> <br>Chronic kidney disease (CKD) on hemodialysis (HD) with Moderate-to Severe Pruritus
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210307005039/en/">
                8/23/2021
              </a> <div class="note">PDUFA date under priority review August 23, 2021.</div></td><td>
              50m
            </td><td>
              0.7b
            </td><td>
              1.8m
            </td><td>
              0.6m
            </td><td>
              3.45
            </td><td>
              $14.11
            </td><td>
              $13.7
            </td><td>
              March 30, 2020
            </td><td>
              142.57m
            </td><td>
              -7.00m
            </td><td>
              20.36
            </td><td>
              124.59m
            </td><td>
              0.54b
            </td><td>
              3.4
            </td><td>
              49,119,725
            </td><td>
              03/08/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALRN" class="margin-bottom-1">
                ALRN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.10</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+8.33%</small></td><td><strong>ALRN-6924</strong> <br>Small Cell Lung Cancer (SCLC)
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.benzinga.com/pressreleases/21/08/g22453987/aileron-therapeutics-reports-second-quarter-2021-financial-results-and-provides-business-update">
                8/25/2021
              </a> <div class="note">Phase 1b/2 final data to be presented at ISEH Virtual Scientific Meeting, August 25-28, 2021.</div></td><td>
              91m
            </td><td>
              100.1m
            </td><td>
              0.7m
            </td><td>
              423.3k
            </td><td>
              1.78
            </td><td>
              $1.07
            </td><td>
              $1.02
            </td><td>
              June 2022
            </td><td>
              57.22m
            </td><td>
              -1.25m
            </td><td>
              45.62
            </td><td>
              52.82m
            </td><td>
              33.11m
            </td><td>
              1.4
            </td><td>
              71,295,333
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AMRX" class="margin-bottom-1">
                AMRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.24</div> <small class="number change-up">+0.39<span>&nbsp;&nbsp;</span>+8.04%</small></td><td><strong>IPX203</strong> <br>Parkinson's disease
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210823005125/en/">
                8/25/2021
              </a> <div class="note">Phase 3 top-line data to be presented August 25, 2021. </div></td><td>
              149m
            </td><td>
              0.8b
            </td><td>
              0.6m
            </td><td>
              0.8m
            </td><td>
              2.26
            </td><td>
              $4.93
            </td><td>
              $4.85
            </td><td>
              June 15, 2021
            </td><td>
              247.15m
            </td><td>
              -17.31m
            </td><td>
              14.28
            </td><td>
              -3.39b
            </td><td>
              3.36b
            </td><td>
              2.1
            </td><td>
              99,459,383
            </td><td>
              08/23/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LPCN" class="margin-bottom-1">
                LPCN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.43</div> <small class="number change-up">+0.04<span>&nbsp;&nbsp;</span>+2.88%</small></td><td><strong>LPCN 1144</strong> <br>Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-second-quarter-ended-june-30-2021-301348161.html">
                August 2021
              </a> <div class="note">Phase 2 top-line change in liver fat data met primary endpoint January 12, 2021. 36-week biopsy data are expected August 2021.</div></td><td>
              88m
            </td><td>
              126.3m
            </td><td>
              272.0k
            </td><td>
              0.9m
            </td><td>
              3.58
            </td><td>
              $1.38
            </td><td>
              $1.39
            </td><td>
              January 2021
            </td><td>
              45.22m
            </td><td>
              -0.79m
            </td><td>
              57.41
            </td><td>
              33.79m
            </td><td>
              80.04m
            </td><td>
              3.5
            </td><td>
              86,149,561
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MITO" class="margin-bottom-1">
                MITO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.15</div> <small class="number change-down">-0.02<span>&nbsp;&nbsp;</span>-1.71%</small></td><td><strong>Elamipretide</strong> <br>Barth
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/stealth-biotherapeutics-reports-second-quarter-2021-financial-results-and-recent-business-highlights-301348928.html">
                August 2021
              </a> <div class="note">Phase 2/3 trial did not meet primary endpoint December 2018. NDA filing due August 2021.</div></td><td>
              58m
            </td><td>
              66.2m
            </td><td>
              293.4k
            </td><td>
              269.5k
            </td><td>
              -2.50
            </td><td>
              $1.18
            </td><td>
              $1.17
            </td><td>
              N/A
            </td><td>
              30.77m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -27.81m
            </td><td>
              42.06m
            </td><td>
              0
            </td><td>
              57,582,815
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INMB" class="margin-bottom-1">
                INMB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$18.32</div> <small class="number change-up">+1.79<span>&nbsp;&nbsp;</span>+10.83%</small></td><td><strong>Quellor</strong> <br>Immune mediated complications from COVID-19
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.inmunebio.com/index.php/en/news-2/2021/465-muneioncnnounceseconduarter2021esultsand20210804">
                August 2021
              </a> <div class="note">Phase 2 DSMB analysis due August 2021.</div></td><td>
              18m
            </td><td>
              324.3m
            </td><td>
              196.4k
            </td><td>
              494.2k
            </td><td>
              7.51
            </td><td>
              $16.9
            </td><td>
              $16.53
            </td><td>
              February 2021
            </td><td>
              76.09m
            </td><td>
              -1.90m
            </td><td>
              39.99
            </td><td>
              58.63m
            </td><td>
              267.61m
            </td><td>
              28.1
            </td><td>
              11,663,924
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ADAP" class="margin-bottom-1">
                ADAP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.21</div> <small class="number change-up">+0.41<span>&nbsp;&nbsp;</span>+10.66%</small></td><td><strong>AFP (ADP-A2AFP)</strong> <br>Hepatocellular carcinoma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.adaptimmune.com/investors-and-media/news-events/press-releases/detail/188/adaptimmune-reports-fourth-quarter-full-year-2020">
                9/2/2021
              </a> <div class="note">Phase 1 update at International Liver Cancer Association (ILCA) conference September 2-5, 2021.</div></td><td>
              156m
            </td><td>
              0.7b
            </td><td>
              0.7m
            </td><td>
              0.7m
            </td><td>
              2.36
            </td><td>
              $3.99
            </td><td>
              $3.8
            </td><td>
              September 2023
            </td><td>
              266.49m
            </td><td>
              -10.49m
            </td><td>
              25.41
            </td><td>
              154.64m
            </td><td>
              330.41m
            </td><td>
              3.3
            </td><td>
              124,957,108
            </td><td>
              02/25/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MRK" class="margin-bottom-1">
                MRK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$78.65</div> <small class="number change-down">-0.03<span>&nbsp;&nbsp;</span>-0.04%</small></td><td><strong>KEYTRUDA (pembrolizumab)and LENVIMA (lenvatinib)</strong> <br>Endometrial carcinoma
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210506005287/en/">
                9/3/2021
              </a> <div class="note">PDUFA date under priority review September 3, 2021.</div></td><td>
              3b
            </td><td>
              199.1b
            </td><td>
              3.5m
            </td><td>
              10.3m
            </td><td>
              5.98
            </td><td>
              $79.11
            </td><td>
              $78.68
            </td><td>
              N/A
            </td><td>
              10.07b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -47.23b
            </td><td>
              217.11b
            </td><td>
              0.1
            </td><td>
              2,529,800,503
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BLU" class="margin-bottom-1">
                BLU
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.32</div> <small class="number change-up">+0.27<span>&nbsp;&nbsp;</span>+8.85%</small></td><td><strong>BLU-5937 (RELIEF)</strong> <br>Chronic cough
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210823005178/en/BELLUS-Health-to-Report-Additional-RELIEF-Data-in-an-Oral-Presentation-at-the-European-Respiratory-Society-International-Congress-2021">
                9/5/2021
              </a> <div class="note">Phase 2a trial did not meet primary endpoint (July 6 2020). Additional data to be released at ERS conference, being held September 5-8, 2021.</div></td><td>
              78m
            </td><td>
              260.1m
            </td><td>
              368.6k
            </td><td>
              419.1k
            </td><td>
              2.07
            </td><td>
              $3.05
            </td><td>
              $3.05
            </td><td>
              N/A
            </td><td>
              66.52m
            </td><td>
              -3.23m
            </td><td>
              20.61
            </td><td>
              56.75m
            </td><td>
              164.77m
            </td><td>
              0
            </td><td>
              78,337,361
            </td><td>
              08/23/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMPL" class="margin-bottom-1">
                IMPL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.66</div> <small class="number change-up">+0.86<span>&nbsp;&nbsp;</span>+6.74%</small></td><td><strong>TRUDHESA (Dihydroergotamine)</strong> <br>Migraine
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://impelnp.com/treatments/">
                9/6/2021
              </a> <div class="note">PDUFA date September 6, 2021.</div></td><td>
              20m
            </td><td>
              266.5m
            </td><td>
              218.3k
            </td><td>
              146.0k
            </td><td>
              5.20
            </td><td>
              $13.12
            </td><td>
              $12.8
            </td><td>
              N/A
            </td><td>
              71.33m
            </td><td>
              -5.34m
            </td><td>
              13.35
            </td><td>
              53.46m
            </td><td>
              197.63m
            </td><td>
              0.6
            </td><td>
              7,107,968
            </td><td>
              08/18/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FBRX" class="margin-bottom-1">
                FBRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$26.92</div> <small class="number change-down">-0.11<span>&nbsp;&nbsp;</span>-0.41%</small></td><td><strong>FB-401</strong> <br>Atopic Dermatitis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.fortebiorx.com/investor-relations/news/news-details/2021/Forte-Biosciences-Inc.-to-Review-the-Second-Quarter-2021-Results-and-Expects-to-Announce-Topline-Data-From-Phase-2-Clinical-Trial-of-FB-401-for-the-Treatment-of-Atopic-Dermatitis-on-Sept.-7/default.aspx">
                9/7/2021
              </a> <div class="note">Phase 2 top-line data due September 7, 2021.</div></td><td>
              14m
            </td><td>
              379.0m
            </td><td>
              454.7k
            </td><td>
              255.5k
            </td><td>
              7.60
            </td><td>
              $27.59
            </td><td>
              $27.03
            </td><td>
              July 2021
            </td><td>
              48.43m
            </td><td>
              -1.31m
            </td><td>
              36.90
            </td><td>
              45.45m
            </td><td>
              329.76m
            </td><td>
              17.2
            </td><td>
              10,279,073
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CRDF" class="margin-bottom-1">
                CRDF
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.01</div> <small class="number change-up">+0.52<span>&nbsp;&nbsp;</span>+9.47%</small></td><td><strong>Onvansertib, FOLFIRI and AVASTIN (bevacizumab)</strong> <br>KRAS-Mutated Colorectal Cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://cardiffoncology.investorroom.com/2021-08-05-Cardiff-Oncology-Reports-Second-Quarter-2021-Results-and-Provides-Business-Updates">
                9/8/2021
              </a> <div class="note">Phase 1b/2 updated data to be presented September 8, 2021.</div></td><td>
              40m
            </td><td>
              237.7m
            </td><td>
              379.8k
            </td><td>
              0.7m
            </td><td>
              1.71
            </td><td>
              $5.56
            </td><td>
              $5.49
            </td><td>
              May 2022
            </td><td>
              137.47m
            </td><td>
              -1.43m
            </td><td>
              95.89
            </td><td>
              132.65m
            </td><td>
              77.50m
            </td><td>
              4.9
            </td><td>
              38,902,247
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CHRS" class="margin-bottom-1">
                CHRS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$15.49</div> <small class="number change-up">+0.49<span>&nbsp;&nbsp;</span>+3.30%</small></td><td><strong>Toripalimab (CHOICE-01)</strong> <br>Non-small cell lung cancer (NSCLC)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.coherus.com/news-releases/news-release-details/coherus-and-junshi-biosciences-announce-positive-interim-results">
                9/13/2021
              </a> <div class="note">Phase 3 PFS primary endpoint reached at interim analysis. Data to be presented at World Conference on Lung Cancer September 13, 2021.</div></td><td>
              76m
            </td><td>
              1.2b
            </td><td>
              336.5k
            </td><td>
              0.7m
            </td><td>
              7.60
            </td><td>
              $15.14
            </td><td>
              $15
            </td><td>
              April 14, 2021
            </td><td>
              454.31m
            </td><td>
              -62.67k
            </td><td>
              7.25k
            </td><td>
              -129.01m
            </td><td>
              1.11b
            </td><td>
              1.4
            </td><td>
              54,173,405
            </td><td>
              08/18/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CALT" class="margin-bottom-1">
                CALT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.60</div> <small class="number change-up">+1.57<span>&nbsp;&nbsp;</span>+7.47%</small></td><td><strong>Nefecon (NefIgArd)</strong> <br>IgA nephropathy
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/fda-grants-priority-review-for-nefecon-for-patients-with-iga-nephropathy-301278761.html">
                9/15/2021
              </a> <div class="note">PDUFA date under priority review September 15, 2021.</div></td><td>
              26m
            </td><td>
              0.6b
            </td><td>
              26.5k
            </td><td>
              20.9k
            </td><td>
              4.72
            </td><td>
              $21.97
            </td><td>
              $21.03
            </td><td>
              February 2023
            </td><td>
              0.69b
            </td><td>
              -44.73m
            </td><td>
              15.39
            </td><td>
              433.62m
            </td><td>
              466.09m
            </td><td>
              0
            </td><td>
              26,170,792
            </td><td>
              04/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NYMX" class="margin-bottom-1">
                NYMX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.99</div> <small class="number change-up">+0.05<span>&nbsp;&nbsp;</span>+2.58%</small></td><td><strong>Fexapotide Triflutate (NX-1207)</strong> <br>BPH
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/05/06/2224875/10918/en/Nymox-Announces-Date-for-Fexapotide-Filing.html#:~:text=HASBROUCK%20HEIGHTS%2C%20N.J.%2C%20May%2006,or%20before%2015%20September%202021.">
                9/15/2021
              </a> <div class="note">NDA filing planned by September 15, 2021.</div></td><td>
              84m
            </td><td>
              166.6m
            </td><td>
              100.2k
            </td><td>
              394.7k
            </td><td>
              33.17
            </td><td>
              $1.88
            </td><td>
              $1.94
            </td><td>
              N/A
            </td><td>
              5.06m
            </td><td>
              -0.63m
            </td><td>
              7.98
            </td><td>
              3.10m
            </td><td>
              156.55m
            </td><td>
              34.4
            </td><td>
              48,376,644
            </td><td>
              06/17/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GRTS" class="margin-bottom-1">
                GRTS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.47</div> <small class="number change-up">+0.94<span>&nbsp;&nbsp;</span>+12.48%</small></td><td><strong>GRANITE-001 (GO-004)</strong> <br>Colorectal Cancer / Gastric Cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-reports-first-quarter-2021-financial-results-and">
                9/16/2021
              </a> <div class="note">Phase 1 and 2 data to be presented at ESMO September 16-21, 2021.</div></td><td>
              49m
            </td><td>
              418.8m
            </td><td>
              0.6m
            </td><td>
              0.7m
            </td><td>
              2.34
            </td><td>
              $7.62
            </td><td>
              $7.53
            </td><td>
              July 2022
            </td><td>
              157.57m
            </td><td>
              -7.56m
            </td><td>
              20.84
            </td><td>
              112.17m
            </td><td>
              223.51m
            </td><td>
              1.5
            </td><td>
              40,257,957
            </td><td>
              08/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MGNX" class="margin-bottom-1">
                MGNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.98</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+4.55%</small></td><td><strong>MARGENZA (margetuximab) and MGA012 (MAHOGANY)</strong> <br>Gastric cancer
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-5">
                9/16/2021
              </a> <div class="note">Phase 2/3 safety and efficacy data due at ESMO September 16-21, 2021.</div></td><td>
              61m
            </td><td>
              1.4b
            </td><td>
              297.3k
            </td><td>
              0.6m
            </td><td>
              4.40
            </td><td>
              $22.34
            </td><td>
              $21.98
            </td><td>
              May 2024
            </td><td>
              269.90m
            </td><td>
              -15.23m
            </td><td>
              17.72
            </td><td>
              163.04m
            </td><td>
              1.07b
            </td><td>
              2.4
            </td><td>
              59,522,546
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CHRS" class="margin-bottom-1">
                CHRS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$15.49</div> <small class="number change-up">+0.49<span>&nbsp;&nbsp;</span>+3.30%</small></td><td><strong>Toripalimab (JUPITER-06)</strong> <br>Esophageal Squamous Cell Carcinoma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.coherus.com/news-releases/news-release-details/coherus-biosciences-reports-second-quarter-2021-financial">
                9/16/2021
              </a> <div class="note">Phase 3 trial met primary endpoints of Progression Free Survival and Overall Survival - April 23, 2021. Data to be presented at ESMO September 16-21, 2021.</div></td><td>
              76m
            </td><td>
              1.2b
            </td><td>
              336.5k
            </td><td>
              0.7m
            </td><td>
              7.60
            </td><td>
              $15.14
            </td><td>
              $15
            </td><td>
              January 31, 2021
            </td><td>
              454.31m
            </td><td>
              -62.67k
            </td><td>
              7.25k
            </td><td>
              -129.01m
            </td><td>
              1.11b
            </td><td>
              1.4
            </td><td>
              54,173,405
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DCPH" class="margin-bottom-1">
                DCPH
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.11</div> <small class="number change-up">+2.48<span>&nbsp;&nbsp;</span>+9.31%</small></td><td><strong>Rebastinib and paclitaxel</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210803005981/en/">
                9/16/2021
              </a> <div class="note">Phase 1b/2 updated data in the endometrial cancer cohort due at ASCO June 4-8, 2021 noted Progression Free Survival of 6.2 months. Platinum-resistant ovarian cancer cohort data due at ESMO September 16-21, 2021.</div></td><td>
              58m
            </td><td>
              1.7b
            </td><td>
              463.7k
            </td><td>
              347.0k
            </td><td>
              3.78
            </td><td>
              $26.98
            </td><td>
              $26.63
            </td><td>
              October 1, 2022
            </td><td>
              364.17m
            </td><td>
              -17.32m
            </td><td>
              21.02
            </td><td>
              270.26m
            </td><td>
              1.18b
            </td><td>
              0.3
            </td><td>
              41,090,493
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AYLA" class="margin-bottom-1">
                AYLA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.11</div> <small class="number change-down">-0.35<span>&nbsp;&nbsp;</span>-2.81%</small></td><td><strong>AL101 (ACCURACY)</strong> <br>Adenoid cystic carcinoma
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ayalapharma.com/news-releases/news-release-details/ayala-pharmaceuticals-reports-second-quarter-2021-financial">
                9/16/2021
              </a> <div class="note">Phase 2 update at ESMO September 16-21, 2021.</div></td><td>
              13m
            </td><td>
              160.4m
            </td><td>
              25.0k
            </td><td>
              35.4k
            </td><td>
              3.75
            </td><td>
              $11.74
            </td><td>
              $12.46
            </td><td>
              October 2021
            </td><td>
              37.48m
            </td><td>
              -3.85m
            </td><td>
              9.74
            </td><td>
              31.77m
            </td><td>
              121.10m
            </td><td>
              1.3
            </td><td>
              4,598,420
            </td><td>
              08/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FSTX" class="margin-bottom-1">
                FSTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.35</div> <small class="number change-up">+0.41<span>&nbsp;&nbsp;</span>+6.90%</small></td><td><strong>FS120</strong> <br>Advanced Cancer
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.f-star.com/news-releases/news-release-details/f-star-therapeutics-reports-second-quarter-2021-financial">
                9/16/2021
              </a> <div class="note">Phase 1 trial in progress update at ESMO September 16-21, 2021</div></td><td>
              21m
            </td><td>
              130.9m
            </td><td>
              90.9k
            </td><td>
              158.7k
            </td><td>
              1.32
            </td><td>
              $6.08
            </td><td>
              $5.94
            </td><td>
              November 2023
            </td><td>
              88.28m
            </td><td>
              -2.98m
            </td><td>
              29.57
            </td><td>
              62.29m
            </td><td>
              54.41m
            </td><td>
              3.2
            </td><td>
              20,549,167
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SBTX" class="margin-bottom-1">
                SBTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$27.58</div> <small class="number change-down">-0.13<span>&nbsp;&nbsp;</span>-0.47%</small></td><td><strong>SBT6050</strong> <br>HER2 Positive Solid Tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210812005212/en/">
                9/16/2021
              </a> <div class="note">Phase 1 presentation at ESMO September 16-21, 2021.</div></td><td>
              35m
            </td><td>
              1.0b
            </td><td>
              242.7k
            </td><td>
              122.5k
            </td><td>
              2.76
            </td><td>
              $28.5
            </td><td>
              $27.71
            </td><td>
              August 2023
            </td><td>
              351.21m
            </td><td>
              -4.71m
            </td><td>
              74.54
            </td><td>
              333.88m
            </td><td>
              0.61b
            </td><td>
              0.8
            </td><td>
              17,656,237
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EPZM" class="margin-bottom-1">
                EPZM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.09</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+4.73%</small></td><td><strong>TAZVERIK (Tazemetostat) and XTANDI (Enzalutamide) - EZH-1101</strong> <br>Prostate Cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005168/en/">
                9/16/2021
              </a> <div class="note">Phase 2 part of trial has been initiated. Phase 1b update due at ESMO September 16-21, 2021.</div></td><td>
              102m
            </td><td>
              0.5b
            </td><td>
              422.7k
            </td><td>
              1.2m
            </td><td>
              16.42
            </td><td>
              $4.91
            </td><td>
              $4.86
            </td><td>
              March 1, 2022
            </td><td>
              235.00m
            </td><td>
              -18.89m
            </td><td>
              12.44
            </td><td>
              -49.92m
            </td><td>
              0.52b
            </td><td>
              1.1
            </td><td>
              64,859,831
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BGNE" class="margin-bottom-1">
                BGNE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$270.83</div> <small class="number change-up">+21.23<span>&nbsp;&nbsp;</span>+8.51%</small></td><td><strong>DKN-01 and Tislelizumab ( DisTinGuish)</strong> <br>Gastric / Gastroesophageal Junction Cancer
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/leap-therapeutics-to-present-at-the-esmo-2021-virtual-congress-301340715.html">
                9/16/2021
              </a> <div class="note">Phase 2a initial data to be presented at ESMO September 16, 2021.</div></td><td>
              93m
            </td><td>
              25.2b
            </td><td>
              273.7k
            </td><td>
              315.1k
            </td><td>
              7.00
            </td><td>
              $256
            </td><td>
              $249.6
            </td><td>
              December 2021
            </td><td>
              4.13b
            </td><td>
              -140.09m
            </td><td>
              29.48
            </td><td>
              2.21b
            </td><td>
              21.09b
            </td><td>
              0.3
            </td><td>
              89,530,472
            </td><td>
              07/26/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LPTX" class="margin-bottom-1">
                LPTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.85</div> <small class="number change-up">+0.17<span>&nbsp;&nbsp;</span>+10.12%</small></td><td><strong>DKN-01 and Tislelizumab ( DisTinGuish)</strong> <br>Gastric / Gastroesophageal Junction Cancer
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/leap-therapeutics-to-present-at-the-esmo-2021-virtual-congress-301340715.html">
                9/16/2021
              </a> <div class="note">Phase 2a initial data to be presented at ESMO September 16, 2021.</div></td><td>
              60m
            </td><td>
              110.4m
            </td><td>
              1.3m
            </td><td>
              387.9k
            </td><td>
              3.70
            </td><td>
              $1.7
            </td><td>
              $1.68
            </td><td>
              December 2021
            </td><td>
              31.08m
            </td><td>
              -2.58m
            </td><td>
              12.03
            </td><td>
              23.03m
            </td><td>
              64.87m
            </td><td>
              0
            </td><td>
              34,644,794
            </td><td>
              07/26/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ADAP" class="margin-bottom-1">
                ADAP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.21</div> <small class="number change-up">+0.41<span>&nbsp;&nbsp;</span>+10.66%</small></td><td><strong>ADP-A2M4CD8 (SURPASS)</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.adaptimmune.com/investors-and-media/news-events/press-releases/detail/188/adaptimmune-reports-fourth-quarter-full-year-2020">
                9/16/2021
              </a> <div class="note">Phase 1 update due at ESMO September 16-21, 2021.</div></td><td>
              156m
            </td><td>
              0.7b
            </td><td>
              0.7m
            </td><td>
              0.7m
            </td><td>
              2.36
            </td><td>
              $3.99
            </td><td>
              $3.8
            </td><td>
              April 30, 2022
            </td><td>
              266.49m
            </td><td>
              -10.49m
            </td><td>
              25.41
            </td><td>
              154.64m
            </td><td>
              330.41m
            </td><td>
              3.3
            </td><td>
              124,957,108
            </td><td>
              08/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MGNX" class="margin-bottom-1">
                MGNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.98</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+4.55%</small></td><td><strong>MGC018</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-5">
                9/16/2021
              </a> <div class="note">Phase 1 trial data due at ESMO Sept 16-21 2021. </div></td><td>
              61m
            </td><td>
              1.4b
            </td><td>
              297.3k
            </td><td>
              0.6m
            </td><td>
              4.40
            </td><td>
              $22.34
            </td><td>
              $21.98
            </td><td>
              March 2022
            </td><td>
              269.90m
            </td><td>
              -15.23m
            </td><td>
              17.72
            </td><td>
              163.04m
            </td><td>
              1.07b
            </td><td>
              2.4
            </td><td>
              59,522,546
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DCPH" class="margin-bottom-1">
                DCPH
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.11</div> <small class="number change-up">+2.48<span>&nbsp;&nbsp;</span>+9.31%</small></td><td><strong>Vimseltinib (DCC-3014)</strong> <br>Tenosynovial Giant Cell tumor
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210803005981/en/">
                9/16/2021
              </a> <div class="note">Phase 1 updated data due at ESMO September 16-21, 2021.</div></td><td>
              58m
            </td><td>
              1.7b
            </td><td>
              463.7k
            </td><td>
              347.0k
            </td><td>
              3.78
            </td><td>
              $26.98
            </td><td>
              $26.63
            </td><td>
              July 2022
            </td><td>
              364.17m
            </td><td>
              -17.32m
            </td><td>
              21.02
            </td><td>
              270.26m
            </td><td>
              1.18b
            </td><td>
              0.3
            </td><td>
              41,090,493
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TCRR" class="margin-bottom-1">
                TCRR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.26</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+6.55%</small></td><td><strong>Gavo-cel (TC-210)</strong> <br>Mesothelin-positive solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-reports-second-quarter-2021-financial-results">
                9/16/2021
              </a> <div class="note">Phase 1 new data to be presented at ESMO September 16-21, 2021.</div></td><td>
              38m
            </td><td>
              0.6b
            </td><td>
              168.5k
            </td><td>
              343.7k
            </td><td>
              1.89
            </td><td>
              $15.43
            </td><td>
              $15.26
            </td><td>
              December 2021
            </td><td>
              305.92m
            </td><td>
              -6.35m
            </td><td>
              48.19
            </td><td>
              266.67m
            </td><td>
              292.96m
            </td><td>
              0.3
            </td><td>
              30,268,156
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ATNX" class="margin-bottom-1">
                ATNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.50</div> <small class="number change-up">+0.21<span>&nbsp;&nbsp;</span>+6.38%</small></td><td><strong>Oral paclitaxel and KEYTRUDA (pembrolizumab)</strong> <br>Solid Tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.athenex.com/news-releases/news-release-details/athenex-provides-second-quarter-2021-corporate-and-financial">
                9/16/2021
              </a> <div class="note">Phase 1 data to be presented September 16-21, 2021.</div></td><td>
              109m
            </td><td>
              382.6m
            </td><td>
              0.9m
            </td><td>
              1.3m
            </td><td>
              2.07
            </td><td>
              $3.3
            </td><td>
              $3.29
            </td><td>
              March 30, 2023
            </td><td>
              106.70m
            </td><td>
              -13.07m
            </td><td>
              8.16
            </td><td>
              -132.38m
            </td><td>
              387.83m
            </td><td>
              6.1
            </td><td>
              77,823,836
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NGM" class="margin-bottom-1">
                NGM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.63</div> <small class="number change-up">+0.94<span>&nbsp;&nbsp;</span>+4.33%</small></td><td><strong>NGM120, GEMZAR (gemcitabine) and ABRAXANE (nab-paclitaxel)</strong> <br>Pancreatic Cancer
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ngmbio.com/news-releases/news-release-details/ngm-bio-provides-business-highlights-and-reports-second-0">
                9/16/2021
              </a> <div class="note">Phase 1b data from dose-finding portion of trial due at ESMO September 16-21, 2021.</div></td><td>
              77m
            </td><td>
              1.8b
            </td><td>
              169.8k
            </td><td>
              391.8k
            </td><td>
              4.70
            </td><td>
              $21.78
            </td><td>
              $21.69
            </td><td>
              January 2023
            </td><td>
              376.56m
            </td><td>
              -7.77m
            </td><td>
              48.46
            </td><td>
              326.63m
            </td><td>
              1.29b
            </td><td>
              1.3
            </td><td>
              31,576,701
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GTBP" class="margin-bottom-1">
                GTBP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.30</div> <small class="number change-down">-0.27<span>&nbsp;&nbsp;</span>-3.62%</small></td><td><strong>GTB-3550</strong> <br>Acute myeloid leukemia / myelodysplastic syndromes
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/gt-biopharma-provides-second-quarter-2021-business-update-301354858.html">
                9/16/2021
              </a> <div class="note">Phase 1/2 interim data released March 29, 2021. Presentation at ESMO September 16-21, 2021.</div></td><td>
              21m
            </td><td>
              154.1m
            </td><td>
              277.9k
            </td><td>
              325.9k
            </td><td>
              6.40
            </td><td>
              $7.6
            </td><td>
              $7.57
            </td><td>
              February 1, 2024
            </td><td>
              37.62m
            </td><td>
              -1.23m
            </td><td>
              30.63
            </td><td>
              33.99m
            </td><td>
              183.97m
            </td><td>
              4.3
            </td><td>
              14,197,981
            </td><td>
              08/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ZYME" class="margin-bottom-1">
                ZYME
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$32.69</div> <small class="number change-up">+1.27<span>&nbsp;&nbsp;</span>+4.04%</small></td><td><strong>Zanidatamab (ZW25)</strong> <br>HER2-positive Gastroesophageal Adenocarcinoma
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210804006023/en/">
                9/16/2021
              </a> <div class="note">Phase 2 data to be presented at ESMO September 16, 2021.</div></td><td>
              39m
            </td><td>
              1.5b
            </td><td>
              309.3k
            </td><td>
              413.9k
            </td><td>
              4.72
            </td><td>
              $32.03
            </td><td>
              $31.42
            </td><td>
              N/A
            </td><td>
              329.60m
            </td><td>
              -16.78m
            </td><td>
              19.64
            </td><td>
              179.12m
            </td><td>
              1.13b
            </td><td>
              1
            </td><td>
              37,499,663
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SYRS" class="margin-bottom-1">
                SYRS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.71</div> <small class="number change-up">+0.48<span>&nbsp;&nbsp;</span>+11.35%</small></td><td><strong>SY-5609</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005216/en/">
                9/16/2021
              </a> <div class="note">Phase 1 dose escalation data to be presented at ESMO September 16-21, 2021.</div></td><td>
              62m
            </td><td>
              291.7m
            </td><td>
              363.2k
            </td><td>
              0.8m
            </td><td>
              2.24
            </td><td>
              $4.3
            </td><td>
              $4.23
            </td><td>
              N/A
            </td><td>
              166.16m
            </td><td>
              -8.82m
            </td><td>
              18.84
            </td><td>
              62.40m
            </td><td>
              145.66m
            </td><td>
              2.3
            </td><td>
              41,620,615
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BIIB" class="margin-bottom-1">
                BIIB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$346.91</div> <small class="number change-up">+5.17<span>&nbsp;&nbsp;</span>+1.51%</small></td><td><strong>SB11</strong> <br>Biosimilar (ranibizumab)
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20201118005595/en/">
                9/17/2021
              </a> <div class="note">BLA filing acceptance announced November 18, 2020. Estimated PDUFA September 17, 2021 based on 10-mth timeline.</div></td><td>
              149m
            </td><td>
              51.7b
            </td><td>
              466.4k
            </td><td>
              1.5m
            </td><td>
              4.81
            </td><td>
              $342.33
            </td><td>
              $341.74
            </td><td>
              N/A
            </td><td>
              3.79b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -9.47b
            </td><td>
              55.51b
            </td><td>
              1.4
            </td><td>
              132,287,800
            </td><td>
              07/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LIFE" class="margin-bottom-1">
                LIFE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.83</div> <small class="number change-up">+0.24<span>&nbsp;&nbsp;</span>+5.23%</small></td><td><strong>ATYR1923</strong> <br>Pulmonary sarcoidosis
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-second-quarter-2021-results-and-provides">
                Mid-September 2021
              </a> <div class="note">Phase 1/2 data due mid-September 2021.</div></td><td>
              17m
            </td><td>
              81.7m
            </td><td>
              99.1k
            </td><td>
              194.4k
            </td><td>
              2.00
            </td><td>
              $4.65
            </td><td>
              $4.59
            </td><td>
              June 29, 2021
            </td><td>
              39.45m
            </td><td>
              -2.56m
            </td><td>
              15.38
            </td><td>
              31.26m
            </td><td>
              35.43m
            </td><td>
              5.1
            </td><td>
              14,670,697
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VSTM" class="margin-bottom-1">
                VSTM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.67</div> <small class="number change-up">+0.12<span>&nbsp;&nbsp;</span>+4.49%</small></td><td><strong>VS-6766 and Defactinib - FRAME</strong> <br>KRAS mutant advanced solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210802005716/en/">
                9/19/2021
              </a> <div class="note">Phase 1/2 updated data due at ESMO September 19, 2021.</div></td><td>
              181m
            </td><td>
              483.5m
            </td><td>
              0.9m
            </td><td>
              2.0m
            </td><td>
              5.46
            </td><td>
              $2.58
            </td><td>
              $2.56
            </td><td>
              July 12, 2021
            </td><td>
              100.08m
            </td><td>
              -4.47m
            </td><td>
              22.37
            </td><td>
              64.40m
            </td><td>
              378.16m
            </td><td>
              2.3
            </td><td>
              179,887,236
            </td><td>
              08/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AGEN" class="margin-bottom-1">
                AGEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.15</div> <small class="number change-up">+0.10<span>&nbsp;&nbsp;</span>+1.65%</small></td><td><strong>Balstilimab (anti-PD-1) and Zalifrelimab - AGEN1884 (anti-CTLA-4)</strong> <br>Cervical cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.agenusbio.com/news-releases/news-release-details/agenus-corporate-update-and-second-quarter-2021-financial-report">
                9/19/2021
              </a> <div class="note">Phase 2 data presented at ESMO September 18, 2020. Balstilimab (PD-1) monotherapy response rates of 14% in all treated patients and 19% in PD-L1 positive patients. Balstilimab (PD-1) + zalifrelimab (CTLA-4) combination trial response rates of 22% in all patients and 27% in PD-L1 positive patients. Data to be be presented at ESMO September 19, 2021.
</div></td><td>
              233m
            </td><td>
              1.4b
            </td><td>
              2.3m
            </td><td>
              3.1m
            </td><td>
              -5.80
            </td><td>
              $6.06
            </td><td>
              $6.05
            </td><td>
              May 4, 2022
            </td><td>
              40.21m
            </td><td>
              -18.52m
            </td><td>
              2.17
            </td><td>
              -407.84m
            </td><td>
              1.39b
            </td><td>
              3.3
            </td><td>
              231,178,523
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BGNE" class="margin-bottom-1">
                BGNE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$270.83</div> <small class="number change-up">+21.23<span>&nbsp;&nbsp;</span>+8.51%</small></td><td><strong>BRUKINSA (zanubrutinib)</strong> <br>Marginal Zone Lymphoma
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210519005166/en/">
                9/19/2021
              </a> <div class="note">PDUFA date under priority review September 19, 2021.</div></td><td>
              93m
            </td><td>
              25.2b
            </td><td>
              273.7k
            </td><td>
              315.1k
            </td><td>
              7.00
            </td><td>
              $256
            </td><td>
              $249.6
            </td><td>
              January 18, 2021
            </td><td>
              4.13b
            </td><td>
              -140.09m
            </td><td>
              29.48
            </td><td>
              2.21b
            </td><td>
              21.09b
            </td><td>
              0.3
            </td><td>
              89,530,472
            </td><td>
              05/19/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INCY" class="margin-bottom-1">
                INCY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$75.55</div> <small class="number change-up">+0.65<span>&nbsp;&nbsp;</span>+0.86%</small></td><td><strong>JAKAFI (Ruxolitinib)</strong> <br>Atopic dermatitis
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210611005030/en/">
                9/21/2021
              </a> <div class="note">PDUFA date under priority review extended by three months to September 21, 2021.</div></td><td>
              221m
            </td><td>
              16.7b
            </td><td>
              283.8k
            </td><td>
              1.3m
            </td><td>
              5.68
            </td><td>
              $75.18
            </td><td>
              $74.9
            </td><td>
              December 23, 2019
            </td><td>
              2.18b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              1.22b
            </td><td>
              14.50b
            </td><td>
              1.5
            </td><td>
              155,219,007
            </td><td>
              06/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ONTX" class="margin-bottom-1">
                ONTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.81</div> <small class="number change-up">+0.18<span>&nbsp;&nbsp;</span>+3.89%</small></td><td><strong>Rigosertib and OPDIVO (Nivolumab)</strong> <br>KRAS+ Non-Small Cell Lung Cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.onconova.com/news-releases/news-release-details/onconova-therapeutics-provides-update-phase-12a-trial-rigosertib">
                9/21/2021
              </a> <div class="note">Phase 1/2a data to be presented at the RAS Targeted Drug Development Summit, September 21-23, 2021.</div></td><td>
              16m
            </td><td>
              75.9m
            </td><td>
              167.9k
            </td><td>
              386.4k
            </td><td>
              2.05
            </td><td>
              $4.59
            </td><td>
              $4.63
            </td><td>
              January 2022
            </td><td>
              41.12m
            </td><td>
              -1.44m
            </td><td>
              28.65
            </td><td>
              29.74m
            </td><td>
              63.57m
            </td><td>
              8.4
            </td><td>
              15,709,003
            </td><td>
              06/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INCY" class="margin-bottom-1">
                INCY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$75.55</div> <small class="number change-up">+0.65<span>&nbsp;&nbsp;</span>+0.86%</small></td><td><strong>JAKAFI (Ruxolitinib)</strong> <br>Steroid-refractory chronic GVHD (Graft versus host disease)
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210608005435/en/">
                9/22/2021
              </a> <div class="note">PDUFA date under priority review extended by three months to September 22, 2021.</div></td><td>
              221m
            </td><td>
              16.7b
            </td><td>
              283.8k
            </td><td>
              1.3m
            </td><td>
              5.68
            </td><td>
              $75.18
            </td><td>
              $74.9
            </td><td>
              May 8, 2020
            </td><td>
              2.18b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              1.22b
            </td><td>
              14.50b
            </td><td>
              1.5
            </td><td>
              155,219,007
            </td><td>
              06/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VRCA" class="margin-bottom-1">
                VRCA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$10.70</div> <small class="number change-up">+0.85<span>&nbsp;&nbsp;</span>+8.63%</small></td><td><strong>VP-102</strong> <br>Molluscum contagiosum
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/05/28/2238179/0/en/Verrica-Pharmaceuticals-Announces-Extension-of-FDA-Review-Period-of-its-NDA-for-VP-102-for-the-Treatment-of-Molluscum-Contagiosum.html">
                9/23/2021
              </a> <div class="note">CRL announced July 14, 2020. NDA resubmitted. Initial PDUFA date extended by three months to September 23, 2021.</div></td><td>
              28m
            </td><td>
              294.4m
            </td><td>
              32.9k
            </td><td>
              59.7k
            </td><td>
              5.63
            </td><td>
              $10.08
            </td><td>
              $9.85
            </td><td>
              N/A
            </td><td>
              91.63m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              44.75m
            </td><td>
              223.73m
            </td><td>
              40.8
            </td><td>
              13,027,725
            </td><td>
              05/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ASND" class="margin-bottom-1">
                ASND
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$122.38</div> <small class="number change-up">+1.93<span>&nbsp;&nbsp;</span>+1.60%</small></td><td><strong>TransCon hGH (Lonapegsomatropin)</strong> <br>Growth hormone deficiency in children
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/06/11/2246137/0/en/Ascendis-Pharma-A-S-Announces-Extension-of-U-S-Food-and-Drug-Administration-Review-Period-for-TransCon-hGH-Lonapegsomatropin-for-Pediatric-Growth-Hormone-Deficiency.html">
                9/25/2021
              </a> <div class="note">PDUFA date extended by three months to September 25, 2021.</div></td><td>
              54m
            </td><td>
              6.6b
            </td><td>
              128.8k
            </td><td>
              187.4k
            </td><td>
              7.01
            </td><td>
              $120.71
            </td><td>
              $120.45
            </td><td>
              N/A
            </td><td>
              0.53b
            </td><td>
              -27.21m
            </td><td>
              19.60
            </td><td>
              370.71m
            </td><td>
              5.82b
            </td><td>
              0
            </td><td>
              53,829,379
            </td><td>
              06/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EDIT" class="margin-bottom-1">
                EDIT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$66.49</div> <small class="number change-up">+6.11<span>&nbsp;&nbsp;</span>+10.12%</small></td><td><strong>AGN-151587 (EDIT-101) - BRILLIANCE</strong> <br>Leber Congenital Amaurosis type 10 (LCA10).
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-enrollment-first-pediatric-cohort">
                9/27/2021
              </a> <div class="note">Phase 1/2 initial data due to be presented at the International Symposium on Retinal Degeneration planned for September 27 – October 2, 2021.</div></td><td>
              68m
            </td><td>
              4.5b
            </td><td>
              1.9m
            </td><td>
              2.1m
            </td><td>
              7.40
            </td><td>
              $65.04
            </td><td>
              $60.38
            </td><td>
              March 22, 2024
            </td><td>
              0.59b
            </td><td>
              -12.99m
            </td><td>
              45.22
            </td><td>
              444.66m
            </td><td>
              3.54b
            </td><td>
              3.1
            </td><td>
              58,072,559
            </td><td>
              06/23/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MIRM" class="margin-bottom-1">
                MIRM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.70</div> <small class="number change-up">+0.52<span>&nbsp;&nbsp;</span>+3.67%</small></td><td><strong>Maralixibat</strong> <br>Alagille Syndrome (ALGS)
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210329005203/en/">
                9/29/2021
              </a> <div class="note">PDUFA date under priority review September 29, 2021.</div></td><td>
              31m
            </td><td>
              448.6m
            </td><td>
              36.1k
            </td><td>
              77.7k
            </td><td>
              4.68
            </td><td>
              $14.35
            </td><td>
              $14.18
            </td><td>
              N/A
            </td><td>
              199.73m
            </td><td>
              -13.40m
            </td><td>
              14.91
            </td><td>
              47.80m
            </td><td>
              211.81m
            </td><td>
              0.5
            </td><td>
              8,253,550
            </td><td>
              03/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ABBV" class="margin-bottom-1">
                ABBV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$119.82</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+0.84%</small></td><td><strong>Atogepant</strong> <br>Chronic migraine
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/us-fda-accepts-abbvies-new-drug-application-for-atogepant-for-the-preventive-treatment-of-migraine-301257758.html">
                Late-3Q 2021
              </a> <div class="note">NDA acceptance announced March 30, 2021. PDUFA date late-3Q 2021.</div></td><td>
              2b
            </td><td>
              211.7b
            </td><td>
              2.6m
            </td><td>
              5.7m
            </td><td>
              16.85
            </td><td>
              $119.8
            </td><td>
              $118.82
            </td><td>
              June 19, 2020
            </td><td>
              11.53b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -123.84b
            </td><td>
              283.51b
            </td><td>
              0.1
            </td><td>
              1,765,652,810
            </td><td>
              03/30/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RGNX" class="margin-bottom-1">
                RGNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$31.30</div> <small class="number change-up">+1.67<span>&nbsp;&nbsp;</span>+5.62%</small></td><td><strong>RGX-314 (AAVIATE)</strong> <br>Wet AMD using suprachoroidal delivery 
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/regenxbio-reports-second-quarter-2021-financial-results-and-operational-highlights-301351442.html">
                9/29/2021
              </a> <div class="note">Phase 2 initial data to be presented at the Retina Society Annual Scientific Meeting, September 29-October 2, 2021.</div></td><td>
              43m
            </td><td>
              1.3b
            </td><td>
              148.8k
            </td><td>
              336.5k
            </td><td>
              2.63
            </td><td>
              $30.18
            </td><td>
              $29.63
            </td><td>
              February 15, 2021
            </td><td>
              356.81m
            </td><td>
              -9.96m
            </td><td>
              35.83
            </td><td>
              27.66m
            </td><td>
              0.97b
            </td><td>
              1.1
            </td><td>
              33,768,385
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLSD" class="margin-bottom-1">
                CLSD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.95</div> <small class="number change-up">+0.30<span>&nbsp;&nbsp;</span>+5.31%</small></td><td><strong>RGX-314 (AAVIATE)</strong> <br>Wet AMD using suprachoroidal delivery 
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/regenxbio-reports-second-quarter-2021-financial-results-and-operational-highlights-301351442.html">
                9/29/2021
              </a> <div class="note">Phase 2 initial data to be presented at the Retina Society Annual Scientific Meeting, September 29-October 2, 2021.</div></td><td>
              59m
            </td><td>
              353.9m
            </td><td>
              0.8m
            </td><td>
              4.0m
            </td><td>
              18.03
            </td><td>
              $5.66
            </td><td>
              $5.65
            </td><td>
              February 15, 2021
            </td><td>
              22.24m
            </td><td>
              -2.32m
            </td><td>
              9.60
            </td><td>
              12.99m
            </td><td>
              310.48m
            </td><td>
              9
            </td><td>
              47,643,724
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVO" class="margin-bottom-1">
                NVO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$106.00</div> <small class="number change-down">-0.62<span>&nbsp;&nbsp;</span>-0.58%</small></td><td><strong>Mim8</strong> <br>Hemophilia A 
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.novonordisk.com/Q1-2021-presentation/?page=27">
                3Q 2021
              </a> <div class="note">Phase 1/2 data due 3Q 2021.</div></td><td>
              2b
            </td><td>
              242.9b
            </td><td>
              1.1m
            </td><td>
              1.0m
            </td><td>
              23.56
            </td><td>
              $106.61
            </td><td>
              $106.62
            </td><td>
              January 29, 2024
            </td><td>
              42.37b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -50.17b
            </td><td>
              242.71b
            </td><td>
              0
            </td><td>
              2,291,903,114
            </td><td>
              06/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MTNB" class="margin-bottom-1">
                MTNB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.71</div> <small class="number change-up">+0.04<span>&nbsp;&nbsp;</span>+6.01%</small></td><td><strong>Oral amphotericin b (MAT2203) - (EnACT)</strong> <br>Cryptococcal meningitis
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.matinasbiopharma.com/investors/news-events/press-releases/detail/401/matinas-biopharma-reports-second-quarter-2021-financial">
                September 2021
              </a> <div class="note">Phase 1/2 DSMB evaluation of safety and efficacy data due September 2021.</div></td><td>
              215m
            </td><td>
              152.6m
            </td><td>
              0.7m
            </td><td>
              1.1m
            </td><td>
              2.45
            </td><td>
              $0.69
            </td><td>
              $0.67
            </td><td>
              May 2022
            </td><td>
              59.32m
            </td><td>
              -288.22k
            </td><td>
              205.83
            </td><td>
              52.26m
            </td><td>
              87.59m
            </td><td>
              5.5
            </td><td>
              206,957,714
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BLU" class="margin-bottom-1">
                BLU
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.32</div> <small class="number change-up">+0.27<span>&nbsp;&nbsp;</span>+8.85%</small></td><td><strong>BLU-5937 (SOOTHE)</strong> <br>Chronic cough
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.benzinga.com/pressreleases/21/08/b22454325/bellus-health-reports-second-quarter-2021-financial-results-and-business-highlights">
                September 2021
              </a> <div class="note">Phase 2b initiation announced December 8, 2020. Administrative interim analysis expected September 2021, with top-line results expected 4Q 2021</div></td><td>
              78m
            </td><td>
              260.1m
            </td><td>
              368.6k
            </td><td>
              419.1k
            </td><td>
              2.07
            </td><td>
              $3.05
            </td><td>
              $3.05
            </td><td>
              N/A
            </td><td>
              66.52m
            </td><td>
              -3.23m
            </td><td>
              20.61
            </td><td>
              56.75m
            </td><td>
              164.77m
            </td><td>
              0
            </td><td>
              78,337,361
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMCR" class="margin-bottom-1">
                IMCR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.70</div> <small class="number change-up">+1.72<span>&nbsp;&nbsp;</span>+6.15%</small></td><td><strong>Tebentafusp</strong> <br>Uveal melanoma
            </td><td>
              BLA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.immunocore.com/news-releases/news-release-details/immunocore-reports-second-quarter-2021-financial-results-and">
                9/30/2021
              </a> <div class="note">BLA filing due 3Q 2021.</div></td><td>
              44m
            </td><td>
              1.3b
            </td><td>
              99.6k
            </td><td>
              65.9k
            </td><td>
              4.26
            </td><td>
              $27.98
            </td><td>
              $27.98
            </td><td>
              N/A
            </td><td>
              259.31m
            </td><td>
              -10.87m
            </td><td>
              23.87
            </td><td>
              128.44m
            </td><td>
              0.93b
            </td><td>
              0
            </td><td>
              43,786,088
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/QURE" class="margin-bottom-1">
                QURE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$28.07</div> <small class="number change-up">+1.27<span>&nbsp;&nbsp;</span>+4.74%</small></td><td><strong>Etranacogene dezaparvovec (AMT-061) - HOPE-B</strong> <br>Hemophilia B
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=3936723&amp;lang=en-GB&amp;companycode=nl-qure&amp;v=">
                3Q 2021
              </a> <div class="note">Phase 3 top-line data released June 22, 2021. FIX levels sustained at a mean of 41.5% at 52 weeks. 78-week follow-up visits to be completed 3Q 2021 at which point the non-inferiority analysis of annualized bleeding rates (ABR) for the primary endpoint will be conducted. BLA filing due 1Q 2022.</div></td><td>
              46m
            </td><td>
              1.3b
            </td><td>
              399.2k
            </td><td>
              382.9k
            </td><td>
              2.04
            </td><td>
              $26.68
            </td><td>
              $26.8
            </td><td>
              March 2021
            </td><td>
              0.93b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              0.78b
            </td><td>
              0.66b
            </td><td>
              2.6
            </td><td>
              45,794,257
            </td><td>
              07/26/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GRAY" class="margin-bottom-1">
                GRAY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.71</div> <small class="number change-up">+0.19<span>&nbsp;&nbsp;</span>+5.40%</small></td><td><strong>GB-102 (ALTISSIMO)</strong> <br>Wet age-related macular degeneration
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.benzinga.com/pressreleases/21/08/g22453150/graybug-vision-announces-financial-results-for-the-three-and-six-months-ended-june-30-2021-and-rec">
                September 2021
              </a> <div class="note">Phase 2b data released March 9, 2021. BCVA approx 9 letters lower across all time points, on average, than that observed in the control (aflibercept) arm. Extension trial top-line data due September 2021. 12-month data to be presented at AAO meeting, November 12-15, 2021.</div></td><td>
              21m
            </td><td>
              79.0m
            </td><td>
              134.9k
            </td><td>
              2.0m
            </td><td>
              1.00
            </td><td>
              $3.49
            </td><td>
              $3.52
            </td><td>
              December 15, 2020
            </td><td>
              68.92m
            </td><td>
              -2.59m
            </td><td>
              26.57
            </td><td>
              64.76m
            </td><td>
              1.34m
            </td><td>
              0
            </td><td>
              11,762,794
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>ALXN1840 (WTX101)</strong> <br>Wilson disease
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210430005085/en/">
                3Q 2021
              </a> <div class="note">Phase 3 top-line data due 3Q 2021.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              February 2021
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MGNX" class="margin-bottom-1">
                MGNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.98</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+4.55%</small></td><td><strong>MARGENZA (margetuximab)</strong> <br>Metastatic breast cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-5">
                3Q 2021
              </a> <div class="note">FDA approval announced December 16, 2020. Final overall survival data due 3Q 2021.</div></td><td>
              61m
            </td><td>
              1.4b
            </td><td>
              297.3k
            </td><td>
              0.6m
            </td><td>
              4.40
            </td><td>
              $22.34
            </td><td>
              $21.98
            </td><td>
              N/A
            </td><td>
              269.90m
            </td><td>
              -15.23m
            </td><td>
              17.72
            </td><td>
              163.04m
            </td><td>
              1.07b
            </td><td>
              2.4
            </td><td>
              59,522,546
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ZLAB" class="margin-bottom-1">
                ZLAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$143.17</div> <small class="number change-up">+9.00<span>&nbsp;&nbsp;</span>+6.71%</small></td><td><strong>MARGENZA (margetuximab)</strong> <br>Metastatic breast cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-5">
                3Q 2021
              </a> <div class="note">FDA approval announced December 16, 2020. Final overall survival data due 3Q 2021.</div></td><td>
              75m
            </td><td>
              10.8b
            </td><td>
              320.4k
            </td><td>
              0.6m
            </td><td>
              33.30
            </td><td>
              $135
            </td><td>
              $134.17
            </td><td>
              N/A
            </td><td>
              1.73b
            </td><td>
              -21.95m
            </td><td>
              78.68
            </td><td>
              1.50b
            </td><td>
              1.78b
            </td><td>
              0
            </td><td>
              75,375,511
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BPTS" class="margin-bottom-1">
                BPTS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.44</div> <small class="number change-down">-0.05<span>&nbsp;&nbsp;</span>-0.59%</small></td><td><strong>Sarconeos (BIO101) - COVA</strong> <br>COVID-19
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.biophytis.com/en/august-16-2021/">
                3Q 2021
              </a> <div class="note">Phase 2 second interim analysis 3Q 2021</div></td><td>
              12m
            </td><td>
              103.0m
            </td><td>
              8.9k
            </td><td>
              2.4k
            </td><td>
              12.79
            </td><td>
              $8.51
            </td><td>
              $8.49
            </td><td>
              July 2021
            </td><td>
              19.96m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -419.39k
            </td><td>
              91.45m
            </td><td>
              0
            </td><td>
              12,207,947
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OBSV" class="margin-bottom-1">
                OBSV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.67</div> <small class="number change-up">+0.10<span>&nbsp;&nbsp;</span>+3.89%</small></td><td><strong>Linzagolix (OBE2109)</strong> <br>Uterine fibroids
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/b4635e4d-f1fd-44fa-8dc6-5444bf128711">
                3Q 2021
              </a> <div class="note">NDA filing due 3Q 2021.</div></td><td>
              78m
            </td><td>
              208.1m
            </td><td>
              0.8m
            </td><td>
              2.1m
            </td><td>
              5.04
            </td><td>
              $2.56
            </td><td>
              $2.57
            </td><td>
              September 16, 2019
            </td><td>
              47.66m
            </td><td>
              -6.26m
            </td><td>
              7.62
            </td><td>
              -5.90m
            </td><td>
              168.19m
            </td><td>
              0
            </td><td>
              64,232,245
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PTCT" class="margin-bottom-1">
                PTCT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$39.58</div> <small class="number change-up">+1.38<span>&nbsp;&nbsp;</span>+3.61%</small></td><td><strong>PTC518</strong> <br>Healthy volunteers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-a-corporate-update-and-reports-second-quarter-2021-financial-results-301344644.html">
                3Q 2021
              </a> <div class="note">Phase 1 trial data due 3Q 2021. Phase 2 trial to be initiated YE 2021. </div></td><td>
              71m
            </td><td>
              2.8b
            </td><td>
              109.5k
            </td><td>
              412.7k
            </td><td>
              14.24
            </td><td>
              $38.84
            </td><td>
              $38.2
            </td><td>
              N/A
            </td><td>
              0.93b
            </td><td>
              -10.38m
            </td><td>
              89.43
            </td><td>
              -0.93b
            </td><td>
              2.29b
            </td><td>
              0.9
            </td><td>
              49,392,128
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LGVN" class="margin-bottom-1">
                LGVN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.40</div> <small class="number change-down">-0.17<span>&nbsp;&nbsp;</span>-4.76%</small></td><td><strong>Lomecel-B (HERA)</strong> <br>Aging Frailty
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.longeveron.com/news/News/news-details/2021/Longeveron-Inc.-Provides-Corporate-Update-and-Reports-Second-Quarter-2021-Financial-Results/default.aspx">
                3Q 2021
              </a> <div class="note">Phase 2 data due 3Q 2021.</div></td><td>
              19m
            </td><td>
              65.0m
            </td><td>
              216.7k
            </td><td>
              168.2k
            </td><td>
              2.64
            </td><td>
              $3.6
            </td><td>
              $3.57
            </td><td>
              April 2021
            </td><td>
              19.62m
            </td><td>
              -0.98m
            </td><td>
              19.94
            </td><td>
              14.41m
            </td><td>
              50.40m
            </td><td>
              45.4
            </td><td>
              3,279,966
            </td><td>
              08/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CERC" class="margin-bottom-1">
                CERC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.90</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+4.69%</small></td><td><strong>CERC-006</strong> <br>Lymphatic Malformations
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.cerecor.com/press-releases/detail/133/cerecor-reports-second-quarter-2021-financial-results-and">
                3Q 2021
              </a> <div class="note">Phase 1/2 data due 3Q 2021.</div></td><td>
              96m
            </td><td>
              278.4m
            </td><td>
              129.3k
            </td><td>
              0.6m
            </td><td>
              13.18
            </td><td>
              $2.82
            </td><td>
              $2.77
            </td><td>
              N/A
            </td><td>
              28.92m
            </td><td>
              -6.40m
            </td><td>
              4.52
            </td><td>
              -13.57m
            </td><td>
              246.42m
            </td><td>
              2.8
            </td><td>
              56,006,748
            </td><td>
              08/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NERV" class="margin-bottom-1">
                NERV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.00</div> <small class="number change-up">+0.17<span>&nbsp;&nbsp;</span>+9.02%</small></td><td><strong>Roluperidone (MIN-101)</strong> <br>Schizophrenia
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://ir.minervaneurosciences.com/news-releases/news-release-details/minerva-neurosciences-reports-second-quarter-2021-financial">
                3Q 2021
              </a> <div class="note">Phase 3 data did not meet primary endpoint - May 29, 2020. Top-line data from pivotal bioequivalence study due 3Q 2021.</div></td><td>
              43m
            </td><td>
              85.2m
            </td><td>
              0.8m
            </td><td>
              0.7m
            </td><td>
              2.35
            </td><td>
              $1.89
            </td><td>
              $1.83
            </td><td>
              May 26, 2020
            </td><td>
              70.66m
            </td><td>
              -1.97m
            </td><td>
              35.78
            </td><td>
              1.50m
            </td><td>
              3.98m
            </td><td>
              1.7
            </td><td>
              25,628,585
            </td><td>
              08/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GRTX" class="margin-bottom-1">
                GRTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.64</div> <small class="number change-up">+0.18<span>&nbsp;&nbsp;</span>+2.13%</small></td><td><strong>Avasopasem (GC4419)</strong> <br>Pancreatic cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.galeratx.com/news-releases/news-release-details/galera-reports-second-quarter-2021-financial-results-and-recent">
                3Q 2021
              </a> <div class="note">Phase 1b/2a median overall survival (OS) 20.1 months compared to 10.9 months for placebo - April 28, 2021. No statistically significant differences in progression-free survival (PFS) compared with placebo (HR=0.6; p=0.29) - October 27, 2020. Final data due 3Q 2021.</div></td><td>
              26m
            </td><td>
              227.8m
            </td><td>
              35.5k
            </td><td>
              120.1k
            </td><td>
              -8.91
            </td><td>
              $8.46
            </td><td>
              $8.46
            </td><td>
              August 26, 2020
            </td><td>
              56.44m
            </td><td>
              -5.60m
            </td><td>
              10.08
            </td><td>
              -84.34m
            </td><td>
              156.98m
            </td><td>
              1.4
            </td><td>
              15,528,662
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BLUE" class="margin-bottom-1">
                BLUE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$18.19</div> <small class="number change-up">+0.60<span>&nbsp;&nbsp;</span>+3.41%</small></td><td><strong>Betibeglogene autotemcel (beti-cel) (LentiGlobin)</strong> <br>β-Thalassemia
            </td><td>
              BLA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005334/en/">
                3Q 2021
              </a> <div class="note">BLA filing to be completed 3Q 2021.</div></td><td>
              68m
            </td><td>
              1.2b
            </td><td>
              480.2k
            </td><td>
              1.5m
            </td><td>
              1.25
            </td><td>
              $17.85
            </td><td>
              $17.59
            </td><td>
              N/A
            </td><td>
              0.86b
            </td><td>
              -48.55m
            </td><td>
              17.76
            </td><td>
              392.41m
            </td><td>
              0.55b
            </td><td>
              1.3
            </td><td>
              53,343,921
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TFFP" class="margin-bottom-1">
                TFFP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.49</div> <small class="number change-up">+0.45<span>&nbsp;&nbsp;</span>+5.60%</small></td><td><strong>Tacrolimus Inhalation Powder</strong> <br>Lung transplant (post)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.tffpharma.com/news-releases/news-release-details/tff-pharmaceuticals-reports-second-quarter-2021-financial">
                3Q 2021
              </a> <div class="note">Phase 1 safety data due 3Q 2021.</div></td><td>
              25m
            </td><td>
              215.4m
            </td><td>
              119.2k
            </td><td>
              169.4k
            </td><td>
              3.88
            </td><td>
              $8.24
            </td><td>
              $8.04
            </td><td>
              N/A
            </td><td>
              48.53m
            </td><td>
              -1.96m
            </td><td>
              24.72
            </td><td>
              47.00m
            </td><td>
              151.92m
            </td><td>
              0.6
            </td><td>
              23,906,511
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LCTX" class="margin-bottom-1">
                LCTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.42</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+5.90%</small></td><td><strong>OpRegen</strong> <br>Dry age-related macular degeneration (AMD)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210713005126/en/">
                9/30/2021
              </a> <div class="note">Phase 1/2a updated data to be presented at Annual Retina Society Meeting September 30, 2021,</div></td><td>
              150m
            </td><td>
              363.7m
            </td><td>
              368.7k
            </td><td>
              1.2m
            </td><td>
              3.11
            </td><td>
              $2.32
            </td><td>
              $2.29
            </td><td>
              December 2021
            </td><td>
              65.50m
            </td><td>
              -1.81m
            </td><td>
              36.28
            </td><td>
              54.34m
            </td><td>
              125.41m
            </td><td>
              0
            </td><td>
              107,005,592
            </td><td>
              07/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AERI" class="margin-bottom-1">
                AERI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.70</div> <small class="number change-up">+0.20<span>&nbsp;&nbsp;</span>+1.38%</small></td><td><strong>AR-15512 (AVX-012) - COMET-1</strong> <br>Dry eye disease
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210804005757/en/">
                3Q 2021
              </a> <div class="note">Phase 2b top-line data due 3Q 2021.</div></td><td>
              47m
            </td><td>
              0.7b
            </td><td>
              118.3k
            </td><td>
              449.8k
            </td><td>
              -17.50
            </td><td>
              $14.73
            </td><td>
              $14.5
            </td><td>
              July 2021
            </td><td>
              176.20m
            </td><td>
              -6.71m
            </td><td>
              26.25
            </td><td>
              -218.94m
            </td><td>
              0.73b
            </td><td>
              2.4
            </td><td>
              46,152,464
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EVLO" class="margin-bottom-1">
                EVLO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.74</div> <small class="number change-up">+0.33<span>&nbsp;&nbsp;</span>+3.45%</small></td><td><strong>EDP1815</strong> <br>Mild to moderate psoriasis
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.evelobio.com/static-files/aca18e7a-0b98-4e1e-a951-25faf8572d9d">
                3Q 2021
              </a> <div class="note">Phase 2b data due 3Q 2021.</div></td><td>
              53m
            </td><td>
              0.5b
            </td><td>
              153.2k
            </td><td>
              190.5k
            </td><td>
              8.40
            </td><td>
              $9.59
            </td><td>
              $9.42
            </td><td>
              N/A
            </td><td>
              114.07m
            </td><td>
              -5.14m
            </td><td>
              22.18
            </td><td>
              31.11m
            </td><td>
              436.90m
            </td><td>
              0.5
            </td><td>
              23,304,546
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OPTN" class="margin-bottom-1">
                OPTN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.50</div> <small class="number change-down">-0.01<span>&nbsp;&nbsp;</span>-0.40%</small></td><td><strong>OPN-019</strong> <br>COVID-19
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://ir.optinose.com/news-releases/news-release-details/optinose-reports-first-quarter-2021-financial-results-and">
                3Q 2021
              </a> <div class="note">Phase 1 top-line data due 3Q 2021.</div></td><td>
              53m
            </td><td>
              133.3m
            </td><td>
              76.9k
            </td><td>
              436.2k
            </td><td>
              -3.57
            </td><td>
              $2.58
            </td><td>
              $2.51
            </td><td>
              N/A
            </td><td>
              80.42m
            </td><td>
              -7.50m
            </td><td>
              10.73
            </td><td>
              -96.17m
            </td><td>
              168.06m
            </td><td>
              3.1
            </td><td>
              30,507,396
            </td><td>
              07/01/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ZGNX" class="margin-bottom-1">
                ZGNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.41</div> <small class="number change-up">+0.67<span>&nbsp;&nbsp;</span>+4.88%</small></td><td><strong>FINTEPLA (fenfluramine)</strong> <br>Lennox-Gastaut syndrome
            </td><td>
              sNDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/05/2275948/0/en/Zogenix-Provides-Corporate-Update-and-Reports-Second-Quarter-2021-Financial-Results.html">
                3Q 2021
              </a> <div class="note">sNDA filing due 3Q 2021.</div></td><td>
              56m
            </td><td>
              0.8b
            </td><td>
              350.2k
            </td><td>
              1.1m
            </td><td>
              2.95
            </td><td>
              $13.85
            </td><td>
              $13.74
            </td><td>
              March 2024
            </td><td>
              367.52m
            </td><td>
              -14.31m
            </td><td>
              25.68
            </td><td>
              100.31m
            </td><td>
              0.54b
            </td><td>
              2
            </td><td>
              55,653,891
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DVAX" class="margin-bottom-1">
                DVAX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.48</div> <small class="number change-up">+1.44<span>&nbsp;&nbsp;</span>+11.97%</small></td><td><strong>S-Trimer COVID-19 Vaccine + CpG 1018 adjuvant plus alum (SPECTRA)</strong> <br>COVID-19 vaccine
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.dynavax.com/static-files/6e046557-2a31-4635-bd67-799c74e594b1">
                3Q 2021
              </a> <div class="note">Phase 2/3 interim analysis due 3Q 2021.</div></td><td>
              115m
            </td><td>
              1.5b
            </td><td>
              2.8m
            </td><td>
              2.3m
            </td><td>
              18.47
            </td><td>
              $12.44
            </td><td>
              $12.04
            </td><td>
              N/A
            </td><td>
              412.28m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -152.25m
            </td><td>
              1.29b
            </td><td>
              1.6
            </td><td>
              90,823,786
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GSK" class="margin-bottom-1">
                GSK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$41.57</div> <small class="number change-down">-0.28<span>&nbsp;&nbsp;</span>-0.67%</small></td><td><strong>S-Trimer COVID-19 Vaccine + CpG 1018 adjuvant plus alum (SPECTRA)</strong> <br>COVID-19 vaccine
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.dynavax.com/static-files/6e046557-2a31-4635-bd67-799c74e594b1">
                3Q 2021
              </a> <div class="note">Phase 2/3 interim analysis due 3Q 2021.</div></td><td>
              3b
            </td><td>
              104.6b
            </td><td>
              2.3m
            </td><td>
              4.2m
            </td><td>
              4.95
            </td><td>
              $41.75
            </td><td>
              $41.85
            </td><td>
              N/A
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -51.10b
            </td><td>
              133.80b
            </td><td>
              0.2
            </td><td>
              2,506,785,977
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SGTX" class="margin-bottom-1">
                SGTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.86</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+6.35%</small></td><td><strong>SIG-001</strong> <br>Hemophilia A
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/10/2277801/0/en/Sigilon-Therapeutics-Reports-Second-Quarter-2021-Financial-Results-and-Business-Highlights.html">
                3Q 2021
              </a> <div class="note">Phase 1/2 clinical hold announced July 9, 2021. 9 month follow-up data for three patients due 3Q 2021.</div></td><td>
              32m
            </td><td>
              155.8m
            </td><td>
              138.0k
            </td><td>
              293.6k
            </td><td>
              1.40
            </td><td>
              $4.68
            </td><td>
              $4.57
            </td><td>
              September 2026
            </td><td>
              152.81m
            </td><td>
              -5.33m
            </td><td>
              28.68
            </td><td>
              77.76m
            </td><td>
              19.39m
            </td><td>
              6.5
            </td><td>
              19,339,106
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TAK" class="margin-bottom-1">
                TAK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.97</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+1.75%</small></td><td><strong>TAK-906</strong> <br>Gastroparesis
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.takeda.com/4a21eb/siteassets/system/investors/report/quarterlyannouncements/fy2021/qr2021_q1_p01_en.pdf">
                3Q 2021
              </a> <div class="note">Phase 2b data due 3Q 2021.</div></td><td>
              3b
            </td><td>
              53.4b
            </td><td>
              0.8m
            </td><td>
              1.9m
            </td><td>
              1.12
            </td><td>
              $16.84
            </td><td>
              $16.68
            </td><td>
              June 14, 2021
            </td><td>
              0.78t
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -6.63t
            </td><td>
              86.30b
            </td><td>
              0
            </td><td>
              3,145,059,016
            </td><td>
              07/30/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NOVN" class="margin-bottom-1">
                NOVN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.27</div> <small class="number change-up">+0.48<span>&nbsp;&nbsp;</span>+5.46%</small></td><td><strong>SB206 - B-SIMPLE4</strong> <br>Molluscum
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2279643/0/en/Novan-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Corporate-Update.html">
                3Q 2021
              </a> <div class="note">Phase 3 trial met primary endpoint. Further data due 3Q 2021. NDA filing due no later than 3Q 2022.</div></td><td>
              19m
            </td><td>
              174.4m
            </td><td>
              298.1k
            </td><td>
              4.8m
            </td><td>
              5.39
            </td><td>
              $8.95
            </td><td>
              $8.79
            </td><td>
              April 28, 2021
            </td><td>
              64.37m
            </td><td>
              -0.80m
            </td><td>
              80.87
            </td><td>
              16.98m
            </td><td>
              102.66m
            </td><td>
              10.6
            </td><td>
              18,701,214
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PHAT" class="margin-bottom-1">
                PHAT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$32.90</div> <small class="number change-up">+1.34<span>&nbsp;&nbsp;</span>+4.26%</small></td><td><strong>Vonoprazan PHALCON-HP</strong> <br>H. pylori
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.phathompharma.com/news-releases/news-release-details/phathom-pharmaceuticals-reports-second-quarter-2021-results-and">
                September 2021
              </a> <div class="note">Phase 3 top-line data met primary endpoints - April 29, 2021. NDA filing due September 2021,</div></td><td>
              31m
            </td><td>
              1.0b
            </td><td>
              66.6k
            </td><td>
              97.7k
            </td><td>
              7.81
            </td><td>
              $31.84
            </td><td>
              $31.55
            </td><td>
              March 10, 2021
            </td><td>
              192.65m
            </td><td>
              -9.45m
            </td><td>
              20.38
            </td><td>
              110.20m
            </td><td>
              0.83b
            </td><td>
              8.1
            </td><td>
              20,563,110
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CRNX" class="margin-bottom-1">
                CRNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.27</div> <small class="number change-up">+0.40<span>&nbsp;&nbsp;</span>+1.92%</small></td><td><strong>CRN04777</strong> <br>Congenital hyperinsulinism (HI)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://crinetics.com/crinetics-second-quarter-2021-financial-results-corporate-update/">
                September 2021
              </a> <div class="note">Phase 1 preliminary safety and pharmacological effect data due September 2021.</div></td><td>
              39m
            </td><td>
              0.8b
            </td><td>
              195.1k
            </td><td>
              200.6k
            </td><td>
              4.16
            </td><td>
              $21.18
            </td><td>
              $20.87
            </td><td>
              N/A
            </td><td>
              206.79m
            </td><td>
              -6.65m
            </td><td>
              31.10
            </td><td>
              191.30m
            </td><td>
              0.62b
            </td><td>
              0.7
            </td><td>
              29,019,031
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INSM" class="margin-bottom-1">
                INSM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$25.16</div> <small class="number change-up">+1.59<span>&nbsp;&nbsp;</span>+6.75%</small></td><td><strong>Brensocatib</strong> <br>COVID-19
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/insmed-reports-first-quarter-2021-financial-results-and-provides-business-update-301285103.html">
                3Q 2021
              </a> <div class="note">Phase 3 top-line data due 3Q 2021.</div></td><td>
              115m
            </td><td>
              2.9b
            </td><td>
              397.2k
            </td><td>
              0.8m
            </td><td>
              5.46
            </td><td>
              $24.12
            </td><td>
              $23.57
            </td><td>
              February 28, 2021
            </td><td>
              0.88b
            </td><td>
              -25.15m
            </td><td>
              35.11
            </td><td>
              184.33m
            </td><td>
              2.38b
            </td><td>
              4.9
            </td><td>
              91,607,437
            </td><td>
              07/01/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SNY" class="margin-bottom-1">
                SNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$52.48</div> <small class="number change-down">-0.64<span>&nbsp;&nbsp;</span>-1.20%</small></td><td><strong>MRT5500</strong> <br>COVID-19 vaccine
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.translate.bio/news-releases/news-release-details/translate-bio-announces-first-quarter-2021-financial-results-and">
                3Q 2021
              </a> <div class="note">Phase 1/2 interim data due 3Q 2021.</div></td><td>
              3b
            </td><td>
              131.7b
            </td><td>
              2.5m
            </td><td>
              1.7m
            </td><td>
              1.78
            </td><td>
              $52.73
            </td><td>
              $53.12
            </td><td>
              N/A
            </td><td>
              9.72b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -39.23b
            </td><td>
              146.90b
            </td><td>
              0
            </td><td>
              2,510,366,030
            </td><td>
              05/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TBIO" class="margin-bottom-1">
                TBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$37.74</div> <small class="number change-down">-0.03<span>&nbsp;&nbsp;</span>-0.07%</small></td><td><strong>MRT5500</strong> <br>COVID-19 vaccine
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.translate.bio/news-releases/news-release-details/translate-bio-announces-first-quarter-2021-financial-results-and">
                3Q 2021
              </a> <div class="note">Phase 1/2 interim data due 3Q 2021.</div></td><td>
              76m
            </td><td>
              2.9b
            </td><td>
              1.1m
            </td><td>
              3.0m
            </td><td>
              6.91
            </td><td>
              $37.71
            </td><td>
              $37.77
            </td><td>
              N/A
            </td><td>
              0.68b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              182.77m
            </td><td>
              2.25b
            </td><td>
              1.4
            </td><td>
              53,617,413
            </td><td>
              05/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ENTA" class="margin-bottom-1">
                ENTA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$53.22</div> <small class="number change-up">+1.90<span>&nbsp;&nbsp;</span>+3.69%</small></td><td><strong>EDP-305 ARGON-2</strong> <br>Non-alcoholic steatohepatitis (NASH)
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005808/en/">
                3Q 2021
              </a> <div class="note">Phase 2b interim analysis due 3Q 2021.</div></td><td>
              20m
            </td><td>
              1.1b
            </td><td>
              67.3k
            </td><td>
              171.6k
            </td><td>
              2.58
            </td><td>
              $51.88
            </td><td>
              $51.32
            </td><td>
              November 2022
            </td><td>
              239.12m
            </td><td>
              -9.84m
            </td><td>
              24.31
            </td><td>
              206.53m
            </td><td>
              0.79b
            </td><td>
              5.9
            </td><td>
              15,917,284
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CERC" class="margin-bottom-1">
                CERC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.90</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+4.69%</small></td><td><strong>CERC-007</strong> <br>Adult Onset Still’s Disease
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.cerecor.com/press-releases/detail/133/cerecor-reports-second-quarter-2021-financial-results-and">
                3Q 2021
              </a> <div class="note">Phase 1b initial data due 3Q 2021.</div></td><td>
              96m
            </td><td>
              278.4m
            </td><td>
              129.3k
            </td><td>
              0.6m
            </td><td>
              13.18
            </td><td>
              $2.82
            </td><td>
              $2.77
            </td><td>
              March 30, 2022
            </td><td>
              28.92m
            </td><td>
              -6.40m
            </td><td>
              4.52
            </td><td>
              -13.57m
            </td><td>
              246.42m
            </td><td>
              2.8
            </td><td>
              56,006,748
            </td><td>
              08/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GRTS" class="margin-bottom-1">
                GRTS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.47</div> <small class="number change-up">+0.94<span>&nbsp;&nbsp;</span>+12.48%</small></td><td><strong>SLATE</strong> <br>Non-small cell lung cancer (NSCLC)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.gritstoneoncology.com/news-releases/news-release-details/gritstone-reports-fourth-quarter-and-full-year-2020-financial">
                3Q 2021
              </a> <div class="note">Phase 2 data due 3Q 2021.</div></td><td>
              49m
            </td><td>
              418.8m
            </td><td>
              0.6m
            </td><td>
              0.7m
            </td><td>
              2.34
            </td><td>
              $7.62
            </td><td>
              $7.53
            </td><td>
              N/A
            </td><td>
              157.57m
            </td><td>
              -7.56m
            </td><td>
              20.84
            </td><td>
              112.17m
            </td><td>
              223.51m
            </td><td>
              1.5
            </td><td>
              40,257,957
            </td><td>
              05/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ACIU" class="margin-bottom-1">
                ACIU
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.72</div> <small class="number change-up">+0.22<span>&nbsp;&nbsp;</span>+3.41%</small></td><td><strong>Semorinemab (LAURIET)</strong> <br>Alzheimer’s disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.acimmune.com/news-releases/news-release-details/ac-immune-reports-second-quarter-2021-financial-results-and">
                3Q 2021
              </a> <div class="note">Phase 2 primary completion (estimated last patient, last visit) 3Q 2021.</div></td><td>
              73m
            </td><td>
              488.3m
            </td><td>
              133.3k
            </td><td>
              258.6k
            </td><td>
              2.37
            </td><td>
              $6.53
            </td><td>
              $6.5
            </td><td>
              September 24, 2021
            </td><td>
              189.52m
            </td><td>
              -5.34m
            </td><td>
              35.48
            </td><td>
              167.71m
            </td><td>
              258.49m
            </td><td>
              0
            </td><td>
              31,782,720
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CALA" class="margin-bottom-1">
                CALA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.24</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+4.19%</small></td><td><strong>CB-280</strong> <br>Cystic fibrosis
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-reports-second-quarter-2021-financial">
                9/30/2021
              </a> <div class="note">Phase 1b interim data due at the  2021 North American Cystic Fibrosis Conference September 30 - October 2, 2021.</div></td><td>
              74m
            </td><td>
              166.0m
            </td><td>
              266.2k
            </td><td>
              0.8m
            </td><td>
              2.00
            </td><td>
              $2.18
            </td><td>
              $2.15
            </td><td>
              December 2021
            </td><td>
              85.53m
            </td><td>
              -3.71m
            </td><td>
              23.07
            </td><td>
              70.69m
            </td><td>
              70.81m
            </td><td>
              1
            </td><td>
              51,184,451
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TGTX" class="margin-bottom-1">
                TGTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$26.38</div> <small class="number change-up">+2.38<span>&nbsp;&nbsp;</span>+9.90%</small></td><td><strong>Ublituximab - ULTIMATE I</strong> <br>Multiple Sclerosis
            </td><td>
              BLA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-provides-business-update-and-reports-second-1">
                3Q 2021
              </a> <div class="note">Phase 3 trial met primary endpoint - December 10. 2020. BLA filing due 3Q 2021.</div></td><td>
              143m
            </td><td>
              3.8b
            </td><td>
              1.8m
            </td><td>
              1.4m
            </td><td>
              9.84
            </td><td>
              $24.54
            </td><td>
              $24
            </td><td>
              July 23, 2020
            </td><td>
              407.36m
            </td><td>
              -20.06m
            </td><td>
              20.31
            </td><td>
              309.09m
            </td><td>
              3.02b
            </td><td>
              16.2
            </td><td>
              114,156,621
            </td><td>
              08/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALT" class="margin-bottom-1">
                ALT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.39</div> <small class="number change-up">+0.71<span>&nbsp;&nbsp;</span>+5.64%</small></td><td><strong>ALT-801</strong> <br>Non-alcoholic steatohepatitis (NASH) - Healthy Overweight and Obese Volunteers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-second-quarter-2021-financial-results-and">
                September 2021
              </a> <div class="note">Phase 1 6-week MAD released June 16, 2021. Weight loss of 5.4% achieved at 6 weeks of treatment with 1.8 mg once weekly dose. 12-week data September 2021. Phase 2 obesity and NASH trials expected to initiate in Q1 2022.</div></td><td>
              40m
            </td><td>
              0.5b
            </td><td>
              1.0m
            </td><td>
              2.2m
            </td><td>
              2.20
            </td><td>
              $12.73
            </td><td>
              $12.68
            </td><td>
              September 2021
            </td><td>
              206.47m
            </td><td>
              -6.31m
            </td><td>
              32.73
            </td><td>
              190.49m
            </td><td>
              287.30m
            </td><td>
              13.2
            </td><td>
              39,275,708
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KTRA" class="margin-bottom-1">
                KTRA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.50</div> <small class="number change-up">+0.03<span>&nbsp;&nbsp;</span>+2.03%</small></td><td><strong>VAL-083</strong> <br>Glioblastoma Multiforme (GBM) - Adjuvant
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://d1io3yog0oux5.cloudfront.net/_df97e7926a026f05fcdbaf030eee7813/kintara/db/241/1956/pdf/Kintara+Therapeutics+May+2021.pdf">
                3Q 2021
              </a> <div class="note">Phase 2 top-line data due 3Q 2021.</div></td><td>
              33m
            </td><td>
              48.9m
            </td><td>
              116.8k
            </td><td>
              0.8m
            </td><td>
              -13.63
            </td><td>
              $1.49
            </td><td>
              $1.47
            </td><td>
              June 2021
            </td><td>
              8.26m
            </td><td>
              -1.54m
            </td><td>
              5.35
            </td><td>
              5.52m
            </td><td>
              52.46m
            </td><td>
              5.6
            </td><td>
              32,038,772
            </td><td>
              05/14/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ENTA" class="margin-bottom-1">
                ENTA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$53.22</div> <small class="number change-up">+1.90<span>&nbsp;&nbsp;</span>+3.69%</small></td><td><strong>EDP-297</strong> <br>Non-alcoholic steatohepatitis (NASH)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005808/en/">
                3Q 2021
              </a> <div class="note">Phase 1 data due 3Q 2021.</div></td><td>
              20m
            </td><td>
              1.1b
            </td><td>
              67.3k
            </td><td>
              171.6k
            </td><td>
              2.58
            </td><td>
              $51.88
            </td><td>
              $51.32
            </td><td>
              February 2021
            </td><td>
              239.12m
            </td><td>
              -9.84m
            </td><td>
              24.31
            </td><td>
              206.53m
            </td><td>
              0.79b
            </td><td>
              5.9
            </td><td>
              15,917,284
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RDHL" class="margin-bottom-1">
                RDHL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.96</div> <small class="number change-up">+0.08<span>&nbsp;&nbsp;</span>+1.16%</small></td><td><strong>YELIVA (Opaganib)</strong> <br>COVID-19
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.accesswire.com/660878/RedHill-Announces-Two-New-US-Patents">
                3Q 2021 est
              </a> <div class="note">Phase 2/3 trial approaching completion - noted August 23, 2021.</div></td><td>
              47m
            </td><td>
              325.2m
            </td><td>
              206.3k
            </td><td>
              273.4k
            </td><td>
              6.11
            </td><td>
              $6.94
            </td><td>
              $6.88
            </td><td>
              July 18, 2021
            </td><td>
              56.22m
            </td><td>
              -4.09m
            </td><td>
              13.75
            </td><td>
              -110.86m
            </td><td>
              333.00m
            </td><td>
              0
            </td><td>
              46,720,013
            </td><td>
              08/23/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FBIO" class="margin-bottom-1">
                FBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.20</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+4.58%</small></td><td><strong>CEVA101</strong> <br>Severe Traumatic Brain Injury
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://d1io3yog0oux5.cloudfront.net/_57a9ebbefa562ec94907d436281246c9/fortressbiotech/db/640/5686/pdf/FBIO+Corporate+Presentation+-+May+2021+1.pdf">
                3Q 2021
              </a> <div class="note">Phase 2 data in children due 3Q 2021.</div></td><td>
              101m
            </td><td>
              323.4m
            </td><td>
              220.5k
            </td><td>
              0.5m
            </td><td>
              2.99
            </td><td>
              $3.07
            </td><td>
              $3.06
            </td><td>
              September 16, 2020
            </td><td>
              254.32m
            </td><td>
              -11.49m
            </td><td>
              22.14
            </td><td>
              84.46m
            </td><td>
              120.76m
            </td><td>
              27.4
            </td><td>
              76,232,955
            </td><td>
              07/01/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SRNE" class="margin-bottom-1">
                SRNE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.96</div> <small class="number change-up">+0.61<span>&nbsp;&nbsp;</span>+7.31%</small></td><td><strong>Abivertinib</strong> <br>COVID-19
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-phase-2-abivertinib-clinical-studies-have">
                3Q 2021
              </a> <div class="note">Phase 2 data due 3Q 2021.</div></td><td>
              298m
            </td><td>
              2.7b
            </td><td>
              4.1m
            </td><td>
              6.6m
            </td><td>
              14.45
            </td><td>
              $8.36
            </td><td>
              $8.35
            </td><td>
              May 5, 2021
            </td><td>
              64.59m
            </td><td>
              -26.17m
            </td><td>
              2.47
            </td><td>
              -0.53b
            </td><td>
              2.54b
            </td><td>
              35.1
            </td><td>
              293,559,311
            </td><td>
              06/22/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BHVN" class="margin-bottom-1">
                BHVN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$125.97</div> <small class="number change-up">+3.13<span>&nbsp;&nbsp;</span>+2.55%</small></td><td><strong>Verdiperstat</strong> <br>Multiple system atrophy (MSA)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/biohaven-reports-second-quarter-2021-financial-results-and-recent-business-developments-301350770.html">
                3Q 2021
              </a> <div class="note">Phase 3 top-line data due 3Q 2021.</div></td><td>
              65m
            </td><td>
              8.2b
            </td><td>
              170.9k
            </td><td>
              0.7m
            </td><td>
              -18.15
            </td><td>
              $124.56
            </td><td>
              $122.84
            </td><td>
              October 20, 2021
            </td><td>
              229.88m
            </td><td>
              -75.68m
            </td><td>
              3.04
            </td><td>
              -1.07b
            </td><td>
              7.94b
            </td><td>
              8.5
            </td><td>
              58,034,591
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GLMD" class="margin-bottom-1">
                GLMD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.92</div> <small class="number change-up">+0.11<span>&nbsp;&nbsp;</span>+3.91%</small></td><td><strong>Amilo-5MER</strong> <br>Chronic inflammatory diseases
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-provides-business-update-and-reports-second-quarter-2021-financial-results-301349181.html">
                3Q 2021
              </a> <div class="note">Phase 1 top-line data due 3Q 2021.</div></td><td>
              21m
            </td><td>
              61.7m
            </td><td>
              55.8k
            </td><td>
              293.8k
            </td><td>
              0.80
            </td><td>
              $2.88
            </td><td>
              $2.81
            </td><td>
              N/A
            </td><td>
              46.49m
            </td><td>
              -2.54m
            </td><td>
              18.28
            </td><td>
              39.16m
            </td><td>
              29.24m
            </td><td>
              0
            </td><td>
              17,575,161
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TBPH" class="margin-bottom-1">
                TBPH
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.13</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+0.60%</small></td><td><strong>Izencitinib</strong> <br>Ulcerative Colitis
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/theravance-biopharma-inc-reports-second-quarter-2021-financial-results-and-provides-business-update-301347426.html">
                3Q 2021
              </a> <div class="note">Phase 2b data due 3Q 2021.</div></td><td>
              73m
            </td><td>
              1.0b
            </td><td>
              180.1k
            </td><td>
              467.1k
            </td><td>
              -3.46
            </td><td>
              $14.08
            </td><td>
              $14.05
            </td><td>
              June 2025
            </td><td>
              234.89m
            </td><td>
              -16.70m
            </td><td>
              14.06
            </td><td>
              -494.74m
            </td><td>
              1.44b
            </td><td>
              7.6
            </td><td>
              41,813,005
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VBLT" class="margin-bottom-1">
                VBLT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.00</div> <small class="number change-up">+0.02<span>&nbsp;&nbsp;</span>+1.01%</small></td><td><strong>VB-111</strong> <br>Recurrent platinum resistant ovarian cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/16/2280945/0/en/VBL-Therapeutics-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Corporate-Update.html">
                3Q 2021
              </a> <div class="note">Phase 3 DSMB review recommended trial to continue as planned - February 22, 2021. Next review 3Q 2021. PFS endpoint readout expected in 2022.</div></td><td>
              62m
            </td><td>
              124.1m
            </td><td>
              138.1k
            </td><td>
              378.7k
            </td><td>
              2.22
            </td><td>
              $1.97
            </td><td>
              $1.98
            </td><td>
              December 2022
            </td><td>
              81.81m
            </td><td>
              -1.82m
            </td><td>
              44.94
            </td><td>
              70.33m
            </td><td>
              68.46m
            </td><td>
              0
            </td><td>
              47,358,345
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/APLS" class="margin-bottom-1">
                APLS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$63.91</div> <small class="number change-up">+2.67<span>&nbsp;&nbsp;</span>+4.35%</small></td><td><strong>EMPAVELI (pegcetacoplan) - OAKS</strong> <br>Geographic atrophy (GA) associated with age-related macular degeneration (AMD)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-reports-second-quarter-2021-financial">
                September 2021
              </a> <div class="note">Phase 3 data due September 2021.</div></td><td>
              87m
            </td><td>
              5.6b
            </td><td>
              465.8k
            </td><td>
              0.9m
            </td><td>
              -39.21
            </td><td>
              $62.26
            </td><td>
              $61.25
            </td><td>
              July 30, 2021
            </td><td>
              0.52b
            </td><td>
              -42.90m
            </td><td>
              12.16
            </td><td>
              -319.61m
            </td><td>
              5.14b
            </td><td>
              4.8
            </td><td>
              60,293,900
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CNTA" class="margin-bottom-1">
                CNTA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.18</div> <small class="number change-up">+0.11<span>&nbsp;&nbsp;</span>+0.52%</small></td><td><strong>SerpinPC (ApcinteX)</strong> <br>Hemophilia A
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-second-quarter-2021-financial">
                3Q 2021
              </a> <div class="note">Phase 2a top-line data due 3Q 2021.</div></td><td>
              90m
            </td><td>
              1.9b
            </td><td>
              32.8k
            </td><td>
              197.6k
            </td><td>
              
            </td><td>
              $21.2
            </td><td>
              $21.07
            </td><td>
              April 2022
            </td><td>
              0.61b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              0.56b
            </td><td>
              1.84b
            </td><td>
              1
            </td><td>
              89,000,772
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVCR" class="margin-bottom-1">
                NVCR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$135.40</div> <small class="number change-up">+2.97<span>&nbsp;&nbsp;</span>+2.24%</small></td><td><strong>Tumor Treating Fields (TTFields) - INNOVATE-3</strong> <br>Ovarian cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210729005357/en/">
                3Q 2021
              </a> <div class="note">Phase 3 interim analysis 3Q 2021 with final data due 2023.</div></td><td>
              104m
            </td><td>
              14.0b
            </td><td>
              153.2k
            </td><td>
              0.7m
            </td><td>
              35.35
            </td><td>
              $133.45
            </td><td>
              $132.43
            </td><td>
              September 2023
            </td><td>
              0.91b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              214.94m
            </td><td>
              13.40b
            </td><td>
              7.7
            </td><td>
              102,348,400
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CTIC" class="margin-bottom-1">
                CTIC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.71</div> <small class="number change-up">+0.11<span>&nbsp;&nbsp;</span>+4.12%</small></td><td><strong>Pacritinib (PRE-VENT)</strong> <br>COVID-19
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/cti-biopharma-reports-second-quarter-2021-financial-results-301349723.html">
                3Q 2021
              </a> <div class="note">Phase 3 interim data due 3Q 2021.</div></td><td>
              93m
            </td><td>
              252.6m
            </td><td>
              494.3k
            </td><td>
              0.6m
            </td><td>
              4.10
            </td><td>
              $2.71
            </td><td>
              $2.6
            </td><td>
              July 31, 2021
            </td><td>
              61.33m
            </td><td>
              -5.86m
            </td><td>
              10.46
            </td><td>
              45.54m
            </td><td>
              174.71m
            </td><td>
              8
            </td><td>
              71,272,835
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/APLT" class="margin-bottom-1">
                APLT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$18.78</div> <small class="number change-up">+2.62<span>&nbsp;&nbsp;</span>+16.21%</small></td><td><strong>AT-007 (ACTION-Galactosemia kids)</strong> <br>Galactosemia
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-reports-second-quarter-2021-financial">
                3Q 2021
              </a> <div class="note">Phase 1/2 trial clinical hold has been lifted - February 1, 2021. NDA filing due 3Q 2021.</div></td><td>
              26m
            </td><td>
              491.6m
            </td><td>
              97.4k
            </td><td>
              86.8k
            </td><td>
              4.37
            </td><td>
              $16.16
            </td><td>
              $16.16
            </td><td>
              N/A
            </td><td>
              110.07m
            </td><td>
              -8.64m
            </td><td>
              12.75
            </td><td>
              85.55m
            </td><td>
              302.12m
            </td><td>
              3.3
            </td><td>
              17,716,529
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GRTS" class="margin-bottom-1">
                GRTS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.47</div> <small class="number change-up">+0.94<span>&nbsp;&nbsp;</span>+12.48%</small></td><td><strong>COVID-19 vaccine - CORAL</strong> <br>COVID-19 vaccine
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-reports-first-quarter-2021-financial-results-and">
                3Q 2021
              </a> <div class="note">Phase 1 initial data due 3Q 2021.</div></td><td>
              49m
            </td><td>
              418.8m
            </td><td>
              0.6m
            </td><td>
              0.7m
            </td><td>
              2.34
            </td><td>
              $7.62
            </td><td>
              $7.53
            </td><td>
              N/A
            </td><td>
              157.57m
            </td><td>
              -7.56m
            </td><td>
              20.84
            </td><td>
              112.17m
            </td><td>
              223.51m
            </td><td>
              1.5
            </td><td>
              40,257,957
            </td><td>
              05/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FGEN" class="margin-bottom-1">
                FGEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.05</div> <small class="number change-down">-0.06<span>&nbsp;&nbsp;</span>-0.50%</small></td><td><strong>Roxadustat (WHITNEY)</strong> <br>Chemotherapy-induced anemia (CIA)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-reports-second-quarter-2021-financial-results">
                3Q 2021
              </a> <div class="note">Phase 2 data due 3Q 2021.</div></td><td>
              93m
            </td><td>
              1.1b
            </td><td>
              1.1m
            </td><td>
              1.5m
            </td><td>
              4.29
            </td><td>
              $12.24
            </td><td>
              $12.11
            </td><td>
              March 26, 2021
            </td><td>
              491.29m
            </td><td>
              -8.85m
            </td><td>
              55.53
            </td><td>
              -37.48m
            </td><td>
              0.72b
            </td><td>
              4.9
            </td><td>
              81,614,674
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/APLS" class="margin-bottom-1">
                APLS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$63.91</div> <small class="number change-up">+2.67<span>&nbsp;&nbsp;</span>+4.35%</small></td><td><strong>EMPAVELI (pegcetacoplan) - DERBY</strong> <br>Geographic atrophy (GA)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-reports-second-quarter-2021-financial">
                September 2021
              </a> <div class="note">Phase 3 data due September 2021.</div></td><td>
              87m
            </td><td>
              5.6b
            </td><td>
              465.8k
            </td><td>
              0.9m
            </td><td>
              -39.21
            </td><td>
              $62.26
            </td><td>
              $61.25
            </td><td>
              July 30, 2021
            </td><td>
              0.52b
            </td><td>
              -42.90m
            </td><td>
              12.16
            </td><td>
              -319.61m
            </td><td>
              5.14b
            </td><td>
              4.8
            </td><td>
              60,293,900
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LPCN" class="margin-bottom-1">
                LPCN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.43</div> <small class="number change-up">+0.04<span>&nbsp;&nbsp;</span>+2.88%</small></td><td><strong>LPCN 1154</strong> <br>Postpartum Depression
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-second-quarter-ended-june-30-2021-301348161.html">
                3Q 2021
              </a> <div class="note">Phase 2 trial planned. Dosing to commence 4Q 2021. PK data due 3Q 2021.</div></td><td>
              88m
            </td><td>
              126.3m
            </td><td>
              272.0k
            </td><td>
              0.9m
            </td><td>
              3.58
            </td><td>
              $1.38
            </td><td>
              $1.39
            </td><td>
              N/A
            </td><td>
              45.22m
            </td><td>
              -0.79m
            </td><td>
              57.41
            </td><td>
              33.79m
            </td><td>
              80.04m
            </td><td>
              3.5
            </td><td>
              86,149,561
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DRMA" class="margin-bottom-1">
                DRMA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.70</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+1.95%</small></td><td><strong>DMT410</strong> <br>Aesthetic conditions
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001853816/000119312521238151/d137089ds1a.htm">
                3Q 2021
              </a> <div class="note">Phase 2 data due 3Q 2021.</div></td><td>
              8m
            </td><td>
              39.1m
            </td><td>
              14.5k
            </td><td>
              
            </td><td>
              58.75
            </td><td>
              $4.6
            </td><td>
              $4.61
            </td><td>
              N/A
            </td><td>
              79.84k
            </td><td>
              -258.74k
            </td><td>
              0.31
            </td><td>
              -0.86m
            </td><td>
              37.25m
            </td><td>
              0
            </td><td>
              1,768,271
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SLNO" class="margin-bottom-1">
                SLNO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.84</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+1.60%</small></td><td><strong>Diazoxide Choline Controlled-Release (DCCR) - DESTINY PWS</strong> <br>Prader-Willi syndrome (PWS)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/07/28/2270692/0/en/Soleno-Therapeutics-Provides-Corporate-Update-and-Reports-Second-Quarter-2021-Financial-Results.html">
                3Q 2021
              </a> <div class="note">Phase 3 trial did not meet its primary endpoint - June 8, 2020. Further trial required. Data to be submitted to FDA 3Q 2021. </div></td><td>
              80m
            </td><td>
              66.8m
            </td><td>
              168.3k
            </td><td>
              0.8m
            </td><td>
              2.46
            </td><td>
              $0.83
            </td><td>
              $0.82
            </td><td>
              May 1, 2020
            </td><td>
              28.79m
            </td><td>
              -2.67m
            </td><td>
              10.78
            </td><td>
              7.45m
            </td><td>
              32.68m
            </td><td>
              2.9
            </td><td>
              52,002,724
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TBPH" class="margin-bottom-1">
                TBPH
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.13</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+0.60%</small></td><td><strong>Ampreloxetine</strong> <br>nOH
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/theravance-biopharma-inc-reports-second-quarter-2021-financial-results-and-provides-business-update-301347426.html">
                3Q 2021
              </a> <div class="note">Phase 3 data due 3Q 2021.</div></td><td>
              73m
            </td><td>
              1.0b
            </td><td>
              180.1k
            </td><td>
              467.1k
            </td><td>
              -3.46
            </td><td>
              $14.08
            </td><td>
              $14.05
            </td><td>
              August 2021
            </td><td>
              234.89m
            </td><td>
              -16.70m
            </td><td>
              14.06
            </td><td>
              -494.74m
            </td><td>
              1.44b
            </td><td>
              7.6
            </td><td>
              41,813,005
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BTAI" class="margin-bottom-1">
                BTAI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$25.74</div> <small class="number change-up">+1.47<span>&nbsp;&nbsp;</span>+6.06%</small></td><td><strong>BXCL701 and KEYTRUDA (pembrolizumab)</strong> <br>Neuroendocrine Prostate Cancer (NEPC)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.bioxceltherapeutics.com/press-releases/detail/171/bioxcel-therapeutics-reports-second-quarter-2021-financial">
                3Q 2021
              </a> <div class="note">Phase 2 data due 3Q 2021.</div></td><td>
              28m
            </td><td>
              0.7b
            </td><td>
              216.5k
            </td><td>
              415.7k
            </td><td>
              2.69
            </td><td>
              $24.68
            </td><td>
              $24.27
            </td><td>
              April 2, 2022
            </td><td>
              259.63m
            </td><td>
              -7.46m
            </td><td>
              34.80
            </td><td>
              245.93m
            </td><td>
              407.01m
            </td><td>
              0.8
            </td><td>
              18,482,964
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ASLN" class="margin-bottom-1">
                ASLN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.56</div> <small class="number change-up">+0.24<span>&nbsp;&nbsp;</span>+10.34%</small></td><td><strong>ASLAN004</strong> <br>Atopic dermatitis
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://aslanpharma.com/app/uploads/2021/08/ASLAN-Pharmaceuticals-2Q2021-Financial-Results.pdf">
                3Q 2021
              </a> <div class="note">Phase 1 top-line data due end of 3Q 2021. Phase 2b trial to be initiated 4Q 2021.</div></td><td>
              70m
            </td><td>
              178.2m
            </td><td>
              396.8k
            </td><td>
              1.1m
            </td><td>
              2.37
            </td><td>
              $2.39
            </td><td>
              $2.32
            </td><td>
              August 30, 2021
            </td><td>
              114.12m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              93.45m
            </td><td>
              82.95m
            </td><td>
              0
            </td><td>
              69,617,212
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TAK" class="margin-bottom-1">
                TAK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.97</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+1.75%</small></td><td><strong>Pevonedistat (TAK-924)</strong> <br>Higher-risk myelodysplastic syndromes (HR-MDS)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.takeda.com/4a21eb/siteassets/system/investors/report/quarterlyannouncements/fy2021/qr2021_q1_p01_en.pdf">
                3Q 2021
              </a> <div class="note">Phase 3 data due 3Q 2021.</div></td><td>
              3b
            </td><td>
              53.4b
            </td><td>
              0.8m
            </td><td>
              1.9m
            </td><td>
              1.12
            </td><td>
              $16.84
            </td><td>
              $16.68
            </td><td>
              N/A
            </td><td>
              0.78t
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -6.63t
            </td><td>
              86.30b
            </td><td>
              0
            </td><td>
              3,145,059,016
            </td><td>
              07/30/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VTVT" class="margin-bottom-1">
                VTVT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.73</div> <small class="number change-up">+0.02<span>&nbsp;&nbsp;</span>+1.18%</small></td><td><strong>HPP737</strong> <br>Psoriasis
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-announces-2021-second-quarter-financial-results">
                3Q 2021
              </a> <div class="note">Phase 1 top-line data due 3Q 2021.</div></td><td>
              83m
            </td><td>
              144.1m
            </td><td>
              165.8k
            </td><td>
              1.2m
            </td><td>
              -3.04
            </td><td>
              $1.74
            </td><td>
              $1.71
            </td><td>
              N/A
            </td><td>
              8.44m
            </td><td>
              -1.33m
            </td><td>
              6.33
            </td><td>
              -61.05m
            </td><td>
              132.34m
            </td><td>
              0.3
            </td><td>
              23,541,468
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CHRS" class="margin-bottom-1">
                CHRS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$15.49</div> <small class="number change-up">+0.49<span>&nbsp;&nbsp;</span>+3.30%</small></td><td><strong>Toripalimab</strong> <br>Nasopharyngeal carcinoma (NPC)
            </td><td>
              BLA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.coherus.com/news-releases/news-release-details/coherus-biosciences-reports-second-quarter-2021-financial">
                3Q 2021
              </a> <div class="note">BLA rolling submission has been initiated - March 3, 2021. To be completed 3Q 2021.</div></td><td>
              76m
            </td><td>
              1.2b
            </td><td>
              336.5k
            </td><td>
              0.7m
            </td><td>
              7.60
            </td><td>
              $15.14
            </td><td>
              $15
            </td><td>
              N/A
            </td><td>
              454.31m
            </td><td>
              -62.67k
            </td><td>
              7.25k
            </td><td>
              -129.01m
            </td><td>
              1.11b
            </td><td>
              1.4
            </td><td>
              54,173,405
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KLDO" class="margin-bottom-1">
                KLDO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.06</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+3.95%</small></td><td><strong>KB295</strong> <br>Ulcerative colitis (UC)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.kaleido.com/news-releases/news-release-details/kaleido-biosciences-reports-second-quarter-2021-financial">
                3Q 2021
              </a> <div class="note">Top-line data due 3Q 2021.</div></td><td>
              43m
            </td><td>
              258.0m
            </td><td>
              74.7k
            </td><td>
              295.6k
            </td><td>
              5.14
            </td><td>
              $5.91
            </td><td>
              $5.83
            </td><td>
              N/A
            </td><td>
              59.93m
            </td><td>
              -6.69m
            </td><td>
              8.95
            </td><td>
              25.91m
            </td><td>
              197.59m
            </td><td>
              4.7
            </td><td>
              20,994,841
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/STOK" class="margin-bottom-1">
                STOK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$26.00</div> <small class="number change-up">+1.10<span>&nbsp;&nbsp;</span>+4.42%</small></td><td><strong>STK-001 - (MONARCH)</strong> <br>Dravet syndrome
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210810005157/en/">
                3Q 2021
              </a> <div class="note">Phase 1/2 preliminary safety and pharmacokinetic data due 3Q 2021.</div></td><td>
              37m
            </td><td>
              1.0b
            </td><td>
              34.7k
            </td><td>
              146.4k
            </td><td>
              3.75
            </td><td>
              $26.42
            </td><td>
              $24.9
            </td><td>
              June 27, 2023
            </td><td>
              241.73m
            </td><td>
              -5.28m
            </td><td>
              45.81
            </td><td>
              232.35m
            </td><td>
              0.66b
            </td><td>
              1.5
            </td><td>
              18,959,096
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PGEN" class="margin-bottom-1">
                PGEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.04</div> <small class="number change-up">+0.42<span>&nbsp;&nbsp;</span>+7.56%</small></td><td><strong>AG019 ActoBiotics</strong> <br>Type 1 diabetes
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/precigen-reports-second-quarter-and-first-half-2021-financial-results-301351238.html">
                10/1/2021
              </a> <div class="note">Phase 1b/2a further data due October 1, 2021.</div></td><td>
              207m
            </td><td>
              1.2b
            </td><td>
              341.3k
            </td><td>
              1.2m
            </td><td>
              7.85
            </td><td>
              $5.75
            </td><td>
              $5.62
            </td><td>
              October 31, 2021
            </td><td>
              110.44m
            </td><td>
              -2.59m
            </td><td>
              42.61
            </td><td>
              -132.94m
            </td><td>
              1.24b
            </td><td>
              2.1
            </td><td>
              94,205,701
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ENTX" class="margin-bottom-1">
                ENTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.70</div> <small class="number change-up">+0.11<span>&nbsp;&nbsp;</span>+2.40%</small></td><td><strong>EB613</strong> <br>Osteoporosis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.enterabio.com/news-releases/news-release-details/entera-bio-present-phase-2-eb613-oral-pth-osteoporosis-treatment">
                10/1/2021
              </a> <div class="note">Phase 2 interim biomarker met primary endpoint - March 11, 2021. Final data released June 23, 2021. Data to be presented October 1-4, 2021 at American Society for Bone and Mineral Research Annual Meeting. Phase 3 trial to be initiated in 2022.</div></td><td>
              18m
            </td><td>
              85.7m
            </td><td>
              110.3k
            </td><td>
              4.0m
            </td><td>
              14.24
            </td><td>
              $4.57
            </td><td>
              $4.59
            </td><td>
              April 27, 2021
            </td><td>
              25.68m
            </td><td>
              -0.69m
            </td><td>
              37.19
            </td><td>
              22.06m
            </td><td>
              28.94m
            </td><td>
              0
            </td><td>
              6,309,570
            </td><td>
              08/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ANVS" class="margin-bottom-1">
                ANVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$39.76</div> <small class="number change-up">+2.66<span>&nbsp;&nbsp;</span>+7.17%</small></td><td><strong>ANVS401</strong> <br>Alzheimer’s disease (AD) and Parkinson’s disease (PD)
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.newsfilecorp.com/release/92796">
                Early-Fall 2021
              </a> <div class="note">Phase 2a completion of dosing announced August 11, 2021 full data due early Fall 2021. Phase 3 trial to be initiated 1Q 2022. </div></td><td>
              8m
            </td><td>
              322.1m
            </td><td>
              342.3k
            </td><td>
              0.9m
            </td><td>
              6.63
            </td><td>
              $37.19
            </td><td>
              $37.1
            </td><td>
              N/A
            </td><td>
              47.34m
            </td><td>
              -1.05m
            </td><td>
              45.16
            </td><td>
              46.45m
            </td><td>
              301.03m
            </td><td>
              31.8
            </td><td>
              5,639,681
            </td><td>
              08/19/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GILD" class="margin-bottom-1">
                GILD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$72.66</div> <small class="number change-up">+0.22<span>&nbsp;&nbsp;</span>+0.30%</small></td><td><strong>TECARTUS (brexucabtagene autoleucel) - (ZUMA-3)</strong> <br>Adult patients with r/r ALL - cancer
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210604005067/en/">
                10/1/2021
              </a> <div class="note">PDUFA date with priority review October 1, 2021.</div></td><td>
              1b
            </td><td>
              91.1b
            </td><td>
              2.8m
            </td><td>
              6.3m
            </td><td>
              4.62
            </td><td>
              $72.68
            </td><td>
              $72.44
            </td><td>
              September 9, 2020
            </td><td>
              7.91b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -40.36b
            </td><td>
              114.48b
            </td><td>
              0.6
            </td><td>
              1,253,507,953
            </td><td>
              06/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LABP" class="margin-bottom-1">
                LABP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.41</div> <small class="number change-down">-0.30<span>&nbsp;&nbsp;</span>-2.19%</small></td><td><strong>Omilancor (BT-11)</strong> <br>Ulcerative Colitis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.landosbiopharma.com/news-releases/news-release-details/landos-biopharmas-phase-2-data-omilancor-ulcerative-colitis">
                10/3/2021
              </a> <div class="note">Phase 2 data to be presented at the United European Gastroenterology Week (UEGW) meeting October 3-5, 2021. Phase 3 trial planned.</div></td><td>
              40m
            </td><td>
              0.5b
            </td><td>
              14.3k
            </td><td>
              45.9k
            </td><td>
              5.10
            </td><td>
              $13.28
            </td><td>
              $13.71
            </td><td>
              N/A
            </td><td>
              120.77m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              108.09m
            </td><td>
              434.89m
            </td><td>
              0.2
            </td><td>
              4,639,108
            </td><td>
              07/22/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OPK" class="margin-bottom-1">
                OPK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.90</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+6.40%</small></td><td><strong>Somatrogon (hGH-CTP)</strong> <br>Children - growth hormone deficiency
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20201008005030/en/">
                October 2021
              </a> <div class="note">BLA filing acceptance announced January 4, 2021. PDUFA date October 2021.</div></td><td>
              1b
            </td><td>
              2.7b
            </td><td>
              3.0m
            </td><td>
              4.3m
            </td><td>
              1.52
            </td><td>
              $3.68
            </td><td>
              $3.67
            </td><td>
              August 2019
            </td><td>
              56.49m
            </td><td>
              -5.15m
            </td><td>
              10.97
            </td><td>
              -0.62b
            </td><td>
              2.68b
            </td><td>
              6.3
            </td><td>
              410,492,692
            </td><td>
              01/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CCXI" class="margin-bottom-1">
                CCXI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.60</div> <small class="number change-up">+0.42<span>&nbsp;&nbsp;</span>+2.96%</small></td><td><strong>Avacopan (CCX168) - (ADVOCATE)</strong> <br>Associated vasculitis (AAV)
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.chemocentryx.com/news-releases/news-release-details/chemocentryx-announces-filing-amendment-nda-submission-and">
                10/7/2021
              </a> <div class="note">Advisory Committee May 6, 2021 voted 10-8 that the benefit-risk and safety profiles are adequate to support approval and 9-9 that the efficacy data supports approval. PDUFA date extended by three months to October 7, 2021.</div></td><td>
              70m
            </td><td>
              1.0b
            </td><td>
              0.7m
            </td><td>
              3.1m
            </td><td>
              3.09
            </td><td>
              $14.28
            </td><td>
              $14.18
            </td><td>
              September 7, 2019
            </td><td>
              301.89m
            </td><td>
              -5.95m
            </td><td>
              50.74
            </td><td>
              164.49m
            </td><td>
              0.75b
            </td><td>
              4.5
            </td><td>
              47,274,691
            </td><td>
              07/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PRLD" class="margin-bottom-1">
                PRLD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$32.49</div> <small class="number change-up">+1.49<span>&nbsp;&nbsp;</span>+4.81%</small></td><td><strong>PRT811</strong> <br>Solid Tumors and Recurrent High-Grade Gliomas
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2279670/0/en/Prelude-Therapeutics-Announces-Second-Quarter-2021-Financial-Results-and-Operations-Update.html">
                10/7/2021
              </a> <div class="note">Phase 1 dose expansion to commence mid-2021 with dose escalation data due at the AACR-NCI-EORTC Annual Meeting, October 7-10, 2021.</div></td><td>
              47m
            </td><td>
              1.5b
            </td><td>
              99.1k
            </td><td>
              201.0k
            </td><td>
              4.58
            </td><td>
              $31.49
            </td><td>
              $31
            </td><td>
              October 2021
            </td><td>
              331.17m
            </td><td>
              -6.64m
            </td><td>
              49.90
            </td><td>
              315.95m
            </td><td>
              1.12b
            </td><td>
              4.2
            </td><td>
              7,203,248
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TPTX" class="margin-bottom-1">
                TPTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$69.07</div> <small class="number change-up">+4.96<span>&nbsp;&nbsp;</span>+7.74%</small></td><td><strong>Repotrectinib (TPX-0005) - TRIDENT-1</strong> <br>Non-small-cell lung cancer (NSCLC) and solid tumors
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.tptherapeutics.com/news-releases/news-release-details/turning-point-therapeutics-reports-second-quarter-financial-0">
                10/7/2021
              </a> <div class="note">Phase 2 update at AACR-NCI-EORTC meeting October 7 - 10, 2021.</div></td><td>
              49m
            </td><td>
              3.4b
            </td><td>
              255.8k
            </td><td>
              462.0k
            </td><td>
              3.20
            </td><td>
              $65.47
            </td><td>
              $64.11
            </td><td>
              March 2021
            </td><td>
              1.05b
            </td><td>
              -14.13m
            </td><td>
              74.48
            </td><td>
              1.02b
            </td><td>
              2.10b
            </td><td>
              4.7
            </td><td>
              41,021,238
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ZLAB" class="margin-bottom-1">
                ZLAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$143.17</div> <small class="number change-up">+9.00<span>&nbsp;&nbsp;</span>+6.71%</small></td><td><strong>TPX-0022 ( SHIELD-1)</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.tptherapeutics.com/news-releases/news-release-details/turning-point-therapeutics-reports-second-quarter-financial-0">
                10/7/2021
              </a> <div class="note">Phase 1 update due at AACR-NCI-EORTC conference October 7 - 10, 2021. Phase 2 trial to be initiated 4Q 2021.</div></td><td>
              75m
            </td><td>
              10.8b
            </td><td>
              320.4k
            </td><td>
              0.6m
            </td><td>
              33.30
            </td><td>
              $135
            </td><td>
              $134.17
            </td><td>
              November 2022
            </td><td>
              1.73b
            </td><td>
              -21.95m
            </td><td>
              78.68
            </td><td>
              1.50b
            </td><td>
              1.78b
            </td><td>
              0
            </td><td>
              75,375,511
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TPTX" class="margin-bottom-1">
                TPTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$69.07</div> <small class="number change-up">+4.96<span>&nbsp;&nbsp;</span>+7.74%</small></td><td><strong>TPX-0022 ( SHIELD-1)</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.tptherapeutics.com/news-releases/news-release-details/turning-point-therapeutics-reports-second-quarter-financial-0">
                10/7/2021
              </a> <div class="note">Phase 1 update due at AACR-NCI-EORTC conference October 7 - 10, 2021. Phase 2 trial to be initiated 4Q 2021.</div></td><td>
              49m
            </td><td>
              3.4b
            </td><td>
              255.8k
            </td><td>
              462.0k
            </td><td>
              3.20
            </td><td>
              $65.47
            </td><td>
              $64.11
            </td><td>
              November 2022
            </td><td>
              1.05b
            </td><td>
              -14.13m
            </td><td>
              74.48
            </td><td>
              1.02b
            </td><td>
              2.10b
            </td><td>
              4.7
            </td><td>
              41,021,238
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FMTX" class="margin-bottom-1">
                FMTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$23.39</div> <small class="number change-up">+0.69<span>&nbsp;&nbsp;</span>+3.06%</small></td><td><strong>FT-7051</strong> <br>Prostate cancer (CRPC)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210813005019/en/">
                10/7/2021
              </a> <div class="note">Phase 1 initial data to be presented at the NCI/AACR/EORTC Virtual International Conference October 7-10, 2021</div></td><td>
              50m
            </td><td>
              1.2b
            </td><td>
              83.0k
            </td><td>
              332.2k
            </td><td>
              2.02
            </td><td>
              $22.94
            </td><td>
              $22.7
            </td><td>
              April 2022
            </td><td>
              0.52b
            </td><td>
              -10.85m
            </td><td>
              47.58
            </td><td>
              482.06m
            </td><td>
              0.60b
            </td><td>
              1.1
            </td><td>
              32,086,456
            </td><td>
              08/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PRLD" class="margin-bottom-1">
                PRLD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$32.49</div> <small class="number change-up">+1.49<span>&nbsp;&nbsp;</span>+4.81%</small></td><td><strong>PRT543</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2279670/0/en/Prelude-Therapeutics-Announces-Second-Quarter-2021-Financial-Results-and-Operations-Update.html">
                10/7/2021
              </a> <div class="note">Phase 1 interim data due at the AACR-NCI-EORTC Annual Meeting, October 7-10, 2021.</div></td><td>
              47m
            </td><td>
              1.5b
            </td><td>
              99.1k
            </td><td>
              201.0k
            </td><td>
              4.58
            </td><td>
              $31.49
            </td><td>
              $31
            </td><td>
              April 30, 2022
            </td><td>
              331.17m
            </td><td>
              -6.64m
            </td><td>
              49.90
            </td><td>
              315.95m
            </td><td>
              1.12b
            </td><td>
              4.2
            </td><td>
              7,203,248
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SGEN" class="margin-bottom-1">
                SGEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$163.53</div> <small class="number change-up">+4.23<span>&nbsp;&nbsp;</span>+2.66%</small></td><td><strong>Tisotumab Vedotin</strong> <br>Cervical Cancer
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/39417f02-cc51-4b42-a4f2-b9ebc579313b">
                10/10/2021
              </a> <div class="note">PDUFA date under priority review October 10, 2021.</div></td><td>
              182m
            </td><td>
              29.8b
            </td><td>
              0.5m
            </td><td>
              0.7m
            </td><td>
              8.77
            </td><td>
              $159.99
            </td><td>
              $159.3
            </td><td>
              N/A
            </td><td>
              2.41b
            </td><td>
              -24.15m
            </td><td>
              99.72
            </td><td>
              1.85b
            </td><td>
              26.59b
            </td><td>
              1.2
            </td><td>
              66,371,701
            </td><td>
              04/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GMAB" class="margin-bottom-1">
                GMAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$48.75</div> <small class="number change-up">+0.73<span>&nbsp;&nbsp;</span>+1.52%</small></td><td><strong>Tisotumab Vedotin</strong> <br>Cervical Cancer
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/39417f02-cc51-4b42-a4f2-b9ebc579313b">
                10/10/2021
              </a> <div class="note">PDUFA date under priority review October 10, 2021.</div></td><td>
              1b
            </td><td>
              31.9b
            </td><td>
              0.5m
            </td><td>
              0.5m
            </td><td>
              10.01
            </td><td>
              $47.72
            </td><td>
              $48.02
            </td><td>
              N/A
            </td><td>
              18.09b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              15.86b
            </td><td>
              28.51b
            </td><td>
              0
            </td><td>
              653,818,780
            </td><td>
              04/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ATRA" class="margin-bottom-1">
                ATRA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.79</div> <small class="number change-up">+1.16<span>&nbsp;&nbsp;</span>+9.18%</small></td><td><strong>ATA188</strong> <br>Multiple sclerosis
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005755/en/">
                10/13/2021
              </a> <div class="note">Phase 1 open-label data to be presented at ECTRIMS meeting October 13-15, 2021. Phase 2 interim analysis 1H 2022.</div></td><td>
              85m
            </td><td>
              1.2b
            </td><td>
              0.6m
            </td><td>
              0.7m
            </td><td>
              3.53
            </td><td>
              $12.7
            </td><td>
              $12.63
            </td><td>
              N/A
            </td><td>
              336.43m
            </td><td>
              -20.53m
            </td><td>
              16.39
            </td><td>
              211.18m
            </td><td>
              0.71b
            </td><td>
              3
            </td><td>
              73,456,041
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MNKD" class="margin-bottom-1">
                MNKD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.45</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+5.45%</small></td><td><strong>TYVASO (treprostinil) DPI</strong> <br>Pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD) (WHO Group 3)
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/united-therapeutics-announces-fda-acceptance-of-tyvaso-dpi-new-drug-application-for-priority-review-301313312.html">
                10/15/2021
              </a> <div class="note">NDA filing acceptance announced June 16, 2021 under priority review. PDUFA date not announced. Estimate October 15, 2021 based on 4-month review.</div></td><td>
              250m
            </td><td>
              1.1b
            </td><td>
              2.2m
            </td><td>
              3.0m
            </td><td>
              -6.01
            </td><td>
              $4.27
            </td><td>
              $4.22
            </td><td>
              N/A
            </td><td>
              149.62m
            </td><td>
              -7.15m
            </td><td>
              20.93
            </td><td>
              -286.72m
            </td><td>
              1.18b
            </td><td>
              3.6
            </td><td>
              245,425,982
            </td><td>
              06/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/UTHR" class="margin-bottom-1">
                UTHR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$207.40</div> <small class="number change-up">+3.18<span>&nbsp;&nbsp;</span>+1.56%</small></td><td><strong>TYVASO (treprostinil) DPI</strong> <br>Pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD) (WHO Group 3)
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/united-therapeutics-announces-fda-acceptance-of-tyvaso-dpi-new-drug-application-for-priority-review-301313312.html">
                10/15/2021
              </a> <div class="note">NDA filing acceptance announced June 16, 2021 under priority review. PDUFA date not announced. Estimate October 15, 2021 based on 4-month review.</div></td><td>
              45m
            </td><td>
              9.3b
            </td><td>
              118.3k
            </td><td>
              348.0k
            </td><td>
              2.56
            </td><td>
              $204.88
            </td><td>
              $204.22
            </td><td>
              N/A
            </td><td>
              2.06b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              0.85b
            </td><td>
              8.00b
            </td><td>
              0.2
            </td><td>
              44,113,197
            </td><td>
              06/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/XENE" class="margin-bottom-1">
                XENE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.39</div> <small class="number change-down">-0.05<span>&nbsp;&nbsp;</span>-0.30%</small></td><td><strong>XEN1101 (X-TOLE)</strong> <br>Adult Focal Epilepsy
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.benzinga.com/pressreleases/21/08/g22452981/xenon-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-corporate-update">
                Late-September ~ mid-October 2021
              </a> <div class="note">Phase 2b completion of enrollment announced July 7, 2021. Top-line data due late-September to mid-October 2021.</div></td><td>
              41m
            </td><td>
              0.7b
            </td><td>
              175.3k
            </td><td>
              201.1k
            </td><td>
              2.70
            </td><td>
              $16.73
            </td><td>
              $16.44
            </td><td>
              June 2021
            </td><td>
              252.68m
            </td><td>
              -4.36m
            </td><td>
              57.97
            </td><td>
              234.95m
            </td><td>
              426.80m
            </td><td>
              1.9
            </td><td>
              40,156,539
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AVDL" class="margin-bottom-1">
                AVDL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.31</div> <small class="number change-up">+0.53<span>&nbsp;&nbsp;</span>+6.74%</small></td><td><strong>FT 218</strong> <br>Excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/03/01/2184208/0/en/Avadel-Pharmaceuticals-Announces-FDA-Acceptance-of-New-Drug-Application-for-FT218-in-Adults-with-Narcolepsy-for-the-Treatment-of-Excessive-Daytime-Sleepiness-and-Cataplexy.html">
                10/15/2021
              </a> <div class="note">PDUFA date October 15, 2021.</div></td><td>
              59m
            </td><td>
              487.2m
            </td><td>
              208.2k
            </td><td>
              282.4k
            </td><td>
              4.10
            </td><td>
              $7.99
            </td><td>
              $7.79
            </td><td>
              March 25, 2020
            </td><td>
              196.75m
            </td><td>
              -3.38m
            </td><td>
              58.14
            </td><td>
              33.04m
            </td><td>
              397.48m
            </td><td>
              2.4
            </td><td>
              57,172,010
            </td><td>
              03/01/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OYST" class="margin-bottom-1">
                OYST
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.25</div> <small class="number change-up">+0.10<span>&nbsp;&nbsp;</span>+0.76%</small></td><td><strong>Varenicline (OC-01)</strong> <br>Dry eye disease
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.oysterpointrx.com/news-releases/news-release-details/oyster-point-pharma-announces-fda-acceptance-filing-new-drug">
                10/17/2021
              </a> <div class="note">PDUFA date October 17, 2021.</div></td><td>
              26m
            </td><td>
              344.7m
            </td><td>
              188.2k
            </td><td>
              88.0k
            </td><td>
              2.27
            </td><td>
              $13.15
            </td><td>
              $13.15
            </td><td>
              May 8, 2020
            </td><td>
              142.47m
            </td><td>
              -6.85m
            </td><td>
              20.79
            </td><td>
              132.75m
            </td><td>
              188.08m
            </td><td>
              1.9
            </td><td>
              11,148,373
            </td><td>
              05/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OMER" class="margin-bottom-1">
                OMER
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.87</div> <small class="number change-up">+0.10<span>&nbsp;&nbsp;</span>+0.68%</small></td><td><strong>Narsoplimab</strong> <br>Hematopoietic stem cell-associated TMA (HSCT-TMA)
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210520005392/en/">
                10/17/2021
              </a> <div class="note">PDUFA date under priority review extended by three months to October 17, 2021. </div></td><td>
              62m
            </td><td>
              0.9b
            </td><td>
              435.1k
            </td><td>
              420.3k
            </td><td>
              -3.77
            </td><td>
              $14.8
            </td><td>
              $14.77
            </td><td>
              N/A
            </td><td>
              57.10m
            </td><td>
              -9.20m
            </td><td>
              6.21
            </td><td>
              -334.58m
            </td><td>
              1.20b
            </td><td>
              4.2
            </td><td>
              59,915,908
            </td><td>
              05/20/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BGNE" class="margin-bottom-1">
                BGNE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$270.83</div> <small class="number change-up">+21.23<span>&nbsp;&nbsp;</span>+8.51%</small></td><td><strong>BRUKINSA (zanubrutinib)</strong> <br>Waldenström’s macroglobulinemia
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210217005324/en/">
                10/18/2021
              </a> <div class="note">PDUFA date October 18, 2021.</div></td><td>
              93m
            </td><td>
              25.2b
            </td><td>
              273.7k
            </td><td>
              315.1k
            </td><td>
              7.00
            </td><td>
              $256
            </td><td>
              $249.6
            </td><td>
              January 18, 2022
            </td><td>
              4.13b
            </td><td>
              -140.09m
            </td><td>
              29.48
            </td><td>
              2.21b
            </td><td>
              21.09b
            </td><td>
              0.3
            </td><td>
              89,530,472
            </td><td>
              05/07/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OCUL" class="margin-bottom-1">
                OCUL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$10.35</div> <small class="number change-up">+0.34<span>&nbsp;&nbsp;</span>+3.40%</small></td><td><strong>DEXTENZA</strong> <br>Allergic conjunctivitis
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210304006018/en/">
                10/18/2021
              </a> <div class="note">PDUFA date October 18, 2021.</div></td><td>
              77m
            </td><td>
              0.8b
            </td><td>
              424.1k
            </td><td>
              0.8m
            </td><td>
              9.86
            </td><td>
              $10.14
            </td><td>
              $10.01
            </td><td>
              N/A
            </td><td>
              179.83m
            </td><td>
              -6.69m
            </td><td>
              26.90
            </td><td>
              29.37m
            </td><td>
              0.63b
            </td><td>
              2.1
            </td><td>
              68,673,532
            </td><td>
              03/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/REGN" class="margin-bottom-1">
                REGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$665.74</div> <small class="number change-up">+2.47<span>&nbsp;&nbsp;</span>+0.37%</small></td><td><strong>DUPIXENT (dupilumab)</strong> <br>Asthma - 6-11 year-olds
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/fda-accepts-dupixent-dupilumab-for-review-in-children-with-moderate-to-severe-asthma-301240295.html">
                10/21/2021
              </a> <div class="note">PDUFA date October 21, 2021.</div></td><td>
              107m
            </td><td>
              71.2b
            </td><td>
              0.7m
            </td><td>
              0.8m
            </td><td>
              4.71
            </td><td>
              $665.21
            </td><td>
              $663.27
            </td><td>
              August 26, 2020
            </td><td>
              4.29b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -2.07b
            </td><td>
              69.73b
            </td><td>
              2.1
            </td><td>
              89,032,197
            </td><td>
              06/18/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SNY" class="margin-bottom-1">
                SNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$52.48</div> <small class="number change-down">-0.64<span>&nbsp;&nbsp;</span>-1.20%</small></td><td><strong>DUPIXENT (dupilumab)</strong> <br>Asthma - 6-11 year-olds
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/fda-accepts-dupixent-dupilumab-for-review-in-children-with-moderate-to-severe-asthma-301240295.html">
                10/21/2021
              </a> <div class="note">PDUFA date October 21, 2021.</div></td><td>
              3b
            </td><td>
              131.7b
            </td><td>
              2.5m
            </td><td>
              1.7m
            </td><td>
              1.78
            </td><td>
              $52.73
            </td><td>
              $53.12
            </td><td>
              August 26, 2020
            </td><td>
              9.72b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -39.23b
            </td><td>
              146.90b
            </td><td>
              0
            </td><td>
              2,510,366,030
            </td><td>
              06/18/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RHHBY" class="margin-bottom-1">
                RHHBY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$50.36</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+0.12%</small></td><td><strong>Port Delivery System with ranibizumab</strong> <br>Neovascular Age-Related Macular Degeneration
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/f391659a-874c-43ed-8462-96087c91004f">
                10/23/2021
              </a> <div class="note">PDUFA date October 23, 2021.</div></td><td>
              7b
            </td><td>
              344.2b
            </td><td>
              0.5m
            </td><td>
              1.0m
            </td><td>
              8.35
            </td><td>
              $50.24
            </td><td>
              $50.3
            </td><td>
              March 27, 2020
            </td><td>
              8.02b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -38.44b
            </td><td>
              356.64b
            </td><td>
              0
            </td><td>
              6,834,087,224
            </td><td>
              06/24/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ADAP" class="margin-bottom-1">
                ADAP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.21</div> <small class="number change-up">+0.41<span>&nbsp;&nbsp;</span>+10.66%</small></td><td><strong>Afami-cel (ADP-A2M4)</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.adaptimmune.com/investors-and-media/news-events/press-releases/detail/188/adaptimmune-reports-fourth-quarter-full-year-2020">
                10/24/2021
              </a> <div class="note">Phase 1 update at American Society for Radiation Oncology (ASTRO) October 24-27, 2021.</div></td><td>
              156m
            </td><td>
              0.7b
            </td><td>
              0.7m
            </td><td>
              0.7m
            </td><td>
              2.36
            </td><td>
              $3.99
            </td><td>
              $3.8
            </td><td>
              September 2032
            </td><td>
              266.49m
            </td><td>
              -10.49m
            </td><td>
              25.41
            </td><td>
              154.64m
            </td><td>
              330.41m
            </td><td>
              3.3
            </td><td>
              124,957,108
            </td><td>
              05/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TAK" class="margin-bottom-1">
                TAK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.97</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+1.75%</small></td><td><strong>Mobocertinib (TAK-788)</strong> <br>Non-small cell lung cancer (NSCLC)
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210427006162/en/">
                10/26/2021
              </a> <div class="note">PDUFA date under priority review October 26, 2021.</div></td><td>
              3b
            </td><td>
              53.4b
            </td><td>
              0.8m
            </td><td>
              1.9m
            </td><td>
              1.12
            </td><td>
              $16.84
            </td><td>
              $16.68
            </td><td>
              N/A
            </td><td>
              0.78t
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -6.63t
            </td><td>
              86.30b
            </td><td>
              0
            </td><td>
              3,145,059,016
            </td><td>
              04/27/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EYEN" class="margin-bottom-1">
                EYEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.20</div> <small class="number change-up">+0.08<span>&nbsp;&nbsp;</span>+1.94%</small></td><td><strong>MydCombi</strong> <br>Mydriasis - pupil dilation
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://eyenoviabio.gcs-web.com/news-releases/news-release-details/eyenovia-reports-fourth-quarter-and-full-year-2020-financial">
                10/28/2021
              </a> <div class="note">PDUFA date October 28, 2021.</div></td><td>
              26m
            </td><td>
              109.0m
            </td><td>
              186.6k
            </td><td>
              84.0k
            </td><td>
              12.00
            </td><td>
              $4.21
            </td><td>
              $4.12
            </td><td>
              N/A
            </td><td>
              23.98m
            </td><td>
              -1.78m
            </td><td>
              13.50
            </td><td>
              2.39m
            </td><td>
              87.68m
            </td><td>
              9.4
            </td><td>
              17,942,157
            </td><td>
              03/25/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ANIP" class="margin-bottom-1">
                ANIP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.65</div> <small class="number change-up">+1.69<span>&nbsp;&nbsp;</span>+6.04%</small></td><td><strong>Cortrophin Gel</strong> <br>Acute exacerbations of multiple sclerosis, rheumatoid arthritis, systemic lupus erythematous and ulcerative colitis
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210806005255/en/">
                10/29/2021
              </a> <div class="note">Refusal to File (RTF) letter announced April 29, 2020. sNDA resubmitted with PDUFA date of October 29, 2021.</div></td><td>
              13m
            </td><td>
              378.1m
            </td><td>
              20.9k
            </td><td>
              62.2k
            </td><td>
              1.97
            </td><td>
              $28.35
            </td><td>
              $27.96
            </td><td>
              N/A
            </td><td>
              24.41m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -263.84m
            </td><td>
              0.54b
            </td><td>
              14.8
            </td><td>
              8,302,600
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLSD" class="margin-bottom-1">
                CLSD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.95</div> <small class="number change-up">+0.30<span>&nbsp;&nbsp;</span>+5.31%</small></td><td><strong>XIPERE (Suprachoroidal CLS-TA)</strong> <br>Macular edema associated with uveitis
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/bausch-health-and-clearside-biomedical-announce-us-fda-filing-acceptance-for-xipere-triamcinolone-acetonide-suprachoroidal-injectable-suspension-301303666.html">
                10/30/2021
              </a> <div class="note">CRL received October 18, 2019. New PDUFA date October 30, 2021.</div></td><td>
              59m
            </td><td>
              353.9m
            </td><td>
              0.8m
            </td><td>
              4.0m
            </td><td>
              18.03
            </td><td>
              $5.66
            </td><td>
              $5.65
            </td><td>
              N/A
            </td><td>
              22.24m
            </td><td>
              -2.32m
            </td><td>
              9.60
            </td><td>
              12.99m
            </td><td>
              310.48m
            </td><td>
              9
            </td><td>
              47,643,724
            </td><td>
              06/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BHC" class="margin-bottom-1">
                BHC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$28.30</div> <small class="number change-up">+0.34<span>&nbsp;&nbsp;</span>+1.23%</small></td><td><strong>XIPERE (Suprachoroidal CLS-TA)</strong> <br>Macular edema associated with uveitis
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/bausch-health-and-clearside-biomedical-announce-us-fda-filing-acceptance-for-xipere-triamcinolone-acetonide-suprachoroidal-injectable-suspension-301303666.html">
                10/30/2021
              </a> <div class="note">CRL received October 18, 2019. New PDUFA date October 30, 2021.</div></td><td>
              355m
            </td><td>
              10.2b
            </td><td>
              0.7m
            </td><td>
              2.3m
            </td><td>
              -14.82
            </td><td>
              $28.26
            </td><td>
              $27.96
            </td><td>
              N/A
            </td><td>
              0.88b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -29.77b
            </td><td>
              32.82b
            </td><td>
              2.5
            </td><td>
              313,448,534
            </td><td>
              06/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ANGN" class="margin-bottom-1">
                ANGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$10.11</div> <small class="number change-up">+0.76<span>&nbsp;&nbsp;</span>+8.13%</small></td><td><strong>ANG-3777</strong> <br>Acute kidney injury (AKI) / Delayed Graft Function
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.angion.com/news-releases/news-release-details/angion-provides-corporate-update-and-reports-second-quarter-2021">
                Early-4Q 2021
              </a> <div class="note">Phase 3 top-line data early-4Q 2021.</div></td><td>
              30m
            </td><td>
              301.3m
            </td><td>
              136.1k
            </td><td>
              84.1k
            </td><td>
              3.90
            </td><td>
              $9.52
            </td><td>
              $9.35
            </td><td>
              September 2021
            </td><td>
              110.99m
            </td><td>
              -3.51m
            </td><td>
              31.62
            </td><td>
              62.82m
            </td><td>
              166.08m
            </td><td>
              13.5
            </td><td>
              16,280,789
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ETTX" class="margin-bottom-1">
                ETTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.49</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+6.48%</small></td><td><strong>SUL-DUR (ATTACK)</strong> <br>Acinetobacter baumannii infections
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.benzinga.com/pressreleases/21/08/g22453135/entasis-therapeutics-reports-second-quarter-2021-financial-results-and-provides-business-update">
                Early-4Q 2021
              </a> <div class="note">Phase 3 top-line data due early-4Q 2021.</div></td><td>
              47m
            </td><td>
              117.9m
            </td><td>
              75.3k
            </td><td>
              328.6k
            </td><td>
              2.23
            </td><td>
              $2.35
            </td><td>
              $2.34
            </td><td>
              July 22, 2021
            </td><td>
              51.32m
            </td><td>
              -2.83m
            </td><td>
              18.15
            </td><td>
              40.81m
            </td><td>
              55.32m
            </td><td>
              0.7
            </td><td>
              27,075,203
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DRNA" class="margin-bottom-1">
                DRNA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$20.96</div> <small class="number change-up">+0.32<span>&nbsp;&nbsp;</span>+1.55%</small></td><td><strong>Nedosiran (PHYOX4)</strong> <br>Primary Hyperoxaluria Type 3
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005221/en/">
                October 2021
              </a> <div class="note">Phase 1 data due October 2021.</div></td><td>
              78m
            </td><td>
              1.6b
            </td><td>
              483.1k
            </td><td>
              1.0m
            </td><td>
              14.66
            </td><td>
              $20.79
            </td><td>
              $20.64
            </td><td>
              September 7, 2021
            </td><td>
              0.69b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -39.15m
            </td><td>
              1.08b
            </td><td>
              0.4
            </td><td>
              74,503,276
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RPTX" class="margin-bottom-1">
                RPTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$33.97</div> <small class="number change-up">+0.57<span>&nbsp;&nbsp;</span>+1.71%</small></td><td><strong>RP-3500 (TRESR)</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210812005844/en/">
                Early-4Q 2021
              </a> <div class="note">Phase 1/2 dosing of first patient announced July 29, 2020. Initial data due early-4Q 2021.</div></td><td>
              37m
            </td><td>
              1.3b
            </td><td>
              41.1k
            </td><td>
              136.9k
            </td><td>
              5.15
            </td><td>
              $33.69
            </td><td>
              $33.4
            </td><td>
              May 30, 2022
            </td><td>
              289.96m
            </td><td>
              -6.02m
            </td><td>
              48.17
            </td><td>
              214.40m
            </td><td>
              0.94b
            </td><td>
              0.3
            </td><td>
              21,615,325
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VTVT" class="margin-bottom-1">
                VTVT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.73</div> <small class="number change-up">+0.02<span>&nbsp;&nbsp;</span>+1.18%</small></td><td><strong>TTP399</strong> <br>Type 1 Diabetes
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-announces-2021-second-quarter-financial-results">
                Late-3Q 2021 /early-4Q 2021
              </a> <div class="note">Phase 1 top-line data from mechanistic trial due late-3Q 2021 or early-4Q 2021. Pivotal trial planned for 1H 2022.</div></td><td>
              83m
            </td><td>
              144.1m
            </td><td>
              165.8k
            </td><td>
              1.2m
            </td><td>
              -3.04
            </td><td>
              $1.74
            </td><td>
              $1.71
            </td><td>
              N/A
            </td><td>
              8.44m
            </td><td>
              -1.33m
            </td><td>
              6.33
            </td><td>
              -61.05m
            </td><td>
              132.34m
            </td><td>
              0.3
            </td><td>
              23,541,468
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PHAT" class="margin-bottom-1">
                PHAT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$32.90</div> <small class="number change-up">+1.34<span>&nbsp;&nbsp;</span>+4.26%</small></td><td><strong>Vonoprazan PHALCON-EE</strong> <br>Erosive esophagitis / Gastroesophageal reflux disease (GERD)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.phathompharma.com/news-releases/news-release-details/phathom-pharmaceuticals-reports-second-quarter-2021-results-and">
                October 2021
              </a> <div class="note">Phase 3 top-line data due October 2021.</div></td><td>
              31m
            </td><td>
              1.0b
            </td><td>
              66.6k
            </td><td>
              97.7k
            </td><td>
              7.81
            </td><td>
              $31.84
            </td><td>
              $31.55
            </td><td>
              July 29, 2021
            </td><td>
              192.65m
            </td><td>
              -9.45m
            </td><td>
              20.38
            </td><td>
              110.20m
            </td><td>
              0.83b
            </td><td>
              8.1
            </td><td>
              20,563,110
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MTCR" class="margin-bottom-1">
                MTCR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.78</div> <small class="number change-up">+0.17<span>&nbsp;&nbsp;</span>+6.51%</small></td><td><strong>MET642</strong> <br>Non-alcoholic steatohepatitis (NASH)
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.metacrine.com/news-releases/news-release-details/metacrine-updates-met642-clinical-development-milestone-and">
                Early-4Q 2021
              </a> <div class="note">Phase 2a interim data due early-4Q 2021. </div></td><td>
              27m
            </td><td>
              73.7m
            </td><td>
              169.1k
            </td><td>
              172.4k
            </td><td>
              1.17
            </td><td>
              $2.62
            </td><td>
              $2.61
            </td><td>
              January 17, 2022
            </td><td>
              68.73m
            </td><td>
              -3.38m
            </td><td>
              20.35
            </td><td>
              50.60m
            </td><td>
              5.30m
            </td><td>
              13.6
            </td><td>
              13,699,229
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SIOX" class="margin-bottom-1">
                SIOX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.85</div> <small class="number change-up">+0.04<span>&nbsp;&nbsp;</span>+2.21%</small></td><td><strong>AXO-AAV-GM1</strong> <br>GM1 gangliosidosis
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.siogtx.com/news-releases/news-release-details/sio-gene-therapies-announces-corporate-updates-and-fiscal-first">
                Late-3Q / early-4Q 2021
              </a> <div class="note">Phase 1/2 12-month data from low-dose cohort due late-3Q / early-4Q 2021. 12-month topline data from the first two patients dosed in the high-dose cohort due 1Q 2022.</div></td><td>
              73m
            </td><td>
              134.9m
            </td><td>
              447.1k
            </td><td>
              0.7m
            </td><td>
              1.19
            </td><td>
              $1.8
            </td><td>
              $1.81
            </td><td>
              April 1, 2024
            </td><td>
              103.38m
            </td><td>
              -4.22m
            </td><td>
              24.51
            </td><td>
              94.87m
            </td><td>
              22.24m
            </td><td>
              1.5
            </td><td>
              54,080,796
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DVAX" class="margin-bottom-1">
                DVAX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.48</div> <small class="number change-up">+1.44<span>&nbsp;&nbsp;</span>+11.97%</small></td><td><strong>VLA2001-301 + alum and CpG 1018 (COV-COMPARE)</strong> <br>COVID-19 vaccine
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/23/2284439/0/en/Valneva-Commences-Rolling-Submission-to-MHRA-for-its-Inactivated-Adjuvanted-COVID-19-Vaccine.html">
                Early-4Q 2021
              </a> <div class="note">Phase 3 top-line data due early-4Q 2021.UK rolling submission has commenced August 23, 2021. </div></td><td>
              115m
            </td><td>
              1.5b
            </td><td>
              2.8m
            </td><td>
              2.3m
            </td><td>
              18.47
            </td><td>
              $12.44
            </td><td>
              $12.04
            </td><td>
              July 15, 2021
            </td><td>
              412.28m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -152.25m
            </td><td>
              1.29b
            </td><td>
              1.6
            </td><td>
              90,823,786
            </td><td>
              08/23/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VALN" class="margin-bottom-1">
                VALN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.43</div> <small class="number change-up">+1.42<span>&nbsp;&nbsp;</span>+4.89%</small></td><td><strong>VLA2001-301 + alum and CpG 1018 (COV-COMPARE)</strong> <br>COVID-19 vaccine
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/23/2284439/0/en/Valneva-Commences-Rolling-Submission-to-MHRA-for-its-Inactivated-Adjuvanted-COVID-19-Vaccine.html">
                Early-4Q 2021
              </a> <div class="note">Phase 3 top-line data due early-4Q 2021.UK rolling submission has commenced August 23, 2021. </div></td><td>
              50m
            </td><td>
              1.5b
            </td><td>
              14.3k
            </td><td>
              8.1k
            </td><td>
              24.74
            </td><td>
              $30.62
            </td><td>
              $29.01
            </td><td>
              July 15, 2021
            </td><td>
              312.54m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -209.22m
            </td><td>
              1.28b
            </td><td>
              0
            </td><td>
              49,890,295
            </td><td>
              08/23/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ETON" class="margin-bottom-1">
                ETON
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.86</div> <small class="number change-up">+0.45<span>&nbsp;&nbsp;</span>+10.20%</small></td><td><strong>Topiramate Oral Solution</strong> <br>Seizures/migraine
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.etonpharma.com/static-files/0f086a1d-e0ea-4b95-98f7-400e06be7182">
                11/6/2021
              </a> <div class="note">PDUFA date November 6, 2021 (delayed three months).</div></td><td>
              25m
            </td><td>
              119.6m
            </td><td>
              293.5k
            </td><td>
              0.7m
            </td><td>
              5.79
            </td><td>
              $4.54
            </td><td>
              $4.41
            </td><td>
              N/A
            </td><td>
              25.58m
            </td><td>
              -123.00k
            </td><td>
              207.97
            </td><td>
              16.41m
            </td><td>
              89.50m
            </td><td>
              8.2
            </td><td>
              19,712,577
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LQDA" class="margin-bottom-1">
                LQDA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.60</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+0.19%</small></td><td><strong>LIQ861</strong> <br>Pulmonary arterial hypertension
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.liquidia.com/news-releases/news-release-details/liquidia-announces-fda-acceptance-new-drug-application">
                11/7/2021
              </a> <div class="note">CRL announced November 25, 2020. New PDUFA date November 7, 2021.</div></td><td>
              52m
            </td><td>
              134.9m
            </td><td>
              86.1k
            </td><td>
              352.0k
            </td><td>
              1.71
            </td><td>
              $2.57
            </td><td>
              $2.59
            </td><td>
              N/A
            </td><td>
              62.93m
            </td><td>
              -2.75m
            </td><td>
              22.86
            </td><td>
              37.57m
            </td><td>
              83.16m
            </td><td>
              1.2
            </td><td>
              28,612,343
            </td><td>
              06/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/STTK" class="margin-bottom-1">
                STTK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.75</div> <small class="number change-up">+1.80<span>&nbsp;&nbsp;</span>+9.02%</small></td><td><strong>SL-172154</strong> <br>Ovarian Cancer
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.shattucklabs.com/news-releases/news-release-details/shattuck-labs-reports-second-quarter-2021-financial-results-and">
                11/10/2021
              </a> <div class="note"> Phase 1 dose escalation data to be presented at SITC meeting November 10-14, 2021.</div></td><td>
              42m
            </td><td>
              0.9b
            </td><td>
              328.8k
            </td><td>
              184.1k
            </td><td>
              3.31
            </td><td>
              $22
            </td><td>
              $19.95
            </td><td>
              July 2022
            </td><td>
              296.19m
            </td><td>
              -4.78m
            </td><td>
              61.97
            </td><td>
              249.50m
            </td><td>
              0.54b
            </td><td>
              1.7
            </td><td>
              22,794,659
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INBX" class="margin-bottom-1">
                INBX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.05</div> <small class="number change-up">+1.59<span>&nbsp;&nbsp;</span>+5.59%</small></td><td><strong>INBRX-109</strong> <br>Chondrosarcoma and mesothelioma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/inhibrx-initiates-a-potential-registration-enabling-phase-2-study-of-inbrx-109-in-conventional-chondrosarcoma-patients-updates-data-for-ongoing-phase-1-study-and-announces-amended-loan-agreement-with-oxford-301316680.html">
                11/10/2021
              </a> <div class="note">Phase 1 interim data released November 11, 2020. 2/12 partial responses. Further data due at CTOS conference November 10-13, 2021. Initiation of Phase 2 trial announced June 21, 2021.</div></td><td>
              38m
            </td><td>
              1.1b
            </td><td>
              40.8k
            </td><td>
              235.2k
            </td><td>
              25.68
            </td><td>
              $29.12
            </td><td>
              $28.46
            </td><td>
              N/A
            </td><td>
              112.30m
            </td><td>
              -7.46m
            </td><td>
              15.05
            </td><td>
              14.73m
            </td><td>
              1.03b
            </td><td>
              0.6
            </td><td>
              22,511,163
            </td><td>
              06/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ADAP" class="margin-bottom-1">
                ADAP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.21</div> <small class="number change-up">+0.41<span>&nbsp;&nbsp;</span>+10.66%</small></td><td><strong>Afami-cel - (SPEARHEAD‑1)</strong> <br>Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/09/2277384/35803/en/Adaptimmune-Reports-Second-Quarter-Financial-Results-and-Business-Update.html">
                11/10/2021
              </a> <div class="note">Phase 2 enrolment has been completed. Initial data at ASCO June 4-8, 2021. Abstract noted overall response rate was 39.3% (13/33), 41.4% (12/29) for synovial sarcoma; 25.0% (1/4) for MRCLS. Next update due at CTOS meeting November 10-13, 2021</div></td><td>
              156m
            </td><td>
              0.7b
            </td><td>
              0.7m
            </td><td>
              0.7m
            </td><td>
              2.36
            </td><td>
              $3.99
            </td><td>
              $3.8
            </td><td>
              October 1, 2021
            </td><td>
              266.49m
            </td><td>
              -10.49m
            </td><td>
              25.41
            </td><td>
              154.64m
            </td><td>
              330.41m
            </td><td>
              3.3
            </td><td>
              124,957,108
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/STTK" class="margin-bottom-1">
                STTK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.75</div> <small class="number change-up">+1.80<span>&nbsp;&nbsp;</span>+9.02%</small></td><td><strong>SL-279252</strong> <br>Solid Tumors or Lymphomas
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.shattucklabs.com/news-releases/news-release-details/shattuck-labs-reports-second-quarter-2021-financial-results-and">
                11/10/2021
              </a> <div class="note">Phase 1 dose-escalation data to be presented at SITC meeting November 10-14, 2021.</div></td><td>
              42m
            </td><td>
              0.9b
            </td><td>
              328.8k
            </td><td>
              184.1k
            </td><td>
              3.31
            </td><td>
              $22
            </td><td>
              $19.95
            </td><td>
              February 2, 2022
            </td><td>
              296.19m
            </td><td>
              -4.78m
            </td><td>
              61.97
            </td><td>
              249.50m
            </td><td>
              0.54b
            </td><td>
              1.7
            </td><td>
              22,794,659
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CRTX" class="margin-bottom-1">
                CRTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$95.68</div> <small class="number change-up">+9.55<span>&nbsp;&nbsp;</span>+11.09%</small></td><td><strong>Atuzaginstat - GAIN</strong> <br>Alzheimer’s disease
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005203/en/">
                Mid-November 2021
              </a> <div class="note">Phase 2/3 top-line data due by mid-November 2021. Open label extension trial has been stopped following partial clinical hold - noted February 15, 2021. </div></td><td>
              30m
            </td><td>
              2.8b
            </td><td>
              176.6k
            </td><td>
              288.1k
            </td><td>
              19.98
            </td><td>
              $87.57
            </td><td>
              $86.13
            </td><td>
              December 31, 2021
            </td><td>
              119.41m
            </td><td>
              -5.85m
            </td><td>
              20.40
            </td><td>
              100.10m
            </td><td>
              2.43b
            </td><td>
              2.5
            </td><td>
              17,097,976
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ADMP" class="margin-bottom-1">
                ADMP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.09</div> <small class="number change-up">+0.03<span>&nbsp;&nbsp;</span>+2.41%</small></td><td><strong>ZIMHI (naloxone HCI Injection)</strong> <br>Opioid overdose
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://ir.adamispharmaceuticals.com/news-releases/news-release-details/adamis-provides-update-zimhitm">
                11/12/2021
              </a> <div class="note">CRL announced November 16, 2020. NDA resubmitted with new PDUFA date November 12, 2021.</div></td><td>
              149m
            </td><td>
              161.6m
            </td><td>
              2.2m
            </td><td>
              4.9m
            </td><td>
              54.27
            </td><td>
              $1.05
            </td><td>
              $1.06
            </td><td>
              N/A
            </td><td>
              44.43m
            </td><td>
              -1.80m
            </td><td>
              24.63
            </td><td>
              17.06m
            </td><td>
              157.82m
            </td><td>
              5.7
            </td><td>
              148,035,493
            </td><td>
              06/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AGTC" class="margin-bottom-1">
                AGTC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.44</div> <small class="number change-up">+0.16<span>&nbsp;&nbsp;</span>+4.88%</small></td><td><strong>AGTC-501</strong> <br>X-linked Retinitis Pigmentosa (XLRP)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://ir.agtc.com/news-releases/news-release-details/agtc-announces-financial-results-and-business-update-quarter-13">
                11/13/2021
              </a> <div class="note">Phase 1/2 12-month data due at the American Academy of Ophthalmology Annual Meeting in November 13-16, 2021; 3-month interim Skyline data due 4Q 2021. Phase 2/3 (VISTA) six-month interim analysis 4Q 2022. </div></td><td>
              43m
            </td><td>
              147.1m
            </td><td>
              287.4k
            </td><td>
              1.1m
            </td><td>
              1.51
            </td><td>
              $3.32
            </td><td>
              $3.28
            </td><td>
              N/A
            </td><td>
              92.61m
            </td><td>
              -3.81m
            </td><td>
              24.31
            </td><td>
              59.95m
            </td><td>
              43.80m
            </td><td>
              0.7
            </td><td>
              42,620,212
            </td><td>
              05/17/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BMRN" class="margin-bottom-1">
                BMRN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$75.36</div> <small class="number change-up">+0.21<span>&nbsp;&nbsp;</span>+0.29%</small></td><td><strong>VOXZOGO (Vosoritide)</strong> <br>Achondroplasia
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/biomarin-announces-first-quarter-2021-financial-results-and-corporate-updates-301280641.html">
                11/20/2021
              </a> <div class="note">PDUFA date extended by three months to November 20, 2021.</div></td><td>
              183m
            </td><td>
              13.8b
            </td><td>
              399.2k
            </td><td>
              1.0m
            </td><td>
              3.26
            </td><td>
              $75.45
            </td><td>
              $75.14
            </td><td>
              October 30, 2019
            </td><td>
              1.17b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -483.86m
            </td><td>
              13.74b
            </td><td>
              1
            </td><td>
              142,192,515
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FENC" class="margin-bottom-1">
                FENC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.55</div> <small class="number change-up">+0.58<span>&nbsp;&nbsp;</span>+8.32%</small></td><td><strong>Pedmark (sodium thiosulfate)</strong> <br>Cisplatin-Induced Hearing Loss 
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/06/22/2250760/0/en/Fennec-Pharmaceuticals-Announces-FDA-Acceptance-of-New-Drug-Application-Resubmission-for-PEDMARK.html#:~:text=(NASDAQ%3A%20FENC%3B%20TSX%3A,of%20ototoxicity%20induced%20by%20cisplatin">
                11/27/2021
              </a> <div class="note">CRL announced August 10, 2020. NDA resubmitted with new PDUFA date of November 27, 2021.</div></td><td>
              26m
            </td><td>
              196.4m
            </td><td>
              75.0k
            </td><td>
              144.9k
            </td><td>
              8.78
            </td><td>
              $7
            </td><td>
              $6.97
            </td><td>
              N/A
            </td><td>
              24.64m
            </td><td>
              -1.48m
            </td><td>
              16.70
            </td><td>
              18.80m
            </td><td>
              160.09m
            </td><td>
              1.3
            </td><td>
              17,586,094
            </td><td>
              06/22/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LEGN" class="margin-bottom-1">
                LEGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$37.92</div> <small class="number change-up">+2.54<span>&nbsp;&nbsp;</span>+7.18%</small></td><td><strong>Ciltacabtagene autoleucel (cilta-cel) (LCAR-B38M/JNJ-4528) - CARTITUDE-1</strong> <br>Multiple myeloma
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210526006114/en/">
                11/29/2021
              </a> <div class="note">PDUFA date under priority review November 29, 2021.</div></td><td>
              145m
            </td><td>
              5.5b
            </td><td>
              339.5k
            </td><td>
              400.5k
            </td><td>
              26.52
            </td><td>
              $37.2
            </td><td>
              $35.38
            </td><td>
              February 24, 2022
            </td><td>
              419.14m
            </td><td>
              -8.93m
            </td><td>
              46.94
            </td><td>
              10.34m
            </td><td>
              4.66b
            </td><td>
              0
            </td><td>
              144,632,059
            </td><td>
              08/23/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/YMTX" class="margin-bottom-1">
                YMTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.27</div> <small class="number change-up">+0.58<span>&nbsp;&nbsp;</span>+6.67%</small></td><td><strong>YTX-7739</strong> <br>Parkinson’s Disease
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.yumanity.com/investor-relations/press-releases/">
                Fall 2021
              </a> <div class="note">Phase 1b preliminary results expected by fall of 2021.</div></td><td>
              10m
            </td><td>
              95.5m
            </td><td>
              51.8k
            </td><td>
              102.6k
            </td><td>
              2.32
            </td><td>
              $8.8
            </td><td>
              $8.69
            </td><td>
              N/A
            </td><td>
              49.86m
            </td><td>
              -3.20m
            </td><td>
              15.56
            </td><td>
              9.72m
            </td><td>
              66.02m
            </td><td>
              8.1
            </td><td>
              7,152,560
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BYSI" class="margin-bottom-1">
                BYSI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.77</div> <small class="number change-up">+2.58<span>&nbsp;&nbsp;</span>+12.78%</small></td><td><strong>Plinabulin + G-CSF Combination</strong> <br>Chemotherapy-induced neutropenia (CIN)
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/06/01/2239327/0/en/BeyondSpring-Announces-U-S-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-Plinabulin-and-G-CSF-Combination-for-the-Prevention-of-Chemotherapy-Induced-Neutropenia-CI.html">
                11/30/2021
              </a> <div class="note">PDUFA date under priority review November 30, 2021.</div></td><td>
              30m
            </td><td>
              0.7b
            </td><td>
              2.5m
            </td><td>
              3.4m
            </td><td>
              28.82
            </td><td>
              $20.16
            </td><td>
              $20.19
            </td><td>
              September 25, 2020
            </td><td>
              60.06m
            </td><td>
              -6.31m
            </td><td>
              9.51
            </td><td>
              33.34m
            </td><td>
              363.10m
            </td><td>
              0
            </td><td>
              10,963,858
            </td><td>
              06/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RCUS" class="margin-bottom-1">
                RCUS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.16</div> <small class="number change-up">+0.78<span>&nbsp;&nbsp;</span>+2.75%</small></td><td><strong>AB680 +Zimberelimab (AB122) - ARC-8</strong> <br>Pancreatic Cancer
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.arcusbio.com/investors-and-media/press-releases/press-release-details/2021/Arcus-Biosciences-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Operational-Highlights/default.aspx">
                Fall 2021
              </a> <div class="note">Phase 1 further data due fall of 2021.</div></td><td>
              71m
            </td><td>
              2.1b
            </td><td>
              139.5k
            </td><td>
              0.7m
            </td><td>
              3.44
            </td><td>
              $28.39
            </td><td>
              $28.38
            </td><td>
              January 30, 2024
            </td><td>
              0.68b
            </td><td>
              -24.66m
            </td><td>
              27.43
            </td><td>
              382.40m
            </td><td>
              1.35b
            </td><td>
              1.2
            </td><td>
              50,339,817
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AMYT" class="margin-bottom-1">
                AMYT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$11.89</div> <small class="number change-up">+0.36<span>&nbsp;&nbsp;</span>+3.12%</small></td><td><strong>FILSUVEZ (Oleogel-S10)</strong> <br>Epidermolysis Bullosa
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://otp.investis.com/clients/uk/amryt_pharmaceuticals_dac1/rns/regulatory-story.aspx?cid=1375&amp;newsid=1480844">
                11/30/2021
              </a> <div class="note">PDUFA date under priority review November 30, 2021.</div></td><td>
              63m
            </td><td>
              0.8b
            </td><td>
              48.1k
            </td><td>
              105.1k
            </td><td>
              15.24
            </td><td>
              $11.56
            </td><td>
              $11.53
            </td><td>
              N/A
            </td><td>
              160.76m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -323.59m
            </td><td>
              0.80b
            </td><td>
              73.1
            </td><td>
              0
            </td><td>
              06/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLDX" class="margin-bottom-1">
                CLDX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$48.69</div> <small class="number change-up">+1.14<span>&nbsp;&nbsp;</span>+2.40%</small></td><td><strong>CDX-0159</strong> <br>Chronic Inducible Urticaria
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.celldex.com/news-releases/news-release-details/celldex-reports-second-quarter-2021-financial-results-and">
                Fall 2021
              </a> <div class="note">Phase 1b data released March 29, 2021. 8/10 complete responses; 1/10 partial responses. Update July 9, 2021 noted 18/19 (95%) complete responses and 1/19 (5%) partial responses. Additional cold urticaria and symptomatic dermographism cohort data due fall of 2021 and data from the cholinergic cohort 1Q 2022.</div></td><td>
              46m
            </td><td>
              2.3b
            </td><td>
              345.8k
            </td><td>
              1.0m
            </td><td>
              12.42
            </td><td>
              $48.35
            </td><td>
              $47.55
            </td><td>
              December 2021
            </td><td>
              444.38m
            </td><td>
              -3.98m
            </td><td>
              111.75
            </td><td>
              422.11m
            </td><td>
              2.05b
            </td><td>
              14.1
            </td><td>
              46,253,150
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ADVM" class="margin-bottom-1">
                ADVM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.31</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+6.68%</small></td><td><strong>ADVM-022 (OPTIC)</strong> <br>Wet age-related macular degeneration (Wet-AMD)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.adverum.com/news-releases/news-release-details/adverum-provides-update-advm-022-and-infinity-trial-patients">
                Fall 2021
              </a> <div class="note">Phase 1 data to be presented in Fall 2021.</div></td><td>
              98m
            </td><td>
              227.2m
            </td><td>
              0.7m
            </td><td>
              2.2m
            </td><td>
              0.60
            </td><td>
              $2.18
            </td><td>
              $2.17
            </td><td>
              June 2022
            </td><td>
              343.49m
            </td><td>
              -11.30m
            </td><td>
              30.38
            </td><td>
              196.49m
            </td><td>
              -21.36m
            </td><td>
              4.6
            </td><td>
              92,400,327
            </td><td>
              07/22/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GSK" class="margin-bottom-1">
                GSK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$41.57</div> <small class="number change-down">-0.28<span>&nbsp;&nbsp;</span>-0.67%</small></td><td><strong>Sotrovimab (VIR-7831 / GSK4182136) - (COMET-PEAK)</strong> <br>COVID-19
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-provides-corporate-update-and-reports-second-0">
                Fall 2021
              </a> <div class="note">Phase 2 data due fall of 2021</div></td><td>
              3b
            </td><td>
              104.6b
            </td><td>
              2.3m
            </td><td>
              4.2m
            </td><td>
              4.95
            </td><td>
              $41.75
            </td><td>
              $41.85
            </td><td>
              March 2022
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -51.10b
            </td><td>
              133.80b
            </td><td>
              0.2
            </td><td>
              2,506,785,977
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VIR" class="margin-bottom-1">
                VIR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$47.20</div> <small class="number change-up">+0.73<span>&nbsp;&nbsp;</span>+1.57%</small></td><td><strong>Sotrovimab (VIR-7831 / GSK4182136) - (COMET-PEAK)</strong> <br>COVID-19
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-provides-corporate-update-and-reports-second-0">
                Fall 2021
              </a> <div class="note">Phase 2 data due fall of 2021</div></td><td>
              131m
            </td><td>
              6.2b
            </td><td>
              1.0m
            </td><td>
              0.9m
            </td><td>
              8.35
            </td><td>
              $47.62
            </td><td>
              $46.47
            </td><td>
              March 2022
            </td><td>
              0.91b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              0.59b
            </td><td>
              5.32b
            </td><td>
              5.6
            </td><td>
              69,593,992
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VBIV" class="margin-bottom-1">
                VBIV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.08</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+5.29%</small></td><td><strong>Sci-B-Vac</strong> <br>Hepatitis B vaccine
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210202005180/en/">
                11/30/2021
              </a> <div class="note">PDUFA date November 30, 2021.</div></td><td>
              231m
            </td><td>
              0.8b
            </td><td>
              1.6m
            </td><td>
              2.7m
            </td><td>
              4.67
            </td><td>
              $2.92
            </td><td>
              $2.93
            </td><td>
              N/A
            </td><td>
              128.60m
            </td><td>
              -3.57m
            </td><td>
              35.99
            </td><td>
              72.05m
            </td><td>
              0.64b
            </td><td>
              0.6
            </td><td>
              186,306,141
            </td><td>
              02/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IONS" class="margin-bottom-1">
                IONS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$39.33</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+0.18%</small></td><td><strong>Tofersen (VALOR study)</strong> <br>Amyotrophic lateral sclerosis (ALS)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ionispharma.com/news-releases/news-release-details/ionis-reports-second-quarter-2021-financial-results-and-recent">
                Fall 2021
              </a> <div class="note">Phase 3 data due by fall of 2021.</div></td><td>
              141m
            </td><td>
              5.6b
            </td><td>
              322.8k
            </td><td>
              1.1m
            </td><td>
              9.52
            </td><td>
              $39.68
            </td><td>
              $39.26
            </td><td>
              July 16, 2021
            </td><td>
              2.05b
            </td><td>
              -20.88m
            </td><td>
              98.00
            </td><td>
              132.28m
            </td><td>
              4.79b
            </td><td>
              0.6
            </td><td>
              119,102,131
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BIIB" class="margin-bottom-1">
                BIIB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$346.91</div> <small class="number change-up">+5.17<span>&nbsp;&nbsp;</span>+1.51%</small></td><td><strong>Tofersen (VALOR study)</strong> <br>Amyotrophic lateral sclerosis (ALS)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ionispharma.com/news-releases/news-release-details/ionis-reports-second-quarter-2021-financial-results-and-recent">
                Fall 2021
              </a> <div class="note">Phase 3 data due by fall of 2021.</div></td><td>
              149m
            </td><td>
              51.7b
            </td><td>
              466.4k
            </td><td>
              1.5m
            </td><td>
              4.81
            </td><td>
              $342.33
            </td><td>
              $341.74
            </td><td>
              July 16, 2021
            </td><td>
              3.79b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -9.47b
            </td><td>
              55.51b
            </td><td>
              1.4
            </td><td>
              132,287,800
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CTIC" class="margin-bottom-1">
                CTIC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.71</div> <small class="number change-up">+0.11<span>&nbsp;&nbsp;</span>+4.12%</small></td><td><strong>Pacritinib</strong> <br>Myelofibrosis
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/cti-biopharma-announces-acceptance-of-nda-granted-with-priority-review-of-pacritinib-for-treatment-of-patients-with-myelofibrosis-301302627.html">
                11/30/2021
              </a> <div class="note">PDUFA date under priority review November 30, 2021.</div></td><td>
              93m
            </td><td>
              252.6m
            </td><td>
              494.3k
            </td><td>
              0.6m
            </td><td>
              4.10
            </td><td>
              $2.71
            </td><td>
              $2.6
            </td><td>
              N/A
            </td><td>
              61.33m
            </td><td>
              -5.86m
            </td><td>
              10.46
            </td><td>
              45.54m
            </td><td>
              174.71m
            </td><td>
              8
            </td><td>
              71,272,835
            </td><td>
              06/01/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RHHBY" class="margin-bottom-1">
                RHHBY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$50.36</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+0.12%</small></td><td><strong>TECENTRIQ (atezolizumab) -  [IMpower010]</strong> <br>Non-Small Cell Lung Cancer
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/15b1099c-bba8-4573-98fe-76689df66df7">
                12/1/2021
              </a> <div class="note">PDUFA date under priority review December 1, 2021.</div></td><td>
              7b
            </td><td>
              344.2b
            </td><td>
              0.5m
            </td><td>
              1.0m
            </td><td>
              8.35
            </td><td>
              $50.24
            </td><td>
              $50.3
            </td><td>
              November 6, 2021
            </td><td>
              8.02b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -38.44b
            </td><td>
              356.64b
            </td><td>
              0
            </td><td>
              6,834,087,224
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MRK" class="margin-bottom-1">
                MRK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$78.65</div> <small class="number change-down">-0.03<span>&nbsp;&nbsp;</span>-0.04%</small></td><td><strong>KEYTRUDA (pembrolizumab)</strong> <br>Melanoma
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005406/en/">
                12/4/2021
              </a> <div class="note">Phase 3 trial met primary endpoint of recurrence-free survival (RFS) - August 5, 2021. PDUFA date under priority review December 4, 2021.</div></td><td>
              3b
            </td><td>
              199.1b
            </td><td>
              3.5m
            </td><td>
              10.3m
            </td><td>
              5.98
            </td><td>
              $79.11
            </td><td>
              $78.68
            </td><td>
              N/A
            </td><td>
              10.07b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -47.23b
            </td><td>
              217.11b
            </td><td>
              0.1
            </td><td>
              2,529,800,503
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EXEL" class="margin-bottom-1">
                EXEL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$18.89</div> <small class="number change-up">+0.46<span>&nbsp;&nbsp;</span>+2.47%</small></td><td><strong>CABOMETYX (Cabozantinib) - COSMIC-311</strong> <br>Thyroid Carcinoma
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005256/en/">
                12/4/2021
              </a> <div class="note">PDUFA date under priority review December 4, 2021.</div></td><td>
              315m
            </td><td>
              6.0b
            </td><td>
              0.6m
            </td><td>
              2.6m
            </td><td>
              2.91
            </td><td>
              $18.6
            </td><td>
              $18.44
            </td><td>
              August 19, 2020
            </td><td>
              1.46b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              1.13b
            </td><td>
              4.52b
            </td><td>
              2
            </td><td>
              279,036,935
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TAK" class="margin-bottom-1">
                TAK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.97</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+1.75%</small></td><td><strong>CABOMETYX (Cabozantinib) - COSMIC-311</strong> <br>Thyroid Carcinoma
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005256/en/">
                12/4/2021
              </a> <div class="note">PDUFA date under priority review December 4, 2021.</div></td><td>
              3b
            </td><td>
              53.4b
            </td><td>
              0.8m
            </td><td>
              1.9m
            </td><td>
              1.12
            </td><td>
              $16.84
            </td><td>
              $16.68
            </td><td>
              August 19, 2020
            </td><td>
              0.78t
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -6.63t
            </td><td>
              86.30b
            </td><td>
              0
            </td><td>
              3,145,059,016
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DARE" class="margin-bottom-1">
                DARE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.62</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+4.35%</small></td><td><strong>DARE-BV1</strong> <br>Bacterial Vaginosis
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-announces-fda-acceptance-and-priority-review-new">
                12/7/2021
              </a> <div class="note">PDUFA date under priority review December 7, 2021.</div></td><td>
              71m
            </td><td>
              114.1m
            </td><td>
              2.0m
            </td><td>
              11.4m
            </td><td>
              14.70
            </td><td>
              $1.53
            </td><td>
              $1.55
            </td><td>
              November 30, 2020
            </td><td>
              38.89m
            </td><td>
              -3.93m
            </td><td>
              9.89
            </td><td>
              31.81m
            </td><td>
              100.69m
            </td><td>
              1.1
            </td><td>
              68,859,431
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARVN" class="margin-bottom-1">
                ARVN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$87.70</div> <small class="number change-up">+1.87<span>&nbsp;&nbsp;</span>+2.18%</small></td><td><strong>ARV-471</strong> <br>ER+ positive / HER2- negative breast cancer
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.arvinas.com/news-releases/news-release-details/arvinas-reports-second-quarter-2021-financial-results-and">
                12/7/2021
              </a> <div class="note">Phase 1 dose escalation data to be presented at the San Antonio Breast Cancer Symposium, December 7-10, 2021. Phase 2 dose expansion trial has been initiated.</div></td><td>
              49m
            </td><td>
              4.3b
            </td><td>
              173.3k
            </td><td>
              0.6m
            </td><td>
              7.40
            </td><td>
              $87.32
            </td><td>
              $85.83
            </td><td>
              N/A
            </td><td>
              1.57b
            </td><td>
              -15.80m
            </td><td>
              99.50
            </td><td>
              1.51b
            </td><td>
              3.63b
            </td><td>
              2.8
            </td><td>
              38,367,143
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RETA" class="margin-bottom-1">
                RETA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$106.04</div> <small class="number change-up">+4.68<span>&nbsp;&nbsp;</span>+4.62%</small></td><td><strong>Bardoxolone methyl</strong> <br>Alport Syndrome
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005740/en/">
                Advisory Committee 12/08/2021; PDUFA 02/25/2022
              </a> <div class="note">PDUFA date February 25, 2022. Advisory committee meeting December 8, 2021.</div></td><td>
              36m
            </td><td>
              3.9b
            </td><td>
              141.2k
            </td><td>
              394.2k
            </td><td>
              12.30
            </td><td>
              $102.46
            </td><td>
              $101.36
            </td><td>
              N/A
            </td><td>
              0.74b
            </td><td>
              -8.53m
            </td><td>
              86.76
            </td><td>
              276.56m
            </td><td>
              3.22b
            </td><td>
              0.5
            </td><td>
              20,077,004
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MRK" class="margin-bottom-1">
                MRK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$78.65</div> <small class="number change-down">-0.03<span>&nbsp;&nbsp;</span>-0.04%</small></td><td><strong>KEYTRUDA (pembrolizumab) - (KEYNOTE-564 )</strong> <br>Renal cell carcinoma (RCC)
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210810005542/en/">
                12/10/2021
              </a> <div class="note">PDUFA date under priority review December 10, 2021.</div></td><td>
              3b
            </td><td>
              199.1b
            </td><td>
              3.5m
            </td><td>
              10.3m
            </td><td>
              5.98
            </td><td>
              $79.11
            </td><td>
              $78.68
            </td><td>
              N/A
            </td><td>
              10.07b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -47.23b
            </td><td>
              217.11b
            </td><td>
              0.1
            </td><td>
              2,529,800,503
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NEXI" class="margin-bottom-1">
                NEXI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.69</div> <small class="number change-down">-0.40<span>&nbsp;&nbsp;</span>-2.84%</small></td><td><strong>NEXI-001</strong> <br>Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome (MDS) after allogeneic HCT
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.neximmune.com/news-releases/news-release-details/neximmune-reports-second-quarter-2021-financial-results-and">
                12/11/2021
              </a> <div class="note">Phase 1/2 further data due at ASH December 11-14, 2021.</div></td><td>
              23m
            </td><td>
              309.8m
            </td><td>
              36.4k
            </td><td>
              38.3k
            </td><td>
              2.82
            </td><td>
              $14.5
            </td><td>
              $14.09
            </td><td>
              October 2022
            </td><td>
              94.63m
            </td><td>
              -4.54m
            </td><td>
              20.85
            </td><td>
              89.14m
            </td><td>
              216.88m
            </td><td>
              10.9
            </td><td>
              17,593,196
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NEXI" class="margin-bottom-1">
                NEXI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.69</div> <small class="number change-down">-0.40<span>&nbsp;&nbsp;</span>-2.84%</small></td><td><strong>NEXI-002</strong> <br>Multiple Myeloma
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.neximmune.com/news-releases/news-release-details/neximmune-reports-second-quarter-2021-financial-results-and">
                12/11/2021
              </a> <div class="note">Phase 1/2  preliminary data presented at EHA meeting June 2021. More complete results due at ASH December 11-14, 2021.</div></td><td>
              23m
            </td><td>
              309.8m
            </td><td>
              36.4k
            </td><td>
              38.3k
            </td><td>
              2.82
            </td><td>
              $14.5
            </td><td>
              $14.09
            </td><td>
              September 1, 2022
            </td><td>
              94.63m
            </td><td>
              -4.54m
            </td><td>
              20.85
            </td><td>
              89.14m
            </td><td>
              216.88m
            </td><td>
              10.9
            </td><td>
              17,593,196
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMGN" class="margin-bottom-1">
                IMGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.59</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+5.47%</small></td><td><strong>IMGN632</strong> <br>Relapse/Refractory AML, ALL, BPDCN
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210730005064/en/">
                12/11/2021
              </a> <div class="note">Phase 1/2 initial AML data due at ASH December 11-14, 2021.</div></td><td>
              202m
            </td><td>
              1.1b
            </td><td>
              0.7m
            </td><td>
              1.4m
            </td><td>
              16.44
            </td><td>
              $5.38
            </td><td>
              $5.3
            </td><td>
              June 2022
            </td><td>
              213.21m
            </td><td>
              -14.63m
            </td><td>
              14.58
            </td><td>
              -19.77m
            </td><td>
              0.85b
            </td><td>
              1.1
            </td><td>
              179,510,656
            </td><td>
              07/30/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AUTL" class="margin-bottom-1">
                AUTL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.17</div> <small class="number change-up">+0.53<span>&nbsp;&nbsp;</span>+9.40%</small></td><td><strong>Obe-cel (AUTO1) - (ALLCAR19)</strong> <br>Adult Acute lymphoblastic leukemia (ALL) / Chronic Lymphocytic Leukemia (CLL) / B-cell non-Hodgkin Lymphoma (B-NHL)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-reports-second-quarter-2021-financial">
                12/11/2021
              </a> <div class="note">Phase 1b/2 data presented at EHA June 11, 2021. 100% remission rate by month 3. 8/9 disease free at last follow up. Data from B-NHL and CLL – ALLCAR19 extension (Cohorts B &amp; C) due at ASH December 11-14, 2021.</div></td><td>
              73m
            </td><td>
              448.8m
            </td><td>
              404.8k
            </td><td>
              1.9m
            </td><td>
              1.58
            </td><td>
              $5.81
            </td><td>
              $5.64
            </td><td>
              N/A
            </td><td>
              194.39m
            </td><td>
              -12.20m
            </td><td>
              15.93
            </td><td>
              147.41m
            </td><td>
              216.60m
            </td><td>
              0
            </td><td>
              72,742,582
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AGIO" class="margin-bottom-1">
                AGIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$44.09</div> <small class="number change-up">+0.89<span>&nbsp;&nbsp;</span>+2.06%</small></td><td><strong>AG-946</strong> <br>Healthy volunteers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.agios.com/news-releases/news-release-details/agios-reports-business-highlights-and-second-quarter-2021">
                12/11/2021
              </a> <div class="note">Phase 1 data to be presented at ASH December 11-14, 2021.</div></td><td>
              59m
            </td><td>
              2.6b
            </td><td>
              163.8k
            </td><td>
              0.9m
            </td><td>
              1.51
            </td><td>
              $43.75
            </td><td>
              $43.2
            </td><td>
              N/A
            </td><td>
              1.60b
            </td><td>
              -39.10m
            </td><td>
              40.99
            </td><td>
              1.45b
            </td><td>
              0.98b
            </td><td>
              1.6
            </td><td>
              35,715,668
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ATNX" class="margin-bottom-1">
                ATNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.50</div> <small class="number change-up">+0.21<span>&nbsp;&nbsp;</span>+6.38%</small></td><td><strong>KUR-502 (ANCHOR)</strong> <br>B-cell lymphomas /acute lymphoblastic leukemia (ALL) / chronic lymphocytic leukemia (CLL)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.athenex.com/news-releases/news-release-details/athenex-provides-second-quarter-2021-corporate-and-financial">
                12/11/2021
              </a> <div class="note">Phase 1 data to be presented at ASH December 11-14, 2021.</div></td><td>
              109m
            </td><td>
              382.6m
            </td><td>
              0.9m
            </td><td>
              1.3m
            </td><td>
              2.07
            </td><td>
              $3.3
            </td><td>
              $3.29
            </td><td>
              N/A
            </td><td>
              106.70m
            </td><td>
              -13.07m
            </td><td>
              8.16
            </td><td>
              -132.38m
            </td><td>
              387.83m
            </td><td>
              6.1
            </td><td>
              77,823,836
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EGRX" class="margin-bottom-1">
                EGRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$50.56</div> <small class="number change-up">+0.69<span>&nbsp;&nbsp;</span>+1.38%</small></td><td><strong>Vasopressin</strong> <br>Increase blood pressure in adults
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210624005316/en/">
                12/15/2021
              </a> <div class="note">GDUFA date December 15, 2021.</div></td><td>
              13m
            </td><td>
              0.7b
            </td><td>
              42.4k
            </td><td>
              119.7k
            </td><td>
              3.40
            </td><td>
              $49.97
            </td><td>
              $49.87
            </td><td>
              N/A
            </td><td>
              113.87m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              44.48m
            </td><td>
              0.58b
            </td><td>
              13.6
            </td><td>
              7,854,528
            </td><td>
              06/24/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AGEN" class="margin-bottom-1">
                AGEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.15</div> <small class="number change-up">+0.10<span>&nbsp;&nbsp;</span>+1.65%</small></td><td><strong>Balstilimab</strong> <br>Cervical cancer
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.agenusbio.com/news-releases/news-release-details/agenus-announces-us-fda-acceptance-and-priority-review">
                12/16/2021
              </a> <div class="note">PDUFA date under priority review December 16, 2021.</div></td><td>
              233m
            </td><td>
              1.4b
            </td><td>
              2.3m
            </td><td>
              3.1m
            </td><td>
              -5.80
            </td><td>
              $6.06
            </td><td>
              $6.05
            </td><td>
              April 16, 2022
            </td><td>
              40.21m
            </td><td>
              -18.52m
            </td><td>
              2.17
            </td><td>
              -407.84m
            </td><td>
              1.39b
            </td><td>
              3.3
            </td><td>
              231,178,523
            </td><td>
              06/17/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ITCI" class="margin-bottom-1">
                ITCI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.66</div> <small class="number change-up">+1.32<span>&nbsp;&nbsp;</span>+4.51%</small></td><td><strong>CAPLYTA  (Lumateperone)</strong> <br>Bipolar depression
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-fda-acceptance-caplytar">
                12/17/2021
              </a> <div class="note">PDUFA date  December 17, 2021.</div></td><td>
              81m
            </td><td>
              2.5b
            </td><td>
              196.9k
            </td><td>
              0.5m
            </td><td>
              4.50
            </td><td>
              $29.7
            </td><td>
              $29.34
            </td><td>
              July 2, 2020
            </td><td>
              0.52b
            </td><td>
              -19.78m
            </td><td>
              26.25
            </td><td>
              447.05m
            </td><td>
              1.86b
            </td><td>
              2.7
            </td><td>
              60,840,721
            </td><td>
              05/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CHRS" class="margin-bottom-1">
                CHRS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$15.49</div> <small class="number change-up">+0.49<span>&nbsp;&nbsp;</span>+3.30%</small></td><td><strong>CHS-1420</strong> <br>Psoriasis
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.coherus.com/news-releases/news-release-details/coherus-bla-filing-adalimumab-biosimilar-candidate-accepted-fda">
                December 2021
              </a> <div class="note">BsUFA date December, 2021.</div></td><td>
              76m
            </td><td>
              1.2b
            </td><td>
              336.5k
            </td><td>
              0.7m
            </td><td>
              7.60
            </td><td>
              $15.14
            </td><td>
              $15
            </td><td>
              N/A
            </td><td>
              454.31m
            </td><td>
              -62.67k
            </td><td>
              7.25k
            </td><td>
              -129.01m
            </td><td>
              1.11b
            </td><td>
              1.4
            </td><td>
              54,173,405
            </td><td>
              02/17/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARGX" class="margin-bottom-1">
                ARGX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$330.66</div> <small class="number change-up">+16.08<span>&nbsp;&nbsp;</span>+5.11%</small></td><td><strong>Efgartigimod (ARGX-113)</strong> <br>Myasthenia gravis (MG)
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/03/02/2184873/0/en/argenx-Announces-FDA-Acceptance-of-BLA-Filing-for-Efgartigimod-for-the-Treatment-of-Generalized-Myasthenia-Gravis.html#:~:text=Breda%2C%20the%20Netherlands%20%E2%80%93%20March%202,for%20review%20the%20Biologics%20License">
                12/17/2021
              </a> <div class="note">PDUFA date December 17, 2021.</div></td><td>
              51m
            </td><td>
              17.0b
            </td><td>
              127.0k
            </td><td>
              127.5k
            </td><td>
              5.76
            </td><td>
              $322.62
            </td><td>
              $314.58
            </td><td>
              N/A
            </td><td>
              2.73b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              2.47b
            </td><td>
              13.42b
            </td><td>
              0
            </td><td>
              51,398,663
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ZLAB" class="margin-bottom-1">
                ZLAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$143.17</div> <small class="number change-up">+9.00<span>&nbsp;&nbsp;</span>+6.71%</small></td><td><strong>Efgartigimod (ARGX-113)</strong> <br>Myasthenia gravis (MG)
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/03/02/2184873/0/en/argenx-Announces-FDA-Acceptance-of-BLA-Filing-for-Efgartigimod-for-the-Treatment-of-Generalized-Myasthenia-Gravis.html#:~:text=Breda%2C%20the%20Netherlands%20%E2%80%93%20March%202,for%20review%20the%20Biologics%20License">
                12/17/2021
              </a> <div class="note">PDUFA date December 17, 2021.</div></td><td>
              75m
            </td><td>
              10.8b
            </td><td>
              320.4k
            </td><td>
              0.6m
            </td><td>
              33.30
            </td><td>
              $135
            </td><td>
              $134.17
            </td><td>
              N/A
            </td><td>
              1.73b
            </td><td>
              -21.95m
            </td><td>
              78.68
            </td><td>
              1.50b
            </td><td>
              1.78b
            </td><td>
              0
            </td><td>
              75,375,511
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AMGN" class="margin-bottom-1">
                AMGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$226.21</div> <small class="number change-up">+2.68<span>&nbsp;&nbsp;</span>+1.20%</small></td><td><strong>OTEZLA</strong> <br>Plaque psoriasis
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/fda-accepts-amgens-supplemental-new-drug-application-for-otezla-apremilast-for-adults-with-mild-to-moderate-plaque-psoriasis-301283931.html">
                12/19/2021
              </a> <div class="note">PDUFA date December 19, 2021.</div></td><td>
              1b
            </td><td>
              128.5b
            </td><td>
              0.9m
            </td><td>
              2.4m
            </td><td>
              15.58
            </td><td>
              $224.18
            </td><td>
              $223.53
            </td><td>
              March 6, 2020
            </td><td>
              8.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -43.19b
            </td><td>
              151.63b
            </td><td>
              0.6
            </td><td>
              566,434,467
            </td><td>
              05/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VERU" class="margin-bottom-1">
                VERU
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.74</div> <small class="number change-up">+0.39<span>&nbsp;&nbsp;</span>+5.31%</small></td><td><strong>Tadalafil and Finasteride combo</strong> <br>Benign prostatic hyperplasia (BPH)
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.stocktitan.net/news/VERU/veru-submits-new-drug-application-for-proprietary-tadfin-for-6l6koefhupmj.html">
                December 2021
              </a> <div class="note">PDUFA date December 2021.</div></td><td>
              80m
            </td><td>
              0.6b
            </td><td>
              411.2k
            </td><td>
              0.7m
            </td><td>
              3.99
            </td><td>
              $7.4
            </td><td>
              $7.35
            </td><td>
              N/A
            </td><td>
              115.46m
            </td><td>
              -4.28m
            </td><td>
              26.99
            </td><td>
              90.35m
            </td><td>
              476.67m
            </td><td>
              19.5
            </td><td>
              64,115,892
            </td><td>
              05/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AQST" class="margin-bottom-1">
                AQST
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.88</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+6.30%</small></td><td><strong>Libervant (diazepam)</strong> <br>Epileptic seizures
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.benzinga.com/pressreleases/21/07/g22039585/aquestive-therapeutics-announces-fda-acceptance-of-new-drug-application-nda-resubmission-for-liber">
                12/23/2021
              </a> <div class="note">CRL announced September 25, 2020. NDA resubmitted with new PDUFA date December 23, 2021.</div></td><td>
              39m
            </td><td>
              150.9m
            </td><td>
              199.6k
            </td><td>
              0.6m
            </td><td>
              -2.81
            </td><td>
              $3.74
            </td><td>
              $3.65
            </td><td>
              N/A
            </td><td>
              33.18m
            </td><td>
              -0.59m
            </td><td>
              56.69
            </td><td>
              -87.46m
            </td><td>
              150.16m
            </td><td>
              5.6
            </td><td>
              25,371,802
            </td><td>
              07/19/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BMY" class="margin-bottom-1">
                BMY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$69.35</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+0.22%</small></td><td><strong>ORENCIA (abatacept)</strong> <br> Graft Versus Host Disease (aGvHD)
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210823005092/en/">
                12/23/2021
              </a> <div class="note">PDUFA date under priority review December 23, 2021.</div></td><td>
              2b
            </td><td>
              154.1b
            </td><td>
              4.1m
            </td><td>
              8.5m
            </td><td>
              4.19
            </td><td>
              $69.26
            </td><td>
              $69.2
            </td><td>
              N/A
            </td><td>
              15.85b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -58.07b
            </td><td>
              186.05b
            </td><td>
              0.3
            </td><td>
              2,219,710,962
            </td><td>
              08/23/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KRYS" class="margin-bottom-1">
                KRYS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$57.19</div> <small class="number change-up">+3.88<span>&nbsp;&nbsp;</span>+7.29%</small></td><td><strong>KB301 (PEARL-1)</strong> <br>Wrinkles and acne scars 
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-reports-second-quarter-2021-financial-results">
                4Q 2021
              </a> <div class="note">Phase 1 initial efficacy data due 4Q 2021.</div></td><td>
              22m
            </td><td>
              1.3b
            </td><td>
              53.6k
            </td><td>
              135.4k
            </td><td>
              3.03
            </td><td>
              $54.1
            </td><td>
              $53.3
            </td><td>
              November 2021
            </td><td>
              361.65m
            </td><td>
              -3.38m
            </td><td>
              107.11
            </td><td>
              336.64m
            </td><td>
              0.82b
            </td><td>
              18.4
            </td><td>
              17,658,435
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ICPT" class="margin-bottom-1">
                ICPT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.02</div> <small class="number change-up">+1.03<span>&nbsp;&nbsp;</span>+7.93%</small></td><td><strong>OCALIVA (obeticholic acid) - REVERSE</strong> <br>NASH patients with compensated cirrhosis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.interceptpharma.com/static-files/3723eb52-46ac-40c9-b59b-1049a21dc952">
                2021
              </a> <div class="note">Phase 3 data due by the end of 2021.</div></td><td>
              33m
            </td><td>
              465.5m
            </td><td>
              485.5k
            </td><td>
              0.8m
            </td><td>
              -2.29
            </td><td>
              $13.1
            </td><td>
              $12.99
            </td><td>
              July 2021
            </td><td>
              448.73m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -277.68m
            </td><td>
              0.60b
            </td><td>
              4.3
            </td><td>
              24,084,333
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARNA" class="margin-bottom-1">
                ARNA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$51.04</div> <small class="number change-up">+4.14<span>&nbsp;&nbsp;</span>+8.83%</small></td><td><strong>Etrasimod</strong> <br>Alopecia areata (AA)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805006093/en/">
                2H 2021
              </a> <div class="note">Phase 2 data due 2H 2021.</div></td><td>
              61m
            </td><td>
              3.1b
            </td><td>
              0.6m
            </td><td>
              464.5k
            </td><td>
              3.21
            </td><td>
              $47.42
            </td><td>
              $46.9
            </td><td>
              N/A
            </td><td>
              0.85b
            </td><td>
              -31.28m
            </td><td>
              27.02
            </td><td>
              0.73b
            </td><td>
              1.94b
            </td><td>
              4.4
            </td><td>
              54,681,471
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ACHL" class="margin-bottom-1">
                ACHL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.49</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+4.68%</small></td><td><strong>ATL001 - THETIS</strong> <br>Melanoma
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.achillestx.com/news-releases/news-release-details/achilles-therapeutics-reports-second-quarter-2021-financial">
                2H 2021
              </a> <div class="note">Phase 1/2 update 4Q 2021.</div></td><td>
              41m
            </td><td>
              263.5m
            </td><td>
              51.4k
            </td><td>
              146.1k
            </td><td>
              0.81
            </td><td>
              $6.23
            </td><td>
              $6.2
            </td><td>
              July 1, 2023
            </td><td>
              299.32m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              269.80m
            </td><td>
              -32.67m
            </td><td>
              0
            </td><td>
              40,603,489
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INO" class="margin-bottom-1">
                INO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.30</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+2.78%</small></td><td><strong>VGX-3100 - REVEAL-1</strong> <br>Cervical dysplasia
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/inovio-reports-second-quarter-2021-financial-results-301351440.html">
                2H 2021
              </a> <div class="note">Phase 3 data released March 1, 2021. Including subjects with missing endpoint data, the percentage of subjects meeting the primary endpoint was 22.5% (31/138) versus 11.1% (7/63) in the placebo group (p=0.029; 11.4% difference in percentage, 95%CI: -0.4,21.2), which was not statistically significant. Data to be presented later in 2021. Full subject-level unblinding also due 2H 2021.</div></td><td>
              210m
            </td><td>
              1.7b
            </td><td>
              2.2m
            </td><td>
              4.7m
            </td><td>
              3.43
            </td><td>
              $8.22
            </td><td>
              $8.08
            </td><td>
              July 8, 2020
            </td><td>
              396.60m
            </td><td>
              -26.15m
            </td><td>
              15.16
            </td><td>
              313.31m
            </td><td>
              1.29b
            </td><td>
              2.6
            </td><td>
              206,917,823
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SNY" class="margin-bottom-1">
                SNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$52.48</div> <small class="number change-down">-0.64<span>&nbsp;&nbsp;</span>-1.20%</small></td><td><strong>Rilzabrutinib PRN1008 - PEGASUS</strong> <br>Pemphigus
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/2021_07_29_Sanofi_Q2_2021_presentation.pdf?la=en&amp;hash=F258C8E98B392E4E9DAF7517ECD8A4B9">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              3b
            </td><td>
              131.7b
            </td><td>
              2.5m
            </td><td>
              1.7m
            </td><td>
              1.78
            </td><td>
              $52.73
            </td><td>
              $53.12
            </td><td>
              August 2021
            </td><td>
              9.72b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -39.23b
            </td><td>
              146.90b
            </td><td>
              0
            </td><td>
              2,510,366,030
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALEC" class="margin-bottom-1">
                ALEC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$26.01</div> <small class="number change-up">+1.50<span>&nbsp;&nbsp;</span>+6.12%</small></td><td><strong>AL003</strong> <br>Alzheimer’s disease
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.alector.com/node/7966/pdf">
                2H 2021
              </a> <div class="note">Phase 1b data due 2H 2021.</div></td><td>
              81m
            </td><td>
              2.1b
            </td><td>
              344.0k
            </td><td>
              1.8m
            </td><td>
              11.41
            </td><td>
              $24.89
            </td><td>
              $24.51
            </td><td>
              May 2021
            </td><td>
              292.84m
            </td><td>
              -14.85m
            </td><td>
              19.72
            </td><td>
              80.25m
            </td><td>
              1.71b
            </td><td>
              7
            </td><td>
              58,130,166
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OBSV" class="margin-bottom-1">
                OBSV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.67</div> <small class="number change-up">+0.10<span>&nbsp;&nbsp;</span>+3.89%</small></td><td><strong>Linzagolix (OBE2109) -  EDELWEISS 3</strong> <br>Endometriosis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/b4635e4d-f1fd-44fa-8dc6-5444bf128711">
                4Q 2021
              </a> <div class="note">Phase 3 data due 4Q 2021.</div></td><td>
              78m
            </td><td>
              208.1m
            </td><td>
              0.8m
            </td><td>
              2.1m
            </td><td>
              5.04
            </td><td>
              $2.56
            </td><td>
              $2.57
            </td><td>
              January 2022
            </td><td>
              47.66m
            </td><td>
              -6.26m
            </td><td>
              7.62
            </td><td>
              -5.90m
            </td><td>
              168.19m
            </td><td>
              0
            </td><td>
              64,232,245
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARVN" class="margin-bottom-1">
                ARVN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$87.70</div> <small class="number change-up">+1.87<span>&nbsp;&nbsp;</span>+2.18%</small></td><td><strong>ARV-110 (ARDENT)</strong> <br>Castration-resistant prostate cancer (CRPC)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.arvinas.com/news-releases/news-release-details/arvinas-reports-second-quarter-2021-financial-results-and">
                2H 2021
              </a> <div class="note">Phase 1 dose escalation data and interim Phase 2 data due 2H 2021. </div></td><td>
              49m
            </td><td>
              4.3b
            </td><td>
              173.3k
            </td><td>
              0.6m
            </td><td>
              7.40
            </td><td>
              $87.32
            </td><td>
              $85.83
            </td><td>
              October 31, 2022
            </td><td>
              1.57b
            </td><td>
              -15.80m
            </td><td>
              99.50
            </td><td>
              1.51b
            </td><td>
              3.63b
            </td><td>
              2.8
            </td><td>
              38,367,143
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ABBV" class="margin-bottom-1">
                ABBV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$119.82</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+0.84%</small></td><td><strong>ABBV-951</strong> <br>Parkinson's disease
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/abbvie-to-present-new-data-from-18-abstracts-at-the-international-congress-of-parkinsons-disease-and-movement-disorders-301128096.html">
                Late-2021
              </a> <div class="note">Phase 3 data due late-2021.</div></td><td>
              2b
            </td><td>
              211.7b
            </td><td>
              2.6m
            </td><td>
              5.7m
            </td><td>
              16.85
            </td><td>
              $119.8
            </td><td>
              $118.82
            </td><td>
              July 4, 2022
            </td><td>
              11.53b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -123.84b
            </td><td>
              283.51b
            </td><td>
              0.1
            </td><td>
              1,765,652,810
            </td><td>
              09/11/2020
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GLPG" class="margin-bottom-1">
                GLPG
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$57.00</div> <small class="number change-up">+1.57<span>&nbsp;&nbsp;</span>+2.83%</small></td><td><strong>GLPG3667</strong> <br>Plaque Psoriasis
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/78c3950d-3658-4568-8276-9fc57b005891">
                2021
              </a> <div class="note">Phase 1 trial initiation announced November 9, 2020. Data due 2021.</div></td><td>
              66m
            </td><td>
              3.7b
            </td><td>
              162.0k
            </td><td>
              330.9k
            </td><td>
              1.20
            </td><td>
              $56.35
            </td><td>
              $55.43
            </td><td>
              May 4, 2021
            </td><td>
              4.96b
            </td><td>
              -27.31m
            </td><td>
              181.54
            </td><td>
              2.19b
            </td><td>
              -2.18b
            </td><td>
              0.1
            </td><td>
              65,469,108
            </td><td>
              05/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ATRA" class="margin-bottom-1">
                ATRA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.79</div> <small class="number change-up">+1.16<span>&nbsp;&nbsp;</span>+9.18%</small></td><td><strong>ATA2271</strong> <br>Mesothelioma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005755/en/">
                4Q 2021
              </a> <div class="note">Phase 1 top-line data due 4Q 2021.</div></td><td>
              85m
            </td><td>
              1.2b
            </td><td>
              0.6m
            </td><td>
              0.7m
            </td><td>
              3.53
            </td><td>
              $12.7
            </td><td>
              $12.63
            </td><td>
              N/A
            </td><td>
              336.43m
            </td><td>
              -20.53m
            </td><td>
              16.39
            </td><td>
              211.18m
            </td><td>
              0.71b
            </td><td>
              3
            </td><td>
              73,456,041
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FBIO" class="margin-bottom-1">
                FBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.20</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+4.58%</small></td><td><strong>MB-108</strong> <br>Glioblastoma multiforme
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s2.q4cdn.com/336946411/files/doc_presentations/2021/07/Mustang-Bio-Corporate-Presentation-30Jun2021.pdf">
                4Q 2021
              </a> <div class="note">Phase 1 first data possible 4Q 2021.</div></td><td>
              101m
            </td><td>
              323.4m
            </td><td>
              220.5k
            </td><td>
              0.5m
            </td><td>
              2.99
            </td><td>
              $3.07
            </td><td>
              $3.06
            </td><td>
              September 2022
            </td><td>
              254.32m
            </td><td>
              -11.49m
            </td><td>
              22.14
            </td><td>
              84.46m
            </td><td>
              120.76m
            </td><td>
              27.4
            </td><td>
              76,232,955
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MBIO" class="margin-bottom-1">
                MBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.81</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+5.24%</small></td><td><strong>MB-108</strong> <br>Glioblastoma multiforme
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s2.q4cdn.com/336946411/files/doc_presentations/2021/07/Mustang-Bio-Corporate-Presentation-30Jun2021.pdf">
                4Q 2021
              </a> <div class="note">Phase 1 first data possible 4Q 2021.</div></td><td>
              91m
            </td><td>
              256.8m
            </td><td>
              0.9m
            </td><td>
              1.5m
            </td><td>
              1.90
            </td><td>
              $2.73
            </td><td>
              $2.67
            </td><td>
              September 2022
            </td><td>
              122.67m
            </td><td>
              -4.03m
            </td><td>
              30.43
            </td><td>
              114.48m
            </td><td>
              116.29m
            </td><td>
              1.8
            </td><td>
              73,639,109
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PCSA" class="margin-bottom-1">
                PCSA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.81</div> <small class="number change-up">+0.38<span>&nbsp;&nbsp;</span>+7.00%</small></td><td><strong>PCS6422</strong> <br>Breast cancer
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://processapharmaceuticals.com/ppt/Processa%20Zooming%20LD%20Micro%20July%2029%202021_Final.pdf">
                2H 2021
              </a> <div class="note">Phase 1b dosing to commence 3Q2021 with interim data due 2H 2021.</div></td><td>
              16m
            </td><td>
              90.7m
            </td><td>
              14.2k
            </td><td>
              103.7k
            </td><td>
              3.11
            </td><td>
              $5.52
            </td><td>
              $5.43
            </td><td>
              N/A
            </td><td>
              19.51m
            </td><td>
              -0.73m
            </td><td>
              26.68
            </td><td>
              17.62m
            </td><td>
              64.03m
            </td><td>
              13.5
            </td><td>
              11,767,617
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ZEAL" class="margin-bottom-1">
                ZEAL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$27.57</div> <small class="number change-up">+0.28<span>&nbsp;&nbsp;</span>+1.04%</small></td><td><strong>Dapiglutide (ZP7570)</strong> <br>Short bowel syndrome (SBS)
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/05/12/2228226/0/en/Zealand-Pharma-receives-first-FDA-approval-and-prepares-for-launch-of-Zegalogue-dasiglucagon-injection.html#:~:text=Zealand%20markets%20V%2DGo%C2%AE,diabetes%20aged%206%20and%20above.">
                2H 2021
              </a> <div class="note">Phase 1b data due later in 2021.</div></td><td>
              43m
            </td><td>
              1.2b
            </td><td>
              37.5k
            </td><td>
              19.1k
            </td><td>
              5.47
            </td><td>
              $27.57
            </td><td>
              $27.29
            </td><td>
              N/A
            </td><td>
              1.09b
            </td><td>
              -109.19m
            </td><td>
              9.95
            </td><td>
              0.55b
            </td><td>
              1.01b
            </td><td>
              0
            </td><td>
              43,323,428
            </td><td>
              05/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KPTI" class="margin-bottom-1">
                KPTI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.02</div> <small class="number change-up">+0.39<span>&nbsp;&nbsp;</span>+8.42%</small></td><td><strong>XPOVIO (selinexor) - SIENDO</strong> <br>Endometrial cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/karyopharm-reports-business-highlights-and-second-quarter-2021-financial-results-301349043.html">
                4Q 2021
              </a> <div class="note">Phase 3 top-line data due 4Q 2021.</div></td><td>
              75m
            </td><td>
              379.0m
            </td><td>
              0.9m
            </td><td>
              1.6m
            </td><td>
              -4.56
            </td><td>
              $4.72
            </td><td>
              $4.63
            </td><td>
              March 2023
            </td><td>
              202.44m
            </td><td>
              -18.58m
            </td><td>
              10.89
            </td><td>
              -167.26m
            </td><td>
              294.84m
            </td><td>
              3.3
            </td><td>
              71,743,134
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PGEN" class="margin-bottom-1">
                PGEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.04</div> <small class="number change-up">+0.42<span>&nbsp;&nbsp;</span>+7.56%</small></td><td><strong>PRGN-3006 UltraCAR-T</strong> <br>Myelodysplastic Syndromes, Acute Myeloid Leukemia
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/precigen-reports-second-quarter-and-first-half-2021-financial-results-301351238.html">
                4Q 2021
              </a> <div class="note">Phase 1 interim data to be presented 4Q 2021.</div></td><td>
              207m
            </td><td>
              1.2b
            </td><td>
              341.3k
            </td><td>
              1.2m
            </td><td>
              7.85
            </td><td>
              $5.75
            </td><td>
              $5.62
            </td><td>
              May 1, 2022
            </td><td>
              110.44m
            </td><td>
              -2.59m
            </td><td>
              42.61
            </td><td>
              -132.94m
            </td><td>
              1.24b
            </td><td>
              2.1
            </td><td>
              94,205,701
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TEVA" class="margin-bottom-1">
                TEVA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.43</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+3.15%</small></td><td><strong>AUSTEDO (deutetrabenazine)</strong> <br>Dyskinetic cerebral palsy (DCP)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s24.q4cdn.com/720828402/files/doc_financials/2019/q4/Q4-2019_Earnings-Presentation_FINAL_Feb12.2019.pdf">
                2021
              </a> <div class="note">Phase 3 data due in 2021.</div></td><td>
              1b
            </td><td>
              10.4b
            </td><td>
              3.5m
            </td><td>
              9.6m
            </td><td>
              1.01
            </td><td>
              $9.25
            </td><td>
              $9.14
            </td><td>
              November 12, 2019
            </td><td>
              2.57b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -35.32b
            </td><td>
              33.52b
            </td><td>
              0.4
            </td><td>
              1,098,121,371
            </td><td>
              02/12/2020
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SPPI" class="margin-bottom-1">
                SPPI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.34</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+2.86%</small></td><td><strong>Poziotinib</strong> <br>Non-small cell lung cancer (NSCLC) with exon 20 insertion mutation in EGFR or HER2
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210812005763/en/">
                Late-2021
              </a> <div class="note">Phase 2 cohort 3 data did not meet primary endpoint - December 22, 2020. NDA submission planned for late-2021. </div></td><td>
              164m
            </td><td>
              383.1m
            </td><td>
              0.9m
            </td><td>
              3.0m
            </td><td>
              3.54
            </td><td>
              $2.29
            </td><td>
              $2.27
            </td><td>
              March 2023
            </td><td>
              141.03m
            </td><td>
              -9.88m
            </td><td>
              14.27
            </td><td>
              74.57m
            </td><td>
              214.95m
            </td><td>
              2.3
            </td><td>
              133,821,999
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TEVA" class="margin-bottom-1">
                TEVA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.43</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+3.15%</small></td><td><strong>Fremanezumab</strong> <br>Fibromyalgia
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s24.q4cdn.com/720828402/files/doc_financials/2019/q4/Q4-2019_Earnings-Presentation_FINAL_Feb12.2019.pdf">
                2021
              </a> <div class="note">Phase 2 data due 2021.</div></td><td>
              1b
            </td><td>
              10.4b
            </td><td>
              3.5m
            </td><td>
              9.6m
            </td><td>
              1.01
            </td><td>
              $9.25
            </td><td>
              $9.14
            </td><td>
              March 12, 2022
            </td><td>
              2.57b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -35.32b
            </td><td>
              33.52b
            </td><td>
              0.4
            </td><td>
              1,098,121,371
            </td><td>
              02/12/2020
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AVXL" class="margin-bottom-1">
                AVXL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$19.41</div> <small class="number change-up">+1.05<span>&nbsp;&nbsp;</span>+5.72%</small></td><td><strong>ANAVEX 3-71 (AF710B)</strong> <br>Healthy volunteers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.anavex.com/wp-content/uploads/2021/08/Anavex-Presentation-August-2021.pdf">
                2H 2021
              </a> <div class="note">Phase 1 top-line data due 2H 2021.</div></td><td>
              76m
            </td><td>
              1.5b
            </td><td>
              0.5m
            </td><td>
              3.2m
            </td><td>
              9.33
            </td><td>
              $18.68
            </td><td>
              $18.36
            </td><td>
              August 2021
            </td><td>
              153.05m
            </td><td>
              -2.51m
            </td><td>
              61.05
            </td><td>
              143.77m
            </td><td>
              1.23b
            </td><td>
              14.5
            </td><td>
              73,309,486
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ANGN" class="margin-bottom-1">
                ANGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$10.11</div> <small class="number change-up">+0.76<span>&nbsp;&nbsp;</span>+8.13%</small></td><td><strong>ANG-3777</strong> <br>Acute Kidney Injury associated with cardiac surgery
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.angion.com/news-releases/news-release-details/angion-provides-corporate-update-and-reports-second-quarter-2021">
                4Q 2021
              </a> <div class="note">Phase 2 data due 4Q 2021.</div></td><td>
              30m
            </td><td>
              301.3m
            </td><td>
              136.1k
            </td><td>
              84.1k
            </td><td>
              3.90
            </td><td>
              $9.52
            </td><td>
              $9.35
            </td><td>
              August 2021
            </td><td>
              110.99m
            </td><td>
              -3.51m
            </td><td>
              31.62
            </td><td>
              62.82m
            </td><td>
              166.08m
            </td><td>
              13.5
            </td><td>
              16,280,789
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VNDA" class="margin-bottom-1">
                VNDA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.02</div> <small class="number change-up">+0.21<span>&nbsp;&nbsp;</span>+1.36%</small></td><td><strong>Tradipitant</strong> <br>Gastroparesis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://vandapharmaceuticalsinc.gcs-web.com/node/14591/pdf">
                YE 2021
              </a> <div class="note">Phase 3 due by end of 2021. </div></td><td>
              56m
            </td><td>
              0.9b
            </td><td>
              104.5k
            </td><td>
              492.5k
            </td><td>
              1.85
            </td><td>
              $15.81
            </td><td>
              $15.81
            </td><td>
              September 2021
            </td><td>
              407.90m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              321.48m
            </td><td>
              496.03m
            </td><td>
              4.8
            </td><td>
              44,555,408
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TLC" class="margin-bottom-1">
                TLC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.00</div> <small class="number change-down">-0.04<span>&nbsp;&nbsp;</span>-0.57%</small></td><td><strong>TLC599 (EXCELLENCE)</strong> <br>Osteoarthritis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.tlcbio.com/static-files/b5b80555-99c9-45c7-8ff7-592027767f12">
                2H 2021
              </a> <div class="note">Phase 3 completion of enrollment announced December 28, 2020 with data due 2H 2021.</div></td><td>
              42m
            </td><td>
              294.5m
            </td><td>
              7.5k
            </td><td>
              51.4k
            </td><td>
              53.85
            </td><td>
              $7.04
            </td><td>
              $7.04
            </td><td>
              December 31, 2021
            </td><td>
              0.70b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -78.45m
            </td><td>
              277.70m
            </td><td>
              0
            </td><td>
              42,077,467
            </td><td>
              05/14/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MGTA" class="margin-bottom-1">
                MGTA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.57</div> <small class="number change-up">+0.08<span>&nbsp;&nbsp;</span>+1.23%</small></td><td><strong>MGTA-145 and plerixafor</strong> <br>Multiple Myeloma
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005403/en/">
                4Q 2021
              </a> <div class="note">Phase 2 final data due 4Q 2021.</div></td><td>
              59m
            </td><td>
              384.8m
            </td><td>
              87.4k
            </td><td>
              250.6k
            </td><td>
              1.90
            </td><td>
              $6.58
            </td><td>
              $6.49
            </td><td>
              July 22, 2021
            </td><td>
              200.01m
            </td><td>
              -4.33m
            </td><td>
              46.16
            </td><td>
              182.52m
            </td><td>
              172.30m
            </td><td>
              1.9
            </td><td>
              44,285,984
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>IMFINZI (Durvalumab) + tremelimumab  - (HIMALAYA)</strong> <br>Hepatocellular carcinoma (HCC) 
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2021/h1-2021/H1_2021_results_presentation.pdf">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              December 30, 2021
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CRSP" class="margin-bottom-1">
                CRSP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$124.83</div> <small class="number change-up">+7.61<span>&nbsp;&nbsp;</span>+6.49%</small></td><td><strong>CTX120</strong> <br>Relapsed or refractory multiple myeloma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/07/29/2271807/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Second-Quarter-2021-Financial-Results.html">
                2021
              </a> <div class="note">Phase 1 top-line data due 2021.</div></td><td>
              76m
            </td><td>
              9.5b
            </td><td>
              0.8m
            </td><td>
              1.4m
            </td><td>
              3.65
            </td><td>
              $120.39
            </td><td>
              $117.22
            </td><td>
              November 2026
            </td><td>
              3.07b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              2.78b
            </td><td>
              6.53b
            </td><td>
              1.9
            </td><td>
              52,414,588
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CAPR" class="margin-bottom-1">
                CAPR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.05</div> <small class="number change-up">+0.18<span>&nbsp;&nbsp;</span>+4.65%</small></td><td><strong>CAP-1002 (INSPIRE)</strong> <br>COVID-19
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://capricor.com/wp-content/uploads/2014/03/CAPR-June-2021.pdf">
                2H 2021
              </a> <div class="note">Phase 2 data due 2H 2021.</div></td><td>
              23m
            </td><td>
              93.2m
            </td><td>
              77.2k
            </td><td>
              390.7k
            </td><td>
              2.79
            </td><td>
              $3.86
            </td><td>
              $3.87
            </td><td>
              September 30, 2021
            </td><td>
              35.37m
            </td><td>
              -1.50m
            </td><td>
              23.50
            </td><td>
              28.82m
            </td><td>
              47.53m
            </td><td>
              14.9
            </td><td>
              22,505,411
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AGEN" class="margin-bottom-1">
                AGEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.15</div> <small class="number change-up">+0.10<span>&nbsp;&nbsp;</span>+1.65%</small></td><td><strong>agenT-797 (iNKT)</strong> <br>Multiple myeloma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.agenusbio.com/news-releases/news-release-details/agenus-corporate-update-and-second-quarter-2021-financial-report">
                4Q 2021
              </a> <div class="note">Phase 1 initiation of dosing announced April 14, 2021. Initial data due 4Q 2021.</div></td><td>
              233m
            </td><td>
              1.4b
            </td><td>
              2.3m
            </td><td>
              3.1m
            </td><td>
              -5.80
            </td><td>
              $6.06
            </td><td>
              $6.05
            </td><td>
              April 15, 2022
            </td><td>
              40.21m
            </td><td>
              -18.52m
            </td><td>
              2.17
            </td><td>
              -407.84m
            </td><td>
              1.39b
            </td><td>
              3.3
            </td><td>
              231,178,523
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CRBP" class="margin-bottom-1">
                CRBP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.19</div> <small class="number change-up">+0.05<span>&nbsp;&nbsp;</span>+4.39%</small></td><td><strong>Lenabasum (Resunab)</strong> <br>Systemic lupus erythematosus (SLE)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.corbuspharma.com/press-releases/detail/362/corbus-pharmaceuticals-reports-second-quarter-2021">
                4Q 2021
              </a> <div class="note">Phase 2 data due 4Q 2021.</div></td><td>
              125m
            </td><td>
              149.0m
            </td><td>
              0.7m
            </td><td>
              2.1m
            </td><td>
              1.95
            </td><td>
              $1.13
            </td><td>
              $1.14
            </td><td>
              July 28, 2021
            </td><td>
              95.93m
            </td><td>
              -5.84m
            </td><td>
              16.42
            </td><td>
              52.28m
            </td><td>
              62.40m
            </td><td>
              2.6
            </td><td>
              124,528,900
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CABA" class="margin-bottom-1">
                CABA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.24</div> <small class="number change-up">+0.55<span>&nbsp;&nbsp;</span>+7.15%</small></td><td><strong>DSG3-CAART</strong> <br>Pemphigus vulgaris
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.cabalettabio.com/news-media/press-releases/detail/47/cabaletta-bio-reports-clinical-data-from-the-second-dose">
                4Q 2021
              </a> <div class="note">Phase 1 28-day second dose cohort data released August 18, 2021. No dose-limiting toxicities (DLTs) or clinically relevant adverse events noted. Biologic activity data from the first two dosing cohorts and third cohort safety data due 4Q 2021.</div></td><td>
              25m
            </td><td>
              205.8m
            </td><td>
              54.8k
            </td><td>
              118.9k
            </td><td>
              2.03
            </td><td>
              $7.87
            </td><td>
              $7.69
            </td><td>
              September 2026
            </td><td>
              98.86m
            </td><td>
              -2.19m
            </td><td>
              45.07
            </td><td>
              93.26m
            </td><td>
              89.23m
            </td><td>
              3.2
            </td><td>
              20,820,940
            </td><td>
              08/18/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VIR" class="margin-bottom-1">
                VIR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$47.20</div> <small class="number change-up">+0.73<span>&nbsp;&nbsp;</span>+1.57%</small></td><td><strong>VIR-1111</strong> <br>HIV T cell vaccine
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-provides-corporate-update-and-reports-second-0">
                2H 2021
              </a> <div class="note">Phase 1 initial data due 2H 2021.</div></td><td>
              131m
            </td><td>
              6.2b
            </td><td>
              1.0m
            </td><td>
              0.9m
            </td><td>
              8.35
            </td><td>
              $47.62
            </td><td>
              $46.47
            </td><td>
              October 2022
            </td><td>
              0.91b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              0.59b
            </td><td>
              5.32b
            </td><td>
              5.6
            </td><td>
              69,593,992
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RVMD" class="margin-bottom-1">
                RVMD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$26.00</div> <small class="number change-up">+0.56<span>&nbsp;&nbsp;</span>+2.20%</small></td><td><strong>RMC-4630 and Sotorasib (AMG 510)</strong> <br>Solid tumors
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.benzinga.com/pressreleases/21/08/g22452977/revolution-medicines-reports-second-quarter-financial-results-and-update-on-corporate-progress">
                2H 2021
              </a> <div class="note">Phase 1b combo dose to be selected 2H 2021.</div></td><td>
              74m
            </td><td>
              1.9b
            </td><td>
              312.5k
            </td><td>
              0.7m
            </td><td>
              2.79
            </td><td>
              $25.76
            </td><td>
              $25.44
            </td><td>
              N/A
            </td><td>
              0.63b
            </td><td>
              -11.36m
            </td><td>
              55.09
            </td><td>
              0.54b
            </td><td>
              1.26b
            </td><td>
              0.7
            </td><td>
              49,649,322
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BLU" class="margin-bottom-1">
                BLU
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.32</div> <small class="number change-up">+0.27<span>&nbsp;&nbsp;</span>+8.85%</small></td><td><strong>BLU-5937 (BLUEPRINT)</strong> <br>Chronic pruritus associated with atopic dermatitis
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.benzinga.com/pressreleases/21/08/b22454325/bellus-health-reports-second-quarter-2021-financial-results-and-business-highlights">
                4Q 2021
              </a> <div class="note">Phase 2b initiation of dosing announced December 14, 2020 with top-line data due 4Q 2021.</div></td><td>
              78m
            </td><td>
              260.1m
            </td><td>
              368.6k
            </td><td>
              419.1k
            </td><td>
              2.07
            </td><td>
              $3.05
            </td><td>
              $3.05
            </td><td>
              N/A
            </td><td>
              66.52m
            </td><td>
              -3.23m
            </td><td>
              20.61
            </td><td>
              56.75m
            </td><td>
              164.77m
            </td><td>
              0
            </td><td>
              78,337,361
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CYAD" class="margin-bottom-1">
                CYAD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.15</div> <small class="number change-up">+0.27<span>&nbsp;&nbsp;</span>+6.96%</small></td><td><strong>CYAD-211 ( IMMUNICY-1)</strong> <br>Multiple Myeloma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://celyad.com/2021/08/04/celyad-oncology-reports-first-half-2021-financial-results-and-recent-business-highlights/">
                YE 2021
              </a> <div class="note">Phase 1 initial data released at EHA meeting June 11, 2021. 2/5 partial responses. Additional data due by year-end 2021.</div></td><td>
              15m
            </td><td>
              64.3m
            </td><td>
              16.8k
            </td><td>
              38.8k
            </td><td>
              2.21
            </td><td>
              $4.12
            </td><td>
              $3.88
            </td><td>
              February 2023
            </td><td>
              12.02m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -25.81m
            </td><td>
              53.07m
            </td><td>
              0
            </td><td>
              15,493,956
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TERN" class="margin-bottom-1">
                TERN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.66</div> <small class="number change-up">+1.47<span>&nbsp;&nbsp;</span>+13.14%</small></td><td><strong>TERN-501</strong> <br>Nonalcoholic steatohepatitis (NASH)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ternspharma.com/news-releases/news-release-details/terns-pharmaceuticals-reports-second-quarter-2021-financial">
                4Q 2021
              </a> <div class="note">Phase 1 trial initiation announced March 22, 2021. Top-line data due 4Q 2021.</div></td><td>
              25m
            </td><td>
              318.2m
            </td><td>
              80.5k
            </td><td>
              81.9k
            </td><td>
              1.75
            </td><td>
              $11.38
            </td><td>
              $11.19
            </td><td>
              N/A
            </td><td>
              179.83m
            </td><td>
              -2.92m
            </td><td>
              61.58
            </td><td>
              173.15m
            </td><td>
              405.27m
            </td><td>
              1.1
            </td><td>
              13,596,996
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CYCC" class="margin-bottom-1">
                CYCC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.91</div> <small class="number change-up">+0.33<span>&nbsp;&nbsp;</span>+7.27%</small></td><td><strong>CYC140</strong> <br>Leukemias
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.cyclacel.com/news-releases/news-release-details/cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-10">
                2021
              </a> <div class="note">Phase 1 initial data due 2021.</div></td><td>
              9m
            </td><td>
              45.4m
            </td><td>
              18.6k
            </td><td>
              81.3k
            </td><td>
              1.05
            </td><td>
              $4.66
            </td><td>
              $4.58
            </td><td>
              October 26, 2020
            </td><td>
              41.11m
            </td><td>
              -1.40m
            </td><td>
              29.26
            </td><td>
              37.99m
            </td><td>
              -1.35m
            </td><td>
              11
            </td><td>
              9,152,307
            </td><td>
              02/25/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMCR" class="margin-bottom-1">
                IMCR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.70</div> <small class="number change-up">+1.72<span>&nbsp;&nbsp;</span>+6.15%</small></td><td><strong>IMC-C103C - MAGE-A4</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.immunocore.com/news-releases/news-release-details/immunocore-reports-second-quarter-2021-financial-results-and">
                4Q 2021
              </a> <div class="note">Phase 1 initial data due 4Q 2021.</div></td><td>
              44m
            </td><td>
              1.3b
            </td><td>
              99.6k
            </td><td>
              65.9k
            </td><td>
              4.26
            </td><td>
              $27.98
            </td><td>
              $27.98
            </td><td>
              July 2025
            </td><td>
              259.31m
            </td><td>
              -10.87m
            </td><td>
              23.87
            </td><td>
              128.44m
            </td><td>
              0.93b
            </td><td>
              0
            </td><td>
              43,786,088
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TRVN" class="margin-bottom-1">
                TRVN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.18</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+6.31%</small></td><td><strong>OLINVYK (oliceridine)</strong> <br>Obesity
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210812005197/en/">
                YE 2021
              </a> <div class="note">Phase 1 initiation announced July 7, 2021. Top-line data due YE 2021.</div></td><td>
              165m
            </td><td>
              194.1m
            </td><td>
              0.9m
            </td><td>
              2.4m
            </td><td>
              2.15
            </td><td>
              $1.1
            </td><td>
              $1.11
            </td><td>
              N/A
            </td><td>
              83.95m
            </td><td>
              -3.89m
            </td><td>
              21.58
            </td><td>
              62.26m
            </td><td>
              99.12m
            </td><td>
              2
            </td><td>
              163,341,823
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MOLN" class="margin-bottom-1">
                MOLN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$20.00</div> <small class="number change-up">+0.25<span>&nbsp;&nbsp;</span>+1.27%</small></td><td><strong>Ensovibep (EMPATHY)</strong> <br>COVID-19
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-reports-continued-progress-ensovibep-global">
                2H 2021
              </a> <div class="note">Phase 2/3 interim data due 2H 2021 and full topline data expected in early 2022.</div></td><td>
              29m
            </td><td>
              0.6b
            </td><td>
              9.6k
            </td><td>
              106.3k
            </td><td>
              4.99
            </td><td>
              $19.97
            </td><td>
              $19.75
            </td><td>
              May 2022
            </td><td>
              173.72m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              93.40m
            </td><td>
              392.24m
            </td><td>
              0
            </td><td>
              29,146,162
            </td><td>
              07/08/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DARE" class="margin-bottom-1">
                DARE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.62</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+4.35%</small></td><td><strong>Sildenafil Cream, 3.6% (RESPOND)</strong> <br>Female Sexual Arousal Disorder (FSAD)
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.darebioscience.com/static-files/b0c8350b-3970-490c-b79c-20bf8b3a09f1">
                YE 2021
              </a> <div class="note">Phase 2b data due year-end 2021.</div></td><td>
              71m
            </td><td>
              114.1m
            </td><td>
              2.0m
            </td><td>
              11.4m
            </td><td>
              14.70
            </td><td>
              $1.53
            </td><td>
              $1.55
            </td><td>
              N/A
            </td><td>
              38.89m
            </td><td>
              -3.93m
            </td><td>
              9.89
            </td><td>
              31.81m
            </td><td>
              100.69m
            </td><td>
              1.1
            </td><td>
              68,859,431
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>LYNPARZA (olaparib) - PROpel</strong> <br>Castration-resistant prostate cancer -first line
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2021/h1-2021/H1_2021_results_presentation.pdf">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              March 31, 2023
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FRLN" class="margin-bottom-1">
                FRLN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.39</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+3.95%</small></td><td><strong>FLT180a</strong> <br>Hemophilia B
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/16/2280970/0/en/Freeline-Appoints-Michael-J-Parini-as-Chief-Executive-Officer-and-Reports-Second-Quarter-2021-Financial-Results.html">
                YE 2021
              </a> <div class="note">Phase 1/2 four-year durability data from the dose-finding trial due by end of 2021. Dose confirmation data due by end of 2022.</div></td><td>
              36m
            </td><td>
              121.3m
            </td><td>
              179.1k
            </td><td>
              488.8k
            </td><td>
              0.65
            </td><td>
              $3.27
            </td><td>
              $3.26
            </td><td>
              N/A
            </td><td>
              144.67m
            </td><td>
              -11.12m
            </td><td>
              13.01
            </td><td>
              129.24m
            </td><td>
              -110.82m
            </td><td>
              0
            </td><td>
              35,802,840
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/REPL" class="margin-bottom-1">
                REPL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$31.79</div> <small class="number change-up">+1.61<span>&nbsp;&nbsp;</span>+5.35%</small></td><td><strong>RP2 and OPDIVO (nivolumab)</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.replimune.com/news-releases/news-release-details/replimune-reports-fiscal-first-quarter-financial-results-and-0">
                2H 2021
              </a> <div class="note">Phase 1 updated data due 2H 2021.</div></td><td>
              47m
            </td><td>
              1.5b
            </td><td>
              136.8k
            </td><td>
              313.0k
            </td><td>
              3.10
            </td><td>
              $30.5
            </td><td>
              $30.17
            </td><td>
              December 2022
            </td><td>
              447.34m
            </td><td>
              -6.10m
            </td><td>
              73.28
            </td><td>
              402.64m
            </td><td>
              0.99b
            </td><td>
              9.6
            </td><td>
              29,656,261
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FRLN" class="margin-bottom-1">
                FRLN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.39</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+3.95%</small></td><td><strong>FLT190 (MARVEL-1)</strong> <br>Fabry disease
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/16/2280970/0/en/Freeline-Appoints-Michael-J-Parini-as-Chief-Executive-Officer-and-Reports-Second-Quarter-2021-Financial-Results.html">
                YE 2021
              </a> <div class="note">Phase 1/2 dosing of second patient announced June 16, 2021. Data to be presented by end of 2021.</div></td><td>
              36m
            </td><td>
              121.3m
            </td><td>
              179.1k
            </td><td>
              488.8k
            </td><td>
              0.65
            </td><td>
              $3.27
            </td><td>
              $3.26
            </td><td>
              December 2022
            </td><td>
              144.67m
            </td><td>
              -11.12m
            </td><td>
              13.01
            </td><td>
              129.24m
            </td><td>
              -110.82m
            </td><td>
              0
            </td><td>
              35,802,840
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IDYA" class="margin-bottom-1">
                IDYA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$24.28</div> <small class="number change-up">+0.59<span>&nbsp;&nbsp;</span>+2.49%</small></td><td><strong>IDE397</strong> <br>Solid tumors 
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/ideaya-biosciences-inc-reports-second-quarter-2021-financial-results-and-provides-business-update-301351733.html">
                4Q 2021
              </a> <div class="note">Phase 1 initial data released June 28, 2021 - generally well tolerated with only grade 1 drug-related adverse events. Additional data due 4Q 2021.</div></td><td>
              38m
            </td><td>
              0.9b
            </td><td>
              226.9k
            </td><td>
              287.5k
            </td><td>
              3.88
            </td><td>
              $24.2
            </td><td>
              $23.69
            </td><td>
              December 31, 2022
            </td><td>
              352.52m
            </td><td>
              -4.31m
            </td><td>
              81.79
            </td><td>
              264.38m
            </td><td>
              0.64b
            </td><td>
              2.4
            </td><td>
              34,383,161
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AGLE" class="margin-bottom-1">
                AGLE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.14</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+1.85%</small></td><td><strong>Pegzilarginase (AEB1102) - PEACE</strong> <br>Arginase I deficiency
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-reports-second-quarter-2021-financial-results-and-corporate-highlights-301348486.html">
                4Q 2021
              </a> <div class="note">Phase 3 data due 4Q 2021.</div></td><td>
              49m
            </td><td>
              350.3m
            </td><td>
              76.5k
            </td><td>
              176.1k
            </td><td>
              2.94
            </td><td>
              $7
            </td><td>
              $7.01
            </td><td>
              September 2021
            </td><td>
              129.83m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              101.87m
            </td><td>
              220.66m
            </td><td>
              2.1
            </td><td>
              43,497,685
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CMPI" class="margin-bottom-1">
                CMPI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.68</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+2.86%</small></td><td><strong>Vidutolimod (CMP-001) and KEYTRUDA (pembrolizumab)</strong> <br>Head and neck squamous cell carcinoma (HNSCC)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.checkmatepharma.com/news-releases/news-release-details/checkmate-pharmaceuticals-announces-second-quarter-2021">
                YE 2021
              </a> <div class="note">Phase 2 initial data from a subset of patients due before the end of 2021. Full data due 2H 2022.</div></td><td>
              22m
            </td><td>
              101.2m
            </td><td>
              9.3k
            </td><td>
              60.2k
            </td><td>
              1.07
            </td><td>
              $4.55
            </td><td>
              $4.55
            </td><td>
              July 31, 2022
            </td><td>
              76.12m
            </td><td>
              -5.13m
            </td><td>
              14.84
            </td><td>
              69.41m
            </td><td>
              13.05m
            </td><td>
              3.8
            </td><td>
              11,182,408
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALDX" class="margin-bottom-1">
                ALDX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.89</div> <small class="number change-up">+0.59<span>&nbsp;&nbsp;</span>+7.17%</small></td><td><strong>Reproxalap (ADX-102) - (TRANQUILITY)</strong> <br>Dry eye syndrome
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005246/en/">
                2H 2021
              </a> <div class="note">Phase 3 data due 4Q 2021.</div></td><td>
              58m
            </td><td>
              0.5b
            </td><td>
              407.7k
            </td><td>
              0.8m
            </td><td>
              2.20
            </td><td>
              $8.37
            </td><td>
              $8.3
            </td><td>
              December 31, 2021
            </td><td>
              244.30m
            </td><td>
              -3.02m
            </td><td>
              80.78
            </td><td>
              221.55m
            </td><td>
              245.99m
            </td><td>
              2.8
            </td><td>
              48,335,686
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GSK" class="margin-bottom-1">
                GSK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$41.57</div> <small class="number change-down">-0.28<span>&nbsp;&nbsp;</span>-0.67%</small></td><td><strong>ZEJULA (Niraparib) and JEMPERLI (dostarlimab) - MOONSTONE</strong> <br>Ovarian cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.gsk.com/media/6844/q1-21-results-slides.pdf">
                2H 2021
              </a> <div class="note">Phase 2 pivotal data due 2H 2021.</div></td><td>
              3b
            </td><td>
              104.6b
            </td><td>
              2.3m
            </td><td>
              4.2m
            </td><td>
              4.95
            </td><td>
              $41.75
            </td><td>
              $41.85
            </td><td>
              May 18, 2022
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -51.10b
            </td><td>
              133.80b
            </td><td>
              0.2
            </td><td>
              2,506,785,977
            </td><td>
              06/08/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VRTX" class="margin-bottom-1">
                VRTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$199.01</div> <small class="number change-up">+3.16<span>&nbsp;&nbsp;</span>+1.61%</small></td><td><strong>VX-147</strong> <br>Focal segmental glomerulosclerosis (FSGS)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210729006087/en/">
                2H 2021
              </a> <div class="note">Phase 2 data due 2H 2021.</div></td><td>
              259m
            </td><td>
              51.6b
            </td><td>
              0.6m
            </td><td>
              2.7m
            </td><td>
              5.61
            </td><td>
              $197.27
            </td><td>
              $195.85
            </td><td>
              December 2021
            </td><td>
              6.59b
            </td><td>
              -66.59m
            </td><td>
              98.94
            </td><td>
              3.56b
            </td><td>
              44.99b
            </td><td>
              0.9
            </td><td>
              259,283,352
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMGO" class="margin-bottom-1">
                IMGO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.83</div> <small class="number change-up">+1.45<span>&nbsp;&nbsp;</span>+7.11%</small></td><td><strong>Bomedemstat</strong> <br>Essential Thrombocythemia
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001623715/000119312521200414/d143204ds1.htm">
                2H 2021
              </a> <div class="note">Phase 2 trial enrolling. Update 2H 2021.</div></td><td>
              33m
            </td><td>
              0.7b
            </td><td>
              112.4k
            </td><td>
              107.9k
            </td><td>
              -9.66
            </td><td>
              $20.47
            </td><td>
              $20.38
            </td><td>
              May 2022
            </td><td>
              
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              0.60b
            </td><td>
              2.5
            </td><td>
              26,402,562
            </td><td>
              07/15/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INCY" class="margin-bottom-1">
                INCY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$75.55</div> <small class="number change-up">+0.65<span>&nbsp;&nbsp;</span>+0.86%</small></td><td><strong>OLUMIANT (baricitinib)</strong> <br>Alopecia Areata
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210803005426/en/">
                2H 2021
              </a> <div class="note">Phase 3 trial met primary endpoint - April 19, 2021. NDA filing due 2H 2021.</div></td><td>
              221m
            </td><td>
              16.7b
            </td><td>
              283.8k
            </td><td>
              1.3m
            </td><td>
              5.68
            </td><td>
              $75.18
            </td><td>
              $74.9
            </td><td>
              February 2, 2021
            </td><td>
              2.18b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              1.22b
            </td><td>
              14.50b
            </td><td>
              1.5
            </td><td>
              155,219,007
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LLY" class="margin-bottom-1">
                LLY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$269.63</div> <small class="number change-down">-1.28<span>&nbsp;&nbsp;</span>-0.47%</small></td><td><strong>OLUMIANT (baricitinib)</strong> <br>Alopecia Areata
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210803005426/en/">
                2H 2021
              </a> <div class="note">Phase 3 trial met primary endpoint - April 19, 2021. NDA filing due 2H 2021.</div></td><td>
              1b
            </td><td>
              257.9b
            </td><td>
              0.8m
            </td><td>
              2.8m
            </td><td>
              40.00
            </td><td>
              $272.3
            </td><td>
              $270.91
            </td><td>
              February 2, 2021
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -36.81b
            </td><td>
              272.39b
            </td><td>
              0.5
            </td><td>
              792,287,037
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMGO" class="margin-bottom-1">
                IMGO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.83</div> <small class="number change-up">+1.45<span>&nbsp;&nbsp;</span>+7.11%</small></td><td><strong>Bomedemstat</strong> <br>Myelofibrosis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001623715/000119312521200414/d143204ds1.htm">
                2H 2021
              </a> <div class="note">Phase 2 update 2H 2021.</div></td><td>
              33m
            </td><td>
              0.7b
            </td><td>
              112.4k
            </td><td>
              107.9k
            </td><td>
              -9.66
            </td><td>
              $20.47
            </td><td>
              $20.38
            </td><td>
              December 2021
            </td><td>
              
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              0.60b
            </td><td>
              2.5
            </td><td>
              26,402,562
            </td><td>
              07/15/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CBIO" class="margin-bottom-1">
                CBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.07</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+3.56%</small></td><td><strong>Marzeptacog alfa (MAA-304) - Crimson 1</strong> <br>Hemophilia
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.catalystbiosciences.com/static-files/4f53026f-3b68-4fd7-82d4-1141183ff4ea">
                2H 2021
              </a> <div class="note">Phase 3 trial initiation announced May 5, 2021. First DSMB analysis due 2H 2021.</div></td><td>
              31m
            </td><td>
              125.3m
            </td><td>
              111.7k
            </td><td>
              307.9k
            </td><td>
              0.96
            </td><td>
              $3.93
            </td><td>
              $3.93
            </td><td>
              January 2022
            </td><td>
              74.45m
            </td><td>
              -6.71m
            </td><td>
              11.10
            </td><td>
              57.83m
            </td><td>
              23.41m
            </td><td>
              0
            </td><td>
              21,939,141
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CYAD" class="margin-bottom-1">
                CYAD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.15</div> <small class="number change-up">+0.27<span>&nbsp;&nbsp;</span>+6.96%</small></td><td><strong>CYAD-02 CYCLE-1</strong> <br>Relapsed/refractory Acute myeloid leukemia (AML) and Myelodysplastic Syndrome (MDS)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://celyad.com/2021/08/04/celyad-oncology-reports-first-half-2021-financial-results-and-recent-business-highlights/">
                YE 2021
              </a> <div class="note">Phase 1 additional data due year-end 2021.</div></td><td>
              15m
            </td><td>
              64.3m
            </td><td>
              16.8k
            </td><td>
              38.8k
            </td><td>
              2.21
            </td><td>
              $4.12
            </td><td>
              $3.88
            </td><td>
              December 2021
            </td><td>
              12.02m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -25.81m
            </td><td>
              53.07m
            </td><td>
              0
            </td><td>
              15,493,956
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ADVM" class="margin-bottom-1">
                ADVM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.31</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+6.68%</small></td><td><strong>ADVM-022 - INFINITY</strong> <br>Diabetic macular edema
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.adverum.com/news-releases/news-release-details/adverum-provides-update-advm-022-and-infinity-trial-patients">
                2H 2021
              </a> <div class="note">Phase 2 data to be presented 2H 2021, however intends not to further develop. </div></td><td>
              98m
            </td><td>
              227.2m
            </td><td>
              0.7m
            </td><td>
              2.2m
            </td><td>
              0.60
            </td><td>
              $2.18
            </td><td>
              $2.17
            </td><td>
              December 2022
            </td><td>
              343.49m
            </td><td>
              -11.30m
            </td><td>
              30.38
            </td><td>
              196.49m
            </td><td>
              -21.36m
            </td><td>
              4.6
            </td><td>
              92,400,327
            </td><td>
              07/22/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SYBX" class="margin-bottom-1">
                SYBX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.67</div> <small class="number change-up">+0.22<span>&nbsp;&nbsp;</span>+8.98%</small></td><td><strong>SYNB1934</strong> <br>Phenylketonuria (PKU)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/synlogic-announces-initiation-of-phase-1-study-of-synb1934-a-next-generation-strain-for-the-treatment-of-phenylketonuria-pku-301334191.html">
                YE 2021
              </a> <div class="note">Phase 1 trial initiation announced July 15, 2021. Data due by the end of 2021.</div></td><td>
              52m
            </td><td>
              139.8m
            </td><td>
              77.7k
            </td><td>
              228.2k
            </td><td>
              1.09
            </td><td>
              $2.49
            </td><td>
              $2.45
            </td><td>
              N/A
            </td><td>
              108.66m
            </td><td>
              -3.78m
            </td><td>
              28.73
            </td><td>
              79.85m
            </td><td>
              34.89m
            </td><td>
              2.7
            </td><td>
              37,099,321
            </td><td>
              07/15/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TSHA" class="margin-bottom-1">
                TSHA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.73</div> <small class="number change-up">+0.80<span>&nbsp;&nbsp;</span>+4.73%</small></td><td><strong>TSHA-101</strong> <br>GM2 gangliosidosis
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210816005196/en/">
                2H 2021
              </a> <div class="note">Phase 1/2 biomarker and preliminary clinical data due 2H 2021 (Queen’s University trial). Phase 1/2 clinical trial in the U.S. to be initiated 2H 2021.</div></td><td>
              38m
            </td><td>
              0.7b
            </td><td>
              22.6k
            </td><td>
              190.5k
            </td><td>
              3.65
            </td><td>
              $17.25
            </td><td>
              $16.93
            </td><td>
              N/A
            </td><td>
              183.68m
            </td><td>
              -7.61m
            </td><td>
              24.15
            </td><td>
              128.32m
            </td><td>
              478.80m
            </td><td>
              26.7
            </td><td>
              16,966,890
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EQ" class="margin-bottom-1">
                EQ
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.12</div> <small class="number change-up">+1.28<span>&nbsp;&nbsp;</span>+26.55%</small></td><td><strong>Itolizumab (EQ001) - (EQUIP)</strong> <br>Asthma
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210810005845/en/">
                2H 2021
              </a> <div class="note">Phase 1b data due 2H 2021.</div></td><td>
              29m
            </td><td>
              180.0m
            </td><td>
              0.6m
            </td><td>
              117.2k
            </td><td>
              2.12
            </td><td>
              $4.9
            </td><td>
              $4.84
            </td><td>
              August 2021
            </td><td>
              93.45m
            </td><td>
              -2.33m
            </td><td>
              40.08
            </td><td>
              78.38m
            </td><td>
              54.64m
            </td><td>
              4.2
            </td><td>
              16,153,503
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MTEM" class="margin-bottom-1">
                MTEM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.61</div> <small class="number change-down">-0.05<span>&nbsp;&nbsp;</span>-0.75%</small></td><td><strong>MT-5111</strong> <br>HER2-positive solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2280164/0/en/Molecular-Templates-Inc-Reports-Second-Quarter-2021-Financial-Results.html">
                4Q 2021
              </a> <div class="note">Phase 1 data from the dose escalation portion presented at AACR April 10, 2021 - well tolerated. Further data due 4Q 2021.</div></td><td>
              56m
            </td><td>
              371.1m
            </td><td>
              102.9k
            </td><td>
              210.5k
            </td><td>
              3.82
            </td><td>
              $6.76
            </td><td>
              $6.66
            </td><td>
              May 2023
            </td><td>
              182.40m
            </td><td>
              -8.44m
            </td><td>
              21.60
            </td><td>
              35.05m
            </td><td>
              224.74m
            </td><td>
              10.5
            </td><td>
              28,015,505
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BBIO" class="margin-bottom-1">
                BBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.45</div> <small class="number change-up">+0.42<span>&nbsp;&nbsp;</span>+0.86%</small></td><td><strong>Encaleret</strong> <br>Autosomal Dominant Hypocalcemia Type 1 (ADH1)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/bridgebio-pharma-inc-reports-second-quarter-2021-financial-results-and-business-update-301348970.html">
                2H 2021
              </a> <div class="note">Phase 2 data presented at ENDO March 20, 2021 well tolerated, no adverse events. Further data due 2H 2021.</div></td><td>
              150m
            </td><td>
              7.4b
            </td><td>
              385.3k
            </td><td>
              0.9m
            </td><td>
              -15.95
            </td><td>
              $49.7
            </td><td>
              $49.03
            </td><td>
              N/A
            </td><td>
              0.78b
            </td><td>
              -30.57m
            </td><td>
              25.60
            </td><td>
              -0.76b
            </td><td>
              7.84b
            </td><td>
              5.3
            </td><td>
              82,237,528
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GILD" class="margin-bottom-1">
                GILD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$72.66</div> <small class="number change-up">+0.22<span>&nbsp;&nbsp;</span>+0.30%</small></td><td><strong>Magrolimab</strong> <br>Myelodysplastic syndromes (MDS)
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.gilead.com/static-files/a67bf84b-ece1-480b-bedf-665c6e4c57a9">
                2H 2021
              </a> <div class="note">Phase 1b data due 2H 2021.</div></td><td>
              1b
            </td><td>
              91.1b
            </td><td>
              2.8m
            </td><td>
              6.3m
            </td><td>
              4.62
            </td><td>
              $72.68
            </td><td>
              $72.44
            </td><td>
              N/A
            </td><td>
              7.91b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -40.36b
            </td><td>
              114.48b
            </td><td>
              0.6
            </td><td>
              1,253,507,953
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PTCT" class="margin-bottom-1">
                PTCT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$39.58</div> <small class="number change-up">+1.38<span>&nbsp;&nbsp;</span>+3.61%</small></td><td><strong>EVRYSDI (risdiplam)</strong> <br>SMA type 1/2/3 switching study
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.roche.com/dam/jcr:3a48ad2b-c695-462c-a42f-ffcae34fa39c/en/irp210421.pdf">
                2021
              </a> <div class="note">Phase 2 data due 2021.</div></td><td>
              71m
            </td><td>
              2.8b
            </td><td>
              109.5k
            </td><td>
              412.7k
            </td><td>
              14.24
            </td><td>
              $38.84
            </td><td>
              $38.2
            </td><td>
              January 31, 2022
            </td><td>
              0.93b
            </td><td>
              -10.38m
            </td><td>
              89.43
            </td><td>
              -0.93b
            </td><td>
              2.29b
            </td><td>
              0.9
            </td><td>
              49,392,128
            </td><td>
              06/18/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RHHBY" class="margin-bottom-1">
                RHHBY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$50.36</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+0.12%</small></td><td><strong>EVRYSDI (risdiplam)</strong> <br>SMA type 1/2/3 switching study
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.roche.com/dam/jcr:3a48ad2b-c695-462c-a42f-ffcae34fa39c/en/irp210421.pdf">
                2021
              </a> <div class="note">Phase 2 data due 2021.</div></td><td>
              7b
            </td><td>
              344.2b
            </td><td>
              0.5m
            </td><td>
              1.0m
            </td><td>
              8.35
            </td><td>
              $50.24
            </td><td>
              $50.3
            </td><td>
              January 31, 2022
            </td><td>
              8.02b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -38.44b
            </td><td>
              356.64b
            </td><td>
              0
            </td><td>
              6,834,087,224
            </td><td>
              06/18/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CGEN" class="margin-bottom-1">
                CGEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.57</div> <small class="number change-up">+0.38<span>&nbsp;&nbsp;</span>+6.14%</small></td><td><strong>COM701, OPDIVO (nivolumab) and BMS-986207</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/compugen-reports-second-quarter-2021-results-301342975.html">
                4Q 2021
              </a> <div class="note">Phase 1/2 initial dose escalation data due 4Q 2021.</div></td><td>
              84m
            </td><td>
              0.6b
            </td><td>
              0.7m
            </td><td>
              0.8m
            </td><td>
              5.34
            </td><td>
              $6.2
            </td><td>
              $6.19
            </td><td>
              August 2022
            </td><td>
              110.41m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              91.02m
            </td><td>
              389.20m
            </td><td>
              0
            </td><td>
              66,755,729
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AMTI" class="margin-bottom-1">
                AMTI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.00</div> <small class="number change-up">+0.76<span>&nbsp;&nbsp;</span>+2.60%</small></td><td><strong>AMT-101 combo with with anti-TNFα (MARKET)</strong> <br>Ulcerative colitis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.appliedmt.com/static-files/4c3f1146-b81c-42c1-8260-c9a2ebbc0a30">
                4Q 2021
              </a> <div class="note">Phase 2 data due 4Q 2021.</div></td><td>
              38m
            </td><td>
              1.2b
            </td><td>
              105.8k
            </td><td>
              238.2k
            </td><td>
              5.54
            </td><td>
              $29.75
            </td><td>
              $29.24
            </td><td>
              N/A
            </td><td>
              186.24m
            </td><td>
              -7.38m
            </td><td>
              25.23
            </td><td>
              170.06m
            </td><td>
              0.93b
            </td><td>
              1.6
            </td><td>
              16,723,522
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RHHBY" class="margin-bottom-1">
                RHHBY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$50.36</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+0.12%</small></td><td><strong>Mosunetuzumab</strong> <br>Follicular lymphoma
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.roche.com/dam/jcr:a1437516-3f73-4112-a483-40c8b1c3836e/en/irp210722.pdf">
                2H 2021
              </a> <div class="note">Phase 1b data due 2H 2021.</div></td><td>
              7b
            </td><td>
              344.2b
            </td><td>
              0.5m
            </td><td>
              1.0m
            </td><td>
              8.35
            </td><td>
              $50.24
            </td><td>
              $50.3
            </td><td>
              November 15, 2023
            </td><td>
              8.02b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -38.44b
            </td><td>
              356.64b
            </td><td>
              0
            </td><td>
              6,834,087,224
            </td><td>
              07/22/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RAPT" class="margin-bottom-1">
                RAPT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$31.53</div> <small class="number change-up">+1.59<span>&nbsp;&nbsp;</span>+5.31%</small></td><td><strong>FLX475</strong> <br>Advanced Cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.rapt.com/static-files/852cc733-5560-43f6-b324-2599c42c8e24">
                2H 2021
              </a> <div class="note">Phase 2 additional data due 2H 2021.</div></td><td>
              29m
            </td><td>
              0.9b
            </td><td>
              144.1k
            </td><td>
              1.2m
            </td><td>
              4.27
            </td><td>
              $30.49
            </td><td>
              $29.94
            </td><td>
              June 2022
            </td><td>
              214.95m
            </td><td>
              -4.64m
            </td><td>
              46.34
            </td><td>
              201.45m
            </td><td>
              0.66b
            </td><td>
              0.9
            </td><td>
              21,288,364
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLLS" class="margin-bottom-1">
                CLLS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.61</div> <small class="number change-up">+1.14<span>&nbsp;&nbsp;</span>+9.14%</small></td><td><strong>ALLO-715 - UNIVERSAL</strong> <br>Multiple myeloma
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-second-quarter-2021-financial">
                4Q 2021
              </a> <div class="note">Phase 1/2 updated data due 4Q 2021.</div></td><td>
              45m
            </td><td>
              0.6b
            </td><td>
              168.0k
            </td><td>
              205.0k
            </td><td>
              2.24
            </td><td>
              $12.76
            </td><td>
              $12.47
            </td><td>
              November 2021
            </td><td>
              244.34m
            </td><td>
              -4.04m
            </td><td>
              60.46
            </td><td>
              89.10m
            </td><td>
              425.67m
            </td><td>
              0
            </td><td>
              45,461,310
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALLO" class="margin-bottom-1">
                ALLO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$24.50</div> <small class="number change-up">+1.05<span>&nbsp;&nbsp;</span>+4.50%</small></td><td><strong>ALLO-715 - UNIVERSAL</strong> <br>Multiple myeloma
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-second-quarter-2021-financial">
                4Q 2021
              </a> <div class="note">Phase 1/2 updated data due 4Q 2021.</div></td><td>
              142m
            </td><td>
              3.5b
            </td><td>
              0.7m
            </td><td>
              1.0m
            </td><td>
              3.40
            </td><td>
              $23.6
            </td><td>
              $23.45
            </td><td>
              November 2021
            </td><td>
              0.56b
            </td><td>
              -13.72m
            </td><td>
              41.03
            </td><td>
              460.09m
            </td><td>
              2.80b
            </td><td>
              3.2
            </td><td>
              87,198,887
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GLYC" class="margin-bottom-1">
                GLYC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.90</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+2.97%</small></td><td><strong>Uproleselan (GMI-1271) - NCI-sponsored</strong> <br>Acute myeloid leukemia (AML) 
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005381/en/">
                YE 2021
              </a> <div class="note">Phase 2 completion due by end of 2021, allowing for interim Event-Free Survival analysis</div></td><td>
              52m
            </td><td>
              98.2m
            </td><td>
              106.0k
            </td><td>
              479.0k
            </td><td>
              0.87
            </td><td>
              $1.96
            </td><td>
              $1.85
            </td><td>
              December 1, 2025
            </td><td>
              110.69m
            </td><td>
              -4.54m
            </td><td>
              24.40
            </td><td>
              98.59m
            </td><td>
              -21.12m
            </td><td>
              2.3
            </td><td>
              41,569,401
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SNDX" class="margin-bottom-1">
                SNDX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.37</div> <small class="number change-up">+0.62<span>&nbsp;&nbsp;</span>+3.94%</small></td><td><strong>SNDX-5613 (AUGMENT-101)</strong> <br>Relapsed/refractory (R/R) acute leukemias
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-clinical-and-business-update-301351309.html">
                4Q 2021
              </a> <div class="note">Phase 1 updated data due 4Q 2021. Phase 2 pivotal part of trial to commence 2Q 2021.</div></td><td>
              49m
            </td><td>
              0.8b
            </td><td>
              309.6k
            </td><td>
              479.0k
            </td><td>
              3.71
            </td><td>
              $15.87
            </td><td>
              $15.75
            </td><td>
              July 1, 2022
            </td><td>
              238.71m
            </td><td>
              -8.01m
            </td><td>
              29.78
            </td><td>
              190.21m
            </td><td>
              0.53b
            </td><td>
              0.4
            </td><td>
              47,742,775
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MDWD" class="margin-bottom-1">
                MDWD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.55</div> <small class="number change-up">+0.02<span>&nbsp;&nbsp;</span>+0.57%</small></td><td><strong>EscharEx</strong> <br>Lower leg ulcers
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.mediwound.com/news-releases/news-release-details/mediwound-reports-second-quarter-financial-results">
                2H 2021
              </a> <div class="note">Phase 2 pharmacology study initiation announced April 21, 2021. Data due 2H 2021. </div></td><td>
              27m
            </td><td>
              96.7m
            </td><td>
              44.3k
            </td><td>
              0.5m
            </td><td>
              44.38
            </td><td>
              $3.54
            </td><td>
              $3.53
            </td><td>
              August 2021
            </td><td>
              16.40m
            </td><td>
              -328.33k
            </td><td>
              49.96
            </td><td>
              -7.68m
            </td><td>
              80.79m
            </td><td>
              0
            </td><td>
              15,908,179
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RYTM" class="margin-bottom-1">
                RYTM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.84</div> <small class="number change-up">+0.38<span>&nbsp;&nbsp;</span>+3.05%</small></td><td><strong>Setmelanotide (basket)</strong> <br>POMC Heterozygous Deficiency Obesity, Alstrom Syndrome, POMC Epigenetic Disorders
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-reports-first-quarter-2021-financial">
                2H 2021
              </a> <div class="note">Phase 2 data released January 26, 2021. 12 of 35 patients (34.3 percent) achieved the primary endpoint. Further data due 2H 2021.</div></td><td>
              50m
            </td><td>
              0.6b
            </td><td>
              77.7k
            </td><td>
              398.0k
            </td><td>
              1.83
            </td><td>
              $12.49
            </td><td>
              $12.46
            </td><td>
              November 2021
            </td><td>
              349.05m
            </td><td>
              -10.61m
            </td><td>
              32.89
            </td><td>
              312.35m
            </td><td>
              260.51m
            </td><td>
              1.8
            </td><td>
              38,689,654
            </td><td>
              05/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALLO" class="margin-bottom-1">
                ALLO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$24.50</div> <small class="number change-up">+1.05<span>&nbsp;&nbsp;</span>+4.50%</small></td><td><strong>ALLO-501 - ALPHA</strong> <br>Non-Hodgkin lymphoma (NHL) 
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-second-quarter-2021-financial">
                Late-2021
              </a> <div class="note">Phase 1 data at ASCO June 4, 2021. Overall Response Rate (ORR) of 75% and CR Rate of 50% across histologies in CAR T Naïve patients. Further data due late-2021.</div></td><td>
              142m
            </td><td>
              3.5b
            </td><td>
              0.7m
            </td><td>
              1.0m
            </td><td>
              3.40
            </td><td>
              $23.6
            </td><td>
              $23.45
            </td><td>
              January 2022
            </td><td>
              0.56b
            </td><td>
              -13.72m
            </td><td>
              41.03
            </td><td>
              460.09m
            </td><td>
              2.80b
            </td><td>
              3.2
            </td><td>
              87,198,887
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RYTM" class="margin-bottom-1">
                RYTM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.84</div> <small class="number change-up">+0.38<span>&nbsp;&nbsp;</span>+3.05%</small></td><td><strong>Setmelanotide</strong> <br>Alstrom Syndrome and Bardet-Biedl Syndrome
            </td><td>
              sNDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-reports-second-quarter-2021-financial">
                2H 2021
              </a> <div class="note">Phase 3 top-line data met primary endpoint - December 22, 2020. All primary endpoint responders were patients with BBS. Alstrom syndrome patients did not meet primary endpoint. sNDA filing due 2H 2021.</div></td><td>
              50m
            </td><td>
              0.6b
            </td><td>
              77.7k
            </td><td>
              398.0k
            </td><td>
              1.83
            </td><td>
              $12.49
            </td><td>
              $12.46
            </td><td>
              November 16, 2020
            </td><td>
              349.05m
            </td><td>
              -10.61m
            </td><td>
              32.89
            </td><td>
              312.35m
            </td><td>
              260.51m
            </td><td>
              1.8
            </td><td>
              38,689,654
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/HOOK" class="margin-bottom-1">
                HOOK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.57</div> <small class="number change-up">+0.04<span>&nbsp;&nbsp;</span>+0.69%</small></td><td><strong>HB-101</strong> <br>Cytomegalovirus (CMV)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.hookipapharma.com/news-releases/news-release-details/hookipa-pharma-reports-second-quarter-2021-financial-results-and">
                2H 2021
              </a> <div class="note">Phase 2  additional safety, immunogenicity, and efficacy data due 2H 2021, with final top-line data 1H 2023.</div></td><td>
              30m
            </td><td>
              196.2m
            </td><td>
              126.4k
            </td><td>
              355.5k
            </td><td>
              1.56
            </td><td>
              $6.67
            </td><td>
              $6.52
            </td><td>
              October 7, 2022
            </td><td>
              90.08m
            </td><td>
              -6.91m
            </td><td>
              13.04
            </td><td>
              49.86m
            </td><td>
              102.02m
            </td><td>
              1
            </td><td>
              22,524,370
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NBIX" class="margin-bottom-1">
                NBIX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$92.61</div> <small class="number change-up">+0.86<span>&nbsp;&nbsp;</span>+0.94%</small></td><td><strong>Valbenazine (KINECT-HD)</strong> <br>Huntington's disease
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/neurocrine-biosciences-reports-second-quarter-2021-financial-results-301347502.html">
                4Q 2021
              </a> <div class="note">Phase 3 data due 4Q 2021.</div></td><td>
              95m
            </td><td>
              8.8b
            </td><td>
              259.9k
            </td><td>
              0.7m
            </td><td>
              6.85
            </td><td>
              $92.12
            </td><td>
              $91.75
            </td><td>
              September 2021
            </td><td>
              0.95b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              269.62m
            </td><td>
              8.23b
            </td><td>
              2.2
            </td><td>
              93,404,406
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BOLT" class="margin-bottom-1">
                BOLT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.65</div> <small class="number change-up">+0.91<span>&nbsp;&nbsp;</span>+6.62%</small></td><td><strong>BDC-1001</strong> <br>HER2-Expressing Solid Tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.boltbio.com/news-releases/news-release-details/bolt-biotherapeutics-reports-second-quarter-2021-financial">
                2H 2021
              </a> <div class="note">Phase 1/2 initial data presented at ASCO June 4-8, 2021 - well tolerated with mild to moderate adverse events. Update due 2H 2021.</div></td><td>
              37m
            </td><td>
              0.5b
            </td><td>
              179.8k
            </td><td>
              161.6k
            </td><td>
              1.84
            </td><td>
              $14.06
            </td><td>
              $13.74
            </td><td>
              January 31, 2023
            </td><td>
              242.60m
            </td><td>
              -1.33m
            </td><td>
              182.59
            </td><td>
              191.42m
            </td><td>
              291.64m
            </td><td>
              0.1
            </td><td>
              21,693,907
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LOGC" class="margin-bottom-1">
                LOGC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.20</div> <small class="number change-up">+0.32<span>&nbsp;&nbsp;</span>+8.25%</small></td><td><strong>LB-001 - (SUNRISE)</strong> <br>Methylmalonic Acidemia (MMA)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/logicbio-therapeutics-reports-second-quarter-2021-financial-results-and-highlights-recent-company-milestones-301350997.html">
                YE 2021
              </a> <div class="note">Phase 1/2 commencement of dosing announced June 2, 2021. Interim data due YE 2021.</div></td><td>
              32m
            </td><td>
              135.4m
            </td><td>
              33.2k
            </td><td>
              175.7k
            </td><td>
              3.02
            </td><td>
              $3.94
            </td><td>
              $3.88
            </td><td>
              N/A
            </td><td>
              70.84m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              37.78m
            </td><td>
              72.36m
            </td><td>
              1.8
            </td><td>
              22,701,642
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BBI" class="margin-bottom-1">
                BBI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.64</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+1.18%</small></td><td><strong>Sofpironium Bromide (Cardigan II)</strong> <br>Axillary Hyperhidrosis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.brickellbio.com/news/detail/64/brickell-biotech-reports-second-quarter-2021-financial">
                4Q 2021
              </a> <div class="note">Phase 3 data due 4Q 2021.</div></td><td>
              86m
            </td><td>
              55.0m
            </td><td>
              309.8k
            </td><td>
              1.3m
            </td><td>
              2.46
            </td><td>
              $0.65
            </td><td>
              $0.63
            </td><td>
              September 2021
            </td><td>
              23.87m
            </td><td>
              -4.77m
            </td><td>
              5.00
            </td><td>
              17.15m
            </td><td>
              30.08m
            </td><td>
              2.2
            </td><td>
              83,870,001
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CADL" class="margin-bottom-1">
                CADL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.75</div> <small class="number change-up">+1.45<span>&nbsp;&nbsp;</span>+23.02%</small></td><td><strong>CAN-3110</strong> <br>Glioma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001841387/000119312521200639/d120909ds1.htm">
                4Q 2021
              </a> <div class="note">Phase 1 trial ongoing. Biomarker data due 4Q 2021.</div></td><td>
              28m
            </td><td>
              215.4m
            </td><td>
              153.7k
            </td><td>
              
            </td><td>
              -7.83
            </td><td>
              $6.8
            </td><td>
              $6.3
            </td><td>
              N/A
            </td><td>
              20.09m
            </td><td>
              -1.88m
            </td><td>
              10.71
            </td><td>
              -42.50m
            </td><td>
              146.94m
            </td><td>
              6.7
            </td><td>
              14,620,612
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALRN" class="margin-bottom-1">
                ALRN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.10</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+8.33%</small></td><td><strong>ALRN-6924</strong> <br>Non-small cell lung cancer
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.benzinga.com/pressreleases/21/08/g22453987/aileron-therapeutics-reports-second-quarter-2021-financial-results-and-provides-business-update">
                4Q 2021
              </a> <div class="note">Phase 1b initiation announced July 1, 2021 with initial results due 4Q 2021 and full results mid-2022.</div></td><td>
              91m
            </td><td>
              100.1m
            </td><td>
              0.7m
            </td><td>
              423.3k
            </td><td>
              1.78
            </td><td>
              $1.07
            </td><td>
              $1.02
            </td><td>
              N/A
            </td><td>
              57.22m
            </td><td>
              -1.25m
            </td><td>
              45.62
            </td><td>
              52.82m
            </td><td>
              33.11m
            </td><td>
              1.4
            </td><td>
              71,295,333
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SNY" class="margin-bottom-1">
                SNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$52.48</div> <small class="number change-down">-0.64<span>&nbsp;&nbsp;</span>-1.20%</small></td><td><strong>SARCLISA (isatuximab) - IMROZ</strong> <br>Multiple myeloma not eligible for transplant
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/2021_07_29_Sanofi_Q2_2021_presentation.pdf?la=en&amp;hash=F258C8E98B392E4E9DAF7517ECD8A4B9">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              3b
            </td><td>
              131.7b
            </td><td>
              2.5m
            </td><td>
              1.7m
            </td><td>
              1.78
            </td><td>
              $52.73
            </td><td>
              $53.12
            </td><td>
              December 2022
            </td><td>
              9.72b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -39.23b
            </td><td>
              146.90b
            </td><td>
              0
            </td><td>
              2,510,366,030
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PRQR" class="margin-bottom-1">
                PRQR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.22</div> <small class="number change-up">+0.69<span>&nbsp;&nbsp;</span>+12.48%</small></td><td><strong>Sepofarsen (InSight extension trial)</strong> <br>Leber Congenital Amaurosis type 10 (LCA10)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.proqr.com/press-releases/proqr-announces-first-quarter-2021-operating-and-financial-results">
                2H 2021
              </a> <div class="note">Phase 1/2 new data to be presented 2H 2021.</div></td><td>
              67m
            </td><td>
              417.2m
            </td><td>
              192.0k
            </td><td>
              478.4k
            </td><td>
              3.02
            </td><td>
              $5.57
            </td><td>
              $5.53
            </td><td>
              N/A
            </td><td>
              133.45m
            </td><td>
              -3.33m
            </td><td>
              40.12
            </td><td>
              88.64m
            </td><td>
              249.39m
            </td><td>
              0
            </td><td>
              57,834,902
            </td><td>
              05/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SGMO" class="margin-bottom-1">
                SGMO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.87</div> <small class="number change-up">+0.51<span>&nbsp;&nbsp;</span>+5.45%</small></td><td><strong>ST-400 (Thales)</strong> <br>beta-thalassemia
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.sangamo.com/static-files/ed989494-b5ef-4b3c-afa6-55aeb993763b">
                2021
              </a> <div class="note">Phase 1/2 further data due in 2021.</div></td><td>
              145m
            </td><td>
              1.4b
            </td><td>
              0.5m
            </td><td>
              1.0m
            </td><td>
              3.21
            </td><td>
              $9.46
            </td><td>
              $9.36
            </td><td>
              November 2022
            </td><td>
              498.11m
            </td><td>
              -17.52m
            </td><td>
              28.43
            </td><td>
              108.21m
            </td><td>
              0.87b
            </td><td>
              2.2
            </td><td>
              120,566,640
            </td><td>
              02/24/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SNY" class="margin-bottom-1">
                SNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$52.48</div> <small class="number change-down">-0.64<span>&nbsp;&nbsp;</span>-1.20%</small></td><td><strong>ST-400 (Thales)</strong> <br>beta-thalassemia
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.sangamo.com/static-files/ed989494-b5ef-4b3c-afa6-55aeb993763b">
                2021
              </a> <div class="note">Phase 1/2 further data due in 2021.</div></td><td>
              3b
            </td><td>
              131.7b
            </td><td>
              2.5m
            </td><td>
              1.7m
            </td><td>
              1.78
            </td><td>
              $52.73
            </td><td>
              $53.12
            </td><td>
              November 2022
            </td><td>
              9.72b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -39.23b
            </td><td>
              146.90b
            </td><td>
              0
            </td><td>
              2,510,366,030
            </td><td>
              02/24/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PHAS" class="margin-bottom-1">
                PHAS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.22</div> <small class="number change-up">+0.02<span>&nbsp;&nbsp;</span>+0.62%</small></td><td><strong>Bentracimab (PB2452) - (REVERSE-IT)</strong> <br>Reversal agent for ticagrelor
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210812005220/en/">
                2H 2021
              </a> <div class="note">Phase 3 completion of enrollment announced August 12, 2021. Top-line data due 2H 2021.</div></td><td>
              48m
            </td><td>
              154.7m
            </td><td>
              261.5k
            </td><td>
              413.4k
            </td><td>
              -8.05
            </td><td>
              $3.22
            </td><td>
              $3.2
            </td><td>
              December 31, 2023
            </td><td>
              57.80m
            </td><td>
              -3.70m
            </td><td>
              15.64
            </td><td>
              -62.01m
            </td><td>
              100.52m
            </td><td>
              0.5
            </td><td>
              38,715,079
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INCY" class="margin-bottom-1">
                INCY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$75.55</div> <small class="number change-up">+0.65<span>&nbsp;&nbsp;</span>+0.86%</small></td><td><strong>Parsaclisib - (CITADEL-203)</strong> <br>Follicular lymphoma
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s21.q4cdn.com/114423841/files/doc_financials/2021/q2/Q2-2021-Slides_vFINAL.pdf">
                2H 2021
              </a> <div class="note">NDA filing due 2H 2021.</div></td><td>
              221m
            </td><td>
              16.7b
            </td><td>
              283.8k
            </td><td>
              1.3m
            </td><td>
              5.68
            </td><td>
              $75.18
            </td><td>
              $74.9
            </td><td>
              July 28, 2021
            </td><td>
              2.18b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              1.22b
            </td><td>
              14.50b
            </td><td>
              1.5
            </td><td>
              155,219,007
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MDNA" class="margin-bottom-1">
                MDNA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.13</div> <small class="number change-up">+0.05<span>&nbsp;&nbsp;</span>+2.40%</small></td><td><strong>MDNA11 (ABILITY)</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/13/2280415/0/en/Medicenna-Reports-First-Quarter-Fiscal-2022-Financial-Results-and-Operational-Highlights.html">
                YE 2021
              </a> <div class="note">Phase 1/2 trial to be initiated 3Q 2021 with top-line safety, PK/PD and biomarker data due end of 2021 and initial efficacy data in 2022.</div></td><td>
              49m
            </td><td>
              114.5m
            </td><td>
              70.9k
            </td><td>
              148.1k
            </td><td>
              4.44
            </td><td>
              $2.13
            </td><td>
              $2.08
            </td><td>
              N/A
            </td><td>
              33.16m
            </td><td>
              -1.52m
            </td><td>
              21.76
            </td><td>
              28.21m
            </td><td>
              81.34m
            </td><td>
              0
            </td><td>
              53,742,255
            </td><td>
              08/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MCRB" class="margin-bottom-1">
                MCRB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.38</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+4.85%</small></td><td><strong>SER-287</strong> <br>Mild-to-Moderate Ulcerative Colitis
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210803005411/en/">
                2H 2021
              </a> <div class="note">Phase 2b trial did not meet primary endpoint - July 22, 2021. Microbiome analyses due 2H 2021.</div></td><td>
              92m
            </td><td>
              0.6b
            </td><td>
              0.7m
            </td><td>
              1.7m
            </td><td>
              5.80
            </td><td>
              $6.15
            </td><td>
              $6.08
            </td><td>
              June 2021
            </td><td>
              365.74m
            </td><td>
              -13.23m
            </td><td>
              27.64
            </td><td>
              197.15m
            </td><td>
              387.93m
            </td><td>
              0.7
            </td><td>
              51,880,686
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IONS" class="margin-bottom-1">
                IONS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$39.33</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+0.18%</small></td><td><strong>IONIS-PKK-LRx</strong> <br>Hereditary Angioedema
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ionispharma.com/news-releases/news-release-details/ionis-reports-second-quarter-2021-financial-results-and-recent">
                2H 2021
              </a> <div class="note">Phase 2 data released March 29, 2021. Primary endpoint met. Full data due 2H 2021.</div></td><td>
              141m
            </td><td>
              5.6b
            </td><td>
              322.8k
            </td><td>
              1.1m
            </td><td>
              9.52
            </td><td>
              $39.68
            </td><td>
              $39.26
            </td><td>
              February 1, 2021
            </td><td>
              2.05b
            </td><td>
              -20.88m
            </td><td>
              98.00
            </td><td>
              132.28m
            </td><td>
              4.79b
            </td><td>
              0.6
            </td><td>
              119,102,131
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RCKT" class="margin-bottom-1">
                RCKT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.32</div> <small class="number change-up">+2.12<span>&nbsp;&nbsp;</span>+7.54%</small></td><td><strong>RP-A501</strong> <br>Danon disease
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005748/en/">
                4Q 2021
              </a> <div class="note">Phase 1 clinical hold lifted August 16, 2021. Longer term data due 4Q 2021. </div></td><td>
              64m
            </td><td>
              1.9b
            </td><td>
              428.3k
            </td><td>
              459.8k
            </td><td>
              3.94
            </td><td>
              $28.55
            </td><td>
              $28.2
            </td><td>
              October 21, 2022
            </td><td>
              403.71m
            </td><td>
              -12.84m
            </td><td>
              31.44
            </td><td>
              358.00m
            </td><td>
              1.39b
            </td><td>
              1.6
            </td><td>
              43,407,962
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GMTX" class="margin-bottom-1">
                GMTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.62</div> <small class="number change-up">+0.12<span>&nbsp;&nbsp;</span>+3.43%</small></td><td><strong>GEM103</strong> <br>Wet Age-Related Macular Degeneration (AMD)
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210812005178/en/">
                Late-2021
              </a> <div class="note">Phase 2a top-line data due late-2021.</div></td><td>
              43m
            </td><td>
              156.1m
            </td><td>
              50.0k
            </td><td>
              0.5m
            </td><td>
              0.99
            </td><td>
              $3.52
            </td><td>
              $3.5
            </td><td>
              N/A
            </td><td>
              157.92m
            </td><td>
              -5.31m
            </td><td>
              29.74
            </td><td>
              143.18m
            </td><td>
              -8.70m
            </td><td>
              0.3
            </td><td>
              22,146,324
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BBIO" class="margin-bottom-1">
                BBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.45</div> <small class="number change-up">+0.42<span>&nbsp;&nbsp;</span>+0.86%</small></td><td><strong>Acoramidis (AG10) - ATTRibute-CM</strong> <br>ATTR-CM
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/bridgebio-pharma-inc-reports-second-quarter-2021-financial-results-and-business-update-301348970.html">
                Late-2021
              </a> <div class="note">Phase 3 top-line Part A data due late-2021. Part B data due 2023.</div></td><td>
              150m
            </td><td>
              7.4b
            </td><td>
              385.3k
            </td><td>
              0.9m
            </td><td>
              -15.95
            </td><td>
              $49.7
            </td><td>
              $49.03
            </td><td>
              April 2023
            </td><td>
              0.78b
            </td><td>
              -30.57m
            </td><td>
              25.60
            </td><td>
              -0.76b
            </td><td>
              7.84b
            </td><td>
              5.3
            </td><td>
              82,237,528
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CMPX" class="margin-bottom-1">
                CMPX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.03</div> <small class="number change-up">+0.08<span>&nbsp;&nbsp;</span>+2.03%</small></td><td><strong>CTX-471</strong> <br>Solid Tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1738021/000119312520271775/d67515ds1.htm">
                2H 2021
              </a> <div class="note">Phase 1 trial ongoing. Part 2 cohort expansion portion of the trial to be completed 2H 2021 with a Phase 2/3 trial to commence early 2022.</div></td><td>
              62m
            </td><td>
              248.6m
            </td><td>
              4.1k
            </td><td>
              6.1k
            </td><td>
              8.57
            </td><td>
              $4
            </td><td>
              $3.95
            </td><td>
              July 2022
            </td><td>
              27.64m
            </td><td>
              -1.98m
            </td><td>
              13.96
            </td><td>
              15.65m
            </td><td>
              230.77m
            </td><td>
              0
            </td><td>
              33,365,202
            </td><td>
              11/13/2020
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KZR" class="margin-bottom-1">
                KZR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.96</div> <small class="number change-up">+0.52<span>&nbsp;&nbsp;</span>+9.45%</small></td><td><strong>KZR-616 (MISSION)</strong> <br>Lupus
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210812005654/en/">
                4Q 2021
              </a> <div class="note">Phase 2 interim data due 4Q 2021 and top-line data are expected 1H 2022.</div></td><td>
              48m
            </td><td>
              287.5m
            </td><td>
              95.1k
            </td><td>
              191.6k
            </td><td>
              2.21
            </td><td>
              $5.41
            </td><td>
              $5.45
            </td><td>
              January 2022
            </td><td>
              121.15m
            </td><td>
              -4.35m
            </td><td>
              27.86
            </td><td>
              111.36m
            </td><td>
              138.64m
            </td><td>
              3.3
            </td><td>
              40,132,157
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LLY" class="margin-bottom-1">
                LLY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$269.63</div> <small class="number change-down">-1.28<span>&nbsp;&nbsp;</span>-0.47%</small></td><td><strong>Mirikizumab</strong> <br>Ulcerative Colitis (Maintenance data)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.lilly.com/static-files/07e528d6-bf01-4258-8190-7b32b28ba24d">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              1b
            </td><td>
              257.9b
            </td><td>
              0.8m
            </td><td>
              2.8m
            </td><td>
              40.00
            </td><td>
              $272.3
            </td><td>
              $270.91
            </td><td>
              November 24, 2021
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -36.81b
            </td><td>
              272.39b
            </td><td>
              0.5
            </td><td>
              792,287,037
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BLUE" class="margin-bottom-1">
                BLUE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$18.19</div> <small class="number change-up">+0.60<span>&nbsp;&nbsp;</span>+3.41%</small></td><td><strong>Lenti-D (Elivaldogene Autotemcel / Eli-Cel) - ALD-104</strong> <br>Cerebral Adrenoleukodystrophy (CALD)
            </td><td>
              BLA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005334/en/">
                2H 2021
              </a> <div class="note">Phase 3 safety data to be presented at EBMT 2020. Noted two adverse events (out of 13 patients) of pancytopenia were considered possibly related to Lenti-D. Phase 3 trial placed on clinical hold - noted August 9, 2021. BLA filing due 2021 subject to resolution of the clinical hold.</div></td><td>
              68m
            </td><td>
              1.2b
            </td><td>
              480.2k
            </td><td>
              1.5m
            </td><td>
              1.25
            </td><td>
              $17.85
            </td><td>
              $17.59
            </td><td>
              February 2024
            </td><td>
              0.86b
            </td><td>
              -48.55m
            </td><td>
              17.76
            </td><td>
              392.41m
            </td><td>
              0.55b
            </td><td>
              1.3
            </td><td>
              53,343,921
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ADAG" class="margin-bottom-1">
                ADAG
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.70</div> <small class="number change-up">+0.20<span>&nbsp;&nbsp;</span>+1.21%</small></td><td><strong>ADG106-2001</strong> <br>Solid tumors
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.adagene.com/news-releases/news-release-details/adagene-reports-full-year-2020-financial-results-and-provides">
                2H 2021
              </a> <div class="note">Phase 2 readout due 2H 2021.</div></td><td>
              54m
            </td><td>
              0.9b
            </td><td>
              5.3k
            </td><td>
              39.8k
            </td><td>
              -8.15
            </td><td>
              $16.5
            </td><td>
              $16.5
            </td><td>
              N/A
            </td><td>
              52.85m
            </td><td>
              -2.85m
            </td><td>
              18.56
            </td><td>
              -120.80m
            </td><td>
              0.65b
            </td><td>
              0
            </td><td>
              54,397,383
            </td><td>
              03/31/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BGNE" class="margin-bottom-1">
                BGNE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$270.83</div> <small class="number change-up">+21.23<span>&nbsp;&nbsp;</span>+8.51%</small></td><td><strong>BGB-3245</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.springworkstx.com/news-releases/news-release-details/springworks-therapeutics-reports-second-quarter-2021-financial">
                2021
              </a> <div class="note">Phase 1 data due 2021.</div></td><td>
              93m
            </td><td>
              25.2b
            </td><td>
              273.7k
            </td><td>
              315.1k
            </td><td>
              7.00
            </td><td>
              $256
            </td><td>
              $249.6
            </td><td>
              May 1, 2023
            </td><td>
              4.13b
            </td><td>
              -140.09m
            </td><td>
              29.48
            </td><td>
              2.21b
            </td><td>
              21.09b
            </td><td>
              0.3
            </td><td>
              89,530,472
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SWTX" class="margin-bottom-1">
                SWTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$79.84</div> <small class="number change-up">+3.70<span>&nbsp;&nbsp;</span>+4.86%</small></td><td><strong>BGB-3245</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.springworkstx.com/news-releases/news-release-details/springworks-therapeutics-reports-second-quarter-2021-financial">
                2021
              </a> <div class="note">Phase 1 data due 2021.</div></td><td>
              49m
            </td><td>
              3.9b
            </td><td>
              102.1k
            </td><td>
              245.7k
            </td><td>
              7.90
            </td><td>
              $77.38
            </td><td>
              $76.14
            </td><td>
              May 1, 2023
            </td><td>
              442.66m
            </td><td>
              -11.18m
            </td><td>
              39.61
            </td><td>
              418.82m
            </td><td>
              3.28b
            </td><td>
              4.6
            </td><td>
              22,977,819
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INAB" class="margin-bottom-1">
                INAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.16</div> <small class="number change-up">+0.45<span>&nbsp;&nbsp;</span>+5.84%</small></td><td><strong>INB-200</strong> <br>Glioblastoma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1740279/000110465920115697/tm2030088-7_s1.htm">
                2021
              </a> <div class="note">Phase 1 top-line data due 2021.</div></td><td>
              19m
            </td><td>
              153.0m
            </td><td>
              23.1k
            </td><td>
              
            </td><td>
              -8.24
            </td><td>
              $8.31
            </td><td>
              $7.71
            </td><td>
              N/A
            </td><td>
              11.01m
            </td><td>
              -0.84m
            </td><td>
              13.18
            </td><td>
              6.91m
            </td><td>
              166.26m
            </td><td>
              12.8
            </td><td>
              2,728,036
            </td><td>
              11/13/2020
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ADAG" class="margin-bottom-1">
                ADAG
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.70</div> <small class="number change-up">+0.20<span>&nbsp;&nbsp;</span>+1.21%</small></td><td><strong>ADG116</strong> <br>Solid Tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.adagene.com/news-releases/news-release-details/adagene-reports-full-year-2020-financial-results-and-provides">
                2H 2021
              </a> <div class="note">Phase 1 efficacy data due 2H 2021.</div></td><td>
              54m
            </td><td>
              0.9b
            </td><td>
              5.3k
            </td><td>
              39.8k
            </td><td>
              -8.15
            </td><td>
              $16.5
            </td><td>
              $16.5
            </td><td>
              September 23, 2022
            </td><td>
              52.85m
            </td><td>
              -2.85m
            </td><td>
              18.56
            </td><td>
              -120.80m
            </td><td>
              0.65b
            </td><td>
              0
            </td><td>
              54,397,383
            </td><td>
              03/31/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VACC" class="margin-bottom-1">
                VACC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.60</div> <small class="number change-down">-0.25<span>&nbsp;&nbsp;</span>-1.68%</small></td><td><strong>VTP-300 (HBV001)</strong> <br>Hepatitis B and healthy volunteers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2279734/0/en/Vaccitech-Reports-Second-Quarter-2021-Financial-Results-and-Recent-Corporate-Developments.html">
                4Q 2021
              </a> <div class="note">Phase 1 safety and immunogenicity data due 4Q 2021.</div></td><td>
              34m
            </td><td>
              0.5b
            </td><td>
              32.1k
            </td><td>
              24.1k
            </td><td>
              2.01
            </td><td>
              $14.78
            </td><td>
              $14.85
            </td><td>
              April 30, 2022
            </td><td>
              234.84m
            </td><td>
              -4.87m
            </td><td>
              48.18
            </td><td>
              224.92m
            </td><td>
              267.74m
            </td><td>
              4.2
            </td><td>
              32,899,041
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ADAG" class="margin-bottom-1">
                ADAG
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.70</div> <small class="number change-up">+0.20<span>&nbsp;&nbsp;</span>+1.21%</small></td><td><strong>ADG126</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.adagene.com/news-releases/news-release-details/adagene-reports-full-year-2020-financial-results-and-provides">
                2H 2021
              </a> <div class="note">Phase 1 trial initiation announced March 16, 2021. Safety and efficacy read out in selected indications in 2H 2021.</div></td><td>
              54m
            </td><td>
              0.9b
            </td><td>
              5.3k
            </td><td>
              39.8k
            </td><td>
              -8.15
            </td><td>
              $16.5
            </td><td>
              $16.5
            </td><td>
              November 16, 2022
            </td><td>
              52.85m
            </td><td>
              -2.85m
            </td><td>
              18.56
            </td><td>
              -120.80m
            </td><td>
              0.65b
            </td><td>
              0
            </td><td>
              54,397,383
            </td><td>
              03/31/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARNA" class="margin-bottom-1">
                ARNA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$51.04</div> <small class="number change-up">+4.14<span>&nbsp;&nbsp;</span>+8.83%</small></td><td><strong>Etrasimod</strong> <br>Crohn's disease
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://invest.arenapharm.com/news-releases/news-release-details/arena-reports-third-quarter-financial-results-strong-cash">
                2021
              </a> <div class="note">Phase 2b trial ongoing. Considering options to help facilitate availability of top-line data in 2021</div></td><td>
              61m
            </td><td>
              3.1b
            </td><td>
              0.6m
            </td><td>
              464.5k
            </td><td>
              3.21
            </td><td>
              $47.42
            </td><td>
              $46.9
            </td><td>
              December 2021
            </td><td>
              0.85b
            </td><td>
              -31.28m
            </td><td>
              27.02
            </td><td>
              0.73b
            </td><td>
              1.94b
            </td><td>
              4.4
            </td><td>
              54,681,471
            </td><td>
              11/23/2020
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INBX" class="margin-bottom-1">
                INBX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.05</div> <small class="number change-up">+1.59<span>&nbsp;&nbsp;</span>+5.59%</small></td><td><strong>INBRX-106</strong> <br>Solid Tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://inhibrx.com/wp-content/uploads/2021/07/Inhibrx-Presentation-June-2021.pdf">
                2H 2021
              </a> <div class="note">Phase 1 dose escalation data due 2H 2021.</div></td><td>
              38m
            </td><td>
              1.1b
            </td><td>
              40.8k
            </td><td>
              235.2k
            </td><td>
              25.68
            </td><td>
              $29.12
            </td><td>
              $28.46
            </td><td>
              December 2, 2022
            </td><td>
              112.30m
            </td><td>
              -7.46m
            </td><td>
              15.05
            </td><td>
              14.73m
            </td><td>
              1.03b
            </td><td>
              0.6
            </td><td>
              22,511,163
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>PT027</strong> <br>Asthma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2021/h1-2021/H1_2021_results_presentation.pdf">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              July 21, 2021
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AFMD" class="margin-bottom-1">
                AFMD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.06</div> <small class="number change-up">+0.33<span>&nbsp;&nbsp;</span>+5.76%</small></td><td><strong>AFM24-101</strong> <br>EGFR-expressing solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.affimed.com/affimed-reports-first-quarter-2021-financial-results-and-highlights-operational-progress/">
                2H 2021
              </a> <div class="note">Phase 1/2a update on the dose escalation and initiation of the dose expansion cohorts due 2H 2021.</div></td><td>
              119m
            </td><td>
              0.7b
            </td><td>
              1.5m
            </td><td>
              1.1m
            </td><td>
              3.65
            </td><td>
              $6
            </td><td>
              $5.73
            </td><td>
              April 1, 2022
            </td><td>
              214.84m
            </td><td>
              -5.34m
            </td><td>
              40.20
            </td><td>
              113.10m
            </td><td>
              413.78m
            </td><td>
              0
            </td><td>
              115,635,174
            </td><td>
              07/01/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MRSN" class="margin-bottom-1">
                MRSN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$11.83</div> <small class="number change-up">+0.17<span>&nbsp;&nbsp;</span>+1.46%</small></td><td><strong>XMT-1592</strong> <br>Non-small cell lung cancer (NSCLC) adenocarcinoma and ovarian cancer
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.mersana.com/news-releases/news-release-details/mersana-therapeutics-announces-second-quarter-2021-financial">
                4Q 2021
              </a> <div class="note">Phase 1 top-line data due 4Q 2021.</div></td><td>
              72m
            </td><td>
              0.8b
            </td><td>
              0.6m
            </td><td>
              0.6m
            </td><td>
              4.35
            </td><td>
              $11.92
            </td><td>
              $11.66
            </td><td>
              N/A
            </td><td>
              206.71m
            </td><td>
              -11.49m
            </td><td>
              17.99
            </td><td>
              148.54m
            </td><td>
              0.63b
            </td><td>
              1.5
            </td><td>
              62,956,935
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INBX" class="margin-bottom-1">
                INBX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.05</div> <small class="number change-up">+1.59<span>&nbsp;&nbsp;</span>+5.59%</small></td><td><strong>INBRX-105 and KEYTRUDA (pembrolizumab)</strong> <br>Solid Tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://inhibrx.com/wp-content/uploads/2021/07/Inhibrx-Presentation-June-2021.pdf">
                4Q 2021
              </a> <div class="note">Phase 1 dose escalation data due 4Q 2021.</div></td><td>
              38m
            </td><td>
              1.1b
            </td><td>
              40.8k
            </td><td>
              235.2k
            </td><td>
              25.68
            </td><td>
              $29.12
            </td><td>
              $28.46
            </td><td>
              November 2022
            </td><td>
              112.30m
            </td><td>
              -7.46m
            </td><td>
              15.05
            </td><td>
              14.73m
            </td><td>
              1.03b
            </td><td>
              0.6
            </td><td>
              22,511,163
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DVAX" class="margin-bottom-1">
                DVAX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.48</div> <small class="number change-up">+1.44<span>&nbsp;&nbsp;</span>+11.97%</small></td><td><strong>Biological E. vaccine with CpG 1018</strong> <br>COVID-19 vaccine
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.dynavax.com/static-files/6e046557-2a31-4635-bd67-799c74e594b1">
                YE 2021
              </a> <div class="note">Phase 3 trial initiated June 2021. Data due year-end 2021.</div></td><td>
              115m
            </td><td>
              1.5b
            </td><td>
              2.8m
            </td><td>
              2.3m
            </td><td>
              18.47
            </td><td>
              $12.44
            </td><td>
              $12.04
            </td><td>
              N/A
            </td><td>
              412.28m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -152.25m
            </td><td>
              1.29b
            </td><td>
              1.6
            </td><td>
              90,823,786
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVS" class="margin-bottom-1">
                NVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$93.88</div> <small class="number change-up">+0.55<span>&nbsp;&nbsp;</span>+0.59%</small></td><td><strong>ZOLGENSMA (AVXS-101) - SPRINT</strong> <br>Pre-symptomatic patients with spinal muscular atrophy (SMA) Types 1, 2 and 3
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.pdf">
                2H 2021
              </a> <div class="note">Phase 3 data May 5, 2019 noted all patients (18/18) were alive and event-free. Readout 2H 2021.</div></td><td>
              2b
            </td><td>
              210.0b
            </td><td>
              0.7m
            </td><td>
              1.7m
            </td><td>
              3.89
            </td><td>
              $93.86
            </td><td>
              $93.33
            </td><td>
              June 15, 2021
            </td><td>
              7.84b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -62.05b
            </td><td>
              238.51b
            </td><td>
              0
            </td><td>
              2,236,739,037
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INBX" class="margin-bottom-1">
                INBX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.05</div> <small class="number change-up">+1.59<span>&nbsp;&nbsp;</span>+5.59%</small></td><td><strong>INBRX-101</strong> <br>Alpha-1 Antitrypsin Deficiency
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://inhibrx.com/wp-content/uploads/2021/07/Inhibrx-Presentation-June-2021.pdf">
                2H 2021
              </a> <div class="note">Phase 1 dose escalation data due 2H 2021.</div></td><td>
              38m
            </td><td>
              1.1b
            </td><td>
              40.8k
            </td><td>
              235.2k
            </td><td>
              25.68
            </td><td>
              $29.12
            </td><td>
              $28.46
            </td><td>
              December 2021
            </td><td>
              112.30m
            </td><td>
              -7.46m
            </td><td>
              15.05
            </td><td>
              14.73m
            </td><td>
              1.03b
            </td><td>
              0.6
            </td><td>
              22,511,163
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/UBX" class="margin-bottom-1">
                UBX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.20</div> <small class="number change-up">+0.04<span>&nbsp;&nbsp;</span>+1.27%</small></td><td><strong>UBX1325</strong> <br>Diabetic macular edema (DME) / wet age-related macular degeneration (AMD)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.unitybiotechnology.com/news-releases/news-release-details/unity-biotechnology-inc-reports-second-quarter-2021-financial">
                YE 2021
              </a> <div class="note">Phase 1 data released July 6, 2021 - favorable safety and tolerability profile. Further data due end of 2021.</div></td><td>
              55m
            </td><td>
              176.3m
            </td><td>
              184.6k
            </td><td>
              0.5m
            </td><td>
              2.67
            </td><td>
              $3.19
            </td><td>
              $3.16
            </td><td>
              N/A
            </td><td>
              75.91m
            </td><td>
              -4.46m
            </td><td>
              17.02
            </td><td>
              5.57m
            </td><td>
              147.11m
            </td><td>
              6.3
            </td><td>
              40,873,871
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>IMFINZI (Durvalumab) - PACIFIC-2</strong> <br>Non-small cell lung cancer (NSCLC)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2021/h1-2021/H1_2021_results_presentation.pdf">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              November 1, 2021
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DNLI" class="margin-bottom-1">
                DNLI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$51.63</div> <small class="number change-up">+2.69<span>&nbsp;&nbsp;</span>+5.50%</small></td><td><strong>DNL788 (SAR443820)</strong> <br>Healthy volunteers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.denalitherapeutics.com/investors/press-release?id=8331&amp;type=api">
                2H 2021
              </a> <div class="note">Phase 1 data due 2H 2021.</div></td><td>
              122m
            </td><td>
              6.3b
            </td><td>
              178.7k
            </td><td>
              0.6m
            </td><td>
              5.85
            </td><td>
              $48.91
            </td><td>
              $48.94
            </td><td>
              N/A
            </td><td>
              1.28b
            </td><td>
              -18.07m
            </td><td>
              70.62
            </td><td>
              0.84b
            </td><td>
              4.71b
            </td><td>
              2.6
            </td><td>
              78,409,082
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CERC" class="margin-bottom-1">
                CERC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.90</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+4.69%</small></td><td><strong>CERC-802</strong> <br>Mannose phosphate isomerase deficiency related CDG (MPI-CDG)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.cerecor.com/press-releases/detail/133/cerecor-reports-second-quarter-2021-financial-results-and">
                2H 2021
              </a> <div class="note">Pivotal trial top line data expected 2H 2021.</div></td><td>
              96m
            </td><td>
              278.4m
            </td><td>
              129.3k
            </td><td>
              0.6m
            </td><td>
              13.18
            </td><td>
              $2.82
            </td><td>
              $2.77
            </td><td>
              N/A
            </td><td>
              28.92m
            </td><td>
              -6.40m
            </td><td>
              4.52
            </td><td>
              -13.57m
            </td><td>
              246.42m
            </td><td>
              2.8
            </td><td>
              56,006,748
            </td><td>
              08/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CRSP" class="margin-bottom-1">
                CRSP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$124.83</div> <small class="number change-up">+7.61<span>&nbsp;&nbsp;</span>+6.49%</small></td><td><strong>CTX110</strong> <br>CD19+ malignancies
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/07/29/2271807/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Second-Quarter-2021-Financial-Results.html">
                2021
              </a> <div class="note">Phase 1 further data due 2021.</div></td><td>
              76m
            </td><td>
              9.5b
            </td><td>
              0.8m
            </td><td>
              1.4m
            </td><td>
              3.65
            </td><td>
              $120.39
            </td><td>
              $117.22
            </td><td>
              July 2026
            </td><td>
              3.07b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              2.78b
            </td><td>
              6.53b
            </td><td>
              1.9
            </td><td>
              52,414,588
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TMBR" class="margin-bottom-1">
                TMBR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.90</div> <small class="number change-up">0.00<span>&nbsp;&nbsp;</span>-0.13%</small></td><td><strong>TMB-001 (CONTROL)</strong> <br>Congenital Ichthyosis
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/10/2277915/0/en/Timber-Pharmaceuticals-Provides-Business-Update-and-Announces-Second-Quarter-2021-Financial-Results.html">
                4Q 2021
              </a> <div class="note">Phase 2b top-line data due 4Q 2021.</div></td><td>
              37m
            </td><td>
              32.9m
            </td><td>
              479.7k
            </td><td>
              0.9m
            </td><td>
              11.23
            </td><td>
              $0.92
            </td><td>
              $0.9
            </td><td>
              August 30, 2021
            </td><td>
              4.72m
            </td><td>
              -0.78m
            </td><td>
              6.01
            </td><td>
              1.81m
            </td><td>
              29.69m
            </td><td>
              0
            </td><td>
              31,120,334
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CNTX" class="margin-bottom-1">
                CNTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td>
              N/A
            </td><td><strong>Onapristone (ONA-XR)</strong> <br>Ovarian cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001842952/000119312521175568/d46596ds1.htm">
                2H 2021
              </a> <div class="note">Phase 2 data 2H 2021.</div></td><td>
              7m
            </td><td>
              
            </td><td>
              
            </td><td>
              
            </td><td>
              
            </td><td>
              $0
            </td><td>
              $0
            </td><td>
              April 2023
            </td><td>
              -1.10m
            </td><td>
              -0.57m
            </td><td>
              1.93
            </td><td>
              -20.83m
            </td><td>
              
            </td><td>
              0
            </td><td>
              5,971,554
            </td><td>
              07/26/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VLON" class="margin-bottom-1">
                VLON
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.23</div> <small class="number change-up">+0.22<span>&nbsp;&nbsp;</span>+5.49%</small></td><td><strong>ADAIR</strong> <br>ADHD / Narcolepsy
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.vallon-pharma.com/news/vallon-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-cor/4822954">
                2H 2021
              </a> <div class="note">NDA filing expected 2Q 2022 following Phase 1 pivotal intranasal abuse study data 2H 2021 (Phase 2/3 trials not required).</div></td><td>
              7m
            </td><td>
              28.8m
            </td><td>
              55.7k
            </td><td>
              70.8k
            </td><td>
              2.92
            </td><td>
              $4.15
            </td><td>
              $4.01
            </td><td>
              N/A
            </td><td>
              8.96m
            </td><td>
              -0.83m
            </td><td>
              10.79
            </td><td>
              7.17m
            </td><td>
              14.58m
            </td><td>
              3.4
            </td><td>
              4,194,758
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/REGN" class="margin-bottom-1">
                REGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$665.74</div> <small class="number change-up">+2.47<span>&nbsp;&nbsp;</span>+0.37%</small></td><td><strong>DUPIXENT (dupilumab)</strong> <br>Prurigo nodularis (PN)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/2021_07_29_Sanofi_Q2_2021_presentation.pdf?la=en&amp;hash=F258C8E98B392E4E9DAF7517ECD8A4B9">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              107m
            </td><td>
              71.2b
            </td><td>
              0.7m
            </td><td>
              0.8m
            </td><td>
              4.71
            </td><td>
              $665.21
            </td><td>
              $663.27
            </td><td>
              October 2021
            </td><td>
              4.29b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -2.07b
            </td><td>
              69.73b
            </td><td>
              2.1
            </td><td>
              89,032,197
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SNY" class="margin-bottom-1">
                SNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$52.48</div> <small class="number change-down">-0.64<span>&nbsp;&nbsp;</span>-1.20%</small></td><td><strong>DUPIXENT (dupilumab)</strong> <br>Prurigo nodularis (PN)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/2021_07_29_Sanofi_Q2_2021_presentation.pdf?la=en&amp;hash=F258C8E98B392E4E9DAF7517ECD8A4B9">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              3b
            </td><td>
              131.7b
            </td><td>
              2.5m
            </td><td>
              1.7m
            </td><td>
              1.78
            </td><td>
              $52.73
            </td><td>
              $53.12
            </td><td>
              October 2021
            </td><td>
              9.72b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -39.23b
            </td><td>
              146.90b
            </td><td>
              0
            </td><td>
              2,510,366,030
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SUPN" class="margin-bottom-1">
                SUPN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$24.85</div> <small class="number change-up">+0.76<span>&nbsp;&nbsp;</span>+3.15%</small></td><td><strong>SPN-830</strong> <br>Motor fluctuations in Parkinson’s disease (PD)
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.supernus.com/news-releases/news-release-details/supernus-announces-second-quarter-2021-financial-results">
                2H 2021
              </a> <div class="note">Refusal to file letter announced November 9, 2020. NDA resubmission due 2H 2021.</div></td><td>
              53m
            </td><td>
              1.3b
            </td><td>
              117.4k
            </td><td>
              447.6k
            </td><td>
              1.68
            </td><td>
              $24.5
            </td><td>
              $24.09
            </td><td>
              N/A
            </td><td>
              437.61m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -349.88m
            </td><td>
              1.28b
            </td><td>
              2
            </td><td>
              37,012,452
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LXRX" class="margin-bottom-1">
                LXRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.91</div> <small class="number change-up">+0.44<span>&nbsp;&nbsp;</span>+12.68%</small></td><td><strong>Sotagliflozin</strong> <br>Heart failure
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/23/2284663/0/en/Lexicon-s-Sotagliflozin-Demonstrates-Additional-Compelling-Benefits-in-Reducing-Cardiovascular-Endpoints-Results-from-Soloist-and-Scored-Trials.html">
                2021
              </a> <div class="note">Phase 3 trial met primary endpoint. NDA filing due in 2021.</div></td><td>
              144m
            </td><td>
              0.6b
            </td><td>
              1.2m
            </td><td>
              0.9m
            </td><td>
              4.12
            </td><td>
              $3.58
            </td><td>
              $3.47
            </td><td>
              N/A
            </td><td>
              105.37m
            </td><td>
              -7.29m
            </td><td>
              14.45
            </td><td>
              70.93m
            </td><td>
              395.53m
            </td><td>
              2.3
            </td><td>
              67,367,491
            </td><td>
              08/23/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RLYB" class="margin-bottom-1">
                RLYB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.32</div> <small class="number change-up">+0.63<span>&nbsp;&nbsp;</span>+4.96%</small></td><td><strong>RLYB211</strong> <br>Fetal and neonatal alloimmune thrombocytopenia (FNAIT)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001739410/000119312521207662/d99471ds1.htm">
                4Q 2021
              </a> <div class="note">Phase 1/2 data due 4Q 2021.</div></td><td>
              32m
            </td><td>
              428.0m
            </td><td>
              99.2k
            </td><td>
              89.7k
            </td><td>
              -7.28
            </td><td>
              $13.4
            </td><td>
              $12.69
            </td><td>
              N/A
            </td><td>
              108.52m
            </td><td>
              -3.98m
            </td><td>
              27.29
            </td><td>
              -79.60m
            </td><td>
              279.99m
            </td><td>
              3.9
            </td><td>
              19,133,924
            </td><td>
              07/26/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TCRR" class="margin-bottom-1">
                TCRR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.26</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+6.55%</small></td><td><strong>TC-110</strong> <br>CD19+ non-Hodgkin lymphoma or adult acute lymphoblastic leukemia
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-reports-second-quarter-2021-financial-results">
                2H 2021
              </a> <div class="note">Phase 1 interim update due 2H 2021.</div></td><td>
              38m
            </td><td>
              0.6b
            </td><td>
              168.5k
            </td><td>
              343.7k
            </td><td>
              1.89
            </td><td>
              $15.43
            </td><td>
              $15.26
            </td><td>
              April 2022
            </td><td>
              305.92m
            </td><td>
              -6.35m
            </td><td>
              48.19
            </td><td>
              266.67m
            </td><td>
              292.96m
            </td><td>
              0.3
            </td><td>
              30,268,156
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PRQR" class="margin-bottom-1">
                PRQR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.22</div> <small class="number change-up">+0.69<span>&nbsp;&nbsp;</span>+12.48%</small></td><td><strong>QR-1123 (Aurora)</strong> <br>autosomal dominant retinitis pigmentosa (adRP)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.proqr.com/press-releases/proqr-announces-second-quarter-2021-operating-and-financial-results">
                4Q 2021
              </a> <div class="note">Phase 1/2 data due 4Q 2021.</div></td><td>
              67m
            </td><td>
              417.2m
            </td><td>
              192.0k
            </td><td>
              478.4k
            </td><td>
              3.02
            </td><td>
              $5.57
            </td><td>
              $5.53
            </td><td>
              October 7, 2021
            </td><td>
              133.45m
            </td><td>
              -3.33m
            </td><td>
              40.12
            </td><td>
              88.64m
            </td><td>
              249.39m
            </td><td>
              0
            </td><td>
              57,834,902
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LLY" class="margin-bottom-1">
                LLY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$269.63</div> <small class="number change-down">-1.28<span>&nbsp;&nbsp;</span>-0.47%</small></td><td><strong>Zagotenemab</strong> <br>Alzheimer's disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.lilly.com/static-files/07e528d6-bf01-4258-8190-7b32b28ba24d">
                2H 2021
              </a> <div class="note">Phase 2 data due 2H 2021.</div></td><td>
              1b
            </td><td>
              257.9b
            </td><td>
              0.8m
            </td><td>
              2.8m
            </td><td>
              40.00
            </td><td>
              $272.3
            </td><td>
              $270.91
            </td><td>
              August 23, 2021
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -36.81b
            </td><td>
              272.39b
            </td><td>
              0.5
            </td><td>
              792,287,037
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AVIR" class="margin-bottom-1">
                AVIR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.62</div> <small class="number change-down">-0.04<span>&nbsp;&nbsp;</span>-0.12%</small></td><td><strong>AT-527 (MORNINGSKY)</strong> <br>COVID-19
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-provides-clinical-and-corporate-update-and">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              83m
            </td><td>
              2.5b
            </td><td>
              497.8k
            </td><td>
              1.4m
            </td><td>
              4.10
            </td><td>
              $30.14
            </td><td>
              $29.66
            </td><td>
              August 3, 2021
            </td><td>
              0.81b
            </td><td>
              -5.78m
            </td><td>
              139.39
            </td><td>
              0.53b
            </td><td>
              1.64b
            </td><td>
              1.9
            </td><td>
              61,062,278
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PFE" class="margin-bottom-1">
                PFE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.98</div> <small class="number change-up">+1.25<span>&nbsp;&nbsp;</span>+2.58%</small></td><td><strong>PF-06425090</strong> <br>C. difficile Infection
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s21.q4cdn.com/317678438/files/doc_presentations/2020/09/Vaccines_FINAL.pdf">
                2021
              </a> <div class="note">Phase 3 interim analysis due 1H 2021.</div></td><td>
              6b
            </td><td>
              280.2b
            </td><td>
              69.5m
            </td><td>
              30.1m
            </td><td>
              4.00
            </td><td>
              $50.29
            </td><td>
              $48.72
            </td><td>
              September 7, 2021
            </td><td>
              28.48b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -71.13b
            </td><td>
              289.19b
            </td><td>
              0.3
            </td><td>
              5,605,213,314
            </td><td>
              06/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/HCM" class="margin-bottom-1">
                HCM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$38.16</div> <small class="number change-up">+0.48<span>&nbsp;&nbsp;</span>+1.29%</small></td><td><strong>HMPL-523</strong> <br>Non-Hodgkin lymphoma (NHL) 
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml.globenewswire.com/Resource/Download/495fc1d8-ba3e-4ecb-9e98-565edce2f91f">
                2H 2021
              </a> <div class="note">Phase 1 dose escalation to be completed 2H 2021.</div></td><td>
              173m
            </td><td>
              6.6b
            </td><td>
              124.7k
            </td><td>
              488.9k
            </td><td>
              6.69
            </td><td>
              $37.95
            </td><td>
              $37.67
            </td><td>
              December 2021
            </td><td>
              0.92b
            </td><td>
              -16.32m
            </td><td>
              56.43
            </td><td>
              0.66b
            </td><td>
              5.59b
            </td><td>
              2.5
            </td><td>
              154,870,219
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/JAGX" class="margin-bottom-1">
                JAGX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.17</div> <small class="number change-up">+0.04<span>&nbsp;&nbsp;</span>+3.41%</small></td><td><strong>Crofelemer (Mytesi)</strong> <br>Chronic Idiopathic Diarrhea in Non-HIV Patients
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.accesswire.com/602346/Jaguar-Health-Provides-Updates-on-Investigator-Initiated-Trials-of-Crofelemer-Mytesi">
                2H 2021
              </a> <div class="note">Phase 4 full enrollment is expected to be reached by the end of 2020, and the study results are expected to be available by mid to late 2021.</div></td><td>
              137m
            </td><td>
              160.5m
            </td><td>
              2.4m
            </td><td>
              5.0m
            </td><td>
              5.08
            </td><td>
              $1.12
            </td><td>
              $1.13
            </td><td>
              April 1, 2022
            </td><td>
              16.05m
            </td><td>
              -3.30m
            </td><td>
              4.86
            </td><td>
              -21.71m
            </td><td>
              159.64m
            </td><td>
              0.7
            </td><td>
              137,133,169
            </td><td>
              08/19/2020
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OLMA" class="margin-bottom-1">
                OLMA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.22</div> <small class="number change-up">+1.68<span>&nbsp;&nbsp;</span>+6.10%</small></td><td><strong>OP-1250</strong> <br>HR+, HER2- Breast Cancer
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/10/2278332/0/en/Olema-Oncology-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Corporate-Update.html">
                4Q 2021
              </a> <div class="note">Phase 1 initial data due 4Q 2021.</div></td><td>
              40m
            </td><td>
              1.2b
            </td><td>
              369.7k
            </td><td>
              264.6k
            </td><td>
              3.68
            </td><td>
              $28.27
            </td><td>
              $27.54
            </td><td>
              October 2023
            </td><td>
              312.80m
            </td><td>
              -2.97m
            </td><td>
              105.38
            </td><td>
              304.66m
            </td><td>
              0.77b
            </td><td>
              9.5
            </td><td>
              24,722,612
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CMPS" class="margin-bottom-1">
                CMPS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$32.37</div> <small class="number change-up">+1.71<span>&nbsp;&nbsp;</span>+5.58%</small></td><td><strong>Psilocybin</strong> <br>Treatment Resistant Depression
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.compasspathways.com/news-releases/news-release-details/compass-pathways-plc-announces-financial-results-and-business-1">
                Late-2021
              </a> <div class="note">Phase 2b data due by end of 2021.</div></td><td>
              42m
            </td><td>
              1.3b
            </td><td>
              211.0k
            </td><td>
              409.2k
            </td><td>
              4.12
            </td><td>
              $30.9
            </td><td>
              $30.66
            </td><td>
              July 2021
            </td><td>
              305.71m
            </td><td>
              -5.90m
            </td><td>
              51.81
            </td><td>
              297.91m
            </td><td>
              1.26b
            </td><td>
              0
            </td><td>
              41,695,335
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BCYC" class="margin-bottom-1">
                BCYC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.84</div> <small class="number change-up">+2.22<span>&nbsp;&nbsp;</span>+7.76%</small></td><td><strong>BT5528 and OPDIVO (nivolumab)</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005135/en/">
                2H 2021
              </a> <div class="note">Phase 1 update due 2H 2021.</div></td><td>
              26m
            </td><td>
              0.8b
            </td><td>
              73.7k
            </td><td>
              141.2k
            </td><td>
              5.54
            </td><td>
              $28.72
            </td><td>
              $28.62
            </td><td>
              December 31, 2022
            </td><td>
              236.32m
            </td><td>
              -4.12m
            </td><td>
              57.31
            </td><td>
              152.32m
            </td><td>
              0.56b
            </td><td>
              1.9
            </td><td>
              25,040,856
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BLCM" class="margin-bottom-1">
                BLCM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.05</div> <small class="number change-up">+0.19<span>&nbsp;&nbsp;</span>+6.64%</small></td><td><strong>BPX-603</strong> <br>HER2+ Solid Tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.bellicum.com/news-releases/news-release-details/bellicum-reports-second-quarter-2021-financial-results-and">
                4Q 2021
              </a> <div class="note">Phase 1 initial data due 4Q 2021.</div></td><td>
              8m
            </td><td>
              25.6m
            </td><td>
              63.1k
            </td><td>
              87.2k
            </td><td>
              -1.79
            </td><td>
              $2.87
            </td><td>
              $2.86
            </td><td>
              December 31, 2023
            </td><td>
              15.60m
            </td><td>
              -2.60m
            </td><td>
              6.01
            </td><td>
              -22.59m
            </td><td>
              3.78m
            </td><td>
              4.2
            </td><td>
              8,383,791
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KYMR" class="margin-bottom-1">
                KYMR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$55.52</div> <small class="number change-up">+1.83<span>&nbsp;&nbsp;</span>+3.42%</small></td><td><strong>KT-474</strong> <br>Hidradenitis suppurativa / atopic dermatitis
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-second-quarter-2021-financial">
                4Q 2021
              </a> <div class="note">Phase 1 healthy volunteer data due 4Q 2021 with AD and HS patient cohort data due 1H 2022.</div></td><td>
              51m
            </td><td>
              2.8b
            </td><td>
              168.1k
            </td><td>
              0.5m
            </td><td>
              10.97
            </td><td>
              $54.69
            </td><td>
              $53.68
            </td><td>
              February 1, 2022
            </td><td>
              0.56b
            </td><td>
              -10.17m
            </td><td>
              55.48
            </td><td>
              388.02m
            </td><td>
              2.40b
            </td><td>
              1.1
            </td><td>
              40,421,438
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMTX" class="margin-bottom-1">
                IMTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$11.76</div> <small class="number change-up">+0.18<span>&nbsp;&nbsp;</span>+1.55%</small></td><td><strong>IMA201 (ACTengine)</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/9a467aba-1196-4651-932f-8a17e8776717">
                2H 2021
              </a> <div class="note">Phase 1 initial data released March 17, 2021. Tumor shrinkage observed in 8 out of 10 patients including one partial response across three trials. Further data due 2H 2021.</div></td><td>
              63m
            </td><td>
              0.7b
            </td><td>
              225.5k
            </td><td>
              89.0k
            </td><td>
              8.28
            </td><td>
              $11.59
            </td><td>
              $11.58
            </td><td>
              December 2022
            </td><td>
              180.84m
            </td><td>
              -6.65m
            </td><td>
              27.20
            </td><td>
              40.77m
            </td><td>
              0.51b
            </td><td>
              0
            </td><td>
              45,727,064
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BCYC" class="margin-bottom-1">
                BCYC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.84</div> <small class="number change-up">+2.22<span>&nbsp;&nbsp;</span>+7.76%</small></td><td><strong>BT8009</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005135/en/">
                2H 2021
              </a> <div class="note">Phase 1/2 update due 2H 2021.</div></td><td>
              26m
            </td><td>
              0.8b
            </td><td>
              73.7k
            </td><td>
              141.2k
            </td><td>
              5.54
            </td><td>
              $28.72
            </td><td>
              $28.62
            </td><td>
              N/A
            </td><td>
              236.32m
            </td><td>
              -4.12m
            </td><td>
              57.31
            </td><td>
              152.32m
            </td><td>
              0.56b
            </td><td>
              1.9
            </td><td>
              25,040,856
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMTX" class="margin-bottom-1">
                IMTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$11.76</div> <small class="number change-up">+0.18<span>&nbsp;&nbsp;</span>+1.55%</small></td><td><strong>IMA202 (ACTengine)</strong> <br>Solid Tumors
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/9a467aba-1196-4651-932f-8a17e8776717">
                2H 2021
              </a> <div class="note">Phase 1 initial data from dose expansion cohort due 2H 2021.</div></td><td>
              63m
            </td><td>
              0.7b
            </td><td>
              225.5k
            </td><td>
              89.0k
            </td><td>
              8.28
            </td><td>
              $11.59
            </td><td>
              $11.58
            </td><td>
              June 2022
            </td><td>
              180.84m
            </td><td>
              -6.65m
            </td><td>
              27.20
            </td><td>
              40.77m
            </td><td>
              0.51b
            </td><td>
              0
            </td><td>
              45,727,064
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CERC" class="margin-bottom-1">
                CERC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.90</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+4.69%</small></td><td><strong>CERC-007</strong> <br>Multiple Myeloma (MM)
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.cerecor.com/press-releases/detail/133/cerecor-reports-second-quarter-2021-financial-results-and">
                2H 2021
              </a> <div class="note">Phase 1b top-line data due 2H 2021.</div></td><td>
              96m
            </td><td>
              278.4m
            </td><td>
              129.3k
            </td><td>
              0.6m
            </td><td>
              13.18
            </td><td>
              $2.82
            </td><td>
              $2.77
            </td><td>
              N/A
            </td><td>
              28.92m
            </td><td>
              -6.40m
            </td><td>
              4.52
            </td><td>
              -13.57m
            </td><td>
              246.42m
            </td><td>
              2.8
            </td><td>
              56,006,748
            </td><td>
              08/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMTX" class="margin-bottom-1">
                IMTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$11.76</div> <small class="number change-up">+0.18<span>&nbsp;&nbsp;</span>+1.55%</small></td><td><strong>IMA203 (ACTengine)</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/9a467aba-1196-4651-932f-8a17e8776717">
                2H 2021
              </a> <div class="note">Phase 1 initial data released March 17, 2021. Tumor shrinkage observed in 8 out of 10 patients including one partial response across three trials. Further data due 2H 2021.</div></td><td>
              63m
            </td><td>
              0.7b
            </td><td>
              225.5k
            </td><td>
              89.0k
            </td><td>
              8.28
            </td><td>
              $11.59
            </td><td>
              $11.58
            </td><td>
              September 2022
            </td><td>
              180.84m
            </td><td>
              -6.65m
            </td><td>
              27.20
            </td><td>
              40.77m
            </td><td>
              0.51b
            </td><td>
              0
            </td><td>
              45,727,064
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NKTR" class="margin-bottom-1">
                NKTR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.89</div> <small class="number change-up">+0.28<span>&nbsp;&nbsp;</span>+2.06%</small></td><td><strong>Bempegaldesleukin (NKTR-214) and KEYTRUDA (pembrolizumab) - (PROPEL)</strong> <br>Solid tumors - cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/nektar-therapeutics-reports-first-quarter-2021-financial-results-301286004.html">
                2H 2021
              </a> <div class="note">Phase 2 data due 2H 2021.</div></td><td>
              184m
            </td><td>
              2.6b
            </td><td>
              287.9k
            </td><td>
              0.8m
            </td><td>
              2.82
            </td><td>
              $13.74
            </td><td>
              $13.61
            </td><td>
              September 2023
            </td><td>
              0.95b
            </td><td>
              -27.63m
            </td><td>
              34.39
            </td><td>
              483.95m
            </td><td>
              1.65b
            </td><td>
              2.1
            </td><td>
              91,286,217
            </td><td>
              05/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/HCM" class="margin-bottom-1">
                HCM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$38.16</div> <small class="number change-up">+0.48<span>&nbsp;&nbsp;</span>+1.29%</small></td><td><strong>Savolitinib + TAGRISSO (osimertinib) - (SAVANNAH)</strong> <br>Non-small cell lung cancer (NSCLC)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml.globenewswire.com/Resource/Download/495fc1d8-ba3e-4ecb-9e98-565edce2f91f">
                2H 2021
              </a> <div class="note">Phase 2 data due 2H 2021.</div></td><td>
              173m
            </td><td>
              6.6b
            </td><td>
              124.7k
            </td><td>
              488.9k
            </td><td>
              6.69
            </td><td>
              $37.95
            </td><td>
              $37.67
            </td><td>
              December 2, 2021
            </td><td>
              0.92b
            </td><td>
              -16.32m
            </td><td>
              56.43
            </td><td>
              0.66b
            </td><td>
              5.59b
            </td><td>
              2.5
            </td><td>
              154,870,219
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BMY" class="margin-bottom-1">
                BMY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$69.35</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+0.22%</small></td><td><strong>Deucravacitinib</strong> <br>Ulcerative Colitis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s21.q4cdn.com/104148044/files/doc_presentations/2021/BMY-2021-Q2-Results-Investor-Presentation.pdf">
                2H 2021
              </a> <div class="note">Phase 2 data due 2H 2021.</div></td><td>
              2b
            </td><td>
              154.1b
            </td><td>
              4.1m
            </td><td>
              8.5m
            </td><td>
              4.19
            </td><td>
              $69.26
            </td><td>
              $69.2
            </td><td>
              N/A
            </td><td>
              15.85b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -58.07b
            </td><td>
              186.05b
            </td><td>
              0.3
            </td><td>
              2,219,710,962
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MREO" class="margin-bottom-1">
                MREO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.50</div> <small class="number change-up">+0.20<span>&nbsp;&nbsp;</span>+8.79%</small></td><td><strong>Alvelestat</strong> <br>COVID-19
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.mereobiopharma.com/news-and-events/press-releases/2021/mereo-biopharma-reports-full-year-2020-financial-results-and-recent-highlights/mereo-biopharma-reports-full-year-2020-financial-results-and-recent-highlights/">
                2H 2021
              </a> <div class="note">Phase 1 data due 2H 2021.</div></td><td>
              108m
            </td><td>
              270.6m
            </td><td>
              0.7m
            </td><td>
              1.5m
            </td><td>
              5.11
            </td><td>
              $2.34
            </td><td>
              $2.3
            </td><td>
              N/A
            </td><td>
              138.57m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              60.65m
            </td><td>
              194.65m
            </td><td>
              0
            </td><td>
              108,142,781
            </td><td>
              03/31/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LGVN" class="margin-bottom-1">
                LGVN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.40</div> <small class="number change-down">-0.17<span>&nbsp;&nbsp;</span>-4.76%</small></td><td><strong>Lomecel-B</strong> <br>Metabolic Syndrome
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021002924/ea133523-s1_longeveron.htm">
                2H 2021
              </a> <div class="note">Phase 2b top-line data due 2H 2021.</div></td><td>
              19m
            </td><td>
              65.0m
            </td><td>
              216.7k
            </td><td>
              168.2k
            </td><td>
              2.64
            </td><td>
              $3.6
            </td><td>
              $3.57
            </td><td>
              December 2022
            </td><td>
              19.62m
            </td><td>
              -0.98m
            </td><td>
              19.94
            </td><td>
              14.41m
            </td><td>
              50.40m
            </td><td>
              45.4
            </td><td>
              3,279,966
            </td><td>
              02/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DCPH" class="margin-bottom-1">
                DCPH
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.11</div> <small class="number change-up">+2.48<span>&nbsp;&nbsp;</span>+9.31%</small></td><td><strong>QINLOCK (ripretinib) - INTRIGUE</strong> <br>Gastrointestinal Stromal Tumors (GIST) - second-line
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210803005981/en/">
                4Q 2021
              </a> <div class="note">Phase 3 top-line data due 4Q 2021.</div></td><td>
              58m
            </td><td>
              1.7b
            </td><td>
              463.7k
            </td><td>
              347.0k
            </td><td>
              3.78
            </td><td>
              $26.98
            </td><td>
              $26.63
            </td><td>
              June 2021
            </td><td>
              364.17m
            </td><td>
              -17.32m
            </td><td>
              21.02
            </td><td>
              270.26m
            </td><td>
              1.18b
            </td><td>
              0.3
            </td><td>
              41,090,493
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ZLAB" class="margin-bottom-1">
                ZLAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$143.17</div> <small class="number change-up">+9.00<span>&nbsp;&nbsp;</span>+6.71%</small></td><td><strong>QINLOCK (ripretinib) - INTRIGUE</strong> <br>Gastrointestinal Stromal Tumors (GIST) - second-line
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210803005981/en/">
                4Q 2021
              </a> <div class="note">Phase 3 top-line data due 4Q 2021.</div></td><td>
              75m
            </td><td>
              10.8b
            </td><td>
              320.4k
            </td><td>
              0.6m
            </td><td>
              33.30
            </td><td>
              $135
            </td><td>
              $134.17
            </td><td>
              June 2021
            </td><td>
              1.73b
            </td><td>
              -21.95m
            </td><td>
              78.68
            </td><td>
              1.50b
            </td><td>
              1.78b
            </td><td>
              0
            </td><td>
              75,375,511
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GRTX" class="margin-bottom-1">
                GRTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.64</div> <small class="number change-up">+0.18<span>&nbsp;&nbsp;</span>+2.13%</small></td><td><strong>Avasopasem (GC4419) - ROMAN</strong> <br>Oral mucositis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.galeratx.com/news-releases/news-release-details/galera-reports-second-quarter-2021-financial-results-and-recent">
                4Q 2021
              </a> <div class="note">Phase 3 completion of enrollment announced June 28, 2021. Data due 4Q 2021. </div></td><td>
              26m
            </td><td>
              227.8m
            </td><td>
              35.5k
            </td><td>
              120.1k
            </td><td>
              -8.91
            </td><td>
              $8.46
            </td><td>
              $8.46
            </td><td>
              December 2021
            </td><td>
              56.44m
            </td><td>
              -5.60m
            </td><td>
              10.08
            </td><td>
              -84.34m
            </td><td>
              156.98m
            </td><td>
              1.4
            </td><td>
              15,528,662
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ACAD" class="margin-bottom-1">
                ACAD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.10</div> <small class="number change-up">+0.42<span>&nbsp;&nbsp;</span>+2.52%</small></td><td><strong>ACP-044</strong> <br>Postoperative pain following bunionectomy surgery
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210804006002/en/">
                4Q 2021
              </a> <div class="note">Phase 2 top-line data due 4Q 2021.</div></td><td>
              161m
            </td><td>
              2.7b
            </td><td>
              0.6m
            </td><td>
              1.7m
            </td><td>
              4.86
            </td><td>
              $16.85
            </td><td>
              $16.68
            </td><td>
              October 2021
            </td><td>
              0.54b
            </td><td>
              -8.44m
            </td><td>
              64.17
            </td><td>
              382.13m
            </td><td>
              2.19b
            </td><td>
              0.4
            </td><td>
              99,144,481
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BHC" class="margin-bottom-1">
                BHC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$28.30</div> <small class="number change-up">+0.34<span>&nbsp;&nbsp;</span>+1.23%</small></td><td><strong>Perfluorohexyloctane (NOV03)</strong> <br>Dry Eye Disease Associated With Meibomian Gland Dysfunction
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.bauschhealth.com/~/media/Files/V/Valeant-IR/reports-and-presentations/2q21-bausch-health-earnings-presentation.pdf">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              355m
            </td><td>
              10.2b
            </td><td>
              0.7m
            </td><td>
              2.3m
            </td><td>
              -14.82
            </td><td>
              $28.26
            </td><td>
              $27.96
            </td><td>
              N/A
            </td><td>
              0.88b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -29.77b
            </td><td>
              32.82b
            </td><td>
              2.5
            </td><td>
              313,448,534
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLSD" class="margin-bottom-1">
                CLSD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.95</div> <small class="number change-up">+0.30<span>&nbsp;&nbsp;</span>+5.31%</small></td><td><strong>CLS-AX (OASIS)</strong> <br>Wet age-related macular degeneration
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedical-announces-second-quarter-2021-financial">
                YE 2021
              </a> <div class="note">Phase 1/2a initial safety data from the first cohort released June 15, 2021 - no treatment related adverse events. Completion due by end of 2021.</div></td><td>
              59m
            </td><td>
              353.9m
            </td><td>
              0.8m
            </td><td>
              4.0m
            </td><td>
              18.03
            </td><td>
              $5.66
            </td><td>
              $5.65
            </td><td>
              May 2022
            </td><td>
              22.24m
            </td><td>
              -2.32m
            </td><td>
              9.60
            </td><td>
              12.99m
            </td><td>
              310.48m
            </td><td>
              9
            </td><td>
              47,643,724
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CERC" class="margin-bottom-1">
                CERC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.90</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+4.69%</small></td><td><strong>CERC-002</strong> <br>Crohn’s disease 
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.cerecor.com/press-releases/detail/131/cerecor-announces-positive-initial-phase-1b-results-for">
                2H 2021
              </a> <div class="note">Phase 1b top-line data released July 26, 2021 with full data due 2H 2021.</div></td><td>
              96m
            </td><td>
              278.4m
            </td><td>
              129.3k
            </td><td>
              0.6m
            </td><td>
              13.18
            </td><td>
              $2.82
            </td><td>
              $2.77
            </td><td>
              N/A
            </td><td>
              28.92m
            </td><td>
              -6.40m
            </td><td>
              4.52
            </td><td>
              -13.57m
            </td><td>
              246.42m
            </td><td>
              2.8
            </td><td>
              56,006,748
            </td><td>
              07/26/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SGMO" class="margin-bottom-1">
                SGMO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.87</div> <small class="number change-up">+0.51<span>&nbsp;&nbsp;</span>+5.45%</small></td><td><strong>Giroctocogene fitelparvovec (SB-525)</strong> <br>Hemophilia A
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s21.q4cdn.com/317678438/files/doc_financials/2021/q1/Q1-2021-Earnings-Charts-FINAL.pdf">
                4Q 2021
              </a> <div class="note">Phase 1/2 data due 4Q 2021.</div></td><td>
              145m
            </td><td>
              1.4b
            </td><td>
              0.5m
            </td><td>
              1.0m
            </td><td>
              3.21
            </td><td>
              $9.46
            </td><td>
              $9.36
            </td><td>
              N/A
            </td><td>
              498.11m
            </td><td>
              -17.52m
            </td><td>
              28.43
            </td><td>
              108.21m
            </td><td>
              0.87b
            </td><td>
              2.2
            </td><td>
              120,566,640
            </td><td>
              05/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PFE" class="margin-bottom-1">
                PFE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.98</div> <small class="number change-up">+1.25<span>&nbsp;&nbsp;</span>+2.58%</small></td><td><strong>Giroctocogene fitelparvovec (SB-525)</strong> <br>Hemophilia A
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s21.q4cdn.com/317678438/files/doc_financials/2021/q1/Q1-2021-Earnings-Charts-FINAL.pdf">
                4Q 2021
              </a> <div class="note">Phase 1/2 data due 4Q 2021.</div></td><td>
              6b
            </td><td>
              280.2b
            </td><td>
              69.5m
            </td><td>
              30.1m
            </td><td>
              4.00
            </td><td>
              $50.29
            </td><td>
              $48.72
            </td><td>
              N/A
            </td><td>
              28.48b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -71.13b
            </td><td>
              289.19b
            </td><td>
              0.3
            </td><td>
              5,605,213,314
            </td><td>
              05/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BLUE" class="margin-bottom-1">
                BLUE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$18.19</div> <small class="number change-up">+0.60<span>&nbsp;&nbsp;</span>+3.41%</small></td><td><strong>Betibeglogene autotemcel (beti-cel) (LentiGlobin) - HGB-206</strong> <br>Sickle cell disease
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005334/en/">
                YE 2021
              </a> <div class="note">Phase 1/2 trial temporarily suspended due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML) - February 16, 2021. Clinical hold lifted June 7, 2021. Data to be presented by end of 2021.</div></td><td>
              68m
            </td><td>
              1.2b
            </td><td>
              480.2k
            </td><td>
              1.5m
            </td><td>
              1.25
            </td><td>
              $17.85
            </td><td>
              $17.59
            </td><td>
              May 2023
            </td><td>
              0.86b
            </td><td>
              -48.55m
            </td><td>
              17.76
            </td><td>
              392.41m
            </td><td>
              0.55b
            </td><td>
              1.3
            </td><td>
              53,343,921
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PTCT" class="margin-bottom-1">
                PTCT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$39.58</div> <small class="number change-up">+1.38<span>&nbsp;&nbsp;</span>+3.61%</small></td><td><strong>PTC299 (FITE19)</strong> <br>COVID-19
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-a-corporate-update-and-reports-second-quarter-2021-financial-results-301344644.html">
                2H 2021
              </a> <div class="note">Phase 2/3 trial expected to be completed 2H 2021.</div></td><td>
              71m
            </td><td>
              2.8b
            </td><td>
              109.5k
            </td><td>
              412.7k
            </td><td>
              14.24
            </td><td>
              $38.84
            </td><td>
              $38.2
            </td><td>
              July 31, 2021
            </td><td>
              0.93b
            </td><td>
              -10.38m
            </td><td>
              89.43
            </td><td>
              -0.93b
            </td><td>
              2.29b
            </td><td>
              0.9
            </td><td>
              49,392,128
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CERC" class="margin-bottom-1">
                CERC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.90</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+4.69%</small></td><td><strong>CERC-803</strong> <br>Leukocyte Adhesion Deficiency Type II (LAD II)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.cerecor.com/press-releases/detail/133/cerecor-reports-second-quarter-2021-financial-results-and">
                2H 2021
              </a> <div class="note">Pivotal trial top-line data due 2H 2021.</div></td><td>
              96m
            </td><td>
              278.4m
            </td><td>
              129.3k
            </td><td>
              0.6m
            </td><td>
              13.18
            </td><td>
              $2.82
            </td><td>
              $2.77
            </td><td>
              N/A
            </td><td>
              28.92m
            </td><td>
              -6.40m
            </td><td>
              4.52
            </td><td>
              -13.57m
            </td><td>
              246.42m
            </td><td>
              2.8
            </td><td>
              56,006,748
            </td><td>
              08/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MREO" class="margin-bottom-1">
                MREO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.50</div> <small class="number change-up">+0.20<span>&nbsp;&nbsp;</span>+8.79%</small></td><td><strong>Alvelestat</strong> <br>Severe alpha-1 antitrypsin deficiency
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.mereobiopharma.com/news-and-events/press-releases/2021/mereo-biopharma-reports-full-year-2020-financial-results-and-recent-highlights/mereo-biopharma-reports-full-year-2020-financial-results-and-recent-highlights/">
                Late-2021
              </a> <div class="note">Phase 2 top-line data due late-2021.</div></td><td>
              108m
            </td><td>
              270.6m
            </td><td>
              0.7m
            </td><td>
              1.5m
            </td><td>
              5.11
            </td><td>
              $2.34
            </td><td>
              $2.3
            </td><td>
              August 2021
            </td><td>
              138.57m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              60.65m
            </td><td>
              194.65m
            </td><td>
              0
            </td><td>
              108,142,781
            </td><td>
              03/31/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/HARP" class="margin-bottom-1">
                HARP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.13</div> <small class="number change-up">+0.49<span>&nbsp;&nbsp;</span>+5.67%</small></td><td><strong>HPN328</strong> <br>Small cell lung cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.harpoontx.com/news-releases/news-release-details/harpoon-therapeutics-reports-second-quarter-2021-financial">
                2H 2021
              </a> <div class="note">Phase 1/2a initial data due 2H 2021.</div></td><td>
              33m
            </td><td>
              298.3m
            </td><td>
              168.7k
            </td><td>
              0.5m
            </td><td>
              3.28
            </td><td>
              $8.64
            </td><td>
              $8.64
            </td><td>
              December 2022
            </td><td>
              131.08m
            </td><td>
              -22.19m
            </td><td>
              5.91
            </td><td>
              25.83m
            </td><td>
              124.19m
            </td><td>
              1.1
            </td><td>
              30,498,283
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GMDA" class="margin-bottom-1">
                GMDA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.75</div> <!----></td><td><strong>NiCord (omidubicel)</strong> <br>Hematologic Malignancies
            </td><td>
              BLA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210811005275/en/">
                4Q 2021
              </a> <div class="note">BLA filing due 4Q 2021.</div></td><td>
              59m
            </td><td>
              281.5m
            </td><td>
              257.6k
            </td><td>
              0.5m
            </td><td>
              4.40
            </td><td>
              $4.78
            </td><td>
              $4.75
            </td><td>
              December 2019
            </td><td>
              138.32m
            </td><td>
              -6.60m
            </td><td>
              20.97
            </td><td>
              15.68m
            </td><td>
              202.31m
            </td><td>
              0
            </td><td>
              49,528,655
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MREO" class="margin-bottom-1">
                MREO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.50</div> <small class="number change-up">+0.20<span>&nbsp;&nbsp;</span>+8.79%</small></td><td><strong>Etigilimab (OMP-313M32)</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.mereobiopharma.com/news-and-events/press-releases/2021/mereo-biopharma-reports-full-year-2020-financial-results-and-recent-highlights/mereo-biopharma-reports-full-year-2020-financial-results-and-recent-highlights/">
                2H 2021
              </a> <div class="note">Phase 1b/2 initial data due 2H 2021.</div></td><td>
              108m
            </td><td>
              270.6m
            </td><td>
              0.7m
            </td><td>
              1.5m
            </td><td>
              5.11
            </td><td>
              $2.34
            </td><td>
              $2.3
            </td><td>
              N/A
            </td><td>
              138.57m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              60.65m
            </td><td>
              194.65m
            </td><td>
              0
            </td><td>
              108,142,781
            </td><td>
              06/15/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GSK" class="margin-bottom-1">
                GSK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$41.57</div> <small class="number change-down">-0.28<span>&nbsp;&nbsp;</span>-0.67%</small></td><td><strong>COVID-19 (Medicago) vaccine</strong> <br>COVID-19 vaccine
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.gsk.com/media/7129/q2-2021-results-slides.pdf">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              3b
            </td><td>
              104.6b
            </td><td>
              2.3m
            </td><td>
              4.2m
            </td><td>
              4.95
            </td><td>
              $41.75
            </td><td>
              $41.85
            </td><td>
              N/A
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -51.10b
            </td><td>
              133.80b
            </td><td>
              0.2
            </td><td>
              2,506,785,977
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FBIO" class="margin-bottom-1">
                FBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.20</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+4.58%</small></td><td><strong>CUTX-101</strong> <br>Menkes disease
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/16/2281500/28889/en/Fortress-Biotech-Reports-Record-Second-Quarter-2021-Financial-Results-and-Recent-Corporate-Highlights.html">
                2H 2021
              </a> <div class="note">Rolling NDA submission expected to start in 2H 2021.</div></td><td>
              101m
            </td><td>
              323.4m
            </td><td>
              220.5k
            </td><td>
              0.5m
            </td><td>
              2.99
            </td><td>
              $3.07
            </td><td>
              $3.06
            </td><td>
              N/A
            </td><td>
              254.32m
            </td><td>
              -11.49m
            </td><td>
              22.14
            </td><td>
              84.46m
            </td><td>
              120.76m
            </td><td>
              27.4
            </td><td>
              76,232,955
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MGTX" class="margin-bottom-1">
                MGTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.83</div> <small class="number change-up">+0.86<span>&nbsp;&nbsp;</span>+7.15%</small></td><td><strong>AAV-CNGA3</strong> <br>Achromatopsia
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.meiragtx.com/static-files/7802670a-fdd3-447f-9d02-92683021929c">
                2H 2021
              </a> <div class="note">Phase 1/2 trial ongoing. Update due 2H 2021.</div></td><td>
              44m
            </td><td>
              0.6b
            </td><td>
              54.2k
            </td><td>
              108.8k
            </td><td>
              2.76
            </td><td>
              $12.25
            </td><td>
              $11.97
            </td><td>
              June 10, 2021
            </td><td>
              159.80m
            </td><td>
              -7.09m
            </td><td>
              22.55
            </td><td>
              38.75m
            </td><td>
              383.42m
            </td><td>
              5.9
            </td><td>
              32,445,473
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FIXX" class="margin-bottom-1">
                FIXX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.71</div> <small class="number change-up">+0.70<span>&nbsp;&nbsp;</span>+11.65%</small></td><td><strong>HMI-102 (pheNIX)</strong> <br>Phenylketonuria (PKU)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.homologymedicines.com/news-story/homology-medicines-reports-second-quarter-2021-financial-results-and-recent">
                YE 2021
              </a> <div class="note">Phase 1/2 dose expansion data due by end of 2021.</div></td><td>
              57m
            </td><td>
              383.1m
            </td><td>
              455.4k
            </td><td>
              475.5k
            </td><td>
              1.71
            </td><td>
              $6.14
            </td><td>
              $6.01
            </td><td>
              June 2023
            </td><td>
              198.83m
            </td><td>
              -8.04m
            </td><td>
              24.74
            </td><td>
              164.49m
            </td><td>
              144.00m
            </td><td>
              0.8
            </td><td>
              46,566,202
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NXTC" class="margin-bottom-1">
                NXTC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.37</div> <small class="number change-up">+0.36<span>&nbsp;&nbsp;</span>+5.14%</small></td><td><strong>NC410</strong> <br>Solid Tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://ir.nextcure.com/news-releases/news-release-details/nextcure-reports-second-quarter-2021-financial-results">
                4Q 2021
              </a> <div class="note">Phase 1 initial data due 4Q 2021.</div></td><td>
              28m
            </td><td>
              203.5m
            </td><td>
              319.9k
            </td><td>
              283.1k
            </td><td>
              0.77
            </td><td>
              $7.01
            </td><td>
              $7.01
            </td><td>
              December 2023
            </td><td>
              239.19m
            </td><td>
              -5.74m
            </td><td>
              41.67
            </td><td>
              227.43m
            </td><td>
              -53.32m
            </td><td>
              2.5
            </td><td>
              25,967,303
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GSK" class="margin-bottom-1">
                GSK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$41.57</div> <small class="number change-down">-0.28<span>&nbsp;&nbsp;</span>-0.67%</small></td><td><strong>Sotrovimab (VIR-7831 / GSK4182136) - (COMET-TAIL)</strong> <br>COVID-19 
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-provides-corporate-update-and-reports-second-0">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              3b
            </td><td>
              104.6b
            </td><td>
              2.3m
            </td><td>
              4.2m
            </td><td>
              4.95
            </td><td>
              $41.75
            </td><td>
              $41.85
            </td><td>
              March 31, 2022
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -51.10b
            </td><td>
              133.80b
            </td><td>
              0.2
            </td><td>
              2,506,785,977
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MGTX" class="margin-bottom-1">
                MGTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.83</div> <small class="number change-up">+0.86<span>&nbsp;&nbsp;</span>+7.15%</small></td><td><strong>AAV-CNGB3</strong> <br>Achromatopsia
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.meiragtx.com/static-files/7802670a-fdd3-447f-9d02-92683021929c">
                2H 2021
              </a> <div class="note">Phase 1/2 trial ongoing. Update due 2H 2021.</div></td><td>
              44m
            </td><td>
              0.6b
            </td><td>
              54.2k
            </td><td>
              108.8k
            </td><td>
              2.76
            </td><td>
              $12.25
            </td><td>
              $11.97
            </td><td>
              October 25, 2019
            </td><td>
              159.80m
            </td><td>
              -7.09m
            </td><td>
              22.55
            </td><td>
              38.75m
            </td><td>
              383.42m
            </td><td>
              5.9
            </td><td>
              32,445,473
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMRA" class="margin-bottom-1">
                IMRA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.58</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+5.29%</small></td><td><strong>Tovinontrine (IMR-687) - (Forte)</strong> <br>b-thalassemia
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.imaratx.com/news-releases/news-release-details/imara-reports-second-quarter-2021-financial-results-and-business">
                4Q 2021
              </a> <div class="note">Phase 2b interim data due 4Q with additional data due 1Q 2022.</div></td><td>
              26m
            </td><td>
              120.2m
            </td><td>
              75.8k
            </td><td>
              305.5k
            </td><td>
              1.85
            </td><td>
              $4.39
            </td><td>
              $4.35
            </td><td>
              May 2022
            </td><td>
              110.55m
            </td><td>
              -3.45m
            </td><td>
              32.00
            </td><td>
              103.05m
            </td><td>
              48.19m
            </td><td>
              0
            </td><td>
              13,205,258
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ACIU" class="margin-bottom-1">
                ACIU
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.72</div> <small class="number change-up">+0.22<span>&nbsp;&nbsp;</span>+3.41%</small></td><td><strong>ACI-35.030</strong> <br>Alzheimer’s Disease
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.acimmune.com/news-releases/news-release-details/ac-immune-reports-second-quarter-2021-financial-results-and">
                4Q 2021
              </a> <div class="note">Phase 1b/2a further interim data due 4Q 2021.</div></td><td>
              73m
            </td><td>
              488.3m
            </td><td>
              133.3k
            </td><td>
              258.6k
            </td><td>
              2.37
            </td><td>
              $6.53
            </td><td>
              $6.5
            </td><td>
              N/A
            </td><td>
              189.52m
            </td><td>
              -5.34m
            </td><td>
              35.48
            </td><td>
              167.71m
            </td><td>
              258.49m
            </td><td>
              0
            </td><td>
              31,782,720
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BCDA" class="margin-bottom-1">
                BCDA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.95</div> <small class="number change-up">+0.05<span>&nbsp;&nbsp;</span>+1.72%</small></td><td><strong>CardiAMP (BCDA-02)</strong> <br>Chronic Myocardial Ischemia
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2279714/0/en/BioCardia-Reports-Second-Quarter-2021-Financial-Results-and-Business-Highlights.html">
                2H 2021
              </a> <div class="note">Phase 3 enrollment to commence 3Q 2021 with roll-in safety data due 2H 2021.</div></td><td>
              17m
            </td><td>
              49.8m
            </td><td>
              27.0k
            </td><td>
              76.2k
            </td><td>
              3.17
            </td><td>
              $2.89
            </td><td>
              $2.9
            </td><td>
              N/A
            </td><td>
              16.82m
            </td><td>
              -0.95m
            </td><td>
              17.62
            </td><td>
              12.28m
            </td><td>
              30.70m
            </td><td>
              0
            </td><td>
              14,246,897
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SELB" class="margin-bottom-1">
                SELB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.11</div> <small class="number change-up">+0.17<span>&nbsp;&nbsp;</span>+4.19%</small></td><td><strong>SEL-399</strong> <br>Healthy volunteers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.selectabio.com/news-releases/news-release-details/selecta-biosciences-reports-second-quarter-2021-financial">
                4Q 2021
              </a> <div class="note">Phase 1 interim data due 4Q 2021.</div></td><td>
              115m
            </td><td>
              472.4m
            </td><td>
              0.5m
            </td><td>
              0.9m
            </td><td>
              -102.62
            </td><td>
              $4.08
            </td><td>
              $3.94
            </td><td>
              N/A
            </td><td>
              146.51m
            </td><td>
              -2.01m
            </td><td>
              72.73
            </td><td>
              -38.23m
            </td><td>
              338.62m
            </td><td>
              8.4
            </td><td>
              68,548,277
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NCNA" class="margin-bottom-1">
                NCNA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.18</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+11.79%</small></td><td><strong>NUC-3373 (NuTide:302)</strong> <br>Colorectal Cancer
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/19/2283856/0/en/NuCana-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Business-Update.html">
                2H 2021
              </a> <div class="note">Phase 1b data due 2H 2021. </div></td><td>
              52m
            </td><td>
              113.7m
            </td><td>
              0.5m
            </td><td>
              473.6k
            </td><td>
              0.90
            </td><td>
              $2.02
            </td><td>
              $1.95
            </td><td>
              December 2022
            </td><td>
              65.62m
            </td><td>
              -2.69m
            </td><td>
              24.38
            </td><td>
              56.21m
            </td><td>
              -4.66m
            </td><td>
              0
            </td><td>
              52,162,000
            </td><td>
              08/19/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PASG" class="margin-bottom-1">
                PASG
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$11.37</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+0.53%</small></td><td><strong>PBGM01</strong> <br>GM1 gangliosidosis
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2021/Passage-Bio-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Recent-Business-Highlights/default.aspx">
                4Q 2021
              </a> <div class="note">Phase 1/2 initial biomarker and safety data due 4Q 2021.</div></td><td>
              54m
            </td><td>
              0.6b
            </td><td>
              159.0k
            </td><td>
              365.3k
            </td><td>
              1.53
            </td><td>
              $11.32
            </td><td>
              $11.31
            </td><td>
              February 2026
            </td><td>
              393.20m
            </td><td>
              -8.11m
            </td><td>
              48.48
            </td><td>
              355.95m
            </td><td>
              204.00m
            </td><td>
              3.1
            </td><td>
              36,863,189
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PGEN" class="margin-bottom-1">
                PGEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.04</div> <small class="number change-up">+0.42<span>&nbsp;&nbsp;</span>+7.56%</small></td><td><strong>PRGN-3005 UltraCAR-T</strong> <br>Ovarian cancer
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/precigen-reports-second-quarter-and-first-half-2021-financial-results-301351238.html">
                4Q 2021
              </a> <div class="note">Phase 1 initiation of dosing announced August 5, 2019. Interim data to be presented 4Q 2021.</div></td><td>
              207m
            </td><td>
              1.2b
            </td><td>
              341.3k
            </td><td>
              1.2m
            </td><td>
              7.85
            </td><td>
              $5.75
            </td><td>
              $5.62
            </td><td>
              December 15, 2023
            </td><td>
              110.44m
            </td><td>
              -2.59m
            </td><td>
              42.61
            </td><td>
              -132.94m
            </td><td>
              1.24b
            </td><td>
              2.1
            </td><td>
              94,205,701
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SNY" class="margin-bottom-1">
                SNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$52.48</div> <small class="number change-down">-0.64<span>&nbsp;&nbsp;</span>-1.20%</small></td><td><strong>Amcenestrant (AMEERA-3)</strong> <br>Breast Cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/2021_07_29_Sanofi_Q2_2021_presentation.pdf?la=en&amp;hash=F258C8E98B392E4E9DAF7517ECD8A4B9">
                2H 2021
              </a> <div class="note">Phase 2 pivotal data due 2H 2021.</div></td><td>
              3b
            </td><td>
              131.7b
            </td><td>
              2.5m
            </td><td>
              1.7m
            </td><td>
              1.78
            </td><td>
              $52.73
            </td><td>
              $53.12
            </td><td>
              November 2021
            </td><td>
              9.72b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -39.23b
            </td><td>
              146.90b
            </td><td>
              0
            </td><td>
              2,510,366,030
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DVAX" class="margin-bottom-1">
                DVAX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.48</div> <small class="number change-up">+1.44<span>&nbsp;&nbsp;</span>+11.97%</small></td><td><strong>HEPLISAV-B</strong> <br>End Stage Renal Disease on Dialysis undergoing hemodialysis
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/dynavax-announces-first-quarter-2021-financial-results-301285853.html">
                YE 2021
              </a> <div class="note">Phase 1 interim safety data released January 7, 2021 - well tolerated; no safety concerns were observed. Full data due by the end of 2021.</div></td><td>
              115m
            </td><td>
              1.5b
            </td><td>
              2.8m
            </td><td>
              2.3m
            </td><td>
              18.47
            </td><td>
              $12.44
            </td><td>
              $12.04
            </td><td>
              October 23, 2020
            </td><td>
              412.28m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -152.25m
            </td><td>
              1.29b
            </td><td>
              1.6
            </td><td>
              90,823,786
            </td><td>
              05/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MDWD" class="margin-bottom-1">
                MDWD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.55</div> <small class="number change-up">+0.02<span>&nbsp;&nbsp;</span>+0.57%</small></td><td><strong>MW005</strong> <br>Basal Cell Carcinoma
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.mediwound.com/news-releases/news-release-details/mediwound-reports-second-quarter-financial-results">
                YE 2021
              </a> <div class="note">Phase 1/2 trial initiation announced July 26, 2021 with data due by end of 2021.</div></td><td>
              27m
            </td><td>
              96.7m
            </td><td>
              44.3k
            </td><td>
              0.5m
            </td><td>
              44.38
            </td><td>
              $3.54
            </td><td>
              $3.53
            </td><td>
              N/A
            </td><td>
              16.40m
            </td><td>
              -328.33k
            </td><td>
              49.96
            </td><td>
              -7.68m
            </td><td>
              80.79m
            </td><td>
              0
            </td><td>
              15,908,179
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>AZD2816</strong> <br>COVID-19 vaccine (variant)
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2021/h1-2021/H1_2021_results_presentation.pdf">
                2H 2021
              </a> <div class="note">Phase 2/3 data due 2H 2021.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              October 8, 2021
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INCY" class="margin-bottom-1">
                INCY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$75.55</div> <small class="number change-up">+0.65<span>&nbsp;&nbsp;</span>+0.86%</small></td><td><strong>JAKAFI (Ruxolitinib)</strong> <br>Vitiligo
            </td><td>
              sNDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s21.q4cdn.com/114423841/files/doc_financials/2021/q2/Q2-2021-Slides_vFINAL.pdf">
                2H 2021
              </a> <div class="note">Phase 3 trial met primary endpoint - May 17, 2021. sNDA filing due 2H 2021.</div></td><td>
              221m
            </td><td>
              16.7b
            </td><td>
              283.8k
            </td><td>
              1.3m
            </td><td>
              5.68
            </td><td>
              $75.18
            </td><td>
              $74.9
            </td><td>
              April 18, 2021
            </td><td>
              2.18b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              1.22b
            </td><td>
              14.50b
            </td><td>
              1.5
            </td><td>
              155,219,007
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RGLS" class="margin-bottom-1">
                RGLS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.68</div> <small class="number change-up">+0.04<span>&nbsp;&nbsp;</span>+6.83%</small></td><td><strong>RGLS4326</strong> <br>Autosomal dominant polycystic kidney disease (ADPKD)
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/regulus-therapeutics-reports-second-quarter-2021-financial-results-and-recent-updates-301352493.html">
                4Q 2021
              </a> <div class="note">Phase 1 data from second cohort due 4Q 2021. </div></td><td>
              87m
            </td><td>
              59.4m
            </td><td>
              398.7k
            </td><td>
              2.1m
            </td><td>
              1.62
            </td><td>
              $0.63
            </td><td>
              $0.64
            </td><td>
              N/A
            </td><td>
              38.43m
            </td><td>
              -1.67m
            </td><td>
              22.95
            </td><td>
              25.74m
            </td><td>
              21.52m
            </td><td>
              4.7
            </td><td>
              73,050,362
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ATNM" class="margin-bottom-1">
                ATNM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.27</div> <small class="number change-up">+0.24<span>&nbsp;&nbsp;</span>+3.98%</small></td><td><strong>Actimab-A and VENCLEXTA (venetoclax)</strong> <br>Relapsed or refractory acute myeloid leukemia (AML)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.diffusionpharma.com/News/news-details/2021/Diffusion-Pharmaceuticals-Completes-Enrollment-and-Dosing-in-TCOM-Study/default.aspx">
                2H 2021
              </a> <div class="note">Phase 1 data due 2H 2021.</div></td><td>
              21m
            </td><td>
              133.7m
            </td><td>
              99.3k
            </td><td>
              166.4k
            </td><td>
              1.66
            </td><td>
              $6.1
            </td><td>
              $6.03
            </td><td>
              January 2021
            </td><td>
              79.16m
            </td><td>
              -1.53m
            </td><td>
              51.81
            </td><td>
              75.21m
            </td><td>
              47.24m
            </td><td>
              2
            </td><td>
              21,322,261
            </td><td>
              05/26/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SWTX" class="margin-bottom-1">
                SWTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$79.84</div> <small class="number change-up">+3.70<span>&nbsp;&nbsp;</span>+4.86%</small></td><td><strong>Nirogacestat and BLENREP (Belantamab)</strong> <br>Multiple Myeloma
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.springworkstx.com/news-releases/news-release-details/springworks-therapeutics-reports-second-quarter-2021-financial">
                2021
              </a> <div class="note">Phase 1b initial data due 2021.</div></td><td>
              49m
            </td><td>
              3.9b
            </td><td>
              102.1k
            </td><td>
              245.7k
            </td><td>
              7.90
            </td><td>
              $77.38
            </td><td>
              $76.14
            </td><td>
              February 21, 2025
            </td><td>
              442.66m
            </td><td>
              -11.18m
            </td><td>
              39.61
            </td><td>
              418.82m
            </td><td>
              3.28b
            </td><td>
              4.6
            </td><td>
              22,977,819
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LCTX" class="margin-bottom-1">
                LCTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.42</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+5.90%</small></td><td><strong>VAC2</strong> <br>Non-small cell lung cancer (NSCLC)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210812005745/en/">
                4Q 2021
              </a> <div class="note">Phase 1 data due estimated 4Q 2021.</div></td><td>
              150m
            </td><td>
              363.7m
            </td><td>
              368.7k
            </td><td>
              1.2m
            </td><td>
              3.11
            </td><td>
              $2.32
            </td><td>
              $2.29
            </td><td>
              October 16, 2022
            </td><td>
              65.50m
            </td><td>
              -1.81m
            </td><td>
              36.28
            </td><td>
              54.34m
            </td><td>
              125.41m
            </td><td>
              0
            </td><td>
              107,005,592
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/HTBX" class="margin-bottom-1">
                HTBX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.61</div> <small class="number change-up">+0.25<span>&nbsp;&nbsp;</span>+3.93%</small></td><td><strong>PTX-35</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.accesswire.com/639842/Heat-Biologics-Announces-New-Preclinical-Data-on-PTX-35-Demonstrating-Decreased-Regulatory-T-cell-Treg-Activity-and-Delayed-Tumor-Progression-at-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2021">
                2H 2021
              </a> <div class="note">Phase 1 initial data due 2H 2021.</div></td><td>
              25m
            </td><td>
              167.9m
            </td><td>
              145.3k
            </td><td>
              426.2k
            </td><td>
              1.28
            </td><td>
              $6.4
            </td><td>
              $6.36
            </td><td>
              September 2021
            </td><td>
              118.84m
            </td><td>
              -2.05m
            </td><td>
              57.95
            </td><td>
              110.52m
            </td><td>
              40.66m
            </td><td>
              8.8
            </td><td>
              24,309,551
            </td><td>
              04/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INFI" class="margin-bottom-1">
                INFI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.27</div> <small class="number change-up">+0.25<span>&nbsp;&nbsp;</span>+8.18%</small></td><td><strong>Eganelisib (IPI-549) + OPDIVO (nivolumab) - (MARIO-275)</strong> <br>Urothelial cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210727005605/en/">
                YE 2021
              </a> <div class="note">Phase 2 update July 27, 2021. Median overall survival 15.4 months compared to 7.9 months on nivolumab control arm. Program update due by end of 2021.</div></td><td>
              89m
            </td><td>
              289.8m
            </td><td>
              2.3m
            </td><td>
              8.9m
            </td><td>
              6.95
            </td><td>
              $3.07
            </td><td>
              $3.02
            </td><td>
              June 2021
            </td><td>
              91.52m
            </td><td>
              -3.19m
            </td><td>
              28.69
            </td><td>
              30.46m
            </td><td>
              222.36m
            </td><td>
              3.8
            </td><td>
              86,803,145
            </td><td>
              07/27/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MBIO" class="margin-bottom-1">
                MBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.81</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+5.24%</small></td><td><strong>MB-102</strong> <br>Acute myeloid leukemia / blastic plasmacytoid dendritic cell neoplasm (BPDCN)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s2.q4cdn.com/336946411/files/doc_presentations/2021/07/Mustang-Bio-Corporate-Presentation-30Jun2021.pdf">
                4Q 2021
              </a> <div class="note">Phase 1/2  follow-up data due 4Q 2021.</div></td><td>
              91m
            </td><td>
              256.8m
            </td><td>
              0.9m
            </td><td>
              1.5m
            </td><td>
              1.90
            </td><td>
              $2.73
            </td><td>
              $2.67
            </td><td>
              March 2023
            </td><td>
              122.67m
            </td><td>
              -4.03m
            </td><td>
              30.43
            </td><td>
              114.48m
            </td><td>
              116.29m
            </td><td>
              1.8
            </td><td>
              73,639,109
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MTCR" class="margin-bottom-1">
                MTCR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.78</div> <small class="number change-up">+0.17<span>&nbsp;&nbsp;</span>+6.51%</small></td><td><strong>MET409 with JARDIANCE (empagliflozin)</strong> <br>Type 2 Diabetes and Nonalcoholic steatohepatitis (NASH)
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.metacrine.com/news-releases/news-release-details/metacrine-updates-met642-clinical-development-milestone-and">
                4Q 2021
              </a> <div class="note">Phase 2a top-line data due 4Q 2021.</div></td><td>
              27m
            </td><td>
              73.7m
            </td><td>
              169.1k
            </td><td>
              172.4k
            </td><td>
              1.17
            </td><td>
              $2.62
            </td><td>
              $2.61
            </td><td>
              April 2022
            </td><td>
              68.73m
            </td><td>
              -3.38m
            </td><td>
              20.35
            </td><td>
              50.60m
            </td><td>
              5.30m
            </td><td>
              13.6
            </td><td>
              13,699,229
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IONS" class="margin-bottom-1">
                IONS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$39.33</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+0.18%</small></td><td><strong>IONIS-C9Rx</strong> <br>Amyotrophic lateral sclerosis (ALS)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/ionis-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent-business-achievements-301234146.html">
                2H 2021
              </a> <div class="note">Phase 1/2 data due 2H 2021.</div></td><td>
              141m
            </td><td>
              5.6b
            </td><td>
              322.8k
            </td><td>
              1.1m
            </td><td>
              9.52
            </td><td>
              $39.68
            </td><td>
              $39.26
            </td><td>
              N/A
            </td><td>
              2.05b
            </td><td>
              -20.88m
            </td><td>
              98.00
            </td><td>
              132.28m
            </td><td>
              4.79b
            </td><td>
              0.6
            </td><td>
              119,102,131
            </td><td>
              02/24/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FBIO" class="margin-bottom-1">
                FBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.20</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+4.58%</small></td><td><strong>MB-101</strong> <br>Glioblastoma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s2.q4cdn.com/336946411/files/doc_presentations/2021/07/Mustang-Bio-Corporate-Presentation-30Jun2021.pdf">
                4Q 2021
              </a> <div class="note">Phase 1 initiation of dosing announced May 18, 2021. Initial data due 4Q 2021.</div></td><td>
              101m
            </td><td>
              323.4m
            </td><td>
              220.5k
            </td><td>
              0.5m
            </td><td>
              2.99
            </td><td>
              $3.07
            </td><td>
              $3.06
            </td><td>
              December 15, 2023
            </td><td>
              254.32m
            </td><td>
              -11.49m
            </td><td>
              22.14
            </td><td>
              84.46m
            </td><td>
              120.76m
            </td><td>
              27.4
            </td><td>
              76,232,955
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MBIO" class="margin-bottom-1">
                MBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.81</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+5.24%</small></td><td><strong>MB-101</strong> <br>Glioblastoma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s2.q4cdn.com/336946411/files/doc_presentations/2021/07/Mustang-Bio-Corporate-Presentation-30Jun2021.pdf">
                4Q 2021
              </a> <div class="note">Phase 1 initiation of dosing announced May 18, 2021. Initial data due 4Q 2021.</div></td><td>
              91m
            </td><td>
              256.8m
            </td><td>
              0.9m
            </td><td>
              1.5m
            </td><td>
              1.90
            </td><td>
              $2.73
            </td><td>
              $2.67
            </td><td>
              December 15, 2023
            </td><td>
              122.67m
            </td><td>
              -4.03m
            </td><td>
              30.43
            </td><td>
              114.48m
            </td><td>
              116.29m
            </td><td>
              1.8
            </td><td>
              73,639,109
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MEIP" class="margin-bottom-1">
                MEIP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.75</div> <small class="number change-up">+0.16<span>&nbsp;&nbsp;</span>+6.18%</small></td><td><strong>Voruciclib</strong> <br>B-Cell Malignancies
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/mei-pharma-reports-third-quarter-fiscal-2021-results-and-operational-highlights-301286036.html">
                2021
              </a> <div class="note">Phase 1 update due 2021.</div></td><td>
              113m
            </td><td>
              309.6m
            </td><td>
              145.9k
            </td><td>
              484.5k
            </td><td>
              6.88
            </td><td>
              $2.63
            </td><td>
              $2.59
            </td><td>
              April 30, 2022
            </td><td>
              139.42m
            </td><td>
              -5.22m
            </td><td>
              26.73
            </td><td>
              -1.74m
            </td><td>
              135.50m
            </td><td>
              0.6
            </td><td>
              112,005,779
            </td><td>
              05/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GILD" class="margin-bottom-1">
                GILD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$72.66</div> <small class="number change-up">+0.22<span>&nbsp;&nbsp;</span>+0.30%</small></td><td><strong>YESCARTA - Axicabtagene ciloleucel - (ZUMA-12)</strong> <br>Diffuse Large B-Cell Lymphoma (DLBCL)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.gilead.com/static-files/a67bf84b-ece1-480b-bedf-665c6e4c57a9">
                2H 2021
              </a> <div class="note">Phase 2 data due 2H 2021.</div></td><td>
              1b
            </td><td>
              91.1b
            </td><td>
              2.8m
            </td><td>
              6.3m
            </td><td>
              4.62
            </td><td>
              $72.68
            </td><td>
              $72.44
            </td><td>
              May 18, 2021
            </td><td>
              7.91b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -40.36b
            </td><td>
              114.48b
            </td><td>
              0.6
            </td><td>
              1,253,507,953
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IONS" class="margin-bottom-1">
                IONS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$39.33</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+0.18%</small></td><td><strong>IONIS-MAPTRx (ISIS 814907; BIIB080)</strong> <br>Alzheimer's disease
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/biogen-and-ionis-report-positive-topline-clinical-data-on-investigational-alzheimers-disease-treatment-at-aaic-301341358.html">
                2H 2021
              </a> <div class="note">Phase 1/2 trial met its primary objective of safety and tolerability. Further data due later in 2021.</div></td><td>
              141m
            </td><td>
              5.6b
            </td><td>
              322.8k
            </td><td>
              1.1m
            </td><td>
              9.52
            </td><td>
              $39.68
            </td><td>
              $39.26
            </td><td>
              May 2022
            </td><td>
              2.05b
            </td><td>
              -20.88m
            </td><td>
              98.00
            </td><td>
              132.28m
            </td><td>
              4.79b
            </td><td>
              0.6
            </td><td>
              119,102,131
            </td><td>
              07/26/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BIIB" class="margin-bottom-1">
                BIIB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$346.91</div> <small class="number change-up">+5.17<span>&nbsp;&nbsp;</span>+1.51%</small></td><td><strong>IONIS-MAPTRx (ISIS 814907; BIIB080)</strong> <br>Alzheimer's disease
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/biogen-and-ionis-report-positive-topline-clinical-data-on-investigational-alzheimers-disease-treatment-at-aaic-301341358.html">
                2H 2021
              </a> <div class="note">Phase 1/2 trial met its primary objective of safety and tolerability. Further data due later in 2021.</div></td><td>
              149m
            </td><td>
              51.7b
            </td><td>
              466.4k
            </td><td>
              1.5m
            </td><td>
              4.81
            </td><td>
              $342.33
            </td><td>
              $341.74
            </td><td>
              May 2022
            </td><td>
              3.79b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -9.47b
            </td><td>
              55.51b
            </td><td>
              1.4
            </td><td>
              132,287,800
            </td><td>
              07/26/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PRVB" class="margin-bottom-1">
                PRVB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.21</div> <small class="number change-up">+0.24<span>&nbsp;&nbsp;</span>+4.02%</small></td><td><strong>PRV-101 - PROVENT</strong> <br>Coxsackievirus B (CVB) vaccine
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/provention-bio-reports-first-quarter-2021-financial-results-and-provides-business-update-301285145.html">
                4Q 2021
              </a> <div class="note">Phase 1 data due 4Q 2021.</div></td><td>
              63m
            </td><td>
              393.6m
            </td><td>
              415.7k
            </td><td>
              1.4m
            </td><td>
              2.49
            </td><td>
              $6.05
            </td><td>
              $5.97
            </td><td>
              October 2021
            </td><td>
              158.32m
            </td><td>
              -10.03m
            </td><td>
              15.78
            </td><td>
              133.03m
            </td><td>
              202.62m
            </td><td>
              12.2
            </td><td>
              58,084,618
            </td><td>
              05/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ERYP" class="margin-bottom-1">
                ERYP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.76</div> <small class="number change-down">-0.10<span>&nbsp;&nbsp;</span>-1.71%</small></td><td><strong>GRASPA (Eryaspase) - (Trybeca-1)</strong> <br>Pancreatic cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/7c3e6d65-f414-4915-a216-f3f4f17ab981">
                4Q 2021
              </a> <div class="note">Phase 3  final data due 4Q 2021.</div></td><td>
              27m
            </td><td>
              157.3m
            </td><td>
              48.9k
            </td><td>
              1.4m
            </td><td>
              5.05
            </td><td>
              $5.9
            </td><td>
              $5.86
            </td><td>
              August 2021
            </td><td>
              74.45m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              20.59m
            </td><td>
              143.78m
            </td><td>
              0
            </td><td>
              27,317,957
            </td><td>
              06/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLLS" class="margin-bottom-1">
                CLLS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.61</div> <small class="number change-up">+1.14<span>&nbsp;&nbsp;</span>+9.14%</small></td><td><strong>UCART22 -  BALLI-01</strong> <br>Relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml.globenewswire.com/Resource/Download/f6b72a8a-7b39-4aae-a04f-c011d602f50e">
                2021
              </a> <div class="note">Phase 1 update due at ASH December 5, 2020. 2 out of 3 Patients at DL1 Achieved CR/CRi. Further data due 2021.</div></td><td>
              45m
            </td><td>
              0.6b
            </td><td>
              168.0k
            </td><td>
              205.0k
            </td><td>
              2.24
            </td><td>
              $12.76
            </td><td>
              $12.47
            </td><td>
              October 14, 2022
            </td><td>
              244.34m
            </td><td>
              -4.04m
            </td><td>
              60.46
            </td><td>
              89.10m
            </td><td>
              425.67m
            </td><td>
              0
            </td><td>
              45,461,310
            </td><td>
              05/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ERYP" class="margin-bottom-1">
                ERYP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.76</div> <small class="number change-down">-0.10<span>&nbsp;&nbsp;</span>-1.71%</small></td><td><strong>GRASPA (Eryaspase)</strong> <br>Acute lymphoblastic leukemia (ALL)
            </td><td>
              BLA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/cd61f351-24dc-4287-b3b8-81dd5c5f80a4">
                4Q 2021
              </a> <div class="note">BLA filing due 4Q 2021.</div></td><td>
              27m
            </td><td>
              157.3m
            </td><td>
              48.9k
            </td><td>
              1.4m
            </td><td>
              5.05
            </td><td>
              $5.9
            </td><td>
              $5.86
            </td><td>
              August 1, 2020
            </td><td>
              74.45m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              20.59m
            </td><td>
              143.78m
            </td><td>
              0
            </td><td>
              27,317,957
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IDYA" class="margin-bottom-1">
                IDYA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$24.28</div> <small class="number change-up">+0.59<span>&nbsp;&nbsp;</span>+2.49%</small></td><td><strong>Darovasertib (IDE196) and MEKTOVI (​binimetinib)</strong> <br>Metastatic uveal melanoma (MUM)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/ideaya-biosciences-inc-reports-second-quarter-2021-financial-results-and-provides-business-update-301351733.html">
                4Q 2021
              </a> <div class="note">Phase 1/2 data released April 16, 2021. 2/9 (22%) partial responses. Update due 4Q 2021.</div></td><td>
              38m
            </td><td>
              0.9b
            </td><td>
              226.9k
            </td><td>
              287.5k
            </td><td>
              3.88
            </td><td>
              $24.2
            </td><td>
              $23.69
            </td><td>
              December 15, 2021
            </td><td>
              352.52m
            </td><td>
              -4.31m
            </td><td>
              81.79
            </td><td>
              264.38m
            </td><td>
              0.64b
            </td><td>
              2.4
            </td><td>
              34,383,161
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KZIA" class="margin-bottom-1">
                KZIA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.18</div> <small class="number change-up">+0.26<span>&nbsp;&nbsp;</span>+2.91%</small></td><td><strong>Paxalisib (GDC-0084)</strong> <br>Brain Metastases
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.kaziatherapeutics.com/site/PDF/c60112d5-cc66-4903-9654-f7fd9520a20a/KaziaCorporatePresentation">
                2H 2021
              </a> <div class="note">Phase 1 data due 2H 2021.</div></td><td>
              13m
            </td><td>
              119.0m
            </td><td>
              5.6k
            </td><td>
              26.4k
            </td><td>
              5.25
            </td><td>
              $9.05
            </td><td>
              $8.92
            </td><td>
              December 2022
            </td><td>
              34.37m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              26.43m
            </td><td>
              102.41m
            </td><td>
              0
            </td><td>
              12,942,234
            </td><td>
              06/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MGTA" class="margin-bottom-1">
                MGTA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.57</div> <small class="number change-up">+0.08<span>&nbsp;&nbsp;</span>+1.23%</small></td><td><strong>MGTA-145 and plerixafor</strong> <br> Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) and Myelodysplastic Syndromes (MDS)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005403/en/">
                4Q 2021
              </a> <div class="note">Phase 2 initial data due 4Q 2021.</div></td><td>
              59m
            </td><td>
              384.8m
            </td><td>
              87.4k
            </td><td>
              250.6k
            </td><td>
              1.90
            </td><td>
              $6.58
            </td><td>
              $6.49
            </td><td>
              August 1, 2022
            </td><td>
              200.01m
            </td><td>
              -4.33m
            </td><td>
              46.16
            </td><td>
              182.52m
            </td><td>
              172.30m
            </td><td>
              1.9
            </td><td>
              44,285,984
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/HRTX" class="margin-bottom-1">
                HRTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$11.04</div> <small class="number change-up">+0.53<span>&nbsp;&nbsp;</span>+4.99%</small></td><td><strong>CINVANTI (HTX-019)</strong> <br>Ppostoperative nausea and vomiting (PONV)
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/heron-therapeutics-announces-financial-results-for-the-three-and-six-months-ended-june-30-2021-and-highlights-recent-corporate-updates-301350792.html">
                Late-2021
              </a> <div class="note">NDA filing due late-2021.</div></td><td>
              102m
            </td><td>
              1.1b
            </td><td>
              0.7m
            </td><td>
              1.4m
            </td><td>
              7.04
            </td><td>
              $10.69
            </td><td>
              $10.52
            </td><td>
              N/A
            </td><td>
              219.88m
            </td><td>
              -21.00m
            </td><td>
              10.47
            </td><td>
              -24.26m
            </td><td>
              0.98b
            </td><td>
              1.6
            </td><td>
              89,086,846
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CDTX" class="margin-bottom-1">
                CDTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.05</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+4.59%</small></td><td><strong>Rezafungin (CD101) ReSTORE</strong> <br>Candidemia
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.cidara.com/news-releases/news-release-details/cidara-therapeutics-and-mundipharma-announce-completion">
                YE 2021
              </a> <div class="note">Phase 3 top-line data due late-2021.</div></td><td>
              50m
            </td><td>
              101.5m
            </td><td>
              344.5k
            </td><td>
              429.0k
            </td><td>
              6.41
            </td><td>
              $1.97
            </td><td>
              $1.96
            </td><td>
              October 2021
            </td><td>
              50.35m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              2.39m
            </td><td>
              54.04m
            </td><td>
              2.1
            </td><td>
              48,564,567
            </td><td>
              08/17/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AGLE" class="margin-bottom-1">
                AGLE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.14</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+1.85%</small></td><td><strong>AGLE-177</strong> <br>Homocystinuria
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-reports-second-quarter-2021-financial-results-and-corporate-highlights-301348486.html">
                YE 2021
              </a> <div class="note">Phase 1/2 initiation of dosing announced June 24, 2021. Update by end of 2021.</div></td><td>
              49m
            </td><td>
              350.3m
            </td><td>
              76.5k
            </td><td>
              176.1k
            </td><td>
              2.94
            </td><td>
              $7
            </td><td>
              $7.01
            </td><td>
              N/A
            </td><td>
              129.83m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              101.87m
            </td><td>
              220.66m
            </td><td>
              2.1
            </td><td>
              43,497,685
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PPBT" class="margin-bottom-1">
                PPBT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.74</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+2.82%</small></td><td><strong>NT-219</strong> <br>Squamous cell carcinoma of the head &amp; neck (SCCHN)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s3.amazonaws.com/b2icontent.irpass.cc/2492/rl101491.pdf">
                2H 2021
              </a> <div class="note">Phase 1/2 initial data presented at ASCO June 4, 2021. 1/6 partial responses. Further data due 2H 2021.</div></td><td>
              18m
            </td><td>
              83.5m
            </td><td>
              93.9k
            </td><td>
              265.9k
            </td><td>
              1.16
            </td><td>
              $4.61
            </td><td>
              $4.61
            </td><td>
              June 2023
            </td><td>
              48.39m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              44.02m
            </td><td>
              32.74m
            </td><td>
              0
            </td><td>
              17,615,824
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PTGX" class="margin-bottom-1">
                PTGX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.56</div> <small class="number change-up">+0.34<span>&nbsp;&nbsp;</span>+0.70%</small></td><td><strong>Rusfertide (PTG-300)</strong> <br>Hereditary hemochromatosis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.protagonist-inc.com/static-files/34c105ef-485b-422c-9352-52dc1cf9a177">
                4Q 2021
              </a> <div class="note">Phase 2 initial data due 2H 2021.</div></td><td>
              48m
            </td><td>
              2.4b
            </td><td>
              161.0k
            </td><td>
              453.6k
            </td><td>
              6.59
            </td><td>
              $49.6
            </td><td>
              $49.22
            </td><td>
              June 2021
            </td><td>
              340.06m
            </td><td>
              -7.90m
            </td><td>
              43.05
            </td><td>
              293.28m
            </td><td>
              1.99b
            </td><td>
              1.5
            </td><td>
              38,115,527
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CRIS" class="margin-bottom-1">
                CRIS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.74</div> <small class="number change-up">+0.52<span>&nbsp;&nbsp;</span>+7.13%</small></td><td><strong>CI-8993</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://investors.curis.com/2021-08-03-Curis-Reports-Second-Quarter-2021-Financial-Results">
                2H 2021
              </a> <div class="note">Phase 1 initial data due 2H 2021.</div></td><td>
              92m
            </td><td>
              0.7b
            </td><td>
              1.1m
            </td><td>
              2.9m
            </td><td>
              6.29
            </td><td>
              $7.4
            </td><td>
              $7.22
            </td><td>
              July 1, 2022
            </td><td>
              148.57m
            </td><td>
              -2.22m
            </td><td>
              66.94
            </td><td>
              79.86m
            </td><td>
              0.51b
            </td><td>
              2.5
            </td><td>
              91,355,825
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARCT" class="margin-bottom-1">
                ARCT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.98</div> <small class="number change-up">+2.08<span>&nbsp;&nbsp;</span>+4.34%</small></td><td><strong>ARCT-154</strong> <br>COVID-19 variant vaccine
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.arcturusrx.com/static-files/198c6d28-bb6b-4162-a7a6-5854a0fd2d6c">
                4Q 2021
              </a> <div class="note">Phase 1/2/3 interim data due 4Q 2021.</div></td><td>
              26m
            </td><td>
              1.3b
            </td><td>
              388.5k
            </td><td>
              1.0m
            </td><td>
              4.30
            </td><td>
              $48.63
            </td><td>
              $47.9
            </td><td>
              N/A
            </td><td>
              413.81m
            </td><td>
              -10.98m
            </td><td>
              37.68
            </td><td>
              270.64m
            </td><td>
              0.90b
            </td><td>
              9.4
            </td><td>
              14,191,083
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CRVS" class="margin-bottom-1">
                CRVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.03</div> <small class="number change-up">+0.12<span>&nbsp;&nbsp;</span>+6.42%</small></td><td><strong>Mupadolimab (CPI-006)</strong> <br>HPV+ Oropharyngeal Cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://corvuspharma.gcs-web.com/news-releases/news-release-details/corvus-pharmaceuticals-provides-business-update-and-reports-8">
                YE 2021
              </a> <div class="note">Phase 1b/2 data due year-end 2021.</div></td><td>
              42m
            </td><td>
              86.2m
            </td><td>
              64.2k
            </td><td>
              227.7k
            </td><td>
              0.90
            </td><td>
              $1.92
            </td><td>
              $1.91
            </td><td>
              N/A
            </td><td>
              58.87m
            </td><td>
              -4.22m
            </td><td>
              13.97
            </td><td>
              45.88m
            </td><td>
              16.35m
            </td><td>
              0.8
            </td><td>
              29,500,551
            </td><td>
              08/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MRTX" class="margin-bottom-1">
                MRTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$145.25</div> <small class="number change-up">+11.12<span>&nbsp;&nbsp;</span>+8.29%</small></td><td><strong>Sitravatinib and tislelizumab</strong> <br>Hepatocellular Carcinoma (HCC) / Gastric/Gastroesophageal Junction Cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s23.q4cdn.com/174398288/files/doc_presentations/11/MRTX-Corporate-Presentation_5November2020_website.pdf">
                2021
              </a> <div class="note">Phase 1 additional data due in 2021.</div></td><td>
              52m
            </td><td>
              7.5b
            </td><td>
              181.2k
            </td><td>
              466.1k
            </td><td>
              6.64
            </td><td>
              $135.44
            </td><td>
              $134.13
            </td><td>
              August 2022
            </td><td>
              1.14b
            </td><td>
              -31.12m
            </td><td>
              36.65
            </td><td>
              0.91b
            </td><td>
              5.77b
            </td><td>
              0.9
            </td><td>
              40,808,627
            </td><td>
              11/22/2020
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BGNE" class="margin-bottom-1">
                BGNE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$270.83</div> <small class="number change-up">+21.23<span>&nbsp;&nbsp;</span>+8.51%</small></td><td><strong>Sitravatinib and tislelizumab</strong> <br>Hepatocellular Carcinoma (HCC) / Gastric/Gastroesophageal Junction Cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s23.q4cdn.com/174398288/files/doc_presentations/11/MRTX-Corporate-Presentation_5November2020_website.pdf">
                2021
              </a> <div class="note">Phase 1 additional data due in 2021.</div></td><td>
              93m
            </td><td>
              25.2b
            </td><td>
              273.7k
            </td><td>
              315.1k
            </td><td>
              7.00
            </td><td>
              $256
            </td><td>
              $249.6
            </td><td>
              August 2022
            </td><td>
              4.13b
            </td><td>
              -140.09m
            </td><td>
              29.48
            </td><td>
              2.21b
            </td><td>
              21.09b
            </td><td>
              0.3
            </td><td>
              89,530,472
            </td><td>
              11/22/2020
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/HARP" class="margin-bottom-1">
                HARP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.13</div> <small class="number change-up">+0.49<span>&nbsp;&nbsp;</span>+5.67%</small></td><td><strong>HPN536</strong> <br>Ovarian cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.harpoontx.com/news-releases/news-release-details/harpoon-therapeutics-reports-second-quarter-2021-financial">
                YE 2021
              </a> <div class="note">Phase 1/2a trial ongoing. Initiation of an expansion cohort is anticipated by 2H 2021, with a presentation of Phase 1 data by year-end 2021.</div></td><td>
              33m
            </td><td>
              298.3m
            </td><td>
              168.7k
            </td><td>
              0.5m
            </td><td>
              3.28
            </td><td>
              $8.64
            </td><td>
              $8.64
            </td><td>
              April 1, 2022
            </td><td>
              131.08m
            </td><td>
              -22.19m
            </td><td>
              5.91
            </td><td>
              25.83m
            </td><td>
              124.19m
            </td><td>
              1.1
            </td><td>
              30,498,283
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FDMT" class="margin-bottom-1">
                FDMT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.28</div> <small class="number change-up">+0.95<span>&nbsp;&nbsp;</span>+3.24%</small></td><td><strong>4D-125</strong> <br>X-linked retinitis pigmentosa (XLRP)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2280075/0/en/4D-Molecular-Therapeutics-Reports-Financial-Results-for-the-Second-Quarter-of-2021-and-Provides-Operational-Highlights.html">
                4Q 2021
              </a> <div class="note">Phase 1/2 initial data due 4Q 2021.</div></td><td>
              27m
            </td><td>
              0.8b
            </td><td>
              91.6k
            </td><td>
              130.9k
            </td><td>
              3.40
            </td><td>
              $29.91
            </td><td>
              $29.33
            </td><td>
              March 2023
            </td><td>
              234.02m
            </td><td>
              -5.40m
            </td><td>
              43.32
            </td><td>
              219.73m
            </td><td>
              0.55b
            </td><td>
              7.6
            </td><td>
              18,557,613
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FDMT" class="margin-bottom-1">
                FDMT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.28</div> <small class="number change-up">+0.95<span>&nbsp;&nbsp;</span>+3.24%</small></td><td><strong>4D-110</strong> <br>Choroideremia
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2280075/0/en/4D-Molecular-Therapeutics-Reports-Financial-Results-for-the-Second-Quarter-of-2021-and-Provides-Operational-Highlights.html">
                4Q 2021
              </a> <div class="note">Phase 1 initial data due 4Q 2021.</div></td><td>
              27m
            </td><td>
              0.8b
            </td><td>
              91.6k
            </td><td>
              130.9k
            </td><td>
              3.40
            </td><td>
              $29.91
            </td><td>
              $29.33
            </td><td>
              November 2021
            </td><td>
              234.02m
            </td><td>
              -5.40m
            </td><td>
              43.32
            </td><td>
              219.73m
            </td><td>
              0.55b
            </td><td>
              7.6
            </td><td>
              18,557,613
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GBT" class="margin-bottom-1">
                GBT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.01</div> <small class="number change-up">+1.46<span>&nbsp;&nbsp;</span>+5.30%</small></td><td><strong>GBT601 (GBT021601-012)</strong> <br>Healthy volunteers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.gbt.com/news-releases/news-release-details/gbt-reports-second-quarter-2021-financial-results">
                YE 2021
              </a> <div class="note">Phase 1 data due by the end of 2021.</div></td><td>
              62m
            </td><td>
              1.8b
            </td><td>
              0.7m
            </td><td>
              1.4m
            </td><td>
              5.73
            </td><td>
              $27.74
            </td><td>
              $27.55
            </td><td>
              N/A
            </td><td>
              410.80m
            </td><td>
              -14.77m
            </td><td>
              27.81
            </td><td>
              111.60m
            </td><td>
              1.51b
            </td><td>
              2.6
            </td><td>
              60,939,309
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KDMN" class="margin-bottom-1">
                KDMN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.21</div> <small class="number change-up">+0.17<span>&nbsp;&nbsp;</span>+3.37%</small></td><td><strong>KD033-101</strong> <br>Advanced Solid Tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.accesswire.com/658562/Kadmon-Provides-Business-Update-and-Reports-Second-Quarter-2021-Financial-Results">
                4Q 2021
              </a> <div class="note">Phase 1 initial safety data presented at ASCO June 4-8, 2021. Abstract noted 1/6 patients showed stable disease. Additional data due 4Q 2021.</div></td><td>
              172m
            </td><td>
              0.9b
            </td><td>
              2.7m
            </td><td>
              4.0m
            </td><td>
              -74.43
            </td><td>
              $5.09
            </td><td>
              $5.04
            </td><td>
              November 2022
            </td><td>
              266.29m
            </td><td>
              -8.35m
            </td><td>
              31.91
            </td><td>
              -10.54m
            </td><td>
              0.88b
            </td><td>
              0.3
            </td><td>
              163,069,909
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FDMT" class="margin-bottom-1">
                FDMT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.28</div> <small class="number change-up">+0.95<span>&nbsp;&nbsp;</span>+3.24%</small></td><td><strong>4D-310</strong> <br>Fabry Disease
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2280075/0/en/4D-Molecular-Therapeutics-Reports-Financial-Results-for-the-Second-Quarter-of-2021-and-Provides-Operational-Highlights.html">
                2H 2021
              </a> <div class="note">Phase 1/2 initial data due 4Q 2021.</div></td><td>
              27m
            </td><td>
              0.8b
            </td><td>
              91.6k
            </td><td>
              130.9k
            </td><td>
              3.40
            </td><td>
              $29.91
            </td><td>
              $29.33
            </td><td>
              February 2024
            </td><td>
              234.02m
            </td><td>
              -5.40m
            </td><td>
              43.32
            </td><td>
              219.73m
            </td><td>
              0.55b
            </td><td>
              7.6
            </td><td>
              18,557,613
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/XENE" class="margin-bottom-1">
                XENE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.39</div> <small class="number change-down">-0.05<span>&nbsp;&nbsp;</span>-0.30%</small></td><td><strong>XEN007</strong> <br>Childhood absence epilepsy
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.benzinga.com/pressreleases/21/08/g22452981/xenon-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-corporate-update">
                4Q 2021
              </a> <div class="note">Phase 2 further data due 4Q 2021.</div></td><td>
              41m
            </td><td>
              0.7b
            </td><td>
              175.3k
            </td><td>
              201.1k
            </td><td>
              2.70
            </td><td>
              $16.73
            </td><td>
              $16.44
            </td><td>
              N/A
            </td><td>
              252.68m
            </td><td>
              -4.36m
            </td><td>
              57.97
            </td><td>
              234.95m
            </td><td>
              426.80m
            </td><td>
              1.9
            </td><td>
              40,156,539
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MDGL" class="margin-bottom-1">
                MDGL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$82.90</div> <small class="number change-up">+2.38<span>&nbsp;&nbsp;</span>+2.96%</small></td><td><strong>Resmetirom (MGL-3196) - MAESTRO-NAFLD-1</strong> <br>Non-Alcoholic Fatty Liver Disease
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-2021-second-quarter-financial">
                YE 2021
              </a> <div class="note">Phase 3 52-week top-line data due by end of 2021. </div></td><td>
              17m
            </td><td>
              1.4b
            </td><td>
              48.0k
            </td><td>
              137.0k
            </td><td>
              5.09
            </td><td>
              $81.39
            </td><td>
              $80.52
            </td><td>
              December 2021
            </td><td>
              295.72m
            </td><td>
              -15.63m
            </td><td>
              18.92
            </td><td>
              238.41m
            </td><td>
              1.01b
            </td><td>
              52.7
            </td><td>
              10,615,167
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NMTR" class="margin-bottom-1">
                NMTR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.13</div> <small class="number change-up">+0.03<span>&nbsp;&nbsp;</span>+2.73%</small></td><td><strong>Vurolenatide (VIBRANT)</strong> <br>Short bowel syndrome 
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.accesswire.com/659341/9-Meters-Biopharma-Provides-Business-Update-and-Reports-Financial-Results-for-the-Second-Quarter-2021">
                4Q 2021
              </a> <div class="note">Phase 2 trial initiation announced June 14, 2021 with top-line data due 4Q 2021.</div></td><td>
              255m
            </td><td>
              287.9m
            </td><td>
              1.6m
            </td><td>
              4.9m
            </td><td>
              4.91
            </td><td>
              $1.13
            </td><td>
              $1.1
            </td><td>
              October 29, 2021
            </td><td>
              59.76m
            </td><td>
              -2.37m
            </td><td>
              25.22
            </td><td>
              52.90m
            </td><td>
              216.40m
            </td><td>
              1.9
            </td><td>
              218,959,804
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALBO" class="margin-bottom-1">
                ALBO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.70</div> <small class="number change-up">+1.89<span>&nbsp;&nbsp;</span>+6.80%</small></td><td><strong>A3907</strong> <br>Liver disease
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.albireopharma.com/news-releases/news-release-details/albireo-reports-q2-financial-results-and-business-update">
                2H 2021
              </a> <div class="note">Phase 1 top-line data due 2H 2021.</div></td><td>
              19m
            </td><td>
              0.6b
            </td><td>
              67.6k
            </td><td>
              262.4k
            </td><td>
              5.04
            </td><td>
              $28.02
            </td><td>
              $27.81
            </td><td>
              N/A
            </td><td>
              167.40m
            </td><td>
              -10.49m
            </td><td>
              15.96
            </td><td>
              61.41m
            </td><td>
              359.08m
            </td><td>
              20.7
            </td><td>
              14,332,622
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CFRX" class="margin-bottom-1">
                CFRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.46</div> <small class="number change-up">+0.27<span>&nbsp;&nbsp;</span>+8.46%</small></td><td><strong>Exebacase (DISRUPT)</strong> <br>Serious infections caused by Staph aureus including MRSA
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.contrafect.com/press-releases/detail/313/contrafect-reports-first-quarter-2021-financial-results-and">
                2H 2021
              </a> <div class="note">Phase 3 interim futility analysis due 2H 2021.</div></td><td>
              39m
            </td><td>
              136.1m
            </td><td>
              101.0k
            </td><td>
              334.3k
            </td><td>
              2.37
            </td><td>
              $3.18
            </td><td>
              $3.19
            </td><td>
              September 30, 2022
            </td><td>
              60.03m
            </td><td>
              -4.15m
            </td><td>
              14.47
            </td><td>
              30.66m
            </td><td>
              61.41m
            </td><td>
              3.7
            </td><td>
              31,904,936
            </td><td>
              05/14/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ASMB" class="margin-bottom-1">
                ASMB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.64</div> <small class="number change-up">+0.12<span>&nbsp;&nbsp;</span>+3.41%</small></td><td><strong>ABI-H2158</strong> <br>Hepatitis B virus (HBV)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-reports-second-quarter-2021-financial">
                2H 2021
              </a> <div class="note">Phase 2 interim data due 2H 2021. </div></td><td>
              45m
            </td><td>
              163.7m
            </td><td>
              0.5m
            </td><td>
              1.3m
            </td><td>
              0.71
            </td><td>
              $3.53
            </td><td>
              $3.52
            </td><td>
              January 19, 2023
            </td><td>
              185.99m
            </td><td>
              -7.27m
            </td><td>
              25.59
            </td><td>
              155.65m
            </td><td>
              -32.81m
            </td><td>
              6.4
            </td><td>
              44,374,862
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALLK" class="margin-bottom-1">
                ALLK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$82.78</div> <small class="number change-up">+2.78<span>&nbsp;&nbsp;</span>+3.48%</small></td><td><strong>Lirentelimab (KRYPTOS)</strong> <br>Eosinophilic esophagitis
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.allakos.com/news-releases/news-release-details/allakos-provides-business-update-and-reports-second-quarter-2021">
                4Q 2021
              </a> <div class="note">Phase 2/3 top-line data due 4Q 2021.</div></td><td>
              54m
            </td><td>
              4.5b
            </td><td>
              103.3k
            </td><td>
              285.4k
            </td><td>
              7.83
            </td><td>
              $80.62
            </td><td>
              $80
            </td><td>
              December 2021
            </td><td>
              0.53b
            </td><td>
              -16.59m
            </td><td>
              31.93
            </td><td>
              445.86m
            </td><td>
              3.81b
            </td><td>
              1.3
            </td><td>
              25,124,435
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INCY" class="margin-bottom-1">
                INCY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$75.55</div> <small class="number change-up">+0.65<span>&nbsp;&nbsp;</span>+0.86%</small></td><td><strong>Pelareorep and retifanlimab (INCMGA00012) - IRENE</strong> <br>Triple-negative breast cancer.
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/oncolytics-biotech-reports-2021-second-quarter-development-highlights-and-financial-results-301350059.html">
                4Q 2021
              </a> <div class="note">Phase 2 interim safety update 4Q 2021.</div></td><td>
              221m
            </td><td>
              16.7b
            </td><td>
              283.8k
            </td><td>
              1.3m
            </td><td>
              5.68
            </td><td>
              $75.18
            </td><td>
              $74.9
            </td><td>
              June 30, 2022
            </td><td>
              2.18b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              1.22b
            </td><td>
              14.50b
            </td><td>
              1.5
            </td><td>
              155,219,007
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ONCY" class="margin-bottom-1">
                ONCY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.26</div> <small class="number change-up">+0.19<span>&nbsp;&nbsp;</span>+9.18%</small></td><td><strong>Pelareorep and retifanlimab (INCMGA00012) - IRENE</strong> <br>Triple-negative breast cancer.
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/oncolytics-biotech-reports-2021-second-quarter-development-highlights-and-financial-results-301350059.html">
                4Q 2021
              </a> <div class="note">Phase 2 interim safety update 4Q 2021.</div></td><td>
              42m
            </td><td>
              124.2m
            </td><td>
              276.6k
            </td><td>
              243.5k
            </td><td>
              3.13
            </td><td>
              $2.08
            </td><td>
              $2.07
            </td><td>
              June 30, 2022
            </td><td>
              46.72m
            </td><td>
              -2.27m
            </td><td>
              20.62
            </td><td>
              36.90m
            </td><td>
              64.30m
            </td><td>
              0
            </td><td>
              54,282,604
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IGMS" class="margin-bottom-1">
                IGMS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$79.19</div> <small class="number change-up">+4.04<span>&nbsp;&nbsp;</span>+5.38%</small></td><td><strong>IGM-8444</strong> <br>Solid Cancers and Non-Hodgkin’s Lymphoma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/09/2277444/0/en/IGM-Biosciences-Announces-Second-Quarter-2021-Financial-Results-and-Provides-Corporate-Update.html">
                2H 2021
              </a> <div class="note">Phase 1 initial data due 2H 2021.</div></td><td>
              32m
            </td><td>
              2.5b
            </td><td>
              72.3k
            </td><td>
              146.7k
            </td><td>
              7.87
            </td><td>
              $76.25
            </td><td>
              $75.15
            </td><td>
              August 2023
            </td><td>
              265.63m
            </td><td>
              -8.78m
            </td><td>
              30.24
            </td><td>
              237.43m
            </td><td>
              2.14b
            </td><td>
              1
            </td><td>
              8,026,991
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NKTR" class="margin-bottom-1">
                NKTR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.89</div> <small class="number change-up">+0.28<span>&nbsp;&nbsp;</span>+2.06%</small></td><td><strong>NKTR-255 and ERBITUX (cetuximab)</strong> <br>Head and Neck Squamous Cell Carcinoma / Colorectal Cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/nektar-therapeutics-reports-first-quarter-2021-financial-results-301286004.html">
                4Q 2021
              </a> <div class="note">Phase 1/2 data due 4Q 2021.</div></td><td>
              184m
            </td><td>
              2.6b
            </td><td>
              287.9k
            </td><td>
              0.8m
            </td><td>
              2.82
            </td><td>
              $13.74
            </td><td>
              $13.61
            </td><td>
              April 2022
            </td><td>
              0.95b
            </td><td>
              -27.63m
            </td><td>
              34.39
            </td><td>
              483.95m
            </td><td>
              1.65b
            </td><td>
              2.1
            </td><td>
              91,286,217
            </td><td>
              05/07/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AUPH" class="margin-bottom-1">
                AUPH
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.29</div> <small class="number change-up">+0.66<span>&nbsp;&nbsp;</span>+4.80%</small></td><td><strong>LUPKYNIS (Voclosporin) - AURORA-2</strong> <br>Lupus Nephritis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805006068/en/">
                YE 2021
              </a> <div class="note">Phase 3 top-line data due by the end of 2021.</div></td><td>
              128m
            </td><td>
              1.8b
            </td><td>
              1.4m
            </td><td>
              3.6m
            </td><td>
              5.52
            </td><td>
              $14.14
            </td><td>
              $13.64
            </td><td>
              August 2021
            </td><td>
              295.95m
            </td><td>
              -12.66m
            </td><td>
              23.38
            </td><td>
              241.94m
            </td><td>
              1.36b
            </td><td>
              0.7
            </td><td>
              127,865,904
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RCKT" class="margin-bottom-1">
                RCKT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.32</div> <small class="number change-up">+2.12<span>&nbsp;&nbsp;</span>+7.54%</small></td><td><strong>RP-L102</strong> <br>Fanconi Anemia (FA)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005748/en/">
                4Q 2021
              </a> <div class="note">Phase 1/2 further data due 4Q 2021.</div></td><td>
              64m
            </td><td>
              1.9b
            </td><td>
              428.3k
            </td><td>
              459.8k
            </td><td>
              3.94
            </td><td>
              $28.55
            </td><td>
              $28.2
            </td><td>
              January 2023
            </td><td>
              403.71m
            </td><td>
              -12.84m
            </td><td>
              31.44
            </td><td>
              358.00m
            </td><td>
              1.39b
            </td><td>
              1.6
            </td><td>
              43,407,962
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ANAB" class="margin-bottom-1">
                ANAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$25.65</div> <small class="number change-up">+1.42<span>&nbsp;&nbsp;</span>+5.86%</small></td><td><strong>Rosnilimab (ANB030)</strong> <br>Healthy volunteers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/09/2277409/0/en/AnaptysBio-Announces-Second-Quarter-2021-Financial-Results-and-Provides-Pipeline-Updates.html">
                4Q 2021
              </a> <div class="note">Phase 1 top-line data due 4Q 2021.</div></td><td>
              27m
            </td><td>
              0.7b
            </td><td>
              43.4k
            </td><td>
              221.0k
            </td><td>
              1.82
            </td><td>
              $24.54
            </td><td>
              $24.23
            </td><td>
              N/A
            </td><td>
              416.61m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              375.77m
            </td><td>
              294.64m
            </td><td>
              2
            </td><td>
              19,169,175
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CUE" class="margin-bottom-1">
                CUE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$10.72</div> <small class="number change-up">+0.20<span>&nbsp;&nbsp;</span>+1.90%</small></td><td><strong>CUE-101 and KEYTRUDA (pembrolizumab) - KEYNOTE-A78</strong> <br>HPV16+ head and neck cancer
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://cuebiopharma.gcs-web.com/node/8141/pdf">
                2H 2021
              </a> <div class="note">Phase 1 initiation of dosing announced February 8, 2021. Initial data due 2H 2021.</div></td><td>
              32m
            </td><td>
              337.8m
            </td><td>
              120.6k
            </td><td>
              188.5k
            </td><td>
              4.64
            </td><td>
              $10.75
            </td><td>
              $10.52
            </td><td>
              July 2022
            </td><td>
              68.06m
            </td><td>
              -3.26m
            </td><td>
              20.90
            </td><td>
              51.30m
            </td><td>
              262.42m
            </td><td>
              4.4
            </td><td>
              30,511,816
            </td><td>
              05/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BCAB" class="margin-bottom-1">
                BCAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$42.01</div> <small class="number change-up">+1.02<span>&nbsp;&nbsp;</span>+2.49%</small></td><td><strong>BA3011 (Mecbotamab Vedotin)</strong> <br>Solid Tumors
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/bioatla-announces-second-quarter-2021-financial-results-and-provides-clinical-update-301355321.html">
                2H 2021
              </a> <div class="note">Phase 2 interim data due 2021. Registration data due 2022.</div></td><td>
              34m
            </td><td>
              1.4b
            </td><td>
              106.0k
            </td><td>
              259.7k
            </td><td>
              7.97
            </td><td>
              $41.57
            </td><td>
              $40.99
            </td><td>
              January 2022
            </td><td>
              199.48m
            </td><td>
              -4.51m
            </td><td>
              44.18
            </td><td>
              160.80m
            </td><td>
              1.18b
            </td><td>
              6.9
            </td><td>
              25,204,556
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BCAB" class="margin-bottom-1">
                BCAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$42.01</div> <small class="number change-up">+1.02<span>&nbsp;&nbsp;</span>+2.49%</small></td><td><strong>BA3021 (Ozuriftamab Vedotin)</strong> <br>Solid Tumors
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1826892/000119312520293235/d258427ds1.htm">
                2021
              </a> <div class="note">Phase 2 trial is enrolling.</div></td><td>
              34m
            </td><td>
              1.4b
            </td><td>
              106.0k
            </td><td>
              259.7k
            </td><td>
              7.97
            </td><td>
              $41.57
            </td><td>
              $40.99
            </td><td>
              May 13, 2020
            </td><td>
              199.48m
            </td><td>
              -4.51m
            </td><td>
              44.18
            </td><td>
              160.80m
            </td><td>
              1.18b
            </td><td>
              6.9
            </td><td>
              25,204,556
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMUX" class="margin-bottom-1">
                IMUX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.76</div> <small class="number change-up">+0.83<span>&nbsp;&nbsp;</span>+9.36%</small></td><td><strong>IMU-935</strong> <br>Healthy volunteers / psoriasis
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/immunic-inc-reports-second-quarter-2021-financial-results-and-highlights-recent-activity-301350113.html">
                2H 2021
              </a> <div class="note">Phase 1 healthy volunteer data due 2H 2021. Initiation of trial in psoriasis to commence 3Q 2021 with initial data 2Q 2022.</div></td><td>
              26m
            </td><td>
              256.1m
            </td><td>
              122.3k
            </td><td>
              268.5k
            </td><td>
              2.12
            </td><td>
              $9.16
            </td><td>
              $8.92
            </td><td>
              N/A
            </td><td>
              114.77m
            </td><td>
              -9.67m
            </td><td>
              11.87
            </td><td>
              99.46m
            </td><td>
              147.99m
            </td><td>
              2.4
            </td><td>
              23,416,743
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BCAB" class="margin-bottom-1">
                BCAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$42.01</div> <small class="number change-up">+1.02<span>&nbsp;&nbsp;</span>+2.49%</small></td><td><strong>BA3071</strong> <br>Oncology (various)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/bioatla-announces-second-quarter-2021-financial-results-and-provides-clinical-update-301355321.html">
                2021
              </a> <div class="note">Phase 1/2 trial to be initiated in 2021.</div></td><td>
              34m
            </td><td>
              1.4b
            </td><td>
              106.0k
            </td><td>
              259.7k
            </td><td>
              7.97
            </td><td>
              $41.57
            </td><td>
              $40.99
            </td><td>
              N/A
            </td><td>
              199.48m
            </td><td>
              -4.51m
            </td><td>
              44.18
            </td><td>
              160.80m
            </td><td>
              1.18b
            </td><td>
              6.9
            </td><td>
              25,204,556
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DRNA" class="margin-bottom-1">
                DRNA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$20.96</div> <small class="number change-up">+0.32<span>&nbsp;&nbsp;</span>+1.55%</small></td><td><strong>Belcesiran</strong> <br>Alpha 1-Antitrypsin deficiency-associated liver disease
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005221/en/">
                2H 2021
              </a> <div class="note">Phase 1 initial data announced July 21, 2021. Data to be be presented 2H 2021 at medical congress. Phase 2 ESTRELLA trial commencement of dosing announced June 22, 2021.</div></td><td>
              78m
            </td><td>
              1.6b
            </td><td>
              483.1k
            </td><td>
              1.0m
            </td><td>
              14.66
            </td><td>
              $20.79
            </td><td>
              $20.64
            </td><td>
              N/A
            </td><td>
              0.69b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -39.15m
            </td><td>
              1.08b
            </td><td>
              0.4
            </td><td>
              74,503,276
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PYPD" class="margin-bottom-1">
                PYPD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.18</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+1.81%</small></td><td><strong>D-PLEX100 - SHIELD I</strong> <br>Abdominal (soft tissue) sternal surgical site infections
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.polypid.com/static-files/96d836f8-fd30-466c-928c-46a1dd69cfc5">
                2H 2021
              </a> <div class="note">Phase 3 data due end of 2021.</div></td><td>
              19m
            </td><td>
              153.3m
            </td><td>
              3.6k
            </td><td>
              29.0k
            </td><td>
              2.70
            </td><td>
              $8
            </td><td>
              $8.03
            </td><td>
              September 2021
            </td><td>
              47.85m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              43.34m
            </td><td>
              102.77m
            </td><td>
              0
            </td><td>
              15,682,034
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ONCR" class="margin-bottom-1">
                ONCR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$10.50</div> <small class="number change-up">+0.57<span>&nbsp;&nbsp;</span>+5.74%</small></td><td><strong>ONCR-177</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.oncorus.com/news-releases/news-release-details/oncorus-reports-second-quarter-2021-financial-results-and">
                4Q 2021
              </a> <div class="note">Phase 1 interim data due 4Q 2021.</div></td><td>
              26m
            </td><td>
              270.4m
            </td><td>
              51.7k
            </td><td>
              129.5k
            </td><td>
              1.66
            </td><td>
              $9.97
            </td><td>
              $9.93
            </td><td>
              January 2025
            </td><td>
              153.22m
            </td><td>
              -3.72m
            </td><td>
              41.19
            </td><td>
              100.25m
            </td><td>
              139.09m
            </td><td>
              1.5
            </td><td>
              17,432,653
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AQST" class="margin-bottom-1">
                AQST
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.88</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+6.30%</small></td><td><strong>AQST-109</strong> <br>Allergic reactions (anaphylaxis)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://aquestive.com/aquestive-therapeutics-reports-second-quarter-2021-financial-results-provides-business-update-and-raises-full-year-revenue-guidance/">
                2H 2021
              </a> <div class="note">Phase 1 data due 2H 2021.</div></td><td>
              39m
            </td><td>
              150.9m
            </td><td>
              199.6k
            </td><td>
              0.6m
            </td><td>
              -2.81
            </td><td>
              $3.74
            </td><td>
              $3.65
            </td><td>
              N/A
            </td><td>
              33.18m
            </td><td>
              -0.59m
            </td><td>
              56.69
            </td><td>
              -87.46m
            </td><td>
              150.16m
            </td><td>
              5.6
            </td><td>
              25,371,802
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ABUS" class="margin-bottom-1">
                ABUS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.15</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+7.88%</small></td><td><strong>AB-729</strong> <br>Hepatitis B (HBV)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-reports-second-quarter-2021-financial-results-and">
                2H 2021
              </a> <div class="note">Phase 1a/b data at EASL meeting June 26, 2021 - HBsAg declines below 100 IU/ml in 75% of treated subjects. Favorable safety and tolerability profile. Further data due 2H 2021.</div></td><td>
              99m
            </td><td>
              312.4m
            </td><td>
              0.8m
            </td><td>
              1.8m
            </td><td>
              -5.62
            </td><td>
              $3.01
            </td><td>
              $2.92
            </td><td>
              N/A
            </td><td>
              69.97m
            </td><td>
              -4.67m
            </td><td>
              14.98
            </td><td>
              35.43m
            </td><td>
              369.89m
            </td><td>
              6
            </td><td>
              80,168,672
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MRTX" class="margin-bottom-1">
                MRTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$145.25</div> <small class="number change-up">+11.12<span>&nbsp;&nbsp;</span>+8.29%</small></td><td><strong>Adagrasib (MRTX-849) and KEYTRUDA (pembrolizumab) - KRYSTAL-01</strong> <br>Solid Tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/mirati-therapeutics-reports-first-quarter-2021-financial-results-and-recent-corporate-updates-301286100.html">
                2H 2021
              </a> <div class="note">Phase 1/2 monotherapy NSCLC and Phase 1 CRC data due 2H 2021. Combo data with KEYTRUDA (pembrolizumab) in NSCLC, and with ERBITUX (cetuximab) in CRC also due 2H 2021.</div></td><td>
              52m
            </td><td>
              7.5b
            </td><td>
              181.2k
            </td><td>
              466.1k
            </td><td>
              6.64
            </td><td>
              $135.44
            </td><td>
              $134.13
            </td><td>
              March 2022
            </td><td>
              1.14b
            </td><td>
              -31.12m
            </td><td>
              36.65
            </td><td>
              0.91b
            </td><td>
              5.77b
            </td><td>
              0.9
            </td><td>
              40,808,627
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ZLAB" class="margin-bottom-1">
                ZLAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$143.17</div> <small class="number change-up">+9.00<span>&nbsp;&nbsp;</span>+6.71%</small></td><td><strong>Adagrasib (MRTX-849) and KEYTRUDA (pembrolizumab) - KRYSTAL-01</strong> <br>Solid Tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/mirati-therapeutics-reports-first-quarter-2021-financial-results-and-recent-corporate-updates-301286100.html">
                2H 2021
              </a> <div class="note">Phase 1/2 monotherapy NSCLC and Phase 1 CRC data due 2H 2021. Combo data with KEYTRUDA (pembrolizumab) in NSCLC, and with ERBITUX (cetuximab) in CRC also due 2H 2021.</div></td><td>
              75m
            </td><td>
              10.8b
            </td><td>
              320.4k
            </td><td>
              0.6m
            </td><td>
              33.30
            </td><td>
              $135
            </td><td>
              $134.17
            </td><td>
              March 2022
            </td><td>
              1.73b
            </td><td>
              -21.95m
            </td><td>
              78.68
            </td><td>
              1.50b
            </td><td>
              1.78b
            </td><td>
              0
            </td><td>
              75,375,511
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RCKT" class="margin-bottom-1">
                RCKT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.32</div> <small class="number change-up">+2.12<span>&nbsp;&nbsp;</span>+7.54%</small></td><td><strong>RP-L401</strong> <br>Infantile Malignant Osteopetrosis (IMO)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005748/en/">
                4Q 2021
              </a> <div class="note">Phase 1 update due 4Q 2021.</div></td><td>
              64m
            </td><td>
              1.9b
            </td><td>
              428.3k
            </td><td>
              459.8k
            </td><td>
              3.94
            </td><td>
              $28.55
            </td><td>
              $28.2
            </td><td>
              January 2023
            </td><td>
              403.71m
            </td><td>
              -12.84m
            </td><td>
              31.44
            </td><td>
              358.00m
            </td><td>
              1.39b
            </td><td>
              1.6
            </td><td>
              43,407,962
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GSK" class="margin-bottom-1">
                GSK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$41.57</div> <small class="number change-down">-0.28<span>&nbsp;&nbsp;</span>-0.67%</small></td><td><strong>Sotrovimab (VIR-7831 / GSK4182136) - (ACTIV-3)</strong> <br>Mild to moderate COVID-19
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-reports-continued-progress-ensovibep-global">
                2H 2021
              </a> <div class="note">Independent Data and Safety Monitoring Board (DSMB) recommended that enrollment to be closed - raised concerns about the magnitude of potential benefit. Further data due 2H 2021. Top-line data due 2022.</div></td><td>
              3b
            </td><td>
              104.6b
            </td><td>
              2.3m
            </td><td>
              4.2m
            </td><td>
              4.95
            </td><td>
              $41.75
            </td><td>
              $41.85
            </td><td>
              July 2022
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -51.10b
            </td><td>
              133.80b
            </td><td>
              0.2
            </td><td>
              2,506,785,977
            </td><td>
              07/08/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VIR" class="margin-bottom-1">
                VIR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$47.20</div> <small class="number change-up">+0.73<span>&nbsp;&nbsp;</span>+1.57%</small></td><td><strong>Sotrovimab (VIR-7831 / GSK4182136) - (ACTIV-3)</strong> <br>Mild to moderate COVID-19
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-reports-continued-progress-ensovibep-global">
                2H 2021
              </a> <div class="note">Independent Data and Safety Monitoring Board (DSMB) recommended that enrollment to be closed - raised concerns about the magnitude of potential benefit. Further data due 2H 2021. Top-line data due 2022.</div></td><td>
              131m
            </td><td>
              6.2b
            </td><td>
              1.0m
            </td><td>
              0.9m
            </td><td>
              8.35
            </td><td>
              $47.62
            </td><td>
              $46.47
            </td><td>
              July 2022
            </td><td>
              0.91b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              0.59b
            </td><td>
              5.32b
            </td><td>
              5.6
            </td><td>
              69,593,992
            </td><td>
              07/08/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MOLN" class="margin-bottom-1">
                MOLN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$20.00</div> <small class="number change-up">+0.25<span>&nbsp;&nbsp;</span>+1.27%</small></td><td><strong>Sotrovimab (VIR-7831 / GSK4182136) - (ACTIV-3)</strong> <br>Mild to moderate COVID-19
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-reports-continued-progress-ensovibep-global">
                2H 2021
              </a> <div class="note">Independent Data and Safety Monitoring Board (DSMB) recommended that enrollment to be closed - raised concerns about the magnitude of potential benefit. Further data due 2H 2021. Top-line data due 2022.</div></td><td>
              29m
            </td><td>
              0.6b
            </td><td>
              9.6k
            </td><td>
              106.3k
            </td><td>
              4.99
            </td><td>
              $19.97
            </td><td>
              $19.75
            </td><td>
              July 2022
            </td><td>
              173.72m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              93.40m
            </td><td>
              392.24m
            </td><td>
              0
            </td><td>
              29,146,162
            </td><td>
              07/08/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PBYI" class="margin-bottom-1">
                PBYI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.38</div> <small class="number change-up">+0.38<span>&nbsp;&nbsp;</span>+5.43%</small></td><td><strong>NERLYNX (Neratinib) - SUMMIT</strong> <br>Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005287/en/">
                4Q 2021
              </a> <div class="note">Phase 2 top line data from the randomized cohort due 4Q 2021.</div></td><td>
              41m
            </td><td>
              300.9m
            </td><td>
              149.8k
            </td><td>
              465.6k
            </td><td>
              10.25
            </td><td>
              $7.06
            </td><td>
              $7
            </td><td>
              March 30, 2022
            </td><td>
              208.93m
            </td><td>
              -24.67k
            </td><td>
              8.47k
            </td><td>
              -21.60m
            </td><td>
              297.77m
            </td><td>
              13.1
            </td><td>
              34,191,064
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RETA" class="margin-bottom-1">
                RETA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$106.04</div> <small class="number change-up">+4.68<span>&nbsp;&nbsp;</span>+4.62%</small></td><td><strong>Bardoxolone (MERLIN)</strong> <br>CKD Patients at Risk of Rapid Progression
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005740/en/">
                4Q 2021
              </a> <div class="note">Phase 2 data due 4Q 2021.</div></td><td>
              36m
            </td><td>
              3.9b
            </td><td>
              141.2k
            </td><td>
              394.2k
            </td><td>
              12.30
            </td><td>
              $102.46
            </td><td>
              $101.36
            </td><td>
              November 2021
            </td><td>
              0.74b
            </td><td>
              -8.53m
            </td><td>
              86.76
            </td><td>
              276.56m
            </td><td>
              3.22b
            </td><td>
              0.5
            </td><td>
              20,077,004
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MOR" class="margin-bottom-1">
                MOR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.96</div> <small class="number change-up">+0.51<span>&nbsp;&nbsp;</span>+3.79%</small></td><td><strong>Felzartamab (MOR202) - (M-PLACE)</strong> <br>Membranous nephropathy
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.morphosys.com/media-investors/media-center/morphosys-ag-reports-second-quarter-and-first-half-2021-results">
                4Q 2021
              </a> <div class="note">Phase 1/2 data due 4Q 2021.</div></td><td>
              137m
            </td><td>
              1.9b
            </td><td>
              18.7k
            </td><td>
              125.1k
            </td><td>
              2.70
            </td><td>
              $13.75
            </td><td>
              $13.45
            </td><td>
              October 2021
            </td><td>
              1.04b
            </td><td>
              -29.79m
            </td><td>
              34.97
            </td><td>
              65.72m
            </td><td>
              0.93b
            </td><td>
              0
            </td><td>
              136,502,236
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KRON" class="margin-bottom-1">
                KRON
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$20.43</div> <small class="number change-up">+0.70<span>&nbsp;&nbsp;</span>+3.55%</small></td><td><strong>KB-0742</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.kronosbio.com/news-releases/news-release-details/kronos-bio-reports-recent-business-progress-and-first-quarter">
                4Q 2021
              </a> <div class="note">Phase 1/2 initial safety and PK data due in 4Q 2021. Expansion cohort data due in 2022.</div></td><td>
              56m
            </td><td>
              1.1b
            </td><td>
              133.4k
            </td><td>
              284.3k
            </td><td>
              2.71
            </td><td>
              $19.84
            </td><td>
              $19.73
            </td><td>
              November 2023
            </td><td>
              404.72m
            </td><td>
              -6.75m
            </td><td>
              59.92
            </td><td>
              357.08m
            </td><td>
              0.73b
            </td><td>
              3
            </td><td>
              40,155,148
            </td><td>
              05/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FLXN" class="margin-bottom-1">
                FLXN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.27</div> <small class="number change-up">+0.59<span>&nbsp;&nbsp;</span>+12.61%</small></td><td><strong>FX301</strong> <br>Post-Operative Pain
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.flexiontherapeutics.com/news-releases/news-release-details/flexion-therapeutics-reports-second-quarter-2021-financial">
                Late-2021
              </a> <div class="note">Phase 1b initiation of dosing announced March 31, 2021. Initial data due later in 2021.</div></td><td>
              50m
            </td><td>
              265.0m
            </td><td>
              0.7m
            </td><td>
              0.8m
            </td><td>
              -4.71
            </td><td>
              $4.83
            </td><td>
              $4.68
            </td><td>
              N/A
            </td><td>
              119.99m
            </td><td>
              -6.25m
            </td><td>
              19.19
            </td><td>
              -146.23m
            </td><td>
              333.02m
            </td><td>
              2.9
            </td><td>
              48,063,471
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/XENE" class="margin-bottom-1">
                XENE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.39</div> <small class="number change-down">-0.05<span>&nbsp;&nbsp;</span>-0.30%</small></td><td><strong>FX301</strong> <br>Post-Operative Pain
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.flexiontherapeutics.com/news-releases/news-release-details/flexion-therapeutics-reports-second-quarter-2021-financial">
                Late-2021
              </a> <div class="note">Phase 1b initiation of dosing announced March 31, 2021. Initial data due later in 2021.</div></td><td>
              41m
            </td><td>
              0.7b
            </td><td>
              175.3k
            </td><td>
              201.1k
            </td><td>
              2.70
            </td><td>
              $16.73
            </td><td>
              $16.44
            </td><td>
              N/A
            </td><td>
              252.68m
            </td><td>
              -4.36m
            </td><td>
              57.97
            </td><td>
              234.95m
            </td><td>
              426.80m
            </td><td>
              1.9
            </td><td>
              40,156,539
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SCPH" class="margin-bottom-1">
                SCPH
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.13</div> <small class="number change-up">+0.20<span>&nbsp;&nbsp;</span>+4.06%</small></td><td><strong>FUROSCIX (furosemide)</strong> <br>Heart failure
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://scpharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/scpharmaceuticals-inc-reports-second-quarter-2021-financial">
                4Q 2021
              </a> <div class="note">CRL announced December 7, 2020. NDA filing to be resubmitted 4Q 2021.</div></td><td>
              27m
            </td><td>
              140.3m
            </td><td>
              28.8k
            </td><td>
              162.3k
            </td><td>
              2.04
            </td><td>
              $5
            </td><td>
              $4.93
            </td><td>
              N/A
            </td><td>
              86.26m
            </td><td>
              -2.09m
            </td><td>
              41.27
            </td><td>
              61.69m
            </td><td>
              65.00m
            </td><td>
              0.4
            </td><td>
              15,210,483
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMGN" class="margin-bottom-1">
                IMGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.59</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+5.47%</small></td><td><strong>Mirvetuximab - SORAYA</strong> <br>Ovarian cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210730005064/en/">
                4Q 2021
              </a> <div class="note">Phase 3 trial data due 4Q 2021.</div></td><td>
              202m
            </td><td>
              1.1b
            </td><td>
              0.7m
            </td><td>
              1.4m
            </td><td>
              16.44
            </td><td>
              $5.38
            </td><td>
              $5.3
            </td><td>
              November 2021
            </td><td>
              213.21m
            </td><td>
              -14.63m
            </td><td>
              14.58
            </td><td>
              -19.77m
            </td><td>
              0.85b
            </td><td>
              1.1
            </td><td>
              179,510,656
            </td><td>
              07/30/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SAGE" class="margin-bottom-1">
                SAGE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$42.82</div> <small class="number change-up">+0.84<span>&nbsp;&nbsp;</span>+2.00%</small></td><td><strong>SAGE-217 - SHORELINE</strong> <br>Major Depressive Disorder (MDD)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210803005320/en/">
                Late-2021
              </a> <div class="note">Phase 3 further 50mg cohort data due late-2021.</div></td><td>
              59m
            </td><td>
              2.5b
            </td><td>
              153.7k
            </td><td>
              1.1m
            </td><td>
              1.30
            </td><td>
              $42.57
            </td><td>
              $41.98
            </td><td>
              February 2022
            </td><td>
              1.85b
            </td><td>
              -34.26m
            </td><td>
              53.99
            </td><td>
              1.76b
            </td><td>
              0.58b
            </td><td>
              1.7
            </td><td>
              43,822,518
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VYNE" class="margin-bottom-1">
                VYNE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.45</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+1.05%</small></td><td><strong>FMX114</strong> <br>Atopic Dermatitis
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2279673/0/en/VYNE-Therapeutics-Reports-Second-Quarter-2021-Financial-Results-and-Announces-New-Strategic-Direction-to-Develop-Treatments-for-Immunological-and-Inflammatory-Diseases.html">
                YE 2021
              </a> <div class="note">Phase 2a trial to be initiated 3Q 2021 with data due by end of 2021.</div></td><td>
              52m
            </td><td>
              74.4m
            </td><td>
              0.6m
            </td><td>
              0.9m
            </td><td>
              1.00
            </td><td>
              $1.46
            </td><td>
              $1.43
            </td><td>
              N/A
            </td><td>
              93.65m
            </td><td>
              -5.42m
            </td><td>
              17.28
            </td><td>
              34.56m
            </td><td>
              4.88m
            </td><td>
              4.1
            </td><td>
              45,361,075
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PCSA" class="margin-bottom-1">
                PCSA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.81</div> <small class="number change-up">+0.38<span>&nbsp;&nbsp;</span>+7.00%</small></td><td><strong>PCS6422</strong> <br>Gastrointestinal Cancer
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://finance.yahoo.com/news/processa-pharmaceuticals-announces-second-quarter-211500186.html">
                YE 2021
              </a> <div class="note">Phase 1b initiation of dosing announced August 4, 2021. Interim data due by end of 2021.</div></td><td>
              16m
            </td><td>
              90.7m
            </td><td>
              14.2k
            </td><td>
              103.7k
            </td><td>
              3.11
            </td><td>
              $5.52
            </td><td>
              $5.43
            </td><td>
              September 20, 2022
            </td><td>
              19.51m
            </td><td>
              -0.73m
            </td><td>
              26.68
            </td><td>
              17.62m
            </td><td>
              64.03m
            </td><td>
              13.5
            </td><td>
              11,767,617
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TNXP" class="margin-bottom-1">
                TNXP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.69</div> <small class="number change-up">+0.03<span>&nbsp;&nbsp;</span>+3.84%</small></td><td><strong>Tonmya (TNX-102 SL)</strong> <br>Fibromyalgia
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.tonixpharma.com/press-releases/detail/1271/tonix-pharmaceuticals-announces-outcome-of-interim-analysis">
                4Q 2021
              </a> <div class="note">Phase 3 top-line met primary endpoint - December 7, 2020. Enrollment in second Phase 3 trial stopped due to futility - July 23, 2021. Top-line data due 4Q 2021.</div></td><td>
              358m
            </td><td>
              245.8m
            </td><td>
              8.2m
            </td><td>
              11.0m
            </td><td>
              1.38
            </td><td>
              $0.67
            </td><td>
              $0.66
            </td><td>
              October 29, 2020
            </td><td>
              154.25m
            </td><td>
              -6.37m
            </td><td>
              24.22
            </td><td>
              145.58m
            </td><td>
              72.02m
            </td><td>
              1
            </td><td>
              357,290,669
            </td><td>
              07/23/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/XNCR" class="margin-bottom-1">
                XNCR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$32.74</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+3.15%</small></td><td><strong>Plamotamab (XmAb13676)</strong> <br>Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210804006054/en/">
                4Q 2021
              </a> <div class="note">Phase 1 data due later in 2021.</div></td><td>
              58m
            </td><td>
              1.9b
            </td><td>
              65.1k
            </td><td>
              228.3k
            </td><td>
              2.95
            </td><td>
              $32.05
            </td><td>
              $31.74
            </td><td>
              August 2021
            </td><td>
              444.26m
            </td><td>
              -3.22m
            </td><td>
              138.05
            </td><td>
              395.59m
            </td><td>
              1.41b
            </td><td>
              13.3
            </td><td>
              34,189,444
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RCKT" class="margin-bottom-1">
                RCKT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.32</div> <small class="number change-up">+2.12<span>&nbsp;&nbsp;</span>+7.54%</small></td><td><strong>RP-L301</strong> <br>Pyruvate Kinase Deficiency (PKD)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005748/en/">
                4Q 2021
              </a> <div class="note">Longer-term Phase 1 data due 4Q 2021.</div></td><td>
              64m
            </td><td>
              1.9b
            </td><td>
              428.3k
            </td><td>
              459.8k
            </td><td>
              3.94
            </td><td>
              $28.55
            </td><td>
              $28.2
            </td><td>
              March 2023
            </td><td>
              403.71m
            </td><td>
              -12.84m
            </td><td>
              31.44
            </td><td>
              358.00m
            </td><td>
              1.39b
            </td><td>
              1.6
            </td><td>
              43,407,962
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PPBT" class="margin-bottom-1">
                PPBT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.74</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+2.82%</small></td><td><strong>CM-24 and OPDIVO (nivolumab)</strong> <br>Non-small cell lung and pancreatic cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s3.amazonaws.com/b2icontent.irpass.cc/2492/rl101491.pdf">
                2H 2021
              </a> <div class="note">Phase 1/2 top-line data to be presented at upcoming conference. No date supplied. Estimate 2H 2021.</div></td><td>
              18m
            </td><td>
              83.5m
            </td><td>
              93.9k
            </td><td>
              265.9k
            </td><td>
              1.16
            </td><td>
              $4.61
            </td><td>
              $4.61
            </td><td>
              February 2024
            </td><td>
              48.39m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              44.02m
            </td><td>
              32.74m
            </td><td>
              0
            </td><td>
              17,615,824
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ITCI" class="margin-bottom-1">
                ITCI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.66</div> <small class="number change-up">+1.32<span>&nbsp;&nbsp;</span>+4.51%</small></td><td><strong>Lumateperone Long Acting Injectable (LLAI) - (ITI-007-025)</strong> <br>Schizophrenia
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-reports-second-quarter-2021-financial">
                2H 2021
              </a> <div class="note">Phase 1 initial data due 2H 2021.</div></td><td>
              81m
            </td><td>
              2.5b
            </td><td>
              196.9k
            </td><td>
              0.5m
            </td><td>
              4.50
            </td><td>
              $29.7
            </td><td>
              $29.34
            </td><td>
              November 2021
            </td><td>
              0.52b
            </td><td>
              -19.78m
            </td><td>
              26.25
            </td><td>
              447.05m
            </td><td>
              1.86b
            </td><td>
              2.7
            </td><td>
              60,840,721
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ETNB" class="margin-bottom-1">
                ETNB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$18.47</div> <small class="number change-up">+1.46<span>&nbsp;&nbsp;</span>+8.58%</small></td><td><strong>BIO89-100 - ENLIVEN</strong> <br>Nonalcoholic steatohepatitis (NASH)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/02/2272848/0/en/89bio-Completed-Target-Enrollment-in-Histology-Cohort-to-Evaluate-BIO89-100-for-the-Treatment-of-NASH.html">
                YE 2021
              </a> <div class="note">Phase 2 trial initiation announced June 10, 2021. Phase 1b/2a topline data from the paired-biopsy, open-label histology cohort due by end of 2021.</div></td><td>
              20m
            </td><td>
              371.0m
            </td><td>
              49.1k
            </td><td>
              102.6k
            </td><td>
              2.15
            </td><td>
              $17.25
            </td><td>
              $17.01
            </td><td>
              January 2023
            </td><td>
              158.90m
            </td><td>
              -6.70m
            </td><td>
              23.71
            </td><td>
              149.89m
            </td><td>
              172.16m
            </td><td>
              0.7
            </td><td>
              9,711,801
            </td><td>
              08/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ITCI" class="margin-bottom-1">
                ITCI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.66</div> <small class="number change-up">+1.32<span>&nbsp;&nbsp;</span>+4.51%</small></td><td><strong>ITI-333 (ITI-333-001)</strong> <br>Opioid use disorder
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-reports-second-quarter-2021-financial">
                2H 2021
              </a> <div class="note">Phase 1 data due 2H 2021.</div></td><td>
              81m
            </td><td>
              2.5b
            </td><td>
              196.9k
            </td><td>
              0.5m
            </td><td>
              4.50
            </td><td>
              $29.7
            </td><td>
              $29.34
            </td><td>
              N/A
            </td><td>
              0.52b
            </td><td>
              -19.78m
            </td><td>
              26.25
            </td><td>
              447.05m
            </td><td>
              1.86b
            </td><td>
              2.7
            </td><td>
              60,840,721
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MGNX" class="margin-bottom-1">
                MGNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.98</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+4.55%</small></td><td><strong>Flotetuzumab</strong> <br>AML
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-5">
                Late-2021
              </a> <div class="note">Phase 1/2 update due late-2021. Enrollment to be completed in 2022.</div></td><td>
              61m
            </td><td>
              1.4b
            </td><td>
              297.3k
            </td><td>
              0.6m
            </td><td>
              4.40
            </td><td>
              $22.34
            </td><td>
              $21.98
            </td><td>
              January 2022
            </td><td>
              269.90m
            </td><td>
              -15.23m
            </td><td>
              17.72
            </td><td>
              163.04m
            </td><td>
              1.07b
            </td><td>
              2.4
            </td><td>
              59,522,546
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CTMX" class="margin-bottom-1">
                CTMX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.74</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+1.61%</small></td><td><strong>PROCLAIM-CX-2029</strong> <br>Solid tumors / diffuse large B-cell lymphoma (DLBCL)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-announces-first-quarter-2021-financial">
                4Q 2021
              </a> <div class="note">Phase 2 initial data due 4Q 2021.</div></td><td>
              65m
            </td><td>
              308.5m
            </td><td>
              384.8k
            </td><td>
              0.7m
            </td><td>
              2.36
            </td><td>
              $4.75
            </td><td>
              $4.66
            </td><td>
              December 2022
            </td><td>
              249.26m
            </td><td>
              -9.40m
            </td><td>
              26.52
            </td><td>
              -22.23m
            </td><td>
              60.78m
            </td><td>
              0.7
            </td><td>
              64,408,878
            </td><td>
              05/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FSTX" class="margin-bottom-1">
                FSTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.35</div> <small class="number change-up">+0.41<span>&nbsp;&nbsp;</span>+6.90%</small></td><td><strong>FS222</strong> <br>Advanced malignancies
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.f-star.com/news-releases/news-release-details/f-star-therapeutics-reports-first-quarter-2021-financial-results">
                4Q 2021
              </a> <div class="note">Phase 1 update on accelerated dose titration and initiation of PK/PD expansion cohorts due 4Q 2021.</div></td><td>
              21m
            </td><td>
              130.9m
            </td><td>
              90.9k
            </td><td>
              158.7k
            </td><td>
              1.32
            </td><td>
              $6.08
            </td><td>
              $5.94
            </td><td>
              N/A
            </td><td>
              88.28m
            </td><td>
              -2.98m
            </td><td>
              29.57
            </td><td>
              62.29m
            </td><td>
              54.41m
            </td><td>
              3.2
            </td><td>
              20,549,167
            </td><td>
              05/17/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TALS" class="margin-bottom-1">
                TALS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.32</div> <small class="number change-down">-0.05<span>&nbsp;&nbsp;</span>-0.37%</small></td><td><strong>FCR001 (FREEDOM-1)</strong> <br>Transplanted Organ Rejection
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2279632/0/en/Talaris-Therapeutics-Announces-Second-Quarter-2021-Financial-Results-and-Provides-Business-Update.html">
                4Q 2021
              </a> <div class="note">Phase 3 initial data 4Q 2021.</div></td><td>
              41m
            </td><td>
              0.6b
            </td><td>
              11.3k
            </td><td>
              101.7k
            </td><td>
              2.06
            </td><td>
              $12.8
            </td><td>
              $13.37
            </td><td>
              April 2023
            </td><td>
              259.63m
            </td><td>
              -3.66m
            </td><td>
              70.92
            </td><td>
              254.17m
            </td><td>
              301.95m
            </td><td>
              14.3
            </td><td>
              25,195,411
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AVXL" class="margin-bottom-1">
                AVXL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$19.41</div> <small class="number change-up">+1.05<span>&nbsp;&nbsp;</span>+5.72%</small></td><td><strong>ANAVEX 2-73 - AVATAR</strong> <br>Rett syndrome
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.anavex.com/wp-content/uploads/2021/08/Anavex-Presentation-August-2021.pdf">
                2H 2021
              </a> <div class="note">Phase 2 data due 2H 2021.</div></td><td>
              76m
            </td><td>
              1.5b
            </td><td>
              0.5m
            </td><td>
              3.2m
            </td><td>
              9.33
            </td><td>
              $18.68
            </td><td>
              $18.36
            </td><td>
              September 2021
            </td><td>
              153.05m
            </td><td>
              -2.51m
            </td><td>
              61.05
            </td><td>
              143.77m
            </td><td>
              1.23b
            </td><td>
              14.5
            </td><td>
              73,309,486
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PRAX" class="margin-bottom-1">
                PRAX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$19.40</div> <small class="number change-up">+0.64<span>&nbsp;&nbsp;</span>+3.41%</small></td><td><strong>PRAX-562</strong> <br>Healthy volunteers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-1">
                YE 2021
              </a> <div class="note">Phase 1 data due by the end of 2021. </div></td><td>
              45m
            </td><td>
              0.9b
            </td><td>
              0.6m
            </td><td>
              294.3k
            </td><td>
              2.60
            </td><td>
              $18.55
            </td><td>
              $18.76
            </td><td>
              N/A
            </td><td>
              321.18m
            </td><td>
              -10.00m
            </td><td>
              32.10
            </td><td>
              301.44m
            </td><td>
              0.50b
            </td><td>
              1.8
            </td><td>
              29,027,417
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RCKT" class="margin-bottom-1">
                RCKT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.32</div> <small class="number change-up">+2.12<span>&nbsp;&nbsp;</span>+7.54%</small></td><td><strong>RP-L201</strong> <br>Leukocyte Adhesion Deficiency-I (LAD-I)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005748/en/">
                4Q 2021
              </a> <div class="note">Phase 2 interim data released April 14, 2021 - well tolerated, no safety issues reported. Further data due 4Q 2021.</div></td><td>
              64m
            </td><td>
              1.9b
            </td><td>
              428.3k
            </td><td>
              459.8k
            </td><td>
              3.94
            </td><td>
              $28.55
            </td><td>
              $28.2
            </td><td>
              November 2022
            </td><td>
              403.71m
            </td><td>
              -12.84m
            </td><td>
              31.44
            </td><td>
              358.00m
            </td><td>
              1.39b
            </td><td>
              1.6
            </td><td>
              43,407,962
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BNTX" class="margin-bottom-1">
                BNTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$381.13</div> <small class="number change-up">+32.45<span>&nbsp;&nbsp;</span>+9.31%</small></td><td><strong>BNT411</strong> <br>Solid tumors 
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.biontech.de/news-releases/news-release-details/biontech-announces-second-quarter-2021-financial-results-and">
                2H 2021
              </a> <div class="note">Phase 1/2a data due 2H 2021.</div></td><td>
              243m
            </td><td>
              92.4b
            </td><td>
              5.5m
            </td><td>
              4.2m
            </td><td>
              14.40
            </td><td>
              $374
            </td><td>
              $348.68
            </td><td>
              July 2022
            </td><td>
              0.85b
            </td><td>
              -33.43m
            </td><td>
              25.56
            </td><td>
              -2.81b
            </td><td>
              83.79b
            </td><td>
              0
            </td><td>
              242,516,955
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CDAK" class="margin-bottom-1">
                CDAK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.84</div> <small class="number change-down">-0.47<span>&nbsp;&nbsp;</span>-2.54%</small></td><td><strong>exoSTING</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/05/2275966/0/en/Codiak-BioSciences-Reports-Second-Quarter-2021-Financial-Results-and-Operational-Progress.html">
                4Q 2021
              </a> <div class="note">Phase 1/2 safety, biomarker and preliminary efficacy data due 4Q 2021.</div></td><td>
              22m
            </td><td>
              398.3m
            </td><td>
              57.5k
            </td><td>
              120.0k
            </td><td>
              7.69
            </td><td>
              $18.34
            </td><td>
              $18.3
            </td><td>
              N/A
            </td><td>
              103.07m
            </td><td>
              -5.89m
            </td><td>
              17.49
            </td><td>
              -20.34m
            </td><td>
              357.85m
            </td><td>
              2.4
            </td><td>
              13,038,485
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IDYA" class="margin-bottom-1">
                IDYA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$24.28</div> <small class="number change-up">+0.59<span>&nbsp;&nbsp;</span>+2.49%</small></td><td><strong>Darovasertib (IDE196) and XALKORI (crizotinib)</strong> <br>Metastatic uveal melanoma (MUM)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/ideaya-biosciences-inc-reports-second-quarter-2021-financial-results-and-provides-business-update-301351733.html">
                4Q 2021
              </a> <div class="note">Phase 1 trial initiation announced January 5, 2021. Update due 4Q 2021.</div></td><td>
              38m
            </td><td>
              0.9b
            </td><td>
              226.9k
            </td><td>
              287.5k
            </td><td>
              3.88
            </td><td>
              $24.2
            </td><td>
              $23.69
            </td><td>
              N/A
            </td><td>
              352.52m
            </td><td>
              -4.31m
            </td><td>
              81.79
            </td><td>
              264.38m
            </td><td>
              0.64b
            </td><td>
              2.4
            </td><td>
              34,383,161
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SPRO" class="margin-bottom-1">
                SPRO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.35</div> <small class="number change-up">+0.89<span>&nbsp;&nbsp;</span>+5.74%</small></td><td><strong>Tebipenem (SPR994)</strong> <br>Complicated urinary tract infections (cUTI)
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.sperotherapeutics.com/news-releases/news-release-details/spero-therapeutics-announces-second-quarter-2021-operating">
                4Q 2021
              </a> <div class="note">NDA filing due 4Q 2021.</div></td><td>
              32m
            </td><td>
              0.5b
            </td><td>
              314.1k
            </td><td>
              171.9k
            </td><td>
              5.82
            </td><td>
              $15.43
            </td><td>
              $15.46
            </td><td>
              May 20, 2020
            </td><td>
              129.28m
            </td><td>
              -5.52m
            </td><td>
              23.41
            </td><td>
              99.94m
            </td><td>
              405.21m
            </td><td>
              0.3
            </td><td>
              25,606,782
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CRIS" class="margin-bottom-1">
                CRIS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.74</div> <small class="number change-up">+0.52<span>&nbsp;&nbsp;</span>+7.13%</small></td><td><strong>CA-4948</strong> <br>Acute Myeloid Leukemia / Myelodysplastic Syndromes
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://investors.curis.com/2021-08-03-Curis-Reports-Second-Quarter-2021-Financial-Results">
                YE 2021
              </a> <div class="note">Phase 1 presentation at EHA meeting June 11, 2021. 5/17 objective responses. Further data due by end of 2021.</div></td><td>
              92m
            </td><td>
              0.7b
            </td><td>
              1.1m
            </td><td>
              2.9m
            </td><td>
              6.29
            </td><td>
              $7.4
            </td><td>
              $7.22
            </td><td>
              February 1, 2022
            </td><td>
              148.57m
            </td><td>
              -2.22m
            </td><td>
              66.94
            </td><td>
              79.86m
            </td><td>
              0.51b
            </td><td>
              2.5
            </td><td>
              91,355,825
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CDAK" class="margin-bottom-1">
                CDAK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.84</div> <small class="number change-down">-0.47<span>&nbsp;&nbsp;</span>-2.54%</small></td><td><strong>exoIL-12</strong> <br>Cutaneous T cell lymphoma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/05/2275966/0/en/Codiak-BioSciences-Reports-Second-Quarter-2021-Financial-Results-and-Operational-Progress.html">
                YE 2021
              </a> <div class="note">Phase 1 biomarker and preliminary efficacy results in CTCL patients due by year-end 2021.



</div></td><td>
              22m
            </td><td>
              398.3m
            </td><td>
              57.5k
            </td><td>
              120.0k
            </td><td>
              7.69
            </td><td>
              $18.34
            </td><td>
              $18.3
            </td><td>
              N/A
            </td><td>
              103.07m
            </td><td>
              -5.89m
            </td><td>
              17.49
            </td><td>
              -20.34m
            </td><td>
              357.85m
            </td><td>
              2.4
            </td><td>
              13,038,485
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CRMD" class="margin-bottom-1">
                CRMD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.08</div> <small class="number change-up">+0.21<span>&nbsp;&nbsp;</span>+3.66%</small></td><td><strong>DEFENCATH (Neutrolin)</strong> <br>Hemodialysis patients with central venous catheters
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://finance.yahoo.com/news/cormedix-inc-reports-second-quarter-200100245.html">
                4Q 2021
              </a> <div class="note">CRL announced March 1, 2021. NDA to be refiled 4Q 2021.</div></td><td>
              38m
            </td><td>
              231.8m
            </td><td>
              72.5k
            </td><td>
              279.8k
            </td><td>
              3.01
            </td><td>
              $5.9
            </td><td>
              $5.87
            </td><td>
              N/A
            </td><td>
              76.40m
            </td><td>
              -1.03m
            </td><td>
              74.14
            </td><td>
              72.41m
            </td><td>
              146.29m
            </td><td>
              10
            </td><td>
              37,609,897
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AUTL" class="margin-bottom-1">
                AUTL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.17</div> <small class="number change-up">+0.53<span>&nbsp;&nbsp;</span>+9.40%</small></td><td><strong>AUTO1/22 - CARPALL</strong> <br>Pediatric Acute lymphoblastic leukemia (ALL)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-reports-second-quarter-2021-financial">
                4Q 2021
              </a> <div class="note">Phase 1/2 data due 4Q 2021.</div></td><td>
              73m
            </td><td>
              448.8m
            </td><td>
              404.8k
            </td><td>
              1.9m
            </td><td>
              1.58
            </td><td>
              $5.81
            </td><td>
              $5.64
            </td><td>
              N/A
            </td><td>
              194.39m
            </td><td>
              -12.20m
            </td><td>
              15.93
            </td><td>
              147.41m
            </td><td>
              216.60m
            </td><td>
              0
            </td><td>
              72,742,582
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BNTX" class="margin-bottom-1">
                BNTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$381.13</div> <small class="number change-up">+32.45<span>&nbsp;&nbsp;</span>+9.31%</small></td><td><strong>BNT211</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.biontech.de/news-releases/news-release-details/biontech-announces-second-quarter-2021-financial-results-and">
                2H 2021
              </a> <div class="note">Phase 1/2 data due 2H 2021.</div></td><td>
              243m
            </td><td>
              92.4b
            </td><td>
              5.5m
            </td><td>
              4.2m
            </td><td>
              14.40
            </td><td>
              $374
            </td><td>
              $348.68
            </td><td>
              September 2022
            </td><td>
              0.85b
            </td><td>
              -33.43m
            </td><td>
              25.56
            </td><td>
              -2.81b
            </td><td>
              83.79b
            </td><td>
              0
            </td><td>
              242,516,955
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ADGI" class="margin-bottom-1">
                ADGI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.41</div> <small class="number change-up">+1.77<span>&nbsp;&nbsp;</span>+6.40%</small></td><td><strong>ADG20 (STAMP)</strong> <br>COVID-19 (treatment)
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1832038/000119312521217506/d549501ds1.htm">
                4Q 2021
              </a> <div class="note">Phase 2/3 trial has been initiated. Interim futility analysis 4Q 2021. </div></td><td>
              109m
            </td><td>
              3.2b
            </td><td>
              306.9k
            </td><td>
              
            </td><td>
              
            </td><td>
              $27.91
            </td><td>
              $27.64
            </td><td>
              January 2022
            </td><td>
              53.00m
            </td><td>
              -7.91m
            </td><td>
              6.70
            </td><td>
              24.31m
            </td><td>
              2.70b
            </td><td>
              0
            </td><td>
              61,281,030
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ASND" class="margin-bottom-1">
                ASND
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$122.38</div> <small class="number change-up">+1.93<span>&nbsp;&nbsp;</span>+1.60%</small></td><td><strong>TransCon CNP - ACcomplisH</strong> <br>Achondroplasia
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-pharma-reports-first-quarter-2021-financial-results">
                4Q 2021
              </a> <div class="note">Phase 2 update due 4Q 2021.</div></td><td>
              54m
            </td><td>
              6.6b
            </td><td>
              128.8k
            </td><td>
              187.4k
            </td><td>
              7.01
            </td><td>
              $120.71
            </td><td>
              $120.45
            </td><td>
              N/A
            </td><td>
              0.53b
            </td><td>
              -27.21m
            </td><td>
              19.60
            </td><td>
              370.71m
            </td><td>
              5.82b
            </td><td>
              0
            </td><td>
              53,829,379
            </td><td>
              05/27/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MRUS" class="margin-bottom-1">
                MRUS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$24.57</div> <small class="number change-up">+2.35<span>&nbsp;&nbsp;</span>+10.58%</small></td><td><strong>MCLA-145</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.merus.nl/news-releases/news-release-details/merus-announces-financial-results-second-quarter-and-provides-0">
                4Q 2021
              </a> <div class="note">Phase 1 update due 4Q 2021.</div></td><td>
              38m
            </td><td>
              0.9b
            </td><td>
              121.7k
            </td><td>
              274.0k
            </td><td>
              4.32
            </td><td>
              $22.53
            </td><td>
              $22.22
            </td><td>
              December 2022
            </td><td>
              338.17m
            </td><td>
              -8.10m
            </td><td>
              41.76
            </td><td>
              177.68m
            </td><td>
              0.51b
            </td><td>
              0.3
            </td><td>
              32,485,140
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BHVN" class="margin-bottom-1">
                BHVN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$125.97</div> <small class="number change-up">+3.13<span>&nbsp;&nbsp;</span>+2.55%</small></td><td><strong>Intranasal zavegepant</strong> <br>Migraine
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/biohaven-reports-second-quarter-2021-financial-results-and-recent-business-developments-301350770.html">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              65m
            </td><td>
              8.2b
            </td><td>
              170.9k
            </td><td>
              0.7m
            </td><td>
              -18.15
            </td><td>
              $124.56
            </td><td>
              $122.84
            </td><td>
              July 20, 2021
            </td><td>
              229.88m
            </td><td>
              -75.68m
            </td><td>
              3.04
            </td><td>
              -1.07b
            </td><td>
              7.94b
            </td><td>
              8.5
            </td><td>
              58,034,591
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMV" class="margin-bottom-1">
                IMV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.66</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+3.75%</small></td><td><strong>Maveropepimut-S (DPX-Survivac) and KEYTRUDA (pembrolizumab) - basket trial</strong> <br>Solid tumors
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210512005286/en/">
                2H 2021
              </a> <div class="note">Phase 2 trial update 2H 2021.</div></td><td>
              82m
            </td><td>
              136.4m
            </td><td>
              414.9k
            </td><td>
              4.1m
            </td><td>
              6.75
            </td><td>
              $1.57
            </td><td>
              $1.6
            </td><td>
              December 31, 2023
            </td><td>
              47.83m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              34.34m
            </td><td>
              94.51m
            </td><td>
              0
            </td><td>
              82,142,629
            </td><td>
              05/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CBIO" class="margin-bottom-1">
                CBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.07</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+3.56%</small></td><td><strong>Marzeptacog alfa  (MAA 202)</strong> <br>FVII Deficiency
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.catalystbiosciences.com/static-files/4f53026f-3b68-4fd7-82d4-1141183ff4ea">
                2H 2021
              </a> <div class="note">Phase 1/2 trial initiation announced May 18, 2021. PK data due 2H 2021.</div></td><td>
              31m
            </td><td>
              125.3m
            </td><td>
              111.7k
            </td><td>
              307.9k
            </td><td>
              0.96
            </td><td>
              $3.93
            </td><td>
              $3.93
            </td><td>
              December 2021
            </td><td>
              74.45m
            </td><td>
              -6.71m
            </td><td>
              11.10
            </td><td>
              57.83m
            </td><td>
              23.41m
            </td><td>
              0
            </td><td>
              21,939,141
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMAB" class="margin-bottom-1">
                IMAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$65.75</div> <small class="number change-up">+5.97<span>&nbsp;&nbsp;</span>+9.99%</small></td><td><strong>Plonmarlimab (TJM2)</strong> <br>Rheumatoid arthritis
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.i-mabbiopharma.com/news-releases/news-release-details/i-mab-reports-financial-results-full-year-2020-and-provides">
                2H 2021
              </a> <div class="note">Phase 1b trial to be completed by 2H 2021.</div></td><td>
              75m
            </td><td>
              4.9b
            </td><td>
              338.1k
            </td><td>
              0.6m
            </td><td>
              5.84
            </td><td>
              $62.5
            </td><td>
              $59.78
            </td><td>
              N/A
            </td><td>
              7.44b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              6.74b
            </td><td>
              3.87b
            </td><td>
              0
            </td><td>
              19,561,299
            </td><td>
              03/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NKTX" class="margin-bottom-1">
                NKTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$33.41</div> <small class="number change-up">+1.21<span>&nbsp;&nbsp;</span>+3.76%</small></td><td><strong>NKX101</strong> <br>Acute myeloid leukemia / myelodysplastic syndromes
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.nkartatx.com/news-releases/news-release-details/nkarta-reports-second-quarter-2021-financial-results-and">
                YE 2021
              </a> <div class="note">Phase 1 interim data due by end of 2021.</div></td><td>
              33m
            </td><td>
              1.1b
            </td><td>
              175.8k
            </td><td>
              285.4k
            </td><td>
              3.81
            </td><td>
              $32.63
            </td><td>
              $32.2
            </td><td>
              July 2023
            </td><td>
              269.33m
            </td><td>
              -5.82m
            </td><td>
              46.30
            </td><td>
              248.60m
            </td><td>
              0.79b
            </td><td>
              1
            </td><td>
              23,915,158
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PSTX" class="margin-bottom-1">
                PSTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.88</div> <small class="number change-down">-0.09<span>&nbsp;&nbsp;</span>-1.00%</small></td><td><strong>P-BCMA-101</strong> <br>Multiple myeloma
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/poseida-therapeutics-reports-program-updates-and-financial-results-for-the-second-quarter-of-2021-301354561.html">
                2H 2021
              </a> <div class="note">Phase 2 update due 2H 2021.</div></td><td>
              62m
            </td><td>
              0.6b
            </td><td>
              62.0k
            </td><td>
              177.3k
            </td><td>
              2.97
            </td><td>
              $8.82
            </td><td>
              $8.97
            </td><td>
              December 31, 2021
            </td><td>
              218.61m
            </td><td>
              -10.36m
            </td><td>
              21.10
            </td><td>
              106.07m
            </td><td>
              382.92m
            </td><td>
              1
            </td><td>
              26,301,053
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KRYS" class="margin-bottom-1">
                KRYS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$57.19</div> <small class="number change-up">+3.88<span>&nbsp;&nbsp;</span>+7.29%</small></td><td><strong>B-VEC (Beremagene Geperpavec)</strong> <br>Epidermolysis Bullosa
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-reports-second-quarter-2021-financial-results">
                4Q 2021
              </a> <div class="note">Phase 3 top-line data due 4Q 2021.</div></td><td>
              22m
            </td><td>
              1.3b
            </td><td>
              53.6k
            </td><td>
              135.4k
            </td><td>
              3.03
            </td><td>
              $54.1
            </td><td>
              $53.3
            </td><td>
              August 2021
            </td><td>
              361.65m
            </td><td>
              -3.38m
            </td><td>
              107.11
            </td><td>
              336.64m
            </td><td>
              0.82b
            </td><td>
              18.4
            </td><td>
              17,658,435
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IONS" class="margin-bottom-1">
                IONS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$39.33</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+0.18%</small></td><td><strong>IONIS-GHR-LRx</strong> <br>Acromegaly
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ionispharma.com/news-releases/news-release-details/ionis-reports-second-quarter-2021-financial-results-and-recent">
                2H 2021
              </a> <div class="note">Phase 2 data due 2H 2021.</div></td><td>
              141m
            </td><td>
              5.6b
            </td><td>
              322.8k
            </td><td>
              1.1m
            </td><td>
              9.52
            </td><td>
              $39.68
            </td><td>
              $39.26
            </td><td>
              April 2, 2021
            </td><td>
              2.05b
            </td><td>
              -20.88m
            </td><td>
              98.00
            </td><td>
              132.28m
            </td><td>
              4.79b
            </td><td>
              0.6
            </td><td>
              119,102,131
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PSTX" class="margin-bottom-1">
                PSTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.88</div> <small class="number change-down">-0.09<span>&nbsp;&nbsp;</span>-1.00%</small></td><td><strong>P-PSMA-101</strong> <br>Castrate-resistant prostate cancer (CRPC)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/poseida-therapeutics-reports-program-updates-and-financial-results-for-the-second-quarter-of-2021-301354561.html">
                2H 2021
              </a> <div class="note">Phase 1 update due 2H 2021.</div></td><td>
              62m
            </td><td>
              0.6b
            </td><td>
              62.0k
            </td><td>
              177.3k
            </td><td>
              2.97
            </td><td>
              $8.82
            </td><td>
              $8.97
            </td><td>
              September 2023
            </td><td>
              218.61m
            </td><td>
              -10.36m
            </td><td>
              21.10
            </td><td>
              106.07m
            </td><td>
              382.92m
            </td><td>
              1
            </td><td>
              26,301,053
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NCNA" class="margin-bottom-1">
                NCNA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.18</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+11.79%</small></td><td><strong>NUC-3373 (NuTide:301)</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/19/2283856/0/en/NuCana-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Business-Update.html">
                2H 2021
              </a> <div class="note">Phase 1 data due 2H 2021.</div></td><td>
              52m
            </td><td>
              113.7m
            </td><td>
              0.5m
            </td><td>
              473.6k
            </td><td>
              0.90
            </td><td>
              $2.02
            </td><td>
              $1.95
            </td><td>
              February 24, 2020
            </td><td>
              65.62m
            </td><td>
              -2.69m
            </td><td>
              24.38
            </td><td>
              56.21m
            </td><td>
              -4.66m
            </td><td>
              0
            </td><td>
              52,162,000
            </td><td>
              08/19/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AGEN" class="margin-bottom-1">
                AGEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.15</div> <small class="number change-up">+0.10<span>&nbsp;&nbsp;</span>+1.65%</small></td><td><strong>AGEN1181 and balstilimab (anti-CTLA-4)</strong> <br>Various cancers
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.agenusbio.com/news-releases/news-release-details/agenus-corporate-update-and-second-quarter-2021-financial-report">
                2H 2021
              </a> <div class="note">Phase 1/2 data presented April 10, 2021. 7 objective responses. Updated data due 2H 2021.</div></td><td>
              233m
            </td><td>
              1.4b
            </td><td>
              2.3m
            </td><td>
              3.1m
            </td><td>
              -5.80
            </td><td>
              $6.06
            </td><td>
              $6.05
            </td><td>
              N/A
            </td><td>
              40.21m
            </td><td>
              -18.52m
            </td><td>
              2.17
            </td><td>
              -407.84m
            </td><td>
              1.39b
            </td><td>
              3.3
            </td><td>
              231,178,523
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SYN" class="margin-bottom-1">
                SYN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.45</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+1.53%</small></td><td><strong>Ribaxamase (SYN-004)</strong> <br>Allogeneic hematopoietic cell transplantation (HCT)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.syntheticbiologics.com/press-releases/detail/308/synthetic-biologics-reports-second-quarter-2021-operational">
                4Q 2021
              </a> <div class="note">Phase 1b/2 top-line data due 4Q 2021.</div></td><td>
              132m
            </td><td>
              59.6m
            </td><td>
              0.7m
            </td><td>
              2.0m
            </td><td>
              0.78
            </td><td>
              $0.45
            </td><td>
              $0.44
            </td><td>
              December 2022
            </td><td>
              72.73m
            </td><td>
              -0.87m
            </td><td>
              84.05
            </td><td>
              69.21m
            </td><td>
              -13.94m
            </td><td>
              4.3
            </td><td>
              131,935,971
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MEIP" class="margin-bottom-1">
                MEIP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.75</div> <small class="number change-up">+0.16<span>&nbsp;&nbsp;</span>+6.18%</small></td><td><strong>Zandelisib (ME-401) - TIDAL</strong> <br>Relapsed/refractory Follicular Lymphoma (FL) Non Hodgkin Lymphoma
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/mei-pharma-and-kyowa-kirin-announce-completion-of-patient-enrollment-in-follicular-lymphoma-primary-efficacy-population-of-global-phase-2-tidal-study-intended-to-support-potential-accelerated-approval-application-from-us-food-an-301267433.html">
                4Q 2021
              </a> <div class="note">Phase 2 top-line data due 4Q 2021.</div></td><td>
              113m
            </td><td>
              309.6m
            </td><td>
              145.9k
            </td><td>
              484.5k
            </td><td>
              6.88
            </td><td>
              $2.63
            </td><td>
              $2.59
            </td><td>
              September 2021
            </td><td>
              139.42m
            </td><td>
              -5.22m
            </td><td>
              26.73
            </td><td>
              -1.74m
            </td><td>
              135.50m
            </td><td>
              0.6
            </td><td>
              112,005,779
            </td><td>
              04/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KDMN" class="margin-bottom-1">
                KDMN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.21</div> <small class="number change-up">+0.17<span>&nbsp;&nbsp;</span>+3.37%</small></td><td><strong>REZUROCK (Belumosudil) (KD025-215) - open label</strong> <br>Diffuse cutaneous systemic sclerosis (dcSSc)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.accesswire.com/658562/Kadmon-Provides-Business-Update-and-Reports-Second-Quarter-2021-Financial-Results">
                YE 2021
              </a> <div class="note">Phase 2 open-label initiation announced April 1, 2021 with initial data due by end of 2021.</div></td><td>
              172m
            </td><td>
              0.9b
            </td><td>
              2.7m
            </td><td>
              4.0m
            </td><td>
              -74.43
            </td><td>
              $5.09
            </td><td>
              $5.04
            </td><td>
              N/A
            </td><td>
              266.29m
            </td><td>
              -8.35m
            </td><td>
              31.91
            </td><td>
              -10.54m
            </td><td>
              0.88b
            </td><td>
              0.3
            </td><td>
              163,069,909
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PRAX" class="margin-bottom-1">
                PRAX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$19.40</div> <small class="number change-up">+0.64<span>&nbsp;&nbsp;</span>+3.41%</small></td><td><strong>PRAX-944</strong> <br>Essential tremor
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-1">
                YE 2021
              </a> <div class="note">Phase 2a topline open-label safety, tolerability and efficacy data are expected by the end of 2021. Phase 2b trial to be initiated 3Q 2021.</div></td><td>
              45m
            </td><td>
              0.9b
            </td><td>
              0.6m
            </td><td>
              294.3k
            </td><td>
              2.60
            </td><td>
              $18.55
            </td><td>
              $18.76
            </td><td>
              N/A
            </td><td>
              321.18m
            </td><td>
              -10.00m
            </td><td>
              32.10
            </td><td>
              301.44m
            </td><td>
              0.50b
            </td><td>
              1.8
            </td><td>
              29,027,417
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SRRK" class="margin-bottom-1">
                SRRK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$41.42</div> <small class="number change-up">+2.82<span>&nbsp;&nbsp;</span>+7.31%</small></td><td><strong>SRK-181 - DRAGON</strong> <br>Solid Tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210810005957/en/">
                2H 2021
              </a> <div class="note">Phase 1 clinical response and safety data anticipated in 2H 2021.</div></td><td>
              34m
            </td><td>
              1.4b
            </td><td>
              88.6k
            </td><td>
              265.7k
            </td><td>
              6.58
            </td><td>
              $38.84
            </td><td>
              $38.6
            </td><td>
              December 2021
            </td><td>
              263.13m
            </td><td>
              -10.60m
            </td><td>
              24.81
            </td><td>
              147.73m
            </td><td>
              1.10b
            </td><td>
              11.4
            </td><td>
              18,808,790
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SAGE" class="margin-bottom-1">
                SAGE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$42.82</div> <small class="number change-up">+0.84<span>&nbsp;&nbsp;</span>+2.00%</small></td><td><strong>SAGE-718 - LUMINARY (718-CNA-201)</strong> <br>Alzheimer’s disease (AD) cognitive dysfunction and mild dementia
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210803005320/en/">
                Late-2021
              </a> <div class="note">Phase 2a top-line data due late-2021.</div></td><td>
              59m
            </td><td>
              2.5b
            </td><td>
              153.7k
            </td><td>
              1.1m
            </td><td>
              1.30
            </td><td>
              $42.57
            </td><td>
              $41.98
            </td><td>
              N/A
            </td><td>
              1.85b
            </td><td>
              -34.26m
            </td><td>
              53.99
            </td><td>
              1.76b
            </td><td>
              0.58b
            </td><td>
              1.7
            </td><td>
              43,822,518
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MGNX" class="margin-bottom-1">
                MGNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.98</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+4.55%</small></td><td><strong>Tebotelimab (MGD013)</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-5">
                2021
              </a> <div class="note">Phase 1 update due later in 2021.</div></td><td>
              61m
            </td><td>
              1.4b
            </td><td>
              297.3k
            </td><td>
              0.6m
            </td><td>
              4.40
            </td><td>
              $22.34
            </td><td>
              $21.98
            </td><td>
              May 2022
            </td><td>
              269.90m
            </td><td>
              -15.23m
            </td><td>
              17.72
            </td><td>
              163.04m
            </td><td>
              1.07b
            </td><td>
              2.4
            </td><td>
              59,522,546
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ZLAB" class="margin-bottom-1">
                ZLAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$143.17</div> <small class="number change-up">+9.00<span>&nbsp;&nbsp;</span>+6.71%</small></td><td><strong>Tebotelimab (MGD013)</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-5">
                2021
              </a> <div class="note">Phase 1 update due later in 2021.</div></td><td>
              75m
            </td><td>
              10.8b
            </td><td>
              320.4k
            </td><td>
              0.6m
            </td><td>
              33.30
            </td><td>
              $135
            </td><td>
              $134.17
            </td><td>
              May 2022
            </td><td>
              1.73b
            </td><td>
              -21.95m
            </td><td>
              78.68
            </td><td>
              1.50b
            </td><td>
              1.78b
            </td><td>
              0
            </td><td>
              75,375,511
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NTLA" class="margin-bottom-1">
                NTLA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$155.90</div> <small class="number change-up">+6.58<span>&nbsp;&nbsp;</span>+4.40%</small></td><td><strong>NTLA-2001</strong> <br>transthyretin amyloidosis (ATTR)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-second-quarter-2021-financial">
                2H 2021
              </a> <div class="note">Phase 1 initial data presented June 26, 2021 at Peripheral Nerve Society Annual Meeting. Mean reductions of 52% among the three patients in the low-dose group, and 87% among the three patients in the high dose group. Further data due later in 2021.</div></td><td>
              73m
            </td><td>
              11.5b
            </td><td>
              0.8m
            </td><td>
              2.6m
            </td><td>
              23.16
            </td><td>
              $153.12
            </td><td>
              $149.32
            </td><td>
              N/A
            </td><td>
              1.19b
            </td><td>
              -17.66m
            </td><td>
              67.23
            </td><td>
              1.01b
            </td><td>
              10.51b
            </td><td>
              2.7
            </td><td>
              61,144,331
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CYCN" class="margin-bottom-1">
                CYCN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.86</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+4.94%</small></td><td><strong>CY6463</strong> <br>Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.cyclerion.com/news-releases/news-release-details/cyclerion-therapeutics-reports-second-quarter-2021-financial">
                YE 2021
              </a> <div class="note">Phase 2 top-line data due by end of 2021.</div></td><td>
              43m
            </td><td>
              124.0m
            </td><td>
              319.6k
            </td><td>
              0.8m
            </td><td>
              1.90
            </td><td>
              $2.75
            </td><td>
              $2.73
            </td><td>
              November 2021
            </td><td>
              67.08m
            </td><td>
              -1.84m
            </td><td>
              36.53
            </td><td>
              56.57m
            </td><td>
              51.26m
            </td><td>
              6.3
            </td><td>
              35,860,025
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALRN" class="margin-bottom-1">
                ALRN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.10</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+8.33%</small></td><td><strong>ALRN-6924</strong> <br>Healthy volunteers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.aileronrx.com/news-releases/news-release-details/aileron-therapeutics-reports-first-quarter-2021-financial">
                2H 2021
              </a> <div class="note">Data due 2H 2021.</div></td><td>
              91m
            </td><td>
              100.1m
            </td><td>
              0.7m
            </td><td>
              423.3k
            </td><td>
              1.78
            </td><td>
              $1.07
            </td><td>
              $1.02
            </td><td>
              N/A
            </td><td>
              57.22m
            </td><td>
              -1.25m
            </td><td>
              45.62
            </td><td>
              52.82m
            </td><td>
              33.11m
            </td><td>
              1.4
            </td><td>
              71,295,333
            </td><td>
              05/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ONCY" class="margin-bottom-1">
                ONCY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.26</div> <small class="number change-up">+0.19<span>&nbsp;&nbsp;</span>+9.18%</small></td><td><strong>Pelareorep and OPDIVO (nivolumab) - (WINSHIP 4398-18)</strong> <br>Multiple myeloma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/oncolytics-biotech-reports-2021-second-quarter-development-highlights-and-financial-results-301350059.html">
                4Q 2021
              </a> <div class="note">Phase 1 interim safety data due 4Q 2021.</div></td><td>
              42m
            </td><td>
              124.2m
            </td><td>
              276.6k
            </td><td>
              243.5k
            </td><td>
              3.13
            </td><td>
              $2.08
            </td><td>
              $2.07
            </td><td>
              October 31, 2021
            </td><td>
              46.72m
            </td><td>
              -2.27m
            </td><td>
              20.62
            </td><td>
              36.90m
            </td><td>
              64.30m
            </td><td>
              0
            </td><td>
              54,282,604
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DTIL" class="margin-bottom-1">
                DTIL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.98</div> <small class="number change-up">+0.57<span>&nbsp;&nbsp;</span>+6.06%</small></td><td><strong>PBCAR20A</strong> <br>Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210812005158/en/">
                2H 2021
              </a> <div class="note">Phase 1/2 interim data due 2H 2021.</div></td><td>
              60m
            </td><td>
              0.6b
            </td><td>
              215.5k
            </td><td>
              0.6m
            </td><td>
              5.91
            </td><td>
              $9.55
            </td><td>
              $9.41
            </td><td>
              March 2022
            </td><td>
              155.14m
            </td><td>
              -10.45m
            </td><td>
              14.85
            </td><td>
              25.58m
            </td><td>
              398.70m
            </td><td>
              11
            </td><td>
              53,284,783
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ONCY" class="margin-bottom-1">
                ONCY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.26</div> <small class="number change-up">+0.19<span>&nbsp;&nbsp;</span>+9.18%</small></td><td><strong>Pelareorep and TECENTRIQ (atezolizumab) - AWARE-1</strong> <br>Breast cancer
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/oncolytics-biotech-reports-2021-second-quarter-development-highlights-and-financial-results-301350059.html">
                2H 2021
              </a> <div class="note">Phase 1 data presented at AACR meeting April 10, 2021. Primary endpoint met. Final biomarker data due 2H 2021.</div></td><td>
              42m
            </td><td>
              124.2m
            </td><td>
              276.6k
            </td><td>
              243.5k
            </td><td>
              3.13
            </td><td>
              $2.08
            </td><td>
              $2.07
            </td><td>
              October 2020
            </td><td>
              46.72m
            </td><td>
              -2.27m
            </td><td>
              20.62
            </td><td>
              36.90m
            </td><td>
              64.30m
            </td><td>
              0
            </td><td>
              54,282,604
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CGEN" class="margin-bottom-1">
                CGEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.57</div> <small class="number change-up">+0.38<span>&nbsp;&nbsp;</span>+6.14%</small></td><td><strong>COM902</strong> <br>Advanced cancer
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/compugen-reports-second-quarter-2021-results-301342975.html">
                4Q 2021
              </a> <div class="note">Phase 1 COM902 monotherapy data due 4Q 2021. Initiation of combination arm of COM902 with COM701 announced July 15, 2021.</div></td><td>
              84m
            </td><td>
              0.6b
            </td><td>
              0.7m
            </td><td>
              0.8m
            </td><td>
              5.34
            </td><td>
              $6.2
            </td><td>
              $6.19
            </td><td>
              September 30, 2021
            </td><td>
              110.41m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              91.02m
            </td><td>
              389.20m
            </td><td>
              0
            </td><td>
              66,755,729
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IFRX" class="margin-bottom-1">
                IFRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.35</div> <small class="number change-up">+0.05<span>&nbsp;&nbsp;</span>+2.17%</small></td><td><strong>Vilobelimab (IFX-1) - (IXCHANGE)</strong> <br>ANCA-associated Vasculitis (AAV)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/05/2275487/0/en/InflaRx-Reports-Second-Quarter-2021-Financial-Operating-Results.html">
                YE 2021
              </a> <div class="note">Phase 2 data due by the end of 2021.</div></td><td>
              44m
            </td><td>
              103.8m
            </td><td>
              148.8k
            </td><td>
              154.3k
            </td><td>
              0.72
            </td><td>
              $2.32
            </td><td>
              $2.3
            </td><td>
              N/A
            </td><td>
              122.49m
            </td><td>
              -2.61m
            </td><td>
              46.87
            </td><td>
              111.08m
            </td><td>
              -45.02m
            </td><td>
              0
            </td><td>
              39,925,277
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SGMO" class="margin-bottom-1">
                SGMO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.87</div> <small class="number change-up">+0.51<span>&nbsp;&nbsp;</span>+5.45%</small></td><td><strong>Giroctocogene fitelparvovec</strong> <br>Hemophilia A 
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.sangamo.com/index.php/static-files/59eafc6d-194e-42ac-94f1-093d77e82abf">
                4Q 2021
              </a> <div class="note">Phase 1/2 2-year data due 4Q 2021.</div></td><td>
              145m
            </td><td>
              1.4b
            </td><td>
              0.5m
            </td><td>
              1.0m
            </td><td>
              3.21
            </td><td>
              $9.46
            </td><td>
              $9.36
            </td><td>
              N/A
            </td><td>
              498.11m
            </td><td>
              -17.52m
            </td><td>
              28.43
            </td><td>
              108.21m
            </td><td>
              0.87b
            </td><td>
              2.2
            </td><td>
              120,566,640
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EQ" class="margin-bottom-1">
                EQ
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.12</div> <small class="number change-up">+1.28<span>&nbsp;&nbsp;</span>+26.55%</small></td><td><strong>Itolizumab (EQ001) - (EQUALISE)</strong> <br>Systemic lupus erythematosus (SLE) and lupus nephritis (LN)
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.equilliumbio.com/news-releases/news-release-details/equillium-announces-update-equalise-study-itolizumab-patients">
                2H 2021
              </a> <div class="note">Phase 1b top-line data from Type A patients (SLE) released March 30, 2021 - safe and well tolerated. Type B data (lupus nephritis) due 2H 2021.</div></td><td>
              29m
            </td><td>
              180.0m
            </td><td>
              0.6m
            </td><td>
              117.2k
            </td><td>
              2.12
            </td><td>
              $4.9
            </td><td>
              $4.84
            </td><td>
              March 2022
            </td><td>
              93.45m
            </td><td>
              -2.33m
            </td><td>
              40.08
            </td><td>
              78.38m
            </td><td>
              54.64m
            </td><td>
              4.2
            </td><td>
              16,153,503
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ZLAB" class="margin-bottom-1">
                ZLAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$143.17</div> <small class="number change-up">+9.00<span>&nbsp;&nbsp;</span>+6.71%</small></td><td><strong>CLN-081</strong> <br>Non-Small Cell Lung Cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.cullinanoncology.com/news-releases/news-release-details/cullinan-oncology-provides-corporate-update-and-reports-second">
                4Q 2021
              </a> <div class="note">Phase 1/2 updated data at ASCO June 4-8, 2021 noted objective partial responses (PR) were observed in 21 of 42 (50%) patients. Update due 4Q 2021.</div></td><td>
              75m
            </td><td>
              10.8b
            </td><td>
              320.4k
            </td><td>
              0.6m
            </td><td>
              33.30
            </td><td>
              $135
            </td><td>
              $134.17
            </td><td>
              September 15, 2021
            </td><td>
              1.73b
            </td><td>
              -21.95m
            </td><td>
              78.68
            </td><td>
              1.50b
            </td><td>
              1.78b
            </td><td>
              0
            </td><td>
              75,375,511
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CGEM" class="margin-bottom-1">
                CGEM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$28.90</div> <small class="number change-up">+0.76<span>&nbsp;&nbsp;</span>+2.70%</small></td><td><strong>CLN-081</strong> <br>Non-Small Cell Lung Cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.cullinanoncology.com/news-releases/news-release-details/cullinan-oncology-provides-corporate-update-and-reports-second">
                4Q 2021
              </a> <div class="note">Phase 1/2 updated data at ASCO June 4-8, 2021 noted objective partial responses (PR) were observed in 21 of 42 (50%) patients. Update due 4Q 2021.</div></td><td>
              44m
            </td><td>
              1.3b
            </td><td>
              141.2k
            </td><td>
              197.4k
            </td><td>
              2.76
            </td><td>
              $28.64
            </td><td>
              $28.14
            </td><td>
              September 15, 2021
            </td><td>
              326.99m
            </td><td>
              -5.40m
            </td><td>
              60.57
            </td><td>
              321.17m
            </td><td>
              0.89b
            </td><td>
              2.9
            </td><td>
              21,370,808
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EYEG" class="margin-bottom-1">
                EYEG
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.59</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+4.60%</small></td><td><strong>PP-001</strong> <br>Dry eye disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2280138/0/en/EyeGate-Pharma-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Business-Update.html">
                4Q 2021
              </a> <div class="note">Phase 2 dosing has commenced (Austria) - June 14, 2021. Top-line data due 4Q 2021. U.S. IND filing due 3Q 2021.</div></td><td>
              13m
            </td><td>
              20.1m
            </td><td>
              0.6m
            </td><td>
              2.0m
            </td><td>
              1.92
            </td><td>
              $1.56
            </td><td>
              $1.52
            </td><td>
              N/A
            </td><td>
              12.83m
            </td><td>
              -0.88m
            </td><td>
              14.59
            </td><td>
              5.18m
            </td><td>
              15.83m
            </td><td>
              15.1
            </td><td>
              9,150,650
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EVLO" class="margin-bottom-1">
                EVLO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.74</div> <small class="number change-up">+0.33<span>&nbsp;&nbsp;</span>+3.45%</small></td><td><strong>EDP1867</strong> <br>Atopic dermatitis
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.evelobio.com/static-files/aca18e7a-0b98-4e1e-a951-25faf8572d9d">
                4Q 2021
              </a> <div class="note">Phase 1b data due 4Q 2021.</div></td><td>
              53m
            </td><td>
              0.5b
            </td><td>
              153.2k
            </td><td>
              190.5k
            </td><td>
              8.40
            </td><td>
              $9.59
            </td><td>
              $9.42
            </td><td>
              N/A
            </td><td>
              114.07m
            </td><td>
              -5.14m
            </td><td>
              22.18
            </td><td>
              31.11m
            </td><td>
              436.90m
            </td><td>
              0.5
            </td><td>
              23,304,546
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ZNTL" class="margin-bottom-1">
                ZNTL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$59.62</div> <small class="number change-up">+4.36<span>&nbsp;&nbsp;</span>+7.89%</small></td><td><strong>ZN-e4</strong> <br>Non-small cell lung cancer
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.zentalis.com/static-files/4cb13119-2721-4c76-9c33-68ed16ae353e">
                2021
              </a> <div class="note">Phase 1 initial data due 2021.</div></td><td>
              45m
            </td><td>
              2.7b
            </td><td>
              253.7k
            </td><td>
              277.3k
            </td><td>
              12.00
            </td><td>
              $56.16
            </td><td>
              $55.26
            </td><td>
              June 20, 2022
            </td><td>
              296.13m
            </td><td>
              -15.37m
            </td><td>
              19.27
            </td><td>
              259.78m
            </td><td>
              2.24b
            </td><td>
              7.4
            </td><td>
              30,593,411
            </td><td>
              03/25/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VIRX" class="margin-bottom-1">
                VIRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.57</div> <small class="number change-up">+0.50<span>&nbsp;&nbsp;</span>+5.51%</small></td><td><strong>Nanatinostat and valganciclovir (VT3996-201)</strong> <br>Epstein-Barr Virus Associated Lymphoma
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/viracta-therapeutics-reports-second-quarter-2021-financial-results-and-provides-clinical-and-corporate-updates-301353857.html">
                2H 2021
              </a> <div class="note">Phase 1/2 updated data due 2H 2021.</div></td><td>
              37m
            </td><td>
              356.3m
            </td><td>
              58.1k
            </td><td>
              285.3k
            </td><td>
              
            </td><td>
              $9.3
            </td><td>
              $9.07
            </td><td>
              December 2021
            </td><td>
              118.77m
            </td><td>
              -2.20m
            </td><td>
              54.04
            </td><td>
              107.18m
            </td><td>
              226.19m
            </td><td>
              0.2
            </td><td>
              37,134,723
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALLK" class="margin-bottom-1">
                ALLK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$82.78</div> <small class="number change-up">+2.78<span>&nbsp;&nbsp;</span>+3.48%</small></td><td><strong>Lirentelimab (ENIGMA 2)</strong> <br>Eosinophilic Gastritis and/or eosinophilic duodenitis (EoD)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.allakos.com/news-releases/news-release-details/allakos-provides-business-update-and-reports-second-quarter-2021">
                4Q 2021
              </a> <div class="note">Phase 3 top-line data due 4Q 2021.</div></td><td>
              54m
            </td><td>
              4.5b
            </td><td>
              103.3k
            </td><td>
              285.4k
            </td><td>
              7.83
            </td><td>
              $80.62
            </td><td>
              $80
            </td><td>
              December 2021
            </td><td>
              0.53b
            </td><td>
              -16.59m
            </td><td>
              31.93
            </td><td>
              445.86m
            </td><td>
              3.81b
            </td><td>
              1.3
            </td><td>
              25,124,435
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ACAD" class="margin-bottom-1">
                ACAD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.10</div> <small class="number change-up">+0.42<span>&nbsp;&nbsp;</span>+2.52%</small></td><td><strong>Trofinetide (LAVENDER)</strong> <br>Rett Syndrome
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210804006002/en/">
                4Q 2021
              </a> <div class="note">Phase 3 data due 4Q 2021.</div></td><td>
              161m
            </td><td>
              2.7b
            </td><td>
              0.6m
            </td><td>
              1.7m
            </td><td>
              4.86
            </td><td>
              $16.85
            </td><td>
              $16.68
            </td><td>
              September 2021
            </td><td>
              0.54b
            </td><td>
              -8.44m
            </td><td>
              64.17
            </td><td>
              382.13m
            </td><td>
              2.19b
            </td><td>
              0.4
            </td><td>
              99,144,481
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARCT" class="margin-bottom-1">
                ARCT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.98</div> <small class="number change-up">+2.08<span>&nbsp;&nbsp;</span>+4.34%</small></td><td><strong>ARCT-021</strong> <br>COVID-19 vaccine
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.arcturusrx.com/static-files/198c6d28-bb6b-4162-a7a6-5854a0fd2d6c">
                4Q 2021
              </a> <div class="note">Phase 2 interim data due 4Q 2021. Phase 3 trial planned for 2H 2021.</div></td><td>
              26m
            </td><td>
              1.3b
            </td><td>
              388.5k
            </td><td>
              1.0m
            </td><td>
              4.30
            </td><td>
              $48.63
            </td><td>
              $47.9
            </td><td>
              N/A
            </td><td>
              413.81m
            </td><td>
              -10.98m
            </td><td>
              37.68
            </td><td>
              270.64m
            </td><td>
              0.90b
            </td><td>
              9.4
            </td><td>
              14,191,083
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LBPH" class="margin-bottom-1">
                LBPH
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.83</div> <small class="number change-down">-0.07<span>&nbsp;&nbsp;</span>-0.79%</small></td><td><strong>LP352</strong> <br>Developmental and epileptic encephalopathies (DEEs)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.longboardpharma.com/news-releases/news-release-details/longboard-pharmaceuticals-provides-corporate-update-and-0">
                2H 2021
              </a> <div class="note">Phase 1 MAD top-line data due 2H 2021. Phase 1b/2a trial to be initiated 1Q 2022.</div></td><td>
              17m
            </td><td>
              152.0m
            </td><td>
              7.6k
            </td><td>
              68.9k
            </td><td>
              1.29
            </td><td>
              $8.78
            </td><td>
              $8.9
            </td><td>
              N/A
            </td><td>
              115.75m
            </td><td>
              -1.72m
            </td><td>
              67.43
            </td><td>
              112.48m
            </td><td>
              34.38m
            </td><td>
              2
            </td><td>
              7,254,510
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/WINT" class="margin-bottom-1">
                WINT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.74</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+3.65%</small></td><td><strong>Istaroxime</strong> <br>Cardiogenic Shock in severe acute heart failure
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://windtreetx.investorroom.com/2021-08-05-Windtree-Therapeutics-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Key-Business-Updates">
                4Q 2021
              </a> <div class="note">Phase 2 trial to be completed 4Q 2021.</div></td><td>
              27m
            </td><td>
              46.5m
            </td><td>
              153.1k
            </td><td>
              0.8m
            </td><td>
              0.82
            </td><td>
              $1.69
            </td><td>
              $1.68
            </td><td>
              August 31, 2021
            </td><td>
              25.52m
            </td><td>
              -2.47m
            </td><td>
              10.34
            </td><td>
              -8.58m
            </td><td>
              18.73m
            </td><td>
              5.1
            </td><td>
              18,697,473
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NCNA" class="margin-bottom-1">
                NCNA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.18</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+11.79%</small></td><td><strong>NUC-7738 (NuTide:701)</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/19/2283856/0/en/NuCana-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Business-Update.html">
                2H 2021
              </a> <div class="note">Phase 1 updated data due 2H 2021. Phase 2 trial to be initiated 2H 2021 with data due 1H 2022.</div></td><td>
              52m
            </td><td>
              113.7m
            </td><td>
              0.5m
            </td><td>
              473.6k
            </td><td>
              0.90
            </td><td>
              $2.02
            </td><td>
              $1.95
            </td><td>
              July 2022
            </td><td>
              65.62m
            </td><td>
              -2.69m
            </td><td>
              24.38
            </td><td>
              56.21m
            </td><td>
              -4.66m
            </td><td>
              0
            </td><td>
              52,162,000
            </td><td>
              08/19/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/XFOR" class="margin-bottom-1">
                XFOR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.91</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+3.15%</small></td><td><strong>Mavorixafor and  IMBRUVICA (ibrutinib)</strong> <br>Waldenström macroglobulinemia
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-key-enrollment-milestone">
                4Q 2021
              </a> <div class="note">Phase 1b initial data released at EHA meeting June 11, 2021. At 6 months, patients achieved median IgM level reductions of 60%-75%. Further data due 4Q 2021.</div></td><td>
              25m
            </td><td>
              121.6m
            </td><td>
              95.6k
            </td><td>
              246.6k
            </td><td>
              1.37
            </td><td>
              $4.87
            </td><td>
              $4.76
            </td><td>
              January 2023
            </td><td>
              83.64m
            </td><td>
              -6.40m
            </td><td>
              13.07
            </td><td>
              31.20m
            </td><td>
              63.01m
            </td><td>
              6.8
            </td><td>
              22,057,851
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/WINT" class="margin-bottom-1">
                WINT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.74</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+3.65%</small></td><td><strong>Lucinactant</strong> <br>COVID-19 / Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://windtreetx.investorroom.com/2021-08-05-Windtree-Therapeutics-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Key-Business-Updates">
                4Q 2021
              </a> <div class="note">Phase 2 data due 4Q 2021.</div></td><td>
              27m
            </td><td>
              46.5m
            </td><td>
              153.1k
            </td><td>
              0.8m
            </td><td>
              0.82
            </td><td>
              $1.69
            </td><td>
              $1.68
            </td><td>
              November 12, 2021
            </td><td>
              25.52m
            </td><td>
              -2.47m
            </td><td>
              10.34
            </td><td>
              -8.58m
            </td><td>
              18.73m
            </td><td>
              5.1
            </td><td>
              18,697,473
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/YMAB" class="margin-bottom-1">
                YMAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.25</div> <small class="number change-up">+0.86<span>&nbsp;&nbsp;</span>+3.03%</small></td><td><strong>Omburtamab</strong> <br>CNS/Leptomeningeal Metastases from Neuroblastoma
            </td><td>
              BLA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/05/2275964/0/en/Y-mAbs-Announces-Second-Quarter-Financial-Results-and-Recent-Corporate-Developments.html">
                YE 2021
              </a> <div class="note">Refusal to file letter issued October 5, 2020. Type B pre-BLA meeting 3Q 2021. Resubmission targeted by end of 2021.</div></td><td>
              44m
            </td><td>
              1.3b
            </td><td>
              132.9k
            </td><td>
              252.2k
            </td><td>
              5.44
            </td><td>
              $28.6
            </td><td>
              $28.39
            </td><td>
              N/A
            </td><td>
              222.33m
            </td><td>
              -6.25m
            </td><td>
              35.56
            </td><td>
              197.17m
            </td><td>
              1.01b
            </td><td>
              1
            </td><td>
              34,634,663
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/XFOR" class="margin-bottom-1">
                XFOR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.91</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+3.15%</small></td><td><strong>Mavorixafor (X4P-001)</strong> <br>Severe Congenital Neutropenia (SCN)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-key-enrollment-milestone">
                4Q 2021
              </a> <div class="note">Phase 1b top-line data due 4Q 2021.</div></td><td>
              25m
            </td><td>
              121.6m
            </td><td>
              95.6k
            </td><td>
              246.6k
            </td><td>
              1.37
            </td><td>
              $4.87
            </td><td>
              $4.76
            </td><td>
              October 15, 2021
            </td><td>
              83.64m
            </td><td>
              -6.40m
            </td><td>
              13.07
            </td><td>
              31.20m
            </td><td>
              63.01m
            </td><td>
              6.8
            </td><td>
              22,057,851
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ACET" class="margin-bottom-1">
                ACET
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.09</div> <small class="number change-up">+0.17<span>&nbsp;&nbsp;</span>+2.46%</small></td><td><strong>ADI-001</strong> <br>Non-Hodgkin’s lymphoma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.adicetbio.com/news-releases/news-release-details/adicet-reports-second-quarter-2021-financial-results-and">
                Late-2021
              </a> <div class="note">Phase 1 trial initiation announced March 10, 2021. Data due late-2021.</div></td><td>
              20m
            </td><td>
              138.9m
            </td><td>
              50.5k
            </td><td>
              189.5k
            </td><td>
              3.65
            </td><td>
              $6.93
            </td><td>
              $6.92
            </td><td>
              March 31, 2023
            </td><td>
              201.06m
            </td><td>
              -4.26m
            </td><td>
              47.20
            </td><td>
              160.62m
            </td><td>
              15.51m
            </td><td>
              0
            </td><td>
              27,844,769
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IDRA" class="margin-bottom-1">
                IDRA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.06</div> <small class="number change-up">+0.04<span>&nbsp;&nbsp;</span>+3.92%</small></td><td><strong>Tilsotolimod + OPDIVO (nivolumab) and YERVOY&nbsp;(ipilimumab)  - ILLUMINATE 206</strong> <br>Squamous Cell Carcinoma of the Head and Neck (SCCHN)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.iderapharma.com/news-releases/news-release-details/idera-pharmaceuticals-reports-first-quarter-2021-financial">
                4Q 2021
              </a> <div class="note">Phase 2 data due 4Q 2021.</div></td><td>
              53m
            </td><td>
              55.9m
            </td><td>
              0.5m
            </td><td>
              2.6m
            </td><td>
              1.47
            </td><td>
              $1.01
            </td><td>
              $1.02
            </td><td>
              December 31, 2021
            </td><td>
              36.83m
            </td><td>
              -2.09m
            </td><td>
              17.66
            </td><td>
              30.15m
            </td><td>
              14.08m
            </td><td>
              4
            </td><td>
              42,138,849
            </td><td>
              05/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RLAY" class="margin-bottom-1">
                RLAY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$32.54</div> <small class="number change-up">+1.01<span>&nbsp;&nbsp;</span>+3.20%</small></td><td><strong>RLY-4008</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-announces-corporate-updates-and-reports">
                2H 2021
              </a> <div class="note">Phase 1 initial data due 2H 2021.</div></td><td>
              93m
            </td><td>
              3.0b
            </td><td>
              184.7k
            </td><td>
              495.7k
            </td><td>
              4.88
            </td><td>
              $31.8
            </td><td>
              $31.53
            </td><td>
              April 2024
            </td><td>
              0.65b
            </td><td>
              -9.38m
            </td><td>
              69.76
            </td><td>
              0.56b
            </td><td>
              2.28b
            </td><td>
              1.9
            </td><td>
              60,465,068
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PFE" class="margin-bottom-1">
                PFE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.98</div> <small class="number change-up">+1.25<span>&nbsp;&nbsp;</span>+2.58%</small></td><td><strong>Oral Protease Inhibitor</strong> <br>COVID-19
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s21.q4cdn.com/317678438/files/doc_financials/2021/q1/Q1-2021-Earnings-Charts-FINAL.pdf">
                4Q 2021
              </a> <div class="note">Phase 2/3 study start 3Q 2021 with readout 4Q 2021.</div></td><td>
              6b
            </td><td>
              280.2b
            </td><td>
              69.5m
            </td><td>
              30.1m
            </td><td>
              4.00
            </td><td>
              $50.29
            </td><td>
              $48.72
            </td><td>
              N/A
            </td><td>
              28.48b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -71.13b
            </td><td>
              289.19b
            </td><td>
              0.3
            </td><td>
              5,605,213,314
            </td><td>
              05/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GILD" class="margin-bottom-1">
                GILD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$72.66</div> <small class="number change-up">+0.22<span>&nbsp;&nbsp;</span>+0.30%</small></td><td><strong>TRODELVY (sacituzumab govitecan) - TROPICS-02</strong> <br>HR+/HER2- metastatic breast cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.gilead.com/static-files/a67bf84b-ece1-480b-bedf-665c6e4c57a9">
                2H 2021
              </a> <div class="note">Phase 3 PFS data due 2H 2021.</div></td><td>
              1b
            </td><td>
              91.1b
            </td><td>
              2.8m
            </td><td>
              6.3m
            </td><td>
              4.62
            </td><td>
              $72.68
            </td><td>
              $72.44
            </td><td>
              November 2021
            </td><td>
              7.91b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -40.36b
            </td><td>
              114.48b
            </td><td>
              0.6
            </td><td>
              1,253,507,953
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALXO" class="margin-bottom-1">
                ALXO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$72.64</div> <small class="number change-up">+10.06<span>&nbsp;&nbsp;</span>+16.08%</small></td><td><strong>ALX148 and Vidaza (azacitidine) - (ASPEN-02)</strong> <br>Myelodysplastic syndromes (MDS)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2280076/0/en/ALX-Oncology-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Clinical-Development-and-Operational-Highlights.html">
                4Q 2021
              </a> <div class="note">Phase 1 final data and Phase 2 initiation due 4Q 2021.</div></td><td>
              40m
            </td><td>
              2.9b
            </td><td>
              1.6m
            </td><td>
              272.2k
            </td><td>
              7.24
            </td><td>
              $73.39
            </td><td>
              $62.58
            </td><td>
              June 2023
            </td><td>
              397.59m
            </td><td>
              -6.87m
            </td><td>
              57.84
            </td><td>
              381.32m
            </td><td>
              2.12b
            </td><td>
              2
            </td><td>
              17,475,653
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CMRX" class="margin-bottom-1">
                CMRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.52</div> <small class="number change-up">+0.32<span>&nbsp;&nbsp;</span>+5.16%</small></td><td><strong>ONC201</strong> <br>H3 K27M-mutant Glioma
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.chimerix.com/news-releases/news-release-details/chimerix-reports-second-quarter-2021-financial-results-and">
                4Q 2021
              </a> <div class="note">Phase 2 blinded independent central review due 4Q 2021.</div></td><td>
              86m
            </td><td>
              0.6b
            </td><td>
              416.7k
            </td><td>
              0.6m
            </td><td>
              4.72
            </td><td>
              $6.32
            </td><td>
              $6.2
            </td><td>
              December 31, 2021
            </td><td>
              124.40m
            </td><td>
              -4.24m
            </td><td>
              29.33
            </td><td>
              96.82m
            </td><td>
              419.37m
            </td><td>
              1.8
            </td><td>
              62,369,079
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ORTX" class="margin-bottom-1">
                ORTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.69</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+9.55%</small></td><td><strong>OTL-201</strong> <br>MPS-IIIA
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-reports-second-quarter-2021-financial">
                2H 2021
              </a> <div class="note">Phase 1/2 further data due 2H 2021 and 2022.</div></td><td>
              125m
            </td><td>
              337.9m
            </td><td>
              324.5k
            </td><td>
              0.6m
            </td><td>
              1.28
            </td><td>
              $2.45
            </td><td>
              $2.46
            </td><td>
              October 30, 2024
            </td><td>
              247.68m
            </td><td>
              -12.02m
            </td><td>
              20.61
            </td><td>
              147.30m
            </td><td>
              100.62m
            </td><td>
              0.5
            </td><td>
              124,780,672
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMMP" class="margin-bottom-1">
                IMMP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.35</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+0.45%</small></td><td><strong>Eftilagimod alpha</strong> <br>COVID-19
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.immutep.com/files/content/investor/press-release/2021/Immutep%20Quarterly%20Activities%20Report%20&amp;%20Appendix%204C%20-%2022Jan2021.pdf">
                2021
              </a> <div class="note">Phase 2 interim safety review noted no adverse events - January 27, 2021. Interim efficacy data due later in 2021.</div></td><td>
              65m
            </td><td>
              217.0m
            </td><td>
              184.3k
            </td><td>
              340.0k
            </td><td>
              4.99
            </td><td>
              $3.33
            </td><td>
              $3.33
            </td><td>
              N/A
            </td><td>
              54.88m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              39.10m
            </td><td>
              171.73m
            </td><td>
              0
            </td><td>
              64,872,528
            </td><td>
              01/27/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALXO" class="margin-bottom-1">
                ALXO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$72.64</div> <small class="number change-up">+10.06<span>&nbsp;&nbsp;</span>+16.08%</small></td><td><strong>ALX148 and HERCEPTIN (Trastuzumab) - (ASPEN-01)</strong> <br>Solid Tumors and Lymphoma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2280076/0/en/ALX-Oncology-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Clinical-Development-and-Operational-Highlights.html">
                4Q 2021
              </a> <div class="note">Phase 1 data presented at ESMO 23rd World Congress on Gastrointestinal Cancer, July 3, 2021 - objective response rate (ORR) of 72% and estimated overall survival (OS) at 12 months of 76%. Final data due 4Q 2021.</div></td><td>
              40m
            </td><td>
              2.9b
            </td><td>
              1.6m
            </td><td>
              272.2k
            </td><td>
              7.24
            </td><td>
              $73.39
            </td><td>
              $62.58
            </td><td>
              March 2022
            </td><td>
              397.59m
            </td><td>
              -6.87m
            </td><td>
              57.84
            </td><td>
              381.32m
            </td><td>
              2.12b
            </td><td>
              2
            </td><td>
              17,475,653
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GSK" class="margin-bottom-1">
                GSK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$41.57</div> <small class="number change-down">-0.28<span>&nbsp;&nbsp;</span>-0.67%</small></td><td><strong>VIR-7832 (AGILE)</strong> <br>COVID-19 vaccine/therapeutic
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/05/06/2225033/0/en/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-First-Quarter-2021-Financial-Results.html">
                2H 2021
              </a> <div class="note">Phase 2 initial safety data due 2H 2021.</div></td><td>
              3b
            </td><td>
              104.6b
            </td><td>
              2.3m
            </td><td>
              4.2m
            </td><td>
              4.95
            </td><td>
              $41.75
            </td><td>
              $41.85
            </td><td>
              November 18, 2021
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -51.10b
            </td><td>
              133.80b
            </td><td>
              0.2
            </td><td>
              2,506,785,977
            </td><td>
              05/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VIR" class="margin-bottom-1">
                VIR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$47.20</div> <small class="number change-up">+0.73<span>&nbsp;&nbsp;</span>+1.57%</small></td><td><strong>VIR-7832 (AGILE)</strong> <br>COVID-19 vaccine/therapeutic
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/05/06/2225033/0/en/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-First-Quarter-2021-Financial-Results.html">
                2H 2021
              </a> <div class="note">Phase 2 initial safety data due 2H 2021.</div></td><td>
              131m
            </td><td>
              6.2b
            </td><td>
              1.0m
            </td><td>
              0.9m
            </td><td>
              8.35
            </td><td>
              $47.62
            </td><td>
              $46.47
            </td><td>
              November 18, 2021
            </td><td>
              0.91b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              0.59b
            </td><td>
              5.32b
            </td><td>
              5.6
            </td><td>
              69,593,992
            </td><td>
              05/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LLY" class="margin-bottom-1">
                LLY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$269.63</div> <small class="number change-down">-1.28<span>&nbsp;&nbsp;</span>-0.47%</small></td><td><strong>Donanemab</strong> <br>Alzheimer's Disease
            </td><td>
              BLA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.lilly.com/static-files/07e528d6-bf01-4258-8190-7b32b28ba24d">
                2H 2021
              </a> <div class="note">Phase 2 trial met primary endpoint - January 11, 2021. Decline of 6.86 points vs 10-point decline for placebo on iARDS noted - March 13, 2021. BLA filing due 2H 2021.</div></td><td>
              1b
            </td><td>
              257.9b
            </td><td>
              0.8m
            </td><td>
              2.8m
            </td><td>
              40.00
            </td><td>
              $272.3
            </td><td>
              $270.91
            </td><td>
              February 14, 2023
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -36.81b
            </td><td>
              272.39b
            </td><td>
              0.5
            </td><td>
              792,287,037
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FHTX" class="margin-bottom-1">
                FHTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$11.00</div> <small class="number change-up">+0.67<span>&nbsp;&nbsp;</span>+6.49%</small></td><td><strong>FHD-286</strong> <br>Acute myeloid leukemia (AML) 
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/10/2277807/0/en/Foghorn-Therapeutics-Provides-Second-Quarter-2021-Corporate-Update.html">
                4Q 2021
              </a> <div class="note">Phase 1 data due 4Q 2021.</div></td><td>
              37m
            </td><td>
              406.3m
            </td><td>
              49.1k
            </td><td>
              127.2k
            </td><td>
              3.90
            </td><td>
              $10.48
            </td><td>
              $10.33
            </td><td>
              June 2022
            </td><td>
              130.18m
            </td><td>
              -6.16m
            </td><td>
              21.13
            </td><td>
              25.85m
            </td><td>
              322.06m
            </td><td>
              13.5
            </td><td>
              19,491,155
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FHTX" class="margin-bottom-1">
                FHTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$11.00</div> <small class="number change-up">+0.67<span>&nbsp;&nbsp;</span>+6.49%</small></td><td><strong>FHD-286</strong> <br>Uveal melanoma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/10/2277807/0/en/Foghorn-Therapeutics-Provides-Second-Quarter-2021-Corporate-Update.html">
                4Q 2021
              </a> <div class="note">Phase 1 data due 4Q 2021.</div></td><td>
              37m
            </td><td>
              406.3m
            </td><td>
              49.1k
            </td><td>
              127.2k
            </td><td>
              3.90
            </td><td>
              $10.48
            </td><td>
              $10.33
            </td><td>
              August 29, 2023
            </td><td>
              130.18m
            </td><td>
              -6.16m
            </td><td>
              21.13
            </td><td>
              25.85m
            </td><td>
              322.06m
            </td><td>
              13.5
            </td><td>
              19,491,155
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/QURE" class="margin-bottom-1">
                QURE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$28.07</div> <small class="number change-up">+1.27<span>&nbsp;&nbsp;</span>+4.74%</small></td><td><strong>AMT-130</strong> <br>Huntington's disease
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=3936723&amp;lang=en-GB&amp;companycode=nl-qure&amp;v=">
                YE 2021
              </a> <div class="note">Phase 1/2 trial first two patient procedures have been completed in the higher dose, second cohort - noted June 16, 2021. Initial imaging and biomarker data due before the end of 2021.</div></td><td>
              46m
            </td><td>
              1.3b
            </td><td>
              399.2k
            </td><td>
              382.9k
            </td><td>
              2.04
            </td><td>
              $26.68
            </td><td>
              $26.8
            </td><td>
              December 2022
            </td><td>
              0.93b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              0.78b
            </td><td>
              0.66b
            </td><td>
              2.6
            </td><td>
              45,794,257
            </td><td>
              07/26/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SCYX" class="margin-bottom-1">
                SCYX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.07</div> <small class="number change-up">+0.20<span>&nbsp;&nbsp;</span>+3.32%</small></td><td><strong>BREXAFEMME (ibrexafungerp) -  SCYNERGIA</strong> <br>Invasive aspergillosis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.scynexis.com/news-media/press-releases/detail/234/scynexis-reports-fourth-quarter-and-full-year-2020">
                2H 2021
              </a> <div class="note">Phase 2 top-line data due 2H 2021.</div></td><td>
              23m
            </td><td>
              140.8m
            </td><td>
              120.1k
            </td><td>
              298.1k
            </td><td>
              4.36
            </td><td>
              $5.87
            </td><td>
              $5.87
            </td><td>
              November 2021
            </td><td>
              105.43m
            </td><td>
              -3.90m
            </td><td>
              27.04
            </td><td>
              16.62m
            </td><td>
              67.55m
            </td><td>
              2.1
            </td><td>
              18,406,695
            </td><td>
              06/19/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MRTX" class="margin-bottom-1">
                MRTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$145.25</div> <small class="number change-up">+11.12<span>&nbsp;&nbsp;</span>+8.29%</small></td><td><strong>Adagrasib (MRTX-849) and ERBITUX (cetuximab) - KRYSTAL-10</strong> <br>Colorectal Cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s27.q4cdn.com/140416303/files/doc_presentation/2021/MRTX-Corporate-Presentation_6May2021.pdf">
                2H 2021
              </a> <div class="note">Phase 3 trial has been initiated. Proof of concept data due 2H 2021.</div></td><td>
              52m
            </td><td>
              7.5b
            </td><td>
              181.2k
            </td><td>
              466.1k
            </td><td>
              6.64
            </td><td>
              $135.44
            </td><td>
              $134.13
            </td><td>
              September 30, 2023
            </td><td>
              1.14b
            </td><td>
              -31.12m
            </td><td>
              36.65
            </td><td>
              0.91b
            </td><td>
              5.77b
            </td><td>
              0.9
            </td><td>
              40,808,627
            </td><td>
              05/07/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PTCT" class="margin-bottom-1">
                PTCT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$39.58</div> <small class="number change-up">+1.38<span>&nbsp;&nbsp;</span>+3.61%</small></td><td><strong>PTC-AADC</strong> <br>AADC deficiency
            </td><td>
              BLA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-a-corporate-update-and-reports-second-quarter-2021-financial-results-301344644.html">
                YE 2021
              </a> <div class="note">BLA filing due YE 2021.</div></td><td>
              71m
            </td><td>
              2.8b
            </td><td>
              109.5k
            </td><td>
              412.7k
            </td><td>
              14.24
            </td><td>
              $38.84
            </td><td>
              $38.2
            </td><td>
              N/A
            </td><td>
              0.93b
            </td><td>
              -10.38m
            </td><td>
              89.43
            </td><td>
              -0.93b
            </td><td>
              2.29b
            </td><td>
              0.9
            </td><td>
              49,392,128
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CALA" class="margin-bottom-1">
                CALA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.24</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+4.19%</small></td><td><strong>Telaglenastat (CB-839) - KEAPSAKE</strong> <br>Non-small cell lung cancer (NSCLC) patients with genetic mutation NRF2/KEAP1
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-reports-second-quarter-2021-financial">
                4Q 2021
              </a> <div class="note">Phase 2 interim data due 4Q 2021.</div></td><td>
              74m
            </td><td>
              166.0m
            </td><td>
              266.2k
            </td><td>
              0.8m
            </td><td>
              2.00
            </td><td>
              $2.18
            </td><td>
              $2.15
            </td><td>
              July 2022
            </td><td>
              85.53m
            </td><td>
              -3.71m
            </td><td>
              23.07
            </td><td>
              70.69m
            </td><td>
              70.81m
            </td><td>
              1
            </td><td>
              51,184,451
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NXTC" class="margin-bottom-1">
                NXTC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.37</div> <small class="number change-up">+0.36<span>&nbsp;&nbsp;</span>+5.14%</small></td><td><strong>NC318</strong> <br>Solid tumors
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://ir.nextcure.com/news-releases/news-release-details/nextcure-reports-second-quarter-2021-financial-results">
                4Q 2021
              </a> <div class="note">Phase 2 monotherapy data due 4Q 2021.</div></td><td>
              28m
            </td><td>
              203.5m
            </td><td>
              319.9k
            </td><td>
              283.1k
            </td><td>
              0.77
            </td><td>
              $7.01
            </td><td>
              $7.01
            </td><td>
              December 15, 2023
            </td><td>
              239.19m
            </td><td>
              -5.74m
            </td><td>
              41.67
            </td><td>
              227.43m
            </td><td>
              -53.32m
            </td><td>
              2.5
            </td><td>
              25,967,303
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GSK" class="margin-bottom-1">
                GSK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$41.57</div> <small class="number change-down">-0.28<span>&nbsp;&nbsp;</span>-0.67%</small></td><td><strong>Adjuvanted COVID-19 vaccine</strong> <br>COVID-19 vaccine
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.gsk.com/media/7129/q2-2021-results-slides.pdf">
                4Q 2021
              </a> <div class="note">Phase 3 trial initiation announced May 27, 2021 with data due around 4Q 2021.</div></td><td>
              3b
            </td><td>
              104.6b
            </td><td>
              2.3m
            </td><td>
              4.2m
            </td><td>
              4.95
            </td><td>
              $41.75
            </td><td>
              $41.85
            </td><td>
              N/A
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -51.10b
            </td><td>
              133.80b
            </td><td>
              0.2
            </td><td>
              2,506,785,977
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SNY" class="margin-bottom-1">
                SNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$52.48</div> <small class="number change-down">-0.64<span>&nbsp;&nbsp;</span>-1.20%</small></td><td><strong>Adjuvanted COVID-19 vaccine</strong> <br>COVID-19 vaccine
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.gsk.com/media/7129/q2-2021-results-slides.pdf">
                4Q 2021
              </a> <div class="note">Phase 3 trial initiation announced May 27, 2021 with data due around 4Q 2021.</div></td><td>
              3b
            </td><td>
              131.7b
            </td><td>
              2.5m
            </td><td>
              1.7m
            </td><td>
              1.78
            </td><td>
              $52.73
            </td><td>
              $53.12
            </td><td>
              N/A
            </td><td>
              9.72b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -39.23b
            </td><td>
              146.90b
            </td><td>
              0
            </td><td>
              2,510,366,030
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVS" class="margin-bottom-1">
                NVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$93.88</div> <small class="number change-up">+0.55<span>&nbsp;&nbsp;</span>+0.59%</small></td><td><strong>Canakinumab (ACZ885) - CANOPY-1</strong> <br>Non-small cell lung cancer (NSCLC)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.pdf">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              2b
            </td><td>
              210.0b
            </td><td>
              0.7m
            </td><td>
              1.7m
            </td><td>
              3.89
            </td><td>
              $93.86
            </td><td>
              $93.33
            </td><td>
              August 9, 2021
            </td><td>
              7.84b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -62.05b
            </td><td>
              238.51b
            </td><td>
              0
            </td><td>
              2,236,739,037
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVS" class="margin-bottom-1">
                NVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$93.88</div> <small class="number change-up">+0.55<span>&nbsp;&nbsp;</span>+0.59%</small></td><td><strong>Ligelizumab (QGE031) - Pearl 1</strong> <br>Chronic spontaneous urticaria 
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.pdf">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              2b
            </td><td>
              210.0b
            </td><td>
              0.7m
            </td><td>
              1.7m
            </td><td>
              3.89
            </td><td>
              $93.86
            </td><td>
              $93.33
            </td><td>
              July 16, 2021
            </td><td>
              7.84b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -62.05b
            </td><td>
              238.51b
            </td><td>
              0
            </td><td>
              2,236,739,037
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TVTX" class="margin-bottom-1">
                TVTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.41</div> <small class="number change-up">+1.22<span>&nbsp;&nbsp;</span>+6.02%</small></td><td><strong>Pegtibatinase (TVT-058)</strong> <br>Classical homocystinuria (HCU) 
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-reports-second-quarter-2021-financial">
                2021
              </a> <div class="note">Phase 1/2 top-line data due 2021.</div></td><td>
              61m
            </td><td>
              1.3b
            </td><td>
              0.6m
            </td><td>
              1.4m
            </td><td>
              3.91
            </td><td>
              $20.31
            </td><td>
              $20.19
            </td><td>
              N/A
            </td><td>
              0.53b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              112.22m
            </td><td>
              0.92b
            </td><td>
              5.5
            </td><td>
              60,239,404
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TENX" class="margin-bottom-1">
                TENX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.50</div> <small class="number change-up">+0.10<span>&nbsp;&nbsp;</span>+7.14%</small></td><td><strong>Imatinib</strong> <br>Pulmonary arterial hypertension (PAH)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210517005819/en/">
                2H 2021
              </a> <div class="note">Phase 1 trial to be completed 2H 2021.</div></td><td>
              25m
            </td><td>
              37.8m
            </td><td>
              29.8k
            </td><td>
              132.5k
            </td><td>
              25.00
            </td><td>
              $1.44
            </td><td>
              $1.4
            </td><td>
              N/A
            </td><td>
              11.08m
            </td><td>
              -0.62m
            </td><td>
              18.01
            </td><td>
              9.66m
            </td><td>
              33.44m
            </td><td>
              6.4
            </td><td>
              20,847,723
            </td><td>
              05/17/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AVXL" class="margin-bottom-1">
                AVXL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$19.41</div> <small class="number change-up">+1.05<span>&nbsp;&nbsp;</span>+5.72%</small></td><td><strong>ANAVEX 2-73-RS-003 EXCELLENCE</strong> <br>Pediatric Rett Syndrome 
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.anavex.com/wp-content/uploads/2021/08/Anavex-Presentation-August-2021.pdf">
                2H 2021
              </a> <div class="note">Phase 2/3 top-line data due 2H 2021.</div></td><td>
              76m
            </td><td>
              1.5b
            </td><td>
              0.5m
            </td><td>
              3.2m
            </td><td>
              9.33
            </td><td>
              $18.68
            </td><td>
              $18.36
            </td><td>
              November 2021
            </td><td>
              153.05m
            </td><td>
              -2.51m
            </td><td>
              61.05
            </td><td>
              143.77m
            </td><td>
              1.23b
            </td><td>
              14.5
            </td><td>
              73,309,486
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RGNX" class="margin-bottom-1">
                RGNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$31.30</div> <small class="number change-up">+1.67<span>&nbsp;&nbsp;</span>+5.62%</small></td><td><strong>RGX-314 - ALTITUDE</strong> <br>Diabetic retinopathy 
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/regenxbio-reports-second-quarter-2021-financial-results-and-operational-highlights-301351442.html">
                4Q 2021
              </a> <div class="note">Phase 2 initial data due 4Q 2021.</div></td><td>
              43m
            </td><td>
              1.3b
            </td><td>
              148.8k
            </td><td>
              336.5k
            </td><td>
              2.63
            </td><td>
              $30.18
            </td><td>
              $29.63
            </td><td>
              May 2021
            </td><td>
              356.81m
            </td><td>
              -9.96m
            </td><td>
              35.83
            </td><td>
              27.66m
            </td><td>
              0.97b
            </td><td>
              1.1
            </td><td>
              33,768,385
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLSD" class="margin-bottom-1">
                CLSD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.95</div> <small class="number change-up">+0.30<span>&nbsp;&nbsp;</span>+5.31%</small></td><td><strong>RGX-314 - ALTITUDE</strong> <br>Diabetic retinopathy 
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/regenxbio-reports-second-quarter-2021-financial-results-and-operational-highlights-301351442.html">
                4Q 2021
              </a> <div class="note">Phase 2 initial data due 4Q 2021.</div></td><td>
              59m
            </td><td>
              353.9m
            </td><td>
              0.8m
            </td><td>
              4.0m
            </td><td>
              18.03
            </td><td>
              $5.66
            </td><td>
              $5.65
            </td><td>
              May 2021
            </td><td>
              22.24m
            </td><td>
              -2.32m
            </td><td>
              9.60
            </td><td>
              12.99m
            </td><td>
              310.48m
            </td><td>
              9
            </td><td>
              47,643,724
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DTIL" class="margin-bottom-1">
                DTIL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.98</div> <small class="number change-up">+0.57<span>&nbsp;&nbsp;</span>+6.06%</small></td><td><strong>PBCAR269A</strong> <br>Multiple myeloma
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210812005158/en/">
                2H 2021
              </a> <div class="note">Phase 1/2 data due 2H 2021.</div></td><td>
              60m
            </td><td>
              0.6b
            </td><td>
              215.5k
            </td><td>
              0.6m
            </td><td>
              5.91
            </td><td>
              $9.55
            </td><td>
              $9.41
            </td><td>
              December 2021
            </td><td>
              155.14m
            </td><td>
              -10.45m
            </td><td>
              14.85
            </td><td>
              25.58m
            </td><td>
              398.70m
            </td><td>
              11
            </td><td>
              53,284,783
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMMP" class="margin-bottom-1">
                IMMP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.35</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+0.45%</small></td><td><strong>Eftilagimod Alpha  - Active Immunotherapy PAClitaxel (AIPAC)</strong> <br>Metastatic breast cancer (MBC) 
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/07/13/2261873/0/en/Immutep-Quarterly-Activities-Report.html">
                2H 2021
              </a> <div class="note">Phase 2b final overall survival data due 2H 2021.</div></td><td>
              65m
            </td><td>
              217.0m
            </td><td>
              184.3k
            </td><td>
              340.0k
            </td><td>
              4.99
            </td><td>
              $3.33
            </td><td>
              $3.33
            </td><td>
              March 2020
            </td><td>
              54.88m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              39.10m
            </td><td>
              171.73m
            </td><td>
              0
            </td><td>
              64,872,528
            </td><td>
              07/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NRIX" class="margin-bottom-1">
                NRIX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$32.99</div> <small class="number change-up">+1.48<span>&nbsp;&nbsp;</span>+4.68%</small></td><td><strong>NX-2127</strong> <br>B-cell malignancies
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-reports-second-quarter-fiscal-2021-financial">
                YE 2021
              </a> <div class="note">Phase 1 initial pharmacokinetic (PK) and pharmacodynamic (PD) data from the dose escalation portion is due by YE 2021.</div></td><td>
              44m
            </td><td>
              1.5b
            </td><td>
              133.1k
            </td><td>
              463.7k
            </td><td>
              3.68
            </td><td>
              $32
            </td><td>
              $31.52
            </td><td>
              October 2023
            </td><td>
              356.59m
            </td><td>
              -10.51m
            </td><td>
              33.92
            </td><td>
              236.79m
            </td><td>
              1.01b
            </td><td>
              0.9
            </td><td>
              31,121,458
            </td><td>
              07/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ZLAB" class="margin-bottom-1">
                ZLAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$143.17</div> <small class="number change-up">+9.00<span>&nbsp;&nbsp;</span>+6.71%</small></td><td><strong>ZEJULA (Niraparib) - PRIME</strong> <br>Ovarian cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://www.zailaboratory.com/in7/index.aspx">
                2H 2021
              </a> <div class="note">Phase 3 (China) data due 2H 2021.</div></td><td>
              75m
            </td><td>
              10.8b
            </td><td>
              320.4k
            </td><td>
              0.6m
            </td><td>
              33.30
            </td><td>
              $135
            </td><td>
              $134.17
            </td><td>
              N/A
            </td><td>
              1.73b
            </td><td>
              -21.95m
            </td><td>
              78.68
            </td><td>
              1.50b
            </td><td>
              1.78b
            </td><td>
              0
            </td><td>
              75,375,511
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PGEN" class="margin-bottom-1">
                PGEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.04</div> <small class="number change-up">+0.42<span>&nbsp;&nbsp;</span>+7.56%</small></td><td><strong>PRGN-2009 AdenoVerse</strong> <br>HPV+ solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/precigen-reports-second-quarter-and-first-half-2021-financial-results-301351238.html">
                4Q 2021
              </a> <div class="note">Phase 1 interim data to be presented 4Q 2021.</div></td><td>
              207m
            </td><td>
              1.2b
            </td><td>
              341.3k
            </td><td>
              1.2m
            </td><td>
              7.85
            </td><td>
              $5.75
            </td><td>
              $5.62
            </td><td>
              October 1, 2023
            </td><td>
              110.44m
            </td><td>
              -2.59m
            </td><td>
              42.61
            </td><td>
              -132.94m
            </td><td>
              1.24b
            </td><td>
              2.1
            </td><td>
              94,205,701
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RDUS" class="margin-bottom-1">
                RDUS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.74</div> <small class="number change-up">+0.59<span>&nbsp;&nbsp;</span>+4.49%</small></td><td><strong>TYMLOS (Abaloparatide) -Transdermal Patch (wearABLe)</strong> <br>Osteoporosis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.radiuspharm.com/news-releases/news-release-details/radius-health-business-update-1">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              47m
            </td><td>
              0.6b
            </td><td>
              160.9k
            </td><td>
              340.8k
            </td><td>
              -2.86
            </td><td>
              $13.22
            </td><td>
              $13.15
            </td><td>
              September 2021
            </td><td>
              90.18m
            </td><td>
              -5.00m
            </td><td>
              18.05
            </td><td>
              -329.76m
            </td><td>
              0.86b
            </td><td>
              0.9
            </td><td>
              33,375,071
            </td><td>
              07/27/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ANNX" class="margin-bottom-1">
                ANNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.34</div> <small class="number change-up">+0.58<span>&nbsp;&nbsp;</span>+3.49%</small></td><td><strong>ANX005</strong> <br>Warm autoimmune hemolytic anemia (WAIHA)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.annexonbio.com/news-releases/news-release-details/annexon-biosciences-reports-third-quarter-2020-financial-results">
                2H 2021
              </a> <div class="note">Phase 2 trial to be initiated early 2021 with data due 2H 2021.</div></td><td>
              38m
            </td><td>
              0.7b
            </td><td>
              64.4k
            </td><td>
              162.5k
            </td><td>
              2.25
            </td><td>
              $17.05
            </td><td>
              $16.75
            </td><td>
              November 15, 2021
            </td><td>
              287.59m
            </td><td>
              -8.22m
            </td><td>
              34.99
            </td><td>
              251.14m
            </td><td>
              366.09m
            </td><td>
              0
            </td><td>
              36,335,026
            </td><td>
              01/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KZIA" class="margin-bottom-1">
                KZIA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.18</div> <small class="number change-up">+0.26<span>&nbsp;&nbsp;</span>+2.91%</small></td><td><strong>Paxalisib (GDC-0084)</strong> <br>Glioblastoma multiforme
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://kza.irmau.com/irm/PDF/38e6c640-ebca-4e21-b9d5-61e5ab9bde2e/KaziapresentstoHCWBIOCONNECT">
                2H 2021
              </a> <div class="note">Phase 2 data to be presented at SNO meeting November 2020. Median PFS 8.4 months vs 5.3 months for temozolomide; OS 17.5 months vs 12.7 months for temozolomide. Final data due 2H 2021.</div></td><td>
              13m
            </td><td>
              119.0m
            </td><td>
              5.6k
            </td><td>
              26.4k
            </td><td>
              5.25
            </td><td>
              $9.05
            </td><td>
              $8.92
            </td><td>
              March 30, 2020
            </td><td>
              34.37m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              26.43m
            </td><td>
              102.41m
            </td><td>
              0
            </td><td>
              12,942,234
            </td><td>
              06/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ANNX" class="margin-bottom-1">
                ANNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.34</div> <small class="number change-up">+0.58<span>&nbsp;&nbsp;</span>+3.49%</small></td><td><strong>ANX005</strong> <br>Huntington’s disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.annexonbio.com/news-releases/news-release-details/annexon-biosciences-reports-second-quarter-2021-financial">
                4Q 2021
              </a> <div class="note">Phase 2 initial data due 4Q 2021.</div></td><td>
              38m
            </td><td>
              0.7b
            </td><td>
              64.4k
            </td><td>
              162.5k
            </td><td>
              2.25
            </td><td>
              $17.05
            </td><td>
              $16.75
            </td><td>
              January 2022
            </td><td>
              287.59m
            </td><td>
              -8.22m
            </td><td>
              34.99
            </td><td>
              251.14m
            </td><td>
              366.09m
            </td><td>
              0
            </td><td>
              36,335,026
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SNDX" class="margin-bottom-1">
                SNDX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.37</div> <small class="number change-up">+0.62<span>&nbsp;&nbsp;</span>+3.94%</small></td><td><strong>Axatilimab (SNDX-6352)</strong> <br>Chronic graft versus host disease (cGVHD)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-clinical-and-business-update-301351309.html">
                4Q 2021
              </a> <div class="note">Phase 1/2 updated data due 4Q 2021.</div></td><td>
              49m
            </td><td>
              0.8b
            </td><td>
              309.6k
            </td><td>
              479.0k
            </td><td>
              3.71
            </td><td>
              $15.87
            </td><td>
              $15.75
            </td><td>
              N/A
            </td><td>
              238.71m
            </td><td>
              -8.01m
            </td><td>
              29.78
            </td><td>
              190.21m
            </td><td>
              0.53b
            </td><td>
              0.4
            </td><td>
              47,742,775
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BLRX" class="margin-bottom-1">
                BLRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.91</div> <small class="number change-up">+0.16<span>&nbsp;&nbsp;</span>+5.82%</small></td><td><strong>AGI-134</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/biolinerx-reports-second-quarter-2021-financial-results-and-provides-corporate-update-301357777.html">
                2H 2021
              </a> <div class="note">Phase 1/2 data due 2H 2021. </div></td><td>
              47m
            </td><td>
              137.6m
            </td><td>
              348.6k
            </td><td>
              1.1m
            </td><td>
              2.12
            </td><td>
              $2.75
            </td><td>
              $2.75
            </td><td>
              March 2022
            </td><td>
              48.05m
            </td><td>
              -2.08m
            </td><td>
              23.14
            </td><td>
              29.10m
            </td><td>
              79.89m
            </td><td>
              0
            </td><td>
              47,274,740
            </td><td>
              08/18/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SWTX" class="margin-bottom-1">
                SWTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$79.84</div> <small class="number change-up">+3.70<span>&nbsp;&nbsp;</span>+4.86%</small></td><td><strong>Nirogacestat (DeFi)</strong> <br>Desmoid tumors
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.springworkstx.com/news-releases/news-release-details/springworks-therapeutics-reports-second-quarter-2021-financial">
                2H 2021
              </a> <div class="note">Phase 3 top-line data due 2H 2021.</div></td><td>
              49m
            </td><td>
              3.9b
            </td><td>
              102.1k
            </td><td>
              245.7k
            </td><td>
              7.90
            </td><td>
              $77.38
            </td><td>
              $76.14
            </td><td>
              December 31, 2021
            </td><td>
              442.66m
            </td><td>
              -11.18m
            </td><td>
              39.61
            </td><td>
              418.82m
            </td><td>
              3.28b
            </td><td>
              4.6
            </td><td>
              22,977,819
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RVNC" class="margin-bottom-1">
                RVNC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$27.34</div> <small class="number change-up">+0.37<span>&nbsp;&nbsp;</span>+1.37%</small></td><td><strong>DAXI  (RT002) - ASPEN-1/ASPEN-OLS</strong> <br>Cervical dystonia
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005976/en/">
                2H 2021
              </a> <div class="note">Phase 3 trial met primary and secondary endpoints - October 14, 2020. Open label safety data due 2H 2021.</div></td><td>
              72m
            </td><td>
              2.0b
            </td><td>
              79.6k
            </td><td>
              432.4k
            </td><td>
              10.56
            </td><td>
              $27.17
            </td><td>
              $26.97
            </td><td>
              December 3, 2019
            </td><td>
              306.89m
            </td><td>
              -16.33m
            </td><td>
              18.79
            </td><td>
              -147.75m
            </td><td>
              1.93b
            </td><td>
              2.5
            </td><td>
              69,053,708
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RARE" class="margin-bottom-1">
                RARE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$84.15</div> <small class="number change-up">+3.99<span>&nbsp;&nbsp;</span>+4.98%</small></td><td><strong>GTX-102</strong> <br>Angelman Syndrome
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-reports-second-quarter-2021-financial-results-and#">
                YE 2021
              </a> <div class="note">Phase 1/2 U.K. and Canada trial to commence 2H 2021 with data due by end of 2021.</div></td><td>
              68m
            </td><td>
              5.7b
            </td><td>
              194.5k
            </td><td>
              0.7m
            </td><td>
              5.87
            </td><td>
              $81.36
            </td><td>
              $80.16
            </td><td>
              January 2022
            </td><td>
              0.81b
            </td><td>
              -21.79m
            </td><td>
              37.02
            </td><td>
              266.27m
            </td><td>
              4.64b
            </td><td>
              1.8
            </td><td>
              41,022,035
            </td><td>
              08/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FNCH" class="margin-bottom-1">
                FNCH
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.11</div> <small class="number change-up">+0.28<span>&nbsp;&nbsp;</span>+2.18%</small></td><td><strong>CP101 (PRISM-EXT)</strong> <br>C. difficile Infection
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.finchtherapeutics.com/news-releases/news-release-details/finch-therapeutics-reports-second-quarter-2021-financial-results">
                2H 2021
              </a> <div class="note">Phase 2 open-label data due 2H 2021.</div></td><td>
              47m
            </td><td>
              0.6b
            </td><td>
              6.7k
            </td><td>
              84.9k
            </td><td>
              2.73
            </td><td>
              $12.65
            </td><td>
              $12.83
            </td><td>
              December 31, 2020
            </td><td>
              153.87m
            </td><td>
              -7.93m
            </td><td>
              19.41
            </td><td>
              131.73m
            </td><td>
              417.56m
            </td><td>
              6.8
            </td><td>
              27,059,349
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLDX" class="margin-bottom-1">
                CLDX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$48.69</div> <small class="number change-up">+1.14<span>&nbsp;&nbsp;</span>+2.40%</small></td><td><strong>CDX-1140</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.celldex.com/news-releases/news-release-details/celldex-reports-second-quarter-2021-financial-results-and">
                2H 2021
              </a> <div class="note">Phase 1 updated data to be presented later in 2021.</div></td><td>
              46m
            </td><td>
              2.3b
            </td><td>
              345.8k
            </td><td>
              1.0m
            </td><td>
              12.42
            </td><td>
              $48.35
            </td><td>
              $47.55
            </td><td>
              August 2021
            </td><td>
              444.38m
            </td><td>
              -3.98m
            </td><td>
              111.75
            </td><td>
              422.11m
            </td><td>
              2.05b
            </td><td>
              14.1
            </td><td>
              46,253,150
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SWTX" class="margin-bottom-1">
                SWTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$79.84</div> <small class="number change-up">+3.70<span>&nbsp;&nbsp;</span>+4.86%</small></td><td><strong>Mirdametinib and lifirafenib</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.springworkstx.com/news-releases/news-release-details/springworks-therapeutics-reports-second-quarter-2021-financial">
                2021
              </a> <div class="note">Phase 1b/2 initial data due 2021.</div></td><td>
              49m
            </td><td>
              3.9b
            </td><td>
              102.1k
            </td><td>
              245.7k
            </td><td>
              7.90
            </td><td>
              $77.38
            </td><td>
              $76.14
            </td><td>
              March 30, 2024
            </td><td>
              442.66m
            </td><td>
              -11.18m
            </td><td>
              39.61
            </td><td>
              418.82m
            </td><td>
              3.28b
            </td><td>
              4.6
            </td><td>
              22,977,819
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ADCT" class="margin-bottom-1">
                ADCT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$25.83</div> <small class="number change-up">+0.58<span>&nbsp;&nbsp;</span>+2.30%</small></td><td><strong>ZYNLONTA (Loncastuximab Tesirine) and RITUXAN (rituximab) - (LOTIS 5)</strong> <br>Diffuse Large B-Cell Lymphoma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210803005236/en/">
                2H 2021
              </a> <div class="note">Phase 3 safety lead-in to be completed 2H 2021.</div></td><td>
              78m
            </td><td>
              2.0b
            </td><td>
              108.0k
            </td><td>
              269.1k
            </td><td>
              8.28
            </td><td>
              $25.42
            </td><td>
              $25.25
            </td><td>
              June 30, 2025
            </td><td>
              337.08m
            </td><td>
              -19.34m
            </td><td>
              17.43
            </td><td>
              116.61m
            </td><td>
              1.75b
            </td><td>
              0
            </td><td>
              31,110,099
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TCON" class="margin-bottom-1">
                TCON
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.80</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+3.83%</small></td><td><strong>Envafolimab (ENVASARC)</strong> <br>Sarcomas
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.traconpharma.com/news-releases/news-release-details/tracon-pharmaceuticals-reports-second-quarter-2021-financial">
                4Q 2021
              </a> <div class="note">Phase 3 trial to continue as planned following second review by DSMB - August 9, 2021. Interim efficacy data 4Q 2021. Final data due 2022.</div></td><td>
              19m
            </td><td>
              73.8m
            </td><td>
              158.2k
            </td><td>
              326.5k
            </td><td>
              6.23
            </td><td>
              $3.65
            </td><td>
              $3.66
            </td><td>
              July 2022
            </td><td>
              38.08m
            </td><td>
              -1.39m
            </td><td>
              27.37
            </td><td>
              23.19m
            </td><td>
              48.30m
            </td><td>
              2.1
            </td><td>
              13,231,871
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CRSP" class="margin-bottom-1">
                CRSP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$124.83</div> <small class="number change-up">+7.61<span>&nbsp;&nbsp;</span>+6.49%</small></td><td><strong>CTX130</strong> <br>T or B Cell Malignancies
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/07/29/2271807/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Second-Quarter-2021-Financial-Results.html">
                2021
              </a> <div class="note">Phase 1 top-line data due 2021.</div></td><td>
              76m
            </td><td>
              9.5b
            </td><td>
              0.8m
            </td><td>
              1.4m
            </td><td>
              3.65
            </td><td>
              $120.39
            </td><td>
              $117.22
            </td><td>
              March 2027
            </td><td>
              3.07b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              2.78b
            </td><td>
              6.53b
            </td><td>
              1.9
            </td><td>
              52,414,588
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IOVA" class="margin-bottom-1">
                IOVA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.93</div> <small class="number change-up">+0.76<span>&nbsp;&nbsp;</span>+3.59%</small></td><td><strong>LN-145 (IOV-COM-202)</strong> <br>Non-small cell lung cancer (NSCLC)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.iovance.com/news-releases/news-release-details/iovance-biotherapeutics-reports-second-quarter-and-first-half">
                2H 2021
              </a> <div class="note">Phase 2 data released June 29, 2021. 21.4% Overall Response Rate (ORR). Further data due 2H 2021.</div></td><td>
              155m
            </td><td>
              3.4b
            </td><td>
              1.0m
            </td><td>
              1.9m
            </td><td>
              4.57
            </td><td>
              $21.49
            </td><td>
              $21.17
            </td><td>
              December 2023
            </td><td>
              0.62b
            </td><td>
              -18.00m
            </td><td>
              34.66
            </td><td>
              0.52b
            </td><td>
              2.68b
            </td><td>
              13.6
            </td><td>
              129,864,177
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MTEM" class="margin-bottom-1">
                MTEM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.61</div> <small class="number change-down">-0.05<span>&nbsp;&nbsp;</span>-0.75%</small></td><td><strong>TAK-169 (CD38 ETB)</strong> <br>Multiple Myeloma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2280164/0/en/Molecular-Templates-Inc-Reports-Second-Quarter-2021-Financial-Results.html">
                4Q 2021
              </a> <div class="note">Phase 1 update 4Q 2021.</div></td><td>
              56m
            </td><td>
              371.1m
            </td><td>
              102.9k
            </td><td>
              210.5k
            </td><td>
              3.82
            </td><td>
              $6.76
            </td><td>
              $6.66
            </td><td>
              January 17, 2023
            </td><td>
              182.40m
            </td><td>
              -8.44m
            </td><td>
              21.60
            </td><td>
              35.05m
            </td><td>
              224.74m
            </td><td>
              10.5
            </td><td>
              28,015,505
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CNTA" class="margin-bottom-1">
                CNTA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.18</div> <small class="number change-up">+0.11<span>&nbsp;&nbsp;</span>+0.52%</small></td><td><strong>ZF874 (Z Factor)</strong> <br>Alpha-1-antitrypsin deficiency (A1ATD)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-second-quarter-2021-financial">
                YE 2021
              </a> <div class="note">Phase 1 update due by the end of 2021.</div></td><td>
              90m
            </td><td>
              1.9b
            </td><td>
              32.8k
            </td><td>
              197.6k
            </td><td>
              
            </td><td>
              $21.2
            </td><td>
              $21.07
            </td><td>
              N/A
            </td><td>
              0.61b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              0.56b
            </td><td>
              1.84b
            </td><td>
              1
            </td><td>
              89,000,772
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RZLT" class="margin-bottom-1">
                RZLT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.61</div> <small class="number change-down">-0.30<span>&nbsp;&nbsp;</span>-3.03%</small></td><td><strong>RZ358</strong> <br>Congenital hyperinsulinism (CHI)
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.rezolutebio.com/news/press-releases/detail/280/rezolute-reports-third-quarter-fiscal-2021-financial">
                2H 2021
              </a> <div class="note">Phase 2b top-line data due 2H 2021.</div></td><td>
              8m
            </td><td>
              81.5m
            </td><td>
              4.3k
            </td><td>
              25.8k
            </td><td>
              2.80
            </td><td>
              $10
            </td><td>
              $9.91
            </td><td>
              December 2021
            </td><td>
              23.29m
            </td><td>
              -1.80m
            </td><td>
              12.95
            </td><td>
              19.49m
            </td><td>
              52.60m
            </td><td>
              47.3
            </td><td>
              3,404,394
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GSK" class="margin-bottom-1">
                GSK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$41.57</div> <small class="number change-down">-0.28<span>&nbsp;&nbsp;</span>-0.67%</small></td><td><strong>BLENREP (belantamab mafodotin) - (DREAMM 5)</strong> <br>Multiple Myeloma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.gsk.com/media/7129/q2-2021-results-slides.pdf">
                2H 2021
              </a> <div class="note">Phase 3 initial data due 2H 2021.</div></td><td>
              3b
            </td><td>
              104.6b
            </td><td>
              2.3m
            </td><td>
              4.2m
            </td><td>
              4.95
            </td><td>
              $41.75
            </td><td>
              $41.85
            </td><td>
              February 21, 2025
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -51.10b
            </td><td>
              133.80b
            </td><td>
              0.2
            </td><td>
              2,506,785,977
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/JAZZ" class="margin-bottom-1">
                JAZZ
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$137.82</div> <small class="number change-up">+4.33<span>&nbsp;&nbsp;</span>+3.24%</small></td><td><strong>SATIVEX (nabiximols)</strong> <br>Spasticity due multiple sclerosis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.gwpharm.com/ir/press-releases/gw-pharmaceuticals-provides-preliminary-fourth-quarter-and-full-year-2020-net">
                2021
              </a> <div class="note">Phase 3 data due 2021.</div></td><td>
              61m
            </td><td>
              8.4b
            </td><td>
              314.3k
            </td><td>
              0.7m
            </td><td>
              2.04
            </td><td>
              $134.38
            </td><td>
              $133.5
            </td><td>
              October 5, 2022
            </td><td>
              0.92b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -8.17b
            </td><td>
              14.19b
            </td><td>
              5.1
            </td><td>
              53,264,605
            </td><td>
              06/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ANAB" class="margin-bottom-1">
                ANAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$25.65</div> <small class="number change-up">+1.42<span>&nbsp;&nbsp;</span>+5.86%</small></td><td><strong>Imsidolimab (ANB019) - (EMERGE)</strong> <br>EGFRi-Mediated Skin Toxicity
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/09/2277409/0/en/AnaptysBio-Announces-Second-Quarter-2021-Financial-Results-and-Provides-Pipeline-Updates.html">
                YE 2021
              </a> <div class="note">Phase 2 interim top-line data due end of 2021.</div></td><td>
              27m
            </td><td>
              0.7b
            </td><td>
              43.4k
            </td><td>
              221.0k
            </td><td>
              1.82
            </td><td>
              $24.54
            </td><td>
              $24.23
            </td><td>
              N/A
            </td><td>
              416.61m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              375.77m
            </td><td>
              294.64m
            </td><td>
              2
            </td><td>
              19,169,175
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IGMS" class="margin-bottom-1">
                IGMS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$79.19</div> <small class="number change-up">+4.04<span>&nbsp;&nbsp;</span>+5.38%</small></td><td><strong>IGM-2323</strong> <br>Relapsed/refractory B cell Non-Hodgkin’s lymphoma (NHL)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/09/2277444/0/en/IGM-Biosciences-Announces-Second-Quarter-2021-Financial-Results-and-Provides-Corporate-Update.html">
                2H 2021
              </a> <div class="note">Phase 1 initial data presented at ASH December 5, 2020. 2/14 complete responses. Expects to establish a recommended Phase 2 dose in 2021.</div></td><td>
              32m
            </td><td>
              2.5b
            </td><td>
              72.3k
            </td><td>
              146.7k
            </td><td>
              7.87
            </td><td>
              $76.25
            </td><td>
              $75.15
            </td><td>
              September 2021
            </td><td>
              265.63m
            </td><td>
              -8.78m
            </td><td>
              30.24
            </td><td>
              237.43m
            </td><td>
              2.14b
            </td><td>
              1
            </td><td>
              8,026,991
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CNTB" class="margin-bottom-1">
                CNTB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.20</div> <small class="number change-down">-0.09<span>&nbsp;&nbsp;</span>-0.41%</small></td><td><strong>CBP-201</strong> <br>Atopic dermatitis
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.connectbiopharm.com/news-releases/news-release-details/connect-biopharma-completes-enrollment-cbp-201-global-phase-2">
                2H 2021
              </a> <div class="note">Phase 2b top-line data due 2H 2021.</div></td><td>
              58m
            </td><td>
              1.3b
            </td><td>
              59.3k
            </td><td>
              64.5k
            </td><td>
              -8.10
            </td><td>
              $21.71
            </td><td>
              $22.29
            </td><td>
              September 30, 2021
            </td><td>
              
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              1.12b
            </td><td>
              0
            </td><td>
              57,504,175
            </td><td>
              05/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KZIA" class="margin-bottom-1">
                KZIA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.18</div> <small class="number change-up">+0.26<span>&nbsp;&nbsp;</span>+2.91%</small></td><td><strong>Paxalisib (GDC-0084)</strong> <br>Breast cancer brain metastases
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.kaziatherapeutics.com/site/PDF/c60112d5-cc66-4903-9654-f7fd9520a20a/KaziaCorporatePresentation">
                2H 2021
              </a> <div class="note">Phase 2 initial data due 2H 2021.</div></td><td>
              13m
            </td><td>
              119.0m
            </td><td>
              5.6k
            </td><td>
              26.4k
            </td><td>
              5.25
            </td><td>
              $9.05
            </td><td>
              $8.92
            </td><td>
              November 30, 2021
            </td><td>
              34.37m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              26.43m
            </td><td>
              102.41m
            </td><td>
              0
            </td><td>
              12,942,234
            </td><td>
              06/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ABBV" class="margin-bottom-1">
                ABBV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$119.82</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+0.84%</small></td><td><strong>Cenicriviroc (CVC)</strong> <br>Nonalcoholic steatohepatitis (NASH)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.allergan.com/news/assets/2q19-faq.aspx">
                2021
              </a> <div class="note">Phase 3 data due 2021.</div></td><td>
              2b
            </td><td>
              211.7b
            </td><td>
              2.6m
            </td><td>
              5.7m
            </td><td>
              16.85
            </td><td>
              $119.8
            </td><td>
              $118.82
            </td><td>
              January 12, 2021
            </td><td>
              11.53b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -123.84b
            </td><td>
              283.51b
            </td><td>
              0.1
            </td><td>
              1,765,652,810
            </td><td>
              05/17/2020
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MTEM" class="margin-bottom-1">
                MTEM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.61</div> <small class="number change-down">-0.05<span>&nbsp;&nbsp;</span>-0.75%</small></td><td><strong>MT-6402</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2280164/0/en/Molecular-Templates-Inc-Reports-Second-Quarter-2021-Financial-Results.html">
                4Q 2021
              </a> <div class="note">Phase 1 commencement of dosing announced July 9, 2021. Update due 4Q 2021.</div></td><td>
              56m
            </td><td>
              371.1m
            </td><td>
              102.9k
            </td><td>
              210.5k
            </td><td>
              3.82
            </td><td>
              $6.76
            </td><td>
              $6.66
            </td><td>
              April 2025
            </td><td>
              182.40m
            </td><td>
              -8.44m
            </td><td>
              21.60
            </td><td>
              35.05m
            </td><td>
              224.74m
            </td><td>
              10.5
            </td><td>
              28,015,505
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ELOX" class="margin-bottom-1">
                ELOX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.47</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+1.03%</small></td><td><strong>ELX-02</strong> <br>Cystic fibrosis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.eloxxpharma.com/news-releases/news-release-details/eloxx-pharmaceuticals-reports-second-quarter-2021-financial-and">
                4Q 2021
              </a> <div class="note">Phase 2 data due 4Q 2021.</div></td><td>
              86m
            </td><td>
              126.3m
            </td><td>
              403.5k
            </td><td>
              1.5m
            </td><td>
              3.12
            </td><td>
              $1.45
            </td><td>
              $1.45
            </td><td>
              May 14, 2021
            </td><td>
              102.61m
            </td><td>
              -3.27m
            </td><td>
              31.42
            </td><td>
              82.64m
            </td><td>
              79.46m
            </td><td>
              22.8
            </td><td>
              73,345,670
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SURF" class="margin-bottom-1">
                SURF
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.16</div> <small class="number change-up">+0.62<span>&nbsp;&nbsp;</span>+11.30%</small></td><td><strong>SRF617</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.surfaceoncology.com/news-releases/news-release-details/surface-oncology-reports-financial-results-and-corporate-12">
                Late-2021
              </a> <div class="note">Phase 1 update June 4, 2021 noted stable disease of 7 of 19 evaluable patients (37%). Further data due late-2021.</div></td><td>
              40m
            </td><td>
              245.6m
            </td><td>
              0.9m
            </td><td>
              0.9m
            </td><td>
              2.14
            </td><td>
              $5.71
            </td><td>
              $5.53
            </td><td>
              N/A
            </td><td>
              156.92m
            </td><td>
              -4.09m
            </td><td>
              38.38
            </td><td>
              99.49m
            </td><td>
              74.24m
            </td><td>
              3.1
            </td><td>
              16,778,222
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FREQ" class="margin-bottom-1">
                FREQ
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.56</div> <small class="number change-up">+0.33<span>&nbsp;&nbsp;</span>+4.56%</small></td><td><strong>FX-322-113</strong> <br>Severe Sensorineural Hearing Loss (SNHL)
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210812005055/en/">
                4Q 2021
              </a> <div class="note">Phase 1b data due 4Q 2021.</div></td><td>
              34m
            </td><td>
              260.2m
            </td><td>
              112.4k
            </td><td>
              358.7k
            </td><td>
              1.57
            </td><td>
              $7.33
            </td><td>
              $7.23
            </td><td>
              May 26, 2021
            </td><td>
              158.28m
            </td><td>
              -5.89m
            </td><td>
              26.87
            </td><td>
              104.11m
            </td><td>
              126.31m
            </td><td>
              3
            </td><td>
              24,730,687
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CNTB" class="margin-bottom-1">
                CNTB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.20</div> <small class="number change-down">-0.09<span>&nbsp;&nbsp;</span>-0.41%</small></td><td><strong>CBP-174</strong> <br>Healthy adults
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.connectbiopharm.com/news-releases/news-release-details/connect-biopharma-announces-first-subject-dosed-phase-i-trial">
                2H 2021
              </a> <div class="note">Phase 1 initiation of dosing announced May 25, 2021 with top-line results due 2H 2021.</div></td><td>
              58m
            </td><td>
              1.3b
            </td><td>
              59.3k
            </td><td>
              64.5k
            </td><td>
              -8.10
            </td><td>
              $21.71
            </td><td>
              $22.29
            </td><td>
              October 30, 2021
            </td><td>
              
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              1.12b
            </td><td>
              0
            </td><td>
              57,504,175
            </td><td>
              05/25/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/HOOK" class="margin-bottom-1">
                HOOK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.57</div> <small class="number change-up">+0.04<span>&nbsp;&nbsp;</span>+0.69%</small></td><td><strong>HB-201 and HB-202</strong> <br>Treatment-refractory HPV16+ cancers
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.hookipapharma.com/news-releases/news-release-details/hookipa-pharma-reports-second-quarter-2021-financial-results-and">
                4Q 2021
              </a> <div class="note">Data due to be presented at ASCO June 4, 2021. Data in abstract noted response rate 2/16 (12.5%) for HB-201 monotherapy, 2/2 patients on combo saw stable disease. Further data 4Q 2021.</div></td><td>
              30m
            </td><td>
              196.2m
            </td><td>
              126.4k
            </td><td>
              355.5k
            </td><td>
              1.56
            </td><td>
              $6.67
            </td><td>
              $6.52
            </td><td>
              January 2022
            </td><td>
              90.08m
            </td><td>
              -6.91m
            </td><td>
              13.04
            </td><td>
              49.86m
            </td><td>
              102.02m
            </td><td>
              1
            </td><td>
              22,524,370
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ATNF" class="margin-bottom-1">
                ATNF
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.60</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+4.38%</small></td><td><strong>Anti-TNF programs</strong> <br>Dupuytren’s disease (DD)
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.180lifesciences.com/news-events/press-releases/detail/29/180-life-sciences-corp-announces-collection-of-all-patient">
                4Q 2021
              </a> <div class="note">Phase 2/3 data due 4Q 2021.</div></td><td>
              24m
            </td><td>
              136.6m
            </td><td>
              487.9k
            </td><td>
              429.2k
            </td><td>
              0.56
            </td><td>
              $5.44
            </td><td>
              $5.37
            </td><td>
              N/A
            </td><td>
              14.43m
            </td><td>
              -1.34m
            </td><td>
              10.79
            </td><td>
              -39.12m
            </td><td>
              48.87m
            </td><td>
              0
            </td><td>
              2,887,714
            </td><td>
              04/20/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SYBX" class="margin-bottom-1">
                SYBX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.67</div> <small class="number change-up">+0.22<span>&nbsp;&nbsp;</span>+8.98%</small></td><td><strong>SYNB1891 and TECENTRIQ (atezolizumab)</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/synlogic-reports-second-quarter-financial-results-and-provides-business-update-301353948.html">
                2H 2021
              </a> <div class="note">Phase 1 data due by end of 2021.</div></td><td>
              52m
            </td><td>
              139.8m
            </td><td>
              77.7k
            </td><td>
              228.2k
            </td><td>
              1.09
            </td><td>
              $2.49
            </td><td>
              $2.45
            </td><td>
              May 17, 2021
            </td><td>
              108.66m
            </td><td>
              -3.78m
            </td><td>
              28.73
            </td><td>
              79.85m
            </td><td>
              34.89m
            </td><td>
              2.7
            </td><td>
              37,099,321
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FBIO" class="margin-bottom-1">
                FBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.20</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+4.58%</small></td><td><strong>MB-105</strong> <br>Prostate cancer
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s2.q4cdn.com/336946411/files/doc_presentations/2021/07/Mustang-Bio-Corporate-Presentation-30Jun2021.pdf">
                4Q 2021
              </a> <div class="note">Phase 1 further data due 4Q 2021.</div></td><td>
              101m
            </td><td>
              323.4m
            </td><td>
              220.5k
            </td><td>
              0.5m
            </td><td>
              2.99
            </td><td>
              $3.07
            </td><td>
              $3.06
            </td><td>
              December 31, 2022
            </td><td>
              254.32m
            </td><td>
              -11.49m
            </td><td>
              22.14
            </td><td>
              84.46m
            </td><td>
              120.76m
            </td><td>
              27.4
            </td><td>
              76,232,955
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MBIO" class="margin-bottom-1">
                MBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.81</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+5.24%</small></td><td><strong>MB-105</strong> <br>Prostate cancer
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s2.q4cdn.com/336946411/files/doc_presentations/2021/07/Mustang-Bio-Corporate-Presentation-30Jun2021.pdf">
                4Q 2021
              </a> <div class="note">Phase 1 further data due 4Q 2021.</div></td><td>
              91m
            </td><td>
              256.8m
            </td><td>
              0.9m
            </td><td>
              1.5m
            </td><td>
              1.90
            </td><td>
              $2.73
            </td><td>
              $2.67
            </td><td>
              December 31, 2022
            </td><td>
              122.67m
            </td><td>
              -4.03m
            </td><td>
              30.43
            </td><td>
              114.48m
            </td><td>
              116.29m
            </td><td>
              1.8
            </td><td>
              73,639,109
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AMGN" class="margin-bottom-1">
                AMGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$226.21</div> <small class="number change-up">+2.68<span>&nbsp;&nbsp;</span>+1.20%</small></td><td><strong>Efavaleukin alfa (AMG 592)</strong> <br>Systemic Lupus Erythematosus
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/amgen-reports-second-quarter-2021-financial-results-301347523.html">
                2H 2021
              </a> <div class="note">Phase 1b data to be presented 2H 2021. Phase 2b trial is enrolling.</div></td><td>
              1b
            </td><td>
              128.5b
            </td><td>
              0.9m
            </td><td>
              2.4m
            </td><td>
              15.58
            </td><td>
              $224.18
            </td><td>
              $223.53
            </td><td>
              October 11, 2021
            </td><td>
              8.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -43.19b
            </td><td>
              151.63b
            </td><td>
              0.6
            </td><td>
              566,434,467
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TRIL" class="margin-bottom-1">
                TRIL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.64</div> <small class="number change-up">+11.55<span>&nbsp;&nbsp;</span>+189.74%</small></td><td><strong>TTI-621-01</strong> <br>Diffuse Large B-cell Lymphoma (DLBCL), Cutaneous T-cell lymphoma (CTCL)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s22.q4cdn.com/183592819/files/doc_presentations/2021/Trillium-Corporate-Overview-30-Jun-2021.pdf">
                2H 2021
              </a> <div class="note">Phase 1 TTI-621 monotherapy showed 18-29% ORR in R/R T- and B-cell lymphomas. Update 2H 2021.</div></td><td>
              85m
            </td><td>
              1.8b
            </td><td>
              53.2m
            </td><td>
              1.1m
            </td><td>
              7.57
            </td><td>
              $17.71
            </td><td>
              $6.09
            </td><td>
              December 2021
            </td><td>
              257.65m
            </td><td>
              -3.83m
            </td><td>
              67.33
            </td><td>
              243.53m
            </td><td>
              389.81m
            </td><td>
              0
            </td><td>
              92,491,948
            </td><td>
              08/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ABBV" class="margin-bottom-1">
                ABBV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$119.82</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+0.84%</small></td><td><strong>VENCLEXTA (venetoclax) - CANOVA</strong> <br>Relapsed or refractory multiple myeloma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.abbvie.com/static-files/0f2e0201-ef33-432c-904e-8cf78d2d0929">
                2021
              </a> <div class="note">Phase 3 data due in 2021.</div></td><td>
              2b
            </td><td>
              211.7b
            </td><td>
              2.6m
            </td><td>
              5.7m
            </td><td>
              16.85
            </td><td>
              $119.8
            </td><td>
              $118.82
            </td><td>
              June 12, 2022
            </td><td>
              11.53b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -123.84b
            </td><td>
              283.51b
            </td><td>
              0.1
            </td><td>
              1,765,652,810
            </td><td>
              05/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PTGX" class="margin-bottom-1">
                PTGX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.56</div> <small class="number change-up">+0.34<span>&nbsp;&nbsp;</span>+0.70%</small></td><td><strong>PN-235</strong> <br>Healthy volunteers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/protagonist-therapeutics-reports-second-quarter-2021-financial-results-and-recent-company-progress-301348266.html">
                2H 2021
              </a> <div class="note">Phase 1 trial to be completed 2H 2021.</div></td><td>
              48m
            </td><td>
              2.4b
            </td><td>
              161.0k
            </td><td>
              453.6k
            </td><td>
              6.59
            </td><td>
              $49.6
            </td><td>
              $49.22
            </td><td>
              June 2021
            </td><td>
              340.06m
            </td><td>
              -7.90m
            </td><td>
              43.05
            </td><td>
              293.28m
            </td><td>
              1.99b
            </td><td>
              1.5
            </td><td>
              38,115,527
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ABUS" class="margin-bottom-1">
                ABUS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.15</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+7.88%</small></td><td><strong>AB-836</strong> <br>Hepatitis B
            </td><td>
              Phase 1a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-reports-second-quarter-2021-financial-results-and">
                2H 2021
              </a> <div class="note">Phase 1a/1b initial data due 2H 2021.</div></td><td>
              99m
            </td><td>
              312.4m
            </td><td>
              0.8m
            </td><td>
              1.8m
            </td><td>
              -5.62
            </td><td>
              $3.01
            </td><td>
              $2.92
            </td><td>
              April 2022
            </td><td>
              69.97m
            </td><td>
              -4.67m
            </td><td>
              14.98
            </td><td>
              35.43m
            </td><td>
              369.89m
            </td><td>
              6
            </td><td>
              80,168,672
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DRNA" class="margin-bottom-1">
                DRNA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$20.96</div> <small class="number change-up">+0.32<span>&nbsp;&nbsp;</span>+1.55%</small></td><td><strong>Nedosiran - PHYOX2</strong> <br>Primary hyperoxaluria (PH) - Type 1
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005221/en/">
                4Q 2021
              </a> <div class="note">Phase 2 pivotal top-line data released August 5, 2021. Primary endpoint met but noted Uox reductions, while significant in participants with PH1 subtype, patients with PH2 subtype showed inconsistent results. NDA filing due 4Q 2021 in PH1 patients.</div></td><td>
              78m
            </td><td>
              1.6b
            </td><td>
              483.1k
            </td><td>
              1.0m
            </td><td>
              14.66
            </td><td>
              $20.79
            </td><td>
              $20.64
            </td><td>
              June 21, 2021
            </td><td>
              0.69b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -39.15m
            </td><td>
              1.08b
            </td><td>
              0.4
            </td><td>
              74,503,276
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALGS" class="margin-bottom-1">
                ALGS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.14</div> <small class="number change-up">+0.98<span>&nbsp;&nbsp;</span>+6.46%</small></td><td><strong>ALG-000184</strong> <br>Hepatitis B
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/05/2275982/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-Second-Quarter-2021-Financial-Results.html">
                2H 2021
              </a> <div class="note">Phase 1 safety and antiviral data from the initial cohort(s) expected in 2H 2021.</div></td><td>
              43m
            </td><td>
              0.7b
            </td><td>
              68.7k
            </td><td>
              301.5k
            </td><td>
              4.08
            </td><td>
              $15.33
            </td><td>
              $15.16
            </td><td>
              July 1, 2022
            </td><td>
              176.84m
            </td><td>
              -7.67m
            </td><td>
              23.05
            </td><td>
              133.85m
            </td><td>
              467.82m
            </td><td>
              7.4
            </td><td>
              19,123,908
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DRMA" class="margin-bottom-1">
                DRMA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.70</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+1.95%</small></td><td><strong>DMT310</strong> <br>Psoriasis
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001853816/000119312521187916/d137089ds1.htm">
                2H 2021
              </a> <div class="note">Phase 1b data due 2H 2021.</div></td><td>
              8m
            </td><td>
              39.1m
            </td><td>
              14.5k
            </td><td>
              
            </td><td>
              58.75
            </td><td>
              $4.6
            </td><td>
              $4.61
            </td><td>
              N/A
            </td><td>
              79.84k
            </td><td>
              -258.74k
            </td><td>
              0.31
            </td><td>
              -0.86m
            </td><td>
              37.25m
            </td><td>
              0
            </td><td>
              1,768,271
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BCYC" class="margin-bottom-1">
                BCYC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.84</div> <small class="number change-up">+2.22<span>&nbsp;&nbsp;</span>+7.76%</small></td><td><strong>BT1718</strong> <br>Solid tumors
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210114005302/en/">
                2021
              </a> <div class="note">Phase 2a update due 2021.</div></td><td>
              26m
            </td><td>
              0.8b
            </td><td>
              73.7k
            </td><td>
              141.2k
            </td><td>
              5.54
            </td><td>
              $28.72
            </td><td>
              $28.62
            </td><td>
              March 31, 2022
            </td><td>
              236.32m
            </td><td>
              -4.12m
            </td><td>
              57.31
            </td><td>
              152.32m
            </td><td>
              0.56b
            </td><td>
              1.9
            </td><td>
              25,040,856
            </td><td>
              01/14/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALVR" class="margin-bottom-1">
                ALVR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$18.76</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+1.57%</small></td><td><strong>Viralym-M (ALVR105)</strong> <br>Multi-virus prevention trial (following allo-HSCT)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210806005012/en/">
                4Q 2021
              </a> <div class="note">Phase 2 interim data due 4Q 2021.</div></td><td>
              63m
            </td><td>
              1.2b
            </td><td>
              110.7k
            </td><td>
              238.7k
            </td><td>
              -5.68
            </td><td>
              $18.85
            </td><td>
              $18.47
            </td><td>
              February 28, 2022
            </td><td>
              299.60m
            </td><td>
              -7.63m
            </td><td>
              39.27
            </td><td>
              274.56m
            </td><td>
              0.59b
            </td><td>
              15.8
            </td><td>
              27,881,595
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ERYP" class="margin-bottom-1">
                ERYP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.76</div> <small class="number change-down">-0.10<span>&nbsp;&nbsp;</span>-1.71%</small></td><td><strong>GRASPA (Eryaspase) - TRYbeCA2</strong> <br>Triple-Negative Breast Cancer (TNBC)
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/7c3e6d65-f414-4915-a216-f3f4f17ab981">
                4Q 2021
              </a> <div class="note">Phase 2 data due 4Q 2021.</div></td><td>
              27m
            </td><td>
              157.3m
            </td><td>
              48.9k
            </td><td>
              1.4m
            </td><td>
              5.05
            </td><td>
              $5.9
            </td><td>
              $5.86
            </td><td>
              December 2020
            </td><td>
              74.45m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              20.59m
            </td><td>
              143.78m
            </td><td>
              0
            </td><td>
              27,317,957
            </td><td>
              05/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLNN" class="margin-bottom-1">
                CLNN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.80</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+1.88%</small></td><td><strong>CNM-Au8 (RESCUE-ALS)</strong> <br>Amyotrophic Lateral Sclerosis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://invest.clene.com/press-releases/Press-Releases/news-details/2021/Clene-Reports-Second-Quarter-2021-Operating-and-Financial-Highlights/default.aspx">
                2H 2021
              </a> <div class="note">Phase 2 Australia data due 2H 2021.</div></td><td>
              61m
            </td><td>
              479.9m
            </td><td>
              105.3k
            </td><td>
              0.6m
            </td><td>
              -18.58
            </td><td>
              $7.68
            </td><td>
              $7.66
            </td><td>
              July 2021
            </td><td>
              57.88m
            </td><td>
              -2.85m
            </td><td>
              20.30
            </td><td>
              -41.33m
            </td><td>
              424.96m
            </td><td>
              2.9
            </td><td>
              28,409,076
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALVR" class="margin-bottom-1">
                ALVR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$18.76</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+1.57%</small></td><td><strong>Viralym-M (ALVR105)</strong> <br>BK viremia
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210806005012/en/">
                4Q 2021
              </a> <div class="note">Phase 2 interim data due 4Q 2021.</div></td><td>
              63m
            </td><td>
              1.2b
            </td><td>
              110.7k
            </td><td>
              238.7k
            </td><td>
              -5.68
            </td><td>
              $18.85
            </td><td>
              $18.47
            </td><td>
              June 2022
            </td><td>
              299.60m
            </td><td>
              -7.63m
            </td><td>
              39.27
            </td><td>
              274.56m
            </td><td>
              0.59b
            </td><td>
              15.8
            </td><td>
              27,881,595
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MBRX" class="margin-bottom-1">
                MBRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.93</div> <small class="number change-up">+0.16<span>&nbsp;&nbsp;</span>+5.64%</small></td><td><strong>Annamycin</strong> <br>Acute myeloid leukemia (AML) 
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/moleculin-reports-second-quarter-2021-financial-results-and-provides-programs-update-301354310.html">
                2H 2021
              </a> <div class="note">Phase 1/2 data due 2H 2021.</div></td><td>
              29m
            </td><td>
              83.5m
            </td><td>
              78.0k
            </td><td>
              238.1k
            </td><td>
              0.98
            </td><td>
              $2.78
            </td><td>
              $2.77
            </td><td>
              N/A
            </td><td>
              75.44m
            </td><td>
              -2.26m
            </td><td>
              33.37
            </td><td>
              66.60m
            </td><td>
              -196.37k
            </td><td>
              2.4
            </td><td>
              27,978,404
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVS" class="margin-bottom-1">
                NVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$93.88</div> <small class="number change-up">+0.55<span>&nbsp;&nbsp;</span>+0.59%</small></td><td><strong>BEOVU (Brolucizumab) - KINGFISHER</strong> <br>Diabetic macular edema (DME)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.pdf">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              2b
            </td><td>
              210.0b
            </td><td>
              0.7m
            </td><td>
              1.7m
            </td><td>
              3.89
            </td><td>
              $93.86
            </td><td>
              $93.33
            </td><td>
              March 24, 2021
            </td><td>
              7.84b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -62.05b
            </td><td>
              238.51b
            </td><td>
              0
            </td><td>
              2,236,739,037
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AVIR" class="margin-bottom-1">
                AVIR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.62</div> <small class="number change-down">-0.04<span>&nbsp;&nbsp;</span>-0.12%</small></td><td><strong>AT-527 (Outpatient Setting) - (MOONSONG)</strong> <br>COVID-19 
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-provides-clinical-and-corporate-update-and">
                2H 2021
              </a> <div class="note">Phase 2 interim virology data expected in 2H 2021.</div></td><td>
              83m
            </td><td>
              2.5b
            </td><td>
              497.8k
            </td><td>
              1.4m
            </td><td>
              4.10
            </td><td>
              $30.14
            </td><td>
              $29.66
            </td><td>
              September 22, 2021
            </td><td>
              0.81b
            </td><td>
              -5.78m
            </td><td>
              139.39
            </td><td>
              0.53b
            </td><td>
              1.64b
            </td><td>
              1.9
            </td><td>
              61,062,278
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ATNM" class="margin-bottom-1">
                ATNM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.27</div> <small class="number change-up">+0.24<span>&nbsp;&nbsp;</span>+3.98%</small></td><td><strong>Iomab-ACT</strong> <br>Targeted conditioning prior to CD19 CAR T-cell therapy
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/actinium-announces-initiation-of-patient-enrollment-in-iomab-act-trial-for-targeted-conditioning-prior-to-cd19-car-t-cell-therapy-301254600.html">
                2H 2021
              </a> <div class="note">Phase 1 trial has commenced enrollment. Data due 2H 2021.</div></td><td>
              21m
            </td><td>
              133.7m
            </td><td>
              99.3k
            </td><td>
              166.4k
            </td><td>
              1.66
            </td><td>
              $6.1
            </td><td>
              $6.03
            </td><td>
              January 2023
            </td><td>
              79.16m
            </td><td>
              -1.53m
            </td><td>
              51.81
            </td><td>
              75.21m
            </td><td>
              47.24m
            </td><td>
              2
            </td><td>
              21,322,261
            </td><td>
              03/24/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IFRX" class="margin-bottom-1">
                IFRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.35</div> <small class="number change-up">+0.05<span>&nbsp;&nbsp;</span>+2.17%</small></td><td><strong>Vilobelimab (IFX-1)</strong> <br>COVID-19
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/05/2275487/0/en/InflaRx-Reports-Second-Quarter-2021-Financial-Operating-Results.html">
                YE 2021
              </a> <div class="note">Phase 3 top-line data due by the end of 2021.</div></td><td>
              44m
            </td><td>
              103.8m
            </td><td>
              148.8k
            </td><td>
              154.3k
            </td><td>
              0.72
            </td><td>
              $2.32
            </td><td>
              $2.3
            </td><td>
              N/A
            </td><td>
              122.49m
            </td><td>
              -2.61m
            </td><td>
              46.87
            </td><td>
              111.08m
            </td><td>
              -45.02m
            </td><td>
              0
            </td><td>
              39,925,277
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PALI" class="margin-bottom-1">
                PALI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.73</div> <small class="number change-up">+0.19<span>&nbsp;&nbsp;</span>+7.48%</small></td><td><strong>LB1148</strong> <br>Reduction in adhesions following abdominal and pelvic surgery
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.palisadebio.com/news-events/press-releases/news-details/2021/Palisade-Bio-Receives-FDA-Fast-Track-Designation-for-LB1148-for-Reduction-of-Adhesions-Following-Abdominal-and-Pelvic-Surgery/default.aspx">
                2021
              </a> <div class="note">Phase 2 data due in 2021.</div></td><td>
              11m
            </td><td>
              30.8m
            </td><td>
              145.4k
            </td><td>
              0.5m
            </td><td>
              4.88
            </td><td>
              $2.47
            </td><td>
              $2.54
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              28.65m
            </td><td>
              0
            </td><td>
              17,258,014
            </td><td>
              06/15/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLNN" class="margin-bottom-1">
                CLNN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.80</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+1.88%</small></td><td><strong>CNM-ZnAg</strong> <br>COVID-19
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://invest.clene.com/press-releases/Press-Releases/news-details/2021/Clene-Reports-Second-Quarter-2021-Operating-and-Financial-Highlights/default.aspx">
                2H 2021
              </a> <div class="note">Phase 2 data due 2H 2021.</div></td><td>
              61m
            </td><td>
              479.9m
            </td><td>
              105.3k
            </td><td>
              0.6m
            </td><td>
              -18.58
            </td><td>
              $7.68
            </td><td>
              $7.66
            </td><td>
              July 2021
            </td><td>
              57.88m
            </td><td>
              -2.85m
            </td><td>
              20.30
            </td><td>
              -41.33m
            </td><td>
              424.96m
            </td><td>
              2.9
            </td><td>
              28,409,076
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TSHA" class="margin-bottom-1">
                TSHA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.73</div> <small class="number change-up">+0.80<span>&nbsp;&nbsp;</span>+4.73%</small></td><td><strong>TSHA-120</strong> <br>Giant axonal neuropathy (GAN)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210816005196/en/">
                2H 2021
              </a> <div class="note">Phase 1/2 data due 2H 2021.</div></td><td>
              38m
            </td><td>
              0.7b
            </td><td>
              22.6k
            </td><td>
              190.5k
            </td><td>
              3.65
            </td><td>
              $17.25
            </td><td>
              $16.93
            </td><td>
              N/A
            </td><td>
              183.68m
            </td><td>
              -7.61m
            </td><td>
              24.15
            </td><td>
              128.32m
            </td><td>
              478.80m
            </td><td>
              26.7
            </td><td>
              16,966,890
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/HARP" class="margin-bottom-1">
                HARP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.13</div> <small class="number change-up">+0.49<span>&nbsp;&nbsp;</span>+5.67%</small></td><td><strong>HPN217</strong> <br>Multiple myeloma
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.harpoontx.com/news-releases/news-release-details/harpoon-therapeutics-reports-second-quarter-2021-financial">
                YE 2021
              </a> <div class="note">Phase 1/2 initiation of dosing announced April 27, 2020. Interim data due year end 2021 with initiation of a dose expansion cohort due 2H 2021.</div></td><td>
              33m
            </td><td>
              298.3m
            </td><td>
              168.7k
            </td><td>
              0.5m
            </td><td>
              3.28
            </td><td>
              $8.64
            </td><td>
              $8.64
            </td><td>
              January 2, 2024
            </td><td>
              131.08m
            </td><td>
              -22.19m
            </td><td>
              5.91
            </td><td>
              25.83m
            </td><td>
              124.19m
            </td><td>
              1.1
            </td><td>
              30,498,283
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SLS" class="margin-bottom-1">
                SLS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.28</div> <small class="number change-up">+0.60<span>&nbsp;&nbsp;</span>+6.91%</small></td><td><strong>NeuVax (Nelipepimut-S) and HERCEPTIN (Trastuzumab)</strong> <br>HER2 3+ breast cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sellaslifesciences.com/investors/news/News-Details/2021/SELLAS-Life-Sciences-Reports-First-Quarter-2021-Financial-Results-and-Provides-Business-Update/default.aspx">
                YE 2021
              </a> <div class="note">Phase 2 primary analysis to be completed by end of 2021.</div></td><td>
              16m
            </td><td>
              147.3m
            </td><td>
              155.0k
            </td><td>
              0.6m
            </td><td>
              4.40
            </td><td>
              $8.78
            </td><td>
              $8.68
            </td><td>
              December 2021
            </td><td>
              26.98m
            </td><td>
              -1.63m
            </td><td>
              16.52
            </td><td>
              16.77m
            </td><td>
              108.77m
            </td><td>
              11
            </td><td>
              15,865,222
            </td><td>
              05/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CYTO" class="margin-bottom-1">
                CYTO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.87</div> <small class="number change-down">-0.03<span>&nbsp;&nbsp;</span>-1.03%</small></td><td><strong>AM-125 (TRAVERS)</strong> <br>Vertigo
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.aurismedical.com/news-releases/news-release-details/auris-medical-provides-business-update-and-reports-second-half-0">
                2H 2021
              </a> <div class="note">Phase 2 data due 2H 2021.</div></td><td>
              7m
            </td><td>
              20.3m
            </td><td>
              159.3k
            </td><td>
              1.0m
            </td><td>
              1.01
            </td><td>
              $2.86
            </td><td>
              $2.9
            </td><td>
              August 2021
            </td><td>
              11.26m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              7.23m
            </td><td>
              -2.55m
            </td><td>
              0
            </td><td>
              1,564,182
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SGMO" class="margin-bottom-1">
                SGMO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.87</div> <small class="number change-up">+0.51<span>&nbsp;&nbsp;</span>+5.45%</small></td><td><strong>SAR445136 (PRECIZN-1)</strong> <br>Sickle Cell Disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.sangamo.com/index.php/static-files/59eafc6d-194e-42ac-94f1-093d77e82abf">
                2021
              </a> <div class="note">Phase 1/2 data due 2021.</div></td><td>
              145m
            </td><td>
              1.4b
            </td><td>
              0.5m
            </td><td>
              1.0m
            </td><td>
              3.21
            </td><td>
              $9.46
            </td><td>
              $9.36
            </td><td>
              November 2023
            </td><td>
              498.11m
            </td><td>
              -17.52m
            </td><td>
              28.43
            </td><td>
              108.21m
            </td><td>
              0.87b
            </td><td>
              2.2
            </td><td>
              120,566,640
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SNY" class="margin-bottom-1">
                SNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$52.48</div> <small class="number change-down">-0.64<span>&nbsp;&nbsp;</span>-1.20%</small></td><td><strong>SAR445136 (PRECIZN-1)</strong> <br>Sickle Cell Disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.sangamo.com/index.php/static-files/59eafc6d-194e-42ac-94f1-093d77e82abf">
                2021
              </a> <div class="note">Phase 1/2 data due 2021.</div></td><td>
              3b
            </td><td>
              131.7b
            </td><td>
              2.5m
            </td><td>
              1.7m
            </td><td>
              1.78
            </td><td>
              $52.73
            </td><td>
              $53.12
            </td><td>
              November 2023
            </td><td>
              9.72b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -39.23b
            </td><td>
              146.90b
            </td><td>
              0
            </td><td>
              2,510,366,030
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EWTX" class="margin-bottom-1">
                EWTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$15.87</div> <small class="number change-up">+1.46<span>&nbsp;&nbsp;</span>+10.13%</small></td><td><strong>EDG-5506</strong> <br>Healthy volunteers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005071/en/">
                YE 2021
              </a> <div class="note">Phase 1 safety, tolerability and PK data for both the multiple ascending dose (MAD) in healthy volunteers and adult Becker muscular dystrophy patients in 2H 2021.</div></td><td>
              49m
            </td><td>
              0.8b
            </td><td>
              18.2k
            </td><td>
              201.1k
            </td><td>
              2.64
            </td><td>
              $14.6
            </td><td>
              $14.41
            </td><td>
              October 2021
            </td><td>
              293.29m
            </td><td>
              -3.26m
            </td><td>
              90.07
            </td><td>
              286.55m
            </td><td>
              410.72m
            </td><td>
              0.6
            </td><td>
              19,497,033
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVS" class="margin-bottom-1">
                NVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$93.88</div> <small class="number change-up">+0.55<span>&nbsp;&nbsp;</span>+0.59%</small></td><td><strong>KISQALI (ribociclib) - MONALEESA-2</strong> <br>Breast cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.pdf">
                2H 2021
              </a> <div class="note">Phase 3 overall survival data due 2H 2021.</div></td><td>
              2b
            </td><td>
              210.0b
            </td><td>
              0.7m
            </td><td>
              1.7m
            </td><td>
              3.89
            </td><td>
              $93.86
            </td><td>
              $93.33
            </td><td>
              January 29, 2016
            </td><td>
              7.84b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -62.05b
            </td><td>
              238.51b
            </td><td>
              0
            </td><td>
              2,236,739,037
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/STRO" class="margin-bottom-1">
                STRO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$20.03</div> <small class="number change-up">+0.88<span>&nbsp;&nbsp;</span>+4.60%</small></td><td><strong>STRO-002</strong> <br>Ovarian and Endometrial Cancer
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/sutro-biopharma-reports-second-quarter-2021-financial-results-business-highlights-and-anticipated-second-half-2021-milestones-301350738.html">
                2H 2021
              </a> <div class="note">Phase 1 commencement of dosing of the first patient in the dose-expansion cohort announced January 21, 2021. Initial dose-expansion data due 2H 2021.</div></td><td>
              46m
            </td><td>
              0.9b
            </td><td>
              65.3k
            </td><td>
              371.2k
            </td><td>
              3.01
            </td><td>
              $19.43
            </td><td>
              $19.15
            </td><td>
              August 2022
            </td><td>
              255.55m
            </td><td>
              -1.75m
            </td><td>
              145.67
            </td><td>
              203.26m
            </td><td>
              0.65b
            </td><td>
              0.7
            </td><td>
              45,721,453
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVS" class="margin-bottom-1">
                NVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$93.88</div> <small class="number change-up">+0.55<span>&nbsp;&nbsp;</span>+0.59%</small></td><td><strong>COSENTYX (secukinumab) - SUNRISE</strong> <br>Hidradenitis Suppurativa (HS)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.pdf">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              2b
            </td><td>
              210.0b
            </td><td>
              0.7m
            </td><td>
              1.7m
            </td><td>
              3.89
            </td><td>
              $93.86
            </td><td>
              $93.33
            </td><td>
              September 27, 2021
            </td><td>
              7.84b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -62.05b
            </td><td>
              238.51b
            </td><td>
              0
            </td><td>
              2,236,739,037
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GLMD" class="margin-bottom-1">
                GLMD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.92</div> <small class="number change-up">+0.11<span>&nbsp;&nbsp;</span>+3.91%</small></td><td><strong>Aramchol - ARMOR</strong> <br>Non-Alcoholic Steatohepatitis (NASH)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-provides-business-update-and-reports-second-quarter-2021-financial-results-301349181.html">
                4Q 2021
              </a> <div class="note">Phase 3 initial histology data due 4Q 2021.</div></td><td>
              21m
            </td><td>
              61.7m
            </td><td>
              55.8k
            </td><td>
              293.8k
            </td><td>
              0.80
            </td><td>
              $2.88
            </td><td>
              $2.81
            </td><td>
              December 2024
            </td><td>
              46.49m
            </td><td>
              -2.54m
            </td><td>
              18.28
            </td><td>
              39.16m
            </td><td>
              29.24m
            </td><td>
              0
            </td><td>
              17,575,161
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SAVA" class="margin-bottom-1">
                SAVA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$113.48</div> <small class="number change-up">+9.42<span>&nbsp;&nbsp;</span>+9.05%</small></td><td><strong>Simufilam (PTI-125)</strong> <br>Alzheimer’s disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.cassavasciences.com/static-files/13794384-53b3-452c-ae6c-7a09828ad389">
                4Q 2021
              </a> <div class="note">Phase 2b trial did not meet primary endpoint - May 15, 2020. Noted improvements in biomarkers of disease pathology September 14, 2020. Phase 2 open-label data 9-month data released July 29, 2021. 12-month data due 4Q 2021. Separate Cognition Maintenance Study (CMS) trial ongoing. Phase 3 trial to be initiated Fall 2021.</div></td><td>
              40m
            </td><td>
              4.5b
            </td><td>
              2.3m
            </td><td>
              4.8m
            </td><td>
              16.42
            </td><td>
              $104.99
            </td><td>
              $104.06
            </td><td>
              January 31, 2023
            </td><td>
              275.17m
            </td><td>
              -1.71m
            </td><td>
              160.64
            </td><td>
              270.35m
            </td><td>
              3.89b
            </td><td>
              5
            </td><td>
              37,922,725
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVS" class="margin-bottom-1">
                NVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$93.88</div> <small class="number change-up">+0.55<span>&nbsp;&nbsp;</span>+0.59%</small></td><td><strong>ECF843</strong> <br>Dry Eye Disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.pdf">
                2H 2021
              </a> <div class="note">Phase 2 data due 2H 2021.</div></td><td>
              2b
            </td><td>
              210.0b
            </td><td>
              0.7m
            </td><td>
              1.7m
            </td><td>
              3.89
            </td><td>
              $93.86
            </td><td>
              $93.33
            </td><td>
              May 13, 2021
            </td><td>
              7.84b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -62.05b
            </td><td>
              238.51b
            </td><td>
              0
            </td><td>
              2,236,739,037
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CBAY" class="margin-bottom-1">
                CBAY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.62</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+4.32%</small></td><td><strong>MBX-2982</strong> <br>Type 1 diabetes
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.stockpr.com/cymabay/press-releases/detail/503">
                Late-2021
              </a> <div class="note">Phase 2a data due late-2021.</div></td><td>
              69m
            </td><td>
              249.8m
            </td><td>
              287.3k
            </td><td>
              0.6m
            </td><td>
              2.34
            </td><td>
              $3.49
            </td><td>
              $3.47
            </td><td>
              December 2021
            </td><td>
              194.61m
            </td><td>
              -6.40m
            </td><td>
              30.38
            </td><td>
              184.66m
            </td><td>
              134.80m
            </td><td>
              0.6
            </td><td>
              58,424,622
            </td><td>
              03/25/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CTMX" class="margin-bottom-1">
                CTMX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.74</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+1.61%</small></td><td><strong>Praluzatamab ravtansine (CX-2009)</strong> <br>Breast cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-announces-first-quarter-2021-financial">
                4Q 2021
              </a> <div class="note">Phase 2 initial data due 4Q 2021.</div></td><td>
              65m
            </td><td>
              308.5m
            </td><td>
              384.8k
            </td><td>
              0.7m
            </td><td>
              2.36
            </td><td>
              $4.75
            </td><td>
              $4.66
            </td><td>
              March 10, 2023
            </td><td>
              249.26m
            </td><td>
              -9.40m
            </td><td>
              26.52
            </td><td>
              -22.23m
            </td><td>
              60.78m
            </td><td>
              0.7
            </td><td>
              64,408,878
            </td><td>
              05/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVS" class="margin-bottom-1">
                NVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$93.88</div> <small class="number change-up">+0.55<span>&nbsp;&nbsp;</span>+0.59%</small></td><td><strong>Remibrutinib (LOU064)</strong> <br>Chronic spontaneous urticaria (CSU) 
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.pdf">
                2H 2021
              </a> <div class="note">Phase 2 data due 2H 2021.</div></td><td>
              2b
            </td><td>
              210.0b
            </td><td>
              0.7m
            </td><td>
              1.7m
            </td><td>
              3.89
            </td><td>
              $93.86
            </td><td>
              $93.33
            </td><td>
              January 14, 2021
            </td><td>
              7.84b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -62.05b
            </td><td>
              238.51b
            </td><td>
              0
            </td><td>
              2,236,739,037
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INSM" class="margin-bottom-1">
                INSM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$25.16</div> <small class="number change-up">+1.59<span>&nbsp;&nbsp;</span>+6.75%</small></td><td><strong>Treprostinil Palmitil Inhalation Powder (TPIP)</strong> <br>Pulmonary arterial hypertension (PAH)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/insmed-reports-second-quarter-2021-financial-results-and-provides-business-update-301348887.html">
                2H 2021
              </a> <div class="note">Phase 1 top-line data released February 19, 2021 - generally safe and well tolerated. Data to be presented at European Society of Cardiology Congress on August 30, 2021. Phase 2 trial planned with initial data due 2H 2021.</div></td><td>
              115m
            </td><td>
              2.9b
            </td><td>
              397.2k
            </td><td>
              0.8m
            </td><td>
              5.46
            </td><td>
              $24.12
            </td><td>
              $23.57
            </td><td>
              N/A
            </td><td>
              0.88b
            </td><td>
              -25.15m
            </td><td>
              35.11
            </td><td>
              184.33m
            </td><td>
              2.38b
            </td><td>
              4.9
            </td><td>
              91,607,437
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FLXN" class="margin-bottom-1">
                FLXN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.27</div> <small class="number change-up">+0.59<span>&nbsp;&nbsp;</span>+12.61%</small></td><td><strong>FX201</strong> <br>Osteoarthritis (OA)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.flexiontherapeutics.com/news-releases/news-release-details/flexion-therapeutics-reports-second-quarter-2021-financial">
                YE 2021
              </a> <div class="note">Phase 1 data presented at ASGCT meeting May 2021. Further data due by end of 2021.</div></td><td>
              50m
            </td><td>
              265.0m
            </td><td>
              0.7m
            </td><td>
              0.8m
            </td><td>
              -4.71
            </td><td>
              $4.83
            </td><td>
              $4.68
            </td><td>
              December 24, 2022
            </td><td>
              119.99m
            </td><td>
              -6.25m
            </td><td>
              19.19
            </td><td>
              -146.23m
            </td><td>
              333.02m
            </td><td>
              2.9
            </td><td>
              48,063,471
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BLUE" class="margin-bottom-1">
                BLUE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$18.19</div> <small class="number change-up">+0.60<span>&nbsp;&nbsp;</span>+3.41%</small></td><td><strong>bb21217 (CRB-402)</strong> <br>Multiple Myeloma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210505006054/en/">
                YE 2021
              </a> <div class="note">Phase 1 data due by end of 2021.</div></td><td>
              68m
            </td><td>
              1.2b
            </td><td>
              480.2k
            </td><td>
              1.5m
            </td><td>
              1.25
            </td><td>
              $17.85
            </td><td>
              $17.59
            </td><td>
              October 2025
            </td><td>
              0.86b
            </td><td>
              -48.55m
            </td><td>
              17.76
            </td><td>
              392.41m
            </td><td>
              0.55b
            </td><td>
              1.3
            </td><td>
              53,343,921
            </td><td>
              05/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/HCM" class="margin-bottom-1">
                HCM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$38.16</div> <small class="number change-up">+0.48<span>&nbsp;&nbsp;</span>+1.29%</small></td><td><strong>HMPL-689</strong> <br>Non-Hodgkin’s lymphoma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml.globenewswire.com/Resource/Download/495fc1d8-ba3e-4ecb-9e98-565edce2f91f">
                2H 2021
              </a> <div class="note">Phase 1 interim data due 2H 2021.</div></td><td>
              173m
            </td><td>
              6.6b
            </td><td>
              124.7k
            </td><td>
              488.9k
            </td><td>
              6.69
            </td><td>
              $37.95
            </td><td>
              $37.67
            </td><td>
              July 2020
            </td><td>
              0.92b
            </td><td>
              -16.32m
            </td><td>
              56.43
            </td><td>
              0.66b
            </td><td>
              5.59b
            </td><td>
              2.5
            </td><td>
              154,870,219
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVS" class="margin-bottom-1">
                NVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$93.88</div> <small class="number change-up">+0.55<span>&nbsp;&nbsp;</span>+0.59%</small></td><td><strong>KYMRIAH (tisagenlecleucel) -  BELINDA</strong> <br>Diffuse large B-cell lymphoma (DLBCL) - 2nd line
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.pdf">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              2b
            </td><td>
              210.0b
            </td><td>
              0.7m
            </td><td>
              1.7m
            </td><td>
              3.89
            </td><td>
              $93.86
            </td><td>
              $93.33
            </td><td>
              October 20, 2026
            </td><td>
              7.84b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -62.05b
            </td><td>
              238.51b
            </td><td>
              0
            </td><td>
              2,236,739,037
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ONCT" class="margin-bottom-1">
                ONCT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.91</div> <small class="number change-up">+0.36<span>&nbsp;&nbsp;</span>+10.26%</small></td><td><strong>TK216</strong> <br>Relapsed or refractory Ewing sarcoma
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.oncternal.com/news-releases/news-release-details/oncternal-provides-business-update-and-announces-second-0">
                4Q 2021
              </a> <div class="note">Phase 1/2 update 4Q 2021.</div></td><td>
              49m
            </td><td>
              193.3m
            </td><td>
              1.1m
            </td><td>
              0.9m
            </td><td>
              1.88
            </td><td>
              $3.75
            </td><td>
              $3.55
            </td><td>
              December 2023
            </td><td>
              99.10m
            </td><td>
              -2.54m
            </td><td>
              39.08
            </td><td>
              93.20m
            </td><td>
              71.82m
            </td><td>
              28.6
            </td><td>
              48,269,725
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SAGE" class="margin-bottom-1">
                SAGE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$42.82</div> <small class="number change-up">+0.84<span>&nbsp;&nbsp;</span>+2.00%</small></td><td><strong>Zuranolone - CORAL (MDD-305)</strong> <br>Major Depressive Disorder
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.springworkstx.com/news-releases/news-release-details/springworks-therapeutics-announces-phase-1b2a-clinical-trial">
                Late-2021
              </a> <div class="note">Phase 3 data due late-2021.</div></td><td>
              59m
            </td><td>
              2.5b
            </td><td>
              153.7k
            </td><td>
              1.1m
            </td><td>
              1.30
            </td><td>
              $42.57
            </td><td>
              $41.98
            </td><td>
              December 2021
            </td><td>
              1.85b
            </td><td>
              -34.26m
            </td><td>
              53.99
            </td><td>
              1.76b
            </td><td>
              0.58b
            </td><td>
              1.7
            </td><td>
              43,822,518
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SAGE" class="margin-bottom-1">
                SAGE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$42.82</div> <small class="number change-up">+0.84<span>&nbsp;&nbsp;</span>+2.00%</small></td><td><strong>ZULRESSO (brexanolone)</strong> <br>COVID-19 related acute respiratory distress syndrome (ARDS)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210504005397/en/">
                Late-2021
              </a> <div class="note">Phase 3 data due late-2021.</div></td><td>
              59m
            </td><td>
              2.5b
            </td><td>
              153.7k
            </td><td>
              1.1m
            </td><td>
              1.30
            </td><td>
              $42.57
            </td><td>
              $41.98
            </td><td>
              July 1, 2021
            </td><td>
              1.85b
            </td><td>
              -34.26m
            </td><td>
              53.99
            </td><td>
              1.76b
            </td><td>
              0.58b
            </td><td>
              1.7
            </td><td>
              43,822,518
            </td><td>
              06/14/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SLS" class="margin-bottom-1">
                SLS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.28</div> <small class="number change-up">+0.60<span>&nbsp;&nbsp;</span>+6.91%</small></td><td><strong>Galinpepimut-S and OPDIVO (nivolumab)</strong> <br>Malignant pleural mesothelioma (MPM)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sellaslifesciences.com/investors/news/News-Details/2021/SELLAS-Reports-Encouraging-Updated-Clinical-Data-from-Ongoing-Mesothelioma-Study-of-Galinpepimut-S-GPS-Combined-with-Opdivo/default.aspx">
                4Q 2021
              </a> <div class="note">Phase 1 data released June 24, 2021. Median overall survival of 35.4 weeks. Updated data due 4Q 2021.</div></td><td>
              16m
            </td><td>
              147.3m
            </td><td>
              155.0k
            </td><td>
              0.6m
            </td><td>
              4.40
            </td><td>
              $8.78
            </td><td>
              $8.68
            </td><td>
              July 2023
            </td><td>
              26.98m
            </td><td>
              -1.63m
            </td><td>
              16.52
            </td><td>
              16.77m
            </td><td>
              108.77m
            </td><td>
              11
            </td><td>
              15,865,222
            </td><td>
              06/24/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ONCT" class="margin-bottom-1">
                ONCT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.91</div> <small class="number change-up">+0.36<span>&nbsp;&nbsp;</span>+10.26%</small></td><td><strong>Cirmtuzumab and IMBRUVICA (Ibrutinib)</strong> <br>Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.oncternal.com/news-releases/news-release-details/oncternal-provides-business-update-and-announces-second-0">
                4Q 2021
              </a> <div class="note">Phase 1/2 poster presented at ASCO June, 2021. Objective response rate (ORR) of 83% (15/18) noted in abstract. Update 4Q 2021.</div></td><td>
              49m
            </td><td>
              193.3m
            </td><td>
              1.1m
            </td><td>
              0.9m
            </td><td>
              1.88
            </td><td>
              $3.75
            </td><td>
              $3.55
            </td><td>
              June 30, 2025
            </td><td>
              99.10m
            </td><td>
              -2.54m
            </td><td>
              39.08
            </td><td>
              93.20m
            </td><td>
              71.82m
            </td><td>
              28.6
            </td><td>
              48,269,725
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARQT" class="margin-bottom-1">
                ARQT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$20.84</div> <small class="number change-up">+0.59<span>&nbsp;&nbsp;</span>+2.94%</small></td><td><strong>Roflumilast Cream (ARQ-151)</strong> <br>Plaque psoriasis
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.arcutis.com/news-releases/news-release-details/arcutis-announces-second-quarter-2021-financial-results-and">
                2H 2021
              </a> <div class="note">Phase 3 data released February 1, 2021, statistically significant superiority over vehicle on primary endpoint. NDA filing due 2H 2021.</div></td><td>
              50m
            </td><td>
              1.0b
            </td><td>
              65.4k
            </td><td>
              180.1k
            </td><td>
              2.53
            </td><td>
              $20.67
            </td><td>
              $20.25
            </td><td>
              November 16, 2020
            </td><td>
              387.87m
            </td><td>
              -11.94m
            </td><td>
              32.47
            </td><td>
              369.46m
            </td><td>
              0.61b
            </td><td>
              4
            </td><td>
              20,923,311
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ATAI" class="margin-bottom-1">
                ATAI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.38</div> <small class="number change-up">+1.54<span>&nbsp;&nbsp;</span>+10.38%</small></td><td><strong>RL-007</strong> <br>Cognitive Impairment Associated with Schizophrenia
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-reports-second-quarter-2021-financial-results">
                Late-2021
              </a> <div class="note">Phase 2a data due late-2021.</div></td><td>
              155m
            </td><td>
              2.5b
            </td><td>
              450.9k
            </td><td>
              0.6m
            </td><td>
              5.34
            </td><td>
              $15.45
            </td><td>
              $14.84
            </td><td>
              N/A
            </td><td>
              454.76m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              433.69m
            </td><td>
              1.85b
            </td><td>
              0
            </td><td>
              114,161,264
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SYBX" class="margin-bottom-1">
                SYBX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.67</div> <small class="number change-up">+0.22<span>&nbsp;&nbsp;</span>+8.98%</small></td><td><strong>SYNB8802</strong> <br>Enteric Hyperoxaluria
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/synlogic-reports-second-quarter-financial-results-and-provides-business-update-301353948.html">
                2H 2021
              </a> <div class="note">Phase 1 Part B data due 2H 2021.</div></td><td>
              52m
            </td><td>
              139.8m
            </td><td>
              77.7k
            </td><td>
              228.2k
            </td><td>
              1.09
            </td><td>
              $2.49
            </td><td>
              $2.45
            </td><td>
              August 16, 2021
            </td><td>
              108.66m
            </td><td>
              -3.78m
            </td><td>
              28.73
            </td><td>
              79.85m
            </td><td>
              34.89m
            </td><td>
              2.7
            </td><td>
              37,099,321
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMRA" class="margin-bottom-1">
                IMRA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.58</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+5.29%</small></td><td><strong>Tovinontrine (IMR-687) - (Ardent)</strong> <br>Sickle cell disease (SCD)
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.imaratx.com/news-releases/news-release-details/imara-announces-completion-patient-enrollment-ardent-phase-2b">
                4Q 2021
              </a> <div class="note">Phase 2b completion of enrollment announced August 5, 2021. Interim analysis due 4Q 2021. Primary endpoint readout due 1Q 2022.</div></td><td>
              26m
            </td><td>
              120.2m
            </td><td>
              75.8k
            </td><td>
              305.5k
            </td><td>
              1.85
            </td><td>
              $4.39
            </td><td>
              $4.35
            </td><td>
              December 2021
            </td><td>
              110.55m
            </td><td>
              -3.45m
            </td><td>
              32.00
            </td><td>
              103.05m
            </td><td>
              48.19m
            </td><td>
              0
            </td><td>
              13,205,258
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TCON" class="margin-bottom-1">
                TCON
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.80</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+3.83%</small></td><td><strong>TRC102</strong> <br>Mesothelioma cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://traconpharma.gcs-web.com/news-releases/news-release-details/tracon-pharmaceuticals-reports-fourth-quarter-and-year-end-2020">
                2H 2021
              </a> <div class="note">Phase 2 data to be presented 2H 2021.</div></td><td>
              19m
            </td><td>
              73.8m
            </td><td>
              158.2k
            </td><td>
              326.5k
            </td><td>
              6.23
            </td><td>
              $3.65
            </td><td>
              $3.66
            </td><td>
              April 11, 2019
            </td><td>
              38.08m
            </td><td>
              -1.39m
            </td><td>
              27.37
            </td><td>
              23.19m
            </td><td>
              48.30m
            </td><td>
              2.1
            </td><td>
              13,231,871
            </td><td>
              02/25/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INCY" class="margin-bottom-1">
                INCY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$75.55</div> <small class="number change-up">+0.65<span>&nbsp;&nbsp;</span>+0.86%</small></td><td><strong>OLUMIANT (baricitinib)</strong> <br>Systemic lupus erythematosus (SLE)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.lilly.com/static-files/07e528d6-bf01-4258-8190-7b32b28ba24d">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              221m
            </td><td>
              16.7b
            </td><td>
              283.8k
            </td><td>
              1.3m
            </td><td>
              5.68
            </td><td>
              $75.18
            </td><td>
              $74.9
            </td><td>
              May 19, 2022
            </td><td>
              2.18b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              1.22b
            </td><td>
              14.50b
            </td><td>
              1.5
            </td><td>
              155,219,007
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LLY" class="margin-bottom-1">
                LLY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$269.63</div> <small class="number change-down">-1.28<span>&nbsp;&nbsp;</span>-0.47%</small></td><td><strong>OLUMIANT (baricitinib)</strong> <br>Systemic lupus erythematosus (SLE)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.lilly.com/static-files/07e528d6-bf01-4258-8190-7b32b28ba24d">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              1b
            </td><td>
              257.9b
            </td><td>
              0.8m
            </td><td>
              2.8m
            </td><td>
              40.00
            </td><td>
              $272.3
            </td><td>
              $270.91
            </td><td>
              May 19, 2022
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -36.81b
            </td><td>
              272.39b
            </td><td>
              0.5
            </td><td>
              792,287,037
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EYPT" class="margin-bottom-1">
                EYPT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$10.11</div> <small class="number change-down">-0.09<span>&nbsp;&nbsp;</span>-0.88%</small></td><td><strong>EYP-1901 (DAVIO)</strong> <br>Wet age-related macular degeneration (AMD)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://investors.eyepointpharma.com/news-releases/news-release-details/eyepoint-pharmaceuticals-reports-second-quarter-2021-financial">
                4Q 2021
              </a> <div class="note">Phase 1 initial data due 4Q 2021.</div></td><td>
              29m
            </td><td>
              290.9m
            </td><td>
              86.9k
            </td><td>
              184.3k
            </td><td>
              2.73
            </td><td>
              $10.2
            </td><td>
              $10.2
            </td><td>
              April 2022
            </td><td>
              121.30m
            </td><td>
              -3.51m
            </td><td>
              34.52
            </td><td>
              49.35m
            </td><td>
              204.07m
            </td><td>
              4.4
            </td><td>
              21,418,267
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LEGN" class="margin-bottom-1">
                LEGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$37.92</div> <small class="number change-up">+2.54<span>&nbsp;&nbsp;</span>+7.18%</small></td><td><strong>Ciltacabtagene autoleucel (cilta-cel) (LCAR-B38M/JNJ-4528) - LEGEND-2</strong> <br>RRMM
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210823005189/en/Legend-Biotech-Reports-Second-Quarter-2021-Financial-Results-and-Recent-Highlights">
                2H 2021
              </a> <div class="note">Manuscript on the clinical data from LEGEND-2 study to be submitted in 2021.</div></td><td>
              145m
            </td><td>
              5.5b
            </td><td>
              339.5k
            </td><td>
              400.5k
            </td><td>
              26.52
            </td><td>
              $37.2
            </td><td>
              $35.38
            </td><td>
              December 31, 2021
            </td><td>
              419.14m
            </td><td>
              -8.93m
            </td><td>
              46.94
            </td><td>
              10.34m
            </td><td>
              4.66b
            </td><td>
              0
            </td><td>
              144,632,059
            </td><td>
              08/23/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OPNT" class="margin-bottom-1">
                OPNT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.67</div> <small class="number change-down">-0.13<span>&nbsp;&nbsp;</span>-0.78%</small></td><td><strong>OPNT003</strong> <br>Opioid Overdose
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.opiant.com/news-releases/news-release-details/opiant-pharmaceuticals-announces-second-quarter-2021-financial">
                4Q 2021
              </a> <div class="note">PD data due 4Q 2021. </div></td><td>
              4m
            </td><td>
              73.3m
            </td><td>
              63.9k
            </td><td>
              181.2k
            </td><td>
              2.02
            </td><td>
              $16.77
            </td><td>
              $16.8
            </td><td>
              October 20, 2021
            </td><td>
              47.27m
            </td><td>
              -0.69m
            </td><td>
              68.31
            </td><td>
              21.87m
            </td><td>
              45.36m
            </td><td>
              9
            </td><td>
              4,179,430
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GMAB" class="margin-bottom-1">
                GMAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$48.75</div> <small class="number change-up">+0.73<span>&nbsp;&nbsp;</span>+1.52%</small></td><td><strong>BNT312/GEN1042</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.biontech.de/news-releases/news-release-details/biontech-announces-second-quarter-2021-financial-results-and">
                2H 2021
              </a> <div class="note">Phase 1/2 first data due 2H 2021.</div></td><td>
              1b
            </td><td>
              31.9b
            </td><td>
              0.5m
            </td><td>
              0.5m
            </td><td>
              10.01
            </td><td>
              $47.72
            </td><td>
              $48.02
            </td><td>
              July 2022
            </td><td>
              18.09b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              15.86b
            </td><td>
              28.51b
            </td><td>
              0
            </td><td>
              653,818,780
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BNTX" class="margin-bottom-1">
                BNTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$381.13</div> <small class="number change-up">+32.45<span>&nbsp;&nbsp;</span>+9.31%</small></td><td><strong>BNT312/GEN1042</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.biontech.de/news-releases/news-release-details/biontech-announces-second-quarter-2021-financial-results-and">
                2H 2021
              </a> <div class="note">Phase 1/2 first data due 2H 2021.</div></td><td>
              243m
            </td><td>
              92.4b
            </td><td>
              5.5m
            </td><td>
              4.2m
            </td><td>
              14.40
            </td><td>
              $374
            </td><td>
              $348.68
            </td><td>
              July 2022
            </td><td>
              0.85b
            </td><td>
              -33.43m
            </td><td>
              25.56
            </td><td>
              -2.81b
            </td><td>
              83.79b
            </td><td>
              0
            </td><td>
              242,516,955
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/REGN" class="margin-bottom-1">
                REGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$665.74</div> <small class="number change-up">+2.47<span>&nbsp;&nbsp;</span>+0.37%</small></td><td><strong>Fasinumab</strong> <br>Osteoarthritis pain of the hip or knee
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2020-financial">
                2021
              </a> <div class="note">Phase 3 data achieved the co-primary endpoints for fasinumab 1 mg monthly. Fasinumab every two months did not reach statistical significance - August 5, 2020. Longer term safety data due 2021.</div></td><td>
              107m
            </td><td>
              71.2b
            </td><td>
              0.7m
            </td><td>
              0.8m
            </td><td>
              4.71
            </td><td>
              $665.21
            </td><td>
              $663.27
            </td><td>
              N/A
            </td><td>
              4.29b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -2.07b
            </td><td>
              69.73b
            </td><td>
              2.1
            </td><td>
              89,032,197
            </td><td>
              02/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TEVA" class="margin-bottom-1">
                TEVA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.43</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+3.15%</small></td><td><strong>Fasinumab</strong> <br>Osteoarthritis pain of the hip or knee
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2020-financial">
                2021
              </a> <div class="note">Phase 3 data achieved the co-primary endpoints for fasinumab 1 mg monthly. Fasinumab every two months did not reach statistical significance - August 5, 2020. Longer term safety data due 2021.</div></td><td>
              1b
            </td><td>
              10.4b
            </td><td>
              3.5m
            </td><td>
              9.6m
            </td><td>
              1.01
            </td><td>
              $9.25
            </td><td>
              $9.14
            </td><td>
              N/A
            </td><td>
              2.57b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -35.32b
            </td><td>
              33.52b
            </td><td>
              0.4
            </td><td>
              1,098,121,371
            </td><td>
              02/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BLPH" class="margin-bottom-1">
                BLPH
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.05</div> <small class="number change-up">+0.27<span>&nbsp;&nbsp;</span>+7.14%</small></td><td><strong>INOpulse</strong> <br>Pulmonary Hypertension-Sarcoidosis (PH-Sarc)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.bellerophon.com/news-releases/news-release-details/bellerophon-provides-clinical-program-update-and-reports-1">
                2H 2021
              </a> <div class="note">Phase 2 top-line data due 2H 2021.</div></td><td>
              10m
            </td><td>
              38.5m
            </td><td>
              28.4k
            </td><td>
              214.5k
            </td><td>
              1.28
            </td><td>
              $3.79
            </td><td>
              $3.78
            </td><td>
              N/A
            </td><td>
              31.08m
            </td><td>
              -1.79m
            </td><td>
              17.36
            </td><td>
              24.10m
            </td><td>
              2.95m
            </td><td>
              39
            </td><td>
              7,891,189
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ATAI" class="margin-bottom-1">
                ATAI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.38</div> <small class="number change-up">+1.54<span>&nbsp;&nbsp;</span>+10.38%</small></td><td><strong>COMP360</strong> <br>Treatment Resistant Depression
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-reports-second-quarter-2021-financial-results">
                Late-2021
              </a> <div class="note">Phase 2b data due late-2021.</div></td><td>
              155m
            </td><td>
              2.5b
            </td><td>
              450.9k
            </td><td>
              0.6m
            </td><td>
              5.34
            </td><td>
              $15.45
            </td><td>
              $14.84
            </td><td>
              July 30, 2021
            </td><td>
              454.76m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              433.69m
            </td><td>
              1.85b
            </td><td>
              0
            </td><td>
              114,161,264
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SRNE" class="margin-bottom-1">
                SRNE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.96</div> <small class="number change-up">+0.61<span>&nbsp;&nbsp;</span>+7.31%</small></td><td><strong>SEMDEXA (SP-102)</strong> <br>Lumbosacral radicular pain (sciatica)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-complete">
                4Q 2021
              </a> <div class="note">Phase 3 completion of enrollment announced July 20, 2021 with top-line data due 4Q 2021.</div></td><td>
              298m
            </td><td>
              2.7b
            </td><td>
              4.1m
            </td><td>
              6.6m
            </td><td>
              14.45
            </td><td>
              $8.36
            </td><td>
              $8.35
            </td><td>
              August 2021
            </td><td>
              64.59m
            </td><td>
              -26.17m
            </td><td>
              2.47
            </td><td>
              -0.53b
            </td><td>
              2.54b
            </td><td>
              35.1
            </td><td>
              293,559,311
            </td><td>
              07/20/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CHRS" class="margin-bottom-1">
                CHRS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$15.49</div> <small class="number change-up">+0.49<span>&nbsp;&nbsp;</span>+3.30%</small></td><td><strong>CHS-305</strong> <br>Avastin (bevacizumab) biosimilar
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/05/06/2224975/33333/en/Coherus-BioSciences-Reports-First-Quarter-2021-Financial-Results-and-Immuno-oncology-and-Biosimilar-Pipeline-Progress.html">
                2021
              </a> <div class="note">Pharmacokinetic study data due 2021.</div></td><td>
              76m
            </td><td>
              1.2b
            </td><td>
              336.5k
            </td><td>
              0.7m
            </td><td>
              7.60
            </td><td>
              $15.14
            </td><td>
              $15
            </td><td>
              N/A
            </td><td>
              454.31m
            </td><td>
              -62.67k
            </td><td>
              7.25k
            </td><td>
              -129.01m
            </td><td>
              1.11b
            </td><td>
              1.4
            </td><td>
              54,173,405
            </td><td>
              05/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/JNJ" class="margin-bottom-1">
                JNJ
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$177.78</div> <small class="number change-down">-0.60<span>&nbsp;&nbsp;</span>-0.34%</small></td><td><strong>JNJ-78436735 (Ad26.COV2-S) -  (ENSEMBLE-2)</strong> <br>COVID-19 vaccine - two-dose regimen
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.cnbc.com/video/2021/02/09/high-hopes-vaccine-update-with-jj-ceo-alex-gorsky-at-cnbc-healthy-returns.html">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              3b
            </td><td>
              468.0b
            </td><td>
              2.8m
            </td><td>
              6.0m
            </td><td>
              6.73
            </td><td>
              $178.39
            </td><td>
              $178.38
            </td><td>
              May 10, 2022
            </td><td>
              28.49b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -78.37b
            </td><td>
              480.55b
            </td><td>
              0.1
            </td><td>
              2,630,875,523
            </td><td>
              02/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARTL" class="margin-bottom-1">
                ARTL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.92</div> <small class="number change-up">+0.03<span>&nbsp;&nbsp;</span>+3.73%</small></td><td><strong>ART27.13 (CAReS)</strong> <br>Cancer-Related Anorexia and Weight Loss
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.artelobio.com/news-events/press-releases/detail/66/artelo-biosciences-reports-third-quarter-fiscal-2021">
                2H 2021
              </a> <div class="note">Phase 1/2 initial safety data due 2H 2021. Full data due 1H 2022.</div></td><td>
              24m
            </td><td>
              22.5m
            </td><td>
              410.5k
            </td><td>
              450.5k
            </td><td>
              1.88
            </td><td>
              $0.89
            </td><td>
              $0.89
            </td><td>
              N/A
            </td><td>
              8.39m
            </td><td>
              -0.59m
            </td><td>
              14.14
            </td><td>
              7.97m
            </td><td>
              11.67m
            </td><td>
              3.8
            </td><td>
              24,129,139
            </td><td>
              07/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GMAB" class="margin-bottom-1">
                GMAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$48.75</div> <small class="number change-up">+0.73<span>&nbsp;&nbsp;</span>+1.52%</small></td><td><strong>BNT311 / GEN1046</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.biontech.de/news-releases/news-release-details/biontech-announces-second-quarter-2021-financial-results-and">
                2H 2021
              </a> <div class="note">Phase 1/2 data update due 2H 2021.</div></td><td>
              1b
            </td><td>
              31.9b
            </td><td>
              0.5m
            </td><td>
              0.5m
            </td><td>
              10.01
            </td><td>
              $47.72
            </td><td>
              $48.02
            </td><td>
              June 2022
            </td><td>
              18.09b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              15.86b
            </td><td>
              28.51b
            </td><td>
              0
            </td><td>
              653,818,780
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BNTX" class="margin-bottom-1">
                BNTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$381.13</div> <small class="number change-up">+32.45<span>&nbsp;&nbsp;</span>+9.31%</small></td><td><strong>BNT311 / GEN1046</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.biontech.de/news-releases/news-release-details/biontech-announces-second-quarter-2021-financial-results-and">
                2H 2021
              </a> <div class="note">Phase 1/2 data update due 2H 2021.</div></td><td>
              243m
            </td><td>
              92.4b
            </td><td>
              5.5m
            </td><td>
              4.2m
            </td><td>
              14.40
            </td><td>
              $374
            </td><td>
              $348.68
            </td><td>
              June 2022
            </td><td>
              0.85b
            </td><td>
              -33.43m
            </td><td>
              25.56
            </td><td>
              -2.81b
            </td><td>
              83.79b
            </td><td>
              0
            </td><td>
              242,516,955
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MRUS" class="margin-bottom-1">
                MRUS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$24.57</div> <small class="number change-up">+2.35<span>&nbsp;&nbsp;</span>+10.58%</small></td><td><strong>MCLA-158</strong> <br>Solid Tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.merus.nl/news-releases/news-release-details/merus-announces-financial-results-second-quarter-and-provides-0">
                4Q 2021
              </a> <div class="note">Phase 1 update 4Q 2021.</div></td><td>
              38m
            </td><td>
              0.9b
            </td><td>
              121.7k
            </td><td>
              274.0k
            </td><td>
              4.32
            </td><td>
              $22.53
            </td><td>
              $22.22
            </td><td>
              January 2021
            </td><td>
              338.17m
            </td><td>
              -8.10m
            </td><td>
              41.76
            </td><td>
              177.68m
            </td><td>
              0.51b
            </td><td>
              0.3
            </td><td>
              32,485,140
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KROS" class="margin-bottom-1">
                KROS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$33.09</div> <small class="number change-up">+1.18<span>&nbsp;&nbsp;</span>+3.70%</small></td><td><strong>KER-050</strong> <br>Myelodysplastic syndromes
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/05/2275967/0/en/Keros-Therapeutics-Reports-Recent-Business-Highlights-and-Second-Quarter-2021-Financial-Results.html">
                YE 2021
              </a> <div class="note">Phase 2 initial data released June 22, 2021. Further data due by end of 2021.</div></td><td>
              23m
            </td><td>
              0.8b
            </td><td>
              35.3k
            </td><td>
              125.1k
            </td><td>
              3.28
            </td><td>
              $32.19
            </td><td>
              $31.91
            </td><td>
              January 31, 2022
            </td><td>
              226.53m
            </td><td>
              -5.88m
            </td><td>
              38.53
            </td><td>
              218.73m
            </td><td>
              0.51b
            </td><td>
              1.5
            </td><td>
              12,863,459
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ORIC" class="margin-bottom-1">
                ORIC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$20.50</div> <small class="number change-up">+1.14<span>&nbsp;&nbsp;</span>+5.89%</small></td><td><strong>ORIC-101 and XTANDI (Enzalutamide)</strong> <br>Prostate cancer
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.oricpharma.com/news-releases/news-release-details/oric-pharmaceuticals-reports-second-quarter-2021-financial">
                2H 2021
              </a> <div class="note">Phase 1b interim data due 2H 2021.</div></td><td>
              39m
            </td><td>
              0.8b
            </td><td>
              129.7k
            </td><td>
              224.1k
            </td><td>
              3.12
            </td><td>
              $19.52
            </td><td>
              $19.36
            </td><td>
              December 2022
            </td><td>
              251.34m
            </td><td>
              -5.40m
            </td><td>
              46.50
            </td><td>
              241.44m
            </td><td>
              0.50b
            </td><td>
              0.2
            </td><td>
              20,021,307
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SNY" class="margin-bottom-1">
                SNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$52.48</div> <small class="number change-down">-0.64<span>&nbsp;&nbsp;</span>-1.20%</small></td><td><strong>MRT5400 and MRT5401</strong> <br>Influenza vaccine
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/06/22/2250634/0/en/Sanofi-and-Translate-Bio-Initiate-Phase-1-Clinical-Trial-of-mRNA-Influenza-Vaccine.html">
                YE 2021
              </a> <div class="note">Phase 1 initiation announced June 22, 2021. Interim data due by end of 2021.</div></td><td>
              3b
            </td><td>
              131.7b
            </td><td>
              2.5m
            </td><td>
              1.7m
            </td><td>
              1.78
            </td><td>
              $52.73
            </td><td>
              $53.12
            </td><td>
              N/A
            </td><td>
              9.72b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -39.23b
            </td><td>
              146.90b
            </td><td>
              0
            </td><td>
              2,510,366,030
            </td><td>
              06/22/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TBIO" class="margin-bottom-1">
                TBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$37.74</div> <small class="number change-down">-0.03<span>&nbsp;&nbsp;</span>-0.07%</small></td><td><strong>MRT5400 and MRT5401</strong> <br>Influenza vaccine
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/06/22/2250634/0/en/Sanofi-and-Translate-Bio-Initiate-Phase-1-Clinical-Trial-of-mRNA-Influenza-Vaccine.html">
                YE 2021
              </a> <div class="note">Phase 1 initiation announced June 22, 2021. Interim data due by end of 2021.</div></td><td>
              76m
            </td><td>
              2.9b
            </td><td>
              1.1m
            </td><td>
              3.0m
            </td><td>
              6.91
            </td><td>
              $37.71
            </td><td>
              $37.77
            </td><td>
              N/A
            </td><td>
              0.68b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              182.77m
            </td><td>
              2.25b
            </td><td>
              1.4
            </td><td>
              53,617,413
            </td><td>
              06/22/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ORMP" class="margin-bottom-1">
                ORMP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$15.66</div> <small class="number change-up">+0.40<span>&nbsp;&nbsp;</span>+2.62%</small></td><td><strong>ORMD-0801</strong> <br>Non-alcoholic steatohepatitis (NASH)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/oramed-issues-letter-to-shareholders-301216292.html">
                2021
              </a> <div class="note">Phase 2 trial to be completed in 2021.</div></td><td>
              33m
            </td><td>
              0.5b
            </td><td>
              374.5k
            </td><td>
              0.8m
            </td><td>
              7.46
            </td><td>
              $15.5
            </td><td>
              $15.26
            </td><td>
              October 2021
            </td><td>
              59.36m
            </td><td>
              -1.88m
            </td><td>
              31.59
            </td><td>
              48.06m
            </td><td>
              432.10m
            </td><td>
              58.6
            </td><td>
              30,034,652
            </td><td>
              01/27/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MRTX" class="margin-bottom-1">
                MRTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$145.25</div> <small class="number change-up">+11.12<span>&nbsp;&nbsp;</span>+8.29%</small></td><td><strong>Sitravatinib and OPDIVO (nivolumab)</strong> <br>Urothelial Carcinoma (Bladder)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s23.q4cdn.com/174398288/files/doc_presentations/2021/02/MRTX-Corporate-Presentation_25Feb2021.pdf">
                2021
              </a> <div class="note">Phase 2 at ESMO September 2020 noted objective response rate of 37% (1 complete response and 10 partial responses). Further data due 2021.</div></td><td>
              52m
            </td><td>
              7.5b
            </td><td>
              181.2k
            </td><td>
              466.1k
            </td><td>
              6.64
            </td><td>
              $135.44
            </td><td>
              $134.13
            </td><td>
              January 31, 2022
            </td><td>
              1.14b
            </td><td>
              -31.12m
            </td><td>
              36.65
            </td><td>
              0.91b
            </td><td>
              5.77b
            </td><td>
              0.9
            </td><td>
              40,808,627
            </td><td>
              05/07/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PSTI" class="margin-bottom-1">
                PSTI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.04</div> <small class="number change-up">+0.10<span>&nbsp;&nbsp;</span>+3.23%</small></td><td><strong>PLX-PAD</strong> <br>COVID-19 / Acute Respiratory Distress Syndrome (ARDS)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://nz.finance.yahoo.com/news/pluristem-brings-ards-associated-covid-111000797.html">
                4Q 2021
              </a> <div class="note">Phase 2 data due 4Q 2021.</div></td><td>
              32m
            </td><td>
              96.3m
            </td><td>
              68.5k
            </td><td>
              253.0k
            </td><td>
              1.41
            </td><td>
              $2.93
            </td><td>
              $2.94
            </td><td>
              N/A
            </td><td>
              55.56m
            </td><td>
              -2.44m
            </td><td>
              22.74
            </td><td>
              44.52m
            </td><td>
              46.94m
            </td><td>
              25.4
            </td><td>
              22,445,595
            </td><td>
              07/08/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IONS" class="margin-bottom-1">
                IONS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$39.33</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+0.18%</small></td><td><strong>Vupanorsen (AKCEA-ANGPTL3-LRx) - (TRANSLATE-TIMI 70)</strong> <br>Cardiovascular (CV) risk reduction and hypertriglyceridemia
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ionispharma.com/news-releases/news-release-details/ionis-reports-second-quarter-2021-financial-results-and-recent">
                2H 2021
              </a> <div class="note">Phase 2b data due 2H 2021.</div></td><td>
              141m
            </td><td>
              5.6b
            </td><td>
              322.8k
            </td><td>
              1.1m
            </td><td>
              9.52
            </td><td>
              $39.68
            </td><td>
              $39.26
            </td><td>
              October 1, 2021
            </td><td>
              2.05b
            </td><td>
              -20.88m
            </td><td>
              98.00
            </td><td>
              132.28m
            </td><td>
              4.79b
            </td><td>
              0.6
            </td><td>
              119,102,131
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PFE" class="margin-bottom-1">
                PFE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.98</div> <small class="number change-up">+1.25<span>&nbsp;&nbsp;</span>+2.58%</small></td><td><strong>Vupanorsen (AKCEA-ANGPTL3-LRx) - (TRANSLATE-TIMI 70)</strong> <br>Cardiovascular (CV) risk reduction and hypertriglyceridemia
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ionispharma.com/news-releases/news-release-details/ionis-reports-second-quarter-2021-financial-results-and-recent">
                2H 2021
              </a> <div class="note">Phase 2b data due 2H 2021.</div></td><td>
              6b
            </td><td>
              280.2b
            </td><td>
              69.5m
            </td><td>
              30.1m
            </td><td>
              4.00
            </td><td>
              $50.29
            </td><td>
              $48.72
            </td><td>
              October 1, 2021
            </td><td>
              28.48b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -71.13b
            </td><td>
              289.19b
            </td><td>
              0.3
            </td><td>
              5,605,213,314
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/REGN" class="margin-bottom-1">
                REGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$665.74</div> <small class="number change-up">+2.47<span>&nbsp;&nbsp;</span>+0.37%</small></td><td><strong>DUPIXENT (dupilumab)</strong> <br>Eosinophilic esophagitis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/2021_07_29_Sanofi_Q2_2021_presentation.pdf?la=en&amp;hash=F258C8E98B392E4E9DAF7517ECD8A4B9">
                2H 2021
              </a> <div class="note">Data from Phase 2 portion of Phase 2/3 trial met co-primary endpoints - May 22, 2020. Phase 3 Part B data due 2H 2021.</div></td><td>
              107m
            </td><td>
              71.2b
            </td><td>
              0.7m
            </td><td>
              0.8m
            </td><td>
              4.71
            </td><td>
              $665.21
            </td><td>
              $663.27
            </td><td>
              September 16, 2021
            </td><td>
              4.29b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -2.07b
            </td><td>
              69.73b
            </td><td>
              2.1
            </td><td>
              89,032,197
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SNY" class="margin-bottom-1">
                SNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$52.48</div> <small class="number change-down">-0.64<span>&nbsp;&nbsp;</span>-1.20%</small></td><td><strong>DUPIXENT (dupilumab)</strong> <br>Eosinophilic esophagitis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/2021_07_29_Sanofi_Q2_2021_presentation.pdf?la=en&amp;hash=F258C8E98B392E4E9DAF7517ECD8A4B9">
                2H 2021
              </a> <div class="note">Data from Phase 2 portion of Phase 2/3 trial met co-primary endpoints - May 22, 2020. Phase 3 Part B data due 2H 2021.</div></td><td>
              3b
            </td><td>
              131.7b
            </td><td>
              2.5m
            </td><td>
              1.7m
            </td><td>
              1.78
            </td><td>
              $52.73
            </td><td>
              $53.12
            </td><td>
              September 16, 2021
            </td><td>
              9.72b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -39.23b
            </td><td>
              146.90b
            </td><td>
              0
            </td><td>
              2,510,366,030
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VBLT" class="margin-bottom-1">
                VBLT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.00</div> <small class="number change-up">+0.02<span>&nbsp;&nbsp;</span>+1.01%</small></td><td><strong>VB-111</strong> <br>Colon cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://ir.vblrx.com/static-files/f43bf7b6-0a92-41d0-b867-c7d1b605505b">
                2H 2021
              </a> <div class="note">Phase 2 initial data due 2H 2021.</div></td><td>
              62m
            </td><td>
              124.1m
            </td><td>
              138.1k
            </td><td>
              378.7k
            </td><td>
              2.22
            </td><td>
              $1.97
            </td><td>
              $1.98
            </td><td>
              N/A
            </td><td>
              81.81m
            </td><td>
              -1.82m
            </td><td>
              44.94
            </td><td>
              70.33m
            </td><td>
              68.46m
            </td><td>
              0
            </td><td>
              47,358,345
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MRTX" class="margin-bottom-1">
                MRTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$145.25</div> <small class="number change-up">+11.12<span>&nbsp;&nbsp;</span>+8.29%</small></td><td><strong>Sitravatinib and OPDIVO (nivolumab)</strong> <br>Renal cell carcinoma (RCC)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s23.q4cdn.com/174398288/files/doc_presentations/2021/02/MRTX-Corporate-Presentation_25Feb2021.pdf">
                2021
              </a> <div class="note">Phase 2 updated data due in 2021.</div></td><td>
              52m
            </td><td>
              7.5b
            </td><td>
              181.2k
            </td><td>
              466.1k
            </td><td>
              6.64
            </td><td>
              $135.44
            </td><td>
              $134.13
            </td><td>
              April 27, 2020
            </td><td>
              1.14b
            </td><td>
              -31.12m
            </td><td>
              36.65
            </td><td>
              0.91b
            </td><td>
              5.77b
            </td><td>
              0.9
            </td><td>
              40,808,627
            </td><td>
              05/07/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/HZNP" class="margin-bottom-1">
                HZNP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$108.15</div> <small class="number change-up">+3.12<span>&nbsp;&nbsp;</span>+2.97%</small></td><td><strong>Krystexxa with Methotrexate - MIRROR RCT</strong> <br>Gout
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20201102005464/en/">
                2H 2021
              </a> <div class="note">Phase 4 initial data due 2021.</div></td><td>
              226m
            </td><td>
              24.4b
            </td><td>
              0.6m
            </td><td>
              1.4m
            </td><td>
              6.00
            </td><td>
              $105.9
            </td><td>
              $105.03
            </td><td>
              March 17, 2021
            </td><td>
              0.89b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -3.24b
            </td><td>
              25.47b
            </td><td>
              1.1
            </td><td>
              218,939,827
            </td><td>
              11/02/2020
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NKTR" class="margin-bottom-1">
                NKTR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.89</div> <small class="number change-up">+0.28<span>&nbsp;&nbsp;</span>+2.06%</small></td><td><strong>NKTR-255</strong> <br>Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/nektar-therapeutics-reports-first-quarter-2021-financial-results-301286004.html">
                4Q 2021
              </a> <div class="note">Phase 1 data due 4Q 2021.</div></td><td>
              184m
            </td><td>
              2.6b
            </td><td>
              287.9k
            </td><td>
              0.8m
            </td><td>
              2.82
            </td><td>
              $13.74
            </td><td>
              $13.61
            </td><td>
              N/A
            </td><td>
              0.95b
            </td><td>
              -27.63m
            </td><td>
              34.39
            </td><td>
              483.95m
            </td><td>
              1.65b
            </td><td>
              2.1
            </td><td>
              91,286,217
            </td><td>
              05/07/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AMGN" class="margin-bottom-1">
                AMGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$226.21</div> <small class="number change-up">+2.68<span>&nbsp;&nbsp;</span>+1.20%</small></td><td><strong>LUMAKRAS (Sotorasib)</strong> <br>Colorectal cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/amgen-reports-second-quarter-2021-financial-results-301347523.html">
                2021
              </a> <div class="note">Phase 2 monotherapy data due 2021.</div></td><td>
              1b
            </td><td>
              128.5b
            </td><td>
              0.9m
            </td><td>
              2.4m
            </td><td>
              15.58
            </td><td>
              $224.18
            </td><td>
              $223.53
            </td><td>
              N/A
            </td><td>
              8.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -43.19b
            </td><td>
              151.63b
            </td><td>
              0.6
            </td><td>
              566,434,467
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/HGEN" class="margin-bottom-1">
                HGEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.96</div> <small class="number change-up">+0.78<span>&nbsp;&nbsp;</span>+4.82%</small></td><td><strong>Lenzilumab and YESCARTA - Axicabtagene ciloleucel (ZUMA-19)</strong> <br>Large B-cell Lymphoma
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210419005250/en/">
                2H 2021
              </a> <div class="note">Phase 1b data released April 18, 2021. ORR 5/6 patients (83%). Phase 2 interim and efficacy data due 2H 2021.</div></td><td>
              59m
            </td><td>
              1.0b
            </td><td>
              0.6m
            </td><td>
              1.2m
            </td><td>
              22.92
            </td><td>
              $15.98
            </td><td>
              $16.18
            </td><td>
              March 16, 2021
            </td><td>
              79.76m
            </td><td>
              -22.65m
            </td><td>
              3.52
            </td><td>
              1.73m
            </td><td>
              0.87b
            </td><td>
              0.9
            </td><td>
              38,115,353
            </td><td>
              06/08/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RDUS" class="margin-bottom-1">
                RDUS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.74</div> <small class="number change-up">+0.59<span>&nbsp;&nbsp;</span>+4.49%</small></td><td><strong>TYMLOS (Abaloparatide) -SC ATOM</strong> <br>Male Osteoporosis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.radiuspharm.com/news-releases/news-release-details/radius-health-business-update-1">
                2H 2021
              </a> <div class="note">Phase 3 data due 2H 2021.</div></td><td>
              47m
            </td><td>
              0.6b
            </td><td>
              160.9k
            </td><td>
              340.8k
            </td><td>
              -2.86
            </td><td>
              $13.22
            </td><td>
              $13.15
            </td><td>
              August 20, 2020
            </td><td>
              90.18m
            </td><td>
              -5.00m
            </td><td>
              18.05
            </td><td>
              -329.76m
            </td><td>
              0.86b
            </td><td>
              0.9
            </td><td>
              33,375,071
            </td><td>
              07/27/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IPHA" class="margin-bottom-1">
                IPHA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.40</div> <small class="number change-up">+0.05<span>&nbsp;&nbsp;</span>+1.49%</small></td><td><strong>Monalizumab in combination with cetuximab</strong> <br>Squamous Cell Carcinoma of the Head and Neck (SCCHN)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://www.innate-pharma.com/media/all-press-releases/innate-pharma-first-quarter-2021-report">
                2021
              </a> <div class="note">Phase 2 cohort 3 data due 2021. Phase 3 commencement of dosing announced October 23, 2020.</div></td><td>
              79m
            </td><td>
              269.1m
            </td><td>
              2.7k
            </td><td>
              16.9k
            </td><td>
              1.47
            </td><td>
              $3.36
            </td><td>
              $3.35
            </td><td>
              September 2022
            </td><td>
              151.64m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              190.00k
            </td><td>
              113.29m
            </td><td>
              0
            </td><td>
              79,145,827
            </td><td>
              05/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RDUS" class="margin-bottom-1">
                RDUS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.74</div> <small class="number change-up">+0.59<span>&nbsp;&nbsp;</span>+4.49%</small></td><td><strong>Elacestrant - EMERALD</strong> <br>Breast cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.radiuspharm.com/news-releases/news-release-details/radius-health-inc-second-quarter-and-year-date-results">
                2H 2021
              </a> <div class="note">Phase 3 top-line data due 2H 2021.</div></td><td>
              47m
            </td><td>
              0.6b
            </td><td>
              160.9k
            </td><td>
              340.8k
            </td><td>
              -2.86
            </td><td>
              $13.22
            </td><td>
              $13.15
            </td><td>
              August 2021
            </td><td>
              90.18m
            </td><td>
              -5.00m
            </td><td>
              18.05
            </td><td>
              -329.76m
            </td><td>
              0.86b
            </td><td>
              0.9
            </td><td>
              33,375,071
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FBIO" class="margin-bottom-1">
                FBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.20</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+4.58%</small></td><td><strong>Cosibelimab (CK-301)</strong> <br>Cutaneous squamous cell carcinoma (CSCC)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/16/2281500/28889/en/Fortress-Biotech-Reports-Record-Second-Quarter-2021-Financial-Results-and-Recent-Corporate-Highlights.html">
                4Q 2021
              </a> <div class="note">Phase 1 pivotal top-line data due 4Q 2021.</div></td><td>
              101m
            </td><td>
              323.4m
            </td><td>
              220.5k
            </td><td>
              0.5m
            </td><td>
              2.99
            </td><td>
              $3.07
            </td><td>
              $3.06
            </td><td>
              July 2021
            </td><td>
              254.32m
            </td><td>
              -11.49m
            </td><td>
              22.14
            </td><td>
              84.46m
            </td><td>
              120.76m
            </td><td>
              27.4
            </td><td>
              76,232,955
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CKPT" class="margin-bottom-1">
                CKPT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.79</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+5.38%</small></td><td><strong>Cosibelimab (CK-301)</strong> <br>Cutaneous squamous cell carcinoma (CSCC)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/16/2281500/28889/en/Fortress-Biotech-Reports-Record-Second-Quarter-2021-Financial-Results-and-Recent-Corporate-Highlights.html">
                4Q 2021
              </a> <div class="note">Phase 1 pivotal top-line data due 4Q 2021.</div></td><td>
              83m
            </td><td>
              231.1m
            </td><td>
              379.2k
            </td><td>
              1.0m
            </td><td>
              4.05
            </td><td>
              $2.73
            </td><td>
              $2.65
            </td><td>
              July 2021
            </td><td>
              61.70m
            </td><td>
              -1.90m
            </td><td>
              32.43
            </td><td>
              52.45m
            </td><td>
              154.14m
            </td><td>
              5.5
            </td><td>
              63,798,958
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/HGEN" class="margin-bottom-1">
                HGEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.96</div> <small class="number change-up">+0.78<span>&nbsp;&nbsp;</span>+4.82%</small></td><td><strong>Lenzilumab</strong> <br>COVID-19
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://9e234b13-0cc4-4c74-b924-d7874342289e.filesusr.com/ugd/6ca631_411f21337d814e12bcbcbcb46dfd89f0.pdf">
                2021
              </a> <div class="note">Phase 2 top-line data due 2021.</div></td><td>
              59m
            </td><td>
              1.0b
            </td><td>
              0.6m
            </td><td>
              1.2m
            </td><td>
              22.92
            </td><td>
              $15.98
            </td><td>
              $16.18
            </td><td>
              December 31, 2021
            </td><td>
              79.76m
            </td><td>
              -22.65m
            </td><td>
              3.52
            </td><td>
              1.73m
            </td><td>
              0.87b
            </td><td>
              0.9
            </td><td>
              38,115,353
            </td><td>
              11/06/2020
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SYBX" class="margin-bottom-1">
                SYBX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.67</div> <small class="number change-up">+0.22<span>&nbsp;&nbsp;</span>+8.98%</small></td><td><strong>SYNB1618 (SynPheny-1)</strong> <br>Phenylketonuria (PKU)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/synlogic-reports-second-quarter-financial-results-and-provides-business-update-301353948.html">
                2H 2021
              </a> <div class="note">Phase 2 data due 2H 2021.</div></td><td>
              52m
            </td><td>
              139.8m
            </td><td>
              77.7k
            </td><td>
              228.2k
            </td><td>
              1.09
            </td><td>
              $2.49
            </td><td>
              $2.45
            </td><td>
              August 2021
            </td><td>
              108.66m
            </td><td>
              -3.78m
            </td><td>
              28.73
            </td><td>
              79.85m
            </td><td>
              34.89m
            </td><td>
              2.7
            </td><td>
              37,099,321
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OCUL" class="margin-bottom-1">
                OCUL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$10.35</div> <small class="number change-up">+0.34<span>&nbsp;&nbsp;</span>+3.40%</small></td><td><strong>OTX-CSI</strong> <br>Dry eye disease (DED)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005723/en/">
                4Q 2021
              </a> <div class="note">Phase 2 data due 4Q 2021.</div></td><td>
              77m
            </td><td>
              0.8b
            </td><td>
              424.1k
            </td><td>
              0.8m
            </td><td>
              9.86
            </td><td>
              $10.14
            </td><td>
              $10.01
            </td><td>
              N/A
            </td><td>
              179.83m
            </td><td>
              -6.69m
            </td><td>
              26.90
            </td><td>
              29.37m
            </td><td>
              0.63b
            </td><td>
              2.1
            </td><td>
              68,673,532
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALNA" class="margin-bottom-1">
                ALNA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.90</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+6.95%</small></td><td><strong>ALLN-346</strong> <br>Hyperuricemia
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/10/2278391/0/en/Allena-Pharmaceuticals-Reports-Second-Quarter-2021-Financial-Results-and-Recent-Corporate-Progress.html">
                4Q 2021
              </a> <div class="note">Phase 1b initial data due 4Q 2021.</div></td><td>
              80m
            </td><td>
              72.5m
            </td><td>
              0.7m
            </td><td>
              3.2m
            </td><td>
              6.03
            </td><td>
              $0.85
            </td><td>
              $0.85
            </td><td>
              N/A
            </td><td>
              47.84m
            </td><td>
              -3.79m
            </td><td>
              12.63
            </td><td>
              29.82m
            </td><td>
              51.68m
            </td><td>
              5.4
            </td><td>
              76,191,870
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BBI" class="margin-bottom-1">
                BBI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.64</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+1.18%</small></td><td><strong>Sofpironium Bromide (Cardigan I)</strong> <br>Axillary hyperhidrosis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.brickellbio.com/news/detail/64/brickell-biotech-reports-second-quarter-2021-financial">
                4Q 2021
              </a> <div class="note">Phase 3 top-line data due 4Q 2021.</div></td><td>
              86m
            </td><td>
              55.0m
            </td><td>
              309.8k
            </td><td>
              1.3m
            </td><td>
              2.46
            </td><td>
              $0.65
            </td><td>
              $0.63
            </td><td>
              June 25, 2021
            </td><td>
              23.87m
            </td><td>
              -4.77m
            </td><td>
              5.00
            </td><td>
              17.15m
            </td><td>
              30.08m
            </td><td>
              2.2
            </td><td>
              83,870,001
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ABBV" class="margin-bottom-1">
                ABBV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$119.82</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+0.84%</small></td><td><strong>RINVOQ (upadacitinib)</strong> <br>Crohn's disease (induction/maintenance) 
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.abbvie.com/static-files/9c3dba8e-5447-4e55-a78f-d167a91b1e99">
                2021
              </a> <div class="note">Phase 3 data due 2021.</div></td><td>
              2b
            </td><td>
              211.7b
            </td><td>
              2.6m
            </td><td>
              5.7m
            </td><td>
              16.85
            </td><td>
              $119.8
            </td><td>
              $118.82
            </td><td>
              N/A
            </td><td>
              11.53b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -123.84b
            </td><td>
              283.51b
            </td><td>
              0.1
            </td><td>
              1,765,652,810
            </td><td>
              05/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CANF" class="margin-bottom-1">
                CANF
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.85</div> <small class="number change-down">-0.02<span>&nbsp;&nbsp;</span>-1.07%</small></td><td><strong>Piclidenoson (CF101)</strong> <br>Psoriasis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210527005132/en/">
                4Q 2021
              </a> <div class="note">Phase 3 top-line data due 4Q 2021.</div></td><td>
              17m
            </td><td>
              31.8m
            </td><td>
              127.1k
            </td><td>
              416.0k
            </td><td>
              4.51
            </td><td>
              $1.87
            </td><td>
              $1.87
            </td><td>
              December 15, 2021
            </td><td>
              21.61m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              15.95m
            </td><td>
              21.13m
            </td><td>
              0
            </td><td>
              17,191,543
            </td><td>
              05/27/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ABBV" class="margin-bottom-1">
                ABBV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$119.82</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+0.84%</small></td><td><strong>IMBRUVICA (Ibrutinib) - (SHINE)</strong> <br>Mantle Cell Lymphoma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.abbvie.com/static-files/9c3dba8e-5447-4e55-a78f-d167a91b1e99">
                2021
              </a> <div class="note">Phase 3 data due 2021.</div></td><td>
              2b
            </td><td>
              211.7b
            </td><td>
              2.6m
            </td><td>
              5.7m
            </td><td>
              16.85
            </td><td>
              $119.8
            </td><td>
              $118.82
            </td><td>
              N/A
            </td><td>
              11.53b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -123.84b
            </td><td>
              283.51b
            </td><td>
              0.1
            </td><td>
              1,765,652,810
            </td><td>
              05/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALNY" class="margin-bottom-1">
                ALNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$199.95</div> <small class="number change-up">+2.17<span>&nbsp;&nbsp;</span>+1.10%</small></td><td><strong>VIR-2218 with pegylated interferon-alpha</strong> <br>Chronic hepatitis B virus (HBV)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-provides-corporate-update-and-reports-second-0">
                2H 2021
              </a> <div class="note">Phase 2 initial data presented at EASL meeting June 2021. Further data due 2H 2021.</div></td><td>
              119m
            </td><td>
              23.8b
            </td><td>
              237.9k
            </td><td>
              0.7m
            </td><td>
              27.85
            </td><td>
              $198.72
            </td><td>
              $197.78
            </td><td>
              N/A
            </td><td>
              1.83b
            </td><td>
              -40.62m
            </td><td>
              44.98
            </td><td>
              -0.83b
            </td><td>
              22.37b
            </td><td>
              0.3
            </td><td>
              102,229,141
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VIR" class="margin-bottom-1">
                VIR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$47.20</div> <small class="number change-up">+0.73<span>&nbsp;&nbsp;</span>+1.57%</small></td><td><strong>VIR-2218 with pegylated interferon-alpha</strong> <br>Chronic hepatitis B virus (HBV)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-provides-corporate-update-and-reports-second-0">
                2H 2021
              </a> <div class="note">Phase 2 initial data presented at EASL meeting June 2021. Further data due 2H 2021.</div></td><td>
              131m
            </td><td>
              6.2b
            </td><td>
              1.0m
            </td><td>
              0.9m
            </td><td>
              8.35
            </td><td>
              $47.62
            </td><td>
              $46.47
            </td><td>
              N/A
            </td><td>
              0.91b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              0.59b
            </td><td>
              5.32b
            </td><td>
              5.6
            </td><td>
              69,593,992
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ABIO" class="margin-bottom-1">
                ABIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.95</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+3.15%</small></td><td><strong>rNAPc2 (AB201) - (ASPEN)</strong> <br>COVID-19
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/04/2275020/0/en/ARCA-biopharma-Announces-Second-Quarter-2021-Financial-Results-and-Provides-Corporate-Update.html">
                4Q 2021
              </a> <div class="note">Phase 2b top-line data due 4Q 2021.</div></td><td>
              14m
            </td><td>
              42.5m
            </td><td>
              58.4k
            </td><td>
              355.3k
            </td><td>
              0.69
            </td><td>
              $2.86
            </td><td>
              $2.86
            </td><td>
              November 30, 2021
            </td><td>
              60.97m
            </td><td>
              -1.24m
            </td><td>
              49.17
            </td><td>
              56.84m
            </td><td>
              -21.55m
            </td><td>
              2.5
            </td><td>
              14,381,919
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ABBV" class="margin-bottom-1">
                ABBV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$119.82</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+0.84%</small></td><td><strong>IMBRUVICA (Ibrutinib) + VENCLEXTA - Venetoclax (GLOW)</strong> <br>Chronic Lymphocytic Leukemia
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.abbvie.com/static-files/9c3dba8e-5447-4e55-a78f-d167a91b1e99">
                2021
              </a> <div class="note">Phase 3 data due 2021.</div></td><td>
              2b
            </td><td>
              211.7b
            </td><td>
              2.6m
            </td><td>
              5.7m
            </td><td>
              16.85
            </td><td>
              $119.8
            </td><td>
              $118.82
            </td><td>
              N/A
            </td><td>
              11.53b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -123.84b
            </td><td>
              283.51b
            </td><td>
              0.1
            </td><td>
              1,765,652,810
            </td><td>
              05/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INO" class="margin-bottom-1">
                INO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.30</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+2.78%</small></td><td><strong>INO-5401 and INO-9012 with LIBTAYO (cemiplimab)</strong> <br>Glioblastoma (GBM)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/inovio-reports-second-quarter-2021-financial-results-301351440.html">
                4Q 2021
              </a> <div class="note">Phase 1/2 24-month overall survival data to be presented 4Q 2021.</div></td><td>
              210m
            </td><td>
              1.7b
            </td><td>
              2.2m
            </td><td>
              4.7m
            </td><td>
              3.43
            </td><td>
              $8.22
            </td><td>
              $8.08
            </td><td>
              December 30, 2021
            </td><td>
              396.60m
            </td><td>
              -26.15m
            </td><td>
              15.16
            </td><td>
              313.31m
            </td><td>
              1.29b
            </td><td>
              2.6
            </td><td>
              206,917,823
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ACHL" class="margin-bottom-1">
                ACHL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.49</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+4.68%</small></td><td><strong>ATL001 - CHIRON</strong> <br>Non Small Cell Lung Cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.achillestx.com/news-releases/news-release-details/achilles-therapeutics-reports-second-quarter-2021-financial">
                2H 2021
              </a> <div class="note">Phase 1/2 update 4Q 2021.</div></td><td>
              41m
            </td><td>
              263.5m
            </td><td>
              51.4k
            </td><td>
              146.1k
            </td><td>
              0.81
            </td><td>
              $6.23
            </td><td>
              $6.2
            </td><td>
              July 1, 2023
            </td><td>
              299.32m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              269.80m
            </td><td>
              -32.67m
            </td><td>
              0
            </td><td>
              40,603,489
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GNCA" class="margin-bottom-1">
                GNCA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.85</div> <small class="number change-up">+0.08<span>&nbsp;&nbsp;</span>+4.52%</small></td><td><strong>GEN-011 (TITAN study)</strong> <br>Various tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.genocea.com/news-releases/news-release-details/genocea-provides-second-quarter-2021-corporate-update">
                Late-4Q 2021 / 1Q 2022
              </a> <div class="note">Phase 1/2 initiation of dosing announced July 13, 2021, with initial data due late-4Q 2021 or 1Q 2022.</div></td><td>
              57m
            </td><td>
              105.5m
            </td><td>
              115.4k
            </td><td>
              129.4k
            </td><td>
              26.43
            </td><td>
              $1.79
            </td><td>
              $1.77
            </td><td>
              May 2024
            </td><td>
              54.09m
            </td><td>
              -3.50m
            </td><td>
              15.44
            </td><td>
              -19.24m
            </td><td>
              59.77m
            </td><td>
              1
            </td><td>
              46,532,142
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALNY" class="margin-bottom-1">
                ALNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$199.95</div> <small class="number change-up">+2.17<span>&nbsp;&nbsp;</span>+1.10%</small></td><td><strong>Inclisiran</strong> <br>Hypercholesterolemia
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.pdf">
                1/1/2022
              </a> <div class="note">CRL received December 18, 2020. NDA refiled with new PDUFA date of January 1, 2022.</div></td><td>
              119m
            </td><td>
              23.8b
            </td><td>
              237.9k
            </td><td>
              0.7m
            </td><td>
              27.85
            </td><td>
              $198.72
            </td><td>
              $197.78
            </td><td>
              N/A
            </td><td>
              1.83b
            </td><td>
              -40.62m
            </td><td>
              44.98
            </td><td>
              -0.83b
            </td><td>
              22.37b
            </td><td>
              0.3
            </td><td>
              102,229,141
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVS" class="margin-bottom-1">
                NVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$93.88</div> <small class="number change-up">+0.55<span>&nbsp;&nbsp;</span>+0.59%</small></td><td><strong>Inclisiran</strong> <br>Hypercholesterolemia
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.pdf">
                1/1/2022
              </a> <div class="note">CRL received December 18, 2020. NDA refiled with new PDUFA date of January 1, 2022.</div></td><td>
              2b
            </td><td>
              210.0b
            </td><td>
              0.7m
            </td><td>
              1.7m
            </td><td>
              3.89
            </td><td>
              $93.86
            </td><td>
              $93.33
            </td><td>
              N/A
            </td><td>
              7.84b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -62.05b
            </td><td>
              238.51b
            </td><td>
              0
            </td><td>
              2,236,739,037
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SBBP" class="margin-bottom-1">
                SBBP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.10</div> <small class="number change-up">+0.19<span>&nbsp;&nbsp;</span>+9.95%</small></td><td><strong>RECORLEV (levoketoconazole)</strong> <br>Endogenous Cushing’s syndrome
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.strongbridgebio.com/news-releases/news-release-details/strongbridge-biopharma-plc-announces-us-food-drug-administration">
                1/1/2022
              </a> <div class="note">PDUFA date January 1, 2022.</div></td><td>
              68m
            </td><td>
              142.4m
            </td><td>
              1.0m
            </td><td>
              0.6m
            </td><td>
              3.23
            </td><td>
              $2.19
            </td><td>
              $1.91
            </td><td>
              N/A
            </td><td>
              57.88m
            </td><td>
              -3.28m
            </td><td>
              17.67
            </td><td>
              5.45m
            </td><td>
              83.93m
            </td><td>
              3.6
            </td><td>
              67,015,719
            </td><td>
              05/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BTAI" class="margin-bottom-1">
                BTAI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$25.74</div> <small class="number change-up">+1.47<span>&nbsp;&nbsp;</span>+6.06%</small></td><td><strong>Dexmedetomidine (BXCL501)</strong> <br>Agitation associated with schizophrenia and bipolar disorders
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.bioxceltherapeutics.com/press-releases/detail/164/bioxcel-therapeutics-announces-fda-acceptance-for-filing-of">
                1/5/2022
              </a> <div class="note">PDUFA date January 5, 2022.</div></td><td>
              28m
            </td><td>
              0.7b
            </td><td>
              216.5k
            </td><td>
              415.7k
            </td><td>
              2.69
            </td><td>
              $24.68
            </td><td>
              $24.27
            </td><td>
              May 6, 2020
            </td><td>
              259.63m
            </td><td>
              -7.46m
            </td><td>
              34.80
            </td><td>
              245.93m
            </td><td>
              407.01m
            </td><td>
              0.8
            </td><td>
              18,482,964
            </td><td>
              05/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AMGN" class="margin-bottom-1">
                AMGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$226.21</div> <small class="number change-up">+2.68<span>&nbsp;&nbsp;</span>+1.20%</small></td><td><strong>Tezepelumab</strong> <br>Asthma
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/tezepelumab-granted-priority-review-by-us-fda-301327578.html">
                1/8/2022
              </a> <div class="note">PDUFA date under priority review estimated around January 8, 2022.</div></td><td>
              1b
            </td><td>
              128.5b
            </td><td>
              0.9m
            </td><td>
              2.4m
            </td><td>
              15.58
            </td><td>
              $224.18
            </td><td>
              $223.53
            </td><td>
              September 8, 2020
            </td><td>
              8.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -43.19b
            </td><td>
              151.63b
            </td><td>
              0.6
            </td><td>
              566,434,467
            </td><td>
              07/08/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>Tezepelumab</strong> <br>Asthma
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/tezepelumab-granted-priority-review-by-us-fda-301327578.html">
                1/8/2022
              </a> <div class="note">PDUFA date under priority review estimated around January 8, 2022.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              September 8, 2020
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              07/08/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BMY" class="margin-bottom-1">
                BMY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$69.35</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+0.22%</small></td><td><strong>Mavacamten (MYK-461) - EXPLORER-HCM</strong> <br>Hypertrophic cardiomyopathy (HCM)
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210319005189/en/">
                1/28/2022
              </a> <div class="note">PDUFA date January 28, 2022.</div></td><td>
              2b
            </td><td>
              154.1b
            </td><td>
              4.1m
            </td><td>
              8.5m
            </td><td>
              4.19
            </td><td>
              $69.26
            </td><td>
              $69.2
            </td><td>
              March 14, 2020
            </td><td>
              15.85b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -58.07b
            </td><td>
              186.05b
            </td><td>
              0.3
            </td><td>
              2,219,710,962
            </td><td>
              03/19/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RHHBY" class="margin-bottom-1">
                RHHBY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$50.36</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+0.12%</small></td><td><strong>Faricimab (RG7716)</strong> <br>Diabetic Macular Edema
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210728006055/en/">
                1/29/2022
              </a> <div class="note">PDUFA under priority review announced July 29, 2021. No date announced. Estimate January 29, 2021 based on 6-month timeline.</div></td><td>
              7b
            </td><td>
              344.2b
            </td><td>
              0.5m
            </td><td>
              1.0m
            </td><td>
              8.35
            </td><td>
              $50.24
            </td><td>
              $50.3
            </td><td>
              October 20, 2020
            </td><td>
              8.02b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -38.44b
            </td><td>
              356.64b
            </td><td>
              0
            </td><td>
              6,834,087,224
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TBPH" class="margin-bottom-1">
                TBPH
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.13</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+0.60%</small></td><td><strong>Izencitinib</strong> <br>Crohn's Disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/theravance-biopharma-inc-reports-second-quarter-2021-financial-results-and-provides-business-update-301347426.html">
                Late-4Q 2021 / early-1Q 2022
              </a> <div class="note">Phase 2 data due late-4Q 2021 / early-1Q 2022.</div></td><td>
              73m
            </td><td>
              1.0b
            </td><td>
              180.1k
            </td><td>
              467.1k
            </td><td>
              -3.46
            </td><td>
              $14.08
            </td><td>
              $14.05
            </td><td>
              January 2022
            </td><td>
              234.89m
            </td><td>
              -16.70m
            </td><td>
              14.06
            </td><td>
              -494.74m
            </td><td>
              1.44b
            </td><td>
              7.6
            </td><td>
              41,813,005
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AGIO" class="margin-bottom-1">
                AGIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$44.09</div> <small class="number change-up">+0.89<span>&nbsp;&nbsp;</span>+2.06%</small></td><td><strong>Mitapivat (AG-348)</strong> <br>Pyruvate kinase deficiency
            </td><td>
              PDUFA priority review
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.agios.com/news-releases/news-release-details/agios-announces-fda-acceptance-and-priority-review-new-drug">
                2/17/2022
              </a> <div class="note">PDUFA date under priority review February 17, 2022.</div></td><td>
              59m
            </td><td>
              2.6b
            </td><td>
              163.8k
            </td><td>
              0.9m
            </td><td>
              1.51
            </td><td>
              $43.75
            </td><td>
              $43.2
            </td><td>
              November 12, 2020
            </td><td>
              1.60b
            </td><td>
              -39.10m
            </td><td>
              40.99
            </td><td>
              1.45b
            </td><td>
              0.98b
            </td><td>
              1.6
            </td><td>
              35,715,668
            </td><td>
              08/17/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SRRA" class="margin-bottom-1">
                SRRA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$20.96</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+0.34%</small></td><td><strong>Momelotinib - MOMENTUM</strong> <br>Myelofibrosis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005214/en/">
                February 2022
              </a> <div class="note">Phase 3 top-line data due by February 2022.</div></td><td>
              13m
            </td><td>
              263.3m
            </td><td>
              7.9k
            </td><td>
              54.2k
            </td><td>
              3.12
            </td><td>
              $20.81
            </td><td>
              $20.89
            </td><td>
              December 2021
            </td><td>
              114.49m
            </td><td>
              -5.67m
            </td><td>
              20.20
            </td><td>
              104.38m
            </td><td>
              172.71m
            </td><td>
              3.9
            </td><td>
              6,808,954
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LLY" class="margin-bottom-1">
                LLY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$269.63</div> <small class="number change-down">-1.28<span>&nbsp;&nbsp;</span>-0.47%</small></td><td><strong>Tyvyt (sintilimab) and ALIMTA (pemetrexed)</strong> <br>Nonsquamous NSCLC
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/us-fda-accepts-regulatory-submission-for-sintilimab-in-combination-with-pemetrexed-and-platinum-chemotherapy-for-the-first-line-treatment-of-people-with-nonsquamous-non-small-cell-lung-cancer-301293152.html">
                March 2022
              </a> <div class="note">PDUFA date March 2022.</div></td><td>
              1b
            </td><td>
              257.9b
            </td><td>
              0.8m
            </td><td>
              2.8m
            </td><td>
              40.00
            </td><td>
              $272.3
            </td><td>
              $270.91
            </td><td>
              N/A
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -36.81b
            </td><td>
              272.39b
            </td><td>
              0.5
            </td><td>
              792,287,037
            </td><td>
              05/18/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MRK" class="margin-bottom-1">
                MRK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$78.65</div> <small class="number change-down">-0.03<span>&nbsp;&nbsp;</span>-0.04%</small></td><td><strong>Gefapixant</strong> <br>Chronic cough
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.merck.com/news/merck-announces-second-quarter-2021-financial-results/">
                3/21/2022
              </a> <div class="note">PDUFA date extended by three months to March 21, 2022. Advisory Committee meeting planned.</div></td><td>
              3b
            </td><td>
              199.1b
            </td><td>
              3.5m
            </td><td>
              10.3m
            </td><td>
              5.98
            </td><td>
              $79.11
            </td><td>
              $78.68
            </td><td>
              August 20, 2020
            </td><td>
              10.07b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -47.23b
            </td><td>
              217.11b
            </td><td>
              0.1
            </td><td>
              2,529,800,503
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TGTX" class="margin-bottom-1">
                TGTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$26.38</div> <small class="number change-up">+2.38<span>&nbsp;&nbsp;</span>+9.90%</small></td><td><strong>UKONIQ (umbralisib) and ublituximab</strong> <br>Chronic Lymphocytic Leukemia (CLL) and small lymphocytic lymphoma (SLL)
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-fda-acceptance-biologics-license">
                3/25/2022
              </a> <div class="note">PDUFA date March 25, 2022.</div></td><td>
              143m
            </td><td>
              3.8b
            </td><td>
              1.8m
            </td><td>
              1.4m
            </td><td>
              9.84
            </td><td>
              $24.54
            </td><td>
              $24
            </td><td>
              N/A
            </td><td>
              407.36m
            </td><td>
              -20.06m
            </td><td>
              20.31
            </td><td>
              309.09m
            </td><td>
              3.02b
            </td><td>
              16.2
            </td><td>
              114,156,621
            </td><td>
              05/25/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MRK" class="margin-bottom-1">
                MRK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$78.65</div> <small class="number change-down">-0.03<span>&nbsp;&nbsp;</span>-0.04%</small></td><td><strong>KEYTRUDA (pembrolizumab)</strong> <br>MSI-H/dMMR Advanced Endometrial Carcinoma
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210810005544/en/">
                3/28/2022
              </a> <div class="note">PDUFA date March 28, 2022.</div></td><td>
              3b
            </td><td>
              199.1b
            </td><td>
              3.5m
            </td><td>
              10.3m
            </td><td>
              5.98
            </td><td>
              $79.11
            </td><td>
              $78.68
            </td><td>
              N/A
            </td><td>
              10.07b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -47.23b
            </td><td>
              217.11b
            </td><td>
              0.1
            </td><td>
              2,529,800,503
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AKBA" class="margin-bottom-1">
                AKBA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.68</div> <small class="number change-up">+0.17<span>&nbsp;&nbsp;</span>+6.77%</small></td><td><strong>Vadadustat</strong> <br>Anemia due to chronic kidney disease (CKD) in patients on dialysis and not on dialysis.
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/akebia-and-otsuka-announce-fda-acceptance-for-filing-of-new-drug-application-for-vadadustat-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-in-adult-patients-on-dialysis-and-not-on-dialysis-301302511.html">
                3/29/2022
              </a> <div class="note">PDUFA date March 29, 2022.</div></td><td>
              175m
            </td><td>
              467.8m
            </td><td>
              1.3m
            </td><td>
              4.0m
            </td><td>
              2.68
            </td><td>
              $2.56
            </td><td>
              $2.51
            </td><td>
              January 31, 2020
            </td><td>
              209.11m
            </td><td>
              -21.05m
            </td><td>
              9.94
            </td><td>
              -228.12m
            </td><td>
              315.32m
            </td><td>
              2
            </td><td>
              150,480,288
            </td><td>
              06/01/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ATRA" class="margin-bottom-1">
                ATRA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.79</div> <small class="number change-up">+1.16<span>&nbsp;&nbsp;</span>+9.18%</small></td><td><strong>Tabelecleucel (ATA 129)</strong> <br>Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT)
            </td><td>
              BLA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005755/en/">
                1Q 2022
              </a> <div class="note">Rolling BLA filing to be completed 1Q 2022.</div></td><td>
              85m
            </td><td>
              1.2b
            </td><td>
              0.6m
            </td><td>
              0.7m
            </td><td>
              3.53
            </td><td>
              $12.7
            </td><td>
              $12.63
            </td><td>
              June 2022
            </td><td>
              336.43m
            </td><td>
              -20.53m
            </td><td>
              16.39
            </td><td>
              211.18m
            </td><td>
              0.71b
            </td><td>
              3
            </td><td>
              73,456,041
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RPHM" class="margin-bottom-1">
                RPHM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.61</div> <small class="number change-down">-0.23<span>&nbsp;&nbsp;</span>-2.93%</small></td><td><strong>REN001</strong> <br>McArdle disease
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/11/2278565/0/en/Reneo-Pharmaceuticals-Reports-Second-Quarter-2021-Financial-Results.html">
                1Q 2022
              </a> <div class="note">Phase 1b data due 1Q 2022.</div></td><td>
              24m
            </td><td>
              185.7m
            </td><td>
              9.7k
            </td><td>
              54.7k
            </td><td>
              1.11
            </td><td>
              $7.54
            </td><td>
              $7.84
            </td><td>
              December 2021
            </td><td>
              161.51m
            </td><td>
              -3.23m
            </td><td>
              49.95
            </td><td>
              157.76m
            </td><td>
              24.01m
            </td><td>
              0.1
            </td><td>
              10,915,953
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BMRN" class="margin-bottom-1">
                BMRN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$75.36</div> <small class="number change-up">+0.21<span>&nbsp;&nbsp;</span>+0.29%</small></td><td><strong>Valoctocogene roxaparvovec (BMN 270)</strong> <br>Hemophilia A
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/biomarin-announces-second-quarter-2021-financial-results-and-corporate-updates-301343556.html">
                Early 2022
              </a> <div class="note">Phase 3 52-week data released January 10, 2021. All endpoints met. 2 year data due early 2022. BLA filing 2Q 2022.</div></td><td>
              183m
            </td><td>
              13.8b
            </td><td>
              399.2k
            </td><td>
              1.0m
            </td><td>
              3.26
            </td><td>
              $75.45
            </td><td>
              $75.14
            </td><td>
              November 2024
            </td><td>
              1.17b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -483.86m
            </td><td>
              13.74b
            </td><td>
              1
            </td><td>
              142,192,515
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RCUS" class="margin-bottom-1">
                RCUS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.16</div> <small class="number change-up">+0.78<span>&nbsp;&nbsp;</span>+2.75%</small></td><td><strong>Domvanalimab (AB154) + Zimberelimab (AB122) (ARC-7)</strong> <br>Non-small cell lung cancer (NSCLC)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.arcusbio.com/investors-and-media/press-releases/press-release-details/2021/Arcus-Biosciences-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Operational-Highlights/default.aspx">
                4Q 2021 / 1Q 2022
              </a> <div class="note">Phase 2 interim analysis noted "encouraging clinical activity" - no specific data released - June 23, 2021. Results will be submitted for presentation 4Q 2021 or 1Q 2022.</div></td><td>
              71m
            </td><td>
              2.1b
            </td><td>
              139.5k
            </td><td>
              0.7m
            </td><td>
              3.44
            </td><td>
              $28.39
            </td><td>
              $28.38
            </td><td>
              March 31, 2022
            </td><td>
              0.68b
            </td><td>
              -24.66m
            </td><td>
              27.43
            </td><td>
              382.40m
            </td><td>
              1.35b
            </td><td>
              1.2
            </td><td>
              50,339,817
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DVAX" class="margin-bottom-1">
                DVAX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.48</div> <small class="number change-up">+1.44<span>&nbsp;&nbsp;</span>+11.97%</small></td><td><strong>CpG 1018 adjuvanted Tdap vaccine</strong> <br>Tetanus/Diphtheria/Pertussis Booster Vaccine
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/dynavax-announces-second-quarter-2021-financial-results-301348607.html">
                1Q 2022
              </a> <div class="note">Phase 1 data due 1Q 2022.</div></td><td>
              115m
            </td><td>
              1.5b
            </td><td>
              2.8m
            </td><td>
              2.3m
            </td><td>
              18.47
            </td><td>
              $12.44
            </td><td>
              $12.04
            </td><td>
              N/A
            </td><td>
              412.28m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -152.25m
            </td><td>
              1.29b
            </td><td>
              1.6
            </td><td>
              90,823,786
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KOD" class="margin-bottom-1">
                KOD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$93.64</div> <small class="number change-up">+2.13<span>&nbsp;&nbsp;</span>+2.33%</small></td><td><strong>KSI-301 (DAZZLE)</strong> <br>Wet age-related macular degeneration (AMD)
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/kodiak-sciences-announces-second-quarter-2021-financial-results-and-recent-business-highlights-301351445.html">
                Early-2022
              </a> <div class="note">Phase 2/3 pivotal trial top-line data due early 2022.</div></td><td>
              51m
            </td><td>
              4.8b
            </td><td>
              119.5k
            </td><td>
              264.7k
            </td><td>
              6.18
            </td><td>
              $93.11
            </td><td>
              $91.51
            </td><td>
              November 2021
            </td><td>
              0.86b
            </td><td>
              -12.22m
            </td><td>
              70.28
            </td><td>
              0.64b
            </td><td>
              3.91b
            </td><td>
              7.6
            </td><td>
              27,057,650
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VRTX" class="margin-bottom-1">
                VRTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$199.01</div> <small class="number change-up">+3.16<span>&nbsp;&nbsp;</span>+1.61%</small></td><td><strong>VX-548</strong> <br>Acute Pain following bunionectomy surgery
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210729006087/en/">
                Early 2022
              </a> <div class="note">Phase 2 data due early 2022.</div></td><td>
              259m
            </td><td>
              51.6b
            </td><td>
              0.6m
            </td><td>
              2.7m
            </td><td>
              5.61
            </td><td>
              $197.27
            </td><td>
              $195.85
            </td><td>
              N/A
            </td><td>
              6.59b
            </td><td>
              -66.59m
            </td><td>
              98.94
            </td><td>
              3.56b
            </td><td>
              44.99b
            </td><td>
              0.9
            </td><td>
              259,283,352
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CYTK" class="margin-bottom-1">
                CYTK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$31.23</div> <small class="number change-up">+0.67<span>&nbsp;&nbsp;</span>+2.19%</small></td><td><strong>Omecamtiv mecarbil METEORIC-HF</strong> <br>Acute heart failure
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-announces-completion-enrollment-meteoric-hf-second">
                Early-2022
              </a> <div class="note">Phase 3 completion of enrollment announced June 15, 2021 with data due in early-2022.</div></td><td>
              84m
            </td><td>
              2.6b
            </td><td>
              275.3k
            </td><td>
              2.1m
            </td><td>
              156.15
            </td><td>
              $30.56
            </td><td>
              $30.56
            </td><td>
              October 31, 2021
            </td><td>
              0.65b
            </td><td>
              -9.83m
            </td><td>
              65.99
            </td><td>
              101.04m
            </td><td>
              2.45b
            </td><td>
              2
            </td><td>
              70,990,561
            </td><td>
              06/15/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AMGN" class="margin-bottom-1">
                AMGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$226.21</div> <small class="number change-up">+2.68<span>&nbsp;&nbsp;</span>+1.20%</small></td><td><strong>Omecamtiv mecarbil METEORIC-HF</strong> <br>Acute heart failure
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-announces-completion-enrollment-meteoric-hf-second">
                Early-2022
              </a> <div class="note">Phase 3 completion of enrollment announced June 15, 2021 with data due in early-2022.</div></td><td>
              1b
            </td><td>
              128.5b
            </td><td>
              0.9m
            </td><td>
              2.4m
            </td><td>
              15.58
            </td><td>
              $224.18
            </td><td>
              $223.53
            </td><td>
              October 31, 2021
            </td><td>
              8.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -43.19b
            </td><td>
              151.63b
            </td><td>
              0.6
            </td><td>
              566,434,467
            </td><td>
              06/15/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AERI" class="margin-bottom-1">
                AERI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.70</div> <small class="number change-up">+0.20<span>&nbsp;&nbsp;</span>+1.38%</small></td><td><strong>AR-13503</strong> <br>Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210804005757/en/">
                1Q 2022
              </a> <div class="note">Phase 1 dose escalation safety evaluation due 1Q 2022.</div></td><td>
              47m
            </td><td>
              0.7b
            </td><td>
              118.3k
            </td><td>
              449.8k
            </td><td>
              -17.50
            </td><td>
              $14.73
            </td><td>
              $14.5
            </td><td>
              January 2022
            </td><td>
              176.20m
            </td><td>
              -6.71m
            </td><td>
              26.25
            </td><td>
              -218.94m
            </td><td>
              0.73b
            </td><td>
              2.4
            </td><td>
              46,152,464
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BTAI" class="margin-bottom-1">
                BTAI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$25.74</div> <small class="number change-up">+1.47<span>&nbsp;&nbsp;</span>+6.06%</small></td><td><strong>Dexmedetomidine (BXCL501) - (PLACIDITY)</strong> <br>Agitation associated with delirium
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.bioxceltherapeutics.com/news-media/press-releases/detail/155/bioxcel-therapeutics-reports-fourth-quarter-and-full-year">
                1Q 2022
              </a> <div class="note">Phase 2 top-line data due 1Q 2022.</div></td><td>
              28m
            </td><td>
              0.7b
            </td><td>
              216.5k
            </td><td>
              415.7k
            </td><td>
              2.69
            </td><td>
              $24.68
            </td><td>
              $24.27
            </td><td>
              N/A
            </td><td>
              259.63m
            </td><td>
              -7.46m
            </td><td>
              34.80
            </td><td>
              245.93m
            </td><td>
              407.01m
            </td><td>
              0.8
            </td><td>
              18,482,964
            </td><td>
              05/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VACC" class="margin-bottom-1">
                VACC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.60</div> <small class="number change-down">-0.25<span>&nbsp;&nbsp;</span>-1.68%</small></td><td><strong>VTP-300 (HBV002)</strong> <br>Hepatitis B
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2279734/0/en/Vaccitech-Reports-Second-Quarter-2021-Financial-Results-and-Recent-Corporate-Developments.html">
                1Q 2022
              </a> <div class="note">Phase 1 interim efficacy review 1Q 2022.</div></td><td>
              34m
            </td><td>
              0.5b
            </td><td>
              32.1k
            </td><td>
              24.1k
            </td><td>
              2.01
            </td><td>
              $14.78
            </td><td>
              $14.85
            </td><td>
              June 22, 2022
            </td><td>
              234.84m
            </td><td>
              -4.87m
            </td><td>
              48.18
            </td><td>
              224.92m
            </td><td>
              267.74m
            </td><td>
              4.2
            </td><td>
              32,899,041
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DNLI" class="margin-bottom-1">
                DNLI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$51.63</div> <small class="number change-up">+2.69<span>&nbsp;&nbsp;</span>+5.50%</small></td><td><strong>DNL310</strong> <br>Hunter syndrome MPS II
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.denalitherapeutics.com/sites/default/files/2021-07/iMPS%20DNL310%20Webinar%20Final_07252021_rPDF.pdf">
                Early-2022
              </a> <div class="note">Phase 1/2 24-week data presented July 25, 2021. 12-month data likely due early-2022. Phase 2/3 trial to be initiated 1H 2022.</div></td><td>
              122m
            </td><td>
              6.3b
            </td><td>
              178.7k
            </td><td>
              0.6m
            </td><td>
              5.85
            </td><td>
              $48.91
            </td><td>
              $48.94
            </td><td>
              N/A
            </td><td>
              1.28b
            </td><td>
              -18.07m
            </td><td>
              70.62
            </td><td>
              0.84b
            </td><td>
              4.71b
            </td><td>
              2.6
            </td><td>
              78,409,082
            </td><td>
              07/26/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARAV" class="margin-bottom-1">
                ARAV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.00</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+3.63%</small></td><td><strong>AVB-500</strong> <br>Platinum Resistant Ovarian Cancer (PROC)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.aravive.com/news-releases/news-release-details/aravive-reports-second-quarter-2021-financial-results-and">
                1Q 2022
              </a> <div class="note">Phase 3 initiation of dosing announced April 26, 2021. Interim analysis due 1Q 2022.</div></td><td>
              21m
            </td><td>
              82.9m
            </td><td>
              59.8k
            </td><td>
              0.7m
            </td><td>
              1.29
            </td><td>
              $3.9
            </td><td>
              $3.86
            </td><td>
              July 2023
            </td><td>
              81.35m
            </td><td>
              -1.72m
            </td><td>
              47.37
            </td><td>
              60.17m
            </td><td>
              12.15m
            </td><td>
              18.4
            </td><td>
              14,903,281
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TMBR" class="margin-bottom-1">
                TMBR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.90</div> <small class="number change-up">0.00<span>&nbsp;&nbsp;</span>-0.13%</small></td><td><strong>Pascomer (TMB-002)</strong> <br>Facial angiofibromas in tuberous sclerosis complex 
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/10/2277915/0/en/Timber-Pharmaceuticals-Provides-Business-Update-and-Announces-Second-Quarter-2021-Financial-Results.html">
                1Q 2022
              </a> <div class="note">Phase 2b enrollment to be completed 3Q 2021 with data due 1Q 2022.</div></td><td>
              37m
            </td><td>
              32.9m
            </td><td>
              479.7k
            </td><td>
              0.9m
            </td><td>
              11.23
            </td><td>
              $0.92
            </td><td>
              $0.9
            </td><td>
              N/A
            </td><td>
              4.72m
            </td><td>
              -0.78m
            </td><td>
              6.01
            </td><td>
              1.81m
            </td><td>
              29.69m
            </td><td>
              0
            </td><td>
              31,120,334
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RLYB" class="margin-bottom-1">
                RLYB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.32</div> <small class="number change-up">+0.63<span>&nbsp;&nbsp;</span>+4.96%</small></td><td><strong>RLYB212</strong> <br>Fetal and neonatal alloimmune thrombocytopenia (FNAIT)
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001739410/000119312521207662/d99471ds1.htm">
                1Q 2022
              </a> <div class="note">Phase 1b trial to be initiated 1Q 2022 with data due mid-2022. </div></td><td>
              32m
            </td><td>
              428.0m
            </td><td>
              99.2k
            </td><td>
              89.7k
            </td><td>
              -7.28
            </td><td>
              $13.4
            </td><td>
              $12.69
            </td><td>
              N/A
            </td><td>
              108.52m
            </td><td>
              -3.98m
            </td><td>
              27.29
            </td><td>
              -79.60m
            </td><td>
              279.99m
            </td><td>
              3.9
            </td><td>
              19,133,924
            </td><td>
              07/26/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALNY" class="margin-bottom-1">
                ALNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$199.95</div> <small class="number change-up">+2.17<span>&nbsp;&nbsp;</span>+1.10%</small></td><td><strong>Fitusiran (ATLAS)</strong> <br>Hemophilia A/B
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210803005132/en/">
                Early-2022
              </a> <div class="note">Phase 3 top-line data due early-2022.</div></td><td>
              119m
            </td><td>
              23.8b
            </td><td>
              237.9k
            </td><td>
              0.7m
            </td><td>
              27.85
            </td><td>
              $198.72
            </td><td>
              $197.78
            </td><td>
              November 25, 2020
            </td><td>
              1.83b
            </td><td>
              -40.62m
            </td><td>
              44.98
            </td><td>
              -0.83b
            </td><td>
              22.37b
            </td><td>
              0.3
            </td><td>
              102,229,141
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SNY" class="margin-bottom-1">
                SNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$52.48</div> <small class="number change-down">-0.64<span>&nbsp;&nbsp;</span>-1.20%</small></td><td><strong>Fitusiran (ATLAS)</strong> <br>Hemophilia A/B
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210803005132/en/">
                Early-2022
              </a> <div class="note">Phase 3 top-line data due early-2022.</div></td><td>
              3b
            </td><td>
              131.7b
            </td><td>
              2.5m
            </td><td>
              1.7m
            </td><td>
              1.78
            </td><td>
              $52.73
            </td><td>
              $53.12
            </td><td>
              November 25, 2020
            </td><td>
              9.72b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -39.23b
            </td><td>
              146.90b
            </td><td>
              0
            </td><td>
              2,510,366,030
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SURF" class="margin-bottom-1">
                SURF
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.16</div> <small class="number change-up">+0.62<span>&nbsp;&nbsp;</span>+11.30%</small></td><td><strong>SRF388</strong> <br>Solid tumors
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.surfaceoncology.com/news-releases/news-release-details/surface-oncology-reports-financial-results-and-corporate-12">
                Early-2022
              </a> <div class="note">Phase 1 data at ASCO June 4, 2021 noted stable disease of 6 of 18 (33%) patients. Further data due early-2022.</div></td><td>
              40m
            </td><td>
              245.6m
            </td><td>
              0.9m
            </td><td>
              0.9m
            </td><td>
              2.14
            </td><td>
              $5.71
            </td><td>
              $5.53
            </td><td>
              N/A
            </td><td>
              156.92m
            </td><td>
              -4.09m
            </td><td>
              38.38
            </td><td>
              99.49m
            </td><td>
              74.24m
            </td><td>
              3.1
            </td><td>
              16,778,222
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BLCM" class="margin-bottom-1">
                BLCM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.05</div> <small class="number change-up">+0.19<span>&nbsp;&nbsp;</span>+6.64%</small></td><td><strong>BPX-601</strong> <br>Pancreatic cancer / Prostate cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.bellicum.com/news-releases/news-release-details/bellicum-reports-second-quarter-2021-financial-results-and">
                1Q 2022
              </a> <div class="note">Phase 1/2 clinical hold lifted January 28, 2021. Phase 1 data due 1Q 2022.</div></td><td>
              8m
            </td><td>
              25.6m
            </td><td>
              63.1k
            </td><td>
              87.2k
            </td><td>
              -1.79
            </td><td>
              $2.87
            </td><td>
              $2.86
            </td><td>
              October 2022
            </td><td>
              15.60m
            </td><td>
              -2.60m
            </td><td>
              6.01
            </td><td>
              -22.59m
            </td><td>
              3.78m
            </td><td>
              4.2
            </td><td>
              8,383,791
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PULM" class="margin-bottom-1">
                PULM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.78</div> <small class="number change-down">-0.01<span>&nbsp;&nbsp;</span>-0.80%</small></td><td><strong>PUR1800</strong> <br>Chronic Obstructive Pulmonary Disease (COPD)
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/pulmatrix-reports-second-quarter-2021-financial-results-and-provides-business-update-301352045.html">
                1Q 2022
              </a> <div class="note">Phase 1b data due 1Q 2022.</div></td><td>
              56m
            </td><td>
              44.0m
            </td><td>
              181.7k
            </td><td>
              432.8k
            </td><td>
              0.83
            </td><td>
              $0.82
            </td><td>
              $0.79
            </td><td>
              July 31, 2021
            </td><td>
              52.99m
            </td><td>
              -2.17m
            </td><td>
              24.37
            </td><td>
              40.65m
            </td><td>
              -11.41m
            </td><td>
              1.2
            </td><td>
              56,216,684
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PFE" class="margin-bottom-1">
                PFE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.98</div> <small class="number change-up">+1.25<span>&nbsp;&nbsp;</span>+2.58%</small></td><td><strong>RSVpreF</strong> <br>Respiratory syncytial virus (RSV) vaccine
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s21.q4cdn.com/317678438/files/doc_financials/2021/q2/Q2-2021-Earnings-Charts-FINAL.pdf">
                1Q 2022
              </a> <div class="note">Phase 3 trial to be initiated in September 2021 with potential conclusion in 1Q 2022.</div></td><td>
              6b
            </td><td>
              280.2b
            </td><td>
              69.5m
            </td><td>
              30.1m
            </td><td>
              4.00
            </td><td>
              $50.29
            </td><td>
              $48.72
            </td><td>
              N/A
            </td><td>
              28.48b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -71.13b
            </td><td>
              289.19b
            </td><td>
              0.3
            </td><td>
              5,605,213,314
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MOR" class="margin-bottom-1">
                MOR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.96</div> <small class="number change-up">+0.51<span>&nbsp;&nbsp;</span>+3.79%</small></td><td><strong>TREANDA (bendamustine) + MONJUVI (tafasitamab - B-MIND</strong> <br>Relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.morphosys.com/sites/default/files/presentations/mor_company_update_0.pdf">
                1Q 2022
              </a> <div class="note">Phase 3 top-line data due 1Q 2022.</div></td><td>
              137m
            </td><td>
              1.9b
            </td><td>
              18.7k
            </td><td>
              125.1k
            </td><td>
              2.70
            </td><td>
              $13.75
            </td><td>
              $13.45
            </td><td>
              March 2022
            </td><td>
              1.04b
            </td><td>
              -29.79m
            </td><td>
              34.97
            </td><td>
              65.72m
            </td><td>
              0.93b
            </td><td>
              0
            </td><td>
              136,502,236
            </td><td>
              06/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARNA" class="margin-bottom-1">
                ARNA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$51.04</div> <small class="number change-up">+4.14<span>&nbsp;&nbsp;</span>+8.83%</small></td><td><strong>Etrasimod  (ELEVATE UC 52)</strong> <br>Ulcerative colitis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805006093/en/">
                1Q 2022
              </a> <div class="note">Phase 3 data due 1Q 2022.</div></td><td>
              61m
            </td><td>
              3.1b
            </td><td>
              0.6m
            </td><td>
              464.5k
            </td><td>
              3.21
            </td><td>
              $47.42
            </td><td>
              $46.9
            </td><td>
              January 2022
            </td><td>
              0.85b
            </td><td>
              -31.28m
            </td><td>
              27.02
            </td><td>
              0.73b
            </td><td>
              1.94b
            </td><td>
              4.4
            </td><td>
              54,681,471
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMMP" class="margin-bottom-1">
                IMMP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.35</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+0.45%</small></td><td><strong>Eftilagimod alpha and KEYTRUDA (pembrolizumab) - TACTI-002</strong> <br>Non-small cell lung cancer; Head and neck cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/07/13/2261873/0/en/Immutep-Quarterly-Activities-Report.html">
                2021 / early-2022
              </a> <div class="note">Phase 2 further interim data due in 2021 or early 2022.</div></td><td>
              65m
            </td><td>
              217.0m
            </td><td>
              184.3k
            </td><td>
              340.0k
            </td><td>
              4.99
            </td><td>
              $3.33
            </td><td>
              $3.33
            </td><td>
              May 2022
            </td><td>
              54.88m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              39.10m
            </td><td>
              171.73m
            </td><td>
              0
            </td><td>
              64,872,528
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARNA" class="margin-bottom-1">
                ARNA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$51.04</div> <small class="number change-up">+4.14<span>&nbsp;&nbsp;</span>+8.83%</small></td><td><strong>Etrasimod (ELEVATE UC 12)</strong> <br>Ulcerative colitis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805006093/en/">
                1Q 2022
              </a> <div class="note">Phase 3 data due 1Q 2022.</div></td><td>
              61m
            </td><td>
              3.1b
            </td><td>
              0.6m
            </td><td>
              464.5k
            </td><td>
              3.21
            </td><td>
              $47.42
            </td><td>
              $46.9
            </td><td>
              November 2021
            </td><td>
              0.85b
            </td><td>
              -31.28m
            </td><td>
              27.02
            </td><td>
              0.73b
            </td><td>
              1.94b
            </td><td>
              4.4
            </td><td>
              54,681,471
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CTXR" class="margin-bottom-1">
                CTXR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.90</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+7.50%</small></td><td><strong>Mino-Lok</strong> <br>Catheter related blood stream infection
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-provides-first-half-2021-business-update-highlights-upcoming-milestones-301326838.html">
                Late-2021 / early-2022
              </a> <div class="note">Phase 3 trial to be completed by the end of 2021 or early 2022.</div></td><td>
              146m
            </td><td>
              277.8m
            </td><td>
              2.6m
            </td><td>
              9.5m
            </td><td>
              2.02
            </td><td>
              $1.77
            </td><td>
              $1.77
            </td><td>
              December 2021
            </td><td>
              112.77m
            </td><td>
              -1.61m
            </td><td>
              70.14
            </td><td>
              103.46m
            </td><td>
              143.78m
            </td><td>
              8.4
            </td><td>
              133,671,489
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TAK" class="margin-bottom-1">
                TAK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.97</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+1.75%</small></td><td><strong>TAK-755</strong> <br>Immune Thrombotic Thrombocytopenic Purpura (iTTP)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.takeda.com/4a21eb/siteassets/system/investors/report/quarterlyannouncements/fy2021/qr2021_q1_p01_en.pdf">
                4Q 2021 / 1Q 2022
              </a> <div class="note">Phase 2 data due 4Q 2021 / 1Q 2022.</div></td><td>
              3b
            </td><td>
              53.4b
            </td><td>
              0.8m
            </td><td>
              1.9m
            </td><td>
              1.12
            </td><td>
              $16.84
            </td><td>
              $16.68
            </td><td>
              N/A
            </td><td>
              0.78t
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -6.63t
            </td><td>
              86.30b
            </td><td>
              0
            </td><td>
              3,145,059,016
            </td><td>
              07/30/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMUX" class="margin-bottom-1">
                IMUX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.76</div> <small class="number change-up">+0.83<span>&nbsp;&nbsp;</span>+9.36%</small></td><td><strong>IMU-856</strong> <br>Healthy Volunteers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/immunic-inc-reports-second-quarter-2021-financial-results-and-highlights-recent-activity-301350113.html">
                1Q 2022
              </a> <div class="note">Phase 1 safety data from the SAD and MAD parts due 1Q 2022.</div></td><td>
              26m
            </td><td>
              256.1m
            </td><td>
              122.3k
            </td><td>
              268.5k
            </td><td>
              2.12
            </td><td>
              $9.16
            </td><td>
              $8.92
            </td><td>
              N/A
            </td><td>
              114.77m
            </td><td>
              -9.67m
            </td><td>
              11.87
            </td><td>
              99.46m
            </td><td>
              147.99m
            </td><td>
              2.4
            </td><td>
              23,416,743
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PHAT" class="margin-bottom-1">
                PHAT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$32.90</div> <small class="number change-up">+1.34<span>&nbsp;&nbsp;</span>+4.26%</small></td><td><strong>Vonoprazan (PHALCON-NERD)</strong> <br>Non-erosive reflux disease (NERD)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.phathompharma.com/news-releases/news-release-details/phathom-pharmaceuticals-reports-second-quarter-2021-results-and">
                1Q 2022
              </a> <div class="note">Phase 2 data due 1Q 2022.</div></td><td>
              31m
            </td><td>
              1.0b
            </td><td>
              66.6k
            </td><td>
              97.7k
            </td><td>
              7.81
            </td><td>
              $31.84
            </td><td>
              $31.55
            </td><td>
              N/A
            </td><td>
              192.65m
            </td><td>
              -9.45m
            </td><td>
              20.38
            </td><td>
              110.20m
            </td><td>
              0.83b
            </td><td>
              8.1
            </td><td>
              20,563,110
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OCUL" class="margin-bottom-1">
                OCUL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$10.35</div> <small class="number change-up">+0.34<span>&nbsp;&nbsp;</span>+3.40%</small></td><td><strong>OTX-DED</strong> <br>Dry eye disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005723/en/">
                1Q 2022
              </a> <div class="note">Phase 2 data due 1Q 2022.</div></td><td>
              77m
            </td><td>
              0.8b
            </td><td>
              424.1k
            </td><td>
              0.8m
            </td><td>
              9.86
            </td><td>
              $10.14
            </td><td>
              $10.01
            </td><td>
              December 15, 2021
            </td><td>
              179.83m
            </td><td>
              -6.69m
            </td><td>
              26.90
            </td><td>
              29.37m
            </td><td>
              0.63b
            </td><td>
              2.1
            </td><td>
              68,673,532
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TARS" class="margin-bottom-1">
                TARS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$24.36</div> <small class="number change-up">+0.44<span>&nbsp;&nbsp;</span>+1.84%</small></td><td><strong>TP-03 (Saturn-2)</strong> <br>Demodex Blepharitis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/04/2275130/0/en/Tarsus-Pharmaceuticals-Inc-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Business-and-Clinical-Updates.html">
                1Q 2022
              </a> <div class="note">Phase 3 top-line data due 1Q 2022.</div></td><td>
              21m
            </td><td>
              0.5b
            </td><td>
              4.9k
            </td><td>
              62.9k
            </td><td>
              2.60
            </td><td>
              $24.1
            </td><td>
              $23.92
            </td><td>
              December 2021
            </td><td>
              189.07m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              178.09m
            </td><td>
              317.54m
            </td><td>
              7.5
            </td><td>
              8,844,776
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OPTN" class="margin-bottom-1">
                OPTN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.50</div> <small class="number change-down">-0.01<span>&nbsp;&nbsp;</span>-0.40%</small></td><td><strong>XHANCE</strong> <br>Chronic sinusitis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://ir.optinose.com/news-releases/news-release-details/optinose-completes-patient-recruitment-pivotal-trial-xhance">
                1Q 2022
              </a> <div class="note">Phase 3 data due 1Q 2022.</div></td><td>
              53m
            </td><td>
              133.3m
            </td><td>
              76.9k
            </td><td>
              436.2k
            </td><td>
              -3.57
            </td><td>
              $2.58
            </td><td>
              $2.51
            </td><td>
              December 2021
            </td><td>
              80.42m
            </td><td>
              -7.50m
            </td><td>
              10.73
            </td><td>
              -96.17m
            </td><td>
              168.06m
            </td><td>
              3.1
            </td><td>
              30,507,396
            </td><td>
              07/30/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ASND" class="margin-bottom-1">
                ASND
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$122.38</div> <small class="number change-up">+1.93<span>&nbsp;&nbsp;</span>+1.60%</small></td><td><strong>TransCon - PaTHway</strong> <br>Hypoparathyroidism
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-pharma-announces-target-enrollment-achieved-phase-3">
                1Q 2022
              </a> <div class="note">Phase 3 top-line data due 1Q 2022.</div></td><td>
              54m
            </td><td>
              6.6b
            </td><td>
              128.8k
            </td><td>
              187.4k
            </td><td>
              7.01
            </td><td>
              $120.71
            </td><td>
              $120.45
            </td><td>
              February 2022
            </td><td>
              0.53b
            </td><td>
              -27.21m
            </td><td>
              19.60
            </td><td>
              370.71m
            </td><td>
              5.82b
            </td><td>
              0
            </td><td>
              53,829,379
            </td><td>
              07/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLVS" class="margin-bottom-1">
                CLVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.50</div> <small class="number change-up">+0.26<span>&nbsp;&nbsp;</span>+6.01%</small></td><td><strong>OPDIVO (nivolumab) and RUBRACA (rucaparib) - ATHENA</strong> <br>Ovarian Cancer - First-line maintenance treatment
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210804005226/en/">
                1Q 2022
              </a> <div class="note">Phase 3 top-line monotherapy data due 1Q 2022. Combo data due 2H 2022.</div></td><td>
              118m
            </td><td>
              0.5b
            </td><td>
              2.3m
            </td><td>
              4.5m
            </td><td>
              -2.57
            </td><td>
              $4.27
            </td><td>
              $4.24
            </td><td>
              December 30, 2024
            </td><td>
              202.15m
            </td><td>
              -15.58m
            </td><td>
              12.97
            </td><td>
              -0.58b
            </td><td>
              0.94b
            </td><td>
              1.8
            </td><td>
              115,771,254
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BMY" class="margin-bottom-1">
                BMY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$69.35</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+0.22%</small></td><td><strong>OPDIVO (nivolumab) and RUBRACA (rucaparib) - ATHENA</strong> <br>Ovarian Cancer - First-line maintenance treatment
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210804005226/en/">
                1Q 2022
              </a> <div class="note">Phase 3 top-line monotherapy data due 1Q 2022. Combo data due 2H 2022.</div></td><td>
              2b
            </td><td>
              154.1b
            </td><td>
              4.1m
            </td><td>
              8.5m
            </td><td>
              4.19
            </td><td>
              $69.26
            </td><td>
              $69.2
            </td><td>
              December 30, 2024
            </td><td>
              15.85b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -58.07b
            </td><td>
              186.05b
            </td><td>
              0.3
            </td><td>
              2,219,710,962
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KNSA" class="margin-bottom-1">
                KNSA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.71</div> <small class="number change-up">+0.51<span>&nbsp;&nbsp;</span>+4.18%</small></td><td><strong>Mavrilimumab</strong> <br>COVID-19-related acute respiratory distress syndrome (ARDS
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-reports-second-quarter-2021-financial-results-and-recent">
                1Q 2022
              </a> <div class="note">Phase 3 data due 1Q 2022.</div></td><td>
              33m
            </td><td>
              0.9b
            </td><td>
              360.1k
            </td><td>
              499.9k
            </td><td>
              3.69
            </td><td>
              $12.29
            </td><td>
              $12.2
            </td><td>
              N/A
            </td><td>
              202.60m
            </td><td>
              -12.93m
            </td><td>
              15.67
            </td><td>
              159.17m
            </td><td>
              0.62b
            </td><td>
              1
            </td><td>
              29,201,443
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AUTL" class="margin-bottom-1">
                AUTL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.17</div> <small class="number change-up">+0.53<span>&nbsp;&nbsp;</span>+9.40%</small></td><td><strong>Obe-cel (AUTO1) - (CAROUSEL)</strong> <br>Primary CNS Lymphoma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-reports-second-quarter-2021-financial">
                1Q 2022
              </a> <div class="note">Phase 1 update 1Q 2022.</div></td><td>
              73m
            </td><td>
              448.8m
            </td><td>
              404.8k
            </td><td>
              1.9m
            </td><td>
              1.58
            </td><td>
              $5.81
            </td><td>
              $5.64
            </td><td>
              December 2024
            </td><td>
              194.39m
            </td><td>
              -12.20m
            </td><td>
              15.93
            </td><td>
              147.41m
            </td><td>
              216.60m
            </td><td>
              0
            </td><td>
              72,742,582
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MRKR" class="margin-bottom-1">
                MRKR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.95</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+7.14%</small></td><td><strong>MT-401</strong> <br>Acute Myeloid Leukemia
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/marker-therapeutics-reports-second-quarter-2021-operating-and-financial-results-301352412.html">
                1Q 2022
              </a> <div class="note">Phase 2 data due 1Q 2022.</div></td><td>
              83m
            </td><td>
              162.0m
            </td><td>
              1.1m
            </td><td>
              0.9m
            </td><td>
              2.57
            </td><td>
              $1.89
            </td><td>
              $1.82
            </td><td>
              July 2022
            </td><td>
              66.21m
            </td><td>
              -2.28m
            </td><td>
              29.02
            </td><td>
              48.99m
            </td><td>
              106.11m
            </td><td>
              21.5
            </td><td>
              58,398,634
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SPRO" class="margin-bottom-1">
                SPRO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.35</div> <small class="number change-up">+0.89<span>&nbsp;&nbsp;</span>+5.74%</small></td><td><strong>SPR206</strong> <br>Multi-drug resistant (MDR) Gram-negative bacterial infections (renal impairment trial)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.sperotherapeutics.com/news-releases/news-release-details/spero-therapeutics-announces-second-quarter-2021-operating">
                Early-2022
              </a> <div class="note">Phase 1 trial initiated June 2021. Data due early-2022.</div></td><td>
              32m
            </td><td>
              0.5b
            </td><td>
              314.1k
            </td><td>
              171.9k
            </td><td>
              5.82
            </td><td>
              $15.43
            </td><td>
              $15.46
            </td><td>
              October 2021
            </td><td>
              129.28m
            </td><td>
              -5.52m
            </td><td>
              23.41
            </td><td>
              99.94m
            </td><td>
              405.21m
            </td><td>
              0.3
            </td><td>
              25,606,782
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OCUP" class="margin-bottom-1">
                OCUP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.38</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+5.54%</small></td><td><strong>Nyxol Eye Drops</strong> <br>Reversal of Mydriasis (RM)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.ocuphire.com/news-media/press-releases/detail/349/ocuphire-announces-financial-results-for-the-second-quarter">
                Early-2022
              </a> <div class="note">Phase 3 trial met primary endpoint - March 15, 2021. Second Phase 3 trial to be initiated 2H 2021 with results expected in early 2022.</div></td><td>
              11m
            </td><td>
              47.5m
            </td><td>
              91.7k
            </td><td>
              1.8m
            </td><td>
              1.77
            </td><td>
              $4.34
            </td><td>
              $4.15
            </td><td>
              N/A
            </td><td>
              21.64m
            </td><td>
              -1.44m
            </td><td>
              15.00
            </td><td>
              18.94m
            </td><td>
              -3.13m
            </td><td>
              0
            </td><td>
              4,009,598
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EGRX" class="margin-bottom-1">
                EGRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$50.56</div> <small class="number change-up">+0.69<span>&nbsp;&nbsp;</span>+1.38%</small></td><td><strong>Landiolol</strong> <br>Supraventricular tachycardia ("SVT") - atrial fibrillation and atrial flutter
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.eagleus.com/press-releases/news-details/2021/Eagle-Pharmaceuticals-Announces-Licensing-Agreement-with-AOP-Orphan-for-U.S.-Commercial-Rights-to-Landiolol-a-Beta-1-Adrenergic-Blocker/default.aspx">
                1Q 2022
              </a> <div class="note">NDA filing due 1Q 2022.</div></td><td>
              13m
            </td><td>
              0.7b
            </td><td>
              42.4k
            </td><td>
              119.7k
            </td><td>
              3.40
            </td><td>
              $49.97
            </td><td>
              $49.87
            </td><td>
              N/A
            </td><td>
              113.87m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              44.48m
            </td><td>
              0.58b
            </td><td>
              13.6
            </td><td>
              7,854,528
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OCUP" class="margin-bottom-1">
                OCUP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.38</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+5.54%</small></td><td><strong>Nyxol Eye Drops (LYNX-1)</strong> <br>Dim Light or Night Vision Disturbances (DLD)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.ocuphire.com/news-media/press-releases/detail/349/ocuphire-announces-financial-results-for-the-second-quarter">
                Early-2022
              </a> <div class="note">Phase 3 data due early-2022.</div></td><td>
              11m
            </td><td>
              47.5m
            </td><td>
              91.7k
            </td><td>
              1.8m
            </td><td>
              1.77
            </td><td>
              $4.34
            </td><td>
              $4.15
            </td><td>
              September 30, 2021
            </td><td>
              21.64m
            </td><td>
              -1.44m
            </td><td>
              15.00
            </td><td>
              18.94m
            </td><td>
              -3.13m
            </td><td>
              0
            </td><td>
              4,009,598
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/REPL" class="margin-bottom-1">
                REPL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$31.79</div> <small class="number change-up">+1.61<span>&nbsp;&nbsp;</span>+5.35%</small></td><td><strong>RP1 (vusolimogene oderparepvec) - (ARTACUS)</strong> <br>Liver and kidney transplant recipients with recurrent Cutaneous squamous cell carcinoma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.replimune.com/news-releases/news-release-details/replimune-reports-fiscal-first-quarter-financial-results-and-0">
                1Q 2022
              </a> <div class="note">Phase 1 initial data to be presented 1Q 2022.</div></td><td>
              47m
            </td><td>
              1.5b
            </td><td>
              136.8k
            </td><td>
              313.0k
            </td><td>
              3.10
            </td><td>
              $30.5
            </td><td>
              $30.17
            </td><td>
              February 2024
            </td><td>
              447.34m
            </td><td>
              -6.10m
            </td><td>
              73.28
            </td><td>
              402.64m
            </td><td>
              0.99b
            </td><td>
              9.6
            </td><td>
              29,656,261
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/REPL" class="margin-bottom-1">
                REPL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$31.79</div> <small class="number change-up">+1.61<span>&nbsp;&nbsp;</span>+5.35%</small></td><td><strong>RP3</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.replimune.com/news-releases/news-release-details/replimune-reports-fiscal-first-quarter-financial-results-and-0">
                1Q 2022
              </a> <div class="note">Phase 1 initial data due 1Q 2022.</div></td><td>
              47m
            </td><td>
              1.5b
            </td><td>
              136.8k
            </td><td>
              313.0k
            </td><td>
              3.10
            </td><td>
              $30.5
            </td><td>
              $30.17
            </td><td>
              N/A
            </td><td>
              447.34m
            </td><td>
              -6.10m
            </td><td>
              73.28
            </td><td>
              402.64m
            </td><td>
              0.99b
            </td><td>
              9.6
            </td><td>
              29,656,261
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RETA" class="margin-bottom-1">
                RETA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$106.04</div> <small class="number change-up">+4.68<span>&nbsp;&nbsp;</span>+4.62%</small></td><td><strong>Omaveloxolone</strong> <br>Friedreich’s ataxia (FA)
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005740/en/">
                1Q 2022
              </a> <div class="note">NDA filing planned for 1Q 2022.</div></td><td>
              36m
            </td><td>
              3.9b
            </td><td>
              141.2k
            </td><td>
              394.2k
            </td><td>
              12.30
            </td><td>
              $102.46
            </td><td>
              $101.36
            </td><td>
              N/A
            </td><td>
              0.74b
            </td><td>
              -8.53m
            </td><td>
              86.76
            </td><td>
              276.56m
            </td><td>
              3.22b
            </td><td>
              0.5
            </td><td>
              20,077,004
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALDX" class="margin-bottom-1">
                ALDX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.89</div> <small class="number change-up">+0.59<span>&nbsp;&nbsp;</span>+7.17%</small></td><td><strong>ADX-629</strong> <br>Psoriasis / atopic asthma / COVID-19
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005246/en/">
                YE 2021 / early-2022
              </a> <div class="note">Phase 2 top-line data due by the end of 2021 or early-2022</div></td><td>
              58m
            </td><td>
              0.5b
            </td><td>
              407.7k
            </td><td>
              0.8m
            </td><td>
              2.20
            </td><td>
              $8.37
            </td><td>
              $8.3
            </td><td>
              N/A
            </td><td>
              244.30m
            </td><td>
              -3.02m
            </td><td>
              80.78
            </td><td>
              221.55m
            </td><td>
              245.99m
            </td><td>
              2.8
            </td><td>
              48,335,686
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/REPL" class="margin-bottom-1">
                REPL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$31.79</div> <small class="number change-up">+1.61<span>&nbsp;&nbsp;</span>+5.35%</small></td><td><strong>RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE)</strong> <br>Melanoma / NSCLC
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.replimune.com/news-releases/news-release-details/replimune-reports-fiscal-first-quarter-financial-results-and-0">
                1Q 2022
              </a> <div class="note">Phase 2 NSCLC data due 1Q 2022. Non-melanoma skin cancer (NMSC) data also due 1Q 2022. Anti-PD-1 failed melanoma data due late-2022 (may be extended by six months). </div></td><td>
              47m
            </td><td>
              1.5b
            </td><td>
              136.8k
            </td><td>
              313.0k
            </td><td>
              3.10
            </td><td>
              $30.5
            </td><td>
              $30.17
            </td><td>
              November 2024
            </td><td>
              447.34m
            </td><td>
              -6.10m
            </td><td>
              73.28
            </td><td>
              402.64m
            </td><td>
              0.99b
            </td><td>
              9.6
            </td><td>
              29,656,261
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RUBY" class="margin-bottom-1">
                RUBY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.63</div> <small class="number change-up">+1.23<span>&nbsp;&nbsp;</span>+6.03%</small></td><td><strong>RTX-321</strong> <br>Human Papillomavirus (HPV) 16+ Cancers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.rubiustx.com/news-releases/news-release-details/rubius-therapeutics-reports-second-quarter-2021-financial">
                1Q 2022
              </a> <div class="note">Phase 1 initial data due 1Q 2022.</div></td><td>
              90m
            </td><td>
              1.9b
            </td><td>
              248.2k
            </td><td>
              453.0k
            </td><td>
              7.36
            </td><td>
              $20.6
            </td><td>
              $20.4
            </td><td>
              August 15, 2023
            </td><td>
              277.41m
            </td><td>
              -11.57m
            </td><td>
              23.97
            </td><td>
              145.44m
            </td><td>
              1.65b
            </td><td>
              7.7
            </td><td>
              35,151,577
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PDSB" class="margin-bottom-1">
                PDSB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$11.05</div> <small class="number change-up">+0.83<span>&nbsp;&nbsp;</span>+8.12%</small></td><td><strong>PDS0101 (VERSATILE-002)</strong> <br>Head and neck cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.pdsbiotech.com/images/pdf/presentation/2021/august/PDSB_Corporate_Overview_-_August_2021_FINAL.pdf">
                4Q 2021 / 1Q 2022
              </a> <div class="note">Phase 2 initial data due 4Q 2021 / 1Q 2022.</div></td><td>
              28m
            </td><td>
              314.1m
            </td><td>
              350.9k
            </td><td>
              0.9m
            </td><td>
              4.30
            </td><td>
              $10.46
            </td><td>
              $10.22
            </td><td>
              May 2023
            </td><td>
              75.32m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              70.92m
            </td><td>
              216.30m
            </td><td>
              10.4
            </td><td>
              26,358,569
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CELC" class="margin-bottom-1">
                CELC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.96</div> <small class="number change-up">+0.68<span>&nbsp;&nbsp;</span>+3.17%</small></td><td><strong>AC-THP - CELsignia (FACT 1)</strong> <br>HER2-Negative Breast Cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.accesswire.com/658819/Celcuity-Inc-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Corporate-Update">
                Late-2021/ early-2022
              </a> <div class="note">Phase 2 interim data due late-2021 or early-2022.</div></td><td>
              15m
            </td><td>
              327.4m
            </td><td>
              22.7k
            </td><td>
              128.6k
            </td><td>
              12.13
            </td><td>
              $21.65
            </td><td>
              $21.29
            </td><td>
              October 30, 2021
            </td><td>
              37.07m
            </td><td>
              -2.54m
            </td><td>
              14.60
            </td><td>
              21.29m
            </td><td>
              290.08m
            </td><td>
              27.7
            </td><td>
              10,515,737
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EXEL" class="margin-bottom-1">
                EXEL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$18.89</div> <small class="number change-up">+0.46<span>&nbsp;&nbsp;</span>+2.47%</small></td><td><strong>CABOMETYX (cabozantinib) + TECENTRIQ (atezolizumab) - (COSMIC-312)</strong> <br>Hepatocellular Carcinoma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805006063/en/">
                Early-2022
              </a> <div class="note">Phase 3 top-line data released June 28, 2021. Progression-free survival (PFS) primary endpoint met. Overall survival (OS) primary endpoint unlikely to be met. Final data due early 2022.</div></td><td>
              315m
            </td><td>
              6.0b
            </td><td>
              0.6m
            </td><td>
              2.6m
            </td><td>
              2.91
            </td><td>
              $18.6
            </td><td>
              $18.44
            </td><td>
              June 1, 2021
            </td><td>
              1.46b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              1.13b
            </td><td>
              4.52b
            </td><td>
              2
            </td><td>
              279,036,935
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TAK" class="margin-bottom-1">
                TAK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.97</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+1.75%</small></td><td><strong>CABOMETYX (cabozantinib) + TECENTRIQ (atezolizumab) - (COSMIC-312)</strong> <br>Hepatocellular Carcinoma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805006063/en/">
                Early-2022
              </a> <div class="note">Phase 3 top-line data released June 28, 2021. Progression-free survival (PFS) primary endpoint met. Overall survival (OS) primary endpoint unlikely to be met. Final data due early 2022.</div></td><td>
              3b
            </td><td>
              53.4b
            </td><td>
              0.8m
            </td><td>
              1.9m
            </td><td>
              1.12
            </td><td>
              $16.84
            </td><td>
              $16.68
            </td><td>
              June 1, 2021
            </td><td>
              0.78t
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -6.63t
            </td><td>
              86.30b
            </td><td>
              0
            </td><td>
              3,145,059,016
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CELC" class="margin-bottom-1">
                CELC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.96</div> <small class="number change-up">+0.68<span>&nbsp;&nbsp;</span>+3.17%</small></td><td><strong>NERLYNX (Neratinib) - CELsignia (FACT 2)</strong> <br>Triple Negative Breast Cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.accesswire.com/658819/Celcuity-Inc-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Corporate-Update">
                Late-2021 / early-2022
              </a> <div class="note">Phase 2 interim data due late-2021 or early-2022.</div></td><td>
              15m
            </td><td>
              327.4m
            </td><td>
              22.7k
            </td><td>
              128.6k
            </td><td>
              12.13
            </td><td>
              $21.65
            </td><td>
              $21.29
            </td><td>
              October 15, 2020
            </td><td>
              37.07m
            </td><td>
              -2.54m
            </td><td>
              14.60
            </td><td>
              21.29m
            </td><td>
              290.08m
            </td><td>
              27.7
            </td><td>
              10,515,737
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KURA" class="margin-bottom-1">
                KURA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.62</div> <small class="number change-up">+1.72<span>&nbsp;&nbsp;</span>+10.82%</small></td><td><strong>KO-539 (KOMET-001)</strong> <br>Relapsed or refractory acute myeloid leukemia (AML)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-reports-second-quarter-2021-financial-results">
                1Q 2022
              </a> <div class="note">Phase 1b enrollment to be completed 1Q 2022, then will assess those patients for safety and tolerability.</div></td><td>
              66m
            </td><td>
              1.2b
            </td><td>
              0.9m
            </td><td>
              0.6m
            </td><td>
              2.09
            </td><td>
              $16.31
            </td><td>
              $15.9
            </td><td>
              February 1, 2022
            </td><td>
              0.55b
            </td><td>
              -9.36m
            </td><td>
              58.84
            </td><td>
              0.52b
            </td><td>
              493.34m
            </td><td>
              0.6
            </td><td>
              55,450,439
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZRX" class="margin-bottom-1">
                AZRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.58</div> <small class="number change-up">0.00<span>&nbsp;&nbsp;</span>-0.40%</small></td><td><strong>Oral niclosamide (RESERVOIR)</strong> <br>COVID-19
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.azurrx.com/investors/press-releases/2021/428-zurxioharmaompletesnitialohortnrollmentintoa20210812040302.html">
                1Q 2022
              </a> <div class="note">Phase 2 top-line data due 1Q 2022.</div></td><td>
              93m
            </td><td>
              54.0m
            </td><td>
              2.9m
            </td><td>
              4.2m
            </td><td>
              7.23
            </td><td>
              $0.58
            </td><td>
              $0.58
            </td><td>
              December 2021
            </td><td>
              10.45m
            </td><td>
              -1.87m
            </td><td>
              5.58
            </td><td>
              3.71m
            </td><td>
              46.64m
            </td><td>
              1.5
            </td><td>
              92,422,898
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CNTB" class="margin-bottom-1">
                CNTB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.20</div> <small class="number change-down">-0.09<span>&nbsp;&nbsp;</span>-0.41%</small></td><td><strong>CBP-307</strong> <br>Ulcerative Colitis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001835268/000119312521060795/d295873df1.htm">
                1Q 2022
              </a> <div class="note">Phase 2 data due 1Q 2022.</div></td><td>
              58m
            </td><td>
              1.3b
            </td><td>
              59.3k
            </td><td>
              64.5k
            </td><td>
              -8.10
            </td><td>
              $21.71
            </td><td>
              $22.29
            </td><td>
              December 2021
            </td><td>
              
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              1.12b
            </td><td>
              0
            </td><td>
              57,504,175
            </td><td>
              03/19/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TAK" class="margin-bottom-1">
                TAK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.97</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+1.75%</small></td><td><strong>TAK-994</strong> <br>Narcolepsy
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.takeda.com/4a21eb/siteassets/system/investors/report/quarterlyannouncements/fy2021/qr2021_q1_p01_en.pdf">
                4Q 2021 / 1Q 2022
              </a> <div class="note">Phase 2 final data due 4Q 2021 / 1Q 2022,</div></td><td>
              3b
            </td><td>
              53.4b
            </td><td>
              0.8m
            </td><td>
              1.9m
            </td><td>
              1.12
            </td><td>
              $16.84
            </td><td>
              $16.68
            </td><td>
              April 26, 2022
            </td><td>
              0.78t
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -6.63t
            </td><td>
              86.30b
            </td><td>
              0
            </td><td>
              3,145,059,016
            </td><td>
              07/30/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ADIL" class="margin-bottom-1">
                ADIL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.40</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+1.80%</small></td><td><strong>AD04 (ONWARD)</strong> <br>Alcohol use disorder
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.adialpharma.com/press-releases/detail/133/adial-pharmaceuticals-reaches-full-enrollment-target-for">
                1Q 2022
              </a> <div class="note">Phase 3 completion of enrollment announced August 20, 2021 with data due 1Q 2022.</div></td><td>
              20m
            </td><td>
              69.0m
            </td><td>
              287.3k
            </td><td>
              1.6m
            </td><td>
              14.17
            </td><td>
              $3.4
            </td><td>
              $3.34
            </td><td>
              July 2021
            </td><td>
              53.29m
            </td><td>
              -1.07m
            </td><td>
              49.91
            </td><td>
              50.05m
            </td><td>
              62.86m
            </td><td>
              7.2
            </td><td>
              14,448,577
            </td><td>
              08/20/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SPRO" class="margin-bottom-1">
                SPRO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.35</div> <small class="number change-up">+0.89<span>&nbsp;&nbsp;</span>+5.74%</small></td><td><strong>SPR206 (BAL)</strong> <br>MDR Gram-negative bacterial infections
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.sperotherapeutics.com/news-releases/news-release-details/spero-therapeutics-announces-fourth-quarter-and-full-year-2020">
                Early-2022
              </a> <div class="note">Phase 1 trial initiated June 2021. Data due early 2022.</div></td><td>
              32m
            </td><td>
              0.5b
            </td><td>
              314.1k
            </td><td>
              171.9k
            </td><td>
              5.82
            </td><td>
              $15.43
            </td><td>
              $15.46
            </td><td>
              September 2021
            </td><td>
              129.28m
            </td><td>
              -5.52m
            </td><td>
              23.41
            </td><td>
              99.94m
            </td><td>
              405.21m
            </td><td>
              0.3
            </td><td>
              25,606,782
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARDS" class="margin-bottom-1">
                ARDS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.85</div> <small class="number change-up">+0.26<span>&nbsp;&nbsp;</span>+7.30%</small></td><td><strong>Panaecin (AR-501)</strong> <br>Chronic bacterial lung infections in patients with cystic fibrosis (CF)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/aridis-pharmaceuticals-announces-second-quarter-2021-results-301354302.html">
                1Q 2022
              </a> <div class="note">Phase 2 top-line data due 1Q 2022.</div></td><td>
              14m
            </td><td>
              54.1m
            </td><td>
              50.5k
            </td><td>
              202.1k
            </td><td>
              -4.01
            </td><td>
              $3.65
            </td><td>
              $3.59
            </td><td>
              April 2022
            </td><td>
              24.63m
            </td><td>
              -2.20m
            </td><td>
              11.18
            </td><td>
              -246.20k
            </td><td>
              40.70m
            </td><td>
              12.8
            </td><td>
              12,624,726
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CERC" class="margin-bottom-1">
                CERC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.90</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+4.69%</small></td><td><strong>CERC 801</strong> <br>Phosphoglucomutase 1 (PGM1) deficiency
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.cerecor.com/press-releases/detail/133/cerecor-reports-second-quarter-2021-financial-results-and">
                1Q 2022
              </a> <div class="note">Pivotal trial top line data expected 1Q 2022.</div></td><td>
              96m
            </td><td>
              278.4m
            </td><td>
              129.3k
            </td><td>
              0.6m
            </td><td>
              13.18
            </td><td>
              $2.82
            </td><td>
              $2.77
            </td><td>
              N/A
            </td><td>
              28.92m
            </td><td>
              -6.40m
            </td><td>
              4.52
            </td><td>
              -13.57m
            </td><td>
              246.42m
            </td><td>
              2.8
            </td><td>
              56,006,748
            </td><td>
              08/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ATAI" class="margin-bottom-1">
                ATAI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.38</div> <small class="number change-up">+1.54<span>&nbsp;&nbsp;</span>+10.38%</small></td><td><strong>DMX-1002</strong> <br>Opioid use disorder
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-reports-second-quarter-2021-financial-results">
                Early-2022
              </a> <div class="note">Phase 1/2 trial to commence 3Q 2021 with safety data due early 2022</div></td><td>
              155m
            </td><td>
              2.5b
            </td><td>
              450.9k
            </td><td>
              0.6m
            </td><td>
              5.34
            </td><td>
              $15.45
            </td><td>
              $14.84
            </td><td>
              N/A
            </td><td>
              454.76m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              433.69m
            </td><td>
              1.85b
            </td><td>
              0
            </td><td>
              114,161,264
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ATAI" class="margin-bottom-1">
                ATAI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.38</div> <small class="number change-up">+1.54<span>&nbsp;&nbsp;</span>+10.38%</small></td><td><strong>GRX-917</strong> <br>Healthy adults
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-reports-second-quarter-2021-financial-results">
                Early-2022
              </a> <div class="note">Phase 1 single ascending dose/multiple ascending dose data expected early in 2022.</div></td><td>
              155m
            </td><td>
              2.5b
            </td><td>
              450.9k
            </td><td>
              0.6m
            </td><td>
              5.34
            </td><td>
              $15.45
            </td><td>
              $14.84
            </td><td>
              N/A
            </td><td>
              454.76m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              433.69m
            </td><td>
              1.85b
            </td><td>
              0
            </td><td>
              114,161,264
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RUBY" class="margin-bottom-1">
                RUBY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.63</div> <small class="number change-up">+1.23<span>&nbsp;&nbsp;</span>+6.03%</small></td><td><strong>RTX-240 and KEYTRUDA (pembrolizumab)</strong> <br>Refractory Acute Myeloid Leukemia (AML) / Solid tumors 
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.rubiustx.com/news-releases/news-release-details/rubius-therapeutics-reports-second-quarter-2021-financial">
                4Q 2021 / 1Q 2022
              </a> <div class="note">Phase 1/2 data due at the end of 2021 or 1Q 2022.</div></td><td>
              90m
            </td><td>
              1.9b
            </td><td>
              248.2k
            </td><td>
              453.0k
            </td><td>
              7.36
            </td><td>
              $20.6
            </td><td>
              $20.4
            </td><td>
              January 2023
            </td><td>
              277.41m
            </td><td>
              -11.57m
            </td><td>
              23.97
            </td><td>
              145.44m
            </td><td>
              1.65b
            </td><td>
              7.7
            </td><td>
              35,151,577
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TAK" class="margin-bottom-1">
                TAK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.97</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+1.75%</small></td><td><strong>TAK-609</strong> <br>Hunter Syndrome
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.takeda.com/4a21eb/siteassets/system/investors/report/quarterlyannouncements/fy2021/qr2021_q1_p01_en.pdf">
                4Q 2021 / 1Q 2022
              </a> <div class="note">NDA filing 4Q 2021 / 1Q 2022.</div></td><td>
              3b
            </td><td>
              53.4b
            </td><td>
              0.8m
            </td><td>
              1.9m
            </td><td>
              1.12
            </td><td>
              $16.84
            </td><td>
              $16.68
            </td><td>
              N/A
            </td><td>
              0.78t
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -6.63t
            </td><td>
              86.30b
            </td><td>
              0
            </td><td>
              3,145,059,016
            </td><td>
              07/30/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALNA" class="margin-bottom-1">
                ALNA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.90</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+6.95%</small></td><td><strong>Reloxaliase (ALLN-177) - (URIROX-2)</strong> <br>Enteric Hyperoxaluria
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/10/2278391/0/en/Allena-Pharmaceuticals-Reports-Second-Quarter-2021-Financial-Results-and-Recent-Corporate-Progress.html">
                1Q 2022
              </a> <div class="note">Phase 3 interim analysis due 1Q 2022.</div></td><td>
              80m
            </td><td>
              72.5m
            </td><td>
              0.7m
            </td><td>
              3.2m
            </td><td>
              6.03
            </td><td>
              $0.85
            </td><td>
              $0.85
            </td><td>
              November 2023
            </td><td>
              47.84m
            </td><td>
              -3.79m
            </td><td>
              12.63
            </td><td>
              29.82m
            </td><td>
              51.68m
            </td><td>
              5.4
            </td><td>
              76,191,870
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMGN" class="margin-bottom-1">
                IMGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.59</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+5.47%</small></td><td><strong>IMGC936</strong> <br>Solid Tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210730005064/en/">
                Early-2022
              </a> <div class="note">Phase 1 initial data due early-2022.</div></td><td>
              202m
            </td><td>
              1.1b
            </td><td>
              0.7m
            </td><td>
              1.4m
            </td><td>
              16.44
            </td><td>
              $5.38
            </td><td>
              $5.3
            </td><td>
              N/A
            </td><td>
              213.21m
            </td><td>
              -14.63m
            </td><td>
              14.58
            </td><td>
              -19.77m
            </td><td>
              0.85b
            </td><td>
              1.1
            </td><td>
              179,510,656
            </td><td>
              07/30/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MGNX" class="margin-bottom-1">
                MGNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.98</div> <small class="number change-up">+1.00<span>&nbsp;&nbsp;</span>+4.55%</small></td><td><strong>IMGC936</strong> <br>Solid Tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210730005064/en/">
                Early-2022
              </a> <div class="note">Phase 1 initial data due early-2022.</div></td><td>
              61m
            </td><td>
              1.4b
            </td><td>
              297.3k
            </td><td>
              0.6m
            </td><td>
              4.40
            </td><td>
              $22.34
            </td><td>
              $21.98
            </td><td>
              N/A
            </td><td>
              269.90m
            </td><td>
              -15.23m
            </td><td>
              17.72
            </td><td>
              163.04m
            </td><td>
              1.07b
            </td><td>
              2.4
            </td><td>
              59,522,546
            </td><td>
              07/30/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OTLK" class="margin-bottom-1">
                OTLK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.30</div> <small class="number change-up">+0.02<span>&nbsp;&nbsp;</span>+0.95%</small></td><td><strong>ONS-5010</strong> <br>Wet age-related macular degeneration (wet AMD)
            </td><td>
              BLA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeutics-reports-financial-results-third-quarter-0">
                1Q 2022
              </a> <div class="note">Phase 3 trial met primary and key secondary endpoints - August 3, 2021. BLA filing due 1Q 2022.</div></td><td>
              175m
            </td><td>
              403.6m
            </td><td>
              441.0k
            </td><td>
              3.7m
            </td><td>
              32.88
            </td><td>
              $2.3
            </td><td>
              $2.28
            </td><td>
              June 7, 2021
            </td><td>
              7.58m
            </td><td>
              -6.73m
            </td><td>
              1.13
            </td><td>
              -12.56m
            </td><td>
              391.76m
            </td><td>
              6.1
            </td><td>
              103,304,563
            </td><td>
              08/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALNY" class="margin-bottom-1">
                ALNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$199.95</div> <small class="number change-up">+2.17<span>&nbsp;&nbsp;</span>+1.10%</small></td><td><strong>Vutrisiran</strong> <br>ATTR amyloidosis
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210624005230/en/">
                4/14/2022
              </a> <div class="note">PDUFA date April 14, 2022.</div></td><td>
              119m
            </td><td>
              23.8b
            </td><td>
              237.9k
            </td><td>
              0.7m
            </td><td>
              27.85
            </td><td>
              $198.72
            </td><td>
              $197.78
            </td><td>
              November 10, 2020
            </td><td>
              1.83b
            </td><td>
              -40.62m
            </td><td>
              44.98
            </td><td>
              -0.83b
            </td><td>
              22.37b
            </td><td>
              0.3
            </td><td>
              102,229,141
            </td><td>
              06/24/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AMRX" class="margin-bottom-1">
                AMRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.24</div> <small class="number change-up">+0.39<span>&nbsp;&nbsp;</span>+8.04%</small></td><td><strong>Bevacizumab</strong> <br>Biosimilar Avastin
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210617005201/en/">
                2Q 2022
              </a> <div class="note">BsUFA date 2Q 2022. Estimate April 17, 2022 based on 10-month review period (announcement made June 17, 2021).</div></td><td>
              149m
            </td><td>
              0.8b
            </td><td>
              0.6m
            </td><td>
              0.8m
            </td><td>
              2.26
            </td><td>
              $4.93
            </td><td>
              $4.85
            </td><td>
              N/A
            </td><td>
              247.15m
            </td><td>
              -17.31m
            </td><td>
              14.28
            </td><td>
              -3.39b
            </td><td>
              3.36b
            </td><td>
              2.1
            </td><td>
              99,459,383
            </td><td>
              06/17/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/HCM" class="margin-bottom-1">
                HCM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$38.16</div> <small class="number change-up">+0.48<span>&nbsp;&nbsp;</span>+1.29%</small></td><td><strong>Surufatinib</strong> <br>Neuroendocrine Tumors
            </td><td>
              PDUFA
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#4078A0" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/07/01/2256328/0/en/U-S-FDA-Accepts-Filing-of-HUTCHMED-s-NDA-for-Surufatinib-for-the-Treatment-of-Advanced-Neuroendocrine-Tumors.html">
                4/30/2022
              </a> <div class="note">PDUFA date April 30, 2022.</div></td><td>
              173m
            </td><td>
              6.6b
            </td><td>
              124.7k
            </td><td>
              488.9k
            </td><td>
              6.69
            </td><td>
              $37.95
            </td><td>
              $37.67
            </td><td>
              N/A
            </td><td>
              0.92b
            </td><td>
              -16.32m
            </td><td>
              56.43
            </td><td>
              0.66b
            </td><td>
              5.59b
            </td><td>
              2.5
            </td><td>
              154,870,219
            </td><td>
              07/01/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LABP" class="margin-bottom-1">
                LABP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.41</div> <small class="number change-down">-0.30<span>&nbsp;&nbsp;</span>-2.19%</small></td><td><strong>Omilancor (BT-11)</strong> <br>Crohn’s Disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.landosbiopharma.com/news-releases/news-release-details/landos-biopharma-reports-second-quarter-2021-financial-results">
                1H 2022
              </a> <div class="note">Phase 2 commencement of dosing announced May 6, 2021. Top-line data due 1H 2022.</div></td><td>
              40m
            </td><td>
              0.5b
            </td><td>
              14.3k
            </td><td>
              45.9k
            </td><td>
              5.10
            </td><td>
              $13.28
            </td><td>
              $13.71
            </td><td>
              November 2021
            </td><td>
              120.77m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              108.09m
            </td><td>
              434.89m
            </td><td>
              0.2
            </td><td>
              4,639,108
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VECT" class="margin-bottom-1">
                VECT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.25</div> <small class="number change-down">-0.06<span>&nbsp;&nbsp;</span>-0.82%</small></td><td><strong>Apraglutide</strong> <br>Short bowel syndrome - colon-in-continuity
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.vectivbio.com/news-releases/news-release-details/vectivbio-announces-first-patient-dosed-metabolic-balance-study">
                1H 2022
              </a> <div class="note">Phase 2 commencement of dosing announced June 15, 2021 with initial data due 2H 2021.</div></td><td>
              36m
            </td><td>
              260.0m
            </td><td>
              0.9k
            </td><td>
              19.4k
            </td><td>
              8.06
            </td><td>
              $7.38
            </td><td>
              $7.31
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              222.09m
            </td><td>
              0
            </td><td>
              23,920,345
            </td><td>
              06/15/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VSTM" class="margin-bottom-1">
                VSTM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.67</div> <small class="number change-up">+0.12<span>&nbsp;&nbsp;</span>+4.49%</small></td><td><strong>VS-6766 and defactinib (RAMP 201)</strong> <br>Low-grade serous ovarian cancer (LGSOC)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210802005716/en/">
                1H 2022
              </a> <div class="note">Phase 2 selection phase top-line data due 1H 2022.</div></td><td>
              181m
            </td><td>
              483.5m
            </td><td>
              0.9m
            </td><td>
              2.0m
            </td><td>
              5.46
            </td><td>
              $2.58
            </td><td>
              $2.56
            </td><td>
              June 2023
            </td><td>
              100.08m
            </td><td>
              -4.47m
            </td><td>
              22.37
            </td><td>
              64.40m
            </td><td>
              378.16m
            </td><td>
              2.3
            </td><td>
              179,887,236
            </td><td>
              08/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LABP" class="margin-bottom-1">
                LABP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.41</div> <small class="number change-down">-0.30<span>&nbsp;&nbsp;</span>-2.19%</small></td><td><strong>NX-13</strong> <br>Ulcerative Colitis
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.landosbiopharma.com/news-releases/news-release-details/landos-biopharma-reports-second-quarter-2021-financial-results">
                1H 2022
              </a> <div class="note">Phase 1b top-line data due 1H 2022.</div></td><td>
              40m
            </td><td>
              0.5b
            </td><td>
              14.3k
            </td><td>
              45.9k
            </td><td>
              5.10
            </td><td>
              $13.28
            </td><td>
              $13.71
            </td><td>
              October 2021
            </td><td>
              120.77m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              108.09m
            </td><td>
              434.89m
            </td><td>
              0.2
            </td><td>
              4,639,108
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RPHM" class="margin-bottom-1">
                RPHM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.61</div> <small class="number change-down">-0.23<span>&nbsp;&nbsp;</span>-2.93%</small></td><td><strong>REN001-102</strong> <br>Long-chain fatty acid oxidation disorders (LC-FAOD)
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/11/2278565/0/en/Reneo-Pharmaceuticals-Reports-Second-Quarter-2021-Financial-Results.html">
                1H 2022
              </a> <div class="note">Phase 1b data due 1H 2022.</div></td><td>
              24m
            </td><td>
              185.7m
            </td><td>
              9.7k
            </td><td>
              54.7k
            </td><td>
              1.11
            </td><td>
              $7.54
            </td><td>
              $7.84
            </td><td>
              December 2021
            </td><td>
              161.51m
            </td><td>
              -3.23m
            </td><td>
              49.95
            </td><td>
              157.76m
            </td><td>
              24.01m
            </td><td>
              0.1
            </td><td>
              10,915,953
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PCSA" class="margin-bottom-1">
                PCSA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.81</div> <small class="number change-up">+0.38<span>&nbsp;&nbsp;</span>+7.00%</small></td><td><strong>PCS499</strong> <br>Necrobiosis Lipoidica
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://finance.yahoo.com/news/processa-pharmaceuticals-announces-second-quarter-211500186.html">
                1H 2022
              </a> <div class="note">Phase 2b initiation of dosing announced May 20, 2021. Interim data due 1H 2022.</div></td><td>
              16m
            </td><td>
              90.7m
            </td><td>
              14.2k
            </td><td>
              103.7k
            </td><td>
              3.11
            </td><td>
              $5.52
            </td><td>
              $5.43
            </td><td>
              August 1, 2022
            </td><td>
              19.51m
            </td><td>
              -0.73m
            </td><td>
              26.68
            </td><td>
              17.62m
            </td><td>
              64.03m
            </td><td>
              13.5
            </td><td>
              11,767,617
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>IMFINZI (Durvalumab) - (PEARL)</strong> <br>Non-small cell lung cancer (NSCLC)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2021/h1-2021/H1_2021_results_presentation.pdf">
                1H 2022
              </a> <div class="note">Phase 3 data due 1H 2022.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              October 29, 2021
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RCUS" class="margin-bottom-1">
                RCUS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.16</div> <small class="number change-up">+0.78<span>&nbsp;&nbsp;</span>+2.75%</small></td><td><strong>Etrumadenant, carboplatin, pemetrexed  (ARC-4)</strong> <br>Non-small cell lung cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.arcusbio.com/investors-and-media/press-releases/press-release-details/2021/Arcus-Biosciences-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Operational-Highlights/default.aspx">
                1H 2022
              </a> <div class="note">Phase 2 data to be presented in 1H 2022.</div></td><td>
              71m
            </td><td>
              2.1b
            </td><td>
              139.5k
            </td><td>
              0.7m
            </td><td>
              3.44
            </td><td>
              $28.39
            </td><td>
              $28.38
            </td><td>
              January 2023
            </td><td>
              0.68b
            </td><td>
              -24.66m
            </td><td>
              27.43
            </td><td>
              382.40m
            </td><td>
              1.35b
            </td><td>
              1.2
            </td><td>
              50,339,817
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CYCC" class="margin-bottom-1">
                CYCC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.91</div> <small class="number change-up">+0.33<span>&nbsp;&nbsp;</span>+7.27%</small></td><td><strong>Fadraciclib  (CYC065-101)</strong> <br>Advanced cancers
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.benzinga.com/pressreleases/21/08/g22453159/cyclacel-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-business-updat">
                1H 2022
              </a> <div class="note">Phase 1/2 initiation of dosing announced July 13, 2021. Data due 1H 2022.</div></td><td>
              9m
            </td><td>
              45.4m
            </td><td>
              18.6k
            </td><td>
              81.3k
            </td><td>
              1.05
            </td><td>
              $4.66
            </td><td>
              $4.58
            </td><td>
              N/A
            </td><td>
              41.11m
            </td><td>
              -1.40m
            </td><td>
              29.26
            </td><td>
              37.99m
            </td><td>
              -1.35m
            </td><td>
              11
            </td><td>
              9,152,307
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TERN" class="margin-bottom-1">
                TERN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.66</div> <small class="number change-up">+1.47<span>&nbsp;&nbsp;</span>+13.14%</small></td><td><strong>TERN-201 (AVIATION)</strong> <br>Nonalcoholic steatohepatitis (NASH)
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ternspharma.com/news-releases/news-release-details/terns-pharmaceuticals-reports-second-quarter-2021-financial">
                1H 2022
              </a> <div class="note">Phase 1b trial initiation announced June 24, 2021 with data due 1H 2022.</div></td><td>
              25m
            </td><td>
              318.2m
            </td><td>
              80.5k
            </td><td>
              81.9k
            </td><td>
              1.75
            </td><td>
              $11.38
            </td><td>
              $11.19
            </td><td>
              August 2022
            </td><td>
              179.83m
            </td><td>
              -2.92m
            </td><td>
              61.58
            </td><td>
              173.15m
            </td><td>
              405.27m
            </td><td>
              1.1
            </td><td>
              13,596,996
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BBIO" class="margin-bottom-1">
                BBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.45</div> <small class="number change-up">+0.42<span>&nbsp;&nbsp;</span>+0.86%</small></td><td><strong>Low-dose infigratinib (PROPEL2)</strong> <br>Achondroplasia
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/bridgebio-pharma-inc-reports-second-quarter-2021-financial-results-and-business-update-301348970.html">
                1H 2022
              </a> <div class="note">Phase 2 initial data due 1H 2022.</div></td><td>
              150m
            </td><td>
              7.4b
            </td><td>
              385.3k
            </td><td>
              0.9m
            </td><td>
              -15.95
            </td><td>
              $49.7
            </td><td>
              $49.03
            </td><td>
              October 2021
            </td><td>
              0.78b
            </td><td>
              -30.57m
            </td><td>
              25.60
            </td><td>
              -0.76b
            </td><td>
              7.84b
            </td><td>
              5.3
            </td><td>
              82,237,528
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PBYI" class="margin-bottom-1">
                PBYI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.38</div> <small class="number change-up">+0.38<span>&nbsp;&nbsp;</span>+5.43%</small></td><td><strong>KADCYLA (trastuzumab emtansine) plus NERLYNX (Neratinib) - (TBCRC-022)</strong> <br>HER2 positive breast cancer with brain metastases
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005287/en/">
                2H 2021 / 1H 2022
              </a> <div class="note">Phase 2 data due 2H 2021 / 1H 2022.</div></td><td>
              41m
            </td><td>
              300.9m
            </td><td>
              149.8k
            </td><td>
              465.6k
            </td><td>
              10.25
            </td><td>
              $7.06
            </td><td>
              $7
            </td><td>
              December 2022
            </td><td>
              208.93m
            </td><td>
              -24.67k
            </td><td>
              8.47k
            </td><td>
              -21.60m
            </td><td>
              297.77m
            </td><td>
              13.1
            </td><td>
              34,191,064
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GSK" class="margin-bottom-1">
                GSK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$41.57</div> <small class="number change-down">-0.28<span>&nbsp;&nbsp;</span>-0.67%</small></td><td><strong>Gepotidacin (EAGLE)</strong> <br>Uncomplicated urinary tract infection (uUTI)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.gsk.com/media/7129/q2-2021-results-slides.pdf">
                1H 2022
              </a> <div class="note">Phase 3 1H 2022.</div></td><td>
              3b
            </td><td>
              104.6b
            </td><td>
              2.3m
            </td><td>
              4.2m
            </td><td>
              4.95
            </td><td>
              $41.75
            </td><td>
              $41.85
            </td><td>
              December 22, 2022
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -51.10b
            </td><td>
              133.80b
            </td><td>
              0.2
            </td><td>
              2,506,785,977
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMUX" class="margin-bottom-1">
                IMUX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.76</div> <small class="number change-up">+0.83<span>&nbsp;&nbsp;</span>+9.36%</small></td><td><strong>IMU-838 (CALDOSE-1)</strong> <br>Ulcerative colitis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/immunic-inc-reports-second-quarter-2021-financial-results-and-highlights-recent-activity-301350113.html">
                1H 2022
              </a> <div class="note">Phase 2 data due 1H 2022.</div></td><td>
              26m
            </td><td>
              256.1m
            </td><td>
              122.3k
            </td><td>
              268.5k
            </td><td>
              2.12
            </td><td>
              $9.16
            </td><td>
              $8.92
            </td><td>
              July 10, 2022
            </td><td>
              114.77m
            </td><td>
              -9.67m
            </td><td>
              11.87
            </td><td>
              99.46m
            </td><td>
              147.99m
            </td><td>
              2.4
            </td><td>
              23,416,743
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INZY" class="margin-bottom-1">
                INZY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$15.91</div> <small class="number change-up">+0.43<span>&nbsp;&nbsp;</span>+2.81%</small></td><td><strong>INZ-701</strong> <br>ABCC6 deficiency
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.inozyme.com/news-releases/news-release-details/inozyme-pharma-reports-q2-2021-financial-results-and-provides">
                1H 2022
              </a> <div class="note">Phase 1/2 trial planned for 4Q 2021 with preliminary safety and biomarker data due 1H 2022.</div></td><td>
              24m
            </td><td>
              376.6m
            </td><td>
              3.6k
            </td><td>
              67.2k
            </td><td>
              2.73
            </td><td>
              $15.75
            </td><td>
              $15.48
            </td><td>
              N/A
            </td><td>
              131.44m
            </td><td>
              -3.34m
            </td><td>
              39.30
            </td><td>
              121.46m
            </td><td>
              232.52m
            </td><td>
              2.3
            </td><td>
              16,473,465
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VIR" class="margin-bottom-1">
                VIR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$47.20</div> <small class="number change-up">+0.73<span>&nbsp;&nbsp;</span>+1.57%</small></td><td><strong>VIR-2218 and VIR-3434 (MARCH)</strong> <br>Hepatitis B
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-provides-corporate-update-and-reports-second-0">
                1H 2022
              </a> <div class="note">Phase 2 initiation announced July 15, 2021. Initial data due 1H 2022.</div></td><td>
              131m
            </td><td>
              6.2b
            </td><td>
              1.0m
            </td><td>
              0.9m
            </td><td>
              8.35
            </td><td>
              $47.62
            </td><td>
              $46.47
            </td><td>
              January 2025
            </td><td>
              0.91b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              0.59b
            </td><td>
              5.32b
            </td><td>
              5.6
            </td><td>
              69,593,992
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TSHA" class="margin-bottom-1">
                TSHA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.73</div> <small class="number change-up">+0.80<span>&nbsp;&nbsp;</span>+4.73%</small></td><td><strong>TSHA-118</strong> <br>CLN1 Batten disease
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210816005196/en/">
                1H 2022
              </a> <div class="note">Phase 1/2 trial to be initiated 2H 2021 with biomarker data due 1H 2022.</div></td><td>
              38m
            </td><td>
              0.7b
            </td><td>
              22.6k
            </td><td>
              190.5k
            </td><td>
              3.65
            </td><td>
              $17.25
            </td><td>
              $16.93
            </td><td>
              N/A
            </td><td>
              183.68m
            </td><td>
              -7.61m
            </td><td>
              24.15
            </td><td>
              128.32m
            </td><td>
              478.80m
            </td><td>
              26.7
            </td><td>
              16,966,890
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IOVA" class="margin-bottom-1">
                IOVA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.93</div> <small class="number change-up">+0.76<span>&nbsp;&nbsp;</span>+3.59%</small></td><td><strong>Lifileucel (LN-144)</strong> <br>Refractory metastatic melanoma
            </td><td>
              BLA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.iovance.com/news-releases/news-release-details/iovance-biotherapeutics-reports-second-quarter-and-first-half">
                1H 2022
              </a> <div class="note">Phase 2 updated data from cohort 2 presented at ASCO June 6, 2021. ORR 36.4%. BLA filing initially planned for 2021 is now expected in 1H 2022.</div></td><td>
              155m
            </td><td>
              3.4b
            </td><td>
              1.0m
            </td><td>
              1.9m
            </td><td>
              4.57
            </td><td>
              $21.49
            </td><td>
              $21.17
            </td><td>
              July 2021
            </td><td>
              0.62b
            </td><td>
              -18.00m
            </td><td>
              34.66
            </td><td>
              0.52b
            </td><td>
              2.68b
            </td><td>
              13.6
            </td><td>
              129,864,177
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/COGT" class="margin-bottom-1">
                COGT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.13</div> <small class="number change-up">+0.17<span>&nbsp;&nbsp;</span>+1.90%</small></td><td><strong>Bezuclastinib (APEX)</strong> <br>Advanced Systemic Mastocytosis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/cogent-biosciences-provides-corporate-updates-and-reports-second-quarter-2021-financial-results-301355446.html">
                1H 2022
              </a> <div class="note">Phase 2 initial data due 1H 2022.</div></td><td>
              40m
            </td><td>
              363.8m
            </td><td>
              108.6k
            </td><td>
              336.8k
            </td><td>
              2.85
            </td><td>
              $9.07
            </td><td>
              $8.96
            </td><td>
              January 2025
            </td><td>
              210.60m
            </td><td>
              -4.17m
            </td><td>
              50.50
            </td><td>
              194.89m
            </td><td>
              228.56m
            </td><td>
              13.3
            </td><td>
              37,347,639
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ELTX" class="margin-bottom-1">
                ELTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td>
              N/A
            </td><td><strong>ELI-002 (AMPLIFY-201)</strong> <br>Solid Tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001555192/000119312521202124/d155288ds1.htm">
                1H 2022
              </a> <div class="note">Phase 1/2 data expected 1H 2022. </div></td><td>
              14m
            </td><td>
              
            </td><td>
              
            </td><td>
              
            </td><td>
              
            </td><td>
              $0
            </td><td>
              $0
            </td><td>
              March 2025
            </td><td>
              
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              
            </td><td>
              0
            </td><td>
              11,721,797
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/UBX" class="margin-bottom-1">
                UBX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.20</div> <small class="number change-up">+0.04<span>&nbsp;&nbsp;</span>+1.27%</small></td><td><strong>UBX1325</strong> <br>Diabetic macular edema / Age-related macular degeneration
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.unitybiotechnology.com/news-releases/news-release-details/unity-biotechnology-inc-reports-second-quarter-2021-financial">
                1H 2022
              </a> <div class="note">Phase 2a data due 1H 2022.</div></td><td>
              55m
            </td><td>
              176.3m
            </td><td>
              184.6k
            </td><td>
              0.5m
            </td><td>
              2.67
            </td><td>
              $3.19
            </td><td>
              $3.16
            </td><td>
              June 2022
            </td><td>
              75.91m
            </td><td>
              -4.46m
            </td><td>
              17.02
            </td><td>
              5.57m
            </td><td>
              147.11m
            </td><td>
              6.3
            </td><td>
              40,873,871
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PHAS" class="margin-bottom-1">
                PHAS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.22</div> <small class="number change-up">+0.02<span>&nbsp;&nbsp;</span>+0.62%</small></td><td><strong>Pemziviptadil (PB1046)</strong> <br>Pulmonary arterial hypertension (PAH)
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210513005990/en/">
                1H 2022
              </a> <div class="note">Phase 2b data due 1H 2022.</div></td><td>
              48m
            </td><td>
              154.7m
            </td><td>
              261.5k
            </td><td>
              413.4k
            </td><td>
              -8.05
            </td><td>
              $3.22
            </td><td>
              $3.2
            </td><td>
              December 31, 2021
            </td><td>
              57.80m
            </td><td>
              -3.70m
            </td><td>
              15.64
            </td><td>
              -62.01m
            </td><td>
              100.52m
            </td><td>
              0.5
            </td><td>
              38,715,079
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MIRM" class="margin-bottom-1">
                MIRM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.70</div> <small class="number change-up">+0.52<span>&nbsp;&nbsp;</span>+3.67%</small></td><td><strong>Maralixibat - MARCH</strong> <br>Progressive Familial Intrahepatic Cholestasis (PFIC)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005953/en/">
                2Q 2022
              </a> <div class="note">Phase 3 top-line data due 2Q 2022.</div></td><td>
              31m
            </td><td>
              448.6m
            </td><td>
              36.1k
            </td><td>
              77.7k
            </td><td>
              4.68
            </td><td>
              $14.35
            </td><td>
              $14.18
            </td><td>
              July 2021
            </td><td>
              199.73m
            </td><td>
              -13.40m
            </td><td>
              14.91
            </td><td>
              47.80m
            </td><td>
              211.81m
            </td><td>
              0.5
            </td><td>
              8,253,550
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CADL" class="margin-bottom-1">
                CADL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.75</div> <small class="number change-up">+1.45<span>&nbsp;&nbsp;</span>+23.02%</small></td><td><strong>CAN-2409</strong> <br>Non-small cell lung cancer (NSCLC)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001841387/000119312521200639/d120909ds1.htm">
                1H 2022
              </a> <div class="note">Phase 2 translational biomarkers and efficacy data to be presented 1H 2022.</div></td><td>
              28m
            </td><td>
              215.4m
            </td><td>
              153.7k
            </td><td>
              
            </td><td>
              -7.83
            </td><td>
              $6.8
            </td><td>
              $6.3
            </td><td>
              June 2022
            </td><td>
              20.09m
            </td><td>
              -1.88m
            </td><td>
              10.71
            </td><td>
              -42.50m
            </td><td>
              146.94m
            </td><td>
              6.7
            </td><td>
              14,620,612
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARCT" class="margin-bottom-1">
                ARCT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.98</div> <small class="number change-up">+2.08<span>&nbsp;&nbsp;</span>+4.34%</small></td><td><strong>ARCT-810</strong> <br>Ornithine Transcarbamylase (OTC) deficiency
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005702/en/">
                2H 2022
              </a> <div class="note">Phase 2 trial planned. Interim data due 2H 2022.</div></td><td>
              26m
            </td><td>
              1.3b
            </td><td>
              388.5k
            </td><td>
              1.0m
            </td><td>
              4.30
            </td><td>
              $48.63
            </td><td>
              $47.9
            </td><td>
              N/A
            </td><td>
              413.81m
            </td><td>
              -10.98m
            </td><td>
              37.68
            </td><td>
              270.64m
            </td><td>
              0.90b
            </td><td>
              9.4
            </td><td>
              14,191,083
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PDSB" class="margin-bottom-1">
                PDSB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$11.05</div> <small class="number change-up">+0.83<span>&nbsp;&nbsp;</span>+8.12%</small></td><td><strong>PDS0101 and chemoradiotherapy (IMMUNOCERV))</strong> <br>Cervical cancer
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.pdsbiotech.com/images/pdf/presentation/2021/august/PDSB_Corporate_Overview_-_August_2021_FINAL.pdf">
                1H 2022
              </a> <div class="note">Phase 2a initial data due 1H 2022.</div></td><td>
              28m
            </td><td>
              314.1m
            </td><td>
              350.9k
            </td><td>
              0.9m
            </td><td>
              4.30
            </td><td>
              $10.46
            </td><td>
              $10.22
            </td><td>
              March 8, 2024
            </td><td>
              75.32m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              70.92m
            </td><td>
              216.30m
            </td><td>
              10.4
            </td><td>
              26,358,569
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VACC" class="margin-bottom-1">
                VACC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.60</div> <small class="number change-down">-0.25<span>&nbsp;&nbsp;</span>-1.68%</small></td><td><strong>VTP-200</strong> <br>Human papillomavirus (HPV)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2279734/0/en/Vaccitech-Reports-Second-Quarter-2021-Financial-Results-and-Recent-Corporate-Developments.html">
                2Q 2022
              </a> <div class="note">Phase 1/2a  interim efficacy review 2Q 2022.</div></td><td>
              34m
            </td><td>
              0.5b
            </td><td>
              32.1k
            </td><td>
              24.1k
            </td><td>
              2.01
            </td><td>
              $14.78
            </td><td>
              $14.85
            </td><td>
              N/A
            </td><td>
              234.84m
            </td><td>
              -4.87m
            </td><td>
              48.18
            </td><td>
              224.92m
            </td><td>
              267.74m
            </td><td>
              4.2
            </td><td>
              32,899,041
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/APTX" class="margin-bottom-1">
                APTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.40</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+3.00%</small></td><td><strong>NYX-2925</strong> <br>Fibromyalgia
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210810005946/en/">
                1H 2022
              </a> <div class="note">Phase 2 data due 1H 2022.</div></td><td>
              68m
            </td><td>
              162.5m
            </td><td>
              187.8k
            </td><td>
              1.2m
            </td><td>
              1.24
            </td><td>
              $2.33
            </td><td>
              $2.33
            </td><td>
              June 2022
            </td><td>
              119.16m
            </td><td>
              -5.59m
            </td><td>
              21.32
            </td><td>
              115.75m
            </td><td>
              28.55m
            </td><td>
              2.9
            </td><td>
              53,798,730
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/APTX" class="margin-bottom-1">
                APTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.40</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+3.00%</small></td><td><strong>NYX-2925</strong> <br>Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210810005946/en/">
                1H 2022
              </a> <div class="note">Phase 2 data due 1H 2022.</div></td><td>
              68m
            </td><td>
              162.5m
            </td><td>
              187.8k
            </td><td>
              1.2m
            </td><td>
              1.24
            </td><td>
              $2.33
            </td><td>
              $2.33
            </td><td>
              June 2022
            </td><td>
              119.16m
            </td><td>
              -5.59m
            </td><td>
              21.32
            </td><td>
              115.75m
            </td><td>
              28.55m
            </td><td>
              2.9
            </td><td>
              53,798,730
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>FARXIGA (Dapagliflozin) - (Deliver)</strong> <br>Chronic Heart Failure (CHF), preserved ejection fraction (HFpEF)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2021/h1-2021/H1_2021_results_clinical_trials_appendix.pdf">
                1H 2022
              </a> <div class="note">Phase 3 data due 1H 2022.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              January 10, 2022
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/HRMY" class="margin-bottom-1">
                HRMY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$32.60</div> <small class="number change-down">-0.49<span>&nbsp;&nbsp;</span>-1.48%</small></td><td><strong>WAKIX (pitolisant)</strong> <br>Excessive daytime sleepiness associated with Prader-Willi Syndrome
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/10/2277884/0/en/Harmony-Biosciences-Reports-Second-Quarter-2021-Financial-Results-and-Business-Updates.html">
                1H 2022
              </a> <div class="note">Phase 2 data due 1H 2022.</div></td><td>
              57m
            </td><td>
              1.9b
            </td><td>
              122.2k
            </td><td>
              288.1k
            </td><td>
              14.69
            </td><td>
              $33.08
            </td><td>
              $33.09
            </td><td>
              May 2022
            </td><td>
              170.53m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -62.62m
            </td><td>
              1.92b
            </td><td>
              0.1
            </td><td>
              18,002,884
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CNTX" class="margin-bottom-1">
                CNTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td>
              N/A
            </td><td><strong>Onapristone (ONA-XR) and Anastrozole</strong> <br>Endometrial Cancer 
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001842952/000119312521175568/d46596ds1.htm">
                1H 2022
              </a> <div class="note">Phase 2 interim data due 1H 2022 with final data due late-2022.</div></td><td>
              7m
            </td><td>
              
            </td><td>
              
            </td><td>
              
            </td><td>
              
            </td><td>
              $0
            </td><td>
              $0
            </td><td>
              December 15, 2022
            </td><td>
              -1.10m
            </td><td>
              -0.57m
            </td><td>
              1.93
            </td><td>
              -20.83m
            </td><td>
              
            </td><td>
              0
            </td><td>
              5,971,554
            </td><td>
              07/26/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CNTX" class="margin-bottom-1">
                CNTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td>
              N/A
            </td><td><strong>Onapristone (ONA-XR) - (ONAWA)</strong> <br>Breast Cancer
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.contexttherapeutics.com/more-info-onward-203">
                1H 2022
              </a> <div class="note">Phase 0 initial data due 1H 2022 with final data late-2022.</div></td><td>
              7m
            </td><td>
              
            </td><td>
              
            </td><td>
              
            </td><td>
              
            </td><td>
              $0
            </td><td>
              $0
            </td><td>
              April 30, 2021
            </td><td>
              -1.10m
            </td><td>
              -0.57m
            </td><td>
              1.93
            </td><td>
              -20.83m
            </td><td>
              
            </td><td>
              0
            </td><td>
              5,971,554
            </td><td>
              07/26/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MRUS" class="margin-bottom-1">
                MRUS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$24.57</div> <small class="number change-up">+2.35<span>&nbsp;&nbsp;</span>+10.58%</small></td><td><strong>Zenocutuzumab (MCLA-128)</strong> <br>Solid tumors - NRG1
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.merus.nl/news-releases/news-release-details/merus-announces-financial-results-second-quarter-and-provides-0">
                6/30/2022
              </a> <div class="note">Phase 1/2 interim data presented at ASCO June 4, 2021. Partial responses in 5 of 12 patients with pancreatic cancer (42%) and in 13 of 45 patients across several NRG1+ tumor types (29%) shown. Update 1H 2022.</div></td><td>
              38m
            </td><td>
              0.9b
            </td><td>
              121.7k
            </td><td>
              274.0k
            </td><td>
              4.32
            </td><td>
              $22.53
            </td><td>
              $22.22
            </td><td>
              September 2021
            </td><td>
              338.17m
            </td><td>
              -8.10m
            </td><td>
              41.76
            </td><td>
              177.68m
            </td><td>
              0.51b
            </td><td>
              0.3
            </td><td>
              32,485,140
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ICVX" class="margin-bottom-1">
                ICVX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$40.01</div> <small class="number change-up">+5.41<span>&nbsp;&nbsp;</span>+15.64%</small></td><td><strong>IVX-121</strong> <br>Respiratory syncytial virus (RSV) vaccine
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1786255/000119312521209031/d916073ds1.htm">
                1H 2022
              </a> <div class="note">Phase 1 trial to commence 1H 2021 with top-line data due 1H 2022.</div></td><td>
              39m
            </td><td>
              1.6b
            </td><td>
              208.8k
            </td><td>
              137.3k
            </td><td>
              -48.79
            </td><td>
              $35.4
            </td><td>
              $34.6
            </td><td>
              N/A
            </td><td>
              115.14m
            </td><td>
              -1.39m
            </td><td>
              82.60
            </td><td>
              109.18m
            </td><td>
              1.38b
            </td><td>
              1.5
            </td><td>
              24,503,946
            </td><td>
              07/26/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ICVX" class="margin-bottom-1">
                ICVX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$40.01</div> <small class="number change-up">+5.41<span>&nbsp;&nbsp;</span>+15.64%</small></td><td><strong>IVX-411</strong> <br>COVID-19 vaccine
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1786255/000119312521209031/d916073ds1.htm">
                1H 2022
              </a> <div class="note">Phase 1/2 trial initiated June 2021. Data due 1H 2022.</div></td><td>
              39m
            </td><td>
              1.6b
            </td><td>
              208.8k
            </td><td>
              137.3k
            </td><td>
              -48.79
            </td><td>
              $35.4
            </td><td>
              $34.6
            </td><td>
              N/A
            </td><td>
              115.14m
            </td><td>
              -1.39m
            </td><td>
              82.60
            </td><td>
              109.18m
            </td><td>
              1.38b
            </td><td>
              1.5
            </td><td>
              24,503,946
            </td><td>
              07/26/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IVA" class="margin-bottom-1">
                IVA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$11.39</div> <small class="number change-up">+0.58<span>&nbsp;&nbsp;</span>+5.41%</small></td><td><strong>Lanifibranor</strong> <br>Nonalcoholic fatty liver disease (NAFLD)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://inventivapharma.com/wp-content/uploads/2021/07/Inventiva-PR-H1-2021-CA-Cash-EN-28072021.pdf">
                1H 2022
              </a> <div class="note">Phase 2 data to be published 1H 2022.</div></td><td>
              39m
            </td><td>
              440.0m
            </td><td>
              4.7k
            </td><td>
              11.3k
            </td><td>
              3.67
            </td><td>
              $10.99
            </td><td>
              $10.8
            </td><td>
              N/A
            </td><td>
              95.27m
            </td><td>
              -2.59m
            </td><td>
              36.73
            </td><td>
              65.31m
            </td><td>
              313.95m
            </td><td>
              0
            </td><td>
              38,630,261
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AMGN" class="margin-bottom-1">
                AMGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$226.21</div> <small class="number change-up">+2.68<span>&nbsp;&nbsp;</span>+1.20%</small></td><td><strong>LUMAKRAS (Sotorasib)</strong> <br>KRAS G12C-mutated solid tumors
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/amgen-reports-second-quarter-2021-financial-results-301347523.html">
                1H 2022
              </a> <div class="note">Phase 2 data due 1H 2022.</div></td><td>
              1b
            </td><td>
              128.5b
            </td><td>
              0.9m
            </td><td>
              2.4m
            </td><td>
              15.58
            </td><td>
              $224.18
            </td><td>
              $223.53
            </td><td>
              N/A
            </td><td>
              8.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -43.19b
            </td><td>
              151.63b
            </td><td>
              0.6
            </td><td>
              566,434,467
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GRTX" class="margin-bottom-1">
                GRTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.64</div> <small class="number change-up">+0.18<span>&nbsp;&nbsp;</span>+2.13%</small></td><td><strong>GC4711 (GRECO-1)</strong> <br>Non-Small Cell Lung Cancer (NSCLC)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.galeratx.com/news-releases/news-release-details/galera-reports-second-quarter-2021-financial-results-and-recent">
                1H 2022
              </a> <div class="note">Phase 1/2 top-line data from first stage due 1H 2022.</div></td><td>
              26m
            </td><td>
              227.8m
            </td><td>
              35.5k
            </td><td>
              120.1k
            </td><td>
              -8.91
            </td><td>
              $8.46
            </td><td>
              $8.46
            </td><td>
              November 2022
            </td><td>
              56.44m
            </td><td>
              -5.60m
            </td><td>
              10.08
            </td><td>
              -84.34m
            </td><td>
              156.98m
            </td><td>
              1.4
            </td><td>
              15,528,662
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DBTX" class="margin-bottom-1">
                DBTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.34</div> <small class="number change-up">+0.26<span>&nbsp;&nbsp;</span>+3.67%</small></td><td><strong>DB-020</strong> <br>Cisplatin-induced hearing loss
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.decibeltx.com/news-releases/news-release-details/decibel-therapeutics-reports-second-quarter-2021-financial">
                1H 2022
              </a> <div class="note">Phase 1b interim data due 1H 2022.</div></td><td>
              25m
            </td><td>
              182.8m
            </td><td>
              6.3k
            </td><td>
              109.7k
            </td><td>
              1.08
            </td><td>
              $7.22
            </td><td>
              $7.08
            </td><td>
              September 2021
            </td><td>
              152.38m
            </td><td>
              -1.88m
            </td><td>
              80.92
            </td><td>
              124.89m
            </td><td>
              20.71m
            </td><td>
              0.3
            </td><td>
              15,577,026
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ETNB" class="margin-bottom-1">
                ETNB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$18.47</div> <small class="number change-up">+1.46<span>&nbsp;&nbsp;</span>+8.58%</small></td><td><strong>BIO89-100  (ENTRIGUE)</strong> <br>Severe hypertriglyceridemia
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/12/2280104/0/en/89bio-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Corporate-Update.html">
                1H 2022
              </a> <div class="note">Phase 2 top-line data due 2H 2021.</div></td><td>
              20m
            </td><td>
              371.0m
            </td><td>
              49.1k
            </td><td>
              102.6k
            </td><td>
              2.15
            </td><td>
              $17.25
            </td><td>
              $17.01
            </td><td>
              April 2022
            </td><td>
              158.90m
            </td><td>
              -6.70m
            </td><td>
              23.71
            </td><td>
              149.89m
            </td><td>
              172.16m
            </td><td>
              0.7
            </td><td>
              9,711,801
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SONN" class="margin-bottom-1">
                SONN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.62</div> <small class="number change-down">-0.01<span>&nbsp;&nbsp;</span>-2.17%</small></td><td><strong>SON-1010</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://d1io3yog0oux5.cloudfront.net/_6b3eaf47d6319e8389086c4c316f75dd/sonnetbio/db/776/6714/pdf/Sonnet+Bio+Corp+Presentation+Aug+2021.pdf">
                1H 2022
              </a> <div class="note">IND filing due by end of 2021 with initial safety data due 1H 2022.</div></td><td>
              25m
            </td><td>
              15.4m
            </td><td>
              8.9m
            </td><td>
              6.1m
            </td><td>
              12.35
            </td><td>
              $0.62
            </td><td>
              $0.63
            </td><td>
              N/A
            </td><td>
              32.53m
            </td><td>
              -1.95m
            </td><td>
              16.70
            </td><td>
              26.72m
            </td><td>
              9.86m
            </td><td>
              4.3
            </td><td>
              23,755,498
            </td><td>
              08/19/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ATHA" class="margin-bottom-1">
                ATHA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.98</div> <small class="number change-up">+0.36<span>&nbsp;&nbsp;</span>+3.79%</small></td><td><strong>ATH-1017 (ACT-AD)</strong> <br>Mild-to-moderate Alzheimer's disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.athira.com/athira-pharma-reports-second-quarter-2021-financial-results-and-business-update/">
                1H 2022
              </a> <div class="note">Phase 2 top-line data due 1H 2022.</div></td><td>
              37m
            </td><td>
              372.4m
            </td><td>
              255.7k
            </td><td>
              1.5m
            </td><td>
              1.06
            </td><td>
              $9.65
            </td><td>
              $9.62
            </td><td>
              February 2022
            </td><td>
              280.55m
            </td><td>
              -2.44m
            </td><td>
              115.03
            </td><td>
              271.13m
            </td><td>
              75.89m
            </td><td>
              4
            </td><td>
              32,130,833
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ANAB" class="margin-bottom-1">
                ANAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$25.65</div> <small class="number change-up">+1.42<span>&nbsp;&nbsp;</span>+5.86%</small></td><td><strong>Imsidolimab (ANB019) - (ACORN)</strong> <br>Acne
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/09/2277409/0/en/AnaptysBio-Announces-Second-Quarter-2021-Financial-Results-and-Provides-Pipeline-Updates.html">
                1H 2022
              </a> <div class="note">Phase 2 data due 1H 2022.</div></td><td>
              27m
            </td><td>
              0.7b
            </td><td>
              43.4k
            </td><td>
              221.0k
            </td><td>
              1.82
            </td><td>
              $24.54
            </td><td>
              $24.23
            </td><td>
              May 15, 2022
            </td><td>
              416.61m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              375.77m
            </td><td>
              294.64m
            </td><td>
              2
            </td><td>
              19,169,175
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CARA" class="margin-bottom-1">
                CARA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.00</div> <small class="number change-up">+0.30<span>&nbsp;&nbsp;</span>+2.19%</small></td><td><strong>KORSUVA (CR845/difelikefalin) oral</strong> <br>Chronic Liver Disease-Associated Pruritus
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-reports-second-quarter-2021-financial-results">
                1H 2022
              </a> <div class="note">Phase 2 data due 1H 2022.</div></td><td>
              50m
            </td><td>
              0.7b
            </td><td>
              1.8m
            </td><td>
              0.6m
            </td><td>
              3.45
            </td><td>
              $14.11
            </td><td>
              $13.7
            </td><td>
              January 2021
            </td><td>
              142.57m
            </td><td>
              -7.00m
            </td><td>
              20.36
            </td><td>
              124.59m
            </td><td>
              0.54b
            </td><td>
              3.4
            </td><td>
              49,119,725
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PTGX" class="margin-bottom-1">
                PTGX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.56</div> <small class="number change-up">+0.34<span>&nbsp;&nbsp;</span>+0.70%</small></td><td><strong>PN-232</strong> <br>Healthy volunteers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.protagonist-inc.com/static-files/34c105ef-485b-422c-9352-52dc1cf9a177">
                2Q 2022
              </a> <div class="note">Phase 1 trial to be completed 2Q 2022.</div></td><td>
              48m
            </td><td>
              2.4b
            </td><td>
              161.0k
            </td><td>
              453.6k
            </td><td>
              6.59
            </td><td>
              $49.6
            </td><td>
              $49.22
            </td><td>
              December 2021
            </td><td>
              340.06m
            </td><td>
              -7.90m
            </td><td>
              43.05
            </td><td>
              293.28m
            </td><td>
              1.99b
            </td><td>
              1.5
            </td><td>
              38,115,527
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARGX" class="margin-bottom-1">
                ARGX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$330.66</div> <small class="number change-up">+16.08<span>&nbsp;&nbsp;</span>+5.11%</small></td><td><strong>Efgartigimod (ADAPTsc)</strong> <br>Generalized Myasthenia Gravis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/07/29/2270853/0/en/argenx-Reports-Half-Year-2021-Financial-Results-and-Provides-Second-Quarter-Business-Update.html">
                1H 2022
              </a> <div class="note">Phase 3 data due 1H 2022</div></td><td>
              51m
            </td><td>
              17.0b
            </td><td>
              127.0k
            </td><td>
              127.5k
            </td><td>
              5.76
            </td><td>
              $322.62
            </td><td>
              $314.58
            </td><td>
              September 10, 2021
            </td><td>
              2.73b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              2.47b
            </td><td>
              13.42b
            </td><td>
              0
            </td><td>
              51,398,663
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ZLAB" class="margin-bottom-1">
                ZLAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$143.17</div> <small class="number change-up">+9.00<span>&nbsp;&nbsp;</span>+6.71%</small></td><td><strong>Efgartigimod (ADAPTsc)</strong> <br>Generalized Myasthenia Gravis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/07/29/2270853/0/en/argenx-Reports-Half-Year-2021-Financial-Results-and-Provides-Second-Quarter-Business-Update.html">
                1H 2022
              </a> <div class="note">Phase 3 data due 1H 2022</div></td><td>
              75m
            </td><td>
              10.8b
            </td><td>
              320.4k
            </td><td>
              0.6m
            </td><td>
              33.30
            </td><td>
              $135
            </td><td>
              $134.17
            </td><td>
              September 10, 2021
            </td><td>
              1.73b
            </td><td>
              -21.95m
            </td><td>
              78.68
            </td><td>
              1.50b
            </td><td>
              1.78b
            </td><td>
              0
            </td><td>
              75,375,511
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PASG" class="margin-bottom-1">
                PASG
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$11.37</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+0.53%</small></td><td><strong>PBFT02</strong> <br>Frontotemporal dementia
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2021/Passage-Bio-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Recent-Business-Highlights/default.aspx">
                1H 2022
              </a> <div class="note">Phase 1/2 trial to be initiated 3Q 2021 with initial data due 1H 2022.</div></td><td>
              54m
            </td><td>
              0.6b
            </td><td>
              159.0k
            </td><td>
              365.3k
            </td><td>
              1.53
            </td><td>
              $11.32
            </td><td>
              $11.31
            </td><td>
              N/A
            </td><td>
              393.20m
            </td><td>
              -8.11m
            </td><td>
              48.48
            </td><td>
              355.95m
            </td><td>
              204.00m
            </td><td>
              3.1
            </td><td>
              36,863,189
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>IMFINZI (durvalumab)</strong> <br>Cervical cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2021/h1-2021/H1_2021_results_clinical_trials_appendix.pdf">
                1H 2022
              </a> <div class="note">Phase 3 data due 1H 2022.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              October 27, 2022
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FHTX" class="margin-bottom-1">
                FHTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$11.00</div> <small class="number change-up">+0.67<span>&nbsp;&nbsp;</span>+6.49%</small></td><td><strong>FHD-609</strong> <br>Synovial sarcoma 
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/23/2284714/0/en/Foghorn-Therapeutics-Announces-First-Patient-Dosed-in-First-in-Human-Clinical-Trial-of-FHD-609.html">
                1H 2022
              </a> <div class="note">Phase 1 data due 1H 2022. Dosing commencement announced August 23, 2021.</div></td><td>
              37m
            </td><td>
              406.3m
            </td><td>
              49.1k
            </td><td>
              127.2k
            </td><td>
              3.90
            </td><td>
              $10.48
            </td><td>
              $10.33
            </td><td>
              December 21, 2024
            </td><td>
              130.18m
            </td><td>
              -6.16m
            </td><td>
              21.13
            </td><td>
              25.85m
            </td><td>
              322.06m
            </td><td>
              13.5
            </td><td>
              19,491,155
            </td><td>
              08/23/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/QLGN" class="margin-bottom-1">
                QLGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.26</div> <small class="number change-up">+0.08<span>&nbsp;&nbsp;</span>+6.93%</small></td><td><strong>QN-165 (AS1411)</strong> <br>COVID-19
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://d1io3yog0oux5.cloudfront.net/_4fb26530ed94ed125683ad636bb42258/qualigeninc/db/865/7478/pdf/Qualigen+Therapeutics_Corporate+Deck_August.pdf">
                1H 2022
              </a> <div class="note">Phase 1/2 trial to commence 4Q 2021. Interim data due 1H 2022.</div></td><td>
              29m
            </td><td>
              36.6m
            </td><td>
              333.3k
            </td><td>
              352.5k
            </td><td>
              3.00
            </td><td>
              $1.16
            </td><td>
              $1.18
            </td><td>
              N/A
            </td><td>
              11.21m
            </td><td>
              -2.23m
            </td><td>
              5.02
            </td><td>
              3.58m
            </td><td>
              19.36m
            </td><td>
              0.8
            </td><td>
              28,767,834
            </td><td>
              08/17/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AUTL" class="margin-bottom-1">
                AUTL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.17</div> <small class="number change-up">+0.53<span>&nbsp;&nbsp;</span>+9.40%</small></td><td><strong>AUTO4</strong> <br>T-cell lymphoma
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-reports-second-quarter-2021-financial">
                1H 2022
              </a> <div class="note">Phase 1 interim data due 1H 2022.</div></td><td>
              73m
            </td><td>
              448.8m
            </td><td>
              404.8k
            </td><td>
              1.9m
            </td><td>
              1.58
            </td><td>
              $5.81
            </td><td>
              $5.64
            </td><td>
              June 2022
            </td><td>
              194.39m
            </td><td>
              -12.20m
            </td><td>
              15.93
            </td><td>
              147.41m
            </td><td>
              216.60m
            </td><td>
              0
            </td><td>
              72,742,582
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ACHV" class="margin-bottom-1">
                ACHV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.13</div> <small class="number change-up">+0.22<span>&nbsp;&nbsp;</span>+3.16%</small></td><td><strong>Cytisine - ORCA-2</strong> <br>Smoking cessation
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.benzinga.com/pressreleases/21/08/ac22453220/achieve-reports-financial-results-for-second-quarter-2021-and-provides-corporate-update">
                1H 2022
              </a> <div class="note">Phase 3 data due 1H 2022.</div></td><td>
              9m
            </td><td>
              67.4m
            </td><td>
              106.3k
            </td><td>
              264.1k
            </td><td>
              1.65
            </td><td>
              $6.99
            </td><td>
              $6.91
            </td><td>
              December 31, 2021
            </td><td>
              36.56m
            </td><td>
              -3.03m
            </td><td>
              12.08
            </td><td>
              31.84m
            </td><td>
              23.42m
            </td><td>
              9.1
            </td><td>
              9,434,389
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MDWD" class="margin-bottom-1">
                MDWD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.55</div> <small class="number change-up">+0.02<span>&nbsp;&nbsp;</span>+0.57%</small></td><td><strong>EscharEx</strong> <br>Venous leg ulcers (VLU’s)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.mediwound.com/news-releases/news-release-details/mediwound-reports-second-quarter-financial-results">
                1H 2022
              </a> <div class="note">Phase 2 trial to continue as planned as per Independent Data Monitoring Committee’s (IDMC) recommendation - July 28, 2021. Data due 1H 2022.</div></td><td>
              27m
            </td><td>
              96.7m
            </td><td>
              44.3k
            </td><td>
              0.5m
            </td><td>
              44.38
            </td><td>
              $3.54
            </td><td>
              $3.53
            </td><td>
              August 2021
            </td><td>
              16.40m
            </td><td>
              -328.33k
            </td><td>
              49.96
            </td><td>
              -7.68m
            </td><td>
              80.79m
            </td><td>
              0
            </td><td>
              15,908,179
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TRVI" class="margin-bottom-1">
                TRVI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.71</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+3.64%</small></td><td><strong>Haduvio - PRISM</strong> <br>Prurigo Nodularis
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-second-quarter-2021-financial-results-and-business-update-301354473.html">
                1H 2022
              </a> <div class="note">Phase 2b/3 top-line data due 1H 2022.</div></td><td>
              22m
            </td><td>
              36.9m
            </td><td>
              36.6k
            </td><td>
              76.8k
            </td><td>
              2.08
            </td><td>
              $1.71
            </td><td>
              $1.65
            </td><td>
              December 2021
            </td><td>
              31.69m
            </td><td>
              -2.63m
            </td><td>
              12.04
            </td><td>
              10.27m
            </td><td>
              13.66m
            </td><td>
              4.5
            </td><td>
              4,109,742
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TRVI" class="margin-bottom-1">
                TRVI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.71</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+3.64%</small></td><td><strong>Haduvio (CANAL)</strong> <br>Chronic cough - Idiopathic pulmonary fibrosis (IPF)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-second-quarter-2021-financial-results-and-business-update-301354473.html">
                1H 2022
              </a> <div class="note">Phase 2 data due 1H 2022.</div></td><td>
              22m
            </td><td>
              36.9m
            </td><td>
              36.6k
            </td><td>
              76.8k
            </td><td>
              2.08
            </td><td>
              $1.71
            </td><td>
              $1.65
            </td><td>
              October 2021
            </td><td>
              31.69m
            </td><td>
              -2.63m
            </td><td>
              12.04
            </td><td>
              10.27m
            </td><td>
              13.66m
            </td><td>
              4.5
            </td><td>
              4,109,742
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ENTA" class="margin-bottom-1">
                ENTA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$53.22</div> <small class="number change-up">+1.90<span>&nbsp;&nbsp;</span>+3.69%</small></td><td><strong>EDP-721</strong> <br>Hepatitis B
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210816005078/en/">
                1H 2022
              </a> <div class="note">Phase 1 commencement of dosing announced August 16, 2021. Data due 1H 2022.</div></td><td>
              20m
            </td><td>
              1.1b
            </td><td>
              67.3k
            </td><td>
              171.6k
            </td><td>
              2.58
            </td><td>
              $51.88
            </td><td>
              $51.32
            </td><td>
              August 2023
            </td><td>
              239.12m
            </td><td>
              -9.84m
            </td><td>
              24.31
            </td><td>
              206.53m
            </td><td>
              0.79b
            </td><td>
              5.9
            </td><td>
              15,917,284
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GOSS" class="margin-bottom-1">
                GOSS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.27</div> <small class="number change-up">+0.40<span>&nbsp;&nbsp;</span>+4.51%</small></td><td><strong>Seralutinib (GB002) - (TORREY)</strong> <br>Pulmonary arterial hypertension (PAH)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005711/en/">
                1H 2022
              </a> <div class="note">Phase 1b data to be presented September 5, 2021. Phase 2 (TORREY) top-line data due 1H 2022.</div></td><td>
              76m
            </td><td>
              0.7b
            </td><td>
              148.5k
            </td><td>
              0.5m
            </td><td>
              3.20
            </td><td>
              $8.96
            </td><td>
              $8.87
            </td><td>
              March 2022
            </td><td>
              377.45m
            </td><td>
              -15.82m
            </td><td>
              23.86
            </td><td>
              165.63m
            </td><td>
              453.38m
            </td><td>
              2.2
            </td><td>
              63,837,740
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NCNA" class="margin-bottom-1">
                NCNA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.18</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+11.79%</small></td><td><strong>NUC-1031 (NuTide:121)</strong> <br>Front-Line Treatment of Advanced Biliary Tract Cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/19/2283856/0/en/NuCana-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Business-Update.html">
                1H 2022
              </a> <div class="note">Phase 3 enrollment to be completed 2021. Interim analysis due 1H 2022.</div></td><td>
              52m
            </td><td>
              113.7m
            </td><td>
              0.5m
            </td><td>
              473.6k
            </td><td>
              0.90
            </td><td>
              $2.02
            </td><td>
              $1.95
            </td><td>
              December 2023
            </td><td>
              65.62m
            </td><td>
              -2.69m
            </td><td>
              24.38
            </td><td>
              56.21m
            </td><td>
              -4.66m
            </td><td>
              0
            </td><td>
              52,162,000
            </td><td>
              08/19/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ADXS" class="margin-bottom-1">
                ADXS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.42</div> <small class="number change-up">+0.02<span>&nbsp;&nbsp;</span>+4.34%</small></td><td><strong>ADXS-504</strong> <br>Prostate Cancer
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.advaxis.com/static-files/ce3c0581-dd99-47fc-bde5-7cf0dbadd5b7">
                1H 2022
              </a> <div class="note">Phase 1 trial initiation announced July 15, 2021 with initial data due 1H 2022.</div></td><td>
              146m
            </td><td>
              60.6m
            </td><td>
              1.3m
            </td><td>
              7.0m
            </td><td>
              1.26
            </td><td>
              $0.4
            </td><td>
              $0.4
            </td><td>
              N/A
            </td><td>
              40.30m
            </td><td>
              -2.04m
            </td><td>
              19.77
            </td><td>
              32.08m
            </td><td>
              9.97m
            </td><td>
              3
            </td><td>
              145,579,134
            </td><td>
              07/15/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/XCUR" class="margin-bottom-1">
                XCUR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.22</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+5.65%</small></td><td><strong>Cavrotolimod</strong> <br>Merkel cell carcinoma / Cutaneous squamous cell carcinoma
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210812005197/en/">
                1H 2022
              </a> <div class="note">Phase 1b/2 interim data noted overall response rate (ORR) of 21% in all evaluable MCC patients - August 5, 2021. Phase 2 ORR data due 1H 2022.</div></td><td>
              88m
            </td><td>
              107.1m
            </td><td>
              239.3k
            </td><td>
              3.1m
            </td><td>
              2.89
            </td><td>
              $1.18
            </td><td>
              $1.15
            </td><td>
              June 30, 2022
            </td><td>
              49.41m
            </td><td>
              -3.69m
            </td><td>
              13.38
            </td><td>
              11.59m
            </td><td>
              70.11m
            </td><td>
              3.1
            </td><td>
              67,467,886
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VSTM" class="margin-bottom-1">
                VSTM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.67</div> <small class="number change-up">+0.12<span>&nbsp;&nbsp;</span>+4.49%</small></td><td><strong>VS-6766 and defactinib (RAMP 202)</strong> <br>KRAS mutant non-small cell lung cancer (NSCLC).
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210802005716/en/">
                1H 2022
              </a> <div class="note">Phase 2 top-line data due 1H 2022.</div></td><td>
              181m
            </td><td>
              483.5m
            </td><td>
              0.9m
            </td><td>
              2.0m
            </td><td>
              5.46
            </td><td>
              $2.58
            </td><td>
              $2.56
            </td><td>
              March 2023
            </td><td>
              100.08m
            </td><td>
              -4.47m
            </td><td>
              22.37
            </td><td>
              64.40m
            </td><td>
              378.16m
            </td><td>
              2.3
            </td><td>
              179,887,236
            </td><td>
              08/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLBS" class="margin-bottom-1">
                CLBS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.21</div> <small class="number change-up">+0.05<span>&nbsp;&nbsp;</span>+4.17%</small></td><td><strong>CLBS201</strong> <br>Pre-dialysis chronic kidney disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.caladrius.com/news-releases/news-release-details/caladrius-biosciences-reports-second-quarter-2021-financial">
                2Q 2022
              </a> <div class="note">Phase 2 trial to be initiated 2H 2021 with safety data 2Q 2022.</div></td><td>
              60m
            </td><td>
              71.9m
            </td><td>
              208.5k
            </td><td>
              414.3k
            </td><td>
              0.69
            </td><td>
              $1.17
            </td><td>
              $1.16
            </td><td>
              N/A
            </td><td>
              103.31m
            </td><td>
              -1.54m
            </td><td>
              66.99
            </td><td>
              99.38m
            </td><td>
              -36.60m
            </td><td>
              14.8
            </td><td>
              58,839,648
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VRNA" class="margin-bottom-1">
                VRNA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.70</div> <small class="number change-up">+0.11<span>&nbsp;&nbsp;</span>+1.97%</small></td><td><strong>Ensifentrine (RPL554) - (ENHANCE-1 and ENHANCE-2)</strong> <br>Chronic obstructive pulmonary disease (COPD)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.veronapharma.com/media/verona-pharma-reports-second-quarter-2021-financial-results-and">
                1H &amp; 2H 2022
              </a> <div class="note">Phase 3 ENHANCE-1 data due 2H 2022 and ENHANCE-2 data due 1H 2022.</div></td><td>
              60m
            </td><td>
              342.2m
            </td><td>
              41.9k
            </td><td>
              75.9k
            </td><td>
              2.22
            </td><td>
              $5.56
            </td><td>
              $5.59
            </td><td>
              July 2022
            </td><td>
              133.91m
            </td><td>
              -6.73m
            </td><td>
              19.88
            </td><td>
              69.81m
            </td><td>
              196.06m
            </td><td>
              9.1
            </td><td>
              17,804,811
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LGND" class="margin-bottom-1">
                LGND
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$113.41</div> <small class="number change-up">+9.31<span>&nbsp;&nbsp;</span>+8.95%</small></td><td><strong>Ensifentrine (RPL554) - (ENHANCE-1 and ENHANCE-2)</strong> <br>Chronic obstructive pulmonary disease (COPD)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.veronapharma.com/media/verona-pharma-reports-second-quarter-2021-financial-results-and">
                1H &amp; 2H 2022
              </a> <div class="note">Phase 3 ENHANCE-1 data due 2H 2022 and ENHANCE-2 data due 1H 2022.</div></td><td>
              17m
            </td><td>
              1.9b
            </td><td>
              171.1k
            </td><td>
              158.2k
            </td><td>
              2.40
            </td><td>
              $105.02
            </td><td>
              $104.1
            </td><td>
              July 2022
            </td><td>
              314.06m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -155.70m
            </td><td>
              1.76b
            </td><td>
              10.4
            </td><td>
              11,870,842
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FUSN" class="margin-bottom-1">
                FUSN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.14</div> <small class="number change-down">-0.20<span>&nbsp;&nbsp;</span>-2.40%</small></td><td><strong>FPI-1434</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-announces-second-quarter-2021-financial-results-and-business-update-301351413.html">
                1H 2022
              </a> <div class="note">Phase 1 multi-dose safety and imaging data due 1H 2022.</div></td><td>
              43m
            </td><td>
              350.2m
            </td><td>
              186.0k
            </td><td>
              80.5k
            </td><td>
              1.33
            </td><td>
              $8.13
            </td><td>
              $8.34
            </td><td>
              April 2022
            </td><td>
              168.13m
            </td><td>
              -5.77m
            </td><td>
              29.14
            </td><td>
              149.53m
            </td><td>
              187.61m
            </td><td>
              0
            </td><td>
              42,433,573
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NKTR" class="margin-bottom-1">
                NKTR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.89</div> <small class="number change-up">+0.28<span>&nbsp;&nbsp;</span>+2.06%</small></td><td><strong>Bempegaldesleukin (NKTR-214) and OPDIVO (nivolumab)</strong> <br>Renal Cell Carcinoma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.nektar.com/static-files/300e2cc1-6dc0-4ba7-b615-959b07e779c2">
                1H 2022
              </a> <div class="note">Phase 3 interim overall survival data due 1H 2022.</div></td><td>
              184m
            </td><td>
              2.6b
            </td><td>
              287.9k
            </td><td>
              0.8m
            </td><td>
              2.82
            </td><td>
              $13.74
            </td><td>
              $13.61
            </td><td>
              December 2021
            </td><td>
              0.95b
            </td><td>
              -27.63m
            </td><td>
              34.39
            </td><td>
              483.95m
            </td><td>
              1.65b
            </td><td>
              2.1
            </td><td>
              91,286,217
            </td><td>
              05/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/HSTO" class="margin-bottom-1">
                HSTO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.79</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+1.56%</small></td><td><strong>HST-003</strong> <br>Knee Cartilage Regeneration
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.benzinga.com/pressreleases/21/08/g22453160/histogen-reports-second-quarter-2021-earnings-and-provides-business-update">
                2Q 2022
              </a> <div class="note">Phase 1/2 top-line data due 2Q 2022.</div></td><td>
              42m
            </td><td>
              32.8m
            </td><td>
              137.4k
            </td><td>
              2.1m
            </td><td>
              1.31
            </td><td>
              $0.77
            </td><td>
              $0.77
            </td><td>
              N/A
            </td><td>
              20.55m
            </td><td>
              -1.44m
            </td><td>
              14.29
            </td><td>
              13.71m
            </td><td>
              13.72m
            </td><td>
              0.1
            </td><td>
              38,843,394
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KZR" class="margin-bottom-1">
                KZR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.96</div> <small class="number change-up">+0.52<span>&nbsp;&nbsp;</span>+9.45%</small></td><td><strong>KZR-616 - (PRESIDIO)</strong> <br>Dermatomyositis and polymyositis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210823005119/en/">
                2Q 2022
              </a> <div class="note">Phase 2 enrollment completed August 23, 2021. Phase 2 top-line data due 2Q 2022.</div></td><td>
              48m
            </td><td>
              287.5m
            </td><td>
              95.1k
            </td><td>
              191.6k
            </td><td>
              2.21
            </td><td>
              $5.41
            </td><td>
              $5.45
            </td><td>
              February 2022
            </td><td>
              121.15m
            </td><td>
              -4.35m
            </td><td>
              27.86
            </td><td>
              111.36m
            </td><td>
              138.64m
            </td><td>
              3.3
            </td><td>
              40,132,157
            </td><td>
              08/23/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MRTX" class="margin-bottom-1">
                MRTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$145.25</div> <small class="number change-up">+11.12<span>&nbsp;&nbsp;</span>+8.29%</small></td><td><strong>Adagrasib (MRTX849) plus TNO155 SHP2 inhibitor - KRYSTAL 2</strong> <br>Non-Small Cell Lung Cancer / Colorectal Cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s27.q4cdn.com/140416303/files/doc_presentation/2021/MRTX-Corporate-Presentation_6May2021.pdf">
                1H 2022
              </a> <div class="note">Phase 1/2 initial data due 1H 2022.</div></td><td>
              52m
            </td><td>
              7.5b
            </td><td>
              181.2k
            </td><td>
              466.1k
            </td><td>
              6.64
            </td><td>
              $135.44
            </td><td>
              $134.13
            </td><td>
              September 2022
            </td><td>
              1.14b
            </td><td>
              -31.12m
            </td><td>
              36.65
            </td><td>
              0.91b
            </td><td>
              5.77b
            </td><td>
              0.9
            </td><td>
              40,808,627
            </td><td>
              05/07/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLSN" class="margin-bottom-1">
                CLSN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.01</div> <small class="number change-up">+0.04<span>&nbsp;&nbsp;</span>+4.54%</small></td><td><strong>GEN-1 OVATION 2</strong> <br>Ovarian cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.celsion.com/static-files/70e45734-e80b-41dd-b6af-e19f435f46c0">
                2Q 2022
              </a> <div class="note">Phase 2 overall response rate (ORR) data due 2Q 2022. PFS data due 2Q 2023.</div></td><td>
              87m
            </td><td>
              87.4m
            </td><td>
              421.7k
            </td><td>
              1.4m
            </td><td>
              1.36
            </td><td>
              $0.97
            </td><td>
              $0.97
            </td><td>
              February 28, 2023
            </td><td>
              56.79m
            </td><td>
              -0.87m
            </td><td>
              65.22
            </td><td>
              37.84m
            </td><td>
              31.97m
            </td><td>
              7.4
            </td><td>
              86,090,872
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLVS" class="margin-bottom-1">
                CLVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.50</div> <small class="number change-up">+0.26<span>&nbsp;&nbsp;</span>+6.01%</small></td><td><strong>RUBRACA (rucaparib) - (TRITON3)</strong> <br>Castration Resistant Prostate Cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210804005226/en/">
                2Q 2022
              </a> <div class="note">Phase 3 data due 2Q 2022.</div></td><td>
              118m
            </td><td>
              0.5b
            </td><td>
              2.3m
            </td><td>
              4.5m
            </td><td>
              -2.57
            </td><td>
              $4.27
            </td><td>
              $4.24
            </td><td>
              February 2022
            </td><td>
              202.15m
            </td><td>
              -15.58m
            </td><td>
              12.97
            </td><td>
              -0.58b
            </td><td>
              0.94b
            </td><td>
              1.8
            </td><td>
              115,771,254
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PFE" class="margin-bottom-1">
                PFE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.98</div> <small class="number change-up">+1.25<span>&nbsp;&nbsp;</span>+2.58%</small></td><td><strong>VLA15-221</strong> <br>Lyme disease vaccine
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/ee183fec-7e21-4b2d-b370-d3730ad4c4cb">
                1H 2022
              </a> <div class="note">Phase 2 top-line data due 1H 2022.</div></td><td>
              6b
            </td><td>
              280.2b
            </td><td>
              69.5m
            </td><td>
              30.1m
            </td><td>
              4.00
            </td><td>
              $50.29
            </td><td>
              $48.72
            </td><td>
              February 2023
            </td><td>
              28.48b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -71.13b
            </td><td>
              289.19b
            </td><td>
              0.3
            </td><td>
              5,605,213,314
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VALN" class="margin-bottom-1">
                VALN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.43</div> <small class="number change-up">+1.42<span>&nbsp;&nbsp;</span>+4.89%</small></td><td><strong>VLA15-221</strong> <br>Lyme disease vaccine
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/ee183fec-7e21-4b2d-b370-d3730ad4c4cb">
                1H 2022
              </a> <div class="note">Phase 2 top-line data due 1H 2022.</div></td><td>
              50m
            </td><td>
              1.5b
            </td><td>
              14.3k
            </td><td>
              8.1k
            </td><td>
              24.74
            </td><td>
              $30.62
            </td><td>
              $29.01
            </td><td>
              February 2023
            </td><td>
              312.54m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -209.22m
            </td><td>
              1.28b
            </td><td>
              0
            </td><td>
              49,890,295
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SPRB" class="margin-bottom-1">
                SPRB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.34</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+1.83%</small></td><td><strong>Tildacerfont - CAHmelia-203</strong> <br>Congenital Adrenal Hyperplasia (poor disease control)
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210810005900/en/">
                1H 2022
              </a> <div class="note">Phase 2b data due 1H 2022.</div></td><td>
              23m
            </td><td>
              195.0m
            </td><td>
              3.3k
            </td><td>
              67.9k
            </td><td>
              1.50
            </td><td>
              $8.33
            </td><td>
              $8.19
            </td><td>
              December 2021
            </td><td>
              103.41m
            </td><td>
              -3.23m
            </td><td>
              32.00
            </td><td>
              90.06m
            </td><td>
              88.91m
            </td><td>
              0
            </td><td>
              17,692,276
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PRAX" class="margin-bottom-1">
                PRAX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$19.40</div> <small class="number change-up">+0.64<span>&nbsp;&nbsp;</span>+3.41%</small></td><td><strong>PRAX-114 (Study 214)</strong> <br>Major depressive disorder
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-1">
                1H 2022
              </a> <div class="note">Phase 2 top-line data due 1H 2022.</div></td><td>
              45m
            </td><td>
              0.9b
            </td><td>
              0.6m
            </td><td>
              294.3k
            </td><td>
              2.60
            </td><td>
              $18.55
            </td><td>
              $18.76
            </td><td>
              April 2022
            </td><td>
              321.18m
            </td><td>
              -10.00m
            </td><td>
              32.10
            </td><td>
              301.44m
            </td><td>
              0.50b
            </td><td>
              1.8
            </td><td>
              29,027,417
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ELYM" class="margin-bottom-1">
                ELYM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$19.75</div> <small class="number change-up">+1.66<span>&nbsp;&nbsp;</span>+9.18%</small></td><td><strong>ETX-810</strong> <br>Diabetic peripheral neuropathic pain (DPNP) 
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1768446/000119312521217529/d105292ds1.htm">
                1H 2022
              </a> <div class="note">Phase 2a data due 1H 2022.</div></td><td>
              26m
            </td><td>
              0.5b
            </td><td>
              162.5k
            </td><td>
              
            </td><td>
              -12.04
            </td><td>
              $18.41
            </td><td>
              $18.09
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              0.52b
            </td><td>
              0
            </td><td>
              7,979,877
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ELDN" class="margin-bottom-1">
                ELDN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.51</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+0.15%</small></td><td><strong>AT-1501</strong> <br>Type 1 diabetes (islet cell transplantation)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-reports-second-quarter-2021-operating-and">
                1H 2022
              </a> <div class="note">Phase 2 interim data due 1H 2022.</div></td><td>
              14m
            </td><td>
              93.1m
            </td><td>
              48.0k
            </td><td>
              73.1k
            </td><td>
              0.52
            </td><td>
              $6.47
            </td><td>
              $6.5
            </td><td>
              N/A
            </td><td>
              96.67m
            </td><td>
              -2.48m
            </td><td>
              38.95
            </td><td>
              90.88m
            </td><td>
              -7.87m
            </td><td>
              6.5
            </td><td>
              14,305,606
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ELYM" class="margin-bottom-1">
                ELYM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$19.75</div> <small class="number change-up">+1.66<span>&nbsp;&nbsp;</span>+9.18%</small></td><td><strong>ETX-810</strong> <br>Lumbosacral radiculopathy (sciatica)
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1768446/000119312521217529/d105292ds1.htm">
                1H 2022
              </a> <div class="note">Phase 2a data due 1H 2022.</div></td><td>
              26m
            </td><td>
              0.5b
            </td><td>
              162.5k
            </td><td>
              
            </td><td>
              -12.04
            </td><td>
              $18.41
            </td><td>
              $18.09
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              0.52b
            </td><td>
              0
            </td><td>
              7,979,877
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PLX" class="margin-bottom-1">
                PLX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.32</div> <small class="number change-down">-0.02<span>&nbsp;&nbsp;</span>-1.49%</small></td><td><strong>Pegunigalsidase alfa  (PRX-102) - BALANCE</strong> <br>Fabry disease
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-and-chiesi-global-rare-diseases-provide-update-regarding-clinical-development-of-prx-102-for-treatment-of-fabry-disease-301303773.html">
                2Q 2022
              </a> <div class="note">Phase 3 interim data released June 2, 2021. Change in eGFR was below pre-specified non-inferiority margin in the ITT (intend to treat) group when compared with Fabrazyme. Final data due 2Q 2022. MAA filing due.</div></td><td>
              46m
            </td><td>
              60.1m
            </td><td>
              0.7m
            </td><td>
              1.4m
            </td><td>
              16.50
            </td><td>
              $1.34
            </td><td>
              $1.34
            </td><td>
              October 2021
            </td><td>
              80.85m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -23.51m
            </td><td>
              46.20m
            </td><td>
              10
            </td><td>
              39,987,633
            </td><td>
              06/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MNPR" class="margin-bottom-1">
                MNPR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.97</div> <small class="number change-up">+0.28<span>&nbsp;&nbsp;</span>+6.07%</small></td><td><strong>Validive (VOICE)</strong> <br>Oral mucositis
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.monopartx.com/press-releases/detail/41/monopar-therapeutics-reports-second-quarter-2021-financial">
                1H 2022
              </a> <div class="note">Phase 2b/3 interim analysis due 1H 2022.</div></td><td>
              11m
            </td><td>
              53.4m
            </td><td>
              5.6k
            </td><td>
              37.0k
            </td><td>
              11.30
            </td><td>
              $4.66
            </td><td>
              $4.69
            </td><td>
              July 2023
            </td><td>
              23.45m
            </td><td>
              -468.71k
            </td><td>
              50.03
            </td><td>
              22.35m
            </td><td>
              92.54m
            </td><td>
              0.2
            </td><td>
              2,942,460
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ANEB" class="margin-bottom-1">
                ANEB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.84</div> <small class="number change-down">-0.23<span>&nbsp;&nbsp;</span>-3.23%</small></td><td><strong>Anebulo</strong> <br>Cannabinoid overdose
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210621005727/en/">
                1H 2022
              </a> <div class="note">Phase 2 trial to commence 4Q 2021 with top-line data due 1H 2022.</div></td><td>
              23m
            </td><td>
              159.7m
            </td><td>
              4.5k
            </td><td>
              8.7k
            </td><td>
              
            </td><td>
              $6.92
            </td><td>
              $7.07
            </td><td>
              N/A
            </td><td>
              1.34m
            </td><td>
              -407.21k
            </td><td>
              3.29
            </td><td>
              -12.39m
            </td><td>
              162.73m
            </td><td>
              55.6
            </td><td>
              4,256,680
            </td><td>
              06/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ELYM" class="margin-bottom-1">
                ELYM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$19.75</div> <small class="number change-up">+1.66<span>&nbsp;&nbsp;</span>+9.18%</small></td><td><strong>ETX-155</strong> <br>Focal onset seizures (FOS)
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1768446/000119312521217529/d105292ds1.htm">
                1H 2022
              </a> <div class="note">Phase 1b trial to be initiated with top-line data due 1H 2022.</div></td><td>
              26m
            </td><td>
              0.5b
            </td><td>
              162.5k
            </td><td>
              
            </td><td>
              -12.04
            </td><td>
              $18.41
            </td><td>
              $18.09
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              0.52b
            </td><td>
              0
            </td><td>
              7,979,877
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AXGN" class="margin-bottom-1">
                AXGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.19</div> <small class="number change-up">+0.64<span>&nbsp;&nbsp;</span>+4.12%</small></td><td><strong>Avance Nerve Graf ( RECON )</strong> <br>Severed peripheral nerves
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://d1io3yog0oux5.cloudfront.net/_74d7622d235a6e88bfa69d89d51a24ae/axogeninc/db/338/8750/pdf/Q2+2021+Corporate+Presentation+FINAL.pdf">
                2022
              </a> <div class="note">Phase 3 preliminary report of trial data due 2Q 2022.</div></td><td>
              41m
            </td><td>
              0.7b
            </td><td>
              67.7k
            </td><td>
              159.4k
            </td><td>
              5.64
            </td><td>
              $15.76
            </td><td>
              $15.55
            </td><td>
              N/A
            </td><td>
              99.50m
            </td><td>
              -231.67k
            </td><td>
              429.50
            </td><td>
              7.67m
            </td><td>
              0.61b
            </td><td>
              8.5
            </td><td>
              33,568,640
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ADGI" class="margin-bottom-1">
                ADGI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.41</div> <small class="number change-up">+1.77<span>&nbsp;&nbsp;</span>+6.40%</small></td><td><strong>ADG20 (EVADE)</strong> <br>COVID-19 (prevention)
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1832038/000119312521217506/d549501ds1.htm">
                1H 2022
              </a> <div class="note">Phase 2/3 trial has been initiated. Interim futility analysis due 1H 2022 with top-line data 2H 2022.</div></td><td>
              109m
            </td><td>
              3.2b
            </td><td>
              306.9k
            </td><td>
              
            </td><td>
              
            </td><td>
              $27.91
            </td><td>
              $27.64
            </td><td>
              July 2022
            </td><td>
              53.00m
            </td><td>
              -7.91m
            </td><td>
              6.70
            </td><td>
              24.31m
            </td><td>
              2.70b
            </td><td>
              0
            </td><td>
              61,281,030
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MITO" class="margin-bottom-1">
                MITO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.15</div> <small class="number change-down">-0.02<span>&nbsp;&nbsp;</span>-1.71%</small></td><td><strong>Elamipretide (ReCLAIM-2)</strong> <br>Geographic atrophy / Age-related macular degeneration (AMD)
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/stealth-biotherapeutics-reports-second-quarter-2021-financial-results-and-recent-business-highlights-301348928.html">
                2Q 2022
              </a> <div class="note">Phase 2b top-line data due 2Q 2022.</div></td><td>
              58m
            </td><td>
              66.2m
            </td><td>
              293.4k
            </td><td>
              269.5k
            </td><td>
              -2.50
            </td><td>
              $1.18
            </td><td>
              $1.17
            </td><td>
              March 2022
            </td><td>
              30.77m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -27.81m
            </td><td>
              42.06m
            </td><td>
              0
            </td><td>
              57,582,815
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SYRS" class="margin-bottom-1">
                SYRS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.71</div> <small class="number change-up">+0.48<span>&nbsp;&nbsp;</span>+11.35%</small></td><td><strong>SY-2101</strong> <br>Acute promyelocytic leukemia (APL)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005278/en/">
                1H 2022
              </a> <div class="note">Dose confirmation trial to be initiated 2H 2021 with data due 1H 2022. Phase 3 trial to be initiated in 2022.</div></td><td>
              62m
            </td><td>
              291.7m
            </td><td>
              363.2k
            </td><td>
              0.8m
            </td><td>
              2.24
            </td><td>
              $4.3
            </td><td>
              $4.23
            </td><td>
              N/A
            </td><td>
              166.16m
            </td><td>
              -8.82m
            </td><td>
              18.84
            </td><td>
              62.40m
            </td><td>
              145.66m
            </td><td>
              2.3
            </td><td>
              41,620,615
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALGS" class="margin-bottom-1">
                ALGS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.14</div> <small class="number change-up">+0.98<span>&nbsp;&nbsp;</span>+6.46%</small></td><td><strong>ALG-010133</strong> <br>Hepatitis B
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/05/2275982/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-Second-Quarter-2021-Financial-Results.html">
                1H 2022
              </a> <div class="note">Phase 1 data from the three cohorts are due 1H 2022.</div></td><td>
              43m
            </td><td>
              0.7b
            </td><td>
              68.7k
            </td><td>
              301.5k
            </td><td>
              4.08
            </td><td>
              $15.33
            </td><td>
              $15.16
            </td><td>
              August 1, 2022
            </td><td>
              176.84m
            </td><td>
              -7.67m
            </td><td>
              23.05
            </td><td>
              133.85m
            </td><td>
              467.82m
            </td><td>
              7.4
            </td><td>
              19,123,908
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PRAX" class="margin-bottom-1">
                PRAX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$19.40</div> <small class="number change-up">+0.64<span>&nbsp;&nbsp;</span>+3.41%</small></td><td><strong>PRAX-114 Aria Study (Study 213)</strong> <br>Major Depressive Disorder
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-1">
                1H 2022
              </a> <div class="note">Phase 2/3 data due 1H 2022.</div></td><td>
              45m
            </td><td>
              0.9b
            </td><td>
              0.6m
            </td><td>
              294.3k
            </td><td>
              2.60
            </td><td>
              $18.55
            </td><td>
              $18.76
            </td><td>
              April 2022
            </td><td>
              321.18m
            </td><td>
              -10.00m
            </td><td>
              32.10
            </td><td>
              301.44m
            </td><td>
              0.50b
            </td><td>
              1.8
            </td><td>
              29,027,417
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EPIX" class="margin-bottom-1">
                EPIX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.83</div> <small class="number change-up">+0.77<span>&nbsp;&nbsp;</span>+9.55%</small></td><td><strong>EPI-7386</strong> <br>Castrate resistant prostate cancer
            </td><td>
              Phase 1a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-third-quarter-ended-june-30-2021-301355521.html">
                1H 2022
              </a> <div class="note">Phase 1a data due 1H 2022.</div></td><td>
              30m
            </td><td>
              256.1m
            </td><td>
              1.4m
            </td><td>
              0.6m
            </td><td>
              3.98
            </td><td>
              $8.37
            </td><td>
              $8.06
            </td><td>
              August 2022
            </td><td>
              198.35m
            </td><td>
              -2.17m
            </td><td>
              91.30
            </td><td>
              194.53m
            </td><td>
              51.81m
            </td><td>
              0
            </td><td>
              13,476,105
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KDNY" class="margin-bottom-1">
                KDNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.55</div> <small class="number change-up">+0.79<span>&nbsp;&nbsp;</span>+6.19%</small></td><td><strong>BION-1301</strong> <br>IgA nephropathy
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.chinooktx.com/news-releases/news-release-details/chinook-therapeutics-provides-business-update-and-reports-second">
                1H 2022
              </a> <div class="note">Phase 1/2 Cohort 2 data due 1H 2022.</div></td><td>
              45m
            </td><td>
              0.6b
            </td><td>
              306.4k
            </td><td>
              301.8k
            </td><td>
              2.05
            </td><td>
              $13.35
            </td><td>
              $12.76
            </td><td>
              June 2022
            </td><td>
              180.69m
            </td><td>
              -9.14m
            </td><td>
              19.76
            </td><td>
              69.55m
            </td><td>
              414.92m
            </td><td>
              0.2
            </td><td>
              25,691,260
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CNSP" class="margin-bottom-1">
                CNSP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.51</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+0.67%</small></td><td><strong>Berubicin</strong> <br>Glioblastoma Multiforme (GBM) 
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/cns-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides-business-outlook-301291412.html">
                1H 2022
              </a> <div class="note">Phase 2 trial to be initiated by WPD Pharmaceuticals (Poland) in 2H 2021 with interim analysis due 1H 2022.</div></td><td>
              27m
            </td><td>
              41.5m
            </td><td>
              75.5k
            </td><td>
              0.6m
            </td><td>
              3.36
            </td><td>
              $1.52
            </td><td>
              $1.5
            </td><td>
              N/A
            </td><td>
              3.89m
            </td><td>
              -1.67m
            </td><td>
              2.33
            </td><td>
              2.06m
            </td><td>
              34.48m
            </td><td>
              4.1
            </td><td>
              17,094,985
            </td><td>
              05/14/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ENTA" class="margin-bottom-1">
                ENTA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$53.22</div> <small class="number change-up">+1.90<span>&nbsp;&nbsp;</span>+3.69%</small></td><td><strong>EDP-938 (RSVP)</strong> <br>Respiratory Syncytial Virus (community-acquired)
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005808/en/">
                1H 2022
              </a> <div class="note">Phase 2b data due 1H 2022.</div></td><td>
              20m
            </td><td>
              1.1b
            </td><td>
              67.3k
            </td><td>
              171.6k
            </td><td>
              2.58
            </td><td>
              $51.88
            </td><td>
              $51.32
            </td><td>
              September 2021
            </td><td>
              239.12m
            </td><td>
              -9.84m
            </td><td>
              24.31
            </td><td>
              206.53m
            </td><td>
              0.79b
            </td><td>
              5.9
            </td><td>
              15,917,284
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/STTK" class="margin-bottom-1">
                STTK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.75</div> <small class="number change-up">+1.80<span>&nbsp;&nbsp;</span>+9.02%</small></td><td><strong>SL-172154</strong> <br>Head and Neck or Skin Squamous Cell Carcinoma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.shattucklabs.com/news-releases/news-release-details/shattuck-labs-reports-second-quarter-2021-financial-results-and">
                1H 2022
              </a> <div class="note">Phase 1 initial dose-escalation data due 1H 2022.</div></td><td>
              42m
            </td><td>
              0.9b
            </td><td>
              328.8k
            </td><td>
              184.1k
            </td><td>
              3.31
            </td><td>
              $22
            </td><td>
              $19.95
            </td><td>
              July 2022
            </td><td>
              296.19m
            </td><td>
              -4.78m
            </td><td>
              61.97
            </td><td>
              249.50m
            </td><td>
              0.54b
            </td><td>
              1.7
            </td><td>
              22,794,659
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PASG" class="margin-bottom-1">
                PASG
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$11.37</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+0.53%</small></td><td><strong>PBKR03 (GALax-C)</strong> <br>Krabbe Disease
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2021/Passage-Bio-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Recent-Business-Highlights/default.aspx">
                1H 2022
              </a> <div class="note">Phase 1/2 trial to be initiated 3Q 2021 with initial data due 1H 2022.</div></td><td>
              54m
            </td><td>
              0.6b
            </td><td>
              159.0k
            </td><td>
              365.3k
            </td><td>
              1.53
            </td><td>
              $11.32
            </td><td>
              $11.31
            </td><td>
              January 2027
            </td><td>
              393.20m
            </td><td>
              -8.11m
            </td><td>
              48.48
            </td><td>
              355.95m
            </td><td>
              204.00m
            </td><td>
              3.1
            </td><td>
              36,863,189
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INZY" class="margin-bottom-1">
                INZY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$15.91</div> <small class="number change-up">+0.43<span>&nbsp;&nbsp;</span>+2.81%</small></td><td><strong>INZ-701</strong> <br>ENPP1 deficiency
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.inozyme.com/news-releases/news-release-details/inozyme-pharma-reports-q2-2021-financial-results-and-provides">
                1H 2022
              </a> <div class="note">Phase 1/2 trial planned for 4Q 2021 with preliminary safety and biomarker data due 1H 2022.</div></td><td>
              24m
            </td><td>
              376.6m
            </td><td>
              3.6k
            </td><td>
              67.2k
            </td><td>
              2.73
            </td><td>
              $15.75
            </td><td>
              $15.48
            </td><td>
              N/A
            </td><td>
              131.44m
            </td><td>
              -3.34m
            </td><td>
              39.30
            </td><td>
              121.46m
            </td><td>
              232.52m
            </td><td>
              2.3
            </td><td>
              16,473,465
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TVTX" class="margin-bottom-1">
                TVTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.41</div> <small class="number change-up">+1.22<span>&nbsp;&nbsp;</span>+6.02%</small></td><td><strong>Sparsentan (DUPLEX)</strong> <br>Focal segmental glomerulosclerosis (FSGS)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-reports-second-quarter-2021-financial">
                1H 2022
              </a> <div class="note">Phase 3 trial met partial remission of proteinuria endpoint - February 2, 2021. Noted May 25, 2021 that current data does not support accelerated approval. Additional estimated glomerular filtration (eGFR) data potentially due due 1H 2022. Full top-line data due 1H 2023.</div></td><td>
              61m
            </td><td>
              1.3b
            </td><td>
              0.6m
            </td><td>
              1.4m
            </td><td>
              3.91
            </td><td>
              $20.31
            </td><td>
              $20.19
            </td><td>
              June 2022
            </td><td>
              0.53b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              112.22m
            </td><td>
              0.92b
            </td><td>
              5.5
            </td><td>
              60,239,404
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CERE" class="margin-bottom-1">
                CERE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$26.20</div> <small class="number change-up">+2.51<span>&nbsp;&nbsp;</span>+10.60%</small></td><td><strong>Darigabat (CVL-865)</strong> <br>Anxiety
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.cerevel.com/news-releases/news-release-details/cerevel-therapeutics-reports-second-quarter-2021-financial">
                1H 2022
              </a> <div class="note">Phase 1 data due 1H 2022.</div></td><td>
              145m
            </td><td>
              3.8b
            </td><td>
              327.6k
            </td><td>
              2.9m
            </td><td>
              12.91
            </td><td>
              $23.95
            </td><td>
              $23.69
            </td><td>
              October 3, 2021
            </td><td>
              0.65b
            </td><td>
              -15.20m
            </td><td>
              42.74
            </td><td>
              0.55b
            </td><td>
              3.14b
            </td><td>
              0.1
            </td><td>
              52,582,057
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARPO" class="margin-bottom-1">
                ARPO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.21</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+3.27%</small></td><td><strong>AKB-4924 (GB004) - SHIFT-UC</strong> <br>Ulcerative Colitis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005711/en/">
                1H 2022
              </a> <div class="note">Phase 2 top-line data due 1H 2022.</div></td><td>
              191m
            </td><td>
              421.3m
            </td><td>
              0.7m
            </td><td>
              7.1m
            </td><td>
              2.99
            </td><td>
              $2.12
            </td><td>
              $2.14
            </td><td>
              March 2022
            </td><td>
              35.48m
            </td><td>
              -0.74m
            </td><td>
              47.80
            </td><td>
              33.27m
            </td><td>
              65.19m
            </td><td>
              1.8
            </td><td>
              35,585,961
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GOSS" class="margin-bottom-1">
                GOSS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.27</div> <small class="number change-up">+0.40<span>&nbsp;&nbsp;</span>+4.51%</small></td><td><strong>AKB-4924 (GB004) - SHIFT-UC</strong> <br>Ulcerative Colitis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005711/en/">
                1H 2022
              </a> <div class="note">Phase 2 top-line data due 1H 2022.</div></td><td>
              76m
            </td><td>
              0.7b
            </td><td>
              148.5k
            </td><td>
              0.5m
            </td><td>
              3.20
            </td><td>
              $8.96
            </td><td>
              $8.87
            </td><td>
              March 2022
            </td><td>
              377.45m
            </td><td>
              -15.82m
            </td><td>
              23.86
            </td><td>
              165.63m
            </td><td>
              453.38m
            </td><td>
              2.2
            </td><td>
              63,837,740
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ABEO" class="margin-bottom-1">
                ABEO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.26</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+7.69%</small></td><td><strong>ABO-101 (Transpher B)</strong> <br>Sanfilippo syndrome type B (MPS IIIB)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.abeonatherapeutics.com/press-releases/detail/213/abeona-therapeutics-reports-second-quarter-financial-results">
                1H 2022
              </a> <div class="note">Phase 1/2 two-year neurocognitive data due 1H 2022. </div></td><td>
              101m
            </td><td>
              127.5m
            </td><td>
              337.5k
            </td><td>
              1.3m
            </td><td>
              1.52
            </td><td>
              $1.18
            </td><td>
              $1.17
            </td><td>
              October 2022
            </td><td>
              70.67m
            </td><td>
              -3.83m
            </td><td>
              18.45
            </td><td>
              24.08m
            </td><td>
              49.08m
            </td><td>
              4.2
            </td><td>
              87,155,163
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RZLT" class="margin-bottom-1">
                RZLT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.61</div> <small class="number change-down">-0.30<span>&nbsp;&nbsp;</span>-3.03%</small></td><td><strong>RZ402</strong> <br>Diabetic macular edema
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://d1io3yog0oux5.cloudfront.net/_744c1bcf2ce2980e10ecf0ef56acf214/rezolutebio/db/146/1802/pdf/Jun2021_Corporate+Presentation.pdf">
                1H 2022
              </a> <div class="note">Phase 1b initiation of dosing announced August 10, 2021 with data due 1H 2022.</div></td><td>
              8m
            </td><td>
              81.5m
            </td><td>
              4.3k
            </td><td>
              25.8k
            </td><td>
              2.80
            </td><td>
              $10
            </td><td>
              $9.91
            </td><td>
              N/A
            </td><td>
              23.29m
            </td><td>
              -1.80m
            </td><td>
              12.95
            </td><td>
              19.49m
            </td><td>
              52.60m
            </td><td>
              47.3
            </td><td>
              3,404,394
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VRDN" class="margin-bottom-1">
                VRDN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.68</div> <small class="number change-up">+0.10<span>&nbsp;&nbsp;</span>+0.74%</small></td><td><strong>VRDN-001</strong> <br>Thyroid eye disease (TED)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.compasspathways.com/news-releases/news-release-details/compass-pathways-plc-announces-financial-results-and-business-1">
                2Q 2022
              </a> <div class="note">Phase 2 trial to be initiated 4Q 2021 with initial data due 2Q 2022. </div></td><td>
              10m
            </td><td>
              131.2m
            </td><td>
              2.8k
            </td><td>
              48.7k
            </td><td>
              -2.37
            </td><td>
              $13.74
            </td><td>
              $13.58
            </td><td>
              N/A
            </td><td>
              100.52m
            </td><td>
              -4.88m
            </td><td>
              20.61
            </td><td>
              81.23m
            </td><td>
              175.67m
            </td><td>
              15.2
            </td><td>
              9,545,467
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GSK" class="margin-bottom-1">
                GSK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$41.57</div> <small class="number change-down">-0.28<span>&nbsp;&nbsp;</span>-0.67%</small></td><td><strong>BLENREP (belantamab mafodotin) and KEYTRUDA (Pembrolizumab) -DREAMM-4</strong> <br>Multiple Myeloma
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.gsk.com/media/7129/q2-2021-results-slides.pdf">
                1H 2022
              </a> <div class="note">Phase 2 pilot data due 1H 2022.</div></td><td>
              3b
            </td><td>
              104.6b
            </td><td>
              2.3m
            </td><td>
              4.2m
            </td><td>
              4.95
            </td><td>
              $41.75
            </td><td>
              $41.85
            </td><td>
              N/A
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -51.10b
            </td><td>
              133.80b
            </td><td>
              0.2
            </td><td>
              2,506,785,977
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DAWN" class="margin-bottom-1">
                DAWN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$27.60</div> <small class="number change-up">+2.38<span>&nbsp;&nbsp;</span>+9.44%</small></td><td><strong>DAY101 (FIREFLY-1)</strong> <br>Low-grade Glioma
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.dayonebio.com/news-releases/news-release-details/day-one-reports-second-quarter-2021-financial-results-and">
                1H 2022
              </a> <div class="note">Phase 2 initial data due 1H 2022.</div></td><td>
              62m
            </td><td>
              1.7b
            </td><td>
              74.5k
            </td><td>
              72.9k
            </td><td>
              5.49
            </td><td>
              $25.25
            </td><td>
              $25.22
            </td><td>
              March 30, 2023
            </td><td>
              301.95m
            </td><td>
              -4.47m
            </td><td>
              67.57
            </td><td>
              297.18m
            </td><td>
              1.25b
            </td><td>
              8.4
            </td><td>
              24,578,204
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FNCH" class="margin-bottom-1">
                FNCH
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.11</div> <small class="number change-up">+0.28<span>&nbsp;&nbsp;</span>+2.18%</small></td><td><strong>CP101</strong> <br>Hepatitis B
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.finchtherapeutics.com/news-releases/news-release-details/finch-therapeutics-reports-second-quarter-2021-financial-results">
                1H 2022
              </a> <div class="note">Phase 1b trial to commence early-2022 with initial safety data due 1H 2022 and top-line data due 2H 2022.</div></td><td>
              47m
            </td><td>
              0.6b
            </td><td>
              6.7k
            </td><td>
              84.9k
            </td><td>
              2.73
            </td><td>
              $12.65
            </td><td>
              $12.83
            </td><td>
              N/A
            </td><td>
              153.87m
            </td><td>
              -7.93m
            </td><td>
              19.41
            </td><td>
              131.73m
            </td><td>
              417.56m
            </td><td>
              6.8
            </td><td>
              27,059,349
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LXRX" class="margin-bottom-1">
                LXRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.91</div> <small class="number change-up">+0.44<span>&nbsp;&nbsp;</span>+12.68%</small></td><td><strong>LX9211 (RELIEF-PHN 1)</strong> <br>Post-herpetic neuralgia
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.lexpharma.com/media-center/news/783-lexicon-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-clinical-update">
                1H 2022
              </a> <div class="note">Phase 2 data due 1H 2022.</div></td><td>
              144m
            </td><td>
              0.6b
            </td><td>
              1.2m
            </td><td>
              0.9m
            </td><td>
              4.12
            </td><td>
              $3.58
            </td><td>
              $3.47
            </td><td>
              N/A
            </td><td>
              105.37m
            </td><td>
              -7.29m
            </td><td>
              14.45
            </td><td>
              70.93m
            </td><td>
              395.53m
            </td><td>
              2.3
            </td><td>
              67,367,491
            </td><td>
              07/30/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AMGN" class="margin-bottom-1">
                AMGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$226.21</div> <small class="number change-up">+2.68<span>&nbsp;&nbsp;</span>+1.20%</small></td><td><strong>LUMAKRAS (Sotorasib) - CodeBreaK 200</strong> <br>Non-small cell lung cancer (NSCLC)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/amgen-reports-second-quarter-2021-financial-results-301347523.html">
                1H 2022
              </a> <div class="note">Phase 3 data due 1H 2022.</div></td><td>
              1b
            </td><td>
              128.5b
            </td><td>
              0.9m
            </td><td>
              2.4m
            </td><td>
              15.58
            </td><td>
              $224.18
            </td><td>
              $223.53
            </td><td>
              November 2, 2021
            </td><td>
              8.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -43.19b
            </td><td>
              151.63b
            </td><td>
              0.6
            </td><td>
              566,434,467
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SLS" class="margin-bottom-1">
                SLS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.28</div> <small class="number change-up">+0.60<span>&nbsp;&nbsp;</span>+6.91%</small></td><td><strong>Galinpepimut-S - REGAL</strong> <br>Acute Myeloid Leukemia (AML)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sellaslifesciences.com/investors/news/News-Details/2021/SELLAS-Life-Sciences-Reports-Full-Year-2020-Financial-Results-and-Provides-Business-Update/default.aspx">
                1H 2022
              </a> <div class="note">Phase 3  interim safety and futility analysis due 1H 2022.</div></td><td>
              16m
            </td><td>
              147.3m
            </td><td>
              155.0k
            </td><td>
              0.6m
            </td><td>
              4.40
            </td><td>
              $8.78
            </td><td>
              $8.68
            </td><td>
              December 2021
            </td><td>
              26.98m
            </td><td>
              -1.63m
            </td><td>
              16.52
            </td><td>
              16.77m
            </td><td>
              108.77m
            </td><td>
              11
            </td><td>
              15,865,222
            </td><td>
              03/23/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARWR" class="margin-bottom-1">
                ARWR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$62.35</div> <small class="number change-up">+2.42<span>&nbsp;&nbsp;</span>+4.04%</small></td><td><strong>Olpasiran (AMG 890)</strong> <br>Cardiovascular disease / Elevated Lipoprotein
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/amgen-reports-second-quarter-2021-financial-results-301347523.html">
                1H 2022
              </a> <div class="note">Phase 2 data due 1H 2022.</div></td><td>
              104m
            </td><td>
              6.5b
            </td><td>
              277.9k
            </td><td>
              0.9m
            </td><td>
              14.88
            </td><td>
              $60.9
            </td><td>
              $59.93
            </td><td>
              January 3, 2022
            </td><td>
              498.55m
            </td><td>
              -9.87m
            </td><td>
              50.51
            </td><td>
              200.51m
            </td><td>
              5.76b
            </td><td>
              6.6
            </td><td>
              89,060,182
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AMGN" class="margin-bottom-1">
                AMGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$226.21</div> <small class="number change-up">+2.68<span>&nbsp;&nbsp;</span>+1.20%</small></td><td><strong>Olpasiran (AMG 890)</strong> <br>Cardiovascular disease / Elevated Lipoprotein
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/amgen-reports-second-quarter-2021-financial-results-301347523.html">
                1H 2022
              </a> <div class="note">Phase 2 data due 1H 2022.</div></td><td>
              1b
            </td><td>
              128.5b
            </td><td>
              0.9m
            </td><td>
              2.4m
            </td><td>
              15.58
            </td><td>
              $224.18
            </td><td>
              $223.53
            </td><td>
              January 3, 2022
            </td><td>
              8.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -43.19b
            </td><td>
              151.63b
            </td><td>
              0.6
            </td><td>
              566,434,467
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SNGX" class="margin-bottom-1">
                SNGX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.93</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+1.10%</small></td><td><strong>HyBryte (SGX301)</strong> <br>Cutaneous T-Cell Lymphoma (CTCL) cancer
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/soligenix-announces-recent-accomplishments-and-second-quarter-2021-financial-results-301354663.html">
                1H 2022
              </a> <div class="note">Phase 3 top-line data met primary endpoint - March 19,2020. Rolling NDA initially set for 2Q 2021 delayed until 1H 2022.</div></td><td>
              40m
            </td><td>
              37.3m
            </td><td>
              259.3k
            </td><td>
              0.7m
            </td><td>
              2.38
            </td><td>
              $0.93
            </td><td>
              $0.92
            </td><td>
              December 2019
            </td><td>
              27.98m
            </td><td>
              -0.55m
            </td><td>
              50.61
            </td><td>
              13.97m
            </td><td>
              17.91m
            </td><td>
              24.7
            </td><td>
              40,001,045
            </td><td>
              08/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RLMD" class="margin-bottom-1">
                RLMD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$24.56</div> <small class="number change-up">+2.13<span>&nbsp;&nbsp;</span>+9.50%</small></td><td><strong>REL-1017 (RELIANCE II)</strong> <br>Major depressive disorder (MDD
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/relmada-therapeutics-provides-corporate-update-and-reports-first-quarter-2021-financial-results-301290205.html">
                1H 2022
              </a> <div class="note">Phase 3 data due 1H 2022.</div></td><td>
              17m
            </td><td>
              429.1m
            </td><td>
              104.4k
            </td><td>
              267.8k
            </td><td>
              4.43
            </td><td>
              $22.5
            </td><td>
              $22.43
            </td><td>
              N/A
            </td><td>
              98.74m
            </td><td>
              -5.74m
            </td><td>
              17.21
            </td><td>
              84.82m
            </td><td>
              275.59m
            </td><td>
              4
            </td><td>
              17,022,489
            </td><td>
              05/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PTIX" class="margin-bottom-1">
                PTIX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.04</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+6.75%</small></td><td><strong>PT00114</strong> <br>Major Depressive Disorder (MDD) / Generalized Anxiety Disorder (GAD) / Post-Traumatic Stress Disorder (PTSD)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://irsites.com/ptixpr/">
                1H 2022
              </a> <div class="note">Phase 1/2a trial to be initiated 1Q 2022 with initial data due 1H 2022.</div></td><td>
              17m
            </td><td>
              34.0m
            </td><td>
              0.6m
            </td><td>
              1.6m
            </td><td>
              3.14
            </td><td>
              $1.91
            </td><td>
              $1.91
            </td><td>
              N/A
            </td><td>
              -0.79m
            </td><td>
              -202.57k
            </td><td>
              3.89
            </td><td>
              -2.97m
            </td><td>
              20.62m
            </td><td>
              30.2
            </td><td>
              13,985,379
            </td><td>
              08/17/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLNN" class="margin-bottom-1">
                CLNN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.80</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+1.88%</small></td><td><strong>CNM-Au8 (HEALEY ALS Platform Trial)</strong> <br>Amyotrophic Lateral Sclerosis
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://invest.clene.com/press-releases/Press-Releases/news-details/2021/Clene-Reports-Second-Quarter-2021-Operating-and-Financial-Highlights/default.aspx">
                1H 2022
              </a> <div class="note">Phase 2/3 data due 1H 2022.</div></td><td>
              61m
            </td><td>
              479.9m
            </td><td>
              105.3k
            </td><td>
              0.6m
            </td><td>
              -18.58
            </td><td>
              $7.68
            </td><td>
              $7.66
            </td><td>
              March 2022
            </td><td>
              57.88m
            </td><td>
              -2.85m
            </td><td>
              20.30
            </td><td>
              -41.33m
            </td><td>
              424.96m
            </td><td>
              2.9
            </td><td>
              28,409,076
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SCYX" class="margin-bottom-1">
                SCYX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.07</div> <small class="number change-up">+0.20<span>&nbsp;&nbsp;</span>+3.32%</small></td><td><strong>BREXAFEMME (ibrexafungerp) - CANDLE</strong> <br>Recurrent Vulvovaginal candidiasis (VVC)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.scynexis.com/press-releases/detail/249/scynexis-reports-second-quarter-2021-financial-results-and">
                1H 2022
              </a> <div class="note">Phase 3 data and sNDA filing due 1H 2022.</div></td><td>
              23m
            </td><td>
              140.8m
            </td><td>
              120.1k
            </td><td>
              298.1k
            </td><td>
              4.36
            </td><td>
              $5.87
            </td><td>
              $5.87
            </td><td>
              September 2021
            </td><td>
              105.43m
            </td><td>
              -3.90m
            </td><td>
              27.04
            </td><td>
              16.62m
            </td><td>
              67.55m
            </td><td>
              2.1
            </td><td>
              18,406,695
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARGX" class="margin-bottom-1">
                ARGX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$330.66</div> <small class="number change-up">+16.08<span>&nbsp;&nbsp;</span>+5.11%</small></td><td><strong>Efgartigimod (ARGX-113) - (ADVANCE)</strong> <br>Immune thrombocytopenia (ITP)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/07/29/2270853/0/en/argenx-Reports-Half-Year-2021-Financial-Results-and-Provides-Second-Quarter-Business-Update.html">
                1H 2022
              </a> <div class="note">Phase 3 top-line data due 1H 2022.</div></td><td>
              51m
            </td><td>
              17.0b
            </td><td>
              127.0k
            </td><td>
              127.5k
            </td><td>
              5.76
            </td><td>
              $322.62
            </td><td>
              $314.58
            </td><td>
              September 30, 2021
            </td><td>
              2.73b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              2.47b
            </td><td>
              13.42b
            </td><td>
              0
            </td><td>
              51,398,663
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ZLAB" class="margin-bottom-1">
                ZLAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$143.17</div> <small class="number change-up">+9.00<span>&nbsp;&nbsp;</span>+6.71%</small></td><td><strong>Efgartigimod (ARGX-113) - (ADVANCE)</strong> <br>Immune thrombocytopenia (ITP)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/07/29/2270853/0/en/argenx-Reports-Half-Year-2021-Financial-Results-and-Provides-Second-Quarter-Business-Update.html">
                1H 2022
              </a> <div class="note">Phase 3 top-line data due 1H 2022.</div></td><td>
              75m
            </td><td>
              10.8b
            </td><td>
              320.4k
            </td><td>
              0.6m
            </td><td>
              33.30
            </td><td>
              $135
            </td><td>
              $134.17
            </td><td>
              September 30, 2021
            </td><td>
              1.73b
            </td><td>
              -21.95m
            </td><td>
              78.68
            </td><td>
              1.50b
            </td><td>
              1.78b
            </td><td>
              0
            </td><td>
              75,375,511
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LVTX" class="margin-bottom-1">
                LVTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.28</div> <small class="number change-up">+0.38<span>&nbsp;&nbsp;</span>+6.36%</small></td><td><strong>LAVA-051</strong> <br>Chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and acute myeloid leukemia (AML)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.lavatherapeutics.com/news-releases/news-release-details/lava-therapeutics-provides-business-update-and-reports-second">
                1H 2022
              </a> <div class="note">Phase 1/2 initiation of dosing announced July 13, 2021. Phase 1 dose escalation data due 1H 2022 with Phase 2a data due 2H 2022.</div></td><td>
              26m
            </td><td>
              161.7m
            </td><td>
              23.1k
            </td><td>
              162.5k
            </td><td>
              1.20
            </td><td>
              $5.9
            </td><td>
              $5.9
            </td><td>
              N/A
            </td><td>
              123.07m
            </td><td>
              -2.94m
            </td><td>
              41.92
            </td><td>
              103.73m
            </td><td>
              6.44m
            </td><td>
              0
            </td><td>
              14,491,057
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BHVN" class="margin-bottom-1">
                BHVN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$125.97</div> <small class="number change-up">+3.13<span>&nbsp;&nbsp;</span>+2.55%</small></td><td><strong>Troriluzole</strong> <br>Spinocerebellar Ataxia (SCA)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/biohaven-reports-second-quarter-2021-financial-results-and-recent-business-developments-301350770.html">
                1H 2022
              </a> <div class="note">Phase 3 top-line data due 1H 2022.</div></td><td>
              65m
            </td><td>
              8.2b
            </td><td>
              170.9k
            </td><td>
              0.7m
            </td><td>
              -18.15
            </td><td>
              $124.56
            </td><td>
              $122.84
            </td><td>
              November 30, 2021
            </td><td>
              229.88m
            </td><td>
              -75.68m
            </td><td>
              3.04
            </td><td>
              -1.07b
            </td><td>
              7.94b
            </td><td>
              8.5
            </td><td>
              58,034,591
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ELDN" class="margin-bottom-1">
                ELDN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.51</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+0.15%</small></td><td><strong>AT-1501</strong> <br>Amyotrophic Lateral Sclerosis
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-reports-second-quarter-2021-operating-and">
                1H 2022
              </a> <div class="note">Phase 2a top-line data due 1H 2022.</div></td><td>
              14m
            </td><td>
              93.1m
            </td><td>
              48.0k
            </td><td>
              73.1k
            </td><td>
              0.52
            </td><td>
              $6.47
            </td><td>
              $6.5
            </td><td>
              March 2022
            </td><td>
              96.67m
            </td><td>
              -2.48m
            </td><td>
              38.95
            </td><td>
              90.88m
            </td><td>
              -7.87m
            </td><td>
              6.5
            </td><td>
              14,305,606
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VOR" class="margin-bottom-1">
                VOR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.87</div> <small class="number change-down">-0.40<span>&nbsp;&nbsp;</span>-3.01%</small></td><td><strong>VOR33</strong> <br>Acute myeloid leukemia (AML)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/09/2277407/0/en/Vor-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Company-Update.html">
                1H 2022
              </a> <div class="note">Phase 1/2a trial to commence enrollment in the next few months with initial data expected 1H 2022</div></td><td>
              37m
            </td><td>
              478.1m
            </td><td>
              87.3k
            </td><td>
              134.0k
            </td><td>
              1.91
            </td><td>
              $13.55
            </td><td>
              $13.27
            </td><td>
              N/A
            </td><td>
              234.70m
            </td><td>
              -5.52m
            </td><td>
              42.50
            </td><td>
              209.66m
            </td><td>
              266.17m
            </td><td>
              1.4
            </td><td>
              14,880,424
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GSK" class="margin-bottom-1">
                GSK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$41.57</div> <small class="number change-down">-0.28<span>&nbsp;&nbsp;</span>-0.67%</small></td><td><strong>BLENREP (belantamab mafodotin) - (DREAMM-3)</strong> <br>Multiple Myeloma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.gsk.com/media/7129/q2-2021-results-slides.pdf">
                1H 2022
              </a> <div class="note">Phase 3 data due 1H 2022.</div></td><td>
              3b
            </td><td>
              104.6b
            </td><td>
              2.3m
            </td><td>
              4.2m
            </td><td>
              4.95
            </td><td>
              $41.75
            </td><td>
              $41.85
            </td><td>
              December 9, 2021
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -51.10b
            </td><td>
              133.80b
            </td><td>
              0.2
            </td><td>
              2,506,785,977
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALT" class="margin-bottom-1">
                ALT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.39</div> <small class="number change-up">+0.71<span>&nbsp;&nbsp;</span>+5.64%</small></td><td><strong>HepTCell</strong> <br>Hepatitis B
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-financial-results-year-ended-december-31-2">
                1H 2022
              </a> <div class="note">Phase 2 commencement of enrollment announced December 30, 2020. Data due 1H 2022.</div></td><td>
              40m
            </td><td>
              0.5b
            </td><td>
              1.0m
            </td><td>
              2.2m
            </td><td>
              2.20
            </td><td>
              $12.73
            </td><td>
              $12.68
            </td><td>
              March 2022
            </td><td>
              206.47m
            </td><td>
              -6.31m
            </td><td>
              32.73
            </td><td>
              190.49m
            </td><td>
              287.30m
            </td><td>
              13.2
            </td><td>
              39,275,708
            </td><td>
              02/25/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FSTX" class="margin-bottom-1">
                FSTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.35</div> <small class="number change-up">+0.41<span>&nbsp;&nbsp;</span>+6.90%</small></td><td><strong>FS118</strong> <br>Advanced Cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.f-star.com/news-releases/news-release-details/f-star-therapeutics-reports-first-quarter-2021-financial-results">
                1H 2022
              </a> <div class="note">Phase 2 update 1H 2022.</div></td><td>
              21m
            </td><td>
              130.9m
            </td><td>
              90.9k
            </td><td>
              158.7k
            </td><td>
              1.32
            </td><td>
              $6.08
            </td><td>
              $5.94
            </td><td>
              December 2022
            </td><td>
              88.28m
            </td><td>
              -2.98m
            </td><td>
              29.57
            </td><td>
              62.29m
            </td><td>
              54.41m
            </td><td>
              3.2
            </td><td>
              20,549,167
            </td><td>
              05/17/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SYN" class="margin-bottom-1">
                SYN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.45</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+1.53%</small></td><td><strong>SYN-020</strong> <br>Healthy volunteers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.syntheticbiologics.com/press-releases/detail/308/synthetic-biologics-reports-second-quarter-2021-operational">
                2Q 2022
              </a> <div class="note">Phase 1 trial to commence 3Q 2021 with top-line data due 2Q 2022.</div></td><td>
              132m
            </td><td>
              59.6m
            </td><td>
              0.7m
            </td><td>
              2.0m
            </td><td>
              0.78
            </td><td>
              $0.45
            </td><td>
              $0.44
            </td><td>
              N/A
            </td><td>
              72.73m
            </td><td>
              -0.87m
            </td><td>
              84.05
            </td><td>
              69.21m
            </td><td>
              -13.94m
            </td><td>
              4.3
            </td><td>
              131,935,971
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LXRX" class="margin-bottom-1">
                LXRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.91</div> <small class="number change-up">+0.44<span>&nbsp;&nbsp;</span>+12.68%</small></td><td><strong>LX9211 (RELIEF-DPN 1)</strong> <br>Diabetic Peripheral Neuropathy
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.lexpharma.com/media-center/news/783-lexicon-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-clinical-update">
                1H 2022
              </a> <div class="note">Phase 2 data due 1H 2022.</div></td><td>
              144m
            </td><td>
              0.6b
            </td><td>
              1.2m
            </td><td>
              0.9m
            </td><td>
              4.12
            </td><td>
              $3.58
            </td><td>
              $3.47
            </td><td>
              August 2021
            </td><td>
              105.37m
            </td><td>
              -7.29m
            </td><td>
              14.45
            </td><td>
              70.93m
            </td><td>
              395.53m
            </td><td>
              2.3
            </td><td>
              67,367,491
            </td><td>
              07/30/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PRQR" class="margin-bottom-1">
                PRQR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.22</div> <small class="number change-up">+0.69<span>&nbsp;&nbsp;</span>+12.48%</small></td><td><strong>Sepofarsen (QR-110) - (ILLUMINATE)</strong> <br>Leber's Congenital Amaurosis (LCA) - Genetic blindness 
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.proqr.com/press-releases/proqr-announces-second-quarter-2021-operating-and-financial-results">
                1H 2022
              </a> <div class="note">Phase 2/3 top-line data due 1H 2022.</div></td><td>
              67m
            </td><td>
              417.2m
            </td><td>
              192.0k
            </td><td>
              478.4k
            </td><td>
              3.02
            </td><td>
              $5.57
            </td><td>
              $5.53
            </td><td>
              December 2021
            </td><td>
              133.45m
            </td><td>
              -3.33m
            </td><td>
              40.12
            </td><td>
              88.64m
            </td><td>
              249.39m
            </td><td>
              0
            </td><td>
              57,834,902
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BGNE" class="margin-bottom-1">
                BGNE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$270.83</div> <small class="number change-up">+21.23<span>&nbsp;&nbsp;</span>+8.51%</small></td><td><strong>Pamiparib (BGB-290)</strong> <br>Maintenance Therapy Ovarian Cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805006018/en/">
                2021 / 1H 2022
              </a> <div class="note">Phase 3 data due 2021 or 1H 2022.</div></td><td>
              93m
            </td><td>
              25.2b
            </td><td>
              273.7k
            </td><td>
              315.1k
            </td><td>
              7.00
            </td><td>
              $256
            </td><td>
              $249.6
            </td><td>
              June 30, 2022
            </td><td>
              4.13b
            </td><td>
              -140.09m
            </td><td>
              29.48
            </td><td>
              2.21b
            </td><td>
              21.09b
            </td><td>
              0.3
            </td><td>
              89,530,472
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SONN" class="margin-bottom-1">
                SONN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.62</div> <small class="number change-down">-0.01<span>&nbsp;&nbsp;</span>-2.17%</small></td><td><strong>SON-080</strong> <br>Diabetic Peripheral Neuropathy
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://d1io3yog0oux5.cloudfront.net/_6b3eaf47d6319e8389086c4c316f75dd/sonnetbio/db/776/6714/pdf/Sonnet+Bio+Corp+Presentation+Aug+2021.pdf">
                1H 2022
              </a> <div class="note">IND filing due 2H 2021 / 1H 2022 with initial data due 1H 2022.</div></td><td>
              25m
            </td><td>
              15.4m
            </td><td>
              8.9m
            </td><td>
              6.1m
            </td><td>
              12.35
            </td><td>
              $0.62
            </td><td>
              $0.63
            </td><td>
              N/A
            </td><td>
              32.53m
            </td><td>
              -1.95m
            </td><td>
              16.70
            </td><td>
              26.72m
            </td><td>
              9.86m
            </td><td>
              4.3
            </td><td>
              23,755,498
            </td><td>
              08/19/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SONN" class="margin-bottom-1">
                SONN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.62</div> <small class="number change-down">-0.01<span>&nbsp;&nbsp;</span>-2.17%</small></td><td><strong>SON-080</strong> <br>Chemotherapy Induced Peripheral Neuropathy (CIPN)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://d1io3yog0oux5.cloudfront.net/_6b3eaf47d6319e8389086c4c316f75dd/sonnetbio/db/776/6714/pdf/Sonnet+Bio+Corp+Presentation+Aug+2021.pdf">
                1H 2022
              </a> <div class="note">Phase 1 trial planned (IND filing due 2H 2021) with initial safety data due 1H 2022.</div></td><td>
              25m
            </td><td>
              15.4m
            </td><td>
              8.9m
            </td><td>
              6.1m
            </td><td>
              12.35
            </td><td>
              $0.62
            </td><td>
              $0.63
            </td><td>
              N/A
            </td><td>
              32.53m
            </td><td>
              -1.95m
            </td><td>
              16.70
            </td><td>
              26.72m
            </td><td>
              9.86m
            </td><td>
              4.3
            </td><td>
              23,755,498
            </td><td>
              08/19/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TSHA" class="margin-bottom-1">
                TSHA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.73</div> <small class="number change-up">+0.80<span>&nbsp;&nbsp;</span>+4.73%</small></td><td><strong>TSHA-104</strong> <br>SURF1-associated Leigh syndrome
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210816005196/en/">
                1H 2022
              </a> <div class="note">Phase 1/2 trial to be initiated by end of 2021 with biomarker data due 1H 2022.</div></td><td>
              38m
            </td><td>
              0.7b
            </td><td>
              22.6k
            </td><td>
              190.5k
            </td><td>
              3.65
            </td><td>
              $17.25
            </td><td>
              $16.93
            </td><td>
              N/A
            </td><td>
              183.68m
            </td><td>
              -7.61m
            </td><td>
              24.15
            </td><td>
              128.32m
            </td><td>
              478.80m
            </td><td>
              26.7
            </td><td>
              16,966,890
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BTX" class="margin-bottom-1">
                BTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.85</div> <small class="number change-up">+0.25<span>&nbsp;&nbsp;</span>+2.59%</small></td><td><strong>IRX-2 - INSPIRE</strong> <br>Head and neck squamous cell cancer
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/20/2284118/0/en/Brooklyn-ImmunoTherapeutics-Provides-Highlights-of-Shareholder-Update-Call-from-August-19-2021.html">
                1H 2022
              </a> <div class="note">Phase 2b top-line data due 1H 2022.</div></td><td>
              52m
            </td><td>
              0.5b
            </td><td>
              0.7m
            </td><td>
              2.3m
            </td><td>
              33.96
            </td><td>
              $9.6
            </td><td>
              $9.6
            </td><td>
              March 2021
            </td><td>
              46.08m
            </td><td>
              -2.27m
            </td><td>
              20.32
            </td><td>
              16.55m
            </td><td>
              450.07m
            </td><td>
              12.1
            </td><td>
              35,906,398
            </td><td>
              08/20/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BLRX" class="margin-bottom-1">
                BLRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.91</div> <small class="number change-up">+0.16<span>&nbsp;&nbsp;</span>+5.82%</small></td><td><strong>Motixafortide (BL-8040) - (GENESIS)</strong> <br>Stem-cell mobilization for autologous transplantation
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/biolinerx-reports-second-quarter-2021-financial-results-and-provides-corporate-update-301357777.html">
                1H 2022
              </a> <div class="note">Phase 3 top-line data met all primary and secondary endpoints - May 4, 2021. NDA filing due 1H 2022.</div></td><td>
              47m
            </td><td>
              137.6m
            </td><td>
              348.6k
            </td><td>
              1.1m
            </td><td>
              2.12
            </td><td>
              $2.75
            </td><td>
              $2.75
            </td><td>
              April 22, 2019
            </td><td>
              48.05m
            </td><td>
              -2.08m
            </td><td>
              23.14
            </td><td>
              29.10m
            </td><td>
              79.89m
            </td><td>
              0
            </td><td>
              47,274,740
            </td><td>
              08/18/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PTGX" class="margin-bottom-1">
                PTGX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.56</div> <small class="number change-up">+0.34<span>&nbsp;&nbsp;</span>+0.70%</small></td><td><strong>PN-943</strong> <br>Ulcerative colitis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/protagonist-therapeutics-reports-second-quarter-2021-financial-results-and-recent-company-progress-301348266.html">
                2Q 2022
              </a> <div class="note">Phase 2 trial to be completed in 2Q 2022.</div></td><td>
              48m
            </td><td>
              2.4b
            </td><td>
              161.0k
            </td><td>
              453.6k
            </td><td>
              6.59
            </td><td>
              $49.6
            </td><td>
              $49.22
            </td><td>
              June 1, 2022
            </td><td>
              340.06m
            </td><td>
              -7.90m
            </td><td>
              43.05
            </td><td>
              293.28m
            </td><td>
              1.99b
            </td><td>
              1.5
            </td><td>
              38,115,527
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CRIS" class="margin-bottom-1">
                CRIS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.74</div> <small class="number change-up">+0.52<span>&nbsp;&nbsp;</span>+7.13%</small></td><td><strong>CA-4948 and IMBRUVICA (Ibrutinib)</strong> <br>Non-Hodgkin Lymphoma (NHL)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/curis-reports-first-quarter-2021-financial-results-301290116.html">
                1H 2022
              </a> <div class="note">Phase 1 initial data due 1H 2022.</div></td><td>
              92m
            </td><td>
              0.7b
            </td><td>
              1.1m
            </td><td>
              2.9m
            </td><td>
              6.29
            </td><td>
              $7.4
            </td><td>
              $7.22
            </td><td>
              December 2022
            </td><td>
              148.57m
            </td><td>
              -2.22m
            </td><td>
              66.94
            </td><td>
              79.86m
            </td><td>
              0.51b
            </td><td>
              2.5
            </td><td>
              91,355,825
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BTX" class="margin-bottom-1">
                BTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.85</div> <small class="number change-up">+0.25<span>&nbsp;&nbsp;</span>+2.59%</small></td><td><strong>IRX-2 and IMFINZI (Durvalumab) - MHN-102</strong> <br>Head and Neck cancer
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.brooklynitx.com/news/news-details/2021/Brooklyn-ImmunoTherapeutics-Announces-Second-Quarter-2021-Financial-Results/default.aspx">
                2Q 2022
              </a> <div class="note">Phase 1 trial recruiting. Final data due 2Q 2022.</div></td><td>
              52m
            </td><td>
              0.5b
            </td><td>
              0.7m
            </td><td>
              2.3m
            </td><td>
              33.96
            </td><td>
              $9.6
            </td><td>
              $9.6
            </td><td>
              May 12, 2022
            </td><td>
              46.08m
            </td><td>
              -2.27m
            </td><td>
              20.32
            </td><td>
              16.55m
            </td><td>
              450.07m
            </td><td>
              12.1
            </td><td>
              35,906,398
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ENLV" class="margin-bottom-1">
                ENLV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$10.77</div> <small class="number change-up">+0.44<span>&nbsp;&nbsp;</span>+4.26%</small></td><td><strong>Allocetra</strong> <br>Prevention of cytokine storms in Sepsis
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/09/2277049/0/en/Enlivex-Announces-Second-Quarter-2021-Financial-Results-and-Provides-a-Business-Update.html">
                2Q 2022
              </a> <div class="note">Phase 2b top-line data due 2Q 2022.</div></td><td>
              13m
            </td><td>
              145.0m
            </td><td>
              148.3k
            </td><td>
              358.7k
            </td><td>
              8.83
            </td><td>
              $10.33
            </td><td>
              $10.33
            </td><td>
              N/A
            </td><td>
              87.95m
            </td><td>
              -1.47m
            </td><td>
              59.83
            </td><td>
              82.97m
            </td><td>
              52.73m
            </td><td>
              0
            </td><td>
              5,719,938
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ZGNX" class="margin-bottom-1">
                ZGNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.41</div> <small class="number change-up">+0.67<span>&nbsp;&nbsp;</span>+4.88%</small></td><td><strong>MT1621</strong> <br>Thymidine kinase 2 deficiency
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/05/2275948/0/en/Zogenix-Provides-Corporate-Update-and-Reports-Second-Quarter-2021-Financial-Results.html">
                1H 2022
              </a> <div class="note">NDA filing due 1H 2022.</div></td><td>
              56m
            </td><td>
              0.8b
            </td><td>
              350.2k
            </td><td>
              1.1m
            </td><td>
              2.95
            </td><td>
              $13.85
            </td><td>
              $13.74
            </td><td>
              N/A
            </td><td>
              367.52m
            </td><td>
              -14.31m
            </td><td>
              25.68
            </td><td>
              100.31m
            </td><td>
              0.54b
            </td><td>
              2
            </td><td>
              55,653,891
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TPST" class="margin-bottom-1">
                TPST
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.22</div> <small class="number change-up">+0.67<span>&nbsp;&nbsp;</span>+4.94%</small></td><td><strong>TPST-1495</strong> <br>Solid Tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.tempesttx.com/news-releases/news-release-details/tempest-reports-second-quarter-2021-financial-results-and">
                1H 2022
              </a> <div class="note">Phase 1 trial ongoing. Recommended Phase 2 dose due 1H 2022.</div></td><td>
              7m
            </td><td>
              95.3m
            </td><td>
              36.5k
            </td><td>
              0.9m
            </td><td>
              1.98
            </td><td>
              $13.42
            </td><td>
              $13.55
            </td><td>
              August 31, 2021
            </td><td>
              68.41m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              41.03m
            </td><td>
              41.49m
            </td><td>
              1.7
            </td><td>
              18,936,701
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BMRN" class="margin-bottom-1">
                BMRN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$75.36</div> <small class="number change-up">+0.21<span>&nbsp;&nbsp;</span>+0.29%</small></td><td><strong>VOXZOGO (Vosoritide)</strong> <br>Children with Achondroplasia
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/biomarin-completes-full-enrollment-in-phase-2-study-of-vosoritide-for-treatment-of-infants-and-young-children-with-achondroplasia-301239664.html">
                Mid-2022
              </a> <div class="note">Phase 2 data due mid-2022.</div></td><td>
              183m
            </td><td>
              13.8b
            </td><td>
              399.2k
            </td><td>
              1.0m
            </td><td>
              3.26
            </td><td>
              $75.45
            </td><td>
              $75.14
            </td><td>
              December 2026
            </td><td>
              1.17b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -483.86m
            </td><td>
              13.74b
            </td><td>
              1
            </td><td>
              142,192,515
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TCDA" class="margin-bottom-1">
                TCDA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.96</div> <small class="number change-up">+0.08<span>&nbsp;&nbsp;</span>+2.06%</small></td><td><strong>TRC101 (VALOR-CKD)</strong> <br>Chronic Kidney Disease
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.tricida.com/news-releases/news-release-details/tricida-announces-second-quarter-2021-financial-results">
                Mid-2022
              </a> <div class="note">Phase 3 interim analysis due mid-2022.</div></td><td>
              50m
            </td><td>
              199.7m
            </td><td>
              52.3k
            </td><td>
              349.8k
            </td><td>
              5.74
            </td><td>
              $3.91
            </td><td>
              $3.88
            </td><td>
              December 2024
            </td><td>
              150.49m
            </td><td>
              -14.04m
            </td><td>
              10.72
            </td><td>
              -9.53m
            </td><td>
              157.66m
            </td><td>
              2.6
            </td><td>
              29,120,641
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMCR" class="margin-bottom-1">
                IMCR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.70</div> <small class="number change-up">+1.72<span>&nbsp;&nbsp;</span>+6.15%</small></td><td><strong>IMC-F106C (PRAME)</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.immunocore.com/news-releases/news-release-details/immunocore-reports-second-quarter-2021-financial-results-and">
                Mid-2022
              </a> <div class="note">Phase 1 data due mid-2022.</div></td><td>
              44m
            </td><td>
              1.3b
            </td><td>
              99.6k
            </td><td>
              65.9k
            </td><td>
              4.26
            </td><td>
              $27.98
            </td><td>
              $27.98
            </td><td>
              February 2022
            </td><td>
              259.31m
            </td><td>
              -10.87m
            </td><td>
              23.87
            </td><td>
              128.44m
            </td><td>
              0.93b
            </td><td>
              0
            </td><td>
              43,786,088
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EYEN" class="margin-bottom-1">
                EYEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.20</div> <small class="number change-up">+0.08<span>&nbsp;&nbsp;</span>+1.94%</small></td><td><strong>MicroLine (VISION-2)</strong> <br>Presbyopia
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.eyenovia.com/news-releases/news-release-details/eyenovia-highlights-recent-progress-three-phase-3-programs-nda">
                Mid-2022
              </a> <div class="note">Phase 3 trial met primary endpoint - May 25, 2021. Further Phase 3 trial to be initiated later in 2021 with data due mid-2022.</div></td><td>
              26m
            </td><td>
              109.0m
            </td><td>
              186.6k
            </td><td>
              84.0k
            </td><td>
              12.00
            </td><td>
              $4.21
            </td><td>
              $4.12
            </td><td>
              N/A
            </td><td>
              23.98m
            </td><td>
              -1.78m
            </td><td>
              13.50
            </td><td>
              2.39m
            </td><td>
              87.68m
            </td><td>
              9.4
            </td><td>
              17,942,157
            </td><td>
              06/15/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KRTX" class="margin-bottom-1">
                KRTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$111.38</div> <small class="number change-up">+5.30<span>&nbsp;&nbsp;</span>+5.00%</small></td><td><strong>KarXT (EMERGENT-2)</strong> <br>Acute psychosis in patients with schizophrenia
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005171/en/">
                Mid-2022
              </a> <div class="note">Phase 3 top-line data due mid-2022.</div></td><td>
              30m
            </td><td>
              3.3b
            </td><td>
              56.6k
            </td><td>
              188.1k
            </td><td>
              5.87
            </td><td>
              $107.95
            </td><td>
              $106.08
            </td><td>
              April 2022
            </td><td>
              0.53b
            </td><td>
              -9.63m
            </td><td>
              54.65
            </td><td>
              0.51b
            </td><td>
              2.60b
            </td><td>
              0.9
            </td><td>
              22,748,344
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ABEO" class="margin-bottom-1">
                ABEO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.26</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+7.69%</small></td><td><strong>EB-101 - VITAL</strong> <br>Recessive dystrophic epidermolysis bullosa (RDEB)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.abeonatherapeutics.com/press-releases/detail/213/abeona-therapeutics-reports-second-quarter-financial-results">
                Mid-2022
              </a> <div class="note">Phase 3 top-line data due mid-2022.</div></td><td>
              101m
            </td><td>
              127.5m
            </td><td>
              337.5k
            </td><td>
              1.3m
            </td><td>
              1.52
            </td><td>
              $1.18
            </td><td>
              $1.17
            </td><td>
              March 2022
            </td><td>
              70.67m
            </td><td>
              -3.83m
            </td><td>
              18.45
            </td><td>
              24.08m
            </td><td>
              49.08m
            </td><td>
              4.2
            </td><td>
              87,155,163
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SAGE" class="margin-bottom-1">
                SAGE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$42.82</div> <small class="number change-up">+0.84<span>&nbsp;&nbsp;</span>+2.00%</small></td><td><strong>Zuranolone (SAGE-217) - SKYLARK Study (PPD-301)</strong> <br>Postpartum depression (PPD)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210803005320/en/">
                Mid-2022
              </a> <div class="note">Phase 3 top-line data due mid-2022.</div></td><td>
              59m
            </td><td>
              2.5b
            </td><td>
              153.7k
            </td><td>
              1.1m
            </td><td>
              1.30
            </td><td>
              $42.57
            </td><td>
              $41.98
            </td><td>
              December 2021
            </td><td>
              1.85b
            </td><td>
              -34.26m
            </td><td>
              53.99
            </td><td>
              1.76b
            </td><td>
              0.58b
            </td><td>
              1.7
            </td><td>
              43,822,518
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BBIO" class="margin-bottom-1">
                BBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.45</div> <small class="number change-up">+0.42<span>&nbsp;&nbsp;</span>+0.86%</small></td><td><strong>BBP-631</strong> <br>Congenital adrenal hyperplasia (CAH
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/bridgebio-pharma-inc-reports-second-quarter-2021-financial-results-and-business-update-301348970.html">
                Mid-2022
              </a> <div class="note">Phase 1/2 initial data due mid-2021.</div></td><td>
              150m
            </td><td>
              7.4b
            </td><td>
              385.3k
            </td><td>
              0.9m
            </td><td>
              -15.95
            </td><td>
              $49.7
            </td><td>
              $49.03
            </td><td>
              N/A
            </td><td>
              0.78b
            </td><td>
              -30.57m
            </td><td>
              25.60
            </td><td>
              -0.76b
            </td><td>
              7.84b
            </td><td>
              5.3
            </td><td>
              82,237,528
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AYLA" class="margin-bottom-1">
                AYLA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.11</div> <small class="number change-down">-0.35<span>&nbsp;&nbsp;</span>-2.81%</small></td><td><strong>AL102 - (RINGSIDE)</strong> <br>Desmoid tumors
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ayalapharma.com/news-releases/news-release-details/ayala-pharmaceuticals-reports-second-quarter-2021-financial">
                Mid-2022
              </a> <div class="note">Phase 2/3 trial to be initiated 1H 2021 with interim data from part 1 due mid-2022.</div></td><td>
              13m
            </td><td>
              160.4m
            </td><td>
              25.0k
            </td><td>
              35.4k
            </td><td>
              3.75
            </td><td>
              $11.74
            </td><td>
              $12.46
            </td><td>
              N/A
            </td><td>
              37.48m
            </td><td>
              -3.85m
            </td><td>
              9.74
            </td><td>
              31.77m
            </td><td>
              121.10m
            </td><td>
              1.3
            </td><td>
              4,598,420
            </td><td>
              08/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALNY" class="margin-bottom-1">
                ALNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$199.95</div> <small class="number change-up">+2.17<span>&nbsp;&nbsp;</span>+1.10%</small></td><td><strong>ONPATTRO (patisiran) - APOLLO-B</strong> <br>Wild-type ATTR amyloidosis patients with cardiomyopathy
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210803005132/en/">
                Mid-2022
              </a> <div class="note">Phase 3 completion of enrollment announced June 1, 2021. Top-line data due mid-2022.</div></td><td>
              119m
            </td><td>
              23.8b
            </td><td>
              237.9k
            </td><td>
              0.7m
            </td><td>
              27.85
            </td><td>
              $198.72
            </td><td>
              $197.78
            </td><td>
              June 2022
            </td><td>
              1.83b
            </td><td>
              -40.62m
            </td><td>
              44.98
            </td><td>
              -0.83b
            </td><td>
              22.37b
            </td><td>
              0.3
            </td><td>
              102,229,141
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OTIC" class="margin-bottom-1">
                OTIC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.33</div> <small class="number change-up">+0.08<span>&nbsp;&nbsp;</span>+6.59%</small></td><td><strong>OTO-313</strong> <br>Tinnitus
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.otonomy.com/news-releases/news-release-details/otonomy-reports-second-quarter-2021-financial-results-and">
                Mid-2022
              </a> <div class="note">Phase 2 initiation announced March 25, 2021 with top-line data due mid-2022.</div></td><td>
              57m
            </td><td>
              75.5m
            </td><td>
              0.6m
            </td><td>
              416.9k
            </td><td>
              0.97
            </td><td>
              $1.24
            </td><td>
              $1.25
            </td><td>
              June 2022
            </td><td>
              92.13m
            </td><td>
              -3.19m
            </td><td>
              28.84
            </td><td>
              54.36m
            </td><td>
              5.19m
            </td><td>
              0.9
            </td><td>
              51,696,433
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VRDN" class="margin-bottom-1">
                VRDN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.68</div> <small class="number change-up">+0.10<span>&nbsp;&nbsp;</span>+0.74%</small></td><td><strong>VRDN-002</strong> <br>Healthy volunteers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.compasspathways.com/news-releases/news-release-details/compass-pathways-plc-announces-financial-results-and-business-1">
                Mid-2022
              </a> <div class="note">Phase 1 dosing to commence 2022. Initial data due mid-2022.</div></td><td>
              10m
            </td><td>
              131.2m
            </td><td>
              2.8k
            </td><td>
              48.7k
            </td><td>
              -2.37
            </td><td>
              $13.74
            </td><td>
              $13.58
            </td><td>
              N/A
            </td><td>
              100.52m
            </td><td>
              -4.88m
            </td><td>
              20.61
            </td><td>
              81.23m
            </td><td>
              175.67m
            </td><td>
              15.2
            </td><td>
              9,545,467
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NXTC" class="margin-bottom-1">
                NXTC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.37</div> <small class="number change-up">+0.36<span>&nbsp;&nbsp;</span>+5.14%</small></td><td><strong>NC762</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://ir.nextcure.com/news-releases/news-release-details/nextcure-reports-second-quarter-2021-financial-results">
                Mid-2022
              </a> <div class="note">Phase 1/2 trial initiation announced July 6, 2021 with initial data due mid-2022.</div></td><td>
              28m
            </td><td>
              203.5m
            </td><td>
              319.9k
            </td><td>
              283.1k
            </td><td>
              0.77
            </td><td>
              $7.01
            </td><td>
              $7.01
            </td><td>
              N/A
            </td><td>
              239.19m
            </td><td>
              -5.74m
            </td><td>
              41.67
            </td><td>
              227.43m
            </td><td>
              -53.32m
            </td><td>
              2.5
            </td><td>
              25,967,303
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VIRI" class="margin-bottom-1">
                VIRI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.73</div> <small class="number change-up">+0.12<span>&nbsp;&nbsp;</span>+2.60%</small></td><td><strong>IMC-1 (FORTRESS)</strong> <br>Fibromyalgia
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210812005079/en/">
                Mid-2022
              </a> <div class="note">Phase 2b data due mid-2022.</div></td><td>
              8m
            </td><td>
              39.4m
            </td><td>
              15.3k
            </td><td>
              99.0k
            </td><td>
              1.73
            </td><td>
              $4.67
            </td><td>
              $4.61
            </td><td>
              June 2022
            </td><td>
              20.18m
            </td><td>
              -0.92m
            </td><td>
              22.02
            </td><td>
              19.28m
            </td><td>
              42.13m
            </td><td>
              10.5
            </td><td>
              6,616,974
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EVFM" class="margin-bottom-1">
                EVFM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.68</div> <small class="number change-up">0.00<span>&nbsp;&nbsp;</span>-0.09%</small></td><td><strong>EVO100 (EVOGUARD)</strong> <br>Chlamydia and gonorrhea
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://filecache.investorroom.com/mr5ir_evofem/243/2021.08.11_EVFM%20Q2%20call%20slides_FINAL.pdf">
                Mid-2022
              </a> <div class="note">Phase 3 data due mid-2022.</div></td><td>
              81m
            </td><td>
              55.2m
            </td><td>
              1.8m
            </td><td>
              8.6m
            </td><td>
              33.98
            </td><td>
              $0.67
            </td><td>
              $0.68
            </td><td>
              April 22, 2022
            </td><td>
              14.84m
            </td><td>
              -17.86m
            </td><td>
              0.83
            </td><td>
              -84.95m
            </td><td>
              146.15m
            </td><td>
              0
            </td><td>
              13,672,588
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PTN" class="margin-bottom-1">
                PTN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.46</div> <small class="number change-up">+0.03<span>&nbsp;&nbsp;</span>+6.29%</small></td><td><strong>PL-8177</strong> <br>Ulcerative colitis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/palatin-reports-financial-results-for-the-third-fiscal-quarter-of-2021-and-provides-corporate-update-301292101.html">
                Mid-2022
              </a> <div class="note">Phase 2 trial to commence 2H 2021 with data due mid-2022.</div></td><td>
              230m
            </td><td>
              106.4m
            </td><td>
              0.6m
            </td><td>
              1.4m
            </td><td>
              1.71
            </td><td>
              $0.43
            </td><td>
              $0.44
            </td><td>
              N/A
            </td><td>
              63.00m
            </td><td>
              -1.17m
            </td><td>
              53.93
            </td><td>
              45.00m
            </td><td>
              32.76m
            </td><td>
              9.8
            </td><td>
              226,985,967
            </td><td>
              05/17/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OTIC" class="margin-bottom-1">
                OTIC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.33</div> <small class="number change-up">+0.08<span>&nbsp;&nbsp;</span>+6.59%</small></td><td><strong>OTO-413</strong> <br>Hearing loss
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.otonomy.com/news-releases/news-release-details/otonomy-reports-second-quarter-2021-financial-results-and">
                Mid-2022
              </a> <div class="note">Phase 1/2 trial expansion announced June 15, 2021 with data due mid-2022.</div></td><td>
              57m
            </td><td>
              75.5m
            </td><td>
              0.6m
            </td><td>
              416.9k
            </td><td>
              0.97
            </td><td>
              $1.24
            </td><td>
              $1.25
            </td><td>
              N/A
            </td><td>
              92.13m
            </td><td>
              -3.19m
            </td><td>
              28.84
            </td><td>
              54.36m
            </td><td>
              5.19m
            </td><td>
              0.9
            </td><td>
              51,696,433
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BLRX" class="margin-bottom-1">
                BLRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.91</div> <small class="number change-up">+0.16<span>&nbsp;&nbsp;</span>+5.82%</small></td><td><strong>Motixafortide (BL-8040) and  LIBTAYO (cemiplimab)</strong> <br>First-line pancreatic ductal adenocarcinoma
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/biolinerx-reports-third-quarter-2020-financial-results-and-provides-corporate-update-301178794.html">
                Mid-2022
              </a> <div class="note">Phase 2 data due mid-2022.</div></td><td>
              47m
            </td><td>
              137.6m
            </td><td>
              348.6k
            </td><td>
              1.1m
            </td><td>
              2.12
            </td><td>
              $2.75
            </td><td>
              $2.75
            </td><td>
              July 1, 2025
            </td><td>
              48.05m
            </td><td>
              -2.08m
            </td><td>
              23.14
            </td><td>
              29.10m
            </td><td>
              79.89m
            </td><td>
              0
            </td><td>
              47,274,740
            </td><td>
              05/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GSK" class="margin-bottom-1">
                GSK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$41.57</div> <small class="number change-down">-0.28<span>&nbsp;&nbsp;</span>-0.67%</small></td><td><strong>JEMPERLI (Dostarlimab) -(RUBY)</strong> <br>Endometrial Cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.gsk.com/media/7129/q2-2021-results-slides.pdf">
                Mid-2022
              </a> <div class="note">Phase 3 data due mid-2022.</div></td><td>
              3b
            </td><td>
              104.6b
            </td><td>
              2.3m
            </td><td>
              4.2m
            </td><td>
              4.95
            </td><td>
              $41.75
            </td><td>
              $41.85
            </td><td>
              July 30, 2021
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -51.10b
            </td><td>
              133.80b
            </td><td>
              0.2
            </td><td>
              2,506,785,977
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARQT" class="margin-bottom-1">
                ARQT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$20.84</div> <small class="number change-up">+0.59<span>&nbsp;&nbsp;</span>+2.94%</small></td><td><strong>Roflumilast foam (ARQ-154) - (STRATUM)</strong> <br>Seborrheic dermatitis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.arcutis.com/news-releases/news-release-details/arcutis-announces-first-patient-enrolled-phase-3-clinical-trial">
                2Q / 3Q 2022
              </a> <div class="note">Phase 3 top-line data due 2Q / 3Q 2022.</div></td><td>
              50m
            </td><td>
              1.0b
            </td><td>
              65.4k
            </td><td>
              180.1k
            </td><td>
              2.53
            </td><td>
              $20.67
            </td><td>
              $20.25
            </td><td>
              N/A
            </td><td>
              387.87m
            </td><td>
              -11.94m
            </td><td>
              32.47
            </td><td>
              369.46m
            </td><td>
              0.61b
            </td><td>
              4
            </td><td>
              20,923,311
            </td><td>
              07/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARDS" class="margin-bottom-1">
                ARDS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.85</div> <small class="number change-up">+0.26<span>&nbsp;&nbsp;</span>+7.30%</small></td><td><strong>Salvecin (AR-301)</strong> <br>Ventilator associated pneumonia (VAP) / Staphylococcus aureus
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/aridis-pharmaceuticals-announces-second-quarter-2021-results-301354302.html">
                Mid-2022
              </a> <div class="note">Phase 3 top-line data due mid-2022.</div></td><td>
              14m
            </td><td>
              54.1m
            </td><td>
              50.5k
            </td><td>
              202.1k
            </td><td>
              -4.01
            </td><td>
              $3.65
            </td><td>
              $3.59
            </td><td>
              August 2020
            </td><td>
              24.63m
            </td><td>
              -2.20m
            </td><td>
              11.18
            </td><td>
              -246.20k
            </td><td>
              40.70m
            </td><td>
              12.8
            </td><td>
              12,624,726
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BPMC" class="margin-bottom-1">
                BPMC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$96.07</div> <small class="number change-up">+2.24<span>&nbsp;&nbsp;</span>+2.39%</small></td><td><strong>AYVAKIT (avapritinib) - PIONEER</strong> <br>Indolent and smoldering systemic mastocytosis (SM)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/blueprint-medicines-reports-second-quarter-2021-financial-results-301343753.html">
                Mid-2022
              </a> <div class="note">Phase 2 top-line data (Part 2) due mid-2022.</div></td><td>
              59m
            </td><td>
              5.6b
            </td><td>
              166.2k
            </td><td>
              0.6m
            </td><td>
              4.23
            </td><td>
              $94.71
            </td><td>
              $93.83
            </td><td>
              March 2022
            </td><td>
              0.59b
            </td><td>
              -21.05m
            </td><td>
              28.04
            </td><td>
              350.46m
            </td><td>
              4.95b
            </td><td>
              1.7
            </td><td>
              58,211,751
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ELEV" class="margin-bottom-1">
                ELEV
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.59</div> <small class="number change-down">-0.16<span>&nbsp;&nbsp;</span>-1.25%</small></td><td><strong>Seribantumab (CRESTONE)</strong> <br>Solid Tumors
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/elevation-oncology-reports-second-quarter-2021-financial-results-301354698.html">
                Mid-2022
              </a> <div class="note">Phase 2 interim analysis due mid-2022. </div></td><td>
              23m
            </td><td>
              292.4m
            </td><td>
              41.6k
            </td><td>
              103.5k
            </td><td>
              1.88
            </td><td>
              $12.5
            </td><td>
              $12.75
            </td><td>
              June 2022
            </td><td>
              155.69m
            </td><td>
              -1.29m
            </td><td>
              120.63
            </td><td>
              151.97m
            </td><td>
              138.11m
            </td><td>
              2.4
            </td><td>
              20,037,868
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VTGN" class="margin-bottom-1">
                VTGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.97</div> <small class="number change-up">+0.28<span>&nbsp;&nbsp;</span>+10.41%</small></td><td><strong>PH94B (PALISADE)</strong> <br>Social Anxiety Disorder (SAD)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.vistagen.com/news-media/press-releases/detail/181/vistagen-therapeutics-reports-fiscal-year-2022-first">
                Mid-2022
              </a> <div class="note">Phase 3 top-line data due mid-2022.</div></td><td>
              193m
            </td><td>
              0.6b
            </td><td>
              0.9m
            </td><td>
              2.2m
            </td><td>
              6.75
            </td><td>
              $2.69
            </td><td>
              $2.69
            </td><td>
              May 2022
            </td><td>
              94.07m
            </td><td>
              -2.06m
            </td><td>
              45.72
            </td><td>
              75.78m
            </td><td>
              424.77m
            </td><td>
              0.3
            </td><td>
              192,420,915
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLDX" class="margin-bottom-1">
                CLDX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$48.69</div> <small class="number change-up">+1.14<span>&nbsp;&nbsp;</span>+2.40%</small></td><td><strong>CDX-0159</strong> <br>Chronic spontaneous urticaria (CSU)
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.celldex.com/news-releases/news-release-details/celldex-reports-second-quarter-2021-financial-results-and">
                Summer 2022
              </a> <div class="note">Phase 1b data to be presented early summer 2022.</div></td><td>
              46m
            </td><td>
              2.3b
            </td><td>
              345.8k
            </td><td>
              1.0m
            </td><td>
              12.42
            </td><td>
              $48.35
            </td><td>
              $47.55
            </td><td>
              December 2021
            </td><td>
              444.38m
            </td><td>
              -3.98m
            </td><td>
              111.75
            </td><td>
              422.11m
            </td><td>
              2.05b
            </td><td>
              14.1
            </td><td>
              46,253,150
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PFE" class="margin-bottom-1">
                PFE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.98</div> <small class="number change-up">+1.25<span>&nbsp;&nbsp;</span>+2.58%</small></td><td><strong>PF-06939926 (CIFFREO)</strong> <br>Duchenne muscular dystrophy (DMD)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s21.q4cdn.com/317678438/files/doc_financials/2021/q2/Q2-2021-Earnings-Charts-FINAL.pdf">
                3Q 2022
              </a> <div class="note">Phase 3 interim data due 3Q 2022.</div></td><td>
              6b
            </td><td>
              280.2b
            </td><td>
              69.5m
            </td><td>
              30.1m
            </td><td>
              4.00
            </td><td>
              $50.29
            </td><td>
              $48.72
            </td><td>
              January 6, 2023
            </td><td>
              28.48b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -71.13b
            </td><td>
              289.19b
            </td><td>
              0.3
            </td><td>
              5,605,213,314
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MDGL" class="margin-bottom-1">
                MDGL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$82.90</div> <small class="number change-up">+2.38<span>&nbsp;&nbsp;</span>+2.96%</small></td><td><strong>Resmetirom (MGL-3196) - MAESTRO-NASH</strong> <br>Non-alcoholic steatohepatitis (NASH)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-2021-second-quarter-financial">
                3Q 2022
              </a> <div class="note">Phase 3 top-line data due 3Q 2022.</div></td><td>
              17m
            </td><td>
              1.4b
            </td><td>
              48.0k
            </td><td>
              137.0k
            </td><td>
              5.09
            </td><td>
              $81.39
            </td><td>
              $80.52
            </td><td>
              December 2021
            </td><td>
              295.72m
            </td><td>
              -15.63m
            </td><td>
              18.92
            </td><td>
              238.41m
            </td><td>
              1.01b
            </td><td>
              52.7
            </td><td>
              10,615,167
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EVLO" class="margin-bottom-1">
                EVLO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.74</div> <small class="number change-up">+0.33<span>&nbsp;&nbsp;</span>+3.45%</small></td><td><strong>EDP1815</strong> <br>Atopic dermatitis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.evelobio.com/static-files/aca18e7a-0b98-4e1e-a951-25faf8572d9d">
                3Q 2022
              </a> <div class="note">Phase 2 trial to be initiated 3Q 2021 with data due 3Q 2022.</div></td><td>
              53m
            </td><td>
              0.5b
            </td><td>
              153.2k
            </td><td>
              190.5k
            </td><td>
              8.40
            </td><td>
              $9.59
            </td><td>
              $9.42
            </td><td>
              N/A
            </td><td>
              114.07m
            </td><td>
              -5.14m
            </td><td>
              22.18
            </td><td>
              31.11m
            </td><td>
              436.90m
            </td><td>
              0.5
            </td><td>
              23,304,546
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PTCT" class="margin-bottom-1">
                PTCT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$39.58</div> <small class="number change-up">+1.38<span>&nbsp;&nbsp;</span>+3.61%</small></td><td><strong>Vatiquinone (MIT-E)</strong> <br>Mitochondrial Epilepsy
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-a-corporate-update-and-reports-second-quarter-2021-financial-results-301344644.html">
                3Q 2022
              </a> <div class="note">Phase 2/3 data due 3Q 2022.</div></td><td>
              71m
            </td><td>
              2.8b
            </td><td>
              109.5k
            </td><td>
              412.7k
            </td><td>
              14.24
            </td><td>
              $38.84
            </td><td>
              $38.2
            </td><td>
              September 1, 2021
            </td><td>
              0.93b
            </td><td>
              -10.38m
            </td><td>
              89.43
            </td><td>
              -0.93b
            </td><td>
              2.29b
            </td><td>
              0.9
            </td><td>
              49,392,128
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AKRO" class="margin-bottom-1">
                AKRO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.33</div> <small class="number change-up">+1.45<span>&nbsp;&nbsp;</span>+6.94%</small></td><td><strong>Efruxifermin (Harmony)</strong> <br>Nonalcoholic Steatohepatitis
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.akerotx.com/news-releases/news-release-details/akero-therapeutics-reports-first-quarter-2021-financial-results">
                3Q 2022
              </a> <div class="note">Phase 2b initial data due 3Q 2022.</div></td><td>
              35m
            </td><td>
              0.8b
            </td><td>
              159.9k
            </td><td>
              248.6k
            </td><td>
              3.54
            </td><td>
              $23.06
            </td><td>
              $20.88
            </td><td>
              September 2022
            </td><td>
              218.01m
            </td><td>
              -6.68m
            </td><td>
              32.65
            </td><td>
              200.13m
            </td><td>
              499.53m
            </td><td>
              2.6
            </td><td>
              22,024,141
            </td><td>
              05/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AEZS" class="margin-bottom-1">
                AEZS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.65</div> <small class="number change-up">+0.03<span>&nbsp;&nbsp;</span>+4.08%</small></td><td><strong>MACRILEN (Macimorelin Acetate) - DETECT(Study P02)</strong> <br>Paediatric patients with suspected growth hormone deficiency (GHD)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.pressviewer.com/profiles/investor/NewsPrint.asp?v=6&amp;b=2533&amp;ID=99297&amp;m=rl&amp;g=1592">
                3Q 2022
              </a> <div class="note">Phase 3 trial initiation announced May 13, 2021. Trial to be completed 3Q 2022.</div></td><td>
              121m
            </td><td>
              78.6m
            </td><td>
              0.6m
            </td><td>
              1.3m
            </td><td>
              1.27
            </td><td>
              $0.64
            </td><td>
              $0.62
            </td><td>
              July 2022
            </td><td>
              67.69m
            </td><td>
              -1.21m
            </td><td>
              55.86
            </td><td>
              44.68m
            </td><td>
              7.76m
            </td><td>
              0
            </td><td>
              121,293,887
            </td><td>
              05/23/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SGMO" class="margin-bottom-1">
                SGMO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.87</div> <small class="number change-up">+0.51<span>&nbsp;&nbsp;</span>+5.45%</small></td><td><strong>Giroctocogene fitelparvovec (SB-525) - AFFINE</strong> <br>Hemophilia A
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.sangamo.com/index.php/static-files/59eafc6d-194e-42ac-94f1-093d77e82abf">
                3Q 2022
              </a> <div class="note"> Phase 3 data due 3Q 2022. </div></td><td>
              145m
            </td><td>
              1.4b
            </td><td>
              0.5m
            </td><td>
              1.0m
            </td><td>
              3.21
            </td><td>
              $9.46
            </td><td>
              $9.36
            </td><td>
              September 10, 2022
            </td><td>
              498.11m
            </td><td>
              -17.52m
            </td><td>
              28.43
            </td><td>
              108.21m
            </td><td>
              0.87b
            </td><td>
              2.2
            </td><td>
              120,566,640
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PFE" class="margin-bottom-1">
                PFE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.98</div> <small class="number change-up">+1.25<span>&nbsp;&nbsp;</span>+2.58%</small></td><td><strong>Giroctocogene fitelparvovec (SB-525) - AFFINE</strong> <br>Hemophilia A
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.sangamo.com/index.php/static-files/59eafc6d-194e-42ac-94f1-093d77e82abf">
                3Q 2022
              </a> <div class="note"> Phase 3 data due 3Q 2022. </div></td><td>
              6b
            </td><td>
              280.2b
            </td><td>
              69.5m
            </td><td>
              30.1m
            </td><td>
              4.00
            </td><td>
              $50.29
            </td><td>
              $48.72
            </td><td>
              September 10, 2022
            </td><td>
              28.48b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -71.13b
            </td><td>
              289.19b
            </td><td>
              0.3
            </td><td>
              5,605,213,314
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BTX" class="margin-bottom-1">
                BTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.85</div> <small class="number change-up">+0.25<span>&nbsp;&nbsp;</span>+2.59%</small></td><td><strong>IRX-2 and KEYTRUDA (pembrolizumab) - GI-106</strong> <br>Gastric or Gastroesophageal Junction Cancer
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0000748592/000149315220022484/forms-4a.htm">
                3Q 2022
              </a> <div class="note">Phase 1/2 ongoing. Final data due 3Q 2022.</div></td><td>
              52m
            </td><td>
              0.5b
            </td><td>
              0.7m
            </td><td>
              2.3m
            </td><td>
              33.96
            </td><td>
              $9.6
            </td><td>
              $9.6
            </td><td>
              February 19, 2022
            </td><td>
              46.08m
            </td><td>
              -2.27m
            </td><td>
              20.32
            </td><td>
              16.55m
            </td><td>
              450.07m
            </td><td>
              12.1
            </td><td>
              35,906,398
            </td><td>
              05/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMGN" class="margin-bottom-1">
                IMGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.59</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+5.47%</small></td><td><strong>Mirvetuximab - MIRASOL</strong> <br>Cancer - ovarian cancer and relapsed endometrial cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210730005064/en/">
                3Q 2022
              </a> <div class="note">Phase 3 top-line data due 3Q 2022.</div></td><td>
              202m
            </td><td>
              1.1b
            </td><td>
              0.7m
            </td><td>
              1.4m
            </td><td>
              16.44
            </td><td>
              $5.38
            </td><td>
              $5.3
            </td><td>
              July 2022
            </td><td>
              213.21m
            </td><td>
              -14.63m
            </td><td>
              14.58
            </td><td>
              -19.77m
            </td><td>
              0.85b
            </td><td>
              1.1
            </td><td>
              179,510,656
            </td><td>
              07/30/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EIGR" class="margin-bottom-1">
                EIGR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.79</div> <small class="number change-up">+0.24<span>&nbsp;&nbsp;</span>+3.18%</small></td><td><strong>ZOKINVY (lonafarnib) - D-LIVR</strong> <br>Chronic hepatitis delta virus (HDV)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-reports-first-quarter-2021-financial-results-and-provides-business-update-301286075.html">
                2022
              </a> <div class="note">Phase 3 enrollment to be completed in 2021. End of treatment data planned in 2022.</div></td><td>
              34m
            </td><td>
              264.5m
            </td><td>
              77.1k
            </td><td>
              196.4k
            </td><td>
              2.43
            </td><td>
              $7.69
            </td><td>
              $7.55
            </td><td>
              April 1, 2021
            </td><td>
              95.14m
            </td><td>
              -6.79m
            </td><td>
              14.00
            </td><td>
              47.42m
            </td><td>
              181.39m
            </td><td>
              1.4
            </td><td>
              29,396,684
            </td><td>
              06/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NGM" class="margin-bottom-1">
                NGM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.63</div> <small class="number change-up">+0.94<span>&nbsp;&nbsp;</span>+4.33%</small></td><td><strong>NGM621 (CATALINA)</strong> <br>Geographic atrophy
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ngmbio.com/news-releases/news-release-details/ngm-bio-provides-business-highlights-and-reports-second-0">
                2H 2022
              </a> <div class="note">Phase 2 topline data to be released 2H 2022. </div></td><td>
              77m
            </td><td>
              1.8b
            </td><td>
              169.8k
            </td><td>
              391.8k
            </td><td>
              4.70
            </td><td>
              $21.78
            </td><td>
              $21.69
            </td><td>
              December 2022
            </td><td>
              376.56m
            </td><td>
              -7.77m
            </td><td>
              48.46
            </td><td>
              326.63m
            </td><td>
              1.29b
            </td><td>
              1.3
            </td><td>
              31,576,701
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARQT" class="margin-bottom-1">
                ARQT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$20.84</div> <small class="number change-up">+0.59<span>&nbsp;&nbsp;</span>+2.94%</small></td><td><strong>Roflumilast Cream (ARQ-151) -INTEGUMENT-PED</strong> <br>Atopic Dermatitis - ages of 2-5 years old
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.arcutis.com/news-releases/news-release-details/arcutis-announces-second-quarter-2021-financial-results-and">
                2H 2022
              </a> <div class="note">Phase 3 trial initiation announced April 12, 2021. Top-line data due 2H 2022.</div></td><td>
              50m
            </td><td>
              1.0b
            </td><td>
              65.4k
            </td><td>
              180.1k
            </td><td>
              2.53
            </td><td>
              $20.67
            </td><td>
              $20.25
            </td><td>
              N/A
            </td><td>
              387.87m
            </td><td>
              -11.94m
            </td><td>
              32.47
            </td><td>
              369.46m
            </td><td>
              0.61b
            </td><td>
              4
            </td><td>
              20,923,311
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLSN" class="margin-bottom-1">
                CLSN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.01</div> <small class="number change-up">+0.04<span>&nbsp;&nbsp;</span>+4.54%</small></td><td><strong>ThermoDox (PanDox)</strong> <br>Pancreatic Cancer
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.celsion.com/news-releases/news-release-details/celsion-corporation-reports-second-quarter-2021-financial">
                2022
              </a> <div class="note">Phase 1 initiation announced July 1, 2021. To be completed in 2022.</div></td><td>
              87m
            </td><td>
              87.4m
            </td><td>
              421.7k
            </td><td>
              1.4m
            </td><td>
              1.36
            </td><td>
              $0.97
            </td><td>
              $0.97
            </td><td>
              May 2022
            </td><td>
              56.79m
            </td><td>
              -0.87m
            </td><td>
              65.22
            </td><td>
              37.84m
            </td><td>
              31.97m
            </td><td>
              7.4
            </td><td>
              86,090,872
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ABOS" class="margin-bottom-1">
                ABOS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.66</div> <small class="number change-up">+0.38<span>&nbsp;&nbsp;</span>+2.17%</small></td><td><strong>ACU193</strong> <br>Alzheimer’s disease
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/16/2281528/0/en/Acumen-Pharmaceuticals-Reports-Financial-Results-for-Second-Quarter-2021-and-Business-Highlights.html">
                YE 2022
              </a> <div class="note">Phase 1 data due by the end of 2022.</div></td><td>
              40m
            </td><td>
              0.7b
            </td><td>
              62.5k
            </td><td>
              157.8k
            </td><td>
              -6.74
            </td><td>
              $17.59
            </td><td>
              $17.28
            </td><td>
              October 2022
            </td><td>
              66.25m
            </td><td>
              -1.42m
            </td><td>
              46.61
            </td><td>
              -112.77m
            </td><td>
              0.63b
            </td><td>
              0.5
            </td><td>
              28,849,266
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RVMD" class="margin-bottom-1">
                RVMD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$26.00</div> <small class="number change-up">+0.56<span>&nbsp;&nbsp;</span>+2.20%</small></td><td><strong>RMC-4630 and Cotellic (cobimetinib) - RMC-4630-02</strong> <br>Solid tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/05/10/2226653/0/en/Revolution-Medicines-Reports-First-Quarter-Financial-Results-and-Update-on-Corporate-Progress.html">
                2022
              </a> <div class="note">Phase 1b/2 initial data due 2022.</div></td><td>
              74m
            </td><td>
              1.9b
            </td><td>
              312.5k
            </td><td>
              0.7m
            </td><td>
              2.79
            </td><td>
              $25.76
            </td><td>
              $25.44
            </td><td>
              March 31, 2022
            </td><td>
              0.63b
            </td><td>
              -11.36m
            </td><td>
              55.09
            </td><td>
              0.54b
            </td><td>
              1.26b
            </td><td>
              0.7
            </td><td>
              49,649,322
            </td><td>
              05/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/STSA" class="margin-bottom-1">
                STSA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.92</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+1.86%</small></td><td><strong>STS101 (ASCEND)</strong> <br>Migraine
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.satsumarx.com/2021-08-10-Satsuma-Pharmaceuticals-Reports-Second-Quarter-2021-Financial-Results-and-Recent-Business-Highlights">
                2H 2022
              </a> <div class="note">Phase 3 open-label safety trial to be completed 2H 2022.</div></td><td>
              32m
            </td><td>
              155.1m
            </td><td>
              33.5k
            </td><td>
              386.2k
            </td><td>
              1.22
            </td><td>
              $4.83
            </td><td>
              $4.83
            </td><td>
              October 2021
            </td><td>
              114.51m
            </td><td>
              -3.70m
            </td><td>
              30.96
            </td><td>
              106.93m
            </td><td>
              33.19m
            </td><td>
              1
            </td><td>
              22,490,828
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>IMFINZI (Durvalumab) - EMERALD-1</strong> <br>Locoregional Hepatocellular carcinoma (HCC)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2021/h1-2021/H1_2021_results_presentation.pdf">
                2H 2022
              </a> <div class="note">Phase 3 data due 2H 2022.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              September 19, 2022
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MRNS" class="margin-bottom-1">
                MRNS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.30</div> <small class="number change-up">+1.05<span>&nbsp;&nbsp;</span>+9.38%</small></td><td><strong>Ganaxolone (RAISE)</strong> <br>Refractory status epilepticus (RSE)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210803005573/en/">
                2H 2022
              </a> <div class="note">Phase 3 data due 2H 2022.</div></td><td>
              37m
            </td><td>
              452.0m
            </td><td>
              156.5k
            </td><td>
              232.7k
            </td><td>
              4.98
            </td><td>
              $11.47
            </td><td>
              $11.25
            </td><td>
              January 2022
            </td><td>
              128.72m
            </td><td>
              -7.65m
            </td><td>
              16.82
            </td><td>
              98.79m
            </td><td>
              316.60m
            </td><td>
              1.3
            </td><td>
              36,687,377
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LGND" class="margin-bottom-1">
                LGND
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$113.41</div> <small class="number change-up">+9.31<span>&nbsp;&nbsp;</span>+8.95%</small></td><td><strong>Ganaxolone (RAISE)</strong> <br>Refractory status epilepticus (RSE)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210803005573/en/">
                2H 2022
              </a> <div class="note">Phase 3 data due 2H 2022.</div></td><td>
              17m
            </td><td>
              1.9b
            </td><td>
              171.1k
            </td><td>
              158.2k
            </td><td>
              2.40
            </td><td>
              $105.02
            </td><td>
              $104.1
            </td><td>
              January 2022
            </td><td>
              314.06m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -155.70m
            </td><td>
              1.76b
            </td><td>
              10.4
            </td><td>
              11,870,842
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>IMFINZI (Durvalumab) - ADRIATIC</strong> <br>Small cell lung cancer (SCLC) limited disease
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2021/h1-2021/H1_2021_results_clinical_trials_appendix.pdf">
                2H 2022
              </a> <div class="note">Phase 3 data due 2H 2022.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              May 10, 2024
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BHVN" class="margin-bottom-1">
                BHVN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$125.97</div> <small class="number change-up">+3.13<span>&nbsp;&nbsp;</span>+2.55%</small></td><td><strong>Troriluzole</strong> <br>Obsessive compulsive disorder (OCD)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/biohaven-reports-second-quarter-2021-financial-results-and-recent-business-developments-301350770.html">
                2H 2022
              </a> <div class="note">Phase 3 data due 2H 2022.</div></td><td>
              65m
            </td><td>
              8.2b
            </td><td>
              170.9k
            </td><td>
              0.7m
            </td><td>
              -18.15
            </td><td>
              $124.56
            </td><td>
              $122.84
            </td><td>
              March 17, 2023
            </td><td>
              229.88m
            </td><td>
              -75.68m
            </td><td>
              3.04
            </td><td>
              -1.07b
            </td><td>
              7.94b
            </td><td>
              8.5
            </td><td>
              58,034,591
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RHHBY" class="margin-bottom-1">
                RHHBY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$50.36</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+0.12%</small></td><td><strong>Gantenerumab - (GRADUATE)</strong> <br>Early Alzheimer's disease
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.roche.com/dam/jcr:a1437516-3f73-4112-a483-40c8b1c3836e/en/irp210722.pdf">
                2022
              </a> <div class="note">Phase 3 enrollment has commenced - noted June 14, 2018. Data due 2022.</div></td><td>
              7b
            </td><td>
              344.2b
            </td><td>
              0.5m
            </td><td>
              1.0m
            </td><td>
              8.35
            </td><td>
              $50.24
            </td><td>
              $50.3
            </td><td>
              September 30, 2022
            </td><td>
              8.02b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -38.44b
            </td><td>
              356.64b
            </td><td>
              0
            </td><td>
              6,834,087,224
            </td><td>
              07/22/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MOR" class="margin-bottom-1">
                MOR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.96</div> <small class="number change-up">+0.51<span>&nbsp;&nbsp;</span>+3.79%</small></td><td><strong>Gantenerumab - (GRADUATE)</strong> <br>Early Alzheimer's disease
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.roche.com/dam/jcr:a1437516-3f73-4112-a483-40c8b1c3836e/en/irp210722.pdf">
                2022
              </a> <div class="note">Phase 3 enrollment has commenced - noted June 14, 2018. Data due 2022.</div></td><td>
              137m
            </td><td>
              1.9b
            </td><td>
              18.7k
            </td><td>
              125.1k
            </td><td>
              2.70
            </td><td>
              $13.75
            </td><td>
              $13.45
            </td><td>
              September 30, 2022
            </td><td>
              1.04b
            </td><td>
              -29.79m
            </td><td>
              34.97
            </td><td>
              65.72m
            </td><td>
              0.93b
            </td><td>
              0
            </td><td>
              136,502,236
            </td><td>
              07/22/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BYSI" class="margin-bottom-1">
                BYSI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.77</div> <small class="number change-up">+2.58<span>&nbsp;&nbsp;</span>+12.78%</small></td><td><strong>Plinabulin + OPDIVO (nivolumab) + YERVOY&nbsp;(ipilimumab)</strong> <br>Small-cell lung cancer (SCLC)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/06/16/2248177/0/en/BeyondSpring-Announces-First-Quarter-2021-Financial-Results-and-Provides-a-Corporate-Update.html">
                2022
              </a> <div class="note">Phase 2 data due 2022.</div></td><td>
              30m
            </td><td>
              0.7b
            </td><td>
              2.5m
            </td><td>
              3.4m
            </td><td>
              28.82
            </td><td>
              $20.16
            </td><td>
              $20.19
            </td><td>
              N/A
            </td><td>
              60.06m
            </td><td>
              -6.31m
            </td><td>
              9.51
            </td><td>
              33.34m
            </td><td>
              363.10m
            </td><td>
              0
            </td><td>
              10,963,858
            </td><td>
              06/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMCR" class="margin-bottom-1">
                IMCR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.70</div> <small class="number change-up">+1.72<span>&nbsp;&nbsp;</span>+6.15%</small></td><td><strong>GSK01</strong> <br>Synovial sarcoma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://nz.finance.yahoo.com/news/immunocore-provides-business-reports-full-110000334.html">
                2022
              </a> <div class="note">Phase 1 final data due 2022.</div></td><td>
              44m
            </td><td>
              1.3b
            </td><td>
              99.6k
            </td><td>
              65.9k
            </td><td>
              4.26
            </td><td>
              $27.98
            </td><td>
              $27.98
            </td><td>
              N/A
            </td><td>
              259.31m
            </td><td>
              -10.87m
            </td><td>
              23.87
            </td><td>
              128.44m
            </td><td>
              0.93b
            </td><td>
              0
            </td><td>
              43,786,088
            </td><td>
              03/25/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GLYC" class="margin-bottom-1">
                GLYC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.90</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+2.97%</small></td><td><strong>Uproleselan with VENCLEXTA (Venetoclax) and VIDAZA (Azacitidine)</strong> <br>Acute myeloid leukemia (AML)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210712005428/en/">
                2022
              </a> <div class="note">Phase 1/2 trial initiation announced July 12, 2021. Interim data due 2022.</div></td><td>
              52m
            </td><td>
              98.2m
            </td><td>
              106.0k
            </td><td>
              479.0k
            </td><td>
              0.87
            </td><td>
              $1.96
            </td><td>
              $1.85
            </td><td>
              N/A
            </td><td>
              110.69m
            </td><td>
              -4.54m
            </td><td>
              24.40
            </td><td>
              98.59m
            </td><td>
              -21.12m
            </td><td>
              2.3
            </td><td>
              41,569,401
            </td><td>
              07/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TARA" class="margin-bottom-1">
                TARA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.64</div> <small class="number change-down">-0.18<span>&nbsp;&nbsp;</span>-2.69%</small></td><td><strong>TARA-002</strong> <br>Non-muscle invasive bladder cancer (NMIBC)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.protaratx.com/news-releases/news-release-details/protara-therapeutics-announces-second-quarter-2021-financial">
                2022
              </a> <div class="note">Phase 1 trial to be initiated by end of 2021 with data due in 2022.</div></td><td>
              11m
            </td><td>
              74.6m
            </td><td>
              203.1k
            </td><td>
              82.9k
            </td><td>
              0.42
            </td><td>
              $7.07
            </td><td>
              $6.82
            </td><td>
              N/A
            </td><td>
              78.98m
            </td><td>
              -3.16m
            </td><td>
              25.01
            </td><td>
              68.49m
            </td><td>
              -393.31k
            </td><td>
              11.4
            </td><td>
              7,610,717
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>ALXN2040 add-on therapy</strong> <br>Paroxysmal nocturnal hemoglobinuria (PNH)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20201006005251/en/">
                2H 2022
              </a> <div class="note">Phase 3 data due 2H 2022.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              October 2022
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TYME" class="margin-bottom-1">
                TYME
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.05</div> <small class="number change-down">-0.01<span>&nbsp;&nbsp;</span>-0.47%</small></td><td><strong>SM-88 and Gemcitabine (PanCAN_Precision Promise)</strong> <br>Pancreatic Cancer
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210610005948/en/">
                2022
              </a> <div class="note">Phase 3 advancement determination decision 2H 2022.</div></td><td>
              172m
            </td><td>
              181.7m
            </td><td>
              0.9m
            </td><td>
              8.7m
            </td><td>
              1.88
            </td><td>
              $1.05
            </td><td>
              $1.06
            </td><td>
              January 20, 2024
            </td><td>
              69.14m
            </td><td>
              -1.94m
            </td><td>
              35.70
            </td><td>
              62.52m
            </td><td>
              109.98m
            </td><td>
              28.2
            </td><td>
              124,516,911
            </td><td>
              06/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MIRM" class="margin-bottom-1">
                MIRM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.70</div> <small class="number change-up">+0.52<span>&nbsp;&nbsp;</span>+3.67%</small></td><td><strong>Volixibat (VISTAS)</strong> <br>Primary sclerosing cholangitis 
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005953/en/">
                2022
              </a> <div class="note">Phase 2b interim analysis due 2022.</div></td><td>
              31m
            </td><td>
              448.6m
            </td><td>
              36.1k
            </td><td>
              77.7k
            </td><td>
              4.68
            </td><td>
              $14.35
            </td><td>
              $14.18
            </td><td>
              December 2022
            </td><td>
              199.73m
            </td><td>
              -13.40m
            </td><td>
              14.91
            </td><td>
              47.80m
            </td><td>
              211.81m
            </td><td>
              0.5
            </td><td>
              8,253,550
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARMP" class="margin-bottom-1">
                ARMP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.73</div> <small class="number change-down">-0.07<span>&nbsp;&nbsp;</span>-1.77%</small></td><td><strong>AP-PA02 (SWARM)</strong> <br>Pseudomonas aeruginosa Infections and and Cystic Fibrosis
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-first-quarter-results-and-provides-general-corporate-update-301290419.html">
                2021 / 2022
              </a> <div class="note">Phase 1b/2 single ascending dose (SAD) cohort to be completed 2021 / 2022.</div></td><td>
              25m
            </td><td>
              93.0m
            </td><td>
              3.5k
            </td><td>
              8.5k
            </td><td>
              3.24
            </td><td>
              $3.7
            </td><td>
              $3.8
            </td><td>
              March 2022
            </td><td>
              14.81m
            </td><td>
              -1.51m
            </td><td>
              9.79
            </td><td>
              -4.85m
            </td><td>
              90.18m
            </td><td>
              2.4
            </td><td>
              24,647,935
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BHC" class="margin-bottom-1">
                BHC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$28.30</div> <small class="number change-up">+0.34<span>&nbsp;&nbsp;</span>+1.23%</small></td><td><strong>IDP-126</strong> <br>Acne
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.bauschhealth.com/~/media/Files/V/Valeant-IR/reports-and-presentations/2q21-bausch-health-earnings-presentation.pdf">
                2H 2022
              </a> <div class="note">Phase 3 second trial met primary endpoints - April 22, 2021. NDA filing due 2H 2022.</div></td><td>
              355m
            </td><td>
              10.2b
            </td><td>
              0.7m
            </td><td>
              2.3m
            </td><td>
              -14.82
            </td><td>
              $28.26
            </td><td>
              $27.96
            </td><td>
              N/A
            </td><td>
              0.88b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -29.77b
            </td><td>
              32.82b
            </td><td>
              2.5
            </td><td>
              313,448,534
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PHVS" class="margin-bottom-1">
                PHVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.06</div> <small class="number change-up">+0.39<span>&nbsp;&nbsp;</span>+2.34%</small></td><td><strong>PHVS416 (RAPIDe-1)</strong> <br>Hereditary angioedema - on demand 
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-reports-second-quarter-2021-financial-results-and">
                2022
              </a> <div class="note">Phase 2 trial initiation announced February 26, 2021. Data due 2022.</div></td><td>
              33m
            </td><td>
              0.6b
            </td><td>
              35.0k
            </td><td>
              23.4k
            </td><td>
              2.17
            </td><td>
              $16.83
            </td><td>
              $16.67
            </td><td>
              September 2022
            </td><td>
              217.20m
            </td><td>
              -3.95m
            </td><td>
              54.94
            </td><td>
              209.71m
            </td><td>
              290.67m
            </td><td>
              0
            </td><td>
              21,057,474
            </td><td>
              07/30/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AMTI" class="margin-bottom-1">
                AMTI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.00</div> <small class="number change-up">+0.76<span>&nbsp;&nbsp;</span>+2.60%</small></td><td><strong>AMT-101 (CASTRO)</strong> <br>Rheumatoid arthritis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.appliedmt.com/static-files/4c3f1146-b81c-42c1-8260-c9a2ebbc0a30">
                2022
              </a> <div class="note">Phase 2 data due 2022.</div></td><td>
              38m
            </td><td>
              1.2b
            </td><td>
              105.8k
            </td><td>
              238.2k
            </td><td>
              5.54
            </td><td>
              $29.75
            </td><td>
              $29.24
            </td><td>
              N/A
            </td><td>
              186.24m
            </td><td>
              -7.38m
            </td><td>
              25.23
            </td><td>
              170.06m
            </td><td>
              0.93b
            </td><td>
              1.6
            </td><td>
              16,723,522
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PHVS" class="margin-bottom-1">
                PHVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.06</div> <small class="number change-up">+0.39<span>&nbsp;&nbsp;</span>+2.34%</small></td><td><strong>PHVS416 (CHAPTER-1)</strong> <br>Hereditary angioedema - prophylactic use
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-reports-second-quarter-2021-financial-results-and">
                2022
              </a> <div class="note">Phase 2 trial to be initiated in 2021 with data due 2022.</div></td><td>
              33m
            </td><td>
              0.6b
            </td><td>
              35.0k
            </td><td>
              23.4k
            </td><td>
              2.17
            </td><td>
              $16.83
            </td><td>
              $16.67
            </td><td>
              N/A
            </td><td>
              217.20m
            </td><td>
              -3.95m
            </td><td>
              54.94
            </td><td>
              209.71m
            </td><td>
              290.67m
            </td><td>
              0
            </td><td>
              21,057,474
            </td><td>
              07/30/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RHHBY" class="margin-bottom-1">
                RHHBY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$50.36</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+0.12%</small></td><td><strong>TECENTRIQ (atezolizumab) - (IMvoke010)</strong> <br>Squamous Cell Carcinoma of the Head and Neck (SCCHN)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.roche.com/dam/jcr:a1437516-3f73-4112-a483-40c8b1c3836e/en/irp210722.pdf">
                2022
              </a> <div class="note">Phase 3 data due 2022.</div></td><td>
              7b
            </td><td>
              344.2b
            </td><td>
              0.5m
            </td><td>
              1.0m
            </td><td>
              8.35
            </td><td>
              $50.24
            </td><td>
              $50.3
            </td><td>
              October 3, 2022
            </td><td>
              8.02b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -38.44b
            </td><td>
              356.64b
            </td><td>
              0
            </td><td>
              6,834,087,224
            </td><td>
              07/22/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RXDX" class="margin-bottom-1">
                RXDX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.93</div> <small class="number change-up">+0.61<span>&nbsp;&nbsp;</span>+2.73%</small></td><td><strong>PRA023 (APOLLO-CD)</strong> <br>Crohn’s Disease
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/02/2272781/0/en/Prometheus-Biosciences-Announces-Initiation-of-APOLLO-CD-Phase-2a-Clinical-Trial-of-PRA023-in-Moderate-to-Severe-Crohn-s-Disease.html">
                4Q 2022
              </a> <div class="note">Phase 2a trial initiation announced August 2, 2021. Top-line data due 4Q 2022.</div></td><td>
              39m
            </td><td>
              0.9b
            </td><td>
              38.8k
            </td><td>
              159.7k
            </td><td>
              3.15
            </td><td>
              $22.37
            </td><td>
              $22.32
            </td><td>
              N/A
            </td><td>
              301.17m
            </td><td>
              -1.79m
            </td><td>
              168.66
            </td><td>
              270.44m
            </td><td>
              0.57b
            </td><td>
              0.2
            </td><td>
              29,995,596
            </td><td>
              08/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AMTI" class="margin-bottom-1">
                AMTI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.00</div> <small class="number change-up">+0.76<span>&nbsp;&nbsp;</span>+2.60%</small></td><td><strong>AMT-101 (FILLMORE)</strong> <br>Pouchitis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.appliedmt.com/static-files/4c3f1146-b81c-42c1-8260-c9a2ebbc0a30">
                2022
              </a> <div class="note">Phase 2 data due 2022.</div></td><td>
              38m
            </td><td>
              1.2b
            </td><td>
              105.8k
            </td><td>
              238.2k
            </td><td>
              5.54
            </td><td>
              $29.75
            </td><td>
              $29.24
            </td><td>
              March 31, 2022
            </td><td>
              186.24m
            </td><td>
              -7.38m
            </td><td>
              25.23
            </td><td>
              170.06m
            </td><td>
              0.93b
            </td><td>
              1.6
            </td><td>
              16,723,522
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/WVE" class="margin-bottom-1">
                WVE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.00</div> <small class="number change-down">-0.04<span>&nbsp;&nbsp;</span>-0.66%</small></td><td><strong>WVE-004 (FOCUS-C9)</strong> <br>Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-reports-second-quarter-2021-financial-results">
                2022
              </a> <div class="note">Phase 1b/2a initiation of dosing announced July 20, 2021. Data due 2022.</div></td><td>
              51m
            </td><td>
              304.6m
            </td><td>
              145.6k
            </td><td>
              429.3k
            </td><td>
              13.95
            </td><td>
              $6.14
            </td><td>
              $6.04
            </td><td>
              February 2023
            </td><td>
              138.20m
            </td><td>
              -3.13m
            </td><td>
              44.10
            </td><td>
              -46.37m
            </td><td>
              190.30m
            </td><td>
              1.9
            </td><td>
              38,697,963
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VOR" class="margin-bottom-1">
                VOR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.87</div> <small class="number change-down">-0.40<span>&nbsp;&nbsp;</span>-3.01%</small></td><td><strong>VCAR33</strong> <br>Acute myeloid leukemia (AML) 
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/09/2277407/0/en/Vor-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Company-Update.html">
                2022
              </a> <div class="note">Phase 1 /2 initial data due 2022.</div></td><td>
              37m
            </td><td>
              478.1m
            </td><td>
              87.3k
            </td><td>
              134.0k
            </td><td>
              1.91
            </td><td>
              $13.55
            </td><td>
              $13.27
            </td><td>
              N/A
            </td><td>
              234.70m
            </td><td>
              -5.52m
            </td><td>
              42.50
            </td><td>
              209.66m
            </td><td>
              266.17m
            </td><td>
              1.4
            </td><td>
              14,880,424
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AMTI" class="margin-bottom-1">
                AMTI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.00</div> <small class="number change-up">+0.76<span>&nbsp;&nbsp;</span>+2.60%</small></td><td><strong>AMT-101 monotherapy (LOMBARD)</strong> <br>Ulcerative colitis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.appliedmt.com/static-files/4c3f1146-b81c-42c1-8260-c9a2ebbc0a30">
                2022
              </a> <div class="note">Phase 2 data due 2022.</div></td><td>
              38m
            </td><td>
              1.2b
            </td><td>
              105.8k
            </td><td>
              238.2k
            </td><td>
              5.54
            </td><td>
              $29.75
            </td><td>
              $29.24
            </td><td>
              June 2022
            </td><td>
              186.24m
            </td><td>
              -7.38m
            </td><td>
              25.23
            </td><td>
              170.06m
            </td><td>
              0.93b
            </td><td>
              1.6
            </td><td>
              16,723,522
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AMGN" class="margin-bottom-1">
                AMGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$226.21</div> <small class="number change-up">+2.68<span>&nbsp;&nbsp;</span>+1.20%</small></td><td><strong>AMG 714 / PRV-015</strong> <br>Celiac disease
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/provention-bio-reports-first-quarter-2021-financial-results-and-provides-business-update-301285145.html">
                2022
              </a> <div class="note">Phase 2b top-line data due 2022.</div></td><td>
              1b
            </td><td>
              128.5b
            </td><td>
              0.9m
            </td><td>
              2.4m
            </td><td>
              15.58
            </td><td>
              $224.18
            </td><td>
              $223.53
            </td><td>
              July 11, 2022
            </td><td>
              8.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -43.19b
            </td><td>
              151.63b
            </td><td>
              0.6
            </td><td>
              566,434,467
            </td><td>
              05/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PRVB" class="margin-bottom-1">
                PRVB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.21</div> <small class="number change-up">+0.24<span>&nbsp;&nbsp;</span>+4.02%</small></td><td><strong>AMG 714 / PRV-015</strong> <br>Celiac disease
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/provention-bio-reports-first-quarter-2021-financial-results-and-provides-business-update-301285145.html">
                2022
              </a> <div class="note">Phase 2b top-line data due 2022.</div></td><td>
              63m
            </td><td>
              393.6m
            </td><td>
              415.7k
            </td><td>
              1.4m
            </td><td>
              2.49
            </td><td>
              $6.05
            </td><td>
              $5.97
            </td><td>
              July 11, 2022
            </td><td>
              158.32m
            </td><td>
              -10.03m
            </td><td>
              15.78
            </td><td>
              133.03m
            </td><td>
              202.62m
            </td><td>
              12.2
            </td><td>
              58,084,618
            </td><td>
              05/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVS" class="margin-bottom-1">
                NVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$93.88</div> <small class="number change-up">+0.55<span>&nbsp;&nbsp;</span>+0.59%</small></td><td><strong>ENTRESTO (Sacubitril/valsartan) -  PERSPECTIVE</strong> <br>Heart failure
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.pdf">
                2022
              </a> <div class="note">Phase 3 trial to be completed 2022.</div></td><td>
              2b
            </td><td>
              210.0b
            </td><td>
              0.7m
            </td><td>
              1.7m
            </td><td>
              3.89
            </td><td>
              $93.86
            </td><td>
              $93.33
            </td><td>
              March 28, 2022
            </td><td>
              7.84b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -62.05b
            </td><td>
              238.51b
            </td><td>
              0
            </td><td>
              2,236,739,037
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CCCC" class="margin-bottom-1">
                CCCC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$41.70</div> <small class="number change-up">+0.76<span>&nbsp;&nbsp;</span>+1.84%</small></td><td><strong>CFT7455</strong> <br>Hematologic malignancies
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.benzinga.com/pressreleases/21/08/g22453029/c4-therapeutics-reports-recent-business-highlights-and-second-quarter-2021-financial-results">
                2022
              </a> <div class="note">Phase 1/2 data due 2022.</div></td><td>
              48m
            </td><td>
              2.0b
            </td><td>
              128.0k
            </td><td>
              477.9k
            </td><td>
              4.85
            </td><td>
              $41.6
            </td><td>
              $40.94
            </td><td>
              September 7, 2024
            </td><td>
              455.11m
            </td><td>
              -6.00m
            </td><td>
              75.84
            </td><td>
              343.12m
            </td><td>
              1.54b
            </td><td>
              1.5
            </td><td>
              39,920,060
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVS" class="margin-bottom-1">
                NVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$93.88</div> <small class="number change-up">+0.55<span>&nbsp;&nbsp;</span>+0.59%</small></td><td><strong>ENTRESTO (Sacubitril/valsartan) -  Panorama</strong> <br>Heart failure
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.pdf">
                2022
              </a> <div class="note">Phase 3 trial readout 2022.</div></td><td>
              2b
            </td><td>
              210.0b
            </td><td>
              0.7m
            </td><td>
              1.7m
            </td><td>
              3.89
            </td><td>
              $93.86
            </td><td>
              $93.33
            </td><td>
              December 31, 2021
            </td><td>
              7.84b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -62.05b
            </td><td>
              238.51b
            </td><td>
              0
            </td><td>
              2,236,739,037
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VKTX" class="margin-bottom-1">
                VKTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.94</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+2.41%</small></td><td><strong>VK0214</strong> <br>X-linked adrenoleukodystrophy
            </td><td>
              Phase 1b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/viking-therapeutics-reports-second-quarter-2021-financial-results-and-provides-corporate-update-301343608.html">
                2022
              </a> <div class="note">Phase 1b trial initiation announced June 23, 2021. Data due 2022.</div></td><td>
              78m
            </td><td>
              464.4m
            </td><td>
              446.3k
            </td><td>
              0.8m
            </td><td>
              2.06
            </td><td>
              $5.8
            </td><td>
              $5.8
            </td><td>
              June 30, 2022
            </td><td>
              220.20m
            </td><td>
              -4.48m
            </td><td>
              49.17
            </td><td>
              207.33m
            </td><td>
              225.44m
            </td><td>
              4.6
            </td><td>
              66,497,689
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RAIN" class="margin-bottom-1">
                RAIN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.98</div> <small class="number change-up">+0.76<span>&nbsp;&nbsp;</span>+4.38%</small></td><td><strong>Milademetan (RAIN-32) - (MANTRA-2 basket trial)</strong> <br>MDM2-amplified advanced solid tumors
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.rainthera.com/news-releases/news-release-details/rain-therapeutics-reports-second-quarter-2021-financial-results">
                2H 2022
              </a> <div class="note">Phase 2 trial to be initiated 2H 2021. Interim data due 2H 2022.</div></td><td>
              26m
            </td><td>
              476.0m
            </td><td>
              25.6k
            </td><td>
              128.5k
            </td><td>
              2.89
            </td><td>
              $17.38
            </td><td>
              $17.23
            </td><td>
              N/A
            </td><td>
              158.12m
            </td><td>
              -3.63m
            </td><td>
              43.58
            </td><td>
              148.40m
            </td><td>
              291.85m
            </td><td>
              13.9
            </td><td>
              13,200,239
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RAIN" class="margin-bottom-1">
                RAIN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.98</div> <small class="number change-up">+0.76<span>&nbsp;&nbsp;</span>+4.38%</small></td><td><strong>Milademetan (RAIN-32)</strong> <br>Intimal sarcoma
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.rainthera.com/news-releases/news-release-details/rain-therapeutics-reports-second-quarter-2021-financial-results">
                Late-2022
              </a> <div class="note">Phase 2 trial to be initiated early 2022 with interim data late-2022.</div></td><td>
              26m
            </td><td>
              476.0m
            </td><td>
              25.6k
            </td><td>
              128.5k
            </td><td>
              2.89
            </td><td>
              $17.38
            </td><td>
              $17.23
            </td><td>
              N/A
            </td><td>
              158.12m
            </td><td>
              -3.63m
            </td><td>
              43.58
            </td><td>
              148.40m
            </td><td>
              291.85m
            </td><td>
              13.9
            </td><td>
              13,200,239
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CNCE" class="margin-bottom-1">
                CNCE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.32</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+4.08%</small></td><td><strong>CTP-543 (THRIVE-AA1)</strong> <br>Alopecia areata
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005047/en/">
                2H 2022
              </a> <div class="note">Phase 3 data due 2H 2022.</div></td><td>
              32m
            </td><td>
              106.8m
            </td><td>
              34.9k
            </td><td>
              255.0k
            </td><td>
              0.87
            </td><td>
              $3.2
            </td><td>
              $3.19
            </td><td>
              February 2022
            </td><td>
              131.25m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              105.26m
            </td><td>
              -6.66m
            </td><td>
              5.3
            </td><td>
              28,625,013
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ORTX" class="margin-bottom-1">
                ORTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.69</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+9.55%</small></td><td><strong>OTL-103</strong> <br>Wiskott-Aldrich Syndrome (WAS)
            </td><td>
              BLA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-announces-regulatory-and-clinical-updates">
                2022
              </a> <div class="note">BLA filing previously due 2022. Timing to be updated following talks with FDA.</div></td><td>
              125m
            </td><td>
              337.9m
            </td><td>
              324.5k
            </td><td>
              0.6m
            </td><td>
              1.28
            </td><td>
              $2.45
            </td><td>
              $2.46
            </td><td>
              February 2022
            </td><td>
              247.68m
            </td><td>
              -12.02m
            </td><td>
              20.61
            </td><td>
              147.30m
            </td><td>
              100.62m
            </td><td>
              0.5
            </td><td>
              124,780,672
            </td><td>
              06/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TGTX" class="margin-bottom-1">
                TGTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$26.38</div> <small class="number change-up">+2.38<span>&nbsp;&nbsp;</span>+9.90%</small></td><td><strong>Ublituximab (TG-1101) + UKONIQ (umbralisib) + VENCLEXTA (venetoclax) - (ULTRA-V)</strong> <br>Chronic Lymphocytic Leukemia
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-launch-ultra-v-phase-3-trial">
                2022
              </a> <div class="note">Phase 3 initiation of enrolment announced April 21, 2021. Phase 2 trial enrollment has been completed with data due in 2022.</div></td><td>
              143m
            </td><td>
              3.8b
            </td><td>
              1.8m
            </td><td>
              1.4m
            </td><td>
              9.84
            </td><td>
              $24.54
            </td><td>
              $24
            </td><td>
              January 1, 2025
            </td><td>
              407.36m
            </td><td>
              -20.06m
            </td><td>
              20.31
            </td><td>
              309.09m
            </td><td>
              3.02b
            </td><td>
              16.2
            </td><td>
              114,156,621
            </td><td>
              05/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MIRM" class="margin-bottom-1">
                MIRM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.70</div> <small class="number change-up">+0.52<span>&nbsp;&nbsp;</span>+3.67%</small></td><td><strong>Volixiba - OHANA</strong> <br>Intrahepatic cholestasis of pregnancy
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005953/en/">
                2022
              </a> <div class="note">Phase 2b trial has been initiated. Interim analysis due in 2022.</div></td><td>
              31m
            </td><td>
              448.6m
            </td><td>
              36.1k
            </td><td>
              77.7k
            </td><td>
              4.68
            </td><td>
              $14.35
            </td><td>
              $14.18
            </td><td>
              January 2024
            </td><td>
              199.73m
            </td><td>
              -13.40m
            </td><td>
              14.91
            </td><td>
              47.80m
            </td><td>
              211.81m
            </td><td>
              0.5
            </td><td>
              8,253,550
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VCNX" class="margin-bottom-1">
                VCNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.27</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+4.13%</small></td><td><strong>Pepinemab and KEYTRUDA (pembrolizumab)</strong> <br>Head and Neck Squamous Cell Carcinoma
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.vaccinex.com/news-releases/news-release-details/vaccinex-reports-second-quarter-2021-financial-results-and">
                2H 2022
              </a> <div class="note">Phase 1/2 data due 2H 2022.</div></td><td>
              31m
            </td><td>
              69.9m
            </td><td>
              67.9k
            </td><td>
              204.2k
            </td><td>
              4.13
            </td><td>
              $2.2
            </td><td>
              $2.18
            </td><td>
              July 21, 2023
            </td><td>
              18.20m
            </td><td>
              -2.33m
            </td><td>
              7.82
            </td><td>
              11.35m
            </td><td>
              48.38m
            </td><td>
              0.9
            </td><td>
              19,205,560
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VYGR" class="margin-bottom-1">
                VYGR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.06</div> <small class="number change-up">+0.17<span>&nbsp;&nbsp;</span>+6.08%</small></td><td><strong>VY-HTT01 (VYTAL)</strong> <br>Huntington’s Disease
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.voyagertherapeutics.com/news-releases/news-release-details/voyager-therapeutics-announces-first-quarter-2021-financial">
                2022
              </a> <div class="note">Phase 1/2 trial to be initiated in 4Q 2021 with initial data due in 2022.</div></td><td>
              38m
            </td><td>
              115.9m
            </td><td>
              91.7k
            </td><td>
              399.9k
            </td><td>
              1.05
            </td><td>
              $2.9
            </td><td>
              $2.88
            </td><td>
              N/A
            </td><td>
              129.35m
            </td><td>
              -7.57m
            </td><td>
              17.08
            </td><td>
              31.16m
            </td><td>
              11.99m
            </td><td>
              5
            </td><td>
              26,272,029
            </td><td>
              05/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CRBU" class="margin-bottom-1">
                CRBU
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.75</div> <small class="number change-up">+3.66<span>&nbsp;&nbsp;</span>+14.03%</small></td><td><strong>CB-010 (ANTLER)</strong> <br>B-Cell Non-Hodgkin Lymphoma
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001619856/000119312521206262/d145328ds1.htm">
                2022
              </a> <div class="note">Phase 1 trial ongoing. Initial data due 2022.</div></td><td>
              57m
            </td><td>
              1.7b
            </td><td>
              1.0m
            </td><td>
              0.5m
            </td><td>
              -47.22
            </td><td>
              $27
            </td><td>
              $26.09
            </td><td>
              August 2025
            </td><td>
              178.65m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              125.15m
            </td><td>
              1.49b
            </td><td>
              6.8
            </td><td>
              52,992,331
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FBIO" class="margin-bottom-1">
                FBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.20</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+4.58%</small></td><td><strong>CEVA101</strong> <br>Severe Traumatic Brain Injury
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://d1io3yog0oux5.cloudfront.net/_c95da293a51b9d0b5c7131e4e07fef9c/fortressbiotech/db/640/5686/pdf/FBIO+Corporate+Presentation+-+Oct+2020+10.20.2020.pdf">
                2022
              </a> <div class="note">Phase 2 data in adults due 2022.</div></td><td>
              101m
            </td><td>
              323.4m
            </td><td>
              220.5k
            </td><td>
              0.5m
            </td><td>
              2.99
            </td><td>
              $3.07
            </td><td>
              $3.06
            </td><td>
              October 2022
            </td><td>
              254.32m
            </td><td>
              -11.49m
            </td><td>
              22.14
            </td><td>
              84.46m
            </td><td>
              120.76m
            </td><td>
              27.4
            </td><td>
              76,232,955
            </td><td>
              11/09/2020
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RHHBY" class="margin-bottom-1">
                RHHBY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$50.36</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+0.12%</small></td><td><strong>Alecensa (ALINA)</strong> <br>Non-small cell lung cancer (NSCLC)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.roche.com/dam/jcr:a1437516-3f73-4112-a483-40c8b1c3836e/en/irp210722.pdf">
                2022
              </a> <div class="note">Phase 3 data 2022.</div></td><td>
              7b
            </td><td>
              344.2b
            </td><td>
              0.5m
            </td><td>
              1.0m
            </td><td>
              8.35
            </td><td>
              $50.24
            </td><td>
              $50.3
            </td><td>
              June 30, 2023
            </td><td>
              8.02b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -38.44b
            </td><td>
              356.64b
            </td><td>
              0
            </td><td>
              6,834,087,224
            </td><td>
              07/22/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ATNX" class="margin-bottom-1">
                ATNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.50</div> <small class="number change-up">+0.21<span>&nbsp;&nbsp;</span>+6.38%</small></td><td><strong>Oraxol (Oral Paclitaxel) - (I-SPY 2)</strong> <br>Neoadjuvant breast cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.athenex.com/news-releases/news-release-details/athenex-provides-second-quarter-2021-corporate-and-financial">
                2022
              </a> <div class="note">Phase 2 data due 2022.</div></td><td>
              109m
            </td><td>
              382.6m
            </td><td>
              0.9m
            </td><td>
              1.3m
            </td><td>
              2.07
            </td><td>
              $3.3
            </td><td>
              $3.29
            </td><td>
              December 2025
            </td><td>
              106.70m
            </td><td>
              -13.07m
            </td><td>
              8.16
            </td><td>
              -132.38m
            </td><td>
              387.83m
            </td><td>
              6.1
            </td><td>
              77,823,836
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GTHX" class="margin-bottom-1">
                GTHX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.35</div> <small class="number change-up">+0.82<span>&nbsp;&nbsp;</span>+6.06%</small></td><td><strong>Oraxol (Oral Paclitaxel) - (I-SPY 2)</strong> <br>Neoadjuvant breast cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.athenex.com/news-releases/news-release-details/athenex-provides-second-quarter-2021-corporate-and-financial">
                2022
              </a> <div class="note">Phase 2 data due 2022.</div></td><td>
              42m
            </td><td>
              0.6b
            </td><td>
              279.6k
            </td><td>
              1.1m
            </td><td>
              2.85
            </td><td>
              $13.83
            </td><td>
              $13.53
            </td><td>
              December 2025
            </td><td>
              222.13m
            </td><td>
              -12.16m
            </td><td>
              18.26
            </td><td>
              158.57m
            </td><td>
              366.37m
            </td><td>
              2.3
            </td><td>
              42,071,302
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RHHBY" class="margin-bottom-1">
                RHHBY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$50.36</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+0.12%</small></td><td><strong>VENCLEXTA (venetoclax)</strong> <br>Multiple Myeloma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.roche.com/dam/jcr:a1437516-3f73-4112-a483-40c8b1c3836e/en/irp210722.pdf">
                2022
              </a> <div class="note">Phase 3 data due 2022.</div></td><td>
              7b
            </td><td>
              344.2b
            </td><td>
              0.5m
            </td><td>
              1.0m
            </td><td>
              8.35
            </td><td>
              $50.24
            </td><td>
              $50.3
            </td><td>
              June 12, 2022
            </td><td>
              8.02b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -38.44b
            </td><td>
              356.64b
            </td><td>
              0
            </td><td>
              6,834,087,224
            </td><td>
              07/22/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RHHBY" class="margin-bottom-1">
                RHHBY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$50.36</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+0.12%</small></td><td><strong>TECENTRIQ (atezolizumab) - (IMbrave050)</strong> <br>Hepatocellular carcinoma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.roche.com/dam/jcr:a1437516-3f73-4112-a483-40c8b1c3836e/en/irp210722.pdf">
                2022
              </a> <div class="note">Phase 3 data due 2022.</div></td><td>
              7b
            </td><td>
              344.2b
            </td><td>
              0.5m
            </td><td>
              1.0m
            </td><td>
              8.35
            </td><td>
              $50.24
            </td><td>
              $50.3
            </td><td>
              March 31, 2023
            </td><td>
              8.02b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -38.44b
            </td><td>
              356.64b
            </td><td>
              0
            </td><td>
              6,834,087,224
            </td><td>
              07/22/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>ENHERTU (trastuzumab deruxtecan) - DESTINY-Breast04</strong> <br>HER low breast cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2021/h1-2021/H1_2021_results_presentation.pdf">
                1H 2022
              </a> <div class="note">Phase 3 data due 1H 2022.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              January 1, 2023
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RHHBY" class="margin-bottom-1">
                RHHBY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$50.36</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+0.12%</small></td><td><strong>TECENTRIQ (atezolizumab) - (IMpower030)</strong> <br>Non-small cell lung cancer (NSCLC) 
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.roche.com/dam/jcr:a1437516-3f73-4112-a483-40c8b1c3836e/en/irp210722.pdf">
                2022
              </a> <div class="note">Phase 3 data due 2022.</div></td><td>
              7b
            </td><td>
              344.2b
            </td><td>
              0.5m
            </td><td>
              1.0m
            </td><td>
              8.35
            </td><td>
              $50.24
            </td><td>
              $50.3
            </td><td>
              January 20, 2024
            </td><td>
              8.02b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -38.44b
            </td><td>
              356.64b
            </td><td>
              0
            </td><td>
              6,834,087,224
            </td><td>
              07/22/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RHHBY" class="margin-bottom-1">
                RHHBY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$50.36</div> <small class="number change-up">+0.06<span>&nbsp;&nbsp;</span>+0.12%</small></td><td><strong>TECENTRIQ (atezolizumab) - (IMmotion010)</strong> <br>Renal Cell Carcinoma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.roche.com/dam/jcr:a1437516-3f73-4112-a483-40c8b1c3836e/en/irp210722.pdf">
                2022
              </a> <div class="note">Phase 3 data due 2022.</div></td><td>
              7b
            </td><td>
              344.2b
            </td><td>
              0.5m
            </td><td>
              1.0m
            </td><td>
              8.35
            </td><td>
              $50.24
            </td><td>
              $50.3
            </td><td>
              January 18, 2022
            </td><td>
              8.02b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -38.44b
            </td><td>
              356.64b
            </td><td>
              0
            </td><td>
              6,834,087,224
            </td><td>
              07/22/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>ENHERTU (trastuzumab deruxtecan) - DESTINY-Breast02</strong> <br>Third line HER2+ breast cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2021/h1-2021/H1_2021_results_clinical_trials_appendix.pdf">
                2H 2022
              </a> <div class="note">Phase 3 data due 2H 2022</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              February 2022
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GKOS" class="margin-bottom-1">
                GKOS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$50.06</div> <small class="number change-up">+1.12<span>&nbsp;&nbsp;</span>+2.30%</small></td><td><strong>iDose TR</strong> <br>Glaucoma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210610005304/en/">
                2022
              </a> <div class="note">Phase 3 completion of enrollment announced June 11, 2021. NDA filing due 2022.</div></td><td>
              47m
            </td><td>
              2.3b
            </td><td>
              88.8k
            </td><td>
              0.6m
            </td><td>
              3.99
            </td><td>
              $49.61
            </td><td>
              $48.94
            </td><td>
              April 2022
            </td><td>
              423.00m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -36.40m
            </td><td>
              2.23b
            </td><td>
              1.5
            </td><td>
              26,455,804
            </td><td>
              06/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/APTX" class="margin-bottom-1">
                APTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.40</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+3.00%</small></td><td><strong>NYX-458</strong> <br>Parkinson’s Disease Cognitive Impairment (healthy volunteers)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210810005946/en/">
                2H 2022
              </a> <div class="note">Phase 2 data due 2H 2022.</div></td><td>
              68m
            </td><td>
              162.5m
            </td><td>
              187.8k
            </td><td>
              1.2m
            </td><td>
              1.24
            </td><td>
              $2.33
            </td><td>
              $2.33
            </td><td>
              December 30, 2022
            </td><td>
              119.16m
            </td><td>
              -5.59m
            </td><td>
              21.32
            </td><td>
              115.75m
            </td><td>
              28.55m
            </td><td>
              2.9
            </td><td>
              53,798,730
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AYLA" class="margin-bottom-1">
                AYLA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.11</div> <small class="number change-down">-0.35<span>&nbsp;&nbsp;</span>-2.81%</small></td><td><strong>AL101 (TENACITY)</strong> <br>Triple negative breast cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ayalapharma.com/news-releases/news-release-details/ayala-pharmaceuticals-reports-second-quarter-2021-financial">
                2022
              </a> <div class="note">Phase 2 initiation of dosing announced January 28, 2021. Initial data due 2022.</div></td><td>
              13m
            </td><td>
              160.4m
            </td><td>
              25.0k
            </td><td>
              35.4k
            </td><td>
              3.75
            </td><td>
              $11.74
            </td><td>
              $12.46
            </td><td>
              November 2023
            </td><td>
              37.48m
            </td><td>
              -3.85m
            </td><td>
              9.74
            </td><td>
              31.77m
            </td><td>
              121.10m
            </td><td>
              1.3
            </td><td>
              4,598,420
            </td><td>
              08/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AVXL" class="margin-bottom-1">
                AVXL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$19.41</div> <small class="number change-up">+1.05<span>&nbsp;&nbsp;</span>+5.72%</small></td><td><strong>ANAVEX2-73-AD-004</strong> <br>Mild to moderate Alzheimer’s disease
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.anavex.com/anavex-life-sciences-provides-business-update-and-reports-fiscal-2021-third-quarter-financial-results/">
                2H 2022
              </a> <div class="note">Phase 2b/3 data due 2H 2022.</div></td><td>
              76m
            </td><td>
              1.5b
            </td><td>
              0.5m
            </td><td>
              3.2m
            </td><td>
              9.33
            </td><td>
              $18.68
            </td><td>
              $18.36
            </td><td>
              May 30, 2022
            </td><td>
              153.05m
            </td><td>
              -2.51m
            </td><td>
              61.05
            </td><td>
              143.77m
            </td><td>
              1.23b
            </td><td>
              14.5
            </td><td>
              73,309,486
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALBO" class="margin-bottom-1">
                ALBO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.70</div> <small class="number change-up">+1.89<span>&nbsp;&nbsp;</span>+6.80%</small></td><td><strong>BYLVAY (odevixibat) - (ASSERT)</strong> <br>Alagille syndrome
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.albireopharma.com/news-releases/news-release-details/albireo-reports-q2-financial-results-and-business-update">
                2022
              </a> <div class="note">Phase 3 data due 2022.</div></td><td>
              19m
            </td><td>
              0.6b
            </td><td>
              67.6k
            </td><td>
              262.4k
            </td><td>
              5.04
            </td><td>
              $28.02
            </td><td>
              $27.81
            </td><td>
              June 2022
            </td><td>
              167.40m
            </td><td>
              -10.49m
            </td><td>
              15.96
            </td><td>
              61.41m
            </td><td>
              359.08m
            </td><td>
              20.7
            </td><td>
              14,332,622
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PRQR" class="margin-bottom-1">
                PRQR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.22</div> <small class="number change-up">+0.69<span>&nbsp;&nbsp;</span>+12.48%</small></td><td><strong>QR-504a</strong> <br> Fuchs
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.proqr.com/press-releases/proqr-announces-second-quarter-2021-operating-and-financial-results">
                2022
              </a> <div class="note">Phase 1 initial data due 2022.</div></td><td>
              67m
            </td><td>
              417.2m
            </td><td>
              192.0k
            </td><td>
              478.4k
            </td><td>
              3.02
            </td><td>
              $5.57
            </td><td>
              $5.53
            </td><td>
              N/A
            </td><td>
              133.45m
            </td><td>
              -3.33m
            </td><td>
              40.12
            </td><td>
              88.64m
            </td><td>
              249.39m
            </td><td>
              0
            </td><td>
              57,834,902
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ITCI" class="margin-bottom-1">
                ITCI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.66</div> <small class="number change-up">+1.32<span>&nbsp;&nbsp;</span>+4.51%</small></td><td><strong>CAPLYTA (Lumateperone) ITI-007-403</strong> <br>Bipolar Depression
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-reports-fourth-quarter-and-full-year-6">
                2H 2022
              </a> <div class="note">Phase 3 data due 2H 2022.</div></td><td>
              81m
            </td><td>
              2.5b
            </td><td>
              196.9k
            </td><td>
              0.5m
            </td><td>
              4.50
            </td><td>
              $29.7
            </td><td>
              $29.34
            </td><td>
              December 2022
            </td><td>
              0.52b
            </td><td>
              -19.78m
            </td><td>
              26.25
            </td><td>
              447.05m
            </td><td>
              1.86b
            </td><td>
              2.7
            </td><td>
              60,840,721
            </td><td>
              05/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/HRMY" class="margin-bottom-1">
                HRMY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$32.60</div> <small class="number change-down">-0.49<span>&nbsp;&nbsp;</span>-1.48%</small></td><td><strong>WAKIX (pitolisant)</strong> <br>Type 1 myotonic dystrophy (DM1)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/10/2277884/0/en/Harmony-Biosciences-Reports-Second-Quarter-2021-Financial-Results-and-Business-Updates.html">
                2H 2022
              </a> <div class="note">Phase 2 top-line data due 2H 2022.</div></td><td>
              57m
            </td><td>
              1.9b
            </td><td>
              122.2k
            </td><td>
              288.1k
            </td><td>
              14.69
            </td><td>
              $33.08
            </td><td>
              $33.09
            </td><td>
              September 15, 2022
            </td><td>
              170.53m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -62.62m
            </td><td>
              1.92b
            </td><td>
              0.1
            </td><td>
              18,002,884
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/REGN" class="margin-bottom-1">
                REGN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$665.74</div> <small class="number change-up">+2.47<span>&nbsp;&nbsp;</span>+0.37%</small></td><td><strong>DUPIXENT (dupilumab)</strong> <br>Bullous pemphigoid (BP)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.regeneron.com/news-releases/news-release-details/regeneron-collaborations-dupixentr-dupilumab-highlighted-during">
                2022
              </a> <div class="note">Phase 3 trial has been initiated. Data likely due 2022.</div></td><td>
              107m
            </td><td>
              71.2b
            </td><td>
              0.7m
            </td><td>
              0.8m
            </td><td>
              4.71
            </td><td>
              $665.21
            </td><td>
              $663.27
            </td><td>
              February 27, 2023
            </td><td>
              4.29b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -2.07b
            </td><td>
              69.73b
            </td><td>
              2.1
            </td><td>
              89,032,197
            </td><td>
              06/18/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SNY" class="margin-bottom-1">
                SNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$52.48</div> <small class="number change-down">-0.64<span>&nbsp;&nbsp;</span>-1.20%</small></td><td><strong>DUPIXENT (dupilumab)</strong> <br>Bullous pemphigoid (BP)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.regeneron.com/news-releases/news-release-details/regeneron-collaborations-dupixentr-dupilumab-highlighted-during">
                2022
              </a> <div class="note">Phase 3 trial has been initiated. Data likely due 2022.</div></td><td>
              3b
            </td><td>
              131.7b
            </td><td>
              2.5m
            </td><td>
              1.7m
            </td><td>
              1.78
            </td><td>
              $52.73
            </td><td>
              $53.12
            </td><td>
              February 27, 2023
            </td><td>
              9.72b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -39.23b
            </td><td>
              146.90b
            </td><td>
              0
            </td><td>
              2,510,366,030
            </td><td>
              06/18/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ZEAL" class="margin-bottom-1">
                ZEAL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$27.57</div> <small class="number change-up">+0.28<span>&nbsp;&nbsp;</span>+1.04%</small></td><td><strong>Glepaglutideb (EASE-SBS 1)</strong> <br>Short bowel syndrome
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/19/2283569/0/en/Zealand-Pharma-Announces-First-Patient-Dosed-in-EASE-SBS-4-Phase-3b-Trial-Assessing-Glepaglutide-in-Patients-with-Short-Bowel-Syndrome.html">
                2022
              </a> <div class="note">Phase 3 data due in 2022.</div></td><td>
              43m
            </td><td>
              1.2b
            </td><td>
              37.5k
            </td><td>
              19.1k
            </td><td>
              5.47
            </td><td>
              $27.57
            </td><td>
              $27.29
            </td><td>
              October 30, 2021
            </td><td>
              1.09b
            </td><td>
              -109.19m
            </td><td>
              9.95
            </td><td>
              0.55b
            </td><td>
              1.01b
            </td><td>
              0
            </td><td>
              43,323,428
            </td><td>
              08/19/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CNSP" class="margin-bottom-1">
                CNSP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.51</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+0.67%</small></td><td><strong>Berubicin</strong> <br>Glioblastoma (adult)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/cns-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-business-outlook-301354752.html">
                2022
              </a> <div class="note">Phase 2 enrollment has commenced - May 19, 2021. Dosing to commence 3Q 2021 with interim analysis due in 2022.</div></td><td>
              27m
            </td><td>
              41.5m
            </td><td>
              75.5k
            </td><td>
              0.6m
            </td><td>
              3.36
            </td><td>
              $1.52
            </td><td>
              $1.5
            </td><td>
              October 2024
            </td><td>
              3.89m
            </td><td>
              -1.67m
            </td><td>
              2.33
            </td><td>
              2.06m
            </td><td>
              34.48m
            </td><td>
              4.1
            </td><td>
              17,094,985
            </td><td>
              08/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KYMR" class="margin-bottom-1">
                KYMR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$55.52</div> <small class="number change-up">+1.83<span>&nbsp;&nbsp;</span>+3.42%</small></td><td><strong>KT-413</strong> <br>Diffuse large B-cell lymphoma (DLBCL)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-second-quarter-2021-financial">
                2022
              </a> <div class="note">Phase 1 trial to commence 2H 2021. Initial proof of concept due 2022.</div></td><td>
              51m
            </td><td>
              2.8b
            </td><td>
              168.1k
            </td><td>
              0.5m
            </td><td>
              10.97
            </td><td>
              $54.69
            </td><td>
              $53.68
            </td><td>
              N/A
            </td><td>
              0.56b
            </td><td>
              -10.17m
            </td><td>
              55.48
            </td><td>
              388.02m
            </td><td>
              2.40b
            </td><td>
              1.1
            </td><td>
              40,421,438
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LLY" class="margin-bottom-1">
                LLY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$269.63</div> <small class="number change-down">-1.28<span>&nbsp;&nbsp;</span>-0.47%</small></td><td><strong>Mirikizumab</strong> <br>Crohn's disease
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.lilly.com/news-releases/news-release-details/lillys-mirikizumab-superior-cosentyxr-secukinumab-phase-3-study">
                2022
              </a> <div class="note">Phase 3 data due 2022.</div></td><td>
              1b
            </td><td>
              257.9b
            </td><td>
              0.8m
            </td><td>
              2.8m
            </td><td>
              40.00
            </td><td>
              $272.3
            </td><td>
              $270.91
            </td><td>
              December 23, 2022
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -36.81b
            </td><td>
              272.39b
            </td><td>
              0.5
            </td><td>
              792,287,037
            </td><td>
              07/17/2020
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KYMR" class="margin-bottom-1">
                KYMR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$55.52</div> <small class="number change-up">+1.83<span>&nbsp;&nbsp;</span>+3.42%</small></td><td><strong>STAT3 program</strong> <br>Oncology
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-second-quarter-2021-financial">
                2022
              </a> <div class="note">Phase 1 trial to be initiated 4Q 2021. Initial proof of concept data due 2022.</div></td><td>
              51m
            </td><td>
              2.8b
            </td><td>
              168.1k
            </td><td>
              0.5m
            </td><td>
              10.97
            </td><td>
              $54.69
            </td><td>
              $53.68
            </td><td>
              N/A
            </td><td>
              0.56b
            </td><td>
              -10.17m
            </td><td>
              55.48
            </td><td>
              388.02m
            </td><td>
              2.40b
            </td><td>
              1.1
            </td><td>
              40,421,438
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LGVN" class="margin-bottom-1">
                LGVN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.40</div> <small class="number change-down">-0.17<span>&nbsp;&nbsp;</span>-4.76%</small></td><td><strong>Lomecel-B (RECOVER)</strong> <br>Acute Respiratory Distress Syndrome
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.longeveron.com/news/News/news-details/2021/Longeveron-Inc.-Provides-Corporate-Update-and-Reports-Second-Quarter-2021-Financial-Results/default.aspx">
                Late-2022
              </a> <div class="note">Phase 1 trial enrollment to be completed in 2021 with data in late-2022.</div></td><td>
              19m
            </td><td>
              65.0m
            </td><td>
              216.7k
            </td><td>
              168.2k
            </td><td>
              2.64
            </td><td>
              $3.6
            </td><td>
              $3.57
            </td><td>
              August 2021
            </td><td>
              19.62m
            </td><td>
              -0.98m
            </td><td>
              19.94
            </td><td>
              14.41m
            </td><td>
              50.40m
            </td><td>
              45.4
            </td><td>
              3,279,966
            </td><td>
              08/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CMRX" class="margin-bottom-1">
                CMRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.52</div> <small class="number change-up">+0.32<span>&nbsp;&nbsp;</span>+5.16%</small></td><td><strong>DSTAT (CX-01) - (DASH AML)</strong> <br>Acute Myeloid Leukemia (AML)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.chimerix.com/news-releases/news-release-details/chimerix-reports-second-quarter-2021-financial-results-and">
                2H 2022
              </a> <div class="note">Phase 3 data due 2H 2022.</div></td><td>
              86m
            </td><td>
              0.6b
            </td><td>
              416.7k
            </td><td>
              0.6m
            </td><td>
              4.72
            </td><td>
              $6.32
            </td><td>
              $6.2
            </td><td>
              May 1, 2024
            </td><td>
              124.40m
            </td><td>
              -4.24m
            </td><td>
              29.33
            </td><td>
              96.82m
            </td><td>
              419.37m
            </td><td>
              1.8
            </td><td>
              62,369,079
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GSK" class="margin-bottom-1">
                GSK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$41.57</div> <small class="number change-down">-0.28<span>&nbsp;&nbsp;</span>-0.67%</small></td><td><strong>Otilimab (MOR103/GSK3196165) - (ContRAst)</strong> <br>Rheumatoid Arthritis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.gsk.com/media/7129/q2-2021-results-slides.pdf">
                2H 2022
              </a> <div class="note">Phase 3 ContRAst trial ongoing. Data due 2H 2022.</div></td><td>
              3b
            </td><td>
              104.6b
            </td><td>
              2.3m
            </td><td>
              4.2m
            </td><td>
              4.95
            </td><td>
              $41.75
            </td><td>
              $41.85
            </td><td>
              September 15, 2021
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -51.10b
            </td><td>
              133.80b
            </td><td>
              0.2
            </td><td>
              2,506,785,977
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MOR" class="margin-bottom-1">
                MOR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.96</div> <small class="number change-up">+0.51<span>&nbsp;&nbsp;</span>+3.79%</small></td><td><strong>Otilimab (MOR103/GSK3196165) - (ContRAst)</strong> <br>Rheumatoid Arthritis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.gsk.com/media/7129/q2-2021-results-slides.pdf">
                2H 2022
              </a> <div class="note">Phase 3 ContRAst trial ongoing. Data due 2H 2022.</div></td><td>
              137m
            </td><td>
              1.9b
            </td><td>
              18.7k
            </td><td>
              125.1k
            </td><td>
              2.70
            </td><td>
              $13.75
            </td><td>
              $13.45
            </td><td>
              September 15, 2021
            </td><td>
              1.04b
            </td><td>
              -29.79m
            </td><td>
              34.97
            </td><td>
              65.72m
            </td><td>
              0.93b
            </td><td>
              0
            </td><td>
              136,502,236
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/EXEL" class="margin-bottom-1">
                EXEL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$18.89</div> <small class="number change-up">+0.46<span>&nbsp;&nbsp;</span>+2.47%</small></td><td><strong>CABOMETYX (Cabozantinib) and OPDIVO (nivolumab)and YERYOY (Ipilimumab) - (COSMIC-313)</strong> <br>Renal Cell Carcinoma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210110005056/en/">
                2022
              </a> <div class="note">Phase 3 data due 2022.</div></td><td>
              315m
            </td><td>
              6.0b
            </td><td>
              0.6m
            </td><td>
              2.6m
            </td><td>
              2.91
            </td><td>
              $18.6
            </td><td>
              $18.44
            </td><td>
              November 2021
            </td><td>
              1.46b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              1.13b
            </td><td>
              4.52b
            </td><td>
              2
            </td><td>
              279,036,935
            </td><td>
              05/07/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BMY" class="margin-bottom-1">
                BMY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$69.35</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+0.22%</small></td><td><strong>CABOMETYX (Cabozantinib) and OPDIVO (nivolumab)and YERYOY (Ipilimumab) - (COSMIC-313)</strong> <br>Renal Cell Carcinoma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210110005056/en/">
                2022
              </a> <div class="note">Phase 3 data due 2022.</div></td><td>
              2b
            </td><td>
              154.1b
            </td><td>
              4.1m
            </td><td>
              8.5m
            </td><td>
              4.19
            </td><td>
              $69.26
            </td><td>
              $69.2
            </td><td>
              November 2021
            </td><td>
              15.85b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -58.07b
            </td><td>
              186.05b
            </td><td>
              0.3
            </td><td>
              2,219,710,962
            </td><td>
              05/07/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TAK" class="margin-bottom-1">
                TAK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.97</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+1.75%</small></td><td><strong>CABOMETYX (Cabozantinib) and OPDIVO (nivolumab)and YERYOY (Ipilimumab) - (COSMIC-313)</strong> <br>Renal Cell Carcinoma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210110005056/en/">
                2022
              </a> <div class="note">Phase 3 data due 2022.</div></td><td>
              3b
            </td><td>
              53.4b
            </td><td>
              0.8m
            </td><td>
              1.9m
            </td><td>
              1.12
            </td><td>
              $16.84
            </td><td>
              $16.68
            </td><td>
              November 2021
            </td><td>
              0.78t
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -6.63t
            </td><td>
              86.30b
            </td><td>
              0
            </td><td>
              3,145,059,016
            </td><td>
              05/07/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ANAB" class="margin-bottom-1">
                ANAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$25.65</div> <small class="number change-up">+1.42<span>&nbsp;&nbsp;</span>+5.86%</small></td><td><strong>Imsidolimab (ANB019) - HARP</strong> <br>Hidradenitis Suppurativa
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/09/2277409/0/en/AnaptysBio-Announces-Second-Quarter-2021-Financial-Results-and-Provides-Pipeline-Updates.html">
                2H 2022
              </a> <div class="note">Phase 2 top-line data due 2H 2022.</div></td><td>
              27m
            </td><td>
              0.7b
            </td><td>
              43.4k
            </td><td>
              221.0k
            </td><td>
              1.82
            </td><td>
              $24.54
            </td><td>
              $24.23
            </td><td>
              October 2022
            </td><td>
              416.61m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              375.77m
            </td><td>
              294.64m
            </td><td>
              2
            </td><td>
              19,169,175
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MACK" class="margin-bottom-1">
                MACK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.65</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+3.33%</small></td><td><strong>Onivyde - RESILIENT (acquired by Ispen)</strong> <br>Small Cell Lung Cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005726/en/">
                2022
              </a> <div class="note">Phase 3 data due 2022.</div></td><td>
              13m
            </td><td>
              62.4m
            </td><td>
              6.6k
            </td><td>
              22.9k
            </td><td>
              4.12
            </td><td>
              $4.5
            </td><td>
              $4.5
            </td><td>
              September 2022
            </td><td>
              15.52m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              14.75m
            </td><td>
              45.44m
            </td><td>
              39.7
            </td><td>
              10,685,047
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVCR" class="margin-bottom-1">
                NVCR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$135.40</div> <small class="number change-up">+2.97<span>&nbsp;&nbsp;</span>+2.24%</small></td><td><strong>Tumor Treating Fields (TTFields) -  PANOVA 3</strong> <br>Pancreatic cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210729005357/en/">
                2022
              </a> <div class="note">Phase 3 interim analysis 2022. Final data due 2023.</div></td><td>
              104m
            </td><td>
              14.0b
            </td><td>
              153.2k
            </td><td>
              0.7m
            </td><td>
              35.35
            </td><td>
              $133.45
            </td><td>
              $132.43
            </td><td>
              September 2023
            </td><td>
              0.91b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              214.94m
            </td><td>
              13.40b
            </td><td>
              7.7
            </td><td>
              102,348,400
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FUSN" class="margin-bottom-1">
                FUSN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.14</div> <small class="number change-down">-0.20<span>&nbsp;&nbsp;</span>-2.40%</small></td><td><strong>FPI-1966</strong> <br>Head and Neck and Bladder Cancers
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-announces-second-quarter-2021-financial-results-and-business-update-301351413.html">
                YE 2022
              </a> <div class="note">Phase 1 trial to be initiated around the end of 2021, with interim data due around the end of 2022.</div></td><td>
              43m
            </td><td>
              350.2m
            </td><td>
              186.0k
            </td><td>
              80.5k
            </td><td>
              1.33
            </td><td>
              $8.13
            </td><td>
              $8.34
            </td><td>
              N/A
            </td><td>
              168.13m
            </td><td>
              -5.77m
            </td><td>
              29.14
            </td><td>
              149.53m
            </td><td>
              187.61m
            </td><td>
              0
            </td><td>
              42,433,573
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>FASENRA (benralizumab) NATRON</strong> <br>Hyper-eosinophilic syndrome
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2021/h1-2021/H1_2021_results_clinical_trials_appendix.pdf">
                2H 2022
              </a> <div class="note">Phase 3 data due 2H 2022.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              August 26, 2022
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>FASENRA (benralizumab) - MESSINA</strong> <br>Eosinophilic Esophagitis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2021/h1-2021/H1_2021_results_clinical_trials_appendix.pdf">
                2H 2022
              </a> <div class="note">Phase 3 data due 2H 2022.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              July 15, 2022
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ATHA" class="margin-bottom-1">
                ATHA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.98</div> <small class="number change-up">+0.36<span>&nbsp;&nbsp;</span>+3.79%</small></td><td><strong>ATH-1017 (LIFT-AD)</strong> <br>Alzheimer’s disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.athira.com/athira-pharma-reports-second-quarter-2021-financial-results-and-business-update/">
                YE 2022
              </a> <div class="note">Phase 2 top-line data due by end of 2022. </div></td><td>
              37m
            </td><td>
              372.4m
            </td><td>
              255.7k
            </td><td>
              1.5m
            </td><td>
              1.06
            </td><td>
              $9.65
            </td><td>
              $9.62
            </td><td>
              September 2022
            </td><td>
              280.55m
            </td><td>
              -2.44m
            </td><td>
              115.03
            </td><td>
              271.13m
            </td><td>
              75.89m
            </td><td>
              4
            </td><td>
              32,130,833
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NLTX" class="margin-bottom-1">
                NLTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.54</div> <small class="number change-up">+0.30<span>&nbsp;&nbsp;</span>+4.89%</small></td><td><strong>NL-201</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://investor.neoleukin.com/news-releases/news-release-details/neoleukin-therapeutics-announces-second-quarter-2021-financial">
                2022
              </a> <div class="note">Phase 1 interim data due 2022.</div></td><td>
              42m
            </td><td>
              277.7m
            </td><td>
              69.3k
            </td><td>
              193.2k
            </td><td>
              1.66
            </td><td>
              $6.29
            </td><td>
              $6.24
            </td><td>
              May 2023
            </td><td>
              156.27m
            </td><td>
              -4.43m
            </td><td>
              35.31
            </td><td>
              136.32m
            </td><td>
              114.04m
            </td><td>
              8.7
            </td><td>
              35,021,963
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BLPH" class="margin-bottom-1">
                BLPH
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.05</div> <small class="number change-up">+0.27<span>&nbsp;&nbsp;</span>+7.14%</small></td><td><strong>INOpulse delivery device (REBUILD)</strong> <br>Pulmonary hypertension associated with Fibrotic Interstitial Lung Disease
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-announces-first-patient-enrolled-phase">
                2022
              </a> <div class="note">Phase 3 initiation of dosing announced December 1, 2020. Top-line data due 2022.</div></td><td>
              10m
            </td><td>
              38.5m
            </td><td>
              28.4k
            </td><td>
              214.5k
            </td><td>
              1.28
            </td><td>
              $3.79
            </td><td>
              $3.78
            </td><td>
              December 2022
            </td><td>
              31.08m
            </td><td>
              -1.79m
            </td><td>
              17.36
            </td><td>
              24.10m
            </td><td>
              2.95m
            </td><td>
              39
            </td><td>
              7,891,189
            </td><td>
              12/01/2020
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BGNE" class="margin-bottom-1">
                BGNE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$270.83</div> <small class="number change-up">+21.23<span>&nbsp;&nbsp;</span>+8.51%</small></td><td><strong>BRUKINSA (zanubrutinib) vs IMBRUVICA (Ibrutinib) - ALPINE</strong> <br>Refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805006018/en/">
                2022
              </a> <div class="note">Phase 3 primary endpoint met. ORR of 78.3%, a statistically significant improvement compared to 62.5% with ibrutinib (p=0.0006). Further data due 2022.</div></td><td>
              93m
            </td><td>
              25.2b
            </td><td>
              273.7k
            </td><td>
              315.1k
            </td><td>
              7.00
            </td><td>
              $256
            </td><td>
              $249.6
            </td><td>
              November 1, 2021
            </td><td>
              4.13b
            </td><td>
              -140.09m
            </td><td>
              29.48
            </td><td>
              2.21b
            </td><td>
              21.09b
            </td><td>
              0.3
            </td><td>
              89,530,472
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GTHX" class="margin-bottom-1">
                GTHX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.35</div> <small class="number change-up">+0.82<span>&nbsp;&nbsp;</span>+6.06%</small></td><td><strong>COSELA (trilaciclib) - (PRESERVE3)</strong> <br>Urothelial carcinoma
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://investor.g1therapeutics.com/news-releases/news-release-details/g1-therapeutics-initiates-preserve-3-randomized-phase-2-study">
                2H 2022
              </a> <div class="note">Phase 2 trial initiation announced June 14, 2021. Initial data due 2H 2022.</div></td><td>
              42m
            </td><td>
              0.6b
            </td><td>
              279.6k
            </td><td>
              1.1m
            </td><td>
              2.85
            </td><td>
              $13.83
            </td><td>
              $13.53
            </td><td>
              March 2023
            </td><td>
              222.13m
            </td><td>
              -12.16m
            </td><td>
              18.26
            </td><td>
              158.57m
            </td><td>
              366.37m
            </td><td>
              2.3
            </td><td>
              42,071,302
            </td><td>
              06/14/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ISEE" class="margin-bottom-1">
                ISEE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.70</div> <small class="number change-up">+0.25<span>&nbsp;&nbsp;</span>+2.65%</small></td><td><strong>Zimura - GATHER2</strong> <br>Geographic atrophy
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210804005074/en/">
                2H 2022
              </a> <div class="note">Phase 3 second trial top-line data due 2H 2022.</div></td><td>
              104m
            </td><td>
              1.0b
            </td><td>
              0.7m
            </td><td>
              2.1m
            </td><td>
              7.24
            </td><td>
              $9.56
            </td><td>
              $9.45
            </td><td>
              N/A
            </td><td>
              247.61m
            </td><td>
              -6.82m
            </td><td>
              36.32
            </td><td>
              221.52m
            </td><td>
              0.83b
            </td><td>
              0.6
            </td><td>
              103,498,881
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SELB" class="margin-bottom-1">
                SELB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.11</div> <small class="number change-up">+0.17<span>&nbsp;&nbsp;</span>+4.19%</small></td><td><strong>SEL-212 (DISSOLVE)</strong> <br>Chronic Refractory Gout
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.selectabio.com/news-releases/news-release-details/selecta-biosciences-reports-second-quarter-2021-financial">
                2H 2022
              </a> <div class="note">Phase 3 commencement announced September 23, 2020. Top-line data due 2H 2022.</div></td><td>
              115m
            </td><td>
              472.4m
            </td><td>
              0.5m
            </td><td>
              0.9m
            </td><td>
              -102.62
            </td><td>
              $4.08
            </td><td>
              $3.94
            </td><td>
              March 2022
            </td><td>
              146.51m
            </td><td>
              -2.01m
            </td><td>
              72.73
            </td><td>
              -38.23m
            </td><td>
              338.62m
            </td><td>
              8.4
            </td><td>
              68,548,277
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MRTX" class="margin-bottom-1">
                MRTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$145.25</div> <small class="number change-up">+11.12<span>&nbsp;&nbsp;</span>+8.29%</small></td><td><strong>Sitravatinib plus OPDIVO (nivolumab) - (SAPPHIRE)</strong> <br>Non-small cell lung cancer (NSCLC)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s27.q4cdn.com/140416303/files/doc_presentation/2021/MRTX-Corporate-Presentation_6May2021.pdf">
                2H 2022
              </a> <div class="note">Phase 3 interim OS analysis 2H 2022.</div></td><td>
              52m
            </td><td>
              7.5b
            </td><td>
              181.2k
            </td><td>
              466.1k
            </td><td>
              6.64
            </td><td>
              $135.44
            </td><td>
              $134.13
            </td><td>
              September 2022
            </td><td>
              1.14b
            </td><td>
              -31.12m
            </td><td>
              36.65
            </td><td>
              0.91b
            </td><td>
              5.77b
            </td><td>
              0.9
            </td><td>
              40,808,627
            </td><td>
              05/07/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ORMP" class="margin-bottom-1">
                ORMP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$15.66</div> <small class="number change-up">+0.40<span>&nbsp;&nbsp;</span>+2.62%</small></td><td><strong>ORMD-0801 (ORA-D-013-1)</strong> <br>Type 2 Diabetes
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/oramed-reaches-50-enrollment-in-phase-3-oral-insulin-study-301307702.html">
                2022
              </a> <div class="note">Phase 3 top-line data due 2022.</div></td><td>
              33m
            </td><td>
              0.5b
            </td><td>
              374.5k
            </td><td>
              0.8m
            </td><td>
              7.46
            </td><td>
              $15.5
            </td><td>
              $15.26
            </td><td>
              September 2022
            </td><td>
              59.36m
            </td><td>
              -1.88m
            </td><td>
              31.59
            </td><td>
              48.06m
            </td><td>
              432.10m
            </td><td>
              58.6
            </td><td>
              30,034,652
            </td><td>
              06/08/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLLS" class="margin-bottom-1">
                CLLS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.61</div> <small class="number change-up">+1.14<span>&nbsp;&nbsp;</span>+9.14%</small></td><td><strong>ALLO-316 - TRAVERSE</strong> <br>Clear cell renal cell carcinoma (ccRCC)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-second-quarter-2021-financial">
                2022
              </a> <div class="note">Phase 1 initial data due 2022.</div></td><td>
              45m
            </td><td>
              0.6b
            </td><td>
              168.0k
            </td><td>
              205.0k
            </td><td>
              2.24
            </td><td>
              $12.76
            </td><td>
              $12.47
            </td><td>
              December 2022
            </td><td>
              244.34m
            </td><td>
              -4.04m
            </td><td>
              60.46
            </td><td>
              89.10m
            </td><td>
              425.67m
            </td><td>
              0
            </td><td>
              45,461,310
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALLO" class="margin-bottom-1">
                ALLO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$24.50</div> <small class="number change-up">+1.05<span>&nbsp;&nbsp;</span>+4.50%</small></td><td><strong>ALLO-316 - TRAVERSE</strong> <br>Clear cell renal cell carcinoma (ccRCC)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-second-quarter-2021-financial">
                2022
              </a> <div class="note">Phase 1 initial data due 2022.</div></td><td>
              142m
            </td><td>
              3.5b
            </td><td>
              0.7m
            </td><td>
              1.0m
            </td><td>
              3.40
            </td><td>
              $23.6
            </td><td>
              $23.45
            </td><td>
              December 2022
            </td><td>
              0.56b
            </td><td>
              -13.72m
            </td><td>
              41.03
            </td><td>
              460.09m
            </td><td>
              2.80b
            </td><td>
              3.2
            </td><td>
              87,198,887
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PYPD" class="margin-bottom-1">
                PYPD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.18</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+1.81%</small></td><td><strong>D-PLEX100 (SHIELD II)</strong> <br>Surgical Site Infection
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.polypid.com/news-releases/news-release-details/polypid-ltd-reports-first-quarter-2021-financial-results-and">
                2022
              </a> <div class="note">Phase 3 data due by the end of 2022.</div></td><td>
              19m
            </td><td>
              153.3m
            </td><td>
              3.6k
            </td><td>
              29.0k
            </td><td>
              2.70
            </td><td>
              $8
            </td><td>
              $8.03
            </td><td>
              March 2022
            </td><td>
              47.85m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              43.34m
            </td><td>
              102.77m
            </td><td>
              0
            </td><td>
              15,682,034
            </td><td>
              05/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/REPL" class="margin-bottom-1">
                REPL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$31.79</div> <small class="number change-up">+1.61<span>&nbsp;&nbsp;</span>+5.35%</small></td><td><strong>RP1 (vusolimogene oderparepvec) and LIBTAYO (cemiplimab)  - CERPASS</strong> <br>Cutaneous squamous cell carcinoma (CSCC)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.replimune.com/news-releases/news-release-details/replimune-reports-fiscal-first-quarter-financial-results-and-0">
                Late-2022
              </a> <div class="note">Phase 2 data due late-2022.</div></td><td>
              47m
            </td><td>
              1.5b
            </td><td>
              136.8k
            </td><td>
              313.0k
            </td><td>
              3.10
            </td><td>
              $30.5
            </td><td>
              $30.17
            </td><td>
              October 2022
            </td><td>
              447.34m
            </td><td>
              -6.10m
            </td><td>
              73.28
            </td><td>
              402.64m
            </td><td>
              0.99b
            </td><td>
              9.6
            </td><td>
              29,656,261
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GKOS" class="margin-bottom-1">
                GKOS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$50.06</div> <small class="number change-up">+1.12<span>&nbsp;&nbsp;</span>+2.30%</small></td><td><strong>Epi-on</strong> <br>Progressive keratoconus
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://s21.q4cdn.com/471661912/files/doc_presentations/2021/03/v2/Glaukos-Investor-Presentation_March-2021_vF-(1).pdf">
                2022
              </a> <div class="note">Phase 3 trial met primary endpoint - February 25, 2021. NDA filing 2022.</div></td><td>
              47m
            </td><td>
              2.3b
            </td><td>
              88.8k
            </td><td>
              0.6m
            </td><td>
              3.99
            </td><td>
              $49.61
            </td><td>
              $48.94
            </td><td>
              November 1, 2019
            </td><td>
              423.00m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -36.40m
            </td><td>
              2.23b
            </td><td>
              1.5
            </td><td>
              26,455,804
            </td><td>
              05/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KRON" class="margin-bottom-1">
                KRON
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$20.43</div> <small class="number change-up">+0.70<span>&nbsp;&nbsp;</span>+3.55%</small></td><td><strong>Entospletinib</strong> <br>FLT3-mutated Acute myeloid leukemia (AML) 
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.kronosbio.com/news-releases/news-release-details/kronos-bio-reports-recent-business-progress-and-second-quarter">
                2H 2022
              </a> <div class="note">Phase 1/2 trial to be initiated 4Q 2021 with initial data due 2H 2022.</div></td><td>
              56m
            </td><td>
              1.1b
            </td><td>
              133.4k
            </td><td>
              284.3k
            </td><td>
              2.71
            </td><td>
              $19.84
            </td><td>
              $19.73
            </td><td>
              N/A
            </td><td>
              404.72m
            </td><td>
              -6.75m
            </td><td>
              59.92
            </td><td>
              357.08m
            </td><td>
              0.73b
            </td><td>
              3
            </td><td>
              40,155,148
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AMTI" class="margin-bottom-1">
                AMTI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$30.00</div> <small class="number change-up">+0.76<span>&nbsp;&nbsp;</span>+2.60%</small></td><td><strong>AMT-126</strong> <br>Healthy volunteers
            </td><td>
              Phase 1a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/10/2278317/0/en/Applied-Molecular-Transport-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Corporate-Update.html">
                2022
              </a> <div class="note">Phase 1a initiation of dosing announced March 1, 2021. Data due 2022.</div></td><td>
              38m
            </td><td>
              1.2b
            </td><td>
              105.8k
            </td><td>
              238.2k
            </td><td>
              5.54
            </td><td>
              $29.75
            </td><td>
              $29.24
            </td><td>
              N/A
            </td><td>
              186.24m
            </td><td>
              -7.38m
            </td><td>
              25.23
            </td><td>
              170.06m
            </td><td>
              0.93b
            </td><td>
              1.6
            </td><td>
              16,723,522
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AXSM" class="margin-bottom-1">
                AXSM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$24.49</div> <small class="number change-up">+2.93<span>&nbsp;&nbsp;</span>+13.61%</small></td><td><strong>Dextromethorphan-bupropion (AXS-05) - ACCORD</strong> <br>Agitation in patients with Alzheimer’s disease (AD)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/09/2276982/0/en/Axsome-Therapeutics-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Business-Update.html">
                4Q 2022
              </a> <div class="note">Phase 3 trial initiation announced December 31, 2020 with top-line data due 4Q 2022.</div></td><td>
              38m
            </td><td>
              0.9b
            </td><td>
              9.0m
            </td><td>
              0.9m
            </td><td>
              12.89
            </td><td>
              $25.2
            </td><td>
              $21.56
            </td><td>
              N/A
            </td><td>
              125.98m
            </td><td>
              -8.46m
            </td><td>
              14.88
            </td><td>
              54.15m
            </td><td>
              0.72b
            </td><td>
              0.5
            </td><td>
              22,349,124
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SPRB" class="margin-bottom-1">
                SPRB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.34</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+1.83%</small></td><td><strong>Tildacerfont - CAHmelia-204</strong> <br>Congenital Adrenal Hyperplasia (good disease control)
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210810005900/en/">
                2H 2022
              </a> <div class="note">Phase 2b data due 2H 2022.</div></td><td>
              23m
            </td><td>
              195.0m
            </td><td>
              3.3k
            </td><td>
              67.9k
            </td><td>
              1.50
            </td><td>
              $8.33
            </td><td>
              $8.19
            </td><td>
              June 2022
            </td><td>
              103.41m
            </td><td>
              -3.23m
            </td><td>
              32.00
            </td><td>
              90.06m
            </td><td>
              88.91m
            </td><td>
              0
            </td><td>
              17,692,276
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ELDN" class="margin-bottom-1">
                ELDN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.51</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+0.15%</small></td><td><strong>AT-1501</strong> <br>Kidney transplant rejection
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-reports-second-quarter-2021-operating-and">
                Late-2022
              </a> <div class="note">Phase 2 trial to be initiated 4Q 2021 with initial data late-2022.</div></td><td>
              14m
            </td><td>
              93.1m
            </td><td>
              48.0k
            </td><td>
              73.1k
            </td><td>
              0.52
            </td><td>
              $6.47
            </td><td>
              $6.5
            </td><td>
              N/A
            </td><td>
              96.67m
            </td><td>
              -2.48m
            </td><td>
              38.95
            </td><td>
              90.88m
            </td><td>
              -7.87m
            </td><td>
              6.5
            </td><td>
              14,305,606
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RVMD" class="margin-bottom-1">
                RVMD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$26.00</div> <small class="number change-up">+0.56<span>&nbsp;&nbsp;</span>+2.20%</small></td><td><strong>RMC-5552</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.benzinga.com/pressreleases/21/08/g22452977/revolution-medicines-reports-second-quarter-financial-results-and-update-on-corporate-progress">
                2022
              </a> <div class="note">Phase 1 commencement of dosing announced April 21, 2021 with initial safety, PK and single agent activity data expected in 2022.</div></td><td>
              74m
            </td><td>
              1.9b
            </td><td>
              312.5k
            </td><td>
              0.7m
            </td><td>
              2.79
            </td><td>
              $25.76
            </td><td>
              $25.44
            </td><td>
              March 31, 2024
            </td><td>
              0.63b
            </td><td>
              -11.36m
            </td><td>
              55.09
            </td><td>
              0.54b
            </td><td>
              1.26b
            </td><td>
              0.7
            </td><td>
              49,649,322
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SYRS" class="margin-bottom-1">
                SYRS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.71</div> <small class="number change-up">+0.48<span>&nbsp;&nbsp;</span>+11.35%</small></td><td><strong>Tamibarotene (SY-1425) with VENCLEXTA (venetoclax) and VIDAZA (azacitidine) - (SELECT-AML-1)</strong> <br>Acute myeloid leukemia (AML)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005278/en/">
                2022
              </a> <div class="note">Phase 2 trial to be initiated 2H 2021 with initial data due 2022.</div></td><td>
              62m
            </td><td>
              291.7m
            </td><td>
              363.2k
            </td><td>
              0.8m
            </td><td>
              2.24
            </td><td>
              $4.3
            </td><td>
              $4.23
            </td><td>
              N/A
            </td><td>
              166.16m
            </td><td>
              -8.82m
            </td><td>
              18.84
            </td><td>
              62.40m
            </td><td>
              145.66m
            </td><td>
              2.3
            </td><td>
              41,620,615
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVS" class="margin-bottom-1">
                NVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$93.88</div> <small class="number change-up">+0.55<span>&nbsp;&nbsp;</span>+0.59%</small></td><td><strong>COSENTYX (secukinumab) - SURPASS</strong> <br>Ankylosing spondylitis (AS)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.pdf">
                2022
              </a> <div class="note">Head-to-head trial versus proposed biosimilar adalimumab initiated. Expected completion 2022.</div></td><td>
              2b
            </td><td>
              210.0b
            </td><td>
              0.7m
            </td><td>
              1.7m
            </td><td>
              3.89
            </td><td>
              $93.86
            </td><td>
              $93.33
            </td><td>
              September 2, 2021
            </td><td>
              7.84b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -62.05b
            </td><td>
              238.51b
            </td><td>
              0
            </td><td>
              2,236,739,037
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALEC" class="margin-bottom-1">
                ALEC
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$26.01</div> <small class="number change-up">+1.50<span>&nbsp;&nbsp;</span>+6.12%</small></td><td><strong>AL101</strong> <br>Healthy volunteers
            </td><td>
              Phase 1a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.alector.com/static-files/48555809-ac9d-4ade-a7c8-37fecb86dbe2">
                2021 / 2022
              </a> <div class="note">Phase 1a data due in 2021 / 2022.</div></td><td>
              81m
            </td><td>
              2.1b
            </td><td>
              344.0k
            </td><td>
              1.8m
            </td><td>
              11.41
            </td><td>
              $24.89
            </td><td>
              $24.51
            </td><td>
              August 19, 2021
            </td><td>
              292.84m
            </td><td>
              -14.85m
            </td><td>
              19.72
            </td><td>
              80.25m
            </td><td>
              1.71b
            </td><td>
              7
            </td><td>
              58,130,166
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AUTL" class="margin-bottom-1">
                AUTL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.17</div> <small class="number change-up">+0.53<span>&nbsp;&nbsp;</span>+9.40%</small></td><td><strong>Obe-cel (AUTO1) - (FELIX study)</strong> <br>B-Cell Acute Lymphoblastic Leukemia
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-reports-second-quarter-2021-financial">
                2022
              </a> <div class="note">Phase 1/2 full data due 2022.</div></td><td>
              73m
            </td><td>
              448.8m
            </td><td>
              404.8k
            </td><td>
              1.9m
            </td><td>
              1.58
            </td><td>
              $5.81
            </td><td>
              $5.64
            </td><td>
              March 2023
            </td><td>
              194.39m
            </td><td>
              -12.20m
            </td><td>
              15.93
            </td><td>
              147.41m
            </td><td>
              216.60m
            </td><td>
              0
            </td><td>
              72,742,582
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RXDX" class="margin-bottom-1">
                RXDX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.93</div> <small class="number change-up">+0.61<span>&nbsp;&nbsp;</span>+2.73%</small></td><td><strong>PRA023 (ARTEMIS-UC)</strong> <br>Ulcerative colitis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/02/2272781/0/en/Prometheus-Biosciences-Announces-Initiation-of-APOLLO-CD-Phase-2a-Clinical-Trial-of-PRA023-in-Moderate-to-Severe-Crohn-s-Disease.html">
                4Q 2022
              </a> <div class="note">Phase 2 trial initiation announced July 19, 2021. Final Phase 1 data due 4Q 2021. Phase 2 data due 4Q 2022.</div></td><td>
              39m
            </td><td>
              0.9b
            </td><td>
              38.8k
            </td><td>
              159.7k
            </td><td>
              3.15
            </td><td>
              $22.37
            </td><td>
              $22.32
            </td><td>
              N/A
            </td><td>
              301.17m
            </td><td>
              -1.79m
            </td><td>
              168.66
            </td><td>
              270.44m
            </td><td>
              0.57b
            </td><td>
              0.2
            </td><td>
              29,995,596
            </td><td>
              08/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RNA" class="margin-bottom-1">
                RNA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.35</div> <small class="number change-up">+1.20<span>&nbsp;&nbsp;</span>+5.96%</small></td><td><strong>AOC 1001 (MARINA)</strong> <br>Myotonic dystrophy type 1 (DM1)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/avidity-biosciences-receives-ind-clearance-from-fda-to-proceed-with-the-phase-12-marina-trial-of-aoc-1001-in-adults-with-myotonic-dystrophy-dm1-301345542.html">
                2H 2022
              </a> <div class="note">Phase 1/2 clearance to proceed with trial announced August 2, 2021. Initial assessment of safety, tolerability and key biomarkers in approximately half of the study participants due 2H 2022.</div></td><td>
              38m
            </td><td>
              0.8b
            </td><td>
              211.0k
            </td><td>
              283.8k
            </td><td>
              3.04
            </td><td>
              $20.56
            </td><td>
              $20.15
            </td><td>
              N/A
            </td><td>
              406.58m
            </td><td>
              -9.38m
            </td><td>
              43.35
            </td><td>
              380.53m
            </td><td>
              480.51m
            </td><td>
              0.2
            </td><td>
              32,364,584
            </td><td>
              08/02/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VERA" class="margin-bottom-1">
                VERA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$19.12</div> <small class="number change-up">+0.22<span>&nbsp;&nbsp;</span>+1.16%</small></td><td><strong>Atacicept (ORIGIN)</strong> <br>IgA Nephropathy
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.veratx.com/static-files/bf0e3b08-4edc-430e-b8e4-d02178d8377b">
                4Q 2022
              </a> <div class="note">Phase 2 top-line data due 4Q 2022.</div></td><td>
              21m
            </td><td>
              406.8m
            </td><td>
              4.0k
            </td><td>
              16.5k
            </td><td>
              4.42
            </td><td>
              $19
            </td><td>
              $18.9
            </td><td>
              December 2022
            </td><td>
              87.03m
            </td><td>
              -2.55m
            </td><td>
              34.06
            </td><td>
              81.53m
            </td><td>
              348.49m
            </td><td>
              0.8
            </td><td>
              10,702,329
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OCUP" class="margin-bottom-1">
                OCUP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.38</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+5.54%</small></td><td><strong>APX3330 Oral Pill - (ZETA-1)</strong> <br>Diabetic Retinopathy (DR)/ Macular Edema (DME)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.ocuphire.com/news-media/press-releases/detail/349/ocuphire-announces-financial-results-for-the-second-quarter">
                2022
              </a> <div class="note">Phase 2 data due 2022.</div></td><td>
              11m
            </td><td>
              47.5m
            </td><td>
              91.7k
            </td><td>
              1.8m
            </td><td>
              1.77
            </td><td>
              $4.34
            </td><td>
              $4.15
            </td><td>
              March 2022
            </td><td>
              21.64m
            </td><td>
              -1.44m
            </td><td>
              15.00
            </td><td>
              18.94m
            </td><td>
              -3.13m
            </td><td>
              0
            </td><td>
              4,009,598
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AXSM" class="margin-bottom-1">
                AXSM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$24.49</div> <small class="number change-up">+2.93<span>&nbsp;&nbsp;</span>+13.61%</small></td><td><strong>Esreboxetine (AXS-14)</strong> <br>Fibromyalgia
            </td><td>
              NDA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/09/2276982/0/en/Axsome-Therapeutics-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Business-Update.html">
                4Q 2022
              </a> <div class="note">Phase 3 trial met primary endpoints. NDA filing due 4Q 2022.</div></td><td>
              38m
            </td><td>
              0.9b
            </td><td>
              9.0m
            </td><td>
              0.9m
            </td><td>
              12.89
            </td><td>
              $25.2
            </td><td>
              $21.56
            </td><td>
              N/A
            </td><td>
              125.98m
            </td><td>
              -8.46m
            </td><td>
              14.88
            </td><td>
              54.15m
            </td><td>
              0.72b
            </td><td>
              0.5
            </td><td>
              22,349,124
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FSTX" class="margin-bottom-1">
                FSTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$6.35</div> <small class="number change-up">+0.41<span>&nbsp;&nbsp;</span>+6.90%</small></td><td><strong>SB 11285</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.f-star.com/news-releases/news-release-details/f-star-therapeutics-reports-second-quarter-2021-financial">
                2022
              </a> <div class="note">Phase 1a/1b update due 2022. Update June 26, 2021 noted treatment was well tolerated.</div></td><td>
              21m
            </td><td>
              130.9m
            </td><td>
              90.9k
            </td><td>
              158.7k
            </td><td>
              1.32
            </td><td>
              $6.08
            </td><td>
              $5.94
            </td><td>
              December 2021
            </td><td>
              88.28m
            </td><td>
              -2.98m
            </td><td>
              29.57
            </td><td>
              62.29m
            </td><td>
              54.41m
            </td><td>
              3.2
            </td><td>
              20,549,167
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ESPR" class="margin-bottom-1">
                ESPR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.87</div> <small class="number change-up">+0.70<span>&nbsp;&nbsp;</span>+5.32%</small></td><td><strong>NEXLETOL (bempedoic acid) - (ETC-1002) CLEAR Outcomes</strong> <br>Cardiovascular Diseases
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://esperion.gcs-web.com/node/12546/pdf">
                2H 2022
              </a> <div class="note">Phase 3 data due 2H 2022.</div></td><td>
              28m
            </td><td>
              392.2m
            </td><td>
              297.4k
            </td><td>
              0.6m
            </td><td>
              -1.29
            </td><td>
              $13.42
            </td><td>
              $13.17
            </td><td>
              August 2022
            </td><td>
              190.47m
            </td><td>
              -15.96m
            </td><td>
              11.94
            </td><td>
              -394.30m
            </td><td>
              429.59m
            </td><td>
              4
            </td><td>
              20,122,764
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVS" class="margin-bottom-1">
                NVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$93.88</div> <small class="number change-up">+0.55<span>&nbsp;&nbsp;</span>+0.59%</small></td><td><strong>Kisqali (NATALEE)</strong> <br>Adjuvant breast cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.pdf">
                2022
              </a> <div class="note">Phase 3 final readout 2022.</div></td><td>
              2b
            </td><td>
              210.0b
            </td><td>
              0.7m
            </td><td>
              1.7m
            </td><td>
              3.89
            </td><td>
              $93.86
            </td><td>
              $93.33
            </td><td>
              May 29, 2026
            </td><td>
              7.84b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -62.05b
            </td><td>
              238.51b
            </td><td>
              0
            </td><td>
              2,236,739,037
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MIST" class="margin-bottom-1">
                MIST
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.75</div> <small class="number change-up">+0.12<span>&nbsp;&nbsp;</span>+2.04%</small></td><td><strong>Etripamil - (RAPID)</strong> <br>Paroxysmal supraventricular tachycardia (PSVT)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.benzinga.com/pressreleases/21/08/n22453945/milestone-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-clinical-and-">
                2H 2022
              </a> <div class="note">Phase 3 data due 2H 2022.</div></td><td>
              30m
            </td><td>
              171.5m
            </td><td>
              15.1k
            </td><td>
              36.4k
            </td><td>
              1.23
            </td><td>
              $6
            </td><td>
              $5.63
            </td><td>
              January 2022
            </td><td>
              136.40m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              130.50m
            </td><td>
              33.07m
            </td><td>
              9
            </td><td>
              25,196,672
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TAK" class="margin-bottom-1">
                TAK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.97</div> <small class="number change-up">+0.29<span>&nbsp;&nbsp;</span>+1.75%</small></td><td><strong>TAK-755</strong> <br>Congenital Thrombotic Thrombocytopenic Purpura
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.takeda.com/4918ab/siteassets/system/investors/quarterly-announcements/fy2020/qr2020_q3_p01_en.pdf">
                2022
              </a> <div class="note">Phase 3 data due 2022.</div></td><td>
              3b
            </td><td>
              53.4b
            </td><td>
              0.8m
            </td><td>
              1.9m
            </td><td>
              1.12
            </td><td>
              $16.84
            </td><td>
              $16.68
            </td><td>
              August 27, 2026
            </td><td>
              0.78t
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -6.63t
            </td><td>
              86.30b
            </td><td>
              0
            </td><td>
              3,145,059,016
            </td><td>
              03/25/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CERE" class="margin-bottom-1">
                CERE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$26.20</div> <small class="number change-up">+2.51<span>&nbsp;&nbsp;</span>+10.60%</small></td><td><strong>Darigabat (CVL-865) - REALIZE</strong> <br>Focal onset epilepsy
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.cerevel.com/news-releases/news-release-details/cerevel-therapeutics-reports-second-quarter-2021-financial">
                2H 2022
              </a> <div class="note">Phase 2 data due 2H 2022.</div></td><td>
              145m
            </td><td>
              3.8b
            </td><td>
              327.6k
            </td><td>
              2.9m
            </td><td>
              12.91
            </td><td>
              $23.95
            </td><td>
              $23.69
            </td><td>
              March 2022
            </td><td>
              0.65b
            </td><td>
              -15.20m
            </td><td>
              42.74
            </td><td>
              0.55b
            </td><td>
              3.14b
            </td><td>
              0.1
            </td><td>
              52,582,057
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ANNX" class="margin-bottom-1">
                ANNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.34</div> <small class="number change-up">+0.58<span>&nbsp;&nbsp;</span>+3.49%</small></td><td><strong>ANX005</strong> <br>Amyotrophic lateral sclerosis (ALS)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.annexonbio.com/news-releases/news-release-details/annexon-biosciences-reports-second-quarter-2021-financial">
                2022
              </a> <div class="note">Phase 2 data due 2022.</div></td><td>
              38m
            </td><td>
              0.7b
            </td><td>
              64.4k
            </td><td>
              162.5k
            </td><td>
              2.25
            </td><td>
              $17.05
            </td><td>
              $16.75
            </td><td>
              July 2021
            </td><td>
              287.59m
            </td><td>
              -8.22m
            </td><td>
              34.99
            </td><td>
              251.14m
            </td><td>
              366.09m
            </td><td>
              0
            </td><td>
              36,335,026
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CERE" class="margin-bottom-1">
                CERE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$26.20</div> <small class="number change-up">+2.51<span>&nbsp;&nbsp;</span>+10.60%</small></td><td><strong>CVL-871</strong> <br>Dementia-related apathy
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.cerevel.com/news-releases/news-release-details/cerevel-therapeutics-reports-second-quarter-2021-financial">
                2H 2022
              </a> <div class="note">Phase 2 data due 2H 2022.</div></td><td>
              145m
            </td><td>
              3.8b
            </td><td>
              327.6k
            </td><td>
              2.9m
            </td><td>
              12.91
            </td><td>
              $23.95
            </td><td>
              $23.69
            </td><td>
              N/A
            </td><td>
              0.65b
            </td><td>
              -15.20m
            </td><td>
              42.74
            </td><td>
              0.55b
            </td><td>
              3.14b
            </td><td>
              0.1
            </td><td>
              52,582,057
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CNCE" class="margin-bottom-1">
                CNCE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.32</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+4.08%</small></td><td><strong>CTP-543 (THRIVE-AA2)</strong> <br>Alopecia Areata
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005047/en/">
                2H 2022
              </a> <div class="note">Phase 3 trial initiation announced May 27, 2021. Data due 2H 2022.</div></td><td>
              32m
            </td><td>
              106.8m
            </td><td>
              34.9k
            </td><td>
              255.0k
            </td><td>
              0.87
            </td><td>
              $3.2
            </td><td>
              $3.19
            </td><td>
              June 2022
            </td><td>
              131.25m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              105.26m
            </td><td>
              -6.66m
            </td><td>
              5.3
            </td><td>
              28,625,013
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/STSA" class="margin-bottom-1">
                STSA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.92</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+1.86%</small></td><td><strong>STS101 (SUMMIT)</strong> <br>Migraine
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.satsumarx.com/2021-08-10-Satsuma-Pharmaceuticals-Reports-Second-Quarter-2021-Financial-Results-and-Recent-Business-Highlights">
                2H 2022
              </a> <div class="note">Phase 3 trial did not meet primary endpoint - September 10, 2020. New Phase 3 trial has been initiated with top-line data due 2H 2022.</div></td><td>
              32m
            </td><td>
              155.1m
            </td><td>
              33.5k
            </td><td>
              386.2k
            </td><td>
              1.22
            </td><td>
              $4.83
            </td><td>
              $4.83
            </td><td>
              September 2022
            </td><td>
              114.51m
            </td><td>
              -3.70m
            </td><td>
              30.96
            </td><td>
              106.93m
            </td><td>
              33.19m
            </td><td>
              1
            </td><td>
              22,490,828
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FNCH" class="margin-bottom-1">
                FNCH
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.11</div> <small class="number change-up">+0.28<span>&nbsp;&nbsp;</span>+2.18%</small></td><td><strong>FIN-211</strong> <br>Autism Spectrum Disorder
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.finchtherapeutics.com/news-releases/news-release-details/finch-therapeutics-reports-second-quarter-2021-financial-results">
                2H 2022
              </a> <div class="note">Phase 1 top-line data due 2H 2022.</div></td><td>
              47m
            </td><td>
              0.6b
            </td><td>
              6.7k
            </td><td>
              84.9k
            </td><td>
              2.73
            </td><td>
              $12.65
            </td><td>
              $12.83
            </td><td>
              N/A
            </td><td>
              153.87m
            </td><td>
              -7.93m
            </td><td>
              19.41
            </td><td>
              131.73m
            </td><td>
              417.56m
            </td><td>
              6.8
            </td><td>
              27,059,349
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RVMD" class="margin-bottom-1">
                RVMD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$26.00</div> <small class="number change-up">+0.56<span>&nbsp;&nbsp;</span>+2.20%</small></td><td><strong>RMC-4630-03 and Sotorasib (AMG 510)</strong> <br>Lung cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.benzinga.com/pressreleases/21/08/g22452977/revolution-medicines-reports-second-quarter-financial-results-and-update-on-corporate-progress">
                2H 2022
              </a> <div class="note">Phase 2 trial to be initiated 2H 2021 with initial data due 2H 2022.</div></td><td>
              74m
            </td><td>
              1.9b
            </td><td>
              312.5k
            </td><td>
              0.7m
            </td><td>
              2.79
            </td><td>
              $25.76
            </td><td>
              $25.44
            </td><td>
              N/A
            </td><td>
              0.63b
            </td><td>
              -11.36m
            </td><td>
              55.09
            </td><td>
              0.54b
            </td><td>
              1.26b
            </td><td>
              0.7
            </td><td>
              49,649,322
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVCR" class="margin-bottom-1">
                NVCR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$135.40</div> <small class="number change-up">+2.97<span>&nbsp;&nbsp;</span>+2.24%</small></td><td><strong>Tumor Treating Fields (TTFields) LUNAR</strong> <br>Non-small cell lung cancer (NSCLC)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210729005357/en/">
                2022
              </a> <div class="note">Phase 3 final data due in 2022.</div></td><td>
              104m
            </td><td>
              14.0b
            </td><td>
              153.2k
            </td><td>
              0.7m
            </td><td>
              35.35
            </td><td>
              $133.45
            </td><td>
              $132.43
            </td><td>
              September 2023
            </td><td>
              0.91b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              214.94m
            </td><td>
              13.40b
            </td><td>
              7.7
            </td><td>
              102,348,400
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ZLAB" class="margin-bottom-1">
                ZLAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$143.17</div> <small class="number change-up">+9.00<span>&nbsp;&nbsp;</span>+6.71%</small></td><td><strong>Tumor Treating Fields (TTFields) LUNAR</strong> <br>Non-small cell lung cancer (NSCLC)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210729005357/en/">
                2022
              </a> <div class="note">Phase 3 final data due in 2022.</div></td><td>
              75m
            </td><td>
              10.8b
            </td><td>
              320.4k
            </td><td>
              0.6m
            </td><td>
              33.30
            </td><td>
              $135
            </td><td>
              $134.17
            </td><td>
              September 2023
            </td><td>
              1.73b
            </td><td>
              -21.95m
            </td><td>
              78.68
            </td><td>
              1.50b
            </td><td>
              1.78b
            </td><td>
              0
            </td><td>
              75,375,511
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PTN" class="margin-bottom-1">
                PTN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$0.46</div> <small class="number change-up">+0.03<span>&nbsp;&nbsp;</span>+6.29%</small></td><td><strong>PL9643</strong> <br>Dry eye disease (DED)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/palatin-announces-positive-end-of-phase-2-meeting-with-fda-on-pl9643-for-the-treatment-of-dry-eye-disease-301321681.html">
                2H 2022
              </a> <div class="note">Phase 3 trial planned for 4Q 2021 with data due 2H 2022.</div></td><td>
              230m
            </td><td>
              106.4m
            </td><td>
              0.6m
            </td><td>
              1.4m
            </td><td>
              1.71
            </td><td>
              $0.43
            </td><td>
              $0.44
            </td><td>
              N/A
            </td><td>
              63.00m
            </td><td>
              -1.17m
            </td><td>
              53.93
            </td><td>
              45.00m
            </td><td>
              32.76m
            </td><td>
              9.8
            </td><td>
              226,985,967
            </td><td>
              06/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ANAB" class="margin-bottom-1">
                ANAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$25.65</div> <small class="number change-up">+1.42<span>&nbsp;&nbsp;</span>+5.86%</small></td><td><strong>Imsidolimab (ANB019) - INSPIRE</strong> <br>Ichthyosis
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/09/2277409/0/en/AnaptysBio-Announces-Second-Quarter-2021-Financial-Results-and-Provides-Pipeline-Updates.html">
                2022
              </a> <div class="note">Phase 2 top-line data due 2022.</div></td><td>
              27m
            </td><td>
              0.7b
            </td><td>
              43.4k
            </td><td>
              221.0k
            </td><td>
              1.82
            </td><td>
              $24.54
            </td><td>
              $24.23
            </td><td>
              August 2022
            </td><td>
              416.61m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              375.77m
            </td><td>
              294.64m
            </td><td>
              2
            </td><td>
              19,169,175
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/APLT" class="margin-bottom-1">
                APLT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$18.78</div> <small class="number change-up">+2.62<span>&nbsp;&nbsp;</span>+16.21%</small></td><td><strong>AT-001 (ARISE-HF)</strong> <br>Diabetic cardiomyopathy (DbCM)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.appliedtherapeutics.com/static-files/177ffa82-b635-41e8-abfe-d735d60b4d83">
                2022
              </a> <div class="note">Phase 3 data due 2022.</div></td><td>
              26m
            </td><td>
              491.6m
            </td><td>
              97.4k
            </td><td>
              86.8k
            </td><td>
              4.37
            </td><td>
              $16.16
            </td><td>
              $16.16
            </td><td>
              December 2022
            </td><td>
              110.07m
            </td><td>
              -8.64m
            </td><td>
              12.75
            </td><td>
              85.55m
            </td><td>
              302.12m
            </td><td>
              3.3
            </td><td>
              17,716,529
            </td><td>
              05/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>IMFINZI (Durvalumab) TOPAZ-1</strong> <br>Biliary-tract cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2021/h1-2021/H1_2021_results_clinical_trials_appendix.pdf">
                2H 2022
              </a> <div class="note">Phase 3 data due 2H 2022.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              June 30, 2022
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BYSI" class="margin-bottom-1">
                BYSI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.77</div> <small class="number change-up">+2.58<span>&nbsp;&nbsp;</span>+12.78%</small></td><td><strong>Plinabulin + PD-1/PD-L1 inhibitor and radiotherapy</strong> <br>Solid Tumors
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/06/16/2248177/0/en/BeyondSpring-Announces-First-Quarter-2021-Financial-Results-and-Provides-a-Corporate-Update.html">
                2022
              </a> <div class="note">Phase 1b initiation of dosing announced June 4, 2021. Data due 2022.</div></td><td>
              30m
            </td><td>
              0.7b
            </td><td>
              2.5m
            </td><td>
              3.4m
            </td><td>
              28.82
            </td><td>
              $20.16
            </td><td>
              $20.19
            </td><td>
              June 1, 2025
            </td><td>
              60.06m
            </td><td>
              -6.31m
            </td><td>
              9.51
            </td><td>
              33.34m
            </td><td>
              363.10m
            </td><td>
              0
            </td><td>
              10,963,858
            </td><td>
              06/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARNA" class="margin-bottom-1">
                ARNA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$51.04</div> <small class="number change-up">+4.14<span>&nbsp;&nbsp;</span>+8.83%</small></td><td><strong>Temanogrel</strong> <br>Coronary Microvascular Obstruction (cMVO)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210608005480/en/">
                2H 2022
              </a> <div class="note">Phase 2 trial first patient has been randomized - June 8, 2021. Data due 2H 2022.</div></td><td>
              61m
            </td><td>
              3.1b
            </td><td>
              0.6m
            </td><td>
              464.5k
            </td><td>
              3.21
            </td><td>
              $47.42
            </td><td>
              $46.9
            </td><td>
              April 2022
            </td><td>
              0.85b
            </td><td>
              -31.28m
            </td><td>
              27.02
            </td><td>
              0.73b
            </td><td>
              1.94b
            </td><td>
              4.4
            </td><td>
              54,681,471
            </td><td>
              06/08/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DARE" class="margin-bottom-1">
                DARE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.62</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+4.35%</small></td><td><strong>Ovaprene</strong> <br>Contraception
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.darebioscience.com/static-files/b0c8350b-3970-490c-b79c-20bf8b3a09f1">
                YE 2022
              </a> <div class="note">Phase 3 trial to commence 2022 with data due by end of 2022.</div></td><td>
              71m
            </td><td>
              114.1m
            </td><td>
              2.0m
            </td><td>
              11.4m
            </td><td>
              14.70
            </td><td>
              $1.53
            </td><td>
              $1.55
            </td><td>
              N/A
            </td><td>
              38.89m
            </td><td>
              -3.93m
            </td><td>
              9.89
            </td><td>
              31.81m
            </td><td>
              100.69m
            </td><td>
              1.1
            </td><td>
              68,859,431
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DRMA" class="margin-bottom-1">
                DRMA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.70</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+1.95%</small></td><td><strong>DMT310</strong> <br>Rosacea
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001853816/000119312521187916/d137089ds1.htm">
                2H 2022
              </a> <div class="note">Phase 2 trial to be initiated 2H 2021 with data due 2H 2022.</div></td><td>
              8m
            </td><td>
              39.1m
            </td><td>
              14.5k
            </td><td>
              
            </td><td>
              58.75
            </td><td>
              $4.6
            </td><td>
              $4.61
            </td><td>
              N/A
            </td><td>
              79.84k
            </td><td>
              -258.74k
            </td><td>
              0.31
            </td><td>
              -0.86m
            </td><td>
              37.25m
            </td><td>
              0
            </td><td>
              1,768,271
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVCR" class="margin-bottom-1">
                NVCR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$135.40</div> <small class="number change-up">+2.97<span>&nbsp;&nbsp;</span>+2.24%</small></td><td><strong>EF-31</strong> <br>Gastric cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210729005357/en/">
                2022
              </a> <div class="note">Phase 2 data due 2022.</div></td><td>
              104m
            </td><td>
              14.0b
            </td><td>
              153.2k
            </td><td>
              0.7m
            </td><td>
              35.35
            </td><td>
              $133.45
            </td><td>
              $132.43
            </td><td>
              September 2021
            </td><td>
              0.91b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              214.94m
            </td><td>
              13.40b
            </td><td>
              7.7
            </td><td>
              102,348,400
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MBRX" class="margin-bottom-1">
                MBRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.93</div> <small class="number change-up">+0.16<span>&nbsp;&nbsp;</span>+5.64%</small></td><td><strong>Annamycin</strong> <br>Soft tissue sarcoma lung metastases
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/moleculin-announces-first-subject-enrolled-and-dosed-in-phase-1b2-clinical-trial-of-annamycin-for-the-treatment-of-sarcoma-lung-metastases-301316273.html">
                2H 2022
              </a> <div class="note">Phase 1/2 interim data due 2H 2022.</div></td><td>
              29m
            </td><td>
              83.5m
            </td><td>
              78.0k
            </td><td>
              238.1k
            </td><td>
              0.98
            </td><td>
              $2.78
            </td><td>
              $2.77
            </td><td>
              January 2023
            </td><td>
              75.44m
            </td><td>
              -2.26m
            </td><td>
              33.37
            </td><td>
              66.60m
            </td><td>
              -196.37k
            </td><td>
              2.4
            </td><td>
              27,978,404
            </td><td>
              06/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RNXT" class="margin-bottom-1">
                RNXT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td>
              N/A
            </td><td><strong>RenovoGem (TIGeR-PaC)</strong> <br>Pancreatic cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001574094/000149315221019398/forms-1a.htm">
                2H 2022
              </a> <div class="note">Phase 3 interim data due 2H 2022.</div></td><td>
              8m
            </td><td>
              
            </td><td>
              
            </td><td>
              
            </td><td>
              
            </td><td>
              $0
            </td><td>
              $0
            </td><td>
              September 2022
            </td><td>
              0.81m
            </td><td>
              -415.67k
            </td><td>
              1.95
            </td><td>
              -18.42m
            </td><td>
              
            </td><td>
              0
            </td><td>
              6,044,179
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PIRS" class="margin-bottom-1">
                PIRS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.28</div> <small class="number change-up">+0.24<span>&nbsp;&nbsp;</span>+5.94%</small></td><td><strong>PRS-060/AZD1402</strong> <br>Asthma
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.accesswire.com/647654/Pieris-Pharmaceuticals-Reports-First-Quarter-2021-Financial-Results-and-Provides-Corporate-Update">
                2022
              </a> <div class="note">Phase 2 data due 2022.</div></td><td>
              67m
            </td><td>
              285.5m
            </td><td>
              0.9m
            </td><td>
              3.2m
            </td><td>
              6.11
            </td><td>
              $4.04
            </td><td>
              $4.04
            </td><td>
              N/A
            </td><td>
              137.04m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              28.73m
            </td><td>
              166.33m
            </td><td>
              0.2
            </td><td>
              66,662,799
            </td><td>
              05/17/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FMTX" class="margin-bottom-1">
                FMTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$23.39</div> <small class="number change-up">+0.69<span>&nbsp;&nbsp;</span>+3.06%</small></td><td><strong>Etavopivat (FT-4202)</strong> <br>Thalassemia / sickle cell disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210813005019/en/">
                2022
              </a> <div class="note">Phase 2 trial to be initiated 2H 2021 with data due in 2022.</div></td><td>
              50m
            </td><td>
              1.2b
            </td><td>
              83.0k
            </td><td>
              332.2k
            </td><td>
              2.02
            </td><td>
              $22.94
            </td><td>
              $22.7
            </td><td>
              N/A
            </td><td>
              0.52b
            </td><td>
              -10.85m
            </td><td>
              47.58
            </td><td>
              482.06m
            </td><td>
              0.60b
            </td><td>
              1.1
            </td><td>
              32,086,456
            </td><td>
              08/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NMTR" class="margin-bottom-1">
                NMTR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.13</div> <small class="number change-up">+0.03<span>&nbsp;&nbsp;</span>+2.73%</small></td><td><strong>Larazotide</strong> <br>Multisystem Inflammatory Syndrome in Children (MIS-C) resulting from COVID-19
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.accesswire.com/659785/9-Meters-Biopharma-Inc-Announces-Collaboration-with-EBRIS-Foundation-for-Planned-Phase-2-Study-of-Larazotide-for-the-Treatment-of-Multisystem-Inflammatory-Syndrome-in-Children-MIS-C-Resulting-from-COVID-19">
                2022
              </a> <div class="note">Phase 2a trial to be initiated 4Q 2021 with data due 2022.</div></td><td>
              255m
            </td><td>
              287.9m
            </td><td>
              1.6m
            </td><td>
              4.9m
            </td><td>
              4.91
            </td><td>
              $1.13
            </td><td>
              $1.1
            </td><td>
              N/A
            </td><td>
              59.76m
            </td><td>
              -2.37m
            </td><td>
              25.22
            </td><td>
              52.90m
            </td><td>
              216.40m
            </td><td>
              1.9
            </td><td>
              218,959,804
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IKNA" class="margin-bottom-1">
                IKNA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$11.44</div> <small class="number change-down">-0.43<span>&nbsp;&nbsp;</span>-3.62%</small></td><td><strong>IK-175 and OPDIVO (nivolumab)</strong> <br>Bladder cancer
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ikenaoncology.com/news-releases/news-release-details/ikena-oncology-reports-second-quarter-2021-financial-results-and">
                2022
              </a> <div class="note">Phase 1 data to be presented 2022.</div></td><td>
              36m
            </td><td>
              410.2m
            </td><td>
              19.4k
            </td><td>
              144.4k
            </td><td>
              1.90
            </td><td>
              $11.9
            </td><td>
              $11.87
            </td><td>
              September 2022
            </td><td>
              254.57m
            </td><td>
              -5.24m
            </td><td>
              48.57
            </td><td>
              192.00m
            </td><td>
              243.00m
            </td><td>
              0.1
            </td><td>
              29,922,440
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/XFOR" class="margin-bottom-1">
                XFOR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.91</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+3.15%</small></td><td><strong>Mavorixafor (X4P-001)</strong> <br>WHIM syndrome
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-key-enrollment-milestone">
                4Q 2022
              </a> <div class="note">Phase 3 data due 4Q 2022.</div></td><td>
              25m
            </td><td>
              121.6m
            </td><td>
              95.6k
            </td><td>
              246.6k
            </td><td>
              1.37
            </td><td>
              $4.87
            </td><td>
              $4.76
            </td><td>
              September 2021
            </td><td>
              83.64m
            </td><td>
              -6.40m
            </td><td>
              13.07
            </td><td>
              31.20m
            </td><td>
              63.01m
            </td><td>
              6.8
            </td><td>
              22,057,851
            </td><td>
              08/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AMAM" class="margin-bottom-1">
                AMAM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.15</div> <small class="number change-down">-0.31<span>&nbsp;&nbsp;</span>-1.88%</small></td><td><strong>ARX788 (ACE-Breast-02)</strong> <br>HER2-positive metastatic breast cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001836056/000119312521177104/d108474df1.htm">
                YE 2022
              </a> <div class="note">Phase 2 trial ongoing in China. Top-line data due by end of 2022.</div></td><td>
              38m
            </td><td>
              0.6b
            </td><td>
              5.4k
            </td><td>
              67.2k
            </td><td>
              -4.37
            </td><td>
              $16.63
            </td><td>
              $16.46
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              0.53b
            </td><td>
              0
            </td><td>
              37,669,455
            </td><td>
              06/15/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TCRX" class="margin-bottom-1">
                TCRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$11.08</div> <small class="number change-up">+0.05<span>&nbsp;&nbsp;</span>+0.45%</small></td><td><strong>TSC-100</strong> <br>Solid tumor
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/19/2283444/0/en/TScan-Therapeutics-Reports-Second-Quarter-2021-Financial-Results-and-Highlights-Recent-Company-Progress.html">
                2H 2022
              </a> <div class="note">Phase 1 trial to be initiated 1H 2022 with initial top-line data 2H 2022.</div></td><td>
              24m
            </td><td>
              265.2m
            </td><td>
              16.3k
            </td><td>
              
            </td><td>
              -5.30
            </td><td>
              $11.21
            </td><td>
              $11.03
            </td><td>
              N/A
            </td><td>
              105.46m
            </td><td>
              -3.32m
            </td><td>
              31.77
            </td><td>
              -85.40m
            </td><td>
              149.69m
            </td><td>
              4.5
            </td><td>
              12,175,130
            </td><td>
              08/19/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TCRX" class="margin-bottom-1">
                TCRX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$11.08</div> <small class="number change-up">+0.05<span>&nbsp;&nbsp;</span>+0.45%</small></td><td><strong>TSC-101</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/08/19/2283444/0/en/TScan-Therapeutics-Reports-Second-Quarter-2021-Financial-Results-and-Highlights-Recent-Company-Progress.html">
                2H 2022
              </a> <div class="note">Phase 1 trial to be initiated 1H 2022 with initial top-line data due 2H 2022.</div></td><td>
              24m
            </td><td>
              265.2m
            </td><td>
              16.3k
            </td><td>
              
            </td><td>
              -5.30
            </td><td>
              $11.21
            </td><td>
              $11.03
            </td><td>
              N/A
            </td><td>
              105.46m
            </td><td>
              -3.32m
            </td><td>
              31.77
            </td><td>
              -85.40m
            </td><td>
              149.69m
            </td><td>
              4.5
            </td><td>
              12,175,130
            </td><td>
              08/19/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FBIO" class="margin-bottom-1">
                FBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.20</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+4.58%</small></td><td><strong>CAEL‐101</strong> <br>AL amyloidosis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210512006005/en/">
                2H 2022
              </a> <div class="note">Phase 3 top-line data due 2H 2022. </div></td><td>
              101m
            </td><td>
              323.4m
            </td><td>
              220.5k
            </td><td>
              0.5m
            </td><td>
              2.99
            </td><td>
              $3.07
            </td><td>
              $3.06
            </td><td>
              August 2, 2022
            </td><td>
              254.32m
            </td><td>
              -11.49m
            </td><td>
              22.14
            </td><td>
              84.46m
            </td><td>
              120.76m
            </td><td>
              27.4
            </td><td>
              76,232,955
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RCUS" class="margin-bottom-1">
                RCUS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.16</div> <small class="number change-up">+0.78<span>&nbsp;&nbsp;</span>+2.75%</small></td><td><strong>AB928, AB680 and zimberelimab - ARC-6</strong> <br>Metastatic castrate-resistant prostate cancer (mCRPC)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.arcusbio.com/investors-and-media/press-releases/press-release-details/2021/Arcus-Biosciences-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Operational-Highlights/default.aspx">
                2022
              </a> <div class="note">Data released in abstract noted overall response rate (ORR) of 41%. Initial data from the Stage 2 randomized portion are expected to be presented in 2022.</div></td><td>
              71m
            </td><td>
              2.1b
            </td><td>
              139.5k
            </td><td>
              0.7m
            </td><td>
              3.44
            </td><td>
              $28.39
            </td><td>
              $28.38
            </td><td>
              April 2023
            </td><td>
              0.68b
            </td><td>
              -24.66m
            </td><td>
              27.43
            </td><td>
              382.40m
            </td><td>
              1.35b
            </td><td>
              1.2
            </td><td>
              50,339,817
            </td><td>
              08/06/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVCR" class="margin-bottom-1">
                NVCR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$135.40</div> <small class="number change-up">+2.97<span>&nbsp;&nbsp;</span>+2.24%</small></td><td><strong>EF-33</strong> <br>Recurrent glioblastoma 
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210729005357/en/">
                2022
              </a> <div class="note">Phase 2 data due in 2022.</div></td><td>
              104m
            </td><td>
              14.0b
            </td><td>
              153.2k
            </td><td>
              0.7m
            </td><td>
              35.35
            </td><td>
              $133.45
            </td><td>
              $132.43
            </td><td>
              January 2022
            </td><td>
              0.91b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              214.94m
            </td><td>
              13.40b
            </td><td>
              7.7
            </td><td>
              102,348,400
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>ULTOMIRIS (ravulizumab-cwvz)</strong> <br> Neuromyelitis Optica Spectrum Disorder (NMOSD)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.alexion.com/static-files/2e774532-380a-4fc3-9469-5217c30d8eed">
                2H 2022
              </a> <div class="note">Phase 3 data top-line data due 2H 2022.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              April 2022
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARQT" class="margin-bottom-1">
                ARQT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$20.84</div> <small class="number change-up">+0.59<span>&nbsp;&nbsp;</span>+2.94%</small></td><td><strong>Roflumilast Cream (ARQ-151) - (INTEGUMENT-1 and INTEGUMENT-2)</strong> <br>Atopic dermatitis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.arcutis.com/news-releases/news-release-details/arcutis-announces-second-quarter-2021-financial-results-and">
                2H 2022
              </a> <div class="note">Phase 3 top-line data due 2H 2022.</div></td><td>
              50m
            </td><td>
              1.0b
            </td><td>
              65.4k
            </td><td>
              180.1k
            </td><td>
              2.53
            </td><td>
              $20.67
            </td><td>
              $20.25
            </td><td>
              N/A
            </td><td>
              387.87m
            </td><td>
              -11.94m
            </td><td>
              32.47
            </td><td>
              369.46m
            </td><td>
              0.61b
            </td><td>
              4
            </td><td>
              20,923,311
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ATAI" class="margin-bottom-1">
                ATAI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.38</div> <small class="number change-up">+1.54<span>&nbsp;&nbsp;</span>+10.38%</small></td><td><strong>VLS-01</strong> <br>Treatment Resistant Depression
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001840904/000119312521123009/d39052ds1.htm">
                2H 2022
              </a> <div class="note">Phase 1 clinical trial to be initiated early 2022, with results expected to be reported 2H 2022.</div></td><td>
              155m
            </td><td>
              2.5b
            </td><td>
              450.9k
            </td><td>
              0.6m
            </td><td>
              5.34
            </td><td>
              $15.45
            </td><td>
              $14.84
            </td><td>
              N/A
            </td><td>
              454.76m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              433.69m
            </td><td>
              1.85b
            </td><td>
              0
            </td><td>
              114,161,264
            </td><td>
              06/15/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ARQT" class="margin-bottom-1">
                ARQT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$20.84</div> <small class="number change-up">+0.59<span>&nbsp;&nbsp;</span>+2.94%</small></td><td><strong>Roflumilast foam (ARQ-154)</strong> <br>Scalp psoriasis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.arcutis.com/news-releases/news-release-details/arcutis-announces-second-quarter-2021-financial-results-and">
                2H 2022
              </a> <div class="note">Phase 3 trial to be initiated 3Q 2021 with top-line data due 2H 2022.</div></td><td>
              50m
            </td><td>
              1.0b
            </td><td>
              65.4k
            </td><td>
              180.1k
            </td><td>
              2.53
            </td><td>
              $20.67
            </td><td>
              $20.25
            </td><td>
              N/A
            </td><td>
              387.87m
            </td><td>
              -11.94m
            </td><td>
              32.47
            </td><td>
              369.46m
            </td><td>
              0.61b
            </td><td>
              4
            </td><td>
              20,923,311
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLDX" class="margin-bottom-1">
                CLDX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$48.69</div> <small class="number change-up">+1.14<span>&nbsp;&nbsp;</span>+2.40%</small></td><td><strong>CDX-527</strong> <br>Solid Tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.celldex.com/news-releases/news-release-details/celldex-reports-second-quarter-2021-financial-results-and">
                2022
              </a> <div class="note">Phase 1 data presented at ASCO June 4-8, 2021 - well tolerated, with no dose-limiting toxicities or treatment related serious adverse events observed. Additional safety, PK, PD and clinical activity data due in 2022.</div></td><td>
              46m
            </td><td>
              2.3b
            </td><td>
              345.8k
            </td><td>
              1.0m
            </td><td>
              12.42
            </td><td>
              $48.35
            </td><td>
              $47.55
            </td><td>
              March 2022
            </td><td>
              444.38m
            </td><td>
              -3.98m
            </td><td>
              111.75
            </td><td>
              422.11m
            </td><td>
              2.05b
            </td><td>
              14.1
            </td><td>
              46,253,150
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FGEN" class="margin-bottom-1">
                FGEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.05</div> <small class="number change-down">-0.06<span>&nbsp;&nbsp;</span>-0.50%</small></td><td><strong>Pamrevlumab (LAPIS)</strong> <br>Pancreatic cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-reports-second-quarter-2021-financial-results">
                2H 2022
              </a> <div class="note">Phase 3 resection data due 2H 2022.</div></td><td>
              93m
            </td><td>
              1.1b
            </td><td>
              1.1m
            </td><td>
              1.5m
            </td><td>
              4.29
            </td><td>
              $12.24
            </td><td>
              $12.11
            </td><td>
              September 30, 2022
            </td><td>
              491.29m
            </td><td>
              -8.85m
            </td><td>
              55.53
            </td><td>
              -37.48m
            </td><td>
              0.72b
            </td><td>
              4.9
            </td><td>
              81,614,674
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CATB" class="margin-bottom-1">
                CATB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.49</div> <small class="number change-up">+0.91<span>&nbsp;&nbsp;</span>+12.01%</small></td><td><strong>QLS-215</strong> <br>Hereditary angioedema (HAE)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005642/en/">
                YE 2022
              </a> <div class="note">Phase 1 trial to be initiated in 2022 with initial data due by the end of 2022.</div></td><td>
              13m
            </td><td>
              108.9m
            </td><td>
              381.8k
            </td><td>
              328.2k
            </td><td>
              2.93
            </td><td>
              $7.28
            </td><td>
              $7.58
            </td><td>
              N/A
            </td><td>
              135.08m
            </td><td>
              -2.47m
            </td><td>
              54.76
            </td><td>
              131.03m
            </td><td>
              58.18m
            </td><td>
              0.7
            </td><td>
              12,407,620
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TSHA" class="margin-bottom-1">
                TSHA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.73</div> <small class="number change-up">+0.80<span>&nbsp;&nbsp;</span>+4.73%</small></td><td><strong>TSHA-102</strong> <br>Rett syndrome
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210816005196/en/">
                YE 2022
              </a> <div class="note">Phase 1/2 trial to be initiated by end of 2021 with data due by year-end 2022.</div></td><td>
              38m
            </td><td>
              0.7b
            </td><td>
              22.6k
            </td><td>
              190.5k
            </td><td>
              3.65
            </td><td>
              $17.25
            </td><td>
              $16.93
            </td><td>
              N/A
            </td><td>
              183.68m
            </td><td>
              -7.61m
            </td><td>
              24.15
            </td><td>
              128.32m
            </td><td>
              478.80m
            </td><td>
              26.7
            </td><td>
              16,966,890
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KROS" class="margin-bottom-1">
                KROS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$33.09</div> <small class="number change-up">+1.18<span>&nbsp;&nbsp;</span>+3.70%</small></td><td><strong>KER-047</strong> <br>Anemia 
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.kerostx.com/static-files/2b84afe9-ffe1-4874-aa07-984fa6caa20b">
                2022
              </a> <div class="note">Phase 2 trials to commence 2H 2021. Initial data due 2022.</div></td><td>
              23m
            </td><td>
              0.8b
            </td><td>
              35.3k
            </td><td>
              125.1k
            </td><td>
              3.28
            </td><td>
              $32.19
            </td><td>
              $31.91
            </td><td>
              N/A
            </td><td>
              226.53m
            </td><td>
              -5.88m
            </td><td>
              38.53
            </td><td>
              218.73m
            </td><td>
              0.51b
            </td><td>
              1.5
            </td><td>
              12,863,459
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IMMP" class="margin-bottom-1">
                IMMP
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.35</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+0.45%</small></td><td><strong>Eftilagimod alpha + chemo+ anti-PD-1 (INSIGHT-003)</strong> <br>Solid tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/07/13/2261873/0/en/Immutep-Quarterly-Activities-Report.html">
                2022
              </a> <div class="note">Phase 1 initiation of dosing announced August 5, 2021 with interim data due 2022.</div></td><td>
              65m
            </td><td>
              217.0m
            </td><td>
              184.3k
            </td><td>
              340.0k
            </td><td>
              4.99
            </td><td>
              $3.33
            </td><td>
              $3.33
            </td><td>
              N/A
            </td><td>
              54.88m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              39.10m
            </td><td>
              171.73m
            </td><td>
              0
            </td><td>
              64,872,528
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KDNY" class="margin-bottom-1">
                KDNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.55</div> <small class="number change-up">+0.79<span>&nbsp;&nbsp;</span>+6.19%</small></td><td><strong>Atrasentan (AFFINITY)</strong> <br>Chronic kidney disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.chinooktx.com/news-releases/news-release-details/chinook-therapeutics-provides-business-update-and-reports-first">
                2022
              </a> <div class="note">Phase 2 initial data due 2022.</div></td><td>
              45m
            </td><td>
              0.6b
            </td><td>
              306.4k
            </td><td>
              301.8k
            </td><td>
              2.05
            </td><td>
              $13.35
            </td><td>
              $12.76
            </td><td>
              December 1, 2022
            </td><td>
              180.69m
            </td><td>
              -9.14m
            </td><td>
              19.76
            </td><td>
              69.55m
            </td><td>
              414.92m
            </td><td>
              0.2
            </td><td>
              25,691,260
            </td><td>
              05/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VRTX" class="margin-bottom-1">
                VRTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$199.01</div> <small class="number change-up">+3.16<span>&nbsp;&nbsp;</span>+1.61%</small></td><td><strong>VX-880</strong> <br>Type 1 Diabetes
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210729006087/en/">
                2022
              </a> <div class="note">Phase 1/2 initial data due 2022.</div></td><td>
              259m
            </td><td>
              51.6b
            </td><td>
              0.6m
            </td><td>
              2.7m
            </td><td>
              5.61
            </td><td>
              $197.27
            </td><td>
              $195.85
            </td><td>
              January 2024
            </td><td>
              6.59b
            </td><td>
              -66.59m
            </td><td>
              98.94
            </td><td>
              3.56b
            </td><td>
              44.99b
            </td><td>
              0.9
            </td><td>
              259,283,352
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RLMD" class="margin-bottom-1">
                RLMD
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$24.56</div> <small class="number change-up">+2.13<span>&nbsp;&nbsp;</span>+9.50%</small></td><td><strong>REL-1017 (RELIANCE I)</strong> <br>Treatment Resistant Depression
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/relmada-therapeutics-provides-corporate-update-and-reports-first-quarter-2021-financial-results-301290205.html">
                1H 2022
              </a> <div class="note">Phase 3 data due 1H 2022. Human abuse trial vs Oxycodone confirmed lack of opioid abuse potential.</div></td><td>
              17m
            </td><td>
              429.1m
            </td><td>
              104.4k
            </td><td>
              267.8k
            </td><td>
              4.43
            </td><td>
              $22.5
            </td><td>
              $22.43
            </td><td>
              June 2022
            </td><td>
              98.74m
            </td><td>
              -5.74m
            </td><td>
              17.21
            </td><td>
              84.82m
            </td><td>
              275.59m
            </td><td>
              4
            </td><td>
              17,022,489
            </td><td>
              07/27/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NMTR" class="margin-bottom-1">
                NMTR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.13</div> <small class="number change-up">+0.03<span>&nbsp;&nbsp;</span>+2.73%</small></td><td><strong>Larazotide</strong> <br>Celiac disease
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.accesswire.com/659341/9-Meters-Biopharma-Provides-Business-Update-and-Reports-Financial-Results-for-the-Second-Quarter-2021">
                2022
              </a> <div class="note">Phase 3 interim analysis and top-line data due 2022.</div></td><td>
              255m
            </td><td>
              287.9m
            </td><td>
              1.6m
            </td><td>
              4.9m
            </td><td>
              4.91
            </td><td>
              $1.13
            </td><td>
              $1.1
            </td><td>
              August 2021
            </td><td>
              59.76m
            </td><td>
              -2.37m
            </td><td>
              25.22
            </td><td>
              52.90m
            </td><td>
              216.40m
            </td><td>
              1.9
            </td><td>
              218,959,804
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BTX" class="margin-bottom-1">
                BTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.85</div> <small class="number change-up">+0.25<span>&nbsp;&nbsp;</span>+2.59%</small></td><td><strong>IRX-2 and Opdivo - HCC-107</strong> <br>Hepatocellular carcinoma (HCC)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0000748592/000149315220022484/forms-4a.htm">
                4Q 2022
              </a> <div class="note">Phase 1 trial ongoing. Final data due 4Q 2022.</div></td><td>
              52m
            </td><td>
              0.5b
            </td><td>
              0.7m
            </td><td>
              2.3m
            </td><td>
              33.96
            </td><td>
              $9.6
            </td><td>
              $9.6
            </td><td>
              June 15, 2022
            </td><td>
              46.08m
            </td><td>
              -2.27m
            </td><td>
              20.32
            </td><td>
              16.55m
            </td><td>
              450.07m
            </td><td>
              12.1
            </td><td>
              35,906,398
            </td><td>
              04/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VKTX" class="margin-bottom-1">
                VKTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.94</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+2.41%</small></td><td><strong>VK2809 (VOYAGE)</strong> <br>Non-alcoholic steatohepatitis (NASH) and fibrosis
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/viking-therapeutics-reports-second-quarter-2021-financial-results-and-provides-corporate-update-301343608.html">
                2022
              </a> <div class="note">Phase 2b data due 2022.</div></td><td>
              78m
            </td><td>
              464.4m
            </td><td>
              446.3k
            </td><td>
              0.8m
            </td><td>
              2.06
            </td><td>
              $5.8
            </td><td>
              $5.8
            </td><td>
              December 2021
            </td><td>
              220.20m
            </td><td>
              -4.48m
            </td><td>
              49.17
            </td><td>
              207.33m
            </td><td>
              225.44m
            </td><td>
              4.6
            </td><td>
              66,497,689
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LGND" class="margin-bottom-1">
                LGND
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$113.41</div> <small class="number change-up">+9.31<span>&nbsp;&nbsp;</span>+8.95%</small></td><td><strong>VK2809 (VOYAGE)</strong> <br>Non-alcoholic steatohepatitis (NASH) and fibrosis
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/viking-therapeutics-reports-second-quarter-2021-financial-results-and-provides-corporate-update-301343608.html">
                2022
              </a> <div class="note">Phase 2b data due 2022.</div></td><td>
              17m
            </td><td>
              1.9b
            </td><td>
              171.1k
            </td><td>
              158.2k
            </td><td>
              2.40
            </td><td>
              $105.02
            </td><td>
              $104.1
            </td><td>
              December 2021
            </td><td>
              314.06m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -155.70m
            </td><td>
              1.76b
            </td><td>
              10.4
            </td><td>
              11,870,842
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NUVB" class="margin-bottom-1">
                NUVB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.31</div> <small class="number change-up">+1.27<span>&nbsp;&nbsp;</span>+15.80%</small></td><td><strong>NUV-422</strong> <br>High-grade gliomas
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/nuvation-bio-reports-second-quarter-2021-financial-results-and-provides-business-update-301354696.html">
                2022
              </a> <div class="note">Phase 1 data due 2022.</div></td><td>
              218m
            </td><td>
              2.0b
            </td><td>
              1.4m
            </td><td>
              0.7m
            </td><td>
              2.57
            </td><td>
              $8.25
            </td><td>
              $8.04
            </td><td>
              August 2023
            </td><td>
              439.44m
            </td><td>
              -5.61m
            </td><td>
              78.33
            </td><td>
              414.11m
            </td><td>
              1.75b
            </td><td>
              27.1
            </td><td>
              84,066,592
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GRPH" class="margin-bottom-1">
                GRPH
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$20.02</div> <small class="number change-up">+2.11<span>&nbsp;&nbsp;</span>+11.78%</small></td><td><strong>GPH101 (CEDAR)</strong> <br>Sickle Cell Disease
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210812005591/en/">
                YE 2022
              </a> <div class="note">Phase 1/2 trial planned for 2H 2021. Initial data due by end of 2022.</div></td><td>
              58m
            </td><td>
              1.2b
            </td><td>
              368.6k
            </td><td>
              417.8k
            </td><td>
              3.07
            </td><td>
              $18.03
            </td><td>
              $17.91
            </td><td>
              May 2026
            </td><td>
              373.69m
            </td><td>
              -4.59m
            </td><td>
              81.33
            </td><td>
              365.77m
            </td><td>
              1.04b
            </td><td>
              9.5
            </td><td>
              29,427,290
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/JNCE" class="margin-bottom-1">
                JNCE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$5.60</div> <small class="number change-up">+0.36<span>&nbsp;&nbsp;</span>+6.87%</small></td><td><strong>Vopratelimab and JTX-4014 - (SELECT)</strong> <br>Second-line non-small cell lung cancer (NSCLC) patients
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.jouncetx.com/news-releases/news-release-details/jounce-therapeutics-reports-second-quarter-2021-financial">
                2022
              </a> <div class="note">Phase 2 initial data due 2022. </div></td><td>
              51m
            </td><td>
              286.9m
            </td><td>
              461.5k
            </td><td>
              0.5m
            </td><td>
              1.03
            </td><td>
              $5.25
            </td><td>
              $5.24
            </td><td>
              December 2021
            </td><td>
              230.19m
            </td><td>
              -8.30m
            </td><td>
              27.72
            </td><td>
              202.49m
            </td><td>
              63.66m
            </td><td>
              1.1
            </td><td>
              36,143,173
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GSK" class="margin-bottom-1">
                GSK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$41.57</div> <small class="number change-down">-0.28<span>&nbsp;&nbsp;</span>-0.67%</small></td><td><strong>BLENREP (belantamab mafodotin) and POMALYST (Pomalidomide) and Dexamethasone - (DREAMM-8)</strong> <br>Multiple Myeloma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.gsk.com/media/7129/q2-2021-results-slides.pdf">
                2H 2022
              </a> <div class="note">Phase 3 data due 2H 2022.</div></td><td>
              3b
            </td><td>
              104.6b
            </td><td>
              2.3m
            </td><td>
              4.2m
            </td><td>
              4.95
            </td><td>
              $41.75
            </td><td>
              $41.85
            </td><td>
              May 31, 2022
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -51.10b
            </td><td>
              133.80b
            </td><td>
              0.2
            </td><td>
              2,506,785,977
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PCVX" class="margin-bottom-1">
                PCVX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$22.97</div> <small class="number change-up">+1.54<span>&nbsp;&nbsp;</span>+7.19%</small></td><td><strong>VAX-24</strong> <br>Pneumococcal conjugate vaccine
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-reports-first-quarter-2021-financial-results-and">
                Late 2022 / Early 2023
              </a> <div class="note">Phase 1/2 IND to be submitted between January and June 2022. Data due late-2022 / early-2023.</div></td><td>
              52m
            </td><td>
              1.2b
            </td><td>
              81.3k
            </td><td>
              222.1k
            </td><td>
              3.78
            </td><td>
              $21.65
            </td><td>
              $21.43
            </td><td>
              N/A
            </td><td>
              278.11m
            </td><td>
              -9.56m
            </td><td>
              29.09
            </td><td>
              237.08m
            </td><td>
              0.83b
            </td><td>
              1.5
            </td><td>
              35,165,007
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VCNX" class="margin-bottom-1">
                VCNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.27</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+4.13%</small></td><td><strong>Pepinemab</strong> <br>Alzheimer’s Disease (AD)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.vaccinex.com/news-releases/news-release-details/vaccinex-reports-second-quarter-2021-financial-results-and">
                Late-2022 / early-2023
              </a> <div class="note">Phase 1/2 topline data due late 2022 or early 2023.</div></td><td>
              31m
            </td><td>
              69.9m
            </td><td>
              67.9k
            </td><td>
              204.2k
            </td><td>
              4.13
            </td><td>
              $2.2
            </td><td>
              $2.18
            </td><td>
              N/A
            </td><td>
              18.20m
            </td><td>
              -2.33m
            </td><td>
              7.82
            </td><td>
              11.35m
            </td><td>
              48.38m
            </td><td>
              0.9
            </td><td>
              19,205,560
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GERN" class="margin-bottom-1">
                GERN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.29</div> <small class="number change-up">+0.02<span>&nbsp;&nbsp;</span>+1.77%</small></td><td><strong>Imetelstat - (IMerge Study)</strong> <br>Myelodysplastic syndromes
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210816005218/en/">
                1Q 2023
              </a> <div class="note">Phase 3 enrollment to be completed 4Q 2021. Data due 1Q 2023.</div></td><td>
              321m
            </td><td>
              414.4m
            </td><td>
              2.9m
            </td><td>
              10.4m
            </td><td>
              2.35
            </td><td>
              $1.27
            </td><td>
              $1.27
            </td><td>
              August 15, 2022
            </td><td>
              187.55m
            </td><td>
              -5.94m
            </td><td>
              31.59
            </td><td>
              111.58m
            </td><td>
              248.76m
            </td><td>
              1.6
            </td><td>
              318,430,617
            </td><td>
              08/17/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ATAI" class="margin-bottom-1">
                ATAI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.38</div> <small class="number change-up">+1.54<span>&nbsp;&nbsp;</span>+10.38%</small></td><td><strong>RLS-01</strong> <br>Treatment Resistant Depression
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001840904/000119312521123009/d39052ds1.htm">
                Late 2022 / Early 2023
              </a> <div class="note">Phase 1 trial to be initiated mid-2022 with data six months later</div></td><td>
              155m
            </td><td>
              2.5b
            </td><td>
              450.9k
            </td><td>
              0.6m
            </td><td>
              5.34
            </td><td>
              $15.45
            </td><td>
              $14.84
            </td><td>
              N/A
            </td><td>
              454.76m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              433.69m
            </td><td>
              1.85b
            </td><td>
              0
            </td><td>
              114,161,264
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ORTX" class="margin-bottom-1">
                ORTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.69</div> <small class="number change-up">+0.23<span>&nbsp;&nbsp;</span>+9.55%</small></td><td><strong>OTL-200</strong> <br>Metachromatic leukodystrophy (MLD)
            </td><td>
              BLA Filing
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#2E9124" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-reports-second-quarter-2021-financial">
                Late-2022 / early-2023
              </a> <div class="note">BLA filing late-2022 or early-2023</div></td><td>
              125m
            </td><td>
              337.9m
            </td><td>
              324.5k
            </td><td>
              0.6m
            </td><td>
              1.28
            </td><td>
              $2.45
            </td><td>
              $2.46
            </td><td>
              August 22, 2022
            </td><td>
              247.68m
            </td><td>
              -12.02m
            </td><td>
              20.61
            </td><td>
              147.30m
            </td><td>
              100.62m
            </td><td>
              0.5
            </td><td>
              124,780,672
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GNFT" class="margin-bottom-1">
                GNFT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.75</div> <small class="number change-down">-0.01<span>&nbsp;&nbsp;</span>-0.35%</small></td><td><strong>Elafibranor</strong> <br>Primary biliary cholangitis (PBC)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://finance.yahoo.com/news/genfit-announces-publication-positive-results-211000032.html">
                1Q 2023
              </a> <div class="note">Phase 3 data due 1Q 2023.</div></td><td>
              46m
            </td><td>
              171.4m
            </td><td>
              5.8k
            </td><td>
              9.6k
            </td><td>
              -9.15
            </td><td>
              $3.78
            </td><td>
              $3.77
            </td><td>
              N/A
            </td><td>
              171.03m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -43.75m
            </td><td>
              193.10m
            </td><td>
              0
            </td><td>
              45,670,200
            </td><td>
              02/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CORT" class="margin-bottom-1">
                CORT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$20.81</div> <small class="number change-up">+0.21<span>&nbsp;&nbsp;</span>+1.02%</small></td><td><strong>Relacorilant (GRACE)</strong> <br>Cushing’s syndrome
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/07/29/2271750/0/en/Corcept-Therapeutics-Announces-Second-Quarter-Financial-Results-and-Provides-Corporate-Update.html">
                2Q 2023
              </a> <div class="note">Phase 3 commencement of enrolment announced November 19, 2018. NDA planned for 2Q 2023.</div></td><td>
              116m
            </td><td>
              2.4b
            </td><td>
              136.0k
            </td><td>
              0.6m
            </td><td>
              4.61
            </td><td>
              $20.8
            </td><td>
              $20.6
            </td><td>
              November 2022
            </td><td>
              396.59m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              350.78m
            </td><td>
              2.02b
            </td><td>
              9.3
            </td><td>
              76,932,520
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CMPI" class="margin-bottom-1">
                CMPI
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.68</div> <small class="number change-up">+0.13<span>&nbsp;&nbsp;</span>+2.86%</small></td><td><strong>Vidutolimod (CMP-001) and OPDIVO (nivolumab)</strong> <br>Melanoma
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.checkmatepharma.com/static-files/9cd62abb-fcd1-44f4-887c-ffb936398612">
                Late-2022 / 1H 2023
              </a> <div class="note">Phase 2 dosing initiated March 2021. Data due late-2022 / 1H 2023.</div></td><td>
              22m
            </td><td>
              101.2m
            </td><td>
              9.3k
            </td><td>
              60.2k
            </td><td>
              1.07
            </td><td>
              $4.55
            </td><td>
              $4.55
            </td><td>
              February 2023
            </td><td>
              76.12m
            </td><td>
              -5.13m
            </td><td>
              14.84
            </td><td>
              69.41m
            </td><td>
              13.05m
            </td><td>
              3.8
            </td><td>
              11,182,408
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GTHX" class="margin-bottom-1">
                GTHX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.35</div> <small class="number change-up">+0.82<span>&nbsp;&nbsp;</span>+6.06%</small></td><td><strong>COSELA (trilaciclib)</strong> <br>Colorectal cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://investor.g1therapeutics.com/news-releases/news-release-details/g1-therapeutics-provides-fourth-quarter-and-full-year-2020">
                1H 2023
              </a> <div class="note">Phase 3 data due 1H 2023.</div></td><td>
              42m
            </td><td>
              0.6b
            </td><td>
              279.6k
            </td><td>
              1.1m
            </td><td>
              2.85
            </td><td>
              $13.83
            </td><td>
              $13.53
            </td><td>
              November 25, 2022
            </td><td>
              222.13m
            </td><td>
              -12.16m
            </td><td>
              18.26
            </td><td>
              158.57m
            </td><td>
              366.37m
            </td><td>
              2.3
            </td><td>
              42,071,302
            </td><td>
              05/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CYTH" class="margin-bottom-1">
                CYTH
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.00</div> <small class="number change-up">+0.02<span>&nbsp;&nbsp;</span>+0.29%</small></td><td><strong>Trappsol Cyclo</strong> <br>Niemann-Pick Disease Type C
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210617005132/en/">
                1H 2023
              </a> <div class="note">Phase 3 trial initiation announced June 17, 2021. Interim analysis due 1H 2023.</div></td><td>
              6m
            </td><td>
              45.1m
            </td><td>
              33.8k
            </td><td>
              132.8k
            </td><td>
              4.05
            </td><td>
              $6.93
            </td><td>
              $6.98
            </td><td>
              December 2023
            </td><td>
              8.80m
            </td><td>
              -1.48m
            </td><td>
              5.95
            </td><td>
              5.68m
            </td><td>
              33.66m
            </td><td>
              0
            </td><td>
              5,806,084
            </td><td>
              06/17/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FGEN" class="margin-bottom-1">
                FGEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.05</div> <small class="number change-down">-0.06<span>&nbsp;&nbsp;</span>-0.50%</small></td><td><strong>Roxadustat (MATTERHORN)</strong> <br>Myelodysplastic syndromes (MDS)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-reports-second-quarter-2021-financial-results">
                2H 2022 / 1H 2023
              </a> <div class="note">Phase 3 data due 2H 2022 / 1H 2023.</div></td><td>
              93m
            </td><td>
              1.1b
            </td><td>
              1.1m
            </td><td>
              1.5m
            </td><td>
              4.29
            </td><td>
              $12.24
            </td><td>
              $12.11
            </td><td>
              January 2022
            </td><td>
              491.29m
            </td><td>
              -8.85m
            </td><td>
              55.53
            </td><td>
              -37.48m
            </td><td>
              0.72b
            </td><td>
              4.9
            </td><td>
              81,614,674
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/AZN" class="margin-bottom-1">
                AZN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$58.84</div> <small class="number change-down">-0.56<span>&nbsp;&nbsp;</span>-0.93%</small></td><td><strong>Roxadustat (MATTERHORN)</strong> <br>Myelodysplastic syndromes (MDS)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-reports-second-quarter-2021-financial-results">
                2H 2022 / 1H 2023
              </a> <div class="note">Phase 3 data due 2H 2022 / 1H 2023.</div></td><td>
              3b
            </td><td>
              182.3b
            </td><td>
              3.4m
            </td><td>
              11.7m
            </td><td>
              11.63
            </td><td>
              $59.09
            </td><td>
              $59.39
            </td><td>
              January 2022
            </td><td>
              16.16b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -41.78b
            </td><td>
              196.21b
            </td><td>
              0.1
            </td><td>
              3,096,187,832
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CLBS" class="margin-bottom-1">
                CLBS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.21</div> <small class="number change-up">+0.05<span>&nbsp;&nbsp;</span>+4.17%</small></td><td><strong>CLBS16 (FREEDOM)</strong> <br>Coronary microvascular dysfunction (CMD)
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.caladrius.com/news-releases/news-release-details/caladrius-biosciences-reports-second-quarter-2021-financial">
                2Q 2023
              </a> <div class="note">Phase 2b data due 2Q 2023.</div></td><td>
              60m
            </td><td>
              71.9m
            </td><td>
              208.5k
            </td><td>
              414.3k
            </td><td>
              0.69
            </td><td>
              $1.17
            </td><td>
              $1.16
            </td><td>
              April 2022
            </td><td>
              103.31m
            </td><td>
              -1.54m
            </td><td>
              66.99
            </td><td>
              99.38m
            </td><td>
              -36.60m
            </td><td>
              14.8
            </td><td>
              58,839,648
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SPRB" class="margin-bottom-1">
                SPRB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.34</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+1.83%</small></td><td><strong>Tildacerfont</strong> <br>Polycystic Ovary Syndrome
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210810005900/en/">
                1H 2023
              </a> <div class="note">Phase 2 trial to be initiated 2H 2021. Data due 1H 2023.</div></td><td>
              23m
            </td><td>
              195.0m
            </td><td>
              3.3k
            </td><td>
              67.9k
            </td><td>
              1.50
            </td><td>
              $8.33
            </td><td>
              $8.19
            </td><td>
              N/A
            </td><td>
              103.41m
            </td><td>
              -3.23m
            </td><td>
              32.00
            </td><td>
              90.06m
            </td><td>
              88.91m
            </td><td>
              0
            </td><td>
              17,692,276
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ELYM" class="margin-bottom-1">
                ELYM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$19.75</div> <small class="number change-up">+1.66<span>&nbsp;&nbsp;</span>+9.18%</small></td><td><strong>ETX-155</strong> <br>Major depressive disorder (MDD)
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1768446/000119312521217529/d105292ds1.htm">
                1H 2023
              </a> <div class="note">Phase 2a trial to be initiated with data due 1H 2023.</div></td><td>
              26m
            </td><td>
              0.5b
            </td><td>
              162.5k
            </td><td>
              
            </td><td>
              -12.04
            </td><td>
              $18.41
            </td><td>
              $18.09
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              0.52b
            </td><td>
              0
            </td><td>
              7,979,877
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ELYM" class="margin-bottom-1">
                ELYM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$19.75</div> <small class="number change-up">+1.66<span>&nbsp;&nbsp;</span>+9.18%</small></td><td><strong>ETX-155</strong> <br>Perimenopausal depression (PMD) 
            </td><td>
              Phase 2a
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1768446/000119312521217529/d105292ds1.htm">
                1H 2023
              </a> <div class="note">Phase 2a trial to be initiated with top-line data due 1H 2023.</div></td><td>
              26m
            </td><td>
              0.5b
            </td><td>
              162.5k
            </td><td>
              
            </td><td>
              -12.04
            </td><td>
              $18.41
            </td><td>
              $18.09
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              0.52b
            </td><td>
              0
            </td><td>
              7,979,877
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CERE" class="margin-bottom-1">
                CERE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$26.20</div> <small class="number change-up">+2.51<span>&nbsp;&nbsp;</span>+10.60%</small></td><td><strong>Tavapadon (TEMPO-3)</strong> <br>Late Parkinson’s disease
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.cerevel.com/static-files/e75deb7b-6273-47e7-8e39-d2371bfb310a">
                1H 2023
              </a> <div class="note">Phase 3 data due 1H 2023.</div></td><td>
              145m
            </td><td>
              3.8b
            </td><td>
              327.6k
            </td><td>
              2.9m
            </td><td>
              12.91
            </td><td>
              $23.95
            </td><td>
              $23.69
            </td><td>
              February 2023
            </td><td>
              0.65b
            </td><td>
              -15.20m
            </td><td>
              42.74
            </td><td>
              0.55b
            </td><td>
              3.14b
            </td><td>
              0.1
            </td><td>
              52,582,057
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FNCH" class="margin-bottom-1">
                FNCH
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.11</div> <small class="number change-up">+0.28<span>&nbsp;&nbsp;</span>+2.18%</small></td><td><strong>CP101 (PRISM4)</strong> <br>Clostridioides difficile infection
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.finchtherapeutics.com/news-releases/news-release-details/finch-therapeutics-reports-second-quarter-2021-financial-results">
                1H 2023
              </a> <div class="note">Phase 3 data due 1H 2023.</div></td><td>
              47m
            </td><td>
              0.6b
            </td><td>
              6.7k
            </td><td>
              84.9k
            </td><td>
              2.73
            </td><td>
              $12.65
            </td><td>
              $12.83
            </td><td>
              N/A
            </td><td>
              153.87m
            </td><td>
              -7.93m
            </td><td>
              19.41
            </td><td>
              131.73m
            </td><td>
              417.56m
            </td><td>
              6.8
            </td><td>
              27,059,349
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FGEN" class="margin-bottom-1">
                FGEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.05</div> <small class="number change-down">-0.06<span>&nbsp;&nbsp;</span>-0.50%</small></td><td><strong>Pamrevlumab -  LELANTOS</strong> <br>Duchenne muscular dystrophy
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-reports-second-quarter-2021-financial-results">
                1H 2023
              </a> <div class="note">Phase 3 data due 1H 2023.</div></td><td>
              93m
            </td><td>
              1.1b
            </td><td>
              1.1m
            </td><td>
              1.5m
            </td><td>
              4.29
            </td><td>
              $12.24
            </td><td>
              $12.11
            </td><td>
              August 31, 2022
            </td><td>
              491.29m
            </td><td>
              -8.85m
            </td><td>
              55.53
            </td><td>
              -37.48m
            </td><td>
              0.72b
            </td><td>
              4.9
            </td><td>
              81,614,674
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TYME" class="margin-bottom-1">
                TYME
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.05</div> <small class="number change-down">-0.01<span>&nbsp;&nbsp;</span>-0.47%</small></td><td><strong>SM-88 (OASIS)</strong> <br>HR+/HER2- breast cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210610005948/en/">
                1H 2023
              </a> <div class="note">Phase 2 trial initiation announced June 10, 2021. Trial status update 1H 2023.</div></td><td>
              172m
            </td><td>
              181.7m
            </td><td>
              0.9m
            </td><td>
              8.7m
            </td><td>
              1.88
            </td><td>
              $1.05
            </td><td>
              $1.06
            </td><td>
              May 2024
            </td><td>
              69.14m
            </td><td>
              -1.94m
            </td><td>
              35.70
            </td><td>
              62.52m
            </td><td>
              109.98m
            </td><td>
              28.2
            </td><td>
              124,516,911
            </td><td>
              06/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FBIO" class="margin-bottom-1">
                FBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.20</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+4.58%</small></td><td><strong>MB-207</strong> <br>X-linked severe combined immunodeficiency (XSCID) -  previously transplanted 
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s2.q4cdn.com/336946411/files/doc_presentations/2021/05/Mustang-Bio-Corporate-Presentation-May-2021.pdf">
                2Q 2023
              </a> <div class="note">Phase 2 IND filing due 2Q 2021. Top-line data due 2Q 2023.</div></td><td>
              101m
            </td><td>
              323.4m
            </td><td>
              220.5k
            </td><td>
              0.5m
            </td><td>
              2.99
            </td><td>
              $3.07
            </td><td>
              $3.06
            </td><td>
              N/A
            </td><td>
              254.32m
            </td><td>
              -11.49m
            </td><td>
              22.14
            </td><td>
              84.46m
            </td><td>
              120.76m
            </td><td>
              27.4
            </td><td>
              76,232,955
            </td><td>
              05/14/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MBIO" class="margin-bottom-1">
                MBIO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.81</div> <small class="number change-up">+0.14<span>&nbsp;&nbsp;</span>+5.24%</small></td><td><strong>MB-207</strong> <br>X-linked severe combined immunodeficiency (XSCID) -  previously transplanted 
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s2.q4cdn.com/336946411/files/doc_presentations/2021/05/Mustang-Bio-Corporate-Presentation-May-2021.pdf">
                2Q 2023
              </a> <div class="note">Phase 2 IND filing due 2Q 2021. Top-line data due 2Q 2023.</div></td><td>
              91m
            </td><td>
              256.8m
            </td><td>
              0.9m
            </td><td>
              1.5m
            </td><td>
              1.90
            </td><td>
              $2.73
            </td><td>
              $2.67
            </td><td>
              N/A
            </td><td>
              122.67m
            </td><td>
              -4.03m
            </td><td>
              30.43
            </td><td>
              114.48m
            </td><td>
              116.29m
            </td><td>
              1.8
            </td><td>
              73,639,109
            </td><td>
              05/14/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IONS" class="margin-bottom-1">
                IONS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$39.33</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+0.18%</small></td><td><strong>AKCEA-TTR-LRx (NEURO-TTRansform)</strong> <br>hATTR Amyloidosis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/ionis-completes-enrollment-in-pivotal-neuro-ttransform-study-of-eplontersen-301343941.html">
                Mid-2022
              </a> <div class="note">Phase 3 completion of enrollment announced July 29, 2021 with interim analysis due mid-2022.</div></td><td>
              141m
            </td><td>
              5.6b
            </td><td>
              322.8k
            </td><td>
              1.1m
            </td><td>
              9.52
            </td><td>
              $39.68
            </td><td>
              $39.26
            </td><td>
              January 2024
            </td><td>
              2.05b
            </td><td>
              -20.88m
            </td><td>
              98.00
            </td><td>
              132.28m
            </td><td>
              4.79b
            </td><td>
              0.6
            </td><td>
              119,102,131
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GLTO" class="margin-bottom-1">
                GLTO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.26</div> <small class="number change-up">+0.17<span>&nbsp;&nbsp;</span>+4.16%</small></td><td><strong>GB0139 (GALACTIC-1)</strong> <br>Idiopathic pulmonary fibrosis (IPF)
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/07/13/2261872/0/en/Galecto-Resumes-Recruitment-in-Phase-2b-Global-GALACTIC-1-Trial-of-GB0139-for-Idiopathic-Pulmonary-Fibrosis.html">
                Mid-2023
              </a> <div class="note">Phase 2b resumption of enrollment announced July 13, 2021. Top-line data due by mid-2023.</div></td><td>
              25m
            </td><td>
              107.6m
            </td><td>
              100.7k
            </td><td>
              1.2m
            </td><td>
              0.76
            </td><td>
              $4.15
            </td><td>
              $4.09
            </td><td>
              December 2022
            </td><td>
              95.11m
            </td><td>
              -3.72m
            </td><td>
              25.55
            </td><td>
              89.72m
            </td><td>
              2.59m
            </td><td>
              0.3
            </td><td>
              19,593,903
            </td><td>
              07/13/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/FGEN" class="margin-bottom-1">
                FGEN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$12.05</div> <small class="number change-down">-0.06<span>&nbsp;&nbsp;</span>-0.50%</small></td><td><strong>Pamrevlumab - (ZEPHYRUS-1)</strong> <br>Idiopathic pulmonary fibrosis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-reports-second-quarter-2021-financial-results">
                Mid-2023
              </a> <div class="note">Phase 3 data due mid-2023.</div></td><td>
              93m
            </td><td>
              1.1b
            </td><td>
              1.1m
            </td><td>
              1.5m
            </td><td>
              4.29
            </td><td>
              $12.24
            </td><td>
              $12.11
            </td><td>
              December 31, 2022
            </td><td>
              491.29m
            </td><td>
              -8.85m
            </td><td>
              55.53
            </td><td>
              -37.48m
            </td><td>
              0.72b
            </td><td>
              4.9
            </td><td>
              81,614,674
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BTX" class="margin-bottom-1">
                BTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.85</div> <small class="number change-up">+0.25<span>&nbsp;&nbsp;</span>+2.59%</small></td><td><strong>IRX-2 (CIN-201)</strong> <br>Cervical Squamous Intraepithelial Neoplasia 3
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0000748592/000149315220022484/forms-4a.htm">
                3Q 2023
              </a> <div class="note">Phase 2 trial ongoing. Final data due 3Q 2023.</div></td><td>
              52m
            </td><td>
              0.5b
            </td><td>
              0.7m
            </td><td>
              2.3m
            </td><td>
              33.96
            </td><td>
              $9.6
            </td><td>
              $9.6
            </td><td>
              November 8, 2022
            </td><td>
              46.08m
            </td><td>
              -2.27m
            </td><td>
              20.32
            </td><td>
              16.55m
            </td><td>
              450.07m
            </td><td>
              12.1
            </td><td>
              35,906,398
            </td><td>
              04/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/VECT" class="margin-bottom-1">
                VECT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.25</div> <small class="number change-down">-0.06<span>&nbsp;&nbsp;</span>-0.82%</small></td><td><strong>Apraglutide (STARS)</strong> <br>Short Bowel Syndrome
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1836379/000162828021005213/vectivbiof-1.htm">
                2H 2023
              </a> <div class="note">Phase 3 top-line data due 2H 2023.</div></td><td>
              36m
            </td><td>
              260.0m
            </td><td>
              0.9k
            </td><td>
              19.4k
            </td><td>
              8.06
            </td><td>
              $7.38
            </td><td>
              $7.31
            </td><td>
              June 30, 2023
            </td><td>
              
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              
            </td><td>
              222.09m
            </td><td>
              0
            </td><td>
              23,920,345
            </td><td>
              04/08/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RPHM" class="margin-bottom-1">
                RPHM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.61</div> <small class="number change-down">-0.23<span>&nbsp;&nbsp;</span>-2.93%</small></td><td><strong>REN001 (STRIDE)</strong> <br>Primary mitochondrial myopathies (PMM)
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/07/28/2270279/0/en/Reneo-Pharmaceuticals-Announces-First-Patient-Dosed-in-the-STRIDE-Study.html">
                2023
              </a> <div class="note">Phase 2b commencement of dosing announced July 28, 2021. Data due in 2023.</div></td><td>
              24m
            </td><td>
              185.7m
            </td><td>
              9.7k
            </td><td>
              54.7k
            </td><td>
              1.11
            </td><td>
              $7.54
            </td><td>
              $7.84
            </td><td>
              December 2022
            </td><td>
              161.51m
            </td><td>
              -3.23m
            </td><td>
              49.95
            </td><td>
              157.76m
            </td><td>
              24.01m
            </td><td>
              0.1
            </td><td>
              10,915,953
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LUMO" class="margin-bottom-1">
                LUMO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.40</div> <small class="number change-up">+0.45<span>&nbsp;&nbsp;</span>+5.03%</small></td><td><strong>LUM-201 (OraGrowtH210)</strong> <br>Pediatric Growth Hormone Deficiency (PGHD)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.lumos-pharma.com/news-releases/news-release-details/lumos-pharma-announces-clinical-updates">
                2H 2023
              </a> <div class="note">Phase 2 data due 2H 2023.</div></td><td>
              8m
            </td><td>
              78.6m
            </td><td>
              51.7k
            </td><td>
              71.6k
            </td><td>
              0.78
            </td><td>
              $9.14
            </td><td>
              $8.95
            </td><td>
              December 2021
            </td><td>
              103.87m
            </td><td>
              -2.12m
            </td><td>
              48.93
            </td><td>
              90.73m
            </td><td>
              -32.18m
            </td><td>
              16.1
            </td><td>
              6,324,282
            </td><td>
              07/20/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MIRM" class="margin-bottom-1">
                MIRM
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.70</div> <small class="number change-up">+0.52<span>&nbsp;&nbsp;</span>+3.67%</small></td><td><strong>Maralixibat (EMBARK)</strong> <br>Biliary atresia 
            </td><td>
              Phase 2b
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005953/en/">
                2023
              </a> <div class="note">Phase 2b data due 2023.</div></td><td>
              31m
            </td><td>
              448.6m
            </td><td>
              36.1k
            </td><td>
              77.7k
            </td><td>
              4.68
            </td><td>
              $14.35
            </td><td>
              $14.18
            </td><td>
              November 2022
            </td><td>
              199.73m
            </td><td>
              -13.40m
            </td><td>
              14.91
            </td><td>
              47.80m
            </td><td>
              211.81m
            </td><td>
              0.5
            </td><td>
              8,253,550
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RAIN" class="margin-bottom-1">
                RAIN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.98</div> <small class="number change-up">+0.76<span>&nbsp;&nbsp;</span>+4.38%</small></td><td><strong>Milademetan (RAIN-32) - (MANTRA)</strong> <br>Liposarcoma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.rainthera.com/news-releases/news-release-details/rain-therapeutics-reports-second-quarter-2021-financial-results">
                2023
              </a> <div class="note">Phase 3 data due 2023.</div></td><td>
              26m
            </td><td>
              476.0m
            </td><td>
              25.6k
            </td><td>
              128.5k
            </td><td>
              2.89
            </td><td>
              $17.38
            </td><td>
              $17.23
            </td><td>
              N/A
            </td><td>
              158.12m
            </td><td>
              -3.63m
            </td><td>
              43.58
            </td><td>
              148.40m
            </td><td>
              291.85m
            </td><td>
              13.9
            </td><td>
              13,200,239
            </td><td>
              08/10/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CADL" class="margin-bottom-1">
                CADL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.75</div> <small class="number change-up">+1.45<span>&nbsp;&nbsp;</span>+23.02%</small></td><td><strong>CAN-2409</strong> <br>Pancreatic Cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001841387/000119312521200639/d120909ds1.htm">
                2023
              </a> <div class="note">Phase 2 interim data due 2023.</div></td><td>
              28m
            </td><td>
              215.4m
            </td><td>
              153.7k
            </td><td>
              
            </td><td>
              -7.83
            </td><td>
              $6.8
            </td><td>
              $6.3
            </td><td>
              December 2021
            </td><td>
              20.09m
            </td><td>
              -1.88m
            </td><td>
              10.71
            </td><td>
              -42.50m
            </td><td>
              146.94m
            </td><td>
              6.7
            </td><td>
              14,620,612
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CADL" class="margin-bottom-1">
                CADL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.75</div> <small class="number change-up">+1.45<span>&nbsp;&nbsp;</span>+23.02%</small></td><td><strong>CAN-2409 (ULYSSES)</strong> <br>Prostate Cancer (Active Surveillance)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001841387/000119312521200639/d120909ds1.htm">
                2023
              </a> <div class="note">Phase 2 data due 2023.</div></td><td>
              28m
            </td><td>
              215.4m
            </td><td>
              153.7k
            </td><td>
              
            </td><td>
              -7.83
            </td><td>
              $6.8
            </td><td>
              $6.3
            </td><td>
              March 2023
            </td><td>
              20.09m
            </td><td>
              -1.88m
            </td><td>
              10.71
            </td><td>
              -42.50m
            </td><td>
              146.94m
            </td><td>
              6.7
            </td><td>
              14,620,612
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INAB" class="margin-bottom-1">
                INAB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$8.16</div> <small class="number change-up">+0.45<span>&nbsp;&nbsp;</span>+5.84%</small></td><td><strong>INB-100</strong> <br>Allogeneic hematopoietic stem cell transplantation (HSCT)
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.in8bio.com/news-releases/news-release-details/in8bio-completes-dosing-first-cohort-phase-1-clinical-trial">
                2023
              </a> <div class="note">Phase 1 completion of dosing of first cohort announced August 11, 2021 with top-line data due 2023.</div></td><td>
              19m
            </td><td>
              153.0m
            </td><td>
              23.1k
            </td><td>
              
            </td><td>
              -8.24
            </td><td>
              $8.31
            </td><td>
              $7.71
            </td><td>
              January 2022
            </td><td>
              11.01m
            </td><td>
              -0.84m
            </td><td>
              13.18
            </td><td>
              6.91m
            </td><td>
              166.26m
            </td><td>
              12.8
            </td><td>
              2,728,036
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/XLRN" class="margin-bottom-1">
                XLRN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$125.64</div> <small class="number change-up">+3.50<span>&nbsp;&nbsp;</span>+2.87%</small></td><td><strong>REBLOZYL (Luspatercept) - COMMANDS</strong> <br>First-line, lower-risk Myelodysplastic syndromes (MDS)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005947/en/">
                2022 / 2023
              </a> <div class="note">Phase 3 data due 2022 / 2023.</div></td><td>
              61m
            </td><td>
              7.7b
            </td><td>
              111.0k
            </td><td>
              273.3k
            </td><td>
              10.03
            </td><td>
              $123.67
            </td><td>
              $122.14
            </td><td>
              June 30, 2022
            </td><td>
              0.57b
            </td><td>
              -28.14m
            </td><td>
              20.35
            </td><td>
              499.68m
            </td><td>
              6.84b
            </td><td>
              1.7
            </td><td>
              53,758,885
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BMY" class="margin-bottom-1">
                BMY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$69.35</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+0.22%</small></td><td><strong>REBLOZYL (Luspatercept) - COMMANDS</strong> <br>First-line, lower-risk Myelodysplastic syndromes (MDS)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005947/en/">
                2022 / 2023
              </a> <div class="note">Phase 3 data due 2022 / 2023.</div></td><td>
              2b
            </td><td>
              154.1b
            </td><td>
              4.1m
            </td><td>
              8.5m
            </td><td>
              4.19
            </td><td>
              $69.26
            </td><td>
              $69.2
            </td><td>
              June 30, 2022
            </td><td>
              15.85b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -58.07b
            </td><td>
              186.05b
            </td><td>
              0.3
            </td><td>
              2,219,710,962
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BMY" class="margin-bottom-1">
                BMY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$69.35</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+0.22%</small></td><td><strong>OPDIVO (Nivolumab) and YERVOY (Ipilimumab)</strong> <br>Hepatocellular Carcinoma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s21.q4cdn.com/104148044/files/doc_presentations/2021/BMY-2021-Q2-Results-Investor-Presentation.pdf">
                2022 / 2023
              </a> <div class="note">Phase 3 data due 2022 / 2023.</div></td><td>
              2b
            </td><td>
              154.1b
            </td><td>
              4.1m
            </td><td>
              8.5m
            </td><td>
              4.19
            </td><td>
              $69.26
            </td><td>
              $69.2
            </td><td>
              March 27, 2023
            </td><td>
              15.85b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -58.07b
            </td><td>
              186.05b
            </td><td>
              0.3
            </td><td>
              2,219,710,962
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BMY" class="margin-bottom-1">
                BMY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$69.35</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+0.22%</small></td><td><strong>ZEPOSIA (Ozanimod)</strong> <br>Crohn's Disease
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s21.q4cdn.com/104148044/files/doc_presentations/2021/BMY-2021-Q2-Results-Investor-Presentation.pdf">
                2022 / 2023
              </a> <div class="note">Phase 3 data due 2022 / 2023.</div></td><td>
              2b
            </td><td>
              154.1b
            </td><td>
              4.1m
            </td><td>
              8.5m
            </td><td>
              4.19
            </td><td>
              $69.26
            </td><td>
              $69.2
            </td><td>
              June 27, 2023
            </td><td>
              15.85b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -58.07b
            </td><td>
              186.05b
            </td><td>
              0.3
            </td><td>
              2,219,710,962
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BMY" class="margin-bottom-1">
                BMY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$69.35</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+0.22%</small></td><td><strong>Abecma (KarMMa-3)</strong> <br>Multiple Myeloma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s21.q4cdn.com/104148044/files/doc_presentations/2021/BMY-2021-Q2-Results-Investor-Presentation.pdf">
                2022 / 2023
              </a> <div class="note">Phase 3 data due 2022 / 2023.</div></td><td>
              2b
            </td><td>
              154.1b
            </td><td>
              4.1m
            </td><td>
              8.5m
            </td><td>
              4.19
            </td><td>
              $69.26
            </td><td>
              $69.2
            </td><td>
              May 16, 2022
            </td><td>
              15.85b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -58.07b
            </td><td>
              186.05b
            </td><td>
              0.3
            </td><td>
              2,219,710,962
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LIXT" class="margin-bottom-1">
                LIXT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$2.30</div> <small class="number change-up">+0.01<span>&nbsp;&nbsp;</span>+0.44%</small></td><td><strong>LB-100</strong> <br>Myelodysplastic Syndromes (MDS)
            </td><td>
              Phase 1/2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001335105/000149315221011088/form10-q.htm">
                July 2023
              </a> <div class="note">Phase 1/2 final data due by July 2023.</div></td><td>
              14m
            </td><td>
              31.6m
            </td><td>
              179.2k
            </td><td>
              462.9k
            </td><td>
              9.58
            </td><td>
              $2.33
            </td><td>
              $2.29
            </td><td>
              May 2021
            </td><td>
              6.17m
            </td><td>
              -347.28k
            </td><td>
              17.78
            </td><td>
              5.80m
            </td><td>
              28.18m
            </td><td>
              0
            </td><td>
              6,133,784
            </td><td>
              07/03/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/INMB" class="margin-bottom-1">
                INMB
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$18.32</div> <small class="number change-up">+1.79<span>&nbsp;&nbsp;</span>+10.83%</small></td><td><strong>XPro1595</strong> <br>Alzheimer’s disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://inmunebio.com/index.php/en/news-2/2021/463-muneioncnnouncesesignofpcominghase2lzhe20210726">
                2H 2023
              </a> <div class="note">Phase 2 trial planned with data due 2H 2023.</div></td><td>
              18m
            </td><td>
              324.3m
            </td><td>
              196.4k
            </td><td>
              494.2k
            </td><td>
              7.51
            </td><td>
              $16.9
            </td><td>
              $16.53
            </td><td>
              N/A
            </td><td>
              76.09m
            </td><td>
              -1.90m
            </td><td>
              39.99
            </td><td>
              58.63m
            </td><td>
              267.61m
            </td><td>
              28.1
            </td><td>
              11,663,924
            </td><td>
              07/26/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NKTR" class="margin-bottom-1">
                NKTR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.89</div> <small class="number change-up">+0.28<span>&nbsp;&nbsp;</span>+2.06%</small></td><td><strong>BEMPEG (Bempegaldesleukin NKTR-214) and OPDIVO (nivolumab)</strong> <br>Melanoma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s21.q4cdn.com/104148044/files/doc_presentations/2021/BMY-2021-Q2-Results-Investor-Presentation.pdf">
                2022 / 2023
              </a> <div class="note">Phase 3 data due 2022 / 2023.</div></td><td>
              184m
            </td><td>
              2.6b
            </td><td>
              287.9k
            </td><td>
              0.8m
            </td><td>
              2.82
            </td><td>
              $13.74
            </td><td>
              $13.61
            </td><td>
              April 25, 2022
            </td><td>
              0.95b
            </td><td>
              -27.63m
            </td><td>
              34.39
            </td><td>
              483.95m
            </td><td>
              1.65b
            </td><td>
              2.1
            </td><td>
              91,286,217
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BMY" class="margin-bottom-1">
                BMY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$69.35</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+0.22%</small></td><td><strong>BEMPEG (Bempegaldesleukin NKTR-214) and OPDIVO (nivolumab)</strong> <br>Melanoma
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s21.q4cdn.com/104148044/files/doc_presentations/2021/BMY-2021-Q2-Results-Investor-Presentation.pdf">
                2022 / 2023
              </a> <div class="note">Phase 3 data due 2022 / 2023.</div></td><td>
              2b
            </td><td>
              154.1b
            </td><td>
              4.1m
            </td><td>
              8.5m
            </td><td>
              4.19
            </td><td>
              $69.26
            </td><td>
              $69.2
            </td><td>
              April 25, 2022
            </td><td>
              15.85b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -58.07b
            </td><td>
              186.05b
            </td><td>
              0.3
            </td><td>
              2,219,710,962
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GTHX" class="margin-bottom-1">
                GTHX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$14.35</div> <small class="number change-up">+0.82<span>&nbsp;&nbsp;</span>+6.06%</small></td><td><strong>COSELA (trilaciclib) - (PRESERVE 2)</strong> <br>Triple-negative breast cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="http://investor.g1therapeutics.com/news-releases/news-release-details/g1-therapeutics-announces-initiation-phase-3-registrational">
                2H 2023
              </a> <div class="note">Phase 3 trial initiation announced April 28, 2021. Data due 2H 2023.</div></td><td>
              42m
            </td><td>
              0.6b
            </td><td>
              279.6k
            </td><td>
              1.1m
            </td><td>
              2.85
            </td><td>
              $13.83
            </td><td>
              $13.53
            </td><td>
              June 30, 2024
            </td><td>
              222.13m
            </td><td>
              -12.16m
            </td><td>
              18.26
            </td><td>
              158.57m
            </td><td>
              366.37m
            </td><td>
              2.3
            </td><td>
              42,071,302
            </td><td>
              08/04/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KRON" class="margin-bottom-1">
                KRON
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$20.43</div> <small class="number change-up">+0.70<span>&nbsp;&nbsp;</span>+3.55%</small></td><td><strong>Entospletinib</strong> <br>Acute myeloid leukemia (AML) 
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.kronosbio.com/news-releases/news-release-details/kronos-bio-reports-recent-business-progress-and-second-quarter">
                2H 2023
              </a> <div class="note">Phase 3 trial to be initiated mid-2021. Data due 2H 2023.</div></td><td>
              56m
            </td><td>
              1.1b
            </td><td>
              133.4k
            </td><td>
              284.3k
            </td><td>
              2.71
            </td><td>
              $19.84
            </td><td>
              $19.73
            </td><td>
              N/A
            </td><td>
              404.72m
            </td><td>
              -6.75m
            </td><td>
              59.92
            </td><td>
              357.08m
            </td><td>
              0.73b
            </td><td>
              3
            </td><td>
              40,155,148
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/OPT" class="margin-bottom-1">
                OPT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.23</div> <small class="number change-down">-0.22<span>&nbsp;&nbsp;</span>-2.95%</small></td><td><strong>OPT-302</strong> <br>Wet age-related macular degeneration (AMD)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://wcsecure.weblink.com.au/pdf/OPT/02353383.pdf">
                2023
              </a> <div class="note">Phase 3 trial initiation announced March 15, 2021 with data due 2H 2023.</div></td><td>
              42m
            </td><td>
              305.2m
            </td><td>
              15.7k
            </td><td>
              143.5k
            </td><td>
              2.36
            </td><td>
              $7.23
            </td><td>
              $7.45
            </td><td>
              December 2023
            </td><td>
              202.54m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              186.92m
            </td><td>
              175.89m
            </td><td>
              0
            </td><td>
              42,208,021
            </td><td>
              03/15/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SNDX" class="margin-bottom-1">
                SNDX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$16.37</div> <small class="number change-up">+0.62<span>&nbsp;&nbsp;</span>+3.94%</small></td><td><strong>Axatilimab (SNDX-6352) - AGAVE-201</strong> <br>Chronic graft versus host disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides-clinical-and-business-update-301289112.html">
                2023
              </a> <div class="note">Phase 2 pivotal trial initiation announced March 8, 2021 with top-line data due 2023.</div></td><td>
              49m
            </td><td>
              0.8b
            </td><td>
              309.6k
            </td><td>
              479.0k
            </td><td>
              3.71
            </td><td>
              $15.87
            </td><td>
              $15.75
            </td><td>
              July 2023
            </td><td>
              238.71m
            </td><td>
              -8.01m
            </td><td>
              29.78
            </td><td>
              190.21m
            </td><td>
              0.53b
            </td><td>
              0.4
            </td><td>
              47,742,775
            </td><td>
              05/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CRNX" class="margin-bottom-1">
                CRNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.27</div> <small class="number change-up">+0.40<span>&nbsp;&nbsp;</span>+1.92%</small></td><td><strong>Paltusotine (PATHFNDR-1)</strong> <br>Acromegaly
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.globenewswire.com/news-release/2021/06/28/2253788/0/en/Crinetics-Pharmaceuticals-Announces-Dosing-of-First-Patient-in-Phase-3-PATHFNDR-1-Study-Evaluating-Oral-Paltusotine-for-the-Treatment-of-Acromegaly.html">
                2023
              </a> <div class="note">Phase 3 initiation of dosing announced June 28, 2021. Top-line data due 2023.</div></td><td>
              39m
            </td><td>
              0.8b
            </td><td>
              195.1k
            </td><td>
              200.6k
            </td><td>
              4.16
            </td><td>
              $21.18
            </td><td>
              $20.87
            </td><td>
              June 2023
            </td><td>
              206.79m
            </td><td>
              -6.65m
            </td><td>
              31.10
            </td><td>
              191.30m
            </td><td>
              0.62b
            </td><td>
              0.7
            </td><td>
              29,019,031
            </td><td>
              06/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IONS" class="margin-bottom-1">
                IONS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$39.33</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+0.18%</small></td><td><strong>AKCEA-TTR-LRx - CARDIO-TTRansform</strong> <br>ATTR cardiomyopathy
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ionispharma.com/static-files/ed4086b4-2eba-49f7-beb8-93f41f5c82e2">
                2023
              </a> <div class="note">Phase 3 trial initiation announced January 10, 2020. Data due 2023.</div></td><td>
              141m
            </td><td>
              5.6b
            </td><td>
              322.8k
            </td><td>
              1.1m
            </td><td>
              9.52
            </td><td>
              $39.68
            </td><td>
              $39.26
            </td><td>
              January 2024
            </td><td>
              2.05b
            </td><td>
              -20.88m
            </td><td>
              98.00
            </td><td>
              132.28m
            </td><td>
              4.79b
            </td><td>
              0.6
            </td><td>
              119,102,131
            </td><td>
              10/12/2020
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/KDNY" class="margin-bottom-1">
                KDNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.55</div> <small class="number change-up">+0.79<span>&nbsp;&nbsp;</span>+6.19%</small></td><td><strong>Atrasentan (ALIGN)</strong> <br>IgA Nephropathy (IgAN)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.chinooktx.com/news-releases/news-release-details/chinook-therapeutics-provides-business-update-and-reports-first">
                2023
              </a> <div class="note">Phase 3 top-line data due 2023.</div></td><td>
              45m
            </td><td>
              0.6b
            </td><td>
              306.4k
            </td><td>
              301.8k
            </td><td>
              2.05
            </td><td>
              $13.35
            </td><td>
              $12.76
            </td><td>
              December 1, 2023
            </td><td>
              180.69m
            </td><td>
              -9.14m
            </td><td>
              19.76
            </td><td>
              69.55m
            </td><td>
              414.92m
            </td><td>
              0.2
            </td><td>
              25,691,260
            </td><td>
              05/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVCR" class="margin-bottom-1">
                NVCR
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$135.40</div> <small class="number change-up">+2.97<span>&nbsp;&nbsp;</span>+2.24%</small></td><td><strong>Tumor Treating Fields (TTFields) METIS</strong> <br>Brain Metastases Originating from Non-Small Cell Lung Cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210729005357/en/">
                2023
              </a> <div class="note">Phase 3 data due 2023.</div></td><td>
              104m
            </td><td>
              14.0b
            </td><td>
              153.2k
            </td><td>
              0.7m
            </td><td>
              35.35
            </td><td>
              $133.45
            </td><td>
              $132.43
            </td><td>
              September 2022
            </td><td>
              0.91b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              214.94m
            </td><td>
              13.40b
            </td><td>
              7.7
            </td><td>
              102,348,400
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TVTX" class="margin-bottom-1">
                TVTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$21.41</div> <small class="number change-up">+1.22<span>&nbsp;&nbsp;</span>+6.02%</small></td><td><strong>Sparsentan (PROTECT)</strong> <br>IgA nephropathy
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-announces-positive-topline-interim-results">
                2H 2023
              </a> <div class="note">Phase 3 initial data released August 16, 2021. Primary efficacy endpoint met. Topline results from the confirmatory endpoint analysis are expected 2H 2023.</div></td><td>
              61m
            </td><td>
              1.3b
            </td><td>
              0.6m
            </td><td>
              1.4m
            </td><td>
              3.91
            </td><td>
              $20.31
            </td><td>
              $20.19
            </td><td>
              March 2023
            </td><td>
              0.53b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              112.22m
            </td><td>
              0.92b
            </td><td>
              5.5
            </td><td>
              60,239,404
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ANNX" class="margin-bottom-1">
                ANNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.34</div> <small class="number change-up">+0.58<span>&nbsp;&nbsp;</span>+3.49%</small></td><td><strong>ANX005</strong> <br>Guillain-Barré Syndrome
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.annexonbio.com/news-releases/news-release-details/annexon-biosciences-reports-second-quarter-2021-financial">
                2023
              </a> <div class="note">Phase 2/3 data due 2023.</div></td><td>
              38m
            </td><td>
              0.7b
            </td><td>
              64.4k
            </td><td>
              162.5k
            </td><td>
              2.25
            </td><td>
              $17.05
            </td><td>
              $16.75
            </td><td>
              March 2023
            </td><td>
              287.59m
            </td><td>
              -8.22m
            </td><td>
              34.99
            </td><td>
              251.14m
            </td><td>
              366.09m
            </td><td>
              0
            </td><td>
              36,335,026
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BMY" class="margin-bottom-1">
                BMY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$69.35</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+0.22%</small></td><td><strong>OPDIVO (Nivolumab) and YERVOY&nbsp;(ipilimumab) - (CheckMate 816)</strong> <br>Non-Small Cell Lung Cancer (NSCLC)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://s21.q4cdn.com/104148044/files/doc_presentations/2021/BMY-2021-Q2-Results-Investor-Presentation.pdf">
                2022/ 2023
              </a> <div class="note">Phase 3 trial met primary endpoint - October 7, 2020. 24% of patients treated with Opdivo plus chemotherapy achieved  pathologic complete response (pCR), compared to 2.2% of patients treated with chemotherapy alone. Further data due 2022/ 2023.</div></td><td>
              2b
            </td><td>
              154.1b
            </td><td>
              4.1m
            </td><td>
              8.5m
            </td><td>
              4.19
            </td><td>
              $69.26
            </td><td>
              $69.2
            </td><td>
              May 8, 2023
            </td><td>
              15.85b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -58.07b
            </td><td>
              186.05b
            </td><td>
              0.3
            </td><td>
              2,219,710,962
            </td><td>
              07/28/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CERE" class="margin-bottom-1">
                CERE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$26.20</div> <small class="number change-up">+2.51<span>&nbsp;&nbsp;</span>+10.60%</small></td><td><strong>Tavapadon  (TEMPO-1)</strong> <br>Early Parkinson’s disease
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investors.cerevel.com/static-files/e75deb7b-6273-47e7-8e39-d2371bfb310a">
                2H 2023
              </a> <div class="note">Phase 3 data due 2H 2023.</div></td><td>
              145m
            </td><td>
              3.8b
            </td><td>
              327.6k
            </td><td>
              2.9m
            </td><td>
              12.91
            </td><td>
              $23.95
            </td><td>
              $23.69
            </td><td>
              July 2023
            </td><td>
              0.65b
            </td><td>
              -15.20m
            </td><td>
              42.74
            </td><td>
              0.55b
            </td><td>
              3.14b
            </td><td>
              0.1
            </td><td>
              52,582,057
            </td><td>
              08/11/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ANNX" class="margin-bottom-1">
                ANNX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.34</div> <small class="number change-up">+0.58<span>&nbsp;&nbsp;</span>+3.49%</small></td><td><strong>ANX007 - ARCHER</strong> <br>Geographic atrophy
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.annexonbio.com/news-releases/news-release-details/annexon-biosciences-reports-fourth-quarter-and-full-year-2020">
                2023
              </a> <div class="note">Phase 2 data due 2023.</div></td><td>
              38m
            </td><td>
              0.7b
            </td><td>
              64.4k
            </td><td>
              162.5k
            </td><td>
              2.25
            </td><td>
              $17.05
            </td><td>
              $16.75
            </td><td>
              N/A
            </td><td>
              287.59m
            </td><td>
              -8.22m
            </td><td>
              34.99
            </td><td>
              251.14m
            </td><td>
              366.09m
            </td><td>
              0
            </td><td>
              36,335,026
            </td><td>
              03/25/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/TIL" class="margin-bottom-1">
                TIL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$17.12</div> <small class="number change-up">+0.41<span>&nbsp;&nbsp;</span>+2.45%</small></td><td><strong>ITIL-168</strong> <br>Melanoma
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.instilbio.com/news-releases/news-release-details/instil-bio-reports-second-quarter-2021-financial-results-and">
                2023
              </a> <div class="note">Phase 2 trial to commence 2H 2021 with top-line data due 2023.</div></td><td>
              129m
            </td><td>
              2.2b
            </td><td>
              52.2k
            </td><td>
              287.9k
            </td><td>
              3.47
            </td><td>
              $16.71
            </td><td>
              $16.71
            </td><td>
              N/A
            </td><td>
              0.55b
            </td><td>
              -10.74m
            </td><td>
              50.96
            </td><td>
              0.51b
            </td><td>
              1.58b
            </td><td>
              2.2
            </td><td>
              16,365,702
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PTCT" class="margin-bottom-1">
                PTCT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$39.58</div> <small class="number change-up">+1.38<span>&nbsp;&nbsp;</span>+3.61%</small></td><td><strong>Vatiquinone (MOVE-FA)</strong> <br>Friedreich ataxia
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-a-corporate-update-and-reports-second-quarter-2021-financial-results-301344644.html">
                2023
              </a> <div class="note">Phase 3 data due 2023.</div></td><td>
              71m
            </td><td>
              2.8b
            </td><td>
              109.5k
            </td><td>
              412.7k
            </td><td>
              14.24
            </td><td>
              $38.84
            </td><td>
              $38.2
            </td><td>
              March 21, 2023
            </td><td>
              0.93b
            </td><td>
              -10.38m
            </td><td>
              89.43
            </td><td>
              -0.93b
            </td><td>
              2.29b
            </td><td>
              0.9
            </td><td>
              49,392,128
            </td><td>
              07/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/MACK" class="margin-bottom-1">
                MACK
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.65</div> <small class="number change-up">+0.15<span>&nbsp;&nbsp;</span>+3.33%</small></td><td><strong>ONIVYDE (NAPOLI 3)</strong> <br>Pancreatic cancer
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210805005726/en/">
                2023
              </a> <div class="note">Acquired by Ipsen. Phase 3 data due 2023.</div></td><td>
              13m
            </td><td>
              62.4m
            </td><td>
              6.6k
            </td><td>
              22.9k
            </td><td>
              4.12
            </td><td>
              $4.5
            </td><td>
              $4.5
            </td><td>
              December 31, 2022
            </td><td>
              15.52m
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              14.75m
            </td><td>
              45.44m
            </td><td>
              39.7
            </td><td>
              10,685,047
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVS" class="margin-bottom-1">
                NVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$93.88</div> <small class="number change-up">+0.55<span>&nbsp;&nbsp;</span>+0.59%</small></td><td><strong>Iptacopan (LNP023) - APPLAUSE-IgAN</strong> <br>IgA nephropathy (IgAN) 
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.pdf">
                2023
              </a> <div class="note">Phase 3 data due 2023.</div></td><td>
              2b
            </td><td>
              210.0b
            </td><td>
              0.7m
            </td><td>
              1.7m
            </td><td>
              3.89
            </td><td>
              $93.86
            </td><td>
              $93.33
            </td><td>
              January 7, 2025
            </td><td>
              7.84b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -62.05b
            </td><td>
              238.51b
            </td><td>
              0
            </td><td>
              2,236,739,037
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/NVS" class="margin-bottom-1">
                NVS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$93.88</div> <small class="number change-up">+0.55<span>&nbsp;&nbsp;</span>+0.59%</small></td><td><strong>Sabatolimab (MBG453)</strong> <br>Myelodysplastic syndromes (MDS)
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.pdf">
                2022 / 2023
              </a> <div class="note">Phase 2 PFS readout 2022 / 2023.</div></td><td>
              2b
            </td><td>
              210.0b
            </td><td>
              0.7m
            </td><td>
              1.7m
            </td><td>
              3.89
            </td><td>
              $93.86
            </td><td>
              $93.33
            </td><td>
              October 27, 2023
            </td><td>
              7.84b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -62.05b
            </td><td>
              238.51b
            </td><td>
              0
            </td><td>
              2,236,739,037
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/LLY" class="margin-bottom-1">
                LLY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$269.63</div> <small class="number change-down">-1.28<span>&nbsp;&nbsp;</span>-0.47%</small></td><td><strong>Donanemab (TRAILBLAZER-ALZ 2)</strong> <br>Alzheimer’s disease
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.lilly.com/static-files/c03e912c-c3fd-49b4-b383-fb0debe5b2f3">
                2023
              </a> <div class="note">Phase 2 data due 2023.</div></td><td>
              1b
            </td><td>
              257.9b
            </td><td>
              0.8m
            </td><td>
              2.8m
            </td><td>
              40.00
            </td><td>
              $272.3
            </td><td>
              $270.91
            </td><td>
              February 14, 2023
            </td><td>
              4.34b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -36.81b
            </td><td>
              272.39b
            </td><td>
              0.5
            </td><td>
              792,287,037
            </td><td>
              01/29/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GALT" class="margin-bottom-1">
                GALT
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$3.59</div> <small class="number change-up">+0.22<span>&nbsp;&nbsp;</span>+6.53%</small></td><td><strong>GR-MD-02</strong> <br>Non-alcoholic steatohepatitis (NASH) with cirrhosis
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://investor.galectintherapeutics.com/news-releases/news-release-details/galectin-therapeutics-reports-financial-results-quarter-ended-2">
                2H 2023
              </a> <div class="note">Phase 2b/3 interim analysis due 2H 2023.</div></td><td>
              59m
            </td><td>
              212.8m
            </td><td>
              293.8k
            </td><td>
              2.7m
            </td><td>
              14.36
            </td><td>
              $3.4
            </td><td>
              $3.37
            </td><td>
              June 2023
            </td><td>
              28.01m
            </td><td>
              -1.99m
            </td><td>
              14.06
            </td><td>
              11.72m
            </td><td>
              180.08m
            </td><td>
              22.4
            </td><td>
              24,687,598
            </td><td>
              08/16/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BTX" class="margin-bottom-1">
                BTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.85</div> <small class="number change-up">+0.25<span>&nbsp;&nbsp;</span>+2.59%</small></td><td><strong>IRX-2 and Opdivo - BAS-104</strong> <br>Solid Tumors
            </td><td>
              Phase 1
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0000748592/000149315220022484/forms-4a.htm">
                4Q 2023
              </a> <div class="note">Phase 1 trial enrolling. Final data due 4Q 2023.</div></td><td>
              52m
            </td><td>
              0.5b
            </td><td>
              0.7m
            </td><td>
              2.3m
            </td><td>
              33.96
            </td><td>
              $9.6
            </td><td>
              $9.6
            </td><td>
              February 2022
            </td><td>
              46.08m
            </td><td>
              -2.27m
            </td><td>
              20.32
            </td><td>
              16.55m
            </td><td>
              450.07m
            </td><td>
              12.1
            </td><td>
              35,906,398
            </td><td>
              04/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALNY" class="margin-bottom-1">
                ALNY
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$199.95</div> <small class="number change-up">+2.17<span>&nbsp;&nbsp;</span>+1.10%</small></td><td><strong>Vutrisiran - HELIOS-B</strong> <br>ATTR amyloidosis with cardiomyopathy
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210809005231/en/">
                Early-2024
              </a> <div class="note">Phase 3 completion of enrollment announced August 9, 2021. Top-line data due early-2024.</div></td><td>
              119m
            </td><td>
              23.8b
            </td><td>
              237.9k
            </td><td>
              0.7m
            </td><td>
              27.85
            </td><td>
              $198.72
            </td><td>
              $197.78
            </td><td>
              June 2024
            </td><td>
              1.83b
            </td><td>
              -40.62m
            </td><td>
              44.98
            </td><td>
              -0.83b
            </td><td>
              22.37b
            </td><td>
              0.3
            </td><td>
              102,229,141
            </td><td>
              08/09/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/DRMA" class="margin-bottom-1">
                DRMA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$4.70</div> <small class="number change-up">+0.09<span>&nbsp;&nbsp;</span>+1.95%</small></td><td><strong>DMT310</strong> <br>Acne
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001853816/000119312521187916/d137089ds1.htm">
                1H 2024
              </a> <div class="note">Phase 3 trial planned for 2H 2022. Top-line data due 1H 2024.</div></td><td>
              8m
            </td><td>
              39.1m
            </td><td>
              14.5k
            </td><td>
              
            </td><td>
              58.75
            </td><td>
              $4.6
            </td><td>
              $4.61
            </td><td>
              N/A
            </td><td>
              79.84k
            </td><td>
              -258.74k
            </td><td>
              0.31
            </td><td>
              -0.86m
            </td><td>
              37.25m
            </td><td>
              0
            </td><td>
              1,768,271
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/BTX" class="margin-bottom-1">
                BTX
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$9.85</div> <small class="number change-up">+0.25<span>&nbsp;&nbsp;</span>+2.59%</small></td><td><strong>IRX-2 and KEYTRUDA (pembrolizumab) - BR-202</strong> <br>Breast Cancer
            </td><td>
              Phase 2
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0000748592/000149315220022484/forms-4a.htm">
                2Q 2024
              </a> <div class="note">Phase 2 trial ongoing. Final data due 2Q 2024.</div></td><td>
              52m
            </td><td>
              0.5b
            </td><td>
              0.7m
            </td><td>
              2.3m
            </td><td>
              33.96
            </td><td>
              $9.6
            </td><td>
              $9.6
            </td><td>
              June 2024
            </td><td>
              46.08m
            </td><td>
              -2.27m
            </td><td>
              20.32
            </td><td>
              16.55m
            </td><td>
              450.07m
            </td><td>
              12.1
            </td><td>
              35,906,398
            </td><td>
              05/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/CADL" class="margin-bottom-1">
                CADL
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$7.75</div> <small class="number change-up">+1.45<span>&nbsp;&nbsp;</span>+23.02%</small></td><td><strong>CAN-2409</strong> <br>Prostate cancer 
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.sec.gov/Archives/edgar/data/0001841387/000119312521200639/d120909ds1.htm">
                2024
              </a> <div class="note">Phase 3 enrollment to be completed in 3Q 2021 with data due 2024.</div></td><td>
              28m
            </td><td>
              215.4m
            </td><td>
              153.7k
            </td><td>
              
            </td><td>
              -7.83
            </td><td>
              $6.8
            </td><td>
              $6.3
            </td><td>
              June 2023
            </td><td>
              20.09m
            </td><td>
              -1.88m
            </td><td>
              10.71
            </td><td>
              -42.50m
            </td><td>
              146.94m
            </td><td>
              6.7
            </td><td>
              14,620,612
            </td><td>
              07/21/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/IONS" class="margin-bottom-1">
                IONS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$39.33</div> <small class="number change-up">+0.07<span>&nbsp;&nbsp;</span>+0.18%</small></td><td><strong>AKCEA-APO(a)-LRx</strong> <br>Hyperlipoproteinemia(a) and established cardiovascular disease
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.ionispharma.com/static-files/ed4086b4-2eba-49f7-beb8-93f41f5c82e2">
                2024
              </a> <div class="note">Phase 3 data due 2024.</div></td><td>
              141m
            </td><td>
              5.6b
            </td><td>
              322.8k
            </td><td>
              1.1m
            </td><td>
              9.52
            </td><td>
              $39.68
            </td><td>
              $39.26
            </td><td>
              N/A
            </td><td>
              2.05b
            </td><td>
              -20.88m
            </td><td>
              98.00
            </td><td>
              132.28m
            </td><td>
              4.79b
            </td><td>
              0.6
            </td><td>
              119,102,131
            </td><td>
              10/12/2020
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/RDUS" class="margin-bottom-1">
                RDUS
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$13.74</div> <small class="number change-up">+0.59<span>&nbsp;&nbsp;</span>+4.49%</small></td><td><strong>RAD011 (SCOUT)</strong> <br>Prader-Willi syndrome
            </td><td>
              Phase 2/3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.radiuspharm.com/news-releases/news-release-details/radius-health-announces-plans-global-prader-willi-syndrome">
                2H 2024
              </a> <div class="note">Phase 2/3 trial planned for late-2021 / early-1Q 2022 with data due 2H 2024.</div></td><td>
              47m
            </td><td>
              0.6b
            </td><td>
              160.9k
            </td><td>
              340.8k
            </td><td>
              -2.86
            </td><td>
              $13.22
            </td><td>
              $13.15
            </td><td>
              N/A
            </td><td>
              90.18m
            </td><td>
              -5.00m
            </td><td>
              18.05
            </td><td>
              -329.76m
            </td><td>
              0.86b
            </td><td>
              0.9
            </td><td>
              33,375,071
            </td><td>
              07/22/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/ALBO" class="margin-bottom-1">
                ALBO
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$29.70</div> <small class="number change-up">+1.89<span>&nbsp;&nbsp;</span>+6.80%</small></td><td><strong>BYLVAY (odevixibat) - (BOLD)</strong> <br>Biliary atresia
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://ir.albireopharma.com/news-releases/news-release-details/albireo-reports-q2-financial-results-and-business-update">
                2024
              </a> <div class="note">Phase 3 data due 2024.</div></td><td>
              19m
            </td><td>
              0.6b
            </td><td>
              67.6k
            </td><td>
              262.4k
            </td><td>
              5.04
            </td><td>
              $28.02
            </td><td>
              $27.81
            </td><td>
              May 2024
            </td><td>
              167.40m
            </td><td>
              -10.49m
            </td><td>
              15.96
            </td><td>
              61.41m
            </td><td>
              359.08m
            </td><td>
              20.7
            </td><td>
              14,332,622
            </td><td>
              08/05/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/GERN" class="margin-bottom-1">
                GERN
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.29</div> <small class="number change-up">+0.02<span>&nbsp;&nbsp;</span>+1.77%</small></td><td><strong>Imetelstat (IMpactMF)</strong> <br>Myelofibrosis
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210816005218/en/">
                2024
              </a> <div class="note">Phase 3 interim analysis due 2024 and final analysis in 2025.</div></td><td>
              321m
            </td><td>
              414.4m
            </td><td>
              2.9m
            </td><td>
              10.4m
            </td><td>
              2.35
            </td><td>
              $1.27
            </td><td>
              $1.27
            </td><td>
              May 1, 2024
            </td><td>
              187.55m
            </td><td>
              -5.94m
            </td><td>
              31.59
            </td><td>
              111.58m
            </td><td>
              248.76m
            </td><td>
              1.6
            </td><td>
              318,430,617
            </td><td>
              08/17/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/SVRA" class="margin-bottom-1">
                SVRA
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$1.28</div> <small class="number change-up">+0.04<span>&nbsp;&nbsp;</span>+3.23%</small></td><td><strong>Molgradex - IMPALA-2</strong> <br>Autoimmune pulmonary alveolar proteinosis (PAP)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://1r7gozkfded3uc1os1otliua-wpengine.netdna-ssl.com/wp-content/uploads/2021/07/20210709_Savara-Corporate-Deck_July-2021_FINAL.pdf">
                2Q 2024
              </a> <div class="note">Phase 3 data June 12, 2019 did not meet primary endpoint. Initiation of second Phase 3 trial announced June 30, 2021. Top-line data due 2Q 2024.</div></td><td>
              114m
            </td><td>
              145.7m
            </td><td>
              255.3k
            </td><td>
              0.7m
            </td><td>
              0.88
            </td><td>
              $1.24
            </td><td>
              $1.24
            </td><td>
              June 2024
            </td><td>
              173.35m
            </td><td>
              -4.06m
            </td><td>
              42.65
            </td><td>
              142.30m
            </td><td>
              -14.02m
            </td><td>
              8.1
            </td><td>
              88,637,863
            </td><td>
              08/12/2021
            </td></tr><tr><td><a href="https://www.biopharmcatalyst.com/company/PFE" class="margin-bottom-1">
                PFE
              </a> <div><a href="https://www.biopharmcatalyst.com/calendars/fda-calendar#" title="Add to portfolio"><span class="grid-x grid-padding-x align-middle"><i title="Add to portfolio" class="fas fa-plus size-24  margin-right-1" aria-hidden="true"></i><span class="sr-only">Add to portfolio</span></span></a></div></td><td><div class="price">$49.98</div> <small class="number change-up">+1.25<span>&nbsp;&nbsp;</span>+2.58%</small></td><td><strong>TALZENNA (talazoparib) and XTANDI (enzalutamide) - TALAPRO-3</strong> <br>Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
            </td><td>
              Phase 3
              <div><svg width="95" height="5" viewBox="1 1 95 5" xmlns="http://www.w3.org/2000/svg"><g transform="translate(1 1)" fill="none"><rect fill="#911C36" width="15" height="5" rx="2"></rect> <rect fill="#D6A960" x="16" width="15" height="5" rx="2"></rect> <rect fill="#E7DE6F" x="32" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="48" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="64" width="15" height="5" rx="2"></rect> <rect fill="#ddd" x="80" width="15" height="5" rx="2"></rect></g></svg></div></td><td><a target="_blank" href="https://www.businesswire.com/news/home/20210728005318/en/">
                Late-2024
              </a> <div class="note">Phase 3 initiation of dosing announced June 22, 2021. Primary completion late-2024.</div></td><td>
              6b
            </td><td>
              280.2b
            </td><td>
              69.5m
            </td><td>
              30.1m
            </td><td>
              4.00
            </td><td>
              $50.29
            </td><td>
              $48.72
            </td><td>
              December 11, 2024
            </td><td>
              28.48b
            </td><td>
              N/A
            </td><td>
              N/A
            </td><td>
              -71.13b
            </td><td>
              289.19b
            </td><td>
              0.3
            </td><td>
              5,605,213,314
            </td><td>
              07/28/2021
            </td></tr></tbody></table></div></div></form></div></div>

	</main>

	<footer id="footer">
		

<style>.qm-footer {
    max-width: 55rem;
    margin: 0 auto 2rem auto;
}

.qmf-link {
    white-space: nowrap;
}

.qmf-logo {
    padding-top: 5px;
}

.qmf-rt, .qmf-non-rt {
    font-style: italic;
    font-weight: bold;
}

.qmf-non-rt {
    color: #333;
}

.qmf-rt {
    color: #080;
}</style>
<div class="qm-footer">
    Market Data copyright © 2017 <a href="http://www.quotemedia.com/" class="qmf-link">QuoteMedia</a>. Data delayed
    15–35 minutes unless otherwise indicated (view <a href="http://www.quotemedia.com/legal/tos/#times" class="qmf-link">delay times</a> for all exchanges). <span class="qmf-rt">RT</span>=Real-Time, <span class="qmf-non-rt">EOD</span>=End of Day, <span class="qmf-non-rt">PD</span>=Previous Day. Market Data powered by <a href="http://www.quotemedia.com/" class="qmf-link">QuoteMedia</a>. <a href="http://www.quotemedia.com/legal/tos/" class="qmf-link">Terms of Use</a>.
    <div class="qmf-logo"><a href="http://www.quotemedia.com/"><img src="https://www.quotemedia.com/footer/logo.png" alt="QuoteMedia logo"></a></div>
</div>
		
<ul id="" class="no-bullet">
<li class="first"><a href="https://www.biopharmcatalyst.com/terms-of-use" title="Terms of Use">Terms of Use</a></li>
<li><a href="https://www.biopharmcatalyst.com/disclaimer" title="Disclaimer">Disclaimer</a></li>
<li><a href="https://www.biopharmcatalyst.com/privacy-policy" title="Privacy Policy">Privacy Policy</a></li>
</ul>
		<p>©
			2021
			BioPharmCatalyst</p>
		<p>
							<a href="https://twitter.com/crusadernz" title="Twitter" class="link-social"></a>
							<a href="https://www.youtube.com/Biopharmcatalyst" title="Youtube" class="link-social"><svg xmlns="http://www.w3.org/2000/svg" width="23" height="17" viewBox="0 0 23 17">
  <path fill="#E52D27" fill-rule="evenodd" d="M675.5,431.35791 C664,431.35791 664,431.35791 664,439.5 C664,447.64209 664,447.64209 675.5,447.64209 C687,447.64209 687,447.64209 687,439.5 C687,431.35791 687,431.35791 675.5,431.35791 L675.5,431.35791 Z M672.625,443.8125 L672.625,435.1875 L679.8125,439.5 L672.625,443.8125 Z" transform="translate(-664 -431)"></path>
</svg>
</a>
							<a href="https://www.facebook.com/biopharmcatalyst" title="Facebook" class="link-social"><svg xmlns="http://www.w3.org/2000/svg" width="17" height="17" viewBox="0 0 17 17">
  <path fill="#3B5998" fill-rule="evenodd" d="M645.9375,431 L631.0625,431 C630.481445,431 630,431.481445 630,432.0625 L630,446.9375 C630,447.518555 630.481445,448 631.0625,448 L639.089355,448 L639.089355,441.392578 L636.964355,441.392578 L636.964355,438.943848 L639.089355,438.943848 L639.089355,436.827148 C639.089355,434.893066 640.268066,433.598145 642.600586,433.598145 C643.629883,433.598145 644.34375,433.714355 644.34375,433.714355 L644.34375,435.922363 L642.75,435.922363 C642.044434,435.922363 641.6875,436.320801 641.6875,437.018066 L641.6875,438.943848 L644.169434,438.943848 L643.8125,441.392578 L641.6875,441.392578 L641.6875,448 L645.9375,448 C646.518555,448 647,447.518555 647,446.9375 L647,432.0625 C647,431.481445 646.518555,431 645.9375,431 L645.9375,431 Z" transform="translate(-630 -431)"></path>
</svg>
</a>
					</p>
		<p class="thefold">
			<a href="http://thefold.co.nz/">Website design &amp; development</a>
			by The Fold</p>
	</footer>
			<!-- ConnectRetarget PowerPixel -->
	<script>
		var CRConfig = {
'pixel_prefix': 'biotechbreakouts',
'init_fb': true,
'fb_pixel_id': '403156013389401'
};
	</script>
		<!-- End ConnectRetarget PowerPixel -->
	<!-- Go to www.addthis.com/dashboard to customize your tools -->
		
                  <script>
                    window.addEventListener("load", function(){
                        window.cookieconsent && window.cookieconsent.initialise({
                        "palette": {
                          "popup": {
                            "background": "#2a537e",
                            "text": "#ffffff"
                          },
                          "button": {
                              "background":  "edgeless" === "wire" ? "transparent" :  "#f1d600",
                              "text": "edgeless" === "wire" ? "#f1d600" : "#000000",
                              "border":  "edgeless" === "wire" ? "#f1d600" : undefined
                          }
                      },
                      "position": "bottom-right" === "toppush" ? "top" : "bottom-right",
                      "static": "bottom-right" === "toppush",
                      "theme": "edgeless",
                      "onStatusChange" : function(e, t) {                          
                          $.getJSON("/actions/bioPharm/sync/getJwtToken", (response) => {
                            if (!response || response.token == false) {
                                return false;
                            }
                            token = response.token;
                            $.ajax({
                              url: `https://api.biopharmcatalyst.com/user-meta`,
                              method: "POST",
                              dataType: "json",
                              data:{consented:this.hasConsented()},
                              beforeSend: (xhr) => xhr.setRequestHeader("Authorization", `Bearer ${token}`),
                            });
                        });
                      },
                      "content": {
                          "message": "We use cookies to analyze traffic and to recognize users who sign in to our premium tools. By using our site, you agree to our use of cookies. For details, read our privacy policy ",
                          "dismiss": "Got it!",
                          "link": "here",
                          "href": "https://www.biopharmcatalyst.com/privacy-policy"
                      }
                    })});
                  </script>
                
<script type="text/javascript" src="./20210823_FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst_files/cookieconsent.min.js.descarga"></script>
<script type="text/javascript">
/*<![CDATA[*/
var tickers = [  'ABBV',  'ABCL',  'ABEO',  'ABIO',  'ABOS',  'ABUS',  'ACAD',  'ACER',  'ACET',  'ACHL',  'ACHV',  'ACIU',  'ACOR',  'ACRS',  'ACRX',  'ACST',  'ACXP',  'ADAG',  'ADAP',  'ADCT',  'ADGI',  'ADIL',  'ADMA',  'ADMP',  'ADMS',  'ADPT',  'ADTX',  'ADVM',  'ADXS',  'AERI',  'AEZS',  'AFMD',  'AGEN',  'AGIO',  'AGLE',  'AGRX',  'AGTC',  'AIM',  'AKBA',  'AKRO',  'AKTX',  'AKUS',  'ALBO',  'ALDX',  'ALEC',  'ALGS',  'ALIM',  'ALKS',  'ALLK',  'ALLO',  'ALNA',  'ALNY',  'ALPN',  'ALRN',  'ALT',  'ALVR',  'ALXO',  'ALZN',  'AMAM',  'AMGN',  'AMPE',  'AMPH',  'AMRN',  'AMRX',  'AMTI',  'AMYT',  'ANAB',  'ANEB',  'ANGN',  'ANIK',  'ANIP',  'ANIX',  'ANNX',  'ANVS',  'APLS',  'APLT',  'APRE',  'APTO',  'APTX',  'APVO',  'AQST',  'ARAV',  'ARCT',  'ARDS',  'ARDX',  'ARGX',  'ARMP',  'ARNA',  'ARPO',  'ARQT',  'ARTL',  'ARVN',  'ARWR',  'ASLN',  'ASMB',  'ASND',  'ASRT',  'ATAI',  'ATHA',  'ATHE',  'ATHX',  'ATNF',  'ATNM',  'ATNX',  'ATOS',  'ATRA',  'ATRS',  'ATXI',  'AUPH',  'AUTL',  'AVDL',  'AVEO',  'AVIR',  'AVRO',  'AVTE',  'AVXL',  'AXGN',  'AXLA',  'AXSM',  'AYLA',  'AYTU',  'AZN',  'AZRX',  'BBI',  'BBIO',  'BCAB',  'BCDA',  'BCEL',  'BCLI',  'BCRX',  'BCTX',  'BCYC',  'BDSI',  'BDTX',  'BEAM',  'BFRA',  'BGNE',  'BHC',  'BHVN',  'BIIB',  'BLCM',  'BLPH',  'BLRX',  'BLU',  'BLUE',  'BMEA',  'BMRN',  'BMY',  'BNTC',  'BNTX',  'BOLT',  'BPMC',  'BPTH',  'BPTS',  'BSGM',  'BTAI',  'BTX',  'BVXV',  'BXRX',  'BYSI',  'CABA',  'CADL',  'CALA',  'CALT',  'CANF',  'CAPR',  'CARA',  'CASI',  'CATB',  'CBAY',  'CBIO',  'CBLI',  'CCCC',  'CCXI',  'CDAK',  'CDMO',  'CDTX',  'CDXS',  'CELC',  'CERC',  'CERE',  'CERS',  'CFRX',  'CGEM',  'CGEN',  'CHMA',  'CHRS',  'CKPT',  'CLBS',  'CLDX',  'CLLS',  'CLNN',  'CLRB',  'CLSD',  'CLSN',  'CLVS',  'CMPI',  'CMPS',  'CMPX',  'CMRX',  'CNCE',  'CNSP',  'CNTA',  'CNTB',  'CNTX',  'COCP',  'COGT',  'COLL',  'CORT',  'CPIX',  'CPRX',  'CRBP',  'CRBU',  'CRDF',  'CRIS',  'CRMD',  'CRNX',  'CRSP',  'CRTX',  'CRVS',  'CSII',  'CTIC',  'CTMX',  'CTXR',  'CUE',  'CVAC',  'CVM',  'CWBR',  'CYAD',  'CYCC',  'CYCN',  'CYDY',  'CYT',  'CYTH',  'CYTK',  'CYTO',  'DARE',  'DAWN',  'DBTX',  'DBVT',  'DCPH',  'DCTH',  'DFFN',  'DMAC',  'DNLI',  'DRMA',  'DRNA',  'DRRX',  'DSGN',  'DTIL',  'DVAX',  'DYAI',  'DYN',  'EBS',  'EDAP',  'EDIT',  'EDSA',  'EGRX',  'EIDX',  'EIGR',  'ELDN',  'ELEV',  'ELOX',  'ELTX',  'ELYM',  'ENDP',  'ENLV',  'ENOB',  'ENTA',  'ENTX',  'EOLS',  'EPIX',  'EPZM',  'EQ',  'ERAS',  'ERYP',  'ESPR',  'ETNB',  'ETON',  'ETTX',  'EVAX',  'EVFM',  'EVLO',  'EVOK',  'EWTX',  'EXAS',  'EXEL',  'EYEG',  'EYEN',  'EYPT',  'FATE',  'FBIO',  'FBRX',  'FDMT',  'FENC',  'FGEN',  'FHTX',  'FIXX',  'FLXN',  'FMTX',  'FNCH',  'FOLD',  'FREQ',  'FRLN',  'FSTX',  'FULC',  'FUSN',  'FWP',  'GALT',  'GANX',  'GBIO',  'GBT',  'GERN',  'GHRS',  'GILD',  'GKOS',  'GLMD',  'GLPG',  'GLSI',  'GLTO',  'GLYC',  'GMAB',  'GMDA',  'GMTX',  'GNCA',  'GNFT',  'GNPX',  'GOSS',  'GOVX',  'GRAY',  'GRCL',  'GRPH',  'GRTS',  'GRTX',  'GSK',  'GTBP',  'GTHX',  'HALO',  'HARP',  'HCM',  'HEPA',  'HGEN',  'HOOK',  'HOTH',  'HOWL',  'HRMY',  'HRTX',  'HSTO',  'HTBX',  'HZNP',  'IBIO',  'IBRX',  'ICPT',  'ICVX',  'IDRA',  'IDYA',  'IFRX',  'IGMS',  'IGXT',  'IKNA',  'IKT',  'IMAB',  'IMCR',  'IMGN',  'IMGO',  'IMMP',  'IMNM',  'IMPL',  'IMRA',  'IMRN',  'IMRX',  'IMTX',  'IMUX',  'IMV',  'IMVT',  'INAB',  'INBX',  'INCY',  'INDP',  'INFI',  'INMB',  'INO',  'INSM',  'INVA',  'INZY',  'IONS',  'IOVA',  'IPHA',  'IPSC',  'IRWD',  'ISEE',  'ITCI',  'ITOS',  'ITRM',  'IVA',  'JAGX',  'JANX',  'JAZZ',  'JNCE',  'JNJ',  'KALA',  'KALV',  'KDMN',  'KDNY',  'KLDO',  'KMDA',  'KMPH',  'KNSA',  'KNTE',  'KOD',  'KPTI',  'KRBP',  'KRON',  'KROS',  'KRTX',  'KRYS',  'KTRA',  'KURA',  'KYMR',  'KZIA',  'KZR',  'LABP',  'LBPH',  'LCTX',  'LEGN',  'LGND',  'LGVN',  'LIFE',  'LIXT',  'LJPC',  'LLY',  'LMNL',  'LNTH',  'LOGC',  'LPCN',  'LPTX',  'LQDA',  'LRMR',  'LTRN',  'LUMO',  'LVTX',  'LXRX',  'LYEL',  'LYRA',  'MACK',  'MBIO',  'MBRX',  'MCRB',  'MDGL',  'MDNA',  'MDWD',  'MEIP',  'MESO',  'MGNX',  'MGTA',  'MGTX',  'MIRM',  'MIST',  'MITO',  'MNKD',  'MNKKQ',  'MNOV',  'MNPR',  'MOLN',  'MOR',  'MORF',  'MREO',  'MRK',  'MRKR',  'MRNA',  'MRNS',  'MRSN',  'MRTX',  'MRUS',  'MTCR',  'MTEM',  'MTNB',  'MYMD',  'MYOV',  'NAVB',  'NBIX',  'NBRV',  'NBTX',  'NBY',  'NCNA',  'NERV',  'NEXI',  'NGM',  'NKTR',  'NKTX',  'NLSP',  'NLTX',  'NMTR',  'NNVC',  'NOVN',  'NRBO',  'NRIX',  'NRXP',  'NTLA',  'NUVB',  'NVAX',  'NVCR',  'NVIV',  'NVO',  'NVS',  'NXTC',  'NYMX',  'OBSV',  'OCEA',  'OCGN',  'OCUL',  'OCUP',  'ODT',  'OGEN',  'OLMA',  'OMER',  'OMGA',  'ONCR',  'ONCS',  'ONCT',  'ONCY',  'ONTX',  'OPK',  'OPNT',  'OPT',  'OPTN',  'ORIC',  'ORMP',  'ORPH',  'ORTX',  'OSMT',  'OTIC',  'OTLK',  'OVID',  'OYST',  'PALI',  'PASG',  'PBLA',  'PBYI',  'PCRX',  'PCSA',  'PCVX',  'PDSB',  'PFE',  'PGEN',  'PHAS',  'PHAT',  'PHIO',  'PHVS',  'PIRS',  'PLRX',  'PLUS',  'PLX',  'PLXP',  'PMCB',  'PMVP',  'PPBT',  'PRAX',  'PRFX',  'PRLD',  'PROG',  'PRQR',  'PRTA',  'PRTK',  'PRVB',  'PSNL',  'PSTI',  'PSTV',  'PSTX',  'PTCT',  'PTGX',  'PTIX',  'PTN',  'PTPI',  'PULM',  'PYPD',  'QLGN',  'QURE',  'RAIN',  'RANI',  'RAPT',  'RARE',  'RCKT',  'RCUS',  'RDHL',  'RDUS',  'REGN',  'REPH',  'REPL',  'RETA',  'RGEN',  'RGLS',  'RGNX',  'RHHBY',  'RIGL',  'RLAY',  'RLMD',  'RLYB',  'RMTI',  'RNA',  'RNAZ',  'RNLX',  'RNXT',  'RPHM',  'RPTX',  'RUBY',  'RVMD',  'RVNC',  'RVPH',  'RXDX',  'RXRX',  'RYTM',  'RZLT',  'SAGE',  'SANA',  'SAVA',  'SBBP',  'SBTX',  'SCPH',  'SCPS',  'SCYX',  'SDGR',  'SEEL',  'SELB',  'SESN',  'SGEN',  'SGMO',  'SGTX',  'SIGA',  'SIOX',  'SLDB',  'SLGL',  'SLNO',  'SLRX',  'SLS',  'SMMT',  'SNDX',  'SNGX',  'SNPX',  'SNSE',  'SNY',  'SONN',  'SPPI',  'SPRB',  'SPRO',  'SQZ',  'SRNE',  'SRPT',  'SRRA',  'SRRK',  'STOK',  'STRO',  'STSA',  'STTK',  'SUPN',  'SURF',  'SVRA',  'SWTX',  'SYBX',  'SYN',  'SYRS',  'TAK',  'TALS',  'TARA',  'TARS',  'TBIO',  'TBPH',  'TCDA',  'TCON',  'TCRR',  'TCRX',  'TENX',  'TERN',  'TEVA',  'TFFP',  'TGTX',  'TIL',  'TKNO',  'TLC',  'TLSA',  'TMBR',  'TNXP',  'TNYA',  'TPST',  'TPTX',  'TRIL',  'TRVI',  'TRVN',  'TSHA',  'TTNP',  'TVTX',  'TXMD',  'TYME',  'UBX',  'UNCY',  'URGN',  'UTHR',  'VACC',  'VALN',  'VBIV',  'VBLT',  'VCEL',  'VCNX',  'VECT',  'VERA',  'VERU',  'VERV',  'VINC',  'VIR',  'VIRI',  'VIRX',  'VKTX',  'VLON',  'VNDA',  'VOR',  'VRCA',  'VRDN',  'VRNA',  'VRPX',  'VRTX',  'VSTM',  'VTGN',  'VTRS',  'VTVT',  'VXRT',  'VYGR',  'VYNE',  'WINT',  'WVE',  'XBIO',  'XBIT',  'XCUR',  'XENE',  'XENT',  'XERS',  'XFOR',  'XLRN',  'XNCR',  'XOMA',  'XTLB',  'YMAB',  'YMTX',  'ZEAL',  'ZGNX',  'ZIOP',  'ZLAB',  'ZNTL',  'ZSAN',  'ZYME',  'ZYNE',  ];

var tickers = [  'ABBV',  'ABCL',  'ABEO',  'ABIO',  'ABOS',  'ABUS',  'ACAD',  'ACER',  'ACET',  'ACHL',  'ACHV',  'ACIU',  'ACOR',  'ACRS',  'ACRX',  'ACST',  'ACXP',  'ADAG',  'ADAP',  'ADCT',  'ADGI',  'ADIL',  'ADMA',  'ADMP',  'ADMS',  'ADPT',  'ADTX',  'ADVM',  'ADXS',  'AERI',  'AEZS',  'AFMD',  'AGEN',  'AGIO',  'AGLE',  'AGRX',  'AGTC',  'AIM',  'AKBA',  'AKRO',  'AKTX',  'AKUS',  'ALBO',  'ALDX',  'ALEC',  'ALGS',  'ALIM',  'ALKS',  'ALLK',  'ALLO',  'ALNA',  'ALNY',  'ALPN',  'ALRN',  'ALT',  'ALVR',  'ALXO',  'ALZN',  'AMAM',  'AMGN',  'AMPE',  'AMPH',  'AMRN',  'AMRX',  'AMTI',  'AMYT',  'ANAB',  'ANEB',  'ANGN',  'ANIK',  'ANIP',  'ANIX',  'ANNX',  'ANVS',  'APLS',  'APLT',  'APRE',  'APTO',  'APTX',  'APVO',  'AQST',  'ARAV',  'ARCT',  'ARDS',  'ARDX',  'ARGX',  'ARMP',  'ARNA',  'ARPO',  'ARQT',  'ARTL',  'ARVN',  'ARWR',  'ASLN',  'ASMB',  'ASND',  'ASRT',  'ATAI',  'ATHA',  'ATHE',  'ATHX',  'ATNF',  'ATNM',  'ATNX',  'ATOS',  'ATRA',  'ATRS',  'ATXI',  'AUPH',  'AUTL',  'AVDL',  'AVEO',  'AVIR',  'AVRO',  'AVTE',  'AVXL',  'AXGN',  'AXLA',  'AXSM',  'AYLA',  'AYTU',  'AZN',  'AZRX',  'BBI',  'BBIO',  'BCAB',  'BCDA',  'BCEL',  'BCLI',  'BCRX',  'BCTX',  'BCYC',  'BDSI',  'BDTX',  'BEAM',  'BFRA',  'BGNE',  'BHC',  'BHVN',  'BIIB',  'BLCM',  'BLPH',  'BLRX',  'BLU',  'BLUE',  'BMEA',  'BMRN',  'BMY',  'BNTC',  'BNTX',  'BOLT',  'BPMC',  'BPTH',  'BPTS',  'BSGM',  'BTAI',  'BTX',  'BVXV',  'BXRX',  'BYSI',  'CABA',  'CADL',  'CALA',  'CALT',  'CANF',  'CAPR',  'CARA',  'CASI',  'CATB',  'CBAY',  'CBIO',  'CBLI',  'CCCC',  'CCXI',  'CDAK',  'CDMO',  'CDTX',  'CDXS',  'CELC',  'CERC',  'CERE',  'CERS',  'CFRX',  'CGEM',  'CGEN',  'CHMA',  'CHRS',  'CKPT',  'CLBS',  'CLDX',  'CLLS',  'CLNN',  'CLRB',  'CLSD',  'CLSN',  'CLVS',  'CMPI',  'CMPS',  'CMPX',  'CMRX',  'CNCE',  'CNSP',  'CNTA',  'CNTB',  'CNTX',  'COCP',  'COGT',  'COLL',  'CORT',  'CPIX',  'CPRX',  'CRBP',  'CRBU',  'CRDF',  'CRIS',  'CRMD',  'CRNX',  'CRSP',  'CRTX',  'CRVS',  'CSII',  'CTIC',  'CTMX',  'CTXR',  'CUE',  'CVAC',  'CVM',  'CWBR',  'CYAD',  'CYCC',  'CYCN',  'CYDY',  'CYT',  'CYTH',  'CYTK',  'CYTO',  'DARE',  'DAWN',  'DBTX',  'DBVT',  'DCPH',  'DCTH',  'DFFN',  'DMAC',  'DNLI',  'DRMA',  'DRNA',  'DRRX',  'DSGN',  'DTIL',  'DVAX',  'DYAI',  'DYN',  'EBS',  'EDAP',  'EDIT',  'EDSA',  'EGRX',  'EIDX',  'EIGR',  'ELDN',  'ELEV',  'ELOX',  'ELTX',  'ELYM',  'ENDP',  'ENLV',  'ENOB',  'ENTA',  'ENTX',  'EOLS',  'EPIX',  'EPZM',  'EQ',  'ERAS',  'ERYP',  'ESPR',  'ETNB',  'ETON',  'ETTX',  'EVAX',  'EVFM',  'EVLO',  'EVOK',  'EWTX',  'EXAS',  'EXEL',  'EYEG',  'EYEN',  'EYPT',  'FATE',  'FBIO',  'FBRX',  'FDMT',  'FENC',  'FGEN',  'FHTX',  'FIXX',  'FLXN',  'FMTX',  'FNCH',  'FOLD',  'FREQ',  'FRLN',  'FSTX',  'FULC',  'FUSN',  'FWP',  'GALT',  'GANX',  'GBIO',  'GBT',  'GERN',  'GHRS',  'GILD',  'GKOS',  'GLMD',  'GLPG',  'GLSI',  'GLTO',  'GLYC',  'GMAB',  'GMDA',  'GMTX',  'GNCA',  'GNFT',  'GNPX',  'GOSS',  'GOVX',  'GRAY',  'GRCL',  'GRPH',  'GRTS',  'GRTX',  'GSK',  'GTBP',  'GTHX',  'HALO',  'HARP',  'HCM',  'HEPA',  'HGEN',  'HOOK',  'HOTH',  'HOWL',  'HRMY',  'HRTX',  'HSTO',  'HTBX',  'HZNP',  'IBIO',  'IBRX',  'ICPT',  'ICVX',  'IDRA',  'IDYA',  'IFRX',  'IGMS',  'IGXT',  'IKNA',  'IKT',  'IMAB',  'IMCR',  'IMGN',  'IMGO',  'IMMP',  'IMNM',  'IMPL',  'IMRA',  'IMRN',  'IMRX',  'IMTX',  'IMUX',  'IMV',  'IMVT',  'INAB',  'INBX',  'INCY',  'INDP',  'INFI',  'INMB',  'INO',  'INSM',  'INVA',  'INZY',  'IONS',  'IOVA',  'IPHA',  'IPSC',  'IRWD',  'ISEE',  'ITCI',  'ITOS',  'ITRM',  'IVA',  'JAGX',  'JANX',  'JAZZ',  'JNCE',  'JNJ',  'KALA',  'KALV',  'KDMN',  'KDNY',  'KLDO',  'KMDA',  'KMPH',  'KNSA',  'KNTE',  'KOD',  'KPTI',  'KRBP',  'KRON',  'KROS',  'KRTX',  'KRYS',  'KTRA',  'KURA',  'KYMR',  'KZIA',  'KZR',  'LABP',  'LBPH',  'LCTX',  'LEGN',  'LGND',  'LGVN',  'LIFE',  'LIXT',  'LJPC',  'LLY',  'LMNL',  'LNTH',  'LOGC',  'LPCN',  'LPTX',  'LQDA',  'LRMR',  'LTRN',  'LUMO',  'LVTX',  'LXRX',  'LYEL',  'LYRA',  'MACK',  'MBIO',  'MBRX',  'MCRB',  'MDGL',  'MDNA',  'MDWD',  'MEIP',  'MESO',  'MGNX',  'MGTA',  'MGTX',  'MIRM',  'MIST',  'MITO',  'MNKD',  'MNKKQ',  'MNOV',  'MNPR',  'MOLN',  'MOR',  'MORF',  'MREO',  'MRK',  'MRKR',  'MRNA',  'MRNS',  'MRSN',  'MRTX',  'MRUS',  'MTCR',  'MTEM',  'MTNB',  'MYMD',  'MYOV',  'NAVB',  'NBIX',  'NBRV',  'NBTX',  'NBY',  'NCNA',  'NERV',  'NEXI',  'NGM',  'NKTR',  'NKTX',  'NLSP',  'NLTX',  'NMTR',  'NNVC',  'NOVN',  'NRBO',  'NRIX',  'NRXP',  'NTLA',  'NUVB',  'NVAX',  'NVCR',  'NVIV',  'NVO',  'NVS',  'NXTC',  'NYMX',  'OBSV',  'OCEA',  'OCGN',  'OCUL',  'OCUP',  'ODT',  'OGEN',  'OLMA',  'OMER',  'OMGA',  'ONCR',  'ONCS',  'ONCT',  'ONCY',  'ONTX',  'OPK',  'OPNT',  'OPT',  'OPTN',  'ORIC',  'ORMP',  'ORPH',  'ORTX',  'OSMT',  'OTIC',  'OTLK',  'OVID',  'OYST',  'PALI',  'PASG',  'PBLA',  'PBYI',  'PCRX',  'PCSA',  'PCVX',  'PDSB',  'PFE',  'PGEN',  'PHAS',  'PHAT',  'PHIO',  'PHVS',  'PIRS',  'PLRX',  'PLUS',  'PLX',  'PLXP',  'PMCB',  'PMVP',  'PPBT',  'PRAX',  'PRFX',  'PRLD',  'PROG',  'PRQR',  'PRTA',  'PRTK',  'PRVB',  'PSNL',  'PSTI',  'PSTV',  'PSTX',  'PTCT',  'PTGX',  'PTIX',  'PTN',  'PTPI',  'PULM',  'PYPD',  'QLGN',  'QURE',  'RAIN',  'RANI',  'RAPT',  'RARE',  'RCKT',  'RCUS',  'RDHL',  'RDUS',  'REGN',  'REPH',  'REPL',  'RETA',  'RGEN',  'RGLS',  'RGNX',  'RHHBY',  'RIGL',  'RLAY',  'RLMD',  'RLYB',  'RMTI',  'RNA',  'RNAZ',  'RNLX',  'RNXT',  'RPHM',  'RPTX',  'RUBY',  'RVMD',  'RVNC',  'RVPH',  'RXDX',  'RXRX',  'RYTM',  'RZLT',  'SAGE',  'SANA',  'SAVA',  'SBBP',  'SBTX',  'SCPH',  'SCPS',  'SCYX',  'SDGR',  'SEEL',  'SELB',  'SESN',  'SGEN',  'SGMO',  'SGTX',  'SIGA',  'SIOX',  'SLDB',  'SLGL',  'SLNO',  'SLRX',  'SLS',  'SMMT',  'SNDX',  'SNGX',  'SNPX',  'SNSE',  'SNY',  'SONN',  'SPPI',  'SPRB',  'SPRO',  'SQZ',  'SRNE',  'SRPT',  'SRRA',  'SRRK',  'STOK',  'STRO',  'STSA',  'STTK',  'SUPN',  'SURF',  'SVRA',  'SWTX',  'SYBX',  'SYN',  'SYRS',  'TAK',  'TALS',  'TARA',  'TARS',  'TBIO',  'TBPH',  'TCDA',  'TCON',  'TCRR',  'TCRX',  'TENX',  'TERN',  'TEVA',  'TFFP',  'TGTX',  'TIL',  'TKNO',  'TLC',  'TLSA',  'TMBR',  'TNXP',  'TNYA',  'TPST',  'TPTX',  'TRIL',  'TRVI',  'TRVN',  'TSHA',  'TTNP',  'TVTX',  'TXMD',  'TYME',  'UBX',  'UNCY',  'URGN',  'UTHR',  'VACC',  'VALN',  'VBIV',  'VBLT',  'VCEL',  'VCNX',  'VECT',  'VERA',  'VERU',  'VERV',  'VINC',  'VIR',  'VIRI',  'VIRX',  'VKTX',  'VLON',  'VNDA',  'VOR',  'VRCA',  'VRDN',  'VRNA',  'VRPX',  'VRTX',  'VSTM',  'VTGN',  'VTRS',  'VTVT',  'VXRT',  'VYGR',  'VYNE',  'WINT',  'WVE',  'XBIO',  'XBIT',  'XCUR',  'XENE',  'XENT',  'XERS',  'XFOR',  'XLRN',  'XNCR',  'XOMA',  'XTLB',  'YMAB',  'YMTX',  'ZEAL',  'ZGNX',  'ZIOP',  'ZLAB',  'ZNTL',  'ZSAN',  'ZYME',  'ZYNE',  ];
/*]]>*/
</script><script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"bam.nr-data.net","licenseKey":"NRJS-26cb7ae1e63182183ea","applicationID":"440198580","transactionName":"MwdXbBFXXBJXVxFeXwpNdFsXX10PGXcXVlYQPmFdDkZeAEJRFnRfChZHVw9aVxMZRgBZVAEQ","queueTime":0,"applicationTime":6896,"atts":"H0BUGllNTxw=","errorBeacon":"bam.nr-data.net","agent":""}</script>

<script src="./20210823_FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst_files/update.min.js.descarga"></script></body></html>